FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Buhl, R
   Heaney, LG
   Loefroth, E
   Larbig, M
   Kostikas, K
   Conti, V
   Cao, H
AF Buhl, Roland
   Heaney, Liam G.
   Loefroth, Emil
   Larbig, Michael
   Kostikas, Konstantinos
   Conti, Valentino
   Cao, Hui
TI One-year follow up of asthmatic patients newly initiated on treatment
   with medium- or high-dose inhaled corticosteroid-long-acting
   beta(2)-agonist in UK primary care settings
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Uncontrolled asthma; Retrospective study; Treatment pathways; Inhaled
   corticosteroid-long-acting beta(2)-agonist (ICS-LABA); Clinical practice
   research datalink (CPRD)
ID PATTERNS; BURDEN
AB Introduction: Global Initiative for Asthma (GINA) recommends medium- or high-dose inhaled corticosteroid-long-acting beta(2)-agonist (ICS-LABA) as preferred treatments for patients with moderate-to-severe asthma. Limited data is available on how step 4/5 patients respond to ICS-LABA and how they step up/down in clinical practice.
   Methods: This retrospective cohort study assessed the characteristics, control status, treatment pathways, and healthcare resource utilization in patients with asthma during one year after initiating medium- or high-dose ICS-LABA. Data from the United Kingdom Clinical Practice Research Datalink were analysed between January 01, 2006 and February 28, 2016.
   Results: Overall, 29,229 and 16,575 patients initiated medium- and high-dose ICS-LABA, and 35.1% and 45.7% of patients, respectively, remained uncontrolled. The proportions of patients who were adherent to treatment (Medication Possession Ratio >= 80%) were 37.8% and 49.1% in the medium- and high-dose ICS-LABA cohorts, respectively. Among these adherent patients, 63.8% in the medium- and 70% in the high-dose cohorts remained uncontrolled. In patients who stepped up therapy in the medium-dose cohort (19.0%), the common step-up choices were add-on leukotriene receptor antagonist (LTRA) (42.2%), long-acting muscarinic antagonist (LAMA) (23.3%), and increase in ICS dose (22.9%). In patients who stepped up therapy in the high-dose cohort (26.1%), the common step-up choices were add-on LAMA (43.8%) and LTRA (42.1%). Healthcare resource utilization was higher in uncontrolled patients, regardless of the ICS-LABA dose.
   Conclusions: Many patients remain uncontrolled on both medium- or high-dose ICS-LABA, highlighting the need for timely assessment of asthma control to increase treatment intensity, following evidence-based treatment pathways.
C1 [Buhl, Roland] Mainz Univ Hosp, Dept Pulm, Mainz, Germany.
   [Heaney, Liam G.] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Loefroth, Emil] Novartis Sverige AB, Kista, Sweden.
   [Larbig, Michael; Kostikas, Konstantinos] Novartis Pharma AG, Basel, Switzerland.
   [Kostikas, Konstantinos] Univ Ioannina, Sch Med, Dept Resp Med, Ioannina, Greece.
   [Conti, Valentino] Novartis Ireland Ltd, Dublin, Ireland.
   [Cao, Hui] Novartis Pharmaceut, E Hanover, NJ USA.
RP Buhl, R (reprint author), Univ Med Mainz, Dept Pulm, Langenbeckstr 1, D-55131 Mainz, Germany.
EM Roland.Buhl@unimedizin-mainz.de
FU Novartis Pharma AG, Basel, Switzerland
FX This study was funded by Novartis Pharma AG, Basel, Switzerland.
CR Aalbers R, 2017, ALLERGY ASTHMA IMMUN, V9, P386, DOI 10.4168/aair.2017.9.5.386
   [Anonymous], 2019, CLIN PRACTICE RES DA
   [Anonymous], 2018, GLOB STRAT ASTHM MAN
   Arellano FM, 2011, PEDIAT ALLERG IMM-UK, V22, P469, DOI 10.1111/j.1399-3038.2010.01121.x
   Asthma G.I.f, 2019, GLOB STRAT ASTHM MAN
   Chapman KR, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0492-5
   Davidsen JR, 2011, PULM PHARMACOL THER, V24, P647, DOI 10.1016/j.pupt.2011.09.001
   KEITH PK, 2009, CAN RESPIR J, V16, P17
   Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606
   Lang DM, 2015, ALLERGY ASTHMA PROC, V36, P418, DOI 10.2500/aap.2015.36.3908
   Price D, 2016, J ASTHMA ALLERGY, V9, P1, DOI 10.2147/JAA.S97973
   Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P570, DOI 10.1016/j.jaip.2014.05.002
   Sobieraj DM, 2018, JAMA-J AM MED ASSOC, V319, P1485, DOI 10.1001/jama.2018.2769
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Wilson SR, 2010, AM J RESP CRIT CARE, V181, P566, DOI 10.1164/rccm.200906-0907OC
NR 15
TC 0
Z9 0
U1 5
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105859
DI 10.1016/j.rmed.2019.105859
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100009
PM 31916534
DA 2020-05-18
ER

PT J
AU Jansson, SA
   Backman, H
   Andersson, M
   Telg, G
   Lindberg, A
   Stridsman, C
   Lundback, B
   Ronmark, E
AF Jansson, Sven-Arne
   Backman, Helena
   Andersson, Maria
   Telg, Gunilla
   Lindberg, Anne
   Stridsman, Caroline
   Lundback, Bo
   Ronmark, Eva
TI Severe asthma is related to high societal costs and decreased health
   related quality of life
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Severe asthma; Costs; Health-related quality of life; Oral
   corticosteroids
ID PREVALENCE; EXACERBATIONS; DATABASE; DISEASE; ADULTS
AB Background: The aim of the present study was to estimate the societal costs and the key cost drivers for patients with severe asthma in Sweden. In addition, health-related quality of life (HRQOL) and morbidity of patients with severe asthma is described.
   Methods: The study population comprised adults with severe asthma recruited from a large asthma cohort within the Obstructive Lung Disease in Northern Sweden (OLIN) studies. During 2017, patients were interviewed quarterly over telephone regarding their resource utilization and productivity losses.
   Results: Estimated mean annual asthma-related costs per patient with severe asthma amounted to (sic)6,500, of which approximately (sic)2400 and (sic)4100 were direct and indirect costs, respectively. The main cost drivers for direct costs were hospitalizations followed by drugs: approximately (sic)1000 and (sic)800, respectively. Patients on treatment with regular oral corticosteroids (OCS) had greater direct costs compared with those without regular OCS treatment. Co-morbid conditions were common and the costs were substantial also for co-morbid conditions, with a total cost of approximately (sic)4200. The OCS group had significantly lower HRQOL compared to the non-OCS group.
   Conclusions: The societal costs due to severe asthma were substantial. Costs for co-morbid conditions contributed substantially to both direct and indirect costs. The direct costs were significantly higher in the maintenance OCS-group compared to the non-maintenance OCS-group. These results indicate a need for improved management and treatment regimens for patients with severe asthma.
C1 [Jansson, Sven-Arne; Backman, Helena; Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Sect Sustainable Hlth, OLIN Unit, SE-90187 Umea, Sweden.
   [Andersson, Maria; Telg, Gunilla] AstraZeneca Nord Balt, Sodertalje, Sweden.
   [Lindberg, Anne] Umea Univ, Dept Publ Hlth & Clin Med, Div Med, Umea, Sweden.
   [Stridsman, Caroline] Lulea Univ Technol, Dept Hlth Sci, Lulea, Sweden.
   [Lundback, Bo] Univ Gothenburg, Krefting Res Ctr, Inst Med, Gothenburg, Sweden.
RP Jansson, SA (reprint author), Umea Univ, Dept Publ Hlth & Clin Med, Sect Sustainable Hlth, OLIN Unit, SE-90187 Umea, Sweden.
EM sven-arne.jansson@umu.se; helena.backman@norrbotten.se;
   maria.a.andersson@astrazeneca.com; gunilla.telg@astrazeneca.com;
   anne.lindberg@algmed.se; caroline.stridsman@norrbotten.se;
   bo.lundback@gu.se; eva.ronmark@norrbotten.se
OI Stridsman, Caroline/0000-0001-6622-3838; Backman,
   Helena/0000-0002-0553-8067
FU AstraZenecaAstraZeneca; Norrbotten County Council; Swedish Heart-Lung
   FoundationSwedish Heart-Lung Foundation
FX This work was supported by AstraZeneca, Norrbotten County Council and
   the Swedish Heart-Lung Foundation.
CR Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904
   Backman H, 2019, CLIN EXP ALLERGY, V49, P819, DOI 10.1111/cea.13378
   Backman H, 2018, RESP MED, V138, P115, DOI 10.1016/j.rmed.2018.03.036
   Backman H, 2017, CLIN EXP ALLERGY, V47, P1426, DOI 10.1111/cea.12963
   Backman H, 2017, EUR CLIN RESPIR J, V4, DOI 10.1080/20018525.2017.1334508
   Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24
   Boulenger Stephanie, 2005, Eur J Health Econ, V6, P334, DOI 10.1007/s10198-005-0322-1
   Brogger J, 2003, EUR RESPIR J, V21, P468, DOI 10.1183/09031936.03.00056103
   Castillo JR, 2017, J ALLER CL IMM-PRACT, V5, P918, DOI 10.1016/j.jaip.2017.05.001
   Chen WJ, 2016, THORAX, V71, P267, DOI 10.1136/thoraxjnl-2015-207530
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   de Marco R, 2012, EUR RESPIR J, V39, P883, DOI 10.1183/09031936.00061611
   Evans C, 1999, PHARMACOECONOMICS, V15, P241, DOI 10.2165/00019053-199915030-00004
   Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871
   Fonseca JA, 2004, ALLERGY, V59, P1198, DOI 10.1111/j.1398-9995.2004.00515.x
   Global Initiative for Asthma, GLOB STRAT ASTHM MAN
   Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001
   Hansen EF, 2000, THORAX, V55, P833, DOI 10.1136/thorax.55.10.833
   Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042
   Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039
   James AL, 2010, EUR RESPIR J, V35, P273, DOI 10.1183/09031936.00194308
   Janson C, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0855-3
   Jansson S.A., 2014, EUROPEAN RESP SOC MO, DOI [10.1183/2312508X.erm6514., DOI 10.1183/2312508X.ERM6514]
   Jansson SA, 2002, CHEST, V122, P1994, DOI 10.1378/chest.122.6.1994
   Jansson SA, 2007, RESP MED, V101, P2263, DOI 10.1016/j.rmed.2007.06.029
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   Kerkhof M, 2018, THORAX, V73, P116, DOI 10.1136/thoraxjnl-2017-210531
   Lotvall J, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-94
   Lundback B, 2016, EXPERT REV RESP MED, V10, P39, DOI 10.1586/17476348.2016.1114417
   Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639
   Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014
   RUTTENVANMOLKEN MPMH, 1994, HEALTH ECON, V3, P333, DOI 10.1002/hec.4730030507
   Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322
   Siroux V, 2008, ALLERGY, V63, P547, DOI 10.1111/j.1398-9995.2008.01638.x
   SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q
   Sweeney J, 2016, THORAX, V71, P339, DOI 10.1136/thoraxjnl-2015-207630
   US Department of Health and Human Services National Institutes of Health National heart Lung and blood Institute, 2004, J ALLERGY CLIN IMMUN, V113, P59
   Varsano S, 2017, RESP MED, V123, P131, DOI 10.1016/j.rmed.2016.12.017
   von Bulow A, 2014, J ALLER CL IMM-PRACT, V2, P759, DOI 10.1016/j.jaip.2014.05.005
   Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP
   Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 42
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105860
DI 10.1016/j.rmed.2019.105860
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100011
PM 32056670
DA 2020-05-18
ER

PT J
AU Lanario, JW
   Hyland, ME
   Wei, YH
   Jones, RC
   Masoli, M
AF Lanario, Joseph W.
   Hyland, Michael E.
   Wei, Yinghui
   Jones, Rupert C.
   Masoli, Matthew
TI Comparison of the effects of pulmonary and extra-pulmonary symptoms on
   health-related quality of life in patients with severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Severe asthma; Quality of life; Health measurements; Extra-pulmonary
   symptoms; OCS burden
ID GUIDELINES; MANAGEMENT; IMPACT
AB Objectives: To survey the frequency of extra-pulmonary symptoms reported by a sample of patients with severe asthma, their contribution to quality of life and relationship to treatment pathways.
   Methods: Consenting patients (N = 100) attending a severe asthma clinic completed questionnaire measures of extra-pulmonary symptoms (the General symptom Questionnaire, GSQ), pulmonary symptoms (Asthma Control Test, ACT), quality of life (the Severe Asthma Questionnaire, SAQ) and health status (EQ-5D-5L).
   Results: A median of 21 extra-pulmonary symptoms were reported per week. GSQ correlated 0.65 with the ACT and 0.69 with the SAQ. Linear regression showed that both the ACT and GSQ were significant predictors of SAQ mean score, p < 0.001. In patients not receiving biologics, those with high cumulative OCS exposure (>= 1120 mg per year) had significantly worse scores (p < 0.05) on all questionnaires except the ACT and GSQ compared to those with low cumulative OCS exposure.
   Discussion: Extra-pulmonary symptoms were common in this sample of people with severe asthma. Extra-pulmonary and pulmonary symptoms contribute equal variance to the score of HRQoL, showing that they are equally important contributors to patients' experience of severe asthma. Extra-pulmonary symptoms are often overlooked in clinical medicine and in measures of quality of life. Participants receiving biologic treatments had lower extra-pulmonary symptoms possibly indicating that biologics reduce systemic symptoms more effectively than other treatments.
C1 [Lanario, Joseph W.; Jones, Rupert C.] Univ Plymouth, Peninsula Sch Med & Dent, Plymouth PL4 8AA, Devon, England.
   [Hyland, Michael E.] Univ Plymouth, Sch Psychol, Plymouth, Devon, England.
   [Hyland, Michael E.] Plymouth Marjon Univ, Res Dept, Plymouth, Devon, England.
   [Wei, Yinghui] Univ Plymouth, Ctr Math Sci, Sch Engn Comp & Math, Plymouth, Devon, England.
   [Masoli, Matthew] Univ Exeter, Exeter, Devon, England.
RP Lanario, JW (reprint author), Univ Plymouth, Peninsula Sch Med & Dent, Plymouth PL4 8AA, Devon, England.
EM joseph.lanario@plymouth.ac.uk
OI Lanario, Joseph/0000-0003-0317-9774
FU AstraZenecaAstraZeneca
FX A non-promotional grant was received from AstraZeneca.
CR Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   BTS /SIGN, 2016, 153 BTSSIGN
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hyland M.E., 1992, REFORMULATION QUALIT
   Hyland Michael E, 2019, Chronic Dis Transl Med, V5, P129, DOI 10.1016/j.cdtm.2019.05.003
   Hyland ME, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00618-2018
   Hyland ME, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0851-9
   Hyland ME, 2015, QUAL LIFE RES, V24, P631, DOI 10.1007/s11136-014-0801-x
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Rodgers G, 2001, THORAX, V56, P24
   Sposato B, 2018, EUR J INTERN MED, V52, P78, DOI 10.1016/j.ejim.2018.01.026
   Strine TW, 2008, J ASTHMA, V45, P123, DOI 10.1080/02770900701840238
   Sweeney J, 2016, THORAX, V71, P339, DOI 10.1136/thoraxjnl-2015-207630
NR 16
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105870
DI 10.1016/j.rmed.2020.105870
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100003
PM 32056677
DA 2020-05-18
ER

PT J
AU Marc-Malovrh, M
   Camlek, L
   Skrgat, S
   Kern, I
   Flezar, M
   Dezman, M
   Korosec, P
AF Marc-Malovrh, Mateja
   Camlek, Luka
   Skrgat, Sabina
   Kern, Izidor
   Flezar, Matjaz
   Dezman, Manca
   Korosec, Peter
TI Elevated eosinophils, IL5 and IL8 in induced sputum in asthma patients
   with accelerated FEV1 decline
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Lung function decline; Eosinophils; IL5; IL8
ID LUNG-FUNCTION DECLINE; ENDOTHELIAL GROWTH-FACTOR; AIR-FLOW LIMITATION;
   FOLLOW-UP; SEVERE EXACERBATIONS; EXPRESSION; ADULTS; EPITHELIUM;
   PERIOSTIN; PROTEINS
AB Background: Some patients with asthma present with accelerated lung function decline. This phenomenon is mostly associated with severe exacerbations and with poor asthma control.
   Objective: Our aim was to detect the extent of FEV1 decline in patients with mild asthma and to discriminate clinical, functional and inflammatory factors associated with accelerated FEV1 decline.
   Methods: We recruited 50 patients with mild asthma for pulmonary function testing and induced sputum sampling 12-15 years after the initial diagnosis. In 33 patients, from whom sputum of a good quality was obtained, inflammatory cells were counted and concentrations of cytokines IL-2, IL-4, IL-5, IL-8, IL-10, IFN-gamma, angiogenin and VEGF in the sputum were measured by cytometric bead array.
   Results: Eighteen of 33 patients presented with accelerated FEV1 decline of more than 30 ml/year, with a mean (SEM) of 43.2 (3.9) ml/year, compared to 15 control patients with a FEV1 decline of 14.4 (2.1) ml/year. In the accelerated FEV1 decline group, we found elevated sputum levels of IL5 with a median (IQR) of 1.8 (0.4-3.2) pg/ml vs. 0.2 (0.1-1.2) pg/ml, p = 0.04; IL8 with a mean (SEM) of 1503 (194) pg/ml vs. 938 (177) pg/ml, p = 0.04; and eosinophils with a median (IQR) of 223 (41-1020) cells/mu l vs. 39 (1-190) cells/mu l, p = 0.03. No significant differences in other measured parameters were detected between the two groups.
   Conclusion: Elevated sputum eosinophils, IL5 and IL8, which have a potential to stimulate airway remodelling, might be a useful non-invasive biomarkers and therapeutic targets of accelerated FEV1 decline in asthma patients.
C1 [Marc-Malovrh, Mateja; Camlek, Luka; Skrgat, Sabina; Kern, Izidor; Flezar, Matjaz; Dezman, Manca; Korosec, Peter] Univ Clin Resp & Allerg Dis Golnik, Golnik, Slovenia.
RP Marc-Malovrh, M (reprint author), Golnik 36, Golnik 4204, Slovenia.
EM mateja.marc@klinika-golnik.si
CR Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106
   Blyth DI, 2000, AM J RESP CELL MOL, V23, P241, DOI 10.1165/ajrcmb.23.2.3999
   Broekema M, 2010, RESP MED, V104, P1254, DOI 10.1016/j.rmed.2010.03.030
   Cataldo D, 2001, CHEST, V120, P1815, DOI 10.1378/chest.120.6.1815
   Chen R, 1999, CLIN CHEM, V45, P1693
   Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x
   Cibella F, 2002, CHEST, V122, P1944, DOI 10.1378/chest.122.6.1944
   Coumou H, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01785-2017
   den Otter I, 2016, EUR RESPIR J, V48, P393, DOI 10.1183/13993003.01525-2015
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974
   Girodet PO, 2011, PHARMACOL THERAPEUT, V130, P325, DOI 10.1016/j.pharmthera.2011.02.001
   Global Initiative for Asthma (GINA), 2019, GLOB STRAT ASTHM MAN
   Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007
   Graff S, 2019, RESP MED, V152, P60, DOI 10.1016/j.rmed.2019.04.020
   Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100
   Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026
   Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR
   Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1
   Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928
   Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x
   Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885
   Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050
   Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242
   Keglowich L F, 2015, Open Respir Med J, V9, P70, DOI 10.2174/1874306401509010070
   Keglowich L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081494
   Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703
   Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066
   Litonjua AA, 2003, ANN ALLERG ASTHMA IM, V90, P422, DOI 10.1016/S1081-1206(10)61827-3
   Marc MM, 2004, AM J RESP CELL MOL, V31, P216, DOI 10.1165/rcmb.2003-0394OC
   Matsumoto H, 2014, ALLERGOL INT, V63, P153, DOI 10.2332/allergolint.13-RAI-0678
   Matsunaga K, 2014, RESP MED, V108, P976, DOI 10.1016/j.rmed.2014.04.014
   MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC
   Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011
   Pasternack R, 2005, J ALLERGY CLIN IMMUN, V116, P1123, DOI 10.1016/j.jaci.2005.08.030
   PEAT JK, 1987, EUR J RESPIR DIS, V70, P171
   Petrovic MG, 2008, MOL VIS, V14, P1382
   Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799
   Sakagami T, 2014, J ASTHMA, V51, P113, DOI 10.3109/02770903.2013.852201
   Tanaka H, 2004, AM J RESP CELL MOL, V31, P62, DOI 10.1165/rcmb.2003-0305OC
   Tang H, 2013, J IMMUNOL, V190, P438, DOI 10.4049/jimmunol.1201827
   ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026
   Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC
   ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14
   van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907
   VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656, DOI 10.1164/ajrccm/151.3_Pt_1.656
   Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110
NR 49
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105875
DI 10.1016/j.rmed.2020.105875
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100004
PM 32056673
DA 2020-05-18
ER

PT J
AU Marques, A
   Pinho, C
   De Francesco, S
   Martins, P
   Neves, J
   Oliveira, A
AF Marques, Alda
   Pinho, Catia
   De Francesco, Silvia
   Martins, Paula
   Neves, Joana
   Oliveira, Ana
TI A randomized controlled trial of respiratory physiotherapy in lower
   respiratory tract infections
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Computerised respiratory sounds; CT; LRTI; Outcome measure;
   Rehabilitation
ID COPD; EXACERBATIONS; GUIDELINES; MANAGEMENT; DISEASE; TIME
AB Introduction: Physiotherapy may play a role in the recovery of signs, symptoms and function of patients with lower respiratory tract infections (LRTI) but its effectiveness is still controversial.
   Objectives: To assess the effects of respiratory physiotherapy compared with standard pharmacological care on symptoms and function in outpatients with LRTI.
   Design: Single-blind, randomised controlled trial.
   Setting: Outpatients were recruited from the casualties of a central hospital.
   Participants: Outpatients with LRTI were recruited and randomly allocated to the control (pharmacological) or experimental (pharmacological and respiratory physiotherapy) group.
   Intervention: The intervention consisted of conventional pharmacological treatment and conventional pharmacological treatment plus respiratory physiotherapy. Respiratory physiotherapy included breathing and airway clearance techniques, exercise training and education during 3-weeks, 3 times per week.
   Main outcome measure: Primary outcome measures - occupation rate of wheezes Wh%; Secondary outcome measures - number of crackles, peripheral oxygen saturation (SpO2) modified Borg scale (mBorg), modified Medical Research Council scale (mMRC), 6-min walk test (6MWT), forced expiratory volume in 1 s and forced vital capacity, and volume and density of the lung and bronchial tree volume.
   Results: Ninety-seven patients (53 controls and 44 experimental) completed the intervention. After the intervention, both groups improved significantly in all variables (0.0001 < p < 0.04; 0.001< eta(2) <0.092), with the exception of the mBorg. The magnitude of improvement of the experimental group exceeded the control group in the number of crackles, SpO2 levels, mMRC and 6MWT (0.002 < p < 0.032; 0.002< eta(2) <0.092).
   Conclusion: Adding respiratory physiotherapy to the pharmacological treatment of outpatients with LRTI results in greater recovery of symptoms and function parameters.
C1 [Marques, Alda; De Francesco, Silvia; Martins, Paula; Oliveira, Ana] Univ Aveiro ESSUA, Sch Hlth Sci, Aveiro, Portugal.
   [Marques, Alda; Oliveira, Ana] Univ Aveiro ESSUA, Sch Hlth Sci, Lab 3R, Aveiro, Portugal.
   [Marques, Alda; Martins, Paula; Oliveira, Ana] Univ Aveiro, Dept Med Sci, Inst Biomed iBiMED, Aveiro, Portugal.
   [Pinho, Catia] Univ Aveiro, IT, P-3810193 Aveiro, Portugal.
   [Pinho, Catia] Univ Aveiro, DETI, P-3810193 Aveiro, Portugal.
   [De Francesco, Silvia; Martins, Paula] Univ Aveiro, Inst Elect & Informat Engn Aveiro IEETA, Aveiro, Portugal.
   [Neves, Joana] Ctr Hosp Baixo Vouga, Dept Internal Med, Aveiro, Portugal.
RP Marques, A (reprint author), Univ Aveiro ESSUA, Sch Hlth Sci, Aveiro, Portugal.
EM amarques@ua.pt; catiap@ua.pt; silvia.francesco@ua.pt; pmartins@ua.pt;
   joana.brrneves@gmail.com; alao@ua.pt
RI Marques, Alda Sofia Pires/K-3150-2013; De Francesco, Silvia/B-4189-2012;
   Pinho, Catia/K-7053-2013; Martins, Paula/L-4836-2014
OI Marques, Alda Sofia Pires/0000-0003-4980-6200; De Francesco,
   Silvia/0000-0003-3982-6224; Pinho, Catia/0000-0002-7530-2375; Martins,
   Paula/0000-0001-5218-388X
FU Portuguese Foundation for Science and Technology (FCT - Fundacao para a
   Ciencia e a Tecnologia)Portuguese Foundation for Science and Technology
   [PTDC/SAU-BEB/101943/2008, UID/BIM/04501/2019]; European Regional
   Development Fund through the Operational program COMPETE/FEDEREuropean
   Union (EU) [FCOMP-01-0124-FEDER-010919, POCI-01-0145-FEDER-007628];
   iBiMED [UID/BIM/04501/2019]
FX This work was funded by the Portuguese Foundation for Science and
   Technology (FCT - Fundacao para a Ciencia e a Tecnologia -
   PTDC/SAU-BEB/101943/2008) (UID/BIM/04501/2019), by the European Regional
   Development Fund through the Operational program COMPETE/FEDER
   (FCOMP-01-0124-FEDER-010919 and POCI-01-0145-FEDER-007628) and by iBiMED
   (UID/BIM/04501/2019).
CR Bausewein C, 2007, RESP MED, V101, P399, DOI 10.1016/j.rmed.2006.07.003
   Becker LA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001726.pub5
   Bohadana A, 2014, NEW ENGL J MED, V370, P744, DOI 10.1056/NEJMra1302901
   Borg G, 1998, BORGS PERCEIVED EXER
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Claessens YE, 2015, AM J RESP CRIT CARE, V192, P974, DOI 10.1164/rccm.201501-0017OC
   Cohen J, 1969, STAT POWER ANAL BEHA
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Doherty D.E., 2006, J FAM PRACT CLIN U S, pS1
   Eaton T, 2009, RESPIROLOGY, V14, P230, DOI 10.1111/j.1440-1843.2008.01418.x
   Fiz JA, 2006, RESPIRATION, V73, P55, DOI 10.1159/000087690
   Global Initiative for Chronic Obstructive Lung Disease, 2019, GLOB STRAT DIAGN MAN
   Greulich T, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-36
   Gruet M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01285
   Holland AE, 2014, J PHYSIOTHER, V60, P181, DOI 10.1016/j.jphys.2014.08.018
   Holland AE, 2014, EUR RESPIR J, V44, P1428, DOI 10.1183/09031936.00150314
   Jose A, 2013, BRAZ J PHYS THER, V17, P351, DOI 10.1590/S1413-35552013005000098
   Lewis LK, 2012, RESP MED, V106, P155, DOI 10.1016/j.rmed.2011.10.014
   Liao LY, 2015, INT J CHRONIC OBSTR, V10, P1703, DOI 10.2147/COPD.S90673
   Medicine A.C.o.S, 2006, GUID EX TEST PRESCR
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Oliveira A, 2016, PHYSIOTHERAPY, V102, P111, DOI 10.1016/j.physio.2015.03.3723
   Oliveira A, 2018, COPD, V15, P479, DOI 10.1080/15412555.2018.1537366
   Oliveira A, 2018, RESP MED, V138, P57, DOI 10.1016/j.rmed.2018.03.023
   Oliveira A, 2017, CLIN RESPIR J, V11, P703, DOI 10.1111/crj.12402
   Pinho Catia, 2016, International Journal of Reliable and Quality E-Healthcare, V5, P34, DOI 10.4018/IJRQEH.2016100103
   Postiaux G, 2014, REV MAL RESPIR, V31, P552, DOI 10.1016/j.rmr.2013.11.009
   Riebe D., 2014, AM COLL SPORTS MED G
   Rossi M., 2000, EUROPEAN RESP REV, V10, P611
   Silva F., 2017, PROCESSAMENTO ANALIS
   Singanayagam A, 2014, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.10003013
   Sookpeng S., 2013, INT J MED HLTH BIOME, V7, P1
   Spruit MA, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01312-2017
   Taplidou SA, 2007, COMPUT BIOL MED, V37, P1073, DOI 10.1016/j.compbiomed.2006.09.007
   Torres-Sanchez I, 2017, PHYSIOTHER CAN, V69, P122, DOI 10.3138/ptc.2015-78
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Troosters T, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.3
   Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016
   WENDT HW, 1972, EUR J SOC PSYCHOL, V2, P463, DOI 10.1002/ejsp.2420020412
   WHO (World Health Organization), 2008, GLOB BURD DIS 2004 U
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x
   Wyrwich KW, 2015, PATIENT-RELAT OUTCOM, V6, P215, DOI 10.2147/PROM.S85779
   Yang M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006338.pub3
NR 43
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105861
DI 10.1016/j.rmed.2019.105861
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100002
PM 31916533
DA 2020-05-18
ER

PT J
AU Milger, K
   Korn, S
   Buhl, R
   Hamelmann, E
   Herth, FJF
   Gappa, M
   Drick, N
   Fuge, J
   Suhling, H
AF Milger, Katrin
   Korn, Stephanie
   Buhl, Roland
   Hamelmann, Eckard
   Herth, Felix J. F.
   Gappa, Monika
   Drick, Nora
   Fuge, Jan
   Suhling, Hendrik
TI Age- and sex-dependent differences in patients with severe asthma
   included in the German Asthma Net cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Severe asthma; Antibody therapy; Sex; Age; Lung function
ID MEPOLIZUMAB; DEFINITION; VALIDATION; DIAGNOSIS
AB Background: Severe asthma affects less than 5% of asthmatics, but is associated with high costs and increased mortality. The aim of this study was to assess age- and sex-dependent differences in this patient group.
   Methods: Retrospective analysis of 1317 children and adults with severe asthma who are included in the German Asthma Net registry.
   Results: There were more adults than children in the registry and patients' mean age was 52. Apart from children <18 years, there were more women (57%) than men. The age of first diagnosis ranged from 0 to 76 years. 38% of patients had a positive bronchial reversibility after short acting bronchodilators. Quality of life, FEV1 and MEF 25 decreased with older age whereas treatment with oral steroids and monoclonal antibodies increased. An antieosinophil treatment was most frequently used in patients aged around 57 years, while an anti-IgE treatment was used in all age-groups including children. There were sex-dependent differences with lower values in men for FEV1, FVC, MEF 25 and DLCO. Yet, women were more frequently unable to work than men due to the disease.
   Conclusion: In patients with severe asthma, clinical characteristics, but also treatments differed between age groups and between the sexes, reflecting different phenotypes of the disease.
C1 [Milger, Katrin] Ludwig Maximilians Univ Munich LMU, Dept Internal Med 5, Munich, Germany.
   [Milger, Katrin] German Ctr Lung Res DZL, Comprehens Pneumol Ctr CPC M, Munich, Germany.
   [Korn, Stephanie; Buhl, Roland] Univ Hosp Mainz, Dept Pulm, Mainz, Germany.
   [Hamelmann, Eckard] Evangel Klinikum Bethel, Bielefeld, Germany.
   [Herth, Felix J. F.] Heidelberg Univ, Thoraxklin, TLRCH, Heidelberg, Germany.
   [Herth, Felix J. F.; Drick, Nora; Fuge, Jan; Suhling, Hendrik] German Ctr Lung Res DZL, Munich, Germany.
   [Gappa, Monika] Evangel Krankenhaus Dusseldorf, Dusseldorf, Germany.
   [Drick, Nora; Fuge, Jan; Suhling, Hendrik] Hannover Med Sch, Dept Pneumol, Hannover, Germany.
RP Suhling, H (reprint author), Hannover Med Sch, Carl Neuberg Str 1, D-30626 Hannover, Germany.
EM suhling.hendrik@mh-hannover.de
CR [Anonymous], 2018, GLOBAL ASTHMA REPORT
   Balzano G, 2007, Monaldi Arch Chest Dis, V67, P135
   Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
   Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S
   Buhl R, 2017, PNEUMOLOGIE, V71, P849, DOI 10.1055/s-0043-119504
   Buhl R., 2019, AM J RESP CRIT CARE, V199, pA1332
   Bundes_arztekammer (B_AK) KrBK, 2018, NAT VERS ASTHM LANGF
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Fuseini H, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0686-1
   Hausen T, 2019, PNEUMOLOGIE, V73, P340, DOI 10.1055/a-0851-5269
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265
   Kaur R, 2019, J ALLERGY CLIN IMMUN, V144, P1, DOI 10.1016/j.jaci.2019.05.031
   Larsson K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0719-x
   Lommatzsch M, 2014, DTSCH ARZTEBL INT, V111, P847, DOI 10.3238/arztebl.2014.0847
   Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   R. Koch-Institut, 2014, ASTHM BRONCH FAKT GE
   Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093
   Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011
   Triebner K, 2016, J ALLERGY CLIN IMMUN, V137, P50, DOI 10.1016/j.jaci.2015.08.019
NR 22
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105858
DI 10.1016/j.rmed.2019.105858
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100001
PM 31916535
DA 2020-05-18
ER

PT J
AU Mingotti, C
   Sarinho, J
   Stanigher, K
   Silva, J
   Roquette, E
   Marchi, E
   Ponte, EV
AF Mingotti, Cintia
   Sarinho, Jose
   Stanigher, Katia
   Silva, Jucara
   Roquette, Eduardo
   Marchi, Evaldo
   Ponte, Eduardo Vieira
TI Evaluating the FEV1/FVC ratio in the lower range of normality as a
   marker of worse clinical outcomes in asthmatic subjects without airway
   obstruction
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Corticosteroids; Exacerbation; Epidemiology; Treatment
ID FLOW OBSTRUCTION; LUNG-FUNCTION
AB Background: We should continually improve tools for evaluating asthma. The aim of this study was to evaluate whether the FEV1/FVC ratio in the lower range of normality is associated with worse outcomes in asthmatics without airway obstruction.
   Methods: We screened asthmatics at eight clinics. Subjects answered the Asthma Control Questionnaire and underwent spirometry. We assigned individuals without airway obstruction in three groups according to the post bronchodilator FEV1/FVC ratio: lower range of normality, intermediary range of normality and upper range of normality. Asthma outcomes were hospital admission due to asthma during the preceding year, non-controlled asthma symptoms and moderate-high inhaled maintenance therapy need.
   Results: In subjects from six to 18 years old, the rate of hospital admission was higher in the group with FEV1/FVC ratio in the lower range of normality as compared with the other two groups but the frequency of non-controlled symptoms of asthma and moderate-high dose of inhaled maintenance therapy need was similar. From 19 to 59 years old, the rate of moderate-high inhaled maintenance therapy need was higher in the group with FEV1/FVC ratio in the lower range of normality as compared with the other two groups, but the frequency of hospital admissions and non-controlled symptoms of asthma was similar. Above 59 years old, there was no difference in clinical asthma outcomes between lung function groups.
   Conclusions: FEV1/FVC ratio in the lower range of normality is a marker of worse clinical outcomes in asthmatics without airway obstruction.
C1 [Mingotti, Cintia; Sarinho, Jose; Stanigher, Katia; Silva, Jucara; Roquette, Eduardo; Marchi, Evaldo; Ponte, Eduardo Vieira] Fac Med Jundiai, Dept Internal Med, Jundiai, SP, Brazil.
RP Ponte, EV (reprint author), R Francisco Teles 250, BR-13202550 Jundiai, SP, Brazil.
EM cintia.bert@gmail.com; ze2005@uol.com.br; shilanara@gmail.com;
   junoely@gmail.com; earoquette@gmail.com; evmarchi@uol.com.br;
   evponte@yahoo.com.br
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/18367-9]
FX This study was funded by FAPESP (grant 2017/18367-9). Funding source had
   no role in study design, data collection, data analysis, interpretation
   of data, manuscript writing or submission.
CR Axelsson I, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010126.pub2
   Bel EH, 2013, NEW ENGL J MED, V369, P549, DOI 10.1056/NEJMcp1214826
   Bem A.J., 2012, REV SAUDE PUBL, V46, P1, DOI [10.1590/S0034-89102012005000013, DOI 10.1590/S0034-89102012005000013]
   Boutin B, 2015, EUR RESPIR J, V45, P107, DOI 10.1183/09031936.00062814
   Broekema M, 2011, AM J RESP CRIT CARE, V183, P310, DOI 10.1164/rccm.201003-0494OC
   Cerveri I, 2008, THORAX, V63, P1040, DOI 10.1136/thx.2008.095554
   Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3
   Ferreira DS, 2018, ALLERGY, V73, P635, DOI 10.1111/all.13323
   Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350
   Leite Mylene, 2008, J. bras. pneumol., V34, P756, DOI 10.1590/S1806-37132008001000002
   Lima-Matos A, 2018, RESP MED, V145, P95, DOI 10.1016/j.rmed.2018.10.025
   McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737
   Muniz IS, 2016, J ASTHMA, V53, P801, DOI 10.3109/02770903.2016.1155220
   Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7
   Perez T, 2013, RESP MED, V107, P1667, DOI 10.1016/j.rmed.2013.08.009
   Ponte EV, 2017, RESPIROLOGY, V22, P1558, DOI 10.1111/resp.13102
   Ponte EV, 2018, CLIN RESPIR J, V12, P410, DOI 10.1111/crj.12530
   Postma DS, 2019, LANCET RESP MED, V7, P402, DOI 10.1016/S2213-2600(19)30049-9
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Saglani S, 2015, EUR RESPIR J, V46, P1796, DOI 10.1183/13993003.01196-2014
   Tat TS, 2016, ANN ALLERG ASTHMA IM, V117, P546, DOI 10.1016/j.anai.2016.09.006
   Wan ES, 2018, AM J RESP CRIT CARE, V198, P1397, DOI 10.1164/rccm.201804-0663OC
NR 22
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105880
DI 10.1016/j.rmed.2020.105880
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100006
PM 32056671
DA 2020-05-18
ER

PT J
AU Moss, BP
   Patel, DC
   Tavee, JO
   Culver, DA
AF Moss, B. P.
   Patel, D. C.
   Tavee, J. O.
   Culver, D. A.
TI Evaluating S100B as a serum biomarker for central neurosarcoidosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE S100B; Biomarker; Sarcoidosis; Neurosarcoidosis
ID MARKER
AB Background: S100B is a calcium-binding protein found primarily in glial cells. In the setting of neuronal injury and disruption of the blood brain barrier, S100B can leak into the cerebrospinal fluid and systemic circulation.
   Objectives: To determine if serum S100B distinguishes patients with central neurosarcoidosis (NS) from patients with extra-neurologic sarcoidosis (ENS) and healthy controls, and if S100B levels correlate with MRI measures of disease burden.
   Methods: Patients were enrolled from the Cleveland Clinic Sarcoidosis Center. Patients with traumatic brain injury, central nervous system (CNS) infections, CNS malignancy, neurodegenerative disorders, schizophrenia, bipolar disorder, or melanoma were excluded. S100B levels were compared between patients with NS, ENS, and healthy controls, and between NS patients with varying degrees of post-contrast enhancement on MRI.
   Results: Median (interquartile range) S100B levels were 101 pg/mL (92, 136) for 11 NS patients, 89 pg/mL (73, 107) for 11 ENS patients, and 60 pg/mL (39, 74) for 26 healthy controls. There was a significant difference between NS and control groups (p = 0.01). The difference between NS and ENS groups did not rise to the level of statistical significance (p = 0.178). S100B levels were significantly different between NS patients with varying degrees of enhancement on MRI (p = 0.04).
   Conclusions: S100B deserves additional study as a biomarker for CNS injury in NS. It may be useful as a longitudinal measure of disease activity.
C1 [Moss, B. P.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
   [Patel, D. C.] Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL USA.
   [Tavee, J. O.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.
   [Culver, D. A.] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.
RP Moss, BP (reprint author), 9500 Euclid Ave,U-10, Cleveland, OH 44195 USA.
EM mossb@ccf.org
OI Moss, Brandon/0000-0001-5319-5129
CR Bartosik-Psujek H, 2011, ACTA NEUROL SCAND, V123, P252, DOI 10.1111/j.1600-0404.2010.01393.x
   Chopra A, 2016, EXPERT REV CLIN IMMU, V12, P1191, DOI 10.1080/1744666X.2016.1196135
   Culver DA, 2017, SEMIN RESP CRIT CARE, V38, P499, DOI 10.1055/s-0037-1604165
   Georgiadis D, 2000, J THORAC CARDIOV SUR, V119, P138, DOI 10.1016/S0022-5223(00)70229-7
   Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003
   Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149
   Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
   Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Petzold A, 2004, MULT SCLER J, V10, P281, DOI 10.1191/1352458504ms1021sr
   R Core Team, 2018, R LANG ENV STAT COMP
NR 11
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105855
DI 10.1016/j.rmed.2019.105855
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100005
PM 31916532
DA 2020-05-18
ER

PT J
AU Pereira, GR
   Barbosa, MS
   Dias, NJD
   dos Santos, FD
   Rauber, KA
   Silva, DR
AF Pereira, Giovana Rodrigues
   Barbosa, Marcia Silva
   Dutra Dias, Natan Jose
   dos Santos, Francine de Fraga
   Rauber, Karin Aline
   Silva, Denise Rossato
TI Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis
   (TB) diagnosis in a city with high TB incidence in Brazil
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Tuberculosis; Diagnosis; Xpert MTB/RIF; Xpert MTB/RIF ultra;
   Smear-negative pulmonary tuberculosis
ID ADULTS
AB Introduction: Since 2018, World Health Organization (WHO) recommended the Xpert MTB/RIF Ultra use for pulmonary and extrapulmonary TB diagnosis, and suggested that Xpert Ultra should be tested in various populations, with different geographical and epidemiological settings.
   Methods: Cross-sectional study with prospective data collection. Outpatients aged >18 years with respiratory symptoms suggestive of pulmonary TB were invited to participate. Sensitivity, specificity, positive and negative predictive values of the test were calculated and compared with the traditional Xpert MTB/RIF.
   Results: During the study period, 180 patients met the inclusion and were included in the analysis. Xpert MTB/ RIF Ultra test was positive in 33 patients (18.3%), and RIF resistance was detected in 1 (3.1%) patient. Considering culture as the gold standard, the sensitivity, specificity, positive predictive value, and negative predictive value of Xpert MTB/RIF Ultra were 100.0% (95% CI 85.2-100.0), 93.6% (95% CI 88.6-96.9), 69.7% (95% CI 55.8-80.7), and 100.0% (95% CI 87.2-100.0), respectively. The area under the ROC curve was 0.97 for the Xpert MTB/RIF Ultra test (95% CI 0.93 to 0.99; p < 0.0001). There was no difference statistically significant between sensitivities and specificities of Xpert MTB/RIF and Xpert MTB/RIF Ultra (p > 0.05).
   Conclusions: This is the first study in Brazil to evaluate the accuracy of Xpert MTB/RIF Ultra in individuals with presumptive pulmonary TB. The test showed an excellent sensitivity and a high specificity, demonstrating that it is a useful tool for pulmonary TB diagnosis.
C1 [Pereira, Giovana Rodrigues; Barbosa, Marcia Silva; Rauber, Karin Aline; Silva, Denise Rossato] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Pneumol, Porto Alegre, RS, Brazil.
   [Pereira, Giovana Rodrigues; Dutra Dias, Natan Jose; dos Santos, Francine de Fraga] Lab Municipal Alvorada, Alvorada, Brazil.
   [Silva, Denise Rossato] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
   [Silva, Denise Rossato] Hosp Clin Porto Alegre, Porto, Portugal.
RP Silva, DR (reprint author), Univ Fed Rio Grande do Sul, 2350 Ramiro Barcelos St,Room 2050, BR-90035903 Porto Alegre, RS, Brazil.
EM drsilva@hcpa.edu.br
OI Rossato Silva, Denise/0000-0003-0230-2734
FU FIPE-HCPA (Fundo de Incentivo a Pesquisa - Hospital de Clinicas de Porto
   Alegre)
FX We acknowledge the support of FIPE-HCPA (Fundo de Incentivo a Pesquisa -
   Hospital de Clinicas de Porto Alegre).
CR [Anonymous], 2017, IEEE T POWER SYSTEMS, VPP, P1, DOI DOI 10.13155/46607
   [Anonymous], 2019, TUBERCULOSIS
   Bahr NC, 2018, LANCET INFECT DIS, V18, P68, DOI [10.1016/s1473-3099(17)30474-7, 10.1016/S1473-3099(17)30474-7]
   Berhanu RH, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00560-18
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Chakravorty S, 2017, MBIO, V8, DOI [10.1128/mbio.00812-17, 10.1128/mBio.00812-17]
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Dorman SE, 2018, LANCET INFECT DIS, V18, P76, DOI [10.1016/S1473-3099(17)30691-6, 10.1016/s1473-3099(17)30691-6]
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141
   Garcia-Basteiro AL, 2017, ARCH BRONCONEUMOL, V53, P665, DOI 10.1016/j.arbres.2017.05.023
   Kolia-Diafouka P, 2019, DIAGN MICR INFEC DIS, V94, P365, DOI 10.1016/j.diagmicrobio.2019.02.008
   Ministerio da Saude, 2018, B EPIDEMIOLOGICO
   Opota O, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01717-18
   World Health Organization, XPERT MTB RIF ASS DI
NR 14
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105876
DI 10.1016/j.rmed.2020.105876
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100007
PM 32056674
DA 2020-05-18
ER

PT J
AU Schwarz, EI
   Mackie, M
   Weston, N
   Tincknell, L
   Beghal, G
   Cheng, MCF
   Ramsay, M
   Suh, ES
   Kaltsakas, G
   Pattani, H
   Marino, P
   Murphy, PB
   Hart, N
   Steier, J
AF Schwarz, Esther I.
   Mackie, Mike
   Weston, Nick
   Tincknell, Laura
   Beghal, Gurpreet
   Cheng, Michael C. F.
   Ramsay, Michelle
   Suh, Eui-Sik
   Kaltsakas, Georgios
   Pattani, Hina
   Marino, Philip
   Murphy, Patrick B.
   Hart, Nicholas
   Steier, Joerg
TI Time-to-death in chronic respiratory failure on home mechanical
   ventilation: A cohort study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Home mechanical ventilation; Mortality; Chronic respiratory failure;
   Non-invasive ventilation
ID POSITIVE-PRESSURE VENTILATION; OBESITY-HYPOVENTILATION SYNDROME;
   DUCHENNE MUSCULAR-DYSTROPHY; NONINVASIVE VENTILATION; SURVIVAL;
   MANAGEMENT; OXYGEN; LIFE; COPD
AB Background and objective: Home mechanical ventilation (HMV) is used in heterogeneous conditions underlying chronic hypercapnic respiratory failure, but there are sparse data on long-term clinical outcomes. The aim was to systematically analyse the time and the circumstances of death on HMV.
   Methods: All-cause mortality data of HMV patients were prospectively collected between 2008 and 2018 in a large tertiary centre. Data were categorised into diagnostic groups including neuromuscular disease (NMD), chest wall disease (CWD), chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), overlap syndrome of COPD and OSA (overlap) and other group. The primary outcome was time-to-death from initiation of HMV.
   Results: 1210 deaths were recorded over a 10-year period. Median time-to-death was 19.5 [6-55] months and differed between groups (Kruskal Wallis p < 0.001). CWD (98.5 [23.5-120] months) and slowly progressive NMD (64.5 [28-120] months) had the longest time-to-death on HMV, while OHS (33 [13-75] months) and overlap syndrome (30.5 [14.5-68.5] months) had a longer median time-to-death than COPD (19.5 [7-42.5] months) and motor neurone disease (7 [3-14] months). Daily adherence to HMV of greater than 4 h/night was associated with better outcomes (10 [3-24] vs. 30 [10-76] months; p < 0.001). 43% with confirmed location of death died outside the hospital.
   Conclusions: The time-to-death on home mechanical ventilation varies widely across disease groups with chronic respiratory failure and seems to be associated with daily usage time.
C1 [Schwarz, Esther I.; Mackie, Mike; Weston, Nick; Cheng, Michael C. F.; Ramsay, Michelle; Suh, Eui-Sik; Kaltsakas, Georgios; Pattani, Hina; Marino, Philip; Murphy, Patrick B.; Hart, Nicholas; Steier, Joerg] Guys & St Thomas Hosp NHS Fdn Trust, Lane Fox Resp Unit, London SE1 7EH, England.
   [Schwarz, Esther I.; Mackie, Mike; Weston, Nick; Cheng, Michael C. F.; Ramsay, Michelle; Suh, Eui-Sik; Kaltsakas, Georgios; Pattani, Hina; Marino, Philip; Murphy, Patrick B.; Hart, Nicholas; Steier, Joerg] Guys & St Thomas Hosp NHS Fdn Trust, Lane Fox Clin Resp Physiol Res Ctr, London SE1 7EH, England.
   [Tincknell, Laura; Beghal, Gurpreet; Ramsay, Michelle; Suh, Eui-Sik; Kaltsakas, Georgios; Marino, Philip; Murphy, Patrick B.; Hart, Nicholas; Steier, Joerg] Kings Coll London, Fac Life Sci & Med, London WC2R 2LS, England.
RP Mackie, M (reprint author), Guys & St Thomas Hosp NHS Fdn Trust, Lane Fox Resp Unit, Westminster Bridge RCOPD, London SE1 7EH, England.
EM mike.mackie@gstt.nhs.uk
OI Schwarz, Esther Irene/0000-0001-8840-981X
FU European Respiratory Society (ERS Long-Term Research Fellowship) [LTRF
   201801-00285]; National Institute for Health Research (NIHR) Biomedical
   Research Centre based at Guy's and St Thomas' NHS Foundation Trust and
   King's College London, UK
FX We acknowledge the support of the European Respiratory Society (ERS
   Long-Term Research Fellowship 2018-2019, LTRF 201801-00285, EIS). The
   funding source had no role in the design and conduct of the study; in
   the collection, analysis, and interpretation of the data; nor in the
   preparation, review, or approval of the manuscript.; Professor Steier's
   contributions were partially supported by the National Institute for
   Health Research (NIHR) Biomedical Research Centre based at Guy's and St
   Thomas' NHS Foundation Trust and King's College London, UK. The views
   expressed are those of the authors and not necessarily those of the NHS,
   the NIHR or the Department of Health.
CR BACH JR, 1987, CHEST, V92, P168, DOI 10.1378/chest.92.1.168
   BACH JR, 1987, CHEST, V91, P859, DOI 10.1378/chest.91.6.859
   Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4
   Budweiser S, 2007, J INTERN MED, V261, P375, DOI 10.1111/j.1365-2796.2007.01765.x
   Dreher M, 2010, THORAX, V65, P303, DOI 10.1136/thx.2009.124263
   Dreyer P, 2014, AMYOTROPH LAT SCL FR, V15, P62, DOI 10.3109/21678421.2013.837929
   Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2
   Gustafson T, 2006, CHEST, V130, P1828, DOI 10.1378/chest.130.6.1828
   Ishikawa Y, 2011, NEUROMUSCULAR DISORD, V21, P47, DOI 10.1016/j.nmd.2010.09.006
   Jager L, 2008, CHEST, V133, P156, DOI 10.1378/chest.07-1522
   King AC, 2012, RESP CARE, V57, P921, DOI 10.4187/respcare.01741
   Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5
   Laub M, 2007, RESP MED, V101, P1074, DOI 10.1016/j.rmed.2006.10.007
   Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704
   Masa JF, 2016, THORAX, V71, P899, DOI 10.1136/thoraxjnl-2016-208501
   Masa JF, 2015, AM J RESP CRIT CARE, V192, P86, DOI 10.1164/rccm.201410-1900OC
   Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451
   Patout M, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA2777
   SIMONDS AK, 1995, THORAX, V50, P604, DOI 10.1136/thx.50.6.604
NR 19
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105877
DI 10.1016/j.rmed.2020.105877
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100012
PM 32056675
DA 2020-05-18
ER

PT J
AU Wan, ES
   Kantorowski, A
   Polak, M
   Kadri, R
   Richardson, CR
   Gagnon, DR
   Garshick, E
   Moy, ML
AF Wan, Emily S.
   Kantorowski, Ana
   Polak, Madeline
   Kadri, Reema
   Richardson, Caroline R.
   Gagnon, David R.
   Garshick, Eric
   Moy, Marilyn L.
TI Long-term effects of web-based pedometer-mediated intervention on COPD
   exacerbations
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Physical activity; Exacerbations; Randomized controlled trial
ID DAILY STEP COUNTS; PHYSICAL-ACTIVITY; US COHORT; TRIAL; PREDICTOR;
   EFFICACY; PROGRAM; RISK
AB Background: Technology-based physical activity (PA) interventions have been shown to improve daily step counts and health-related quality of life, but their effect on long-term clinical outcomes like acute exacerbations (AEs) is unknown in persons with COPD.
   Methods: U.S. Veterans with stable COPD were randomized (1:1) to either pedometer alone (control) or pedometer plus a website with feedback, goal-setting, disease education, and a community forum (intervention) for 3 months. AEs were assessed every 3 months over a follow-up period of approximately 15 months. Pedometer-assessed daily step counts, health-related quality-of-life (HRQL), and self-efficacy were assessed at baseline, end-of-intervention at 3 months, and during follow-up approximately 6 and 12 months after enrollment. Zero-inflated Poisson models assessed the effect of the intervention on risk for AEs, compared to controls. Generalized linear mixed-effects models for repeated measures examined between-group and within-group changes in daily step count, HRQL, and self-efficacy.
   Results: There were no significant differences in age, FEV1% predicted, baseline daily step count, AEs the year prior to enrollment, or duration of follow-up between the intervention (n = 57) and control (n = 52) groups. The intervention group had a significantly reduced risk of AEs (rate ratio = 0.51, [95%CI 0.31-0.85]), compared to the control group. There were no significant between-group differences in change in average daily step count, HRQL, or self-efficacy at 6 and 12 months after enrollment.
   Conclusions: A 3-month internet-mediated, pedometer-based PA intervention was associated with reduced risk for AEs of COPD over 12-15 months of follow-up.
C1 [Wan, Emily S.; Kantorowski, Ana; Polak, Madeline; Garshick, Eric; Moy, Marilyn L.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA.
   [Wan, Emily S.; Garshick, Eric] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Wan, Emily S.; Kantorowski, Ana; Garshick, Eric] Harvard Med Sch, Boston, MA 02115 USA.
   [Kadri, Reema; Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA.
   [Gagnon, David R.; Moy, Marilyn L.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Gagnon, David R.] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
RP Moy, ML (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Sect, 1400 VFW Pkwy,Mail Code 111PI, West Roxbury, MA 02132 USA.
EM marilyn.moy@va.gov
FU United States Department of Veterans Affairs, Rehabilitation Research
   and Development ServiceUS Department of Veteran Affairs [F6847W, CDA2
   IK2RX002165, Merit O1150-R]
FX United States Department of Veterans Affairs, Rehabilitation Research
   and Development Service [Career Development Award 2, F6847W (Moy); CDA2
   IK2RX002165 (Wan); Merit O1150-R (Moy)].
CR Altenburg WA, 2015, RESP MED, V109, P112, DOI 10.1016/j.rmed.2014.10.020
   ArbillagaEtxarri A., 2018, EUR RESP J, V52
   Bandura A., 1997, SELF EFFICACY EXERCI
   Barberan-Garcia A, 2014, RESP MED, V108, P628, DOI 10.1016/j.rmed.2013.12.006
   Blackstock FC, 2018, J CARDIOPULM REHABIL, V38, P333, DOI 10.1097/HCR.0000000000000322
   Coultas DB, 2018, ANN AM THORAC SOC, V15, P470, DOI 10.1513/AnnalsATS.201704-308OC
   Davis AHT, 2007, HEART LUNG, V36, P205, DOI 10.1016/j.hrtlng.2006.08.007
   Demeyer H, 2017, THORAX, V72, P415, DOI 10.1136/thoraxjnl-2016-209026
   Durheim MT, 2015, ANN AM THORAC SOC, V12, P349, DOI 10.1513/AnnalsATS.201408-365OC
   Global iniative for chronic obstrutive pulmonary disease. GOLD, 2019, GLOBAL STRATEGY DIAG
   Hornikx M, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0126-8
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Liacos A, 2019, PHYSIOTHERAPY, V105, P90, DOI 10.1016/j.physio.2018.07.009
   Ng M, 2014, JAMA-J AM MED ASSOC, V311, P183, DOI 10.1001/jama.2013.284692
   Martinez CH, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-12
   Mendoza L, 2015, EUR RESPIR J, V45, P347, DOI 10.1183/09031936.00084514
   Moy ML, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5622
   Moy ML, 2015, CHEST, V148, P128, DOI 10.1378/chest.14-1466
   Moy ML, 2014, CHEST, V145, P542, DOI 10.1378/chest.13-1052
   Moy ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060400
   Moy ML, 2012, RESP MED, V106, P962, DOI 10.1016/j.rmed.2012.03.016
   Moy ML, 2016, ERJ OPEN RES, V2, P1
   Nguyen Huong Q, 2014, Ann Am Thorac Soc, V11, P695, DOI 10.1513/AnnalsATS.201401-017OC
   Nguyen Huong Q, 2009, Int J Chron Obstruct Pulmon Dis, V4, P301
   Robinson SA, 2019, J BEHAV MED, V42, P1082, DOI 10.1007/s10865-019-00042-3
   Sievi NA, 2018, RESP MED, V141, P1, DOI 10.1016/j.rmed.2018.06.013
   van der Weegen S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4579
   Van Remoortel H, 2013, THORAX, V68, P962, DOI 10.1136/thoraxjnl-2013-203534
   Voncken-Brewster V, 2015, INT J CHRONIC OBSTR, V10, P1061, DOI 10.2147/COPD.S81295
   Vorrink SNW, 2016, EUR RESPIR J, V48, P1019, DOI 10.1183/13993003.00083-2016
   Wan ES, 2017, RESP MED, V130, P102, DOI 10.1016/j.rmed.2017.07.057
   Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521
   Xu J., 2018, NATL VITAL STAT REP, V67
   Zanoria SJT, 2013, CHRON RESP DIS, V10, P207, DOI 10.1177/1479972313505880
NR 34
TC 1
Z9 1
U1 3
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105878
DI 10.1016/j.rmed.2020.105878
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100008
PM 32056676
DA 2020-05-18
ER

PT J
AU Zhou, M
   Sen Tan, K
   Guan, WJ
   Jiang, LJ
   Deng, J
   Gao, WX
   Lee, YM
   Xu, ZF
   Luo, X
   Liu, C
   Shi, JB
   Lai, YY
AF Zhou, Min
   Sen Tan, Kai
   Guan, Wei-jie
   Jiang, Li-jie
   Deng, Jie
   Gao, Wen-xiang
   Lee, Yew Mun
   Xu, Zhao-feng
   Luo, Xin
   Liu, Chen
   Shi, Jian-bo
   Lai, Yinyan
TI Proteomics profiling of epithelium-derived exosomes from nasal polyps
   revealed signaling functions affecting cellular proliferation
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Exosomes; Chronic rhinosinusitis; Nasal polyps; Asthma; Mass
   spectrometry; Proliferation
ID CHRONIC RHINOSINUSITIS; PREVALENCE; CELLS; VESICLES; RELEASE; CANCER
AB Background: Nasal polyps are a significantly associated pathology of chronic rhinosinusitis (CRS) whose mechanisms of pathogenesis are not fully elucidated, especially the interaction of the polyp with its environment that allows its growth on the nasal epithelial lining. Exosomes are nanovesicles that serve important biological functions, including cell-to-cell signaling and communication.
   Objective: Hence, we sought to explore the roles of the epithelial-derived exosomal proteome obtained from the human nasal epithelium in the modulation of CRS with nasal polyp (CRSwNP) pathogenesis.
   Methods: We sampled exosomes from nasal lavage fluid and primary human nasal epithelial cells (hNECs) from healthy controls and patients with CRSwNP with and without coexisting asthma. The presence of exosomes was confirmed using a NanoSight assay, transmission electron microscopy and western blotting. The exosomal proteome was profiled with mass spectrometry. The Cell Counting Kit-8 was used to confirm the roles of exosomes in mediating cellular proliferation.
   Results: The hNEC-derived exosomes from diseased epithelium contained differentially expressed proteins that were mainly involved in epithelial remodeling via pathways such as p53. An in vitro study further demonstrated that epithelial-derived exosomes from patients with CRSwNP (with and without coexisting asthma) significantly reduced the rate of proliferation of control hNECs at an effective concentration of >= 10 mu g/ml.
   Conclusions: Exosomes secreted by hNECs from patients with CRSwNP, regardless of their coexistence with asthma, are laden with proteins that influence cell proliferation pathways, potentially leading to remodeling of the sinonasal mucosa.
C1 [Zhou, Min; Jiang, Li-jie; Deng, Jie; Gao, Wen-xiang; Xu, Zhao-feng; Luo, Xin; Liu, Chen; Shi, Jian-bo; Lai, Yinyan] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, 58 Zhongshan Second Rd, Guangzhou 510080, Peoples R China.
   [Sen Tan, Kai] Natl Univ Singapore, Dept Otolaryngol, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Guan, Wei-jie] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Affiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Guangdong, Peoples R China.
   [Lee, Yew Mun] Natl Univ Singapore, Dept Biol Sci, Fac Sci, Singapore, Singapore.
RP Shi, JB; Lai, YY (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, 58 Zhongshan Second Rd, Guangzhou 510080, Peoples R China.
EM tsjbent@163.com; Laiyy3@mail.sysu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81770975]
FX This study was supported by the National Natural Science Foundation of
   China (81770975), China.
CR Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004
   Bhattacharyya N, 2018, OTOLARYNG HEAD NECK, V159, P522, DOI 10.1177/0194599818774006
   Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153
   Chen CY, 2018, THERANOSTICS, V8, P1607, DOI 10.7150/thno.22958
   Pilan RRD, 2012, RHINOLOGY, V50, P129, DOI [10.4193/Rhino11.256, 10.4193/Rhin11.256]
   Ek A, 2013, ALLERGY, V68, P1314, DOI 10.1111/all.12222
   Farooqi AA, 2018, BIOTECHNOL ADV, V36, P328, DOI 10.1016/j.biotechadv.2017.12.010
   FOKKENS WJ, 2012, RHINOLOGY, V50, P1, DOI DOI 10.4193/RHINO50E2
   Gupta R, 2019, AM J RESP CELL MOL, V60, P209, DOI 10.1165/rcmb.2018-0156OC
   Haj-Salem I, 2018, ALLERGY, V73, P178, DOI 10.1111/all.13234
   Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x
   Imamura K, 2018, EMBO J, V37, DOI 10.15252/embj.201797723
   Jiang R, 2020, J APPL TOXICOL, V40, P224, DOI 10.1002/jat.3898
   Kang YT, 2017, NANOSCALE, V9, P13495, DOI 10.1039/c7nr04557c
   Kristjansson RP, 2019, NAT GENET, V51, P267, DOI 10.1038/s41588-018-0314-6
   Kulshreshtha A, 2013, J ALLERGY CLIN IMMUN, V131, P1194, DOI 10.1016/j.jaci.2012.12.1565
   Lai YY, 2011, J ALLERGY CLIN IMMUN, V128, P1207, DOI 10.1016/j.jaci.2011.09.001
   Lasser C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0927-4
   Lasser C, 2011, AM J RHINOL ALLERGY, V25, P89, DOI 10.2500/ajra.2011.25.3573
   Lloret-Llinares M, 2018, NUCLEIC ACIDS RES, V46, P11502, DOI 10.1093/nar/gky817
   Lucchetti D, 2017, AM J PATHOL, V187, P1633, DOI 10.1016/j.ajpath.2017.03.015
   Mueller SK, 2019, INT FORUM ALLERGY RH, V9, P177, DOI 10.1002/alr.22226
   Mueller SK, 2018, INT FORUM ALLERGY RH, V8, P1438, DOI 10.1002/alr.22189
   Nocera AL, 2017, LARYNGOSCOPE, V127, pE295, DOI 10.1002/lary.26614
   Samitas K, 2018, ALLERGY, V73, P993, DOI 10.1111/all.13373
   Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401
   Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577
   Thomi G, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080855
   VIDAL M, 1989, J CELL PHYSIOL, V140, P455, DOI 10.1002/jcp.1041400308
   Wang XG, 2019, J CELL BIOCHEM, V120, P1492, DOI 10.1002/jcb.27347
   Wu GP, 2015, ALLERGY ASTHMA IMMUN, V7, P449, DOI 10.4168/aair.2015.7.5.449
   Xu H, 2018, THERANOSTICS, V8, P5419, DOI 10.7150/thno.27876
   Xu Y, 2016, JAMA OTOLARYNGOL, V142, P1063, DOI 10.1001/jamaoto.2016.2227
   Yang SL, 2018, INT J MED SCI, V15, P228, DOI 10.7150/ijms.22408
   Zhang D, 2018, MOL THER, V26, P2119, DOI 10.1016/j.ymthe.2018.06.007
   Zhang W, 2018, MOL MED REP, V17, P5921, DOI 10.3892/mmr.2018.8634
   Zhou M, 2019, INT ARCH ALLERGY IMM, V178, P229, DOI 10.1159/000493582
NR 37
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2020
VL 162
AR UNSP 105871
DI 10.1016/j.rmed.2020.105871
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KK7MQ
UT WOS:000512923100010
PM 32056672
DA 2020-05-18
ER

PT J
AU Arger, NK
   Ho, ME
   Allen, IE
   Benn, BS
   Woodruff, PG
   Koth, LL
AF Arger, Nicholas K.
   Ho, Melissa E.
   Allen, Isabel E.
   Benn, Bryan S.
   Woodruff, Prescott G.
   Koth, Laura L.
TI CXCL9 and CXCL10 are differentially associated with systemic organ
   involvement and pulmonary disease severity in sarcoidosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; CXCL9; CXCL10; CXCL11; Interferon-gamma; Chemokine
ID CHEMOKINE RECEPTOR CXCR3; GAMMA-INTERFERON; IFN-GAMMA; T-CELLS;
   INDUCIBLE PROTEIN-10; ENDOTHELIAL-CELLS; ELEVATED LEVELS; UCSD
   SHORTNESS; I-TAC; LIGANDS
AB Background: Sarcoidosis is a granulomatous inflammatory disease with limited blood markers to predict outcomes. The interferon-gamma (IFN-gamma)-inducible chemotactic cytokines (chemokines), CXCL9 and CXCL10, are both increased in sarcoidosis patients, yet they possess important molecular differences. Our study determined if serum chemokines correlated with different aspects of disease severity.
   Methods: We measured CXCL9 and CXCL10 serum levels at initial study visits and longitudinally in sarcoidosis subjects using ELISA. We examined these chemokines' relationships with pulmonary and organ involvement outcomes, their gene expression, peripheral blood immune cell populations, and immunosuppression use.
   Results: Higher CXCL10 levels negatively correlated with FVC, TLC, and DLCO at subjects' initial visit and when measured repeatedly over two years. CXCL10 also positively correlated with longitudinal respiratory symptom severity. Additionally, for every log(10)(CXCL10) increase, the risk of longitudinal pulmonary function decline increased 8.8 times over the 5-year study period (95% CI 1.6-50, p = 0.014, log(10)(CXCL0) range 0.84-2.7). In contrast, CXCL9 levels positively correlated with systemic organ involvement at initial study visit (1.5 additional organs involved for every log(10)(CXCL9) increase, 95% CI 1.1-2.0, p = 0.022, log(10)(CXCL9) range 1.3-3.3). CXCL10, not CXCL9, positively correlated with its own blood gene expression and monocyte level. Immunosuppressive treatment was associated with lower levels of both chemokines.
   Conclusions: In sarcoidosis subjects, serum CXCL9 levels correlated with systemic organ involvement and CXCL10 levels strongly correlated with respiratory outcomes, which may ultimately prove helpful in clinical management. These differing associations may be due to differences in cellular regulation and tissue origin.
C1 [Arger, Nicholas K.; Ho, Melissa E.; Benn, Bryan S.; Woodruff, Prescott G.; Koth, Laura L.] Univ Calif San Francisco, Div Pulm & Crit Care, 505 Parnassus Ave, San Francisco, CA 94143 USA.
   [Allen, Isabel E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16ThSt, San Francisco, CA 94158 USA.
RP Arger, NK (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM nicholas.arger@ucsf.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R56IO87652,
   T32HL007185]
FX This work was supported by the National Institutes of Health (R56IO87652
   and T32HL007185).
CR Agostini C, 1998, J IMMUNOL, V161, P6413
   Aksoy MO, 2006, AM J PHYSIOL-LUNG C, V290, pL909, DOI 10.1152/ajplung.00430.2005
   Amichay D, 1996, J IMMUNOL, V157, P4511
   Antoniou KM, 2006, CHEST, V130, P982, DOI 10.1378/chest.130.4.982
   Arakelyan A, 2009, CLIN EXP IMMUNOL, V155, P457, DOI 10.1111/j.1365-2249.2008.03832.x
   Aranday-Cortes E, 2013, TRANSBOUND EMERG DIS, V60, P525, DOI 10.1111/j.1865-1682.2012.01370.x
   Arger NK, 2019, RESP MED, V152, P89, DOI 10.1016/j.rmed.2019.04.005
   Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046
   Benn BS, 2017, LUNG, V195, P553, DOI 10.1007/s00408-017-0037-y
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Busuttil A, 2009, EUR RESPIR J, V34, P676, DOI 10.1183/09031936.00157508
   Chappell AG, 2000, SARCOIDOSIS VASC DIF, V17, P167
   Chung W, 2015, INT J TUBERC LUNG D, V19, P1476, DOI 10.5588/ijtld.15.0325
   Ciesielski CJ, 2002, EUR J IMMUNOL, V32, P2037, DOI 10.1002/1521-4141(200207)32:7<2037::AID-IMMU2037>3.0.CO;2-I
   Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009
   Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200
   Cui A, 2010, RESPIRATION, V80, P372, DOI 10.1159/000245332
   Dwyer-Lindgren L, 2017, JAMA-J AM MED ASSOC, V318, P1136, DOI 10.1001/jama.2017.11747
   Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619
   FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238
   Gerke AK, 2017, ANN AM THORAC SOC, V14, pS421, DOI 10.1513/AnnalsATS.201707-564OT
   Gerke AK, 2014, CURR OPIN PULM MED, V20, P472, DOI 10.1097/MCP.0000000000000080
   Grimm MC, 1996, INFLAMM BOWEL DIS, V2, P88, DOI 10.1002/ibd.3780020204
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975
   Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149
   Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714
   Inui N, 2001, J ALLERGY CLIN IMMUN, V107, P337, DOI 10.1067/mai.2001.112273
   Judson MA, 2003, SARCOIDOSIS VASC DIF, V20, P204
   Keir G, 2010, SEMIN RESP CRIT CARE, V31, P409, DOI 10.1055/s-0030-1262209
   Kim S, 2015, J MOL DIAGN, V17, P90, DOI 10.1016/j.jmoldx.2014.08.005
   Kishi J, 2011, EUR RESPIR J, V38, P415, DOI 10.1183/09031936.00070610
   Koth LL, 2011, AM J RESP CRIT CARE, V184, P1153, DOI 10.1164/rccm.201106-1143OC
   Kriegova E, 2011, EUR RESPIR J, V38, P1136, DOI 10.1183/09031936.00089910
   Lee K, 2015, INT J TUBERC LUNG D, V19, P191, DOI 10.5588/ijtld.14.0525
   Li HY, 2017, GENE, V596, P98, DOI 10.1016/j.gene.2016.09.037
   Liu LP, 2005, CURR TOP DEV BIOL, V68, P149, DOI 10.1016/S0070-2153(05)68006-4
   Loos T, 2006, LAB INVEST, V86, P902, DOI 10.1038/labinvest.3700453
   LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0
   LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084
   MCLEAN RA, 1991, AM STAT, V45, P54, DOI 10.2307/2685241
   Medoff BD, 2006, J IMMUNOL, V176, P7087, DOI 10.4049/jimmunol.176.11.7087
   Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524
   Moller DR, 2015, ANN AM THORAC SOC, V12, P1561, DOI 10.1513/AnnalsATS.201503-172OT
   Mollers M, 2001, THORAX, V56, P487, DOI 10.1136/thorax.56.6.487
   Nagata K, 2012, INVEST OPHTH VIS SCI, V53, P3827, DOI 10.1167/iovs.11-9244
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Nishioka Y, 2007, CLIN EXP IMMUNOL, V149, P317, DOI 10.1111/j.1365-2249.2007.03423.x
   Nureki SI, 2008, RESP MED, V102, P239, DOI 10.1016/j.rmed.2007.09.006
   OHMORI Y, 1993, AM J PATHOL, V142, P861
   Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669
   Pignatti P, 2006, AM J RESP CRIT CARE, V173, P310, DOI 10.1164/rccm.200502-244OC
   Piotrowski WJ, 2014, POL ARCH MED WEWN, V124, P395, DOI 10.20452/pamw.2349
   Prasse A, 2000, CLIN EXP IMMUNOL, V122, P241, DOI 10.1046/j.1365-2249.2000.01365.x
   PRIOR C, 1991, AM REV RESPIR DIS, V143, P53, DOI 10.1164/ajrccm/143.1.53
   Proost P, 2004, J LEUKOCYTE BIOL, V75, P777, DOI 10.1189/jlb.1003524
   Proost P, 2003, EUR J IMMUNOL, V33, P3146, DOI 10.1002/eji.200324136
   Rabin DL, 2001, EUR RESPIR J, V18, P499, DOI 10.1183/09031936.01.00056201
   ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852
   Schnerch J, 2016, AM J RESP CELL MOL, V55, P749, DOI 10.1165/rcmb.2015-0278OC
   SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.2307/2335876
   SNIJDERS TAB, 1994, SOCIOL METHOD RES, V22, P342, DOI 10.1177/0049124194022003004
   Strieter RM, 2005, CYTOKINE GROWTH F R, V16, P593, DOI 10.1016/j.cytogfr.2005.04.007
   Su R, 2014, EUR RESPIR J, V44, P985, DOI 10.1183/09031936.00039714
   Su R, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-121
   Sugiyama K, 2006, RESPIROLOGY, V11, P708, DOI 10.1111/j.1440-1843.2006.00933.x
   Swigris JJ, 2012, RESP MED, V106, P1447, DOI 10.1016/j.rmed.2012.06.018
   Swigris JJ, 2010, RESP MED, V104, P1350, DOI 10.1016/j.rmed.2010.03.027
   Takeuchi M, 2006, INVEST OPHTH VIS SCI, V47, P1063, DOI 10.1167/iovs.05-0966
   Torraca V, 2015, DIS MODEL MECH, V8, P253, DOI 10.1242/dmm.017756
   Van Raemdonck K, 2015, CYTOKINE GROWTH F R, V26, P311, DOI 10.1016/j.cytogfr.2014.11.009
   Vittinghoff E., 2012, STAT BIOL HLTH, P7
   Wahlstrom J, 2001, AM J RESP CRIT CARE, V163, P115, DOI 10.1164/ajrccm.163.1.9906071
   Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386
   Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787
   ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1
   Zohar Y, 2014, J CLIN INVEST, V124, P2009, DOI 10.1172/JCI71951
NR 77
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105822
DI 10.1016/j.rmed.2019.105822
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400004
PM 31783271
OA Bronze
DA 2020-05-18
ER

PT J
AU Balamurugan, S
   Apte, K
   Singh, BP
   Deb, AK
   Deshmukh, C
   Modi, K
   Godse, A
   Dhar, R
   Lahiri, KR
   Singh, V
   Pandya, H
   Rajan, S
   Vaidya, A
   Gaur, V
   Gogtay, J
AF Balamurugan, Santhalingam
   Apte, Komalkirti
   Singh, Bhanu Pratap
   Deb, Ashish Kumar
   Deshmukh, Chandrahas
   Modi, Kinjal
   Godse, Ajay
   Dhar, Raja
   Lahiri, Keya Rani
   Singh, Virendra
   Pandya, Hiren
   Rajan, Sujeet
   Vaidya, Abhijit
   Gaur, Vaibhav
   Gogtay, Jaideep
TI Device-handling study of a novel breath-actuated inhaler, Synchrobreathe
   (R), versus a pMDI
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Synchrobreathe; Breathactuated inhalers; BAIs; Asthma; COPD; pMDI
ID METERED-DOSE INHALERS; PATIENT PREFERENCE; ASTHMA; COPD; FLOW;
   NONADHERENCE; SATISFACTION; THERAPY; CHOICE
AB Introduction: Synchrobreathe (R), a new-generation, novel breath-actuated inhaler (BAI) can address the key issues arising during the use of both pressurised metered dose inhalers ([pMDIs]; hand-breath coordination) and dry powder inhalers ([DPIs]; high inspiratory flow required) with respect to optimal drug deposition.
   Materials and methods: This was an open-label, prospective, 2-week, multicentre study that assessed device handling, ease of use, errors and participant perception regarding the use of Synchrobreathe (R) versus a pMDI in patients with chronic obstructive pulmonary disease (COPD) (n = 162) or asthma (n = 239) and inhaler-naive healthy volunteers (n = 59). Ability to use the device without errors at the first attempt, total number of errors before and after training, time taken to use the device correctly and total number of training sessions, and number of attempts to perform the correct technique on Day 1 and Day 14 were evaluated. Device handling and preference questionnaires were also administered on Day 14.
   Results: Of 460 participants, 421 completed the study. The number of participants using Synchrobreathe without any error after reading the patient information leaflet (PIL) was significantly low (p < 0.05) on Day 1. On Day 14, significantly more number of participants used Synchrobreathe without any error (p < 0.001). The total number of errors before and after training with Synchrobreathe was significantly less (p < 0.001). The average time required to perform the inhalation technique correctly (p < 0.01) and the total number of attempts (P < 0.001) with Synchrobreathe were significantly lower. The average number of attempts to inhale correctly was significantly (p < 0.001) less with Synchrobreathe on Day1 and Day 14. Most participants rated Synchrobreathe as their choice of inhaler.
   Conclusion: Synchrobreathe is an easy-to-use and easy-to-handle device with significantly less number of errors, which may have positive implications for disease control in asthma and COPD.
C1 [Balamurugan, Santhalingam] Sri Muthukumaran Med Coll Hosp & Res Inst, Chennai, Tamil Nadu, India.
   [Apte, Komalkirti] Chest Res Fdn, Pune, Maharashtra, India.
   [Singh, Bhanu Pratap] Midland Hosp, Lucknow, Uttar Pradesh, India.
   [Deb, Ashish Kumar] Sudbhawana Hosp, Varanasi, Uttar Pradesh, India.
   [Deshmukh, Chandrahas] KEM Hosp & SGS Med Coll, Mumbai, Maharashtra, India.
   [Modi, Kinjal] Meeti Lifeline Hosp, Mumbai, Maharashtra, India.
   [Godse, Ajay] Bhaktivedanta Hosp, Mumbai, Maharashtra, India.
   [Dhar, Raja] Fortis Hosp, Kolkata, India.
   [Lahiri, Keya Rani] Hosp & Res Ctr, Padmashree Dr DY Patil Med Coll, Navi Mumbai, India.
   [Singh, Virendra] Asthma Bhawan, Jaipur, Rajasthan, India.
   [Pandya, Hiren] Ratandeep Multispecialty Hosp, Ahmadabad, Gujarat, India.
   [Rajan, Sujeet] Bhatia Gen Hosp, Mumbai, Maharashtra, India.
   [Vaidya, Abhijit; Gaur, Vaibhav; Gogtay, Jaideep] Cipla Ltd, Med Affairs Dept, Mumbai, Maharashtra, India.
RP Apte, K (reprint author), Chest Res Fdn, Pune, Maharashtra, India.
EM drkomalapte@crfindia.com
FU Cipla Ltd.
FX The study was funded by Cipla Ltd. The authors would like to thank Dr
   Sonali Jadhav (Cipla Ltd.) who helped in conducting the study.
CR AL-Jahdali H, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-8
   Al-Showair RAM, 2007, RESP MED, V101, P2395, DOI 10.1016/j.rmed.2007.06.008
   Anderson P, 2005, EUR RESPIR REV, V14, P109, DOI 10.1183/09059180.05.00009606
   Aydemir Y, 2015, RESP MED, V109, P451, DOI 10.1016/j.rmed.2015.02.011
   Bjermer L, 2014, RESPIRATION, V88, P346, DOI 10.1159/000363771
   Capstick TGD, 2012, EXPERT REV RESP MED, V6, P91, DOI [10.1586/ers.11.89, 10.1586/ERS.11.89]
   CROMPTON G, 1989, PRACTITIONER, V233, P268
   Dhar R, 2015, J ASTHMA, V52, P1065, DOI 10.3109/02770903.2015.1050499
   Ferguson GT, 2013, INT J CHRONIC OBSTR, V8, P139, DOI 10.2147/COPD.S38577
   Fink James B, 2005, Respir Care, V50, P1360
   George J, 2005, CHEST, V128, P3198, DOI 10.1378/chest.128.5.3198
   Giraud V, 2011, RESP MED, V105, P1815, DOI 10.1016/j.rmed.2011.07.004
   GOLD, 2015, GLOB IN CHRON OBSTR
   GOLD, 2019, GLOB IN CHRON OBSTR
   Gross G, 2003, J ASTHMA, V40, P487, DOI 10.1081/JAS-120018777
   Hodder Richard, 2009, Int J Chron Obstruct Pulmon Dis, V4, P381
   Janssens W, 2008, EUR RESPIR J, V31, P78, DOI 10.1183/09031936.00024807
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Lavorini Federico, 2013, ISRN Allergy, V2013, P102418, DOI 10.1155/2013/102418
   Lavorini F, 2010, PRIM CARE RESP J, V19, P335, DOI 10.4104/pcrj.2010.00065
   Leach CL, 2005, J AEROSOL MED, V18, P379, DOI 10.1089/jam.2005.18.379
   Lee-Wong M, 2003, POSTGRAD MED J, V79, P221, DOI 10.1136/pmj.79.930.221
   Lenney J, 2000, RESP MED, V94, P496, DOI 10.1053/rmed.1999.0767
   Levy ML, 2013, PRIM CARE RESP J, V22, P406, DOI 10.4104/pcrj.2013.00084
   LIARD R, 1995, REV EPIDEMIOL SANTE, V43, P242
   Melani AS, 2012, RESP MED, V106, P668, DOI 10.1016/j.rmed.2011.11.016
   Melani AS, 2011, RESP MED, V105, P930, DOI 10.1016/j.rmed.2011.01.005
   Melani Andrea S, 2007, Acta Biomed, V78, P233
   Mirici A, 2001, SOLUNUM HAST, V12, P13
   NEWMAN SP, 1991, THORAX, V46, P712, DOI 10.1136/thx.46.10.712
   ONEILL C, 2011, PHARM MED, V25, P379
   PEDERSEN S, 1990, ARCH DIS CHILD, V65, P308, DOI 10.1136/adc.65.3.308
   Salvi S, 2014, EXPERT REV RESP MED, V8, P89, DOI 10.1586/17476348.2014.854168
   Sen E, 2006, ANKARA U TIP FAKULTE, V59, P1
   Small M, 2011, ADV THER, V28, P202, DOI 10.1007/s12325-010-0108-4
   Toy EL, 2011, RESP MED, V105, P435, DOI 10.1016/j.rmed.2010.09.006
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Virchow JC, 2005, CURR MED RES OPIN, V21, pS19, DOI 10.1185/030079905X61758
NR 38
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105707
DI 10.1016/j.rmed.2019.05.014
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400006
PM 32056719
OA Bronze
DA 2020-05-18
ER

PT J
AU Brestovac, B
   Lawrence, C
   Speers, DJ
   Sammels, LM
   Mulrennan, S
AF Brestovac, Brian
   Lawrence, Charleigh
   Speers, David J.
   Sammels, Leanne M.
   Mulrennan, Siobhain
TI Respiratory viral infections in Western Australians with cystic fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cystic fibrosis; Respiratory viruses; Human rhinovirus; Influenza A
ID TRACT INFECTIONS; YOUNG-CHILDREN; VIRUSES; EXACERBATIONS; RHINOVIRUS;
   ADULTS; EPIDEMIOLOGY; ASSOCIATION; MORTALITY; IMPACT
AB Background: Viral respiratory infections (VRI) in people living with Cystic fibrosis (CF) is less well understood than respiratory bacterial infections, particularly adults with CF and few studies have compared children with adults. This study evaluated the frequency of respiratory viruses in patients with cystic fibrosis (CF) in Western Australia (WA). We determined the VRI in CF and compared them with non-CF patients. Further, we compared CF patients that were hospitalised with those that were not.
   Patients/methods: Nucleic acid from sputum of 157 CF and 348 non-CF patients was analysed for influenzavirus A (Flu A) and B, (Flu B), respiratory syncytial virus (RSV), human metapneumovirus (hMPV), human rhinovirus (RV), and parainfluenza viruses (PIV 1-3) by RT-PCR, during the 2016 winter respiratory season.
   Results: No significant difference in the frequency of respiratory virus detection between CF and non-CF patients was found. RV was the most frequently detected virus in CF patients, and in hospitalised CF. RSV and hMPV were found less frequently in CF patients and RSV was not found in any hospitalised CF patient. A trend for fewer influenzavirus detections in adult CF patients was observed, however the trend was opposite for paediatric patients. RV and Flu A were the most common viruses detected in hospitalised CF patients.
   Conclusion: There was no significant difference in VRI between CF and non-CF patients. RV and influenza A were most commonly found in hospitalised CF patients, suggesting that infection with these viruses may contribute to hospitalisation for CF respiratory exacerbations.
C1 [Brestovac, Brian; Lawrence, Charleigh] Curtin Univ, Sch Pharm & Biomed Sci, GPO Box U1987, Perth, WA 6102, Australia.
   [Speers, David J.; Sammels, Leanne M.] PathWest Lab Med, Dept Microbiol, Perth, WA, Australia.
   [Mulrennan, Siobhain] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA, Australia.
RP Brestovac, B (reprint author), Curtin Univ, Sch Pharm & Biomed Sci, GPO Box U1987, Perth, WA 6102, Australia.
EM B.Brestovac@curtin.edu.au
CR AEBI C, 1995, EUR J PEDIATR, V154, pS69, DOI 10.1007/BF02191510
   Armstrong D, 1998, PEDIATR PULM, V26, P371, DOI 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.3.CO;2-E
   Asner S, 2012, J CYST FIBROS, V11, P433, DOI 10.1016/j.jcf.2012.04.006
   Burns JL, 2012, INFLUENZA OTHER RESP, V6, P218, DOI 10.1111/j.1750-2659.2011.00292.x
   Ciofu O, 2015, ADV DRUG DELIVER REV, V85, P7, DOI 10.1016/j.addr.2014.11.017
   Collinson J, 1996, THORAX, V51, P1115, DOI 10.1136/thx.51.11.1115
   Davis PB, 2006, AM J RESP CRIT CARE, V173, P475, DOI 10.1164/rccm.200505-840OE
   de Almeida MB, 2010, EMERG INFECT DIS, V16, P996, DOI 10.3201/eid1606.100063
   Dijkema JS, 2016, PEDIATR INFECT DIS J, V35, P379, DOI 10.1097/INF.0000000000001014
   Dodge JA, 2007, EUR RESPIR J, V29, P522, DOI 10.1183/09031936.00099506
   Etherington C, 2014, J CYST FIBROS, V13, P49, DOI 10.1016/j.jcf.2013.06.004
   Flight WG, 2014, THORAX, V69, P247, DOI 10.1136/thoraxjnl-2013-204000
   Foweraker J, 2009, BRIT MED BULL, V89, P93, DOI 10.1093/bmb/ldn050
   Gerretsen HE, 2017, J INFECTION, V74, pS143, DOI 10.1016/S0163-4453(17)30205-0
   Hoek RAS, 2013, SCAND J INFECT DIS, V45, P65, DOI 10.3109/00365548.2012.708942
   Jamieson KC, 2015, CHEST, V148, P1508, DOI 10.1378/chest.15-1335
   Kahn JS, 2003, CURR OPIN INFECT DIS, V16, P255, DOI 10.1097/00001432-200306000-00012
   Khieu TQT, 2015, VACCINE, V33, P4087, DOI 10.1016/j.vaccine.2015.06.080
   Mrugacz M, 2007, CYTOM PART B-CLIN CY, V72B, P204, DOI 10.1002/cyto.b.20159
   Psoter KJ, 2013, CLIN MICROBIOL INFEC, V19, pE483, DOI 10.1111/1469-0691.12272
   Psoter KJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2511-9
   Ramsay KA, 2017, J CYST FIBROS, V16, P70, DOI 10.1016/j.jcf.2016.07.010
   Reid DW, 2011, MED J AUSTRALIA, V195, P392, DOI 10.5694/mja10.11229
   Salsgiver EL, 2016, CHEST, V149, P390, DOI 10.1378/chest.15-0676
   Stelzer-Braid S, 2017, J MED VIROL, V89, P1494, DOI 10.1002/jmv.24794
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602
   Wat D, 2003, POSTGRAD MED J, V79, P201, DOI 10.1136/pmj.79.930.201
   Zhang DM, 2014, INT J INFECT DIS, V25, P159, DOI 10.1016/j.ijid.2014.02.019
NR 29
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105854
DI 10.1016/j.rmed.2019.105854
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400018
PM 32056728
OA Bronze
DA 2020-05-18
ER

PT J
AU Cruz, AA
   Riley, JH
   Barisal, AT
   Ponte, EV
   Souza-Machado, A
   Almeida, PCA
   Biao-Lima, V
   Davis, M
   Bates, S
   Adcock, IM
   Sterk, PJ
   Chung, KF
AF Cruz, Alvaro A.
   Riley, John H.
   Barisal, Aruna T.
   Ponte, Eduardo, V
   Souza-Machado, Adelmir
   Almeida, Paula C. A.
   Biao-Lima, Valmar
   Davis, Maggie
   Bates, Stewart
   Adcock, Ian M.
   Sterk, Peter J.
   Chung, Kian Fan
CA ProAR Study Grp
   U-BIOPRED Study Grp
TI Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult
   cohorts of contrasting locations, ethnicity and socioeconomic status
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Disease management; Phenotypes; Biomarkers; Cohort studies;
   Cross sectional study
ID REFERENCE VALUES; SEVERITY; INFECTIONS; PREVALENCE; SPIROMETRY; COUNT;
   BLOOD
AB Background: Asthma prevalence is 339 million globally. 'Severe asthma' (SA) comprises subjects with uncontrolled asthma despite proper management.
   Objectives: To compare asthma from diverse ethnicities and environments.
   Methods: A cross-sectional analysis of two adult cohorts, a Brazilian (ProAR) and a European (U-BIOPRED). U-BIOPRED comprised of 311 non-smoking with Severe Asthma (SAn), 110 smokers or ex-smokers with SA (SAs) and 88 mild to moderate asthmatics (MMA) while ProAR included 544 SA and 452 MMA. Although these projects were independent, there were similarities in objectives and methodology, with ProAR adopting operating procedures of U-BIOPRED.
   Results: Among SA subjects, age, weight, proportion of former smokers and FEV1 pre-bronchodilator were similar. The proportion of SA with a positive skin prick tests (SPT) to aeroallergens, the scores of sino-nasal symptoms and quality of life were comparable. In addition, blood eosinophil counts (EOS) and the % of subjects with EOS > 300 cells/mu l were not different. The Europeans with SA however, were more severe with a greater proportion of continuous oral corticosteroids (OCS), worse symptoms and more frequent exacerbations. FEV1/FVC pre- and post-bronchodilator were lower among the Europeans. The MMA cohorts were less comparable in control and treatment, but similar in the proportion of allergic rhinitis, gastroesophageal reflux disease and EOS >3%.
   Conclusions: ProAR and U-BIOPRED cohorts, with varying severity, ethnicity and environment have similarities, which provide the basis for global external validation of asthma phenotypes. This should stimulate collaboration between asthma consortia with the aim of understanding SA, which will lead to better management.
C1 [Cruz, Alvaro A.; Souza-Machado, Adelmir; Almeida, Paula C. A.; Biao-Lima, Valmar] ProAR Fdn, Salvador, BA, Brazil.
   [Cruz, Alvaro A.; Souza-Machado, Adelmir; Almeida, Paula C. A.; Biao-Lima, Valmar] Univ Fed Bahia, Salvador, BA, Brazil.
   [Riley, John H.; Davis, Maggie; Bates, Stewart] GSK, Stevenage, Herts, England.
   [Barisal, Aruna T.] Acclarogen Ltd, Cambridge, England.
   [Ponte, Eduardo, V] Fac Med Jundiai, Sao Paulo, Brazil.
   [Chung, Kian Fan] Imperial Coll, Natl Heart & Lung Inst, London, England.
   [Adcock, Ian M.; Sterk, Peter J.] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
RP Cruz, AA (reprint author), ProAR Fed Univ Bahia, Rua Carlos Gomes,170 7 Andar, BR-40060330 Salvador, BA, Brazil.
EM cruz.proar@gmail.com
RI Cruz, Constanca Margarida Sampaio/M-7576-2015; Sterk,
   P.J./AAK-8175-2020; Figueiredo, Camila/H-3525-2015; Singer,
   Florian/O-7651-2015
OI Cruz, Constanca Margarida Sampaio/0000-0002-3885-4314; Biao Lima,
   Valmar/0000-0001-8479-3666; Knox, Alan/0000-0002-5906-4143; MONTUSCHI,
   Paolo/0000-0001-5589-1750; Fleming, Louise/0000-0002-7268-7433; Fowler,
   Stephen/0000-0002-4524-1663; Adcock, Ian/0000-0003-2101-8843;
   Figueiredo, Camila/0000-0003-1356-6188; Singer,
   Florian/0000-0003-3471-5664; Djukanovic, Ratko/0000-0001-6039-5612
FU ProAR - Conselho Nacional de Desenvolvimento Cientifico e Tecnologico do
   Brasil (CNPq)National Council for Scientific and Technological
   Development (CNPq) [471057/2014-2]; Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB); GlaxoSmilthKline; U-BIOPRED - IMI EUEuropean
   Union (EU) [115010]
FX For ProAR - Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico do Brasil (CNPq) -Grant #471057/2014-2, Fundacao de Amparo a
   Pesquisa do Estado da Bahia (FAPESB) and GlaxoSmilthKline investigator
   initiated grant. For U-BIOPRED - IMI EU funded project (no. 115010).
CR Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903
   Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015
   [Anonymous], 1997, NIH PUBLICATION, V97-4051
   Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664
   Bigler J, 2017, AM J RESP CRIT CARE, V195, P1311, DOI 10.1164/rccm.201604-0866OC
   Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019
   Cruz AA, 2017, J ALLERGY CLIN IMMUN, V140, P1217, DOI 10.1016/j.jaci.2017.09.005
   Cruz AA, 2017, CURR OPIN ALLERGY CL, V17, P188, DOI 10.1097/ACI.0000000000000360
   Delgado-Eckert E, 2018, THORAX, V73, P107, DOI 10.1136/thoraxjnl-2016-209919
   Global Asthma Network, 2018, GLOB ASTHM REP
   Global Initiative for Asthma (GINA), 2018, GLOB STRAT ASTHM MAN
   Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042
   Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020
   Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192
   Kim TB, 2009, ANN ALLERG ASTHMA IM, V103, P311, DOI 10.1016/S1081-1206(10)60530-3
   Lima-Matos A, 2018, RESP MED, V145, P95, DOI 10.1016/j.rmed.2018.10.025
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Fernandes AGO, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0235-6
   Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6
   Prata TA, 2018, J BRAS PNEUMOL, V44, P449, DOI [10.1590/s1806-37562018000000082, 10.1590/S1806-37562018000000082]
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Salzer HJF, 2017, TRAVEL MED INFECT DI, V20, P49, DOI 10.1016/j.tmaid.2017.09.001
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   Souza-Machado C, 2010, EUR RESPIR J, V35, P515, DOI 10.1183/09031936.00101009
   Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046
NR 25
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105817
DI 10.1016/j.rmed.2019.105817
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400003
PM 31790928
OA Bronze
DA 2020-05-18
ER

PT J
AU Di Bona, D
   Magista, S
   Masciopinto, L
   Lovecchio, A
   Loiodice, R
   Bilancia, M
   Albanesi, M
   Caiaffa, MF
   Nettis, E
   Macchia, L
AF Di Bona, Danilo
   Magista, Stefania
   Masciopinto, Lucia
   Lovecchio, Antonella
   Loiodice, Roberto
   Bilancia, Massimo
   Albanesi, Marcello
   Caiaffa, Maria Filomena
   Nettis, Eustachio
   Macchia, Luigi
CA AIT Study Grp
TI Safety and treatment compliance of subcutaneous immunotherapy: A 30-year
   retrospective study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Side effects; Allergy; Anaphylaxis; Vaccine; AIT
ID SEASONAL ALLERGIC RHINITIS; SYSTEMIC REACTIONS; SUBLINGUAL
   IMMUNOTHERAPY; RISK-FACTORS; ANAPHYLAXIS; EFFICACY
AB Background: Safety and treatment compliance are still considered important shortcomings of subcutaneous immunotherapy (SCIT).
   Objective: To assess the rate of side effects (SE) to SCIT and treatment compliance at a hospital medically supervised facility.
   Methods: A retrospective review of patients with allergic rhino-conjunctivitis (ARC) with or without asthma, who received SCIT to mites and pollens from 1988 to 2018, was performed. The information was collected from patient's allergen immunotherapy forms that had been prospectically filled in by expert physicians.
   Results: Two thousand two hundred patients (50.2% males; mean age 29.4 +/- 11.7 years) received 3037 SCIT courses. A total of 91,187 injections were given, with a mean SCIT duration of 2.5 +/- 1.9 years. Nine hundred fifty-seven patients (43.5%) were compliant as they completed the minimally required treatment duration of 3 years. A total of 1087 SE (1.2% of all injections; 76.8% local reactions) were reported in 513 patients (23.3%). There were 42 anaphylactic reactions (in 29 patients) during the study period; two of these were severe. Adrenalin was administered only once. No anaphylactic shock was reported. Only 39 patients (1.8%) discontinued SCIT because of SE, the majority of whom (24; 61.5%) because of systemic reactions (urticaria, asthma, anaphylaxis). Parietaria vaccines were the most frequently associated to SE. Female gender, number of vaccines administered (2 vaccine vs. 1 vaccine) and year of SCIT inception (1996-2018 vs. 1988-1995) were independently associated to SE.
   Conclusion: SCIT, although not absolutely free of risk, is safe and well tolerated. There is still room for improvement of treatment compliance.
C1 [Di Bona, Danilo; Magista, Stefania; Masciopinto, Lucia; Lovecchio, Antonella; Loiodice, Roberto; Albanesi, Marcello; Nettis, Eustachio; Macchia, Luigi] Univ Bari Aldo Moro, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
   [Bilancia, Massimo] Univ Bari Aldo Moro, Ion Dept Legal & Econ Syst Mediterranean Soc Envi, Bari, Italy.
   [Caiaffa, Maria Filomena] Univ Foggia, Dept Med & Surg Sci, Foggia, Italy.
RP Di Bona, D (reprint author), Univ Bari Aldo Moro, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
EM danilo.dibona@uniba.it
OI DI BONA, DANILO/0000-0002-9728-3806
CR Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2
   Barrio I, 2017, STAT METHODS MED RES, V26, P2586, DOI 10.1177/0962280215601873
   Bernstein DI, 2011, IMMUNOL ALLERGY CLIN, V31, P241, DOI 10.1016/j.iac.2011.02.007
   Calderon MA, 2017, ALLERGY, V72, P462, DOI 10.1111/all.13066
   Cavalieri M., 2006, HLTH EXPENDITURE ITA
   Committee on Safety in Medicine, 1986, BMJ-BRIT MED J, V293, P948, DOI DOI 10.1136/BMJ.293.6552.948
   Cox L, 2013, J ALLER CL IMM-PRACT, V1, P455, DOI 10.1016/j.jaip.2013.08.001
   Di Bona D, 2015, JAMA INTERN MED, V175, P1301, DOI 10.1001/jamainternmed.2015.2840
   Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012
   Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013
   Egert-Schmidt AM, 2014, PATIENT PREFER ADHER, V8, P1475, DOI 10.2147/PPA.S70326
   Epstein TG, 2016, ANN ALLERG ASTHMA IM, V116, P354, DOI 10.1016/j.anai.2016.02.001
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013
   LIN MS, 1993, ANN ALLERGY, V71, P557
   Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437
   Nacaroglu HT, 2016, ANN ALLERG ASTHMA IM, V116, P349, DOI 10.1016/j.anai.2016.01.015
   R. R Core Team, 2018, LANG ENV STAT COMP
   Ragusa V Franco, 2004, Eur Ann Allergy Clin Immunol, V36, P52
   Rank MA, 2008, ALLERGY ASTHMA PROC, V29, P400, DOI 10.2500/aap.2008.29.3141
   Roberts G, 2018, ALLERGY, V73, P765, DOI 10.1111/all.13317
   Schiappoli M, 2009, CLIN EXP ALLERGY, V39, P1569, DOI 10.1111/j.1365-2222.2009.03286.x
   Sieber J, 2011, CURR MED RES OPIN, V27, P855, DOI 10.1185/03007995.2011.559538
   Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1
   Worm M, 2012, ALLERGY, V67, P691, DOI 10.1111/j.1398-9995.2012.02795.x
NR 25
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105843
DI 10.1016/j.rmed.2019.105843
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400019
PM 31778936
OA Bronze
DA 2020-05-18
ER

PT J
AU Gao, J
   Guo, YL
   Liu, Y
   Yan, J
   Zhou, J
   An, XG
   Su, PX
AF Gao, Jie
   Guo, Yulin
   Liu, Yan
   Yan, Jun
   Zhou, Jian
   An, Xiangguang
   Su, Pixiong
TI Protective effect of FBXL10 in myocardial ischemia reperfusion injury
   via inhibiting endoplasmic reticulum stress
SO RESPIRATORY MEDICINE
LA English
DT Article
DE FBXL10; Myocardial ischemia injury; Endoplasmic reticulum stress(ERs);
   Apoptosis; Inflammatory response
ID HEART-DISEASE; ACTIVATION
AB Objective: The aim of the study was to investigate the mechanism and effect of FBXL10 in myocardial ischemia reperfusion injury in vivo and in vitro.
   Methods: The myocardial ischemia reperfusion (I/R) model was established by 30 min of coronary occlusion followed by 2 h of reperfusion in rats. Western blot and TUNEL assay were used to measure the apoptosis during I/R. The expression levels of endoplasmic reticulum related proteins in myocardial tissues and H9c2 cells were detected by immunohistochemistry staining and immunofluorescence staining. Flow cytometry and CCK-8 were used to detect the apoptosis and viability of H9c2 cells.
   Results: The results revealed that FBXL10 significantly reduced myocardial infarction, improved the pathological morphology of myocardium, markedly reduced inflammatory response in the myocardial ischemia reperfusion rats. Moreover the expressions of endoplasmic reticulum stress key proteins were caused by I/R were suppressed significantly by FBXL10 treatment, including CHOP, GRP78, ATF4 and p-PERK. Additionally FBXL10 inhibited the expression of endoplasmic reticulum stress key proteins in H/R H9c2 cells. Furthermore, FBXL10 reduced the levels of apoptotic cells and inflammatory response compared with I/R and H/R group.
   Conclusion: Taken together, we found that FBXL10 could attenuate I/R injury through inhibiting endoplasmic reticulum stress (ERs).
C1 [Gao, Jie; Guo, Yulin; Liu, Yan; Yan, Jun; Zhou, Jian; An, Xiangguang; Su, Pixiong] Capital Univ Med Sci, Beijing Chaoyang Hosp, Dept Cardiac Surg, Beijing, Peoples R China.
RP Su, PX (reprint author), Capital Univ Med Sci, Beijing Chaoyang Hosp, Dept Cardiac Surg, Beijing, Peoples R China.
EM supixiong1130@163.com
FU project of 1351 talent training plan of Beijing chaoyang hospital
   affiliated to capital medical university [CYMY-2017-18]
FX We are grateful to all participates for their contributions for the
   present study. The study was supported by the funded project of 1351
   talent training plan of Beijing chaoyang hospital affiliated to capital
   medical university (No. CYMY-2017-18).
CR Arora M, 2014, MOL CELL BIOCHEM, V392, P49, DOI 10.1007/s11010-014-2017-3
   Azfer A, 2006, AM J PHYSIOL-HEART C, V291, pH1411, DOI 10.1152/ajpheart.01378.2005
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326
   Cavalcante Rafael, 2016, HEART, V103
   Chang LL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6173685
   Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Groenendyk J, 2010, CIRC RES, V107, P1185, DOI 10.1161/CIRCRESAHA.110.227033
   Gu YH, 2017, ENVIRON TOXICOL PHAR, V49, P194, DOI 10.1016/j.etap.2017.01.003
   Hackert JK, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00130
   Jiang Q., 2017, AMINO ACIDS
   Jichun W., 2015, INT J CARDIOL, V203, P779
   Konstantinidis K, 2012, ARTERIOSCL THROM VAS, V32, P1552, DOI 10.1161/ATVBAHA.111.224915
   Li S.H., 2017, NEUROCHEM INT
   Li Sheng-Hua, NEUROCHEM INT
   Liu XY, 2014, HYPERTENSION, V64, P738, DOI 10.1161/HYPERTENSIONAHA.114.03811
   Minamino T., 2010, J MOL CELL CARDIOL, V48
   Mozaffarian D., 2015, CIRCULATION, V131
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Senthil V, 2005, CIRC RES, V97, P285, DOI 10.1161/01.RES.0000177090.07296.ac
   Yao YF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00171-w
   Yin LL, 2019, J CELL MOL MED, V23, P2558, DOI 10.1111/jcmm.14146
   Yuhan T., 2016, OXID MED CELL LONGEV, P1, DOI DOI 10.1007/S13042-015-0411-0
   Yujia W., 2018, PERFUSION
   Zhao ER, 2017, CELL SIGNAL, V36, P222, DOI 10.1016/j.cellsig.2017.05.011
NR 26
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105852
DI 10.1016/j.rmed.2019.105852
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400017
PM 32056726
OA Bronze
DA 2020-05-18
ER

PT J
AU Hamazaki, N
   Kamiya, K
   Matsuzawa, R
   Nozaki, K
   Ichikawa, T
   Tanaka, S
   Nakamura, T
   Yamashita, M
   Maekawa, E
   Noda, C
   Yamaoka-Tojo, M
   Matsunaga, A
   Masuda, T
   Ako, J
AF Hamazaki, Nobuaki
   Kamiya, Kentaro
   Matsuzawa, Ryota
   Nozaki, Kohei
   Ichikawa, Takafumi
   Tanaka, Shinya
   Nakamura, Takeshi
   Yamashita, Masashi
   Maekawa, Emi
   Noda, Chiharu
   Yamaoka-Tojo, Minako
   Matsunaga, Atsuhiko
   Masuda, Takashi
   Ako, Junya
TI Prevalence and prognosis of respiratory muscle weakness in heart failure
   patients with preserved ejection fraction
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Heart failure; Preserved ejection fraction; Respiratory muscle;
   Prognosis
ID STRENGTH; DYSFUNCTION; DIAGNOSIS
AB Background: Although respiratory muscle weakness (RMW) is known to predict prognosis in patients with heart failure with reduced ejection fraction (HFrEF), RMW prevalence and its prognosis in those with preserved ejection fraction (HFpEF) remain unknown. We aimed to investigate whether the RMW predicted mortality in HFpEF patients.
   Methods: We conducted a single-centre observational study with consecutive 1023 heart failure patients (445 in HFrEF and 578 in HFpEF). Maximal inspiratory pressure (PImax) was measured to assess respiratory muscle strength at hospital discharge, and RMW was defined as PImax <70% of predicted value. Endpoint was all-cause mortality after hospital discharge, and we examined the influence of RMW on the endpoint.
   Results: Over a median follow-up of 1.8 years, 134 patients (13.1%) died; of these 53 (11.9%) were in HFrEF and 81 (14.0%) in HFpEF. RMW was evident in 190 (42.7%) HFrEF and 226 (39.1%) HFpEF patients and was independently associated with all-cause mortality in both HFrEF (adjusted hazard ratio [HR]: 2.13, 95% confidence interval [CI]: 1.17-3.88) and HFpEF (adjusted HR: 2.85, 95% CI: 1.74-4.67) patients. Adding RMW to the multivariate logistic regression model significantly increased area under the receiver-operating characteristic curve (AUC) for all-cause mortality in HFpEF (AUC including RMW: 0.78, not including RMW: 0.74, P = 0.026) but not in HFrEF (AUC including RMW: 0.84, not including RMW: 0.82, P = 0.132).
   Conclusions: RMW was observed in 39% of HFpEF patients, which was independently associated with poor prognosis. The additive effect of RMW on prognosis was detected only in HFpEF but not in HFrEF.
C1 [Hamazaki, Nobuaki; Nozaki, Kohei; Ichikawa, Takafumi] Kitasato Univ Hosp, Dept Rehabil, Sagamihara, Kanagawa, Japan.
   [Kamiya, Kentaro; Yamaoka-Tojo, Minako; Matsunaga, Atsuhiko; Masuda, Takashi] Kitasato Univ, Dept Rehabil, Sch Allied Hlth Sci, Sagamihara, Kanagawa, Japan.
   [Matsuzawa, Ryota] Hyogo Univ Hlth Sci, Sch Rehabil, Dept Phys Therapy, Kobe, Hyogo, Japan.
   [Tanaka, Shinya] Nagoya Univ Hosp, Dept Rehabil, Nagoya, Aichi, Japan.
   [Nakamura, Takeshi; Yamashita, Masashi] Kitasato Univ, Dept Rehabil Sci, Grad Sch Med Sci, Sagamihara, Kanagawa, Japan.
   [Maekawa, Emi; Noda, Chiharu; Ako, Junya] Kitasato Univ, Dept Cardiovasc Med, Sch Med, Sagamihara, Kanagawa, Japan.
RP Hamazaki, N (reprint author), Kitasato Univ Hosp, Dept Rehabil, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan.
EM hamanobu0317@gmail.com
OI Yamaoka-Tojo, Minako/0000-0003-3890-3777; Tanaka,
   Shinya/0000-0002-0077-9726; Hamazaki, Nobuaki/0000-0002-8338-2141;
   Yamashita, Masashi/0000-0003-4680-1068
FU Japan Society for the Promotion of Science [JSPS KAKENHI Grant]Ministry
   of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [JP16K16442]
FX This work was supported by Japan Society for the Promotion of Science
   Grant-in-Aid [JSPS KAKENHI Grant Number JP16K16442].
CR Agarwal SK, 2012, EUR J HEART FAIL, V14, P414, DOI 10.1093/eurjhf/hfs016
   Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Andrea R, 2018, RESP MED, V134, P124, DOI 10.1016/j.rmed.2017.12.004
   Borlaug BA, 2011, EUR HEART J, V32, P670, DOI 10.1093/eurheartj/ehq426
   Bowen TS, 2015, EUR J HEART FAIL, V17, P263, DOI 10.1002/ejhf.239
   Chen YJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004297
   CHUA TP, 1995, BRIT HEART J, V74, P381
   CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107
   Dall'Ago P, 2006, J AM COLL CARDIOL, V47, P757, DOI 10.1016/j.jacc.2005.09.052
   Farr MJ, 2008, AM J CARDIOL, V102, P203, DOI 10.1016/j.amjcard.2008.03.041
   Frankenstein L, 2009, EUR J CARDIOV PREV R, V16, P424, DOI 10.1097/HJR.0b013e3283030a7e
   Habedank D, 2013, J CACHEXIA SARCOPENI, V4, P277, DOI 10.1007/s13539-013-0109-7
   Hamaguchi S, 2012, CIRC J, V76, P1662, DOI 10.1253/circj.CJ-11-1355
   Hamazaki N, 2019, RESPIROLOGY, V24, P154, DOI 10.1111/resp.13432
   Kelley RC, 2017, HEART FAIL REV, V22, P191, DOI 10.1007/s10741-016-9549-4
   Laghi F, 2003, AM J RESP CRIT CARE, V168, P10, DOI 10.1164/rccm.2206020
   Lam CSP, 2011, EUR J HEART FAIL, V13, P18, DOI 10.1093/eurjhf/hfq121
   Meyer FJ, 2001, CIRCULATION, V103, P2153
   Neder JA, 2019, RESP MED, V158, P6, DOI 10.1016/j.rmed.2019.09.007
   Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256
   Palau P, 2017, J CARD FAIL, V23, P480, DOI 10.1016/j.cardfail.2017.04.016
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Senni M, 2014, EUR HEART J, V35, P2797, DOI 10.1093/eurheartj/ehu204
   Smart NA, 2013, INT J CARDIOL, V167, P1502, DOI 10.1016/j.ijcard.2012.04.029
   Stassijns G, 1998, AM J RESP CRIT CARE, V158, P1963, DOI 10.1164/ajrccm.158.6.9710028
   Suzuki M, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P1305
   Tojo Naoko, 2005, Rinsho Byori, V53, P77
   Vaduganathan M, 2017, J AM COLL CARDIOL, V69, P556, DOI 10.1016/j.jacc.2016.10.078
   van Hees HWH, 2007, AM J PHYSIOL-HEART C, V293, pH819, DOI 10.1152/ajpheart.00085.2007
   Yamada K, 2016, J CARD FAIL, V22, P38, DOI 10.1016/j.cardfail.2015.10.010
   Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019
NR 31
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105834
DI 10.1016/j.rmed.2019.105834
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400014
PM 31783270
OA Bronze
DA 2020-05-18
ER

PT J
AU Harder, EM
   Small, AM
   Fares, WH
AF Harder, Eileen M.
   Small, Aeron M.
   Fares, Wassim H.
TI Primary cardiac hospitalizations in pulmonary arterial hypertension:
   Trends and outcomes from 2001 to 2014
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pulmonary arterial hypertension; Cardiac hospitalizations; Outcomes
ID PROGNOSTIC VALUE; HEART-FAILURE; CLASSIFICATION; ARRHYTHMIAS;
   DYSFUNCTION; PREVALENCE; MANAGEMENT; DISEASES; REGISTRY; VOLUME
AB Background: Hospitalizations in pulmonary arterial hypertension (PAH) are common and are often for cardiac conditions. Using the National (Nationwide) Inpatient Sample (NIS), we examined characteristics and mortality of primary cardiac hospitalizations in PAH from 2001 to 2014.
   Methods: Adult hospitalizations with any diagnosis code for PAH were identified. Primary cardiac disease was defined as a primary discharge diagnosis of congestive heart failure (CHF), pulmonary heart disease, coronary atherosclerosis, acute myocardial infarction, dysrhythmia, conduction disorder, cardiomyopathy or carditis, heart valve disorder, or cardiac arrest. Temporal trends, characteristics, and in-hospital mortality were analyzed.
   Results: From 2001 to 2014, there were 207,095 hospitalizations in PAH, of which 100,509 (48.5%) carried a primary cardiac diagnosis. Most primary cardiac hospitalizations in PAH were for CHF, and pneumonia was the most common primary non-cardiac diagnosis. Over the study period, primary cardiac hospitalizations in PAH fell from 52.9% to 41.4% (p < 0.001). CHF was the most frequent primary cardiac diagnosis associated with death, with sepsis representing the most common primary non-cardiac disease (1,226; 25.0%). Overall, the mortality in primary cardiac hospitalizations in PAH was 5.3% (vs. in primary non-cardiac, 6.9%, p < 0.001). On multi-variable analysis, a primary cardiac discharge diagnosis remained associated with a decreased risk of death (odds ratio 0.85, p = 0.010).
   Conclusion: Primary cardiac hospitalizations in PAH are common and are associated with decreased mortality compared to admissions for primary non-cardiac diagnoses.
C1 [Harder, Eileen M.; Small, Aeron M.] Yale Univ, Dept Internal Med, Sch Med, POB 208030, New Haven, CT 06520 USA.
   [Fares, Wassim H.] Actel Clin Res, Allschwil, Switzerland.
RP Harder, EM (reprint author), Brigham & Womens Hosp, Pulm & Crit Care Div, 15 Francis St, Boston, MA 02115 USA.
EM eharder1@bwh.harvard.edu; aeron.small@yale.edu; wfares@its.jnj.com
CR Anand V, 2016, JAMA CARDIOL, V1, P1021, DOI 10.1001/jamacardio.2016.3591
   [Anonymous], 2018, HCUP CLIN CLASS SOFT
   [Anonymous], 2018, PARTNER ORG PROVIDIN
   [Anonymous], 2015, INTRO HCUP NATL INPA
   Benza RL, 2010, CIRCULATION, V122, P164, DOI 10.1161/CIRCULATIONAHA.109.898122
   Burger CD, 2014, CHEST, V146, P1263, DOI 10.1378/chest.14-0193
   Burke JP, 2015, AM J MANAG CARE, V21, pS47
   Campo A, 2011, EUR RESPIR J, V38, P359, DOI 10.1183/09031936.00148310
   Channick RN, 2015, JACC-HEART FAIL, V3, P1, DOI 10.1016/j.jchf.2014.07.013
   Chin KM, 2005, CORONARY ARTERY DIS, V16, P13, DOI 10.1097/00019501-200502000-00003
   Delcroix M, 2010, EUR RESPIR REV, V19, P204, DOI 10.1183/09059180.00004910
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Frost AE, 2013, CHEST, V144, P1521, DOI 10.1378/chest.12-3023
   Frumkin LR, 2012, PHARMACOL REV, V64, P583, DOI 10.1124/pr.111.005587
   Galie N, 2015, NEW ENGL J MED, V373, P834, DOI 10.1056/NEJMoa1413687
   Haddad F, 2011, CIRC-HEART FAIL, V4, P692, DOI 10.1161/CIRCHEARTFAILURE.110.949933
   Hardegree EL, 2013, CIRC-HEART FAIL, V6, P748, DOI 10.1161/CIRCHEARTFAILURE.112.000098
   Hoeper MM, 2013, INT J CARDIOL, V168, P871, DOI 10.1016/j.ijcard.2012.10.026
   Hoeper MM, 2002, AM J RESP CRIT CARE, V165, P341, DOI 10.1164/ajrccm.165.3.200109-0130c
   Houchens R, 2014, HCUP NIS RELATED REP
   Humbert M, 2016, THORAX, V71, P73, DOI 10.1136/thoraxjnl-2015-207170
   Kasner M, 2012, AM J RESP CRIT CARE, V186, P181, DOI 10.1164/rccm.201110-1860OC
   Khera R, 2017, JAMA-J AM MED ASSOC, V318, P2011, DOI 10.1001/jama.2017.17653
   Lajoie AC, 2017, PULM CIRC, V7, P312, DOI 10.1177/2045893217710639
   Link J, 2011, CHEST, V139, P497, DOI 10.1378/chest.10-0837
   Meloche J, 2017, ARTERIOSCL THROM VAS, V37, P1513, DOI 10.1161/ATVBAHA.117.309156
   Mueller-Mottet S, 2015, RESPIRATION, V89, P127, DOI 10.1159/000370125
   Nickel NP, 2017, PULM CIRC, V7, P38, DOI 10.1086/690018
   Noordegraaf AV, 2011, EUR RESPIR REV, V20, P243, DOI 10.1183/09059180.00006511
   Pabst S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035310
   Rajdev A, 2012, PROG CARDIOVASC DIS, V55, P180, DOI 10.1016/j.pcad.2012.06.002
   Ruiz-Cano MJ, 2011, INT J CARDIOL, V146, P105, DOI 10.1016/j.ijcard.2010.09.065
   Shimony A, 2011, AM J CARDIOL, V108, P460, DOI 10.1016/j.amjcard.2011.03.066
   Simonneau G, 2013, J AM COLL CARDIOL, V62, pD34, DOI 10.1016/j.jacc.2013.10.029
   Sztrymf B, 2013, CHEST, V144, P1512, DOI 10.1378/chest.12-2659
   Thenappan T, 2018, BMJ J, Vj5492, P360
   Tonelli AR, 2013, AM J RESP CRIT CARE, V188, P365, DOI 10.1164/rccm.201209-1640OC
   Tonelli AR, 2012, CHEST, V141, P1457, DOI 10.1378/chest.11-1903
   Tongers J, 2007, AM HEART J, V153, P127, DOI 10.1016/j.ahj.2006.09.008
   Tsuchida K, 2014, ANN RHEUM DIS, V73, P708, DOI 10.1136/annrheumdis-2014-eular.4878
   van Wolferen SA, 2007, EUR HEART J, V28, P1250, DOI 10.1093/eurheartj/ehl477
   Vonk-Noordegraaf A, 2005, CHEST, V128, p628S, DOI 10.1378/chest.128.6_suppl.628S
   Wen L, 2014, AM J CARDIOL, V114, P1420, DOI 10.1016/j.amjcard.2014.07.079
NR 43
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105850
DI 10.1016/j.rmed.2019.105850
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400015
PM 32056724
OA Bronze
DA 2020-05-18
ER

PT J
AU Huang, HL
   Lee, MR
   Liu, CJ
   Cheng, MH
   Lu, PL
   Wang, JY
   Chong, IW
AF Huang, Hung-Ling
   Lee, Meng-Rui
   Liu, Chia-Jung
   Cheng, Meng-Hsuan
   Lu, Po-Liang
   Wang, Jann-Yuan
   Chong, Inn-Wen
TI Predictors of radiographic progression for NTM-pulmonary disease
   diagnosed by bronchoscopy
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchoscopy; Clinical course; Nontuberculous mycobacterium; Pulmonary
   disease; Radiographic progression
ID HIV-NEGATIVE PATIENTS; LUNG-DISEASE; INHALED CORTICOSTEROIDS;
   MYCOBACTERIUM-ABSCESSUS; PROGNOSTIC-FACTORS; RISK-FACTORS;
   DETERIORATION; PERSISTENCE; INFECTION; PNEUMONIA
AB Objectives: A single isolate of nontuberculous mycobacterium (NTM) from bronchoscopic samples satisfies the microbiological criterion for diagnosing NTM-pulmonary disease (PD). Studies investigating patients with NTM-PD and multiple culture-negative sputum samples but culture-positive bronchoscopic samples are lacking. We investigated the clinical characteristics, outcome, and predictors of radiographic progression in this special population.
   Methods: Patients with negative NTM culture from >= 2 expectorated sputum samples within the 3 months prior to bronchoscopy diagnosis of NTM-PD between 2009 and 2017 were included. Patient characteristics and clinical course were described. Predictors for radiographic progression of NTM-PD within 2 years were analysed by using multivariate logistic regression.
   Results: Among 66 patients with bronchoscopy-diagnosed NTM-PD, radiographic progression occurred within 2 years in 17 (26%). Of the 60 patients not initially treated, radiographic progression occurred in 17 (28%). Among them, 10 never received treatment, with 6 deteriorating and 3 dying. Of the 6 and 7 patients who received treatment immediately after NTM-PD diagnosis and after radiographic progression, respectively, none had further radiographic progression. The independent predictors of radiographic progression were male sex, body mass index <18.5 kg/m(2), use of inhaled corticosteroids, and acid-fast smear grade >= 2 of index bronchoscopic samples.
   Conclusions: Among patients with bronchoscopy-diagnosed NTM-PD, one fourth experienced radiographic progression within 2 years. The risk was even higher in those with the aforementioned predictors, immediate treatment or close monitoring is recommended. For others, conservative management by regular microbiological monitoring for sputum samples and image follow-up may be the optimal choice.
C1 [Huang, Hung-Ling; Cheng, Meng-Hsuan; Lu, Po-Liang; Chong, Inn-Wen] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.
   [Cheng, Meng-Hsuan; Chong, Inn-Wen] Kaohsiung Med Univ Hosp, Dept Resp Therapy, Kaohsiung, Taiwan.
   [Lu, Po-Liang] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan.
   [Huang, Hung-Ling; Cheng, Meng-Hsuan; Lu, Po-Liang; Chong, Inn-Wen] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.
   [Huang, Hung-Ling] Kaohsiung Municipal Tatung Hosp, Dept Internal Med, Kaohsiung, Taiwan.
   [Lee, Meng-Rui; Liu, Chia-Jung] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan.
   [Lee, Meng-Rui; Liu, Chia-Jung; Wang, Jann-Yuan] Natl Taiwan Univ Hosp, Dept Internal Med, 7 Zhongshan South Rd, Taipei 10002, Taiwan.
   [Lee, Meng-Rui; Wang, Jann-Yuan] Natl Taiwan Univ, Coll Med, Taipei, Taiwan.
RP Wang, JY (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Zhongshan South Rd, Taipei 10002, Taiwan.
EM jywang@ntu.edu.tw
OI WANG, JANN-YUAN/0000-0003-3406-366X
FU Taiwan Ministry of Science and Technology [MOST107-2314-B-037-106-MY3];
   Ministry of Health and WelfareMinistry of Health, Labour and Welfare,
   Japan [MOHW108-TDU-B-212-133006]; Kaohsiung Medical University Hospital
   Research Program [KMUH107-7R12]
FX This study was supported by the Taiwan Ministry of Science and
   Technology (MOST107-2314-B-037-106-MY3), Ministry of Health and Welfare
   (MOHW108-TDU-B-212-133006), and Kaohsiung Medical University Hospital
   Research Program (KMUH107-7R12). The funders had no role in the study
   design, data analysis, or manuscript writing.
CR Andrejak C, 2013, THORAX, V68, P256, DOI 10.1136/thoraxjnl-2012-201772
   Andrejak C, 2010, AM J RESP CRIT CARE, V181, P514, DOI 10.1164/rccm.200905-0778OC
   Cowman SA, 2018, AM J RESP CELL MOL, V58, P510, DOI 10.1165/rcmb.2017-0230OC
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Festic E, 2015, AM J RESP CRIT CARE, V191, P141, DOI 10.1164/rccm.201409-1654PP
   Griffith D.E., 2018, NONTUBERCULOUS MYCOB
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Hayashi M, 2012, AM J RESP CRIT CARE, V185, P575, DOI 10.1164/rccm.201107-1203OC
   Hojo M, 2012, RESPIROLOGY, V17, P185, DOI 10.1111/j.1440-1843.2011.02076.x
   Hong SJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003978
   Huang HL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16559-z
   Huang JH, 1999, CHEST, V115, P1033, DOI 10.1378/chest.115.4.1033
   Hwang JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00537-2016
   Janson C, 2017, INT J CHRONIC OBSTR, V12, P3055, DOI 10.2147/COPD.S143656
   Jeon K, 2009, AM J RESP CRIT CARE, V180, P896, DOI 10.1164/rccm.200905-0704OC
   Kang HK, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004540
   Kartalija M, 2013, AM J RESP CRIT CARE, V187, P197, DOI 10.1164/rccm.201206-1035OC
   Kim HJ, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4078-0
   Kim SJ, 2014, INT J TUBERC LUNG D, V18, P730, DOI 10.5588/ijtld.13.0792
   Kitada S, 2012, INT J TUBERC LUNG D, V16, P660, DOI 10.5588/ijtld.11.0534
   Lee MR, 2012, J INFECTION, V64, P228, DOI 10.1016/j.jinf.2011.11.006
   Liu CJ, 2019, RESP MED, V151, P19, DOI 10.1016/j.rmed.2019.03.015
   Liu VX, 2018, ANN AM THORAC SOC, V15, P1169, DOI 10.1513/AnnalsATS.201804-245OC
   Nagano Hiroaki, 2013, Kansenshogaku Zasshi, V87, P726
   Ni SS, 2014, J THORAC DIS, V6, P971, DOI 10.3978/j.issn.2072-1439.2014.07.03
   Pan SW, 2017, CLIN INFECT DIS, V65, P927, DOI 10.1093/cid/cix479
   Park J, 2017, CLIN INFECT DIS, V64, P301, DOI 10.1093/cid/ciw723
   Patterson CM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-40
   Perrin FMR, 2010, INT J TUBERC LUNG D, V14, P1596
   Shin SJ, 2013, CLIN INFECT DIS, V57, P32, DOI 10.1093/cid/cit172
   Singh D., 2019, EUR RESP J, V53
   SNIDER GL, 1971, AM REV RESPIR DIS, V103, P625
   Sugihara Eiichiro, 2003, Journal of Infection and Chemotherapy, V9, P328, DOI 10.1007/s10156-003-0267-1
   Tanaka E, 1997, AM J RESP CRIT CARE, V155, P2041, DOI 10.1164/ajrccm.155.6.9196113
   Yamazaki Y, 1999, AM J RESP CRIT CARE, V160, P1851, DOI 10.1164/ajrccm.160.6.9902019
NR 36
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105847
DI 10.1016/j.rmed.2019.105847
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400013
PM 31785506
DA 2020-05-18
ER

PT J
AU Im, Y
   Lee, J
   Kim, SJ
   Koh, WJ
   Jhun, BW
   Lee, SH
AF Im, Yunjoo
   Lee, Jeeyun
   Kim, Seok Jin
   Koh, Won-Jung
   Jhun, Byung Woo
   Lee, Se-Hoon
TI Development of tuberculosis in cancer patients receiving immune
   checkpoint inhibitors
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Tuberculosis; Immune checkpoint inhibitor; Lung cancer; Melanoma;
   Lymphoma
ID REACTIVATION; RISK
AB Background: Limited data exist on the development of tuberculosis (TB) in cancer patients receiving immune checkpoint inhibitors (ICIs).
   Method: s: We evaluated the development of TB in 1144 solid-cancer patients who started ICIs (pembrolizumab, nivolumab, or atezolizumab) between July 2014 and December 2018.
   Results: A total of 1144 cancer patients were treated with ICIs. The median age of the patients at the start of ICI treatment was 62 years (interquartile range [IQR]; 53-69 years). Lung cancer (n = 796, 69.6%) was the most common cancer followed by melanoma (n = 115, 10.1%), and lymphoma (n = 85, 7.4%). Pembrolizumab (n = 612, 53.5%) was the most common treatment, followed by nivolumab (n = 474, 41.4%) and atezolizumab (n = 58, 5.1%). The median treatment duration with ICIs was 42 days (IQR; 18-154 days), and the median follow-up duration after initiating ICIs was 187 days (IQR; 70-342 days). Overall, three patients developed TB, two of whom received nivolumab and one who received pembrolizumab.
   Conclusions: Our data showed that TB can develop in cancer patients receiving ICIs. However, due to the small number of study population, it is insufficient to draw accurate conclusions about the role of ICIs in the development of TB. Moreover, it is unclear whether the incidence of TB would be comparable with the incidence of TB in elderly cancer patients. Further studies are needed to evaluate whether diagnosis and treatment of latent TB infections before starting ICIs could be helpful in preventing the development of TB in these patients.
C1 [Im, Yunjoo; Koh, Won-Jung; Jhun, Byung Woo] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Pulm & Crit Care Med,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Lee, Jeeyun; Kim, Seok Jin; Lee, Se-Hoon] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol & Oncol,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Lee, Se-Hoon] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea.
RP Jhun, BW (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Pulm & Crit Care Med,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.; Lee, SH (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol & Oncol,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM byungwoo.jhun@gmail.com; shlee119@skku.edu
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI19C0137]
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea
   (HI19C0137). The sponsor had no role in the design of the study, the
   collection and analysis of the data, or the preparation of the
   manuscript.
CR Barber DL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat2702
   Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304
   Chen TW, 2015, ANN ONCOL, V26, P1824, DOI 10.1093/annonc/mdv182
   Cho K.S., 2018, EPIDEMIOL HLTH, V40
   Chu Yi-Chun, 2017, J Thorac Oncol, V12, pe111, DOI 10.1016/j.jtho.2017.03.012
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1
   Delaunay M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00050-2017
   Elkington PT, 2018, AM J RESP CRIT CARE, V198, P1451, DOI 10.1164/rccm.201807-1250LE
   Fujita K, 2016, J THORAC ONCOL, V11, P2238, DOI 10.1016/j.jtho.2016.07.006
   Inthasot V, 2019, ACTA CLIN BELG, DOI 10.1080/17843286.2019.1629078
   Jung SM, 2015, INT J RHEUM DIS, V18, P323, DOI 10.1111/1756-185X.12530
   KCDC, 2018, 2018 ANN REP NOT TUB
   Kim HR, 2008, RESPIROLOGY, V13, P413, DOI 10.1111/j.1440-1843.2008.01282.x
   Lee JJX, 2016, ACTA ONCOL, V55, P519, DOI 10.3109/0284186X.2015.1125017
   Lee J, 2017, ANN AM THORAC SOC, V14, P690, DOI [10.1513/AnnalsATS.201608-647OC, 10.1513/annalsats.201608-647oc]
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Picchi H, 2018, CLIN MICROBIOL INFEC, V24, P216, DOI 10.1016/j.cmi.2017.12.003
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Seo GH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004919
   Takata S, 2019, J INFECT CHEMOTHER, V25, P54, DOI 10.1016/j.jiac.2018.06.016
   Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112
NR 21
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105853
DI 10.1016/j.rmed.2019.105853
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400005
PM 32056727
OA Bronze
DA 2020-05-18
ER

PT J
AU Kornmann, O
   Mucsi, J
   Kolosa, N
   Bandelli, L
   Sen, B
   Satlin, LC
   D'Andrea, P
AF Kornmann, Oliver
   Mucsi, Janos
   Kolosa, Nadezda
   Bandelli, Lorraine
   Sen, Biswajit
   Satlin, Lisa C.
   D'Andrea, Peter
TI Efficacy and safety of inhaled once-daily low-dose indacaterol
   acetate/mometasone furoate in patients with inadequately controlled
   asthma: Phase III randomised QUARTZ study findings
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Treatment; Long acting beta agonists; Inhaled corticosteroids
ID COMBINATION THERAPY; FLUTICASONE PROPIONATE; MOMETASONE FUROATE;
   BUDESONIDE/FORMOTEROL; QUESTIONNAIRE
AB Background: Global initiative for asthma (GINA) 2019 recommends adding a long-acting beta(2)-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma. Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients.
   Objective: This phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80 mu g once daily (o.d.) versus MF 200 mu g o.d. in adult and adolescent patients with inadequately controlled asthma.
   Methods: Eligible patients (n = 802) were randomised (1:1) to receive either low-dose IND/MF 150/80 mu g o.d. via Breezhaler (R) or MF 200 mu g o.d. via Twisthaler (R) for 12 weeks. Primary endpoint was trough forced expiratory volume in 1 s (FEV1) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment. Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment. Safety was also assessed including serious asthma outcomes.
   Results: Low-dose IND/MF significantly improved trough FEV1 (least squares mean treatment difference [LSMTD]: 0.182 L; p < 0.001) and ACQ-7 (LSMTD: -0.218; p < 0.001) versus MF at Week 12. Improvements in all other secondary endpoints favoured low-dose IND/MF. Safety was comparable.
   Conclusion: These results support the use of low-dose IND/MF 150/80 mu g o.d. as a potential therapy for adult and adolescent patients with inadequately controlled asthma.
C1 [Kornmann, Oliver] Clin Res Ctr Resp Dis, IKF Pneumol Frankfurt, Frankfurt, Germany.
   [Mucsi, Janos] Erzsebet Gondozohaz, Godollo, Hungary.
   [Kolosa, Nadezda] Daugavpils Reg Hosp LTD, Daugavpils, Latvia.
   [Bandelli, Lorraine; Satlin, Lisa C.; D'Andrea, Peter] Novartis Pharmaceut, E Hanover, NJ USA.
   [Sen, Biswajit] Novartis Healthcare Pvt Ltd, Hyderabad, India.
RP Kornmann, O (reprint author), IKF Pneumol GmbH & Co KG, Inst Klin Forsch Pneumol, Clin Res Ctr Resp Dis, Schaumainkai 101-103,Stresemannallee 3, D-60596 Frankfurt, Germany.
EM kornmann@ikf-pneumologie.de; mucsitrial@erzsebetgondozohaz.hu;
   kolosa-nadezda@hotmail.com; lorraine.bandelli@novartis.com;
   biswajit.sen@novartis.com; lisa.satlin@novartis.com;
   peter.dandrea@novartis.com
FU Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
FX This study was supported by Novartis Pharmaceuticals Corporation, East
   Hanover, New Jersey, USA.
CR [Anonymous], 2018, GLOBAL ASTHMA REPORT
   Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC
   Bateman ED, 2015, J ALLERGY CLIN IMMUN, V136, P914, DOI 10.1016/j.jaci.2015.03.023
   Beasley RW, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006131
   Bell AD, 2007, CAN FAM PHYSICIAN, V53, P687
   Berger WE, 2011, EXPERT REV RESP MED, V5, P739, DOI [10.1586/ERS.11.71, 10.1586/ers.11.71]
   Chuchalin AG, 2007, RESP MED, V101, P2065, DOI 10.1016/j.rmed.2007.06.002
   Chung VCH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070784
   Corren J, 2013, RESP MED, V107, P180, DOI 10.1016/j.rmed.2012.10.025
   Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P11, DOI 10.1046/j.1365-2125.2003.01831.x
   Global Initiative for Asthma (GINA), 2019, GLOB STRAT ASTHM MAN
   Ichinose M, 2017, ALLERGOL INT, V66, P163, DOI 10.1016/j.alit.2016.12.005
   Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   Kanniess F., 2014, EUR RESPIR J, V44, P915
   LaForce C, 2008, ALLERGY, V63, P103, DOI 10.1111/j.1398-9995.2007.01555.x
   Mackay AJ, 2018, AM J RESP CRIT CARE, V198, P730, DOI 10.1164/rccm.201712-2482CI
   McCormack PL, 2006, DRUGS, V66, P1151, DOI 10.2165/00003495-200666080-00011
   Miller-Larsson A, 2006, CURR PHARM DESIGN, V12, P3261, DOI 10.2174/138161206778194187
   Noonan M, 2001, ANN ALLERG ASTHMA IM, V86, P36, DOI 10.1016/S1081-1206(10)62353-8
   O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC
   Pearlman DS, 2004, J ASTHMA, V41, P797, DOI 10.1081/JAS-200038368
   Pertseva T, 2013, CURR MED RES OPIN, V29, P1357, DOI 10.1185/03007995.2013.825592
   Risquez C.F., 2016, CLIN PULM MED, V23, P238
   Rodrigo GJ, 2012, THORAX, V67, P342, DOI 10.1136/thx.2010.155648
   Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x
   Sears MR, 2009, RESP MED, V103, P1960, DOI 10.1016/j.rmed.2009.08.007
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Tan Ricardo A, 2008, Ther Clin Risk Manag, V4, P1201
   Vaidya S, 2012, EUR RESPIR J, V40, P2145
   Wedzicha JA, 2016, NEW ENGL J MED, V374, P2222, DOI 10.1056/NEJMoa1516385
   Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801
NR 32
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105809
DI 10.1016/j.rmed.2019.105809
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400007
PM 32056721
OA Bronze
DA 2020-05-18
ER

PT J
AU Kulkarni, T
   Kurundkar, AR
   Kim, YI
   de Andrade, J
   Luckhardt, T
   Thannickal, VJ
AF Kulkarni, Tejaswini
   Kurundkar, Ashish R.
   Kim, Young-il
   de Andrade, Joao
   Luckhardt, Tracy
   Thannickal, Victor J.
TI The senescence-associated matricellular protein CCN1 in plasma of human
   subjects with idiopathic pulmonary fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; CCN1; Cellular senescence;
   Transplant-free survival
AB Introduction: Cellular senescence has been linked to the pathogenesis of idiopathic pulmonary fibrosis (IPF). CCN1 is a matricellular protein that has been shown to induce cellular senescence and contribute to lung fibrosis in pre-clinical models. In this report, we determined plasma CCN1 levels in patients with IPF and its potential role in clinical outcomes.
   Methods and Results: We evaluated 88 patients diagnosed with IPF at the University of Alabama at Birmingham. CCN1 levels were measured in plasma specimens by ELISA. The primary outcome measure was transplant-free survival (TFS) duration. High-CCN1 levels were associated with a lower transplant-free survival independent of %FVC and %DLCO compared to patients with low plasma CCN1 (HR = 2.15; 95%CI 1.04-4.45, p = 0.04).
   Conclusion: This study demonstrates that plasma levels of CCN1 may be predictive of survival in IPF. Given the plausible role of CCN1 in cellular senescence and pathobiology of IPF, the predictive value of CCN1 in disease progression among patients with IPF warrants further investigation.
C1 [Kulkarni, Tejaswini; Kurundkar, Ashish R.; Kim, Young-il; Luckhardt, Tracy; Thannickal, Victor J.] Univ Alabama Birmingham, Dept Med, Div Pulm, Allergy,Crit Care Med, Birmingham, AL 35294 USA.
   [Kim, Young-il] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
   [de Andrade, Joao] Vanderbilt Univ, Med Ctr, Dept Med, Div Pulm,Allergy,Crit Care Med, Nashville, TN USA.
RP Kulkarni, T (reprint author), 1900 Univ Blvd,THT 541D, Birmingham, AL 35294 USA.
EM tkulkarni@uabmc.edu
OI Kurundkar, Ashish/0000-0001-9078-1039
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P01 HL114470, R01
   AG046210]; VA Merit AwardUS Department of Veteran Affairs [I01BX003056]
FX This study was funded by National Institutes of Health grants, P01
   HL114470 and R01 AG046210 (VJT), and VA Merit Award I01BX003056 (VJT)
CR Du J, 2014, AM J PHYSIOL-CELL PH, V306, pC28, DOI 10.1152/ajpcell.00066.2013
   Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182
   Horowitz JC, 2019, PHYSIOLOGY, V34, P43, DOI 10.1152/physiol.00033.2018
   Jun JI, 2010, AGING-US, V2, P627, DOI 10.18632/aging.100201
   Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070
   Kim KH, 2018, J CELL COMMUN SIGNAL, V12, P273, DOI 10.1007/s12079-018-0450-x
   Kurundkar AR, 2016, FASEB J, V30, P2135, DOI 10.1096/fj.201500173
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532
   Thannickal VJ, 2015, AM J RESP CRIT CARE, V191, P261, DOI 10.1164/rccm.201410-1876PP
   Thannickal VJ, 2013, BIOGERONTOLOGY, V14, P609, DOI 10.1007/s10522-013-9451-6
NR 11
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105821
DI 10.1016/j.rmed.2019.105821
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400022
PM 31765873
DA 2020-05-18
ER

PT J
AU Liu, BC
   Huang, TX
   Yang, D
   Yang, L
   Liu, CT
AF Liu, Bi-cui
   Huang, Ting-xuan
   Yang, Dan
   Yang, Ling
   Liu, Chun-Tao
TI Asthma-associated bronchiectasis: More attention needed!
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Asthma; Bronchiectasis; BMI; Exacerbation; Lung function
C1 [Liu, Bi-cui; Huang, Ting-xuan; Yang, Dan; Yang, Ling; Liu, Chun-Tao] Sichuan Univ, West China Sch Med, Dept Resp & Crit Care Med, Chengdu 610041, Peoples R China.
   [Liu, Bi-cui; Huang, Ting-xuan; Yang, Dan; Yang, Ling; Liu, Chun-Tao] Sichuan Univ, West China Hosp, Chengdu 610041, Peoples R China.
   [Liu, Bi-cui] Bishan Hosp Chongqing, Resp Dept, Chongqing, Peoples R China.
RP Liu, CT (reprint author), Sichuan Univ, West China Sch Med, Dept Resp & Crit Care Med, Chengdu 610041, Peoples R China.; Liu, CT (reprint author), Sichuan Univ, West China Hosp, Chengdu 610041, Peoples R China.
EM taosen666999@163.com
CR Mantyla J, 2019, RESP MED, V152, P105, DOI 10.1016/j.rmed.2019.04.022
   Perez-Miranda J, 2019, CURR OPIN PULM MED, V25, P71, DOI 10.1097/MCP.0000000000000542
NR 2
TC 0
Z9 0
U1 3
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105789
DI 10.1016/j.rmed.2019.09.009
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400002
PM 31561926
OA Bronze
DA 2020-05-18
ER

PT J
AU Mahler, DA
AF Mahler, Donald A.
TI The role of inspiratory flow in selection and use of inhaled therapy for
   patients with chronic obstructive pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Chronic obstructive pulmonary disease; Hand-held inhalers; Inhalation
   technique; Inspiratory flow; Peak inspiratory flow
ID DRY POWDER INHALER; SOFT MIST(TM) INHALER; LUNG DEPOSITION; COPD;
   INHALATION; DELIVERY; ASTHMA; BRONCHODILATOR; TURBUHALER(R);
   PERSPECTIVES
AB Inhalation therapy is the mainstay of chronic obstructive pulmonary disease management, and inhaler selection can have a profound impact on drug delivery and medication adherence, as well as on treatment outcomes. Although multiple delivery systems, such as pressurized metered-dose inhalers, dry powder inhalers, slow-mist inhalers, and nebulizers, are available, clinical benefits achieved by patients rely on effective delivery of the inhaled medication to the airways. Among several factors influencing drug deposition, inspiratory flow is one of the most important. Inspiratory flow impacts drug delivery and subsequent clinical efficacy, making it necessary to adequately train patients to ensure correct inhaler use. Peak inspiratory flow is the maximal airflow generated during a forced inspiratory maneuver. Health care professionals need to select the appropriate delivery system after carefully considering patient characteristics, including lung function, optimal inspiratory flow, manual dexterity, and cognitive function. Herein, the role of inspiratory flow in the selection and use of inhaled therapy in patients with COPD is reviewed.
C1 [Mahler, Donald A.] Geisel Sch Med Dartmouth, Med, One Rope Ferry Rd, Hanover, NH 03755 USA.
   [Mahler, Donald A.] Valley Reg Hosp, Kane Ctr, 243 Elm St, Claremont, NH 03743 USA.
RP Mahler, DA (reprint author), Geisel Sch Med Dartmouth, Med, One Rope Ferry Rd, Hanover, NH 03755 USA.; Mahler, DA (reprint author), Valley Reg Hosp, Kane Ctr, 243 Elm St, Claremont, NH 03743 USA.
EM mahlerdonald@gmail.com
FU Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim
FX This work was funded by Boehringer Ingelheim Pharmaceuticals, Inc.
CR Al-Showair RAM, 2007, RESP MED, V101, P2395, DOI 10.1016/j.rmed.2007.06.008
   Ammari WG, 2017, PULM PHARMACOL THER, V43, P46, DOI 10.1016/j.pupt.2017.02.002
   [Anonymous], 2018, SPIR RESP
   Atkins Paul J, 2005, Respir Care, V50, P1304
   Azouz W, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0043-x
   Azouz W, 2014, J AEROSOL MED PULM D, V27, P193, DOI 10.1089/jamp.2012.1031
   Bellemare F, 2003, AM J RESP CRIT CARE, V168, P305, DOI 10.1164/rccm.200208-876OC
   Biswas R, 2017, J AEROSOL MED PULM D, V30, P256, DOI 10.1089/jamp.2015.1278
   Bonini M, 2015, COPD RES PRACT, V1, P9, DOI DOI 10.1186/S40749-015-0011-0
   BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069
   Brand P., 2007, PULM, V61, pA1
   Brand Peter, 2008, Int J Chron Obstruct Pulmon Dis, V3, P763
   Broeders Marielle E A C, 2009, Prim Care Respir J, V18, P76, DOI 10.4104/pcrj.2009.00025
   Broeders MEAC, 2004, RESP MED, V98, P1173, DOI 10.1016/j.rmed.2004.04.010
   Capstick TGD, 2012, EXPERT REV RESP MED, V6, P91, DOI [10.1586/ers.11.89, 10.1586/ERS.11.89]
   Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304
   Chapman KR, 2005, EUR RESPIR REV, V14, P117, DOI 10.1183/09059180.05.00009607
   Chodosh S, 2001, J AEROSOL MED, V14, P309, DOI 10.1089/089426801316970268
   Chrystyn H, 2012, INT J CLIN PRACT, V66, P309, DOI 10.1111/j.1742-1241.2011.02832.x
   Chrystyn Henry, 2009, Prim Care Respir J, V18, P243, DOI 10.4104/pcrj.2009.00029
   Dal Negro RW, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0012-5
   Dalby RN, 2011, MED DEVICES-EVID RES, V4, P145, DOI 10.2147/MDER.S7409
   Dekhuijzen PNR, 2016, PATIENT PREFER ADHER, V10, P1561, DOI 10.2147/PPA.S82857
   Dhand R, 2017, RESP CARE, V62, P978, DOI 10.4187/respcare.05624
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   Duarte AG, 2019, CHRON OBSTR PULM DIS, V6, P246, DOI 10.15326/jcopdf.6.3.2018.0163
   Everard ML, 1997, RESP MED, V91, P624, DOI 10.1016/S0954-6111(97)90009-3
   Ghosh S, 2017, J AEROSOL MED PULM D, V30, P381, DOI 10.1089/jamp.2017.1416
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), GLOB STRAT DIAGN MAN
   Grant AC, 2015, J AEROSOL MED PULM D, V28, P474, DOI 10.1089/jamp.2015.1223
   Haidl P, 2016, RESP MED, V118, P65, DOI 10.1016/j.rmed.2016.07.013
   Hanania NA, 2018, CHRON OBSTR PULM DIS, V5, P111, DOI 10.15326/jcopdf.5.2.2017.0168
   Hill LS, 1998, RESP MED, V92, P105, DOI 10.1016/S0954-6111(98)90040-3
   Hira D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193082
   Hochrainer D, 2005, J AEROSOL MED, V18, P273, DOI 10.1089/jam.2005.18.273
   Jameson JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMsb1503104
   Janssens W, 2008, EUR RESPIR J, V31, P78, DOI 10.1183/09031936.00024807
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Lavorini F, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0092-5
   Leach C, 1999, J ALLERGY CLIN IMMUN, V104, pS250, DOI 10.1016/S0091-6749(99)70041-2
   Loh CH, 2017, ANN AM THORAC SOC, V14, P1305, DOI 10.1513/AnnalsATS.201611-903OC
   Magnussen H, 2009, RESP MED, V103, P1832, DOI 10.1016/j.rmed.2009.07.006
   Mahler D.A., 2017, BREATHE EASY RELIEVI
   Mahler DA, 2019, CHRON OBSTR PULM DIS, V6, P321, DOI 10.15326/jcopdf.6.4.2019.0137
   Mahler DA, 2019, AM J RESP CRIT CARE, V199, P1577, DOI 10.1164/rccm.201901-0005LE
   Mahler DA, 2017, ANN AM THORAC SOC, V14, P1103, DOI 10.1513/AnnalsATS.201702-156PS
   Mahler DA, 2014, J AEROSOL MED PULM D, V27, P103, DOI 10.1089/jamp.2013.1038
   Mahler DA, 2013, J AEROSOL MED PULM D, V26, P174, DOI 10.1089/jamp.2012.0987
   Malmberg L Pekka, 2010, Int J Chron Obstruct Pulmon Dis, V5, P257
   Miravitlles M, 2013, PRIM CARE RESP J, V22, P117, DOI 10.4104/pcrj.2013.00016
   NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3
   O'Donnell DE, 2017, ANN AM THORAC SOC, V14, pS30, DOI 10.1513/AnnalsATS.201610-834FR
   Pauwels R, 1997, EUR RESPIR J, V10, P2127, DOI 10.1183/09031936.97.10092127
   Pavkov R, 2010, CURR MED RES OPIN, V26, P2527, DOI 10.1185/03007995.2010.518916
   Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008
   Sanchis J, 2016, CHEST, V150, P394, DOI 10.1016/j.chest.2016.03.041
   Sanders MJ, 2017, PULM MED, V2017, DOI 10.1155/2017/1495867
   Sharma G, 2006, CLIN INTERV AGING, V1, P253, DOI 10.2147/ciia.2006.1.3.253
   Sharma G, 2017, CHRON OBSTR PULM DIS, V4, P217, DOI 10.15326/jcopdf.4.3.2017.0183
   Stein SW, 2017, J AEROSOL MED PULM D, V30, P20, DOI 10.1089/jamp.2016.1297
   Tarsin W, 2004, J AEROSOL MED, V17, P25, DOI 10.1089/089426804322994433
   Taylor TE, 2018, CHEST, V153, P710, DOI 10.1016/j.chest.2017.08.1162
   Taylor TE, 2015, IEEE ENG MED BIO, P2227, DOI 10.1109/EMBC.2015.7318834
   Usmani OS, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0710-y
   Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC
   Wise RA, 2017, CHRON OBSTR PULM DIS, V4, P7, DOI 10.15326/jcopdf.4.1.2016.0141
   Yokoyama H, 2007, BIOL PHARM BULL, V30, P1167, DOI 10.1248/bpb.30.1167
NR 68
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105857
DI 10.1016/j.rmed.2019.105857
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400021
PM 32056720
DA 2020-05-18
ER

PT J
AU Masarweh, K
   Gur, M
   Leiba, R
   Bar-Yoseph, R
   Toukan, Y
   Nir, V
   Gut, G
   Ben-David, Y
   Hakim, F
   Bentur, L
AF Masarweh, Kamal
   Gur, Michal
   Leiba, Ronit
   Bar-Yoseph, Ronen
   Toukan, Yazeed
   Nir, Vered
   Gut, Guy
   Ben-David, Yael
   Hakim, Fahed
   Bentur, Lea
TI Factors predicting length of stay in bronchiolitis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiolitis; Length of stay; MDClone
ID SYNCYTIAL VIRUS-INFECTION; DISEASE SEVERITY; INTENSIVE-CARE; INFANTS;
   CHILDREN; MORTALITY; RISK; MORBIDITY; MANAGEMENT; IMPACT
AB Introduction: Despite advances in medical knowledge, the treatment of viral bronchiolitis is mainly supportive. Antiviral therapies are being investigated in clinical trials. Identifying population-attributable risk factors for RSV hospitalization may help prioritizing targeted treatment.
   Aim: To utilize MDClone, a data acquisition tool, to examine factors associated with the risk of hospitalization and length of stay (LOS) in bronchiolitis.
   Methods: A single tertiary medical center retrospective study. Infants discharged with a diagnosis of bronchiolitis between January 2001 and March 2019 were included. Demographic, clinical, laboratory, microbiologic parameters and co-morbidities were collected. Correlations with the risk of hospitalization and LOS were examined.
   Results: A total of 4793 infants with bronchiolitis, 3851 (80.3%) previously healthy, were seen; 975 visited emergency room only; 3311 were hospitalized in pediatric wards and 507 required pediatric intensive care unit. O-2 saturation, age and fever correlated with the risk of hospitalization (OR = 0.703, p < 0.0001, OR = 0.4, p = 0.024 and OR = 2.388, p < 0.0001, respectively). Saturation, fever, gestational age and birth weight correlated with LOS (r = -0.283, p = 0.000; r = 0.16, p = 0.000; r = -0.12, p = 0.00; and r = -0.117, p = 0.00, respectively). Rates of hospitalization were higher (81.1% vs. 75.6%, p = 0.0008) and LOS was longer (median 2.97 vs. 2.73 days, p < 0.001) in Arabs than in Jews. In a multivariate model, saturation, fever, gestational age and age predicted LOS. Saturation and ethnicity predicted LOS for previously healthy infants. Prematurity and cardiac anomalies increased LOS (p = 0.016 and p < 0.0001, respectively).
   Conclusions: Population-based data may enable predicting disease severity and LOS in bronchiolitis. Focusing on children at greatest risk may aid targeting new therapies.
C1 [Masarweh, Kamal; Gur, Michal; Bar-Yoseph, Ronen; Toukan, Yazeed; Nir, Vered; Gut, Guy; Ben-David, Yael; Hakim, Fahed; Bentur, Lea] Rappaport Childrens Hosp, Pediat Pulm Inst, Rambam Hlth Care Campus, POB 9602, IL-3109601 Haifa, Israel.
   [Masarweh, Kamal; Gur, Michal; Bar-Yoseph, Ronen; Toukan, Yazeed; Nir, Vered; Gut, Guy; Ben-David, Yael; Hakim, Fahed; Bentur, Lea] Rappaport Childrens Hosp, CF Ctr, Rambam Hlth Care Campus, Haifa, Israel.
   [Gur, Michal; Toukan, Yazeed; Hakim, Fahed; Bentur, Lea] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Leiba, Ronit] Rambam Hlth Care Campus, Med Stat Unit, Haifa, Israel.
RP Bentur, L (reprint author), Rappaport Childrens Hosp, Pediat Pulm Inst, Rambam Hlth Care Campus, POB 9602, IL-3109601 Haifa, Israel.
EM l_bentur@rambam.health.gov.il
OI Masarweh, Kamal/0000-0003-0310-1512
CR Rodriguez DA, 2014, PEDIATR PULM, V49, P269, DOI 10.1002/ppul.22781
   Baron-Epel O, 2007, HEALTH SERV RES, V42, P1008, DOI 10.1111/j.1475-6773.2006.00645.x
   Brand HK, 2012, PEDIATR PULM, V47, P393, DOI 10.1002/ppul.21552
   Bush A, 2007, BMJ-BRIT MED J, V335, P1037, DOI 10.1136/bmj.39374.600081.AD
   Chatzimichael A, 2007, Minerva Pediatr, V59, P199
   Checchia PA, 2017, INFECT DIS THER, V6, P37, DOI 10.1007/s40121-016-0142-x
   Costa S, 2009, REV PORT PNEUMOL, V15, P55
   DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006
   Figueras-Aloy J, 2016, INFECT DIS THER, V5, P417, DOI 10.1007/s40121-016-0130-1
   Ghazaly M, 2018, EUR J PEDIATR, V177, P913, DOI 10.1007/s00431-018-3138-6
   Gorelik Y, 2019, INVEST RADIOL, V54, P312, DOI 10.1097/RLI.0000000000000534
   Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211
   Hasegawa Kohei, 2015, Hosp Pediatr, V5, P385, DOI 10.1542/hpeds.2015-0022
   Kassem E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214197
   Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669
   Marlais M, 2011, ARCH DIS CHILD, V96, P648, DOI 10.1136/adc.2010.201079
   Mazur N, 2015, LANCET RESP MED, V3, P888, DOI 10.1016/S2213-2600(15)00255-6
   MEERT K, 1990, CRIT CARE MED, V18, P1357, DOI 10.1097/00003246-199012000-00009
   Ramos-Fernandez JM, 2017, AN PEDIATR, V87, P260, DOI 10.1016/j.anpedi.2016.10.002
   Moler FW, 1999, AM J RESP CRIT CARE, V159, P1234, DOI 10.1164/ajrccm.159.4.9807075
   National Insurance Institute of Israel, 2014, POV SOC GAPS REP PUB
   Paes B, 2016, INFECT DIS THER, V5, P453, DOI 10.1007/s40121-016-0137-7
   Papoff P, 2011, ACTA PAEDIATR, V100, pe17, DOI 10.1111/j.1651-2227.2011.02181.x
   Ricart S, 2013, PEDIATR PULM, V48, P456, DOI 10.1002/ppul.22633
   Richard N, 2008, PEDIATR INFECT DIS J, V27, P213, DOI 10.1097/INF.0b013e31815b4935
   Rodriguez-Martinez CE, 2018, J INVEST MED, V66, P986, DOI 10.1136/jim-2018-000708
   Schroeder AR, 2004, ARCH PEDIAT ADOL MED, V158, P527, DOI 10.1001/archpedi.158.6.527
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Slain KN, 2018, CLIN PEDIATR, V57, P1027, DOI 10.1177/0009922817740666
   Tsugawa Y., 2013, TRENDS BRONCHIOLITIS, V8530, P28, DOI [10.1542/ peds.2012-3877, DOI 10.1542/PEDS.2012-3877]
   Wang EEL, 1996, J PEDIATR-US, V129, P390, DOI 10.1016/S0022-3476(96)70071-9
   Weisgerber MC, 2011, J HOSP MED, V6, P264, DOI 10.1002/jhm.903
   Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092
NR 33
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105824
DI 10.1016/j.rmed.2019.105824
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400009
PM 31759271
OA Bronze
DA 2020-05-18
ER

PT J
AU Massierer, D
   Alsowayan, W
   Lima, VP
   Bourbeau, J
   Janaudis-Ferreira, T
AF Massierer, Daniela
   Alsowayan, Waleed
   Lima, Vanessa Pereira
   Bourbeau, Jean
   Janaudis-Ferreira, Tania
TI Prognostic value of simple measures of physical function and muscle
   strength in COPD: A systematic review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Chronic obstructive pulmonary disease; Physical function; Muscle
   strength; Systematic review
ID OBSTRUCTIVE PULMONARY-DISEASE; PERFORMANCE TESTS; HANDGRIP STRENGTH;
   MORTALITY; PREDICTORS; DISABILITY; OUTCOMES; QUALITY
AB Purpose: There has been an increased interest in simple measures of physical function and muscle strength that can be used in all clinical settings to assess individuals with chronic obstructive pulmonary disease (COPD) and predict their prognosis. The main objective was to examine the prognostic value of simple measures of physical function and muscle strength in relation to exacerbation, hospitalization and mortality in individuals with COPD.
   Methods: Medline, EMBASE, Cochrane and Web of Science were searched. We included prospective observational studies that examined the prognostic value of simple performed-based tests or self-reported measures of physical function or muscle strength in relation to exacerbation, hospitalization and mortality in individuals with COPD.
   Results: Seven articles met the inclusion criteria. The most commonly used tests were the handgrip strength (HGS) (n = 4) and 1-min sit-to-stand (STS) (n = 2). There were considerable variations in terms of characteristics of patients included, setting of recruitment, type of tests used, duration of follow-up and outcome measures of interest. The majority of the studies were classified as having "fair" or "poor" methodological quality.
   Conclusions: There is a limited number of studies examining the prognostic value of simple measures of physical function and muscle strength in relation to exacerbations, hospitalizations and mortality in individuals with COPD. To date, the HGS and 1-min STS tests are the most studied tests and seem to be suitable for prognosis purposes in individuals with COPD. However, more studies with better methodological quality are needed to confirm these findings.
C1 [Massierer, Daniela] McGill Univ, Sch Phys & Occupat Therapy, 3654 Prom Sir William Osler,Hosmer House,Room 200, Montreal, PQ H3G 1Y5, Canada.
   [Alsowayan, Waleed] McGill Univ, Hlth Ctr, Resp Div, 1001 Decarie Blvd, Montreal, PQ H4A 3J, Canada.
   [Lima, Vanessa Pereira] Univ Fed Vales Jequitinhonha & Mucuri, Dept Phys Therapy, Campus JK,Rodovia MGT 367,Km 583,5000, BR-39100000 Diamantina, MG, Brazil.
   [Bourbeau, Jean; Janaudis-Ferreira, Tania] McGill Univ, Hlth Ctr, RECRU, 5252 Boul Maisonneuve Ouest, Montreal, PQ H4A 3S5, Canada.
   [Massierer, Daniela; Bourbeau, Jean; Janaudis-Ferreira, Tania] McGill Univ, Hlth Ctr, Res Inst, Translat Res Resp Dis Program, 1001 Decarie Blvd,Block E, Montreal, PQ H4A 3J1, Canada.
   [Massierer, Daniela; Janaudis-Ferreira, Tania] McGill Univ, Hlth Ctr, Res Inst, Ctr Hlth Outcomes Res & Evaluat CORE, 5252 Boul Maisonneuve Ouest,Room 3E-01, Montreal, PQ H4A 3S5, Canada.
RP Janaudis-Ferreira, T (reprint author), 3630 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada.
EM tania.janaudis-ferreira@mcgill.ca
CR Bisca GW, 2015, ARCH PHYS MED REHAB, V96, P2221, DOI 10.1016/j.apmr.2015.07.017
   Brummel NE, 2017, AM J RESP CRIT CARE, V196, P64, DOI 10.1164/rccm.201605-0939OC
   Bui KL, 2017, ANN AM THORAC SOC, V14, P785, DOI 10.1513/AnnalsATS.201609-734AS
   Bui KL, 2017, ANN AM THORAC SOC, V14, P778, DOI 10.1513/AnnalsATS.201609-733AS
   Celli BR, 2010, RESP MED, V104, P773, DOI 10.1016/j.rmed.2009.12.017
   Crook S, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0598-6
   De Buyser SL, 2013, EUR J CLIN INVEST, V43, P379, DOI 10.1111/eci.12056
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dunlay SM, 2015, CIRC-HEART FAIL, V8, P261, DOI 10.1161/CIRCHEARTFAILURE.114.001542
   Eisner MD, 2008, AM J MED, V121, P789, DOI 10.1016/j.amjmed.2008.04.030
   Eisner MD, 2011, THORAX, V66, P108, DOI 10.1136/thx.2010.137661
   Habraken JM, 2011, EUR RESPIR J, V37, P280, DOI 10.1183/09031936.00149309
   Holland AE, 2014, EUR RESPIR J, V44, P1428, DOI 10.1183/09031936.00150314
   Johnston KN, 2017, PHYS THER, V97, P926, DOI 10.1093/ptj/pzx063
   Maltais F, 2014, AM J RESP CRIT CARE, V189, P1121, DOI 10.1164/rccrn.201402-0373ST
   Martinez CH, 2017, ANN AM THORAC SOC, V14, P1638, DOI 10.1513/AnnalsATS.201610-821OC
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Puhan MA, 2013, EUR RESPIR J, V42, P956, DOI 10.1183/09031936.00131612
   Ramos LR, 2001, J AM GERIATR SOC, V49, P1168, DOI 10.1046/j.1532-5415.2001.49233.x
   Spruit MA, 2013, J AM MED DIR ASSOC, V14, DOI 10.1016/j.jamda.2013.06.013
   Strassmann A, 2013, INT J PUBLIC HEALTH, V58, P949, DOI 10.1007/s00038-013-0504-z
   Swallow EB, 2007, THORAX, V62, P115, DOI 10.1136/thx.2006.062026
   Vaidya T, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S115439
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wang YC, 2018, J ORTHOP SPORT PHYS, V48, P685, DOI 10.2519/jospt.2018.7851
   *WHO, 2002, COMM LANG FUNCT DIS, P56303
   Wong S.L., 2016, HLTH REP, V27, P3
   Yohannes AM, 2005, AGE AGEING, V34, P491, DOI 10.1093/ageing/afi163
   Yohannes AM, 2002, AGE AGEING, V31, P137, DOI 10.1093/ageing/31.2.137
NR 29
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105856
DI 10.1016/j.rmed.2019.105856
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400016
PM 32056729
OA Bronze
DA 2020-05-18
ER

PT J
AU Meys, R
   Sillen, MJ
   Franssen, FME
   Stoffels, AAF
   Wouters, EFM
   van Hees, HWH
   van den Borst, B
   Klijn, PH
   Spruit, MA
AF Meys, Roy
   Sillen, Maurice J.
   Franssen, Frits M. E.
   Stoffels, Anouk A. F.
   Wouters, Emiel F. M.
   van Hees, Hieronymus W. H.
   van den Borst, Bram
   Klijn, Peter H.
   Spruit, Martijn A.
CA BASES-consortium
TI Impact of mild-to-moderate exacerbations on outcomes of neuromuscular
   electrical stimulation (NMES) in patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Neuromuscular electrical stimulation; Chronic obstructive pulmonary
   disease; Exacerbation; Pulmonary rehabilitation
ID DYSPNEIC INDIVIDUALS; MUSCLE FUNCTION; PULMONARY; REHABILITATION;
   DETERIORATION; MEN
AB Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common among patients attending pulmonary rehabilitation (PR) and may compromise its outcomes. Neuromuscular electrical stimulation (NMES) seems one of the few exercise modalities that can actually be continued during AECOPD, due to its low burden on the impaired respiratory and cardiovascular system. However, the quality of evidence is low. The purpose of this study was to assess the impact of mild-to-moderate AECOPD on adherence/outcomes of a high-frequency (HF) or low-frequency (LF) NMES training program, as part of inpatient PR, in severely dyspneic, weakened individuals with COPD. 62 patients who received NMES as the sole supervised muscle training modality during an 8-week PR program (HF-NMES: n = 33; LF-NMES: n = 29) were analyzed retrospectively. 48.4% experienced >= 1 AECOPD during PR and were classified as exacerbators. Exacerbators completed 75 NMES sessions (interquartile range: 73-78) and were able to increase training intensity with 24 mA (15-39), while non-exacerbators completed 76 sessions (73-79) and increased training intensity with 35 mA (22-50), with no between-group differences (p = 0.474 and p = 0.065, respectively). The median change in 6-min walking distance, cycle endurance time, and isokinetic quadriceps strength and endurance did not differ between the exacerbation and non-exacerbation group. To conclude, the occurrence of mild-to-moderate AECOPD during a PR program primarily focused on NMES, does not affect adherence, intensity, and clinical outcomes in patients with severe COPD. Continuing NMES seems a feasible way to potentially counteract exacerbation-related lower-limb muscle dysfunction and improve outcomes of PR, with HF-NMES being the preferential muscle training modality.
C1 [Meys, Roy; Franssen, Frits M. E.; Stoffels, Anouk A. F.; Wouters, Emiel F. M.; Spruit, Martijn A.] CIRO, Dept Res & Dev, NL-6085 NM Horn, Netherlands.
   [Sillen, Maurice J.] CIRO, Dept Physiotherapy, Horn, Netherlands.
   [Franssen, Frits M. E.; Wouters, Emiel F. M.; Spruit, Martijn A.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Resp Med, Med Ctr, Maastricht, Netherlands.
   [Stoffels, Anouk A. F.; van Hees, Hieronymus W. H.; van den Borst, Bram] Radboud UMC Dekkerswald, Dept Pulm Dis, Nijmegen, Netherlands.
   [Stoffels, Anouk A. F.; Klijn, Peter H.] Merem Pulm Rehabil Ctr, Dept Pulmonol, Hilversum, Netherlands.
   [Klijn, Peter H.] Amsterdam UMC, Dept Pulm Med, Amsterdam, Netherlands.
   [Spruit, Martijn A.] Hasselt Univ, Fac Rehabil Sci, Biomed Res Inst, Reval Rehabil Res, Diepenbeek, Belgium.
RP Meys, R (reprint author), CIRO, Dept Res & Dev, NL-6085 NM Horn, Netherlands.
EM roymeys@ciro-horn.nl
OI Meys, Roy/0000-0002-4855-530X
FU Lung Foundation Netherlands [3.4.09.024]; Weijerhorst Foundation
   Netherlands
FX The BASES project is supported by the Lung Foundation Netherlands
   (#5.1.18.232). The DICES trial was supported by the Lung Foundation
   Netherlands (#3.4.09.024) and the Weijerhorst Foundation Netherlands.
CR Abdellaoui A, 2011, EUR RESPIR J, V38, P781, DOI 10.1183/09031936.00167110
   Abdulai RM, 2018, AM J RESP CRIT CARE, V197, P433, DOI 10.1164/rccm.201703-0615CI
   BORGES O, 1989, SCAND J REHABIL MED, V21, P45
   Braeken DCW, 2017, RESPIROLOGY, V22, P942, DOI 10.1111/resp.12987
   Burtin C, 2011, EUR RESPIR J, V38, P702, DOI 10.1183/09031936.00079111
   Franssen FME, 2005, MED SCI SPORT EXER, V37, P2, DOI 10.1249/01.MSS.0000150082.59155.4F
   Giavedoni S, 2012, RESP MED, V106, P1429, DOI 10.1016/j.rmed.2012.05.005
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), GLOB STRAT DIAGN MAN
   Holland AE, 2015, BREATHE, V11, P129, DOI 10.1183/20734735.021314
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Maltais F, 1997, AM J RESP CRIT CARE, V155, P555, DOI 10.1164/ajrccm.155.2.9032194
   Moon JR, 2013, EUR J CLIN NUTR, V67, pS40, DOI 10.1038/ejcn.2012.163
   Neder JA, 2002, THORAX, V57, P333, DOI 10.1136/thorax.57.4.333
   Pitta F, 2006, CHEST, V129, P536, DOI 10.1378/chest.129.3.536
   Puhan MA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005305.pub4
   Sillen MJH, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-146
   Sillen MJH, 2014, THORAX, V69, P525, DOI 10.1136/thoraxjnl-2013-204388
   Sillen MJH, 2013, RESP MED, V107, P1186, DOI 10.1016/j.rmed.2013.04.020
   Sillen MJH, 2011, LUNG, V189, P21, DOI 10.1007/s00408-010-9265-0
   Spruit MA, 2003, THORAX, V58, P752, DOI 10.1136/thorax.58.9.752
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Steele BG, 2010, J CARDIOPULM REHABIL, V30, P53, DOI 10.1097/HCR.0b013e3181c85845
   van 't Hul Alex, 2003, J Cardiopulm Rehabil, V23, P143, DOI 10.1097/00008483-200303000-00012
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053
NR 24
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105851
DI 10.1016/j.rmed.2019.105851
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400010
PM 32056725
OA Bronze
DA 2020-05-18
ER

PT J
AU Parekh, TM
   Bhatia, S
   Cherrington, A
   Kim, YI
   Lambert, A
   Iyer, A
   Regan, EA
   DeMeo, DL
   Han, ML
   Dransfield, MT
AF Parekh, Trisha M.
   Bhatia, Smita
   Cherrington, Andrea
   Kim, Young-Il
   Lambert, Allison
   Iyer, Anand
   Regan, Elizabeth A.
   DeMeo, Dawn L.
   Han, MeiLan
   Dransfield, Mark T.
TI Factors influencing decline in quality of life in smokers without
   airflow obstruction: The COPDGene study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE PRISM; Quality of life; Smoker
ID HEALTH-STATUS; PULMONARY-DISEASE; LUNG-DISEASE; EXACERBATIONS; IMPACT;
   DETERIORATION; SYMPTOMS; SMOKING
AB Introduction: Current and former smokers with normal spirometry and with Preserved Ratio Impaired Spirometry (PRISm) experience respiratory events similar to chronic obstructive pulmonary disease (COPD) exacerbations. Exacerbations significantly reduce quality of life (QoL) in COPD patients however the effect of respiratory exacerbations on QoL in these groups is unknown. We hypothesized that exacerbations and change in exacerbation status would predict QoL decline among normal spirometry and PRISm participants in COPDGene.
   Methods: COPDGene is a multicenter, longitudinal study in the U.S. designed to identify genetic determinants of COPD. We enrolled study subjects in Phase 1 of COPDGene and performed multivariable logistic regression models to determine independent predictors of decline in quality of life [>4 points on the St George's Respiratory Questionnaire (SGRQ)]. Separate analyses were performed for current and former smokers with normal spirometry and PRISm. Frequent exacerbator status was defined by > 2 moderate or >1 severe exacerbations in the year prior to the baseline and year 5 follow-up visits.
   Results: Independent predictors of QoL deterioration included current smoking, higher exacerbation frequency, and a change from infrequent to frequent exacerbation status (REF: infrequent to infrequent exacerbation status) in both groups [PRISm (OR = 3.15,95%CI, 1.67-5.94), normal spirometry (OR = 4.72,95%CI, 3.25-6.86)]. A change from frequent to infrequent exacerbation status did not lower the odds of QoL decline in either cohort.
   Conclusion: Continued smoking and the onset of frequent exacerbations were predictors of QoL decline in smokers with normal spirometry and PRISm. Further studies are needed to identify modifiable factors associated with decline in QoL in smokers.
C1 [Parekh, Trisha M.; Kim, Young-Il; Iyer, Anand; Dransfield, Mark T.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA.
   [Bhatia, Smita] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Birmingham, AL USA.
   [Cherrington, Andrea] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
   [Lambert, Allison] Univ Washington, Div Pulm Crit Care & Sleep Med, Spokane, WA USA.
   [Regan, Elizabeth A.] Natl Jewish Hlth, Dept Med, Denver, CO USA.
   [DeMeo, Dawn L.] Harvard Med Sch, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Han, MeiLan] Univ Michigan, Div Pulm Allergy & Crit Care, Ann Arbor, MI 48109 USA.
   [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Parekh, TM (reprint author), 1900 Univ Blvd,THT 422-433, Birmingham, AL 35294 USA.
EM trishaparekh@uabmc.edu
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [5T32HL105346-07, U01
   HL089897, U01 HL089856]; UAB Patient Centered Outcomes Research K12 from
   the Agency for Healthcare Research and Quality [HS023009]
FX TMP is supported by the 5T32HL105346-07 grant from the National Heart,
   Lung, and Blood Institute. ASI has received support from a UAB Patient
   Centered Outcomes Research K12 (HS023009) from the Agency for Healthcare
   Research and Quality. The project described was supported by Award
   Number U01 HL089897 and Award Number U01 HL089856 from the National
   Heart, Lung, and Blood Institute. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Heart, Lung, and Blood Institute or the
   National Institutes of Health.
CR [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   [Anonymous], 2019, THE BELM REP
   Barile JP, 2013, QUAL LIFE RES, V22, P1201, DOI 10.1007/s11136-012-0246-z
   Blakemore A, 2014, INT J CHRONIC OBSTR, V9, P501, DOI 10.2147/COPD.S58136
   Booth CM, 2014, BRIT J CANCER, V110, P551, DOI 10.1038/bjc.2013.725
   Bowler RP, 2014, CHEST, V146, P941, DOI 10.1378/chest.13-2946
   Corlateanu A, 2016, RESPIRATION, V92, P229, DOI 10.1159/000448625
   Danesh D, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140053
   Dransfield MT, 2017, AM J RESP CRIT CARE, V195, P324, DOI 10.1164/rccm.201605-1014OC
   Esteban C, 2009, RESP MED, V103, P1201, DOI 10.1016/j.rmed.2009.02.002
   Goldenberg M, 2014, AM J ADDICTION, V23, P540, DOI 10.1111/j.1521-0391.2014.12148.x
   Guerra S, 2010, THORAX, V65, P499, DOI 10.1136/thx.2009.126052
   Han MK, 2011, CHEST, V140, P1169, DOI 10.1378/chest.10-2869
   Hays JT, 2012, EUR J PUBLIC HEALTH, V22, P224, DOI 10.1093/eurpub/ckq137
   Jia HM, 2013, QUAL LIFE RES, V22, P27, DOI 10.1007/s11136-012-0118-6
   Jones Paul W, 2005, COPD, V2, P75
   Jones PW, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-71
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702
   MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580
   Mama SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154035
   Mannino DM, 2003, J INTERN MED, V254, P540, DOI 10.1111/j.1365-2796.2003.01211.x
   Martin AL, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0356-1
   Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730
   Naberan K, 2012, RESP MED, V106, P367, DOI 10.1016/j.rmed.2011.09.014
   Putcha N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114438
   Raherison C, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-31
   Regan EA, 2015, JAMA INTERN MED, V175, P1539, DOI 10.1001/jamainternmed.2015.2735
   Regan EA, 2010, COPD, V7, P32, DOI 10.3109/15412550903499522
   Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032
   Sheehan AE, 2018, J PSYCHIATR RES, V107, P114, DOI 10.1016/j.jpsychires.2018.10.019
   Spencer S, 2004, EUR RESPIR J, V23, P698, DOI 10.1183/09031936.04.00121404
   Spencer S, 2001, AM J RESP CRIT CARE, V163, P122, DOI 10.1164/ajrccm.163.1.2005009
   Tan WC, 2014, THORAX, V69, P709, DOI 10.1136/thoraxjnl-2013-205048
   Tomioka H, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000047
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Wan E.S., 2018, AM J RESP CRIT CARE, V198
   Wan ES, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0089-y
   Wan ES, 2011, AM J RESP CRIT CARE, V184, P57, DOI 10.1164/rccm.201101-0021OC
   Wilke S, 2015, THORAX, V70, P420, DOI 10.1136/thoraxjnl-2014-205697
   WMA, 2019, WORLD MED ASS WMA DE
   Woodruff PG, 2016, NEW ENGL J MED, V374, P1811, DOI 10.1056/NEJMoa1505971
   Yoo JY, 2016, INT J TUBERC LUNG D, V20, P738, DOI 10.5588/ijtld.15.0504
NR 43
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105820
DI 10.1016/j.rmed.2019.105820
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400008
PM 31759270
OA Bronze
DA 2020-05-18
ER

PT J
AU Piubello, A
   Souleymane, MB
   Hassane-Harouna, S
   Yacouba, A
   Lempens, P
   Assao-Neino, MM
   Maman-Lawan, I
   Attaher, S
   Moustapha, B
   Soumana, A
   Gagara-Issoufou, A
   Ortuno-Gutierrez, N
   Roggi, A
   Gumusboga, M
   Hamidou-Harouna, Z
   Dockx, J
   Mamadou, S
   de Jong, BC
   Decroo, T
   Van Deun, A
AF Piubello, Alberto
   Souleymane, Mahamadou Bassirou
   Hassane-Harouna, Souleymane
   Yacouba, Abdourahamane
   Lempens, Pauline
   Assao-Neino, Mourtala Mohamed
   Maman-Lawan, Ibrahim
   Attaher, Sala
   Moustapha, Boubacar
   Soumana, Alphazazi
   Gagara-Issoufou, Assiatou
   Ortuno-Gutierrez, Nimer
   Roggi, Alberto
   Gumusboga, Mourad
   Hamidou-Harouna, Zelika
   Dockx, Jeroen
   Mamadou, Saidou
   de Jong, Bouke C.
   Decroo, Tom
   Van Deun, Armand
TI Management of multidrug-resistant tuberculosis with shorter treatment
   regimen in Niger: Nationwide programmatic achievements
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Multidrug-resistant tuberculosis; Shorter treatment regimen; Niger
ID MYCOBACTERIUM-TUBERCULOSIS; ETHIONAMIDE
AB Background: In Niger, the Shorter Treatment Regimen (STR) has been implemented nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication has shown the results from countrywide programmatic implementation using few exclusion criteria, nor exhaustively assessed the effect of initial resistance to companion drugs on outcomes.
   Methods: The National Tuberculosis Programme and the Damien Foundation conducted a retrospective observational study to evaluate the management of RR-TB from 2008 to 2016. Baseline resistance to drugs was assessed phenotypically, complemented by screening the inhA, katG and pncA genes. Cured patients were followed-up for a period of one year after cure.
   Findings: Among 1044 patients tested for rifampicin resistance, mainly previously treated patients, 332 were diagnosed with pulmonary RR/TB, 288 were enrolled on treatment and 255 started on STR. Six patients received a modified STR.
   Among 249 patients on standardised STR, 207 (83.1%) were cured relapse-free, eight (3.2%) had failure, 23 (9.2%) died, seven (2.8%) were lost to follow-up and four (1.6%) relapsed.
   The risk of unfavourable outcome was higher in patients with initial resistance to fluoroquinolones (aOR 20.4, 95%CI:5.6-74.6) and very severely underweight (aOR 3.9, 95%CI:1.5-10.1). Successful outcome was not affected by initial resistance to companion drugs. Serious ototoxicity was reported in eight patients (3.2%).
   Interpretation: A comprehensive nationwide approach to multidrug-resistant tuberculosis management using the STR was feasible and successful. Outcomes were not affected by initial resistance to companion drugs. Our study confirms the effectiveness and safety of the STR.
C1 [Piubello, Alberto; Souleymane, Mahamadou Bassirou; Hassane-Harouna, Souleymane; Maman-Lawan, Ibrahim] Damien Fdn, Niamey, Niger.
   [Piubello, Alberto; Van Deun, Armand] Int Union TB & Lung Dis, Paris, France.
   [Yacouba, Abdourahamane; Van Deun, Armand] Reg Hosp Agadez, Agadez, Niger.
   [Lempens, Pauline; Gumusboga, Mourad; Dockx, Jeroen; de Jong, Bouke C.; Van Deun, Armand] Inst Trop Med, Dept Biomed Sci, Unit Mycobacteriol, Antwerp, Belgium.
   [Assao-Neino, Mourtala Mohamed; Moustapha, Boubacar] Natl TB Programme, Niamey, Niger.
   [Attaher, Sala] Reg Hosp, Maradi, Niger.
   [Soumana, Alphazazi] Natl Antitb Ctr, Niamey, Niger.
   [Gagara-Issoufou, Assiatou] Univ Hosp Lamorde, Niamey, Niger.
   [Ortuno-Gutierrez, Nimer; Roggi, Alberto] Damien Fdn, Brussels, Belgium.
   [Hamidou-Harouna, Zelika] Natl Reference Lab TB, Niamey, Niger.
   [Mamadou, Saidou] Abdou Moumouni Univ, Niamey, Niger.
   [Decroo, Tom] Inst Trop Med, Dept Clin Sci, Unit HIV & Coinfect, Antwerp, Belgium.
   [Decroo, Tom] Res Fdn Flanders, Brussels, Belgium.
RP Piubello, A (reprint author), Damien Fdn & Int Union Against TB & Lung Dis, BP 1065, Niamey, Niger.
EM apiubello@theunion.org
OI abdourahamane, YACOUBA/0000-0002-0950-2205; Decroo,
   Tom/0000-0002-1205-1484; Piubello, Alberto/0000-0002-6937-3126
FU Damien Foundation, Brussels, Belgium
FX This work was funded by Damien Foundation, Brussels, Belgium. The
   Institute of Tropical Medicine, Antwerp, Belgium, contributed with
   bacteriological investigations.
CR Agence nationale de recherche sur le SIDA et les hepatites virales, 2008, ANRS SCAL GRAD SEV A
   Aung KJM, 2014, INT J TUBERC LUNG D, V18, P1180, DOI 10.5588/ijtld.14.0100
   Brossier F, 2011, ANTIMICROB AGENTS CH, V55, P355, DOI 10.1128/AAC.01030-10
   Global Laboratory Initiative, 2017, GLI PRACT GUID TB LA
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997
   Khan FA, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00061-2017
   Kuaban C, 2015, INT J TUBERC LUNG D, V19, P517, DOI 10.5588/ijtld.14.0535
   Kurbatova EV, 2012, TUBERCULOSIS, V92, P397, DOI 10.1016/j.tube.2012.06.003
   Lai HH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170104
   Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003
   Ngabonziza J.C., 2019, INT J TUBERC LUNG DI
   Nunn AJ, 2019, NEW ENGL J MED, V380, P1201, DOI 10.1056/NEJMoa1811867
   Piubello A, 2014, INT J TUBERC LUNG D, V18, P1188, DOI 10.5588/ijtld.13.0075
   Rigouts L, 2016, J ANTIMICROB CHEMOTH, V71, P314, DOI 10.1093/jac/dkv360
   Schwoebel V, 2019, INT J TUBERC LUNG D, V23, P619, DOI 10.5588/ijtld.18.0798
   Theron G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010705.pub3
   Trebucq A, 2018, INT J TUBERC LUNG D, V22, P17, DOI 10.5588/ijtld.17.0498
   Van Deun A, 2019, INT J TUBERC LUNG D, V23, P965, DOI 10.5588/ijtld.19.0053
   Van Deun A, 2018, INT J TUBERC LUNG D, V22, P239, DOI 10.5588/ijtld.17.0660
   Van Deun A, 2010, AM J RESP CRIT CARE, V182, P684, DOI 10.1164/rccm.201001-0077OC
   World Health Organization, 2011, WHOHTMTB20116
   World Health Organization, WHOCDSTB20193
   World Health Organization, WHOCDSTB201824
   World Health Organization, 2014, DEF REP FRAM TUB 201
   World Health Organization, 2016, WHOHTMTB201604
   World Health Organization, WHOCDSTB201915
   World Health Organization, WHOHTMTB2009422
NR 27
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105844
DI 10.1016/j.rmed.2019.105844
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400011
PM 32056722
OA Bronze
DA 2020-05-18
ER

PT J
AU Proulx, F
   Laberge, S
   Macovoz, N
   Tse, SM
AF Proulx, Frederic
   Laberge, Sophie
   Macovoz, Nicoleta
   Tse, Sze Man
TI Predictive factors for a shortened methacholine challenge protocol in
   children
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pediatrics; Methacholine challenge; Shortened protocol;
   Bronchoprovocation
ID HISTAMINE
AB Rationale: Although the methacholine challenge test is useful in the diagnosis of asthma, it is time-consuming in children. While protocols that quadruple methacholine concentrations are widely used in adults to shorten testing time, this has not been evaluated in children. Studies have not identified predictors associated with the safe use of a quadrupled concentration protocol.
   Objectives: To identify clinical predictors associated with the preclusion of a quadrupled concentration protocol in children.
   Methods: We included subjects <18 years who performed a methacholine challenge tests between April 2016 to February 2017 (derivation cohort) and March 2017 to September 2017 (validation cohort). We determined the eligibility of a subject to omit the 0.5 mg/ml and 2.0 mg/ml concentrations based on their PC20 and identified baseline characteristics that are associated with the preclusion of the quadrupled protocol using bivariate analysis. The derived algorithm was applied to the validation cohort.
   Results: We included 399 and 195 patients in the derivation and validation cohorts, respectively. A baseline FEV1 <= 90% predicted, FEV1/FVC <= 0.8, FEF25-75 <= 70% predicted, and a decrease in FEV1 >= 10% with the previous concentration significantly precluded the omission of the 0.5 mg/ml concentration. A baseline FEF25-75 <= 70% predicted and a drop in FEV1.10% with the previous concentration significantly precluded the omission of the 2.0 mg/ml concentration. Applying these 4 criteria to the validation cohort resulted in an overall sensitivity and specificity of 74.0% and 84.6%, respectively.
   Conclusions: We identified objective pulmonary function measures that may personalize and shorten the methacholine challenge protocol in children by quadrupling concentrations.
C1 [Proulx, Frederic; Laberge, Sophie; Tse, Sze Man] St Justine Univ Hosp Ctr, Dept Pediat Montreal, Div Resp Med, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
   [Proulx, Frederic; Laberge, Sophie; Macovoz, Nicoleta; Tse, Sze Man] Univ Montreal, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
RP Tse, SM (reprint author), St Justine Univ Hosp Ctr, Dept Pediat Montreal, Div Resp Med, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.; Tse, SM (reprint author), Univ Montreal, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM sze.man.tse@umontreal.ca
CR Balfour-Lynn IM, 2002, THORAX, V57, P742, DOI 10.1136/thorax.57.8.742
   Coates AL, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01526-2016
   Coates AL, 2014, J AEROSOL MED PULM D, V27, P66, DOI 10.1089/jamp.2013.1036
   Cockcroft DW, 2015, ANN AM THORAC SOC, V12, P291, DOI 10.1513/AnnalsATS.201501-049ED
   Cockeroft DW, 2001, CHEST, V120, P1857, DOI 10.1378/chest.120.6.1857
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Global Initiative for Asthma (GINA), 2018, GLOB STRAT ASTHM MAN
   Izbicki G, 2001, EUR RESPIR J, V17, P46, DOI 10.1183/09031936.01.17100460
   Jorres RA, 1997, CHEST, V111, P866, DOI 10.1378/chest.111.4.866
   JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705
   Kim YY, 1997, CLIN EXP ALLERGY, V27, P761, DOI 10.1111/j.1365-2222.1997.tb01210.x
   Kivastik J, 2006, PEDIATR PULM, V41, P146, DOI 10.1002/ppul.20341
   Lougheed M Diane, 2012, Can Respir J, V19, pe81
   Lougheed MD, 2010, CAN RESPIR J, V17, P15, DOI 10.1155/2010/827281
   Mazi A, 2014, ANN ALLERG ASTHMA IM, V113, P393, DOI 10.1016/j.anai.2014.06.024
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Proulx F, AM J RESP CRIT CARE, V197, pA3647
   SCHMIDT LE, 1992, CHEST, V101, P141, DOI 10.1378/chest.101.1.141
   SEARS MR, 1986, CHEST, V41, P283
   Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC
NR 20
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105823
DI 10.1016/j.rmed.2019.105823
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400012
PM 31756408
OA Bronze
DA 2020-05-18
ER

PT J
AU Rossides, M
   Kullberg, S
   Eklund, A
   Grunewald, J
   Arkema, EV
AF Rossides, Marios
   Kullberg, Susanna
   Eklund, Anders
   Grunewald, Johan
   Arkema, Elizabeth, V
TI Sarcoidosis diagnosis and treatment in Sweden: A register-based
   assessment of variations by region and calendar period
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Diagnosis; Treatment; Regional patterns; Time trends
AB Background: In Sweden, sarcoidosis prevalence varies geographically, but it is unclear whether diagnosis and treatment patterns vary by geographical area and calendar period. We sought to investigate differences in sarcoidosis diagnosis and treatment by healthcare region and calendar period using nationwide register data.
   Methods: We included 4777 adults who had at least two ICD-coded visits for sarcoidosis in the National Patient Register (2007-2012). We compared patterns of healthcare use (visits and medication dispensations), and data on sarcoidosis diagnosis and treatment spanning two years before to two years after diagnosis stratified by healthcare region and calendar period at diagnosis.
   Results: Compared to other regions, individuals diagnosed in Stockholm were younger, more likely female, and had a higher education level. In all regions, there was an increase in healthcare use at least six months before sarcoidosis diagnosis with small variation among regions. Most patients were diagnosed in pulmonary and internal medicine outpatient clinics, but compared to the national average more patients were diagnosed in rheumatology in the West and ophthalmology and cardiology in the South. Corticosteroid dispensations at diagnosis varied widely by region (48% in the South/Southeast vs. 30% in Stockholm/North). Demographic factors could not explain these differences. We found no differences by calendar period.
   Conclusion: Our findings suggest a six-month delay in sarcoidosis diagnosis irrespective of region. The observed regional variation likely reflects differences in diagnosis and treatment patterns. Stakeholders should ensure diagnosis and treatment recommendations are closely followed.
C1 [Rossides, Marios; Arkema, Elizabeth, V] Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.
   [Kullberg, Susanna; Eklund, Anders; Grunewald, Johan] Karolinska Inst, Dept Med Solna, Resp Med Div, Stockholm, Sweden.
   [Kullberg, Susanna; Eklund, Anders; Grunewald, Johan] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.
   [Kullberg, Susanna; Eklund, Anders; Grunewald, Johan] Karolinska Univ Hosp, Stockholm, Sweden.
   [Kullberg, Susanna; Eklund, Anders; Grunewald, Johan] Karolinska Univ Hosp, Resp Med Theme Inflammat & Infect, Stockholm, Sweden.
RP Rossides, M (reprint author), Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Karolinska Univ Hosp, T2, S-17176 Stockholm, Sweden.
EM marios.rossides@ki.se
RI Kullberg, Susanna/AAF-4057-2020; Rossides, Marios/L-4270-2016
OI Rossides, Marios/0000-0002-9769-324X; Arkema,
   Elizabeth/0000-0002-3677-9736
FU Swedish Heart-Lung Foundation (Hjart-Lungfonden); Swedish Society of
   Medicine (Svenska Lakaresallskapet)
FX This study was supported by funding from the Swedish Heart-Lung
   Foundation (Hjart-Lungfonden). The register linkage used in this study
   was funded by grants from the Swedish Society of Medicine (Svenska
   Lakaresallskapet).
CR [Anonymous], 2014, VARDPR SARK
   [Anonymous], 2014, OPPNA JAMFORELSER FO
   Arkema EV, 2018, THER ADV CHRONIC DIS, V9, P227, DOI 10.1177/2040622318790197
   Arkema EV, 2018, RESP MED, V144, pS7, DOI 10.1016/j.rmed.2018.09.016
   Arkema EV, 2016, EUR RESPIR J, V48, P1690, DOI 10.1183/13993003.00477-2016
   Arkema EV, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4342
   Baughman RP, 2006, QJM-INT J MED, V99, P307, DOI 10.1093/qjmed/hcl038
   Gerke AK, 2014, SARCOIDOSIS VASC DIF, V31, P256
   Gibson GJ, 1996, THORAX, V51, P238, DOI 10.1136/thx.51.3.238
   Grunewald J, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0096-x
   Halsooch sjukvardsrapporten, 2018, HLTH HLTH CAR REP 20
   Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
   Judson MA, 2003, SARCOIDOSIS VASC DIF, V20, P204
   Ma SP, 2019, AM J OPHTHALMOL, V198, P30, DOI 10.1016/j.ajo.2018.09.013
   Mana J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007595
   Martusewicz-Boros MM, 2018, CLIN RESPIR J, V12, P1367, DOI 10.1111/crj.12664
   Mooney J, 2019, ANN AM THORAC SOC, V16, P393, DOI 10.1513/AnnalsATS.201806-376RL
   Neovius M, 2011, SCAND J RHEUMATOL, V40, P8, DOI 10.3109/03009742.2010.493895
   Rossides M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01815-2017
   Selroos O., 2005, STUDENT LIT
   Sikjaer MG, 2019, RESP MED, V152, P7, DOI 10.1016/j.rmed.2019.04.004
   Socialstyrelsen, SOC KVAL INN PAT UTS
   Spagnolo P, 2018, LANCET RESP MED, V6, P389, DOI 10.1016/S2213-2600(18)30064-X
   Statistiska Centralbyran, 2018, KONS
   Statistiska Centralbyran, 2018, BEF
   Thillai M, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000357
NR 26
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105846
DI 10.1016/j.rmed.2019.105846
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400020
PM 32056723
OA Bronze
DA 2020-05-18
ER

PT J
AU Vahdatpour, CA
   Darnell, ML
   Palevsky, HI
AF Vahdatpour, Cyrus A.
   Darnell, Melinda L.
   Palevsky, Harold I.
TI Acute Respiratory Failure in Interstitial Lung Disease Complicated by
   Pulmonary Hypertension
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Pulmonary hypertension; Interstitial lung disease; Acute respiratory
   failure; Critical care
ID RIGHT-VENTRICULAR FAILURE; ARTERIAL-HYPERTENSION; SYSTEMIC-SCLEROSIS;
   MECHANICAL VENTILATION; HEART-FAILURE; CONTEMPORARY MANAGEMENT;
   NONINVASIVE VENTILATION; OXYGEN-THERAPY; WORKING GROUP; FIBROSIS
AB Interstitial lung disease represents a group of diffuse parenchymal lung diseases with overwhelming morbidity and mortality when complicated by acute respiratory failure. Recently, trials investigating outcomes and their determinants have provided insight into these high mortality rates. Pulmonary hypertension is a known complication of interstitial lung disease and there is high prevalence in idiopathic pulmonary fibrosis, connective tissue disease, and sarcoidosis subtypes. Interstitial lung disease associated pulmonary hypertension has further increased mortality with acute respiratory failure, and there is limited evidence to guide management. This review describes investigations and management of interstitial lung disease associated acute respiratory failure complicated by pulmonary hypertension. Despite the emerging attention on interstitial lung disease associated acute respiratory failure and the influence of pulmonary hypertension, critical care management remains a clinical and ethical challenge.
C1 [Vahdatpour, Cyrus A.; Darnell, Melinda L.] Univ Penn Hlth Syst, Penn Hosp, Dept Med, Philadelphia, PA USA.
   [Palevsky, Harold I.] Penn Presbyterian Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA USA.
   [Palevsky, Harold I.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Vahdatpour, CA (reprint author), Penn Hosp, Dept Med, 800 Spruce St, Philadelphia, PA 19107 USA.
EM cyrus.vahdatpour@pennmedicine.upenn.edu
CR Akira M, 1997, AM J ROENTGENOL, V168, P79, DOI 10.2214/ajr.168.1.8976924
   Alajaji W, 2016, INT J CARDIOL, V223, P320, DOI 10.1016/j.ijcard.2016.08.018
   Aliberti S, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-194
   Andersen CU, 2012, RESP MED, V106, P875, DOI 10.1016/j.rmed.2012.02.015
   Antoniou KM, 2014, EUR RESPIR REV, V23, P40, DOI 10.1183/09059180.00009113
   Arcasoy SM, 2003, AM J RESP CRIT CARE, V167, P735, DOI 10.1164/rccm.200210-1130OC
   Awerbach JD, 2019, RESP MED, V150, P126, DOI 10.1016/j.rmed.2019.03.004
   Barratt S, 2014, QJM-INT J MED, V107, P515, DOI 10.1093/qjmed/hcu012
   Bauchmuller K., 2015, INTENSIVE CARE MED E, V3, DOI DOI 10.1186/2197-425X-3-S1-A358.
   Baughman R.P., 2006, SARCOIDOSIS VASC DIF, V23
   Behr J, 2008, EUR RESPIR J, V31, P1357, DOI 10.1183/09031936.00171307
   Caminati A, 2013, EUR RESPIR REV, V22, P292, DOI 10.1183/09059180.00002713
   Campo A, 2011, EUR RESPIR J, V38, P359, DOI 10.1183/09031936.00148310
   Cannillo M, 2015, AM J CARDIOL, V116, P1883, DOI 10.1016/j.amjcard.2015.09.039
   Cavusoglu Y, 2007, EXPERT OPIN PHARMACO, V8, P665, DOI 10.1517/14656566.8.5.665
   Chaisson NF, 2013, CHEST, V144, P1346, DOI 10.1378/chest.12-2396
   Chaouat A, 2005, AM J RESP CRIT CARE, V172, P189, DOI 10.1164/rccm.200401-006OC
   Chin K.M., 2019, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.118.039360, DOI 10.1161/CIRCULATIONAHA.118.039360.]
   Coghlan JG, 2014, ANN RHEUM DIS, V73, P1340, DOI 10.1136/annrheumdis-2013-203301
   Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI
   Condliffe R, 2017, BJA EDUC, V17, P228, DOI 10.1093/bjaed/mkw074
   Condliffe R, 2009, AM J RESP CRIT CARE, V179, P151, DOI 10.1164/rccm.200806-953OC
   de Denus S, 2013, CAN J CARDIOL, V29, P1021, DOI 10.1016/j.cjca.2013.01.007
   Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC
   Faller M, 1997, EUR RESPIR J, V10, P2159, DOI 10.1183/09031936.97.10092159
   Farkas L, 2011, AM J RESP CELL MOL, V45, P1, DOI 10.1165/rcmb.2010-0365TR
   Faverio P, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0643-3
   Fernandez-Perez ER, 2008, CHEST, V133, P1113, DOI 10.1378/chest.07-1481
   Fox B.D., 2013, EUR RESP J, V42
   Frat J.-P., 2015, N ENGL J MED, V372
   Frat JP, 2019, CURR OPIN ANESTHESIO, V32, P150, DOI 10.1097/ACO.0000000000000705
   Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317
   Gall H, 2017, J HEART LUNG TRANSPL, V36, P957, DOI 10.1016/j.healun.2017.02.016
   Gannon WD, 2018, CHEST, V153, P1387, DOI 10.1016/j.chest.2018.01.006
   Gaudry S, 2014, J THORAC CARDIOV SUR, V147, P47, DOI 10.1016/j.jtcvs.2013.06.039
   Green Eric M, 2012, Curr Heart Fail Rep, V9, P228, DOI 10.1007/s11897-012-0104-x
   Gungor G., 2013, RESP CARE, V58
   Gunnarsson R, 2016, BEST PRACT RES CL RH, V30, P95, DOI 10.1016/j.berh.2016.03.002
   Hallowell Robert W, 2012, Pulm Circ, V2, P101, DOI 10.4103/2045-8932.94842
   Hamada K, 2007, CHEST, V131, P650, DOI 10.1378/chest.06-1466
   Handa T, 2006, CHEST, V129, P1246, DOI 10.1378/chest.129.5.1246
   Handoko ML, 2009, AM J PHYSIOL-HEART C, V297, pH1752, DOI 10.1152/ajpheart.00555.2009
   Hansen L., 2018, VOLUME MANAGEMENT PU
   Harari S, 2018, CHEST, V153, P217, DOI 10.1016/j.chest.2017.06.008
   Harjola VP, 2016, EUR J HEART FAIL, V18, P226, DOI 10.1002/ejhf.478
   Hemnes AR, 2008, AM J PHYSIOL-LUNG C, V294, pL24, DOI 10.1152/ajplung.00245.2007
   Hoeper M.M., 2018, EUR RESPIR J
   Hoeper MM, 2011, AM J RESP CRIT CARE, V184, P1114, DOI 10.1164/rccm.201104-0662CI
   Hoeper MM, 2002, AM J RESP CRIT CARE, V165, P341, DOI 10.1164/ajrccm.165.3.200109-0130c
   Hoffmann J, 2014, AM J RESP CRIT CARE, V190, P98, DOI 10.1164/rccm.201401-0037OC
   Hu EC, 2015, EXP THER MED, V9, P2109, DOI 10.3892/etm.2015.2376
   Huynh TN, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.08.006
   Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140-6736(18)31080-8
   Jarman ER, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12133
   Jentzer JC, 2016, J INTENSIVE CARE MED, V31, P369, DOI 10.1177/0885066615583652
   Klinger JR, 2019, CHEST, V155, P565, DOI 10.1016/j.chest.2018.11.030
   Kondoh Y, 2005, EUR RESPIR J, V25, P528, DOI 10.1183/09031936.05.00071004
   Koyauchi T, 2018, RESPIRATION, V96, P323, DOI 10.1159/000489890
   Kraut JA, 2019, AM J KIDNEY DIS, V73, P572, DOI 10.1053/j.ajkd.2018.08.011
   Kroeker CAG, 2006, AM J PHYSIOL-HEART C, V290, pH2432, DOI 10.1152/ajpheart.01140.2005
   Lacedonia D., 2016, 4 3 PULMONARY CIRCUL, pPA2425, DOI 10.1183/13993003.congress-2016.PA2425
   Launay D, 2007, J RHEUMATOL, V34, P1005
   Le Pavec J, 2011, ARTHRITIS RHEUM-US, V63, P2456, DOI 10.1002/art.30423
   Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751
   Lettieri CJ, 2006, CHEST, V129, P746, DOI 10.1378/chest.129.3.746
   Levy SD, 2016, LANCET, V387, P1867, DOI 10.1016/S0140-6736(16)30245-8
   Liu C, 2014, J CARD FAIL, V20, P625, DOI 10.1016/j.cardfail.2014.06.353
   Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569
   Mallick S, 2008, RESP MED, V102, P1355, DOI 10.1016/j.rmed.2008.06.003
   Mathai SC, 2009, ARTHRITIS RHEUM-US, V60, P569, DOI 10.1002/art.24267
   Mebazaa A., 2004, INTENSIVE CARE MED, V30
   Mercurio V, 2018, PULM CIRC, V8, DOI 10.1177/2045894018769874
   Meyer Keith C, 2014, Transl Respir Med, V2, P4, DOI 10.1186/2213-0802-2-4
   Mollica C, 2010, RESPIRATION, V79, P209, DOI 10.1159/000225932
   Mooney JJ, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0426-2
   Nathan SD, 2018, EUR RESPIR J
   Noordegraaf A. Vonk, 2018, EUR RESPIR J
   Olsson K.M., 2015, RESP RES, V16, DOI [10.1186/s12931-015-0298-z, DOI 10.1186/S12931-015-0298-Z.]
   Panagiotou M, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0053-2016
   Polomis D, 2008, CURR OPIN PULM MED, V14, P462, DOI 10.1097/MCP.0b013e3283043e30
   REDINGTON AN, 1990, BRIT HEART J, V63, P45
   Rich S, 1998, CHEST, V114, P787, DOI 10.1378/chest.114.3.787
   Rosas Ivan O, 2014, Ann Am Thorac Soc, V11 Suppl 3, pS169, DOI 10.1513/AnnalsATS.201312-429LD
   Rush B, 2016, RESP MED, V111, P72, DOI 10.1016/j.rmed.2015.12.005
   Ryu JH, 2007, MAYO CLIN PROC, V82, P342
   Savale L, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0092-2017
   Saydain G, 2002, AM J RESP CRIT CARE, V166, P839, DOI 10.1164/rccm.2104038
   Seeger W, 2013, J AM COLL CARDIOL, V62, pD109, DOI 10.1016/j.jacc.2013.10.036
   Shahane A, 2013, RHEUMATOL INT, V33, P1655, DOI 10.1007/s00296-012-2659-y
   Shekerdemian L, 1999, ARCH DIS CHILD, V80, P475, DOI 10.1136/adc.80.5.475
   Shorr AF, 2007, EUR RESPIR J, V30, P715, DOI 10.1183/09031936.00107206
   Shorr AF, 2005, EUR RESPIR J, V25, P783, DOI 10.1183/09031936.05.00083404
   Steen VD, 2007, ANN RHEUM DIS, V66, P940, DOI 10.1136/ard.2006.066068
   Teboul JL, 2011, CRIT CARE, V15, DOI 10.1186/cc10491
   Trudzinski FC, 2016, AM J RESP CRIT CARE, V193, P527, DOI 10.1164/rccm.201508-1701OC
   Tselios K, 2017, OPEN ACCESS RHEUMATO, V9, P1, DOI 10.2147/OARRR.S123549
   van Diepen S, 2017, CIRCULATION, V136, pE232, DOI 10.1161/CIR.0000000000000525
   Vemulapalli S, 2017, SCAND J RHEUMATOL, V46, P281, DOI 10.1080/03009742.2016.1206963
   Vianello A, 2014, J CRIT CARE, V29, P562, DOI 10.1016/j.jcrc.2014.03.019
   Wanamaker B, 2018, ARRHYTH ELECTROPHYSI, V7, P43, DOI 10.15420/aer.2018.3.2
   Wiese J., 2010, TEACHING HOSP
   Wilcox SR, 2015, ANN EMERG MED, V66, P619, DOI 10.1016/j.annemergmed.2015.07.525
   Xu SL, 2019, CLIN RESPIR J, V13, P82, DOI 10.1111/crj.12991
   Zafrani L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104897
NR 104
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2020
VL 161
AR UNSP 105825
DI 10.1016/j.rmed.2019.105825
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA KH7MN
UT WOS:000510834400001
PM 31785507
OA Bronze
DA 2020-05-18
ER

PT J
AU Bianchi, F
   Piccioli, C
   Rosi, E
   Carobene, L
   Spina, D
   Mazzei, MA
   Bartolucci, M
   Moroni, C
   Novelli, L
   Rottoli, P
   Bargagli, E
AF Bianchi, F.
   Piccioli, C.
   Rosi, E.
   Carobene, L.
   Spina, D.
   Mazzei, M. A.
   Bartolucci, M.
   Moroni, C.
   Novelli, L.
   Rottoli, P.
   Bargagli, E.
TI Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel
   disease phenotype?
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Sarcoidosis; Idiopathic pulmonary fibrosis; Diagnosis
ID DIAGNOSIS
C1 [Bianchi, F.; Carobene, L.; Rottoli, P.; Bargagli, E.] Siena Univ Hosp, Dept Med & Surg Sci & Neurosci, Resp Dis & Lung Transplantat, Siena, Italy.
   [Piccioli, C.; Rosi, E.] Florence Univ Hosp, SOD Resp Dis, Florence, Italy.
   [Spina, D.] Siena Univ Hosp, Dept Pathol, Siena, Italy.
   [Mazzei, M. A.] Siena Univ Hosp, Dept Med & Surg Sci & Neurosci, Sect Radiol, Siena, Italy.
   [Bartolucci, M.; Moroni, C.] Florence Univ Hosp, UOC Radiol, Florence, Italy.
   [Novelli, L.] Florence Univ Hosp, UOC Pathol, Florence, Italy.
RP Bargagli, E (reprint author), Univ Hosp Siena, I-53100 Siena, Italy.
EM bianchif@unisi.it; piccioli@unifi.it; rosi@libero.it;
   carobene@studentunisi.it; spina@unisi.it; mazzeima@unisi.it;
   bartolucci@libero.it; moroni@libero.it; novelli@libero.it;
   rottoli@unisi.it; bargagli2@unisi.it
CR Abehsera M, 2000, AM J ROENTGENOL, V174, P1751, DOI 10.2214/ajr.174.6.1741751
   Bennett D, 2019, RESP MED, V147, P31, DOI 10.1016/j.rmed.2018.12.011
   Bennett D, 2017, RESP MED, V126, P75, DOI 10.1016/j.rmed.2017.03.020
   Collins BF, 2018, RESP MED, V144, pS20, DOI 10.1016/j.rmed.2018.08.008
   Kalchiem-Dekel O, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120476
   Zhang C, 2016, CHEST, V149, P499, DOI 10.1378/chest.15-0615
NR 6
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105650
DI 10.1016/j.rmed.2019.02.022
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000007
PM 30922726
DA 2020-05-18
ER

PT J
AU Boutou, AK
   Papathanassiou, M
   Chloros, A
AF Boutou, Afroditi K.
   Papathanassiou, Maria
   Chloros, Adamantios
TI Bone mineral density and associated fractures in COPD patients: The role
   of inflammation and pulmonary rehabilitation
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Osteoporosis; Chronic obstructive pulmonary disease; Anemia; Pulmonary
   rehabilitation
ID PREVALENCE; DISEASE; ANEMIA
C1 [Boutou, Afroditi K.; Papathanassiou, Maria; Chloros, Adamantios] G Papanikolaou Hosp, Dept Resp Med, Thessaloniki 57010, Greece.
RP Boutou, AK (reprint author), G Papanikolaou Hosp, Dept Resp Med, Thessaloniki 57010, Greece.
EM afboutou@yahoo.com
CR Benedetti MG, 2018, BIOMED RES INT, DOI 10.1155/2018/4840531
   Boutou AK, 2012, QJM-INT J MED, V105, P657, DOI 10.1093/qjmed/hcs024
   Boutou AK, 2015, CLIN SCI, V128, P283, DOI 10.1042/CS20140344
   Corlateanu A, 2016, RESPIR INVESTIG, V54, P387, DOI 10.1016/j.resinv.2016.07.001
   Kameyama N, 2019, RESP MED, V148, P13, DOI 10.1016/j.rmed.2019.01.005
NR 5
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105708
DI 10.1016/j.rmed.2019.05.015
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000012
PM 31153675
DA 2020-05-18
ER

PT J
AU Calender, A
   Valeyre, D
   Israel-Biet, D
   Pacheco, Y
AF Calender, Alain
   Valeyre, Dominique
   Israel-Biet, Dominique
   Pacheco, Yves
TI Correspondence for "clinical epidemiology of familial sarcoidosis: A
   systematic literature review"
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Sarcoidosis; Genetics; Heritability; Epidemiology; Predisposition
C1 [Calender, Alain] Univ Hosp Lyon 1, Hosp Civils Lyon, Dept Mol & Med Genet, Bron, France.
   [Valeyre, Dominique] Univ Paris 13, INSERM, U1272, Bobigny, France.
   [Valeyre, Dominique] Avicenne Hosp, AP HP, Bobigny, France.
   [Israel-Biet, Dominique] Hop Europeen Georges Pompidou, Dept Pulmonol, Paris, France.
   [Pacheco, Yves] Lyon 1 Claude Bernard Univ, Inflammat & Immun Resp Epithelium, EA 7426, PI3, Pierre Benite, France.
RP Calender, A (reprint author), Univ Hosp Lyon 1, Hosp Civils Lyon, Dept Mol & Med Genet, Bron, France.
EM alain.calender@chu-lyon.fr
CR Calender A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00430-2019
   Kishore A, 2018, HUM GENET, V137, P705, DOI 10.1007/s00439-018-1915-y
   Pacheco Y, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0546-4
   Rossides M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00385-2018
   Sverrild A, 2008, THORAX, V63, P894, DOI 10.1136/thx.2007.094060
   Terwiel M, 2019, RESP MED, V149, P36, DOI 10.1016/j.rmed.2018.11.022
NR 6
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105717
DI 10.1016/j.rmed.2019.06.002
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000009
PM 31202573
DA 2020-05-18
ER

PT J
AU Collins, BF
   Raghu, G
AF Collins, Bridget F.
   Raghu, Ganesh
TI Sarcoidosis and idiopathic pulmonary fibrosis: The same tale or a tale
   of two diseases in one
SO RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Collins, Bridget F.; Raghu, Ganesh] Univ Washington, Med Ctr, Div Pulm & Crit Care & Sleep Med, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
RP Raghu, G (reprint author), Univ Washington, Med Ctr, Div Pulm & Crit Care & Sleep Med, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
EM graghu@uw.edu
CR Collins BF, 2018, RESP MED, V144, pS20, DOI 10.1016/j.rmed.2018.08.008
   HARDY HL, 1946, J IND HYG TOXICOL, V28, P197
   Hubbard R, 1996, LANCET, V347, P284, DOI 10.1016/S0140-6736(96)90465-1
   Nalysnyk L, 2012, EUR RESPIR REV, V21, P355, DOI 10.1183/09059180.00002512
   Raghu G, 2014, NEW ENGL J MED, V370, P2154, DOI 10.1056/NEJMc1404786
   Sack C, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01699-2018
NR 6
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105668
DI 10.1016/j.rmed.2019.03.021
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000006
PM 30975546
DA 2020-05-18
ER

PT J
AU Corsico, AG
   Braido, F
   Contoli, M
   Di Marco, F
   Rogliani, P
   Scognamillo, C
   Olivi, I
   Santus, P
   Scichilone, N
   Lazzaro, C
AF Corsico, Angelo G.
   Braido, Fulvio
   Contoli, Marco
   Di Marco, Fabiano
   Rogliani, Paola
   Scognamillo, Carla
   Olivi, Irene
   Santus, Pierachille
   Scichilone, Nicola
   Lazzaro, Carlo
TI Healthcare costs of the SATisfaction and adherence to COPD treatment
   (SAT) study follow-up (vol 153, pg 68, 2019)
SO RESPIRATORY MEDICINE
LA English
DT Correction
C1 [Corsico, Angelo G.] IRCCS Policlin San Matteo Fdn, Div Resp Dis, Pavia, Italy.
   [Corsico, Angelo G.] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Braido, Fulvio] Univ Genoa, Dept Internal Med Di MI, Genoa, Italy.
   [Contoli, Marco] Univ Ferrara, Dept Med Sci, Ferrara, Italy.
   [Di Marco, Fabiano] Univ Milan, Dept Biomed & Clin Sci DIBIC, Milan, Italy.
   [Rogliani, Paola] Univ Roma Tor Vergata, Dept Expt Med & Surg, Resp Unit, Rome, Italy.
   [Scognamillo, Carla; Olivi, Irene] Boehringer Ingelheim GmbH & Co KG, Milan, Italy.
   [Santus, Pierachille] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Scichilone, Nicola] Univ Palermo, DIBIMIS, Palermo, Italy.
   [Lazzaro, Carlo] Studio Econ Sanit, Milan, Italy.
RP Corsico, AG (reprint author), IRCCS Policlin San Matteo Fdn, Div Resp Dis, Pavia, Italy.; Corsico, AG (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
EM corsico@unipv.it
OI Rogliani, Paola/0000-0001-7801-5040; Corsico, Angelo
   Guido/0000-0002-8716-4694; Lazzaro, Carlo/0000-0003-4795-1834
CR Corsico AG, 2019, RESP MED, V153, P68, DOI 10.1016/j.rmed.2019.05.017
NR 1
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105724
DI 10.1016/j.rmed.2019.06.009
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000016
PM 31202574
OA Bronze
DA 2020-05-18
ER

PT J
AU de Jong, CCM
   Mozun, R
AF de Jong, Carmen C. M.
   Mozun, R.
TI The reference standard in diagnostic studies on childhood asthma
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Asthma; Diagnostic testing; Children; Epidemiology; Diagnostic accuracy
ID FENO
C1 [de Jong, Carmen C. M.; Mozun, R.] Univ Bern, Inst Social & Prevent Med, Mittelstr 43, CH-3012 Bern, Switzerland.
RP de Jong, CCM (reprint author), Univ Bern, Inst Social & Prevent Med, Mittelstr 43, CH-3012 Bern, Switzerland.
EM carmen.dejong@ispm.unibe.ch
RI Mozun, Rebeca/Y-6809-2019
OI Mozun, Rebeca/0000-0002-5237-8668; de Jong, Carmen Cornelia
   Maria/0000-0002-3051-4542
CR Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   de Jong C.C.M., 2019, EUROPEAN RESP J
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   GINA, GLOB STRAT ASTHM MAN
   Kessler A, 2019, RESP MED, V157, P21, DOI 10.1016/j.rmed.2019.08.008
   National Institute for Health and Care Excellence (NICE), GUID ASTHM DIAGN MON
   NIH EPR3, GUID DIAGN MAN ASTHM
   Woo SI, 2012, RESP MED, V106, P1103, DOI 10.1016/j.rmed.2012.03.022
NR 8
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105812
DI 10.1016/j.rmed.2019.105812
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000015
PM 31748173
DA 2020-05-18
ER

PT J
AU dos Santos, VM
AF dos Santos, Vitorino Modesto
TI Unilateral pulmonary hypoplasia
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Developmental anomalies; Hypoplasia; Lung
C1 [dos Santos, Vitorino Modesto] Armed Forces Hosp, Dept Internal Med, Estr Contorno Bosque S-N, BR-70630900 Brasilia, DF, Brazil.
   [dos Santos, Vitorino Modesto] Catholic Univ, Estr Contorno Bosque S-N, BR-70630900 Brasilia, DF, Brazil.
RP dos Santos, VM (reprint author), Armed Forces Hosp, Dept Internal Med, Estr Contorno Bosque S-N, BR-70630900 Brasilia, DF, Brazil.; dos Santos, VM (reprint author), Catholic Univ, Estr Contorno Bosque S-N, BR-70630900 Brasilia, DF, Brazil.
EM vitorinomodesto@gmail.com
CR Cherian SV, 2019, RESP MED, V155, P86, DOI 10.1016/j.rmed.2019.07.011
   Dewan G, 2015, J NEPAL MED ASSOC, V53, P37, DOI 10.31729/jnma.2703
   Santos V.M., 2011, ARCH IRAN MED, V14, P423
NR 3
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105818
DI 10.1016/j.rmed.2019.105818
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000014
PM 31744677
DA 2020-05-18
ER

PT J
AU Franconeri, A
   Marasco, E
   Dore, R
   Codullo, V
   Calliada, F
   Disabella, E
   Meloni, F
   Zanframundo, G
   Montecucco, C
   Valentini, A
   Cavagna, L
AF Franconeri, Andrea
   Marasco, Emiliano
   Dore, Roberto
   Codullo, Veronica
   Calliada, Fabrizio
   Disabella, Eliana
   Meloni, Federica
   Zanframundo, Giovanni
   Montecucco, Carlomaurizio
   Valentini, Adele
   Cavagna, Lorenzo
TI Pulmonary emphysema not combined with lung fibrosis in systemic
   sclerosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Interstitial lung disease; High Resolution Computed Tomography; Systemic
   Sclerosis; Emphysema
ID DISEASE
AB Interstitial Lung Disease (ILD) is a common finding of Systemic Sclerosis (SSc) mainly presenting in the form of Nonspecific Interstitial Pneumonia (NSIP) and deeply affecting patients' prognosis. Beside NSIP, other types of ILD have been reported. The most recently described pattern is the so-called Combined-pulmonary emphysema and lung fibrosis, characterized by the coexistence of both upper lobes centrilobular and paraseptal emphysema and lower lobes ILD. We presented three cases of patients with SSc, in which High Resolution Computed Tomography examinations showed emphysema with atypical distribution and radiological presentation, without or with mild signs of fibrosing lung disease, that stabilized after immunosuppressive treatment.
C1 [Franconeri, Andrea; Calliada, Fabrizio; Valentini, Adele] Univ Pavia, Dept Radiol, I-27100 Pavia, Italy.
   [Franconeri, Andrea; Marasco, Emiliano; Codullo, Veronica; Calliada, Fabrizio; Meloni, Federica; Zanframundo, Giovanni; Montecucco, Carlomaurizio; Valentini, Adele; Cavagna, Lorenzo] IRCCS Policlin S Matteo Fdn, I-27100 Pavia, Italy.
   [Marasco, Emiliano; Codullo, Veronica; Zanframundo, Giovanni; Montecucco, Carlomaurizio; Cavagna, Lorenzo] Univ Pavia, Div Rheumatol, I-27100 Pavia, Italy.
   [Dore, Roberto] Isituti Clin Citta Pavia, Radiol Unit, I-27100 Pavia, Italy.
   [Codullo, Veronica] Hop Cochin, Rheumatol Dept, Paris, France.
   [Disabella, Eliana] IRCCS Fdn Policlin San Matteo, Ctr Inherited Cardiovasc Dis, Transplant Res Area, Pavia, Italy.
   [Meloni, Federica] Univ Pavia, Div Pneumol, I-27100 Pavia, Italy.
RP Franconeri, A (reprint author), Univ Pavia, Dept Radiol, I-27100 Pavia, Italy.; Franconeri, A (reprint author), IRCCS Policlin S Matteo Fdn, I-27100 Pavia, Italy.
EM andrea.franconeri01@universitadipavia.it
OI Franconeri, Andrea/0000-0001-5474-5479; Disabella,
   Eliana/0000-0003-3440-8883
CR Antoniou KM, 2016, ARTHRITIS RHEUMATOL, V68, P1004, DOI 10.1002/art.39528
   Awano N, 2017, HISTOPATHOLOGY, V70, P896, DOI 10.1111/his.13153
   Champtiaux N, 2019, SEMIN ARTHRITIS RHEU, V49, P98, DOI 10.1016/j.semarthrit.2018.10.011
   Ciccarese F, 2016, RADIOL MED, V121, P564, DOI 10.1007/s11547-016-0627-4
   Cottin V, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0980-7
   Cottin V, 2013, EUR RESPIR REV, V22, P153, DOI 10.1183/09059180.00000813
   Cottin V, 2012, CURR OPIN PULM MED, V18, P418, DOI 10.1097/MCP.0b013e328356803b
   Cottin V, 2011, ARTHRITIS RHEUM-US, V63, P295, DOI 10.1002/art.30077
   Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9
   Inomata M, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-104
   Jankowich MD, 2012, CHEST, V141, P222, DOI 10.1378/chest.11-1062
   Lynch DA, 2018, LANCET RESP MED, V6, P138, DOI 10.1016/S2213-2600(17)30433-2
   Lynch DA, 2015, RADIOLOGY, V277, P192, DOI 10.1148/radiol.2015141579
   Yamakawa H, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0591-y
NR 14
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105816
DI 10.1016/j.rmed.2019.105816
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000005
PM 31739247
DA 2020-05-18
ER

PT J
AU Manon-Jensen, T
   Langholm, LL
   Ronnow, SR
   Karsdal, MA
   Tal-Singer, R
   Vestbo, J
   Leeming, DJ
   Miller, BE
   Sand, JMB
AF Manon-Jensen, Tina
   Langholm, Lasse L.
   Ronnow, Sarah Rank
   Karsdal, Morten Asser
   Tal-Singer, Ruth
   Vestbo, Jorgen
   Leeming, Diana Julie
   Miller, Bruce E.
   Sand, Jannie Marie Bulow
TI End-product of fibrinogen is elevated in emphysematous chronic
   obstructive pulmonary disease and is predictive of mortality in the
   ECLIPSE cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Fibrinogen; ECLIPSE; COPD; X-FIB; Emphysema; Mortality
ID D-DIMER; SYSTEMIC INFLAMMATION; ACUTE EXACERBATIONS; PLASMA-FIBRINOGEN;
   GLOBAL STRATEGY; LUNG-FUNCTION; BIOMARKER; OUTCOMES; PREVENTION;
   MANAGEMENT
AB Background: Chronic obstructive pulmonary disease (COPD) is characterized by abnormal epithelial repair process that may result in intra-airway accumulation of fibrin. Given that plasma fibrinogen is the only FDA approved biomarker that predicts mortality and COPD exacerbations, we hypothesized that changes in the processing of fibrinogen may provide additional characterization of disease phenotype and COPD progression.
   Methods: A subpopulation of subjects with COPD, (n = 983) smoker (n = 205) and non-smoker controls (n = 98) were included from The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) cohort. Two biomarkers that specifically target the thrombin-mediated conversion of fibrinogen into fibrin (PRO-FIB), and plasmin-mediated degradation of cross-linked fibrin (X-FIB) were measured and compared with fibrinogen measurements.
   Results: X-FIB had a predictive value for two-year mortality, with an adjusted hazard ratio of 1.48 per SD (n = 980; 95% Cl 1.18-1.84; p < 0.0001), and comparable to the fibrinogen hazard ratio of 1.59 per SD (n = 983; 95% Cl 1.29-1.96; p = 0.0003). X-FIB (p < 0.001), fibrinogen (p < 0.0001) and PRO-FIB (p < 0.05) were significantly elevated in symptomatic COPD (mMRC >= 2) as compared to asymptomatic COPD. X-FIB was the only biomarker that was associated with emphysema (p < 0.001), and only plasma fibrinogen (p < 0.05) was associated with exacerbations.
   Conclusion: There is a need for biomarkers to characterize the heterogeneity of COPD, to continuously improve clinical trial design and to identify disease progressors for efficient health care utilization. Each of three fibrinogen biomarkers studied provide information representing distinct aspects of COPD which may be used to characterize disease endotypes and to assess mortality risk in COPD.
C1 [Manon-Jensen, Tina; Langholm, Lasse L.; Ronnow, Sarah Rank; Karsdal, Morten Asser; Leeming, Diana Julie; Sand, Jannie Marie Bulow] Nordic Biosci AS, Herlev Hovedgade 205-207, DK-2730 Herlev, Denmark.
   [Langholm, Lasse L.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark.
   [Ronnow, Sarah Rank] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark.
   [Tal-Singer, Ruth; Miller, Bruce E.] GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA.
   [Vestbo, Jorgen] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Vestbo, Jorgen] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
RP Manon-Jensen, T (reprint author), Nordic Biosci AS, Herlev Hovedgade 205-207, DK-2730 Herlev, Denmark.
EM TMJ@nordicbio.com
OI Langholm, Lasse Locke/0000-0003-0549-5797; Vestbo,
   Jorgen/0000-0001-6355-6362; Rank Ronnow, Sarah/0000-0002-9022-8775
FU GlaxoSmithKlineGlaxoSmithKline; Danish Agency for Science, Technology
   and Innovation; Danish Research Foundation; National Institute of Health
   Research Manchester Biomedical Research Centre (NIHR Manchester BRC)
FX The study was sponsored by GlaxoSmithKline; the Danish Agency for
   Science, Technology and Innovation; and the Danish Research Foundation.
   JV is supported by the National Institute of Health Research Manchester
   Biomedical Research Centre (NIHR Manchester BRC). The authors
   acknowledge all participants, medical, nursing, and technical staff
   involved in the ECLIPSE study.
CR Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015
   Akgun M, 2006, RESPIRATION, V73, P428, DOI 10.1159/000092952
   ALESSANDRI C, 1994, THROMB HAEMOSTASIS, V72, P343
   Arregui MAA, AN SIST SANIT NAVAR, V33, P43
   Bihlet AR, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0509-x
   Celli BR, 2012, AM J RESP CRIT CARE, V185, P1065, DOI 10.1164/rccm.201110-1792OC
   COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303
   Danese S, 2007, AM J GASTROENTEROL, V102, P174, DOI 10.1111/j.1572-0241.2006.00943.x
   Dempfle CE, 2001, THROMB HAEMOSTASIS, V85, P671
   Duvoix A, 2013, THORAX, V68, P670, DOI 10.1136/thoraxjnl-2012-201871
   E. Medicines Agency, 2018, PROD DEV SCI SUPP DE
   Fruchter O, 2015, AM J MED SCI, V349, P29, DOI 10.1097/MAJ.0000000000000332
   Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588
   Gan WQ, 2005, CHEST, V127, P558, DOI 10.1378/chest.127.2.558
   Groenewegen KH, 2008, CHEST, V133, P350, DOI 10.1378/chest.07-1342
   Hartmann IJC, 2000, AM J RESP CRIT CARE, V162, P2232, DOI 10.1164/ajrccm.162.6.2006030
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Hu GP, 2016, INT J CHRONIC OBSTR, V11, P2729, DOI 10.2147/COPD.S112882
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Ishikawa G, 2017, RESP MED, V128, P78, DOI 10.1016/j.rmed.2017.05.009
   Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532
   Levitzky YS, 2008, ATHEROSCLEROSIS, V201, P217, DOI 10.1016/j.atherosclerosis.2007.12.058
   Liu BH, J BIOL REGUL HOMEOST, V30, P839
   Mannino DM, 2015, CHRON OBSTR PULM DIS, V2, P23, DOI 10.15326/jcopdf.2.1.2014.0138
   Manon-Jensen T, 2016, J THROMB HAEMOST, V14, P438, DOI 10.1111/jth.13249
   Miller BE, 2016, AM J RESP CRIT CARE, V193, P607, DOI 10.1164/rccm.201509-1722PP
   Miller J, 2013, RESP MED, V107, P1376, DOI 10.1016/j.rmed.2013.05.001
   Patel IS, 2003, EUR RESPIR J, V22, P94, DOI 10.1183/09031936.03.00093703
   Patil SP, 2003, ARCH INTERN MED, V163, P1180, DOI 10.1001/archinte.163.10.1180
   Petecchia L, 2009, CHEST, V135, P1502, DOI 10.1378/chest.08-1780
   Polosa R, 2013, INTERN EMERG MED, V8, P567, DOI [10.1007/s11739-011-0636-1, 10.1007/s11739-013-0977-z]
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Sand JMB, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0225-3
   Silva DR, 2012, COPD, V9, P426, DOI 10.3109/15412555.2012.683840
   Stalker TJ, 2013, BLOOD, V121, P1875, DOI 10.1182/blood-2012-09-457739
   Stolz D, 2017, CHEST, V151, P47, DOI 10.1016/j.chest.2016.08.1440
   Sun S, 2019, J GASTROINTEST LIVER, V28, P175, DOI 10.15403/jgld-178
   Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707
   Vestbo J, 2014, CLIN CHEST MED, V35, P1, DOI 10.1016/j.ccm.2013.10.010
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Zhang M, 2016, CLIN CHIM ACTA, V455, P55, DOI 10.1016/j.cca.2016.01.024
NR 41
TC 1
Z9 1
U1 5
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105814
DI 10.1016/j.rmed.2019.105814
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000002
PM 31739246
DA 2020-05-18
ER

PT J
AU Matucci, A
   Maggi, E
   Vultaggio, A
AF Matucci, Andrea
   Maggi, Enrico
   Vultaggio, Alessandra
TI Eosinophils, the IL-5/IL-5R alpha axis, and the biologic effects of
   benralizumab in severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Bronchial asthma; Eosinophils; Interleukin 5; Monoclonal antibodies;
   Benralizumab
ID INNATE LYMPHOID-CELLS; IL-5 RECEPTOR-ALPHA; AIRWAY EOSINOPHILS;
   MAST-CELLS; DIFFERENTIAL ACTIVATION; DECREASED EXPRESSION;
   IMMUNE-RESPONSE; GM-CSF; INFLAMMATION; ANTIBODY
AB Bronchial asthma is a chronic inflammatory disease characterized, in a percentage of patients, as an eosinophilic inflammation of the airways. Eosinophils are recognized as a proinflammatory granulocyte playing a major role in the T2-high phenotype, which includes severe eosinophilic asthma. Eosinophilic asthma represents the majority of the phenotypic variants clinically characterized by severity and frequent exacerbations. For patients with severe uncontrolled asthma, monoclonal antibodies are used as add-on treatments. Among them, in addition to anti-immunoglobulin E therapy, biologic agents directed toward the interleukin (IL)-5/IL-5R alpha axis and, thus, interfering with the pathologic functions of eosinophils, are now available. Unlike the other anti IL-5 monoclonal antibodies which exert an indirect effect on eosinophils, benralizumab, an afucosylated IgG(1) kappa antibody directed against the a subunit of IL-5R, directly depletes eosinophils and their associated bone marrow progenitor cells through induction of antibody-dependent cell-mediated cytotoxicity, through recruitment of natural killer cells. This article reviews the role of eosinophils in the pathogenesis of bronchial asthma and discusses the potential advantageous biologic effects of benralizumab in comparison with other monoclonal antibodies targeting the IL-5 ligand.
C1 [Matucci, Andrea; Vultaggio, Alessandra] Azienda Osped Univ Careggi, Immunoallergol Unit, Florence, Italy.
   [Maggi, Enrico] IRCCS Pediat Hosp Bambino Gesu, Rome, Italy.
RP Matucci, A (reprint author), Largo Brambilla 3, I-50134 Florence, Italy.
EM andrea.matucci@unifi.it
FU AstraZeneca ItalyAstraZeneca
FX The authors thank Ray Hill, an independent medical writer, for
   English-language editing assistance. This assistance was funded by
   AstraZeneca Italy.
CR Abdala-Valencia H, 2018, J LEUKOCYTE BIOL, V104, P95, DOI 10.1002/JLB.1MR1117-442RR
   Anderson EL, 2016, ALLERGY, V71, P977, DOI 10.1111/all.12861
   Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024
   Berek C, 2018, J EXP MED, V215, P1967, DOI 10.1084/jem.20181152
   Bochner BS, 2009, CLIN EXP ALLERGY, V39, P317, DOI 10.1111/j.1365-2222.2008.03173.x
   BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505
   Broughton SE, 2015, CYTOKINE, V74, P247, DOI 10.1016/j.cyto.2015.02.005
   Busse WW, 2019, LANCET RESP MED, V7, P46, DOI 10.1016/S2213-2600(18)30406-5
   Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005
   Carretero R, 2015, NAT IMMUNOL, V16, P609, DOI 10.1038/ni.3159
   Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005
   COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169
   Cosmi L, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0735-9
   Motran CC, 2017, SEMIN IMMUNOPATHOL, V39, P199, DOI 10.1007/s00281-016-0588-7
   Dahl C, 2004, ALLERGY, V59, P1087, DOI 10.1111/j.1398-9995.2004.00606.x
   DVORAK AM, 1994, CLIN EXP ALLERGY, V24, P10, DOI 10.1111/j.1365-2222.1994.tb00910.x
   Esnault S, 2016, CRIT REV IMMUNOL, V36, P429, DOI 10.1615/CritRevImmunol.2017020172
   Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786
   Farahi N, 2014, METHODS MOL BIOL, V1178, P165, DOI 10.1007/978-1-4939-1016-8_15
   Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739
   Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC
   Flores-Torres AS, 2019, VIRAL IMMUNOL, V32, P198, DOI 10.1089/vim.2018.0150
   Garcia G, 2013, EUR RESPIR REV, V22, P251, DOI 10.1183/09059180.00004013
   Gleich GJ, 2013, ALLERGY, V68, P829, DOI 10.1111/all.12169
   Global Initiative for Asthma (GINA), 2018, GLOB STRAT ASTHM MAN
   HAGAN P, 1985, PARASITE IMMUNOL, V7, P625, DOI 10.1111/j.1365-3024.1985.tb00106.x
   Hassani M, 2018, ALLERGY, V73, P1979, DOI 10.1111/all.13451
   Jacobsen EA, 2015, ALLERGY, V70, P1148, DOI 10.1111/all.12655
   Januskevicius A, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0254-9
   Johnston LK, 2016, J IMMUNOL, V197, P3445, DOI 10.4049/jimmunol.1600611
   Kankaanranta H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090298
   Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024
   Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050
   Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   Larose MC, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00136
   Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020
   Li BWS, 2013, IMMUNOLOGY, V140, P281, DOI 10.1111/imm.12153
   Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617
   Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459
   Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452
   McBrien CN, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00093
   Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382
   Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664
   Mukherjee M, 2018, ALLERGY ASTHMA IMMUN, V10, P428, DOI 10.4168/aair.2018.10.5.428
   Muniz VS, 2012, J LEUKOCYTE BIOL, V92, P281, DOI 10.1189/jlb.0212067
   Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X
   Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435
   O'Sullivan JA, 2018, J ALLERGY CLIN IMMUN, V141, P505, DOI 10.1016/j.jaci.2017.09.022
   Pineros Y.S. Sabogal, 2019, ALLERGY
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Provost V, 2013, J LEUKOCYTE BIOL, V94, P213, DOI 10.1189/jlb.0212074
   Ricci Mario, 1997, Recenti Progressi in Medicina, V88, P530
   Sehmi R, 2016, CLIN EXP ALLERGY, V46, P793, DOI 10.1111/cea.12695
   Sehmi R, 2018, J ALLERGY CLIN IMMUN, V141, P1529, DOI 10.1016/j.jaci.2018.01.008
   Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037
   Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017
   STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9
   Tachimoto H, 2002, INT ARCH ALLERGY IMM, V128, P18, DOI 10.1159/000059414
   Thompson-Souza GA, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00106
   Pham TH, 2016, RESP MED, V111, P21, DOI 10.1016/j.rmed.2016.01.003
   van Meerten T, 2006, CLIN CANCER RES, V12, P4027, DOI 10.1158/1078-0432.CCR-06-0066
   Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585
   Wang W, 2018, J IMMUNOL, V201, P2221, DOI 10.4049/jimmunol.1800709
   Wen T, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0020-2015
   Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC
   Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC
   Wright AKA, 2017, J ALLERGY CLIN IMMUN, V140, P1430, DOI 10.1016/j.jaci.2017.04.025
   Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151
   Yoshimura-Uchiyama C, 2003, BIOCHEM BIOPH RES CO, V309, P26, DOI 10.1016/S0006-291X(03)01526-2
   Zaynagetdinov R, 2015, CANCER RES, V75, P1624, DOI 10.1158/0008-5472.CAN-14-2379
NR 71
TC 1
Z9 1
U1 3
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105819
DI 10.1016/j.rmed.2019.105819
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000001
PM 31734469
DA 2020-05-18
ER

PT J
AU O'Conor, R
   Muellers, K
   Arvanitis, M
   Vicencio, DP
   Wolf, MS
   Wisnivesky, JP
   Federman, AD
AF O'Conor, Rachel
   Muellers, Kimberly
   Arvanitis, Marina
   Vicencio, Daniel P.
   Wolf, Michael S.
   Wisnivesky, Juan P.
   Federman, Alex D.
TI Effects of health literacy and cognitive abilities on COPD
   self-management behaviors: A prospective cohort study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Self care; Cognition; Health literacy; Chronic obstructive pulmonary
   disease
ID OBSTRUCTIVE PULMONARY-DISEASE; OLDER-ADULTS; MEDICATION ADHERENCE;
   RISK-FACTORS; ASTHMA; MEMORY; OUTCOMES; INTERVENTIONS; NONADHERENCE;
   VALIDATION
AB Introduction: Low rates of adherence to self-management behaviors are common among patients with COPD. Health literacy and cognitive abilities may influence engagement in self-management behaviors. We sought to assess the association between health literacy and cognitive abilities with self-management behaviors in patients with COPD.
   Methods: We conducted an observational cohort study among American adults with COPD in New York, New York, and Chicago, Illinois. Outcomes included adherence to COPD medication, metered dose inhaler (MDI) and dry powder inhaler (DPI) technique, receipt of vaccination, and routine healthcare appointments. Health literacy was measured with the Short Test of Functional Health Literacy in Adults. Cognitive function was assessed in terms of global, fluid (working memory, processing speed, executive function) and crystallized (verbal) ability.
   Results: Adequate health literacy was associated with adequate adherence to COPD medications (OR 1.46; 95% CI, 1.02-2.08), correct MDI (OR 1.66; 95% CI, 1.13-2.44) and DPI (OR 2.17; 95% CI, 1.30-3.64) technique. Fluid abilities were also associated with medication behaviors and visiting a regular healthcare provider, while crystalized abilities were not. Global cognitive abilities were associated with correct inhaler technique. No other associations were found with non-medication self-management behaviors.
   Conclusions: COPD patients with limited health literacy and deficits in fluid cognitive abilities have lower rates of adherence and poorer inhaler technique than individuals with adequate health literacy and greater fluid cognitive abilities. These findings highlight the importance of considering the health literacy level and cognitive ability when caring for and educating patients with COPD.
C1 [O'Conor, Rachel; Arvanitis, Marina; Wolf, Michael S.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA.
   [Muellers, Kimberly; Wisnivesky, Juan P.; Federman, Alex D.] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA.
   [Vicencio, Daniel P.] Mercy Hosp, Chicago, IL USA.
   [Vicencio, Daniel P.] Med Ctr, Chicago, IL USA.
   [Wisnivesky, Juan P.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
RP O'Conor, R (reprint author), Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med & Geriatr, 750 N Lakeshore Dr,10th Floor, Chicago, IL 60611 USA.
EM r-oconor@northwestern.edu
OI Arvanitis, Marina/0000-0002-2186-5164
FU National Heart, Lung and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL105385]
FX This work was supported by the National Heart, Lung and Blood Institute
   (R01HL105385).
CR Baker DW, 2011, J HEALTH COMMUN, V16, P73, DOI 10.1080/10810730.2011.604379
   Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5
   Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005
   Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007
   Cherry KE, 2007, J GEN PSYCHOL, V134, P43, DOI 10.3200/GENP.134.1.43-65
   CHERRY KE, 1993, PSYCHOL AGING, V8, P517, DOI 10.1037/0882-7974.8.4.517
   Cohen JL, 2009, ANN ALLERG ASTHMA IM, V103, P325, DOI 10.1016/S1081-1206(10)60532-7
   Dhamane AD, 2017, INT J CHRONIC OBSTR, V12, P115, DOI 10.2147/COPD.S114802
   Doak CC, 1985, TEACHING PATIENTS LO
   Dodd JW, 2013, CHEST, V144, P119, DOI 10.1378/chest.12-2099
   DOLCE JJ, 1991, CHEST, V99, P837, DOI 10.1378/chest.99.4.837
   Eisner MD, 2005, CHEST, V127, P1890, DOI 10.1378/chest.127.6.1890
   Federman AD, 2015, CONTEMP CLIN TRIALS, V44, P103, DOI 10.1016/j.cct.2015.07.018
   Federman AD, 2014, J AM GERIATR SOC, V62, P872, DOI 10.1111/jgs.12797
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   George J, 2005, CHEST, V128, P3198, DOI 10.1378/chest.128.5.3198
   George J, 2004, ANN PHARMACOTHER, V38, P1369, DOI 10.1345/aph.1D479
   Goodman ER, 2016, J AM GERIATR SOC, V64, P1133, DOI 10.1111/jgs.14124
   Hendeles L, 2007, NEW ENGL J MED, V356, P1344, DOI 10.1056/NEJMra050380
   Heron M., 2015, NATL VITAL STAT REP, V64
   Hsu DJ, 2016, CHRON OBSTR PULM DIS, V3, P620, DOI 10.15326/jcopdf.3.3.2015.0156
   Khdour MR, 2012, EUR J CLIN PHARMACOL, V68, P1365, DOI 10.1007/s00228-012-1279-5
   Kluger A, 1999, J GERIATR PSYCH NEUR, V12, P168, DOI 10.1177/089198879901200402
   Neugaard BI, 2011, POPUL HEALTH MANAG, V14, P99, DOI 10.1089/pop.2010.0020
   Nurss J.R., 2003, TOFHLA TEST FUNCTION
   O'Conor R, 2015, CHEST, V147, P1307, DOI 10.1378/chest.14-0914
   Omachi TA, 2013, J GEN INTERN MED, V28, P74, DOI 10.1007/s11606-012-2177-3
   Park DC, 1999, J AM GERIATR SOC, V47, P172, DOI 10.1111/j.1532-5415.1999.tb04575.x
   Park DC, 2002, PSYCHOL AGING, V17, P299, DOI 10.1037//0882-7974.17.2.299
   Press VG, 2016, ANN AM THORAC SOC, V13, P816, DOI 10.1513/AnnalsATS.201509-603OC
   Press VG, 2012, J GEN INTERN MED, V27, P1001, DOI 10.1007/s11606-012-2058-9
   Press VG, 2011, J GEN INTERN MED, V26, P635, DOI 10.1007/s11606-010-1624-2
   Prince MJ, 1999, INT J METH PSYCH RES, V8, P49, DOI DOI 10.1002/MPR.56
   Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008
   Roncero C, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S100850
   Rosenthal E., 2013, NY TIMES, V12
   Roy A, 2010, ANN ALLERG ASTHMA IM, V104, P132, DOI 10.1016/j.anai.2009.11.024
   SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763
   Schaffler J, 2018, J GEN INTERN MED, V33, P510, DOI 10.1007/s11606-017-4265-x
   Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83
   Sobel RM, 2009, J COMMUN HEALTH, V34, P321, DOI 10.1007/s10900-009-9153-9
   Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80
   Spreen O., 1998, COMPENDIUM NEUROPSYC
   Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940
   Taffet GE, 2014, CLIN INTERV AGING, V9, P23, DOI 10.2147/CIA.S52999
   Thakur Neeta, 2010, Int J Chron Obstruct Pulmon Dis, V5, P263
   The Institute of Medicine, 2004, HLTH LITERACY PRESCR
   Tseng CW, 2017, JAMA INTERN MED, V177, P585, DOI 10.1001/jamainternmed.2016.9386
   van Beerendonk I, 1998, J ASTHMA, V35, P273, DOI 10.3109/02770909809068218
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wilson EAH, 2010, PATIENT EDUC COUNS, V80, P393, DOI 10.1016/j.pec.2010.07.011
   Wisnivesky JP, 2009, MED CARE, V47, P243, DOI 10.1097/MLR.0b013e3181847606
   Wolf MS, 2012, J GEN INTERN MED, V27, P1300, DOI 10.1007/s11606-012-2079-4
   Zwerink M, 2014, SELF MANAGEMENT PATI
NR 54
TC 4
Z9 4
U1 2
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105630
DI 10.1016/j.rmed.2019.02.006
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000003
PM 30850277
DA 2020-05-18
ER

PT J
AU Ocal, S
   Portakal, O
   Ocal, A
   Demir, AU
   Topeli, A
   Coplu, L
AF Ocal, Serpil
   Portakal, Oytun
   Ocal, Arslan
   Demir, Ahmet Ugur
   Topeli, Arzu
   Coplu, Lutfi
TI Factors associated with pulmonary hypertension and long-term survival in
   bronchiectasis subjects (vol 119, pg 109, 2016)
SO RESPIRATORY MEDICINE
LA English
DT Correction
C1 [Ocal, Serpil; Topeli, Arzu] Hacettepe Univ, Dept Med Intens Care Unit, Fac Med, Ankara, Turkey.
   [Portakal, Oytun] Hacettepe Univ, Dept Biochem, Fac Med, Ankara, Turkey.
   [Ocal, Arslan] Dept Koru Hosp, Ankara, Turkey.
   [Demir, Ahmet Ugur; Coplu, Lutfi] Hacettepe Univ, Dept Chest Dis, Fac Med, Ankara, Turkey.
RP Ocal, S (reprint author), Hacettepe Univ, Dept Med Intens Care Unit, Fac Med, Ankara, Turkey.
EM drserpilgocmen@yahoo.com
CR Ocal S, 2016, RESP MED, V119, P109, DOI 10.1016/j.rmed.2016.08.027
NR 1
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105706
DI 10.1016/j.rmed.2019.05.013
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000017
PM 31200983
OA Bronze
DA 2020-05-18
ER

PT J
AU Phillips, DB
   Collins, SE
   Bryan, TL
   Wong, EYL
   McMurtry, MS
   Bhutani, M
   Stickland, MK
AF Phillips, Devin B.
   Collins, Sophie E.
   Bryan, Tracey L.
   Wong, Eric Y. L.
   McMurtry, M. Sean
   Bhutani, Mohit
   Stickland, Michael K.
TI The effect of carotid chemoreceptor inhibition on exercise tolerance in
   chronic obstructive pulmonary disease: A randomized-controlled crossover
   trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Exercise tolerance; Carotid chemoreceptor; Dyspnea
ID NEAR-INFRARED SPECTROSCOPY; EXERTIONAL DYSPNEA; BLOOD-FLOW; VENTILATORY
   INEFFICIENCY; DYNAMIC HYPERINFLATION; MUSCLE DEOXYGENATION; CYCLE
   EXERCISE; CARDIAC-OUTPUT; LUNG-FUNCTION; GAS-EXCHANGE
AB +/-: Patients with chronic obstructive pulmonary disease (COPD) have an exaggerated ventilatory response to exercise, contributing to exertional dyspnea and exercise intolerance. We recently demonstrated enhanced activity and sensitivity of the carotid chemoreceptor (CC) in COPD which may alter ventilatory and cardiovascular regulation and negatively affect exercise tolerance. We sought to determine whether CC inhibition improves ventilatory and cardiovascular regulation, dyspnea and exercise tolerance in COPD.
   Methods: Twelve mild-moderate COPD patients (FEV1 83 +/- 15 %predicted) and twelve age- and sex-matched healthy controls completed two time-to-symptom limitation (T-LIM) constant load exercise tests at 75% peak power output with either intravenous saline or low-dose dopamine (2 mu g.kg(-1).min(-1), order randomized) to inhibit the CC. Ventilatory responses were evaluated using expired gas data and dyspnea was evaluated using a modified Borg scale. Inspiratory capacity maneuvers were performed to determine operating lung volumes. Cardiac output was estimated using impedance cardiography and vascular conductance was calculated as cardiac output/mean arterial pressure (MAP).
   Results: At a standardized exercise time of 4-min and at T-LIM; ventilation, operating volumes and dyspnea were unaffected by dopamine in COPD patients and controls. In COPD, dopamine decreased MAP and increased vascular conductance at all time points. In controls, dopamine increased vascular conductance at T-LIM, while MAP was unaffected.
   Conclusion: There was no change in time to exhaustion in either group with dopamine. These data suggest that the CC plays a role in cardiovascular regulation during exercise in COPD; however, ventilation, dyspnea and exercise tolerance were unaffected by CC inhibition in COPD patients.
C1 [Phillips, Devin B.; Collins, Sophie E.; Bryan, Tracey L.; Wong, Eric Y. L.; Bhutani, Mohit; Stickland, Michael K.] Univ Alberta, Fac Med & Dent, Div Pulm Med, Edmonton, AB, Canada.
   [Phillips, Devin B.] Univ Alberta, Fac Kinesiol Sport & Recreat, Edmonton, AB, Canada.
   [Collins, Sophie E.] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada.
   [McMurtry, M. Sean] Univ Alberta, Fac Med & Dent, Div Cardiol, Edmonton, AB, Canada.
   [Stickland, Michael K.] Covenant Hlth, GF MacDonald Ctr Lung Hlth, Edmonton, AB, Canada.
RP Stickland, MK (reprint author), 3-135 Clin Sci Bldg, Edmonton, AB T6G 2J3, Canada.
EM michael.stickland@ualberta.ca
OI Phillips, Devin/0000-0002-0664-5171
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR); Lung Association of Alberta/Northwest
   Territories (AB/NWT); Motyl Endowment Studentship in Cardiac Sciences
FX This study was supported by the Canadian Institutes of Health Research
   (CIHR). DBP was supported by a graduate scholarship from the Lung
   Association of Alberta/Northwest Territories (AB/NWT). S.EC was
   supported by the Motyl Endowment Studentship in Cardiac Sciences. The
   funders had no role in the study design, data collection and analysis,
   or preparation of the manuscript.
CR Neder JA, 2015, EUR RESPIR J, V45, P377, DOI 10.1183/09031936.00135514
   BOETGER CL, 1986, J APPL PHYSIOL, V61, P2102
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Boushel R, 1998, EUR J APPL PHYSIOL O, V79, P41, DOI 10.1007/s004210050471
   Boushel R, 2001, SCAND J MED SCI SPOR, V11, P213, DOI 10.1034/j.1600-0838.2001.110404.x
   Buckwalter JB, 1999, AM J PHYSIOL-HEART C, V277, pH33
   Charloux A, 2000, EUR J APPL PHYSIOL, V82, P313, DOI 10.1007/s004210000226
   Chung F, 2016, CHEST, V149, P631, DOI 10.1378/chest.15-0903
   Ciarka A, 2007, PULM PHARMACOL THER, V20, P607, DOI 10.1016/j.pupt.2006.10.011
   Collins S.E., 2019, FRONT PHYSL
   DEJOURS P, 1962, PHYSIOL REV, V42, P335
   Dempsey JA, 2014, EUR RESPIR J, V44, P495, DOI 10.1183/09031936.00048514
   Edgell H, 2015, J APPL PHYSIOL, V118, P839, DOI 10.1152/japplphysiol.00898.2014
   EDMUNDS AT, 1982, CLIN SCI, V63, P107, DOI 10.1042/cs0630107
   Elbehairy AF, 2015, AM J RESP CRIT CARE, V191, P1384, DOI 10.1164/rccm.201501-0157OC
   Eves ND, 2006, AM J RESP CRIT CARE, V174, P763, DOI 10.1164/rccm.200509-1533OC
   Grassi B, 1999, J APPL PHYSIOL, V87, P348
   Guenette JA, 2013, PULM MED, V2013, DOI 10.1155/2013/956081
   Guenette JA, 2014, EUR RESPIR J, V44, P1177, DOI 10.1183/09031936.00034714
   Guenette JA, 2012, EUR RESPIR J, V40, P322, DOI 10.1183/09031936.00157711
   Guenette JA, 2011, RESP PHYSIOL NEUROBI, V177, P218, DOI 10.1016/j.resp.2011.04.011
   Gutierrez C.A., 2004, EUR RESPIR J, V11, P12
   Hirai DM, 2017, J APPL PHYSIOL, V122, P1351, DOI 10.1152/japplphysiol.00990.2016
   HOFFMAN B B, 1990, P187
   Homma S, 1996, J Biomed Opt, V1, P418, DOI 10.1117/12.252417
   Jensen D, 2008, THORAX, V63, P606, DOI 10.1136/thx.2007.085993
   Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007
   JONES NL, 1979, J APPL PHYSIOL, V47, P954
   JOYNER MJ, 1992, AM J PHYSIOL, V263, pH1078
   LAHIRI S, 1980, J APPL PHYSIOL, V49, P45
   Laveneziana P, 2014, RESP PHYSIOL NEUROBI, V199, P24, DOI 10.1016/j.resp.2014.04.005
   Laveneziana P, 2011, AM J RESP CRIT CARE, V184, P1367, DOI 10.1164/rccm.201106-1128OC
   Limberg JK, 2016, J APPL PHYSIOL, V120, P138, DOI 10.1152/japplphysiol.00723.2015
   Louvaris Z, 2019, CLIN RESPIR J, V13, P222, DOI 10.1111/crj.13002
   MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Neder JA, 2016, COPD, V13, P416, DOI 10.3109/15412555.2016.1158801
   O'Donnell DE, 2016, EUR RESPIR REV, V25, P333, DOI 10.1183/16000617.0054-2016
   O'Donnell DE, 2016, RESPIROLOGY, V21, P211, DOI 10.1111/resp.12619
   O'Donnell DE, 2012, CHEST, V141, P753, DOI 10.1378/chest.11-0787
   O'Donnell DE, 2008, J APPL PHYSIOL, V105, P753, DOI 10.1152/japplphysiol.90336.2008b
   ODonnell DE, 1997, AM J RESP CRIT CARE, V155, P530, DOI 10.1164/ajrccm.155.2.9032190
   Ofir D, 2008, AM J RESP CRIT CARE, V177, P622, DOI 10.1164/rccm.200707-1064OC
   Oliveira CC, 2010, EUR J APPL PHYSIOL, V109, P681, DOI 10.1007/s00421-010-1408-8
   Peters MM, 2006, THORAX, V61, P559, DOI 10.1136/thx.2005.053470
   Phillips D.B., 2018, J PHYSL, V15, P3233
   Puente-Maestu L, 2009, EUR RESPIR J, V34, P340, DOI 10.1183/09031936.00078308
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   READ DJC, 1967, AUSTRALAS ANN MED, V16, P20
   ROWELL LB, 1990, J APPL PHYSIOL, V69, P407
   Shadgan B, 2011, RESP PHYSIOL NEUROBI, V178, P202, DOI 10.1016/j.resp.2011.06.001
   Somfay A, 2002, CHEST, V121, P393, DOI 10.1378/chest.121.2.393
   Stickland MK, 2008, J PHYSIOL-LONDON, V586, P1743, DOI 10.1113/jphysiol.2007.147421
   Stickland MK, 2007, CIRC RES, V100, P1371, DOI 10.1161/01.RES.0000266974.84590.d2
   Stickland MK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158341
   Stickland MK, 2011, J PHYSIOL-LONDON, V589, P6219, DOI 10.1113/jphysiol.2011.218099
   Torchio R, 2017, MONALDI ARCH CHEST D, V87, P85, DOI 10.4081/monaldi.2017.817
   Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005
   Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521
   WILSON JR, 1989, CIRCULATION, V80, P1668, DOI 10.1161/01.CIR.80.6.1668
   Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003
NR 61
TC 1
Z9 1
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105815
DI 10.1016/j.rmed.2019.105815
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000004
PM 31739245
DA 2020-05-18
ER

PT J
AU Rossides, M
   Grunewald, J
   Eklund, A
   Kullberg, S
   Askling, J
   Arkema, EV
AF Rossides, Marios
   Grunewald, Johan
   Eklund, Anders
   Kullberg, Susanna
   Askling, Johan
   Arkema, Elizabeth V.
TI Correspondence for "Clinical epidemiology of familial sarcoidosis: A
   systematic literature review"
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Sarcoidosis; Familial aggregation; Familial risk; Heritability
C1 [Rossides, Marios; Askling, Johan; Arkema, Elizabeth V.] Karolinska Inst, Dept Med Solna, Div Clin Epidemiol, Stockholm, Sweden.
   [Grunewald, Johan; Eklund, Anders; Kullberg, Susanna] Karolinska Inst, Div Resp Med, Dept Med Solna, Stockholm, Sweden.
   [Grunewald, Johan; Eklund, Anders; Kullberg, Susanna] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.
   [Grunewald, Johan; Eklund, Anders; Kullberg, Susanna] Karolinska Univ Hosp, Resp Med Theme Inflammat & Infect, Stockholm, Sweden.
   [Askling, Johan] Karolinska Univ Hosp, Rheumatol Theme Inflammat & Infect, Stockholm, Sweden.
RP Rossides, M (reprint author), Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Clin Epidemiol, Eugeniahemmet T2, S-17176 Stockholm, Sweden.
EM marios.rossides@ki.se
RI Rossides, Marios/L-4270-2016
OI Rossides, Marios/0000-0002-9769-324X; Arkema,
   Elizabeth/0000-0002-3677-9736
CR HEADINGS VE, 1976, ANN NY ACAD SCI, V278, P377, DOI 10.1111/j.1749-6632.1976.tb47049.x
   Rossides M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00385-2018
   Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001
   Sverrild A, 2008, THORAX, V63, P894, DOI 10.1136/thx.2007.094060
   Terwiel M, 2019, RESP MED, V149, P36, DOI 10.1016/j.rmed.2018.11.022
NR 5
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105696
DI 10.1016/j.rmed.2019.05.003
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000010
PM 31104964
DA 2020-05-18
ER

PT J
AU Terwiel, M
   van Moorsel, CHM
AF Terwiel, Michelle
   van Moorsel, Coline H. M.
TI Correspondence for "Clinical epidemiology of familial sarcoidosis: A
   systematic literature review"
SO RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Terwiel, Michelle; van Moorsel, Coline H. M.] St Antonius Hosp, St Antonius ILD Ctr Excellence, Dept Pulmonol, Nieuwegein, Netherlands.
RP van Moorsel, CHM (reprint author), St Antonius Hosp, St Antonius ILD Ctr Excellence, Dept Pulmonol, Nieuwegein, Netherlands.
EM c.van.moorsel@antoniusziekenhuis.nl
CR Arkema EV, 2016, EUR RESPIR J, V48, P1690, DOI 10.1183/13993003.00477-2016
   Calender A., 2019, RESP MED
   Elford J, 2000, THORAX, V55, P343, DOI 10.1136/thorax.55.4.343
   Fite E, 1998, RESPIRATION, V65, P34, DOI 10.1159/000029225
   HEADINGS VE, 1976, ANN NY ACAD SCI, V278, P377, DOI 10.1111/j.1749-6632.1976.tb47049.x
   Karakaya B, 2017, SEMIN RESP CRIT CARE, V38, P463, DOI 10.1055/s-0037-1602380
   Pacheco Y, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0546-4
   Rossides M., 2019, RESP MED
   Rossides M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00385-2018
   Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001
   Sverrild A, 2008, THORAX, V63, P894, DOI 10.1136/thx.2007.094060
   Tenesa A, 2013, NAT REV GENET, V14, P139, DOI 10.1038/nrg3377
   Terwiel M., 2019, CURR OPIN PULM MED, P1
   Terwiel M, 2019, RESP MED, V149, P36, DOI 10.1016/j.rmed.2018.11.022
NR 14
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105753
DI 10.1016/j.rmed.2019.07.012
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000008
PM 31331737
DA 2020-05-18
ER

PT J
AU Yang, D
   Huang, TX
   Liu, BC
   Liu, CT
AF Yang, Dan
   Huang, Tingxuan
   Liu, Bicui
   Liu, Chuntao
TI To the editor: Does Continuous Positive Airway Pressure (CPAP) treatment
   of obstructive sleep apnoea (OSA) improve asthma-related clinical
   outcomes in patients with co-existing conditions?
SO RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Yang, Dan; Huang, Tingxuan; Liu, Bicui; Liu, Chuntao] Sichuan Univ, West China Sch Med, Dept Resp & Crit Care Med, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.
   [Yang, Dan; Huang, Tingxuan; Liu, Bicui; Liu, Chuntao] Sichuan Univ, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.
RP Liu, CT (reprint author), Sichuan Univ, West China Sch Med, Dept Resp & Crit Care Med, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.; Liu, CT (reprint author), Sichuan Univ, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.
EM royyangdan@163.com; 2658508062@qq.com; liuyuan2469@163.com;
   liuchuntaohxyy@163.com
OI Liu, Bicui/0000-0001-9148-1046
CR Davies SE, 2018, RESP MED, V143, P18, DOI 10.1016/j.rmed.2018.08.004
   Global Initiative for Asthma, GLOB STRAT ASTHM MAN
   Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x
   JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1
   Lafond C, 2007, EUR RESPIR J, V29, P307, DOI 10.1183/09031936.00059706
   Serrano-Pariente J, 2017, ALLERGY, V72, P802, DOI 10.1111/all.13070
NR 6
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105651
DI 10.1016/j.rmed.2018.12.019
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000013
PM 30929952
DA 2020-05-18
ER

PT J
AU Zaccagnini, M
   Esquinas, AM
   Karim, HMR
AF Zaccagnini, Marco
   Esquinas, Antonio M.
   Karim, Habib M. R.
TI In response to Galindo-Filho et al. A mesh nebulizer is more effective
   than jet nebulizer during noninvasive ventilation of COPD subjects: A
   few practical points
SO RESPIRATORY MEDICINE
LA English
DT Letter
DE Nebulizers; Noninvasive ventilation; Pulmonary function; Radioaerosol
ID DRUG-DELIVERY
C1 [Zaccagnini, Marco] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
   [Esquinas, Antonio M.] Hosp Morales Meseguer, Murcia, Spain.
   [Karim, Habib M. R.] All India Inst Med Sci Raipur, Raipur, Madhya Pradesh, India.
RP Zaccagnini, M (reprint author), McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
EM marco.zaccagnini@mcgill.ca
RI Karim, Habib Md Reazaul/C-8154-2016; Zaccagnini, Marco/AAA-1185-2020
OI Karim, Habib Md Reazaul/0000-0002-6632-0491; Zaccagnini,
   Marco/0000-0002-9627-430X
CR Clark AR, 2015, CURR PHARM DESIGN, V21, P3974, DOI 10.2174/1381612821666150820105800
   Dhand R, 2007, CURR OPIN CRIT CARE, V13, P27, DOI 10.1097/MCC.0b013e328012e022
   Galindo VC, 2019, RESP MED, V153, P60, DOI 10.1016/j.rmed.2019.05.016
   Haidl P, 2016, RESP MED, V118, P65, DOI 10.1016/j.rmed.2016.07.013
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Walenga RL, 2017, J AEROSOL MED PULM D, V30, P190, DOI 10.1089/jamp.2016.1343
NR 6
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV-DEC
PY 2019
VL 160
AR UNSP 105754
DI 10.1016/j.rmed.2019.07.013
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4ID
UT WOS:000500954000011
PM 31324523
DA 2020-05-18
ER

PT J
AU Albers, FC
   Licskai, C
   Chanez, P
   Bratton, DJ
   Bradford, ES
   Yancey, SW
   Kwon, N
   Quirce, S
AF Albers, Frank C.
   Licskai, Christopher
   Chanez, Pascal
   Bratton, Daniel J.
   Bradford, Eric S.
   Yancey, Steven W.
   Kwon, Namhee
   Quirce, Santiago
TI Baseline blood eosinophil count as a predictor of treatment response to
   the licensed dose of mepolizumab in severe eosinophilic asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Mepolizumab; Blood eosinophil; Predictor; Exacerbation; Lung function
ID DOUBLE-BLIND; BENRALIZUMAB; MULTICENTER; DREAM
AB Background: Previous analyses examining the relationship between blood eosinophil count and mepolizumab treatment effects in severe eosinophilic asthma have used a range of doses and administration routes.
   Methods: This post hoc meta-analysis included data from the MENSA (MEA115588/NCT01691521) and MUSCA (200862/NCT02281318) trials. Patients (> 12 years) with severe eosinophilic asthma who experienced > 2 exacerbations in the prior year received either mepolizumab 100 mg subcutaneously (SC) or 75 mg intravenously, or placebo plus standard of care every 4 weeks. This meta-analysis reports data from patients receiving the licensed dose of mepolizumab (100 mg SC) or placebo only. The primary endpoint was the annual rate of clinically significant exacerbations; secondary endpoints included rate of exacerbations requiring hospitalization/emergency room (ER) visit, proportion of patients with no clinically significant exacerbations, and changes from baseline in forced expiratory volume in 1 s, Asthma Control Questionnaire-5 and St George's Respiratory Questionnaire scores. Analyses were stratified by baseline blood eosinophil count (<150, >= 150, >= 300, >= 400, >= 500, >= 750, >= 1000, >= 150-<300, or >= 300-<500 cells/mu L).
   Results: Mepolizumab reduced annual clinically significant exacerbation rates by 45%-85%, exacerbations requiring hospitalization/ER visit by 60%-70%, and increased the odds of no clinically significant exacerbations across all eosinophil threshold subgroups versus placebo, and improved all other secondary endpoints in subgroups >= 150 cells/mu L. Greater treatment effects with increasing blood eosinophil count were observed.
   Conclusions: Mepolizumab demonstrated consistent clinical benefits in patients with baseline blood eosinophil counts >= 150 cells/mu L, confirming the suitability of this cut-off for identifying patients responsive to the licensed mepolizumab dose.
C1 [Albers, Frank C.] GSK, Resp Med Franchise, Res Triangle Pk, NC USA.
   [Licskai, Christopher] Univ Western Ontario, Dept Med, London, ON, Canada.
   [Licskai, Christopher] London Hlth Sci, London, ON, Canada.
   [Chanez, Pascal] Aix Marseille Univ, INSERM INRA UMR1062, INSERM C2VN Ctr, Unites Mixtes Rech, Marseille, France.
   [Chanez, Pascal] Hop Nord Marseille, AP HM, Dept Resp Dis, Marseille, France.
   [Chanez, Pascal] Hop Nord Marseille, AP HM, Clin Invest Ctr, Marseille, France.
   [Bratton, Daniel J.] GSK, Clin Stat, Stockley Pk, Uxbridge, Middx, England.
   [Bradford, Eric S.; Yancey, Steven W.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA.
   [Kwon, Namhee] GSK, Resp Med Franchise, Brentford, Middx, England.
   [Quirce, Santiago] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, CIBER Enfermedades Resp CIBERES, Madrid, Spain.
   [Albers, Frank C.] Avill Us Inc, Med Dept, Northbrook, IL 60062 USA.
RP Albers, FC (reprint author), 103 Glade St, Chapel Hill, NC 27516 USA.
EM frank-c.albers@t-online.de; Chris.Licskai@sjhc.london.on.ca;
   Pascal.CHANEZ@univ-amu.fr; daniel.x.bratton@gsk.com;
   eric.s.bradford@gsk.com; steve.w.yancey@gsk.com; namhee.n.kwon@gsk.com;
   squirce@gmail.com
RI s, q/AAD-7171-2020
OI Albers, Frank/0000-0001-7039-4621
FU GSKGlaxoSmithKline [208115, MEA115588/NCT01691521, 200862/NCT02281318];
   GSKGlaxoSmithKline
FX This post hoc meta-analysis (GlaxoSmithKline [GSK] ID: 208115) and the
   parent studies (MENSA, MEA115588/NCT01691521; MUSCA, 200862/NCT02281318)
   were funded by GSK. Editorial support (in the form of writing
   assistance, including development of the initial draft based on author
   direction, assembling tables and figures, collating authors' comments,
   grammatical editing and referencing) was funded by GSK. All authors had
   roles in the conception, design, and interpretation of the analysis. All
   authors participated in the development of the manuscript and had access
   to the data from the studies. The decision to submit for publication was
   that of the authors alone. The sponsor did not place any restrictions on
   access to the data or on the statements made in the manuscript. The
   corresponding author had final responsibility for the decision to submit
   for publication.
CR Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
   Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032
   Busse W, 2019, J ALLERGY CLIN IMMUN, V143, P190, DOI 10.1016/j.jaci.2018.08.031
   Cabon Y, 2017, CLIN EXP ALLERGY, V47, P129, DOI 10.1111/cea.12853
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   FitzGerald JM, 2018, LANCET RESP MED, V6, P51, DOI 10.1016/S2213-2600(17)30344-2
   FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
   GlaxoSmithKline, 2015, MEP NUCALA HIGHL PRE
   GlaxoSmithKline, 2018, GSK CLIN STUD REG
   GlaxoSmithKline, 2015, MEP SUMM PROD CHAR
   Mukherjee M, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-32
   Ortega H, 2018, J ALLER CL IMM-PRACT, V6, P980, DOI 10.1016/j.jaip.2017.12.019
   Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Suruki RY, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0409-3
   Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
   Zeiger RS, 2016, J ALLER CL IMM-PRACT, V4, P120, DOI 10.1016/j.jaip.2015.08.003
NR 21
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105806
DI 10.1016/j.rmed.2019.105806
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200003
PM 31751853
DA 2020-05-18
ER

PT J
AU Cabibel, V
   Alexandre, F
   Oliver, N
   Varray, A
   Heraud, N
AF Cabibel, Vincent
   Alexandre, Francois
   Oliver, Nicolas
   Varray, Alain
   Heraud, Nelly
TI Psychoactive medications in chronic obstructive pulmonary disease
   patients: From prevalence to effects on motor command and strength
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Psychoactive medications; COPD; Muscle weakness; Motor command; Brain;
   TMS
ID PERIPHERAL MUSCLE WEAKNESS; DIRECT-CURRENT STIMULATION; INTRACORTICAL
   INHIBITION; VOLUNTARY ACTIVATION; CORTICAL EXCITABILITY; COGNITIVE
   FUNCTION; SILENT PERIOD; LACTIC-ACID; DEPRESSION; EXERCISE
AB Introduction: In chronic-obstructive pulmonary disease (COPD) patients, the peripheral muscle weakness is partly due to reduced motor command. The psychoactive medications, which are often prescribed in COPD, are mainly inhibitory and thus may contribute to motor command reduction. The aims were to characterize and quantify the use of these drugs and determine their effects on cortical excitability and inhibition and thus on motor command and muscle weakness in these patients.
   Methods: First, a prevalence study was conducted on 421 COPD patients. Second, cortical excitability, inhibition and voluntary activation were assessed in 40 patients (15 under psychoactive medications vs. 25 controls) by transcranial magnetic stimulation of the rectus femoris. Quadriceps maximal isometric strength was also assessed.
   Results: About 48% of the patients were taking psychoactive medication. Benzodiazepines (21%) and antidepressants (13.5%) were the most prescribed. Patients with medications tended to be younger and isolated (p < 0.05). They also showed impaired cortical inhibition and decreased cortical excitability (+36%, p = 0.02). Voluntary activation was reduced (-3.6%, p = 0.04) but quadriceps strength was comparable between groups.
   Conclusions: Psychoactive medications are prevalent in COPD patients. Patients under these medications exhibited brain impairment and reduced motor command. Paradoxically, voluntary strength was unaltered.
C1 [Cabibel, Vincent; Varray, Alain] Univ Montpellier, EuroMov Lab, 700 Ave Pic St, F-34090 Montpellier, France.
   [Cabibel, Vincent; Alexandre, Francois; Oliver, Nicolas; Heraud, Nelly] Grp 5 Sante, Clin Souffle, Montpellier, France.
RP Cabibel, V (reprint author), Univ Montpellier, EuroMov Lab, 700 Ave Pic St, F-34090 Montpellier, France.
EM vincent.cabibel@gmail.com
OI Varray, Alain/0000-0003-3876-1211
FU French Agency for Research and Technology (ANRT)French National Research
   Agency (ANR) [CIFRE 2016/088]
FX Vincent Cabibel was supported by the French Agency for Research and
   Technology (ANRT, CIFRE 2016/088).
CR Alexandre F, 2016, SLEEP, V39, P327, DOI 10.5665/sleep.5438
   Alexandre F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100961
   Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303
   Arnold I, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0183-0
   Barnes PJ, 2016, J ALLERGY CLIN IMMUN, V138, P16, DOI 10.1016/j.jaci.2016.05.011
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2
   Bernard S, 1998, AM J RESP CRIT CARE, V158, P629, DOI 10.1164/ajrccm.158.2.9711023
   Blain GM, 2016, J PHYSIOL-LONDON, V594, P5303, DOI 10.1113/JP272283
   Brooks TWA, 2007, PHARMACOTHERAPY, V27, P684, DOI 10.1592/phco.27.5.684
   Bulloch AGM, 2017, J AFFECT DISORDERS, V223, P65, DOI 10.1016/j.jad.2017.06.007
   Cabibel V, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.OA3433
   Cabibel V, 2018, J NEUROPHYSIOL, V119, P1266, DOI 10.1152/jn.00861.2017
   Cleland JA, 2007, FAM PRACT, V24, P217, DOI 10.1093/fampra/cmm009
   Cullu N, 2013, ACTA MEDICA MEDITERR, V29, P255
   Darques JL, 1998, NEUROSCI LETT, V257, P109
   Debigare R, 2003, CHEST, V124, P83, DOI 10.1378/chest.124.1.83
   Decramer M, 1997, EUR RESPIR J, V10, P417, DOI 10.1183/09031936.97.10020417
   Di Lazzaro V, 2007, CLIN NEUROPHYSIOL, V118, P2207, DOI 10.1016/j.clinph.2007.07.005
   Di Lazzaro V, 2005, J PHYSIOL-LONDON, V569, P315, DOI 10.1113/jphysiol.2005.092155
   Di Lazzaro V, 2000, CLIN NEUROPHYSIOL, V111, P794, DOI 10.1016/S1388-2457(99)00314-4
   Di Lazzaro V, 2006, J PHYSIOL-LONDON, V575, P721, DOI 10.1113/jphysiol.2006.114694
   Dodd JW, 2010, EUR RESPIR J, V35, P913, DOI 10.1183/09031936.00125109
   Frazer A, 2016, MUSCLE NERVE, V54, P903, DOI 10.1002/mus.25143
   Gagnon P, 2012, AM J RESP CRIT CARE, V186, P606, DOI 10.1164/rccm.201203-0404OC
   GOLD, 2016, GLOB IN CHRON OBSTR
   Gosselink R, 1996, AM J RESP CRIT CARE, V153, P976, DOI 10.1164/ajrccm.153.3.8630582
   Herbert RD, 1999, J NEUROPHYSIOL, V82, P2271
   Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226
   Iyer AS, 2019, J PSYCHOSOM RES, V118, P18, DOI 10.1016/j.jpsychores.2019.01.002
   Janssen Daisy J A, 2010, Chron Respir Dis, V7, P147, DOI 10.1177/1479972310369285
   Janssens T, 2011, CHEST, V140, P618, DOI 10.1378/chest.10-3257
   Kimiskidis VK, 2006, EXP BRAIN RES, V173, P603, DOI 10.1007/s00221-006-0402-1
   Kooistra RD, 2007, EUR J APPL PHYSIOL, V100, P309, DOI 10.1007/s00421-007-0425-8
   Lewer D, 2015, BRIT J PSYCHIAT, V207, P221, DOI 10.1192/bjp.bp.114.156786
   Maltais F, 1996, AM J RESP CRIT CARE, V153, P288, DOI 10.1164/ajrccm.153.1.8542131
   Mapel DW, 2000, ARCH INTERN MED, V160, P2653, DOI 10.1001/archinte.160.17.2653
   Marengoni A, 2012, INT PSYCHOGERIATR, V24, P606, DOI 10.1017/S1041610211002353
   Marillier M, 2018, MED SCI SPORT EXER, V50, P1529, DOI 10.1249/MSS.0000000000001625
   McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2
   Miyata A, 2015, PSYCHOPHARMACOLOGY, V232, P2127, DOI 10.1007/s00213-014-3843-4
   Mohamed-Hussein AAR, 2007, INT J TUBERC LUNG D, V11, P515
   Mohammadi B, 2006, MUSCLE NERVE, V33, P778, DOI 10.1002/mus.20531
   Muller-Dahlhaus JFM, 2008, J PHYSIOL-LONDON, V586, P495, DOI 10.1113/jphysiol.2007.142059
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Palmieri MG, 1999, BRAIN RES, V815, P192, DOI 10.1016/S0006-8993(98)01164-0
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   R.D.C. Team, 2008, A LANG ENV STAT COMP
   Rebar AL, 2015, HEALTH PSYCHOL REV, V9, P366, DOI 10.1080/17437199.2015.1022901
   Robol E, 2004, J NEUROL SCI, V221, P41, DOI 10.1016/j.jns.2004.03.007
   Rochester CL, 2015, AM J RESP CRIT CARE, V192, P1373, DOI 10.1164/rccm.201510-1966ST
   ROTTO DM, 1988, J APPL PHYSIOL, V64, P2306
   Ruotsalainen I, 2014, EUR J APPL PHYSIOL, V114, P1545, DOI 10.1007/s00421-014-2884-z
   Seymour JM, 2010, EUR RESPIR J, V36, P81, DOI 10.1183/09031936.00104909
   Shrikrishna D, 2012, EUR RESPIR J, V40, P1115, DOI 10.1183/09031936.00170111
   Simoneau EM, 2009, J ELECTROMYOGR KINES, V19, pE123, DOI 10.1016/j.jelekin.2007.11.006
   Skarabot J, 2019, EXP PHYSIOL, V104, P635, DOI 10.1113/EP087557
   Stranks EK, 2014, J CLIN EXP NEUROPSYC, V36, P691, DOI 10.1080/13803395.2014.928268
   Swallow EB, 2007, THORAX, V62, P115, DOI 10.1136/thx.2006.062026
   Teo W., 2015, ANN PHYS REHABIL MED, V58, pe1, DOI DOI 10.1016/J.REHAB.2015.07.008
   Tremblay S, 2013, NEUROREPORT, V24, P46, DOI 10.1097/WNR.0b013e32835c36b8
   Vivodtzev I, 2008, MUSCLE NERVE, V37, P27, DOI 10.1002/mus.20867
   Vozoris NT, 2014, EUR RESPIR J, V44, P332, DOI 10.1183/09031936.00008014
   Wang MT, 2017, JAMA PSYCHIAT, V74, P252, DOI 10.1001/jamapsychiatry.2016.3793
   Yohannes AM, 2014, EUR RESPIR REV, V23, P345, DOI 10.1183/09059180.00007813
   Zar JH, 2010, BIOSTATISTICAL ANAL
   Zhang H, 2013, AM J NEURORADIOL, V34, P334, DOI 10.3174/ajnr.A3235
   Zhang HY, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000844
   Ziemann U, 1996, EXP BRAIN RES, V109, P127
NR 69
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105805
DI 10.1016/j.rmed.2019.105805
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200004
PM 31704592
DA 2020-05-18
ER

PT J
AU Campo, P
   Campos, GS
   Aparicio, MB
   Jorge, AM
   Exposito, HMG
   Quirce, S
   Davila, I
AF Campo, Paloma
   Soto Campos, Gregorio
   Blanco Aparicio, Marina
   Moreira Jorge, Ana
   Gonzalez Exposito, Hector Manuel
   Quirce, Santiago
   Davila, Ignacio
TI Severe asthma phenotypes in patients controlled with omalizumab: A
   real-world study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Clinical phenotypes; Omalizumab; Oral corticosteroids; Response to
   omalizumab
ID ANTI-IGE; CLUSTER-ANALYSIS; ALLERGIC-ASTHMA; PREVALENCE; VALIDATION;
   SYMPTOMS; MULTICENTER; HEALTH; COHORT
AB Background: The appropriate identification of asthma phenotypes of responders to omalizumab would optimize the selection of treatment.
   Objective: To describe the most frequent clinical phenotypes in patients with severe asthma responding to omalizumab and their clinical and pulmonary function improvement.
   Methods: This was an observational, retrospective, multicenter study. Adult patients with severe asthma, who achieved good control after the first year of treatment with omalizumab were included. Omalizumab was prescribed according to clinical routine practice. Responders were assigned to one pre-established phenotype based on the most predominant one before they had started treatment with omalizumab, all according to the physician's criteria. Data about asthma symptoms, number of non-severe asthma exacerbations, medication intake (inhaled and oral corticosteroids and rescue medication), lung function, high fractional exhaled nitric oxide (FeNO) and peripheral eosinophils counts were recorded.
   Results: Among the 345 patients included, the main phenotypes were severe asthma with frequent exacerbations (29.9%), early-onset allergic asthma (23.8%), severe steroid-dependent asthma (18.8%), and severe eosinophilic asthma (13.6%). Clinical and respiratory changes observed after first year of treatment with omalizumab included: reduction in asthma symptoms, reduction in the use and dose of corticosteroids and need for rescue therapy, improvement of pulmonary function, reduction in the number of episodes of non-severe asthma exacerbations regardless of the duration of severe disease since the diagnosis. Increased blood levels of peripheral eosinophils and high FeNO levels were found at baseline.
   Conclusion: Several heterogeneous severe asthma phenotypes were observed as good responders to omalizumab.
C1 [Campo, Paloma] IBIMA Reg Univ Hosp Malaga, Allergy Unit, ARADyAL, Malaga, Spain.
   [Soto Campos, Gregorio] Hosp Univ Jerez, Pneumol & Allergy Unit, Cadiz, Spain.
   [Blanco Aparicio, Marina] Complexo Hosp Univ A Coruna, Pneumol Serv, La Coruna, Spain.
   [Moreira Jorge, Ana] Novartis Farmaceut, Barcelona, Spain.
   [Gonzalez Exposito, Hector Manuel] Hosp Univ Canarias, Pneumol Serv, Santa Cruz De Tenerife, Spain.
   [Quirce, Santiago] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain.
   [Quirce, Santiago] CIBERES, CIBER Enfermedades Resp, Madrid, Spain.
   [Davila, Ignacio] Univ Hosp Salamanca, Allergy Serv, Salamanca, Spain.
   [Davila, Ignacio] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain.
   [Davila, Ignacio] Salamanca Univ, Biomed & Diag Sci Dept, Sch Med, Salamanca, Spain.
RP Campos, GS (reprint author), Hosp Univ Jerez, Pneumol & Allergy Unit, Cadiz, Spain.
EM campomozo@gmail.com; josesoto@separ.es; mba@mundo-r.com;
   ana.moreirajorge@novartis.com; hectorbrezo@gmail.com; squirce@gmail.com;
   idg@usal.es
RI s, q/AAD-7171-2020; Davila, Ignacio/K-4453-2012; Soto campos, jose
   gregorio/Q-2888-2017
OI Davila, Ignacio/0000-0001-8485-5513; Soto campos, jose
   gregorio/0000-0003-4052-0417
FU Novartis Farmac.eutica SA, Spain
FX This study was sponsored by Novartis Farmac.eutica SA, Spain, in
   accordance with principles of ICH for Good Clinical Practices (GCP).
CR Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903
   Asher MI, 1998, EUR RESPIR J, V12, P315
   Bhutani M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183869
   Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011
   Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x
   Braunstahl GJ, 2013, RESP MED, V107, P1141, DOI 10.1016/j.rmed.2013.04.017
   Braunstahl GJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-47
   Burney P, 1996, EUR RESPIR J, V9, P687
   Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880
   Campo P, 2013, J INVEST ALLERG CLIN, V23, P76
   Casale TB, 2019, J ALLER CL IMM-PRACT, V7, P156, DOI 10.1016/j.jaip.2018.04.043
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Vennera MD, 2014, ARCH BRONCONEUMOL, V50, P384, DOI 10.1016/j.arbres.2014.03.002
   Executive Committee GEMA 2009, 2010, J Investig Allergol Clin Immunol, V20 Suppl 1, P1
   Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871
   FitzGerald J Mark, 2006, Can Respir J, V13, P253
   Garcia G, 2013, CHEST, V144, P411, DOI 10.1378/chest.12-1961
   Global Initiative for Asthma (GINA), 2019, GLOB STRAT ASTHM MAN
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC
   Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002
   Humbert M, 2008, ALLERGY, V63, P592, DOI 10.1111/j.1398-9995.2008.01654.x
   John F., 2012, CLUSTER ANAL OBESITY
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   Konno S, 2018, ANN AM THORAC SOC, V15, P33, DOI 10.1513/AnnalsATS.201701-065OC
   Mann CJ, 2003, EMERG MED J, V20, P54, DOI 10.1136/emj.20.1.54
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Massanari M, 2010, RESP MED, V104, P188, DOI 10.1016/j.rmed.2009.09.011
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   de Llano LP, 2013, J ASTHMA, V50, P296, DOI 10.3109/02770903.2012.757780
   Tordera MP, 2009, ARCH BRONCONEUMOL, V45, P218, DOI 10.1016/j.arbres.2008.06.006
   Porsbjerg C, 2017, RESPIROLOGY, V22, P651, DOI 10.1111/resp.13026
   Quirce S, 2011, J INVEST ALLERG CLIN, V21, P466
   Sendin-Hernandez M.P., 2018, J ALLERGY CLIN IMMUN, V6
   Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322
   Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101
   Tabatabaian F, 2018, J ASTHMA ALLERGY, V11, P53, DOI 10.2147/JAA.S107982
   Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032
   Thomson N.C., 2012, OMALIZUMAB CLIN USE, V6, pS7793
   To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204
   Vega JM, 2007, J ASTHMA, V44, P867, DOI 10.1080/02770900701752615
   Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
   Wahn U, 2009, ALLERGY, V64, P1780, DOI 10.1111/j.1398-9995.2009.02119.x
   WALKER S, 2004, COCHRANE DB SYST REV
   Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x
   Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6
NR 46
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105804
DI 10.1016/j.rmed.2019.105804
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200002
PM 31704593
DA 2020-05-18
ER

PT J
AU Cerri, S
   Monari, M
   Guerrieri, A
   Donatelli, P
   Bassi, I
   Garuti, M
   Luppi, F
   Betti, S
   Bandelli, G
   Carpano, M
   Reggiani, MLB
   Tonelli, R
   Clini, E
   Nava, S
AF Cerri, Stefania
   Monari, Matteo
   Guerrieri, Aldo
   Donatelli, Pierluigi
   Bassi, Ilaria
   Garuti, Martina
   Luppi, Fabrizio
   Betti, Sara
   Bandelli, Gianpiero
   Carpano, Marco
   Reggiani, Maria Letizia Bacchi
   Tonelli, Roberto
   Clini, Enrico
   Nava, Stefano
TI Real-life comparison of pirfenidone and nintedanib in patients with
   idiopathic pulmonary fibrosis: A 24-month assessment
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Forced vital capacity; Nintedanib;
   Pirfenidone
ID EFFICACY; SAFETY; EXPERIENCE; CAPACITY
AB Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathic pulmonary fibrosis (IPF) are still scarce.
   Methods: We compared the efficacy of either pirfenidone (n = 78) or nintedanib (n = 28) delivered over a 24-month period in patients with IPF, followed at two regional clinic centers in Italy, with a group of patients who refused the treatment (n = 36), and who were considered to be controls. All patients completed regular visits at 1- to 3-month intervals, where primary [forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)] and secondary outcomes (side effects, treatment compliance, and mortality) were recorded.
   Results: Over time, the decline in FVC and DLCO was significantly higher (p = 0.0053 and p = 0.037, respectively) in controls when compared with the combined treated group, with no significant difference between the two treated groups. Compared to patients with less advanced disease (GAP (Gender, Age, Physiology) stage I), those in GAP stages II and III showed a significantly higher decline in both FVC and DLCO irrespective of the drug taken. Side effects were similarly reported in patients receiving pirfenidone and nintedanib (5% and 7%, respectively), whereas mortality did not differ among the three groups.
   Conclusion: This real-life study demonstrated that both pirfenidone and nintedanib were equally effective in reducing the decline of FVC and DLCO versus non-treated patients after 24 months of treatment; however, patients with more advanced disease were likely to show a more rapid decline in respiratory function.
C1 [Cerri, Stefania; Clini, Enrico] Univ Hosp Modena Policlin, Pneumol Unit, Modena, Italy.
   [Monari, Matteo; Bassi, Ilaria; Betti, Sara; Bandelli, Gianpiero; Carpano, Marco; Clini, Enrico; Nava, Stefano] Alma Mater Univ, S Orsola Malpighi Hosp Bologna, Dept Clin Integrated & Expt Med DIMES, Resp & Crit Care Unit, Bologna, Italy.
   [Guerrieri, Aldo; Clini, Enrico] S Orsola Malpighi Hosp Bologna, Resp & Crit Care Unit, Bologna, Italy.
   [Donatelli, Pierluigi; Garuti, Martina; Tonelli, Roberto; Clini, Enrico] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Modena, Italy.
   [Donatelli, Pierluigi; Garuti, Martina; Tonelli, Roberto; Clini, Enrico] Univ Modena & Reggio Emilia, Postdoctoral Sch Resp Dis, Modena, Italy.
   [Luppi, Fabrizio] Univ Milano Bicocca, Cardiothorac Vasc Dept, Monza, Italy.
   [Luppi, Fabrizio] San Gerardo Hosp, Resp Unit, Monza, Italy.
   [Reggiani, Maria Letizia Bacchi] Alma Mater Univ, S Orsola Malpighi Hosp Bologna, Dept Clin Integrated & Expt Med DIMES, Stat Serv, Bologna, Italy.
   [Tonelli, Roberto] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy.
RP Nava, S (reprint author), St Orsola Hosp, Resp & Crit Care Unit, Via Massarenti 7, I-40138 Bologna, Italy.
EM stefanava@gmail.com
RI Clini, Enrico/A-4496-2017
OI Clini, Enrico/0000-0002-1515-5094; Tonelli, Roberto/0000-0002-6202-0758;
   LUPPI, FABRIZIO/0000-0001-5775-5947
CR Arai T, 2014, RESPIR INVESTIG, V52, P136, DOI 10.1016/j.resinv.2013.09.002
   Azuma A, 2005, AM J RESP CRIT CARE, V171, P1040, DOI 10.1164/rccm.200404-571OC
   Bargagli E, 2019, PULMONOLOGY, V25, P149, DOI 10.1016/j.pulmoe.2018.06.003
   Bonella F, 2013, DEUT MED WOCHENSCHR, V138, P518, DOI 10.1055/s-0032-1332930
   Chaudhuri N, 2014, RESP MED, V108, P224, DOI 10.1016/j.rmed.2013.11.005
   Fleetwood Kelly, 2017, J Manag Care Spec Pharm, V23, pS5, DOI 10.18553/jmcp.2017.23.3-b.s5
   Harari S, 2015, RESP MED, V109, P904, DOI 10.1016/j.rmed.2015.04.010
   Harari S, 2018, RESPIRATION, V95, P433, DOI 10.1159/000487711
   Harari S, 2015, EUR RESPIR REV, V24, P420, DOI 10.1183/16000617.0042-2015
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Loeh B, 2015, AM J RESP CRIT CARE, V191, P110, DOI 10.1164/rccm.201406-1106LE
   Margaritopoulos GA, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0736-z
   Caro FM, 2019, ARCH BRONCONEUMOL, V55, P75, DOI 10.1016/j.arbres.2018.06.014
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Okuda R, 2013, RESP MED, V107, P1431, DOI 10.1016/j.rmed.2013.06.011
   Oltmanns U, 2014, RESPIRATION, V88, P199, DOI 10.1159/000363064
   Paterniti MO, 2017, ANN AM THORAC SOC, V14, P1395, DOI 10.1513/AnnalsATS.201606-458OC
   Raghu G, 2018, JAMA-J AM MED ASSOC, V319, P2299, DOI 10.1001/jama.2018.6129
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Richeldi L, 2011, NEW ENGL J MED, V365, P1079, DOI 10.1056/NEJMoa1103690
   Salih GN, 2016, EUR CLIN RESPIR J, V3, DOI 10.3402/ecrj.v3.32608
   Tzouvelekis A, 2018, PULM PHARMACOL THER, V49, P61, DOI 10.1016/j.pupt.2018.01.006
   Tzouvelekis A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00213
   Vancheri C, 2019, RESP MED, V156, P78, DOI 10.1016/j.rmed.2019.08.006
   Vancheri C, 2018, AM J RESP CRIT CARE, V197, P356, DOI 10.1164/rccm.201706-1301OC
NR 26
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105803
DI 10.1016/j.rmed.2019.105803
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200007
PM 31670147
DA 2020-05-18
ER

PT J
AU Gibson, J
   Baird, T
   Pandey, S
   Tolson, C
   Coulter, C
   Eather, G
   Thomson, R
AF Gibson, Justine
   Baird, Tim
   Pandey, Sushil
   Tolson, Carla
   Coulter, Chris
   Eather, Geoffrey
   Thomson, Rachel
TI The clinical significance of Mycobacterium triplex
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Nontuberculous mycobacteria; Mycobacterium triplex; Macrolides; Drug
   susceptibility testing
ID NONTUBERCULOUS MYCOBACTERIA; PULMONARY INFECTION; EPIDEMIOLOGY;
   RESISTANCE
AB Objectives: Mycobacterium triplex is a slow-growing nontuberculous mycobacteria (NTM) and is a rare cause of human disease. The pathogenicity, natural history and spectrum of disease is unknown. The aim of this study was to review the clinical features, outcomes and drug susceptibility testing (DST) of all M. triplex isolates in Queensland, Australia to guide management of this rare NTM infection in the future.
   Methods: This retrospective study included all patients who isolated M. triplex in Queensland, Australia from the 1st January 2000 to 31st December 2016. Clinical information was obtained from medical records to determine the clinical significance of isolates, natural history of disease and treatment outcomes. DST was performed on 15 isolates.
   Results: Forty-three patients (21 male) had positive cultures for M. triplex. Thirty-nine patients had isolates from pulmonary specimens and 17 (43.6%) met the American Thoracic Society criteria for NTM lung disease. Six patients with pulmonary infection received antimicrobial therapy with 5 patients demonstrating treatment success. Four patients had localised extrapulmonary disease and were cured with surgical management +/- antimicrobial therapy. DST suggests 93% of isolates are susceptible to macrolides.
   Conclusion: This is the largest case series of M. triplex isolates and confirms it is a rare human pathogen. Extrapulmonary disease responded well to surgical management. Treatment of M. triplex pulmonary disease is challenging, and the optimal antimicrobial regimen is unknown. However, the DST data suggests macrolide resistance is rare and macrolides should be included in treatment regimens.
C1 [Gibson, Justine; Eather, Geoffrey] Princess Alexandra Hosp, Brisbane, Qld, Australia.
   [Gibson, Justine; Coulter, Chris; Eather, Geoffrey; Thomson, Rachel] Metro South Clin TB Serv, Brisbane, Qld, Australia.
   [Baird, Tim] Sunshine Coast Univ Hosp, Birtinya, Qld, Australia.
   [Pandey, Sushil; Tolson, Carla; Coulter, Chris] QMRL, Pathol Queensland, Brisbane, Qld, Australia.
   [Thomson, Rachel] Univ Queensland, Brisbane, Qld, Australia.
   [Thomson, Rachel] Gallipoli Med Res Inst, Brisbane, Qld, Australia.
   [Thomson, Rachel] Greenslopes Private Hosp, Brisbane, Qld, Australia.
RP Gibson, J (reprint author), Princess Alexandra Hosp, Dept Resp & Sleep Med, 199 Ipswich Rd, Woolloongabba, Qld 4102, Australia.
EM Justine.Gibson@health.qld.gov.au
RI Thomson, Rachel/C-1009-2011
OI Thomson, Rachel/0000-0003-0686-171X; Gibson, Justine/0000-0001-6695-9490
CR Caruso G, 2013, INDIAN J MICROBIOL, V53, P241, DOI 10.1007/s12088-013-0367-2
   Cingolani A, 2000, CLIN INFECT DIS, V31, P177, DOI 10.1086/313903
   Clinical and Laboratory Standards Institute from:CLSI, 2018, M62 CLSI S
   Campos CED, 2016, INT J MYCOBACT, V5, P89, DOI 10.1016/j.ijmyco.2015.09.004
   Dylewski J.S., 2011, CLIN MICROBIOL NEWSL, V33, P77
   Floyd MM, 1996, J CLIN MICROBIOL, V34, P2963, DOI 10.1128/JCM.34.12.2963-2967.1996
   Gcebe N, 2013, TRANSBOUND EMERG DIS, V60, P74, DOI 10.1111/tbed.12133
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2006, AM J RESP CRIT CARE, V174, P928, DOI 10.1164/rccm.200603-450OC
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Hazra R, 2001, J CLIN MICROBIOL, V39, P1227, DOI 10.1128/JCM.39.4.1227-1230.2001
   Henry MT, 2004, EUR RESPIR J, V23, P741, DOI 10.1183/09031936.04.00114004
   Hoff E, 2001, J CLIN MICROBIOL, V39, P2033, DOI 10.1128/JCM.39.5.2033-2034.2001
   HOFFNER SE, 1987, EUR J CLIN MICROBIOL, V6, P530, DOI 10.1007/BF02014241
   Honeybourne D, 2003, J ANTIMICROB CHEMOTH, V51, P1431, DOI 10.1093/jac/dkg262
   Ley S, 2015, WEST PAC SURVEILL RE, V6, P24, DOI [10.5365/wpsar.2015.6.2.004, 10.5365/WPSAR.2015.6.2.004]
   Mandell DL, 2003, ARCH OTOLARYNGOL, V129, P341, DOI 10.1001/archotol.129.3.341
   Matsuda S, 2018, CLIN MICROBIOL INFEC, V24, P671, DOI 10.1016/j.cmi.2017.12.018
   McMullan R, 2002, J INFECTION, V44, P263, DOI 10.1053/jinf.2002.0980
   Piersimoni C, 2004, EMERG INFECT DIS, V10, P1859, DOI 10.3201/eid1010.040217
   Prevots DR, 2015, CLIN CHEST MED, V36, P13, DOI 10.1016/j.ccm.2014.10.002
   Schon T, 2017, INT J INFECT DIS, V55, P122, DOI 10.1016/j.ijid.2016.12.027
   Song M., 2009, CHEST, V136
   Suomalainen S, 2001, J CLIN MICROBIOL, V39, P2668, DOI 10.1128/JCM.39.7.2668-2671.2001
   Thomson RM, 2010, EMERG INFECT DIS, V16, P1576, DOI 10.3201/eid1610.091201
   van Ingen J, 2012, DRUG RESIST UPDATE, V15, P149, DOI 10.1016/j.drup.2012.04.001
   Zeller V, 2003, J CLIN MICROBIOL, V41, P2785, DOI 10.1128/JCM.41.6.2785-2787.2003
NR 27
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105808
DI 10.1016/j.rmed.2019.105808
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200005
PM 31731086
DA 2020-05-18
ER

PT J
AU Kamiya, Y
   Fujisawa, T
   Kono, M
   Nakamura, H
   Yokomura, K
   Koshimizu, N
   Toyoshima, M
   Imokawa, S
   Sumikawa, H
   Johkoh, T
   Yasui, H
   Hozumi, H
   Suzuki, Y
   Karayama, M
   Furuhashi, K
   Enomoto, N
   Nakamura, Y
   Inui, N
   Suda, T
AF Kamiya, Yosuke
   Fujisawa, Tomoyuki
   Kono, Masato
   Nakamura, Hidenori
   Yokomura, Koshi
   Koshimizu, Naoki
   Toyoshima, Mikio
   Imokawa, Shiro
   Sumikawa, Hiromitsu
   Johkoh, Takeshi
   Yasui, Hideki
   Hozumi, Hironao
   Suzuki, Yuzo
   Karayama, Masato
   Furuhashi, Kazuki
   Enomoto, Noriyuki
   Nakamura, Yutaro
   Inui, Naoki
   Suda, Takafumi
TI Prognostic factors for primary Sjogren's syndrome-associated
   interstitial lung diseases
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sjorgen's syndrome; Interstitial lung disease; Prognostic factors;
   Forced vital capacity; KL-6
ID IDIOPATHIC PULMONARY-FIBROSIS; FLEISCHNER-SOCIETY; MORTALITY;
   MANIFESTATIONS; CLASSIFICATION; CRITERIA; INDEX; KL-6
AB Objective: Interstitial lung disease (ILD) is a condition characterized by a higher mortality rate in primary Sjogren's syndrome (pSS). However, factors influencing the outcome of patients with pSS-associated ILD remain unclear. The aim of the present study was to evaluate predictive factors associated with a worse prognosis in pSS-ILD.
   Methods: This retrospective study included 99 consecutive patients with pSS-ILD. Clinical characteristics, laboratory findings, and pulmonary function tests at the time of diagnosis were analyzed. Chest HRCT images were reviewed by two experienced chest radiologists. Prognostic factors were assessed by univariate and multivariate analyses, using Cox proportional hazards regression model.
   Results: Median age was 68 years (73% women). In the total patient population, the 5- and 10-year survival rates were 89.8% and 79.0%, respectively. Univariate analysis revealed a significant association between prognosis and age, serum Krebs von den Lungen-6 (KL-6) levels, and %FVC. None of the chest HRCT findings were related to patient outcomes. Based on multivariate analyses adjusted by age and gender, lower levels of %FVC and higher levels of KL-6 were significantly associated with poor outcomes. Using optimal cutoff levels, according to receiver operating characteristic curve analyses, KL-6 > 800 U/mL were significantly associated with worse prognosis (HR: 2.91, 95% CI: 1.04-8.10). Patients with elevated serum KL-6 levels (>800 U/mL) showed a higher mortality rate than those without elevated serum KL-6 levels (p = 0.02).
   Conclusions: Lower %FVC and higher serum KL-6 levels are predictive factors for poor outcome in patients with pSS-ILD.
C1 [Kamiya, Yosuke; Fujisawa, Tomoyuki; Yasui, Hideki; Hozumi, Hironao; Suzuki, Yuzo; Karayama, Masato; Furuhashi, Kazuki; Enomoto, Noriyuki; Nakamura, Yutaro; Suda, Takafumi] Hamamatsu Univ, Dept Internal Med, Div 2, Sch Med,Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Kono, Masato; Nakamura, Hidenori] Seirei Hamamatsu Gen Hosp, Dept Resp Med, Naka Ku, 2-12-12 Sumiyoshi, Hamamatsu, Shizuoka 4308558, Japan.
   [Yokomura, Koshi] Seirei Mikatahara Gen Hosp, Dept Resp Med, Kita Ku, 3453 Mikataharacho, Hamamatsu, Shizuoka 4338558, Japan.
   [Koshimizu, Naoki] Fujieda Municipal Gen Hosp, Dept Resp Med, 4-1-11 Surugadai, Fujieda, Shizuoka 4268677, Japan.
   [Toyoshima, Mikio] Hamamatsu Rosai Hosp, Dept Resp Med, Higashi Ku, 25 Shogencho, Hamamatsu, Shizuoka 4308525, Japan.
   [Imokawa, Shiro] Iwata City Hosp, Dept Resp Med, 512-3 Okubocho, Iwata 4388550, Japan.
   [Sumikawa, Hiromitsu] Sakai City Med Ctr, Dept Radiol, Nishi Ku, 1-1-1 Ebarajicho, Sakai, Osaka 5938304, Japan.
   [Johkoh, Takeshi] Kansai Rosai Hosp, Dept Radiol, 3-1-69 Inabaso, Amagasaki, Hyogo 6608511, Japan.
   [Inui, Naoki] Hamamatsu Univ, Dept Clin Pharmacol & Therapeut, Sch Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
RP Fujisawa, T (reprint author), 1-20-1 Handayama Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan.
EM fujisawa@hama-med.ac.jp
RI Suzuki, Yuzo/AAE-6747-2020
OI Suzuki, Yuzo/0000-0001-6154-9791
CR Dong X, 2018, CLIN RHEUMATOL, V37, P2981, DOI 10.1007/s10067-018-4289-6
   Enomoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073774
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Flament T, 2016, EUR RESPIR REV, V25, P110, DOI 10.1183/16000617.0011-2016
   Fujisawa T, 2019, J RHEUMATOL, V46, P935, DOI 10.3899/jrheum.180825
   Fujisawa T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098824
   Gao H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011003
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Ishikawa N, 2012, RESPIR INVESTIG, V50, P3, DOI 10.1016/j.resinv.2012.02.001
   Ito I, 2005, AM J RESP CRIT CARE, V171, P632, DOI 10.1164/rccm.200403-417OC
   Kakugawa T, 2018, RESP MED, V137, P95, DOI 10.1016/j.rmed.2018.02.023
   Lee JS, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1835-9
   Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
   Lynch DA, 2018, LANCET RESP MED, V6, P138, DOI 10.1016/S2213-2600(17)30433-2
   Nannini C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003569
   Palm O, 2013, RHEUMATOLOGY, V52, P173, DOI 10.1093/rheumatology/kes311
   Parambil JG, 2006, CHEST, V130, P1489, DOI 10.1378/chest.130.5.1489
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Ramos-Casals M, 2015, RHEUMATOLOGY, V54, P2230, DOI 10.1093/rheumatology/kev200
   Roca F, 2017, AUTOIMMUN REV, V16, P48, DOI 10.1016/j.autrev.2016.09.017
   Salazar GA, 2018, J RHEUMATOL, V45, P1153, DOI 10.3899/jrheum.170518
   Salisbury ML, 2016, CHEST, V149, P491, DOI 10.1378/chest.15-0530
   Satoh H, 2006, J INTERN MED, V260, P429, DOI 10.1111/j.1365-2796.2006.01704.x
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
   Wang Y, 2018, J THORAC DIS, V10, P2108, DOI 10.21037/jtd.2018.03.120
   Winstone TA, 2014, CHEST, V146, P422, DOI 10.1378/chest.13-2626
   Yokoyama A, 2006, RESPIROLOGY, V11, P164, DOI 10.1111/j.1440-1843.2006.00834.x
NR 29
TC 0
Z9 0
U1 6
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105811
DI 10.1016/j.rmed.2019.105811
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200008
PM 31710871
DA 2020-05-18
ER

PT J
AU Kochli, S
   Endes, K
   Bartenstein, T
   Usemann, J
   Schmidt-Trucksass, A
   Frey, U
   Zahner, L
   Hanssen, H
AF Koechli, Sabrina
   Endes, Katharina
   Bartenstein, Tim
   Usemann, Jakob
   Schmidt-Trucksaess, Arno
   Frey, Urs
   Zahner, Lukas
   Hanssen, Henner
TI Lung function, obesity and physical fitness in young children: The
   EXAMIN YOUTH study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Body mass index; Blood pressure; Cardiorespiratory fitness; Pulmonary
   function
ID PULMONARY-FUNCTION; BLOOD-PRESSURE; ASTHMA; ADOLESCENCE; SPIROMETRY;
   CHILDHOOD; HEALTH
AB Objective: The prevalence of obesity and physical inactivity in children are increasing globally. The study aimed to investigate the association of obesity and cardiorespiratory fitness (CRF) with patterns of lung function in young children.
   Methods: In this cross-sectional study, lung function, body mass index (BMI), blood pressure (BP) and CRF (shuttle run stages) were measured in an unselected cohort of 1246 children aged 7.2 +/- 0.4 years. All parameters and lung function, such as the ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC), were assessed by standardized procedures for children. Statistical models were applied for systematic adjustment of potential confounders.
   Results: Obese children had significantly higher FEV1 (Coef. (95% CI) (1.57 (1.50; 1.64) L) and FVC (1.75 (1.67; 1.83) L) compared to normal weight children (1.38 (1.37; 1.40) L; (1.53 (1.51; 1.54) L, respectively). However, with each unit increase of BMI, FEV1/FVC decreased (-0.003 (-0.005; -0.001)) due to a disproportional increase in FVC compared to FEV1. Per stage increase of CRF, FEV1 (0.017 (0.008; 0.025) L) and FVC increased (0.022 (0.012; 0.031) L)). In obese children, higher CRF was independently associated with higher FEV1/FVC (0.03 (0.5E-4; 0.06)) due to a higher increase of FEV1 over FVC with increasing fitness.
   Conclusions: The decrease of FEV1/FVC with increasing BMI suggests that childhood obesity is associated with an imbalance of ventilation and airway flow. In children with obesity, higher CRF is associated with an improved FEV1/FVC ratio. Physical exercise programs may have the potential to improve patterns of lung function in children with obesity.
C1 [Koechli, Sabrina; Endes, Katharina; Bartenstein, Tim; Schmidt-Trucksaess, Arno; Zahner, Lukas; Hanssen, Henner] Univ Basel, Med Fac, Dept Sport Exercise & Hlth, Basel, Switzerland.
   [Usemann, Jakob; Frey, Urs] Univ Basel, Univ Childrens Hosp UKBB, Pediat Pulmonol, Basel, Switzerland.
   [Usemann, Jakob] Univ Bern, Bern Univ Hosp, Inselspital, Pediat Resp Med, Bern, Switzerland.
RP Hanssen, H (reprint author), Univ Basel, Dept Sport Exercise & Hlth, Birsstr 320B, CH-4052 Basel, Switzerland.
EM henner.hanssen@unibas.ch
RI Schmidt-Trucksass, Arno/I-7673-2015; Kochli, Sabrina/L-5160-2018
OI Kochli, Sabrina/0000-0003-0766-7476; Schmidt-Trucksass,
   Arno/0000-0002-4662-3911
FU Cantonal Office of Sport of Basel-Stadt; Department of Education of
   Basel-Stadt
FX The authors of this manuscript thank the children, as well as their
   parents and teachers, and the heads of schools, who participated in this
   study. We also would like to acknowledge the support and cooperation of
   the Cantonal Office of Sport of Basel-Stadt and the Department of
   Education of Basel-Stadt.
CR Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST
   Bos K, 1987, SPORTUNTERRICHT, V36, P145
   Chlif M, 2009, RESP PHYSIOL NEUROBI, V168, P198, DOI 10.1016/j.resp.2009.06.012
   Cibella F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127154
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Eising JB, 2015, EUR J PREV CARDIOL, V22, P140, DOI 10.1177/2047487313510410
   Falaschetti E, 2004, EUR RESPIR J, V23, P456, DOI 10.1183/09031936.04.00055204
   Falkner B, 2010, PEDIATR NEPHROL, V25, P1219, DOI 10.1007/s00467-009-1200-3
   Forno E, 2018, J ALLER CL IMM-PRACT, V6, P570, DOI 10.1016/j.jaip.2017.07.010
   Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016
   Frey U, 2015, ALLERGY, V70, P26, DOI 10.1111/all.12525
   Gochicoa-Rangel L, 2013, PEDIATR PULM, V48, P1231, DOI 10.1002/ppul.22765
   Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1
   Han YY, 2014, AM J RESP CRIT CARE, V190, P32, DOI 10.1164/rccm.201403-0565OC
   Hancox RJ, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01374-2017
   Jakes RW, 2002, AM J EPIDEMIOL, V156, P139, DOI 10.1093/aje/kwf021
   Ji J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066098
   Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827
   Lu Y, 2017, J HYPERTENS, V35, P2185, DOI 10.1097/HJH.0000000000001455
   Lurbe E, 1998, AM J HYPERTENS, V11, P418, DOI 10.1016/S0895-7061(97)00493-7
   Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001
   Neuhauser HK, 2011, PEDIATRICS, V127, pE978, DOI 10.1542/peds.2010-1290
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Pelkonen M, 2003, AM J RESP CRIT CARE, V168, P494, DOI 10.1164/rccm.200208-954OC
   Quanjer PH, 2010, EUR RESPIR J, V36, P1391, DOI 10.1183/09031936.00164109
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Rendo-Urteaga T, 2015, INT J CARDIOL, V186, P186, DOI [10.1016/j.ijcard.2015.03.176, 10.1016/j.ijcard.2014.11.175]
   Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC
   Steier J, 2014, THORAX, V69, P752, DOI 10.1136/thoraxjnl-2014-205148
   Tepper RS, 1999, AM J RESP CRIT CARE, V160, P835, DOI 10.1164/ajrccm.160.3.9811025
   Vale S, 2015, J PEDIATR-US, V167, P98, DOI 10.1016/j.jpeds.2015.04.031
   VANMECHELEN W, 1986, EUR J APPL PHYSIOL O, V55, P503, DOI 10.1007/BF00421645
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053
   Yao TC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174691
   Zahner L, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-147
NR 35
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105813
DI 10.1016/j.rmed.2019.105813
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200001
PM 31731085
DA 2020-05-18
ER

PT J
AU von Siemens, SM
   Alter, P
   Lutter, JI
   Kauczor, HU
   Jobst, B
   Bals, R
   Trudzinski, FC
   Sohler, S
   Behr, J
   Watz, H
   Waschki, B
   Bewig, B
   Jones, PW
   Welte, T
   Vogelmeier, CF
   Jorres, RA
   Kahnert, K
AF von Siemens, Sarah Marietta
   Alter, Peter
   Lutter, Johanna, I
   Kauczor, Hans-Ulrich
   Jobst, Bertram
   Bals, Robert
   Trudzinski, Franziska C.
   Soehler, Sandra
   Behr, Juergen
   Watz, Henrik
   Waschki, Benjamin
   Bewig, Burkhard
   Jones, Paul W.
   Welte, Tobias
   Vogelmeier, Claus F.
   Joerres, Rudolf A.
   Kahnert, Kathrin
CA COSYCONET Study Grp
TI CAT score single item analysis in patients with COPD: Results from
   COSYCONET
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Emphysema; CAT score
ID CATEGORIZATION; POPULATION; SPIROMETRY; DIAGNOSIS
AB The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema.
   Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items against a panel of comorbidities, lung function, or CT characteristics (qualitative score, 15th percentile of mean lung density), with age, BMI and gender as covariates. This was supported by exploratory factor analysis.
   Regarding the relationship to comorbidities and emphysema, there were marked differences between CAT items, especially items 1 and 2 versus 3 to 8. This grouping was basically confirmed by factor analysis. Items 4 and 5, and to a lower degree 1, 2 and 6, appeared to be informative regarding the presence of emphysema, whereas the total score was not or less informative. Regarding comorbidities, similar findings as for the total CAT score were obtained for the modified Medical Research Council scale (mMRC) which was also informative regarding emphysema.
   Our findings suggest that the usefulness of the CAT can be increased if evaluated on the basis of single items which may be indicating the presence of comorbidities and emphysema.
C1 [von Siemens, Sarah Marietta; Joerres, Rudolf A.] Ludwig Maximilians Univ Munchen, CPC M, Inst & Outpatient Clin Occupat Social & Environm, Ziemssenstr 1, D-80336 Munich, Germany.
   [Alter, Peter; Vogelmeier, Claus F.] Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med Pulm & Crit Care Med, Baldingerstr, D-35043 Marburg, Germany.
   [Alter, Peter; Vogelmeier, Claus F.] German Ctr Lung Res DZL, Baldingerstr, D-35043 Marburg, Germany.
   [Lutter, Johanna, I] Helmholtz Zentrum Munchen GmbH, German Res Ctr Environm Hlth, CPC M, Inst Hlth Econ & Hlth Care Management, Ingolstadter Landstr 1, D-85764 Munich, Germany.
   [Lutter, Johanna, I] German Ctr Lung Res, Ingolstadter Landstr 1, D-85764 Munich, Germany.
   [Kauczor, Hans-Ulrich; Jobst, Bertram] Univ Hosp Heidelberg, Dept Diagnost & Intervent Radiol, Heidelberg, Germany.
   [Kauczor, Hans-Ulrich; Jobst, Bertram] Translat Lung Res Ctr Heidelberg TLRC, Heidelberg, Germany.
   [Kauczor, Hans-Ulrich; Jobst, Bertram] German Ctr Lung Res, Heidelberg, Germany.
   [Kauczor, Hans-Ulrich; Jobst, Bertram] Univ Hosp Heidelberg, Thoraxklin, Dept Diagnost & Intervent Radiol Nucl Med, Heidelberg, Germany.
   [Bals, Robert; Trudzinski, Franziska C.] Saarland Univ Hosp, Intens Care Med, Dept Internal Med Pulmonol 5, Allergol, Kirrberger Str 1, D-66424 Homburg, Germany.
   [Soehler, Sandra] Univ Marburg, ASCONET Study Coordinat Off, Baldingerstr, D-35043 Marburg, Germany.
   [Behr, Juergen; Kahnert, Kathrin] Univ Munich LMU, Comprehens Pneumol Ctr, Dept Internal Med 5, Ziemssenstr 1, D-80336 Munich, Germany.
   [Behr, Juergen; Kahnert, Kathrin] German Ctr Lung Res, Ziemssenstr 1, D-80336 Munich, Germany.
   [Behr, Juergen] Asklepios Fachkliniken Munchen Gauting, Robert Koch Allee 2, D-82131 Gauting, Germany.
   [Watz, Henrik; Waschki, Benjamin] ARCN, LungenClin Grosshansdorf, Grosshansdorf, Germany.
   [Watz, Henrik; Waschki, Benjamin] German Ctr Lung Res DZL, Grosshansdorf, Germany.
   [Waschki, Benjamin] Univ Heart Ctr Hamburg, Dept Gen & Intervent Cardiol, Hamburg, Germany.
   [Bewig, Burkhard] Univ Hosp Schleswig Holstein, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany.
   [Jones, Paul W.] St Georges Univ London, Inst Infect & Immun, London SW19 0RE, England.
   [Welte, Tobias] Hannover Med Sch, Dept Pneurnol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
RP Kahnert, K (reprint author), Univ Munich LMU, Dept Internal Med 5, Ziemssenstr 1, D-80336 Munich, Germany.
EM Kathrin.Kahnert@med.uni-muenchen.de
RI ; Alter, Peter/G-2673-2015; Ficker, Joachim H./A-1153-2015
OI Seeger, Werner/0000-0003-1946-0894; Alter, Peter/0000-0002-2115-1743;
   Ficker, Joachim H./0000-0002-7175-5852
CR Celli BR, 2015, AM J RESP CRIT CARE, V191, P831, DOI 10.1164/rccm.201501-0044ST
   Chai CS, 2019, INT J CHRONIC OBSTR, V14, P565, DOI 10.2147/COPD.S196109
   Criee CP, 2015, PNEUMOLOGIE, V69, P147, DOI 10.1055/s-0034-1391345
   Ghobadi Hassan, 2012, Tanaffos, V11, P22
   Gupta N, 2014, EUR RESPIR J, V44, P873, DOI 10.1183/09031936.00025214
   Houben-Wilke S, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1034-4
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Jones PW, 2014, EUR RESPIR J, V44, P833, DOI 10.1183/09031936.00125214
   Jones PW, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-42
   Kahnert K, 2018, CHRON RESP DIS, V16, DOI 10.1177/1479972318775423
   Kahnert K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0815-y
   Kahnert K, 2018, RESP MED, V134, P79, DOI 10.1016/j.rmed.2017.12.003
   Kahnert K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177501
   Kahnert K, 2017, RESP RES, V18, DOI 10.1186/s12931-016-0499-0
   Karch A, 2016, RESP MED, V114, P27, DOI 10.1016/j.rmed.2016.03.008
   Karloh M, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.PA3705
   Lee SD, 2014, RESP MED, V108, P600, DOI 10.1016/j.rmed.2013.12.014
   Lucke T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163408
   Lynch DA, 2018, RADIOLOGY, V288, P859, DOI 10.1148/radiol.2018172294
   Miyazaki M, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-13
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Raghavan N, 2012, COPD, V9, P175, DOI 10.3109/15412555.2011.650802
   Stanojevic S, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00010-2017
   Suzuki T, 2015, INT J CHRONIC OBSTR, V10, P1199, DOI 10.2147/COPD.S82910
   Vogelmeier CF, 2017, RESPIROLOGY, V22, P575, DOI 10.1111/resp.13012
   von Siemens SM, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0997-y
   Yorgancioglu A., 2012, RELIABILITY VALIDITY, V69, P4
   Zhang Y, 2015, INT J CHRONIC OBSTR, V10, P507, DOI 10.2147/COPD.S77257
NR 28
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2019
VL 159
AR UNSP 105810
DI 10.1016/j.rmed.2019.105810
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HV
UT WOS:000500953200006
PM 31739262
DA 2020-05-18
ER

PT J
AU Mehtonen, IT
   Rantala, AK
   Hugg, TT
   Jaakkola, MS
   Jaakkola, JJK
AF Mehtonen, Ilkka T.
   Rantala, Aino K.
   Hugg, Timo T.
   Jaakkola, Maritta S.
   Jaakkola, Jouni J. K.
TI Dental caries is associated with lower respiratory tract infections: A
   population-based cohort study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Filled teeth; Dental caries; Respiratory tract infections; Lower
   respiratory tract infections; Cohort studies
ID HOME DAMPNESS; CHILDHOOD; ASTHMA; MOLDS; DETERMINANTS; PREVALENCE;
   6-YEAR
AB Introduction: Dental caries and respiratory tract infections are among the most common infectious diseases worldwide and they both are appearing in the respiratory system. However, their relations are still unclear. This study investigated the association of dental caries on the risk of lower respiratory tract infections (LRTI) in young adulthood.
   Methods: The study population consisted of 1,592 Finnish young adults participating in the 20-year follow-up of The Espoo Cohort Study. The information on the occurrence of LRTIs (pneumonia or acute bronchitis) during the preceding 12 months was based on the follow-up questionnaire and the National Hospital Discharge Register. Lifelong caries on permanent teeth was defined as a self-reported number of filled teeth (FT). The risk ratios (RR) of LRTIs with 95% confidence intervals (CI) were estimated using Poisson regression models.
   Results: High FT number was associated with an increased occurrence of LRTIs with an adjusted RR of 1.24 per interquartile range (IQR) of FT (95% CI 1.06-1.44). The risk of LRTIs increased according to the increasing number of FTs, being highest among those subjects with 10 or more filled teeth (adjusted RR 2.30; 1.27-4.17). Family's socioeconomic status or smoking did not modify the effect.
   Conclusions: Our results suggest that dental caries increases the risk of LRTIs. We did not find any significant effect modification by shared determinants of caries and LRTIs. However, it is possible, that common risk factors might explain at least partly the observed relation between FT and LRTIs or that the causality is bidirectional.
C1 [Mehtonen, Ilkka T.; Rantala, Aino K.; Hugg, Timo T.; Jaakkola, Maritta S.; Jaakkola, Jouni J. K.] Univ Oulu, Ctr Environm & Resp Hlth Res, POB 5000, FI-90014 Oulu, Finland.
   [Mehtonen, Ilkka T.; Rantala, Aino K.; Hugg, Timo T.; Jaakkola, Maritta S.; Jaakkola, Jouni J. K.] Univ Oulu, Med Res Ctr Oulu, POB 5000, FI-90014 Oulu, Finland.
RP Jaakkola, JJK (reprint author), Univ Oulu, Ctr Environm & Resp Hlth Res, POB 5000, FI-90014 Oulu, Finland.
EM jouni.jaakkola@oulu.fi
OI Jaakkola, Jouni/0000-0003-4168-4683
FU Academy of FinlandAcademy of Finland [129419, 138691, 266314]; Finnish
   Lung Health Association; Research Foundation of the Pulmonary Diseases
   (HES)
FX This study was funded by the Academy of Finland (grant number 129419 of
   Responding to Public Health Challenges Research Programme (SALVE) and
   grant numbers 138691 and 266314), Finnish Lung Health Association and
   The Research Foundation of the Pulmonary Diseases (HES) (I.T. Mehtonen's
   personal grant). The funding sources had no role in study design, data
   collection and analysis, or preparation of the manuscript.
CR Abd-Elmeguid A, 2013, J ENDODONT, V39, P865, DOI 10.1016/j.joen.2012.12.035
   Alaki SM, 2008, PEDIATR DENT, V30, P105
   Americano GCA, 2017, INT J PAEDIATR DENT, V27, P11, DOI 10.1111/ipd.12233
   Bhat TA, 2018, J IMMUNOL, V200, P2927, DOI 10.4049/jimmunol.1701417
   Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242
   JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129
   Jaakkola JJK, 2010, AM J EPIDEMIOL, V172, P451, DOI 10.1093/aje/kwq110
   Jalevik B, 2001, EUR J ORAL SCI, V109, P230, DOI 10.1034/j.1600-0722.2001.00047.x
   Julihn A, 2018, JDR Clin Trans Res, V3, P395, DOI 10.1177/2380084418788066
   Kaspersen KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164220
   Kumar S, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-41
   Pajunen P, 2005, EUR J CARDIOV PREV R, V12, P132, DOI 10.1097/00149831-200504000-00007
   Pitiphat W, 2002, J PUBLIC HEALTH DENT, V62, P122, DOI 10.1111/j.1752-7325.2002.tb03432.x
   Rantala AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168141
   Rantala AK, 2015, AM J EPIDEMIOL, V182, P615, DOI 10.1093/aje/kwv093
   Rechenberg DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167289
   Tanner T, 2013, ACTA ODONTOL SCAND, V71, P1436, DOI 10.3109/00016357.2013.767932
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Vargas-Ferreira F, 2015, J DENT, V43, P619, DOI 10.1016/j.jdent.2015.03.011
   World Health Organization, 2018, ORAL HLTH
NR 20
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 1
EP 5
DI 10.1016/j.rmed.2019.09.002
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100001
PM 31526970
DA 2020-05-18
ER

PT J
AU Neder, JA
   Berton, DC
   Marillier, M
   Bernard, AC
   Donnell, DEO
AF Neder, J. Alberto
   Berton, Danilo C.
   Marillier, Mathieu
   Bernard, Anne-Catherine
   Donnell, Denis E. O.
CA Canadian Resp Res Network
TI The role of evaluating inspiratory constraints and ventilatory
   inefficiency in the investigation of dyspnea of unclear etiology
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Dyspnea; Exertion; Exercise testing; Lung mechanics; Gas exchange;
   Ventilation
ID OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE; RECOMMENDATIONS; MECHANISMS;
   PHYSIOLOGY; HEALTHY; UPDATE
AB Background: Exertional dyspnea increases when the mechanical output of the respiratory muscles becomes uncoupled from increases in neural respiratory drive. Combining measurements of inspiratory constraints and ventilatory inefficiency may better uncover the role of mechanical-ventilatory abnormalities on exertional dyspnea than the currently-recommended approach, i.e., a low breathing reserve.
   Methods: We determined the presence of a low breathing reserve (1-(peak ventilation (<(V)over dot>E)/estimated maximal voluntary ventilation) x 100 < 15%), critical inspiratory constraints (tidal volume (<(V)over dot>T)/exercise inspiratory capacity (ICdyn) > 0.7) and ventilatory inefficiency (<(V)over dot>E/CO2 output (<(V)over dot>CO2) nadir > 34) in 284 subjects (161 males) with "disproportionate dyspnea" (N = 148), "dyspnea with multiple potential causes" (N = 93) and "dyspnea without an apparent cause.
   Results: The agreement between breathing reserve and assessment of inspiratory constraints was only "fair" (kappa [confidence interval (CI)]= 0.264 [0.169-0.358]). Attainment of critical inspiratory constraints and an upward inflection in dyspnea ratings systematically preceded a low breathing reserve. Of note, similar to 55% (93/167) of subjects with normal breathing reserve showed critical inspiratory constraints despite largely preserved lung function. Regardless of the breathing reserve, subjects showing critical inspiratory constraints and/or poor ventilatory efficiency reported higher dyspnea and more impaired exercise tolerance compared to their counterparts (p < 0.05). Poor ventilatory efficiency strongly predicted a high dyspnea/work rate in subjects without critical inspiratory constraints regardless of the breathing reserve (odds ratio [95% CI]= 4.21 [2.01-6.42; p < 0.001).
   Conclusion: An integrated analysis of inspiratory constraints and ventilatory inefficiency is key to uncover physiological abnormalities germane to dyspnea in clinical populations in whom the origins of this distressing symptom are uncertain.
C1 [Neder, J. Alberto; Berton, Danilo C.; Marillier, Mathieu; Bernard, Anne-Catherine; Donnell, Denis E. O.] Queens Univ, Lab Clin Exercise Physiol, Kingston, ON, Canada.
   [Neder, J. Alberto; Berton, Danilo C.; Marillier, Mathieu; Bernard, Anne-Catherine; Donnell, Denis E. O.] Queens Univ, Resp Invest Unit, Kingston, ON, Canada.
   [Neder, J. Alberto; Berton, Danilo C.; Marillier, Mathieu; Bernard, Anne-Catherine; Donnell, Denis E. O.] Kingston Gen Hosp, Kingston, ON, Canada.
   [Berton, Danilo C.] Fed Univ Rio Grande do Su, Div Respirol, Porto Alegre, RS, Brazil.
RP Neder, JA (reprint author), 102 Stuart St, Kingston, ON K7L 2V6, Canada.
EM alberto.neder@queensu.ca
OI Berton, Danilo/0000-0002-8393-3126; MARILLIER,
   Mathieu/0000-0003-2272-7633
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Ambrosino N, 2006, Chron Respir Dis, V3, P117, DOI 10.1191/1479972306cd110ra
   ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211
   BABB TG, 1993, J APPL PHYSIOL, V74, P2016
   Berliner D, 2016, DTSCH ARZTEBL INT, V113, P834, DOI 10.3238/arztebl.2016.0834
   Borel B, 2014, PEDIATR PULM, V49, P221, DOI 10.1002/ppul.22804
   Brooks SM, 1982, ATS NEWS, V8, P12
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Faisal A, 2016, AM J RESP CRIT CARE, V193, P299, DOI 10.1164/rccm.201504-0841OC
   Guazzi M, 2016, CIRCULATION, V133, pE694, DOI 10.1161/CIR.0000000000000406
   Guenette JA, 2013, PULM MED, V2013, DOI 10.1155/2013/956081
   Huang W, 2017, EUR J PREV CARDIOL, V24, P1190, DOI 10.1177/2047487317709605
   Johnson BD, 1999, CHEST, V116, P488, DOI 10.1378/chest.116.2.488
   Jolley Caroline, 2015, Lancet, V385 Suppl 1, pS51, DOI 10.1016/S0140-6736(15)60366-X
   Jolley CJ, 2015, EUR RESPIR J, V45, P355, DOI 10.1183/09031936.00063014
   JONES NL, 1985, AM REV RESPIR DIS, V131, P700
   Laveneziana P, 2007, APPL PHYSIOL NUTR ME, V32, P1225, DOI 10.1139/H07-119
   MAHLER DA, 1994, CLIN CHEST MED, V15, P259
   Mahler DA, 2015, CHEST, V147, P232, DOI 10.1378/chest.14-0800
   Neder JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02036-2016
   Neder JA, 2018, EUROPEAN RESP SOC J, px
   O'Donnell Denis E, 2007, COPD, V4, P225, DOI 10.1080/15412550701480455
   O'Donnell Denis E, 2007, Proc Am Thorac Soc, V4, P145, DOI 10.1513/pats.200611-159CC
   O'Donnell DE, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00082
   O'Donnell DE, 2016, EUR RESPIR REV, V25, P333, DOI 10.1183/16000617.0054-2016
   O'Donnell DE, 2014, CLIN CHEST MED, V35, P51, DOI 10.1016/j.ccm.2013.09.008
   Palange P, 2007, EUR RESPIR J, V29, P185, DOI 10.1183/09031936.00046906
   Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST
   Reilly CC, 2011, THORAX, V66, P240, DOI 10.1136/thx.2010.142646
   Robertson HT, 2015, EUR RESPIR J, V45, P1704, DOI 10.1183/09031936.00137614
   SRIDHAR MK, 1995, SCOT MED J, V40, P113, DOI 10.1177/003693309504000404
   Sun XG, 2002, AM J RESP CRIT CARE, V166, P1443, DOI 10.1164/rccm.2202033
   Taylor BJ, 2010, SEMIN RESP CRIT CARE, V31, P528, DOI 10.1055/s-0030-1265894
   WASSERMAN K, 1975, AM REV RESPIR DIS, V112, P219
   Wasserman K, 1987, PRINCIPLES EXERCISE
   Weisman IM, 2001, CLIN CHEST MED, V22, P679, DOI 10.1016/S0272-5231(05)70060-5
NR 36
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 6
EP 13
DI 10.1016/j.rmed.2019.09.007
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100002
PM 31541929
DA 2020-05-18
ER

PT J
AU Nurmi, HM
   Latti, AM
   Brannan, JD
   Koskela, HO
AF Nurmi, Hanna M.
   Latti, Anne M.
   Brannan, John D.
   Koskela, Heikki O.
TI Comparison of mannitol and citric acid cough provocation tests
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic cough; Mannitol; Citric acid
ID HYPERTONIC SALINE; VAGAL AFFERENT; HEALTH-STATUS; CHALLENGE;
   SENSITIVITY; CAPSAICIN
AB Rationale: Citric acid has been used as a cough provocation test for decades. However, the methods of administration have not been standardized. Inhaled mannitol is a novel cough provocation test, which has regulatory approval and can be performed utilizing a simple disposable inhaler in a standardized manner.
   Objective: To compare the mannitol and citric acid cough provocation tests with respect to their ability to identify subjects with chronic cough and their tolerability.
   Methods: Subjects with chronic cough (n=36) and controls (n=25) performed provocation tests with mannitol and citric acid. Both tests were video recorded. Cough sensitivity was expressed as coughs-to-dose ratios (CDR) and the cumulative doses to mannitol or concentration to citric acid evoking 5 coughs (C5). Forced expiratory volume in 1 s (FEV1), visual analogue scales (VAS), test completion rates and the total cough frequencies were analysed.
   Results: Mannitol and citric acid CDR both effectively separated those with cough and the control subjects (AUC 0.847 and 0.803, respectively) as did C5 (AUC 0.823 and 0.763, respectively). There was a good correlation between the cough sensitivity provoked by the two stimuli, either expressed as CDR (r=0.65, p < 0.001) or C5 (r=0.53, p=0.001). Both tests were similarly tolerated in terms of VAS, although more patients discontinued the mannitol test early, primarily due to cough.
   Conclusions: Mannitol and citric acid tests correlated well, equally identified subjects with chronic cough and their tolerability was similar. The feasibility issues, strict standardisation and regulatory approval may favour mannitol to be used in clinical cough research.
C1 [Nurmi, Hanna M.; Koskela, Heikki O.] Univ Eastern Finland, Fac Hlth Sci, Sch Med, Div Resp Med,Inst Clin Med, POB 1627, Kuopio 70211, Finland.
   [Nurmi, Hanna M.; Latti, Anne M.; Koskela, Heikki O.] Kuopio Univ Hosp, Ctr Med & Clin Res, Div Resp Med, POB 100, Kuopio 70029, Finland.
   [Brannan, John D.] John Hunter Hosp, Dept Resp & Sleep Med, New Lambton 2305, Australia.
RP Nurmi, HM (reprint author), Kuopio Univ Hosp, Ctr Med & Clin Res, Div Resp Med, POB 100, Kuopio 70029, Finland.
EM hanna.nurmi@kuh.fi
FU Kuopio region Respiratory Foundation; Research Foundation of Pulmonary
   Diseases
FX The study was funded by grants from the Kuopio region Respiratory
   Foundation and the Research Foundation of Pulmonary Diseases. They have
   no role in the development of the research and manuscript.
CR BICKERMAN HA, 1954, AM J MED SCI, V228, P156, DOI 10.1097/00000441-195408000-00005
   Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339
   Birring SS, 2006, RESP MED, V100, P1105, DOI 10.1016/j.rmed.2005.09.023
   Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144
   Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403
   Brannan John D, 2009, Expert Rev Respir Med, V3, P457, DOI 10.1586/ers.09.38
   Cho YS, 2003, ALLERGY, V58, P486, DOI 10.1034/j.1398-9995.2003.00183.x
   Chung KF, 2011, PULM PHARMACOL THER, V24, P267, DOI 10.1016/j.pupt.2011.01.012
   El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269
   Fokkens WJ, 2012, RHINOLOGY, V50, P1
   French CL, 1998, ARCH INTERN MED, V158, P1657, DOI 10.1001/archinte.158.15.1657
   Fujimura M, 1996, EUR RESPIR J, V9, P1624, DOI 10.1183/09031936.96.09081624
   Hosmer DW, 2013, APPL LOGISTIC REGRES
   Johansson EL, 2009, PULM PHARMACOL THER, V22, P543, DOI 10.1016/j.pupt.2009.07.001
   Kastelik JA, 2002, AM J RESP CRIT CARE, V166, P961, DOI 10.1164/rccm.2109061
   Koskela HO, 2008, CLIN EXP ALLERGY, V38, P1100, DOI 10.1111/j.1365-2222.2008.02996.x
   Koskela HO, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00294-2018
   Koskela HO, 2004, CHEST, V125, P1985, DOI 10.1378/chest.125.6.1985
   Krishnan R. M., 2013, J CLIN INVEST, V10, P7, DOI DOI 10.3109/00365518209168377
   LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082
   Latti AM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022950
   Morice AH, 2006, THORAX, V61, pI1, DOI 10.1136/thx.2006.065144
   Morice AH, 2007, EUR RESPIR J, V29, P1256, DOI 10.1183/09031936.00101006
   Morice AH, 2001, BRIT J CLIN PHARMACO, V52, P365, DOI 10.1046/j.0306-5251.2001.01475.x
   Morice AH, 2014, EUR RESPIR J, V44, P1149, DOI 10.1183/09031936.00217813
   Morice Alyn H, 2013, Cough, V9, P14, DOI 10.1186/1745-9974-9-14
   NIEMINEN MM, 1988, THORAX, V43, P896, DOI 10.1136/thx.43.11.896
   PISARRI TE, 1992, J APPL PHYSIOL, V73, P2305
   Purokivi Minna, 2011, Cough, V7, P8, DOI 10.1186/1745-9974-7-8
   Rai ZL, 2018, RESP PHYSIOL NEUROBI, V257, P51, DOI 10.1016/j.resp.2018.02.013
   Riccio MM, 1996, J PHYSIOL-LONDON, V496, P521, DOI 10.1113/jphysiol.1996.sp021703
   Sa-Sousa A, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-24
   Singapuri Amisha, 2008, Cough, V4, P10, DOI 10.1186/1745-9974-4-10
   Song WJ, 2014, ALLERGY ASTHMA IMMUN, V6, P401, DOI 10.4168/aair.2014.6.5.401
   SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164
   Spector S, 2010, LUNG, V188, pS99, DOI 10.1007/s00408-009-9174-2
   Wallace E, 2019, PULM PHARMACOL THER, V58, DOI 10.1016/j.pupt.2019.101827
   Wandell P, 2013, FAM PRACT, V30, P506, DOI 10.1093/fampra/cmt033
NR 38
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 14
EP 20
DI 10.1016/j.rmed.2019.09.011
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100003
PM 31542680
DA 2020-05-18
ER

PT J
AU Snell, N
   Gibson, J
   Jarrold, I
   Quint, JK
AF Snell, Noel
   Gibson, Jack
   Jarrold, Ian
   Quint, Jennifer K.
TI Epidemiology of bronchiectasis in the UK: Findings from the British lung
   foundation's 'Respiratory health of the nation' project
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiectasis; Epidemiology
ID PREVALENCE; MORTALITY
AB Key findings of this national survey of non-cystic fibrosis bronchiectasis epidemiology were that its prevalence, incidence and mortality have all increased over recent years; we estimate that around 212,000 people are currently living with bronchiectasis in the UK, very much higher than commonly quoted figures. Bronchiectasis is more common in females than males; 60% of diagnoses are made in the over-70 age group. Regional differences in prevalence, incidence, mortality, and hospital admission were identified. An intriguing finding was that bronchiectasis is more commonly diagnosed in the least deprived sections of the population, in contrast to other respiratory disorders.
C1 [Snell, Noel; Jarrold, Ian] British Lung Fdn, 73-75 Goswell Rd, London EC1V 7ER, England.
   [Snell, Noel; Quint, Jennifer K.] Imperial Coll, Natl Heart & Lung Inst, London SW3 6LR, England.
   [Gibson, Jack] Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, Clin Sci Bldg Phase 2,Hucknall Rd, Nottingham NG5 1PB, England.
RP Quint, JK (reprint author), Imperial Coll London, NHLI, Resp Epidemiol, Emmanuel Kaye Bldg,Manresa Rd, London SW3 6LR, England.
EM j.quint@imperial.ac.uk
OI Quint, Jennifer/0000-0003-0149-4869
FU British Lung Foundation
FX The Respiratory Health of the Nation project was funded by the British
   Lung Foundation.
CR [Anonymous], 2016, BATTL BREATH IMP LUN
   Chandrasekaran R, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0638-0
   King Paul T, 2009, Int J Chron Obstruct Pulmon Dis, V4, P411
   Loebinger MR, 2009, EUR RESPIR J, V34, P843, DOI 10.1183/09031936.00003709
   Monteagudo M, 2016, RESP MED, V121, P26, DOI 10.1016/j.rmed.2016.10.014
   Navaratnam V, 2014, THORAX, V69, pA111, DOI 10.1136/thoraxjnl-2014-206260.222
   Quint JK, 2019, RESPIROLOGY, V24, P413, DOI 10.1111/resp.13495
   Quint JK, 2016, EUR RESPIR J, V47, P186, DOI 10.1183/13993003.01033-2015
   Ringshausen FC, 2015, EUR RESPIR J, V46, P1805, DOI 10.1183/13993003.00954-2015
   Roberts HJ, 2010, RESP MED, V104, P981, DOI 10.1016/j.rmed.2010.02.022
   Seitz AE, 2012, CHEST, V142, P432, DOI 10.1378/chest.11-2209
   Tiwari RC, 2006, STAT METHODS MED RES, V15, P547, DOI 10.1177/0962280206070621
NR 12
TC 0
Z9 0
U1 4
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 21
EP 23
DI 10.1016/j.rmed.2019.09.012
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100004
PM 31550642
DA 2020-05-18
ER

PT J
AU Henry, C
   Audibert, R
   Keller, M
   Quaglia, B
   Vecellio, L
   Roche, N
AF Henry, Chrystyn
   Audibert, Raphaele
   Keller, Manfred
   Quaglia, Benjamin
   Vecellio, Laurent
   Roche, Nicolas
TI Real-life inhaler adherence and technique: Time to get smarter!
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Smart inhaler; Adherence; Inhaler technique
ID AUDIOVISUAL REMINDER FUNCTION; METERED-DOSE INHALER; DRY POWDER INHALER;
   CLINICAL-OUTCOMES; MONITORING DEVICE; ASTHMA CONTROL; LONG-TERM;
   CORTICOSTEROIDS; INHALATION; THERAPY
AB Smart inhalers, connected to smartphones, can provide real-life objective information about the patterns of a patient's adherence and their inhaler technique during routine use. The e-modules contain the battery and measuring sensors. Many of these are add-on modules attached externally whilst others are integrated inside the inhaler. Smart inhalers that identify a dose has either been actuated or prepared do not confirm the dose was inhaled but they can send missed dose reminders and clinical studies have highlighted their potential to improve adherence and outcomes. The e-modules that measure an inhalation profile confirm a dose has been inhaled together with providing useful information about the inhaler technique. Studies confirm that the sensors are accurate and confirm their usefulness to provide information about real-life inhaler use. Add-on e-modules are generic whereas integrated smart inhalers can be approved containing active agents and, therefore, prescribed and instructed under healthcare guidance. Real-life studies need to be carried out to demonstrate their potential to improve disease control and prevent exacerbations to justifying their increased cost.
C1 [Henry, Chrystyn] Inhalat Consultancy Ltd, Tarn House,77 High St, Leeds LS19 7SP, W Yorkshire, England.
   [Henry, Chrystyn] Observat & Pragmat Res Inst Pte Ltd, Singapore, Singapore.
   [Audibert, Raphaele; Quaglia, Benjamin; Vecellio, Laurent] Nemera, La Verpilliere, France.
   [Keller, Manfred] Keller Pharmaconsult, Munich, Germany.
   [Vecellio, Laurent] Univ Tours, CEPR, INSERM, UMR 1100, Tours, France.
   [Roche, Nicolas] Univ Paris, Cochin Hosp, Resp Med, Inst Cochin UMR1016, Paris, France.
RP Henry, C (reprint author), Inhalat Consultancy Ltd, Tarn House,77 High St, Leeds LS19 7SP, W Yorkshire, England.
EM h.chrystyn@gmail.com
CR Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489
   Al-Showair RAM, 2007, CHEST, V131, P1776, DOI 10.1378/chest.06-2765
   Bardin PG, 2017, LANCET RESP MED, V5, P376, DOI 10.1016/S2213-2600(17)30124-8
   Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC
   Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Blum E, 2019, J AM PHARM ASSOC, V59, P252, DOI 10.1016/j.japh.2018.10.012
   Bosnic-Anticevich S, 2018, J ASTHMA, V55, P79, DOI 10.1080/02770903.2017.1310227
   Bourbeau J, 2008, THORAX, V63, P831, DOI 10.1136/thx.2007.086041
   Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140
   Breekveldt-Postma N.S., 2018, PHARMACOEPIDEM DR S, V17, P11
   Burgess SW, 2010, J ASTHMA, V47, P198, DOI 10.3109/02770900903483840
   Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1407, DOI 10.1016/j.jaci.2008.03.019
   Chan AHY, 2015, LANCET RESP MED, V3, P210, DOI 10.1016/S2213-2600(15)00008-9
   Chan AHY, 2017, EXPERT REV MED DEVIC, V14, P401, DOI 10.1080/17434440.2017.1322505
   Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700
   Chrystyn H, 2003, RESP MED, V97, P181, DOI 10.1053/rmed.2003.1351
   CHRYSTYN H, 2018, [No title captured], V197
   Chrystyn H., 2019, RESP DRUG DELIVERY E, P85
   Chrystyn H, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA681
   Chrystyn H, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0016-z
   Chrystyn H, 2014, RESP MED, V108, P358, DOI 10.1016/j.rmed.2013.09.021
   Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542
   Colthorpe P., 2018, RESP DRUG DELIVERY 2, P71
   Cushen B, 2018, AM J RESP CRIT CARE, V197, P1630, DOI 10.1164/rccm.201712-2469LE
   de Marco R, 2005, INT ARCH ALLERGY IMM, V138, P225, DOI 10.1159/000088723
   Demonceau J, 2013, DRUGS, V73, P545, DOI 10.1007/s40265-013-0041-3
   Ding B, 2019, CHRON RESP DIS, V16, P1
   Earl M., FUTURE RESP DRUG DEV
   El Larhrib H, 2015, J AEROSOL MED PULM D, V28
   FARR SJ, 1995, THORAX, V50, P639, DOI 10.1136/thx.50.6.639
   Foster JM, 2017, RESP MED, V129, P39, DOI 10.1016/j.rmed.2017.05.013
   Foster JM, 2014, J ALLERGY CLIN IMMUN, V134, P1260, DOI 10.1016/j.jaci.2014.05.041
   FREEDMAN T, 1956, Postgrad Med, V20, P667
   Fuchs C, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA2781
   Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC
   Ghosh S, 2017, J AEROSOL MED PULM D, V30, P381, DOI 10.1089/jamp.2017.1416
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Global Strategy for the Diagnosis Management and Prevention of COPD., 2017, GLOBAL STRATEGY DIAG
   Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026
   Hew M, 2019, JAMA-J AM MED ASSOC, V321, P1045, DOI 10.1001/jama.2019.1289
   Horne R, 2004, INT J STD AIDS, V15, P38, DOI 10.1258/095646204322637245
   Kesten S, 2018, PULM PHARMACOL THER, V53, P27, DOI 10.1016/j.pupt.2018.08.007
   Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056
   Kocks JWH, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0110-x
   Kuipers E, 2019, J MED INTERNET RES, V21, DOI 10.2196/13551
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Lee J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01836-2017
   Lewis A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1482-7
   Merchant RK, 2016, J ALLER CL IMM-PRACT, V4, P455, DOI 10.1016/j.jaip.2015.11.022
   Morton RW, 2017, THORAX, V72, P347, DOI 10.1136/thoraxjnl-2015-208171
   Murphy AC, 2010, THORAX, V65, pA151, DOI 10.1136/thx.2010.151043.25
   Nsour WM, 2001, RESP MED, V95, P965, DOI 10.1053/rmed.2001.1190
   Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906
   Papi A, 2018, J ALLER CL IMM-PRACT, V6, P1989, DOI 10.1016/j.jaip.2018.03.008
   Partridge M.R., 2016, BMC PULM MED, V6, P13
   Patel M, 2013, CLIN EXP ALLERGY, V43, P1144, DOI 10.1111/cea.12166
   Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001
   Price D., 2011, RESP MED
   Price D, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0075-y
   Price D, 2013, PRIM CARE RESP J, V22, P161, DOI 10.4104/pcrj.2013.00017
   Price D, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-1
   Price DB, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0665-x
   Price DB, 2017, J ALLER CL IMM-PRACT, V5, P1071, DOI 10.1016/j.jaip.2017.01.004
   RAND CS, 1995, AM J RESP CRIT CARE, V152, P580, DOI 10.1164/ajrccm.152.2.7633711
   Reddel HK, 2012, CLIN CHEST MED, V33, P505, DOI 10.1016/j.ccm.2012.06.005
   Roy A, 2011, PRIM CARE RESP J, V20, P148, DOI 10.4104/pcrj.2011.00022
   Safioti G, 2019, AM J RESP CRIT CARE, V199
   Sanchis J, 2016, CHEST, V150, P394, DOI 10.1016/j.chest.2016.03.041
   Seheult JN, 2014, PHARM RES-DORDR, V31, P2735, DOI 10.1007/s11095-014-1371-x
   Stallberg B, 2003, RESP MED, V97, P835, DOI 10.1016/S0954-6111(03)00040-4
   Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504
   Sulaiman I, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01126-2017
   Sulaiman I, 2017, J AEROSOL MED PULM D, V30, P247, DOI 10.1089/jamp.2016.1334
   Sulaiman I, 2017, AM J RESP CRIT CARE, V195, P1333, DOI 10.1164/rccm.201604-0733OC
   Sulaiman I, 2016, ANN AM THORAC SOC, V13, P1894, DOI 10.1513/AnnalsATS.201603-222OC
   Sulaiman I, 2016, J ALLER CL IMM-PRACT, V4, P900, DOI 10.1016/j.jaip.2016.07.009
   Sumino K, 2018, J AEROSOL MED PULM D, V31, P191, DOI 10.1089/jamp.2017.1383
   Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100
   van Boven JFM, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0092-8
   Vestbo J, 2009, THORAX, V64, P939, DOI 10.1136/thx.2009.113662
NR 81
TC 2
Z9 2
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 24
EP 32
DI 10.1016/j.rmed.2019.09.008
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100005
PM 31563027
DA 2020-05-18
ER

PT J
AU Maio, S
   Baldacci, S
   Carrozzi, L
   Pistelli, F
   Simoni, M
   Angino, A
   La Grutta, S
   Muggeo, V
   Viegi, G
AF Maio, Sara
   Baldacci, Sandra
   Carrozzi, Laura
   Pistelli, Francesco
   Simoni, Marzia
   Angino, Anna
   La Grutta, Stefania
   Muggeo, Vito
   Viegi, Giovanni
TI 18-yr cumulative incidence of respiratory/allergic symptoms/diseases and
   risk factors in the Pisa epidemiological study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Allergy; Asthma; COPD; Environmental & occupational health and
   epidemiology; Tobacco
ID OBSTRUCTIVE PULMONARY-DISEASE; GENERAL-POPULATION SAMPLES; ADULT-ONSET
   ASTHMA; AIR-POLLUTION; OCCUPATIONAL-EXPOSURE; CHRONIC-BRONCHITIS;
   ALLERGIC RHINITIS; PREVALENCE RATES; LUNG-DISEASE; SYMPTOMS
AB Background: Few population-based studies on the effects of environmental exposure variation exist.
   Aim: Assessing respiratory symptom/disease incidence related to risk factor exposure changes.
   Methods: A longitudinal general population sample from two surveys (PISA2:1991-1993; PISA3:2009-2011; no. = 970), aged >= 20 years at baseline, completed a questionnaire on respiratory symptoms/diseases, risk factor exposure and performed spirometry. 18-year follow-up cumulative incidence of respiratory symptoms/diseases and longitudinal changes (persistence, incidence, remittance) in risk factor exposure were computed.
   Results: Cumulative incidence values were: 3.2% (corresponding to a 1.8%/year incidence rate), asthma; 6.6% (3.8%/year), asthma attacks; 4.5% (2.6%/year), wheeze; 31.7% (21.0%/year), allergic rhinitis-AR; 7.6% (4.4%/year), chronic obstructive pulmonary disease-COPD; 16.1% (9.7%/year), usual cough; 18.5% (11.3%/year), usual phlegm; 30.7% (20.1%/year), dyspnoea 1+; 13.9% (8.3%/year), airway obstruction. The following associations emerged among respiratory symptom/disease cumulative incidence and risk factor exposure changes: a two-to-five fold higher risk for COPD, phlegm, cough, dyspnoea, asthma attacks, airway obstruction in persistent smokers; a two-to-three fold higher risk for COPD in remittent smokers; a two-fold higher risk for AR, phlegm and a four-fold higher risk for asthma in subjects with persistent occupational exposure; a two-fold higher risk for cough, phlegm, dyspnoea, AR in subjects with incident occupational exposure; a two-fold higher risk for AR, asthma attacks, COPD in subjects with incident traffic exposure.
   Conclusions: Our study showed noteworthy respiratory symptom/disease incidence values and indicated that lifestyle and environmental exposure changes can differently influence onset. This information could be useful for primary prevention strategies in order to reduce the chronic disease burden in the general population.
C1 [Maio, Sara; Baldacci, Sandra; Simoni, Marzia; Angino, Anna; Viegi, Giovanni] CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol IFC, Pisa, Italy.
   [Maio, Sara; Muggeo, Vito] Univ Palermo, Dept Econ Business & Stat, Palermo, Italy.
   [Carrozzi, Laura] Univ Pisa, Dept Surg, Mol Pathol & Crit Area, Med, Pisa, Italy.
   [Pistelli, Francesco] Univ Hosp Pisa, Cardio Thorac & Vasc Dept, Unit Pulmonol, Pisa, Italy.
   [La Grutta, Stefania; Viegi, Giovanni] CNR, IRIB, Palermo, Italy.
RP Maio, S (reprint author), CNR, Inst Clin Physiol, Via Trieste 41, I-56126 Pisa, Italy.
EM saramaio@ifc.cnr.it
RI MAIO, SARA/K-4065-2016
OI MAIO, SARA/0000-0001-6363-8544
FU CNR-ENEL (Italian Electric Power Authority); Italian National Research
   CouncilItalian National Research Council [91.00171.PF41]; Italian
   Ministry of Labour and Social Security [587-1997]; Italian Medicines
   Agency (AIFA) [FARM8YRYZC]; European CommissionEuropean Commission Joint
   Research Centre [2005121 - IMCA II]; National Institute for the
   Insurance of Occupational Injuries (INAIL) [04/2016: BEEP]
FX This work was supported in part by the CNR-ENEL (Italian Electric Power
   Authority) 'Interaction of Energy Systems with Human Health and
   Environment' Project (1989), by the Italian National Research Council
   Targeted Project 'Prevention and Control Disease Factors-SP 2' (Contract
   No. 91.00171.PF41; 1991), by the Italian Ministry of Labour and Social
   Security (Contract No. 587-1997; 1997), by the Italian Medicines Agency
   (AIFA), within the independent drug research program (Contract No.
   FARM8YRYZC; 2010), by the European Commission (Grant Agreement 2005121 -
   IMCA II) and by the National Institute for the Insurance of Occupational
   Injuries (INAIL) in the framework of the Call on Research and
   Collaboration 2016-2018 (project No 04/2016: BEEP).
CR Afonso ASM, 2011, RESP MED, V105, P1872, DOI 10.1016/j.rmed.2011.06.012
   [Anonymous], 1987, Am Rev Respir Dis, V136, P1285
   Backman H, 2017, CLIN EXP ALLERGY, V47, P1426, DOI 10.1111/cea.12963
   Bakke PS, 2011, EUR RESPIR J, V38, P1261, DOI 10.1183/09031936.00193809
   Baldacci S, 2015, RESP MED, V109, P1089, DOI 10.1016/j.rmed.2015.05.017
   Bergqvist J, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S115086
   Blanc PD, 2019, AM J RESP CRIT CARE, V199, P1312, DOI 10.1164/rccm.201904-0717ST
   BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954
   Burte E, 2018, ENVIRON INT, V115, P257, DOI 10.1016/j.envint.2018.03.021
   Carrozzi L, 2014, INT J ENV RES PUB HE, V11, P2395, DOI 10.3390/ijerph110302395
   D'Amato M, 2018, J INVEST ALLERG CLIN, V28, P91, DOI 10.18176/jiaci.0228
   de Marco R, 2012, EUR RESPIR J, V39, P883, DOI 10.1183/09031936.00061611
   Eagan TML, 2002, EUR RESPIR J, V19, P599, DOI 10.1183/09031936.02.00247302
   Eagan TML, 2002, AM J RESP CRIT CARE, V166, P933, DOI 10.1164/rccm.200203-238OC
   Ekerljung L, 2008, RESP MED, V102, P1730, DOI 10.1016/j.rmed.2008.07.011
   Gallmeier K, 2014, EUR RESPIR J, V43, P92, DOI 10.1183/09031936.00012813
   Gershon AS, 2010, ARCH INTERN MED, V170, P560, DOI 10.1001/archinternmed.2010.17
   Hansel NN, 2016, COPD, V13, P372, DOI 10.3109/15412555.2015.1089846
   Hansen S, 2015, EUR RESPIR J, V46, P1011, DOI 10.1183/13993003.02278-2014
   Holm M, 2014, INT J TUBERC LUNG D, V18, P870, DOI 10.5588/ijtld.13.0652
   Holm M, 2012, INT J TUBERC LUNG D, V16, P553, DOI 10.5588/ijtld.11.0288
   Holm M, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0158-0
   Institute for Health Metrics and Evaluation (IHME), 2017, GBD COMP DAT VIS
   Jacquemin B, 2015, ENVIRON HEALTH PERSP, V123, P613, DOI 10.1289/ehp.1408206
   Johannessen A, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-63
   Liu Y, 2015, INT J CHRONIC OBSTR, V10, P1409, DOI 10.2147/COPD.S82259
   Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802
   Luoto JA, 2016, EUR RESPIR J, V47, P461, DOI 10.1183/13993003.00635-2015
   Lytras T, 2018, THORAX, V73, P1008, DOI 10.1136/thoraxjnl-2017-211158
   Maio S, 2016, RESP MED, V110, P58, DOI 10.1016/j.rmed.2015.11.006
   Marcon A, 2018, THORAX, V73, P825, DOI 10.1136/thoraxjnl-2017-211289
   Matheson MC, 2011, J ALLERGY CLIN IMMUN, V128, P816, DOI 10.1016/j.jaci.2011.05.039
   Mehta AJ, 2012, AM J RESP CRIT CARE, V185, P1292, DOI 10.1164/rccm.201110-1917OC
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mirabelli MC, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-24
   Pallasaho P, 2004, INT J TUBERC LUNG D, V8, P1292
   Pallasaho P, 2011, RESP MED, V105, P1449, DOI 10.1016/j.rmed.2011.04.013
   Pallasaho P, 2014, COPD, V11, P88, DOI 10.3109/15412555.2013.830095
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pesce G, 2016, SCI TOTAL ENVIRON, V544, P645, DOI 10.1016/j.scitotenv.2015.12.015
   Pistelli F, 2007, RESP MED, V101, P814, DOI 10.1016/j.rmed.2006.06.032
   Pistelli F, 2014, EUR RESPIR MONOGR, P257, DOI 10.1183/2312508X.10014313
   Probst-Hensch NM, 2010, THORAX, V65, P150, DOI 10.1136/thx.2009.115063
   Pruss-Ustun A., 2016, PREVENTING DIS HLTH
   Radon K, 2008, OCCUP ENVIRON MED, V65, P38, DOI 10.1136/oem.2006.031542
   Riu E, 2007, EUR RESPIR J, V30, P549, DOI 10.1183/09031936.00149206
   Ronmark E, 1997, ALLERGY, V52, P1071, DOI 10.1111/j.1398-9995.1997.tb00178.x
   Simpson CR, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X514729
   Skorge TD, 2009, SCAND J WORK ENV HEA, V35, P454, DOI 10.5271/sjweh.1352
   Storaas T, 2015, EUR RESPIR J, V46, P1290, DOI 10.1183/13993003.02345-2014
   Terzikhan N, 2016, EUR J EPIDEMIOL, V31, P785, DOI 10.1007/s10654-016-0132-z
   Toren K, 2004, EUR RESPIR J, V24, P942, DOI 10.1183/09031936.04.00044804
   Toren K, 2011, RESP MED, V105, P1622, DOI 10.1016/j.rmed.2011.06.003
   Traulsen LK, 2018, CLIN RESPIR J, V12, P1021, DOI 10.1111/crj.12622
   US Department of Health Education and Welfare, 1971, P 1 NHLBI EP WORKSH
   Verlato G, 2016, INT ARCH ALLERGY IMM, V170, P149, DOI 10.1159/000446509
   Viegi G, 1999, INT J TUBERC LUNG D, V3, P1034
   Viegi G, 2004, CHEST, V126, P1093, DOI 10.1378/chest.126.4.1093
   VIEGI G, 1991, ENVIRON HEALTH PERSP, V94, P95, DOI 10.2307/3431299
   World Health Organization, 2007, REP GLOB SURV PREV C
NR 60
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 33
EP 41
DI 10.1016/j.rmed.2019.09.013
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100006
PM 31585374
DA 2020-05-18
ER

PT J
AU Jo, KW
   Kim, JS
   Kwon, HS
   Park, YE
   Kim, JY
   Hong, MJ
   Shim, TS
AF Jo, Kyung-Wook
   Kim, Ju Sang
   Kwon, Hyouk-Soo
   Park, Yea Eun
   Kim, Ja Young
   Hong, Min Jee
   Shim, Tae Sun
TI Adverse event and treatment completion rates of a 12-dose weekly
   isoniazid and rifapentine course for South Korean healthcare workers
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Rifapentine; Anaphylaxis; Latent tuberculosis infection; Adverse events;
   Treatment completion
ID LATENT TUBERCULOSIS INFECTION; RIFAMPICIN; REGIMENS
AB Purpose: We investigated the adverse events (AEs) and treatment completion rates of a 3 month course of once-weekly isoniazid and rifapentine (3H(1)P(1)) in South Korean health care workers (HCWs) with latent tuberculosis infection (LTBI).
   Methods: HCWs who were candidates for LTBI treatment were enrolled from two tertiary referral centers between December 2016 and October 2017. From December 2016 through March 2017, HCWs who agreed were treated with the 3H(1)P(1) regimen (3H(1)P(1) group). Their compliance and AEs were prospectively collected. From April 2017 onward, HCWs who required LTBI treatment received 3 months of isoniazid plus rifampin (3HR group), and their medical records were retrospectively reviewed.
   Results: During the study period, 406 HCWs were treated, 226 (55.7%) in the 3H(1)P(1) group, and 180 (44.3%) in the 3HR group. The number of subjects with AEs was significantly greater in the 3H(1)P(1) group (75.2% vs 56.7%, P < 0.001), in particular a flu-like syndrome (19.0% vs. 0%, P < 0.001). However, hepatotoxicity occurred less frequently in those receiving 3H(1)P(1) (7.5% vs. 20.0%, P < 0.001). Per protocol definition, anaphylaxis developed in 1.8% of the 3H(1)P(1) group. The overall treatment completion rate was greater in the 3H(1)P(1) group (92.9% vs 86.7%, P = 0.036).
   Conclusions: The 3H(1)P(1) regimen had a higher treatment completion rate and lower hepatotoxicity compared with the 3HR regimen. However, it resulted in a higher rate of flu-like syndromes. Additionally, a few subjects had anaphylaxis, although there were no fatalities.
C1 [Jo, Kyung-Wook; Park, Yea Eun; Shim, Tae Sun] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Kim, Ju Sang] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Incheon, South Korea.
   [Kwon, Hyouk-Soo] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Allergy & Clin Immunol,Coll Med, Seoul, South Korea.
   [Kim, Ja Young; Hong, Min Jee] Asan Med Ctr, Off Infect Control, Seoul, South Korea.
RP Shim, TS (reprint author), Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM shimts@amc.seoul.kr
CR [Anonymous], 1974, Tubercle, V55, P193
   AQUINAS M, 1972, BRIT MED J, V1, P765
   Belknap R, 2017, ANN INTERN MED, V167, P689, DOI [10.7326/M17-1150, 10.7326/m17-1150]
   Bliven-Sizemore EE, 2015, INT J TUBERC LUNG D, V19, P1039, DOI 10.5588/ijtld.14.0829
   Bock NN, 2002, AM J RESP CRIT CARE, V165, P1526, DOI 10.1164/rccm.200201-047OC
   Chan PC, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02396-2018
   Chee CBE, 2018, RESPIROLOGY, V23, P893, DOI 10.1111/resp.13346
   DUTT AK, 1983, AM REV RESPIR DIS, V128, P419, DOI 10.1164/arrd.1983.128.3.419
   Gao L, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01470-2018
   Getahun H, 2017, ANN INTERN MED, V167, P742, DOI 10.7326/M17-2639
   GIRLING DJ, 1977, J ANTIMICROB CHEMOTH, V3, P115, DOI 10.1093/jac/3.2.115
   GROSSET J, 1983, REV INFECT DIS, V5, pS440
   Jeong YJ, 2012, J KOREAN MED SCI, V27, P761, DOI 10.3346/jkms.2012.27.7.761
   Jereb John A., 2011, Morbidity and Mortality Weekly Report, V60, P1650
   Joint Committee for the Revision of Korean Guidelines for Tuberculosis Korea Centers for Disease Control and Prevention, 2017, KOR GUID TUB
   Kim HW, 2018, TUBERC RESPIR DIS, V81, P6, DOI 10.4046/trd.2017.0052
   Kim JH, 2015, EMERG INFECT DIS, V21, P1913, DOI 10.3201/eid2111.141894
   Lee SH, 2015, TUBERC RESPIR DIS, V78, P56, DOI 10.4046/trd.2015.78.2.56
   Martinson NA, 2011, NEW ENGL J MED, V365, P11, DOI 10.1056/NEJMoa1005136
   Park SJ, 2015, INT J TUBERC LUNG D, V19, P342, DOI 10.5588/ijtld.14.0554
   RISKA N, 1972, SCAND J RESPIR DIS, V53, P87
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   Sandul AL, 2017, CLIN INFECT DIS, V65, P1085, DOI 10.1093/cid/cix505
   Shepardson D, 2013, INT J TUBERC LUNG D, V17, P1531, DOI 10.5588/ijtld.13.0423
   Stennis NL, 2016, CLIN INFECT DIS, V62, P53, DOI 10.1093/cid/civ766
   Sterling TR, 2016, AIDS, V30, P1607, DOI 10.1097/QAD.0000000000001098
   Sterling TR, 2015, CLIN INFECT DIS, V61, P527, DOI 10.1093/cid/civ323
   Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875
   Swindells S, 2019, NEW ENGL J MED, V380, P1001, DOI 10.1056/NEJMoa1806808
   U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute, COMMON TERMINOLOGY C
   Villarino ME, 2015, JAMA PEDIATR, V169, P247, DOI 10.1001/jamapediatrics.2014.3158
   WHO, 2018, GLOB TUB REP 2018
   World Health Organization, 2018, LAT TUB INF UPD CONS
NR 33
TC 1
Z9 1
U1 3
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 42
EP 48
DI 10.1016/j.rmed.2019.10.005
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100007
PM 31605920
DA 2020-05-18
ER

PT J
AU Huang, CT
   Lee, MR
   Ruan, SY
   Tsai, YJ
   Wang, JY
   Yu, CJ
AF Huang, Chun-Ta
   Lee, Meng-Rui
   Ruan, Sheng-Yuan
   Tsai, Yi-Ju
   Wang, Jann-Yuan
   Yu, Chong-Jen
TI Prognostic value of the mitogen response in the interferon-gamma release
   assay in patients with culture-confirmed tuberculosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Interferon-gamma; Interferon-gamma release assay; Mortality; Prognosis;
   Tuberculosis
ID ACTIVE TUBERCULOSIS; SPUTUM SMEAR; DIAGNOSIS; MECHANISMS; CONVERSION;
   MORTALITY; DEATH; TIME
AB Background: _The mitogen response in interferon-gamma(IFN-gamma) release assays(IGRAs) measures IFN-gamma after binding to CD2, a surface adhesion marker found on T-cells and NK cells. A lower mitogen response implies either peripheral blood mononuclear cells have fewer adhesion molecules either in absolute numbers or per T-cells, or the pathway from adhesion molecules to IFN-gamma production is not functioning well. To date, it remains poorly understood whether the mitogen response is associated with outcomes in tuberculosis patients.
   Methods: _From 2012 to 2017, patients with culture-confirmed tuberculosis were tested for QuantiFERON-TB Gold In-Tube(QFT-GIT). The associations between patient outcomes and QFT-GIT as well as IFN-gamma responses to the mitogen were investigated. Outcomes of interest included 1-year mortality after tuberculosis diagnosis and 2-month culture conversion.
   Results: _In total, 466 culture-confirmed tuberculosis patients were enrolled and QFT-GIT was positive in 309 (66%). Within 1 year of diagnosis, 20(4%) died and notably, 15(11%) out of 137 patients with a lower mitogen response did so. The multivariate Cox model showed that a lower mitogen response (hazard ratio, 8.789; 95% confidence interval, 3.074-25.129) was independently associated with 1-year mortality. Moreover, among 160 patients with smear-positive culture-confirmed pulmonary tuberculosis, multivariate logistic analysis indicated that a lower mitogen response (odds ratio, 3.966; 95% confidence interval, 1.182-13.303) was significantly associated with 2-month culture persistence.
   Conclusions: _This study found that a lower mitogen response was associated with worse 1-year survival in tuberculosis patients and correlated with 2-month culture persistence in patients with sputum smear-positive culture-confirmed tuberculosis. These findings suggest another application of QFT-GIT for prognostication of tuberculosis patients.
C1 [Huang, Chun-Ta; Lee, Meng-Rui; Ruan, Sheng-Yuan; Wang, Jann-Yuan; Yu, Chong-Jen] Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 10002, Taiwan.
   [Huang, Chun-Ta] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan.
   [Lee, Meng-Rui] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan.
   [Tsai, Yi-Ju] Fu Jen Catholic Univ, Coll Med, Grad Inst Biomed & Pharmaceut Sci, New Taipei, Taiwan.
RP Wang, JY (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 10002, Taiwan.
EM jywang@ntu.edu.tw
OI WANG, JANN-YUAN/0000-0003-3406-366X
FU National Taiwan University HospitalNational Taiwan University
   [NTUH.104-N2899, NTUH.107-S3741]
FX We thank the staff of the Eighth Core Lab, Department of Medical
   Research, National Taiwan University Hospital for technical support
   during the study. This work was supported by National Taiwan University
   Hospital (NTUH.104-N2899, NTUH.107-S3741). The funding sources had no
   role in design of the study, in data collection, analysis, or
   interpretation, and no role in writing the report or in the decision to
   submit the paper for publication.
CR Ahn SS, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1404-z
   [Anonymous], 2015, WHO END TB STRATEGY
   [Anonymous], 2013, CELL QUANTIFERON TB
   Auld SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078779
   Bae W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156917
   Bhargava A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077979
   Borgdorff MW, 1998, EUR RESPIR J, V11, P816, DOI 10.1183/09031936.98.11040816
   Crump JA, 2003, CLIN INFECT DIS, V37, P1037, DOI 10.1086/378273
   Denkinger CM, 2013, J CLIN MICROBIOL, V51, P607, DOI 10.1128/JCM.02278-12
   Diel R, 2011, EUR RESPIR J, V37, P88, DOI 10.1183/09031936.00115110
   Falk A, 1969, DIAGNOSTIC STANDARDS, V12, P68
   Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1
   Guler M, 2007, INT J CLIN PRACT, V61, P231, DOI 10.1111/j.1742-1241.2006.01131.x
   Huang CT, 2014, J INFECTION, V68, P440, DOI 10.1016/j.jinf.2013.12.012
   Huang HC, 2018, LUNG CANCER, V115, P64, DOI 10.1016/j.lungcan.2017.11.016
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968
   Lewinsohn DM, 2017, CLIN INFECT DIS, V64, P111, DOI 10.1093/cid/ciw778
   Lin CH, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-5
   Mathew TA, 2006, INT J TUBERC LUNG D, V10, P857
   Moorman J, 1999, INT J TUBERC LUNG D, V3, P786
   Nguyen DT, 2018, EMERG INFECT DIS, V24, P534, DOI 10.3201/eid2403.171633
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255
   Sester M, 2011, EUR RESPIR J, V37, P100, DOI 10.1183/09031936.00114810
   Singla R, 2003, INT J TUBERC LUNG D, V7, P58
   Sterling TR, 2006, INT J TUBERC LUNG D, V10, P542
   Wallis RS, 2009, LANCET INFECT DIS, V9, P162, DOI 10.1016/S1473-3099(09)70042-8
   Walpola HC, 2003, INT J TUBERC LUNG D, V7, P742
   Wang JY, 2009, RESPIROLOGY, V14, P1012, DOI 10.1111/j.1440-1843.2009.01598.x
   WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310
   World Health Organisation, 2011, US TUB INT GAMM REL
   Yen YF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002300
   YEW WW, 1995, TUBERCLE LUNG DIS, V76, P275, DOI 10.1016/S0962-8479(05)80019-X
NR 34
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 49
EP 54
DI 10.1016/j.rmed.2019.10.004
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100008
PM 31605921
DA 2020-05-18
ER

PT J
AU Lababidi, HMS
   AlSowayigh, OM
   BinHowemel, SF
   AlReshaid, KM
   Alotaiq, SA
   Bahnassay, AA
AF Lababidi, Hani M. S.
   AlSowayigh, Omar M.
   BinHowemel, Samar F.
   AlReshaid, Khoolod M.
   Alotaiq, Sultan A.
   Bahnassay, Ahmed A.
TI Refractory asthma phenotyping based on immunoglobulin E levels and
   eosinophilic counts: A real life study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Refractory asthma; Severe asthma; Immunoglobulin E; IgE; Eosinophils;
   Asthma control test (ACT); Biological therapy; anti-IgE; Anti IL-5; Real
   life
ID MONOCLONAL-ANTIBODY; DISEASE SEVERITY; DOUBLE-BLIND; IGE LEVELS;
   BENRALIZUMAB; ASSOCIATION; MULTICENTER; MEPOLIZUMAB; OMALIZUMAB;
   EFFICACY
AB Background: Asthma is an inflammatory heterogeneous disease with variable severity. The serum IgE level and Eosinophilic count have been used as biomarkers to define treatment strategies with biological agents in severe refractory asthma.
   Objective: The aim of this study is to determine the concurrence of high eosinophil count and elevated serum IgE levels in patients with severe refractory asthma.
   Methods: A retrospective cross-sectional real-life study was conducted on patients attending adult refractory asthma outpatient clinic between 2015 and 2018. Serum total IgE level and blood EOS count on matched dates with spirometry and Asthma Control Test (ACT) scores were collected. All data were obtained while patients were not on biological agents.
   Results: A total of 142 patients with severe refractory asthma were included. The mean age was 43 years, mean eosinophilic count 564 cells/mu L and mean serum IgE levels of 520 IU/ml. There was a significant correlation between serum IgE level and eosinophilic count. Serum IgE and eosinophilic count were concurrently elevated in 110 patients (78%). The patients were further categorized into four subgroups. Group A: IgE 30-100 IU/mL and EOS 150-300 cells/mu L (7.3%), Group B: IgE >100 IU/mL and EOS 150-300 cells/mu L (19.1%), Group C: IgE 30-100 IU/mL and EOS >300 cells/mu L (14.5%) and Group D: IgE >100 IU/mL, EOS >300 cells/mu L (59.1%).
   Conclusion: The majority of severe refractory asthma patients exhibits both elevated serum IgE level and eosinophilic counts.
C1 [Lababidi, Hani M. S.] King Fahad Med City, Pulm & Crit Care Dept, Riyadh, Saudi Arabia.
   [AlSowayigh, Omar M.] King Faisal Univ, Coll Med, Alahsa, Saudi Arabia.
   [BinHowemel, Samar F.; AlReshaid, Khoolod M.] AlMaarefa Univ, Coll Med, Riyadh, Saudi Arabia.
   [Alotaiq, Sultan A.] Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi Arabia.
   [Bahnassay, Ahmed A.] King Fahad Med City, Fac Med, Riyadh, Saudi Arabia.
RP Lababidi, HMS (reprint author), King Fahad Med City, Pulm & Crit Care Dept, Riyadh, Saudi Arabia.
EM hanilab@hotmail.com; omar-m-008@hotmail.com; samaralhuwaimel@gmail.com;
   kholodmoh94@gmail.com; sultan73atq@gmail.com
OI AL Sowayigh, Omar/0000-0003-0201-0563
CR Aghasafari P, 2019, INFLAMM RES, V68, P59, DOI 10.1007/s00011-018-1191-2
   Al-Moamary MS, 2019, ANN THORAC MED, V14, P3, DOI 10.4103/atm.ATM_327_18
   [Anonymous], 2019, DIFF TO TREAT SEV AS
   Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032
   Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1
   BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505
   Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880
   Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092
   Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]
   Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018
   Davila I, 2015, J INVEST ALLERG CLIN, V25, P120
   Eger KAB, 2019, CURR OPIN PHARMACOL, V46, P108, DOI 10.1016/j.coph.2019.05.005
   Erjefalt JS, 2019, CURR OPIN PULM MED, V25, P79, DOI 10.1097/MCP.0000000000000536
   FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
   Global Initiative for Asthma (GINA), 2019, GINA REP GLOB STRAT
   Haughney J, 2018, RESP MED, V134, P117, DOI 10.1016/j.rmed.2017.12.001
   Lima-Matos A, 2018, RESP MED, V145, P95, DOI 10.1016/j.rmed.2018.10.025
   Maalej Sonia, 2012, Tanaffos, V11, P38
   Matucci A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0813-0
   Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045
   Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Patel TR, 2017, CURR OPIN ALLERGY CL, V17, P42, DOI 10.1097/ACI.0000000000000336
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Rajendra C, 2012, ANN ALLERG ASTHMA IM, V108, P429, DOI 10.1016/j.anai.2012.04.008
   Santus P, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104296
   Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053
   Scott L, 2016, J ASTHMA, V53, P644, DOI 10.3109/02770903.2015.1126847
   Tajiri T, 2014, ANN ALLERG ASTHMA IM, V113, P470, DOI 10.1016/j.anai.2014.06.004
   Tanaka A, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0144-8
   de Jesus JPV, 2018, J BRAS PNEUMOL, V44, P207, DOI [10.1590/S1806-37562017000000034, 10.1590/s1806-37562017000000034]
NR 32
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 55
EP 58
DI 10.1016/j.rmed.2019.10.003
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100009
PM 31605922
DA 2020-05-18
ER

PT J
AU Rabe, KF
   Martinez, FJ
   Ferguson, GT
   Wang, C
   Singh, D
   Wedzicha, JA
   Trivedi, R
   St Rose, E
   Ballal, S
   McLaren, J
   Darken, P
   Reisner, C
   Dorinsky, P
AF Rabe, Klaus F.
   Martinez, Fernando J.
   Ferguson, Gary T.
   Wang, Chen
   Singh, Dave
   Wedzicha, Jadwiga A.
   Trivedi, Roopa
   St Rose, Earl
   Ballal, Shaila
   McLaren, Julie
   Darken, Patrick
   Reisner, Colin
   Dorinsky, Paul
TI A phase III study of triple therapy with budesonide/glycopyrrolate/
   formoterol fumarate metered dose inhaler 320/18/9.6 mu g and 160/18/9.6
   mu g using co-suspension delivery technology in moderate-to-very severe
   COPD: The ETHOS study protocol
SO RESPIRATORY MEDICINE
LA English
DT Article
DE BGF MDI; Chronic obstructive pulmonary disease; Exacerbations; Inhaled
   corticosteroid; Study protocol; Triple therapy
ID OBSTRUCTIVE PULMONARY-DISEASE; FLUTICASONE PROPIONATE/SALMETEROL 250/50;
   POST-HOC ANALYSIS; PARALLEL-GROUP; DOUBLE-BLIND; RISK; CORTICOSTEROIDS;
   EXACERBATIONS; BUDESONIDE; VILANTEROL
AB Background: Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta(2)-agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD). Nevertheless, questions remain regarding the optimal patient population for triple therapy as well as the benefit:risk ratio of ICS treatment.
   Methods: ETHOS is an ongoing, randomized, double-blind, multicenter, parallel-group, 52-week study in symptomatic patients with moderate-to-very severe COPD and a history of exacerbation(s) in the previous year. Two doses of single inhaler triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI 320/18/9.6 mu g and 160/18/9.6 mu g) will be compared to glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 mu g and budesonide/formoterol fumarate (BFF) MDI 320/9.6 mu g, all formulated using co-suspension delivery technology. Outcomes include the rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality. Sub-studies will assess lung function and cardiovascular safety.
   Study population: From June 2015-July 2018, 16,044 patients were screened and 8572 were randomized. Preliminary baseline demographics show that 55.9% of patients had experienced >= 2 moderate/severe exacerbations in the previous year, 79.1% were receiving an ICS-containing treatment at study entry, and 59.9% had blood eosinophil counts >= 150 cells/mm(3).
   Conclusions: ETHOS will provide data on exacerbations, patient-reported outcomes, mortality, and safety in 8572 patients with moderate-to-very severe COPD receiving triple and dual fixed-dose combinations. For the first time, ICS/LAMA/LABA triple therapy with two different doses of ICS will be compared to dual ICS/LABA and LAMA/LABA therapies.
C1 [Rabe, Klaus F.] LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany.
   [Rabe, Klaus F.] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res DZL, Grosshansdorf, Germany.
   [Martinez, Fernando J.] Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY USA.
   [Ferguson, Gary T.] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA.
   [Wang, Chen] China Japan Friendship Hosp, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China.
   [Singh, Dave] Univ Manchester, Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England.
   [Wedzicha, Jadwiga A.] Natl Heart & Lung Inst, Resp Div, London, England.
   [Trivedi, Roopa; Dorinsky, Paul] AstraZeneca, Durham, NC USA.
   [St Rose, Earl; Ballal, Shaila; Darken, Patrick; Reisner, Colin] AstraZeneca, Morristown, NJ USA.
   [McLaren, Julie] AstraZeneca, Gaithersburg, MD USA.
RP Rabe, KF (reprint author), LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany.
EM k.f.rabe@lungenclinic.de
RI Singh, Dave/AAH-4342-2020
OI Singh, Dave/0000-0001-8918-7075; Wedzicha, Jadwiga/0000-0001-9642-1261;
   Martinez, Fernando/0000-0002-2412-3182
FU AstraZeneca, Cambridge, UKAstraZeneca
FX We thank all the patients, their families and the team of investigators,
   research nurses, and operations staff involved in ETHOS. Medical writing
   support, under the direction of the authors, was provided by Julia King,
   PhD, of CMC Connect, a division of McCann Health Medical Communications
   Ltd, Glasgow, UK, which was funded by AstraZeneca, Cambridge, UK in
   accordance with Good Publication Practice (GPP3) guidelines [30].
CR Anzueto A, 2009, COPD, V6, P320, DOI 10.1080/15412550903140881
   Bafadhel M, 2018, LANCET RESP MED, V6, P117, DOI 10.1016/S2213-2600(18)30006-7
   Barnes NC, 2016, EUR RESPIR J, V47, P1374, DOI 10.1183/13993003.01370-2015
   Battisti WP, 2015, ANN INTERN MED, V163, P461, DOI 10.7326/M15-0288
   Brusselle G, 2018, RESP MED, V138, P21, DOI 10.1016/j.rmed.2018.03.016
   Chapman KR, 2018, AM J RESP CRIT CARE, V198, P329, DOI 10.1164/rccm.201803-0405OC
   ClinicalTrials.gov, 2017, STUD ASS EFF SAF PT0
   ClinicalTrials.gov, 2017, STUD ASS SAF EFF PT0
   ClinicalTrials.gov, 2018, STUD ASS SAF TOL PT0
   Crim C, 2015, ANN AM THORAC SOC, V12, P27, DOI 10.1513/AnnalsATS.201409-413OC
   European Medicines Agency, 2016, INH CORT ICS CONT ME
   Ferguson GT, 2008, RESP MED, V102, P1099, DOI 10.1016/j.rmed.2008.04.019
   Ferguson GT, 2018, LANCET RESP MED, V6, P747, DOI 10.1016/S2213-2600(18)30327-8
   Ferguson GT, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01334-2018
   Kerwin EM, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1126-7
   Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2
   Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901
   Lipson DA, 2017, AM J RESP CRIT CARE, V196, P438, DOI 10.1164/rccm.201703-0449OC
   Lipworth B, 2018, INT J CHRONIC OBSTR, V13, P3003, DOI 10.2147/COPD.S177333
   Magnussen H, 2014, NEW ENGL J MED, V371, P1285, DOI 10.1056/NEJMoa1407154
   Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1
   Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X
   Price D, 2013, PRIM CARE RESP J, V22, P92, DOI 10.4104/pcrj.2012.00092
   Sin DD, 2009, LANCET, V374, P712, DOI 10.1016/S0140-6736(09)61250-2
   Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019
   Singh D, 2016, LANCET, V388, P963, DOI 10.1016/S0140-6736(16)31354-X
   Suissa S, 2013, THORAX, V68, P1029, DOI 10.1136/thoraxjnl-2012-202872
   Vestbo J, 2017, LANCET, V389, P1919, DOI 10.1016/S0140-6736(17)30188-5
   Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4
   Wedzicha JA, 2016, NEW ENGL J MED, V374, P2222, DOI 10.1056/NEJMoa1516385
NR 30
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 59
EP 66
DI 10.1016/j.rmed.2019.08.010
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100010
PM 31605923
OA Bronze
DA 2020-05-18
ER

PT J
AU Morimoto, K
   Izumi, K
   Ato, M
   Hasegawa, N
   Mitarai, S
AF Morimoto, Kozo
   Izumi, Kiyohiko
   Ato, Manabu
   Hasegawa, Naoki
   Mitarai, Satoshi
TI Actual practice of standard treatment for pulmonary nontuberculous
   mycobacteriosis in Japan
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Treatment; Clarithromycin resistant; Guideline; Insurance claim
ID LUNG-DISEASE; THERAPY; RESISTANCE
AB Introduction: The details of the practice of treating nontuberculous mycobacterial pulmonary disease (NTMPD) have not been studied in Japan.
   Methods: We studied a random sample of 2% (184) of the 9,200 patients with incident NTM-PD in 2010 who received standard three-drug therapy for at least some of their treatment between 2010 and 2014.
   Results: The median duration of the standard treatment period was 248 days (IQR 56-540 days). Although 59% of the patients were treated with standard therapy for more than 6 months, only 41% were treated for 12 months. Fifty-three patients (29%) initiated treatment with substandard regimen, and 18 (34%) of those patients received treatment regimens that can lead to the development of macrolide resistance (MR)(CLR monotherapy or CLR + RIF). Furthermore, initially, 184 receiving the standard treatment, 49 patients (27%) eventually deviated from it, and 31 patients (63%) received regimens increasing the risk of developing MR. The sporadic administration of macrolide monotherapy was observed before and after the administration of the standard treatment for 50 patients (27.7%) and 41 patients (27.2%), respectively.
   Conclusions: Approximately 60% of the treated patients did not continue the standard regimen for more than 12 months and 42% were at risk for developing MR before and after receiving the standard treatment. It is important to educate physicians and patients about the correct and safe management of NTMPD.
C1 [Morimoto, Kozo] Japan Antitb Assoc, Fukujuji Hosp, 3-1-24 Matsuyama, Tokyo 2048522, Japan.
   [Morimoto, Kozo; Izumi, Kiyohiko; Mitarai, Satoshi] Japan Antitb Assoc, Res Inst TB, Tokyo, Japan.
   [Ato, Manabu] Natl Inst Infect Dis, Tokyo, Japan.
   [Hasegawa, Naoki] Keio Univ, Sch Med, Tokyo, Japan.
   [Mitarai, Satoshi] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki, Japan.
RP Morimoto, K (reprint author), Japan Antitb Assoc, Fukujuji Hosp, 3-1-24 Matsuyama, Tokyo 2048522, Japan.
EM morimotok@fukujuji.org
OI Morimoto, Kozo/0000-0002-8239-9275
FU Japan Agency for Medical Research and Development, AMEDJapan Agency for
   Medical Research and Development (AMED) [JP18fk0108043]
FX We would like to thank BIO Communications Inc. for preparing the
   dataset. This work was supported by the Research Programme on Emerging
   and Re-emerging Infectious Diseases from the Japan Agency for Medical
   Research and Development, AMED, under grant number JP18fk0108043.
CR Adjemian Jennifer, 2014, Ann Am Thorac Soc, V11, P9, DOI 10.1513/AnnalsATS.201304-085OC
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2006, AM J RESP CRIT CARE, V174, P928, DOI 10.1164/rccm.200603-450OC
   Griffith DE, 2000, CLIN INFECT DIS, V30, P288, DOI 10.1086/313644
   Jeong BH, 2015, AM J RESP CRIT CARE, V191, P96, DOI 10.1164/rccm.201408-1545OC
   Kadota T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1384-7
   Kobashi Y, 2007, RESP MED, V101, P130, DOI 10.1016/j.rmed.2006.04.002
   Moon SM, 2016, ANTIMICROB AGENTS CH, V60, P6758, DOI 10.1128/AAC.01240-16
   Morimoto K, 2017, ANN AM THORAC SOC, V14, P49, DOI [10.1513/AnnalsATS.201607-573OC, 10.1513/annalsats.201607-573oc]
   Morimoto K, 2016, ANN AM THORAC SOC, V13, P1904, DOI 10.1513/AnnalsATS.201604-246OC
   Morimoto Kozo, 2014, Ann Am Thorac Soc, V11, P1, DOI 10.1513/AnnalsATS.201303-067OC
   van Ingen J, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01855-2016
   Wallace RJ, 2014, CHEST, V146, P276, DOI 10.1378/chest.13-2538
NR 13
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 67
EP 69
DI 10.1016/j.rmed.2019.10.002
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100011
PM 31605924
DA 2020-05-18
ER

PT J
AU Temam, S
   Chanoine, S
   Bedard, A
   Dumas, O
   Sanchez, M
   Boutron-Ruault, MC
   Siroux, V
   Rican, S
   Varraso, R
   Le Moual, N
AF Temam, Sofia
   Chanoine, Sebastien
   Bedard, Annabelle
   Dumas, Orianne
   Sanchez, Margaux
   Boutron-Ruault, Marie-Christine
   Siroux, Valerie
   Rican, Stephane
   Varraso, Raphaelle
   Le Moual, Nicole
TI Low socioeconomic position and neighborhood deprivation are associated
   with uncontrolled asthma in elderly
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma control; Elderly; Neighborhood deprivation; Socioeconomic
   position
ID OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROIDS; HEALTH;
   INEQUALITIES; RISK; VALIDATION; PREDICTORS; MORTALITY; QUALITY; IMPACT
AB Background: While uncontrolled asthma in adults is frequent in Europe, the impact of socioeconomic position (SEP) was little investigated. We aimed to investigate the respective association of individual- and area-level SEP with uncontrolled asthma among French elderly women.
   Methods: Analyses were conducted in the Asthma-E3N study, among participants with current asthma (i.e., asthma attacks, treatment, or symptoms in previous year). Asthma control was evaluated using Asthma Control Test (uncontrolled: score <= 19); SEP was defined at both individual- and area-level, using educational level (low, medium, high), the French Deprivation index (tertiles defined at national level), and by merging them in a combined-SEP index. Associations between SEP and asthma control were estimated for 2258 women by logistic regression adjusted for age. Analyses were stratified by asthma controller medication use estimated through a drug reimbursement database.
   Results: Women were 70 years on average and 24% had uncontrolled asthma. A low educational level (11%) was associated with an increased risk of uncontrolled asthma [odds ratio (95% confidence interval) = 1.9 (1.4,2.6)], especially among women not using controller medication [3.1 (1.9,5.1)]. Using the combined-SEP index, the highest risk of uncontrolled asthma was observed among women with the most disadvantaged socioeconomic profile (low educational level and low-SEP neighborhood) [2.5 (1.5,4.2)].
   Conclusions: Women with low SEP had more often uncontrolled asthma, which might be partly explained by inadequate asthma treatment. To achieve the best management of asthma for elderly patients, a specific attention should be given not only to disadvantaged population and neighborhoods, but also to disadvantaged populations in affluent neighborhoods.
C1 [Temam, Sofia; Bedard, Annabelle; Dumas, Orianne; Sanchez, Margaux; Varraso, Raphaelle; Le Moual, Nicole] INSERM U1168, VIMA Aging & Chron Dis Epidemiol & Publ Hlth Appr, F-94807 Villejuif, France.
   [Temam, Sofia; Bedard, Annabelle; Dumas, Orianne; Sanchez, Margaux; Varraso, Raphaelle; Le Moual, Nicole] Univ Versailles St Quentin En Yvelines, UMR S 1168, F-78180 Montigny Le Bretonneux, France.
   [Temam, Sofia; Boutron-Ruault, Marie-Christine] Univ Paris Sud, Fac Med, UMR S 1018, F-94276 Le Kremlin Bicetre, France.
   [Chanoine, Sebastien; Siroux, Valerie] IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, UGA INSERM U1209 CNRS UMR 5309, F-38700 La Tronche, France.
   [Chanoine, Sebastien; Siroux, Valerie] Univ Grenoble Alpes, F-38400 St Martin Dheres, France.
   [Chanoine, Sebastien; Siroux, Valerie] CHU Grenoble Alpes, Pole Pharm, F-38700 La Tronche, France.
   [Boutron-Ruault, Marie-Christine] INSERM U1018, Ctr Rech Epidemiol & Sante Populat CESP, Equipe Mode Vie Genes & Sante Epidemiol Integree, F-94807 Villejuif, France.
   [Rican, Stephane] CNRS UMR 7533 LADYSS, F-92100 Nanterre, France.
RP Boutron-Ruault, MC (reprint author), Ctr Res Epidemiol & Populat Hlth CESP, UMRS 1018, Hlth Generat Team, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.
EM marie-christine.boutron@gustaveroussy.fr
RI Le Moual, Nicole/R-8976-2016; Dumas, Orianne/R-8636-2016
OI Le Moual, Nicole/0000-0002-2723-5569; Dumas, Orianne/0000-0001-8423-2826
FU Institut pour la Recherche en Sante Publique (IRESP); Direction Generale
   de la Sante (DGS); Mission recherche de la Direction de la recherche,
   des etudes, de l'evaluation et des statistiques (Mire-DREES); Caisse
   nationale d'assurance maladie des travailleurs salaries (CNAMTS); Regime
   Social des Independants (RSI); Caisse nationale de solidarite pour
   l'autonomie (CNSA); Mutuelle Generale de l'Education Nationale (MGEN);
   French League against Cancer (LNCC); Gustave Roussy; French Research
   Agency (ANR)French National Research Agency (ANR) [ANR-10-COHO-0006]
FX This work was supported by a grant of The Institut pour la Recherche en
   Sante Publique (IRESP), and of the joint help of Direction Generale de
   la Sante (DGS), Mission recherche de la Direction de la recherche, des
   etudes, de l'evaluation et des statistiques (Mire-DREES), Caisse
   nationale d'assurance maladie des travailleurs salaries (CNAMTS), Regime
   Social des Independants (RSI) & Caisse nationale de solidarite pour
   l'autonomie (CNSA). The E3N study is supported by the Mutuelle Generale
   de l'Education Nationale (MGEN); the French League against Cancer
   (LNCC); Gustave Roussy; and the French Research Agency (ANR grant,
   ANR-10-COHO-0006).
CR Afrite A, 2008, QUEST EC SANTE, V138, P1
   Arnlind MH, 2013, J ASTHMA, V50, P842, DOI 10.3109/02770903.2013.816318
   Ban GY, 2016, CURR OPIN ALLERGY CL, V16, P237, DOI 10.1097/ACI.0000000000000273
   Bedard A, 2017, AM J EPIDEMIOL, V186, P21, DOI 10.1093/aje/kwx038
   Bellamy David, 2005, Prim Care Respir J, V14, P252, DOI 10.1016/j.pcrj.2005.04.003
   Blanc PD, 2006, EUR RESPIR J, V27, P85, DOI 10.1183/09031936.06.00061205
   Borrell LN, 2006, AM J PUBLIC HEALTH, V96, P332, DOI 10.2105/AJPH.2004.055277
   Cho KH, 2016, RESP MED, V114, P9, DOI 10.1016/j.rmed.2016.03.003
   Clavel-Chapelon F, 2015, INT J EPIDEMIOL, V44, P801, DOI 10.1093/ije/dyu184
   Davidsen JR, 2011, RESP MED, V105, P683, DOI 10.1016/j.rmed.2010.11.009
   De Vries MP, 2005, J ASTHMA, V42, P659, DOI 10.1080/02770900500264903
   Delpierre C, 2009, J EPIDEMIOL COMMUN H, V63, P426, DOI 10.1136/jech.2008.080085
   Demakakos P., 2018, EUR J EPIDEMIOL, V123456789, P1
   Demoly P, 2012, EUR RESPIR REV, V21, P66, DOI 10.1183/09059180.00008111
   Doz M, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-15
   Evans-Agnew R., 2012, J HLTH DISPAR RES PR, V5, P1
   Galobardes B, 2006, J EPIDEMIOL COMMUN H, V60, P95, DOI 10.1136/jech.2004.028092
   Gibson PG, 2010, LANCET, V376, P803, DOI 10.1016/S0140-6736(10)61087-2
   Barcala FJG, 2010, ARCH BRONCONEUMOL, V46, P358, DOI 10.1016/j.arbres.2010.01.007
   Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9
   Greaves CJ, 2002, THORAX, V57, P217, DOI 10.1136/thorax.57.3.217
   Jacquemin B, 2015, ENVIRON HEALTH PERSP, V123, P613, DOI 10.1289/ehp.1408206
   Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265
   Kampe M, 2014, EUR CLIN RESPIR J, V1, DOI 10.3402/ecrj.v1.24109
   Kondla A, 2016, RESP MED, V118, P58, DOI 10.1016/j.rmed.2016.07.012
   Laurent O, 2008, J EPIDEMIOL COMMUN H, V62, P1014, DOI 10.1136/jech.2007.064220
   Le Moual N, 2012, EUR RESPIR J, V40, P1381, DOI 10.1183/09031936.00197611
   Mackenbach JP, 2012, SOC SCI MED, V75, P761, DOI 10.1016/j.socscimed.2012.02.031
   Morello-Frosch R, 2011, HEALTH AFFAIR, V30, P879, DOI 10.1377/hlthaff.2011.0153
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   O'Byrne PM, 2013, CHEST, V143, P511, DOI 10.1378/chest.12-0412
   Patel S, 2012, EUR J EPIDEMIOL, V27, P623, DOI 10.1007/s10654-012-9703-9
   Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015
   Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33
   Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011
   Schatz M, 2012, CURR OPIN ALLERGY CL, V12, P263, DOI 10.1097/ACI.0b013e32835335ac
   Schatz M, 2011, J ALLERGY CLIN IMMUN, V128, P273, DOI 10.1016/j.jaci.2011.03.027
   Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053
   Siroux V, 2009, J ALLERGY CLIN IMMUN, V124, P681, DOI 10.1016/j.jaci.2009.06.010
   Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Stafford M, 2003, INT J EPIDEMIOL, V32, P357, DOI 10.1093/ije/dyg084
   Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880
   Temam S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4967-3
   Tottenborg SS, 2016, RESP MED, V119, P160, DOI 10.1016/j.rmed.2016.09.007
   Uphoff E, 2015, EUR RESPIR J, V46, P364, DOI 10.1183/09031936.00114514
   van Boven JFM, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00076-2017
   Sanchez MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080607
   Watson JP, 1996, EUR RESPIR J, V9, P2087, DOI 10.1183/09031936.96.09102087
   Winkleby M, 2006, AM J PUBLIC HEALTH, V96, P2145, DOI 10.2105/AJPH.2004.060970
   Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066
NR 51
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 70
EP 77
DI 10.1016/j.rmed.2019.09.010
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100012
PM 31610380
DA 2020-05-18
ER

PT J
AU Gaveikaite, V
   Grundstrom, C
   Winter, S
   Chouvarda, I
   Maglaveras, N
   Priori, R
AF Gaveikaite, Violeta
   Grundstrom, Casandra
   Winter, Stefan
   Chouvarda, Ioanna
   Maglaveras, Nicos
   Priori, Rita
TI A systematic map and in-depth review of European telehealth
   interventions efficacy for chronic obstructive pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Review
DE COPD; Europe; Telehealth; Systematic mapping; Integrated care;
   Policymakers
ID HEALTH-CARE; SEVERE COPD; HOME TELEHEALTH; INTEGRATED CARE;
   EXACERBATIONS; TELEMEDICINE; TRIAL; HOSPITALIZATION; METAANALYSIS;
   PROGRAM
AB Background: Evidence to support the implementation of telehealth (TH) interventions in the management of chronic obstructive pulmonary disease (COPD) varies throughout Europe. Despite more than ten years of TH research in COPD management, it is still not possible to define which TH interventions are beneficial to which patient group. Therefore, informing policymakers on TH implementation is complicated. We aimed to examine the provision and efficacy of TH for COPD management to guide future decision-making.
   Methods: A mapping study of twelve systematic reviews of TH interventions for COPD management was conducted. This was followed by an in-depth review of fourteen clinical trials performed in Europe extracted from the systematic reviews. Efficacy outcomes for COPD management were synthesized.
   Results: The mapping study revealed that systematic reviews with a meta-analysis often report positive clinical outcomes. Despite this, we identified a lack of pragmatic trial design affecting the synthesis of reported outcomes. The in-depth review visualized outcomes for three TH categories, which revealed a plethora of heterogeneous outcomes. Suggestions for reporting within these three outcomes are synthesized as targets for future empirical research reporting.
   Conclusion: The present study indicates the need for more standardized and updated systematic reviews. Policymakers should advocate for improved TH trial designs, focusing on the entire intervention's adoption process evaluation. One of the policymakers' priorities should be the harmonization of the outcome sets, which would be considered suitable for deciding about subsequent reimbursement. We propose possible outcome sets in three TH categories which could be used for discussion with stakeholders.
C1 [Gaveikaite, Violeta; Chouvarda, Ioanna; Maglaveras, Nicos] Aristotle Univ Thessaloniki, Lab Comp Med Informat & Biomed Imaging Technol, Thessaloniki 54636, Greece.
   [Gaveikaite, Violeta] Philips Res, Dept Chron Dis Management, High Tech Campus 34, NL-5656 AE Eindhoven, Netherlands.
   [Grundstrom, Casandra] Univ Oulu, M3S, Dept Informat Proc Sci, Pentti Kaiteran Katu 1, FI-90014 Oulu, Finland.
   [Winter, Stefan] Philips Res, Dept Chron Dis Management, Pauwelsstr 17, D-52074 Aachen, Germany.
   [Maglaveras, Nicos] Northwestern Univ, Dept IEMS, McCormick Sch Engn, 2145 Sheridan Rd Tech C210, Evanston, IL 60208 USA.
   [Priori, Rita] Philips Res, Dept Smart Interfaces & Modules, High Tech Campus 34, NL-5656 AE Eindhoven, Netherlands.
RP Gaveikaite, V (reprint author), Philips Res, High Tech Campus 34, NL-5656 AE Eindhoven, Netherlands.
EM violeta.gaveikaite@philips.com; casandra.grundstrom@oulu.fi;
   stefan.winter@philips.com; ioannach@auth.gr; nicmag@certh.gr;
   rita.priori@philips.com
OI Grundstrom, Casandra/0000-0001-6410-144X; Maglaveras,
   Nicos/0000-0002-4919-0664
FU European UnionEuropean Union (EU) [676201]
FX Authors V. Gaveikaite and C. Grundstrom have received funding from the
   European Union's Horizon 2020 research and innovation program - Marie
   Sklodowska-Curie Actions Grant Agreement No. 676201 - CHESS - Connected
   Health Early Stage Researcher Support System.
CR Abbas Z., 2008, J PAK MED ASS, V58
   Amelung E., 2017, HDB INTEGRATED CARE, P297
   [Anonymous], 2018, GLOBAL STRATEGY DIAG, DOI [10.1097/00008483-200207000-00004, DOI 10.1097/00008483-200207000-00004]
   Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055
   Aslam Sadaf, 2010, Indian J Sex Transm Dis AIDS, V31, P47, DOI 10.4103/0253-7184.69003
   Baroi S, 2018, TELEMED E-HEALTH, V24, P415, DOI 10.1089/tmj.2017.0160
   Berkhof FF, 2015, RESPIROLOGY, V20, P279, DOI 10.1111/resp.12437
   Biener A.A.I., 2019, JAMA INFOGRAPHIC DOW, V322, P10241
   Bolton CE, 2011, J EVAL CLIN PRACT, V17, P1216, DOI 10.1111/j.1365-2753.2010.01536.x
   Bourbeau J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00851-2018
   Burge S, 2003, EUR RESPIR J, V21, p46S, DOI 10.1183/09031936.03.00078002
   Burns J, 2018, RES SYNTH METHODS, V9, P132, DOI 10.1002/jrsm.1284
   Casas A, 2006, EUR RESPIR J, V28, P123, DOI 10.1183/09031936.06.00063205
   Chambers D, 2011, MILBANK Q, V89, P131, DOI 10.1111/j.1468-0009.2011.00622.x
   Cruz J, 2014, INT J MED INFORM, V83, P249, DOI 10.1016/j.ijmedinf.2014.01.008
   Dinesen B, 2012, J TELEMED TELECARE, V18, P221, DOI 10.1258/jtt.2012.110704
   Donner CF, 2018, RESP MED, V143, P91, DOI 10.1016/j.rmed.2018.09.003
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   Ford ES, 2015, CHEST, V147, P31, DOI 10.1378/chest.14-0972
   Gough N., 2003, SYSTEMATIC MAP SYNTH, P1
   Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x
   Gregersen TL, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S96079
   Gruffydd-Jones K, 2011, PRIM CARE RESP J, V20, P199, DOI 10.4104/pcrj.2011.00011
   Halpin DMG, 2011, PRIM CARE RESP J, V20, P324, DOI 10.4104/pcrj.2011.00057
   Higgins J. P. T., 2008, COCHRANE HDB SYSTEMA, P187, DOI DOI 10.1002/9780470712184
   Jakobsen AS, 2015, TELEMED E-HEALTH, V21, P364, DOI 10.1089/tmj.2014.0098
   Jodar-Sanchez F, 2013, J TELEMED TELECARE, V19, P11, DOI 10.1177/1357633X12473909
   Jolly K, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2241
   Jones PW, 2014, RESP MED, V108, P129, DOI 10.1016/j.rmed.2013.08.015
   Kamei T, 2013, JPN J NURS SCI, V10, P180, DOI 10.1111/j.1742-7924.2012.00228.x
   Khan KS, 2003, J ROY SOC MED, V96, P118, DOI 10.1258/jrsm.96.3.118
   Krier A, 2006, SPRINGER SERIES OPTI, P359
   Lewis D., 2016, DELIVERABLE D7 6 INT, P1
   Lewis KE, 2010, J TELEMED TELECARE, V16, P253, DOI 10.1258/jtt.2009.090907
   Lewis KE, 2010, COPD, V7, P44, DOI 10.3109/15412550903499555
   Lundell S, 2015, RESP MED, V109, P11, DOI 10.1016/j.rmed.2014.10.008
   Majothi S, 2015, INT J CHRONIC OBSTR, V10, P853, DOI 10.2147/COPD.S74162
   McDowell JE, 2015, J TELEMED TELECARE, V21, P80, DOI 10.1177/1357633X14566575
   McLean S, 2011, BMJ-BRIT MED J, V342, P120
   McLean S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071238
   McLean S, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X658269
   NICE Guideline Updates Team, 2018, CHRON OBSTR PULM DIS, P1
   Oh EG, 2016, ASIAN NURS RES, V10, P89, DOI 10.1016/j.anr.2016.05.001
   Pasquale MK, 2012, INT J CHRONIC OBSTR, V7, P757, DOI 10.2147/COPD.S36997
   Pedone Claudio, 2015, Pneumonol Alergol Pol, V83, P476, DOI 10.5603/PiAP.2015.0077
   Pedone C, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-82
   Pinnock H, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6070
   Polisena J, 2010, J TELEMED TELECARE, V16, P120, DOI 10.1258/jtt.2009.090812
   Ringbaek T, 2015, INT J CHRONIC OBSTR, V10, P1801, DOI 10.2147/COPD.S85596
   Rush KL, 2018, PATIENT EDUC COUNS, V101, P1310, DOI 10.1016/j.pec.2018.02.006
   Schou L, 2013, J TELEMED TELECARE, V19, P160, DOI 10.1177/1357633X13483255
   Calvo GS, 2014, RESP MED, V108, P453, DOI 10.1016/j.rmed.2013.12.003
   Sharma U, 2012, STUD HEALTH TECHNOL, V180, P323, DOI 10.3233/978-1-61499-101-4-323
   So CF, 2018, J TELEMED TELECARE, V24, P356, DOI 10.1177/1357633X17700552
   Sorknaes AD, 2013, J TELEMED TELECARE, V19, P466, DOI 10.1177/1357633X13512067
   Thomson HJ, 2013, RES SYNTH METHODS, V4, P95, DOI 10.1002/jrsm.1060
   Trappenburg JCA, 2008, TELEMED J E-HEALTH, V14, P138, DOI 10.1089/tmj.2007.0037
   Udsen FW, 2014, J TELEMED TELECARE, V20, P212, DOI 10.1177/1357633X14533896
   Vitacca M., 2018, THER ADV RESPIR DIS, V12, P153
   Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
   Wade V, 2017, J TELEMED TELECARE, V23, P786, DOI 10.1177/1357633X16671240
   Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016
   Yang F, 2017, COPD, V14, P251, DOI 10.1080/15412555.2016.1256384
NR 63
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 78
EP 88
DI 10.1016/j.rmed.2019.09.005
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100013
PM 31614305
DA 2020-05-18
ER

PT J
AU Kwon, YS
   Levin, A
   Kasperbauer, SH
   Huitt, GA
   Daley, CL
AF Kwon, Yong-Soo
   Levin, Adrah
   Kasperbauer, Shannon H.
   Huitt, Gwen A.
   Daley, Charles L.
TI Efficacy and safety of tigecycline for Mycobacterium abscessus disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Nontuberculous mycobacteria; Mycobacterium abscessus; Tigecycline;
   Efficacy; Safety
AB Purpose: Mycobacterium abscessus disease is one of the most difficult mycobacterial infections to cure, as the bacterium is highly resistant to conventional antibiotics. The purpose of this study was to evaluate the efficacy and safety of tigecycline treatment of M. abscessus disease.
   Procedure: We performed retrospective chart reviews of patients with M. abscessus disease receiving tigecycline-containing regimens at National Jewish Health from January 2009 to December 2017.
   Main findings: Among the 35 patients, pulmonary disease was the most common presentation of M. abscessus disease (n = 29, 82.9%). Of those receiving tigecycline treatment, 17.4% (4/23) showed microbiological improvement (>= 2 consecutive negative sputum cultures), while 86.2% (25/29) and 59.3% (16/27) showed symptomatic and radiological improvements, respectively. The rate of dose reduction or discontinuation of tigecycline owing to adverse drug reactions was 57.1% (20/35) at a median of 56.5 days (IQR 10.8-122.3). The most common adverse drug reactions were gastrointestinal side effects, including nausea, vomiting, and diarrhea.
   Conclusions: Tigecycline-containing regimens for M. abscessus disease have a high rate of symptomatic and radiological improvement. However, considering the poor microbiological response and the common adverse effects, selection of patients for tigecycline treatment and monitoring for adverse drug reactions should be performed carefully.
C1 [Kwon, Yong-Soo] Chonnam Natl Univ Hosp, Dept Internal Med, 42 Jebongro, Gwangju 61469, South Korea.
   [Kwon, Yong-Soo; Levin, Adrah; Kasperbauer, Shannon H.; Huitt, Gwen A.; Daley, Charles L.] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Room J204,1400 Jackson St, Denver, CO 80206 USA.
   [Kasperbauer, Shannon H.; Huitt, Gwen A.; Daley, Charles L.] Univ Colorado, Dept Med, Denver, CO USA.
RP Kwon, YS (reprint author), Chonnam Natl Univ Hosp, Dept Internal Med, 42 Jebongro, Gwangju 61469, South Korea.; Kwon, YS; Daley, CL (reprint author), Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Room J204,1400 Jackson St, Denver, CO 80206 USA.
EM yskwon@jnu.ac.kr; daleyc@njhealth.org
OI Kwon, Yong-Soo/0000-0001-5121-4488
FU National Research Foundation of Korea - Korean GovernmentNational
   Research Foundation of KoreaKorean Government [2016R1D1A1B03931132]
FX This study was supported by the National Research Foundation of Korea
   funded by the Korean Government (Grant 2016R1D1A1B03931132) and generous
   support from Eileen Polinger.
CR Floto RA, 2016, THORAX, V71, P1, DOI 10.1136/thoraxjnl-2015-207360
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Kaewpoowat Q, 2015, EXPERT OPIN DRUG SAF, V14, P335, DOI 10.1517/14740338.2015.997206
   Kasperbauer SH, 2015, CLIN CHEST MED, V36, P67, DOI 10.1016/j.ccm.2014.10.004
   Muralidharan G, 2005, ANTIMICROB AGENTS CH, V49, P220, DOI 10.1128/AAC.49.1.220-229.2005
   Nessar R, 2012, J ANTIMICROB CHEMOTH, V67, P810, DOI 10.1093/jac/dkr578
   Pankey GA, 2005, J ANTIMICROB CHEMOTH, V56, P470, DOI 10.1093/jac/dki248
   Pasipanodya J.G., 2017, ANTIMICROB AGENTS CH, V61
   Regnier S, 2009, CLIN INFECT DIS, V49, P1358, DOI 10.1086/606050
   Sfeir M, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy022
   van Ingen J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00170-2018
   Wallace RJ, 2014, J ANTIMICROB CHEMOTH, V69, P1945, DOI 10.1093/jac/dku062
   Wallace RJ, 2002, ANTIMICROB AGENTS CH, V46, P3164, DOI 10.1128/AAC.46.10.3164-3167.2002
NR 14
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 89
EP 91
DI 10.1016/j.rmed.2019.10.006
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100014
PM 31622813
DA 2020-05-18
ER

PT J
AU Radchenko, CC
   Cho, PK
   Kang, L
   Saettele, TM
AF Radchenko, Christopher C.
   Cho, Paul K.
   Kang, Le
   Saettele, Timothy M.
TI Performance of endobronchial-ultrasound guided miniforceps biopsy of
   targeted mediastinal and hilar lesions
SO RESPIRATORY MEDICINE
LA English
DT Article
ID TRANSBRONCHIAL NEEDLE ASPIRATION; FORCEPS; LYMPHADENOPATHY; DIAGNOSIS
C1 [Radchenko, Christopher C.] Univ Cincinnati, Med Ctr, Intervent Pulmonol, 234 Goodman St, Cincinnati, OH 45219 USA.
   [Cho, Paul K.] Univ Missouri, Columbia Sch Med, 1 Hosp Dr, Columbia, MO 65212 USA.
   [Kang, Le] Virginia Commonwealth Univ, Dept Biostat, Biostat, POB 980032, Richmond, VA 23298 USA.
   [Saettele, Timothy M.] Midwest Pulm Consultants, Intervent Pulmonol, 4321 Washington Ste 6000, Kansas City, MO 64111 USA.
RP Radchenko, CC (reprint author), 234 Goodman St, Cincinnati, OH 45219 USA.
EM Radchecr@uc.edu; Pkc797@health.missouri.edu; Le.kang@vcuhealth.org;
   Tsaettele@saint-lukes.org
OI Cho, Paul/0000-0002-6475-3277
CR Bramley K, 2016, ANN THORAC SURG, V101, P1870, DOI 10.1016/j.athoracsur.2015.11.051
   Chrissian A, 2011, ANN THORAC SURG, V92, P284, DOI 10.1016/j.athoracsur.2011.03.069
   Darwiche K, 2013, RESPIRATION, V86, P229, DOI 10.1159/000350867
   Dziedzic DA, 2017, CLIN RESPIR J, V11, P58, DOI 10.1111/crj.12304
   Evison M, 2014, BMJ OPEN RESP RES, V1, P11, DOI DOI 10.1136/
   Franke KJ, 2012, LUNG, V190, P227, DOI 10.1007/s00408-011-9341-0
   Gomez Mario, 2009, Proc Am Thorac Soc, V6, P180, DOI 10.1513/pats.200808-081LC
   Herth FJF, 2006, THORAX, V61, P795, DOI 10.1136/thx.2005.047829
   Herth FJF, 2012, EUR RESPIR J, V39, P373, DOI 10.1183/09031936.00033311
   Holty JEC, 2005, THORAX, V60, P949, DOI 10.1136/thx.2005.041525
   Navani N, 2012, AM J RESP CRIT CARE, V186, P255, DOI 10.1164/rccm.201203-0393OC
   Navasakulpong A, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000144
   Ost DE, 2011, CHEST, V140, P1557, DOI 10.1378/chest.10-2914
   Silvestri GA, 2013, CHEST, V143, pE211, DOI 10.1378/chest.12-2355
   Velu PP, 2017, J ROY COLL PHYS EDIN, V47, P52, DOI 10.4997/JRCPE.2017.111
NR 15
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 92
EP 96
DI 10.1016/j.rmed.2019.10.001
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100015
PM 31627081
DA 2020-05-18
ER

PT J
AU Casale, TB
   Aalbers, R
   Bleecker, ER
   Meltzer, EO
   Zaremba-Pechmann, L
   de la Hoz, A
   Kerstjens, HAM
AF Casale, Thomas B.
   Aalbers, Rene
   Bleecker, Eugene R.
   Meltzer, Eli O.
   Zaremba-Pechmann, Liliana
   de la Hoz, Alberto
   Kerstjens, Huib A. M.
TI Tiotropium Respimat (R) add-on therapy to inhaled corticosteroids in
   patients with symptomatic asthma improves clinical outcomes regardless
   of baseline characteristics
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Tiotropium; FEV1; Respimat; Exacerbation; Asthma Control Questionnaire
ID CIGARETTE-SMOKING; LUNG-FUNCTION; BODY-MASS; ADULTS; ADOLESCENTS;
   SALMETEROL
AB Background: Despite currently available therapies and detailed treatment guidelines, many patients with asthma remain symptomatic. Tiotropium delivered by the soft mist inhaler Respimat (R), as add-on therapy to medium-dose inhaled corticosteroids (ICS), has been shown to improve lung function and asthma control in patients with symptomatic moderate asthma.
   Objective: To determine whether the efficacy of tiotropium Respimat (R) in asthma differs by patients' study baseline characteristics.
   Methods: Two replicate Phase III, randomized, double-blind, placebo-controlled, parallel-group studies (Mezzo-TinA-asthma (R); NCT01172808 and NCT01172821) of once-daily tiotropium Respimat 5 mu g and 2.5 mu g add-on to ICS were conducted in patients with symptomatic asthma despite treatment with medium-dose ICS with or without additional controllers. Subgroup analyses of peak forced expiratory volume in 1 s (FEV1), trough FEV1, risk of severe asthma exacerbation and Asthma Control Questionnaire responder rate were performed to determine whether results were influenced by patients' baseline characteristics.
   Results: In this analysis, 523 patients received placebo while 517 and 519 patients received the 5 mu g and 2.5 mu g dose of tiotropium Respimat, respectively. The magnitude of the improvements in lung function and asthma control, as well as the reduced risk of severe exacerbation with both doses of tiotropium Respimat versus placebo, was independent of a broad range of baseline characteristics.
   Conclusions: Once-daily tiotropium Respimat as add-on to ICS is a beneficial treatment option for patients with asthma who remain symptomatic despite at least medium-dose ICS, regardless of baseline characteristics.
C1 [Casale, Thomas B.] Univ S Florida, Div Allergy & Immunol, Morsani Coll Med, Tampa, FL 33612 USA.
   [Aalbers, Rene] Martini Hosp, Groningen, Netherlands.
   [Bleecker, Eugene R.] Univ Arizona Hlth Sci, Ctr Appl Genet & Genom Med, Tucson, AZ USA.
   [Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA.
   [Zaremba-Pechmann, Liliana] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany.
   [de la Hoz, Alberto] Boehringer Ingelheim Int GmbH, TA Resp Biosimilars Med, Ingelheim, Germany.
   [Kerstjens, Huib A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, Groningen, Netherlands.
   [Kerstjens, Huib A. M.] Groningen Res Inst Asthma & COPD, Groningen, Netherlands.
RP Casale, TB (reprint author), Univ S Florida, Div Allergy & Immunol, 12901 Bruce B Downs Blvd,MDC 19, Tampa, FL 33612 USA.
EM tbcasale@health.usf.edu
FU Boehringer IngelheimBoehringer Ingelheim
FX This work was supported by Boehringer Ingelheim.
CR Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004
   Bateman ED, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-38
   Boehringer Ingelheim Asthma, 2018, ASTHM EXP IND SPIRIV
   Boehringer Ingelheim Limited, 2018, SPIRIVA RESP
   Casale TB, 2018, J ALLER CL IMM-PRACT, V6, P923, DOI 10.1016/j.jaip.2017.08.037
   Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226
   Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC
   Demoly P, 2009, EUR RESPIR REV, V18, P105, DOI 10.1183/09059180.00001209
   Global Initiative for Asthma, GINA REP GLOB STRAT
   Hamelmann E, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01100-2016
   Hamelmann E, 2016, J ALLERGY CLIN IMMUN, V138, P441, DOI 10.1016/j.jaci.2016.01.011
   Hasegawa Kohei, 2014, Ann Am Thorac Soc, V11, P1439, DOI 10.1513/AnnalsATS.201406-270BC
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558
   Kerstjens HAM, 2016, RESP MED, V117, P198, DOI 10.1016/j.rmed.2016.06.013
   Kerstjens HAM, 2015, INT J TUBERC LUNG D, V19, P1553, DOI 10.5588/ijtld.15.0409
   Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4
   Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606
   Meltzer EO, 2018, ALLERGY ASTHMA PROC, V39, P14, DOI 10.2500/aap.2018.39.4103
   Nie ZY, 2014, AM J RESP CELL MOL, V51, P251, DOI 10.1165/rcmb.2013-0452OC
   Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109
   Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017
   Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9
   Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519, DOI 10.1164/ajrccm.153.5.8630596
   Peters SP, 2013, J ALLERGY CLIN IMMUN, V132, P1068, DOI 10.1016/j.jaci.2013.08.003
   Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770
   Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205
   Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849
   Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC
   Szefler SJ, 2017, J ALLERGY CLIN IMMUN, V140, P1277, DOI 10.1016/j.jaci.2017.01.014
   Ulrik CS, 2016, EXPERT REV CLIN PHAR, V9, P5, DOI 10.1586/17512433.2016.1093415
   Vogelberg C, 2018, J ALLER CL IMM-PRACT, V6, P2160, DOI 10.1016/j.jaip.2018.04.032
NR 32
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 97
EP 109
DI 10.1016/j.rmed.2019.09.014
PG 13
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100016
PM 31654891
DA 2020-05-18
ER

PT J
AU Gondalia, R
   Bender, BG
   Theye, B
   Stempel, DA
AF Gondalia, Rahul
   Bender, Bruce G.
   Theye, Benjamin
   Stempel, David A.
TI Higher short-acting beta-agonist use is associated with greater COPD
   burden
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; COPD assessment test;
   Short-acting beta-agonists; Digital health
ID ASTHMA CONTROL TEST; FLUTICASONE FUROATE/VILANTEROL; EXACERBATIONS;
   VALIDATION
AB Introduction: The COPD Assessment Test (CAT) is a self-administered questionnaire that measures symptomatic burden. CAT is used as part of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines refined ABCD tool and is usually performed during office visit assessment. Electronic medication monitors (EMMs) capture utilization of short-acting beta-agonists (SABA) that may indicate disease worsening in real-time. The primary objective was to assess the relationship of CAT with SABA utilization.
   Methods: From 8/2017-1/2019, COPD patients >= 40 years of age were enrolled in a digital health platform consisting of EMMs and a mobile application to track time and date of SABA use. Patients with a completed CAT and >= 81 days of continuous EMM data were included in analyses. Using one-way ANOVA, SABA use and maintenance medication adherence were compared by CAT score categories: <10 (low burden), 10-20 (medium), 21-30 (high), and 31-40 (very high). Associations were additionally estimated in patients who used >= 1 puff/week of their rescue and maintenance medication.
   Results: The population included 2196 COPD patients (mean age: 60 years). CAT scores from low to high burden were associated with greater SABA use, from 0.8 to 1.9 puffs/day (+1.1 [95% CI: 0.6, 1.6 puffs/day], P < 0.001), and lower adherence, from 69% to 59%, (-10% [95% CI: 1, 19%], P = 0.04). Sensitivity analyses yielded similar results.
   Conclusions: This study found a significant association between greater SABA use and lower adherence with higher burden CAT scores. This finding may suggest that passive collection of inhaled medications could serve as a surrogate for CAT.
C1 [Gondalia, Rahul; Theye, Benjamin; Stempel, David A.] Propeller Hlth, 47 Maiden Lane,3rd Floor, San Francisco, CA 94108 USA.
   [Bender, Bruce G.] Natl Jewish Hosp, Dept Pediat, Denver, CO USA.
RP Gondalia, R (reprint author), Propeller Hlth, 47 Maiden Lane,3rd Floor, San Francisco, CA 94108 USA.
EM rahul.gondalia@propellerhealth.com
FU Propeller Health
FX This research - the study design; collection, analysis and
   interpretation of data; and writing and critically reviewing the
   manuscript - was supported by Propeller Health. This research did not
   receive any specific grant from funding agencies in the public,
   commercial, or not-for-profit sectors.
CR Agusti A, 2014, EUR RESPIR J, V43, P763, DOI 10.1183/09031936.00054213
   Anderson WC, 2019, J ALLER CL IMM-PRACT, V7, P2065, DOI 10.1016/j.jaip.2019.02.006
   Bender B.G., PEDIAT ALLERGY PRINC, DOI 10.1016/B978-0-323-29875-9.00038-0
   Cajigal S, 2017, J ALLER CL IMM-PRACT, V5, P121, DOI 10.1016/j.jaip.2016.06.025
   Dransfield MT, 2013, LANCET RESP MED, V1, P210, DOI 10.1016/S2213-2600(13)70040-7
   Global Initiative for Chronic Obstructive Lung Disease, 2019, GLOB STRAT DIAGN MAN
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   Make BJ, 2015, INT J CHRONIC OBSTR, V10, P201, DOI 10.2147/COPD.S69589
   Martinez FJ, 2013, RESP MED, V107, P550, DOI 10.1016/j.rmed.2012.12.016
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011
NR 13
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 110
EP 113
DI 10.1016/j.rmed.2019.10.007
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100017
PM 31655317
DA 2020-05-18
ER

PT J
AU Ronmark, E
   Virchow, JC
   Lundback, B
AF Ronmark, Eva
   Virchow, Johann Christian
   Lundback, Bo
TI Longitudinal studies based on the general population - Important studies
   becoming rare nowadays
SO RESPIRATORY MEDICINE
LA English
DT Editorial Material
ID OBSTRUCTIVE LUNG-DISEASE; INCIDENT ASTHMA; ADULTS; DETERMINANTS; RISK
C1 [Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Div Sustainable Hlth, OLIN Unit, SE-90187 Umea, Sweden.
   [Virchow, Johann Christian] Univ Rostock, Dept Internal Med, Rostock, Germany.
   [Lundback, Bo] Univ Gothenburg, Inst Med, Krefting Res Ctr, Gothenburg, Sweden.
RP Ronmark, E (reprint author), Umea Univ, Dept Publ Hlth & Clin Med, Div Sustainable Hlth, OLIN Unit, SE-90187 Umea, Sweden.
EM eva.ronmark@nottbotten.se
CR Aaron SD, 2017, JAMA-J AM MED ASSOC, V317, P269, DOI 10.1001/jama.2016.19627
   Basagana X, 2001, AM J RESP CRIT CARE, V164, P1133, DOI 10.1164/ajrccm.164.7.2012143
   Ekerljung L, 2008, RESP MED, V102, P1730, DOI 10.1016/j.rmed.2008.07.011
   Jensen HH, 2006, EUR RESPIR J, V28, P781, DOI 10.1183/09031936.06.00152205
   Lamprecht B, 2015, CHEST, V148, P971, DOI 10.1378/chest.14-2535
   Lundback B, 2001, RESP MED, V95, P685, DOI 10.1053/rmed.2001.1126
   Maio S, 2019, RESP MED, V158, P33, DOI 10.1016/j.rmed.2019.09.013
   Pallasaho P, 2011, RESP MED, V105, P1449, DOI 10.1016/j.rmed.2011.04.013
   Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035
   Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304
   Ronmark E, 1997, ALLERGY, V52, P1071, DOI 10.1111/j.1398-9995.1997.tb00178.x
   Sator L, 2019, CHEST, V156, P277, DOI 10.1016/j.chest.2019.01.015
   Soriano JB, 2009, LANCET, V374, P721, DOI 10.1016/S0140-6736(09)61290-3
   TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557
   VIEGI G, 1988, EUR RESPIR J, V1, P311
NR 15
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT-NOV
PY 2019
VL 158
BP 114
EP 115
DI 10.1016/j.rmed.2019.105807
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA JT4HA
UT WOS:000500951100018
PM 31735486
DA 2020-05-18
ER

PT J
AU Dima, E
   Kyriakoudi, A
   Kaponi, M
   Vasileiadis, I
   Stamou, P
   Koutsoukou, A
   Koulouris, NG
   Rovina, N
AF Dima, Efrosini
   Kyriakoudi, Anna
   Kaponi, Maria
   Vasileiadis, Ioannis
   Stamou, Panagiota
   Koutsoukou, Antonia
   Koulouris, Nikolaos G.
   Rovina, Nikoletta
TI The lung microbiome dynamics between stability and exacerbation in
   chronic obstructive pulmonary disease (COPD): Current perspectives
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Microbiome; Inflammation; Immune responses; Chronic obstructive
   pulmonary disease
ID BRONCHIAL MICROBIOME; AIRWAY MICROBIOME; BACTERIAL; DIVERSITY; SPUTUM;
   COMMUNITIES; INFECTIONS; VIRUS; AGE
AB Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disorder with a course that is not uniform for all COPD patients. Although smoking is considered as the major cause of the disease, persistent or recurrent infections seem to play a particular role in the disease establishment and progression. COPD is characterized by dysregulated immunity that has been associated with the bacterial colonization and infections.
   The establishment of culture-independent techniques has shed new light on the relationships between bacterial ecology and health status and expanded our knowledge on the lung microbiome. Interactions between the host and lung microbiome result in inflammation and activation of resident cells. The lung microbiome contains populations of symbionts and pathobionts in balance which lose their equilibrium and disturb the balance of T-helper and regulatory T-cells (Treg) upon infection, or lung disease. In COPD factors such as disease severity, exacerbations, degree of inflammation, and type of treatment used (e.g inhaled or systemic steroids and antibiotics) affect the composition of lung microbiota. Recent data indicate that the presence of specific bacterial taxa in the airways has the potential to influence the host immune response and possibly to interfere with disease phenotype. Although, there is a growing body of evidence for the role of microbiome in COPD several unanswered questions still exist for its clinical relevance.
C1 [Dima, Efrosini; Kyriakoudi, Anna; Kaponi, Maria; Vasileiadis, Ioannis; Stamou, Panagiota; Koutsoukou, Antonia; Koulouris, Nikolaos G.; Rovina, Nikoletta] Univ Athens, Dept Resp Med 1, Sch Med, Athens 11527, Greece.
   [Dima, Efrosini; Kyriakoudi, Anna; Kaponi, Maria; Vasileiadis, Ioannis; Stamou, Panagiota; Koutsoukou, Antonia; Koulouris, Nikolaos G.; Rovina, Nikoletta] Sotiria Chest Dis Hosp, Athens 11527, Greece.
RP Rovina, N (reprint author), Univ Athens, Dept Pulm Med 1, Sotiria Hosp, Athens Med Sch, 152 Mesoge Ave, Athens 11527, Greece.
EM nikrovina@med.uoa.gr
OI Rovina, Nikoletta/0000-0003-0138-5582; KYRIAKOUDI,
   ANNA/0000-0002-6908-6194
CR Backhed F, 2015, CELL HOST MICROBE, V17, P852, DOI 10.1016/j.chom.2015.05.012
   Barker BL, 2015, CHEST, V147, P46, DOI 10.1378/chest.14-0764
   Bernasconi E, 2016, AM J RESP CRIT CARE, V194, P1252, DOI 10.1164/rccm.201512-2424OC
   Biedermann L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059260
   Cabrera-Rubio R, 2012, J CLIN MICROBIOL, V50, P3562, DOI 10.1128/JCM.00767-12
   Cameron SJS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149095
   Charlson ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015216
   Christenson SA, 2019, J CLIN INVEST, V129, P169, DOI 10.1172/JCI121087
   Cui LJ, 2015, AM J RESP CRIT CARE, V191, P932, DOI 10.1164/rccm.201409-1583OC
   Deriu E, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005572
   Dickson RP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004923
   Dickson RP, 2014, LANCET, V384, P691, DOI 10.1016/S0140-6736(14)61136-3
   Dollive S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071806
   Engel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180859
   Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384
   Feng ZH, 2017, CHINESE MED J-PEKING, V130, P1122, DOI 10.4103/0366-6999.204934
   Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111
   Galiana A, 2014, EUR RESPIR J, V43, P1787, DOI 10.1183/09031936.00191513
   Garcha DS, 2012, THORAX, V67, P1075, DOI 10.1136/thoraxjnl-2012-201924
   Garcia-Nunez M, 2014, J CLIN MICROBIOL, V52, P4217, DOI 10.1128/JCM.01967-14
   Ghebre MA, 2018, J ALLERGY CLIN IMMUN, V141, P2027, DOI 10.1016/j.jaci.2018.04.013
   Gronseth R, 2014, EUR CLIN RESPIR J, V1, DOI 10.3402/ecrj.v1.26196
   Grunwell JR, 2018, J IMMUNOL, V200, P2115, DOI 10.4049/jimmunol.1701325
   Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183
   Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC
   Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P535, DOI 10.1111/j.1348-0421.2002.tb02731.x
   Hewitt R, 2016, THER ADV RESPIR DIS, V10, P158, DOI 10.1177/1753465815618113
   HILL AT, 2000, J CLIN VIROL, V109, P188
   Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578
   Huang YJ, 2014, J CLIN MICROBIOL, V52, P2813, DOI 10.1128/JCM.00035-14
   Huang YJ, 2010, OMICS, V14, P9, DOI 10.1089/omi.2009.0100
   Jones B, 2017, RESPIROLOGY, V22, P21, DOI 10.1111/resp.12908
   Jubinville E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194355
   Kalinowski A, 2018, MUCOSAL IMMUNOL, V11, P958, DOI 10.1038/mi.2017.120
   Kc R, 2017, MICROBIOL-SGM, V163, P421, DOI 10.1099/mic.0.000434
   Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030
   Knights D, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0107-1
   Knobloch J, 2011, AM J RESP CRIT CARE, V183, P204, DOI 10.1164/rccm.201002-0199OC
   Larsen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031245
   Mayhew D, 2018, THORAX, V73, P422, DOI 10.1136/thoraxjnl-2017-210408
   Millares L, 2014, EUR J CLIN MICROBIOL, V33, P1101, DOI 10.1007/s10096-013-2044-0
   Millares L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144448
   Miravitlles M, 1999, CHEST, V116, P40, DOI 10.1378/chest.116.1.40
   Modi SR, 2014, J CLIN INVEST, V124, P4212, DOI 10.1172/JCI72333
   Molyneaux PL, 2013, AM J RESP CRIT CARE, V188, P1224, DOI 10.1164/rccm.201302-0341OC
   Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC
   Pragman AA, 2015, J CLIN MICROBIOL, V53, P1050, DOI 10.1128/JCM.03320-14
   Pragman AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047305
   Relman DA, 2002, J INFECT DIS, V186, pS254, DOI 10.1086/344935
   Segal LN, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.31, 10.1038/NMICROBIOL.2016.31]
   Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19
   Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Singh R, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0114-1
   Sinha R., 2018, PLOS ONE, V8
   Stewart CJ, 2018, J INFECT DIS, V217, P1160, DOI 10.1093/infdis/jix680
   Suau A, 1999, APPL ENVIRON MICROB, V65, P4799
   Sze MA, 2015, AM J RESP CRIT CARE, V192, P438, DOI 10.1164/rccm.201502-0223OC
   Sze MA, 2012, AM J RESP CRIT CARE, V185, P1073, DOI 10.1164/rccm.201111-2075OC
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Wang Z., 2016, EUR RESP J, V47
   Wang Z, 2018, THORAX, V73, P331, DOI 10.1136/thoraxjnl-2017-210741
   Willner D, 2012, ISME J, V6, P471, DOI 10.1038/ismej.2011.104
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
   Zuo L, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00312
NR 65
TC 4
Z9 3
U1 4
U2 13
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 1
EP 6
DI 10.1016/j.rmed.2019.08.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900001
PM 31450162
DA 2020-05-18
ER

PT J
AU Riley, LE
   Ataya, A
AF Riley, Leonard E.
   Ataya, Ali
TI Clinical approach and review of causes of a chylothorax
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Chylothorax; Chylous effusion; Pseudochylothorax; Pleural effusion
ID YELLOW NAIL SYNDROME; BILATERAL CHYLOTHORAX; CHYLOUS ASCITES;
   THORACIC-DUCT; MANAGEMENT; COMPLICATIONS; LYMPHOSCINTIGRAPHY;
   LYMPHOGRAPHY; DISEASE; EXPERIENCE
AB A chylothorax, also known as chylous pleural effusion, is an uncommon cause of pleural effusion with a wide differential diagnosis characterized by the accumulation of bacteriostatic chyle in the pleural space. The pleural fluid will have either or both triglycerides > 110 mg/dL and the presence of chylomicrons. It may be encountered following a surgical intervention, usually in the chest, or underlying disease process. Management of a chylothorax requires a multidisciplinary approach employing medical therapy and possibly surgical intervention for post-operative patients and patients who have failed medical therapy. In this review, we aim to discuss the anatomy, fluid characteristics, etiology, and approach to the diagnosis of a chylothorax.
C1 [Riley, Leonard E.; Ataya, Ali] Univ Florida, Coll Med, Div Pulm Crit Care & Sleep Med, Gainesville, FL 32610 USA.
RP Ataya, A (reprint author), Univ Florida, Div Pulm Crit Care & Sleep Med, 1600 SW Archer Rd,M452,POB 100225, Gainesville, FL 32610 USA.
EM AliAtaya@gmail.com
OI Ataya, Ali/0000-0001-8505-1680
CR Abdel-Galil K, 2009, BRIT J ORAL MAX SURG, V47, P478, DOI 10.1016/j.bjoms.2009.04.030
   Abreu SC, 2004, J UROLOGY, V171, P1451, DOI 10.1097/01.ju.0000116352.15266.57
   Agrawal V, 2008, CHEST, V133, P1436, DOI 10.1378/chest.07-2232
   Agrawal V, 2008, AM J MED SCI, V335, P16, DOI 10.1097/MAJ.0b013e31815d2634
   Agrawal V, 2007, CHEST, V132, P690, DOI 10.1378/chest.07-0535
   Air ME, 2012, AM J PHYS MED REHAB, V91, P1086, DOI 10.1097/PHM.0b013e31825f14c2
   Al-Zubairy SA, 2003, ANN PHARMACOTHER, V37, P679, DOI 10.1345/aph.1C265
   Alejandre-Lafont E, 2011, ACTA RADIOL, V52, P305, DOI 10.1258/ar.2010.090356
   Allaham AH, 2006, CHEST, V130, P1138, DOI 10.1378/chest.130.4.1138
   Apostolakis E, 2009, J CARDIAC SURG, V24, P220, DOI 10.1111/j.1540-8191.2009.00828.x
   Bhattarai B, 2015, J COMMUNITY HOSP INT, V5, DOI 10.3402/jchimp.v5.28300
   BLOOM B, 1951, AM J PHYSIOL, V166, P451
   Bruch-Gerharz D, 2007, J AM ACAD DERMATOL, V56, pS21, DOI 10.1016/j.jaad.2006.01.063
   CAMMARATA SK, 1991, CHEST, V99, P1539, DOI 10.1378/chest.99.6.1539
   CESPEDES RD, 1993, J UROLOGY, V150, P1895, DOI 10.1016/S0022-5347(17)35927-X
   Chang PY, 2005, CLIN ONCOL-UK, V17, P291, DOI 10.1016/j.clon.2004.07.014
   Cho HJ, 2014, ANN THORAC SURG, V97, P408, DOI 10.1016/j.athoracsur.2013.10.065
   Colak HB, 2007, CLIN NEPHROL, V67, P333
   Collard JM, 2000, CHEST, V117, P902, DOI 10.1378/chest.117.3.902
   Cousins E, 2018, LYMPHAT RES BIOL, V16, P340, DOI 10.1089/lrb.2018.0009
   DAVIS SN, 1986, J ROY SOC MED, V79, P49, DOI 10.1177/014107688607900117
   Devlin RD, 1996, J CLIN ENDOCR METAB, V81, P1893, DOI 10.1210/jc.81.5.1893
   Doerr CH, 2005, MAYO CLIN PROC, V80, P867, DOI 10.4065/80.7.867
   DOLAN PA, 1966, RADIOLOGY, V86, P876, DOI 10.1148/86.5.876
   Dugue L, 1998, BRIT J SURG, V85, P1147
   Faul JL, 2000, AM J RESP CRIT CARE, V161, P1037, DOI 10.1164/ajrccm.161.3.9904056
   Fernandes FF, 2016, REV INST MED TROP SP, V58, DOI 10.1590/S1678-9946201658057
   Garcia-Tirado J, 2017, ARCH BRONCONEUMOL, V53, P32, DOI 10.1016/j.arbres.2016.05.017
   Guermazi A, 2003, RADIOGRAPHICS, V23, P1541, DOI 10.1148/rg.236035704
   Gupta N, 2017, AM J RESP CRIT CARE, V196, P1337, DOI 10.1164/rccm.201709-1965ST
   HASHIM SA, 1964, NEW ENGL J MED, V270, P756, DOI 10.1056/NEJM196404092701502
   HERRIDGE MS, 1995, J THORAC CARDIOV SUR, V110, P22, DOI 10.1016/S0022-5223(05)80005-4
   Hooper C, 2010, THORAX, V65, P4, DOI 10.1136/thx.2010.136978
   Hoque SR, 2007, BRIT J DERMATOL, V156, P1230, DOI 10.1111/j.1365-2133.2007.07894.x
   Huggins JT, 2010, SEMIN RESP CRIT CARE, V31, P743, DOI 10.1055/s-0030-1269834
   JARMAN PR, 1995, THORAX, V50, P1324, DOI 10.1136/thx.50.12.1324
   Johnson SR, 2010, EUR RESPIR J, V35, P14, DOI 10.1183/09031936.00076209
   Kalomenidis I, 2006, CURR OPIN PULM MED, V12, P264, DOI 10.1097/01.mcp.0000230629.73139.26
   Kelly RF, 2000, ANN THORAC SURG, V69, P1944, DOI 10.1016/S0003-4975(00)01279-0
   KEOUGH KMW, 1979, DIGEST DIS SCI, V24, P797, DOI 10.1007/BF01317214
   Kim EY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003109
   Kim KJ, 2014, INFECT CHEMOTHER, V46, P50, DOI 10.3947/ic.2014.46.1.50
   Kiyonaga M, 2012, BRIT J RADIOL, V85, P1052, DOI 10.1259/bjr/19379150
   KNOCHEL JQ, 1979, AM J ROENTGENOL, V132, P981, DOI 10.2214/ajr.132.6.981
   Kwong KF, 2005, ANN THORAC SURG, V80, P1063, DOI 10.1016/j.athoracsur.2005.03.076
   Lagarde SM, 2005, ANN THORAC SURG, V80, P449, DOI 10.1016/j.athoracsur.2005.02.076
   Lama A, 2016, J THORAC DIS, V8, P2093, DOI 10.21037/jtd.2016.07.84
   Liang WQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154964
   Lichter I, 1968, Ann Thorac Surg, V5, P352
   Light RW, 1995, PLEURAL DIS
   Limsukon A, 2011, J EMERG MED, V40, P280, DOI 10.1016/j.jemermed.2007.12.023
   Lin JN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-321
   Lin WY, 2009, NEPHROLOGY, V14, P700, DOI 10.1111/j.1440-1797.2008.01078.x
   Lonie SJ, 2015, ANN THORAC SURG, V100, P2336, DOI 10.1016/j.athoracsur.2015.02.099
   Mafe JJ, 2003, EUR J CARDIO-THORAC, V24, P466, DOI 10.1016/S1010-7940(03)00335-X
   Maldonado F, 2008, CHEST, V134, P375, DOI 10.1378/chest.08-0137
   Maldonado F, 2009, MAYO CLIN PROC, V84, P129, DOI 10.1016/S0025-6196(11)60820-3
   Marulli G, 2013, J THORAC CARDIOV SUR, V145, P730, DOI 10.1016/j.jtcvs.2012.12.031
   Mehta K, 2015, J TROP PEDIATRICS, V61, P468, DOI 10.1093/tropej/fmv059
   Merki V, 2016, J OTOLARYNGOL-HEAD N, V45, DOI 10.1186/s40463-016-0166-y
   Merrigan BA, 1997, BRIT J SURG, V84, P15, DOI 10.1002/bjs.1800840107
   Milonakis M, 2009, J CARDIAC SURG, V24, P369, DOI 10.1111/j.1540-8191.2008.00781.x
   Mongelli F, 2018, ANN THORAC MED, V13, P114, DOI 10.4103/atm.ATM_340_17
   Nikolaou VS, 2014, WORLD J ORTHOP, V5, P694, DOI 10.5312/wjo.v5.i5.694
   Odendaal J, 2017, ANN ROY COLL SURG, V99, P390, DOI 10.1308/rcsann.2017.0022
   Pamarthi V, 2014, J VASC INTERV RADIOL, V25, P1398, DOI 10.1016/j.jvir.2014.03.027
   PANDYA K, 1988, CHEST, V94, P1316, DOI 10.1378/chest.94.6.1316b
   Paul S, 2009, THORAC CARDIOV SURG, V57, P226, DOI 10.1055/s-0029-1185457
   Phang K, 2014, CLIN ANAT, V27, P637, DOI 10.1002/ca.22337
   Prabhu V, 2012, J LARYNGOL OTOL, V126, P648, DOI 10.1017/S002221511200062X
   Radhakrishnan K, 2008, ANN NY ACAD SCI, V1131, P203, DOI 10.1196/annals.1413.022
   Rajagopala S, 2018, RESPIRATION, V95, DOI 10.1159/000484694
   REILLY KM, 1975, JAMA-J AM MED ASSOC, V233, P536, DOI 10.1001/jama.233.6.536
   Reisenauer JS, 2018, ANN THORAC SURG, V105, P254, DOI 10.1016/j.athoracsur.2017.07.021
   Repko BM, 2009, OTOLARYNG HEAD NECK, V141, P426, DOI 10.1016/j.otohns.2009.02.017
   Restrepo JM, 2004, CLIN NUCL MED, V29, P440, DOI 10.1097/01.rlu.0000129125.05486.c5
   RICHARDSON P, 1966, CAN MED ASSOC J, V94, P1086
   Romero S, 2000, Curr Opin Pulm Med, V6, P287, DOI 10.1097/00063198-200007000-00006
   Romero S, 1998, CHEST, V114, P154, DOI 10.1378/chest.114.1.154
   RUPPIN DC, 1980, DRUGS, V20, P216, DOI 10.2165/00003495-198020030-00005
   Ryu JH, 2003, CHEST, V123, P623, DOI 10.1378/chest.123.2.623
   SASSOON CS, 1985, CLIN CHEST MED, V6, P163
   SELLE JG, 1973, ANN SURG, V177, P245, DOI 10.1097/00000658-197302000-00022
   Shen YX, 2014, J AM COLL SURGEONS, V218, P108, DOI 10.1016/j.jamcollsurg.2013.09.014
   Skouras V, 2010, CURR OPIN PULM MED, V16, P387, DOI 10.1097/MCP.0b013e328338dde2
   Soferman R, 2003, CLIN PEDIATR, V42, P831, DOI 10.1177/000992280304200910
   SOKOL GH, 1977, AM J ROENTGENOL, V128, P43, DOI 10.2214/ajr.128.1.43
   Soskel N T, 2000, Curr Opin Pulm Med, V6, P455, DOI 10.1097/00063198-200009000-00012
   Sriram K, 2016, NUTRITION, V32, P281, DOI 10.1016/j.nut.2015.08.002
   STAATS BA, 1980, MAYO CLIN PROC, V55, P700
   Stavngaard T, 2002, THORAC CARDIOV SURG, V50, P250, DOI 10.1055/s-2002-33099
   Suga K, 1999, CLIN NUCL MED, V24, P716, DOI 10.1097/00003072-199909000-00026
   Sugimoto S, 2015, ANN THORAC SURG, V99, P1425, DOI 10.1016/j.athoracsur.2014.05.098
   Teng CL, 2012, EUR J CANCER CARE, V21, P599, DOI 10.1111/j.1365-2354.2012.01329.x
   Thomas R, 2007, RESPIRATION, V74, P338, DOI 10.1159/000087365
   TIE MLH, 1994, CHEST, V105, P208, DOI 10.1378/chest.105.1.208
   Valdes L, 2014, RESPIROLOGY, V19, P985, DOI 10.1111/resp.12357
   VALENTINE VG, 1992, CHEST, V102, P586, DOI 10.1378/chest.102.2.586
   VILLENA V, 1995, EUR RESPIR J, V8, P1235, DOI 10.1183/09031936.95.08071235
   Waikar HD, 2018, ANN CARD ANAESTH, V21, P300, DOI 10.4103/aca.ACA_212_17
   Wright RS, 2011, CHEST, V140, P1064, DOI 10.1378/chest.10-2168
   Wu C, 2019, J PEDIATR SURG, V54, P1293, DOI 10.1016/j.jpedsurg.2018.05.008
   Yekeler E, 2012, ANN THORAC SURG, V94, pE21, DOI 10.1016/j.athoracsur.2012.01.023
   Yin R, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007594
   Yoshida RY, 2016, TECH VASC INTERV RAD, V19, P273, DOI 10.1053/j.tvir.2016.10.009
   Yu DX, 2013, EUR RADIOL, V23, P702, DOI 10.1007/s00330-012-2642-8
   Zerrweck C, 2009, OBES SURG, V19, P667, DOI 10.1007/s11695-008-9798-y
NR 107
TC 0
Z9 0
U1 3
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 7
EP 13
DI 10.1016/j.rmed.2019.08.014
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900002
PM 31454675
DA 2020-05-18
ER

PT J
AU Crivelli, P
   Ledda, RE
   Terraneo, S
   Conti, M
   Imeri, G
   Lesma, E
   Di Marco, F
AF Crivelli, Paola
   Ledda, Roberta Eufrasia
   Terraneo, Silvia
   Conti, Maurizio
   Imeri, Gianluca
   Lesma, Elena
   Di Marco, Fabiano
TI Role of thoracic imaging in the management of lymphangioleiomyomatosis
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Lymphangioleiomyomatosis; HRCT; Diagnosis; Tuberous sclerosis complex;
   Radiological findings
ID CYSTIC LUNG-DISEASES; HIGH-RESOLUTION CT; HOGG-DUBE SYNDROME;
   THIN-SECTION CT; LOW-DOSE CT; COMPUTED-TOMOGRAPHY; PULMONARY
   LYMPHANGIOLEIOMYOMATOSIS; ITERATIVE RECONSTRUCTION; SPONTANEOUS
   PNEUMOTHORAX; PLEURAL METASTASES
AB Lymphangioleiomyomatosis (LAM) is a rare diffuse lung cystic disease (DLCD) that occurs sporadically or in association with Tuberous Sclerosis Complex (TSC). The diagnostic pathway is tracked on the identification of the disease hallmarks on chest High-Resolution Computed Tomography (HRCT).
   Aim of this review is to discuss the thoracic HRCT pathognomonic features, essential to rule out other DLCD. It also examines the new evidences emerging from Computed Tomography (CT) quantitative studies that, by demonstrating a specific cysts distribution and a pathological aspect of the parenchyma near the cysts, could improve our understanding of this rare disorder and supply pulmonologists with a new tool for a more appropriate long-term management. Finally, the contribution of other image techniques as low dose chest CT, Magnetic Resonance Imaging (MRI) and Ultrasound (US) is discussed.
C1 [Crivelli, Paola] AOU Sassari, Inst Diagnost Imaging 2, Sassari, Italy.
   [Ledda, Roberta Eufrasia] Univ Parma, Sect Radiol, Unit Surg Sci, Dept Med & Surg DiMeC, Parma, Italy.
   [Terraneo, Silvia; Imeri, Gianluca; Lesma, Elena; Di Marco, Fabiano] Univ Milan, Dept Med Sci, Resp Unit, Milan, Italy.
   [Conti, Maurizio] Univ Sassari, Dept Clin & Expt Med, Inst Diagnost Imaging 2, Sassari, Italy.
RP Crivelli, P (reprint author), AOU Sassari, Inst Diagnost Imaging 2, Sassari, Italy.
EM paocri2000@gmail.com
OI di marco, fabiano/0000-0002-1743-0504; Ledda, Roberta
   Eufrasia/0000-0003-3184-2676
CR Abbott GF, 2004, RADIOGRAPHICS, V24, P821, DOI 10.1148/rg.243045005
   Adriaensen MEAPM, 2011, CLIN RADIOL, V66, P625, DOI 10.1016/j.crad.2011.02.009
   Almoosa KF, 2006, CHEST, V129, P1274, DOI 10.1378/chest.129.5.1274
   Amaxopoulou C, 2018, PEDIATR RADIOL, V48, P165, DOI 10.1007/s00247-017-4021-8
   Ando K, 2012, EUR J RADIOL, V81, P3925, DOI 10.1016/j.ejrad.2012.05.033
   Avila NA, 2006, AM J ROENTGENOL, V186, P1007, DOI 10.2214/AJR.04.1912
   Avila NA, 2002, RADIOLOGY, V223, P189, DOI 10.1148/radiol.2231010315
   Avila NA, 2000, RADIOLOGY, V216, P147, DOI 10.1148/radiology.216.1.r00jl42147
   Avila NA, 2007, RADIOLOGY, V242, P277, DOI 10.1148/radiol.2421051767
   Baldi BG, 2017, J BRAS PNEUMOL, V43, P140, DOI [10.1590/S1806-37562016000000341, 10.1590/s1806-37562016000000341]
   Bauman G, 2013, EUR J RADIOL, V82, P2371, DOI 10.1016/j.ejrad.2013.08.018
   Biederer J, 2012, INSIGHTS IMAGING, V3, P355, DOI 10.1007/s13244-011-0146-8
   Boddu P., 2017, PATHOL RES INT, V2017
   Bonelli FS, 1998, AM J ROENTGENOL, V170, P1507, DOI 10.2214/ajr.170.6.9609163
   Chou CW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000768
   Chu SC, 1999, CHEST, V115, P1041, DOI 10.1378/chest.115.4.1041
   Ciet P, 2015, PEDIATR RADIOL, V45, P1901, DOI 10.1007/s00247-015-3420-y
   Cudzilo CJ, 2013, CHEST, V144, P578, DOI 10.1378/chest.12-2813
   Davidsen JR, 2017, EUR CLIN RESPIR J, V4, DOI 10.1080/20018525.2017.1330111
   Di Marco F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155331
   Fain SB, 2007, J MAGN RESON IMAGING, V25, P910, DOI 10.1002/jmri.20876
   Francisco FAF, 2015, EUR RESPIR REV, V24, P552, DOI 10.1183/16000617.0046-2015
   Fortes HR, 2017, RESP MED, V126, P116, DOI 10.1016/j.rmed.2017.03.030
   Gafoor K, 2018, CHEST, V153, P1443, DOI 10.1016/j.chest.2018.02.026
   Gopalakrishnan V, 2019, CHEST, V155, P962, DOI 10.1016/j.chest.2019.01.004
   Gupta N, 2019, CHEST, V155, P288, DOI 10.1016/j.chest.2018.06.016
   Gupta N, 2017, AM J RESP CRIT CARE, V196, P1337, DOI 10.1164/rccm.201709-1965ST
   Gupta N, 2015, EUR RESPIR J, V46, P1196, DOI 10.1183/13993003.00570-2015
   Harari S, 2011, EUR RESPIR REV, V20, P34, DOI 10.1183/09059180.00011010
   Harari S, 2015, EUR RESPIR J, V46, P1471, DOI 10.1183/13993003.00412-2015
   Hardak E, 2010, LUNG, V188, P159, DOI 10.1007/s00408-009-9214-y
   Hohman DW, 2008, EUR J INTERN MED, V19, P319, DOI 10.1016/j.ejim.2007.10.015
   Johnson S, 1999, THORAX, V54, P254, DOI 10.1136/thx.54.3.254
   Johnson SR, 2010, EUR RESPIR J, V35, P14, DOI 10.1183/09031936.00076209
   Kim NR, 2003, PATHOL INT, V53, P231, DOI 10.1046/j.1320-5463.2003.01460.x
   Kim Y, 2015, AM J ROENTGENOL, V204, P1197, DOI 10.2214/AJR.14.13629
   Kirchner J, 1999, EUR RADIOL, V9, P49, DOI 10.1007/s003300050626
   Koyama M, 2003, AM J ROENTGENOL, V180, P827, DOI 10.2214/ajr.180.3.1800827
   Lee SW, 2014, EUR RADIOL, V24, P817, DOI 10.1007/s00330-013-3090-9
   Liagaman JT, 2010, AM J RESP CRIT CARE, V181, P1376, DOI 10.1164/rccm.200910-1553OC
   Lim KE, 2004, CLIN IMAG, V28, P1, DOI 10.1016/S0899-7071(03)00030-5
   Martnez-Jimenez S, 2014, RADIOGRAPHICS, V34, P1742, DOI 10.1148/rg.346140052
   Matsui K, 2000, HUM PATHOL, V31, P1242, DOI 10.1053/hupa.2000.18500
   McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898
   McCormack FX, 2016, AM J RESP CRIT CARE, V194, P748, DOI 10.1164/rccm.201607-1384ST
   Menko FH, 2009, LANCET ONCOL, V10, P1199, DOI 10.1016/S1470-2045(09)70188-3
   MERCHANT RN, 1985, AM REV RESPIR DIS, V131, P295
   Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311
   Moir LM, 2016, PHARMACOL THERAPEUT, V158, P114, DOI 10.1016/j.pharmthera.2015.12.008
   MULLER NL, 1990, RADIOLOGY, V175, P335
   Murray JG, 1997, AM J ROENTGENOL, V168, P359, DOI 10.2214/ajr.168.2.9016206
   Neroladaki A, 2013, EUR RADIOL, V23, P360, DOI 10.1007/s00330-012-2627-7
   Ohno Y, 2012, AM J ROENTGENOL, V199, pW477, DOI 10.2214/AJR.11.8275
   Paciocco G, 2004, CHEST, V125, P135, DOI 10.1378/chest.125.1.135
   Pallisa E, 2002, RADIOGRAPHICS, V22, pS185, DOI 10.1148/radiographics.22.suppl_1.g02oc13s185
   Pontana F, 2011, EUR RADIOL, V21, P627, DOI 10.1007/s00330-010-1990-5
   Raoof S, 2016, CHEST, V150, P945, DOI 10.1016/j.chest.2016.04.026
   RAPPAPORT DC, 1989, AM J ROENTGENOL, V152, P961, DOI 10.2214/ajr.152.5.961
   Ryu JH, 2012, RESP MED, V106, P1586, DOI 10.1016/j.rmed.2012.07.007
   Ryu JH, 2003, CHEST, V123, P623, DOI 10.1378/chest.123.2.623
   Sagara Y, 2010, AM J ROENTGENOL, V195, P713, DOI 10.2214/AJR.09.2989
   Salvatore M, 2016, AM J ROENTGENOL, V206, P487, DOI 10.2214/AJR.15.15537
   Schmithorst VJ, 2009, AM J ROENTGENOL, V192, P1037, DOI 10.2214/AJR.07.3334
   Skoura E, 2015, INT J INFECT DIS, V32, P87, DOI 10.1016/j.ijid.2014.12.007
   Sluimer I, 2006, IEEE T MED IMAGING, V25, P385, DOI 10.1109/TMI.2005.862753
   Smith-Bindman R, 2012, JAMA-J AM MED ASSOC, V307, P2400, DOI 10.1001/jama.2012.5960
   Taveira-DaSilva Angelo M, 2006, Cancer Control, V13, P276
   TAYLOR JR, 1990, NEW ENGL J MED, V323, P1254, DOI 10.1056/NEJM199011013231807
   Theilig D, 2015, EUR J RADIOL, V84, P732, DOI 10.1016/j.ejrad.2014.12.019
   Tobino K, 2015, EUR J RADIOL, V84, P534, DOI 10.1016/j.ejrad.2014.12.008
   Tobino K, 2012, EUR J RADIOL, V81, P1340, DOI 10.1016/j.ejrad.2011.03.039
   Tobino K, 2011, EUR J RADIOL, V77, P403, DOI 10.1016/j.ejrad.2009.09.004
   Toro JR, 2007, AM J RESP CRIT CARE, V175, P1044, DOI 10.1164/rccm.200610-1483OC
   Trotman-Dickenson B, 2014, EUR J RADIOL, V83, P39, DOI 10.1016/j.ejrad.2013.11.027
   Uppaluri R, 1999, AM J RESP CRIT CARE, V160, P648, DOI 10.1164/ajrccm.160.2.9804094
   van Rikxoort EM, 2009, IEEE T MED IMAGING, V28, P621, DOI 10.1109/TMI.2008.2008968
   Weiss N, 2003, CLIN NUCL MED, V28, P811, DOI 10.1097/01.rlu.0000089522.86184.49
   Wild JM, 2012, INSIGHTS IMAGING, V3, P345, DOI 10.1007/s13244-012-0176-x
   Yao JH, 2012, AM J ROENTGENOL, V199, P787, DOI 10.2214/AJR.11.7888
   Zoumot Z, 2014, RESPIROLOGY, V19, P714, DOI 10.1111/resp.12287
NR 80
TC 0
Z9 0
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 14
EP 20
DI 10.1016/j.rmed.2019.08.013
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900003
PM 31470185
DA 2020-05-18
ER

PT J
AU Kessler, A
   Kragl, U
   Glass, A
   Schmidt, S
   Fischer, DC
   Ballmann, M
AF Kessler, Anja
   Kragl, Uwe
   Glass, Anne
   Schmidt, Sebastian
   Fischer, Dagmar-C
   Ballmann, Manfred
TI Exhaled nitric oxide can't replace the methacholine challenge in
   suspected pediatric asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Methacholine challenge testing; Children; Allergic asthma; Skin prick
   test; FENO
ID LUNG-FUNCTION; CHILDREN; CHILDHOOD; FENO; SPIROMETRY; MANAGEMENT;
   STATEMENT; ACCURACY; SOCIETY; SAMPLE
AB Background: In adults, measurement of FENO has been recently suggested as a substitute for the methacholine challenge test (MCT) for diagnosis of asthma. This study aimed to evaluate whether FeNO is a substitute for MCH also in children with suspicious asthma.
   Methods: During a single visit steroid naive children (5-17 years) with suspicious asthma underwent skin prick test (SPT), FENO measurement and spirometry prior and during MCT (one concentration procedure). Results of the SPT (atopy/non-atopy) and MCT (asthma/non-asthma) were used for categorization. ROC analysis in atopy non-atopy subgroups yielded sensitivity, specificity, positive and negative predictive value (PPV and NPV) for FENO.
   Results: The SPT revealed atopy in 134 out of 222 children (age 9.7 +/- 3.2 years) investigated and asthma was diagnosed in 114 (77/37 atopy/non-atopy) patients. FENO values in patients with atopic asthma were significantly higher compared to those with either non-atopic asthma or atopia without asthma (18 ppb (5-89) vs 7 ppb (5-36); p < 0.001; 18 ppb (5-89) vs 11 ppb (5-98); p < 0.05). Sensitivity and specificity of FENO for diagnosing atopic asthma (FENO >= 15.5 ppb; AUC = 0.635, p < 0.01) were 61.1% and 64.9% and non-atopic asthma (FENO >= 6.5 ppb; AUC = 0.445, p = 0.382) 54.1% and 39.2%, respectively. The PPV/NPV for FENO were 0.70/0.55 in atopy and 0.39/0.54 in non-atopy patients, respectively.
   Conclusion: In children, FENO is not appropriate to substitute for the MCT. However, in patients with a negative SPT a FENO in the normal range makes the presence of atopic asthma unlikely.
C1 [Kessler, Anja; Fischer, Dagmar-C; Ballmann, Manfred] Rostock Univ Med Hosp, Dept Pediat, Rostock, Germany.
   [Glass, Anne] Rostock Univ Med Hosp, Inst Biostat & Informat Med & Ageing Res, Rostock, Germany.
   [Schmidt, Sebastian] Greifswald Univ Med Hosp, Dept Pediat, Greifswald, Germany.
RP Fischer, DC (reprint author), Rostock Univ Med Ctr, Dept Pediat, Ernst Heydemann Str 8, D-18057 Rostock, Germany.
EM dagmar-christiane.fischer@med.uni-rostock.de
RI Ballmann, Manfred/AAE-3730-2019
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   Barreto M, 2005, PEDIAT ALLERG IMM-UK, V16, P52, DOI 10.1111/j.1399-3038.2005.00220.x
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST
   Chan EY, 2005, PEDIATR PULM, V39, P558, DOI 10.1002/ppul.20227
   Cibella F, 2008, ANN ALLERG ASTHMA IM, V101, P407, DOI 10.1016/S1081-1206(10)60318-3
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Ferrante G, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-50
   Ferraro Valentina, 2018, Asthma Res Pract, V4, P9, DOI 10.1186/s40733-018-0045-6
   Gomersal T, 2016, PEDIATR PULM, V51, P316, DOI 10.1002/ppul.23371
   Ito Y, 2010, PEDIATR PULM, V45, P1005, DOI 10.1002/ppul.21286
   Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x
   Karrasch S, 2017, THORAX, V72, P109, DOI 10.1136/thoraxjnl-2016-208704
   Kim HB, 2016, ALLERGY ASTHMA IMMUN, V8, P12, DOI 10.4168/aair.2016.8.1.12
   Kromeyer-Hauschild K, 2001, PERZENTILE BODY MASS, P807
   Lex C, 2015, MONATSSCHR KINDERH, V163, P826, DOI 10.1007/s00112-015-3337-4
   Linkosalo L, 2012, PEDIAT ALLERG IMM-UK, V23, P360, DOI 10.1111/j.1399-3038.2011.01223.x
   Petsky HL, 2018, THORAX, V73, P1110, DOI 10.1136/thoraxjnl-2018-211540
   Petsky HL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005603.pub3
   Piacentini GL, 2012, J BREATH RES, V6, DOI 10.1088/1752-7155/6/2/027103
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Rao DR, 2016, EXPERT REV CLIN IMMU, V12, P521, DOI 10.1586/1744666X.2016.1141049
   Sano H, 2019, ALLERGOL INT, V68, P191, DOI 10.1016/j.alit.2018.08.013
   Schulze J, 2012, RESP MED, V106, P627, DOI 10.1016/j.rmed.2012.01.007
   Schulze J, 2009, RESP MED, V103, P1898, DOI 10.1016/j.rmed.2009.06.007
   Sivan Y, 2009, J PEDIATR-US, V155, P211, DOI 10.1016/j.jpeds.2009.02.034
   Tang SQ, 2019, CLIN REV ALLERG IMMU, V56, P129, DOI 10.1007/s12016-016-8573-4
   van Amsterdam JGC, 2003, CLIN EXP ALLERGY, V33, P187, DOI 10.1046/j.1365-2222.2003.01597.x
   Voorend-van Bergen S, 2015, THORAX, V70, P543, DOI 10.1136/thoraxjnl-2014-206161
   Wang Z, 2018, MAYO CLIN PROC, V93, P191, DOI 10.1016/j.mayocp.2017.11.012
   Woo SI, 2012, RESP MED, V106, P1103, DOI 10.1016/j.rmed.2012.03.022
NR 32
TC 1
Z9 1
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 21
EP 25
DI 10.1016/j.rmed.2019.08.008
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900004
PM 31476569
DA 2020-05-18
ER

PT J
AU El-Menyar, A
   Sathian, B
   Al-Thani, H
AF El-Menyar, Ayman
   Sathian, Brijesh
   Al-Thani, Hassan
TI Elevated serum cardiac troponin and mortality in acute pulmonary
   embolism: Systematic review and meta-analysis
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Pulmonary embolism; All-cause mortality; Serum cardiac troponin;
   High-sensitive; Conventional assay
ID RIGHT-VENTRICULAR DYSFUNCTION; ACID-BINDING PROTEIN; HEMODYNAMICALLY
   STABLE PATIENTS; BRAIN NATRIURETIC PEPTIDE; IN-HOSPITAL MORTALITY; RISK
   STRATIFICATION; NORMOTENSIVE PATIENTS; PROGNOSTIC VALUE; SEVERITY INDEX;
   PREDICTIVE-VALUE
AB Objectives: To evaluate whether elevated levels of cardiac troponin increases the risk of mortality in patients with acute PE.
   Methods: We conducted a systematic review and meta-analysis with rigorous statistical evaluation using publications (2000-2018) from Cochrane Library, MEDLINE, PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and Google Scholar databases. We searched for retrospective, prospective, and randomized controlled trials (RCT) or quasi-RCT studies that assessed the effect of elevated troponin versus normal levels on the outcomes of PE. The main outcome of interest was all-cause mortality. Extracted data included authors, the origin of studies, source population, study settings and duration, inclusion/exclusion criteria, data sources and measurement, sample size, and mortality. Data heterogeneity was assessed using the Cochrane Q homogeneity test with a significance set at p < 0.10. If the studies were statistically homogeneous, a fixed effect model was selected.
   Results: Out of 1825 references, 46 analytical studies were included with a total of 10842 patients with PE. The effect of elevated troponin on mortality had a pooled odd ratio (OR) of 4.33 for all studies, 3.7 for HsTnT, 14.81 for HsTnI, 7.85 for cTnT, 2.81 for cTnI, 9.02 for low-risk PE and 4.80 for 90-day mortality. The pooled negative likelihood ratios for all-cause mortality using HsTnI, cTnI and cTnT assay were 0.21, 0.33 and 0.65, respectively.
   Conclusion: Regardless of the troponin assay, pooled analysis indicates that elevated troponin is significantly associated with higher mortality in patients with PE.
C1 [El-Menyar, Ayman; Sathian, Brijesh] Hamad Med Corp, Dept Surg Clin Res Trauma & Vasc Surg, Doha, Qatar.
   [El-Menyar, Ayman] Weill Cornell Med Coll, Med Clin, Doha, Qatar.
   [Al-Thani, Hassan] Hamad Med Corp, Dept Surg Trauma & Vasc Surg, Doha, Qatar.
RP El-Menyar, A (reprint author), Hamad Gen Hosp, Weill Cornell Med Coll, Clin Med Clin Res Trauma & Vasc Surg, Doha, Qatar.
EM aelmenyar@hamad.qa
RI Sathian, Brijesh/G-7576-2014; El-Menyar, Ayman/F-6734-2015
OI Sathian, Brijesh/0000-0003-0851-4762; El-Menyar,
   Ayman/0000-0003-2584-953X
CR Aksay E, 2007, AM J EMERG MED, V25, P138, DOI 10.1016/j.ajem.2006.06.005
   Amorim Sandra, 2006, Rev Port Cardiol, V25, P181
   Bajaj A, 2015, HEART LUNG, V44, P327, DOI 10.1016/j.hrtlng.2015.03.007
   Barco S, 2019, EUR HEART J, V40, P902, DOI 10.1093/eurheartj/ehy873
   Barrios D, 2018, THROMB RES, V163, P246, DOI 10.1016/j.thromres.2017.09.007
   Becattini C, 2007, CIRCULATION, V116, P427, DOI 10.1161/CIRCULATIONAHA.106.680421
   Becattini C, 2013, CHEST, V144, P1539, DOI 10.1378/chest.12-2938
   Binder L, 2005, CIRCULATION, V112, P1573, DOI 10.1161/CIRCULATIONAHA.105.552216
   Bova C, 2005, HAEMATOLOGICA, V90, P423
   Bova C, 2009, J THROMB HAEMOST, V7, P938, DOI 10.1111/j.1538-7836.2009.03345.x
   Bulj N, 2013, CROAT MED J, V54, P561, DOI 10.3325/cmj.2013.54.561
   Coutance G, 2008, CRIT CARE, V12, DOI 10.1186/cc6996
   Darwish OS, 2018, J HOSP MED, V13, P509, DOI 10.12788/jhm.3060
   Douketis JD, 2005, J THROMB HAEMOST, V3, P508, DOI 10.1111/j.1538-7836.2005.01189.x
   Douketis JD, 2002, ARCH INTERN MED, V162, P79, DOI 10.1001/archinte.162.1.79
   El-Menyar A, 2019, AM J EMERG MED, V37, P133, DOI 10.1016/j.ajem.2018.10.002
   El-Menyar A, 2017, CARDIOL REV, V25, P279, DOI 10.1097/CRD.0000000000000167
   Enea Iolanda, 2004, Ital Heart J Suppl, V5, P29
   Ferrari E, 2012, HEART, V98, P732, DOI 10.1136/heartjnl-2012-301724
   Ghaffari S, 2018, J CRIT CARE, V44, P383, DOI 10.1016/j.jcrc.2017.12.023
   Giannitsis E, 2000, CIRCULATION, V102, P211, DOI 10.1161/01.CIR.102.2.211
   Goldhaber SZ, 2012, LANCET, V379, P1835, DOI 10.1016/S0140-6736(11)61904-1
   Hakemi EU, 2015, CHEST, V147, P685, DOI 10.1378/chest.14-0700
   Hsu JT, 2006, INT HEART J, V47, P775, DOI 10.1536/ihj.47.775
   Janata K, 2003, BRIT MED J, V326, P312, DOI 10.1136/bmj.326.7384.312
   Jimenez D, 2008, EUR RESPIR J, V31, P847, DOI 10.1183/09031936.00113307
   Jimenez D, 2011, THORAX, V66, P75, DOI 10.1136/thx.2010.150656
   Jimenez D, 2009, CHEST, V136, P974, DOI 10.1378/chest.09-0608
   Kaczynska A, 2006, CLIN CHIM ACTA, V371, P117, DOI 10.1016/j.cca.2006.02.032
   Kang DK, 2011, AM J CARDIOL, V108, P133, DOI 10.1016/j.amjcard.2011.03.009
   Kline JA, 2006, CRIT CARE MED, V34, P2773, DOI 10.1097/01.CCM.0000241154.55444.63
   Kostrubiec M, 2005, EUR HEART J, V26, P2166, DOI 10.1093/eurheartj/ehi336
   Kostrubiec M, 2010, J THROMB HAEMOST, V8, P651, DOI 10.1111/j.1538-7836.2010.03762.x
   Kucher N, 2005, ARCH INTERN MED, V165, P1777, DOI 10.1001/archinte.165.15.1777
   Kucher N, 2003, EUR HEART J, V24, P1651, DOI 10.1016/S0195-668X(03)00394-4
   La Vecchia L, 2004, HEART, V90, P633, DOI 10.1136/hrt.2003.019745
   Lankeit M, 2011, CIRCULATION, V124, P2716, DOI 10.1161/CIRCULATIONAHA.111.051177
   Lankeit M, 2010, EUR HEART J, V31, P1836, DOI 10.1093/eurheartj/ehq234
   Lauque D, 2014, ACAD EMERG MED, V21, P1143, DOI 10.1111/acem.12484
   Mehta NJ, 2003, AM HEART J, V145, P821, DOI 10.1016/S0002-8703(02)94704-6
   Meyer T, 2000, J AM COLL CARDIOL, V36, P1632, DOI 10.1016/S0735-1097(00)00905-0
   Moores L, 2010, J THROMB HAEMOST, V8, P517, DOI 10.1111/j.1538-7836.2009.03725.x
   Ng ACC, 2013, INT J CARDIOL, V165, P126, DOI 10.1016/j.ijcard.2011.07.107
   Ozsu S, 2015, LUNG, V193, P559, DOI 10.1007/s00408-015-9727-5
   Ozsu S, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-34
   Ozsu S, 2010, THROMB RES, V126, P486, DOI 10.1016/j.thromres.2010.08.021
   Palmieri V, 2008, INTERN EMERG MED, V3, P131, DOI 10.1007/s11739-008-0134-2
   Post F, 2009, CLIN RES CARDIOL, V98, P401, DOI 10.1007/s00392-009-0017-1
   Pruszczyk P, 2003, CHEST, V123, P1947, DOI 10.1378/chest.123.6.1947
   Ruan LB, 2014, CHEST, V146, P1462, DOI 10.1378/chest.13-1008
   Sanchez O, 2013, EUR RESPIR J, V42, P681, DOI 10.1183/09031936.00097512
   Scridon T, 2005, AM J CARDIOL, V96, P303, DOI 10.1016/j.amjcard.2005.03.062
   Singanayagam A, 2011, QJM-INT J MED, V104, P125, DOI 10.1093/qjmed/hcq168
   Stein PD, 2010, AM J CARDIOL, V106, P558, DOI 10.1016/j.amjcard.2010.03.071
   Tanabe Y, 2015, J CARDIOL, V66, P460, DOI 10.1016/j.jjcc.2015.03.002
   Thielmann M, 2012, EUR J CARDIO-THORAC, V42, P951, DOI 10.1093/ejcts/ezs122
   Tulevski II, 2007, INT J CARDIOL, V116, P161, DOI 10.1016/j.ijcard.2006.03.030
   Vanni S, 2011, J THROMB HAEMOST, V9, P1916, DOI 10.1111/j.1538-7836.2011.04459.x
   Vuilleumier N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155973
   Yalamanchili K, 2004, AM J CARDIOL, V93, P263, DOI 10.1016/j.amjcard.2003.09.058
   Yazici S, 2016, WIEN KLIN WOCHENSCHR, V128, pS596, DOI 10.1007/s00508-016-1081-y
NR 61
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 26
EP 35
DI 10.1016/j.rmed.2019.08.011
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900005
PM 31476570
DA 2020-05-18
ER

PT J
AU Grosbois, JM
   Coquart, J
   Fry, S
   Le Rouzic, O
   Grosbois, T
   Wallaert, B
   Chenivesse, C
AF Grosbois, Jean-Marie
   Coquart, Jeremy
   Fry, Stephanie
   Le Rouzic, Olivier
   Grosbois, Thomas
   Wallaert, Benoit
   Chenivesse, Cecile
TI Long-term effect of home-based pulmonary rehabilitation in severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Exercise tolerance; 6-Min stepper test; Quality of life; Anxiety;
   Depression; Chronic obstructive pulmonary disease
ID DISEASE
AB Introduction: Home-based pulmonary rehabilitation (PR) has demonstrated its effectiveness amongst patients with chronic obstructive pulmonary disease (COPD) but has never been investigated in severe asthma.
   Methods: In a retrospective study, we included 28 patients with severe asthma (61.5 +/- 16.2 years, FEV1: 51.4 +/- 17.3%) and 164 matched COPD patients (64.3 +/- 11.6 years, FEV1: 47.7 +/- 15.5%) who had completed a home-based PR program and pursued at least 12 months of follow-up. The number of steps performed during a 6-min stepper test (6MST), the Hospital Anxiety and Depression (HAD) scores, and the Visual Simplified Respiratory Questionnaire score (VSRQ) were compared between baseline, the post-PR period (post-PR) and after 12 months of follow-up (M12) within each group. The evolution of the 6MST, HAD and VSRQ values between baseline, post-PR and M12 was compared between severe asthma and COPD patients.
   Results: In the severe asthma group, the 6MST was higher post-PR (504 +/- 150, p = 0.043) and at M12 (538 +/- 163, p = 0.016) compared with baseline (450 +/- 148). The VSRQ score was higher at M12 (39.0 +/- 18.6, p = 0.049) but not post-PR (38.7 +/- 15.8, p = 0.119) in comparison with baseline (32.2 +/- 12.4). There was no difference in the HAD scores between baseline, post-PR and M12. PR outcome was not significantly different between severe asthma and COPD patients at short and long term (p > 0.05).
   Conclusion: In severe asthma, home-based PR is associated with improved exercise tolerance and quality of life on a long-term basis but does not modify anxiety and depression.
C1 [Grosbois, Jean-Marie] FormAct Sante, F-59840 Perenchies, France.
   [Coquart, Jeremy] Univ Rouen, Fac Sci Sport, CETAPS, EA 3832, F-76821 Mont St Aignan, France.
   [Fry, Stephanie; Le Rouzic, Olivier; Grosbois, Thomas; Wallaert, Benoit; Chenivesse, Cecile] CHU Lille, Serv Pneumol & Immunoallergol, Ctr Reference Constitutif Malad Pulm Rares, F-59000 Lille, France.
   [Fry, Stephanie; Le Rouzic, Olivier; Wallaert, Benoit; Chenivesse, Cecile] Inst Pasteur, CNRS, UMR 8204, CIIL,Inserm,U1019, F-59000 Lille, France.
   [Le Rouzic, Olivier; Wallaert, Benoit; Chenivesse, Cecile] Univ Lille, F-59000 Lille, France.
RP Chenivesse, C (reprint author), CHU Lille Hop, Calmette Serv Pneumol & Immunoallergol, 1 Blvd Prof Jules Leclercq, F-59037 Lille, France.
EM cecile.chenivesse@chru-lille.fr
OI Coquart, Jeremy/0000-0001-6515-7736
CR [Anonymous], 2013, DG
   Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904
   Bahmer T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01827-2016
   Bellocq A, 2019, J ASTHMA, V56, P1325, DOI 10.1080/02770903.2018.1541351
   BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Bourbeau J, 2015, SEMIN RESP CRIT CARE, V36, P630, DOI 10.1055/s-0035-1556059
   Carson KV, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001116.pub4
   Carthy B., 2015, COCHRANE DB SYST REV
   Chipps BE, 2018, J ALLERGY CLIN IMMUN, V141, pAB16, DOI 10.1016/j.jaci.2017.12.049
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Cohen J., 1988, STAT POWER ANAL BEHA
   Coquart JB, 2017, INT J CHRONIC OBSTR, V12, P3549, DOI 10.2147/COPD.S150827
   Cordova-Rivera L, 2018, J ALLER CL IMM-PRACT, V6, P814, DOI 10.1016/j.jaip.2017.09.022
   Di Marco F, 2010, RESP MED, V104, P22, DOI 10.1016/j.rmed.2009.08.005
   Eichenberger PA, 2013, SPORTS MED, V43, P1157, DOI 10.1007/s40279-013-0077-2
   Fabre C, 2017, INT J CHRONIC OBSTR, V12, P1483, DOI 10.2147/COPD.S129889
   Gaga M, 2012, CLIN CHEST MED, V33, P571, DOI 10.1016/j.ccm.2012.06.008
   Grosbois JM, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S98635
   Grosbois JM, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S90534
   Hennegrave Florence, 2018, Health Sci Rep, V1, pe84, DOI 10.1002/hsr2.84
   Lingner H, 2015, J ASTHMA, V52, P614, DOI 10.3109/02770903.2014.996650
   Liu XL, 2014, REHABIL NURS, V39, P36, DOI 10.1002/rnj.112
   Perez T, 2009, Int J Chron Obstruct Pulmon Dis, V4, P9
   Pichon R, 2016, RESPIRATION, V91, P367, DOI 10.1159/000446517
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46
   Renolleau-Courtois D, 2014, J ASTHMA, V51, P552, DOI 10.3109/02770903.2014.885039
   Sahin H, 2019, J ASTHMA, V56, P87, DOI 10.1080/02770903.2018.1443468
   Schaper C, 2011, RESP MED, V105, P3, DOI 10.1016/j.rmed.2010.07.023
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 30
TC 1
Z9 1
U1 2
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 36
EP 41
DI 10.1016/j.rmed.2019.08.015
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900006
PM 31479806
DA 2020-05-18
ER

PT J
AU Tay, TR
   Choo, XN
   Yii, A
   Chung, KF
   Chan, YH
   Wong, HS
   Chan, A
   Tee, A
   Koh, MS
AF Tay, Tunn Ren
   Choo, Xue Ning
   Yii, Anthony
   Chung, Kian Fan
   Chan, Yiong Huak
   Wong, Hang Siang
   Chan, Adrian
   Tee, Augustine
   Koh, Mariko S.
TI Asthma phenotypes in a multi-ethnic Asian cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Ethnicity; Phenotype; Asia; Chinese; Obesity; Race
ID CLUSTER-ANALYSIS; IDENTIFICATION; CHINESE; ADULTS
AB Background: Identification of asthma phenotypes facilitates our understanding of asthma pathobiologies. Phenotypes observed in homogenous Asian cohorts have distinct differences from those described in Caucasian cohorts, suggesting that ethnicity may influence phenotypic expression. Phenotypic clusters in a multi-ethnic Southeast Asian cohort have not been described before, and direct comparisons of these clusters within a single study may reveal how ethnicity affects phenotypic expression.
   Methods: Six hundred and thirty adult asthma patients from two healthcare institutions in Singapore were randomly assigned in a 2:1 fashion to a test and validation cohort. Latent class analysis was performed on both cohorts using age of asthma onset, sex, ethnicity, smoking status, body mass index, lung function, blood eosinophil count, asthma control test score, and exacerbation frequency as input variables. Phenotypic clusters between the test and validation cohorts were compared
   Results: Three clusters were identified in both the test and validation cohorts, with corresponding clusters of each cohort sharing similar characteristics. Ethnic representation and asthma control were significantly different between clusters. Cluster one comprised Chinese females with late-onset asthma and the best asthma control. Cluster two comprised non-Chinese females with obesity and the worst asthma control. Cluster three was multi-ethnic with the greatest proportion of atopic patients.
   Conclusion: We identified three phenotypic clusters in our multi-ethnic Southeast Asian population, with distinct differences in ethnicity which may be attributable to inherent differences in baseline characteristics among ethnic groups.
C1 [Tay, Tunn Ren; Choo, Xue Ning; Yii, Anthony; Wong, Hang Siang; Tee, Augustine] Changi Gen Hosp, Dept Resp & Crit Care Med, 2 Simei St 3, Singapore 529889, Singapore.
   [Chan, Adrian; Koh, Mariko S.] Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore.
   [Yii, Anthony; Koh, Mariko S.] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Chung, Kian Fan] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis, London, England.
   [Chung, Kian Fan] Royal Brompton Hosp, London, England.
   [Chan, Yiong Huak] Natl Univ Singapore, Yong Loo Lin Sch Med, Biostat Unit, Singapore, Singapore.
RP Tay, TR (reprint author), Changi Gen Hosp, Dept Resp & Crit Care Med, 2 Simei St 3, Singapore 529889, Singapore.
EM tay.tunn.ren@singhealth.com.sg
RI Chung, Kian Fan/B-1872-2012
OI Chung, Kian Fan/0000-0001-7101-1426; Koh, Mariko/0000-0002-1230-0129
CR Agache I, 2016, ALLERGOL INT, V65, P243, DOI 10.1016/j.alit.2016.04.011
   Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC
   Cazzola M, 2018, EXPERT OPIN DRUG MET, V14, P435, DOI 10.1080/17425255.2018.1449833
   Chotirmall SH, 2017, RESPIROLOGY, V22, P240, DOI 10.1111/resp.12971
   Chung KF, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0064-2017
   Clark VL, 2017, RESPIROLOGY, V22, P1262, DOI 10.1111/resp.13134
   Fingleton J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00957-2017
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Haldar P, 2017, BIOL-TARGETS THER, V11, P81, DOI 10.2147/BTT.S93954
   Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042
   Hsiao HP, 2019, J ALLER CL IMM-PRACT, V7, P556, DOI 10.1016/j.jaip.2018.08.008
   Ilmarinen P, 2017, J ALLER CL IMM-PRACT, V5, P967, DOI 10.1016/j.jaip.2017.01.027
   Kaneko Y, 2013, ALLERGOL INT, V62, P113, DOI 10.2332/allergolint.12-OA-0467
   Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811
   Konno S, 2018, ANN AM THORAC SOC, V15, P33, DOI 10.1513/AnnalsATS.201701-065OC
   Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048
   Leung TF, 2014, J ALLERGY CLIN IMMUN, V133, P42, DOI 10.1016/j.jaci.2013.09.018
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Newby C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102987
   Ortega Hector, 2014, Ann Am Thorac Soc, V11, P1011, DOI 10.1513/AnnalsATS.201312-454OC
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006
   Wang L, 2017, ANN ALLERG ASTHMA IM, V119, P324, DOI 10.1016/j.anai.2017.07.016
   Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8
   Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042
   Yii ACA, 2017, ALLERGY, V72, P1398, DOI 10.1111/all.13159
NR 26
TC 2
Z9 2
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 42
EP 48
DI 10.1016/j.rmed.2019.08.016
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900007
PM 31499296
DA 2020-05-18
ER

PT J
AU Weinstock, TG
   Tewari, A
   Patel, H
   Kelley, K
   Tananbaum, R
   Flores, A
   Shah, AT
   Abujaber, SY
   Khorashadi, L
   Shortsleeve, MJ
   Thomson, CC
AF Weinstock, T. G.
   Tewari, A.
   Patel, H.
   Kelley, K.
   Tananbaum, R.
   Flores, A.
   Shah, A. T.
   Abujaber, S. Y.
   Khorashadi, L.
   Shortsleeve, M. J.
   Thomson, C. C.
TI No stone unturned: Nodule Net, an intervention to reduce loss to
   follow-up of lung nodules
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Lung nodules; Lung cancer
ID PULMONARY NODULES; CANCER; MANAGEMENT
AB Objective: Inadequate lung nodule surveillance leads to diagnostic delays. We implemented a retrospective intervention program, Nodule Net, to improve surveillance in our hospital.
   Methods: 9,224 Chest computed tomography (CT) scans between January 1, 2015 and December 31, 2016 were manually reviewed for lung nodules. For patients without follow-up, charts were reviewed to assess follow-up. If follow-up appeared indicated, the clinician or patient was contacted, and follow-up was tracked.
   Results: Lung nodules were identified on 5,101 (55%) of 9,224 scans. Follow-up was potentially indicated and not completed in 1,385 (27%). 183 (13%) were excluded after imaging review. 1,202 received outreach. Of the 801 (66%) with a provider in our system, 225 (27%) returned for follow-up. Nodules were stable in 199 (88%), new or growing in 23 (11%), resolved in 3 (1%), and stage 1 lung cancer in 2 (1%). 90 (11%) had follow-up outside our system and 431 (51%) had no follow-up due to a clinical contraindication. 55 (7%) have imaging pending and 14 (2%) are awaiting pulmonary evaluation. Of the 302 (25%) patients with providers outside our system, 121 (40%) had followed-up elsewhere. 146 (48%) had no follow-up due to a clinical reason. 35 (12%) providers did not respond to outreach.
   Conclusions: We identified 1,202 patients with lung nodules who needed follow-up over a two-year period. Compliance was more successful with providers within our hospital system. We recommend robust surveillance for patients to ensure follow-up is completed and clinical contraindications are well documented.
C1 [Weinstock, T. G.; Kelley, K.; Flores, A.; Thomson, C. C.] Mt Auburn Hosp, Div Pulm & Crit Care, Cambridge, MA USA.
   [Weinstock, T. G.; Tewari, A.; Patel, H.; Shah, A. T.; Abujaber, S. Y.; Thomson, C. C.] Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA.
   [Weinstock, T. G.; Khorashadi, L.; Shortsleeve, M. J.; Thomson, C. C.] Harvard Med Sch, Boston, MA 02115 USA.
   [Tananbaum, R.] Washington Univ, St Louis, MO 63110 USA.
   [Khorashadi, L.; Shortsleeve, M. J.] Mt Auburn Hosp, Dept Radiol, 330 Mt Auburn St, Cambridge, MA 02238 USA.
RP Tewari, A (reprint author), Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA.
EM atewari@mah.harvard.edu
RI Thomson, Carey/AAF-3905-2019
CR Bach PB, 2012, JAMA-J AM MED ASSOC, V307, P2418, DOI 10.1001/jama.2012.5521
   Bates R, 2017, J HOSP MED, V12, P454, DOI 10.12788/jhm.2757
   Brandman S, 2011, J THORAC IMAG, V26, P90, DOI 10.1097/RTI.0b013e31821639a9
   Gould MK, 2007, CHEST, V132, p108S, DOI 10.1378/chest.07-1353
   Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6
   Hoffman J., 2018, MALPRACTICE RISKS FR
   Ma JM, 2013, CANCER-AM CANCER SOC, V119, P1381, DOI 10.1002/cncr.27813
   Mackillop WJ, 2007, RADIOTHER ONCOL, V84, P1, DOI 10.1016/j.radonc.2007.05.006
   Noone A.M., 2017, SEER CANC STAT REV, P1975
   Ost DE, 2012, AM J RESP CRIT CARE, V185, P363, DOI 10.1164/rccm.201104-0679CI
   Pinsky PF, 2015, ANN INTERN MED, V162, P485, DOI 10.7326/M14-2086
   Sethi S, 2016, J THORAC DIS, V8, pS494, DOI 10.21037/jtd.2016.05.48
   Singh H, 2010, J CLIN ONCOL, V28, P3307, DOI 10.1200/JCO.2009.25.6636
   Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9
   Tanoue L.T., 2002, YEAR B PULM DIS  AUG, P78
NR 15
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 49
EP 51
DI 10.1016/j.rmed.2019.09.003
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900008
PM 31518707
DA 2020-05-18
ER

PT J
AU Noh, CS
   Kim, HI
   Choi, H
   Kim, Y
   Kim, CH
   Choi, JH
   Hyun, IG
   Baek, MS
AF Noh, Chang Suk
   Kim, Hwan Il
   Choi, Hayoung
   Kim, Youlim
   Kim, Cheol-Hong
   Choi, Jeong-Hee
   Hyun, In Gyu
   Baek, Moon Seong
TI Completion rate of latent tuberculosis infection treatment in patients
   aged 65 years and older
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Latent tuberculosis infection; Interferon-gamma release assay; Elderly;
   Treatment; Completion
ID PREVENTIVE THERAPY; HEPATOTOXICITY; RIFAMPIN; TRIAL
AB Introduction: There are insufficient data on the treatment of latent tuberculosis infection (LTBI) in elderly patients. We investigated the completion rate of treatment in elderly LTBI patients.
   Methods: A retrospective multicentre study was conducted at five university hospitals in South Korea. We reviewed the electronic medical records of patients aged 65 years and older who were diagnosed with LTBI via positive interferon-gamma release assay results between January 2016 and December 2018. Treatment completion was defined as ingestion of more than 80% of all prescribed medications without loss to follow-up. Results: During the study period, 127 LTBI patients aged 65 years and older visited outpatient department. Among them, 77 patients aged 65-78 years (median age, 69 years [interquartile range, 66-71 years]) who received LTBI treatment were analysed. Common reasons for IGRA testing in elderly patients were health-care worker (n = 33, 42.9%) and household contact with infectious TB patients (n = 18, 23.4%).
   The overall completion rate of LTBI treatment was 83.1% (n = 64), and the completion rate of 3-month isoniazid plus rifampin regimen was 88.4%. Adverse effects were reported in 23 patients (29.9%), and an increase in aminotransferase level was the most common adverse effect (n = 11, 14.3%). Three patients (3.9%) with the adverse effect discontinued treatment and 10 (13.0%) patients were lost to follow-up.
   Conclusions: LTBI treatment in patients aged 65-78 years was relatively well tolerated. In LTBI treatment in elderly patients, the majority of discontinuation of treatment was due to loss to follow-up rather than adverse effects of anti-TB medications.
C1 [Noh, Chang Suk] Hallym Univ, Hangang Sacred Heart Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Seoul, South Korea.
   [Kim, Hwan Il] Hallym Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Sacred Heart Hosp, Anyang Si, Gyeonggi Do, South Korea.
   [Choi, Hayoung] Hallym Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Kangnam Sacred Heart Hosp, Seoul, South Korea.
   [Kim, Youlim] Hallym Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Chuncheon Sacred Heart Hosp, Chunchon, South Korea.
   [Kim, Cheol-Hong; Choi, Jeong-Hee; Hyun, In Gyu; Baek, Moon Seong] Hallym Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Dongtan Sacred Heart Hosp, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea.
RP Baek, MS (reprint author), Hallym Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Dongtan Sacred Heart Hosp, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea.
EM wido21@hallym.or.kr
RI Choi, Hayoung/AAI-8638-2020
OI Choi, Hayoung/0000-0003-4812-0653; Baek, Moon Seong/0000-0001-6455-0376
CR [Anonymous], 2017, JOINT COMMITTEE FOR
   Behr MA, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2738
   Byng-Maddick R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1451-0
   Chan PC, 2012, INT J TUBERC LUNG D, V16, P633, DOI 10.5588/ijtld.11.0504
   Chan PC, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02396-2018
   Cho Kyung Sook, 2018, Epidemiol Health, V40, pe2018036, DOI 10.4178/epih.e2018036
   Devarbhavi Harshad, 2011, Trop Gastroenterol, V32, P167
   Erkens CGM, 2016, EUR RESPIR J, V47, P1492, DOI 10.1183/13993003.01397-2015
   Fountain FF, 2005, CHEST, V128, P116, DOI 10.1378/chest.128.1.116
   Gray EL, 2016, INTERN MED J, V46, P281, DOI 10.1111/imj.12979
   Hosford JD, 2015, TUBERCULOSIS, V95, P112, DOI 10.1016/j.tube.2014.10.006
   Jimenez-Fuentes MA, 2013, INT J TUBERC LUNG D, V17, P326, DOI 10.5588/ijtld.12.0510
   Kunst H, 2010, INT J TUBERC LUNG D, V14, P1374
   Lee EH, 2018, INT J TUBERC LUNG D, V22, P1336, DOI 10.5588/ijtld.18.0280
   LoBue PA, 2003, AM J RESP CRIT CARE, V168, P443, DOI 10.1164/rccm.200303-390OC
   Menzies D, 2004, AM J RESP CRIT CARE, V170, P445, DOI 10.1164/rccm.200404-478OC
   Menzies D, 2018, NEW ENGL J MED, V379, P440, DOI 10.1056/NEJMoa1714283
   Menzies D, 2008, ANN INTERN MED, V149, P689, DOI 10.7326/0003-4819-149-10-200811180-00003
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC
   National Cancer Institute, 2017, COMMON TERMINOLOGY C
   Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014
   Nwana N., 2019, TREATMENT LATENT MYC, V14, P3, DOI [10.1371/journal.pone.0213524, DOI 10.1371/JOURNAL.PONE.0213524]
   Pease C, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2377-x
   Rajagopalan S, 2001, CLIN INFECT DIS, V33, P1034, DOI 10.1086/322671
   Rim S. J. Y. Kim Hye, 2019, NOTIFIED TUBERCULOSI, V2018
   Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST
   Schaaf HS, 2010, RESPIROLOGY, V15, P747, DOI 10.1111/j.1440-1843.2010.01784.x
   Schein YL, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3468-z
   Sester M, 2015, EUR RESPIR J, V46, P1836, DOI 10.1183/13993003.01047-2015
   Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875
   Sun HY, 2018, TUBERCULOSIS, V111, P121, DOI 10.1016/j.tube.2018.05.013
   WHO, 2018, GLOBAL TUBERCULOSIS
   Young H, 2009, CLIN INFECT DIS, V49, P424, DOI 10.1086/600394
NR 33
TC 1
Z9 1
U1 1
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 52
EP 58
DI 10.1016/j.rmed.2019.09.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900009
PM 31522030
DA 2020-05-18
ER

PT J
AU Berton, DC
   Marques, RD
   Palmer, B
   O'Donnell, DE
   Neder, JA
AF Berton, Danilo C.
   Marques, Renata D.
   Palmer, Brandon
   O'Donnell, Denis E.
   Neder, J. Alberto
TI Effects of lung deflation induced by tiotropium/olodaterol on the
   cardiocirculatory responses to exertion in COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchodilator; Cardiac output; Exertion; COPD; Lung mechanics; Blood
   flow; Dyspnea
ID OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; PERCENT EMPHYSEMA;
   OXYGEN DELIVERY; BLOOD-FLOW; EXERCISE; ATHEROSCLEROSIS; HYPERINFLATION;
   LIMITATION; IMPACT
AB Background: Hyperinflation has been associated with negative cardiocirculatory consequences in patients with chronic obstructive pulmonary disease (COPD). These abnormalities are likely to worsen when the demands for O-2 increase, e.g., under the stress of exercise. Thus, pharmacologically-induced lung deflation may improve cardiopulmonary interactions and exertional cardiac output leading to higher limb muscle blood flow and oxygenation in hyperinflated patients with COPD.
   Methods: 20 patients (residual volume = 201.6 +/- 63.6% predicted) performed endurance cardiopulmonary exercise tests (75% peak) 1 h after placebo or tiotropium/olodaterol 5/5 mu g via the Respimat (R) inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany). Cardiac output was assessed by signal-morphology impedance cardiography. Near-infrared spectroscopy determined quadriceps blood flow (indocyanine green dye) and intra-muscular oxygenation.
   Results: Tiotropium/olodaterol was associated with marked lung deflation (p < 0.01): residual volume decreased by at least 0.4 L in 14/20 patients (70%). The downward shift in the resting static lung volumes was associated with less exertional inspiratory constraints and dyspnoea thereby increasing exercise endurance by similar to 50%. Contrary to our premises, however, neither central and peripheral hemodynamics nor muscle oxygenation improved after active intervention compared to placebo. These results were consistent with those found in a subgroup of patients showing the largest decrements in residual volume (p < 0.05).
   Conclusions: The beneficial effects of tiotropium/olodaterol on resting and operating lung volumes are not translated into enhanced cardiocirculatory responses to exertion in hyperinflated patients with COPD. Improvement in exercise tolerance after dual bronchodilation is unlikely to be mechanistically linked to higher muscle blood flow and/or O-2 delivery.
C1 [Berton, Danilo C.; Marques, Renata D.; Palmer, Brandon; O'Donnell, Denis E.; Neder, J. Alberto] Queens Univ, Resp Invest Unit, Kingston, ON, Canada.
   [Berton, Danilo C.; Marques, Renata D.; Palmer, Brandon; O'Donnell, Denis E.; Neder, J. Alberto] Queens Univ, Lab Clin Exercise Physiol, 76 Stuart St, Kingston, ON K7L 2VT, Canada.
   [Berton, Danilo C.; Marques, Renata D.; Palmer, Brandon; O'Donnell, Denis E.; Neder, J. Alberto] Kingston Gen Hosp, 76 Stuart St, Kingston, ON K7L 2VT, Canada.
   [Berton, Danilo C.; Marques, Renata D.] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Pneumol, Porto Alegre, RS, Brazil.
RP Neder, JA (reprint author), Queens Univ, Lab Clin Exercise Physiol, 76 Stuart St, Kingston, ON K7L 2VT, Canada.; Neder, JA (reprint author), Kingston Gen Hosp, 76 Stuart St, Kingston, ON K7L 2VT, Canada.
EM alberto.neder@queensu.ca
OI Berton, Danilo/0000-0002-8393-3126
FU Boehringer Ingelheim CanadaBoehringer Ingelheim [1237-0054]
FX The authors thank the patients for their effort and enthusiastic
   participation. The authors are also indebted to Mrs. Filipa Saramago for
   secretarial assistance and Joan Stethem, RN and Claire Roantree for
   venipuncture and venous catheter insertion. This study was sponsored by
   a research grant from Boehringer Ingelheim Canada (Investigator
   Initiated Trial # 1237-0054).
CR Barr RG, 2012, EUR RESPIR J, V39, P846, DOI 10.1183/09031936.00165410
   Barr RG, 2018, ANN AM THORAC SOC, V15, pS30, DOI 10.1513/AnnalsATS.201708-667KV
   Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836
   Berton DC, 2010, THORAX, V65, P588, DOI 10.1136/thx.2009.120857
   Boerrigter BG, 2012, CHEST, V142, P1166, DOI 10.1378/chest.11-2798
   Borghi-Silva A, 2008, AM J PHYSIOL-HEART C, V294, pH2465, DOI 10.1152/ajpheart.91520.2007
   Calzetta L, 2017, RESP MED, V129, P189, DOI 10.1016/j.rmed.2017.06.020
   Casaburi Richard, 2005, COPD, V2, P131
   Charloux A, 2000, EUR J APPL PHYSIOL, V82, P313, DOI 10.1007/s004210000226
   Chiappa G. R., 1985, J APPL PHYSL BETHESD, V104, P1341, DOI [10.1152/japplphysiol.01364.20072008, DOI 10.1152/JAPPLPHYSIOL.01364.20072008]
   Chiappa GR, 2009, AM J RESP CRIT CARE, V179, P1004, DOI 10.1164/rccm.200811-1793OC
   Elbehairy AF, 2018, RESP PHYSIOL NEUROBI, V252, P64, DOI 10.1016/j.resp.2018.03.012
   Faisal A, 2016, CHEST, V149, P435, DOI 10.1378/chest.15-0404
   Ferreira EM, 2012, CLIN PHYSIOL FUNCT I, V32, P343, DOI 10.1111/j.1475-097X.2012.01135.x
   Gagnon P, 2012, AM J RESP CRIT CARE, V186, P606, DOI 10.1164/rccm.201203-0404OC
   *GOLD EX COMM, GLOB STRAT DIAGN MAN
   Grau M, 2013, CHEST, V144, P136, DOI 10.1378/chest.12-1779
   Guenette JA, 2013, PULM MED, V2013, DOI 10.1155/2013/956081
   Habazettl H, 2010, J APPL PHYSIOL, V108, P962, DOI 10.1152/japplphysiol.01269.2009
   Hohlfeld JM, 2018, LANCET RESP MED, V6, P368, DOI 10.1016/S2213-2600(18)30054-7
   Kovacs G, 2018, AM J RESP CRIT CARE, V198, P1000, DOI 10.1164/rccm.201801-0095PP
   Laveneziana P, 2009, EUR J APPL PHYSIOL, V107, P633, DOI 10.1007/s00421-009-1169-4
   Louvaris Z, 2018, J APPL PHYSIOL, V125, P947, DOI 10.1152/japplphysiol.00959.2017
   Louvaris Z, 2012, J APPL PHYSIOL, V113, P1012, DOI 10.1152/japplphysiol.00481.2012
   Maclay JD, 2013, CHEST, V143, P798, DOI 10.1378/chest.12-0938
   MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580
   Mahler DA, 2015, CHEST, V147, P232, DOI 10.1378/chest.14-0800
   Maltais F, 2001, MED SCI SPORT EXER, V33, P916, DOI 10.1097/00005768-200106000-00010
   Maltais F, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02049-2018
   Nasis I, 2015, RESP PHYSIOL NEUROBI, V217, P8, DOI 10.1016/j.resp.2015.06.006
   Neder JA, 2019, CLIN CHEST MED, V40, P421, DOI 10.1016/j.ccm.2019.02.006
   Neder JA, 2018, EXPERT REV CARDIOVAS, V16, P653, DOI 10.1080/14779072.2018.1510319
   O'Donnell DE, 2014, CLIN CHEST MED, V35, P51, DOI 10.1016/j.ccm.2013.09.008
   O'Donnell DE, 2012, CHEST, V141, P753, DOI 10.1378/chest.11-0787
   O'Donnell DE, 2008, J APPL PHYSIOL, V105, P753, DOI 10.1152/japplphysiol.90336.2008b
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Puente-Maestu L, 2016, EUR RESPIR J, V47, P429, DOI 10.1183/13993003.00745-2015
   Rahaghi FN, 2014, J THORAC IMAG, V29, P80, DOI 10.1097/RTI.0000000000000076
   Rocha A, 2017, AM J RESP CRIT CARE, V196, P1264, DOI 10.1164/rccm.201704-0675OC
   Simon M, 2001, J APPL PHYSIOL, V90, P1013
   Stone IS, 2016, AM J RESP CRIT CARE, V193, P717, DOI 10.1164/rccm.201508-1647OC
   Vogel-Claussen J, 2019, AM J RESP CRIT CARE, V199, P1086, DOI 10.1164/rccm.201805-0995OC
   Watz H, 2019, AM J RESP CRIT CARE, V199, P1047, DOI 10.1164/rccm.201901-0061ED
   Watz H, 2010, CHEST, V138, P32, DOI 10.1378/chest.09-2810
   WHIPP BJ, 1982, J EXP BIOL, V100, P175
NR 45
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 59
EP 68
DI 10.1016/j.rmed.2019.09.006
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900010
PM 31522031
DA 2020-05-18
ER

PT J
AU Gangemi, AJ
   Myers, CN
   Zheng, M
   Brown, J
   Butler-LeBair, M
   Cordova, F
   Marchetti, N
   Criner, GJ
   Gupta, R
   Mamary, AJ
AF Gangemi, Andrew J.
   Myers, Catherine N.
   Zheng, Matthew
   Brown, James
   Butler-LeBair, Marianne
   Cordova, Francis
   Marchetti, Nathaniel
   Criner, Gerard J.
   Gupta, Rohit
   Mamary, A. James
TI Mortality for sarcoidosis patients on the transplant wait list in the
   Lung Allocation Score era: Experience from a high volume center
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Lung transplantation; Wait list outcomes
ID CLINICAL CHARACTERISTICS; POPULATION; OUTCOMES; SYSTEM
AB Rationale: Sarcoidosis progresses to end stage fibrotic lung disease in 10% of patients and may necessitate lung transplantation. Organ allocation is currently determined by the Lung Allocation Score (LAS), but its performance in a sarcoidosis population has not been evaluated.
   Objectives: To determine sarcoidosis-specific wait list mortality and identify predictive factors of death on the transplantation wait list.
   Methods: This was a single-center retrospective study of all sarcoidosis patients listed for lung transplant from March 2012 to February 2019. We compared patients who were transplanted to those who died awaiting organs. We collected baseline listing characteristics, physiologic testing, and outcomes data. Statistical analysis was performed by 2-tailed Student's t-test, Mann-Whitney U test, and Chi-Square analysis (where appropriate). Receiver-operating characteristic curves were constructed for variables reaching statistical significance.
   Results: Twenty eight sarcoidosis patients were included in analysis. Mortality among wait listed patients was 18%, which exceeded the mortality of COPD and IPF. LAS scores did not differ at initial listing (41 vs. 46, p = 0.35) or at transplant/death (41 vs. 41, p = 0.91); wait list times also did not statistically differ (307 days vs. 177 days, p = 0.19). We identified bilirubin (AUC = 0.92), DLCO (AUC = 0.84), FEV1/FVC at transplant/death (AUC = 0.85), and composite physiologic index (AUC = 0.86) as predictors of death on the transplant list. Pulmonary hypertension was not associated with death.
   Conclusion: Unexpected sudden death was common in our cohort and was associated with markers of advanced fibrotic disease, not pulmonary hypertension.
C1 [Gangemi, Andrew J.; Myers, Catherine N.; Zheng, Matthew; Brown, James; Butler-LeBair, Marianne; Cordova, Francis; Marchetti, Nathaniel; Criner, Gerard J.; Gupta, Rohit; Mamary, A. James] Temple Univ, Lewis Katz Sch Med, Dept Thorac Med & Surg, Philadelphia, PA 19122 USA.
RP Gangemi, AJ (reprint author), 3401 North Broad St,7th Floor Parkinson Pavil, Philadelphia, PA 19140 USA.
EM Andrew.Gangemi@tuhs.temple.edu
CR Arcasoy SM, 2001, CHEST, V120, P873, DOI 10.1378/chest.120.3.873
   Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046
   Cremers J, 2012, EUR J GASTROEN HEPAT, V24, P17, DOI 10.1097/MEG.0b013e32834c7b71
   Egan TM, 2006, AM J TRANSPLANT, V6, P1212, DOI 10.1111/j.1600-6143.2006.01276.x
   GANGEMI A, 2019, AM J RESP CRIT CARE, V199
   Hu XW, 2016, SARCOIDOSIS VASC DIF, V33, P275
   Judson MA, 2003, SARCOIDOSIS VASC DIF, V20, P204
   Kandolin R, 2015, CIRCULATION, V131, P624, DOI 10.1161/CIRCULATIONAHA.114.011522
   Kirkil G, 2018, CHEST, V153, P105, DOI 10.1016/j.chest.2017.07.008
   Nardi A, 2011, EUR RESPIR J, V38, P1368, DOI 10.1183/09031936.00187410
   Shah L, 2007, SEMIN RESP CRIT CARE, V28, P134, DOI 10.1055/s-2007-970339
   Shlobin OA, 2012, EUR RESPIR J, V39, P1520, DOI 10.1183/09031936.00175511
   Shorr AF, 2003, CHEST, V124, P922, DOI 10.1378/chest.124.3.922
   Shorr AF, 2002, CHEST, V122, P233, DOI 10.1378/chest.122.1.233
   Taimeh Z, 2016, THORAX, V71, P378, DOI 10.1136/thoraxjnl-2015-207497
   Ungprasert P, 2017, AM J GASTROENTEROL, V112, P1556, DOI 10.1038/ajg.2017.231
   Uzunhan Y., 2017, EUR RESPIR J, V49, P2016
   Valapour M, 2019, Am J Transplant, V19 Suppl 2, P404, DOI 10.1111/ajt.15279
   Walsh SLF, 2014, LANCET RESP MED, V2, P123, DOI 10.1016/S2213-2600(13)70276-5
   Weill D, 2015, J HEART LUNG TRANSPL, V34, P1, DOI 10.1016/j.healun.2014.06.014
   Wells AU, 2003, AM J RESP CRIT CARE, V167, P962, DOI 10.1164/rccm.2111053
   Yserbyt J, 2017, SEMIN RESP CRIT CARE, V38, P538, DOI 10.1055/s-0037-1602383
NR 22
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD OCT
PY 2019
VL 157
BP 69
EP 76
DI 10.1016/j.rmed.2019.09.001
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IY2DF
UT WOS:000486199900011
PM 31522032
DA 2020-05-18
ER

PT J
AU Alves, AM
   de Mello, LM
   Matos, ASL
   Cruz, AA
AF Alves, Alexssandra Maia
   de Mello, Luane Marques
   Matos, Aline Silva Lima
   Cruz, Alvaro Augusto
TI Severe asthma: Comparison of different classifications of severity and
   control
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Therapy; Classifications; Disease management
ID ADULT SEVERE ASTHMA; DEFINITION; PREVALENCE; ADHERENCE
AB Background: Criteria of asthma severity and control lack standardization.
   Objective: to compare classifications of asthma severity and control, applied to patients from a severe asthma clinic.
   Methods: Cross-sectional study of 473 patients followed up for >= 6 months, reclassified using three criteria: 1) the World Health Organization (WHO) 2010, 2) the American Thoracic Society (ATS) 2000, and 3) the European Respiratory Society (ERS)/ATS 2014. In order to evaluate disease control, the 2012 and 2014 Global Initiative for Asthma (GINA) classifications were compared.
   Results: According to the definition of WHO 2010, 429 had Difficult-to-treat severe asthma and only 12 presented Treatment-resistant severe asthma. 114 patients had Refractory asthma by ATS 2000 and 88 had Severe asthma by ERS/ATS 2014. Considering the definitions of WHO 2010, only 9 out of 12 with Treatment-resistant and 64 out of 429 with Difficult-to-treat severe asthma met the criteria of ATS 2000 and ERS/ATS 2014. As for GINA classification of control, 208 (44%) of the 473 subjects were classified as having asthma controlled by the 2014 criteria, whereas only 45 (10%) patients had controlled asthma by the GINA 2012 criteria. The Kappa statistic indicates the highest agreement of the severity classification occurred between the criteria of ATS 2000 and ERS/ATS 2014 (0.64).
   Conclusion: Good agreement was found between Refractory asthma ATS 2000 and Severe asthma ERS/ATS 2014 classifications. However, poor agreement was observed between the severity rating proposed by the WHO and other classifications. The GINA control classifications of 2012 and 2014 also agreed poorly.
C1 [Alves, Alexssandra Maia; Matos, Aline Silva Lima; Cruz, Alvaro Augusto] Univ Fed Bahia, ProAR Fdn, Salvador, BA, Brazil.
   [de Mello, Luane Marques] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
RP Alves, AM (reprint author), Univ Fed Bahia, Programa Posgrad Ciencias Saude, Ctr Saude Carlos Gomes, Rua Carlos Gomes 270,7 Andar, BR-40060330 Salvador, BA, Brazil.
EM alexssandra.maia@yahoo.com
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [471057/2014-2]; Fundacao de Amparo a Pesquisa do Estado da
   Bahia; Trust in Science, a GlaxoSmithKline's programme
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico Brazil -
   Grant #471057/2014-2, Fundacao de Amparo a Pesquisa do Estado da Bahia.
   An additional grant was obtained by an investigator-initiated proposal
   of Alvaro A. Cruz supported by Trust in Science, a GlaxoSmithKline's
   programme.
CR [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341
   [Anonymous], 2014, 63 NHLBWHO, P932
   [Anonymous], 1997, NIH PUBL
   [Anonymous], 2000, WHO TECH REP SER
   Backman H, 2019, CLIN EXP ALLERGY
   Barnes CB, 2015, RESP CARE, V60, P455, DOI 10.4187/respcare.03200
   Bourdin A, 2012, CLIN EXP ALLERGY, V42, P1566, DOI 10.1111/j.1365-2222.2012.04018.x
   Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x
   Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019
   Chipps BE, 2018, J ALLERGY CLIN IMMUN, V141, P1590, DOI 10.1016/j.jaci.2017.07.014
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   de Andrade WCC, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0029-8
   Cruz A. A., 2018, A34 ASTHMA CLIN STUD, VI
   Dias SA, 2009, J BRAS PNEUMOL, V35, P261, DOI 10.1590/S1806-37132009000300011
   Fuseini H, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0686-1
   Global Initiative for Asthma (GINA), 2019, POCK GUID HLTH PROF
   Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leite Mylene, 2008, J. bras. pneumol., V34, P756, DOI 10.1590/S1806-37132008001000002
   Lima-Matos A, 2018, RESP MED, V145, P95, DOI 10.1016/j.rmed.2018.10.025
   Marchioro J, 2014, J BRAS PNEUMOL, V40, P487, DOI 10.1590/S1806-37132014000500004
   National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94
   National Institutes of Health National Heart Lung. And Blood Institute, 2002, GLOB STRAT ASTHM MAN
   O'Neill S, 2015, THORAX, V70, P376, DOI 10.1136/thoraxjnl-2013-204114
   Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Pinheiro GP, 2018, J BRAS PNEUMOL, V44, P477, DOI [10.1590/S1806-37562017000000018, 10.1590/s1806-37562017000000018]
   Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.9
   Santos Pablo de Moura, 2008, J. bras. pneumol., V34, P995, DOI 10.1590/S1806-37132008001200003
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307
   Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032
   de Jesus JPV, 2018, J BRAS PNEUMOL, V44, P207, DOI [10.1590/S1806-37562017000000034, 10.1590/s1806-37562017000000034]
   von Bulow A, 2018, RESP MED, V145, P41, DOI 10.1016/j.rmed.2018.10.020
   World Health Organization, 2018, WHO GLOB REP TRENDS
   Zein JG, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0528-y
NR 38
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 1
EP 7
DI 10.1016/j.rmed.2019.07.015
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800001
PM 31376674
DA 2020-05-18
ER

PT J
AU Roche, N
   Aguilaniu, B
   Li, PZ
   Hess, D
AF Roche, Nicolas
   Aguilaniu, Bernard
   Li, Pei Zhi
   Hess, David
CA COLIBRI Collaborators
TI Trends over time in COPD treatment choices by respiratory physicians: An
   analysis from the COLIBRI-COPD French cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE 6/6): COLIBRI; COPD; GOLD; Real-world; Treatment; Trends
ID TRIPLE THERAPY; DOUBLE-BLIND; REAL-LIFE; TIOTROPIUM; SALMETEROL;
   GLYCOPYRRONIUM; EXACERBATIONS; FLUTICASONE; GUIDELINES; TRIAL
AB Introduction: Over the last decade, new evidence and many guidelines have been published on COPD pharmacological treatments; prescriptions are often not in accordance with guidelines.
   Materials and methods: Trends in physician treatment choices from February 2012 to November 2018 (Feb. 2012/Nov. 2018) were analyzed using data from COPD patients (spirometry-confirmed diagnosis) included in the COLIBRI-COPD cohort. Inhaled drug treatments (short-or long-acting beta 2-agonist [SABA or LABA], short-or long-acting anticholinergic [SAMA or LAMA], or corticosteroid [ICS]) were classified into 5 treatment categories: "No initial maintenance treatment (IMT)" (untreated, or only SAMA or SABA); "1 long-acting bronchodilator (LABD)" (LABA or LAMA); "2 LABDs" (LABA + LAMA); "1 LABD + ICS" (LABA or LAMA + ICS); " 2 LABDs+ICS" (LABA+LAMA+ICS). For the purpose of the study, 4 periods were defined to achieve balanced samples (T1-T4).
   Results: Data from 4537 patients were collected. Over time, 3 major changes were observed: (1) an increase in treatment category "No IMT", mostly for GOLD 1 or GOLD A categories (GOLD A: from 19.1% at T1 to 41.2% at T4); (2) an increase in treatment category "2 LABDs" for GOLD 2 to 4 and GOLD A to D categories (GOLD B: from 15.4% to 29.7%); (3) a decrease in ICS use ("1 LABD + ICS" or "2 LABDs + ICS"), mostly for GOLD 1 to 3 and GOLD A categories (GOLD A, 2 LABDs + ICS: from 35.3% to 11.1%).
   Conclusion: Changes over time in therapeutic profiles suggest that new evidence from scientific publications and recommendations may have had a rapid impact on clinical practice.
C1 [Roche, Nicolas] Hop Cochin, Hop Univ Paris Ctr, AP HP, Serv Pneumol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
   [Roche, Nicolas] Univ Paris 05, Inst Cochin, Sorbonne Paris Cite, UMR1016, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
   [Aguilaniu, Bernard; Hess, David] aCCPP, Programme Colibri, 19 Ave Marcelin Berthelot, F-38100 Grenoble, France.
   [Aguilaniu, Bernard] Univ Grenoble Alpes, Fac Med & Pharm, 23 Ave Maquis Gresivaudan, F-38700 La Tronche, France.
   [Li, Pei Zhi] McGill Univ, Ctr Hlth, Res Inst, Resp Epidemiol & Clin Res Unit, 5252 Blvd Maisonneuve Ouest, Montreal, PQ H4A 3S5, Canada.
RP Roche, N (reprint author), Hop Cochin, Pneumol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
EM nicolas.roche@aphp.fr; b.aguilaniu@me.com; pei.li@mail.mcgill.ca;
   david.hess@colibri-pneumo.fr
CR Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015
   [Anonymous], 2019, GLOBAL STRATEGY DIAG
   Bateman ED, 2013, EUR RESPIR J, V42, P1484, DOI 10.1183/09031936.00200212
   Burgel PR, 2014, EUR RESPIR J, V43, P1201, DOI 10.1183/09031936.00162313
   Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
   Decramer M, 2009, LANCET, V374, P1171, DOI 10.1016/S0140-6736(09)61298-8
   Di Marco F, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0051-9
   Global Initiative for Chronic Obstructive Lung Disease, 2017, GLOBAL STRATEGY DIAG
   Gruffydd-Jones K, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/npjpcrm.2017.4
   James GD, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.15
   Kainu Annette, 2016, ERJ Open Res, V2, DOI 10.1183/23120541.00084-2015
   Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2
   Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901
   Lipson DA, 2017, AM J RESP CRIT CARE, V196, P438, DOI 10.1164/rccm.201703-0449OC
   Mahler D. A., 2013, EUR RESPIR J, DOI [10.1183/090300124013, DOI 10.1183/090300124013]
   Mak V, 2017, TREATMENT GUIDELINES, V4
   Miravitlles M, 2016, EUR RESPIR J, V47, P625, DOI 10.1183/13993003.01170-2015
   Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1
   Roche N, IS THERE CLIN RATION
   Rodrigo GJ, 2017, INT J CHRONIC OBSTR, V12, P907, DOI 10.2147/COPD.S130482
   Singh D, 2016, LANCET, V388, P963, DOI 10.1016/S0140-6736(16)31354-X
   Tariq SM, 2017, INT J CHRONIC OBSTR, V12, P1877, DOI 10.2147/COPD.S138006
   Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800
   Troosters T, 2010, EUR RESPIR J, V36, P65, DOI 10.1183/09031936.00127809
   Vestbo J, 2014, AM J RESP CRIT CARE, V189, P1022, DOI 10.1164/rccm.201311-2006PP
   Visentin E, 2016, CURR MED RES OPIN, V32, P1493, DOI 10.1080/03007995.2016.1182900
   Vogelmeier C, 2011, NEW ENGL J MED, V364, P1093, DOI 10.1056/NEJMoa1008378
   Wedzicha JA, 2016, NEW ENGL J MED, V374, P2222, DOI 10.1056/NEJMoa1516385
   Wedzicha JA, 2013, LANCET RESP MED, V1, P199, DOI 10.1016/S2213-2600(13)70052-3
   White P., OVERTREATMENT COPD I, DOI [10.1371/journal.pone.0075221, DOI 10.1371/JOURNAL.PONE.0075221]
   Worth H, 2017, RESP MED, V131, P77, DOI 10.1016/j.rmed.2017.08.008
NR 31
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 8
EP 14
DI 10.1016/j.rmed.2019.07.023
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800002
PM 31374262
DA 2020-05-18
ER

PT J
AU Elsheikh, MS
   Mohamed, NH
   Alsharkawy, AAA
AF Elsheikh, Mai S.
   Mohamed, Nagwa H.
   Alsharkawy, Asmaa A. A.
TI Improvement of asthma control after laser acupuncture and its impact on
   exhaled 8-isoprostane as an oxidative biomarker in chronic bronchial
   asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
ID BREATH CONDENSATE; ALLERGIC-ASTHMA; SMALL AIRWAYS; BEE VENOM; STRESS;
   ELECTROACUPUNCTURE; CHILDREN; MARKERS
AB Traditional medicine may not control bronchial asthma. Many patients have uncontrolled symptoms and the underlying ongoing inflammation is persistent.
   Objective: to assess efficacy of laser acupuncture in improving asthma symptoms and underlying oxidative stress through monitoring exhaled 8-isoprostane.
   Method: 48 asthmatic (case group) received successive low level laser acupuncture sessions to stimulate acupoints for chronic asthma and 24 asthmatics received deactivated laser acupuncture sessions (control group). Asthma symptoms, asthma control questionnaire, concentration of 8-Isoprostane in exhaled breath condensate and airway resistance were assessed before and after laser acupuncture therapy.
   Results: After the completion of the course of laser acupuncture therapy, we observed significant improvement of asthma symptoms. Asthma control questionnaire improved from 9.7 +/- 3.3 to 21.8 +/- 3.6 (p 0.001). EBC 8-Isoprostane dropped from 14.7 +/- 5.4 to 8.1 +/- 5.0 (p 0.001). The airway resistance at R5 and R20 significantly decreased from 116.6 +/- 25.8 & 124.5 +/- 31.2 to 101.5 +/- 25.6 & 110.9 +/- 29.9 respectively (p 0.001). Control patients who received sham acupuncture therapy did not show such improvement.
   Conclusion: Laser acupuncture is an effective modality in treating bronchial asthma as evidenced by improved symptoms, airway resistance, and oxidative biomarkers.
C1 [Elsheikh, Mai S.; Mohamed, Nagwa H.] Natl Res Ctr, Complementary Med Dept, Giza, Egypt.
   [Alsharkawy, Asmaa A. A.] Ain Shams Univ, Pediat Dept, Fac Med, Cairo, Egypt.
RP Elsheikh, MS (reprint author), Natl Res Ctr, Complementary Med Dept, Med Div, El Buhuoth St, Cairo, Egypt.
EM Mai.seoudy@yahoo.com
OI alsharkawy, asmaa/0000-0001-5939-2844
CR Baraldi E., 2003, ARCH DIS CHILD, V36, P729
   Battaglia S, 2005, THORAX, V60, P639, DOI 10.1136/thx.2004.035279
   Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1
   Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644
   Brinkhaus B, 2017, J ALTERN COMPLEM MED, V23, P268, DOI 10.1089/acm.2016.0357
   Chen Y, 2012, BRAIN RES, V1432, P36, DOI 10.1016/j.brainres.2011.11.002
   Chernyshova L A, 1995, Vopr Kurortol Fizioter Lech Fiz Kult, P11
   Chung YR, 2011, PEDIATR PULM, V46, P530, DOI 10.1002/ppul.21426
   Corradi M, 2001, AM J RESP CRIT CARE, V163, P854, DOI 10.1164/ajrccm.163.4.2001108
   Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51
   Gentil H., 2015, GLOB ADV RES J MED M, V4, P546
   Global Initiative Asthma, 2012, GLOB STRAT ASTHM MAN
   Hu WL, 2010, AM J CHINESE MED, V38, P861, DOI 10.1142/S0192415X10008305
   Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067
   Ji L, 2001, CHIN J INTEGR MED, V7, P69
   Karlson G, 2013, ALTERN THER HEALTH M, V19, P13
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Kharitonov SA, 2006, CHEST, V130, P1541, DOI 10.1378/chest.130.5.1541
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Li Zhong-ren, 2005, Chin J Integr Med, V11, P156
   Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-16
   Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6
   Masao S., 2009, J JAPAN SOC ACUPUNCT, V56, P616
   Milojevic Momir, 2003, Med Pregl, V56, P413, DOI 10.2298/MPNS0310413M
   Mohamed AR, 2014, EGYPT J CHEST DIS TU, V63, P1065, DOI 10.1016/j.ejcdt.2014.06.012
   Mori H, 2002, NEUROSCI LETT, V320, P21, DOI 10.1016/S0304-3940(02)00012-5
   Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731, DOI 10.1164/ajrccm.164.5.2101032
   Nedeljkovic Miroslav, 2008, Med Pregl, V61, P123
   Silva TSN, 2011, ACTA CIR BRAS, V26, P7, DOI 10.1590/S0102-86502011000100003
   Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403
   Acioli PCP, 2014, ACTA CIR BRAS, V29, P450, DOI 10.1590/S0102-86502014000700007
   Price D., 2013, CLIN TRANSL ALLERGY, V3, P1
   Reinhold T, 2014, J ALTERN COMPLEM MED, V20, P169, DOI 10.1089/acm.2012.0719
   Robroeks CMHHT, 2007, CLIN EXP ALLERGY, V37, P1303, DOI 10.1111/j.1365-2222.2007.02788.x
   Scheewe S, 2011, COMPLEMENT THER MED, V19, P239, DOI 10.1016/j.ctim.2011.07.002
   Shahid SK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-79
   Shi GX, 2012, J TRADIT CHIN MED, V32, P199, DOI 10.1016/S0254-6272(13)60011-4
   Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002
   Slader CA, 2006, RESPIROLOGY, V11, P373, DOI 10.1111/j.1440-1843.2006.00861.x
   Suh SJ, 2006, TOXICOL IN VITRO, V20, P1465, DOI 10.1016/j.tiv.2006.06.016
   Sun ZR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-360
   Van De Kant K., 2009, BMC PUBLIC HEALTH, V9, P1
   Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319
   World Association for Laser Therapy, 2012, REC TREATM DOS LOW L
   Zhang QH, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-7
NR 45
TC 0
Z9 0
U1 4
U2 15
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 15
EP 19
DI 10.1016/j.rmed.2019.07.022
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800003
PM 31382164
DA 2020-05-18
ER

PT J
AU Richeldi, L
   Crestani, B
   Azuma, A
   Kolb, M
   Selman, M
   Stansen, W
   Quaresma, M
   Stowasser, S
   Cottin, V
AF Richeldi, Luca
   Crestani, Bruno
   Azuma, Arata
   Kolb, Martin
   Selman, Moises
   Stansen, Wibke
   Quaresma, Manuel
   Stowasser, Susanne
   Cottin, Vincent
TI Outcomes following decline in forced vital capacity in patients with
   idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON
   trials of nintedanib
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Interstitial lung disease
ID EFFICACY; MORTALITY; SAFETY
AB Background: We explored the impact of FVC decline on subsequent FVC decline and mortality in the INPULSIS trials of nintedanib in patients with IPF and their open-label extension, INPULSIS-ON.
   Methods: Changes in FVC and mortality between weeks 24 and 52 of the INPULSIS trials were assessed in patients with an increase/no decline in FVC % predicted and with declines in FVC < 10% and >= 10% predicted from baseline to week 24. Changes in FVC and mortality in the first year of INPULSIS-ON were assessed in patients treated with nintedanib in the preceding INPULSIS trial who did and did not have a decline in FVC >= 10% predicted at week 52.
   Results: The proportion of placebo-treated patients with decline in FVC >= 10% predicted between weeks 24 and 52 of INPULSIS was similar in patients with increase/no decline in FVC and with decline in FVC >= 10% predicted between baseline and week 24 ( 20.5% and 18.9%, respectively). Mortality between weeks 24 and 52 of INPULSIS was higher in patients with FVC decline >= 10% predicted than < 10% predicted between baseline and week 24 ( 13.2% vs 3.8%). Among nintedanib-treated patients in INPULSIS who had decline in FVC >= 10% versus < 10% predicted at week 52, 34.0% versus 21.4%, respectively, had decline in FVC >= 10% predicted in the first year of INPULSIS-ON. Mortality in the first year of INPULSIS-ON was 21.3% vs 5.7% in these groups, respectively.
   Conclusions: Decline in FVC did not predict FVC decline but was associated with mortality in patients with IPF.
C1 [Richeldi, Luca] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli IRCCS, Rome, Italy.
   [Crestani, Bruno] Univ Paris Diderot, Hop Bichat, AP HP, Serv Pneumol A,DHU FIRE,INSERM,Unite 1152, Paris, France.
   [Azuma, Arata] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan.
   [Kolb, Martin] McMaster Univ, Hamilton, ON, Canada.
   [Kolb, Martin] St Josephs Healthcare, Hamilton, ON, Canada.
   [Selman, Moises] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Mexico City, DF, Mexico.
   [Stansen, Wibke] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.
   [Quaresma, Manuel; Stowasser, Susanne] Boehringer Ingelheim Int GmbH, Ingelheim, Germany.
   [Cottin, Vincent] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis, Lyon, France.
RP Richeldi, L (reprint author), Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli IRCCS, Rome, Italy.
EM luca.richeldi@policlinicogemelli.it
OI Cottin, Vincent/0000-0002-5591-0955; Azuma, Arata/0000-0003-0506-9966;
   Richeldi, Luca/0000-0001-8594-1448
FU Boehringer IngelheimBoehringer Ingelheim
FX The INPULSIS and INPULSIS-ON trials were funded by Boehringer Ingelheim.
CR Brown KK, 2019, RESP MED, V146, P42, DOI 10.1016/j.rmed.2018.11.012
   Costabel U, 2016, AM J RESP CRIT CARE, V193, P178, DOI 10.1164/rccm.201503-0562OC
   Crestani B, 2019, LANCET RESP MED, V7, P60, DOI 10.1016/S2213-2600(18)30339-4
   Fisher Mark, 2017, J Manag Care Spec Pharm, V23, pS17, DOI 10.18553/jmcp.2017.23.3-b.s17
   Flaherty KR, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.02593-2017
   Guenther A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0845-5
   Jo HE, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0575-y
   Jo HE, 2017, RESPIROLOGY, V22, P1436, DOI 10.1111/resp.13146
   Kim HJ, 2015, RESP MED, V109, P661, DOI 10.1016/j.rmed.2015.02.002
   Kolb M, 2017, THORAX, V72, P340, DOI 10.1136/thoraxjnl-2016-208710
   Lancaster L, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000397
   Ley B, 2016, AM J RESP CRIT CARE, V194, P711, DOI 10.1164/rccm.201508-1546OC
   Maher TM, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.OA4499
   Nathan SD, 2016, THORAX, V71, P429, DOI 10.1136/thoraxjnl-2015-207011
   National Institute for Health and Care Excellence, 2016, NINT TREAT ID PULM F
   National Institute for Health and Care Excellence, 2018, PIRF TREAT ID PULM F
   Paterniti MO, 2017, ANN AM THORAC SOC, V14, P1395, DOI 10.1513/AnnalsATS.201606-458OC
   QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Reichmann WM, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0161-5
   Richeldi L, 2016, RESP MED, V113, P74, DOI 10.1016/j.rmed.2016.02.001
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Richeldi L, 2012, THORAX, V67, P407, DOI 10.1136/thoraxjnl-2011-201184
   Rinciog C, 2017, PHARMACOECONOMICS, V35, P479, DOI 10.1007/s40273-016-0480-2
   Schmidt SL, 2014, CHEST, V145, P579, DOI 10.1378/chest.13-0844
   Wuyts WA, 2016, LUNG, V194, P739, DOI 10.1007/s00408-016-9912-1
   Zurkova M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0977-2
NR 27
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 20
EP 25
DI 10.1016/j.rmed.2019.08.002
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800004
PM 31404749
DA 2020-05-18
ER

PT J
AU Gloeckl, R
   Jarosch, I
   Schneeberger, T
   Fiedler, C
   Lausen, M
   Weingaertner, J
   Hitzl, W
   Kenn, K
   Koczulla, AR
AF Gloeckl, Rainer
   Jarosch, Inga
   Schneeberger, Tessa
   Fiedler, Claudia
   Lausen, Melody
   Weingaertner, Julian
   Hitzl, Wolfgang
   Kenn, Klaus
   Koczulla, Andreas Rembert
TI Comparison of supplemental oxygen delivery by continuous versus demand
   based flow systems in hypoxemic COPD patients - A randomized,
   single-blinded cross-over study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Long-term oxygen therapy; Exercise; Endurance shuttle walk test; Oxygen
   concentrator; Liquid oxygen; Pulmonary rehabilitation
ID LIQUID-OXYGEN; EXERCISE; THERAPY; CONCENTRATOR; REST; DEVICES; WALK
AB Background: Supplemental oxygen is a recommended therapy option in stable hypoxemic COPD patients. Often, supplemental oxygen is provided by continuous flow (CF). However, demand oxygen delivery systems (DODS) that provide an oxygen bolus only during inspiration have gained increasing use as they prolong oxygen cylinder life (beside battery life). However, there is a lack of evidence if different DODS and CF devices are equivalent.
   Methods: Seventy hypoxemic COPD patients (FEV1 32 +/- 9% predicted, PaO2 56 +/- 7 mmHg) on long-term oxygen therapy were included in this prospective single-blinded, randomized cross-over trial. Following an initial incremental shuttle walk test, patients performed 3 endurance shuttle walk tests (ESWT) at 85% of their maximum walking speed in random order with: (A) CF (ESWT-CF), (B) a DODS based on liquid oxygen (ESWT-DL) and (C) an DODS oxygen concentrator (ESWT-DC). The primary outcome was oxygen saturation (SpO(2)) at ESWT isotime. Secondary outcomes were total ESWT duration, heart rate (HR) and breathing frequency (BF) at isotime and dyspnea at end-exercise.
   Results: SpO(2) at ESWT isotime was not clinically different between devices: 90 +/- 4% (CF), 89 +/- 5% (DL) and 90 +/- 5% (DC). However, 20% of the patients showed a >= 4% lower oxygen desaturation while using a DODS device. Secondary outcomes were similar under the three conditions.
   Conclusion: Oxygen supplementation via DODS (based on liquid oxygen or as a concentrator) yielded comparable physiological effects during standardized walking in stable hypoxemic COPD patients like CF. However, 20% of patients showed a clinically relevant lower oxygen saturation while using a DODS device. Therefore, we suggest individual testing of oxygen saturation of DODS suitability.
C1 [Gloeckl, Rainer; Jarosch, Inga; Schneeberger, Tessa; Kenn, Klaus; Koczulla, Andreas Rembert] Schoen Klin Berchtesgadener Land, Inst Pulm Rehabil Res, Malterhoeh 1, D-83471 Schoenau, Germany.
   [Gloeckl, Rainer; Fiedler, Claudia] Tech Univ Munich, Dept Prevent Rehabil & Sports Med, Munich, Germany.
   [Schneeberger, Tessa; Kenn, Klaus; Koczulla, Andreas Rembert] Philipps Univ Marburg, Dept Pulm Rehabil, German Ctr Lung Res DZL, Marburg, Germany.
   [Lausen, Melody; Weingaertner, Julian] Philipps Univ Marburg, Dept Internal Med, Marburg, Germany.
   [Hitzl, Wolfgang] Paracelsus Med Univ, Res Off Biostat, Salzburg, Austria.
   [Hitzl, Wolfgang] Paracelsus Med Univ, Dept Ophthalmol & Optometry, Salzburg, Austria.
   [Hitzl, Wolfgang] Paracelsus Med Univ, Res Program Expt Ophthalmol & Glaucoma Res, Salzburg, Austria.
RP Gloeckl, R (reprint author), Schoen Klin Berchtesgadener Land, Inst Pulm Rehabil Res, Malterhoeh 1, D-83471 Schoenau, Germany.
EM rgloeckl@schoen-klinik.de
FU Linde Healthcare (Germany)
FX This study was kindly funded by Linde Healthcare (Germany). Consumable
   materials for the SenTec Digital Monitoring System were kindly provided
   by SenTec (Therwil, Switzerland). However, neither company was involved
   in any aspect of study design, study procedures, data analysis or
   manuscript preparation.
CR [Anonymous], 1980, Ann Intern Med, V93, P391
   ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211
   Bliss Peter L, 2004, Respir Care, V49, P160
   BOWER JS, 1988, CHEST, V94, P77, DOI 10.1378/chest.94.1.77
   BRAUN SR, 1992, CHEST, V102, P694, DOI 10.1378/chest.102.3.694
   Dheda K, 2004, EUR RESPIR J, V24, P954, DOI 10.1183/09031936.04.00089504
   FLENLEY DC, 1981, LANCET, V1, P681
   Fuhrman C, 2004, RESP MED, V98, P938, DOI 10.1016/j.rmed.2004.03.010
   Gallegos LC, 2006, RESPIR CARE, V51, P25
   Garrod R, 1999, THORAX, V54, P242, DOI 10.1136/thx.54.3.242
   Gimeno-Santos E, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA1539
   Global iniative for chronic obstrutive pulmonary disease. GOLD, 2019, GLOBAL STRATEGY DIAG
   Gloeckl R, 2019, RESPIROLOGY, V24, P329, DOI 10.1111/resp.13457
   Hardinge M, 2015, THORAX, V70, P1, DOI 10.1136/thoraxjnl-2015-206865
   Jarosch I, 2016, RESPIRATION, V92, P339, DOI 10.1159/000449509
   Katsenos S, 2006, RESPIRATION, V73, P777, DOI 10.1159/000094393
   Magnussen H, 2014, Pneumologie, V68, P591, DOI 10.1055/s-0034-1377329
   Magnussen H, 2008, Pneumologie, V62, P748, DOI 10.1055/s-2008-1038290
   Marti S, 2013, RESP CARE, V58, P1606, DOI 10.4187/respcare.02260
   Nasilowski J, 2008, RESP MED, V102, P1021, DOI 10.1016/j.rmed.2008.02.005
   Revill SM, 1999, THORAX, V54, P213, DOI 10.1136/thx.54.3.213
   Roberts CM, 1996, THORAX, V51, P831, DOI 10.1136/thx.51.8.831
   SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019
   Strickland SL, 2009, RESP CARE, V54, P344
   Su CL, 2014, J FORMOS MED ASSOC, V113, P23, DOI 10.1016/j.jfma.2012.03.013
   Tiep B, 2008, Chron Respir Dis, V5, P109, DOI 10.1177/1479972308090691
   TIEP BL, 1985, CHEST, V87, P636, DOI 10.1378/chest.87.5.636
   Tiep Brian L, 2002, Respir Care, V47, P887
   Troy L. K., 2015, RESPIROLOGY
   Yanez AM, 2015, RESP CARE, V60, P382, DOI 10.4187/respcare.03470
NR 30
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 26
EP 32
DI 10.1016/j.rmed.2019.08.001
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800005
PM 31404750
DA 2020-05-18
ER

PT J
AU Laddha, AP
   Kulkarni, YA
AF Laddha, Ankit P.
   Kulkarni, Yogesh A.
TI VEGF and FGF-2: Promising targets for the treatment of respiratory
   disorders
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Angiogenesis; Vascular endothelial growth factor; Basic fibroblast
   growth factor; Asthma; COPD; Lung cancer
ID ENDOTHELIAL GROWTH-FACTOR; OBSTRUCTIVE PULMONARY-DISEASE;
   VASCULAR-PERMEABILITY FACTOR; SMOOTH-MUSCLE-CELLS; LUNG-CANCER; INHIBITS
   ANGIOGENESIS; TYROSINE KINASE; EGFR INHIBITOR; TUMOR-GROWTH; MAST-CELLS
AB The endothelial cells play a crucial role in the progression of angiogenesis, which causes cell re-modulation, proliferation, adhesion, migration, invasion and survival. Angiogenic factors like cytokines, cell adhesion molecules, growth factors, vasoactive peptides, proteolytic enzymes (metalloproteinases) and plasminogen activators bind to their receptors on endothelial cells and activate the signal transduction pathways like epidermal growth factor receptor (EGFR phosphatidylinositol 3-kinase and (PI3K)/AKT/mammalian target of rapamycin (mTOR) which initiate the process of angiogenesis.
   Cytokines that stimulate angiogenesis include direct and indirect proangiogenic markers. The direct proangiogenic group of markers consists of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and hepatocyte growth factor (HGF) whereas the indirect proangiogenic markers include transforming growth factor-beta (TGF-beta), interleukin 6 (IL-6), interleukin 8 (IL-8) and platelet-derived growth factor (PDGF).
   VEGF and FGF-2 are the strongest activators of angiogenesis which stimulate migration and proliferation of endothelial cells in existing vessels to generate and stabilize new blood vessels. VEGF is released in hypoxic conditions as an effect of the hypoxia-inducible factor (HIF-1 alpha) and causes re-modulation and inflammation of bronchi cell. Cell re-modulation and inflammation leads to the development of various lung disorders like pulmonary hypertension, chronic obstructive pulmonary disease, asthma, fibrosis and lung cancer.
   This indicates that there is a firm link between overexpression of VEGF and FGF-2 with lung disorders. Various natural and synthetic drugs are available for reducing the overexpression of VEGF and FGF-2 which can be helpful in treating lung disorders. Researchers are still searching for new angiogenic inhibitors which can be helpful in the treatment of lung disorders.
   The present review emphasizes on molecular mechanisms and new drug discovery focused on VEGF and FGF-2 inhibitors and their role as anti-angiogenetic agents in lung disorders.
C1 [Laddha, Ankit P.; Kulkarni, Yogesh A.] SVKMs NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, VL Mehta Rd,Vile Parle W, Mumbai 400056, Maharashtra, India.
RP Kulkarni, YA (reprint author), SVKMs NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, VL Mehta Rd,Vile Parle W, Mumbai 400056, Maharashtra, India.
EM yogeshkulkarni101@yahoo.com
RI Kulkarni, Yogesh A./B-8622-2016; Laddha, Ankit/X-8458-2018
OI Kulkarni, Yogesh A./0000-0002-1686-7907; Laddha,
   Ankit/0000-0002-6223-9645
CR A. C. Society, 2014, WHAT IS NONSM CELL L
   Abdolmaleki Z, 2016, REV BRAS FARMACOGN, V26, P326, DOI 10.1016/j.bjp.2015.11.008
   Acarregui MJ, 1999, AM J RESP CELL MOL, V20, P14, DOI 10.1165/ajrcmb.20.1.3251
   AMACHER DE, 1993, MUTAT RES, V300, P79, DOI 10.1016/0165-1218(93)90125-W
   Ambade AS, 2019, TRANSL RES, V203, P15, DOI 10.1016/j.trsl.2018.07.010
   Anfosso L, 2006, PHARMACOGENOMICS J, V6, P269, DOI 10.1038/sj.tpj.6500371
   [Anonymous], 2017, J Neuroimmune Pharmacol, V12, P3, DOI 10.1007/s11481-017-9731-z
   [Anonymous], 2016, CANCER DISCOV, V6, P120
   [Anonymous], GEF CHEM ANT NSCLC P
   [Anonymous], 2010, DATA I BV LINIFANIB, V10, P111, DOI [10.2165/11584520-000000000-00000, DOI 10.2165/11584520-000000000-00000]
   [Anonymous], STUD XL647 SUBJ NONS
   [Anonymous], 3 4 LIN PLAC CONTR T
   [Anonymous], 2015, P IDENTIFIER O IDENT, P1
   [Anonymous], 2005, EFF AZD2171 PAT NONS
   Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744
   Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797
   Bai XH, 2003, J BIOL CHEM, V278, P35501, DOI 10.1074/jbc.M302967200
   Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037
   Barrios R., 2017, J AM PHYSL CELL MOL, V273, pL451, DOI [10.1152/ajplung.1997.273.2.l451, DOI 10.1152/AJPLUNG.1997.273.2.L451]
   Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755
   Black SM, 2008, AM J PHYSIOL-CELL PH, V294, pC345, DOI 10.1152/ajpcell.00216.2007
   Brown AC, 2009, PHYTOTHER RES, V23, P640, DOI 10.1002/ptr.2677
   Chaudhary N, 2014, J FUNCT FOODS, V7, P479, DOI 10.1016/j.jff.2014.01.008
   Chen Ming-wei, 2005, Zhonghua Jiehe He Huxi Zazhi, V28, P37
   Chetty C, 2010, INT J CANCER, V127, P1081, DOI 10.1002/ijc.25134
   Chlebova K, 2009, CELL MOL LIFE SCI, V66, P225, DOI 10.1007/s00018-008-8440-4
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Copd D., 2008, CHRONIC OBSTRUCTIVE, P41, DOI [10.1093/med/9780199549146.001.0001, DOI 10.1093/MED/9780199549146.001.0001]
   Cosgrove GP, 2004, AM J RESP CRIT CARE, V170, P242, DOI 10.1164/rccm.200308-1151OC
   Dallinger C, 2016, J CLIN PHARMACOL, V56, P1387, DOI 10.1002/jcph.752
   De Luisi A, 2009, EUR RESPIR J, V34, P958, DOI 10.1183/09031936.00165308
   Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429
   Dittrich C, 2002, EUR J CANCER, V38, P1072, DOI 10.1016/S0959-8049(02)00020-5
   DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27
   E. H. Association for research in vision and ophthalmology, 2008, INVESTIG OPHTHALMOL, V49, P4579
   E. M. Agency, 2009, ASS REP IRESSA REACT, P86, DOI [10.2165/00128415-200912820-00006, DOI 10.2165/00128415-200912820-00006]
   Elluru SR, 2009, ANTICANCER RES, V29, P2945
   European Medicines Agency, 2012, EUR PUBL ASS REP INL, P44
   Falardeau P, 2001, SEMIN ONCOL, V28, P620, DOI 10.1053/sonc.2001.28598
   Farkas L, 2009, J CLIN INVEST, V119, P1298, DOI 10.1172/JCI36136
   FDA, 1988, REVIEW, V9, P22
   Feltis BN, 2006, AM J RESP CRIT CARE, V173, P1201, DOI 10.1164/rccm.200507-1105OC
   Feng P, 2013, ASIAN PAC J TROP MED, V6, P57, DOI 10.1016/S1995-7645(12)60201-6
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690
   Frezzetti D, 2017, EXPERT OPIN THER TAR, V21, P959, DOI 10.1080/14728222.2017.1371137
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Gainor JF, 2017, LANCET, V390, P3, DOI 10.1016/S0140-6736(17)31074-7
   Galgani M, 2010, CLIN IMMUNOL, V137, P102, DOI 10.1016/j.clim.2010.06.010
   Gauler TC, 2012, ANN ONCOL, V23, P678, DOI 10.1093/annonc/mdr255
   Ge A, 2015, ACTA BIOCH BIOPH SIN, V47, P604, DOI 10.1093/abbs/gmv052
   Geng XC, 2018, REGUL TOXICOL PHARM, V95, P190, DOI 10.1016/j.yrtph.2018.03.017
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Goralczyk Barbara, 2012, MED BIOSCI, V26, P19, DOI DOI 10.12775/V10251-012-0050-6
   Grutzkau A, 1998, MOL BIOL CELL, V9, P875, DOI 10.1091/mbc.9.4.875
   Grzela K, 2016, ARCH IMMUNOL THER EX, V64, P47, DOI 10.1007/s00005-015-0345-y
   Ha EVS, 2016, PHARMACOLOGY, V97, P84, DOI 10.1159/000442794
   Hemnes A. R., 2015, NATL ORGAN RARE DIS
   HENKE C, 1993, AM J PATHOL, V143, P1189
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Huang CW, 2016, BIOCHEM BIOPH RES CO, V478, P181, DOI 10.1016/j.bbrc.2016.07.072
   Hur GY, 2007, EXP MOL MED, V39, P367, DOI 10.1038/emm.2007.41
   Inoue Y, 1996, AM J PATHOL, V149, P2037
   Janer J, 2006, AM J RESP CRIT CARE, V174, P326, DOI 10.1164/rccm.200508-1291OC
   Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172
   Jiang C, 2000, BIOCHEM BIOPH RES CO, V276, P371, DOI 10.1006/bbrc.2000.3474
   Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203
   Jonson-Reid M., 2013, SCH SERV SOURCEB GUI, V5, P903, DOI [10.12688/f1000research.9236.1, DOI 10.12688/F1000RESEARCH.9236.1]
   Kanazawa H, 2007, RECENT PATENTS INFLA, V1, P1, DOI 10.2174/187221307779815066
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Keane MP, 1997, J IMMUNOL, V159, P1437
   Kessler R, 2001, AM J RESP CRIT CARE, V164, P219, DOI 10.1164/ajrccm.164.2.2006129
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Khalil N, 2005, J BIOL CHEM, V280, P43000, DOI 10.1074/jbc.M510441200
   KIHLSTROM I, 1987, ARZNEIMITTEL-FORSCH, V37-1, P43
   Kim SH, 2017, RESP RES, V18, DOI 10.1186/s12931-016-0490-9
   King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4
   Kranenburg AR, 2005, THORAX, V60, P106, DOI 10.1136/thx.2004.023986
   Landskron G, 2014, J IMMUNOL RES, DOI 10.1155/2014/149185
   Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105
   Lee G, 2009, CURR OPIN PULM MED, V15, P303, DOI 10.1097/MCP.0b013e32832c975a
   Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326
   Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039
   Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1
   Li S, 2015, CLIN LUNG CANCER, V16, P86, DOI 10.1016/j.cllc.2014.09.011
   Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066
   Lieu C, 2011, CLIN CANCER RES, V17, P6130, DOI 10.1158/1078-0432.CCR-11-0659
   Liu J, 2018, EBIOMEDICINE, V33, P196, DOI 10.1016/j.ebiom.2018.06.003
   Louzier V, 2003, AM J PHYSIOL-LUNG C, V284, pL926, DOI 10.1152/ajplung.00247.2002
   LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256
   Lv XM, 2018, ACTA PHARMACOL SIN, V39, P1501, DOI 10.1038/aps.2017.202
   Marech I, 2016, CANCER LETT, V380, P216, DOI 10.1016/j.canlet.2015.07.028
   Matarese A, 2012, TRANSL MED UNISA, V3, P49
   Medford ARL, 2006, THORAX, V61, P621, DOI 10.1136/thx.2005.040204
   Medford ARL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-27
   Mishra A, 2011, LUNG INDIA, V28, P174, DOI 10.4103/0970-2113.83972
   MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Murthy KNC, 2002, J AGR FOOD CHEM, V50, P5909, DOI 10.1021/jf0257042
   Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044
   Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x
   Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703
   PETERS SG, 1993, CHEST, V103, P101, DOI 10.1378/chest.103.1.101
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Psarras S, 2006, J ALLERGY CLIN IMMUN, V117, P291, DOI 10.1016/j.jaci.2005.11.005
   Rabinovitch M, 2008, J CLIN INVEST, V118, P2372, DOI 10.1172/JCI33452
   Ray L. R. K. Gandharba, 27 PULMONARY ARTERIA
   Ribatti D, 2008, ENDOTHELIUM-J ENDOTH, V15, P1, DOI 10.1080/10623320802092377
   Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304, DOI 10.1164/ajrccm.163.6.2009116
   SANGSTER AJ, 1960, BRIT MED J, V1, P127, DOI 10.1136/bmj.1.5166.127-b
   Schuliga M, 2015, BIOMOLECULES, V5, P1266, DOI 10.3390/biom5031266
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Seyfarth HJ, 2015, PNEUMOLOGIE, V69, P207, DOI 10.1055/s-0034-1391775
   Shehata SMK, 1999, THORAX, V54, P427, DOI 10.1136/thx.54.5.427
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shingyoji M, 2009, ANTICANCER RES, V29, P2635
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Siafakas Nikolaos M, 2007, Int J Chron Obstruct Pulmon Dis, V2, P453
   Simler NR, 2004, THORAX, V59, P581, DOI 10.1136/thx.2003.009860
   Stuttfeld E, 2009, IUBMB LIFE, V61, P915, DOI 10.1002/iub.234
   Sussex W., 2015, EPAR CERITINIB, P44
   T. A. Society A. Rcc A. Rcc P. Iii, 2006, NEX EPAR SCI DISC EM, V1-49
   Tahergorabi Z, 2012, IRAN J BASIC MED SCI, V15, P1110
   Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P2165
   Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081
   Tan EH, 2011, J THORAC ONCOL, V6, P1418, DOI 10.1097/JTO.0b013e318220c93e
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   To M, 2012, CHEST, V141, P1233, DOI 10.1378/chest.11-1536
   TUDER RM, 1994, AM J PATHOL, V144, P275
   Tuder RM, 2007, J MOL MED, V85, P1317, DOI 10.1007/s00109-007-0280-4
   TURNER-WARWICK MARGARET, 1963, THORAX, V18, P225, DOI 10.1136/thx.18.3.225
   Valenzuela C., 2015, PARENCHYMAL LUNG DIS, DOI 10.1183/13993003.congress-2015.pa3044
   Varet J, 2010, AM J PHYSIOL-LUNG C, V298, pL768, DOI 10.1152/ajplung.00353.2009
   Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005
   Walters EH, 2008, CURR OPIN ALLERGY CL, V8, P39, DOI 10.1097/ACI.0b013e3282f42696
   Wan YY, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-56
   Wang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41202
   Wang X., 2013, POPULATION PHARMACOK
   Wang XS, 2010, PATHOLOGY, V42, P457, DOI 10.3109/00313025.2010.493864
   Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455
   Who, 2013, WHO ASTHM, DOI [10.1017/S0003598X00065108, DOI 10.1017/S0003598X00065108]
   Wilczynska KM, 2006, J BIOL CHEM, V281, P34955, DOI 10.1074/jbc.M604616200
   Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914
   World Health Organization, ASTHMA
   Xiao QL, 2005, BIOCHEM J, V388, P913, DOI 10.1042/BJ20041739
   Yang W, 2017, INT J CLIN EXP PATHO, V10, P2824
   Yu ZG, 2017, KAOHSIUNG J MED SCI, V33, P433, DOI 10.1016/j.kjms.2017.05.014
   Z. International, 2016, CED, P44
   Zanini Andrea, 2008, Ther Adv Respir Dis, V2, P179, DOI 10.1177/1753465808092339
   Zhang L., 2001, ACTA PHARM SIN
   Zhao X., J BIOL REGUL HOMEOST, V32, P1079
NR 154
TC 3
Z9 4
U1 10
U2 17
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 33
EP 46
DI 10.1016/j.rmed.2019.08.003
PG 14
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800006
PM 31421589
DA 2020-05-18
ER

PT J
AU Cazzola, M
   Rogliani, P
   Matera, MG
AF Cazzola, Mario
   Rogliani, Paola
   Matera, Maria Gabriella
TI Ultra-LABAs for the treatment of asthma
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Abediterol; Asthma; Indacaterol; Olodaterol; Vilanterol
ID INHALED BETA(2)-ADRENOCEPTOR AGONIST; LONG-ACTING BETA(2)-AGONISTS;
   PHARMACOLOGICAL CHARACTERIZATION; IN-VITRO; VILANTEROL TRIFENATATE;
   ABEDITEROL LAS100977; ADRENOCEPTOR AGONIST; FLUTICASONE FUROATE;
   PERSISTENT ASTHMA; 24-H DURATION
AB The term ultra-LABA indicates once-daily beta 2-AR agonists (abediterol, indacaterol, olodaterol and vilanterol) that are single enantiomers of the (R)-configuration. All have a near full-agonist profile at human beta 2-AR. They can be prescribed in asthmatics only when associated with an with ICS, although further confirmations need to clarify what really these agents add if used in association to ICS and in what asthmatic patients this association may have more value. They are also under development in triple inhalers that include an ultra-LABA, a LAMA and an ICS. The once-daily posology might increase adherence in long-term treatment of asthma but superiority to twice-daily LABAs has not yet been fully demonstrated. In any case, still no ultra-LABA can be recommended as preferred.
C1 [Cazzola, Mario; Rogliani, Paola] Univ Roma Tor Vergata, Dept Expt Med, Unit Resp Med, Rome, Italy.
   [Matera, Maria Gabriella] Univ Campania Luigi Vanvitelli, Dept Expt Med, Unit Pharmacol, Naples, Italy.
RP Cazzola, M (reprint author), Univ Roma Tor Vergata, Dept Expt Med, Unit Resp Med, Rome, Italy.
EM mario.cazzola@uniroma2.it
OI Rogliani, Paola/0000-0001-7801-5040
CR [Anonymous], NOVARTISS PHASE 3 QU
   [Anonymous], SINGLE INHALER TRIPL
   Aparici M, 2016, EUR J PHARMACOL, V770, P61, DOI 10.1016/j.ejphar.2015.11.053
   Aparici M, 2012, J PHARMACOL EXP THER, V342, P497, DOI 10.1124/jpet.112.193284
   Atsuta Ryo, 2018, Pulm Ther, V4, P135, DOI 10.1007/s41030-018-0084-4
   Baddar S, 2014, J ASTHMA, V51, P429, DOI 10.3109/02770903.2013.871558
   BARNES N, 2017, AM J RESP CRIT CARE, V195
   Battram C, 2006, J PHARMACOL EXP THER, V317, P762, DOI 10.1124/jpet.105.098251
   Beasley R, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02338-2017
   Beasley RW, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006131
   Beeh KM, 2007, EUR RESPIR J, V29, P871, DOI 10.1183/09031936.00060006
   Beeh KM, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0243-1
   Beier J, 2019, AM J RESP CRIT CARE, V199
   Beier J, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.356
   Blais CM, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0628-4
   Bollmeier SG, 2016, PATIENT PREFER ADHER, V10, P825, DOI 10.2147/PPA.S83946
   Bonini M., 2016, MEDICINE, V44, P271
   Bouyssou T, 2010, J PHARMACOL EXP THER, V334, P53, DOI 10.1124/jpet.110.167007
   Brookman LJ, 2007, CURR MED RES OPIN, V23, P3113, DOI 10.1185/030079907X242863
   Cazzola M, 2005, EXPERT OPIN INV DRUG, V14, P775, DOI 10.1517/13543784.14.7.775
   Cazzola Mario, 2007, Ther Adv Respir Dis, V1, P35, DOI 10.1177/1753465807081747
   Cazzola M, 2016, EXPERT OPIN INV DRUG, V25, P861, DOI 10.1080/13543784.2016.1188078
   Cazzola M, 2013, AM J RESP CRIT CARE, V187, P690, DOI 10.1164/rccm.201209-1739PP
   Cazzola M, 2011, BRIT J PHARMACOL, V163, P4, DOI 10.1111/j.1476-5381.2011.01216.x
   Cazzola M, 2010, CURR OPIN PULM MED, V16, P6, DOI 10.1097/MCP.0b013e32833303d2
   Chuchalin AG, 2007, RESP MED, V101, P2065, DOI 10.1016/j.rmed.2007.06.002
   Crisafulli E, 2017, EXPERT OPIN PHARMACO, V18, P1499, DOI 10.1080/14656566.2017.1378348
   Davis BE, 2018, J ASTHMA ALLERGY, V11, P89, DOI 10.2147/JAA.S160607
   Hanania NA, 2010, CURR OPIN PULM MED, V16, P1, DOI 10.1097/MCP.0b013e328333def8
   Kempsford R, 2013, PULM PHARMACOL THER, V26, P256, DOI 10.1016/j.pupt.2012.12.001
   LaForce C, 2009, CURR MED RES OPIN, V25, P2353, DOI 10.1185/03007990903143143
   Lotvall J, 2014, J NEGAT RESULTS BIOM, V13, DOI 10.1186/1477-5751-13-9
   Lotvall J, 2012, EUR RESPIR J, V40, P570, DOI 10.1183/09031936.00121411
   Mansfield L, 2019, RESP MED, V154, P47, DOI 10.1016/j.rmed.2019.06.008
   Martin A, 2019, J ASTHMA, DOI 10.1080/02770903.2019.1648505
   Matera MG, 2007, DRUGS, V67, P503, DOI 10.2165/00003495-200767040-00002
   Matera MG, 2017, EXPERT OPIN DRUG MET, V13, P129, DOI 10.1080/17425255.2017.1234604
   Murphy L, 2014, DRUGS, V74, P1635, DOI 10.1007/s40265-014-0284-7
   Naline E, 2007, EUR RESPIR J, V29, P575, DOI 10.1183/09031936.00032806
   O'Byrne PM, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0249-8
   O'Byrne PM, 2009, J ALLERGY CLIN IMMUN, V124, P1217, DOI 10.1016/j.jaci.2009.08.047
   Oliver A, 2013, ALLERGY, V68, P1136, DOI 10.1111/all.12205
   Oliver A, 2014, CLIN PHARM DRUG DEV, V3, P215, DOI 10.1002/cpdd.92
   Oliver AJ, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0353-4
   Ramos I, 2018, EUR J PHARMACOL, V819, P89, DOI 10.1016/j.ejphar.2017.11.043
   Roig Jorge, 2009, Open Respir Med J, V3, P27, DOI 10.2174/1874306400903010027
   Rosethorne EM, 2010, N-S ARCH PHARMACOL, V382, P255, DOI 10.1007/s00210-010-0533-6
   Silva D, 2016, BREATHE, V12, P379, DOI 10.1183/20734735.017116
   Slack RJ, 2013, J PHARMACOL EXP THER, V344, P218, DOI 10.1124/jpet.112.198481
   Stanford RH, 2019, J ALLER CL IMM-PRACT, V7, P1488, DOI 10.1016/j.jaip.2018.12.021
   Sterling R, 2012, RESP MED, V106, P1110, DOI 10.1016/j.rmed.2012.03.007
   Sturton RG, 2008, J PHARMACOL EXP THER, V324, P270, DOI 10.1124/jpet.107.129296
   Syed YY, 2015, DRUGS, V75, P407, DOI 10.1007/s40265-015-0354-5
   WATZ H, 2019, AM J RESP CRIT CARE, V199
   Westbury GLM, 2018, ANN ALLERG ASTHMA IM, V121, P328, DOI 10.1016/j.anai.2018.07.005
   Woodcock A, 2017, LANCET, V390, P2247, DOI 10.1016/S0140-6736(17)32397-8
NR 56
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 47
EP 52
DI 10.1016/j.rmed.2019.08.005
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800007
PM 31425937
DA 2020-05-18
ER

PT J
AU Okonkwo, CS
   Davis, BE
   Blais, CM
   Cockcroft, DW
AF Okonkwo, Chiamaka S.
   Davis, Beth E.
   Blais, Christianne M.
   Cockcroft, Donald W.
TI Short-term effect of once-daily fluticasone furoate on
   methacholine-induced bronchoconstriction in mild asthmatics
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Airway hyperresponsiveness; Fluticasone furoate; Methacholine
   challenge testing; Fractional exhaled nitric oxide
ID INHALED BUDESONIDE; AIRWAY INFLAMMATION; LUNG-FUNCTION;
   HYPERRESPONSIVENESS; PROPIONATE; CORTICOSTEROIDS; RESPONSIVENESS;
   CESSATION; MARKERS; FLUID
AB Background: Inhaled corticosteroids (ICS) decrease airway inflammation and airway hyperresponsiveness (AHR). Previous studies have generally investigated the effect of ICS on methacholine-induced AHR following weeks or months of medium to high dose treatment.
   Purpose: The short-term effects of once-daily fluticasone furoate (FF) 100 mcg on methacholine-induced AHR and airway inflammation were examined over the course of one week.
   Methods: Eleven mild asthmatics completed this randomized, double-blind crossover study. Once-daily FF (100 mcg) and identical appearing placebo Ellipta (R) inhalers were given for 7 days with a 2-week washout. Methacholine challenges were performed before and 24 h after the first, third and seventh doses. Fractional exhaled nitric oxide (FeNO) was measured initially and at 7 days.
   Results: FF significantly (p = 0.0009-0.0078) increased methacholine PD20 (provocative dose causing 20% fall in forced expiratory volume in 1 s) at all times. Doubling dose shifts (95% CI) were 1.23 (0.60-1.86), 1.17 (0.68-1.67) and 1.44 (0.93-1.94) after the first, third and seventh dose respectively. FeNO (geometric mean, 95% CI) decreased significantly (p = 0.0049) following FF treatment from 37.9 ppb (23.7-60.5) initially to 22.9 ppb (14.8-35.5) at 7 days. Placebo did not affect methacholine PD20 or FeNO.
   Conclusion: Single-dose FF 100 mcg decreased methacholine AHR at 24 h without significant further improvement with continued daily use over 7 days. The inhibition in AHR after one week of daily dosing coincided with a significant decrease in FeNO at 7 days. Contrary to past assumptions, the ICS FF appears to rapidly reduce AHR to methacholine.
C1 [Okonkwo, Chiamaka S.; Davis, Beth E.; Cockcroft, Donald W.] Univ Saskatchewan, Dept Anat Physiol & Pharmacol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
   [Davis, Beth E.; Blais, Christianne M.; Cockcroft, Donald W.] Univ Saskatchewan, Dept Med, Div Respirol Crit Care & Sleep Med, 103 Hosp Dr,Ellis Hall,5th Floor, Saskatoon, SK S7N 0W8, Canada.
RP Cockcroft, DW (reprint author), Univ Saskatchewan, Dept Med, Div Respirol Crit Care & Sleep Med, 103 Hosp Dr,Ellis Hall,5th Floor, Saskatoon, SK S7N 0W8, Canada.
EM don.cockcroft@usask.ca
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   Barnes PJ, 2010, PHARMACEUTICALS, V3, P514, DOI 10.3390/ph3030514
   Biggadike K, 2011, CLIN RESPIR J, V5, P183, DOI 10.1111/j.1752-699X.2011.00244.x
   Booms P, 1997, J ALLERGY CLIN IMMUN, V99, P330, DOI 10.1016/S0091-6749(97)70050-2
   Coates AL, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01526-2016
   COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505
   Daley-Yates PT, 2015, BRIT J CLIN PHARMACO, V80, P372, DOI 10.1111/bcp.12637
   Davis BE, 2002, CHEST, V122, P1499, DOI 10.1378/chest.122.4.1499
   Davis BE, 2018, J ASTHMA ALLERGY, V11, P89, DOI 10.2147/JAA.S160607
   Davis BE, 2017, CHEST, V152, P1251, DOI 10.1016/j.chest.2017.09.001
   Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5
   Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889
   KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44
   Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   O'Byrne PM, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0473-x
   OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704
   Oliver A, 2013, ALLERGY, V68, P1136, DOI 10.1111/all.12205
   Overbeek SE, 1996, MEDIAT INFLAMM, V5, P224, DOI 10.1155/S0962935196000324
   Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799
   Prosperini G, 2002, J ALLERGY CLIN IMMUN, V110, P855, DOI 10.1067/mai.2002.130050
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Sovijarvi ARA, 2003, THORAX, V58, P500, DOI 10.1136/thorax.58.6.500
   Valotis A, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-54
   van den Berge M, 2010, ALLERGY, V65, P1531, DOI 10.1111/j.1398-9995.2010.02414.x
   van Grunsven PM, 1999, THORAX, V54, P316, DOI 10.1136/thx.54.4.316
   VANESSENZANDVLIET EEM, 1993, EUR RESPIR J, V6, P383
   Westbury GLM, 2018, ANN ALLERG ASTHMA IM, V121, P328, DOI 10.1016/j.anai.2018.07.005
   Woodcock A, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-113
NR 29
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 53
EP 57
DI 10.1016/j.rmed.2019.08.007
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800008
PM 31434037
DA 2020-05-18
ER

PT J
AU Hoesterey, D
   Das, N
   Janssens, W
   Buhr, RG
   Martinez, FJ
   Cooper, CB
   Tashkin, DP
   Barjaktarevic, I
AF Hoesterey, Daniel
   Das, Nilakash
   Janssens, Wim
   Buhr, Russell G.
   Martinez, Fernando J.
   Cooper, Christopher B.
   Tashkin, Donald P.
   Barjaktarevic, Igor
TI Spirometric indices of early airflow impairment in individuals at risk
   of developing COPD: Spirometry beyond FEV1/FVC
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Early COPD; Spirometry; Obstruction
ID OBSTRUCTIVE PULMONARY-DISEASE; INSPIRATORY VITAL CAPACITY; FORCED
   EXPIRATORY FLOW; VOLUME CURVE; SMALL AIRWAYS; ISOLATED REDUCTION;
   REFERENCE VALUES; FEV3/FVC RATIO; LOWER LIMIT; LUNG
AB Spirometry is the current gold standard for diagnosing and monitoring the progression of Chronic Obstructive Pulmonary Disease (COPD). However, many current and former smokers who do not meet established spirometric criteria for the diagnosis of this disease have symptoms and clinical courses similar to those with diagnosed COPD. Large longitudinal observational studies following individuals at risk of developing COPD offer us additional insight into spirometric patterns of disease development and progression. Analysis of forced expiratory maneuver changes over time may allow us to better understand early changes predictive of progressive disease. This review discusses the theoretical ability of spirometry to capture fine pathophysiologic changes in early airway disease, highlights the shortcomings of current diagnostic criteria, and reviews existing evidence for spirometric measures which may be used to better detect early airflow impairment.
C1 [Hoesterey, Daniel; Buhr, Russell G.; Cooper, Christopher B.; Tashkin, Donald P.; Barjaktarevic, Igor] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Das, Nilakash; Janssens, Wim] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Lab Resp Dis, Leuven, Belgium.
   [Buhr, Russell G.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA.
   [Buhr, Russell G.] Greater Los Angeles Vet Affairs Healthcare Syst, Med Serv, Los Angeles, CA USA.
   [Martinez, Fernando J.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
   [Cooper, Christopher B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
RP Barjaktarevic, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care, 10833 Le Conte Ave,43-229 CHS,Mail Code 169017, Los Angeles, CA 90095 USA.
EM ibarjaktarevic@mednet.ucla.edu
OI Buhr, Russell/0000-0001-6159-7435; Martinez,
   Fernando/0000-0002-2412-3182; Barjaktarevic, Igor/0000-0002-8096-0858
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [TL1 TR001883]; NHLBI NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [L30
   HL134025]
CR Abston E, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000231
   Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
   Anderson WH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184606
   Anogeianaki A, 2007, Hippokratia, V11, P187
   ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497
   Bhatt SP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35930-2
   Bhatt SP, 2014, THORAX, V69, P409, DOI 10.1136/thoraxjnl-2012-202810
   Bhatt Surya P, 2014, Ann Am Thorac Soc, V11, P335, DOI 10.1513/AnnalsATS.201308-251OC
   Bird Y, 2016, INT J CHRONIC OBSTR, V11, P1459, DOI 10.2147/COPD.S102999
   Brusasco V, 1997, EUR RESPIR J, V10, P1316, DOI 10.1183/09031936.97.10061316
   Celli B. R., 2018, ERJ OPEN RES, V4
   Cerveri I, 2004, CHEST, V125, P1714, DOI 10.1378/chest.125.5.1714
   Chen CZ, 2012, COPD, V9, P276, DOI 10.3109/15412555.2012.654529
   Chhabra SK, 1998, J ASTHMA, V35, P361, DOI 10.3109/02770909809075669
   Ciprandi G, 2006, AM J RHINOL, V20, P641, DOI 10.2500/ajr.2006.20.2914
   Ciprandi G, 2012, ALLERGY ASTHMA PROC, V33, pE5, DOI 10.2500/aap.2012.33.3524
   COCHRANE GM, 1977, THORAX, V32, P171, DOI 10.1136/thx.32.2.171
   Cohen J, 2007, CHEST, V132, P1198, DOI 10.1378/chest.06-2763
   COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303
   Crystal RG, 2014, AM J RESP CRIT CARE, V190, P1355, DOI 10.1164/rccm.201408-1492PP
   Csikesz NG, 2014, INT J CHRONIC OBSTR, V9, P277, DOI 10.2147/COPD.S46198
   Culver BH, 2017, AM J RESP CRIT CARE, V196, P1463, DOI 10.1164/rccm.201710-1981ST
   Das N, 2019, INT J CHRONIC OBSTR, V14, P409, DOI 10.2147/COPD.S185931
   Das N, 2018, CURR OPIN PULM MED, V24, P117, DOI 10.1097/MCP.0000000000000459
   Decramer M, 2010, THORAX, V65, P837, DOI 10.1136/thx.2009.133355
   Decramer M, 2009, LANCET, V374, P1171, DOI 10.1016/S0140-6736(09)61298-8
   Degens P, 2008, EUR RESPIR J, V31, P687, DOI 10.1183/09031936.00145507
   DETELS R, 1982, CHEST, V82, P630, DOI 10.1378/chest.82.5.630
   Diaz O, 2000, EUR RESPIR J, V16, P269, DOI 10.1034/j.1399-3003.2000.16b14.x
   Dominelli PB, 2015, RESP PHYSIOL NEUROBI, V219, P30, DOI 10.1016/j.resp.2015.08.002
   DUNNILL MS, 1969, P ROY SOC MED, V62, P1024, DOI 10.1177/003591576906201020
   ENGEL T, 1990, EUR RESPIR J, V3, P1037
   Enright PL, 2004, AM J RESP CRIT CARE, V169, P235, DOI 10.1164/rccm.200204-347OC
   Fortis S, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000213
   Fortis S, 2015, RESP CARE, V60, P113, DOI 10.4187/respcare.03403
   Frith P., 2011, CARE RESP J, V20
   Ghosh S, 2017, J AEROSOL MED PULM D, V30, P381, DOI 10.1089/jamp.2017.1416
   Gong SG, 2015, INT J CLIN EXP MED, V8, P21400
   Guder G, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0081-4
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   Hansen JE, 2007, CHEST, V131, P349, DOI 10.1378/chest.06-1349
   Hansen JE, 2015, CHRON OBSTR PULM DIS, V2, P94, DOI 10.15326/jcopdf.2.2.2014.0144
   Hansen JE, 2006, CHEST, V129, P369, DOI 10.1378/chest.129.2.369
   Haroon S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008133
   Harvey BG, 2015, EUR RESPIR J, V46, P1589, DOI 10.1183/13993003.02377-2014
   Hoesein FAAM, 2011, RESP MED, V105, P907, DOI 10.1016/j.rmed.2011.01.008
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Jenkins CR, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-59
   Jing JY, 2009, CHEST, V135, P991, DOI 10.1378/chest.08-0723
   Johns DP, 2014, J THORAC DIS, V6, P1557, DOI 10.3978/j.issn.2072-1439.2014.08.18
   Johnson R., FVC MEASUREMENTS ARE
   KAPP MC, 1988, CHEST, V94, P799, DOI 10.1378/chest.94.4.799
   Kendzerska T, 2017, AM J RESP CRIT CARE, V195
   KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587
   Koo HK, 2018, LANCET RESP MED, V6, P591, DOI 10.1016/S2213-2600(18)30196-6
   Kornmann O, 2003, RESPIRATION, V70, P67, DOI 10.1159/000068417
   KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1
   KUNZLI N, 1995, EUR RESPIR J, V8, P371, DOI 10.1183/09031936.95.08030371
   Lee J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0182-8
   Lee SM, 2016, EUR RADIOL, V26, P2184, DOI 10.1007/s00330-015-4070-z
   [李洪 Li Hong], 2017, [渔业科学进展, Progress in Fishery Sciences], V38, P62
   Loeckx M, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.OA3404
   Loh CH, 2017, ANN AM THORAC SOC, V14, P1305, DOI 10.1513/AnnalsATS.201611-903OC
   Lutfi MF, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0084-5
   Lutfi MF, 2016, INT J HEALTH SCI-IJH, V10, P3, DOI 10.12816/0031221
   Macklem PT, 2010, EUR RESPIR J, V35, P676, DOI 10.1183/09031936.00120609
   MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395
   Madan K, 2014, CHEST, V145, P662, DOI 10.1378/chest.13-2435
   Malerba M, 2016, RESPIRATION, V91, P206, DOI 10.1159/000443797
   Mannino DM, 2007, THORAX, V62, P237, DOI 10.1136/thx.2006.068379
   Mannino DM, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-136
   Marin JM, 2001, AM J RESP CRIT CARE, V163, P1395, DOI 10.1164/ajrccm.163.6.2003172
   Marsh Suzanne, 2006, N Z Med J, V119, pU2281
   Martinez FJ, 2018, AM J RESP CRIT CARE, V197, P1540, DOI 10.1164/rccm.201710-2028PP
   Martinez FJ, 2017, AM J RESP CRIT CARE, V195, P748, DOI 10.1164/rccm.201603-0622OC
   MEAD J, 1978, J APPL PHYSIOL, V44, P156
   Medarov BI, 2008, INT J CLIN EXP MED, V1, P267
   MILLER RD, 1969, MAYO CLIN PROC, V44, P145
   MILLER RD, 1973, AM REV RESPIR DIS, V108, P475
   MORRIS JF, 1975, AM REV RESPIR DIS, V111, P755
   Morris ZQ, 2014, CHEST, V145, P662, DOI 10.1378/chest.13-2550
   Morris ZQ, 2013, CHEST, V144, P1117, DOI 10.1378/chest.12-2816
   Morris ZQ, 2012, COPD, V9, P22, DOI 10.3109/15412555.2012.630701
   Neve V, 2016, EUR RESPIR J, V48, P420, DOI 10.1183/13993003.01391-2015
   O'Donnell DE, 2017, ANN AM THORAC SOC, V14, pS30, DOI 10.1513/AnnalsATS.201610-834FR
   ODONNELL CR, 1990, CHEST, V98, P643, DOI 10.1378/chest.98.3.643
   Oh A, 2017, RESP CARE, V62, P928, DOI 10.4187/respcare.04850
   Oppenheimer BW, 2009, COPD, V6, P162, DOI 10.1080/15412550902918410
   Park HJ, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0896-7
   Patterson GM, 1996, J HEART LUNG TRANSPL, V15, P175
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pirozzi C. S., HETEROGENEOUS BURDEN
   Prats E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140855
   QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693
   Quanjer PH, 2014, EUR RESPIR J, V43, P1051, DOI 10.1183/09031936.00128113
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Regan EA, 2015, JAMA INTERN MED, V175, P1539, DOI 10.1001/jamainternmed.2015.2735
   REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132
   Rennard SI, 2015, SEMIN RESP CRIT CARE, V36, P478, DOI 10.1055/s-0035-1555609
   Rennard SI, 2015, LANCET, V385, P1778, DOI 10.1016/S0140-6736(15)60647-X
   Rennard SI, 2013, AM J RESP CRIT CARE, V187, P1036, DOI 10.1164/rccm.201212-2321ED
   Rodrigues MT, 2010, J BRAS PNEUMOL, V36, P44, DOI 10.1590/S1806-37132010000100009
   Rodriguez-Roisin R, 2017, AM J RESP CRIT CARE, V195, P17, DOI 10.1164/rccm.201607-1376PP
   Saint-Pierre M, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.PA2229
   SALTZMAN HP, 1976, CHEST, V69, P51, DOI 10.1378/chest.69.1.51
   Sanchez-Salcedo P, 2014, EUR RESPIR J, V44, P324, DOI 10.1183/09031936.00208613
   Schroeder JD, 2013, AM J ROENTGENOL, V201, pW460, DOI 10.2214/AJR.12.10102
   SHARMA M M, 1986, Indian Journal of Physiology and Pharmacology, V30, P329
   Shaykhiev Renat, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS252, DOI 10.1513/AnnalsATS.201402-049AW
   Siafakas N, 2018, RESP MED, V140, P127, DOI 10.1016/j.rmed.2018.06.007
   Singh D, 2017, TUBERC RESPIR DIS, V80, P317, DOI 10.4046/trd.2017.0080
   SORBELLO A, 1981, J AM OSTEOPATH ASSOC, V80, P731
   Sritippayawan S, 2003, PEDIATR TRANSPLANT, V7, P200, DOI 10.1034/j.1399-3046.2003.00069.x
   Staudt MR, 2014, AM J RESP CRIT CARE, V190, P955, DOI 10.1164/rccm.201406-1167LE
   Stein D, 2015, PNEUMOLOGIE, V69, P199, DOI 10.1055/s-0034-1391401
   Swanney MP, 2008, THORAX, V63, P1046, DOI 10.1136/thx.2008.098483
   Tantucci C, 2008, RESP MED, V102, P613, DOI 10.1016/j.rmed.2007.11.004
   Tantucci C, 2012, INT J CHRONIC OBSTR, V7, P95, DOI 10.2147/COPD.S27480
   Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785
   THURLBECK W. M., 1964, THORAX, V19, P436, DOI 10.1136/thx.19.5.436
   Topalovic M, 2015, RESPIROLOGY, V20, P925, DOI 10.1111/resp.12540
   Topalovic M, 2014, MED BIOL ENG COMPUT, V52, P997, DOI 10.1007/s11517-014-1202-6
   Topalovic M, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-131
   Van de Moortele T., 2017, CLIN BIOMECH
   VANBRABANDT H, 1983, J APPL PHYSIOL, V55, P1733
   Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707
   Vestbo J, 2014, AM J RESP CRIT CARE, V189, P1022, DOI 10.1164/rccm.201311-2006PP
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Vollmer WM, 2009, EUR RESPIR J, V34, P588, DOI 10.1183/09031936.00164608
   Wan ES, 2018, AM J RESP CRIT CARE, V198, P1397, DOI 10.1164/rccm.201804-0663OC
   Wang W, 2016, INT J CHRONIC OBSTR, V11, P3015, DOI 10.2147/COPD.S118415
   WEBSTER PM, 1977, AM REV RESPIR DIS, V115, P805
   Weiner DJ, 2016, ANN AM THORAC SOC, V13, P1089, DOI 10.1513/AnnalsATS.201511-774OC
   Williams EM, 2014, J CLIN MONIT COMPUT, V28, P67, DOI 10.1007/s10877-013-9497-7
   Woodruff PG, 2016, NEW ENGL J MED, V374, P1811, DOI 10.1056/NEJMoa1505971
   Yetkin O, 2008, CLIN RESPIR J, V2, P36, DOI 10.1111/j.1752-699X.2007.00040.x
   Yuan W, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-16
   Zaman M, 2010, AM J MED SCI, V339, P411, DOI 10.1097/MAJ.0b013e3181d6578c
   Zapletal A, 2008, RESPIRATION, V75, P40, DOI 10.1159/000099615
   Zheng CJ, 2006, RESPIR CARE, V51, P40
NR 141
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 58
EP 68
DI 10.1016/j.rmed.2019.08.004
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800009
PM 31437649
DA 2020-05-18
ER

PT J
AU Roden, L
   Gorlich, D
   Omran, H
   Peters, G
   Grosse-Onnebrink, J
   Kahl, BC
AF Roden, Lukas
   Goerlich, Dennis
   Omran, Heymut
   Peters, Georg
   Grosse-Onnebrink, Jorg
   Kahl, Barbara C.
TI A retrospective analysis of the pathogens in the airways of patients
   with primary ciliary dyskinesia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE P. aeruginosa; S. aureus; Primary ciliary dyskinesia; Lung function;
   Prevalence; Susceptibility; Microbiological diversity
ID PSEUDOMONAS-AERUGINOSA; BACTERIAL COMMUNITIES; STAPHYLOCOCCUS-AUREUS;
   LUNG-FUNCTION; COLONIZATION; AGE; STABILITY; SPECIMENS; GENOTYPE; IMPACT
AB Introduction: Primary ciliary dyskinesia (PCD) is a rare genetically heterogeneous disorder of motile cilia, which leads to recurrent and chronic airway infections. Detailed information about infection causing pathogens is scarce. With this study, we aimed to determine the prevalence and susceptibility of the most common respiratory pathogens in PCD patients retrospectively in a cross-sectional and the dynamics of the microbiological diversity in a longitudinal study.
   Methods: Microbiological and clinical data of 106 patients between 2010 and 2016 were analysed cross-sectionally and of 28 patients longitudinally. Dynamics in microbiological diversity were assessed by calculating the mean rate of alteration (MRA).
   Results: Haemophilus influenzae was the most common pathogen (n=41; 38.7%) followed by Staphylococcus aureus (n=36; 34%), Moraxella catarrhalis (n=18; 17%) and Pseudomonas aeruginosa (n=16; 15.1%). Nontuberculous mycobacteria were cultured from two patients (1.9%). H. influenzae was the most prevalent pathogen in children (n=31; 45.6%), S. aureus in adults (n=15; 39%). Two patients were infected by methicillin-resistant S. aureus. P. aeruginosa was mostly susceptible to standard antibiotics with highest rates of resistance against fosfomycin (63.6%; 7/11). The culture of P. aeruginosa correlated negatively with age adjusted FEV1% predicted (p=0.04), while the MRA was positively associated with age (rho 0.411, p=0.032).
   Discussion: In PCD patients, the prevalence of pathogens differed in children and adults with H. influenzae and S. aureus being the most common pathogens in children, S. aureus and P. aeruginosa in adults, respectively. Unexpectedly, the MRA increased by age.
C1 [Roden, Lukas; Peters, Georg; Kahl, Barbara C.] Univ Hosp Munster, Inst Med Microbiol, Domagkstr 10, D-48149 Munster, Germany.
   [Goerlich, Dennis] Univ Hosp Munster, Inst Biostat & Clin Res, Munster, Germany.
   [Omran, Heymut; Grosse-Onnebrink, Jorg] Univ Hosp Munster, Dept Gen Pediat, Munster, Germany.
RP Kahl, BC (reprint author), Univ Hosp Munster, Inst Med Microbiol, Domagkstr 10, D-48149 Munster, Germany.
EM l_rode04@uni-muenster.de; dennis.goerlich@ukmuenster.de;
   heymut.omran@ukmuenster.de; georg.peters@uni-muenster.de;
   joerg.grosse-onnebrink@ukmuenster.de; kahl@uni-muenster.de
RI Gorlich, Dennis/C-8950-2012
OI Gorlich, Dennis/0000-0002-2574-9419; Kahl, Barbara/0000-0001-5155-3383
CR Afzelius BA, 2004, J PATHOL, V204, P470, DOI 10.1002/path.1652
   Alanin MC, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.08.020
   Angrill J, 2002, THORAX, V57, P15, DOI 10.1136/thorax.57.1.15
   Armbruster CE, 2010, MBIO, V1, DOI 10.1128/mBio.00102-10
   Blainey PC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004458
   Cohen-Cymberknoh M, 2017, RESP MED, V131, P241, DOI 10.1016/j.rmed.2017.08.028
   Cystic Fibrosis Foundation, 2015, CFF PAT REG ANN DAT, V2016
   Dasenbrook EC, 2008, AM J RESP CRIT CARE, V178, P814, DOI 10.1164/rccm.200802-327OC
   Davies G, 2006, EUR RESPIR J, V28, P974, DOI 10.1183/09031936.06.00074605
   Davis SD, 2015, AM J RESP CRIT CARE, V191, P316, DOI 10.1164/rccm.201409-1672OC
   Frija-Masson J, 2017, THORAX, V72, P154, DOI 10.1136/thoraxjnl-2015-207891
   Goddard AF, 2012, P NATL ACAD SCI USA, V109, P13769, DOI 10.1073/pnas.1107435109
   Hogardt M., 2006, ATEMWEGSINFEKTIONEN
   King PT, 2007, RESP MED, V101, P1633, DOI 10.1016/j.rmed.2007.03.009
   Klepac-Ceraj V, 2010, ENVIRON MICROBIOL, V12, P1293, DOI 10.1111/j.1462-2920.2010.02173.x
   Krishnamurthy A, 2009, MICROBES INFECT, V11, P545, DOI 10.1016/j.micinf.2009.03.001
   Kuehni CE, 2010, EUR RESPIR J, V36, P1248, DOI 10.1183/09031936.00001010
   Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8
   Lobo J, 2015, SEMIN RESP CRIT CARE, V36, P169, DOI 10.1055/s-0035-1546748
   Lucas JS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01090-2016
   Maglione M, 2014, PEDIATR PULM, V49, P1243, DOI 10.1002/ppul.22984
   Mirra V, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00135
   Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC
   Parker D, 2012, SEMIN IMMUNOPATHOL, V34, P281, DOI 10.1007/s00281-011-0291-7
   Pena MT, 2013, JAMA OTOLARYNGOL, V139, P223, DOI 10.1001/jamaoto.2013.1703
   Peters BM, 2012, CLIN MICROBIOL REV, V25, P193, DOI 10.1128/CMR.00013-11
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Raidt L, 2015, PEDIATR INFECT DIS J, V34, P700, DOI 10.1097/INF.0000000000000714
   REVILLA E, 2016, ERJ OPEN RES, V2, DOI DOI 10.1183/23120541.00096-1993(02)00141-8
   Rogers GB, 2013, J CLIN MICROBIOL, V51, P4029, DOI 10.1128/JCM.02164-13
   Shah A, 2016, EUR RESPIR J, V48, P441, DOI 10.1183/13993003.00209-2016
   Silby MW, 2011, FEMS MICROBIOL REV, V35, P652, DOI 10.1111/j.1574-6976.2011.00269.x
   Sommer LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28732
   Stover CK, 2000, NATURE, V406, P959
   Stressmann FA, 2012, THORAX, V67, P867, DOI 10.1136/thoraxjnl-2011-200932
   Werner Claudius, 2015, Cilia, V4, P2, DOI 10.1186/s13630-014-0011-8
   Winstanley C, 2016, TRENDS MICROBIOL, V24, P327, DOI 10.1016/j.tim.2016.01.008
   Zhao JC, 2012, P NATL ACAD SCI USA, V109, P5809, DOI 10.1073/pnas.1120577109
NR 38
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 69
EP 77
DI 10.1016/j.rmed.2019.08.009
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800010
PM 31437650
DA 2020-05-18
ER

PT J
AU Vancheri, C
   Sebastiani, A
   Tomassetti, S
   Pesci, A
   Rogliani, P
   Tavanti, L
   Luppi, F
   Harari, S
   Rottoli, P
   Ghirardini, A
   Kirchgaessler, KU
   Albera, C
AF Vancheri, Carlo
   Sebastiani, Alfredo
   Tomassetti, Sara
   Pesci, Alberto
   Rogliani, Paola
   Tavanti, Laura
   Luppi, Fabrizio
   Harari, Sergio
   Rottoli, Paola
   Ghirardini, Alessandra
   Kirchgaessler, Klaus-Uwe
   Albera, Carlo
TI Pirfenidone in real life: A retrospective observational multicentre
   study in Italian patients with idiopathic pulmonary fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Interstitial lung disease; Antifibrotic therapy; Effectiveness; Disease
   progression; Pirfenidone
ID LONG-TERM SAFETY; CLINICAL-TRIALS; DIAGNOSIS; EFFICACY
AB Rationale: Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (IPF) are limited. This study assessed the effectiveness of pirfenidone in a large real-life Italian IPF cohort.
   Methods: IRENE was an observational, retrospective study of patients with IPF treated with pirfenidone in routine clinical practice (18 centres). At Month 6, a mandatory re-evaluation of forced vital capacity (FVC) decline (absolute change < 10%) was required to continue pirfenidone. The primary effectiveness outcomes were absolute change from baseline in FVC and the percentage of patients with >= 10% absolute decline in % predicted FVC at Month 12. Safety was described by adverse event (AE) occurrence. Prespecified subgroups included sex, age, presence/absence of emphysema, usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography, and baseline lung function.
   Results: The study included 379 patients (mean age, 67.6 years; 78.1% male). Mean change from baseline in FVC and the percentage of patients with >= 10% absolute decline in % predicted FVC at Month 12 were -81.8 mL (SD, 419.6 mL; P=0.002) and 16.0% (95% CI, 12.2-20.9%), respectively. Disease progression was similar across prespecified subgroups, including patients with definite vs possible UIP. Overall, 211 AEs occurred in 149 patients (39.3%), with serious AEs in 31 patients (8.2%) and 9 discontinuations due to AEs. Skin and gastrointestinal AEs were most frequent. Fifteen patients (4.0%) died.
   Conclusions: The decline in FVC and the safety profile observed in this real-world IPF cohort were consistent with the findings of the Phase III pirfenidone trials.
C1 [Vancheri, Carlo] Univ Catania, Catania, Italy.
   [Sebastiani, Alfredo] San Camillo Forlanini Hosp, Rome, Italy.
   [Tomassetti, Sara] Osped GB Morgagni, Dept Dis Thorax, Forli, Italy.
   [Pesci, Alberto] Univ Milano Bicocca, Monza, Italy.
   [Rogliani, Paola] Univ Rome, Resp Unit, Rome, Italy.
   [Tavanti, Laura] Univ Hosp Pisa, Pisa, Italy.
   [Luppi, Fabrizio] Univ Hosp Policlin Modena, Modena, Italy.
   [Harari, Sergio] MultiMed IRCCS, Osped San Giuseppe, Milan, Italy.
   [Rottoli, Paola] AOUS Univ Siena, Resp Dis Unit, Siena, Italy.
   [Ghirardini, Alessandra] Roche SpA, Monza, Italy.
   [Kirchgaessler, Klaus-Uwe] F Hoffmann La Roche Ltd, Basel, Switzerland.
   [Albera, Carlo] Univ Turin, Turin, Italy.
RP Vancheri, C (reprint author), Univ Catania, Dept Resp Med, Via Santa Sofia 78, I-95125 Catania, Italy.
EM vancheri@unict.it
RI Luppi, Fabrizio/AAG-8099-2019
OI LUPPI, FABRIZIO/0000-0001-5775-5947; Rogliani, Paola/0000-0001-7801-5040
FU F. Hoffmann-La Roche Ltd./Genentech, Inc.Hoffmann-La RocheRoche
   HoldingGenentech
FX This work was supported by F. Hoffmann-La Roche Ltd./Genentech, Inc.
CR Chaudhuri N, 2014, RESP MED, V108, P224, DOI 10.1016/j.rmed.2013.11.005
   Conti S, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00397-2017
   Costabel U, 2017, RESPIRATION, V94, P408, DOI 10.1159/000479976
   Cottin V., 2018, ERJ OPEN RES, P4
   Cottin V, 2015, EUR RESPIR REV, V24, P58, DOI 10.1183/09059180.00011514
   Gotfried Mark H, 2018, Pulm Ther, V4, P59, DOI 10.1007/s41030-018-0053-y
   Guenther A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0845-5
   Harari S, 2015, RESP MED, V109, P904, DOI 10.1016/j.rmed.2015.04.010
   Harari S, 2015, EUR RESPIR REV, V24, P420, DOI 10.1183/16000617.0042-2015
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Lancaster L, 2016, AM J RESP CRIT CARE, V193
   Lancaster Lisa, 2017, Pulm Ther, V3, P317, DOI 10.1007/s41030-017-0049-z
   Lancaster L, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000105
   Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Loeh B, 2015, AM J RESP CRIT CARE, V191, P110, DOI 10.1164/rccm.201406-1106LE
   Lynch DA, 2018, LANCET RESP MED, V6, P138, DOI 10.1016/S2213-2600(17)30433-2
   Mason WR, 2017, AM J RESP CRIT CARE, V195
   Nathan SD, 2017, LANCET RESP MED, V5, P33, DOI 10.1016/S2213-2600(16)30326-5
   Nathan SD, 2016, THORAX, V71, P429, DOI 10.1136/thoraxjnl-2015-207011
   Noble PW, 2016, EUR RESPIR J, V47, P243, DOI 10.1183/13993003.00026-2015
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Ogura T, 2015, RESPIR INVESTIG, V53, P232, DOI 10.1016/j.resinv.2015.06.001
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Ryerson C, 2020, CAN J RESP CRIT CARE, V4, P25, DOI 10.1080/24745332.2019.1586496
   Tzouvelekis A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00213
   Valeyre D, 2014, RESPIROLOGY, V19, P740, DOI 10.1111/resp.12297
NR 30
TC 3
Z9 3
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD SEP
PY 2019
VL 156
BP 78
EP 84
DI 10.1016/j.rmed.2019.08.006
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IU9SD
UT WOS:000483919800011
PM 31445389
DA 2020-05-18
ER

PT J
AU Ozyigit, LP
   Aktas, EC
   Senbas, ZA
   Ozturk, AB
   Ozturk, E
   Ergonul, MO
   Tabak, L
   Ferhanoglu, B
   Cetiner, M
   Deniz, G
AF Ozyigit, Leyla Pur
   Aktas, Esin Cetin
   Senbas, Zarif Asucan
   Ozturk, Ayse Bilge
   Ozturk, Erman
   Ergonul, Mehmet Onder
   Tabak, Levent
   Ferhanoglu, Burhan
   Cetiner, Mustafa
   Deniz, Gunnur
TI The role of atopy in the pathogenesis of bleomycin pulmonary toxicity
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Atopy; Bleomycin; Pulmonary toxicity; Bleomycin hydrolase; Amphiregulin
ID LUNG FIBROSIS; AMPHIREGULIN; EXPRESSION; RESPONSES; THERAPY; DISEASE;
   INJURY; TESTS
AB Introduction: Bleomycin pulmonary toxicity (BPT) is a potentially life-threatening consequence of bleomycin usage in patients. An overproduction of epithelium-derived cytokines, habitually linked to allergic inflammation, has been recently revealed in experimental models of BPT.
   Methods: We assessed retrospectively our cohort of patients with Hodgkin Lymphoma treated with bleomycin between 2014 and 2016 for their demographic, clinical features, including BPT development, atopy status and risk factors for BPT. Then they were invited for allergy testing and blood sample collection. The samples were stimulated with different stimuli (Bleomycin, IL-33, TSLP) for 24 h on cell culture. The culture supernatants were analysed for TGF-beta, Galectin3, Arginin, Amphiregulin, Eotaxin, IFN gamma, TNF alpha, IL1 beta, 4, 5, 6, 10, 13, 17, MIP-1 alpha, and bleomycin hydrolase (BLH) levels.
   Results: The cohort consisted of 51 patients showed that atopy was the only significant risk factor for BPT occurrence (OR: 7.2, p=0.007). Fourteen subjects were included for blood analysis. The analysis of supernatants at the unstimulated condition revealed that BLH and Amphiregulin were significantly lower in patients who had BPT than controls. The BLH cut-off that best identified a history of BPT was 175.31 (Sensitivity: 62.5%, specificity: 100%). Following the stimulation, BLH reduced compared to the unstimulated condition and the difference between groups remained significant (p < 0.05).
   Conclusion: Our study is the first to report that low levels of bleomycin hydrolase in allergic individuals may be predisposing to a possible pathway of fibrosis.
C1 [Ozyigit, Leyla Pur; Senbas, Zarif Asucan] Koc Univ, Sch Med, Dept Allergy & Immunol, Istanbul, Turkey.
   [Aktas, Esin Cetin; Deniz, Gunnur] Istanbul Univ, Aziz Sancar Inst Expt Med, Dept Immunol, Istanbul, Turkey.
   [Ozturk, Ayse Bilge] Koc Univ Hosp, Dept Allergy & Immunol, Istanbul, Turkey.
   [Ozturk, Erman] Koc Univ Hosp, Dept Haematol, Istanbul, Turkey.
   [Ergonul, Mehmet Onder] Koc Univ, Sch Med, Dept Infect Dis, Istanbul, Turkey.
   [Tabak, Levent] Koc Univ, Sch Med, Dept Resp Med, Istanbul, Turkey.
   [Ferhanoglu, Burhan; Cetiner, Mustafa] Koc Univ, Sch Med, Dept Haematol, Istanbul, Turkey.
RP Ozyigit, LP (reprint author), Koc Univ, Sch Med, Dept Allergy & Immunol, Istanbul, Turkey.
EM lozyigit@ku.edu.tr
RI Deniz, Gunnur/AAC-2909-2020; Ozyigit, Leyla Pur/O-9045-2015
OI Ozyigit, Leyla Pur/0000-0002-7113-9988; Ergonul,
   Onder/0000-0003-1935-9235
FU Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [116S019]
FX This work was supported by the Scientific and Technological Research
   Council of Turkey (TUBITAK), (Grant No: 116S019). The funder of the
   study had no role in study design, data collection, data analysis, data
   interpretation, or writing of the report. The author had access to all
   the data in the study, and made the final decision to submit for
   publication.
CR Azambuja E, 2005, PULM PHARMACOL THER, V18, P363, DOI 10.1016/j.pupt.2005.01.007
   Barbarin V, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-112
   Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x
   Datta A, 2013, J IMMUNOL, V191, P4867, DOI 10.4049/jimmunol.1300588
   Ding L, 2016, J IMMUNOL, V197, P303, DOI 10.4049/jimmunol.1502479
   Falay O, 2017, LEUKEMIA LYMPHOMA, V58, P1114, DOI 10.1080/10428194.2016.1236379
   FILDERMAN AE, 1988, BIOCHEM PHARMACOL, V37, P1111, DOI 10.1016/0006-2952(88)90518-7
   Frankovich J, 2001, BIOL BLOOD MARROW TR, V7, P49, DOI 10.1053/bbmt.2001.v7.pm11215699
   Fukumoto J, 2010, AM J PHYSIOL-LUNG C, V298, pL131, DOI 10.1152/ajplung.90576.2008
   GharaeeKermani M, 1997, AM J RESP CELL MOL, V16, P438, DOI 10.1165/ajrcmb.16.4.9115755
   Ho JE, 2016, AM J RESP CRIT CARE, V194, P77, DOI 10.1164/rccm.201509-1753OC
   Hoyle GW, 2001, AM J RESP CELL MOL, V24, P365, DOI 10.1165/ajrcmb.24.4.f205
   Huaux F, 2003, J IMMUNOL, V171, P5470, DOI 10.4049/jimmunol.171.10.5470
   Jona A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157651
   Kamata Y, 2011, J BIOL CHEM, V286, P8204, DOI 10.1074/jbc.M110.169292
   Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200
   Lee HC, 2013, HEPATOLOGY, V57, P1314, DOI 10.1002/hep.26128
   Lee Jimin, 2017, Animal Systematics Evolution and Diversity, V33, P17, DOI 10.5635/ASED.2017.33.1.058
   LEWIS BM, 1980, JAMA-J AM MED ASSOC, V243, P347, DOI 10.1001/jama.243.4.347
   LI D, 2014, J ALLERGY CLIN IMMUN, V13
   MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106-0965OC
   Madabhavi I, 2017, J CANCER RES THER, V13, P466, DOI 10.4103/0973-1482.204887
   Martin WG, 2005, J CLIN ONCOL, V23, P7614, DOI 10.1200/JCO.2005.02.7243
   Mizutani N, 2015, IMMUNOLOGY, V146, P568, DOI 10.1111/imm.12528
   Pellerin L, 2014, J ALLERGY CLIN IMMUN, V134, P1459, DOI 10.1016/j.jaci.2014.07.056
   Pendaries V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.29
   Saito F, 2008, AM J RESP CELL MOL, V38, P566, DOI 10.1165/rcmb.2007-0299OC
   SIKIC BI, 1986, CANCER SURV, V5, P81
   Simpson AB, 1998, BRIT J CANCER, V78, P1061, DOI 10.1038/bjc.1998.628
   Sleijfer S, 2001, CHEST, V120, P617, DOI 10.1378/chest.120.2.617
   Smith RE, 1998, J LEUKOCYTE BIOL, V64, P528
   Sun HW, 2017, LEUKEMIA LYMPHOMA, V58, P2607, DOI 10.1080/10428194.2017.1307980
   Tashiro J, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00118
   Wang SW, 2005, J ALLERGY CLIN IMMUN, V115, P287, DOI 10.1016/j.jaci.2004.11.037
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020
NR 36
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 1
EP 5
DI 10.1016/j.rmed.2019.06.020
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500001
PM 31255902
DA 2020-05-18
ER

PT J
AU Grosso, A
   Pesce, G
   Marcon, A
   Piloni, D
   Albicini, F
   Gini, E
   Marchetti, P
   Battaglia, S
   Ferrari, M
   Fois, A
   Piccioni, P
   Antonicelli, L
   Verlato, G
   Corsico, AG
AF Grosso, Amelia
   Pesce, Giancarlo
   Marcon, Alessandro
   Piloni, Davide
   Albicini, Federica
   Gini, Erica
   Marchetti, Pierpaolo
   Battaglia, Salvatore
   Ferrari, Marcello
   Fois, Alessandro
   Piccioni, Pavilio
   Antonicelli, Leonardo
   Verlato, Giuseppe
   Corsico, Angelo Guido
TI Depression is associated with poor control of symptoms in asthma and
   rhinitis: A population-based study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma control; Atopy; Depression; General population; Rhinitis control
ID QUALITY-OF-LIFE; PRIMARY-CARE; PSYCHOLOGICAL DISTRESS; MENTAL-DISORDERS;
   MILD ASTHMA; HEALTH; IMPACT; ADULTS; RISK; DISEASES
AB Background: Although many studies have highlighted the link between asthma/rhinitis and depression, it is still unclear which characteristics of these diseases are associated with the risk of depression. We aimed to explore the relationship between depression and asthma or rhinitis in a representative sample of the Italian general population.
   Methods: The data were collected in GEIRD, an Italian multicenter, population-based, multicase-control study. 2227 participants (age 21-86 years, female 50%) underwent standardized interviews, skin prick and lung function tests, and were divided into cases of current asthma (n=528), rhinitis without asthma (n=972), and controls (n=727). Two specific questions from the Patient Health Questionnaire (PHQ-2) were asked to identify symptoms of depressed mood and anhedonia, which were used as a proxy of major depression disorder.
   Results: The prevalence of depression was 16.7%, 11.9%, and 5.1% in subjects with asthma, rhinitis and controls, respectively. Both in asthma and rhinitis, subjects with depression had worse respiratory-health related quality of life and more frequent disease-related symptoms than their non-depressed counterparts. In asthma, depression was associated with poorer disease control. In rhinitis, depression was significantly associated with a disease-related limitations in daily activities and greater risk of symptom exacerbations and prescriptions of medicines for breathing. Cases of rhinitis with depression were less likely to be atopic.
   Conclusions: Our results suggest that rhinitis exacerbations, particularly in non-atopic subjects, and low asthma control are strongly related to the presence of depressed mood in adults from the general population.
C1 [Grosso, Amelia; Piloni, Davide; Albicini, Federica; Gini, Erica; Corsico, Angelo Guido] Univ Pavia, IRCCS San Matteo Hosp Fdn, Div Resp Dis, Pavia, Italy.
   [Pesce, Giancarlo; Marcon, Alessandro; Marchetti, Pierpaolo; Verlato, Giuseppe] Univ Verona, Dept Diagnost & Publ Hlth, Unit Epidemiol & Med Stat, Verona, Italy.
   [Pesce, Giancarlo] Sorbonne Univ, INSERM, IPLESP, Unit Epidemiol Allerg & Resp Dis EPAR, F-75012 Paris, France.
   [Battaglia, Salvatore] Univ Palermo, Dept Sci & Promot Hlth & Maternal Infancy G DAles, Palermo, Italy.
   [Ferrari, Marcello] Univ Verona, Sect Resp Med, Dept Med, Verona, Italy.
   [Fois, Alessandro] Univ Sassari, Dept Clin Surg & Expt Sci, Sassari, Italy.
   [Piccioni, Pavilio] ASL TO2, Natl Hlth Serv, Unit Resp Med, Turin, Italy.
   [Antonicelli, Leonardo] Univ Hosp, Allergol Unit, Ancona, Italy.
RP Grosso, A (reprint author), Univ Pavia, IRCCS San Matteo Hosp Fdn, Div Resp Dis, Pavia, Italy.
EM amelia.grosso@gmail.com
RI Corsico, Angelo Guido/AAC-8138-2019; Piloni, Davide/K-6331-2016;
   Battaglia, Salvatore/D-7042-2015; Grosso, Amelia/Y-9632-2019
OI Corsico, Angelo Guido/0000-0002-8716-4694; Piloni,
   Davide/0000-0002-7275-4229; Battaglia, Salvatore/0000-0002-2867-917X;
   Grosso, Amelia/0000-0002-4442-8522; Gini, Erica/0000-0003-4843-5890;
   Pesce, Giancarlo/0000-0003-4925-6325; Marchetti,
   Pierpaolo/0000-0003-4139-925X
FU Cariverona FoundationFondazione Cariverona; Italian Ministry of
   HealthMinistry of Health, Italy [RF-2009-1471235]; Italian Medicines
   Agency (AIFA); Chiesi Farmaceutici
FX The GEIRD project was funded by the Cariverona Foundation (Bando 2006),
   the Italian Ministry of Health (RF-2009-1471235), Chiesi Farmaceutici
   and the Italian Medicines Agency (AIFA). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams RJ, 2004, THORAX, V59, P930, DOI 10.1136/thx.2003.010256
   Amritwar Ameya U, 2017, Curr Treat Options Allergy, V4, P71, DOI 10.1007/s40521-017-0110-z
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Arroll B, 2003, BMJ-BRIT MED J, V327, P1144, DOI 10.1136/bmj.327.7424.1144
   Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139
   Baiardini I, 2003, ALLERGY, V58, P289, DOI 10.1034/j.1398-9995.2003.00079.x
   Bedolla-Barajas M, 2017, BRAZ J OTORHINOLAR, V83, P432, DOI 10.1016/j.bjorl.2016.05.008
   Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Braido F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031178
   Brandsted R, 2007, AM J RHINOL, V21, P50, DOI 10.2500/ajr.2007.21.2987
   BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160
   Chapman KR, 2005, RESP MED, V99, P1350, DOI 10.1016/j.rmed.2005.03.020
   Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495
   de Man-van Ginkel JM, 2012, NURS RES, V61, P333, DOI 10.1097/NNR.0b013e31825d9e9e
   de Marco R, 2010, INT ARCH ALLERGY IMM, V152, P255, DOI 10.1159/000283034
   de Menezes ST, 2017, J AFFECT DISORDERS, V208, P448, DOI 10.1016/j.jad.2016.10.046
   Erskine SE, 2017, RHINOLOGY, V55, P113, DOI [10.4193/Rhino16.111, 10.4193/Rhin16.111]
   Feldman JM, 2005, PSYCHOSOM MED, V67, P989, DOI 10.1097/01.psy.0000188556.97979.13
   Fleming S. L., 2004, COCHRANE DB SYST REV, V1
   Goodwin RD, 2003, ARCH GEN PSYCHIAT, V60, P1125, DOI 10.1001/archpsyc.60.11.1125
   Gotlib IH, 2010, ANNU REV CLIN PSYCHO, V6, P285, DOI 10.1146/annurev.clinpsy.121208.131305
   Guglani L, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-45
   Haddad M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078493
   Lind N, 2014, PSYCHOL HEALTH MED, V19, P316, DOI 10.1080/13548506.2013.806814
   Lisspers K, 2018, RESP MED, V136, P15, DOI 10.1016/j.rmed.2018.01.020
   Lu ZY, 2018, ANN ALLERG ASTHMA IM, V120, P310, DOI 10.1016/j.anai.2017.12.011
   Mailing H. J., 1993, ALLERGY, V48, P55, DOI DOI 10.1111/J.1398-9995.1993.TB04757.X
   Marcon A, 2013, INT ARCH ALLERGY IMM, V161, P181, DOI 10.1159/000345137
   Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Opolski M, 2005, CLIN PRACTICE EPIDEM, V27, P1
   Oraka E, 2010, CHEST, V137, P609, DOI 10.1378/chest.09-1777
   Papadopoulos NG, 2015, ALLERGY, V70, P474, DOI 10.1111/all.12573
   Phillips KM, 2017, OTOLARYNG HEAD NECK, V157, P150, DOI 10.1177/0194599817696294
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Sanna L, 2014, J AFFECT DISORDERS, V155, P261, DOI 10.1016/j.jad.2013.11.009
   Sastre J, 2018, J ALLER CL IMM-PRACT, V6, P1953, DOI 10.1016/j.jaip.2018.02.002
   Schlosser RJ, 2016, AM J RHINOL ALLERGY, V30, P250, DOI 10.2500/ajra.2016.30.4343
   Scott KM, 2007, GEN HOSP PSYCHIAT, V29, P123, DOI 10.1016/j.genhosppsych.2006.12.006
   Seino Y, 2018, INTERNAL MED, V57, P1967, DOI 10.2169/internalmedicine.9073-17
   Shin JH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191115
   Steppuhn H, 2014, PRIM CARE RESP J, V23, P22, DOI 10.4104/pcrj.2013.00107
   Strine TW, 2008, J ASTHMA, V45, P123, DOI 10.1080/02770900701840238
   Tay TR, 2018, ALLERGY, V73, P1369, DOI 10.1111/all.13370
   Thom R, 2019, PSYCHOSOM MED, V81, P246, DOI 10.1097/PSY.0000000000000678
   Tomoum MO, 2015, INT FORUM ALLERGY RH, V5, P674, DOI 10.1002/alr.21528
   Van Lieshout RJ, 2009, PSYCHOSOM MED, V71, P187, DOI 10.1097/PSY.0b013e3181907012
   Walters P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020750
   Wong KO, 2013, PULM MED, V2013, DOI 10.1155/2013/929028
NR 50
TC 1
Z9 1
U1 1
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 6
EP 12
DI 10.1016/j.rmed.2019.06.025
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500002
PM 31272012
DA 2020-05-18
ER

PT J
AU Milesi, I
   Porta, R
   Barbano, L
   Cacciatore, S
   Vitacca, M
   Dellaca, RL
AF Milesi, Ilaria
   Porta, Roberto
   Barbano, Luca
   Cacciatore, Simona
   Vitacca, Michele
   Dellaca, Raffaele L.
TI Automatic tailoring of the lowest PEEP to abolish tidal expiratory flow
   limitation in seated and supine COPD patients
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Lung function monitoring; Forced oscillation technique; Non-invasive
   ventilation; Intrinsic PEEP; Supine position
ID PRESSURE SUPPORT VENTILATION; FORCED OSCILLATION; ASSOCIATION
AB Rationale: In COPD patients, the development of tidal expiratory flow limitation (EFLT) results in intrinsic positive end-expiratory pressure (PEEPi), leading to increased work of breathing and worsening patient-ventilator interaction. An external PEEP can mitigate these consequences, but how to optimize its value it is still unknown.
   Objective: To measure the minimum PEEP able to abolish EFLT by a new automatic non-invasive ventilation (NIV) mode in stable hypercapnic COPD patients in the seated and supine positions.
   Methods: Twenty-six hypercapnic COPD patients (mean +/- SD: FEV1%pred=39.2 +/- 16.1, FEV1/FVC% pred=46.3 +/- 16.3%) were studied while receiving NIV during two consecutive 15-min periods, with patients studied seated in the first and supine in the second. A ventilator able to identify EFLT breath-by-breath by using the forced oscillation technique optimized in real-time PEEP to the lowest pressure able to abolish EFLT (PEEPO).
   Results: The ventilator was always able to identify a PEEPO. Its values were highly variable among patients and increased from median(iqr) 4.0 (0.03) (range: 4.0-8.3cmH(2)O) to 6 (6.1) cmH(2)O (range: 4.0-15.7 cmH(2)O) when patients moved from the seated to the supine position, respectively. PEEPO in supine position did not correlate to any spirometric or anthropometric variable.
   Conclusions: PEEPO in COPD patients is highly variable and increases in supine position. It is not predicted by spirometric nor anthropometric variables, but had a considerable variability among the patients. We suggest that PEEPo may be used as a phenotyping variable in COPD patients.
C1 [Milesi, Ilaria; Cacciatore, Simona; Dellaca, Raffaele L.] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Via Giuseppe Colombo 40, I-20133 Milan, Italy.
   [Porta, Roberto; Barbano, Luca; Vitacca, Michele] Ist Clin Sci Maugeri IRCCS, Pneumol Riabilitat Ist Lumezzane, Brescia, Italy.
RP Dellaca, RL (reprint author), Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Via Giuseppe Colombo 40, I-20133 Milan, Italy.
EM raffaele.dellaca@polimi.it
RI Dellaca', Raffaele/AAF-7078-2019; Barbano, Luca/AAB-8941-2020; VITACCA,
   MICHELE/AAB-8883-2020
OI Dellaca', Raffaele/0000-0002-3672-4591; Barbano,
   Luca/0000-0002-2450-1497; VITACCA, MICHELE/0000-0002-9389-7915
FU Philips
FX Istituti Clinici Scientifici Maugeri received a free loan of part of the
   equipment used for this study and a research grant from Philips.
CR Aarli BB, 2017, INT J CHRONIC OBSTR, V12, P2179, DOI 10.2147/COPD.S138720
   Akita T, 2016, RESP PHYSIOL NEUROBI, V220, P62, DOI 10.1016/j.resp.2015.09.002
   Aliverti A, 2001, ANN BIOMED ENG, V29, P60, DOI 10.1114/1.1332084
   AMBROSINO N, 1993, THORAX, V48, P523, DOI 10.1136/thx.48.5.523
   Ambrosino N, 2017, COPD, V14, P396, DOI 10.1080/15412555.2017.1298582
   Appendini L, 1996, AM J RESP CRIT CARE, V154, P1301, DOI 10.1164/ajrccm.154.5.8912740
   BAIGORRI F, 1994, CRIT CARE MED, V22, P1782
   Boni E, 2002, THORAX, V57, P528, DOI 10.1136/thorax.57.6.528
   Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304
   COUSSA ML, 1993, J APPL PHYSIOL, V75, P1711
   DAWSON SV, 1977, J APPL PHYSIOL, V43, P498
   Dellaca RL, 2007, EUR RESPIR J, V29, P363, DOI 10.1183/09031936.00038006
   Dellaca RL, 2009, EUR RESPIR J, V33, P1329, DOI 10.1183/09031936.00139608
   Dellaca RL, 2006, EUR RESPIR J, V27, P983, DOI 10.1183/09031936.06.00080005
   Dellaca RL, 2004, EUR RESPIR J, V23, P232, DOI 10.1183/09031936.04.00046804
   ELLIOTT MW, 1993, ANAESTHESIA, V48, P8
   Global Strategy for the Diagnosis Management and Prevention of COPD., 2017, GLOBAL STRATEGY DIAG
   Krieger BP, 2009, RESPIRATION, V77, P344, DOI 10.1159/000192790
   MEAD J, 1953, J APPL PHYSIOL, V5, P779
   Nava S, 1997, EUR RESPIR J, V10, P177, DOI 10.1183/09031936.97.10010177
   PATEL H, 1995, CRIT CARE MED, V23, P1074, DOI 10.1097/00003246-199506000-00013
   Ranieri VM, 1996, EUR RESPIR J, V9, P1283, DOI 10.1183/09031936.96.09061283
   Vitacca M, 2000, CHEST, V118, P1286, DOI 10.1378/chest.118.5.1286
   Vitacca M, 2004, Monaldi Arch Chest Dis, V61, P81
NR 24
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 13
EP 18
DI 10.1016/j.rmed.2019.06.022
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500003
PM 31276979
DA 2020-05-18
ER

PT J
AU Walters, GI
   Mokhlis, JM
   Moore, VC
   Robertson, AS
   Burge, GA
   Bhomra, PS
   Burge, PS
AF Walters, Gareth I.
   Mokhlis, Justin M.
   Moore, Vicky C.
   Robertson, Alastair S.
   Burge, Geraldine A.
   Bhomra, Parminder S.
   Burge, P. Sherwood
TI Characteristics of hypersensitivity pneumonitis diagnosed by
   interstitial and occupational lung disease multi-disciplinary team
   consensus
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Hypersensitivity pneumonitis; Metalworking fluid; Interstitial lung
   disease; Diagnosis; Avian protein
ID SURVIVAL; FIBROSIS; ANTIGEN
AB Introduction: The causes of hypersensitivity pneumonitis (HP) in the UK are changing as working practices evolve, and metalworking fluid (MWF) is now a frequently reported causative exposure. We aimed to review and describe all cases of HP from our UK regional service, with respect to the causative exposure and diagnostic characteristics.
   Methods: In a retrospective, cross-sectional study, we collected patient data for all 206 cases of HP diagnosed within our UK-based regional NHS interstitial and occupational lung disease service, 2002-17. This included demographics, environmental and occupational exposures, clinical features, and diagnostic tests (CT imaging, bronchiolo-alveolar cell count, lung function, histology). We grouped the data by cause (occupational, non-occupational and unknown) and by presence or absence of fibrosis on CT, in order to undertake hypothesis testing.
   Results: Cases were occupational (n=50), non-occupational (n=56) or cryptogenic (n=100) in aetiology. The commonest causes were birds=37 (18%) and MWF=36 (17%). Other occupational causes included humidifiers and household or commercial waste, but only one case of farmers' lung. Cryptogenic cases were associated with significantly older age, female gender, lower lung function parameters, fewer alveolar lymphocyte counts>20%, and fibrosis on CT; exposure information was missing in 22-33% of cryptogenic cases.
   Conclusion: MWF is the commonest occupational cause of HP, where workers usually present with more acute/subacute features and less fibrosis on CT; refuse work is an emerging cause. Cryptogenic HP has a fibrotic phenotype, and a full occupational history should be taken, as historical workplace exposures may be relevant.
C1 [Walters, Gareth I.; Mokhlis, Justin M.; Moore, Vicky C.; Robertson, Alastair S.; Burge, Geraldine A.; Bhomra, Parminder S.; Burge, P. Sherwood] Birmingham Chest Clin, Univ Hosp Birmingham NHS Fdn Trust, Birmingham Reg NHS Occupat Lung Dis Serv, 151 Great Charles St,Queensway, Birmingham B3 3HX, W Midlands, England.
   [Walters, Gareth I.; Robertson, Alastair S.; Burge, P. Sherwood] Univ Birmingham, Inst Clin Sci, Occupat & Environm Med, Birmingham, W Midlands, England.
RP Walters, GI (reprint author), Birmingham Chest Clin, Birmingham Reg NHS Occupat Lung Dis Serv, 151 Great Charles St,Queensway, Birmingham B3 3HX, W Midlands, England.
EM gareth.walters@heartofengland.nhs.uk
CR Barber CM, 2017, OCCUP ENVIRON MED, V74, P528, DOI 10.1136/oemed-2016-103838
   Barber CM, 2014, AM J IND MED, V57, P872, DOI 10.1002/ajim.22337
   Blanc PD, 2019, AM J RESP CRIT CARE, V199, P1312, DOI 10.1164/rccm.201904-0717ST
   BOYD G, 1982, CLIN ALLERGY, V12, P53
   Burton CM, 2012, ANN OCCUP HYG, V56, P374, DOI 10.1093/annhyg/mer121
   Caillaud Denis M., 2012, Inflammation & Allergy Drug Targets, V11, P15
   Cormican LJ, 2006, RESPIRATION, V73, P836, DOI 10.1159/000095911
   Hanak V, 2007, MAYO CLIN PROC, V82, P812, DOI 10.4065/82.7.812
   Health and Safety Executive (HSE), 2013, CONTR SUBST HAZ HLTH
   Heinzer R, 2004, THORAX, V59, P541
   HSE, 2011, WORK SAF MET FLUIDS
   James PL, 2018, THORAX, V73, P151, DOI 10.1136/thoraxjnl-2017-210226
   Kolb M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1022-1
   Lacasse Y, 2003, AM J RESP CRIT CARE, V168, P952, DOI 10.1164/rccm.200301-137OC
   Lacasse Y, 2009, INT ARCH ALLERGY IMM, V149, P161, DOI 10.1159/000189200
   Mooney JJ, 2013, CHEST, V144, P586, DOI 10.1378/chest.12-2623
   Morell F, 2013, LANCET RESP MED, V1, P685, DOI 10.1016/S2213-2600(13)70191-7
   Morisset J, 2018, AM J RESP CRIT CARE, V197, P1036, DOI 10.1164/rccm.201710-1986OC
   PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21
   Perez ERF, 2013, CHEST, V144, P1644, DOI 10.1378/chest.12-2685
   Poole CJM, 2017, OCCUP MED-OXFORD, V67, P626, DOI 10.1093/occmed/kqx153
   Quirce S, 2016, ALLERGY, V71, P765, DOI 10.1111/all.12866
   RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7
   Robertson W, 2007, THORAX, V62, P981, DOI 10.1136/thx.2006.072199
   Tanaka Y, 2016, RESPIROL CASE REP, V4, DOI 10.1002/rcr2.152
   Vasakova M, 2017, AM J RESP CRIT CARE, V196, P680, DOI 10.1164/rccm.201611-2201PP
   Walsh SLF, 2016, LANCET RESP MED, V4, P557, DOI 10.1016/S2213-2600(16)30033-9
   Walters GI, 2017, OCCUP MED-OXFORD, V67, P308, DOI 10.1093/occmed/kqx039
   Xu JF, 2014, CLIN RESPIR J, V8, P297, DOI 10.1111/crj.12071
   Ziegler K, 2019, MED MYCOL CASE REP, V24, P44, DOI 10.1016/j.mmcr.2019.03.005
NR 30
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 19
EP 25
DI 10.1016/j.rmed.2019.06.026
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500004
PM 31295673
DA 2020-05-18
ER

PT J
AU Condreay, LD
   Gao, C
   Bradford, E
   Yancey, SW
   Ghosh, S
AF Condreay, Lynn D.
   Gao, Chuan
   Bradford, Eric
   Yancey, Steven W.
   Ghosh, Soumitra
TI No genetic associations with mepolizumab efficacy in COPD with
   peripheral blood eosinophilia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Mepolizumab; Pharmacogenetics; Eosinophilia; Exacerbation; SGRQ
ID DOUBLE-BLIND; PLACEBO; BENRALIZUMAB; MULTICENTER; SIROCCO; DREAM
AB Introduction: Improved understanding of genetic effects on response to treatments with novel approaches for COPD with peripheral blood eosinophilia, such as mepolizumab (a humanized monoclonal antibody to IL-5), may improve treatment outcomes. We conducted a study to identify genetic variants associated with efficacy of mepolizumab COPD.
   Materials and methods: Using generalized linear and logistic regression models, genome-wide association analyses were performed to investigate genetic associations with frequency of moderate and/or severe COPD exacerbations in COPD subjects receiving mepolizumab (weeks 0-52). Additional analyses included: (i) frequency of COPD exacerbations requiring hospitalization or emergency department visit (weeks 0-52), (ii) change from baseline mean total St. George's Respiratory Questionnaire (SGRQ) score (week 24), and (iii) SGRQ response defined as achieving a 4 unit or greater decrease of SGRQ score from baseline (week 24). This study included 610 patients with COPD, a subset of the Intent-to-treat (ITT) populations in two phase III double-blind trials assessing the efficacy and safety of mepolizumab, METREX (NCT02105948) and METREO (NCT02105961). All subjects had elevated eosinophil levels (>= 150 cells/mu L at screening or >= 300 cell/mu L in the 12 months prior to study), were treated with mepolizumab, and provided consent for genetic analysis.
   Results: From this post-hoc analysis, no genetic variant was significantly associated with moderate and/or severe COPD exacerbations or any of the other endpoints tested (threshold for statistical significance at the genome-wide level, p=5x10(-8)).
   Conclusions: In this exploratory study in patients with COPD, with peripheral blood eosinophilia, no genetic effects on mepolizumab-treatment response were identified.
C1 [Condreay, Lynn D.; Gao, Chuan] PAREXEL Int, Durham, NC 27713 USA.
   [Bradford, Eric; Yancey, Steven W.] GlaxoSmithKline, Res Triangle Pk, NC USA.
   [Ghosh, Soumitra] GlaxoSmithKline, King Of Prussia, PA USA.
RP Condreay, LD (reprint author), PAREXEL Int, Durham, NC 27713 USA.
EM Lynn.Condreay@parexel.com
FU GlaxoSmithKlineGlaxoSmithKline [GSK ID 208653]; GSKGlaxoSmithKline
   [117106/NCT02105948, 117113/NCT02105961]
FX This study (GSK ID 208653) was sponsored by GlaxoSmithKline. The studies
   METREX (117106/NCT02105948) and METREO (117113/NCT02105961) were also
   sponsored by GSK.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1
   Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0
   Condreay L, 2017, RESP MED, V132, P178, DOI 10.1016/j.rmed.2017.10.019
   FitzGerald JM, 2018, LANCET RESP MED, V6, P51, DOI 10.1016/S2213-2600(17)30344-2
   FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
   Henriksen DP, 2018, EUR CLIN RESPIR J, V5, DOI 10.1080/20018525.2018.1536097
   Kuang FL, 2017, J ALLER CL IMM-PRACT, V5, P1502, DOI 10.1016/j.jaip.2017.08.001
   Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007
   Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079
   Zheng X, 2014, PHARMACOGENOMICS J, V14, P192, DOI 10.1038/tpj.2013.18
NR 15
TC 1
Z9 1
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 26
EP 28
DI 10.1016/j.rmed.2019.07.004
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500005
PM 31295674
DA 2020-05-18
ER

PT J
AU Azar, M
   Krishnan, S
   Stump, TE
   Gutteridge, D
   Roe, DW
   Hage, C
AF Azar, Michella
   Krishnan, Sheila
   Stump, Timothy E.
   Gutteridge, Daniel
   Roe, David W.
   Hage, Chadi
TI Peak post-transplant lung function in bilateral lung transplant
   recipients using a prediction model based on donor and recipient
   demographic characteristics
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bilateral lung transplant; Pulmonary function testing; Lung function
ID PULMONARY-FUNCTION; REFERENCE VALUES; SPIROMETRY; HEART; COMPLICATIONS
AB Rationale: There are no reliable methods to predict lung function following lung transplantation. We sought to devise a prediction model of peak pulmonary function testing (PFT) post-transplant based on donor and recipient demographic characteristics.
   Methods: Single center retrospective analysis of bilateral lung transplant recipients between 2011 and 2015 without evidence of allograft dysfunction in the first year was performed. Peak PFT post-transplant was determined by serially measured FEV1 and FVC. Using the NHANES III equation, donor demographic characteristics were used to calculate predicted lung function. Multivariable linear regression helped determine which donor and recipient characteristics affected peak lung function and identify the discrepancy between donor predicted and recipient observed PFT post-transplant.
   Results: 146 donor/recipient patients were analyzed. 80 had obstructive lung disease, 66 had restrictive disease. Peak post-transplant FEV1 and FVC was reached in 64.30 +/- 48.96 and 78.14 +/- 50.68 weeks, respectively. Spirometry values peaked earlier in restrictive lung disease recipients. Higher peak FEV1 was significantly associated with younger donor age, non-African American donor race, male recipient sex, greater recipient height, underlying obstructive lung disease. Greater absolute differences between donor predicted and observed FEV1 were significantly associated with male donor sex, greater donor height, non-African-American donor race, female recipient sex, greater recipient height.
   Conclusions: Donor and recipient characteristics can help predict lung function post-transplant. Patients without complications in the first year post-transplant may take greater than one year to achieve peak lung function. Such predictions can help guide clinical decision making in the right setting.
C1 [Azar, Michella; Roe, David W.; Hage, Chadi] Indiana Univ Sch Med, Dept Med, 1120 W Michigan St, Indianapolis, IN 46202 USA.
   [Krishnan, Sheila; Roe, David W.; Hage, Chadi] Indiana Univ Sch Med, Div Pulm Crit Care Sleep & Occupat Med, 1120 W Michigan St, Indianapolis, IN 46202 USA.
   [Stump, Timothy E.] Indiana Univ Sch Med, Dept Biostat, 410 W 10th St,HITS 3000, Indianapolis, IN 46202 USA.
   [Gutteridge, Daniel; Roe, David W.; Hage, Chadi] Indiana Univ, Hlth Thorac Transplant Program, Thorac Transplant Program, 1801 N Senate Blvd,Suite 2000, Indianapolis, IN 46202 USA.
   [Azar, Michella] Marion Gen, 1406 W Bella Dr, Marion, IN 46953 USA.
   [Krishnan, Sheila] UNC Hlth Care, 101 Manning Dr, Chapel Hill, NC 27514 USA.
RP Hage, C (reprint author), Indiana Univ Sch Med, Clin Med, IUH Profess Ctr 2, Thorac Transplant Program, 1801 N Senate Blvd,Suite 2000, Indianapolis, IN 46202 USA.
EM michella.azar@gmail.com; krishnan.sheila@gmail.com; tstump@iupui.edu;
   dgutteridge@iuhealth.org; droe@iuhealth.org; chage@iu.edu
RI Hage, Chadi/Z-4903-2019
OI Azar, Michella/0000-0002-4424-5865
CR Bartels MN, 2011, CHEST, V140, P1604, DOI 10.1378/chest.10-2721
   BRUNSTING LA, 1994, J THORAC CARDIOV SUR, V107, P1337, DOI 10.1016/S0022-5223(94)70056-7
   Navarro JC, 2015, ARCH BRONCONEUMOL, V51, P109, DOI 10.1016/j.arbres.2014.06.012
   DIMARCO AF, 1983, AM REV RESPIR DIS, V127, P425, DOI 10.1164/arrd.1983.127.4.425
   ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125, DOI 10.1164/ajrccm/147.1.125
   Ferrer J, 2003, J HEART LUNG TRANSPL, V22, P1217, DOI 10.1016/S1053-2498(02)01230-5
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   HOEPER MM, 1992, CHEST, V102, P864, DOI 10.1378/chest.102.3.864
   Inci I, 2011, EUR J CARDIO-THORAC, V39, P115, DOI 10.1016/j.ejcts.2010.05.019
   Janssens JP, 2005, CLIN CHEST MED, V26, P469, DOI 10.1016/j.ccm.2005.05.004
   Jastrzebski Dariusz, 2008, Pneumonol Alergol Pol, V76, P131
   Kutner M. H., 2004, APPL LINEAR STAT MOD
   Liu J, 2018, J HEART LUNG TRANSPL, V37, P895, DOI 10.1016/j.healun.2018.02.014
   Martinez JAB, 1997, AM J RESP CRIT CARE, V155, P285, DOI 10.1164/ajrccm.155.1.9001326
   Mason DP, 2008, ANN THORAC SURG, V85, P1193, DOI 10.1016/j.athoracsur.2007.12.023
   Nava S, 1999, THORAX, V54, P390, DOI 10.1136/thx.54.5.390
   Pego-Fernandes PM, 2009, CLINICS, V64, P519, DOI 10.1590/S1807-59322009000600006
   Santacruz Jose Fernando, 2009, Proc Am Thorac Soc, V6, P79, DOI 10.1513/pats.200808-094GO
   Sheather SJ, 2009, SPRINGER TEXTS STAT, P1, DOI 10.1007/978-0-387-09608-7_1
   VanMuylem A, 1997, THORAX, V52, P643, DOI 10.1136/thx.52.7.643
   Yusen RD, 2016, J HEART LUNG TRANSPL, V35, P1170, DOI 10.1016/j.healun.2016.09.001
NR 21
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 29
EP 35
DI 10.1016/j.rmed.2019.07.009
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500006
PM 31295675
DA 2020-05-18
ER

PT J
AU Hatziparasides, G
   Loukou, I
   Moustaki, M
   Douros, K
AF Hatziparasides, Gregorios
   Loukou, Ioanna
   Moustaki, Maria
   Douros, Konstantinos
TI Vitamin K and cystic fibrosis: A gordian knot that deserves our
   attention
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Vitamin K; Cystic fibrosis; Fat soluble vitamins; Cystic fibrosis bone
   disease
ID BONE-MINERAL DENSITY; FACTOR-KAPPA-B; UNDERCARBOXYLATED OSTEOCALCIN;
   POSTMENOPAUSAL WOMEN; FAT MALABSORPTION; YOUNG-ADULTS; SUPPLEMENTATION;
   CHILDREN; DEFICIENCY; PHYLLOQUINONE
AB Cystic fibrosis (CF) is an inherited genetic disorder with multiorgan involvement. Gastrointestinal tract dysfunction leads to fat and fat-soluble vitamins (A, D, E, K) malabsorption and deficiency of these vitamins. Subclinical vitamin K (VK) deficiency seems to be a common problem in CF patients. However, despite the rest of fat-soluble vitamins being routinely supplemented, this is not a universal clinical practice for VK. Inefficient levels of VK may have significant effects on blood coagulation and bone formation. There are also some data indicating that VK may play a key role on regulation of inflammation. Supplementing CF patients with VK seems rational, but the appropriate dosing regimens are still a matter of debate. This review will try to delineate the problem and communicate the latest opinions on this controversial issue.
C1 [Hatziparasides, Gregorios; Douros, Konstantinos] Univ Athens, Univ Gen Hosp Attikon, Sch Med, Pediat Allergy & Resp Unit,Dept Pediat 3, Athens, Greece.
   [Loukou, Ioanna; Moustaki, Maria] Aghia Sophia Childrens Hosp, Cyst Fibrosis Dept, Athens, Greece.
RP Douros, K (reprint author), Attikon Hosp, Dept Pediat 3, 1 Rimini Str, Athens 12464, Greece.
EM costasdouros@gmail.com
OI Douros, Konstantinos/0000-0001-7632-1159
CR Andrade JC, 2017, SAUDI J BIOL SCI, V24, P59, DOI 10.1016/j.sjbs.2015.09.004
   Aoganghua A, 2011, INT J MOL MED, V28, P937, DOI 10.3892/ijmm.2011.773
   Aris RM, 2005, J CLIN ENDOCR METAB, V90, P1888, DOI 10.1210/jc.2004-1629
   Aris RM, 1998, ANN INTERN MED, V128, P186, DOI 10.7326/0003-4819-128-3-199802010-00004
   BACHRACH LK, 1994, AM J MED, V96, P27, DOI 10.1016/0002-9343(94)90112-0
   Balfour-Lynn IM, 2005, PEDIATR PULM, V39, P306, DOI 10.1002/ppul.20181
   Barker M, 2005, PEDIATR PULM, V39, P156, DOI 10.1002/ppul.20158
   Barker N, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00011
   Beker LT, 1997, J PEDIATR GASTR NUTR, V24, P512, DOI 10.1097/00005176-199705000-00003
   Beulens JWJ, 2013, BRIT J NUTR, V110, P1357, DOI 10.1017/S0007114513001013
   Blanco P, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02453-16
   Bolton-Smith C, 2007, J BONE MINER RES, V22, P509, DOI 10.1359/JBMR.070116
   Booth SL, 2000, AM J CLIN NUTR, V71, P1201
   Booth SL, 2003, J NUTR, V133, P2565
   Booth SL, 1997, NUTR REV, V55, P282, DOI 10.1111/j.1753-4887.1997.tb01619.x
   Borowitz D., 2002, J PEDIAT GASTROENTER, V35
   Braam LAJLM, 2003, CALCIFIED TISSUE INT, V73, P21, DOI 10.1007/s00223-002-2084-4
   Bugel S, 2003, P NUTR SOC, V62, P839, DOI 10.1079/PNS2003305
   Buntain HM, 2004, THORAX, V59, P149, DOI 10.1136/thorax.2003.006726
   Card DJ, 2014, MOL NUTR FOOD RES, V58, P1590, DOI 10.1002/mnfr.201300683
   Castellani C, 2017, CELL MOL LIFE SCI, V74, P129, DOI 10.1007/s00018-016-2393-9
   Cheung AM, 2008, PLOS MED, V5, P1461, DOI 10.1371/journal.pmed.0050196
   Chinzei R, 2011, PANCREAS, V40, P84, DOI 10.1097/MPA.0b013e3181f69fc9
   Choi Q, 2013, THROMB RES, V132, pE70, DOI 10.1016/j.thromres.2013.05.015
   Conway SP, 2005, PEDIATRICS, V115, P1325, DOI 10.1542/peds.2004-1242
   Conway SP, 2004, J ROY SOC MED, V97, P48
   Cottam ST, 2015, PAEDIATR RESPIR REV, V16, P22, DOI 10.1016/j.prrv.2015.07.012
   COUPER RTL, 1992, PEDIATR RES, V32, P179, DOI 10.1203/00006450-199208000-00011
   d'Angelo I, 2016, BIOMACROMOLECULES, V17, P1561, DOI 10.1021/acs.biomac.5b01646
   Dodge JA, 2006, BEST PRACT RES CL GA, V20, P531, DOI 10.1016/j.bpg.2005.11.006
   Doisy EA, 1940, SCIENCE, V91, P58, DOI 10.1126/science.91.2351.58
   Donovan DS, 1998, AM J RESP CRIT CARE, V157, P1892, DOI 10.1164/ajrccm.157.6.9712089
   Dougherty KA, 2010, AM J CLIN NUTR, V92, P660, DOI 10.3945/ajcn.2010.29350
   Douros K, 2008, INT J CLIN EXP MED, V1, P345
   Douros K, 2008, J PAEDIATR CHILD H, V44, P681, DOI 10.1111/j.1440-1754.2008.01406.x
   Drury D, 2008, J CYST FIBROS, V7, P457, DOI 10.1016/j.jcf.2008.04.001
   Drzymala-Czyz S, 2016, EUR J GASTROEN HEPAT, V28, P645, DOI 10.1097/MEG.0000000000000593
   Elborn JS, 2016, LANCET, V388, P2519, DOI 10.1016/S0140-6736(16)00576-6
   Elkin SL, 2002, AM J RESP CRIT CARE, V166, P1470, DOI 10.1164/rccm.200206-578OC
   Elkin SL, 2001, OSTEOPOROSIS INT, V12, P366, DOI 10.1007/s001980170104
   Ferland G, 2012, ANN NUTR METAB, V61, P213, DOI 10.1159/000343108
   FERNLUND P, 1975, J BIOL CHEM, V250, P6125
   Feskanich D, 1999, AM J CLIN NUTR, V69, P74
   Fewtrell MS, 2008, J CYST FIBROS, V7, P307, DOI 10.1016/j.jcf.2007.11.006
   FURIE B, 1990, BLOOD, V75, P1753
   Furiga A, 2016, ANTIMICROB AGENTS CH, V60, P1676, DOI 10.1128/AAC.02533-15
   Fusaro M, 2017, CLIN CHEM LAB MED, V55, P789, DOI 10.1515/cclm-2016-0783
   Gibbons S, 2004, NAT PROD REP, V21, P263, DOI 10.1039/b212695h
   Hajar Rachel, 2012, Heart Views, V13, P24, DOI 10.4103/1995-705X.96668
   Hamidi MS, 2013, J CLIN DENSITOM, V16, P409, DOI 10.1016/j.jocd.2013.08.017
   Harrington DJ, 2005, J LIPID RES, V46, P1053, DOI 10.1194/jlr.D400033-JLR200
   Harshman Stephanie G, 2016, Curr Nutr Rep, V5, P90, DOI 10.1007/s13668-016-0162-x
   Harshman SG, 2014, CURR OPIN CLIN NUTR, V17, P531, DOI 10.1097/MCO.0000000000000112
   HENDERSON RC, 1994, J PEDIATR-US, V125, P208, DOI 10.1016/S0022-3476(94)70194-6
   Inoue T, 2001, ENDOCR J, V48, P11, DOI 10.1507/endocrj.48.11
   Jagannath V. A., 2017, VITAMIN K SUPPLEMENT
   Kalivianakis M, 1999, AM J CLIN NUTR, V69, P127
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   Kleinman RE, 2010, AM J CLIN NUTR, V92, P469, DOI 10.3945/ajcn.2010.30138
   Knapen MHJ, 2007, OSTEOPOROSIS INT, V18, P963, DOI 10.1007/s00198-007-0337-9
   Knapen MHJ, 2013, OSTEOPOROSIS INT, V24, P2499, DOI 10.1007/s00198-013-2325-6
   Kuwabara A, 2011, ASIA PAC J CLIN NUTR, V20, P50
   MAGNUSSO.S, 1974, FEBS LETT, V44, P189, DOI 10.1016/0014-5793(74)80723-4
   Marquette M, 2016, PAEDIATR RESPIR REV, V20, P2, DOI 10.1016/j.prrv.2016.06.003
   Matsunaga S, 1999, CALCIFIED TISSUE INT, V65, P285, DOI 10.1007/s002239900700
   McPhail GL, 2010, J EMERG MED, V38, P320, DOI 10.1016/j.jemermed.2007.10.038
   Merelle ME, 2001, LANCET, V358, P1960, DOI 10.1016/S0140-6736(01)06963-X
   Mosler Katharina, 2003, J Cyst Fibros, V2, P91, DOI 10.1016/S1569-1993(03)00025-0
   Munck A, 2015, J CYST FIBROS, V14, P97, DOI 10.1016/j.jcf.2014.05.015
   NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347
   Ngo B, 2011, ACTA CLIN BELG, V66, P142, DOI 10.2143/ACB.66.2.2062536
   Nicolaidou P, 2006, EUR J PEDIATR, V165, P540, DOI 10.1007/s00431-006-0132-1
   Ohsaki Y, 2006, BIOSCI BIOTECH BIOCH, V70, P926, DOI 10.1271/bbb.70.926
   Ohsaki Y, 2010, J NUTR BIOCHEM, V21, P1120, DOI 10.1016/j.jnutbio.2009.09.011
   Olson RE, 2002, BRIT J NUTR, V87, P543, DOI 10.1079/BJN2002565
   Palermo A, 2017, METABOLISM, V70, P57, DOI 10.1016/j.metabol.2017.01.032
   Papaioannou A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-125
   Paranjape SM, 2008, CLIN REV ALLERG IMMU, V35, P116, DOI 10.1007/s12016-008-8083-0
   Pretto JB, 2004, Z NATURFORSCH C, V59, P657
   RAMSEY BW, 1992, AM J CLIN NUTR, V55, P108
   Rashid M, 1999, AM J CLIN NUTR, V70, P378
   Rossini M, 2007, CALCIFIED TISSUE INT, V80, P44, DOI 10.1007/s00223-006-0117-0
   Schaafsma A, 2000, EUR J CLIN NUTR, V54, P626, DOI 10.1038/sj.ejcn.1601065
   Sermet-Gaudelus I, 2011, J CYST FIBROS, V10, pS16, DOI 10.1016/S1569-1993(11)60004-0
   Shea MK, 2008, AM J EPIDEMIOL, V167, P313, DOI 10.1093/aje/kwm306
   Shea MK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010008
   Shea MK, 2014, THROMB HAEMOSTASIS, V112, P438, DOI 10.1160/TH13-12-1003
   Shearer M J, 2000, Curr Opin Clin Nutr Metab Care, V3, P433, DOI 10.1097/00075197-200011000-00004
   Shearer MJ, 2008, THROMB HAEMOSTASIS, V100, P530, DOI 10.1160/TH08-03-0147
   Shearer MJ, 2012, ADV NUTR, V3, P182, DOI 10.3945/an.111.001800
   SHEARER MJ, 1992, BLOOD REV, V6, P92, DOI 10.1016/0268-960X(92)90011-E
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   Sinaasappel M, 2002, J Cyst Fibros, V1, P51, DOI 10.1016/S1569-1993(02)00032-2
   Sokol RJ, 1999, J PEDIATR GASTR NUTR, V28, pS1, DOI 10.1097/00005176-199900001-00001
   Stalvey MS, 2013, CURR OPIN ENDOCRINOL, V20, P547, DOI 10.1097/01.med.0000436191.87727.ec
   SUTTIE JW, 1995, ANNU REV NUTR, V15, P399, DOI 10.1146/annurev.nu.15.070195.002151
   SUTTIE JW, 1992, J AM DIET ASSOC, V92, P585
   Takemoto CM, 2012, PEDIATR PULM, V47, P105, DOI 10.1002/ppul.21566
   Tanaka S, 2010, CLIN EXP IMMUNOL, V160, P283, DOI 10.1111/j.1365-2249.2009.04083.x
   TORSTENS.OL, 1970, PEDIATRICS, V45, P857
   Turina AD, 2006, BIOPHYS CHEM, V122, P101, DOI 10.1016/j.bpc.2006.02.007
   Urquhart DS, 2007, J HUM NUTR DIET, V20, P605, DOI 10.1111/j.1365-277X.2007.00830.x
   USUI Y, 1990, AM J CLIN NUTR, V51, P846
   Verghese T, 2003, ARCH DIS CHILD, V88, P553, DOI 10.1136/adc.88.6.553
   Vermeer C, 1998, J CLIN PATHOL, V51, P424, DOI 10.1136/jcp.51.6.424
   VONKRIES R, 1987, PEDIATR RES, V22, P513
   Walkowiak J, 2008, EUR J GASTROEN HEPAT, V20, P157, DOI 10.1097/MEG.0b013e3282f36d16
   Williams V, 2010, CLIN APPL THROMB-HEM, V16, P71, DOI 10.1177/1076029609334627
   Wilson DC, 2001, J PEDIATR-US, V138, P851, DOI 10.1067/mpd.2001.113633
   Wouthuyzen-Bakker M, 2011, J CYST FIBROS, V10, P150, DOI 10.1016/j.jcf.2011.03.008
NR 110
TC 0
Z9 0
U1 3
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 36
EP 42
DI 10.1016/j.rmed.2019.07.005
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500007
PM 31295676
DA 2020-05-18
ER

PT J
AU Ghang, B
   Lee, J
   Kwon, OC
   Ahn, SM
   Oh, JS
   Hong, S
   Kim, YG
   Yoo, B
   Jeong, WS
   Kim, J
   Lee, CK
AF Ghang, Byeongzu
   Lee, Jungsun
   Kwon, Oh Chan
   Ahn, Soo Min
   Oh, Ji Seon
   Hong, Seokchan
   Kim, Yong-Gil
   Yoo, Bin
   Jeong, Woo Seong
   Kim, Jinseok
   Lee, Chang-Keun
TI Clinical significance of autoantibody positivity in idiopathic pulmonary
   fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Autoantibodies; Autoimmunity; Pulmonary fibrosis; DMARDs (synthetic);
   Treatment
ID INTERSTITIAL LUNG-DISEASE; RHEUMATOID-ARTHRITIS; DIAGNOSIS; PNEUMONIA;
   CYCLOPHOSPHAMIDE
AB Rationale: The concept of interstitial pneumonia with autoimmune features (IPAF) was recently proposed by the American Thoracic Society. However, the clinical significance of the serologic domain of IPAF has not yet been established in idiopathic pulmonary fibrosis (IPF).
   Objectives: We aimed to investigate the clinical significance of autoantibody positivity in IPF.
   Methods: We retrospectively reviewed the records of 512 patients diagnosed as IPF from January 2007 through March 2014. The patients were divided into two subgroups: (i) an autoantibody-positive IPF subgroup (n=138), consisting of patients with anti-neutrophil cytoplasmic antibody (ANCA) or autoantibodies that met the criteria for the IPAF serologic domain; (ii) a lone IPF subgroup (n=374), consisting of the rest of the IPF patients.
   Measurements and main results: Autoantibody-positivity (HR 0.736, p=0.043) was an independent risk factors for 5-year mortality on multivariable analysis in the overall IPF patients. In the autoantibody-positive IPF patients, use of glucocorticoid (not for management of acute exacerbation, HR 2.121, p=0.019), use of immunomodulators (HR 0.310, p=0.002), malignancy (HR 3.359, p=0.002), baseline forced vital capacity (HR 0.974, p=0.017), baseline diffusing capacity of the lung for carbon monoxide (HR 0.981, p=0.041), and baseline 6-min walk test distance (HR 0.996, p=0.002) were independent risk factors for 5-year mortality.
   Conclusions: Presence of ANCA or autoantibodies of the IPAF serologic domain in IPF patients is associated with better survival outcomes, and the use of immunomodulators is associated with superior survival outcomes.
C1 [Ghang, Byeongzu; Lee, Jungsun; Kwon, Oh Chan; Ahn, Soo Min; Oh, Ji Seon; Hong, Seokchan; Kim, Yong-Gil; Yoo, Bin; Lee, Chang-Keun] Univ Ulsan, Coll Med, Asan Med Ctr, Div Rheumatol,Dept Internal Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Ghang, Byeongzu; Jeong, Woo Seong; Kim, Jinseok] Jeju Natl Univ, Sch Med, Dept Internal Med, Div Rheumatol, Aran 13 Gil 15,Ara 1 Dong, Jeju Si 63241, Jeju Special Se, South Korea.
RP Lee, CK (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Rheumatol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM cklee@amc.seoul.kr
OI Ghang, Byeong-zu/0000-0001-7284-4964
CR Alba MA, 2017, AUTOIMMUN REV, V16, P722, DOI 10.1016/j.autrev.2017.05.008
   Ando M, 2013, RESP MED, V107, P608, DOI 10.1016/j.rmed.2013.01.006
   Behr J, 2012, NEW ENGL J MED, V367, P869, DOI 10.1056/NEJMc1207471
   Collins BF, 2017, CHEST, V152, P103, DOI 10.1016/j.chest.2017.03.004
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Hu Y, 2016, CHEST, V149, P201, DOI 10.1378/chest.15-1145
   Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715
   Kagiyama N, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2014-000058
   Kang BH, 2013, J KOREAN MED SCI, V28, P731, DOI 10.3346/jkms.2013.28.5.731
   Katsumata Y, 2015, CLIN MED INSIGHTS-CI, V9, P51, DOI [10.4137/CCRPM.S23314, 10.4137/CCRPRPM.S23314]
   Kim EJ, 2009, CHEST, V136, P1397, DOI 10.1378/chest.09-0444
   Lum S, 2016, EUR RESPIR J, V47, P1292, DOI 10.1183/13993003.02028-2015
   Moua T, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0154-6
   Moua T, 2014, MAYO CLIN PROC, V89, P319, DOI 10.1016/j.mayocp.2013.11.018
   Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018
   Park JH, 2007, AM J RESP CRIT CARE, V175, P705, DOI 10.1164/rccm.200607-912OC
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Song JW, 2009, CHEST, V136, P23, DOI 10.1378/chest.08-2572
   Tashkin DP, 2006, NEW ENGL J MED, V354, P2655, DOI 10.1056/NEJMoa055120
   Tashkin DP, 2016, LANCET RESP MED, V4, P708, DOI 10.1016/S2213-2600(16)30152-7
   Vij R, 2013, CHEST, V143, P814, DOI 10.1378/chest.12-0741
   Wells AU, 2014, NAT REV RHEUMATOL, V10, P728, DOI 10.1038/nrrheum.2014.149
   Wilfong EM, 2018, ARTHRITIS RHEUMATOL, V70, P1901, DOI 10.1002/art.40679
NR 25
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 43
EP 48
DI 10.1016/j.rmed.2019.07.001
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500008
PM 31299466
DA 2020-05-18
ER

PT J
AU Altree, T
   Bussell, L
   Nguyen, P
   Johnston, S
AF Altree, Thomas
   Bussell, Lauren
   Nguyen, Phan
   Johnston, Sonya
TI Adverse cardiac outcomes after pulmonary function testing with recent
   myocardial infarction
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; Pulmonary function testing;
   Spirometry; Pre-operative assessment
ID PRESSURE
AB ATS/ERS Guidelines list pulmonary function testing (PFT) within one month of myocardial infarction (MI) as a contraindication, based on expert opinion. This retrospective review of 136 patients undergoing Coronary Artery Bypass Graft (CABG) surgery identified 21 patients who had PFTs despite MI in the preceding month (MI + PFT group). The MI + PFT Group had zero incidence of MI or serious cardiac arrhythmia between PFTs and surgery. Comparison of post-operative outcomes between the MI + PFT Group and all other CABG patients showed no significant differences. In this small sample size, PFTs appear safe within one month of MI.
C1 [Altree, Thomas; Bussell, Lauren; Nguyen, Phan; Johnston, Sonya] Royal Adelaide Hosp, Dept Thorac Med, Port Rd, Adelaide, SA 5000, Australia.
   [Nguyen, Phan] Univ Adelaide, Fac Hlth & Med Sci, Level 3,Helen Mayo North,Frome Rd,North Terrace, Adelaide, SA 5000, Australia.
RP Altree, T (reprint author), Woolcock Inst Med Res, 431 Glebe Point Rd, Glebe, NSW 2037, Australia.
EM tom.altree@sydney.edu.au; lauren.bussell@adelaide.edu.au;
   phantien.nguyen@adelaide.edu.au; sonya.johnston@adelaide.edu.au
OI Altree, Thomas/0000-0003-1979-8975
CR BUDA AJ, 1979, NEW ENGL J MED, V301, P453, DOI 10.1056/NEJM197908303010901
   Cooper BG, 2011, THORAX, V66, P714, DOI 10.1136/thx.2010.139881
   Denault AY, 2001, J APPL PHYSIOL, V91, P298
   KINGMA I, 1983, CIRCULATION, V68, P1304, DOI 10.1161/01.CIR.68.6.1304
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miller W.F., 1987, LAB EVALUATION PULMO, P541
   MONTENEGRO HD, 1978, CHEST, V73, P133, DOI 10.1378/chest.73.2.133
   Shahian DM, 2009, ANN THORAC SURG, V88, pS2, DOI 10.1016/j.athoracsur.2009.05.053
NR 8
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 49
EP 50
DI 10.1016/j.rmed.2019.07.003
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500009
PM 31299467
DA 2020-05-18
ER

PT J
AU Condreay, LD
   Qu, XYA
   Anderson, J
   Compton, C
   Ghosh, S
AF Condreay, Lynn D.
   Qu, Xiaoyan A.
   Anderson, Julie
   Compton, Chris
   Ghosh, Soumitra
TI Genetic effects on efficacy to fluticasone propionate/salmeterol
   treatment in COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Pharmacogenetic; Fluticasone propionate/salmeterol; St George's
   respiratory questionnaire; FEV1
ID POLYMORPHISMS; EXPRESSION; PLATFORM
AB Purpose: No studies have investigated genetic effects on quality of life (QoL) measurements like improvements in the St George's Respiratory Questionnaire (SGRQ) scores for chronic obstructive pulmonary disease treatments with fluticasone propionate/salmeterol (FSC). Therefore, in addition to testing genetic effects on change from baseline in trough forced expiratory volume in 1 s (FEV1), genetic associations that may predict SGRQ response to FSC treatment were investigated in this analysis.
   Methods: This post hoc exploratory genome-wide genetic analysis included subjects from 10 clinical trials: NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328. The Genetics Analysis Population (subjects who provided written consent, a blood sample for genetic research, and were successfully genotyped) included 2005/2900 subjects in the intent-to-treat sample, who received FSC, for testing association with change from baseline in trough FEV1 and 1188/2005 subjects for testing SGRQ responses (change from baseline SGRQ score and categorical response by SGRQ score with Responders achieving > 4 unit decrease at end of study treatment).
   Main findings: One locus on chromosome 20 with seven variants with low minor allele frequencies significantly associated with change from baseline SGRQ score. The binary SGRQ response provided similar trends for association but did not attain genome-wide significance levels. No genetic association was detected with change from baseline in trough FEV1.
   Conclusions: Common variants are unlikely to play a role in response to FSC.
C1 [Condreay, Lynn D.; Qu, Xiaoyan A.] PAREXEL Int, 2520 Meridian Pkwy, Durham, NC 27713 USA.
   [Anderson, Julie] GlaxoSmithKline, Stockley Pk, Uxbridge, Middx, England.
   [Compton, Chris] GlaxoSmithKline, GSK House, Brentford, Middx, England.
   [Ghosh, Soumitra] GlaxoSmithKline, King Of Prussia, PA USA.
RP Condreay, LD (reprint author), PAREXEL Int, 2520 Meridian Pkwy, Durham, NC 27713 USA.
EM Lynn.Condreay@parexel.com
FU GlaxoSmithKlineGlaxoSmithKline [207388]
FX This study, 207388, was conceived and implemented by the coauthors and
   sponsored and funded by GlaxoSmithKline. Information on
   GlaxoSmithKline's data sharing commitments and requesting access to
   anonymized individual participant data and associated documents from
   GlaxoSmithKline sponsored studies can be found at
   www.clinicalstudydatarequest.com.
CR Hardin M, 2016, PHARMACOGENOMICS J, V16, P326, DOI 10.1038/tpj.2015.65
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   Kim WJ, 2009, RESP MED, V103, P552, DOI 10.1016/j.rmed.2008.10.025
   Koscielny G, 2017, NUCLEIC ACIDS RES, V45, pD985, DOI 10.1093/nar/gkw1055
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Mosteller M., 2017, COPD RES PRACT, V3, P2, DOI [10.1186/s40749-017-0020-2, DOI 10.1186/S40749-017-0020-2]
   Nielsen AO, 2017, COPD, V14, P451, DOI 10.1080/15412555.2017.1320370
   Papatheodorou I, 2018, NUCLEIC ACIDS RES, V46, pD246, DOI 10.1093/nar/gkx1158
   Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Rabe KF, 2014, LANCET RESP MED, V2, P44, DOI 10.1016/S2213-2600(13)70248-0
   Shen JD, 2017, BIOINFORMATICS, V33, P2784, DOI 10.1093/bioinformatics/btx274
   Smith CL, 2018, NUCLEIC ACIDS RES, V46, pD836, DOI 10.1093/nar/gkx1006
   Wang XW, 2015, GENET TEST MOL BIOMA, V19, P566, DOI 10.1089/gtmb.2015.0108
NR 14
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 51
EP 53
DI 10.1016/j.rmed.2019.06.023
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500010
PM 31299468
DA 2020-05-18
ER

PT J
AU Kuo, CR
   Spears, M
   Haughney, J
   Smith, A
   Miller, J
   Bradshaw, T
   Murray, L
   Williamson, P
   Lipworth, B
AF Kuo, Chris RuiWen
   Spears, Mark
   Haughney, John
   Smith, Andrew
   Miller, Joy
   Bradshaw, Tracey
   Murray, Lorna
   Williamson, Peter
   Lipworth, Brian
TI Scottish consensus statement on the role of FeNO in adult asthma
SO RESPIRATORY MEDICINE
LA English
DT Review
DE FeNO; Asthma; Type 2 Inflammation
ID EXHALED NITRIC-OXIDE; CORTICOSTEROID DOSE-RESPONSE; AIRWAY
   HYPERRESPONSIVENESS; EOSINOPHIL COUNTS; PERSISTENT ASTHMA; INFLAMMATION;
   EXACERBATIONS; MEPOLIZUMAB; BIOMARKERS; MANNITOL
AB Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.
C1 [Kuo, Chris RuiWen; Lipworth, Brian] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland.
   [Spears, Mark] Forth Valley Royal Hosp, Resp Med, Larbert FK5 4WR, Scotland.
   [Haughney, John] Queen Elizabeth Univ Hosp, Clin R&D, Glasgow G51 4TF, Lanark, Scotland.
   [Smith, Andrew] Univ Hosp Wishaw, Dept Resp Med, Wishaw ML2 0DP, Scotland.
   [Miller, Joy] Univ Aberdeen, Aberdeen Royal Infirm, Resp Med Unit, Aberdeen AB25 2ZN, Scotland.
   [Bradshaw, Tracey] Royal Infirm Edinburgh NHS Trust, Resp Med Unit, Edinburgh EH16 4SA, Midlothian, Scotland.
   [Murray, Lorna] Raigmore Hosp, Dept Resp Med, Inverness IV2 4AG, Scotland.
   [Williamson, Peter] Perth Royal Infirm, Resp Med, Perth PH1 1NX, Scotland.
RP Lipworth, B (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland.
EM b.j.ipworth@dundee.ac.uk
OI Lipworth, Brian/0000-0002-8140-2014
FU Circassia Ltd (Oxford, UK)
FX The authors would like to thank Circassia Ltd (Oxford, UK) for providing
   an unrestricted educational grant to support the meeting in Perth on 9th
   October 2018 which formed the basis of this manuscript. Circassia were
   not present at the meeting and had no input into preparation of the
   manuscript. All of the authors who were present at the meeting had an
   input into writing the paper.
CR Anderson WJ, 2017, ANN ALLERG ASTHMA IM, V118, P179, DOI 10.1016/j.anai.2016.11.018
   Anderson WJ, 2012, CHEST, V142, P1553, DOI 10.1378/chest.12-1310
   Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092
   Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x
   Clearie KL, 2012, CHEST, V141, P330, DOI 10.1378/chest.11-0392
   Colak Y., 2018, EUR RESP J, V52
   Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469
   Currie GP, 2003, ALLERGY, V58, P762, DOI 10.1034/j.1398-9995.2003.00226.x
   Galli J, 2012, OTOLARYNG HEAD NECK, V147, P351, DOI 10.1177/0194599812442322
   Global Initiative for Asthma, 2018, GUIDELINES
   Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991
   Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC
   Heaney LG, 2019, AM J RESP CRIT CARE, V199, P454, DOI 10.1164/rccm.201806-1182OC
   Honkoop PJ, 2015, J ALLERGY CLIN IMMUN, V135, P682, DOI 10.1016/j.jaci.2014.07.016
   Jabbal S, 2018, CLIN EXP ALLERGY, V48, P93, DOI 10.1111/cea.13057
   Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91
   Lipworth BJ, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01433-2017
   Lipworth BJ, 2012, CHEST, V141, P607, DOI 10.1378/chest.11-1748
   Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007
   Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494
   McNicholl DM, 2012, AM J RESP CRIT CARE, V186, P1102, DOI 10.1164/rccm.201204-0587OC
   National Institute for Health and Care Excellence, RESL TREAT SEV EOS A
   National Institute for Health and Care Excellence, OM TREAT SEV PERS AL
   National Institute for Health and Care Excellence, MEP TREAT SEV REFR E
   National Institute for Health and Care Excellence, 2017, ASTHM DIAGN MON CHRO
   Pavord ID, 2017, CLIN EXP ALLERGY, V47, P148, DOI 10.1111/cea.12881
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145
   Petsky HL, 2018, THORAX, V73, P1110, DOI 10.1136/thoraxjnl-2018-211540
   Price D, 2009, ALLERGY, V64, P431, DOI 10.1111/j.1398-9995.2008.01855.x
   Price DB, 2018, LANCET RESP MED, V6, P29, DOI 10.1016/S2213-2600(17)30424-1
   Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093
   Russell RJ, 2018, LANCET RESP MED, V6, P499, DOI 10.1016/S2213-2600(18)30201-7
   Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052
   Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040
   Wilson AM, 2000, AM J MED, V108, P269, DOI 10.1016/S0002-9343(99)00435-0
NR 38
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 54
EP 57
DI 10.1016/j.rmed.2019.07.010
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500011
PM 31299469
DA 2020-05-18
ER

PT J
AU Graham, LM
   Kerstjens, HAM
   Vogelberg, C
   Hamelmann, E
   Szefler, SJ
   Pisternick-Ruf, W
   Engel, M
   El Azzi, G
   Unseld, A
   Foggs, MB
AF Graham, LeRoy M.
   Kerstjens, Huib A. M.
   Vogelberg, Christian
   Hamelmann, Eckard
   Szefler, Stanley J.
   Pisternick-Ruf, Wendelgard
   Engel, Michael
   El Azzi, Georges
   Unseld, Anna
   Foggs, Michael B.
TI Safety of tiotropium Respimat (R) in black or African-American patients
   with symptomatic asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Black or african american; Adult; Pediatric; Tiotropium; Safety
ID INHALED CORTICOSTEROIDS; ADD-ON; CHILDREN
AB Background: Black patients with asthma have a higher disease burden and greater morbidity compared with other racial/ethnic groups. Tiotropium Respimat (R), as add-on to at least inhaled corticosteroids (ICS), improves lung function and asthma control and reduces asthma exacerbation risk in patients, with a safety profile comparable with placebo. This study aimed to assess the safety of tiotropium Respimat (R), compared with placebo, in black or African-American patients.
   Methods: Data were pooled from 12 randomized, placebo-controlled, parallel-group, Phase II or III trials from the global Boehringer Ingelheim program with once-daily tiotropium Respimat (R) (5 mu g or 2.5 mu g). Trial participants had symptomatic persistent asthma with a broad range of severities and were aged 1-75 years. The safety results of black or African-American patients were compared with the overall trial population.
   Results: Of the 5165 patients treated with tiotropium or placebo, 3.2% were black or African American. For both doses of tiotropium, the proportion of patients reporting adverse events (AEs) was approximately 10% lower compared with placebo and was generally comparable with the proportion of patients reporting AEs in all groups of the overall population. The number of investigator-assessed drug-related AEs, AEs leading to trial drug discontinuation or serious AEs reported by patients was low and comparable between treatment groups and with the overall population.
   Conclusion: Tiotropium Respimat (R) appears to be a generally safe add-on bronchodilator treatment option to ICS with or without other controllers in pediatric and adult black or African-American patients with asthma.
C1 [Graham, LeRoy M.] Mercy Care Atlanta, City Refuge Clin, Atlanta, GA USA.
   [Kerstjens, Huib A. M.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
   [Vogelberg, Christian] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Hamelmann, Eckard] Evangel Klinikum Bethel gGmbH, Bielefeld, Germany.
   [Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pediat, Breathing Inst,Childrens Hosp Colorado, Aurora, CO USA.
   [Pisternick-Ruf, Wendelgard; Unseld, Anna] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
   [Engel, Michael; El Azzi, Georges] Boehringer Ingelheim Int GmbH, Ingelheim, Germany.
   [Foggs, Michael B.] Advocate Hlth Care, Chicago, IL USA.
RP Graham, LM (reprint author), Bridge Atlanta Med Ctr, Norcross, GA 30093 USA.
EM lmg254@gmail.com; h.a.m.kerstjens@umcg.nl;
   christian.vogelberg@uniklinikum-dresden.de; Eckard.Hamelmann@evkb.de;
   Stanley.Szefler@childrenscolorado.org;
   wendelgard.pisternick-ruf@boehringer-ingelheim.com;
   michael.engel@boehringer-ingelheim.com;
   georges.el_azzi@boehringer-ingelheim.com;
   anna.unseld@boehringer-ingelheim.com; immunotype@aol.com
FU Boehringer IngelheimBoehringer Ingelheim
FX This work was supported by Boehringer Ingelheim.
CR Busse WW, 2016, EUR RESPIR REV, V25, DOI 10.1183/16000617.0052-2015
   Dahl R, 2016, RESP MED, V118, P102, DOI 10.1016/j.rmed.2016.07.001
   Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024
   Global Initiative for asthma, 2018, GINA REP GLOB STRAT
   Hamelmann E, 2018, DRUGS, V78, P327, DOI 10.1007/s40265-018-0862-1
   Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109
   Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017
   Vogelberg C, 2017, ALLERGY, V72, P414
   Wechsler ME, 2015, JAMA-J AM MED ASSOC, V314, P1720, DOI 10.1001/jama.2015.13277
NR 9
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 58
EP 60
DI 10.1016/j.rmed.2019.07.002
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500012
PM 31302579
DA 2020-05-18
ER

PT J
AU Gearhart, AM
   Furmanek, S
   English, C
   Ramirez, J
   Cavallazzi, R
AF Gearhart, Alessandra Morello
   Furmanek, Stephen
   English, Connor
   Ramirez, Julio
   Cavallazzi, Rodrigo
TI Predicting the need for ICU admission in community-acquired pneumonia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pneumonia; ICU; Prediction; Prognosis; Infection; Cohort
ID INFECTIOUS-DISEASES-SOCIETY; IDSA/ATS MINOR CRITERIA; VALIDATION;
   GUIDELINES; SEVERITY; MANAGEMENT; ADULTS; TOOLS
AB Background: Multiple criteria have been proposed to define community-acquired pneumonia (CAP) severity and predict ICU admission. Validity studies have found differing results. We tested four models to assess severe CAP built upon the criteria included in the 2007 IDSA/ATS guidelines, hypothesizing that a model providing different weights for each individual criterion may be of better predictability.
   Methods: Retrospective analysis of a prospective cohort study of adult hospitalizations for CAP at nine hospitals in Louisville, KY from June 2014 to May 2016. Four models were tested. Model 1: original 2007 IDSA/ATS criteria. Model 2: modified IDSA/ATS criteria by removing multilobar infiltrates and changing BUN threshold to >= 30 mg/dL; adding lactate level > 2 mmol/L and requirement of non-invasive mechanical ventilation (NIMV). CAP was severe with 1 major criterion or 3 minor criteria. Model 3: same criteria as model 2, CAP was severe with 1 major criterion or 4 minor criteria. Model 4: multiple regression analysis including the modified criteria as described in models 2 and 3 with a score assigned to each variable according to the magnitude of association between variable and need for ICU.
   Results: 8284 CAP hospitalizations were included. 1458 (18%) required ICU. Model 4 showed highest prediction of need for ICU with an area under the curve of 0.91, highest accuracy, specificity, positive predictive value, and agreement among models.
   Conclusion: Assigning differential weights to clinical predictive variables generated a score with accuracy that outperformed the original 2007 IDSA/ATS criteria for severe CAP and ICU admission.
C1 [Gearhart, Alessandra Morello; Cavallazzi, Rodrigo] Univ Louisville, Div Pulm Crit Care & Sleep Med, Louisville, KY 40292 USA.
   [Furmanek, Stephen; English, Connor; Ramirez, Julio] Univ Louisville, Div Infect Dis, Louisville, KY 40292 USA.
RP Gearhart, AM (reprint author), 550 S Jackson St,A3R43, Louisville, KY 40202 USA.
EM alemorello19@gmail.com
OI Ramirez, Julio/0000-0001-7801-5374
FU Division of Infectious Diseases, University of Louisville, KY;
   PfizerPfizer
FX This work was supported primarily by the Division of Infectious
   Diseases, University of Louisville, KY. Partial support was given by
   Pfizer.
CR Athlin S., 2017, MANAGEMENT COMMUNITY, P1
   Brown SM, 2009, CRIT CARE MED, V37, P3010, DOI 10.1097/CCM.0b013e3181b030d9
   Chalmers JD, 2011, CLIN INFECT DIS, V53, P503, DOI 10.1093/cid/cir463
   Chalmers JD, 2011, INTENS CARE MED, V37, P1409, DOI 10.1007/s00134-011-2261-x
   Charles PGP, 2008, CLIN INFECT DIS, V47, P375, DOI 10.1086/589754
   Fan JH, 2019, ORG CHEM FRONT, V6, P22, DOI 10.1039/c8qo01089g
   File TM, 2010, POSTGRAD MED, V122, P130, DOI 10.3810/pgm.2010.03.2130
   Guo Q, 2011, RESP MED, V105, P1543, DOI 10.1016/j.rmed.2011.06.010
   Kochanek Kenneth D, 2016, Natl Vital Stat Rep, V65, P1
   Kontou P, 2009, AM J EMERG MED, V27, P968, DOI 10.1016/j.ajem.2008.07.037
   LEROY O, 1995, INTENS CARE MED, V21, P24, DOI 10.1007/BF02425150
   Li HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001474
   Liapikou A, 2009, CLIN INFECT DIS, V48, P377, DOI 10.1086/596307
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Marti C, 2012, CRIT CARE, V16, DOI 10.1186/cc11447
   Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885
   NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418
   Phua J, 2009, THORAX, V64, P598, DOI 10.1136/thx.2009.113795
   Prina E, 2015, LANCET, V386, P1097, DOI 10.1016/S0140-6736(15)60733-4
   R Core Team, 2016, R LANG ENV STAT COMP
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Restrepo MI, 2010, CHEST, V137, P552, DOI 10.1378/chest.09-1547
   Salih W, 2014, EUR RESPIR J, V43, P842, DOI 10.1183/09031936.00089513
   Shah Bashir Ahmed, 2010, Indian J Chest Dis Allied Sci, V52, P9
   Sibila O, 2013, J CRIT CARE, V28, P284, DOI 10.1016/j.jcrc.2012.09.010
   Wiemken T, 2013, INFECT DIS CLIN N AM, V27, P33, DOI 10.1016/j.idc.2012.11.015
   Wunderink RG, 2014, NEW ENGL J MED, V370, P543, DOI 10.1056/NEJMcp1214869
NR 28
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 61
EP 65
DI 10.1016/j.rmed.2019.07.007
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500013
PM 31302580
DA 2020-05-18
ER

PT J
AU Martina, F
   Fabio, P
   Ambra, N
   Rosalba, M
   Anna, P
   Mariano, M
   Andrea, B
   Cecilia, C
AF Martina, Flora
   Fabio, Perrotta
   Ambra, Nicolai
   Rosalba, Maffucci
   Anna, Pratillo
   Mariano, Mollica
   Andrea, Bianco
   Cecilia, Calabrese
TI Staphylococcus Aureus in chronic airway diseases: An overview
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Staphylococcus aureus; Enterotoxins; Airway diseases; Severe asthma;
   Chronic rhinosinusitis
ID ENTEROTOXIN-SPECIFIC IGE; CHRONIC RHINOSINUSITIS; IMMUNOGLOBULIN-E;
   CONTROLLED-TRIAL; POLYCLONAL IGE; NASAL CARRIAGE; ANTI-IGE; ASTHMA;
   SENSITIZATION; ASSOCIATION
AB This review investigates about the role of Staphylococcus Aureus (S. aureus) and S. aureus enterotoxins (SEs) in the pathogenesis of several chronic airway diseases. S. aureus is part of normal human flora and may colonize the skin and the upper airways. SEs acting as superantigens can induce an intense T cell activation and through the release of interleukin (IL) - 4, 5, and 13, can promote a polyclonal IgE response and eosinophilic inflammation. S. aureus can damage epithelial cells inducing the release of the so-called "alarmins" responsible of the activation of Type 2 innate lymphoid cells (ILC-2) linked to an IL-5 mediated airway eosinophilic inflammation. SEs sensitization has been recently associated with the eosinophilic endotypes of both nasal polyps and late onset severe asthma. Studies investigating the effect of biological therapies in SEs sensitized patients should be performed in order to better define the role played by S. aureus in the different endotypes of severe asthma and/or chronic rhinosinusitis.
C1 [Martina, Flora; Ambra, Nicolai; Rosalba, Maffucci; Anna, Pratillo; Mariano, Mollica; Andrea, Bianco; Cecilia, Calabrese] Univ Campania L Vanvitelli, Dept Translat Med Sci, Caserta, Italy.
   [Fabio, Perrotta] Univ Molise, Dept Med & Hlth Sci V Tiberio, Campobasso, Italy.
RP Cecilia, C (reprint author), Univ Campania, Dept Translat Med Sci, Via Leonardo Bianchi, I-80131 Naples, Italy.
EM cecilia.calabrese@unicampania.it
RI Nicolai, Ambra/AAD-6243-2020; perrotta, fabio/T-5858-2017
OI perrotta, fabio/0000-0002-7223-7037
CR Altunbulakli C., J ALLERGY CLIN IMMUN
   Ba L, 2011, ALLERGY, V66, P1296, DOI 10.1111/j.1398-9995.2011.02637.x
   Bachert C, 2002, ALLERGY, V57, P480, DOI 10.1034/j.1398-9995.2002.02156.x
   Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x
   Bachert C., 2017, J ALLERGY CLIN IMMUN, P31081
   Bachert C., 2015, J ALLERGY CLIN IMMUN
   Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012
   Barnes PJ, 2009, CLIN EXP ALLERGY, V39, P1145, DOI 10.1111/j.1365-2222.2009.03298.x
   Baroody FM, 1997, J ALLERGY CLIN IMMUN, V100, P563, DOI 10.1016/S0091-6749(97)70151-9
   Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x
   Bright JJ, 1999, J LEUKOCYTE BIOL, V65, P665
   Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092
   Chen JB, 2017, J ALLERGY CLIN IMMUN, V139, P1195, DOI 10.1016/j.jaci.2016.06.066
   Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064
   Derycke Lara, 2010, World Allergy Organ J, V3, P223, DOI 10.1097/WOX.0b013e3181ecd8ae
   Desouza IA, 2002, TOXICON, V40, P1709, DOI 10.1016/S0041-0101(02)00237-4
   Gangl K, 2009, ALLERGY, V64, P398, DOI 10.1111/j.1398-9995.2008.01861.x
   Garcia G, 2013, CHEST, V144, P411, DOI 10.1378/chest.12-1961
   Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000
   Gevaert P., 2011, J ALLERGY CLIN IMMUN, V128
   Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031
   Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3
   Hollams EM, 2010, EUR RESPIR J, V36, P509, DOI 10.1183/09031936.00184109
   Horvath KM, 2011, AM J RESP CELL MOL, V45, P237, DOI 10.1165/rcmb.2010-0190OC
   Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x
   Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x
   Kowalski ML, 2011, ALLERGY, V66, P32, DOI 10.1111/j.1398-9995.2010.02379.x
   Krismer B, 2017, NAT REV MICROBIOL, V15, P675, DOI 10.1038/nrmicro.2017.104
   Krouse JH, 2007, OTOLARYNG HEAD NECK, V136, pS75, DOI 10.1016/j.otohns.2007.02.019
   Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x
   Lan F, 2018, AM J RESP CRIT CARE, V198, P452, DOI 10.1164/rccm.201710-2112OC
   Lee JY, 2006, ALLERGY ASTHMA PROC, V27, P341, DOI 10.2500/aap.2006.27.2908
   LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711
   Li CW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003918
   Matsumoto H, 2017, ANN ALLERG ASTHMA IM, V118, P197, DOI 10.1016/j.anai.2016.11.013
   Miller EJ, 1996, INFLAMM RES, V45, P386, DOI 10.1007/BF02252933
   Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005
   Naclerio RM, 2013, J ALLERGY CLIN IMMUN, V132, P247, DOI 10.1016/j.jaci.2013.04.001
   Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005
   Nagasaki T, 2013, CLIN EXP ALLERGY, V43, P608, DOI 10.1111/cea.12073
   Nagasaki T., 2017, ANN ALLERG ASTHMA IM, V119
   Ou J, 2014, EUR ARCH OTO-RHINO-L, V271, P2729, DOI 10.1007/s00405-014-2955-0
   de Llano LP, 2013, J ASTHMA, V50, P296, DOI 10.3109/02770903.2012.757780
   Pillai P, 2016, EUR RESPIR J, V48, P1593, DOI 10.1183/13993003.01501-2015
   Pinto JM, 2010, RHINOLOGY, V48, P318, DOI 10.4193/Rhin09.144
   Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093
   Refaat MM, 2008, PAN AFR MED J, V1
   Riechelmann H, 2005, ALLERGY, V60, P1418, DOI 10.1111/j.1398-9995.2005.00902.x
   Rivero A, 2017, ANN OTO RHINOL LARYN, V126, P739, DOI 10.1177/0003489417731782
   Rohde G, 2004, RESP MED, V98, P858, DOI 10.1016/j.rmed.2004.02.012
   Salgado-Pabon W, 2013, METHODS MOL BIOL, V185, P169, DOI 10.1007/978-1-62703-664-1_10
   Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446
   Schreiber J, 2019, J ALLERGY CLIN IMMUN, V143, P2279, DOI 10.1016/j.jaci.2019.01.018
   Semic-Jusufagic A, 2007, J ALLERGY CLIN IMMUN, V119, P930, DOI 10.1016/j.jaci.2006.12.639
   Shiomori T, 2000, J ALLERGY CLIN IMMUN, V105, P449, DOI 10.1067/mai.2000.104256
   Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159
   Song WJ, 2014, CLIN EXP ALLERGY, V44, P553, DOI 10.1111/cea.12239
   Song WJ, 2016, CLIN EXP ALLERGY, V46, P411, DOI 10.1111/cea.12652
   Song WJ, 2013, ASIA PAC ALLERGY, V3, P120, DOI 10.5415/apallergy.2013.3.2.120
   Tanaka A., 2015, ANN ALLERG ASTHMA IM, V115
   Tomassen P, 2013, ALLERGY, V68, P1289, DOI 10.1111/all.12230
   Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324
   Tyurin YA, 2017, J IMMUNOL RES, DOI 10.1155/2017/3054217
   Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018
   Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013
   Wedi B, 2002, J ALLERGY CLIN IMMUN, V109, P477, DOI 10.1067/mai.2002.121702
   Yii ACA, 2018, ALLERGY, V73, P1964, DOI 10.1111/all.13496
   Yu JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039032
   Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x
   Zhu LD, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0208-1
NR 70
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 66
EP 71
DI 10.1016/j.rmed.2019.07.008
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500014
PM 31302581
DA 2020-05-18
ER

PT J
AU Skold, CM
   Arnheim-Dahlstrom, L
   Bartley, K
   Janson, C
   Kirchgaessler, KU
   Levine, A
   Ferrara, G
AF Skold, C. Magnus
   Arnheim-Dahlstrom, Lisen
   Bartley, Karen
   Janson, Christer
   Kirchgaessler, Klaus-Uwe
   Levine, Aaron
   Ferrara, Giovanni
TI y Patient journey and treatment patterns in adults with IPF based on
   health care data in Sweden from 2001 to 2015
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Treatment patterns; Real-world evidence;
   Retrospective cohort; Sweden
ID IDIOPATHIC PULMONARY-FIBROSIS; CLINICAL-PRACTICE; PIRFENIDONE;
   ADHERENCE; PERSISTENCE; PREVALENCE; NINTEDANIB; DIAGNOSIS; SURVIVAL;
   DISEASE
AB Background: For patients with idiopathic pulmonary fibrosis (IPF), there is limited real-world data on patient journey and treatment patterns.
   Aim: To explore predictors of early diagnosis and treatment initiation, and treatment patterns in IPF patients using linked data from Swedish registers and electronic medical records (EMRs).
   Population: A national cohort (C1) of 17,247 pulmonary fibrosis patients (ICD-10 code J84.1; no competing diagnosis) diagnosed between 2001 and 2015, and an EMR-based regional subset (C2) comprising 1755 IPF patients diagnosed between 2004 and 2017. The time from early disease symptoms to diagnosis, use of anti-fibrotic medications, time from diagnosis to initiation of anti-fibrotic treatment, and adherence, persistence and treatment length with pirfenidone were explored in these patients.
   Results: In C1, the median time to diagnosis from the first symptoms dyspnoea, cough and fatigue were 307, 563 and 639 days, respectively. Glucocorticoids were the most frequently prescribed medication. Less than 10% of patients undergoing or initiating treatment, used pirfenidone or nintedanib. Males had a higher probability of initiating anti-fibrotic treatment than females within a year of diagnosis. One-year persistence in pirfenidone patients was 42% in C1 and 25% in C2.
   Conclusion: Diagnosis of pulmonary fibrosis was delayed in patients with cough and fatigue, which are early symptoms of IPF. This, and lower than expected utilisation of anti-fibrotic medications, suggests missed opportunities for early disease diagnosis and treatment. The high rate of treatment discontinuation underscores the importance of supporting and guiding patients to persist with their medications to ensure an accrual benefit of treatment.
C1 [Skold, C. Magnus; Ferrara, Giovanni] Karolinska Univ Hosp, Stockholm, Sweden.
   [Skold, C. Magnus; Ferrara, Giovanni] Karolinska Inst, Dept Med Solna, S-17176 Stockholm, Sweden.
   [Arnheim-Dahlstrom, Lisen; Levine, Aaron] IQVIA, Solna, Sweden.
   [Arnheim-Dahlstrom, Lisen] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Bartley, Karen] Genentech Inc, San Francisco, CA 94080 USA.
   [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden.
   [Kirchgaessler, Klaus-Uwe] F Hoffmann La Roche Ltd, Basel, Switzerland.
RP Ferrara, G (reprint author), Karolinska Inst, Dept Med Solna, S-17176 Stockholm, Sweden.
EM Giovanni.ferrara@ki.se
OI Ferrara, Giovanni/0000-0002-3807-3315; Janson,
   Christer/0000-0001-5093-6980
FU F. Hoffmann-La Roche, Ltd./Genentech, Inc.Hoffmann-La RocheRoche
   HoldingGenentech
FX This study was sponsored by F. Hoffmann-La Roche, Ltd./Genentech, Inc.
CR Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
   Behr J, 2015, EUR RESPIR J, V46, P186, DOI 10.1183/09031936.00217614
   Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1
   Cottin V., 2018, ERJ OPEN RES, P4
   Cottin V, 2015, EUR RESPIR REV, V24, P58, DOI 10.1183/09059180.00011514
   CRESTANI B, 2017, EUR RESPIR J, V50
   De Vries J, 2001, EUR RESPIR J, V17, P954, DOI 10.1183/09031936.01.17509540
   du Bois RM, 2012, EUR RESPIR REV, V21, P141, DOI 10.1183/09059180.00000812
   European Medicines Agency (EMA), 2011, ESBR PIRF AUTH DET
   European Medicines Agency (EMA), 2015, OF NINT AUTH DET
   Galli JA, 2017, RESPIROLOGY, V22, P1171, DOI 10.1111/resp.13024
   Hughes G, 2016, J CLIN MED, V5, DOI 10.3390/jcm5090078
   Jakobsson GL, 2017, SCAND J GASTROENTERO, V52, P216, DOI 10.1080/00365521.2016.1246605
   King CS, 2015, CURR OPIN PULM MED, V21, P479, DOI 10.1097/MCP.0000000000000190
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kondoh Y, 2010, SARCOIDOSIS VASC DIF, V27, P103
   LALLA D, 2017, AM J RESP CRIT CARE, V195
   Lancaster L, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000105
   Larsson K, 2013, J INTERN MED, V273, P584, DOI 10.1111/joim.12067
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450
   Martinell M, 2012, UPSALA J MED SCI, V117, P52, DOI 10.3109/03009734.2011.653015
   National Board of Health and Welfare (NBHW), LAK
   National Board of Health and Welfare (NBHW), HALS
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Oldham JM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00123
   Ortqvist AK, 2013, PHARMACOEPIDEM DR S, V22, P850, DOI 10.1002/pds.3465
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Pesonen I, 2018, MULTIDISCIP RESP MED, V13, DOI 10.1186/s40248-018-0126-7
   Raebel MA, 2013, MED CARE, V51, pS11, DOI 10.1097/MLR.0b013e31829b1d2a
   Raghu G, 2016, EUR RESPIR J, V48, P179, DOI 10.1183/13993003.01653-2015
   Raghu G, 2015, EUR RESPIR J, V46, P1113, DOI 10.1183/13993003.02316-2014
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2014, LANCET RESP MED, V2, P566, DOI 10.1016/S2213-2600(14)70101-8
   Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Raimundo K, 2017, CHEST, V152, p441A, DOI 10.1016/j.chest.2017.08.468
   Rajala K., 2017, ERJ OPEN RES, V3
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015
   Skold CM, 2017, J INTERN MED, V281, P149, DOI 10.1111/joim.12571
   Takeda Y, 2014, PATIENT PREFER ADHER, V8, P361, DOI 10.2147/PPA.S37233
   Tzouvelekis A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00213
   Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914
NR 44
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 72
EP 78
DI 10.1016/j.rmed.2019.06.001
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500015
PM 31306950
OA Other Gold, Green Published
DA 2020-05-18
ER

PT J
AU Lonzetti, L
   Zanon, M
   Pacini, GS
   Altmayer, S
   de Oliveira, DM
   Rubin, AS
   Gazzoni, FF
   Barros, MC
   Hochhegger, B
AF Lonzetti, Lilian
   Zanon, Matheus
   Pacini, Gabriel Sartori
   Altmayer, Stephan
   de Oliveira, Diogo Martins
   Rubin, Adalberto Sperb
   Gazzoni, Fernando Ferreira
   Barros, Marcelo Cardoso
   Hochhegger, Bruno
TI Magnetic resonance imaging of interstitial lung diseases: A
   state-of-the-art review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Interstitial lung disease; Computed tomography; Magnetic resonance
   imaging; Idiopathic pulmonary fibrosis; Connective tissue disease;
   Sarcoidosis
ID EMBOLISM DIAGNOSTIC-ACCURACY; HYPERPOLARIZED XE-129; ENHANCED MRI;
   PERFUSION CHARACTERISTICS; PULMONARY-FIBROSIS; GAS-TRANSFER; CHEST;
   SARCOIDOSIS; SEQUENCE; SPECTROSCOPY
AB Magnetic resonance imaging (MRI) has been emerging as an imaging modality to assess interstitial lung diseases (ILD). An optimal chest MRI protocol for ILDs should include non-contrast breath-holding sequences, steady-state free-precession sequences, and contrast-enhanced sequences. One of the main MRI applications in ILDs is the differentiation between areas of active inflammation (i.e. reversible stage) and fibrosis. Alveolitis presents high signal intensity on T2-weighted sequences (WS) and early-enhancement on contrast-enhanced MR sequences, while fibrotic-predominant lesions present low signal and late-enhancement in these sequences, respectively. MRI can be useful in connective tissue diseases, idiopathic pulmonary fibrosis, and sarcoidosis. The aim of this state-of-the-art review was to perform a state-of-the-art review on the use of MRI in ILDs, and propose the optimal MRI protocols for imaging ILDs.
C1 [Lonzetti, Lilian] Irmandade Santa Casa Misericordia Porto Alegre, Dept Rheumatol, R Sarmento Leite 245, BR-90050170 Porto Alegre, RS, Brazil.
   [Zanon, Matheus; Pacini, Gabriel Sartori; Altmayer, Stephan; Gazzoni, Fernando Ferreira; Barros, Marcelo Cardoso; Hochhegger, Bruno] Irmandade Santa Casa Misericordia Porto Alegre, Pavilhao Pereira Filho Hosp, Dept Radiol, Med Imaging Res Lab,LABIMED, Av Independencia 75, BR-90020160 Porto Alegre, RS, Brazil.
   [Altmayer, Stephan; de Oliveira, Diogo Martins; Barros, Marcelo Cardoso; Hochhegger, Bruno] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Postgrad Program Med & Hlth Sci, Av Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
   [Rubin, Adalberto Sperb; Barros, Marcelo Cardoso; Hochhegger, Bruno] Irmandade Santa Casa Misericordia Porto Alegre, Pavilhao Pereira Filho Hosp, Dept Pulmonol, Av Independencia 75, BR-90020160 Porto Alegre, RS, Brazil.
RP Hochhegger, B (reprint author), Fed Univ Hlth Sci Porto Alegre, Radiol Inst Affiliat, R Sarmento Leite 245, BR-90050170 Porto Alegre, RS, Brazil.
EM lilianlonzetti@hotmail.com; mhgzanon@hotmail.com;
   gabrielsartorip@gmail.com; stephanaltmayer@gmail.com;
   oliveira.diogo1@hotmail.com; arubin@terra.com.br; gazzoni4@gmail.com;
   macardosob@gmail.com; brunoho@ufcspa.edu.br
RI Hochhegger, Bruno/AAH-9945-2019; Pacini, Gabriel Sartori/W-3052-2018
OI Pacini, Gabriel Sartori/0000-0002-4822-7082; Zanon,
   Matheus/0000-0001-7851-5125; Hochhegger, Bruno/0000-0003-1984-4636;
   Martins de Oliveira, Diogo/0000-0002-0896-0810
CR Antoniou KM, 2014, EUR RESPIR REV, V23, P40, DOI 10.1183/09059180.00009113
   Arkema EV, 2018, THER ADV CHRONIC DIS, V9, P227, DOI 10.1177/2040622318790197
   ATS/ERS, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
   Bhalla Ashu S, 2017, Indian J Radiol Imaging, V27, P380, DOI 10.4103/ijri.IJRI_201_17
   Biederer J, 2002, ROFO-FORTSCHR RONTG, V174, P1033, DOI 10.1055/s-2002-32923
   Biederer J, 2012, INSIGHTS IMAGING, V3, P373, DOI 10.1007/s13244-011-0142-z
   Both M, 2005, EUR J RADIOL, V53, P478, DOI 10.1016/j.ejrad.2004.05.007
   Brady D, 2016, QJM-INT J MED, V109, P257, DOI 10.1093/qjmed/hcv200
   Buzan MTA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177689
   Carmona E. M., 2016, MAYO CLIN P
   Chung JH, 2014, J THORAC IMAG, V29, P125, DOI 10.1097/RTI.0b013e3182a4378b
   Chung JH, 2013, EUR J RADIOL, V82, P2378, DOI 10.1016/j.ejrad.2013.08.019
   Dournes G, 2015, RADIOLOGY, V276, P258, DOI 10.1148/radiol.15141655
   Elicker Brett, 2008, J. bras. pneumol., V34, P715, DOI 10.1590/S1806-37132008000900013
   Fain SB, 2007, J MAGN RESON IMAGING, V25, P910, DOI 10.1002/jmri.20876
   Gaeta M, 2000, CHEST, V117, P1173, DOI 10.1378/chest.117.4.1173
   Gorkem SB, 2017, PEDIATR PULM, V52, P494, DOI 10.1002/ppul.23614
   Grodzki DM, 2012, MAGN RESON MED, V67, P510, DOI 10.1002/mrm.23017
   Hochhegger Bruno, 2015, Radiol Bras, V48, P373, DOI 10.1590/0100-3984.2014.0017
   Hosch W, 2014, EMERG RADIOL, V21, P151, DOI 10.1007/s10140-013-1176-y
   Junker K, 2008, Pathologe, V29 Suppl 2, P273, DOI 10.1007/s00292-008-1026-y
   Kalb B, 2012, RADIOLOGY, V263, P271, DOI 10.1148/radiol.12110224
   Kaushik SS, 2014, J APPL PHYSIOL, V117, P577, DOI 10.1152/japplphysiol.00326.2014
   Kim EJ, 2009, CHEST, V136, P1397, DOI 10.1378/chest.09-0444
   Kirby M, 2010, RADIOLOGY, V256, P280, DOI 10.1148/radiol.10091937
   Kramer D, 2011, PHYS TODAY, V64, P20, DOI 10.1063/1.3591998
   Kreider ME, 2007, ANN THORAC SURG, V83, P1140, DOI 10.1016/j.athoracsur.2006.10.002
   Kumar V, 2017, ROBBINS BASIC PATHOL
   Kusmirek JE, 2016, RADIOL CLIN N AM, V54, P997, DOI 10.1016/j.rcl.2016.05.004
   Lavelle LP, 2017, DIAGN INTERV RADIOL, V23, P106, DOI 10.5152/dir.2016.15331
   Leslie KO, 2009, J CLIN PATHOL, V62, P387, DOI 10.1136/jcp.2008.059782
   Leslie KO, 2004, CLIN CHEST MED, V25, P657, DOI 10.1016/j.ccm.2004.05.002
   Lettieri CJ, 2005, CHEST, V127, P1600, DOI 10.1378/chest.127.5.1600
   Leutner C., 2001, MRT LUNGENPARENCHYMS
   Luboldt W, 2006, EUR J MED RES, V11, P336
   Lutterbey G, 2007, EUR J RADIOL, V61, P256, DOI 10.1016/j.ejrad.2006.09.005
   Lynch D. A., 2017, DIAGNOSTIC CRITERIA
   Margaritopoulos GA, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0027-2016
   Mariappan YK, 2011, J MAGN RESON IMAGING, V33, P1351, DOI 10.1002/jmri.22550
   Marinelli JP, 2017, J MAGN RESON IMAGING, V46, P365, DOI 10.1002/jmri.25579
   Mathai SC, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6819
   Muller CD, 2017, REV BRAS REUMATOL, V57, P419, DOI 10.1016/j.rbre.2017.02.001
   MULLER NL, 1992, AM J ROENTGENOL, V158, P1205
   Ogasawara N, 2002, INVEST RADIOL, V37, P448, DOI 10.1097/00004424-200208000-00006
   Ohno Y, 2016, J MAGN RESON IMAGING, V43, P512, DOI 10.1002/jmri.25008
   Ohno Y, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0546-8
   Ohno Y, 2014, EUR J RADIOL, V83, P391, DOI 10.1016/j.ejrad.2013.11.001
   Ohno Y, 2013, EUR J RADIOL, V82, P1359, DOI 10.1016/j.ejrad.2013.02.031
   Pasin L, 2017, LUNG, V195, P193, DOI 10.1007/s00408-017-9975-7
   Patz S, 2008, ACAD RADIOL, V15, P713, DOI 10.1016/j.acra.2008.01.008
   Pinal-Fernandez I, 2016, CLIN RHEUMATOL, V35, P2339, DOI 10.1007/s10067-016-3267-0
   Puderbach M, 2007, EUR J RADIOL, V64, P345, DOI 10.1016/j.ejrad.2007.08.009
   Qing K, 2014, J MAGN RESON IMAGING, V39, P346, DOI 10.1002/jmri.24181
   Rajaram S, 2012, RADIOLOGY, V263, P569, DOI 10.1148/radiol.12110990
   Revel MP, 2013, EUR RADIOL, V23, P2374, DOI 10.1007/s00330-013-2852-8
   Romei C, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0062-2018
   Roos JE, 2015, MAGN RESON IMAGING C, V23, P217, DOI 10.1016/j.mric.2015.01.003
   Rosenson J, 2010, NEW ENGL J MED, V363, P1973, DOI 10.1056/NEJMc1009061
   Sprunger DB, 2012, EUR RESPIR J, V39, P125, DOI 10.1183/09031936.00041411
   Stewart NJ, 2015, MAGN RESON MED, V74, P196, DOI 10.1002/mrm.25400
   Suga K, 2001, INVEST RADIOL, V36, P386, DOI 10.1097/00004424-200107000-00005
   Swift AJ, 2005, EUR J RADIOL, V54, P352, DOI 10.1016/j.ejrad.2004.08.002
   Thomen RP, 2015, RADIOLOGY, V274, P250, DOI 10.1148/radiol.14140080
   Ungprasert P., 2016, MAYO CLIN P
   Vij R, 2013, CHEST, V143, P814, DOI 10.1378/chest.12-0741
   Visscher Daniel W, 2006, Proc Am Thorac Soc, V3, P322, DOI 10.1513/pats.200602-019TK
   Wang JM, 2018, THORAX, V73, P21, DOI 10.1136/thoraxjnl-2017-210070
   Weatherley ND, 2019, THORAX, V74, P500, DOI 10.1136/thoraxjnl-2018-211851
   Wild JM, 2012, INSIGHTS IMAGING, V3, P345, DOI 10.1007/s13244-012-0176-x
   Wild J. M., 2018, IMAGING PATHOPHYSIOL
   Yi CA, 2008, AM J ROENTGENOL, V190, P878, DOI 10.2214/AJR.07.2833
NR 71
TC 1
Z9 1
U1 3
U2 11
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 79
EP 85
DI 10.1016/j.rmed.2019.07.006
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500016
PM 31323528
DA 2020-05-18
ER

PT J
AU Cherian, SV
   Kumar, A
   Ocazionez, D
   Estrada-Y-Martin, RM
   Restrepo, CS
AF Cherian, Sujith V.
   Kumar, Anupam
   Ocazionez, Daniel
   Estrada-Y-Martin, Rosa M.
   Restrepo, Carlos Santiago
TI Developmental lung anomalies in adults: A pictorial review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Developmental anomalies; Lung; Vascular; Radiology
ID CONGENITAL LOBAR EMPHYSEMA; CYSTIC ADENOMATOID MALFORMATION; ISOLATED
   UNILATERAL ABSENCE; RIGHT PULMONARY AGENESIS; EXTRALOBAR SEQUESTRATION;
   PROXIMAL INTERRUPTION; SCIMITAR SYNDROME; ARTERY; CARCINOMA; WOMAN
AB Developmental lung anomalies represent a heterogeneous group of diverse, yet related abnormalities that involve the lung parenchyma, pulmonary vasculature or a combination of both-which usually present prenatally and in early childhood. However, a substantial number of cases go unnoticed during childhood and present either incidentally or with recurrent respiratory infections progressing into adulthood. Defective development of the tracheobronchial tree and the pulmonary vasculature are proposed to cause these developmental anomalies. Encountering these lung anomalies in adults is a diagnostic challenge given their rarity and they are often mistaken as other serious pathological conditions, resulting in unnecessary diagnostic tests and procedures. The developmental lung anomalies in adults can be broadly divided into three categories: bronchopulmonary anomalies encompassing congenital bronchial atresia, bronchogenic cysts, congenital lobar emphysema and congenital pulmonary airway malformations. Vascular anomalies include pulmonary agenesis-aplasia-hypoplasia complex, unilateral absence of the pulmonary artery, pulmonary artery sling, partial anomalous pulmonary venous return, pulmonary venous varix and pulmonary arteriovenous malformations. Finally combined lung parenchymal-vascular anomalies of the lung involve hypogenetic lung (scimitar) syndrome and bronchopulmonary sequestration. This article discusses the spectrum of these developmental anomalies of the lung, their etiopathogenesis, clinical and radiographic presentations in adults and management in brief.
C1 [Cherian, Sujith V.; Kumar, Anupam; Estrada-Y-Martin, Rosa M.] Div Pulm, Houston, TX USA.
   [Cherian, Sujith V.; Kumar, Anupam; Estrada-Y-Martin, Rosa M.] Div Crit Care & Sleep Med, Houston, TX USA.
   [Cherian, Sujith V.; Ocazionez, Daniel; Estrada-Y-Martin, Rosa M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA.
   [Kumar, Anupam] Michigan State Univ, Coll Human Med, Spectrum Health, Grand Rapids, MI 49503 USA.
   [Ocazionez, Daniel] Dept Diagnost & Intervent Imaging, Houston, TX USA.
   [Restrepo, Carlos Santiago] Univ Texas Hlth Sci Ctr San Antonio, UT Hlth, San Antonio, TX 78229 USA.
RP Cherian, SV (reprint author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA.
EM sujith.v.cherian@uth.tmc.edu; anupamkumarmd@gmail.com;
   Daniel.OcazionezTrujillo@uth.tmc.edu;
   rosa.m.estrada.y.martin@uth.tmc.edu; restrepoc@uthscsa.edu
OI Cherian, Sujith/0000-0003-0177-9979
CR Abbey P., 2014, CURR RADIOL REP, V2, P71
   Anand SH, 2015, J CLIN DIAGN RES, V9, pTD04, DOI 10.7860/JCDR/2015/16198.6980
   Anantham Devanand, 2011, Diagn Ther Endosc, V2011, P468237, DOI 10.1155/2011/468237
   Arnaud D., 2017, CASE REP PULMONOL, V2017
   Avishai V, 1996, CHEST, V109, P843, DOI 10.1378/chest.109.3.843
   BAKER EL, 1982, AM J ROENTGENOL, V138, P956, DOI 10.2214/ajr.138.5.956
   Belcher E, 2007, EUR RESPIR J, V30, P801, DOI 10.1183/09031936.00153906
   BELLTHOMSON J, 1979, CANCER, V44, P334, DOI 10.1002/1097-0142(197907)44:1<334::AID-CNCR2820440157>3.0.CO;2-6
   Berrocal Teresa, 2004, Radiographics, V24, pe17, DOI 10.1148/rg.e17
   Biyyam DR, 2010, RADIOGRAPHICS, V30, P1721, DOI 10.1148/rg.306105508
   Boulton BJ, 2011, ANN THORAC SURG, V92, pE27, DOI 10.1016/j.athoracsur.2011.03.045
   Cardenas-Garcia J, 2014, RESPIR MED CASE REP, V12, P59, DOI 10.1016/j.rmcr.2014.04.004
   Castaner E, 2006, RADIOGRAPHICS, V26, P349, DOI 10.1148/rg.262055092
   CHIN KY, 1949, ARCH PATHOL, V48, P221
   Collins RT, 2008, CIRCULATION, V117, P2403, DOI 10.1161/CIRCULATIONAHA.107.744169
   Conran RM, 1999, PEDIATR DEVEL PATHOL, V2, P454, DOI 10.1007/s100249900149
   Cooke CR, 2006, RESP CARE, V51, P661
   CRITCHLEY PS, 1995, THORAX, V50, P909, DOI 10.1136/thx.50.8.909
   Dhand S, 2008, THORAX, V63, P386, DOI 10.1136/thx.2007.078071
   Dillman JR, 2009, AM J ROENTGENOL, V192, P1272, DOI 10.2214/AJR.08.1526
   DUPUIS C, 1992, AM J CARDIOL, V70, P502, DOI 10.1016/0002-9149(92)91198-D
   Farha S, 2005, J BRONCHOL INTERN PU, V12, P217, DOI 10.1097/01.lab.0000186341.62154.9a
   Fiore AC, 2005, ANN THORAC SURG, V79, P38, DOI 10.1016/j.athoracsur.2004.06.005
   Frazier AA, 1997, RADIOGRAPHICS, V17, P725, DOI 10.1148/radiographics.17.3.9153708
   Gipson MG, 2009, RADIOGRAPHICS, V29, P1531, DOI 10.1148/rg.295085239
   Glaevecke H. D. W., 1897, MUNCHEN MED WOCHEN, V44, P950
   Gleason J. B., 2017, CLIN PULM MED, V24, P87
   Gunbey HP, 2014, J CLIN DIAGN RES, V8, pRD1, DOI [10.7860/JCDR/014/7968.4420, 10.7860/JCDR/2014/7968.4420]
   HACKETT PH, 1980, NEW ENGL J MED, V302, P1070, DOI 10.1056/NEJM198005083021907
   HALASZ NA, 1956, CIRCULATION, V14, P826, DOI 10.1161/01.CIR.14.5.826
   Halkic N, 1998, EUR J CARDIO-THORAC, V14, P127, DOI 10.1016/S1010-7940(98)00154-7
   Hall NJ, 2017, SEMIN PEDIATR SURG, V26, P311, DOI 10.1053/j.sempedsurg.2017.09.001
   Hekelaar N, 2000, EUR RESPIR J, V16, P1025
   Inui T, 2017, CLIN CASE REP, V5, P863, DOI 10.1002/ccr3.960
   Jeung MY, 2002, RADIOGRAPHICS, V22, P351, DOI 10.1148/radiographics.22.2.g02mr01351
   Katsenos S, 2014, RESP CARE, V59, pE47, DOI 10.4187/respcare.02740
   Kebbe J, 2016, ANN AM THORAC SOC, V13, P753, DOI 10.1513/AnnalsATS.201601-008LE
   KENNEDY CD, 1991, RADIOLOGY, V180, P189, DOI 10.1148/radiology.180.1.2052691
   Khurshid I, 2002, POSTGRAD MED J, V78, P191, DOI 10.1136/pmj.78.918.191
   Kim SR, 2011, CHEST, V140, P544, DOI 10.1378/chest.10-1932
   King N, 2017, ANN THORAC SURG, V104, pE367, DOI 10.1016/j.athoracsur.2017.06.068
   Kirmani B, 2010, INTERACT CARDIOV TH, V11, P649, DOI 10.1510/icvts.2010.233114
   Komoto K, 2013, INTERNAL MED, V52, P1271, DOI 10.2169/internalmedicine.52.9282
   Kruzliak P, 2013, ARCH CARDIOVASC DIS, V106, P448, DOI 10.1016/j.acvd.2013.05.004
   Kumar P, 2016, J CLIN DIAGN RES, V10, pOD15, DOI 10.7860/JCDR/2016/21623.8547
   LaBelle MF, 2010, ANN THORAC SURG, V90, P1009, DOI 10.1016/j.athoracsur.2009.12.088
   Laberge Jean-Martin, 2005, Semin Pediatr Surg, V14, P16, DOI 10.1053/j.sempedsurg.2004.10.022
   Lai PS, 2009, CHEST, V136, P622, DOI 10.1378/chest.08-2902
   Lee EY, 2008, RADIOLOGY, V247, P632, DOI 10.1148/radiol.2473062124
   Lee EY, 2011, RADIOL CLIN N AM, V49, P921, DOI 10.1016/j.rcl.2011.06.009
   Majdalany DS, 2010, CONGENIT HEART DIS, V5, P537, DOI 10.1111/j.1747-0803.2010.00458.x
   Makhija Z, 2011, ANN THORAC SURG, V91, P1568, DOI 10.1016/j.athoracsur.2011.01.080
   Maldonado JA, 2010, RADIOL CLIN N AM, V48, P85, DOI 10.1016/j.rcl.2009.09.004
   McDonough RJ, 2012, RESP CARE, V57, P302, DOI 10.4187/respcare.00727
   Milliron B, 2015, RADIOGRAPHICS, V35, P1011, DOI 10.1148/rg.2015140214
   Najm HK, 1996, J THORAC CARDIOV SUR, V112, P1161, DOI 10.1016/S0022-5223(96)70129-0
   NAJM HK, 1996, J THORAC CARDIOVASC, V112, P8
   Nemec SF, 2013, AM J ROENTGENOL, V200, pW101, DOI 10.2214/AJR.12.8917
   Niggemann B, 2002, EUR RESPIR J, V19, P582, DOI 10.1183/09031936.02.00271602
   Odell DD, 2011, J BRONCHOL INTERN PU, V18, P278, DOI 10.1097/LBR.0b013e318228f45b
   PAKSOY N, 1992, THORAX, V47, P837, DOI 10.1136/thx.47.10.837
   Pike D, 2015, J RADIOL CASE REP, V9, P9, DOI 10.3941/jrcr.v9i2.2048
   PRYCE DM, 1946, J PATHOL BACTERIOL, V58, P457
   Psathakis K, 2004, Monaldi Arch Chest Dis, V61, P28
   Ramirez-Marrero Miguel Angel, 2012, Case Rep Vasc Med, V2012, P138541, DOI 10.1155/2012/138541
   ROSADOCHRISTENSON ML, 1993, RADIOGRAPHICS, V13, P425, DOI 10.1148/radiographics.13.2.8460228
   RUBIN EM, 1994, CHEST, V106, P954, DOI 10.1378/chest.106.3.954
   Ryu DS, 2004, J THORAC IMAG, V19, P171, DOI 10.1097/01.rti.0000130598.86945.b9
   Sadaqat M, 2011, LUNG INDIA, V28, P67, DOI 10.4103/0970-2113.76307
   Sagawa M, 2015, AM J RESP CRIT CARE, V191, P1083, DOI 10.1164/rccm.201501-0122IM
   Sasieta HC, 2016, AM J RESP CRIT CARE, V194, P377, DOI 10.1164/rccm.201602-0289IM
   SAVIC B, 1979, THORAX, V34, P96, DOI 10.1136/thx.34.1.96
   SHAKIBI JG, 1978, JPN HEART J, V19, P439
   STERN EJ, 1994, AM J ROENTGENOL, V162, P279, DOI 10.2214/ajr.162.2.8310909
   STILLER RJ, 1988, AM J OBSTET GYNECOL, V158, P172, DOI 10.1016/0002-9378(88)90805-8
   Stocker J. T., 2008, DAIL HAMMARS PULMONA, V1, P132
   Ten Harkel ADJ, 2002, CHEST, V122, P1471, DOI 10.1378/chest.122.4.1471
   Thacker PG, 2014, RADIOL CLIN N AM, V52, P155, DOI 10.1016/j.rcl.2013.09.001
   Trotman-Dickenson B, 2015, J THORAC IMAG, V30, P46, DOI 10.1097/RTI.0000000000000127
   Ueda T, 2011, INTERNAL MED, V50, P463, DOI 10.2169/internalmedicine.50.4470
   Van Raemdonck D, 2001, EUR J CARDIO-THORAC, V19, P388, DOI 10.1016/S1010-7940(01)00603-0
   Porres DV, 2013, RADIOGRAPHICS, V33, P999, DOI 10.1148/rg.334125043
   WOODRING JH, 1994, RADIOGRAPHICS, V14, P349, DOI 10.1148/radiographics.14.2.8190958
   Zylak CJ, 2002, RADIOGRAPHICS, V22, pS25, DOI 10.1148/radiographics.22.suppl_1.g02oc26s25
NR 84
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 86
EP 96
DI 10.1016/j.rmed.2019.07.011
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500017
PM 31326738
DA 2020-05-18
ER

PT J
AU Visser, SK
   Bye, PTP
   Fox, GJ
   Burr, LD
   Chang, AB
   Holmes-Liew, CL
   King, P
   Middleton, PG
   Maguire, GP
   Smith, D
   Thomson, RM
   Stroil-Salama, E
   Britton, WJ
   Morgan, LC
AF Visser, Simone K.
   Bye, Peter T. P.
   Fox, Greg J.
   Burr, Lucy D.
   Chang, Anne B.
   Holmes-Liew, Chien-Li
   King, Paul
   Middleton, Peter G.
   Maguire, Graeme P.
   Smith, Daniel
   Thomson, Rachel M.
   Stroil-Salama, Enna
   Britton, Warwick J.
   Morgan, Lucy C.
TI Australian adults with bronchiectasis: The first report from the
   Australian Bronchiectasis Registry
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiectasis; Exacerbations; Phenotype; Quality of life; Respiratory
   function tests; Registry
ID CHILDREN
AB Background: /objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).
   Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (>= 18 years).
   Results: From March 2016-August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64-77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (r(s) between -0.09 and -0.58). The frequent exacerbator phenotype (>= 3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p <= 0.001) and more hospitalisations (p < 0.001) than those with < 3 exacerbations.
   Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.
C1 [Visser, Simone K.; Bye, Peter T. P.; Fox, Greg J.] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW 2006, Australia.
   [Visser, Simone K.; Bye, Peter T. P.; Fox, Greg J.] Royal Prince Alfred Hosp, Dept Resp Med, Level 11,Missenden Rd, Camperdown, NSW 2050, Australia.
   [Burr, Lucy D.] Mater Hlth, Dept Resp & Sleep Med, South Brisbane, Qld, Australia.
   [Burr, Lucy D.] Univ Queensland, Mater Res, Brisbane, Qld, Australia.
   [Chang, Anne B.] Queensland Univ Technol, Queensland Childrens Hosp, Dept Resp & Sleep Med, Brisbane, Qld, Australia.
   [Chang, Anne B.] Charles Darwin Univ, Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT, Australia.
   [Holmes-Liew, Chien-Li] Univ Adelaide, Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia.
   [King, Paul] Monash Med Ctr, Monash Resp & Sleep Med, Melbourne, Vic, Australia.
   [Middleton, Peter G.] Westmead Hosp, Dept Resp Med, Westmead, NSW 2145, Australia.
   [Maguire, Graeme P.] Univ Melbourne, Western Clin Sch, Melbourne, Vic 3021, Australia.
   [Maguire, Graeme P.] Western Hlth, Gen Internal Med, Melbourne, Vic 3011, Australia.
   [Smith, Daniel] Prince Charles Hosp, Thorac Med, Brisbane, Qld, Australia.
   [Smith, Daniel] QIMR Berghofer Med Res Inst, Lung Inflammat & Infect Lab, Herston, Qld, Australia.
   [Thomson, Rachel M.] Greenslopes Private Hosp, Dept Resp Med, Greenslopes, Qld 4120, Australia.
   [Stroil-Salama, Enna] Lung Fdn Australia, Milton, Qld, Australia.
   [Britton, Warwick J.] Univ Sydney, Centenary Inst, Sydney, NSW 2006, Australia.
   [Morgan, Lucy C.] Univ Sydney, Fac Med & Hlth, Concord Clin Sch, Sydney, NSW 2006, Australia.
   [Morgan, Lucy C.] Concord Gen Repatriat Hosp, Dept Resp Med, Concord, NSW 2137, Australia.
RP Visser, SK (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, Level 11,Missenden Rd, Camperdown, NSW 2050, Australia.
EM simone.visser@health.nsw.gov.au
RI Thomson, Rachel/C-1009-2011; Smith, Daniel/K-4978-2018; Burr, Lucy
   D/F-8296-2015
OI Thomson, Rachel/0000-0003-0686-171X; Smith, Daniel/0000-0002-8945-1531;
   Stroil-Salama, Enna/0000-0003-0618-0746; Burr, Lucy
   D/0000-0003-4010-3787; Morgan, Lucy/0000-0001-6389-1953
FU Aradigm; National Health and Medical Research Council (NHMRC)National
   Health and Medical Research Council of Australia [1154302];
   NHMRCNational Health and Medical Research Council of Australia
   [1134081]; Bayer HealthCareBayer AGBayer Healthcare Pharmaceuticals;
   Insmed
FX The ABR is an initiative of Lung Foundation Australia and was
   established with the generous support of sponsors Aradigm, Bayer
   HealthCare, Insmed and philanthropic donations. These sponsors had no
   input to the interpretation of data or preparation of the manuscript. We
   thank all the participants as well as all clinicians, volunteers and
   support staff.; ABC is funded by a National Health and Medical Research
   Council (NHMRC) practitioner fellowship (grant 1154302) and SKV by a
   NHMRC postgraduate scholarship (grant 1134081).
CR Aksamit T, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02053-2017
   Aksamit TR, 2017, CHEST, V151, P982, DOI 10.1016/j.chest.2016.10.055
   Aliberti S, 2016, EUR RESPIR J, V47, P1113, DOI 10.1183/13993003.01899-2015
   Bell SC, 2018, RESPIROLOGY, V23, P1006, DOI 10.1111/resp.13398
   Blackall SR, 2018, RESPIROLOGY, V23, P743, DOI 10.1111/resp.13280
   Bryant JM, 2016, SCIENCE, V354, P751, DOI 10.1126/science.aaf8156
   Chalmers JD, 2018, LANCET RESP MED, V6, P715, DOI 10.1016/S2213-2600(18)30053-5
   Chalmers JD, 2018, AM J RESP CRIT CARE, V197, P1410, DOI 10.1164/rccm.201711-2202OC
   Chalmers JD, 2014, AM J RESP CRIT CARE, V189, P576, DOI 10.1164/rccm.201309-1575OC
   Chandrasekaran R., 2018, BMC PULM MED, V18, P1
   Chang AB, 2002, MED J AUSTRALIA, V177, P200, DOI 10.5694/j.1326-5377.2002.tb04733.x
   Chang AB, 2010, MED J AUSTRALIA, V193, P356, DOI 10.5694/j.1326-5377.2010.tb03949.x
   Culver BH, 2017, AM J RESP CRIT CARE, V196, P1463, DOI 10.1164/rccm.201710-1981ST
   Dudgeon EK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0631-7
   Finch S, 2015, ANN AM THORAC SOC, V12, P1602, DOI 10.1513/AnnalsATS.201506-333OC
   Floto RA, 2016, THORAX, V71, P1, DOI 10.1136/thoraxjnl-2015-207360
   Grimwood K, 2019, LANCET RESP MED, V7, P188, DOI 10.1016/S2213-2600(18)30456-9
   Haworth CS, 2019, LANCET RESP MED, V7, P213, DOI [10.1016/s2213-2600(18)30427-2, 10.1016/S2213-2600(18)30427-2]
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Martinez-Garcia MA, 2014, EUR RESPIR J, V43, P1357, DOI 10.1183/09031936.00026313
   McDonnell MJ, 2016, THORAX, V71, P1110, DOI 10.1136/thoraxjnl-2016-208481
   Olveira C, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00208-2017
   Polverino E, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00328-2018
   Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Quint JK, 2016, EUR RESPIR J, V47, P186, DOI 10.1183/13993003.01033-2015
   Quittner AL, 2015, THORAX, V70, P12, DOI 10.1136/thoraxjnl-2014-205918
   Ringshausen FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071109
   Seitz AE, 2012, CHEST, V142, P432, DOI 10.1378/chest.11-2209
   Singleton RJ, 2014, PEDIATR PULM, V49, P189, DOI 10.1002/ppul.22763
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Webb WR, 2015, HIGH RESOLUTION CT L
NR 32
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 97
EP 103
DI 10.1016/j.rmed.2019.07.016
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500018
PM 31326739
DA 2020-05-18
ER

PT J
AU Feldman, LY
   Zhu, JQ
   To, T
AF Feldman, Laura Y.
   Zhu, Jingqin
   To, Teresa
TI Estimating age-specific influenza-associated asthma morbidity in
   Ontario, Canada
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Influenza; Health services; Health administrative data
ID RESPIRATORY VIRUSES; VACCINATION; CHILDREN; EXACERBATIONS; MORTALITY;
   INFECTIONS; EFFICACY; IMPACT
AB Background: There is a need to quantify the potential benefits of influenza-focused interventions in reducing asthma morbidity at a population level. This study aims to estimate age-specific annual excess asthma morbidity attributable to influenza in Ontario, Canada.
   Methods: Weekly counts of hospitalizations, emergency department (ED) visits and outpatient physician office visits for asthma were obtained from health administrative data in Ontario from 2010 to 2015, for ages 0-14, 15-59 and 60+. Asthma morbidity was modelled as a function of influenza A and B activity using linear regression, controlling for seasonal and long-term trend, mean temperature and respiratory syncytial virus. Excess asthma morbidity attributable to influenza was calculated as the difference between full model predictions and model predictions with influenza A and B variables set to 0.
   Results: Annually, influenza was associated with the following rates of excess asthma morbidity, per 100,000 people with prevalent asthma: 12.5 hospitalizations for ages 15-59 (95% confidence interval (CI): 1.1-23.5); 35.7 hospitalizations for ages 60+ (95% CI: 3.3-67.1); 114.1 ED visits for ages 15-59 (95% CI: 46.9-181.6); 154.6 ED visits for ages 60+ (95% CI: 86.7-223.3); and 1025.7 outpatient physician office visits for ages 60+ (95% CI: 79.0-1877.3).
   Conclusions: Influenza was associated with excess asthma hospitalizations and ED visits for ages 15-59 and 60+ and outpatient physician office visits for ages 60+. Individuals with asthma aged 15-59 and 60+ might be important targets for influenza-focused interventions, to reduce asthma morbidity at the population level.
C1 [Feldman, Laura Y.; Zhu, Jingqin; To, Teresa] Hosp Sick Children, Child Hlth Evaluat Sci, 686 Bay St, Toronto, ON M5G 0A4, Canada.
   [Zhu, Jingqin; To, Teresa] ICES, Toronto, ON, Canada.
   [To, Teresa] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
RP To, T (reprint author), Hosp Sick Children, Child Hlth Evaluat Sci, 686 Bay St, Toronto, ON M5G 0A4, Canada.
EM teresa.to@sickkids.ca
FU Ontario Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health
   and Long-Term Care, Ontario; Ontario MOHLTCMinistry of Health and
   Long-Term Care, Ontario
FX The Ontario Asthma Surveillance Information System (OASIS) is funded by
   the Ontario Ministry of Health and Long-Term Care (MOHLTC). Data are
   provided by Public Health Ontario (PHO) and ICES, which is funded by an
   annual grant from the Ontario MOHLTC. The opinions, results and
   conclusions reported in this paper are those of the authors and are
   independent from the funding source. No endorsement by PHO, ICES or the
   Ontario MOHLTC is intended or should be inferred. Parts of this material
   are based on data and information compiled and provided by the Canadian
   Institute for Health Information (CIHI). However, the analyses,
   conclusions, opinions and statements expressed herein are those of the
   authors and not necessarily those of CIHI. The authors have no other
   relevant sources of funding to declare.
CR Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC
   Bueving HJ, 2004, EUR RESPIR J, V24, P925, DOI 10.1183/09031936.04.00060504
   Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3
   Cates CJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000364.pub4
   Gershon AS, 2009, CAN RESPIR J, V16, P183, DOI 10.1155/2009/963098
   Goldstein E, 2012, EPIDEMIOLOGY, V23, P829, DOI 10.1097/EDE.0b013e31826c2dda
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4
   Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kim J. H., 2005, Computational Economics, V25, P255, DOI 10.1007/s10614-005-2208-9
   Kwong JC, 2007, VACCINE, V25, P1270, DOI 10.1016/j.vaccine.2006.10.004
   Larsen K, 2016, ANN AM THORAC SOC, V13, P231, DOI 10.1513/AnnalsATS.201508-545OC
   Li L, 2018, AM J EPIDEMIOL, V187, P378, DOI 10.1093/aje/kwx270
   NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2017, REL INFL MED RISK FA
   Public Health Ontario, 2016, PUBL HLTH ONT LAB RE
   Public Health Ontario, 2018, COMMUNICATION
   R Core Team, 2017, R LANG ENV STAT COMP
   Schanzer DL, 2008, INFLUENZA OTHER RESP, V2, P1, DOI 10.1111/j.1750-2659.2008.00035.x
   Schanzer DL, 2006, PEDIATR INFECT DIS J, V25, P795, DOI 10.1097/01.inf.0000232632.86800.8c
   Schanzer DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080481
   Schanzer DL, 2013, ACAD EMERG MED, V20, P388, DOI 10.1111/acem.12111
   Schwartz Kevin L, 2016, CMAJ Open, V4, pE463
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   To T, 2006, PEDIAT ALLERG IMM-UK, V17, P69, DOI 10.1111/j.1399-3038.2005.00346.x
NR 27
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 104
EP 112
DI 10.1016/j.rmed.2019.07.017
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500019
PM 31326737
DA 2020-05-18
ER

PT J
AU Tashkin, DP
   Goodin, T
   Bowling, A
   Price, B
   Ozol-Godfrey, A
   Sharma, S
   Sanjar, S
AF Tashkin, Donald P.
   Goodin, Thomas
   Bowling, Alyssa
   Price, Barry
   Ozol-Godfrey, Ayca
   Sharma, Sanjay
   Sanjar, Shahin
TI Effect of smoking status on lung function, patient-reported outcomes,
   and safety among patients with COPD treated with
   indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2
   studies
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchodilator; COPD; Glycopyrrolate; Indacaterol; Smoking status
ID OBSTRUCTIVE PULMONARY-DISEASE; CESSATION; TIOTROPIUM; EFFICACY; THERAPY;
   DECLINE; ASTHMA
AB Background: Smoking continues to be a major risk factor for COPD and may impact the efficacy of COPD treatments, with guidelines supporting the crucial importance for current smokers of smoking cessation. A post-hoc analysis of the FLIGHT1 and FLIGHT2 studies assessed the impact of smoking status on the efficacy and safety of indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 mu g twice daily versus its monocomponents or placebo in patients with COPD.
   Methods: This post-hoc analysis of pooled data from the replicate, 12-week, placebo-controlled FLIGHT1 and FLIGHT2 studies compared the efficacy and safety of IND/GLY with that of IND, GLY, and placebo in patients with moderate-to-severe COPD. Baseline data from 2038 patients were pooled and grouped by smoking status (52% were current smokers and 48% were ex-smokers). The effects of treatment on lung function, patient-reported outcomes (PROs), and safety were evaluated by baseline smoking status.
   Results: Treatment with IND/GLY resulted in significant improvements in lung function measurements compared with placebo, irrespective of smoking status. Improvements in St George's Respiratory Questionnaire and transition dyspnea index were significantly greater than placebo in both current and ex-smokers, whereas changes in COPD assessment test were significant only among current smokers. Improvements in lung function and PROs were greater with IND/GLY compared with its monocomponents in current and ex-smokers. The incidences of AEs and SAEs were similar between current and ex-smokers.
   Conclusions: IND/GLY demonstrated significant improvements in lung function and PROs, independent of baseline smoking status. The safety profile of IND/GLY did not differ between current and ex-smokers.
C1 [Tashkin, Donald P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Goodin, Thomas; Bowling, Alyssa; Price, Barry; Ozol-Godfrey, Ayca; Sharma, Sanjay; Sanjar, Shahin] Sunovion Pharmaceut Inc, Marlborough, MA USA.
RP Tashkin, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
EM dtashkin@mednet.ucla.edu
FU Sunovion Pharmaceuticals Inc.
FX This post-hoc analysis was funded by Sunovion Pharmaceuticals Inc.
   Medical writing support was provided by Hashem Dbouk, PhD, of FireKite,
   an Ashfield company, part of UDG Healthcare plc, and funded by Sunovion
   Pharmaceuticals Inc.
CR Anzueto A, 2018, AM J MED, V131, P608, DOI 10.1016/j.amjmed.2017.12.018
   Braganza Georgina, 2008, Ther Adv Respir Dis, V2, P95, DOI 10.1177/1753465808089697
   Calverley PMA, 2018, AM J RESP CRIT CARE, V197, P47, DOI 10.1164/rccm.201610-2086OC
   Calzetta L, 2016, CHEST, V149, P1181, DOI 10.1016/j.chest.2016.02.646
   Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC
   Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226
   Diaz-Guzman E, 2014, CLIN CHEST MED, V35, P7, DOI 10.1016/j.ccm.2013.10.002
   Global Initiative for Chronic Obstructive Lung Disease ( GOLD ), 2019, GLOBAL STRATEGY DIAG
   Jimenez-Ruiz CA, 2015, EUR RESPIR J, V46, P61, DOI 10.1183/09031936.00092614
   Jones Paul W, 2005, COPD, V2, P75
   Kon SSC, 2014, LANCET RESP MED, V2, P195, DOI 10.1016/S2213-2600(14)70001-3
   Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC
   Livingston E, 2005, DRUGS, V65, P1521, DOI 10.2165/00003495-200565110-00005
   Mahler Donald A, 2005, COPD, V2, P99
   Mahler DA, 2015, AM J RESP CRIT CARE, V192, P1068, DOI 10.1164/rccm.201505-1048OC
   Moita J, 2008, PULM PHARMACOL THER, V21, P146, DOI 10.1016/j.pupt.2007.04.003
   Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3
   Rabe KF, 2017, LANCET, V389, P1931, DOI 10.1016/S0140-6736(17)31222-9
   Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381, DOI 10.1164/ajrccm.161.2.9901044
   Sunovion Pharmaceuticals Inc, 2018, UT NEOH IND GLYC INH
   Tamimi A, 2012, RESP MED, V106, P319, DOI 10.1016/j.rmed.2011.11.003
   Tashkin DP, 2008, EUR RESPIR J, V31, P742, DOI 10.1183/09031936.00129607
   Tashkin DP, 2011, RESP MED, V105, P1682, DOI 10.1016/j.rmed.2011.04.016
   Tashkin DP, 2010, EUR RESPIR J, V35, P287, DOI 10.1183/09031936.00082909
   Tonnesen P, 2006, CHEST, V130, P334, DOI 10.1378/chest.130.2.334
   Van Overveld FJ, 2006, J PHYSIOL PHARMACOL, V57, P273
   Vestbo J, 2012, CLIN RESPIR J, V6, P208, DOI 10.1111/crj.12002
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Wheaton AG, 2015, MMWR-MORBID MORTAL W, V64, P289
   World Health Organization, WHO GLOB REP MORT AT
NR 30
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 113
EP 120
DI 10.1016/j.rmed.2019.07.019
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500020
PM 31344660
DA 2020-05-18
ER

PT J
AU Hisinger-Molkanen, H
   Pallasaho, P
   Haahtela, T
   Lindqvist, A
   Sovijarvi, A
   Piirila, P
AF Hisinger-Molkanen, Hanna
   Pallasaho, Paula
   Haahtela, Tari
   Lindqvist, Ari
   Sovijarvi, Anssi
   Piirila, Paivi
TI The increase of asthma prevalence has levelled off and symptoms
   decreased in adults during 20 years from 1996 to 2016 in Helsinki,
   Finland
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Asthma prevalence; Physician diagnosed asthma; Respiratory
   symptoms; Rhinoconjunctivitis
ID SELF-REPORTED ASTHMA; FINNISH; ALLERGY; CHILDHOOD; SEVERITY; PROGRAM;
   TRENDS; CARE
AB Background: Mortality and hospitalization due to asthma have decreased in many European countries, but asthma symptoms still cause a lot of morbidity and costs.
   Objectives: We evaluated prevalence trends of asthma, asthma symptoms and allergic rhinoconjunctivitis in adults aged 20-69 years during a 20-year period from 1996 to 2016 in the city of Helsinki, the capital of Finland.
   Methods: Three cross-sectional postal surveys were conducted in random population samples 10 years apart. In 1996, 2006 and 2016, a total of 6062 (response rate 75.9%), 2449 (61.9%) and 4026 subjects (50.3%) took part, respectively.
   Results: In all responders, the prevalence of physician-diagnosed asthma was 6.6% in 1996, 10% in 2006 and 10.9% in 2016. The prevalence increased from 1996 to 2006, but stabilized from 2006 to 2016, both in men and women and in smokers and non-smokers. The prevalence of current asthma (8.5% in 2006 and 8.8% in 2016) and of asthma with rhinoconjunctivitis (7.6% in 2006 and 7.5% in 2016) remained also at the same level. Allergic rhinoconjunctivitis decreased significantly from 2006 (42.7%) to 2016 (39.0%, p=0.004). Those with physician diagnosed asthma reported significantly less symptoms in 2016 compared to 2006 and 1996, although there was no change in smoking habits or medication use. Young asthmatics (20-29 years) without rhinoconjunctivitis reported least symptoms.
   Conclusion: Previously observed increase of physician-diagnosed asthma prevalence in adults seems to be levelling off in Helsinki, and patients have fewer symptoms than 20 years ago. In addition, allergic rhinoconjunctivitis is less frequent than 10 years earlier. (247 words).
C1 [Hisinger-Molkanen, Hanna; Haahtela, Tari; Sovijarvi, Anssi] Univ Helsinki, Helsinki, Finland.
   [Pallasaho, Paula] Espoo City Hlth Serv, Espoo, Finland.
   [Haahtela, Tari] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
   [Lindqvist, Ari] Helsinki Univ Hosp, Clin Res Unit Pulm Dis, Helsinki, Finland.
   [Sovijarvi, Anssi] Helsinki Univ Hosp, HUS Med Imaging Ctr, Helsinki, Finland.
   [Piirila, Paivi] Univ Helsinki, Helsinki Univ Hosp, HUS Med Imaging Ctr, Unit Clin Physiol, Helsinki, Finland.
RP Hisinger-Molkanen, H (reprint author), Univ Helsinki, Helsinki, Finland.
EM hanna.hisinger-molkanen@helsinki.fi
RI ; Piirila, Paivi/H-2291-2018
OI Hisinger-Molkanen, Hanna/0000-0003-2293-0279; Piirila,
   Paivi/0000-0002-2535-4409
FU Helsinki University Central Hospital [TYH 2013354, Y2017SK004]; Nummela
   Sanatorium Foundation; Vaino and Laina Kivi Foundation; Ida Montin
   Foundation; Research Foundation for Pulmonary Diseases (Heli);
   Foundation of the Finnish Anti-Tuberculosis; Nordic Council of
   Ministers: NordForsk (Nordic Epilung Study)
FX This study was supported by a special governmental subsidy for health
   sciences research (Helsinki University Central Hospital project grants
   TYH 2013354 and Y2017SK004), Nummela Sanatorium Foundation, Research
   Foundation for Pulmonary Diseases (Heli), Vaino and Laina Kivi
   Foundation, and Ida Montin Foundation, the Foundation of the Finnish
   Anti-Tuberculosis and the Nordic Council of Ministers: NordForsk (Nordic
   Epilung Study).
CR Andrianasolo RM, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.02572-2017
   Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0
   Backman H, 2017, CLIN EXP ALLERGY, V47, P1426, DOI 10.1111/cea.12963
   Backman H, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-1
   Barraclough R, 2002, EUR RESPIR J, V20, P826, DOI 10.1183/09031936.02.00822002
   Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7
   Belvisi MG, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0799-7
   Borna E, 2019, ALLERGY, V74, P1703, DOI 10.1111/all.13840
   Browatzki A, 2009, EUR RESPIR J, V34, P1046, DOI 10.1183/09031936.00177908
   Bunne J, 2017, J ALLER CL IMM-PRACT, V5, P457, DOI 10.1016/j.jaip.2016.09.025
   de Marco R, 2012, EUR RESPIR J, V39, P883, DOI 10.1183/09031936.00061611
   Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308
   Egan KB, 2014, ACTA PAEDIATR, V103, P1270, DOI 10.1111/apa.12775
   Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699
   Haahtela T, 2015, CLIN EXP ALLERGY, V45, P891, DOI 10.1111/cea.12527
   Haahtela T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00470-2017
   Haahtela T, 2017, J ALLERGY CLIN IMMUN, V139, P408, DOI 10.1016/j.jaci.2016.12.001
   Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109
   Hazell Michelle L, 2009, Prim Care Respir J, V18, P165, DOI 10.3132/pcrj.2009.00001
   Ilmarinen P, 2017, J ALLER CL IMM-PRACT, V5, P967, DOI 10.1016/j.jaip.2017.01.027
   Ilmarinen P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/514868
   Jousilahti P, 2016, EUR RESPIR J, V47, P985, DOI 10.1183/13993003.01702-2015
   Kainu A, 2013, PRIM CARE RESP J, V22, P64, DOI 10.4104/pcrj.2013.00002
   Kauppi P, 2015, ASIA PAC ALLERGY, V5, P32, DOI 10.5415/apallergy.2015.5.1.32
   Kauppi P, 2013, THORAX, V68, P292, DOI 10.1136/thoraxjnl-2011-201028
   Kotaniemi JT, 2001, EUR J EPIDEMIOL, V17, P809, DOI 10.1023/A:1015615130459
   Laatikainen T, 2011, ALLERGY, V66, P886, DOI 10.1111/j.1398-9995.2010.02533.x
   Lahdensuo A, 1996, BRIT MED J, V312, P748
   Li Z, 2017, THORAX, V72, P206, DOI 10.1136/thoraxjnl-2016-208375
   Mincheva R, 2018, J ALLERGY CLIN IMMUN, V141, P2256, DOI 10.1016/j.jaci.2017.07.047
   Neophytou AM, 2018, THORAX, V73, P1041, DOI 10.1136/thoraxjnl-2017-211383
   Pallasaho P, 1999, RESP MED, V93, P798, DOI 10.1016/S0954-6111(99)90265-2
   Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169
   Roberts CK, 2005, J APPL PHYSIOL, V98, P3, DOI 10.1152/japplphysiol.00852.2004
   Romieu I, 2006, THORAX, V61, P209, DOI 10.1136/thx.2004.039123
   Ronmark EP, 2009, RESP MED, V103, P1807, DOI 10.1016/j.rmed.2009.07.014
   Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x
   Stewart AW, 2001, INT J EPIDEMIOL, V30, P173, DOI 10.1093/ije/30.1.173
   Tuomisto LE, 2016, RESP MED, V117, P223, DOI 10.1016/j.rmed.2016.06.017
   Uddenfeldt M, 2010, RESP MED, V104, P972, DOI 10.1016/j.rmed.2009.12.013
   Wennergren G, 2010, PEDIAT ALLERG IMM-UK, V21, P806, DOI 10.1111/j.1399-3038.2010.01057.x
   Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623
   Zhang X, 2018, ENVIRON RES, V166, P35, DOI 10.1016/j.envres.2018.05.022
NR 43
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 121
EP 126
DI 10.1016/j.rmed.2019.07.014
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500021
PM 31344661
OA Green Published
DA 2020-05-18
ER

PT J
AU Chen, F
   Zuo, Y
   Li, SS
   Shi, JL
   Wang, GC
   Shu, XM
AF Chen, Fang
   Zuo, Yu
   Li, Shanshan
   Shi, Jingli
   Wang, Guochun
   Shu, Xiaoming
TI Clinical characteristics of dermatomyositis patients with isolated
   anti-Ro-52 antibody associated rapid progressive interstitial lung
   disease: Data from the largest single Chinese center
SO RESPIRATORY MEDICINE
LA English
DT Article
DE anti-Ro-52 antibody; RP-ILD; Dermatomyositis
ID SUBSETS; TRIM21; AUTOANTIBODIES; POLYMYOSITIS; PROFILES; FEATURES;
   SERIES
AB Aim: To describe and expand the phenotype of isolated anti-Ro-52-associated rapid progressive interstitial lung disease (RP-ILD) in Dermatomyositis(DM) in Chinese patients.
   Methods: 491 patients with PM/DM-ILD hospitalized in the China-Japan Friendship Hospital from 2000 to 2017 were screened retrospectively. All proven cases of isolated anti-Ro-52-associated RP-ILD were selected for inclusion. The clinical features in this group were recorded.
   Results: Isolated Ro-52 antibodies existed in 20 PM/DM-ILD patients. Among them 5 patients developed RP-ILD. The 5 patients had typical rashes including Gottron's sign (80%), Helitrope rash (80%) and mechanic's hands (100%), but only few patients (20%) had arthralgia and muscle weakness. All patients had elevated levels of serum ferritin and decreased counts of CD3(+) T cells. The estimated high-resolution computed tomography (HRCT) patterns of the five patients showed organizing pneumonia (OP) while RP-ILD patients without Ro-52 antibodies and non-RP-ILD patients with isolated Ro-52 antibodies mainly showed non-specific interstitial pneumonia (NSIP) patterns(P < 0.05). Although one patient died of infection after one month, 80%(4/5) of patients had good response to glucocorticoid treatment and these four patients survived were all alive at the end of follow-up. The survival rate in this group was the highest than those in RP-ILD patients with other myositis specific autoantibodies though the difference had no statistically significance.
   Conclusions: A small group of patients with isolated anti-Ro-52 antibody in DM could develop RP-ILD, which mainly presented OP on HRCT. Patients with isolated anti-Ro-52 antibody associated RP-ILD responded well to therapy and had good prognosis in DM.
C1 [Chen, Fang; Zuo, Yu; Li, Shanshan; Shi, Jingli; Wang, Guochun; Shu, Xiaoming] China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China.
RP Shu, XM (reprint author), China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China.
EM sxm992283@hotmail.com
RI Ming, Shu Xiao/AAF-3356-2019
OI Shu, Xiao ming/0000-0001-5425-6157
FU Youth Program of the National Natural Science Foundation of China
   [81601367, 81401363, 81601833]
FX We wish to thank the experts in the Department of Radiology, Pathology
   and Respiratory Disease at China-Japan Friendship Hospital for their
   help with analyzing pulmonary data. This study was funded by the Youth
   Program of the National Natural Science Foundation of China (Grant No.
   81601367, 81401363, and 81601833).
CR Ahuja J, 2016, RADIOL CLIN N AM, V54, P1015, DOI 10.1016/j.rcl.2016.05.005
   BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
   Ceribelli A, 2014, CLIN EXP RHEUMATOL, V32, P891
   Chen F, 2018, AM J MED SCI, V355, P48, DOI 10.1016/j.amjms.2017.07.013
   Chen F, 2012, RHEUMATOL INT, V32, P3909, DOI 10.1007/s00296-011-2323-y
   Conway R, 2014, QJM-INT J MED, V107, P593, DOI 10.1093/qjmed/hct246
   Ernste FC, 2013, MAYO CLIN PROC, V88, P83, DOI 10.1016/j.mayocp.2012.10.017
   Ghillani P, 2011, AUTOIMMUN REV, V10, P509, DOI 10.1016/j.autrev.2011.03.004
   Gomez-Martin D, 2017, CLIN EXP IMMUNOL, V188, P154, DOI 10.1111/cei.12914
   Gono T, 2010, RHEUMATOLOGY, V49, P1713, DOI 10.1093/rheumatology/keq149
   Hall JC, 2013, ARTHRIT CARE RES, V65, P1307, DOI 10.1002/acr.21992
   Hoogendijk Jessica E, 2004, Neuromuscul Disord, V14, P337, DOI 10.1016/j.nmd.2004.02.006
   Hozumi H, 2016, RESP MED, V121, P91, DOI 10.1016/j.rmed.2016.10.019
   Lee AYS, 2017, RHEUMATOL INT, V37, P1323, DOI 10.1007/s00296-017-3718-1
   Marie I, 2012, SEMIN ARTHRITIS RHEU, V41, P890, DOI 10.1016/j.semarthrit.2011.09.008
   Mimori T, 2012, CURR RHEUMATOL REP, V14, P264, DOI 10.1007/s11926-012-0246-6
   Muro Y, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3547
   Oke V, 2012, J AUTOIMMUN, V39, P77, DOI 10.1016/j.jaut.2012.01.014
   Pan JA, 2016, MOL CELL, V61, P720, DOI 10.1016/j.molcel.2016.02.007
   Cruellas MGP, 2013, CLINICS, V68, P909, DOI 10.6061/clinics/2013(07)04
   Rutjes SA, 1997, CLIN EXP IMMUNOL, V109, P32, DOI 10.1046/j.1365-2249.1997.4081308.x
   Sabbagh S, 2019, ANN RHEUM DIS, V78, P988, DOI 10.1136/annrheumdis-2018-215004
   Selva-O'Callaghan A, 2006, ARTHRIT RHEUM-ARTHR, V55, P791, DOI 10.1002/art.22237
   Shi JL, 2017, J RHEUMATOL, V44, P1051, DOI 10.3899/jrheum.161480
   Tanizawa K, 2011, RESP MED, V105, P1380, DOI 10.1016/j.rmed.2011.05.006
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Venables PJW, 1997, CLIN EXP IMMUNOL, V109, P403, DOI 10.1046/j.1365-2249.1997.4761369.x
   Yamasaki Y, 2016, MOD RHEUMATOL, V26, P403, DOI 10.3109/14397595.2015.1091155
NR 28
TC 0
Z9 0
U1 3
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 127
EP 132
DI 10.1016/j.rmed.2019.07.020
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500022
PM 31344662
DA 2020-05-18
ER

PT J
AU Moore, LE
   Kapoor, K
   Byers, BW
   Brotto, AR
   Ghods-Esfahani, D
   Henry, SL
   St James, RB
   Stickland, MK
AF Moore, Linn E.
   Kapoor, Karishma
   Byers, Bradley W.
   Brotto, Andrew R.
   Ghods-Esfahani, Daniel
   Henry, Shelby L.
   St James, Ryan B.
   Stickland, Michael K.
TI Acute effects of salbutamol on systemic vascular function in people with
   asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Beta-agonist; Cardiovascular
ID SYMPATHETIC-NERVE ACTIVITY; ARTERIAL STIFFNESS; INHALED SALBUTAMOL;
   PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION;
   HEART-FAILURE; BETA-AGONISTS; RISK; TOLERANCE
AB Background: Asthmatics are at increased cardiovascular disease risk, which has been linked to beta2(beta(2))-agonist use. Inhalation of beta(2)-agonists increases sympathetic nerve activity (SNA) in healthy individuals, however the systemic impact of salbutamol in asthmatics using beta(2)-agonists regularly is unknown.
   Objectives: This study compared the systemic vascular responses to a clinical dose of salbutamol (Phase I) and following an acute increase in SNA (Phase II) in asthmatics and controls.
   Methods: Fourteen controls and 14 asthmatics were recruited for Phase I. On separate days, flow-mediated dilation (FMD) and peripheral arterial stiffness (pPWV) were evaluated at baseline and following either 400 mu g inhaled salbutamol or a placebo inhaler. For Phase II, heart rate, blood pressure, vascular conductance, pPWV, and central (c)PWV were evaluated in response to a large increase in SNA brought on by cold-water hand immersion (i.e. cold-pressor test) or body-temperature water hand immersion (i.e. control) in 10 controls and 10 asthmatics.
   Results: Following salbutamol, asthmatics demonstrated reduced FMD (-3.0%, p < 0.05) and increased pPWV (+0.7 m/s, p < 0.05); however, salbutamol had no effect in controls. The cold-pressor test resulted in similar increases in blood pressure, vascular flow rates and conductance, pPWV, and cPWV in both asthmatics and controls, suggesting similar neurovascular transduction in asthmatics and controls.
   Conclusion: Inhaled Salbutamol leads to increased arterial stiffness and reduced FMD in asthmatics. As asthmatics and controls had similar vascular responses to an increase in SNA, these findings suggest asthmatics have heightened sympathetic responses to beta(2)-agonists which may contribute to the increased cardiovascular risk in asthma.
C1 [Moore, Linn E.; Kapoor, Karishma; Byers, Bradley W.; Brotto, Andrew R.; Henry, Shelby L.; Stickland, Michael K.] Univ Alberta, Fac Med & Dent, Dept Med, Pulm Div, Edmonton, AB, Canada.
   [Moore, Linn E.; Byers, Bradley W.; Brotto, Andrew R.; St James, Ryan B.] Univ Alberta, Fac Kinesiol Sport & Recreat, Edmonton, AB, Canada.
   [Kapoor, Karishma] Univ Alberta, Fac Sci, Dept Psychol, Edmonton, AB, Canada.
   [Ghods-Esfahani, Daniel] Univ Alberta, Fac Sci, Dept Biol Sci, Edmonton, AB, Canada.
   [Henry, Shelby L.] Univ Alberta, Fac Rehabil Med, Dept Rehabil Sci, Edmonton, AB, Canada.
RP Stickland, MK (reprint author), 3-125 Clin Sci Bldg,11350 83 Ave, Edmonton, AB T6G 2J3, Canada.
EM michael.stickland@ualberta.ca
OI Moore, Linn/0000-0003-0451-460X
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR)
FX This study was funded by the Canadian Institutes of Health Research.
CR Appleton SL, 2008, OBES RES CLIN PRACT, V2, P91, DOI 10.1016/j.orcp.2008.04.005
   Appleton SL, 2009, J ALLERGY CLIN IMMUN, V123, P124, DOI 10.1016/j.jaci.2008.10.032
   Au DH, 2000, AM J RESP CRIT CARE, V161, P827, DOI 10.1164/ajrccm.161.3.9904006
   Bang DW, 2016, J ALLER CL IMM-PRACT, V4, P917, DOI 10.1016/j.jaip.2016.02.018
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Beloka SP, 2011, EUR J APPL PHYSIOL, V111, P2239, DOI 10.1007/s00421-011-1856-9
   BRISTOW MR, 1989, MOL PHARMACOL, V35, P295
   BRODDE OE, 1986, J CARDIOVASC PHARM, V8, P1235, DOI 10.1097/00005344-198611000-00021
   Cekici L, 2009, BRIT J CLIN PHARMACO, V67, P394, DOI 10.1111/j.1365-2125.2009.03377.x
   CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136
   Dagnone AJ, 1997, CHEST, V111, P1514, DOI 10.1378/chest.111.6.1514
   de Lucia C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00904
   DeBeck LD, 2010, AM J PHYSIOL-REG I, V299, pR80, DOI 10.1152/ajpregu.00246.2009
   Dinenno FA, 2000, AM J PHYSIOL-HEART C, V278, pH1205
   Edgell H, 2016, RESP PHYSIOL NEUROBI, V231, P14, DOI 10.1016/j.resp.2016.05.014
   Elers Jimmi, 2010, Open Respir Med J, V4, P48, DOI 10.2174/1874306401004010048
   Ford ES, 2003, CHEST, V124, P432, DOI 10.1378/chest.124.2.432
   Green DJ, 2011, HYPERTENSION, V57, P363, DOI 10.1161/HYPERTENSIONAHA.110.167015
   Harris RA, 2010, HYPERTENSION, V55, P1075, DOI 10.1161/HYPERTENSIONAHA.110.150821
   Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994
   Imadojemu VA, 2007, CHEST, V131, P1406, DOI 10.1378/chest.06-2580
   Iribarren C, 2012, AM J EPIDEMIOL, V176, P1014, DOI 10.1093/aje/kws181
   Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254
   Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677
   Liang W, 2003, J BIOL CHEM, V278, P39773, DOI 10.1074/jbc.M304482200
   Lougheed M Diane, 2012, Can Respir J, V19, pe81
   Mak JC, 2013, ISRN ALLERGY, V2013
   Middlekauff HR, 1998, INTERNAL MED, V37, P112, DOI 10.2169/internalmedicine.37.112
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Moore LE, 2017, RESP MED, V132, P56, DOI 10.1016/j.rmed.2017.09.011
   Moore LE, 2015, J ALLERGY CLIN IMMUN, V136, P809, DOI 10.1016/j.jaci.2015.02.033
   Narkiewicz K, 1999, CIRCULATION, V100, P262, DOI 10.1161/01.CIR.100.3.262
   Payvandi L, 2009, VASC MED, V14, P193, DOI 10.1177/1358863X08101018
   Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309
   Salpeter SR, 2004, ANN INTERN MED, V140, P802, DOI 10.7326/0003-4819-140-10-200405180-00010
   Snyder EM, 2011, PHARMACOTHERAPY, V31, P748, DOI 10.1592/phco.31.8.748
   SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801
   Stewart SL, 2012, ANN ALLERG ASTHMA IM, V109, P454, DOI 10.1016/j.anai.2012.08.003
   Stickland M. K., 2013, RESP PHYSL NEUROBIOL
   Sun WX, 2014, RESP MED, V108, P57, DOI 10.1016/j.rmed.2013.10.021
   Tahvanainen A, 2009, BRIT J CLIN PHARMACO, V68, P23, DOI 10.1111/j.1365-2125.2009.03434.x
   Tahvanainen AM, 2012, J HYPERTENS, V30, P297, DOI 10.1097/HJH.0b013e32834e4b26
   Teramoto M, 2011, J ASTHMA, V48, P517, DOI 10.3109/02770903.2011.567426
   Toren K, 1996, INT J EPIDEMIOL, V25, P617, DOI 10.1093/ije/25.3.617
   VICTOR RG, 1987, HYPERTENSION, V9, P429, DOI 10.1161/01.HYP.9.5.429
   Vlachopoulos C, 2005, CIRCULATION, V112, P2193, DOI 10.1161/CIRCULATIONAHA.105.535435
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Weiler Z, 2010, RESP MED, V104, P197, DOI 10.1016/j.rmed.2009.09.004
   Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838
   Yildiz P, 2004, J ASTHMA, V41, P159, DOI 10.1081/JAS-120026073
   Zietkowski Z, 2009, RESP MED, V103, P379, DOI 10.1016/j.rmed.2008.10.003
NR 51
TC 0
Z9 1
U1 4
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 133
EP 140
DI 10.1016/j.rmed.2019.07.018
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500023
PM 31349187
DA 2020-05-18
ER

PT J
AU Colak, Y
   Afzal, S
   Marott, JL
   Nordestgaard, BG
   Vestbo, J
   Ingebrigtsen, TS
   Lange, P
AF Colak, Yunus
   Afzal, Shoaib
   Marott, Jacob L.
   Nordestgaard, Borge G.
   Vestbo, Jorgen
   Ingebrigtsen, Truls S.
   Lange, Peter
TI Prognosis of COPD depends on severity of exacerbation history: A
   population-based analysis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Airway obstruction; Spirometry; Forced expiratory volume; Chronic
   bronchitis; Emphysema
ID OBSTRUCTIVE PULMONARY-DISEASE; 2017 CLASSIFICATION; NATURAL-HISTORY;
   MORTALITY; PREDICTION; FREQUENCY; HOSPITALIZATION; DECLINE; SMOKERS;
   TIME
AB Background: Differences in previous exacerbation history may influence prognosis of chronic obstructive pulmonary disease (COPD). We hypothesized that prognosis differs between individuals with a history of only medically treated exacerbations (moderate exacerbations) and those with a history of hospitalised exacerbations (severe exacerbations).
   Methods: We included 98 614 adults from the Copenhagen General Population Study and assessed risk of moderate and severe exacerbations, pneumonia hospitalisation, and respiratory and all-cause mortality from 2003 until 2013 according to exacerbation history.
   Results: Among 6545 individuals with COPD, 6290 had no exacerbations in the preceding year, 109 had one moderate exacerbation, 108 had two or more moderate exacerbations, and 38 had one or more severe exacerbations. During 9.4 years of follow-up, we observed 926 moderate and 244 severe exacerbations, 477 pneumonias, and 707 deaths, including 69 from respiratory disease. Compared to individuals without previous exacerbations, lung function and symptom adjusted hazard ratios (HRs) for future moderate exacerbation were 4.68 (95% confidence interval: 3.31-6.62) for individuals with one previous moderate exacerbation, 21 (13-33) for individuals with two or more previous moderate exacerbations, and 5.30 (3.44-8.15) for individuals with one or more previous severe exacerbations. Corresponding HRs were 1.62(0.78-3.34), 1.29(0.57-2.89), and 5.43 (2.56-12) for severe exacerbation, 1.86(1.06-3.27), 1.74(1.01-2.99), and 4.85 (2.94-8.02) for pneumonia, 0.53(0.10-2.99), 1.65(0.53-5.17), and 2.98 (1.14-7.83) for respiratory mortality, and 1.34(0.79-2.29), 1.57(1.00-2.47), and 1.49 (0.85-2.62) for all-cause mortality, respectively.
   Conclusion: Individuals with COPD and a history of hospitalised exacerbations carried the poorest prognosis compared to those with a history of only medically treated exacerbations, suggesting difference in risk profile.
C1 [Colak, Yunus; Afzal, Shoaib; Nordestgaard, Borge G.] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Clin Biochem, Herlev, Denmark.
   [Colak, Yunus; Afzal, Shoaib; Marott, Jacob L.; Nordestgaard, Borge G.; Ingebrigtsen, Truls S.; Lange, Peter] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Copenhagen Gen Populat Study, Herlev, Denmark.
   [Colak, Yunus; Afzal, Shoaib; Marott, Jacob L.; Nordestgaard, Borge G.; Ingebrigtsen, Truls S.; Lange, Peter] Copenhagen Univ Hosp, Bispebjerg & Frederiksberg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark.
   [Colak, Yunus; Afzal, Shoaib; Nordestgaard, Borge G.; Lange, Peter] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Vestbo, Jorgen] Univ Manchester, Manchester Acad Hlth Sci Ctr, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Vestbo, Jorgen] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England.
   [Ingebrigtsen, Truls S.] Copenhagen Univ Hosp, Hvidovre Hosp, Resp Sect, Med Unit, Hvidovre, Denmark.
   [Lange, Peter] Univ Copenhagen, Sect Epidemiol, Dept Publ Hlth, Copenhagen, Denmark.
   [Lange, Peter] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Sect Resp Med, Dept Internal Med, Herlev, Denmark.
RP Lange, P (reprint author), Univ Copenhagen, Sect Epidemiol, Dept Publ Hlth, Resp Med, Oster Farimagsgade 5,Postal Box 2099, DK-1014 Copenhagen K, Denmark.
EM peter.lange@sund.ku.dk
RI Afzal, Shoaib/B-6763-2012; Colak, Yunus/C-3090-2014
OI Afzal, Shoaib/0000-0002-1442-4694; Vestbo, Jorgen/0000-0001-6355-6362;
   Colak, Yunus/0000-0003-2045-829X
FU Lundbeck FoundationLundbeckfonden
FX The Lundbeck Foundation. The funder had no role in the design and
   conduct of the study; collection, management, analysis, or
   interpretation of the data; preparation, review, or approval of the
   manuscript; or decision to submit the manuscript for publication.
CR Andersen PK, 2004, LIFETIME DATA ANAL, V10, P335, DOI 10.1007/s10985-004-4771-0
   Colak Y, 2017, LANCET RESP MED, V5, P426, DOI 10.1016/S2213-2600(17)30119-4
   Donaldson GC, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-79
   Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
   Dransfield MT, 2017, AM J RESP CRIT CARE, V195, P324, DOI 10.1164/rccm.201605-1014OC
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Garcia-Aymerich J, 2011, THORAX, V66, P585, DOI 10.1136/thx.2010.152876
   Gedebjerg A, 2018, LANCET RESP MED, V6, P204, DOI 10.1016/S2213-2600(18)30002-X
   *GLOB IN CHRON OBS, GLOB STRAT DIAGN MAN
   Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459
   Halpin DMG, 2017, INT J CHRONIC OBSTR, V12, P2891, DOI 10.2147/COPD.S139470
   Halpin DMG, 2012, INT J CHRONIC OBSTR, V7, P653, DOI 10.2147/COPD.S34186
   Han MK, 2017, LANCET RESP MED, V5, P619, DOI 10.1016/S2213-2600(17)30207-2
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Husted MG, 2014, BMJ SUPPORT PALLIAT, V4, P146, DOI 10.1136/bmjspcare-2013-000601
   Ingebrigtsen TS, 2015, RESP MED, V109, P1562, DOI 10.1016/j.rmed.2015.10.015
   Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017
   Lange P, 2012, AM J RESP CRIT CARE, V186, P975, DOI 10.1164/rccm.201207-1299OC
   Lokke A, 2013, CLIN RESPIR J, V7, P153, DOI 10.1111/j.1752-699X.2012.00297.x
   McGhan R, 2007, CHEST, V132, P1748, DOI 10.1378/chest.06-3018
   Muellerova H, 2015, CHEST, V147, P999, DOI 10.1378/chest.14-0655
   Piquet J, 2013, EUR RESPIR J, V42, P946, DOI 10.1183/09031936.00180312
   Reilev M, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0029-7
   Rothnie KJ, 2018, AM J RESP CRIT CARE, V198, P464, DOI 10.1164/rccm.201710-2029OC
   Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527
   Soriano JB, 2018, RESP MED, V142, P81, DOI 10.1016/j.rmed.2018.07.019
   Soriano JB, 2015, LANCET RESP MED, V3, P443, DOI 10.1016/S2213-2600(15)00157-5
   Suissa S, 2012, THORAX, V67, P957, DOI 10.1136/thoraxjnl-2011-201518
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482
   Wedzicha JA, 2007, LANCET, V370, P786, DOI 10.1016/S0140-6736(07)61382-8
NR 31
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD AUG
PY 2019
VL 155
BP 141
EP 147
DI 10.1016/j.rmed.2019.07.021
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IM3VP
UT WOS:000477923500024
PM 31362177
DA 2020-05-18
ER

PT J
AU Ratwani, AP
   Ahmad, KI
   Barnett, SD
   Nathan, SD
   Brown, AW
AF Ratwani, Ankush P.
   Ahmad, Kareem I.
   Barnett, Scott D.
   Nathan, Steven D.
   Brown, A. Whitney
TI Connective tissue disease-associated interstitial lung disease and
   outcomes after hospitalization: A cohort study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Connective tissue disease interstitial lung disease; Pulmonary fibrosis;
   Hospitalization; Length of stay; Outcomes
ID IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; CLINICAL-TRIALS;
   END-POINTS; PNEUMONIA; SURVIVAL; DIAGNOSIS
AB Background: The impact of hospitalization on patient outcomes is increasingly recognized and considered in the prognostication of many pulmonary disorders. We sought to evaluate the impact of hospitalization on survival in connective tissue disease-interstitial lung disease (CTD-ILD) patients.
   Methods: A chart review of patients with CTD-ILD followed at a tertiary care center was performed. Patients were stratified into two groups based on hospitalization status. Outcomes of the groups were compared using Kaplan-Meier survival analyses as well as multivariate competing risk analysis.
   Results: There were 137 patients identified with confirmed CTD-ILD. Patients who underwent hospitalization for any reason had a significant decrease in transplant-free survival compared to the never hospitalized cohort (3-year survival 60% vs. 94%; p=0.0001). Hospitalization for >= 7 days was associated with worse outcomes than those hospitalized for < 7 days (median survival 1.59 years vs. 7.17 years, p=0.0012). Based on multivariate competing risk analysis, factors associated with death, with lung transplantation as a competing risk, were age (HR=1.05 [95% 1.01-1.09]; P=0.0443), male gender (HR=4.94 [95% CI: 1.58-15.41]; P=0.006), and all cause hospitalization (HR=11.97 [95% CI: 1.36-105.49]; P=0.0253).
   Conclusion: This study highlights the impact of hospitalization on subsequent outcomes in the CTD-ILD population with a significantly reduced transplant-free survival demonstrated, especially after cardiopulmonary hospitalization events.
C1 [Ratwani, Ankush P.] Medstar Georgetown Univ Hosp, Dept Internal Med, Washington, DC USA.
   [Ahmad, Kareem I.; Barnett, Scott D.; Nathan, Steven D.; Brown, A. Whitney] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, 3300 Gallows Rd, Falls Church, VA 22042 USA.
RP Brown, AW (reprint author), Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, 3300 Gallows Rd, Falls Church, VA 22042 USA.
EM anne.brown@inova.org
CR Brown AW, 2015, CHEST, V147, P173, DOI 10.1378/chest.13-2424
   Disayabutr S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0487-0
   Ellaffi M, 2005, AM J RESP CRIT CARE, V171, P158, DOI 10.1164/rccm.200405-667OC
   Fischer A, 2012, LANCET, V380, P689, DOI 10.1016/S0140-6736(12)61079-4
   Gunen H, 2005, EUR RESPIR J, V26, P234, DOI 10.1183/09031936.05.00024804
   Kim D, 2017, RHEUMATOL INT, V37, P1735, DOI 10.1007/s00296-017-3781-7
   Kim EJ, 2010, EUR RESPIR J, V35, P1322, DOI 10.1183/09031936.00092309
   Lammi MR, 2015, CURR RESPIR MED REV, V11, P163, DOI 10.2174/1573398X11666150619183527
   Ley B, 2017, ANN AM THORAC SOC, V14, P1383, DOI 10.1513/AnnalsATS.201706-423ED
   Moua T, 2016, CHEST, V149, P1205, DOI 10.1016/j.chest.2015.12.026
   Moua T, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0154-6
   Nathan SD, 2017, CURR OPIN PULM MED, V23, P426, DOI 10.1097/MCP.0000000000000407
   Nathan SD, 2014, CURR OPIN PULM MED, V20, P463, DOI 10.1097/MCP.0000000000000091
   Ryerson CJ, 2014, CHEST, V145, P723, DOI 10.1378/chest.13-1474
   Suda T, 2009, RESP MED, V103, P846, DOI 10.1016/j.rmed.2008.12.019
   Tachikawa R, 2012, RESPIRATION, V83, P20, DOI 10.1159/000329893
   Vij R, 2013, CHEST, V143, P814, DOI 10.1378/chest.12-0741
   Zannad F, 2013, EUR J HEART FAIL, V15, P1082, DOI 10.1093/eurjhf/hft095
NR 18
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 1
EP 5
DI 10.1016/j.rmed.2019.05.020
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800001
PM 31176795
DA 2020-05-18
ER

PT J
AU Huapaya, JA
   Hallowell, R
   Silhan, L
   Pinal-Fernandez, I
   Casal-Dominguez, M
   Johnson, C
   Albayda, J
   Paik, JJ
   Lin, CT
   Hussien, A
   Mammen, AL
   Christopher-Stine, L
   Danoff, SK
AF Huapaya, J. A.
   Hallowell, R.
   Silhan, L.
   Pinal-Fernandez, I.
   Casal-Dominguez, M.
   Johnson, C.
   Albayda, J.
   Paik, J. J.
   Lin, C. T.
   Hussien, A.
   Mammen, A. L.
   Christopher-Stine, L.
   Danoff, S. K.
TI Long-term treatment with human immunoglobulin for antisynthetase
   syndrome-associated interstitial lung disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Interstitial lung disease; Human intravenous immunoglobulin; Therapy;
   Antisynthetase syndrome and refractory disease
ID IDIOPATHIC INFLAMMATORY MYOPATHIES; INTRAVENOUS IMMUNOGLOBULIN; JAPANESE
   PATIENTS; POLYMYOSITIS; THERAPY; MYOSITIS; ANTIBODIES; MANAGEMENT;
   RITUXIMAB; RESISTANT
AB Background: Interstitial lung disease-associated antisynthetase syndrome (AS-ILD) carries significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are the mainstay of treatment. Human immunoglobulin (IVIg), an immunomodulator without immunosuppressive properties, is effective in myositis but the evidence supporting its use in ILD is scarce.
   Objective: To describe clinical outcomes of AS-ILD patients receiving IVIg.
   Methods: Retrospective analysis of AS-ILD patients. Linear mixed models using restricted maximum likelihood estimation was used to estimate the change in lung function and corticosteroid dose over time.
   Results: Data from 17 patients was analyzed. Median follow-up was 24.6 months. Fourteen patients had refractory disease. The mean percent-predicted forced vital capacity (FVC%) (p=0.048) and percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%) (p=0.0223) increased over time, while the mean prednisone dose (p<0.001) decreased over time. Seven patients achieved a>10% increase in FVC%, including two who used IVIg as initial treatment. Five patients showed a>10% increase in DLCO% and TLC%. Nine (53%) patients experienced side effects.
   Conclusions: IVIg may be a useful complementary therapy in active progressive AS-ILD but is associated with potential side effects. Fssssurther investigation is required to determine the value of IVIg as an initial treatment in AS-ILD.
C1 [Huapaya, J. A.; Danoff, S. K.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA.
   [Huapaya, J. A.] MedStar Georgetown Univ Hosp, Div Internal Med, Washington, DC 20007 USA.
   [Hallowell, R.] Harvard Med Sch, Div Pulm Crit Care & Sleep Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Silhan, L.] Univ Texas Southwestern Med Ctr Dallas, Div Pulm & Crit Care Med, Dallas, TX USA.
   [Pinal-Fernandez, I.; Casal-Dominguez, M.; Mammen, A. L.] NIAMSD, Muscle Dis Unit, Lab Muscle Stem Cells & Gene Regulat, NIH, Bethesda, MD 20892 USA.
   [Mammen, A. L.; Christopher-Stine, L.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Casal-Dominguez, M.; Albayda, J.; Paik, J. J.; Mammen, A. L.; Christopher-Stine, L.] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA.
   [Johnson, C.] Univ Penn, Div Pulm Allergy & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Lin, C. T.; Hussien, A.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA.
RP Danoff, SK (reprint author), Div Pulm & Crit Care Med, 1830 E Monument St,5th Floor, Baltimore, MD 21205 USA.
EM sdanoff@jhmi.edu
OI Huapaya, Julio/0000-0001-8093-4855
FU Arricale Family Research Fund for Pediatric Interstitial Lung Disease
   Pilot and Feasibility Grant; Rheumatology Research Foundation; Huayi and
   Siuling Zhang Discovery Fund
FX This research was funded by the Arricale Family Research Fund for
   Pediatric Interstitial Lung Disease Pilot and Feasibility Grant, the
   Rheumatology Research Foundation and the Huayi and Siuling Zhang
   Discovery Fund. The sponsors had no role on the conception of this work.
CR Allenbach Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133702
   Bakewell CJ, 2011, CHEST, V139, P441, DOI 10.1378/chest.10-0360
   Behr J, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0462-y
   BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807
   BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
   Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006
   Chartrand S, 2015, SARCOIDOSIS VASC DIF, V32, P296
   Connors GR, 2010, CHEST, V138, P1464, DOI 10.1378/chest.10-0180
   Dalakas MC, 2004, JAMA-J AM MED ASSOC, V291, P2367, DOI 10.1001/jama.291.19.2367
   DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704
   Diot E, 2011, CHEST, V140, P562, DOI 10.1378/chest.11-0492
   EUWER RL, 1991, J AM ACAD DERMATOL, V24, P959, DOI 10.1016/0190-9622(91)70153-S
   Hallowell RW, 2016, ANN AM THORAC SOC, V13, P1682, DOI 10.1513/AnnalsATS.201603-179PS
   Hallowell RW, 2014, CURR OPIN RHEUMATOL, V26, P684, DOI 10.1097/BOR.0000000000000104
   Hervier B, 2012, AUTOIMMUN REV, V12, P210, DOI 10.1016/j.autrev.2012.06.006
   Hervier B, 2010, RHEUMATOLOGY, V49, P972, DOI 10.1093/rheumatology/kep455
   Kafaja S, 2017, AM J RESP CRIT CARE
   Kamali S, 2005, RHEUMATOL INT, V25, P211, DOI 10.1007/s00296-003-0422-0
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   Mathai SC, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6819
   Matsushita T, 2007, J RHEUMATOL, V34, P1012
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mimori T, 2012, CURR RHEUMATOL REP, V14, P264, DOI 10.1007/s11926-012-0246-6
   Miyasaka N, 2012, MOD RHEUMATOL, V22, P382, DOI 10.1007/s10165-011-0534-4
   Morisset J, 2016, CHEST, V150, P1118, DOI 10.1016/j.chest.2016.04.007
   Murota Hiroyuki, 2006, Allergol Int, V55, P199, DOI 10.2332/allergolint.55.199
   Oddis CV, 2016, J INTERN MED, V280, P63, DOI 10.1111/joim.12511
   Quick A, 2011, CURR RHEUMATOL REP, V13, P192, DOI 10.1007/s11926-011-0171-0
   Saito E, 2008, MOD RHEUMATOL, V18, P34, DOI 10.1007/s10165-007-0013-0
   Sharp C, 2016, RHEUMATOLOGY, V55, P1318, DOI 10.1093/rheumatology/kew195
   Suzuki Y, 2009, LUNG, V187, P201, DOI 10.1007/s00408-009-9146-6
   Taniguchi H, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-93
   Wallace B, 2016, CURR OPIN RHEUMATOL, V28, P236, DOI 10.1097/BOR.0000000000000270
NR 33
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 6
EP 11
DI 10.1016/j.rmed.2019.05.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800002
PM 31176796
DA 2020-05-18
ER

PT J
AU Vetrano, DL
   Zucchelli, A
   Bianchini, E
   Cricelli, C
   Piraino, A
   Zibellini, M
   Ricci, A
   Onder, G
   Lapi, F
AF Vetrano, Davide L.
   Zucchelli, Alberto
   Bianchini, Elisa
   Cricelli, Claudio
   Piraino, Alessio
   Zibellini, Marco
   Ricci, Alberto
   Onder, Graziano
   Lapi, Francesco
TI Triple inhaled therapy in COPD patients: determinants of prescription in
   primary care
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Triple inhaled therapy; Primary care; Clinical guidelines
ID OBSTRUCTIVE PULMONARY-DISEASE; MISDIAGNOSIS; SALMETEROL; TIOTROPIUM;
   BURDEN
AB Objective: To assess the incidence and determinants of the triple inhaled therapy in chronic obstructive pulmonary disease (COPD) primary care patients.
   Methods: Data derived from the Health Search Database (HSD) gathering information on 700 Italian general practitioners. A cohort of COPD patients, prescribed for the first time with inhaled treatments, was followed-up between January 2002 and December 2014. The outcome was the first incident prescription of a triple inhaled therapy, namely the combination of inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA). Cox regressions were used to test the association (hazard ratios, HR) between candidate determinants and the outcome.
   Results: Out of 17589 patients (mean age 71.1 +/- 11.3 years; 37.4% females), 3693 (21%) were prescribed with a triple inhaled therapy during follow-up. Older age (HR=1.79 to 2.61), current and former smoking habit (HR=1.72 and 1.66), higher GOLD stage (HR=1.45 to 2.79), the number of moderate and severe COPD exacerbations (HR=1.10 to 2.63), and heart failure (HR=1.17) resulted statistically significantly associated with an increased incident prescription of the triple inhaled therapy. Female sex (HR=0.80) and some co-morbidities (HR=0.21 to 0.87) resulted negatively associated with the outcome. Furthermore, patients initially treated with LAMA (HR=1.5) and LABA/ICS (HR=1.23) were more likely to escalate to the triple therapy, than those on LABA. Conversely, patients initially treated with ICS presented a negative hazard (HR=0.72).
   Conclusions: The knowledge of demographic and clinical determinants of the escalation to the triple inhaled therapy in real-world COPD patients may help clinicians to better personalize respiratory pharmacological treatments of their patients, and inform international societies that issue clinical guidelines.
C1 [Vetrano, Davide L.; Onder, Graziano] Univ Cattolica Sacro Cuore, Dept Geriatr, Rome, Italy.
   [Vetrano, Davide L.; Onder, Graziano] IRCCS Fdn Policlin A Gemelli, Rome, Italy.
   [Vetrano, Davide L.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Aging Res Ctr, Stockholm, Sweden.
   [Vetrano, Davide L.] Stockholm Univ, Stockholm, Sweden.
   [Zucchelli, Alberto] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy.
   [Bianchini, Elisa; Lapi, Francesco] Italian Coll Gen Practitioners & Primary Care, Hlth Search, Via Sansovino 179, I-50141 Florence, Italy.
   [Cricelli, Claudio] Italian Coll Gen Practitioners & Primary Care, Florence, Italy.
   [Piraino, Alessio; Zibellini, Marco] Chiesi Farmaceut SpA, Parma, Italy.
   [Ricci, Alberto] Sapienza Univ, S Andrea Hosp, Dept Clin & Mol Med, Rome, Italy.
RP Lapi, F (reprint author), Italian Coll Gen Practitioners & Primary Care, Hlth Search, Via Sansovino 179, I-50141 Florence, Italy.
EM lapi.francesco@simg.it
OI PIRAINO, Alessio/0000-0002-8029-2159
FU Chiesi Farmaceutici S.p.A.
FX This study was funded by Chiesi Farmaceutici S.p.A., which approved the
   study design but played no role in development of the research and
   manuscript, including data analysis, results interpretation and writing.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI [10.7189/jogh.05-020415, 10.7189/jogh.05.020415]
   Anzueto A, 2018, CHEST, V154, P242, DOI 10.1016/j.chest.2018.02.023
   Bloom CI, 2019, INT J CHRONIC OBSTR, V14, P279, DOI 10.2147/COPD.S190086
   Brusselle G, 2015, INT J CHRONIC OBSTR, V10, P2207, DOI 10.2147/COPD.S91694
   Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
   Carrasco-Garrido Pilar, 2009, BMC Pulm Med, V9, P2, DOI 10.1186/1471-2466-9-2
   Decramer ML, 2013, LANCET RESP MED, V1, P524, DOI 10.1016/S2213-2600(13)70158-9
   Delaney JAC, 2008, PHARMACOEPIDEM DR S, V17, P535, DOI 10.1002/pds.1553
   Di Marco F, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0051-9
   Di Martino M, 2014, COPD, V11, P414, DOI 10.3109/15412555.2013.839646
   Ernst P, 2015, EUR RESPIR J, V45, P525, DOI 10.1183/09031936.00128914
   Gold PM, 2009, RESP CARE, V54, P1040
   Hawkins NM, 2013, EUR HEART J, V34, P2795, DOI 10.1093/eurheartj/eht192
   Hurst JR, 2018, INT J CHRONIC OBSTR, V13, P781, DOI 10.2147/COPD.S153655
   Jacobsen R, 2016, RESP CARE, V61, P943, DOI 10.4187/respcare.04335
   Nannini LJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003794.pub4
   Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901
   Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957
   Mapel D, 2017, INT J CHRONIC OBSTR, V12, P1825, DOI 10.2147/COPD.S129007
   Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2
   Nishi Shawn P E, 2013, Ann Am Thorac Soc, V10, P565, DOI 10.1513/AnnalsATS.201302-037OC
   Price D, 2014, INT J CHRONIC OBSTR, V9, P889, DOI 10.2147/COPD.S62750
   Rodriguez-Roisin R, 2017, EUR RESPIR J, V50, P1, DOI DOI 10.1183/13993003.00711-2017
   Simeone JC, 2017, INT J CHRONIC OBSTR, V12, P73, DOI 10.2147/COPD.S122013
   Singh D, 2016, LANCET, V388, P963, DOI 10.1016/S0140-6736(16)31354-X
   Souliotis K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154960
   Sundh J, 2017, EUR CLIN RESPIR J, V4, DOI 10.1080/20018525.2017.1409060
   Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800
   Tinkelman DG, 2006, J ASTHMA, V43, P75, DOI 10.1080/02770900500448738
   Tsiligianni I, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0013-2
   Vetrano DL, 2017, GERIATR GERONTOL INT, V17, P2500, DOI 10.1111/ggi.13115
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Walters JA, 2011, PRIM CARE RESP J, V20, P396, DOI 10.4104/pcrj.2011.00039
NR 33
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 12
EP 17
DI 10.1016/j.rmed.2019.05.022
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800003
PM 31202120
DA 2020-05-18
ER

PT J
AU Trudzinski, FC
   Kahnert, K
   Vogelmeier, CF
   Alter, P
   Seiler, F
   Fahndrich, S
   Watz, H
   Welte, T
   Speer, T
   Zewinger, S
   Biertz, F
   Kauczor, HU
   Jorres, RA
   Bals, R
   Stefan, A
   Robert, B
   Jurgen, B
   Kathrin, K
   Burkhard, B
   Roland, B
   Ralf, E
   Beate, S
   Joachim, HF
   Manfred, G
   Christian, G
   Rainer, H
   Matthias, H
   Berthold, J
   Markus, H
   Felix, H
   Gerd, H
   Hugo, AK
   Anne-Mariez, K
   Henrik, W
   Rembert, K
   Klaus, K
   Juliane, K
   Cornelia, KS
   Christoph, L
   Peter, Z
   Michael, P
   Winfried, JR
   Werner, E
   Michael, S
   Christian, T
   Helmut, T
   Hartmut, T
   Christian, VJ
   Claus, V
   Ulrich, W
   Tobias, W
   Hubert, W
AF Trudzinski, F. C.
   Kahnert, K.
   Vogelmeier, C. F.
   Alter, P.
   Seiler, F.
   Faehndrich, S.
   Watz, H.
   Welte, T.
   Speer, T.
   Zewinger, S.
   Biertz, F.
   Kauczor, H. -U.
   Joerres, R. A.
   Bals, R.
   Stefan, Andreas
   Robert, Bals
   Juergen, Behr
   Kathrin, Kahnert
   Burkhard, Bewig
   Roland, Buhl
   Ralf, Ewert
   Beate, Stubbe
   Joachim, Ficker H.
   Manfred, Gogol
   Christian, Grohe
   Rainer, Hauck
   Matthias, Held
   Berthold, Jany
   Markus, Henke
   Felix, Herth
   Gerd, Hoeffken
   Hugo, Katus A.
   Anne-Mariez, Kirsten
   Henrik, Watz
   Rembert, Koczulla
   Klaus, Kenn
   Juliane, Kronsbein
   Cornelia, Kropf-Sanchen
   Christoph, Lange
   Peter, Zabel
   Michael, Pfeifer
   Winfried, Randerath J.
   Werner, Eeger
   Michael, Studnicka
   Christian, Taube
   Helmut, Teschler
   Hartmut, Timmermann
   Christian, Virchow J.
   Claus, Vogelmeier
   Ulrich, Wagner
   Tobias, Welte
   Hubert, Wirtz
CA COSYCONET Consortium
TI Combined effects of lung function, blood gases and kidney function on
   the exacerbation risk in stable COPD: Results from the COSYCONET cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Exacerbation risk; Acid-base metabolism; Renal function; Blood
   gases
ID OBSTRUCTIVE PULMONARY-DISEASE; HYPERCAPNIC RESPIRATORY-FAILURE; HOME
   VENTILATION; BASE EXCESS; STANDARDIZATION; ALKALOSIS; PREVALENCE;
   PREDICTORS; MANAGEMENT; SURVIVAL
AB Rationale: Alterations of acid-base metabolism are an important outcome predictor in acute exacerbations of COPD, whereas sufficient metabolic compensation and adequate renal function are associated with decreased mortality. In stable COPD there is, however, only limited information on the combined role of acid-base balance, blood gases, renal and respiratory function on exacerbation risk grading.
   Methods: We used baseline data of the COPD cohort COSYCONET, applying linear and logistic regression analyses, the results of which were implemented into a comprehensive structural equation model. As most informative parameters it comprised the estimated glomerular filtration rate (eGFR), lung function defined via forced expiratory volume in 1 s (FEV1), intrathoracic gas volume (ITGV) and (diffusing capacity for carbon monoxide (DLCO), moreover arterial oxygen content (CaO2), partial pressure of oxygen (PaCO2), base exess (BE) and exacerbation risk according to GOLD criteria. All measures were adjusted for age, gender, body-mass index, the current smoking status and pack years.
   Results: 1506 patients with stable COPD (GOLD grade 1-4; mean age 64.5 +/- 8.1 y; mean FEV1 54 +/- 18 % predicted, mean eGFR 82.3 +/- 16.9 mL/min/1.73m(2)) were included. BE was linked to eGFR, lung function and PaCO2 and played a role as indirect predictor of exacerbation risk via these measures; moreover, eGFR was directly linked to exacerbation risk. These associations remained significant after taking into account medication (diuretics, oral and inhaled corticosteroids), whereby corticosteroids had effects on exacerbation risk and lung function, diuretics on eGFR, BE and lung function.
   Conclusion: Even in stable COPD acid-base metabolism plays a key integrative role in COPD risk assessment despite rather small deviations from normality. It partially mediates the effects of impairments in kidney function, which are also directly linked to exacerbation risk.
C1 [Trudzinski, F. C.; Seiler, F.; Bals, R.] Saarland Univ Hosp, Dept Internal Med Pulmonol 5, Allergol, Crit Care Care Med, Homburg, Germany.
   [Kahnert, K.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Internal Med 5, Comprehens Pneumol Ctr,German Ctr Lung Res, Munich, Germany.
   [Vogelmeier, C. F.; Alter, P.] Philipps Univ Marburg, UMR, Dept Med Pulm & Crit Care Med, German Ctr Lung Res DZL, Marburg, Germany.
   [Faehndrich, S.] Univ Hosp Freiburg, Dept Pneumol, Freiburg, Germany.
   [Watz, H.] LungenClin Grosshansdorf, Pulm Res Inst, Airway Res Ctr North, German Ctr Lung Res, Grosshansdorf, Germany.
   [Welte, T.] Hannover Med Sch, Clin Pneumol, German Ctr Lung Res, Hannover, Germany.
   [Speer, T.; Zewinger, S.] Saarland Univ Hosp, Dept Internal Med Nephrol 4, Homburg, Germany.
   [Biertz, F.] Hannover Med Sch, Inst Biostat, Hannover, Germany.
   [Kauczor, H. -U.] Heidelberg Univ Hosp, Dept Diagnost & Intervent Radiol, German Ctr Lung Res, Heidelberg, Germany.
   [Joerres, R. A.] Ludwig Maximilians Univ Munchen, Inst & Outpatient Clin Occupat Social & Environm, Comprehens Pneumol Ctr Munich, German Ctr Lung Res DZL, Munich, Germany.
   [Stefan, Andreas] Lungenfachklin, Immenhausen, Germany.
   [Robert, Bals] Univ Klinikum Saarlandes, Homburg, Germany.
   [Juergen, Behr; Kathrin, Kahnert] Klinikum Ludwig Maximilians Univ Munchen, Munich, Germany.
   [Burkhard, Bewig] Univ Klinikum Schleswig Holstein, Kiel, Germany.
   [Roland, Buhl] Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany.
   [Ralf, Ewert; Beate, Stubbe] Univ Med Greifswald, Greifswald, Germany.
   [Joachim, Ficker H.] Paracelsus Med Privatuniv Nurnberg, Klinikum Nurnberg, Nurnberg, Germany.
   [Manfred, Gogol] Heidelberg Univ, Inst Gerontol, Heidelberg, Germany.
   [Christian, Grohe] Ev Lungenklin Berlin, Berlin, Germany.
   [Rainer, Hauck] Kliniken Sudostbayern AG, Kreisklin Bad Reichenhall, Bad Reichenhall, Germany.
   [Matthias, Held; Berthold, Jany] Klinikum Wurzburg Mitte gGmbH, Standort Missioklin, Wurzburg, Germany.
   [Markus, Henke] Asklepios Fachkliniken Munchen Gauting, Munich, Germany.
   [Felix, Herth] Thoraxklin Heidelberg gGmbH, Heidelberg, Germany.
   [Gerd, Hoeffken] Fachkrankenhaus Coswig GmbH, Coswig, Germany.
   [Hugo, Katus A.] Univ Klinikum Heidelberg, Heidelberg, Germany.
   [Anne-Mariez, Kirsten; Henrik, Watz] Lungenclin Grosshansdorf GmbH, Pneumol Forschungsinst, Grosshansdorf, Germany.
   [Rembert, Koczulla; Klaus, Kenn] Schon Klin Berchtesgadener Land, Schonau, Germany.
   [Juliane, Kronsbein] Berufsgenossenschaftl Univ Klinikum Bergmannsheil, Bochum, Germany.
   [Cornelia, Kropf-Sanchen] Univ Klinikum Ulm, Ulm, Germany.
   [Christoph, Lange; Peter, Zabel] Orschungszentrum Borstel, Sulfeld, Germany.
   [Michael, Pfeifer] Klin Donaustauf, Donaustauf, Germany.
   [Winfried, Randerath J.] Wissenschaftl Inst Bethanien eV, Solingen, Germany.
   [Werner, Eeger] Justus Liebig Univ Giessen, Giessen, Germany.
   [Michael, Studnicka] Uniklinikum Salzburg, Salzburg, Austria.
   [Christian, Taube; Helmut, Teschler] Ruhrlandklin gGmbH Essen, Essen, Germany.
   [Hartmut, Timmermann] Hamburger Inst Therapieforsch GmbH, Hamburg, Germany.
   [Christian, Virchow J.] Univ Klinikum Rostock, Rostock, Germany.
   [Claus, Vogelmeier] Univ Klinikum Giessen & Marburg GmbH, Standort Marburg, Germany.
   [Ulrich, Wagner] Klin Lowenstein gGmbH, Lunen, Germany.
   [Tobias, Welte] Hannover Med Sch, Hannover, Germany.
   [Hubert, Wirtz] Univ Klinikum Leipzig, Leipzig, Germany.
RP Trudzinski, FC (reprint author), Saarland Univ, Med Ctr, Dept Internal Med 5, Homburg, Germany.
EM franziska.trudzinski@uks.eu
RI Trudzinski, Franziska/I-9912-2019
OI Trudzinski, Franziska/0000-0002-0980-7586; Speer,
   Thimoteus/0000-0002-2491-6393
FU German Federal Ministry of Education and Research (BMBF) Competence
   Network Asthma and COPD (ASCONET)Federal Ministry of Education &
   Research (BMBF); German Centre for Lung Research(DZL); BMBFFederal
   Ministry of Education & Research (BMBF) [01 GI 0881]; AstraZeneca
   GmbHAstraZeneca; BayerSchering Pharma AGBayer AG; Boehringer Ingelheim
   Pharma GmbH Co. KGBoehringer Ingelheim; ChiesiGmbH;
   GlaxoSmithKlineGlaxoSmithKline; Grifols Deutschland GmbH; MSD Sharp
   DohmeGmbH; Mundipharma GmbH; Novartis Deutschland GmbH; Pfizer
   PharmaGmbH; Takeda Pharma Vertrieb GmbH Co. KG; Teva GmbH
FX This work was supported by the German Federal Ministry of Education and
   Research (BMBF) Competence Network Asthma and COPD (ASCONET) and
   performed in collaboration with the German Centre for Lung
   Research(DZL). The project is funded by the BMBF with grant number 01 GI
   0881, and is funded by unrestricted grants from AstraZeneca GmbH,
   BayerSchering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG,
   ChiesiGmbH, GlaxoSmithKline, Grifols Deutschland GmbH, MSD Sharp &
   DohmeGmbH, Mundipharma GmbH, Novartis Deutschland GmbH, Pfizer
   PharmaGmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Teva GmbH for patient
   investigations and laboratory measurements.
CR Alter P, 2018, RESP MED, V137, P14, DOI 10.1016/j.rmed.2018.02.011
   Babitt JL, 2012, J AM SOC NEPHROL, V23, P1631, DOI 10.1681/ASN.2011111078
   Baty F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063285
   Brijker F, 2001, RESP PHYSIOL, V124, P151, DOI 10.1016/S0034-5687(00)00196-1
   Bruno CM, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/915150
   Budweiser S, 2007, INT J CLIN PRACT, V61, P1516, DOI 10.1111/j.1742-1241.2007.01427.x
   Budweiser S, 2009, Pneumologie, V63, P484, DOI 10.1055/s-0029-1214993
   Budweiser S, 2007, CHEST, V131, P1650, DOI 10.1378/chest.06-2124
   Criee CP, 2011, RESP MED, V105, P959, DOI 10.1016/j.rmed.2011.02.006
   Criee C-P, 2006, Pneumologie, V60, P576, DOI 10.1055/s-2006-944245
   Duke JW, 2016, J PHYSIOL-LONDON, V594, P4981, DOI 10.1113/JP272211
   Fedeli Ugo, 2017, Int J Chron Obstruct Pulmon Dis, V12, P443, DOI 10.2147/COPD.S119390
   Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P844, DOI 10.1001/jama.291.7.844
   Galla JH, 2000, J AM SOC NEPHROL, V11, P369
   Gjerde B, 2012, RESP MED, V106, P361, DOI 10.1016/j.rmed.2011.10.004
   Hamm LL, 2015, CLIN J AM SOC NEPHRO, V10, P2232, DOI 10.2215/CJN.07400715
   Haroun MK, 2003, J AM SOC NEPHROL, V14, P2934, DOI 10.1097/01.ASN.0000095249.99803.85
   HODGKIN JE, 1980, CRIT CARE MED, V8, P725, DOI 10.1097/00003246-198012000-00005
   Hopkins E, 2018, PHYSL ACID BASE BALA
   Inker LA, 2014, AM J KIDNEY DIS, V63, P713, DOI 10.1053/j.ajkd.2014.01.416
   Kahnert K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0815-y
   Kahnert K, 2018, RESP MED, V134, P79, DOI 10.1016/j.rmed.2017.12.003
   Kahnert K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177501
   Karch A, 2016, RESP MED, V114, P27, DOI 10.1016/j.rmed.2016.03.008
   Khanna A, 2006, J NEPHROL, V19, pS86
   Kraut JA, 2005, AM J KIDNEY DIS, V45, P978, DOI 10.1053/j.ajkd.2005.03.003
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lucke T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163408
   Luke RG, 2012, J AM SOC NEPHROL, V23, P204, DOI 10.1681/ASN.2011070720
   MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905
   Magder S, 2015, ANN AM THORAC SOC, V12, P111, DOI 10.1513/AnnalsATS.201409-426OI
   MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580
   Marin JM, 2010, AM J RESP CRIT CARE, V182, P325, DOI 10.1164/rccm.200912-1869OC
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   Polverino F, 2017, AM J RESP CRIT CARE, V195, P1464, DOI 10.1164/rccm.201609-1765OC
   Saran R, 2017, AM J KIDNEY DIS, V69, DOI 10.1053/j.ajkd.2016.12.004
   Schiavo A, 2016, MULTIDISCIP RESP MED, V11, DOI 10.1186/s40248-016-0063-2
   Seiler F, 2019, MED KLIN-INTENSIVMED, V114, P234, DOI 10.1007/s00063-017-0318-5
   SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P123, DOI 10.1111/j.1399-6576.1995.tb04346.x
   SIGGAARDANDERSEN O, 1990, SCAND J CLIN LAB INV, V50, P17, DOI 10.3109/00365519009087488
   Terzano C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035245
   Ucgun I, 2008, RESPIRATION, V76, P270, DOI 10.1159/000131707
   Verbraecken J, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-132
   Vogelmeier CF, 2017, EUR RESPIR J, V49, P3
   Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005
   Wedzicha JA, 2014, CLIN CHEST MED, V35, P157, DOI 10.1016/j.ccm.2013.11.001
   Westerik JAM, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0512-2
   WHO, CHRON OBSTR PULM DIS
   Yasuda K, 2016, J CLIN ENDOCR METAB, V101, P2390, DOI 10.1210/jc.2016-1324
   Yoshizawa T, 2015, INT J CHRONIC OBSTR, V10, P1283, DOI 10.2147/COPD.S80673
NR 51
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 18
EP 26
DI 10.1016/j.rmed.2019.06.007
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800004
PM 31203096
DA 2020-05-18
ER

PT J
AU Djamin, RS
   Bafadhel, M
   Uzun, S
   Russell, REK
   Ermens, AAM
   Kerstens, R
   Aerts, JGJV
   Pavord, ID
   van der Eerden, MM
AF Djamin, Remco S.
   Bafadhel, Mona
   Uzun, Sevim
   Russell, Richard E. K.
   Ermens, Anton A. M.
   Kerstens, Rene
   Aerts, Joachim G. J. V.
   Pavord, Ian D.
   van der Eerden, Menno M.
TI Blood eosinophil count and GOLD stage predict response to maintenance
   azithromycin treatment in COPD patients with frequent exacerbations
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Eosinophils; Azithromycin; Exacerbations
ID OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC FIBROSIS BRONCHIECTASIS;
   DOUBLE-BLIND; LONG-TERM; THERAPY; PREVENTION; RESISTANCE;
   CLARITHROMYCIN; ERYTHROMYCIN; CARRIAGE
AB Introduction: Maintenance treatment with macrolides are useful in preventing COPD exacerbations. We investigated which characteristics of COPD patients with frequent exacerbations predicted the best response to maintenance treatment with azithromycin.
   Methods: This study was part of the COLUMBUS trial, a prospective randomized, double-blind, placebo-controlled study in 92 COPD patients with frequent exacerbations. During the 1-year treatment period, follow-up data were collected for spirometry, mMRC scores, sputum cultures and blood inflammatory markers.
   Results: In the azithromycin group a significant lower number of exacerbations per patient was observed in patients with the following characteristics: baseline blood eosinophil count >= 2.0% ((x) over bar =1.26), compared to an eosinophil count <2.0% (<(x)over bar>=2.50; p=0.02), GOLD stage 1-2 ((x) over bar =1.06), versus GOLD stage 4 ((x) over bar =2.62; p=0.02) and GOLD group C ((x) over bar =0.45) compared to group D ((x) over bar =2.18; p <0.01). Moreover, the number of hospitalizations was significantly lower in patients, with a blood eosinophil count >= 2.0% (<(x)over bar>=0.26) compared to an eosinophil count <2.0% (<(x)over bar>=0.90; p=0.01) and in GOLD stages 1-2 ((x) over bar =1.06) compared to stage 4 ((x) over bar =2.62; p=0.04).
   Conclusion: In conclusion, azithromycin maintenance treatment appears to be effective in COPD patients with frequent exacerbations, who are either classified in GOLD stage 1-2 or GOLD C and those with a blood eosinophil count of >= 2.0%.
C1 [Djamin, Remco S.; Uzun, Sevim; Aerts, Joachim G. J. V.] Amphia Hosp, Dept Resp Med, Molengracht 21, NL-4818 CK Breda, Netherlands.
   [Bafadhel, Mona; Russell, Richard E. K.; Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Dept Resp Med, Oxford, England.
   [Ermens, Anton A. M.] Amphia Hosp, Lab Clin Chem & Haematol, Breda, England.
   [Kerstens, Rene] Amphia Hosp, Breda, England.
   [Aerts, Joachim G. J. V.; van der Eerden, Menno M.] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands.
RP Djamin, RS (reprint author), Amphia Hosp, Dept Resp Med, Molengracht 21, NL-4818 CK Breda, Netherlands.
EM m.vandereerden@erasmusmc.nl
OI Bafadhel, Mona/0000-0002-9993-2478
CR Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623
   Altenburg J, 2013, JAMA-J AM MED ASSOC, V309, P1251, DOI 10.1001/jama.2013.1937
   ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196
   Bafadhel M, 2016, CHEST, V150, P320, DOI 10.1016/j.chest.2016.01.026
   Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC
   Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC
   Barnes NC, 2016, EUR RESPIR J, V47, P1374, DOI 10.1183/13993003.01370-2015
   Berg HF, 2004, ANTIMICROB AGENTS CH, V48, P4183, DOI 10.1128/AAC.48.11.4183-4188.2004
   Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698
   Clement A, 2006, THORAX, V61, P895, DOI 10.1136/thx.2005.057950
   Corris PA, 2015, THORAX, V70, P442, DOI 10.1136/thoraxjnl-2014-205998
   Dahl M, 2007, AM J RESP CRIT CARE, V175, P250, DOI 10.1164/rccm.200605-713OC
   Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
   Fenoll A, 2009, J CLIN MICROBIOL, V47, P1012, DOI 10.1128/JCM.01454-08
   Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0
   Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402-0207OC
   Kadota J, 2003, RESP MED, V97, P844, DOI 10.1016/S0954-6111(03)00042-8
   Malhotra-Kumar S, 2007, LANCET, V369, P482, DOI 10.1016/S0140-6736(07)60235-9
   Miravitlles M, 2002, CHEST, V121, P1449, DOI 10.1378/chest.121.5.1449
   Montagnani F, 2009, INFECTION, V37, P353, DOI 10.1007/s15010-008-8023-1
   Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X
   Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC
   Serisier DJ, 2013, LANCET RESP MED, V1, P262, DOI 10.1016/S2213-2600(13)70038-9
   Serisier DJ, 2013, JAMA-J AM MED ASSOC, V309, P1260, DOI 10.1001/jama.2013.2290
   Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE
   Stolz D, 2008, CHEST, V134, P263, DOI 10.1378/chest.08-0047
   Suissa S, 2012, THORAX, V67, P957, DOI 10.1136/thoraxjnl-2011-201518
   Takizawa H, 1997, AM J RESP CRIT CARE, V156, P266, DOI 10.1164/ajrccm.156.1.9612065
   The European Committee on Antimicrobial Susceptibility Testing (EUCAST), CLIN BREAKP
   Uzun S, 2014, LANCET RESP MED, V2, P361, DOI 10.1016/S2213-2600(14)70019-0
   Uzun S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-82
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wenzel RP, 2012, NEW ENGL J MED, V367, P340, DOI 10.1056/NEJMct1115170
   Zuur-Telgen MC, 2014, CHEST, V145, P534, DOI 10.1378/chest.13-1063
NR 37
TC 0
Z9 0
U1 4
U2 7
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 27
EP 33
DI 10.1016/j.rmed.2019.06.005
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800005
PM 31203097
DA 2020-05-18
ER

PT J
AU Pelkonen, MK
   Laatikainen, TK
   Jousilahti, P
AF Pelkonen, Margit K.
   Laatikainen, Tiina K.
   Jousilahti, Pekka
TI The relation of environmental tobacco smoke (ETS) to chronic bronchitis
   and mortality over two decades
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Environmental tobacco smoke; Smoking; Chronic bronchitis; Mortality
ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC RESPIRATORY SYMPTOMS; SECONDHAND
   SMOKE; PASSIVE SMOKING; EUROPEAN COUNTRIES; 2ND-HAND SMOKE; EXPOSURE;
   PREVALENCE; TRENDS; RISK
AB Introduction: Our aim was to describe how the prevalence of subjects exposed to environmental tobacco smoke (ETS) has changed from 1992 to 2012 in Finland. We also investigated the association between ETS and chronic bronchitis and cause-specific and all-cause mortality.
   Methods: The study population is composed of 38 494 subjects aged 25-74 years who participated in the National FINRISK Study between 1992 and 2012. Each survey included a standardized questionnaire on exposure to ETS, symptoms of chronic bronchitis, smoking habits and other risk factors, and clinical measurements at the study site. Data on mortality was obtained from the National Causes of Death Register.
   Results: In 2012, 5% of the participants were exposed to ETS compared to 25% in 1992. The adjusted odds ratio (OR) for ETS exposure in 2012 compared with that in 1992 was 0.27, p < 0.001. Exposure to ETS was more common in men than in women and among smokers than in non-smokers. Exposure to ETS was in turn associated with chronic bronchitis, OR 1.63 (95% confidence interval 1.49-1.78),-also separately both at work (OR 1.36) and at home (OR 1.69). Subjects with exposure to ETS had significantly increased all-cause (hazard ratio=HR 1.15, 1.05-1.26) and cardiovascular mortality (HR 1.26, 1.07-1.47). However, when stratified by smoking ETS was associated with all-cause mortality only in smokers (HR 1.31, 1.15-1.48).
   Conclusion: The proportion of subjects exposed to ETS decreased substantially during the study. Additionally, ETS exposure was associated with chronic bronchitis throughout the study and increased all-cause and cardiovascular mortality.
C1 [Pelkonen, Margit K.] Kuopio Univ Hosp, Dept Resp Med, Ctr Med & Clin Res, POB 1777, Kuopio 70211, Finland.
   [Pelkonen, Margit K.] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland.
   [Laatikainen, Tiina K.; Jousilahti, Pekka] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Laatikainen, Tiina K.] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland.
   [Laatikainen, Tiina K.] Joint Municipal Author North Karelia Social & Hl, Joensuu, Finland.
RP Pelkonen, MK (reprint author), Kuopio Univ Hosp, Dept Resp Med, Ctr Med & Clin Res, POB 1777, Kuopio 70211, Finland.
EM Margit.Pelkonen@kuh.fi
FU VTR Funding of the Kuopio University Hospital; Finnish Medical
   Foundation
FX Supported by the VTR Funding of the Kuopio University Hospital and the
   Finnish Medical Foundation.
CR Backman H, 2016, RESP MED, V114, P103, DOI 10.1016/j.rmed.2016.03.013
   Backman H, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-1
   Bhatta L, 2018, RESP MED, V138, P50, DOI 10.1016/j.rmed.2018.03.020
   David GL, 2005, THORAX, V60, P1052, DOI 10.1136/thx.2005.042960
   Eisner MD, 2007, ANN EPIDEMIOL, V17, P364, DOI 10.1016/j.annepidem.2006.10.008
   Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7
   Flexeder C, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0996-z
   Giskes K, 2005, J EPIDEMIOL COMMUN H, V59, P395, DOI 10.1136/jech.2004.025684
   Halldin CN, 2015, CHRON RESP DIS, V12, P47, DOI 10.1177/1479972314562409
   Heloma A, 2011, SCAND J PUBLIC HEALT, V39, P723, DOI 10.1177/1403494811420325
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Hulin M, 2012, EUR RESPIR J, V40, P1033, DOI 10.1183/09031936.00159011
   Jaakkola MS, 2000, EUR RESP MONOGR, V15, P322
   Janssen F, 2004, B WORLD HEALTH ORGAN, V82, P904
   Jousilahti P, 2002, SCAND J WORK ENV HEA, V28, P16
   Jousilahti P, 2002, SCAND J WORK ENV HEA, V28, P41
   LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222, DOI 10.1164/ajrccm.150.5.7952544
   Liu R, 2011, 2011 INTERNATIONAL CONFERENCE ON FUTURE COMPUTER SCIENCE AND APPLICATION (FCSA 2011), VOL 3, P9
   Oberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8
   Pelkonen M, 2006, CHEST, V130, P1129, DOI 10.1378/chest.130.4.1129
   Pelkonen MK, 2017, RESP MED, V123, P87, DOI 10.1016/j.rmed.2016.12.018
   Pelkonen MK, 2014, RESP MED, V108, P1633, DOI 10.1016/j.rmed.2014.08.007
   Perlman SE, 2016, NICOTINE TOB RES, V18, P2065, DOI 10.1093/ntr/ntw135
   Pirkle J. L., 1996, J AM MED ASS, V275
   Protano C, 2017, ENVIRON INT, V107, P190, DOI 10.1016/j.envint.2017.07.014
   Radon K, 2002, CHEST, V122, P1086, DOI 10.1378/chest.122.3.1086
   Reed RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174354
   Reijula JP, 2010, SCAND J PUBLIC HEALT, V38, P724, DOI 10.1177/1403494810379168
   Ronmark EP, 2009, RESP MED, V103, P1807, DOI 10.1016/j.rmed.2009.07.014
   ROSE GA, 1968, MONOGRAPH SERIES, P177
   Sethi JM, 2000, CLIN CHEST MED, V21, P67, DOI 10.1016/S0272-5231(05)70008-3
   Simoni M, 2007, RESP MED, V101, P531, DOI 10.1016/j.rmed.2006.06.021
   Tolonen H, 2002, RECOMMENDATION INDIC
   Ukawa S, 2017, INT J PUBLIC HEALTH, V62, P489, DOI 10.1007/s00038-016-0938-1
   Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330
   Vasankari TM, 2010, EUR RESPIR J, V36, P766, DOI 10.1183/09031936.00178109
   Vineis P, 2005, BRIT MED J, V330, P277, DOI 10.1136/bmj.38327.648472.82
   Waked M, 2012, INT J CHRONIC OBSTR, V7, P577, DOI 10.2147/COPD.S35044
   Wen WQ, 2006, BMJ-BRIT MED J, V333, P376, DOI 10.1136/bmj.38834.522894.2F
   1988, J CLIN EPIDEMIOL, V41, P105, DOI DOI 10.1016/0895-4356(88)90084-4
NR 40
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 34
EP 39
DI 10.1016/j.rmed.2019.06.006
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800006
PM 31207539
DA 2020-05-18
ER

PT J
AU Alcaraz-Serrano, V
   Fernandez-Barat, L
   Scioscia, G
   Llorens-Llacuna, J
   Gimeno-Santos, E
   Herrero-Cortina, B
   Vazquez, N
   de la Bellacasa, JP
   Gabarrus, A
   Amaro-Rodriguez, R
   Menendez, R
   Torres, A
AF Alcaraz-Serrano, Victoria
   Fernandez-Barat, Laia
   Scioscia, Giulia
   Llorens-Llacuna, Joan
   Gimeno-Santos, Elena
   Herrero-Cortina, Beatriz
   Vazquez, Nil
   Puig de la Bellacasa, Jordi
   Gabarrus, Albert
   Amaro-Rodriguez, Rosanel
   Menendez, Rosario
   Torres, Antoni
TI Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients
   with non-cystic fibrosis bronchiectasis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Rheology; Mucoid Pseudomonas aeruginosa; Bronchiectasis; Sputum;
   Viscoelastic properties
ID BRONCHIAL MUCUS; LONG-TERM; EXACERBATIONS; MUCOCILIARY; VALIDATION;
   INFECTION; MORTALITY; AIRWAY; TIME
AB Introduction and aim: Pseudomonas aeruginosa could acquire a mucoid phenotype due to mutations in mucA (mucoid Pseudomonas aeruginosa-mPA) that is a hallmark of poor prognosis in patients with bronchiectasis. Despite the higher prevalence of Pseudomonas aeruginosa in bronchiectasis, how mPA and non-mucoid Pseudomonas aeruginosa (non-mPA) phenotypes could affect viscoelastic properties of sputum is unknown. Our aim was to determine the relationship between Pseudomonas aeruginosa phenotypes isolation, the viscoelastic properties of sputum and the clinical outcomes in patients with bronchiectasis.
   Methods: A cross-sectional study was conducted of sputum samples obtained by spontaneous expectoration and sent for microbiology and rheology analysis. Elasticity and viscosity were measured at two oscillatory frequencies (1 and 100 rad/s). Socio-demographic and clinical data were recorded.
   Results: We analyzed 17 patients with mPA, 14 with non-mPA and 17 with no organism reported (NOR). Compared with the NOR group, the mPA group showed higher elasticity (median 10.30 vs. 5.70, p=0.023), viscosity (2.40 vs. 1.50, p=0.039), and stiffness (10.70 vs. 6.00, p=0.024). Values in the mPA group tended to be higher compared with non-mPA. Clinically, the mPA group showed greater hospitalizations during the previous year and greater affected lobes than the non-mPA and NOR groups.
   Conclusions: The mPA phenotype is associated with increased elasticity, viscosity and stiffness of bronchiectatic sputum. Viscoelastic properties could be used as a marker of poor mucociliary clearance in mPA, with potentially important clinical implications.
C1 [Alcaraz-Serrano, Victoria; Gimeno-Santos, Elena; Gabarrus, Albert] Hosp Clin Barcelona, FCRB, Barcelona, Spain.
   [Alcaraz-Serrano, Victoria; Fernandez-Barat, Laia; Gimeno-Santos, Elena; Vazquez, Nil; Gabarrus, Albert; Amaro-Rodriguez, Rosanel; Torres, Antoni] Inst Invest Biomed August Pi I Sunyer IDIBAPS, CibeRes Ctr Invest Biomed Red Enfermedades Resp, Barcelona, Spain.
   [Fernandez-Barat, Laia; Vazquez, Nil; Torres, Antoni] Univ Barcelona, Sch Med, Cellex Lab, Barcelona, Spain.
   [Scioscia, Giulia] Univ Foggia, Dept Med & Surg Sci, Inst Resp Dis, Foggia, Italy.
   [Llorens-Llacuna, Joan] Univ Barcelona, Lab Chem Engn, Barcelona, Spain.
   [Herrero-Cortina, Beatriz] Univ San Jorge, Zaragoza, Spain.
   [Puig de la Bellacasa, Jordi] Hosp Clin Barcelona, Microbiol Serv, Barcelona, Spain.
   [Amaro-Rodriguez, Rosanel; Torres, Antoni] Hosp Clin Barcelona, Inst Clin Resp, Pneumol Dept, Barcelona, Spain.
   [Menendez, Rosario] Hosp La Fe, Pneumol Dept, Valencia, Spain.
RP Torres, A (reprint author), Hosp Clin Barcelona, Pneumol Unit, Carrer Villarroel 170, E-08036 Barcelona, Spain.
EM victoriaalcarazserrano@gmail.com; lfernan1@clinic.cat;
   giuliascioscia84@gmail.com; jllorensl@ub.edu; elenagimeno@gmail.com;
   beafisiorespi@gmail.com; nilsaxo@gmail.com; jpuig1949@gmail.com;
   gabarrus@clinic.cat; ramaro@clinic.cat; rosmenend@gmail.com;
   atorres@clinic.cat
RI Scioscia, Giulia/AAA-5055-2020; Torres, Antoni/H-6128-2017; Menendez,
   Rosario/G-9723-2016; Llorens, Joan/K-9349-2014
OI Scioscia, Giulia/0000-0002-2667-077X; Torres,
   Antoni/0000-0002-8643-2167; Menendez, Rosario/0000-0002-3592-3839;
   Alcaraz, Victoria/0000-0001-6036-9545; Llorens, Joan/0000-0002-2361-8968
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [FIS
   PI1800145]; Sociedad Espanola de Neumologia y Cirugia Toracica [SEPAR
   052/2014]; Collegi Fisioterapeutes Catalunya [047913/2016]; ICREA
   AcademyICREA; SGR (Generalitat de Catalunya)Generalitat de Catalunya;
   CibeRes (Ciber Intramural) [ES18PI01/2018]
FX Instituto de Salud Carlos III (FIS PI1800145), Sociedad Espanola de
   Neumologia y Cirugia Toracica (SEPAR 052/2014), Collegi Fisioterapeutes
   Catalunya (047913/2016), ICREA Academy award of Prof. Antoni Torres, SGR
   (Generalitat de Catalunya), CibeRes (Ciber Intramural ES18PI01/2018).
   The funding sources had no involvement in study design, collection,
   analysis and interpretation of data, in the writing of the report and in
   the decision to submit the article for publication.
CR Barker AF, 2002, NEW ENGL J MED, V346, P1383, DOI 10.1056/NEJMra012519
   Camoez M., 2016, CLIN MICROBIOL INFEC, V22
   Chalmers JD, 2014, AM J RESP CRIT CARE, V189, P576, DOI 10.1164/rccm.201309-1575OC
   Chalmers JD, 2012, AM J RESP CRIT CARE, V186, P657, DOI 10.1164/rccm.201203-0487OC
   Chandrasekaran R., 2018, BMC PULM MED, V18, P1
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cohen M, 1999, CHEST, V116, P1063, DOI 10.1378/chest.116.4.1063
   Davies G, 2006, EUR RESPIR J, V28, P974, DOI 10.1183/09031936.06.00074605
   Dhand R, 2018, J AEROSOL MED PULM D, V31, P121, DOI 10.1089/jamp.2017.1415
   Fernandez-Barat L, 2017, J CYST FIBROS, V16, P222, DOI 10.1016/j.jcf.2016.08.005
   Flume PA, 2018, LANCET, V392, P880, DOI 10.1016/S0140-6736(18)31767-7
   Gastaldi AC, 2000, BIORHEOLOGY, V37, P203
   Gloag ES, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28009-5
   Goeminne PC, 2014, RESP MED, V108, P287, DOI 10.1016/j.rmed.2013.12.015
   Goltermann L, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02696-16, 10.1128/aac.02696-16]
   Hester KLM, 2012, QJM-INT J MED, V105, P235, DOI 10.1093/qjmed/hcr184
   Hill AT, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00051-2017
   KING M, 1987, BIORHEOLOGY, V24, P589
   King PT, 2006, RESP MED, V100, P2183, DOI 10.1016/j.rmed.2006.03.012
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lee S, 2018, CLIN EXP VACCINE RES, V7, P111, DOI 10.7774/cevr.2018.7.2.111
   Li ZH, 2005, JAMA-J AM MED ASSOC, V293, P581, DOI 10.1001/jama.293.5.581
   Locke LW, 2016, EUR RESPIR J, V47, P1392, DOI 10.1183/13993003.01880-2015
   Loebinger MR, 2009, EUR RESPIR J, V34, P843, DOI 10.1183/09031936.00003709
   Malhotra S, 2018, MBIO, V9, DOI 10.1128/mBio.00275-18
   Martinez-Garcia MA, 2014, EUR RESPIR J, V43, P1357, DOI 10.1183/09031936.00026313
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Murray MP, 2009, EUR RESPIR J, V34, P361, DOI 10.1183/09031936.00163208
   MURRAY PR, 1975, MAYO CLIN PROC, V50, P339
   Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017
   Powell LC, 2018, NPJ BIOFILMS MICROBI, V4, DOI 10.1038/s41522-018-0056-3
   Pryor JA, 2004, CLIN PULM MED, V11, P201
   PUCHELLE E, 1987, BIORHEOLOGY, V24, P557
   Ramos EMC, 2015, RESP CARE, V60, P724, DOI 10.4187/respcare.02429
   Rogers Geraint B, 2014, Ann Am Thorac Soc, V11, P496, DOI 10.1513/AnnalsATS.201310-335OC
   Rubin BK, 2009, RESP CARE, V54, P726, DOI 10.4187/002013209790983269
   Soler N, 2007, THORAX, V62, P29, DOI 10.1136/thx.2005.056374
   van der Schans CP, 2007, RESP CARE, V52, P1150
   Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF
   Wang HZ, 2011, ANTIMICROB AGENTS CH, V55, P4469, DOI 10.1128/AAC.00126-11
   Wilson CB, 1997, EUR RESPIR J, V10, P1754, DOI 10.1183/09031936.97.10081754
NR 41
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 40
EP 46
DI 10.1016/j.rmed.2019.06.012
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800007
PM 31212120
DA 2020-05-18
ER

PT J
AU Mansfield, L
   Bernstein, JA
AF Mansfield, Lyndon
   Bernstein, Jonathan A.
TI Tiotropium in asthma: From bench to bedside
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Adolescents; Adults; Anticholinergic; Asthma; Long-acting muscarinic
   antagonists; Pediatric
ID ADD-ON THERAPY; INHALED CORTICOSTEROIDS; ANTICHOLINERGIC AGENTS;
   MUSCARINIC ANTAGONIST; ECONOMIC-EVALUATION; SYSTEMATIC ANALYSIS;
   RESPIMAT INHALER; GLOBAL BURDEN; LUNG-FUNCTION; 195 COUNTRIES
AB Objective: Tiotropium is a long-acting muscarinic antagonist approved for maintenance treatment of asthma in children, adolescents, and adults in the United States, and recommended as add-on treatment for uncontrolled asthma despite treatment with inhaled corticosteroids and/or long-acting beta-2 agonists. This review traces the journey of tiotropium from its historical origins through early preclinical testing to human clinical trials and real-life studies.
   Data sources: A search was performed in PubMed using search terms 'tiotropium' and 'asthma.' Relevant references cited in those articles were reviewed.
   Study selections: English language articles published from December 2008-December 2018 were screened. Articles evaluating the efficacy, cost-effectiveness, real-life evidence, and steroid-sparing effect of tiotropium with inadequately controlled asthma were included.
   Results: Anticholinergics have a long history of use in the treatment of obstructive airway diseases. Evidence indicates that tiotropium's mechanism of action consists of bronchodilation and diminished mucus secretion, with preclinical evidence suggesting an anti-inflammatory effect as well. Phase 2 and 3 clinical trials have demonstrated that tiotropium is efficacious and safe, resulting in significant improvements in lung function in adults, adolescents, and children across asthma severities. Emerging evidence suggests that add-on tiotropium might potentially enable reductions in inhaled corticosteroid dose in patients with uncontrolled asthma. Further, tiotropium is a cost-effective treatment option that is also effective in the clinical practice setting.
   Conclusions: An increasing body of evidence indicates that tiotropium can play a significant role in the treatment of patients with uncontrolled asthma.
C1 [Mansfield, Lyndon] Paul L Foster Sch Med, Dept Pediat, El Paso, TX USA.
   [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Clin Med, Cincinnati, OH 45221 USA.
RP Bernstein, JA (reprint author), Univ Cincinnati, Coll Med, Dept Clin Med, Cincinnati, OH 45221 USA.
EM bernstja@ucmail.uc.edu
FU BIPI
FX This study was supported by BIPI. BIPI was involved in analysis,
   interpretation of data and, in the decision to submit the article for
   publication.
CR Abadoglu O, 2016, CLIN RESPIR J, V10, P421, DOI 10.1111/crj.12230
   AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916
   Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x
   BARNES PJ, CHEST S, V117, P63, DOI DOI 10.1378/CHEST.117.2_SUPPL.63S.
   Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020
   Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004
   Beeh KM, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-61
   Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907
   Bosnjak B, 2014, PULM PHARMACOL THER, V27, P44, DOI 10.1016/j.pupt.2013.09.004
   Busse W., 2007, 3 NHLBI US DEP HLTH, P1
   Cook AL, 2014, CLIN PEDIATR, V53, P1393, DOI 10.1177/0009922814525836
   Dalby RN, 2011, MED DEVICES-EVID RES, V4, P145, DOI 10.2147/MDER.S7409
   Disse B, 1999, LIFE SCI, V64, P457, DOI 10.1016/S0024-3205(98)00588-8
   Donohue James F, 2004, Chest, V126, p125S, DOI 10.1378/chest.126.2_suppl_1.125S
   Echave M, 2015, VALUE HEALTH, V18, pA501, DOI 10.1016/j.jval.2015.09.1420
   Fardon T, 2007, RESP MED, V101, P1218, DOI 10.1016/j.rmed.2006.11.001
   Food and Drug Administration, 2004, APPL 21 395 APPR LET
   Food and Drug Administration, 2016, 3819832 FDA DEP HHS
   GANDEVIA B, 1975, POSTGRAD MED J, V51, P13
   Global Initiative for Asthma, 2015, POCK GUID ASTHM MAN
   Global Initiative for Asthma, 2018, GLOBAL STRATEGY FOR
   Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC
   Gosens R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-73
   GROSS NJ, 1988, AM REV RESPIR DIS, V138, P765, DOI 10.1164/ajrccm/138.4.765
   GROSS NJ, 1988, NEW ENGL J MED, V319, P486
   GROSS NJ, 1984, NEW ENGL J MED, V311, P421, DOI 10.1056/NEJM198408163110701
   HADDAD EB, 1994, MOL PHARMACOL, V45, P899
   Hamelmann E, 2016, J ALLERGY CLIN IMMUN, V138, P441, DOI 10.1016/j.jaci.2016.01.011
   Hodder Rick, 2009, Int J Chron Obstruct Pulmon Dis, V4, P225
   Huang J, 2016, PAK J MED SCI, V32, P462, DOI 10.12669/pjms.322.8836
   Jackson M, 2010, MED HIST, V54, P171, DOI 10.1017/S0025727300000235
   James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]
   Kanazawa H, 2006, CURR OPIN PULM MED, V12, P60, DOI 10.1097/01.mcp.0000198066.73328.3a
   Kang JY, 2012, ANN ALLERG ASTHMA IM, V109, P29, DOI 10.1016/j.anai.2012.05.005
   Kapoor AS, 2009, CAN RESPIR J, V16, P99, DOI 10.1155/2009/206506
   Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4
   Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606
   Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039
   Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941
   Moulton BC, 2011, BRIT J PHARMACOL, V163, P44, DOI 10.1111/j.1476-5381.2010.01190.x
   OConnor BJ, 1996, AM J RESP CRIT CARE, V154, P876, DOI 10.1164/ajrccm.154.4.8887578
   Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109
   Ohta S, 2010, CLIN EXP ALLERGY, V40, P1266, DOI 10.1111/j.1365-2222.2010.03478.x
   Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017
   Panning CA, 2003, PHARMACOTHERAPY, V23, P183, DOI 10.1592/phco.23.2.183.32082
   Pawlik M, 2015, VALUE HEALTH, V18, pA502, DOI 10.1016/j.jval.2015.09.1425
   Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC
   Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770
   Price D, 2015, J ASTHMA ALLERGY, V8, P1, DOI 10.2147/JAA.S76639
   Proskocil BJ, 2004, ENDOCRINOLOGY, V145, P2498, DOI 10.1210/en.2003-1728
   Restrepo RD, 2007, RESP CARE, V52, P833
   ROCHE WR, 1989, LANCET, V1, P520
   ROFFEL A F, 1990, Pulmonary Pharmacology, V3, P47, DOI 10.1016/0952-0600(90)90009-8
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Salpeter SR, 2006, CLIN REV ALLERG IMMU, V31, P219, DOI 10.1385/CRIAI:31:2:219
   Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380
   Schmidt O, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.PA4398
   Schurmann Wolfgang, 2005, Treat Respir Med, V4, P53
   Scott GD, 2012, CHEM IMMUNOL ALLERGY, V98, P48, DOI 10.1159/000336498
   Miguel LS, 2015, VALUE HEALTH, V18, pA502, DOI 10.1016/j.jval.2015.09.1426
   Soni Priyanka, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P1002, DOI 10.1016/S2221-1691(13)60014-3
   Szefler S. J., 2017, J ALLERGY CLIN IMMUN, V6749
   Terzano C, 2004, Eur Rev Med Pharmacol Sci, V8, P259
   Timmer W, 2015, RESP MED, V109, P329, DOI 10.1016/j.rmed.2014.12.005
   Vogelberg C, 2018, J ALLER CL IMM-PRACT, V6, P2160, DOI 10.1016/j.jaip.2018.04.032
   Vogelberg C, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0175-9
   Vogelberg C, 2014, RESP MED, V108, P1268, DOI 10.1016/j.rmed.2014.06.011
   Vrijlandt EJLE, 2018, LANCET RESP MED, V6, P127, DOI 10.1016/S2213-2600(18)30012-2
   Westby M, 2004, COCHRANE DB SYST REV, V3
   Willson J, 2016, APPL HEALTH ECON HEA, V14, P119, DOI 10.1007/s40258-015-0216-z
   Wise RA, 2013, NEW ENGL J MED, V369, P1491, DOI 10.1056/NEJMoa1303342
   Zafari Z, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0089-8
NR 72
TC 1
Z9 1
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 47
EP 55
DI 10.1016/j.rmed.2019.06.008
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800008
PM 31212121
DA 2020-05-18
ER

PT J
AU Honkamaki, J
   Hisinger-Molkanen, H
   Ilmarinen, P
   Piirila, P
   Tuomisto, LE
   Andersen, H
   Huhtala, H
   Sovijarvi, A
   Backman, H
   Lundback, B
   Ronmark, E
   Lehtimaki, L
   Kankaanranta, H
AF Honkamaki, Jasmin
   Hisinger-Molkanen, Hanna
   Ilmarinen, Pinja
   Piirila, Paivi
   Tuomisto, Leena E.
   Andersen, Heidi
   Huhtala, Heini
   Sovijarvi, Anssi
   Backman, Helena
   Lundback, Bo
   Ronmark, Eva
   Lehtimaki, Lauri
   Kankaanranta, Hannu
TI Age- and gender-specific incidence of new asthma diagnosis from
   childhood to late adulthood
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Incidence; Prevalence; Gender; Adult; Phenotype
ID OBSTRUCTIVE LUNG-DISEASE; ONSET ASTHMA; RESPIRATORY SYMPTOMS; NORTHERN
   SWEDEN; REPORTED ASTHMA; NATURAL-HISTORY; PREVALENCE; REMISSION;
   SMOKING; HEALTH
AB Background: Asthma is currently divided into different phenotypes, with age at onset as a relevant differentiating factor. In addition, asthma with onset in adulthood seems to have a poorer prognosis, but studies investigating age-specific incidence of asthma with a wide age span are scarce.
   Objective: To evaluate incidence of asthma diagnosis at different ages and differences between child- and adult-diagnosed asthma in a large population-based study, with gender-specific analyzes included.
   Methods: In 2016, a respiratory questionnaire was sent to 8000 randomly selected subjects aged 20-69 years in western Finland. After two reminders, 4173 (52.3%) subjects responded. Incidence rate of asthma was retrospectively estimated based on the reported age of asthma onset. Adult-diagnosed asthma was defined as a physician-diagnosis of asthma made at >= 18 years of age.
   Results: Among those with physician-diagnosed asthma, altogether, 63.7% of subjects, 58.4% of men and 67.8% of women, reported adult-diagnosed asthma. Incidence of asthma diagnosis was calculated in 10-year age groups and it peaked in young boys (0-9 years) and middle-aged women (40-49 years) and the average incidence rate during the examined period between 1946 and 2015 was 2.2/1000/year. Adult-diagnosed asthma became the dominant phenotype among those with physician-diagnosed asthma by age of 50 years and 38 years in men and women, respectively.
   Conclusions: Asthma is mainly diagnosed during adulthood and the incidence of asthma diagnosis peaks in middle-aged women. Asthma diagnosed in adulthood should be considered more in clinical practice and management guidelines.
C1 [Honkamaki, Jasmin; Lehtimaki, Lauri; Kankaanranta, Hannu] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.
   [Hisinger-Molkanen, Hanna] Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland.
   [Ilmarinen, Pinja; Tuomisto, Leena E.; Kankaanranta, Hannu] Seinajoki Cent Hosp, Dept Resp Med, FIN-60220 Seinajoki, Finland.
   [Piirila, Paivi; Sovijarvi, Anssi] Univ Helsinki, Cent Hosp, HUS Med Imaging Ctr, Unit Clin Physiol, Helsinki, Finland.
   [Piirila, Paivi; Sovijarvi, Anssi] Univ Helsinki, Helsinki, Finland.
   [Andersen, Heidi] Vaasa Cent Hosp, Dept Resp Med, Vaasa, Finland.
   [Huhtala, Heini] Tampere Univ, Fac Social Sci, Tampere, Finland.
   [Backman, Helena; Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Div Occupat & Environm Med, OLIN Unit, Umea, Sweden.
   [Lundback, Bo] Univ Gothenburg, Inst Med, Krefting Res Ctr, Gothenburg, Sweden.
   [Lehtimaki, Lauri] Tampere Univ Hosp, Allergy Ctr, Tampere, Finland.
RP Kankaanranta, H (reprint author), Seinajoki Cent Hosp, Dept Resp Med, FIN-60220 Seinajoki, Finland.
EM hannu.kankaanranta@epshp.fi
RI ; Piirila, Paivi/H-2291-2018
OI Andersen, Heidi/0000-0001-5923-5865; Ilmarinen,
   Pinja/0000-0002-8758-2431; Backman, Helena/0000-0002-0553-8067;
   Hisinger-Molkanen, Hanna/0000-0003-2293-0279; Lehtimaki,
   Lauri/0000-0003-1586-4998; Piirila, Paivi/0000-0002-2535-4409
FU Tampere Tuberculosis Foundation (Tampere, Finland); Finnish
   Anti-Tuberculosis Association Foundation (Helsinki, Finland); Research
   Foundation of The Pulmonary Diseases (Helsinki, Finland); Competitive
   State Research Financing of the Expert Responsibility Area of Tampere
   University Hospital (Tampere, Finland); Medical Research Fund of
   Seinajoki Central Hospital (Seinajoki, Finland)
FX This work was supported by Tampere Tuberculosis Foundation (Tampere,
   Finland), The Finnish Anti-Tuberculosis Association Foundation
   (Helsinki, Finland), The Research Foundation of The Pulmonary Diseases
   (Helsinki, Finland), The Competitive State Research Financing of the
   Expert Responsibility Area of Tampere University Hospital (Tampere,
   Finland) and The Medical Research Fund of Seinajoki Central Hospital
   (Seinajoki, Finland). None of the sponsors had any involvement in the
   planning, execution, drafting or write-up of this study.
CR Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x
   Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741
   Backman H, 2017, CLIN EXP ALLERGY, V47, P1426, DOI 10.1111/cea.12963
   Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011
   Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018
   Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050
   de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008
   de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600
   de Nijs SB, 2013, EUR RESPIR REV, V22, P44, DOI 10.1183/09059180.00007112
   Eagan TML, 2005, INT J TUBERC LUNG D, V9, P603
   Ekerljung L, 2008, RESP MED, V102, P1730, DOI 10.1016/j.rmed.2008.07.011
   Gibson PG, 2010, LANCET, V376, P803, DOI 10.1016/S0140-6736(10)61087-2
   Haahtela Tari, 2013, Duodecim, V129, P994
   Hazell Michelle L, 2009, Prim Care Respir J, V18, P165, DOI 10.3132/pcrj.2009.00001
   Hedman Linnea, 2012, Clin Transl Allergy, V2, P1, DOI 10.1186/2045-7022-2-1
   Ilmarinen P, 2017, J ALLER CL IMM-PRACT, V5, P967, DOI 10.1016/j.jaip.2017.01.027
   Jousilahti P, 2016, EUR RESPIR J, V47, P985, DOI 10.1183/13993003.01702-2015
   Kankaanranta H, 2017, J ALLER CL IMM-PRACT, V5, P189, DOI 10.1016/j.jaip.2016.08.015
   Larsson ML, 2003, EUR RESPIR J, V21, P672, DOI 10.1183/09031936.03.00033702
   Lindstrom M, 2001, CHEST, V119, P852, DOI 10.1378/chest.119.3.852
   LUNDBACK B, 1991, EUR RESPIR J, V4, P257
   Lundback B, 2001, RESP MED, V95, P685, DOI 10.1053/rmed.2001.1126
   Macsali F, 2012, EXPERT REV RESP MED, V6, P187, DOI [10.1586/ERS.12.15, 10.1586/ers.12.15]
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Pallasaho P, 2011, RESP MED, V105, P1449, DOI 10.1016/j.rmed.2011.04.013
   Pattaro C, 2007, J CLIN EPIDEMIOL, V60, P704, DOI 10.1016/j.jclinepi.2006.10.010
   Pelkonen MK, 2014, RESP MED, V108, P1633, DOI 10.1016/j.rmed.2014.08.007
   Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035
   Polosa R, 2013, EUR RESPIR J, V41, P716, DOI 10.1183/09031936.00073312
   Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863
   Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304
   Ronmark EP, 2009, RESP MED, V103, P1807, DOI 10.1016/j.rmed.2009.07.014
   Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011
   Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363
   Skytt N, 2012, J ALLERGY CLIN IMMUN, V130, P403, DOI 10.1016/j.jaci.2012.04.043
   Sood Akshay, 2013, Ann Am Thorac Soc, V10, P188, DOI 10.1513/AnnalsATS.201212-115OC
   Strachan DP, 1996, BRIT MED J, V312, P1195
   Tan DJ, 2015, EXPERT REV RESP MED, V9, P109, DOI 10.1586/17476348.2015.1000311
   Toren K, 2006, J CLIN EPIDEMIOL, V59, P90, DOI 10.1016/j.jclinepi.2005.03.019
   Toren K, 2004, EUR RESPIR J, V24, P942, DOI 10.1183/09031936.04.00044804
   Toren K, 2011, RESP MED, V105, P1622, DOI 10.1016/j.rmed.2011.06.003
   Triebner K, 2016, J ALLERGY CLIN IMMUN, V137, P50, DOI 10.1016/j.jaci.2015.08.019
   Tuomisto LE, 2015, RESP MED, V109, P944, DOI 10.1016/j.rmed.2015.05.001
   Wallis S, 2013, J QUANT LINGUIST, V20, P178, DOI 10.1080/09296174.2013.799918
   Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678
NR 45
TC 4
Z9 4
U1 2
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 56
EP 62
DI 10.1016/j.rmed.2019.06.003
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800009
PM 31212122
DA 2020-05-18
ER

PT J
AU Krubiner, M
   Shapira, U
   Zeltser, D
   Shapira, I
   Berliner, S
   Shenhar-Tsarfaty, S
   Rogowski, O
   Bar-Shai, A
AF Krubiner, Mor
   Shapira, Udi
   Zeltser, David
   Shapira, Itzhak
   Berliner, Shlomo
   Shenhar-Tsarfaty, Shani
   Rogowski, Ori
   Bar-Shai, Amir
TI Lung function deterioration predicts elevated troponin levels in
   apparently healthy individuals throughout a 5-year follow-up
SO RESPIRATORY MEDICINE
LA English
DT Article
DE High-sensitive troponin; Spirometry; Healthy population; Pulmonary
   function test
ID HIGHLY SENSITIVE ASSAY; CORONARY-HEART-DISEASE; FAILURE; MORTALITY;
   RISK; IMPAIRMENT
AB Background: Lung function is inversely associated with coronary heart disease and cardiovascular disease. High-sensitive cardiac troponin T (hs-cTnT) was recently found to represent early subclinical cardiac disease even in healthy individuals. We explored the inter-relationship between lung function and hs-cTnT and the changes over time in these two measurements.
   Methods: Lung function test and hs-cTnT were determined in apparently healthy individuals from the Tel Aviv Medical Center Inflammatory Survey. Participants with normal lung function were followed up for 5 years in order to evaluate the effect of lung function deterioration on hs-cTnT levels. The correlation between annual Forced vital capacity (FVC) % predicted decline and hs-cTnT levels were analyzed.
   Results: A 5-year follow-up of 2,618 participants with normal lung function at baseline revealed a mean annual FVC deterioration of 31.9 (+/- 91.3) ml/year. Lung function decline>5% was associated with an increased risk of having hs-cTnT>5 ng/L (Exp. beta=1.55 1.20-1.99, p=0.001). Delta FVC between two consecutive visits was inversely correlated with an increase of hs-cTnT (r=-0.24, p<0.001).
   Conclusions: Deterioration of lung function predicts elevated troponin levels and may be a sign of early sub-clinical cardiac disease.
C1 [Krubiner, Mor; Bar-Shai, Amir] Ben Gurion Univ Negev, Fac Hlth Sci, Barzilai Med Ctr, Div Pulm Med, Ashqelon, Israel.
   [Shapira, Udi; Zeltser, David; Shapira, Itzhak; Berliner, Shlomo; Shenhar-Tsarfaty, Shani; Rogowski, Ori] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Internal Med C D & E, Tel Aviv, Israel.
   [Shapira, Udi; Zeltser, David; Shapira, Itzhak; Berliner, Shlomo; Shenhar-Tsarfaty, Shani; Rogowski, Ori] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Bar-Shai, A (reprint author), Barzilai Govt Hosp, Div Pulm Med, 2 Hahistadrut St, Ashqelon, Israel.
EM amirb@bmc.gov.il
CR Armon G, 2013, J PERS, V81, P452, DOI 10.1111/jopy.12021
   Baum C, 2016, INT J CARDIOL, V218, P298, DOI 10.1016/j.ijcard.2016.05.034
   Brekke PH, 2008, EUR RESPIR J, V31, P563, DOI 10.1183/09031936.00015807
   Brekke Pal H, 2009, BMC Pulm Med, V9, P35, DOI 10.1186/1471-2466-9-35
   Brzezinski RY, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12930
   Brzezinski RY, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0560-4
   Chen PW, 2014, 2014 INTERNATIONAL CONFERENCE ON POWER SYSTEM TECHNOLOGY (POWERCON), P1314, DOI 10.1109/POWERCON.2014.6993643
   Chow SL, 2017, CIRCULATION, V135, pE1054, DOI 10.1161/CIR.0000000000000490
   de Lemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503, DOI 10.1001/jama.2010.1768
   Engstrom G, 2010, THORAX, V65, P633, DOI 10.1136/thx.2010.135392
   Gimenez MR, 2014, EUR HEART J, V35, P2303, DOI 10.1093/eurheartj/ehu188
   Greenberg S, 2016, AM J PHYSIOL-RENAL, V310, pF1192, DOI 10.1152/ajprenal.00481.2015
   Hattori K, 2015, INT J CHRONIC OBSTR, V10, P309, DOI 10.2147/COPD.S76293
   Johnston AK, 2008, THORAX, V63, P599, DOI 10.1136/thx.2007.088112
   McEvoy JW, 2016, JAMA CARDIOL, V1, P519, DOI 10.1001/jamacardio.2016.0765
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Milwidsky A, 2014, J METAB SYNDR, V3, P1, DOI DOI 10.4172/2167-0943.1000151
   Neukamm AMC, 2013, HEART, V99, P382, DOI 10.1136/heartjnl-2012-303429
   Pizarro Carmen, 2016, Int J Chron Obstruct Pulmon Dis, V11, P2081
   Saunders JT, 2011, CIRCULATION, V123, P1367, DOI 10.1161/CIRCULATIONAHA.110.005264
   Seliger SL, 2017, CIRCULATION, V135, P1494, DOI 10.1161/CIRCULATIONAHA.116.025505
   Sin DD, 2005, CHEST, V127, P1952, DOI 10.1378/chest.127.6.1952
NR 22
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 63
EP 68
DI 10.1016/j.rmed.2019.05.021
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800010
PM 31220805
DA 2020-05-18
ER

PT J
AU Humbert, M
   Albers, FC
   Bratton, DJ
   Yancey, SW
   Liu, MC
   Hozawa, S
   Llanos, JP
   Kwon, N
AF Humbert, Marc
   Albers, Frank C.
   Bratton, Daniel J.
   Yancey, Steven W.
   Liu, Mark C.
   Hozawa, Soichiro
   Llanos, Jean-Pierre
   Kwon, Namhee
TI Effect of mepolizumab in severe eosinophilic asthma according to
   omalizumab eligibility
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Asthma interventions; Eosinophilic asthma; Allergic asthma;
   Atopic asthma; Treatment
ID ADD-ON THERAPY; ALLERGIC-ASTHMA; DOUBLE-BLIND; MULTICENTER; EFFICACY;
   BIOMARKERS; PHENOTYPES; ANTIBODY; SAFETY; DREAM
AB Background: Patients with severe asthma can present with overlapping eosinophilic and allergic phenotypes, which makes it challenging when deciding which biologic therapy is most appropriate to reduce exacerbations and help achieve asthma control.
   Objective: This post hoc meta-analysis evaluated the efficacy of the licensed dose of mepolizumab (100 mg administered subcutaneously [SC]) versus placebo in patients with severe eosinophilic asthma (SEA), according to omalizumab eligibility and associated allergic characteristics.
   Methods: Data from two Phase 3 studies (MENSA [MEA115588/NCT01691521]; MUSCA [200862/NCT02281318]) were analyzed. Patients >= 12 years of age with SEA who experienced >= 2 exacerbations in the previous year received placebo, mepolizumab 100 mg SC or 75 mg intravenously, plus standard of care (high-dose inhaled corticosteroids and other controllers), every 4 weeks. Data from patients who received >= 1 dose placebo or mepolizumab 100 mg SC were used for this analysis. The primary endpoint was the rate of clinically significant exacerbations; other outcomes included forced expiratory volume in 1 s (FEV1), Asthma Control Questionnaire (ACQ-5) score and quality of life measured using St George's Respiratory Questionnaire (SGRQ).
   Results: Rate reductions in clinically significant exacerbations with mepolizumab versus placebo were similar in omalizumab eligible and ineligible patients (57% vs 55%). FEV1, ACQ-5 and SGRQ scores improved with mepolizumab versus placebo regardless of omalizumab eligibility, Immunoglobulin E levels, or atopic status.
   Conclusion: This analysis indicated that mepolizumab 100 mg SC has clinical benefit in patients with blood eosinophil counts >= 150 cells/mu L (or history of >= 300 cells/mu L), regardless of allergic characteristics or omalizumab eligibility.
C1 [Humbert, Marc] Univ Paris Sud, INSERM, U999, Serv Pneumol,Publ Hop Paris,Hop Bicetre, Le Kremlin Bicetre, France.
   [Albers, Frank C.] GSK, Resp Med Franchise, Res Triangle Pk, NC USA.
   [Bratton, Daniel J.] GSK, Clin Stat, Stockley Pk, Uxbridge, Middx, England.
   [Yancey, Steven W.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA.
   [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA.
   [Hozawa, Soichiro] Hiroshima Allergy & Resp Clin, Hiroshima, Japan.
   [Llanos, Jean-Pierre] GSK, US Med Affairs, Res Triangle Pk, NC USA.
   [Kwon, Namhee] GSK, Resp Med Franchise, Brentford, Middx, England.
RP Kwon, N (reprint author), GSK House, 980 Great West Rd, Brentford TW8 9GS, Middx, England.
EM mjc.humbert@gmail.com; frank.c.albers@gsk.com; daniel.x.bratton@gsk.com;
   steve.w.yancey@gsk.com; mcl@jhmi.edu; hozawa@vesta.ocn.ne.jp;
   jean-pierre.r.llanos-ackert@gsk.com; namhee.n.kwon@gsk.com
RI Humbert, Marc/AAC-8459-2019
OI Humbert, Marc/0000-0003-0703-2892; LLanos,
   Jean-Pierre/0000-0002-7785-6881
FU GlaxoSmithKlineGlaxoSmithKline [208116, MEA115588/NCT01691521,
   200862/NCT02281318]; GSKGlaxoSmithKline
FX This post hoc meta-analysis (GSK ID: 208116) and the parent studies
   (MENSA, MEA115588/NCT01691521; MUSCA, 200862/NCT02281318) were funded by
   GlaxoSmithKline. Editorial support (in the form of writing assistance,
   including development of the initial draft from the study report,
   assembling tables and figures, collating author comments, grammatical
   editing and referencing) was provided by Laura Pearce PhD, and Elizabeth
   Hutchinson PhD, CMPP, at Fishawack Indicia Ltd, UK, and was funded by
   GSK.
CR Albers F., 2018, J ALLERGY CLIN IMMUN, V141, pAB402, DOI [10.1016/j.jaci, DOI 10.1016/J.JACI]
   Albers FC, 2018, J ASTHMA, V55, P152, DOI 10.1080/02770903.2017.1322611
   Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
   Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011
   Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378
   Bousquet J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01782-2017
   Buhl R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00634-2017
   Caminati M, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0192-5
   Canonica GW, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0130-3
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   Galkin D, 2018, J ALLERGY CLIN IMMUN, V141, pAB409, DOI [DOI 10.1016/J.JACI.2017.12.965, 10.1016/j.jaci.2017.12.965]
   Genentech, US PRESCR INF
   GlaxoSmithKline, US PRESCR INF
   GlaxoSmithKline (GSK), GSK CLIN STUD REG
   GlaxoSmithKline UK, EU SUMM PROD CHAR
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Gunsoy NB, 2018, J ALLER CL IMM-PRACT, V6, P874, DOI 10.1016/j.jaip.2017.11.026
   Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC
   Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002
   Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x
   Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x
   Khatri S., 2018, J ALLERGY CLIN IMMUN, V143, DOI 10.1016/j.jaci.2018.09
   Lugogo N, 2016, CLIN THER, V38, P2058, DOI 10.1016/j.clinthera.2016.07.010
   Magnan A, 2016, ALLERGY, V71, P1335, DOI 10.1111/all.12914
   Niven RM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011857
   Ortega H, 2014, EUR RESPIR J, V44, P239, DOI 10.1183/09031936.00220413
   Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Tabatabaian F, 2018, J ASTHMA ALLERGY, V11, P53, DOI 10.2147/JAA.S107982
   Tran TN, 2016, ANN ALLERG ASTHMA IM, V116, P37, DOI 10.1016/j.anai.2015.10.027
   van Rijt L, 2016, SEMIN IMMUNOPATHOL, V38, P483, DOI 10.1007/s00281-016-0556-2
   Wahn U, 2009, ALLERGY, V64, P1780, DOI 10.1111/j.1398-9995.2009.02119.x
   Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x
   WHO, 2017, ASTHM FACT SHEET
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
NR 37
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 69
EP 75
DI 10.1016/j.rmed.2019.06.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800011
PM 31220806
DA 2020-05-18
ER

PT J
AU Johansson, H
   Norlander, K
   Malinovschi, A
AF Johansson, Henrik
   Norlander, Katarina
   Malinovschi, Andrei
TI Increased prevalence of exercise-induced airway symptoms - A five-year
   follow-up from adolescence to young adulthood
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Adolescence; Exercise: airway symptoms; Prevalence; Gender
ID ASTHMA-LIKE SYMPTOMS; RESPIRATORY SYMPTOMS; PHYSICAL SYMPTOMS; INDUCED
   DYSPNEA; CHILDHOOD; CHILDREN; GENDER; ALLERGIES; RISK
AB Background: Exercise-induced airway symptoms are common in adolescents. Little is known about the development of symptoms from adolescence to early adulthood. Therefore, we studied the prevalence, incidence, and remission of exercise-induced airway symptoms (including wheeze, cough, chest and throat tightness, hoarseness, and stridor) in adolescents, over a five-year period.
   Methods: In 2011, all adolescents aged 12-13 years in Uppsala (n=3 838) were invited to answer a questionnaire on exercise-induced airway symptoms. All responding adolescents (n=2 309) were invited to answer the same questionnaire again after five years. In total, 1 002 adolescents responded (43.4%).
   Results: The prevalence of exercise-induced airway symptoms increased from 25% at baseline to 49% at follow-up (p<0.001). More females than males reported symptoms at both time points. The incidence of airway symptoms was 42.2%, with no sex differences. More males than females reported symptom remission (20.2 vs. 10.7%, p<0.001). Females reported a higher asthma prevalence at follow-up than at baseline (7.6 vs. 15.2%), while males did not (10.9 vs. 8.0%), leading to a sex difference in prevalence at follow-up (p<0.001). Smoking and baseline respiratory symptoms were associated with an increased risk of reporting symptoms at follow-up.
   Conclusions: A twofold increase in the prevalence of exercise-induced airway symptoms over a five-year period was found in this cohort. Females were more likely to report symptoms at both time points. Knowledge of these age-related changes in symptoms and their association to female gender is useful for future studies and healthcare providers.
C1 [Johansson, Henrik; Malinovschi, Andrei] Uppsala Univ, Dept Med Sci, Clin Physiol, Box 256, SE-75105 Uppsala, Sweden.
   [Johansson, Henrik] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Box 256, SE-75105 Uppsala, Sweden.
   [Johansson, Henrik] Uppsala Univ, Dept Neurosci, Physiotherapy, Box 256, SE-75105 Uppsala, Sweden.
   [Norlander, Katarina] Uppsala Univ, Dept Surg Sci, Otorhinolaryngol & Head & Neck Surg, Box 256, SE-75105 Uppsala, Sweden.
RP Johansson, H (reprint author), Uppsala Univ, Dept Med Sci, Clin Physiol, Box 256, SE-75105 Uppsala, Sweden.
EM henrik.johansson@neuro.uu.se
FU Signhild Engkvist Foundation, Sweden; Bror Hjerpstedts Foundation,
   Sweden
FX This work was supported by The Signhild Engkvist Foundation, Sweden, and
   The Bror Hjerpstedts Foundation, Sweden.
CR Abu-Hasan M, 2005, ANN ALLERG ASTHMA IM, V94, P366, DOI 10.1016/S1081-1206(10)60989-1
   Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x
   ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483
   Brozek G, 2015, RESP MED, V109, P982, DOI 10.1016/j.rmed.2015.05.010
   Currie C, 2009, INT J PUBLIC HEALTH, V54, P131, DOI 10.1007/s00038-009-5404-x
   Ekstrom M., 2017, EUR RESP J, V49
   Grassi M, 2003, J CLIN EPIDEMIOL, V56, P238, DOI 10.1016/S0895-4356(02)00613-3
   Hallstrand TS, 2002, J PEDIATR-US, V141, P343, DOI 10.1067/mpd.2002.125729
   Halvorsen T, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02221-2016
   Hammo AH, 1999, ANN ALLERG ASTHMA IM, V82, P574, DOI 10.1016/S1081-1206(10)63169-9
   Hedman L, 2005, PEDIAT ALLERG IMM-UK, V16, P176, DOI 10.1111/j.1399-3038.2005.00231.x
   Hong SJ, 2004, CLIN EXP ALLERGY, V34, P1556, DOI 10.1111/j.1365-2222.2004.02084.x
   Huurre TM, 2004, J ASTHMA, V41, P311, DOI 10.1081/JAS-120026088
   Johansson H, 2014, RESP MED, V108, P852, DOI 10.1016/j.rmed.2014.03.010
   Johansson H, 2015, THORAX, V70, P57, DOI 10.1136/thoraxjnl-2014-205738
   Jurca M, 2017, PEDIATR PULM, V52, P1250, DOI 10.1002/ppul.23783
   Jurca M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177485
   Mahut B, 2014, PEDIATR PULM, V49, P772, DOI 10.1002/ppul.22905
   Movahed MR, 2008, CARDIOL YOUNG, V18, P303, DOI 10.1017/S104795110800214X
   Murakami Y, 2014, ALLERGOL INT, V63, P251, DOI 10.2332/allergolint.13-OA-0644
   Mvula M, 2005, J ASTHMA, V42, P9, DOI 10.1081/JAS-200044746
   Nystad W, 2001, EUR J EPIDEMIOL, V17, P209, DOI 10.1023/A:1017926403763
   Ostrom NK, 2011, ALLERGY ASTHMA PROC, V32, P425, DOI 10.2500/aap.2011.32.3502
   Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169
   Prochaska JJ, 2001, ARCH PEDIAT ADOL MED, V155, P554, DOI 10.1001/archpedi.155.5.554
   Seear M, 2005, ARCH DIS CHILD, V90, P898, DOI 10.1136/adc.2004.063974
   Sheel AW, 2016, EXP PHYSIOL, V101, P213, DOI 10.1113/EP085366
   Tollefsen E, 2006, RESP MED, V100, P471, DOI 10.1016/j.rmed.2005.06.007
   Tollefsen E, 2007, RESP MED, V101, P896, DOI 10.1016/j.rmed.2006.09.022
   VanWijk CMTG, 1997, SOC SCI MED, V45, P231, DOI 10.1016/S0277-9536(96)00340-1
   Weiler John M, 2010, Ann Allergy Asthma Immunol, V105, pS1, DOI 10.1016/j.anai.2010.09.021
   Yeatts K, 2003, EUR RESPIR J, V22, P781, DOI 10.1183/09031936.03.00095803
NR 32
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 76
EP 81
DI 10.1016/j.rmed.2019.06.011
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800012
PM 31226623
DA 2020-05-18
ER

PT J
AU Barnikel, M
   Million, M
   Knoop, H
   Behr, J
AF Barnikel, M.
   Million, M.
   Knoop, H.
   Behr, J.
TI The natural course of lung function decline in asbestos exposed subjects
   with pleural plaques and asbestosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asbestosis; Interstitial lung disease; Forced vital capacity; Lung
   fibrosis
ID IDIOPATHIC PULMONARY-FIBROSIS; PIRFENIDONE
AB While there is a good knowledge of the natural course of lung function in interstitial lung diseases (ILD) like idiopathic lung fibrosis (IPF), many ambiguities remain in patients with asbestosis. Therefore, we evaluated the change in lung function in asbestos exposed subjects with pleural plaques and asbestosis and analysed corresponding morphology of computer tomography of the thorax.
   Methods: 93 asbestos exposed subjects with pleural plaques and asbestosis were analysed retrospectively at the Klinikum Bergmannsheil of the Ruhr-University of Bochum. Parameters of lung function were obtained at least twice and annual changes of FVC, TLC and DLCOsb were calculated. In addition, we assessed the predominant pattern in high-resolution computer tomography of the thorax (HRCT) and differentiated three phenotypes: p (pleural)-type, f (fibrosis)-type and m (mixed)-type.
   Results: FU data are available in 56/93 (60.2%) patients. The annual deterioration (Mean +/- SEM) of FVC is -31.46 +/- 17.34 ml, of TLC -55.55 +/- 25.67 ml, of DLCOsb -0.38 +/- 0.07 mmol/min/kPa and of DLCOva -0.05 +/- 0.01 mmol/min/kPa/L. A categorical change of FVC > -100 ml was found in 12/56 (21.4%) and 18/56 (32.1%) patients showed an annual loss of TLC > -100 ml. The greatest annual decline of FVC was observed in patients with the fibrotic phenotype on HRCT (-76.76 +/- 66.43 ml) and the mixed phenotype (-81.52 +/- 24.79 ml), while the pleural phenotype was less affected (-10.52 +/- 25.07 ml).
   Conclusion: More than 20% of our cohort have a progressive disease with an annual loss of FVC > -100 ml. Patients with the fibrotic-phenotype or mixed-phenotype on HRCT are particularly at risk.
C1 [Barnikel, M.; Behr, J.] Ludwig Maximilians Univ Munchen, LMU, Dept Internal Med 5, Munich, Germany.
   [Barnikel, M.; Behr, J.] German Ctr Lung Res, Giessen, Germany.
   [Million, M.] Kliniken Landkreis Diepholz, Abt Plast & Handchirurg, Bassum, Germany.
   [Knoop, H.] Gemeinschaftspraxis Innere Med & Pneumol, Allergol, Schlafmed, Gelsenkirchen, Germany.
   [Behr, J.] Asklepios Fachkliniken Munchen Gauting, Gauting, Germany.
RP Behr, J (reprint author), Univ Munich, LMU, Dept Internal Med 5, Marchioninistr 15, D-81377 Munich, Germany.
EM juergen.behr@med.uni-muenchen.de
FU Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von
   Lungenkrankheiten (WATL)
FX Supported by Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von
   Lungenkrankheiten (WATL).
CR Baur X, 2011, Pneumologie, V65, pe1, DOI 10.1055/s-0030-1255992
   Behr J, 2015, PNEUMOLOGIE, V69, P455, DOI 10.1055/s-0034-1392602
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kishimoto T, 2011, INT J ENV RES PUB HE, V8, P899, DOI 10.3390/ijerph8030899
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Meyer KC, 2017, THER CLIN RISK MANAG, V13, P427, DOI 10.2147/TCRM.S81141
   Norbet C, 2015, CURR PROBL DIAGN RAD, V44, P371, DOI 10.1067/j.cpradiol.2014.10.002
   Park HJ, 2016, AM J ROENTGENOL, V207, P976, DOI 10.2214/AJR.16.16054
   Roggli VL, 2010, ARCH PATHOL LAB MED, V134, P462, DOI 10.1043/1543-2165-134.3.462
   Solbes E, 2018, J INVEST MED, V66, P721, DOI 10.1136/jim-2017-000628
   Takahashi K, 2016, ANN GLOB HEALTH, V82, P209, DOI 10.1016/j.aogh.2016.01.019
   Tarride JE, 2018, CLINICOECONOMIC OUTC, V10, P127, DOI 10.2147/CEOR.S154323
   Wang XR, 2010, J OCCUP HEALTH, V52, P272, DOI 10.1539/joh.L10062
   Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005
   Yang X L, 2016, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V34, P687, DOI 10.3760/cma.j.issn.1001-9391.2016.09.013
NR 15
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 82
EP 85
DI 10.1016/j.rmed.2019.06.013
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800013
PM 31226624
DA 2020-05-18
ER

PT J
AU Rogliani, P
   Matera, MG
   Calzetta, L
   Hanania, NA
   Page, C
   Rossi, I
   Andreadi, A
   Galli, A
   Coppola, A
   Cazzola, M
   Lauro, D
AF Rogliani, Paola
   Matera, Maria Gabriella
   Calzetta, Luigino
   Hanania, Nicola A.
   Page, Clive
   Rossi, Immacolata
   Andreadi, Aikaterini
   Galli, Angelica
   Coppola, Angelo
   Cazzola, Mario
   Lauro, Davide
TI Long-term observational study on the impact of GLP-1R agonists on lung
   function in diabetic patients
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Glucagon like Peptide-1 receptors; Type 2 diabetes mellitus; Airway
   smooth muscle; Lung function
ID OBSTRUCTIVE PULMONARY-DISEASE; HUMAN ISOLATED BRONCHI; PHARMACOLOGICAL
   CHARACTERIZATION; SMOOTH-MUSCLE; SMALL AIRWAYS; METFORMIN; COPD;
   EXPRESSION; RECEPTOR; INSULIN
AB Introduction: Preclinical research suggests a role of Glucagon Like Peptide-1 Receptors (GLP-1R) on the regulation of human bronchial tone. We investigated the effect of GLP-1R agonists on lung function of Type 2 Diabetes Mellitus (T2DM) population without co-existing chronic obstructive respiratory disorders.
   Methods: This was a prospective cohort study that examined change in lung function measurements over two years of T2DM patients (n= 32) treated with metformin monotherapy (control cohort), metformin plus GLP-1R agonists (GLP-1R agonists cohort), or metformin plus insulin (insulin cohort).
   Results: After 24 months of treatment, the forced expiratory volume in 1 s (FEV1) significantly (p < 0.05) increased from baseline in the GLP-1R agonists cohort (218 ml [95% CI 88-246]), but not in the control and insulin cohorts (94 ml [95% CI -28 -216] and 26 ml [95% CI -174 -226], respectively; p > 0.05 vs. baseline). The average increase in FEV1 in the GLP-1R agonists cohort was significantly greater than that in the control and insulin cohorts (delta: 110 ml [95% CI 18-202] and 177 ml [95% CI 85-270], respectively, p < 0.05). The forced vital capacity (FVC) also increased significantly more in the GLP-1R agonists cohort than in the control and insulin cohorts (overall delta FVC: 183 ml [95% CI 72-295], p < 0.05). The maximal expiratory flow at 50-75% significantly (p < 0.05) improved from baseline in the GLP-1R agonists cohort, but not in the control and insulin cohorts (p > 0.05).
   Conclusion: Our preliminary results suggest a potential new therapeutic perspective to treat airway disorders with GLP-1R agonists.
C1 [Rogliani, Paola; Calzetta, Luigino; Rossi, Immacolata; Coppola, Angelo; Cazzola, Mario] Univ Roma Tor Vergata, Dept Expt Med, Resp Unit, Rome, Italy.
   [Matera, Maria Gabriella] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Hanania, Nicola A.] Baylor Coll Med, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA.
   [Page, Clive] Kings Coll London, Inst Pharmaceut Sci, Sackler Inst Pulm Pharmacol, London, England.
   [Andreadi, Aikaterini; Galli, Angelica; Lauro, Davide] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
RP Calzetta, L (reprint author), Univ Roma Tor Vergata, Dept Expt Med, Via Montpellier 1, I-00133 Rome, Italy.
EM luigino.calzetta@uniroma2.it
RI Hanania, Nicola A/C-5875-2016
OI Hanania, Nicola A/0000-0003-3087-9530; Rogliani,
   Paola/0000-0001-7801-5040
CR Bishwakarma R, 2018, INT J CHRONIC OBSTR, V13, P793, DOI 10.2147/COPD.S150047
   Calixto MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076786
   Calzetta L, 2018, EQUINE VET J, V50, P594, DOI 10.1111/evj.12815
   Calzetta L, 2018, CURR OPIN PHARMACOL, V40, P95, DOI 10.1016/j.coph.2018.03.011
   Calzetta L, 2015, PULM PHARMACOL THER, V32, P15, DOI 10.1016/j.pupt.2015.03.007
   Cazzola M, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0010-2018
   Cazzola M, 2017, TRENDS PHARMACOL SCI, V38, P940, DOI 10.1016/j.tips.2017.07.003
   Cazzola M, 2017, COPD, V14, P552, DOI 10.1080/15412555.2017.1347918
   Cazzola M, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0386-8
   Cazzola M, 2012, AM J RESP CELL MOL, V47, P509, DOI 10.1165/rcmb.2011-0449OC
   Cefalu WT, 2019, DIABETES CARE, V42, pS13, DOI 10.2337/dc19-S002
   Cefalu WT, 2019, DIABETES CARE, V42, pS90, DOI 10.2337/dc19-S009
   Claudot F, 2009, INT J EPIDEMIOL, V38, P1104, DOI 10.1093/ije/dyp164
   Ehrlich SF, 2010, DIABETES CARE, V33, P55, DOI 10.2337/dc09-0880
   Evans DJ, 1998, THORAX, V53, P629, DOI 10.1136/thx.53.8.629
   Hsia CCW, 2007, DIABETES TECHNOL THE, V9, pS73, DOI 10.1089/dia.2007.0227
   Ito K, 2012, INT J CHRONIC OBSTR, V7, P641, DOI 10.2147/COPD.S28250
   Jiang SS, 2016, J MOL ENDOCRINOL, V57, P151, DOI 10.1530/JME-16-0099
   Kaparianos A, 2008, Chron Respir Dis, V5, P101, DOI 10.1177/1479972307086313
   Ke J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41085
   Kloth C, 2016, J THORAC DIS, V8, P3521, DOI 10.21037/jtd.2016.12.20
   LANGE P, 1989, EUR RESPIR J, V2, P14
   Lazarus R, 1998, EUR RESPIR J, V12, P641, DOI 10.1183/09031936.98.12030641
   Lecube A, 2010, DIABETOLOGIA, V53, P1210, DOI 10.1007/s00125-010-1700-5
   Litonjua AA, 2005, RESP MED, V99, P1583, DOI 10.1016/j.rmed.2005.03.023
   Maida A, 2011, DIABETOLOGIA, V54, P339, DOI 10.1007/s00125-010-1937-z
   Marino MT, 2010, CLIN PHARMACOL THER, V88, P243, DOI 10.1038/clpt.2010.85
   McKeever TM, 2005, AM J EPIDEMIOL, V161, P546, DOI 10.1093/aje/kwi076
   Mendivil CO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123344
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Pryor R, 2015, BIOCHEM J, V471, P307, DOI 10.1042/BJ20150497
   RICHTER G, 1990, FEBS LETT, V267, P78, DOI 10.1016/0014-5793(90)80292-Q
   RICHTER G, 1993, AM J PHYSIOL, V265, pL374
   Rogliani P, 2016, AM J RESP CELL MOL, V55, P804, DOI 10.1165/rcmb.2015-0311OC
   Rogliani P, 2014, ACTA DIABETOL, V51, P933, DOI 10.1007/s00592-014-0584-0
   Schaafsma D, 2007, BRIT J PHARMACOL, V150, P136, DOI 10.1038/sj.bjp.0706985
   Schaafsma D, 2007, AM J PHYSIOL-CELL PH, V293, pC429, DOI 10.1152/ajpcell.00502.2006
   Steier J, 2014, THORAX, V69, P752, DOI 10.1136/thoraxjnl-2014-205148
   Viby NE, 2013, ENDOCRINOLOGY, V154, P4503, DOI 10.1210/en.2013-1666
   Vilsboll T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7771
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Walter RE, 2003, AM J RESP CRIT CARE, V167, P911, DOI 10.1164/rccm.2203022
   WEI Y, 1995, FEBS LETT, V358, P219, DOI 10.1016/0014-5793(94)01430-9
   Yeh HC, 2005, DIABETES CARE, V28, P1472, DOI 10.2337/diacare.28.6.1472
   Zhu T, 2015, INT J MOL SCI, V16, P20195, DOI 10.3390/ijms160920195
NR 46
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 86
EP 92
DI 10.1016/j.rmed.2019.06.015
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800014
PM 31228775
DA 2020-05-18
ER

PT J
AU Cordova-Rivera, L
   Gibson, PG
   Gardiner, PA
   Hiles, SA
   McDonald, VM
AF Cordova-Rivera, Laura
   Gibson, Peter G.
   Gardiner, Paul A.
   Hiles, Sarah A.
   McDonald, Vanessa M.
TI Extrapulmonary associations of health status in severe asthma and
   bronchiectasis: Comorbidities and functional outcomes
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Health-related quality of life; Severe asthma; Bronchiectasis; Physical
   activity
ID QUALITY-OF-LIFE; GEORGES RESPIRATORY QUESTIONNAIRE; MULTIDIMENSIONAL
   ASSESSMENT; SOCIETY STATEMENT; PHYSICAL-ACTIVITY; MEPOLIZUMAB; ANXIETY;
   PEOPLE; INFLAMMATION; LIMITATION
AB Background: Severe asthma and bronchiectasis are heterogeneous diseases that contribute to disability beyond the pulmonary system. The magnitude of the impact that these extrapulmonary features has on health-related quality of life (HRQoL) is unknown.
   Methods: We analysed the cross-sectional relationships between HRQoL (St. George's Respiratory Questionnaire; SGRQ) and extrapulmonary characteristics, including physical activity (steps/day), anxiety and depression, isometric leg strength, systemic inflammation, and several comorbidities in adults with severe asthma (n=70) and bronchiectasis (n=61).
   Results: Participants with severe asthma and bronchiectasis had similar SGRQ total scores (mean scores 43.7 and 37.8 for severe asthma and bronchiectasis; p > 0.05), and similar pulmonary and extrapulmonary characteristics. The associations between extrapulmonary variables and HRQoL did not differ according to diagnosis (all interactions p > 0.05). Greater anxiety and depressive symptoms, fewer steps/day and greater systemic inflammation were statistically associated with poorer HRQoL in both diseases (p < 0.05). Lower isometric leg strength in severe asthma, and greater Charlson Comorbidity Index in bronchiectasis were also associated with poorer HRQoL (p < 0.05). In the multivariable regression model performed in the combined disease groups, anxiety and depression, steps/day, systemic inflammation and isometric leg strength remained independently associated with HRQoL. Associations between extrapulmonary characteristics and SGRQ domains were stronger for the activity and impact domains, than symptoms.
   Conclusion: In severe asthma and bronchiectasis, extrapulmonary features including physical activity and leg strength have a significant impact on HRQoL, especially within the activity and impact domains. These features should be considered as part of the assessment of these conditions, and they may represent additional treatment targets to improve HRQoL.
C1 [Cordova-Rivera, Laura; Gibson, Peter G.; Hiles, Sarah A.; McDonald, Vanessa M.] Natl Hlth & Med Res Council, Ctr Excellence Severe Asthma, Newcastle, NSW, Australia.
   [Cordova-Rivera, Laura; Gibson, Peter G.; Hiles, Sarah A.; McDonald, Vanessa M.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia.
   [Cordova-Rivera, Laura; Gibson, Peter G.; Hiles, Sarah A.; McDonald, Vanessa M.] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Gibson, Peter G.; McDonald, Vanessa M.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia.
   [Gardiner, Paul A.] Univ Queensland, Ctr Hlth Serv Res, Woolloongabba, Qld, Australia.
   [Gardiner, Paul A.] Univ Queensland, Mater Res Inst, South Brisbane, Australia.
RP McDonald, VM (reprint author), Level 2,West Wing,1 Kookaburra Circuit, New Lambton Hts, NSW 2305, Australia.
EM Laura.cordovarivera@uon.edu.au; Peter.Gibson@hnehealth.nsw.gov.au;
   p.gardiner@uq.edu.au; sarah.hiles@newcastle.edu.au;
   vanessa.mcdonald@newcastle.edu.au
RI Hiles, Sarah/AAE-3430-2019
OI Hiles, Sarah/0000-0002-2723-2798
FU University of Newcastle; Priority Research Centre for Healthy Lungs
   postgraduate scholarship; John Hunter Hospital Charitable Trust Grant;
   Hunter Medical Research Institute, Australia
FX This research was supported by a University of Newcastle and Priority
   Research Centre for Healthy Lungs postgraduate scholarship; a John
   Hunter Hospital Charitable Trust Grant and the Hunter Medical Research
   Institute, Australia.
CR Agusti A., 2016, EUR RESP J, V47
   [Anonymous], 2004, SUMM M REP BRUSS BEL
   Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520
   Broekhuizen R, 2006, THORAX, V61, P17, DOI 10.1136/thx.2005.041996
   Burgel PR, 2013, RESP MED, V107, P233, DOI 10.1016/j.rmed.2012.10.002
   Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306
   Chalmers JD, 2015, EUR RESPIR J, V45, P1446, DOI 10.1183/09031936.00119114
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   Clark VL, 2017, RESPIROLOGY, V22, P1262, DOI 10.1111/resp.13134
   Coelho CM, 2018, J SPORT SCI, V36, P1186, DOI 10.1080/02640414.2017.1364402
   Cordova-Rivera L., 2018, J ALLERGY CLIN PRACT, V2213-2198, P30127
   Cordova-Rivera L, 2019, RESPIROLOGY, V24, P352, DOI 10.1111/resp.13428
   de Camargo AA, 2018, PHYS THER, V98, P153, DOI 10.1093/ptj/pzx123
   Department of Health and Human Services US Government D. o. H. a. H. Services, 2018, PHYSICAL ACTIVITY GU
   Dogra S, 2010, J ASTHMA, V47, P972, DOI 10.1080/02770903.2010.508857
   Dudgeon EK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0631-7
   Ebmeier S, 2017, LANCET, V390, P935, DOI [10.1016/S0140-6736(17)31448-4, 10.1016/s0140-6736(17)31448-4]
   Foster JM, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00765-2017
   Franca-Pinto A, 2015, THORAX, V70, P732, DOI 10.1136/thoraxjnl-2014-206070
   Gibson PG, 2010, LANCET, V376, P803, DOI 10.1016/S0140-6736(10)61087-2
   Gillis Angela, 2005, Can Nurse, V101, P16
   Jones Paul W, 2005, COPD, V2, P75
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   JONES PW, 1991, THORAX, V46, P676, DOI 10.1136/thx.46.9.676
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702
   King MT, 2009, QUAL LIFE RES, V18, P301, DOI 10.1007/s11136-009-9448-4
   Lavoie KL, 2006, CHEST, V130, P1039, DOI 10.1378/chest.130.4.1039
   Lee AL, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-44
   Maltais F, 2014, AM J RESP CRIT CARE, V189, P1121, DOI 10.1164/rccrn.201402-0373ST
   McDonald VM, 2019, RESPIROLOGY, V24, P37, DOI 10.1111/resp.13389
   McDonald VM, 2018, MED J AUSTRALIA, V209, pS28, DOI 10.5694/mja18.00207
   McDonald VM, 2011, AGE AGEING, V40, P42, DOI 10.1093/ageing/afq134
   Mendes FAR, 2010, CHEST, V138, P331, DOI 10.1378/chest.09-2389
   Nelsen LM, 2017, RESP MED, V126, P32, DOI 10.1016/j.rmed.2017.02.021
   O'Neill S, 2015, THORAX, V70, P376, DOI 10.1136/thoraxjnl-2013-204114
   Olveira C, 2013, QUAL LIFE RES, V22, P597, DOI 10.1007/s11136-012-0188-5
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Ozalp O, 2012, MULTIDISCIP RESP MED, V7, DOI 10.1186/2049-6958-7-3
   Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6
   Pavord ID, 2017, LANCET RESP MED, V5, P362, DOI 10.1016/S2213-2600(17)30132-7
   Polverino E, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00328-2018
   Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017
   Ramos E, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/2049-6958-10-3
   Reardon JZ, 2006, AM J MED, V119, pS32, DOI 10.1016/j.amjmed.2006.08.005
   Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813
   Schakman O., 2013, INT J BIOCH CELL BIO, V45
   Shrikrishna D, 2012, EUR RESPIR J, V40, P1115, DOI 10.1183/09031936.00170111
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Urrutia I, 2012, J ASTHMA, V49, P201, DOI 10.3109/02770903.2011.654022
   Vermeulen F, 2016, RESP MED, V117, P122, DOI 10.1016/j.rmed.2016.06.003
   Villa F, 2011, ARCH DIS CHILD, V96, P554, DOI 10.1136/adc.2011.212431
   Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814
   Wilson CB, 1997, AM J RESP CRIT CARE, V156, P536, DOI 10.1164/ajrccm.156.2.9607083
   Wilson CB, 1998, EUR RESPIR J, V12, P820, DOI 10.1183/09031936.98.12040820
   Yorke J, 2017, J ASTHMA, V54, P543, DOI 10.1080/02770903.2016.1229335
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 59
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 93
EP 101
DI 10.1016/j.rmed.2019.06.010
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800015
PM 31229944
DA 2020-05-18
ER

PT J
AU Katsumata, M
   Hozumi, H
   Yasui, H
   Suzuki, Y
   Kono, M
   Karayama, M
   Furuhashi, K
   Enomoto, N
   Fujisawa, T
   Inui, N
   Nakamura, Y
   Suda, T
AF Katsumata, Mineo
   Hozumi, Hironao
   Yasui, Hideki
   Suzuki, Yuzo
   Kono, Masato
   Karayama, Masato
   Furuhashi, Kazuki
   Enomoto, Noriyuki
   Fujisawa, Tomoyuki
   Inui, Naoki
   Nakamura, Yutaro
   Suda, Takafumi
TI Frequency and clinical relevance of anti-cyclic citrullinated peptide
   antibody in idiopathic interstitial pneumonias
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Autoantibodies; Autoimmune; Connective tissue diseases; Interstitial
   lung disease; Rheumatic diseases; Rheumatoid arthritis
ID RHEUMATOID-ARTHRITIS; PULMONARY-FIBROSIS; LUNG-DISEASE; AUTOIMMUNE
   FEATURES; CLASSIFICATION; AUTOANTIBODIES; DIAGNOSIS; CRITERIA; UPDATE
AB Rationale: Although anti-cyclic citrullinated peptide antibody (ACPA) is highly specific for rheumatoid arthritis (RA), some patients with idiopathic interstitial pneumonia (IIP) are ACPA-positive, but do not fulfill the diagnostic criteria for RA. The clinical significance of ACPA in such patients is as yet unclear.
   Objective: We aimed to investigate the frequency of ACPA positivity and its clinical significance in patients initially diagnosed with IIP.
   Methods: We retrospectively analyzed 370 consecutive patients who were diagnosed with IIP and for whom serum ACPA results were available. The incidence of ACPA positivity and its predictive role for subsequent onset of RA was examined. Risk factors for development of RA were evaluated by Cox hazards analysis.
   Results: Of 370 patients, 24 (6.5%) were ACPA-positive, including 7 of 144 patients (4.9%) initially diagnosed with idiopathic pulmonary fibrosis (IPF) and 17 of 226 patients (7.5%) with non-IPF. The cumulative 3-year incidence of overt RA was significantly higher in patients who were positive rather than negative for ACPA (28.9% vs. 1.1%, P < 0.01). On multivariate analysis, younger age was independently associated with development of RA in patients who were ACPA-positive (per one year increase: hazard ratio = 0.93, 95% confidence interval 0.87-0.99, P = 0.03).
   Conclusion: Among patients initially diagnosed with IIP, a small proportion was positive for ACPA, of whom approximately one-third subsequently developed RA within 3 years from IIP diagnosis. Clinicians should be alert to the possibility of RA developing in patients with IIP who are ACPA-positive, particularly those patients who are younger.
C1 [Katsumata, Mineo; Hozumi, Hironao; Yasui, Hideki; Suzuki, Yuzo; Kono, Masato; Karayama, Masato; Furuhashi, Kazuki; Enomoto, Noriyuki; Fujisawa, Tomoyuki; Inui, Naoki; Nakamura, Yutaro; Suda, Takafumi] Hamamatsu Univ, Sch Med, Dept Internal Med, Div 2, Hamamatsu, Shizuoka, Japan.
   [Inui, Naoki] Hamamatsu Univ, Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka, Japan.
   [Kono, Masato] Seirei Hamamatsu Gen Hosp, Dept Resp Med, Hamamatsu, Shizuoka, Japan.
RP Hozumi, H (reprint author), Hamamatsu Univ, Sch Med, Div 2, Dept Internal Med,Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
EM hozumi@hama-med.ac.jp
RI Suzuki, Yuzo/AAE-6747-2020
OI Suzuki, Yuzo/0000-0001-6154-9791; Yasui, Hideki/0000-0002-7134-3364;
   Hozumi, Hironao/0000-0001-5439-1543; Furuhashi,
   Kazuki/0000-0003-4079-5509
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [JP 18K15947]
FX This work was supported by a grant from the Japan Society for the
   Promotion of Science [grant number JP 18K15947 to H.H.].
CR Ahmad K, 2017, RESP MED, V123, P56, DOI 10.1016/j.rmed.2016.10.017
   American Thoracic Society European Respiratory Society. American Thoracic Society/ European Respiratory Society International Multidisciplinary Con-sensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Baka Z, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2751
   Berglin E, 2006, ANN RHEUM DIS, V65, P453, DOI 10.1136/ard.2005.041376
   Rocha-Munoz AD, 2015, J IMMUNOL RES, DOI 10.1155/2015/151626
   Farid SS, 2013, INT J RHEUM DIS, V16, P379, DOI 10.1111/1756-185X.12129
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Fischer A, 2012, RESP MED, V106, P1040, DOI 10.1016/j.rmed.2012.03.006
   Gizinski AM, 2009, CLIN RHEUMATOL, V28, P611, DOI 10.1007/s10067-009-1128-9
   Hozumi H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199659
   Hozumi H, 2016, LUNG, V194, P235, DOI 10.1007/s00408-016-9851-x
   Kang BH, 2013, J KOREAN MED SCI, V28, P731, DOI 10.3346/jkms.2013.28.5.731
   Kelly CA, 2014, RHEUMATOLOGY, V53, P1676, DOI 10.1093/rheumatology/keu165
   Klareskog L, 2011, SEMIN IMMUNOL, V23, P92, DOI 10.1016/j.smim.2011.01.014
   Kono M, 2016, RESP MED, V117, P40, DOI 10.1016/j.rmed.2016.05.030
   Kono M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094775
   Neogi T, 2010, ARTHRITIS RHEUM-US, V62, P2582, DOI 10.1002/art.27580
   Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018
   Oldham JM, 2016, EUR RESPIR J, V47, P1767, DOI 10.1183/13993003.01565-2015
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Schellekens GA, 2000, ARTHRITIS RHEUM, V43, P155, DOI 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
   Shaw M, 2015, EUR RESPIR REV, V24, P1, DOI 10.1183/09059180.00008014
   Tanaka R, 2010, CLIN CHIM ACTA, V411, P22, DOI 10.1016/j.cca.2009.09.032
   Terao C, 2014, ARTHRIT CARE RES, V66, P1818, DOI 10.1002/acr.22385
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Vallbracht I, 2004, ANN RHEUM DIS, V63, P1079, DOI 10.1136/ard.2003.019877
   Yoshimura K, 2018, RESP MED, V137, P167, DOI 10.1016/j.rmed.2018.02.024
   Zeng XF, 2003, J RHEUMATOL, V30, P1451
NR 31
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 102
EP 108
DI 10.1016/j.rmed.2019.06.016
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800016
PM 31229943
DA 2020-05-18
ER

PT J
AU Hoo, ZH
   Bramley, NR
   Curley, R
   Edenborough, FP
   Walters, SJ
   Campbell, MJ
   Wildman, MJ
AF Hoo, Zhe Hui
   Bramley, Nicole R.
   Curley, Rachael
   Edenborough, Frank P.
   Walters, Stephen J.
   Campbell, Michael J.
   Wildman, Martin J.
TI Intravenous antibiotic use and exacerbation events in an adult cystic
   fibrosis centre: A prospective observational study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cystic fibrosis; Epidemiology; Patient outcome assessment; Pulmonary
   exacerbation
ID PULMONARY EXACERBATIONS; STANDARDIZED TREATMENT; RESPIRATORY SYMPTOMS;
   LUNG-FUNCTION; OUTCOMES; RISK; CARE; PROBABILITY; ADHERENCE; CHILDREN
AB Introduction: In CF, people with higher FEV1 are less aggressively treated with intravenous (IV) antibiotics, with resultant negative impact on their health outcomes. This could be entirely clinician-driven, but patient choice may also influence IV use. In this prospective observational study, we explored IV recommendations by clinicians and IV acceptance by adults with CF to understand how clinical presentations consistent with exacerbations resulted in IV use.
   Methods: Clinical presentations consistent with exacerbations, IV recommendation by clinicians and IV acceptance by patients were prospectively identified for every adult with CF in Sheffield throughout 2016, excluding those who had lung transplantation (n=7) or on ivacaftor (n=13). Relevant demographic data, e. g. %FEV1, were extracted from medical records. Multi-level mixed-effects logistic regression models were used to compare IV recommendations vs non-recommendations for all clinical encounters, and IV acceptance vs non-acceptance for all IV recommendations.
   Results: Among 186 adults (median age 27 years, median FEV1 78.5%), there were 434 exacerbation events and 318 IV use episodes following 1010 clinical encounters. Only 254 (58.5%) of exacerbations were IV treated. A diagnosis of exacerbation, higher number of symptoms and lower %FEV1 were independent predictors for IV recommendation by clinicians. Higher number of symptoms and lower %FEV1 were also independent predictors for IV acceptance by adults with CF.
   Conclusions: Lower IV use among adults with higher %FEV1 was influenced by both clinicians' and patients' decisions. Using IV antibiotics as an exacerbation surrogate could under-estimate exacerbation rates and conceal differential treatment decisions according to varying clinical characteristics.
C1 [Hoo, Zhe Hui; Bramley, Nicole R.; Curley, Rachael; Walters, Stephen J.; Campbell, Michael J.; Wildman, Martin J.] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England.
   [Hoo, Zhe Hui; Bramley, Nicole R.; Curley, Rachael; Edenborough, Frank P.; Wildman, Martin J.] Northern Gen Hosp, Sheffield Adult CF Ctr, Sheffield, S Yorkshire, England.
RP Hoo, ZH (reprint author), Innovat Ctr, Room 2-13,217 Portobello, Sheffield S1 4DP, S Yorkshire, England.
EM z.hoo@sheffield.ac.uk
OI Hoo, Zhe Hui/0000-0002-7067-3783
FU National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [DRF-2014-07-092]
FX This report is independent research arising from a Doctoral Research
   Fellowship, Zhe Hui Hoo, DRF-2014-07-092 supported by the National
   Institute for Health Research. The views expressed in this publication
   are those of the authors and not necessarily those of the NHS, the
   National Institute for Health Research or the Department of Health.
CR Abbott J, 2009, J CYST FIBROS, V8, P356, DOI 10.1016/j.jcf.2009.07.003
   Beach MC, 2006, J GEN INTERN MED, V21, P661, DOI 10.1111/j.1525-1497.2006.00399.x
   Bilton D, 2011, J CYST FIBROS, V10, pS79, DOI 10.1016/S1569-1993(11)60012-X
   Castellani C, 2008, J CYST FIBROS, V7, P179, DOI 10.1016/j.jcf.2008.03.009
   Cogen JD, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2642
   Cystic Fibrosis Trust, 2011, STANDARDS CLIN CARE
   De Rse V, 2002, EUR RESPIR J, V19, P333, DOI 10.1183/09031936.02.00229202
   Etherington C, 2014, J CYST FIBROS, V13, P49, DOI 10.1016/j.jcf.2013.06.004
   Frederiksen B, 1996, PEDIATR PULM, V21, P153, DOI 10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.3.CO;2-W
   FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003
   Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0
   Goss CH, 2013, PEDIATR PULM, V48, P295
   Greenop D, 2014, QUAL SOC WORK, V13, P389, DOI 10.1177/1473325013479392
   Hansen RA, 2015, ANN PHARMACOTHER, V49, P293, DOI 10.1177/1060028014563266
   Heltshe SL, 2018, CONTEMP CLIN TRIALS, V64, P35, DOI 10.1016/j.cct.2017.11.012
   Heltshe SL, 2016, THORAX, V71, P223, DOI 10.1136/thoraxjnl-2014-206750
   Hoo ZH, 2018, J CYST FIBROS, V17, P360, DOI 10.1016/j.jcf.2017.10.005
   Hoo ZH, 2018, RESPIROLOGY, V23, P190, DOI 10.1111/resp.13174
   Kraynack NC, 2011, PEDIATR PULM, V46, P870, DOI 10.1002/ppul.21442
   Lechtzin N, 2017, AM J RESP CRIT CARE, V196, P1144, DOI 10.1164/rccm.201610-2172OC
   Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8
   Martina R, 2015, PHARM STAT, V14, P151, DOI 10.1002/pst.1664
   McCourt F, 2015, J CYST FIBROS, V14, P90, DOI 10.1016/j.jcf.2014.06.007
   Meachery G, 2008, THORAX, V63, P725, DOI 10.1136/thx.2007.092056
   Morgan WJ, 2017, ANN AM THORAC SOC, V14, P937, DOI [10.1513/annalsats.201608-615oc, 10.1513/AnnalsATS.201608-615OC]
   Morgan WJ, 2016, J PEDIATR-US, V169, P116, DOI 10.1016/j.jpeds.2015.08.042
   Morgan WJ, 2013, J PEDIATR-US, V163, P1152, DOI 10.1016/j.jpeds.2013.05.013
   Parkins MD, 2012, CHEST, V141, P485, DOI 10.1378/chest.11-0917
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Rabin HR, 2004, PEDIATR PULM, V37, P400, DOI 10.1002/ppul.20023
   Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185
   Rubin JL, 2017, CURR MED RES OPIN, V33, P667, DOI 10.1080/03007995.2016.1277196
   Sanders DB, 2017, J CYST FIBROS, V16, P592, DOI 10.1016/j.jcf.2017.04.005
   Schechter MS, 2015, PEDIATR PULM, V50, P431, DOI 10.1002/ppul.23147
   Somayaji R, 2017, CLIN INFECT DIS, V64, P1760, DOI 10.1093/cid/cix203
   Ullrich G, 1997, Pneumologie, V51, P822
   VanDevanter DR, 2016, J CYST FIBROS, V15, P783, DOI 10.1016/j.jcf.2016.04.005
   VanDevanter DR, 2011, J CYST FIBROS, V10, P453, DOI 10.1016/j.jcf.2011.07.003
   VanDevanter DR, 2016, J CYST FIBROS, V15, P372, DOI 10.1016/j.jcf.2015.10.006
   VanDevanter DR, 2013, J CYST FIBROS, V12, P332, DOI 10.1016/j.jcf.2012.11.011
   Wagener JS, 2013, PEDIATR PULM, V48, P666, DOI 10.1002/ppul.22652
   Wainwright CE, 2015, NEW ENGL J MED, V373, P220, DOI 10.1056/NEJMoa1409547
   West NE, 2017, J CYST FIBROS, V16, P600, DOI 10.1016/j.jcf.2017.04.003
NR 44
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 109
EP 115
DI 10.1016/j.rmed.2019.06.017
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800017
PM 31234038
DA 2020-05-18
ER

PT J
AU Vogt, S
   Schreiber, S
   Kollewe, K
   Korner, S
   Heinze, HJ
   Dengler, R
   Petri, S
   Vielhaber, S
AF Vogt, S.
   Schreiber, S.
   Kollewe, K.
   Koerner, S.
   Heinze, H. -J.
   Dengler, R.
   Petri, S.
   Vielhaber, S.
TI Dyspnea in amyotrophic lateral sclerosis: The Dyspnea-ALS-Scale
   (DALS-15) essentially contributes to the diagnosis of respiratory
   impairment
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Amyotrophic lateral sclerosis; Dyspnea; Respiratory impairment;
   Spirometry; Blood gases; Non-invasive ventilation
ID FUNCTIONAL RATING-SCALE; MOTOR-NEURON DISEASE; NONINVASIVE VENTILATION;
   NATURAL-HISTORY; VITAL CAPACITY; PATIENT; VALIDATION; SURVIVAL;
   MANAGEMENT; THERAPIES
AB Background: Dyspnea is a cardinal but often underestimated symptom in amyotrophic lateral sclerosis (ALS). The newly developed Dyspnea-ALS-Scale (DALS-15) is highly relevant for therapeutic decisions because dyspnea is a separate criterion to consider noninvasive ventilation (NIV) in ALS. In comparison to the limited effects of neuroprotective compounds, NIV has the greatest impact on survival and improves quality of life.
   Objective: To investigate whether dyspnea corresponds to parameters of respiratory status mainly used in clinical neurological practice. We also investigated if the DALS-15 could help identify patients for consideration of NIV in whom neither spirometry nor blood gas parameters indicate the need for NIV (forced vital capacity (FVC) < 50% or probable < 75%, pCO(2) >= 45 mmHg).
   Methods: Seventy ALS patients with dyspnea according to the DALS-15 obtained blood gas analysis and spirometry (FVC in sitting and supine positions). The supine decline in FVC was calculated.
   Results: There was no linear relationship between dyspnea and spirometry as well as blood gases. 83% of our patients had an upright FVC still greater than 50% and no daytime hypercapnia.
   Conclusions: Our study clearly shows that dyspnea can occur independently of objective indicators of respiratory impairment like spirometry or blood gases. Hence, the DALS-15 covers another aspect of respiratory impairment than these tests and refers to the subjective component of respiratory impairment. It detects dyspnea in a considerable proportion of patients in whom NIV should thus be considered although their spirometric and blood gas results do not point towards NIV. The DALS-15 therefore may help to improve the stratification of patients with respiratory impairment for more efficient symptom management and timely coordination of care.
C1 [Vogt, S.; Schreiber, S.; Heinze, H. -J.; Vielhaber, S.] Otto Von Guericke Univ, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.
   [Kollewe, K.; Koerner, S.; Dengler, R.; Petri, S.] Hannover Med Sch, Dept Neurol, Hannover, Germany.
   [Heinze, H. -J.; Vielhaber, S.] German Ctr Neurodegenerat Dis, Magdeburg, Germany.
   [Heinze, H. -J.] Leibniz Inst Neurobiol, Magdeburg, Germany.
RP Vogt, S (reprint author), Otto Von Guericke Univ, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.
EM Susanne.Vogt@med.ovgu.de
RI Schreiber, Stefanie/S-3223-2019
OI Schreiber, Stefanie/0000-0003-4439-4374
FU Deutsche Gesellschaft fur Muskelkranke e.V.; DGM Freiburg, Germany
FX The work was supported by a grant to Susanne Vogt from the Deutsche
   Gesellschaft fur Muskelkranke e.V., DGM Freiburg, Germany.
CR Abdulla S, 2014, AMYOTROPH LAT SCL FR, V15, P392, DOI 10.3109/21678421.2014.932380
   Abdulla S, 2013, J NEUROL, V260, P2242, DOI 10.1007/s00415-013-6955-6
   Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1
   ALLEN SM, 1985, BRIT J DIS CHEST, V79, P267, DOI 10.1016/S0007-0971(85)80029-2
   Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x
   Berlowitz DJ, 2016, J NEUROL NEUROSUR PS, V87, P280, DOI 10.1136/jnnp-2014-310055
   Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Cudkowicz Merit, 2004, NeuroRx, V1, P273, DOI 10.1007/BF03206611
   Dougan CF, 2000, J NEUROL SCI, V180, P86, DOI 10.1016/S0022-510X(00)00415-9
   Ellis CM, 1999, NEUROLOGY, V53, P1051, DOI 10.1212/WNL.53.5.1051
   Georges M, 2017, AMYOTROPH LAT SCL FR, V18, P46, DOI 10.1080/21678421.2016.1236817
   Gruis KL, 2012, MUSCLE NERVE, V46, P313, DOI 10.1002/mus.23282
   HARRISON BD, 1971, THORAX, V26, P579, DOI 10.1136/thx.26.5.579
   Haugdahl HS, 2015, AM J RESP CRIT CARE, V192, P1440, DOI 10.1164/rccm.201503-0419OC
   HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707
   Jenkins TM, 2014, CURR OPIN NEUROL, V27, P524, DOI 10.1097/WCO.0000000000000135
   Just N, 2010, EUR RESPIR J, V35, P353, DOI 10.1183/09031936.00184908
   Lechtzin N, 2002, CHEST, V121, P436, DOI 10.1378/chest.121.2.436
   Lechtzin N, 2007, MUSCLE NERVE, V35, P98, DOI 10.1002/mus.20669
   Leigh PN, 2003, J NEUROL NEUROSUR PS, V74, P32
   Leonardis L, 2012, EUR J NEUROL, V19, P1518, DOI 10.1111/j.1468-1331.2012.03754.x
   Lyall RA, 2001, BRAIN, V124, P2000, DOI 10.1093/brain/124.10.2000
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141
   Morelot-Panzini C, 2019, RESPIROLOGY, V24, P521, DOI 10.1111/resp.13525
   Morelot-Panzini C, 2018, RESP MED, V145, P1, DOI 10.1016/j.rmed.2018.10.010
   Nicholson K, 2018, MUSCLE NERVE, V57, P20, DOI 10.1002/mus.25712
   O'Neill CL, 2012, J NEUROL NEUROSUR PS, V83, P371, DOI 10.1136/jnnp-2011-300480
   Polkey MI, 1998, AM J RESP CRIT CARE, V158, P734, DOI 10.1164/ajrccm.158.3.9710072
   Polkey MI, 2017, AM J RESP CRIT CARE, V195, P86, DOI 10.1164/rccm.201604-0848OC
   Prell T, 2016, J NEUROL NEUROSUR PS, V87, P1022, DOI 10.1136/jnnp-2015-312185
   Radunovic A, 2007, LANCET NEUROL, V6, P913, DOI 10.1016/S1474-4422(07)70244-2
   RINGEL SP, 1993, NEUROLOGY, V43, P1316, DOI 10.1212/WNL.43.7.1316
   Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351
   Shoesmith CL, 2007, J NEUROL NEUROSUR PS, V78, P629, DOI 10.1136/jnnp.2006.103564
   Similowski T., 2018, EUR RESP J, V51
   Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108
   Tilanus T B M, 2018, J Neuromuscul Dis, V5, P431, DOI 10.3233/JND-180302
   Tilanus TBM, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0624-8
   Turner MR, 2011, J NEUROL NEUROSUR PS, V82, P853, DOI 10.1136/jnnp.2010.208413
   Varrato J, 2001, NEUROLOGY, V57, P357, DOI 10.1212/WNL.57.2.357
   Vender RL, 2007, AMYOTROPH LATERAL SC, V8, P36, DOI 10.1080/17482960600863951
   Vogt S, 2018, J PAIN SYMPTOM MANAG, V56, P736, DOI 10.1016/j.jpainsymman.2018.08.009
   Wicks P, 2009, EUR J NEUROL, V16, P353, DOI 10.1111/j.1468-1331.2008.02434.x
NR 46
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 116
EP 121
DI 10.1016/j.rmed.2019.06.014
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800018
PM 31234039
DA 2020-05-18
ER

PT J
AU Kono, M
   Fujita, Y
   Takeda, K
   Miyashita, K
   Tsutsumi, A
   Kobayashi, T
   Miki, Y
   Hashimoto, D
   Enomoto, N
   Nakamura, Y
   Suda, T
   Nakamura, H
AF Kono, Masato
   Fujita, Yuiko
   Takeda, Kenichiro
   Miyashita, Koichi
   Tsutsumi, Akari
   Kobayashi, Takeshi
   Miki, Yoshihiro
   Hashimoto, Dai
   Enomoto, Noriyuki
   Nakamura, Yutaro
   Suda, Takafumi
   Nakamura, Hidenori
TI Clinical significance of lower-lobe interstitial lung disease on
   high-resolution computed tomography in patients with idiopathic
   pleuroparenchymal fibroelastosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pleuroparenchymal fibroelastosis; Interstitial lung disease; Usual
   interstitial pneumonia; High-resolution computed tomography; Prognostic
   factor
ID PULMONARY-FIBROSIS; FEATURES; DIAGNOSIS; CT
AB Background: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare form of idiopathic interstitial pneumonias (IIP) and may have other patterns of interstitial lung disease (ILD) in the lower lobe, such as usual interstitial pneumonia (UIP). However, the clinical significance of lower-lobe ILD in patients with IPPFE is unclear.
   Methods: A retrospective review of 40 consecutive patients with clinically diagnosed IPPFE in our institution from 2005 to 2016 was conducted. The presence of lower-lobe ILD on high-resolution computed tomography (HRCT) was assessed and classified into UIP or non-UIP pattern according to a modification of diagnostic criteria for idiopathic pulmonary fibrosis. Clinical characteristics and prognostic factors were evaluated.
   Results: Among the 40 patients with IPPFE, 21 (53%) had lower-lobe ILD, including 13 with UIP pattern and 8 with non-UIP pattern. Patients with IPPFE who had lower-lobe ILD had significantly older age, higher frequency of fine crackles, higher serum KL-6 level, lower residual volume (RV), and lower total lung capacity (TLC) than those without lower-lobe ILD. In addition, those with lower-lobe ILD, especially UIP pattern, had a significantly poorer survival than those without lower-lobe ILD (log-rank test; p=0.014, p<0.001, respectively). Multivariate Cox proportional hazards regression analysis revealed that low %forced vital capacity (%FVC) at baseline and coexistence of UIP pattern were significantly associated with poor prognosis in patients with IPPFE.
   Conclusions: The coexistence of lower-lobe ILD on HRCT, especially the UIP pattern, may predict poor survival in patients with IPPFE.
C1 [Kono, Masato; Fujita, Yuiko; Takeda, Kenichiro; Miyashita, Koichi; Tsutsumi, Akari; Kobayashi, Takeshi; Miki, Yoshihiro; Hashimoto, Dai; Nakamura, Hidenori] Seirei Hamamatsu Gen Hosp, Dept Pulm Med, Hamamatsu, Shizuoka, Japan.
   [Enomoto, Noriyuki; Nakamura, Yutaro; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Hamamatsu, Shizuoka, Japan.
RP Kono, M (reprint author), 2-12-12 Sumiyoshi, Hamamatsu, Shizuoka 4308558, Japan.
EM masato.k@sis.seirei.or.jp
CR Amitani R, 1992, KOKYU, V11, P693
   Bonifazi M, 2017, CURR PULMONOL REP, V6, P9, DOI 10.1007/s13665-017-0160-5
   Camus P, 2014, EUR RESPIR J, V44, P289, DOI 10.1183/09031936.00088414
   Chung JH, 2015, CHEST, V147, P450, DOI 10.1378/chest.14-0976
   Enomoto Y, 2017, RESP MED, V133, P1, DOI 10.1016/j.rmed.2017.11.003
   Frankel SK, 2004, CHEST, V126, P2007, DOI 10.1378/chest.126.6.2007
   Harada T, 2014, EUR RESPIR REV, V23, P263, DOI 10.1183/09059180.00006713
   Ishii H, 2018, RESP MED, V141, P190, DOI 10.1016/j.rmed.2018.06.022
   Kato M, 2019, RESPIRATION, V97, P319, DOI 10.1159/000494061
   Khiroya R, 2017, AM J SURG PATHOL, V41, P1683, DOI 10.1097/PAS.0000000000000928
   Kusagaya H, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-72
   Lynch DA, 2018, LANCET RESP MED, V6, P138, DOI 10.1016/S2213-2600(17)30433-2
   Nakatani T, 2015, EUR RESPIR J, V45, P1183, DOI 10.1183/09031936.00214714
   Nunes H, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02022-2016
   Oda T, 2014, CHEST, V146, P1248, DOI 10.1378/chest.13-2866
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2014, LANCET RESP MED, V2, P277, DOI 10.1016/S2213-2600(14)70011-6
   Reddy TL, 2012, EUR RESPIR J, V40, P377, DOI 10.1183/09031936.00165111
   Rosenbaum JN, 2015, HUM PATHOL, V46, P137, DOI 10.1016/j.humpath.2014.10.007
   Shioya M, 2018, CAN RESPIR J, DOI 10.1155/2018/6043053
   Sugino K, 2018, J THORAC DIS, V10, P899, DOI 10.21037/jtd.2018.01.56
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Watanabe K, 2013, CURR RESPIR MED REV, V9, P229, DOI 10.2174/1573398X0904140129125307
   Watanabe K, 2012, RESPIR INVESTIG, V50, P88, DOI 10.1016/j.resinv.2012.06.003
   Watanabe S, 2015, RESPIR INVESTIG, V53, P149, DOI 10.1016/j.resinv.2015.02.003
   Yoshida Y, 2016, RESPIR INVESTIG, V54, P162, DOI 10.1016/j.resinv.2015.11.002
NR 26
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 122
EP 126
DI 10.1016/j.rmed.2019.06.018
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800019
PM 31238182
DA 2020-05-18
ER

PT J
AU Haarmann, H
   Koch, J
   Bonsch, N
   Mende, M
   Werhahn, SM
   Luers, C
   Stahrenberg, R
   Edelmann, F
   Holzendorf, V
   von Haehling, S
   Pieske, B
   Andreas, S
   Luthje, L
   Wachter, R
AF Haarmann, Helge
   Koch, Jennifer
   Bonsch, Nina
   Mende, Meinhard
   Werhahn, Stefanie Maria
   Lueers, Claus
   Stahrenberg, Raoul
   Edelmann, Frank
   Holzendorf, Volker
   von Haehling, Stephan
   Pieske, Burkert
   Andreas, Stefan
   Luethje, Lars
   Wachter, Rolf
TI Morbidity and mortality in patients with cardiovascular risk factors and
   obstructive sleep apnoea: results from the DIAST-CHF cohort
SO RESPIRATORY MEDICINE
LA English
DT Article
DE MACE; MACCE; Sleep related breathing disorders; AHI; Sleep disordered
   breathing; OSA
ID POSITIVE AIRWAY PRESSURE; ALL-CAUSE MORTALITY; DAYTIME SLEEPINESS;
   FOLLOW-UP; DISEASE; HYPERTENSION; EVENTS; PREVALENCE; MECHANISMS; STROKE
AB Study objectives: Aim of the study was to investigate the association between obstructive sleep apnoea (OSA) and cardiovascular morbidity and mortality in a cohort of patients with cardiovascular risk factors.
   Methods: In this prospective study, 378 patients of the DIAST-CHF cohort were screened for OSA by home polygraphy. Inclusion criteria were risk factors for diastolic heart failure, such as hypertension, diabetes mellitus, atherosclerotic disease, or history of chronic heart failure. Patients were followed up after 1, 2, 5, 9 and 10 years for the occurrence of major adverse cardiac and cerebrovascular events (MACE and MACCE).
   Results: 344 patients were included in the analysis, of which 60% were diagnosed with OSA (apnoea-hypopnoea index >= 5/h). Overall mortality was higher in the OSA group (14.9% vs. 5.9%; p=0.007), but significance disappeared after adjustment for age and sex (hazard ratio (HR) 1.89, 95% confidence interval (CI) 0.86-4.16, p=0.12). There was no significant difference in the occurrence of MACE or MACCE in patients with OSA compared to those without OSA (MACE: 31% vs. 30%; p=0.61; MACCE: 32% vs. 30%; p=0.53).
   Conclusion: We did not find evidence of an adverse effect of OSA on cardiovascular morbidity and mortality in a cohort of patients with cardiovascular risk factors.
C1 [Haarmann, Helge; Koch, Jennifer; Bonsch, Nina; Werhahn, Stefanie Maria; Edelmann, Frank; von Haehling, Stephan; Andreas, Stefan; Luethje, Lars; Wachter, Rolf] Univ Med Ctr Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany.
   [Mende, Meinhard; Holzendorf, Volker] Univ Leipzig, Coordinating Ctr Clin Trials, Leipzig, Germany.
   [Lueers, Claus] Carl von Ossietzky Univ Oldenburg, European Med Sch Oldenburg Groningen, Oldenburg, Germany.
   [Stahrenberg, Raoul] Helios Kliniken Northeim, Northeim, Germany.
   [Edelmann, Frank; Pieske, Burkert] Charite Univ Med Berlin, Campus Virchow Klinikum, Dept Cardiol, Berlin, Germany.
   [Andreas, Stefan] Lung Clin Immenhausen, Immenhausen, Krs Kassel, Germany.
   [Wachter, Rolf] Univ Hosp Leipzig, Clin & Policlin Cardiol, Liebigstr 20, D-04103 Leipzig, Germany.
   [Haarmann, Helge; Werhahn, Stefanie Maria; Edelmann, Frank; von Haehling, Stephan; Wachter, Rolf] German Cardiovasc Res Ctr, Partner Site Gottingen, Gottingen, Germany.
   [Edelmann, Frank] German Cardiovasc Res Ctr, Partner Site Berlin, Berlin, Germany.
RP Wachter, R (reprint author), Univ Hosp Leipzig, Clin & Policlin Cardiol, Liebigstr 20, D-04103 Leipzig, Germany.
EM rolf.wachter@medizin.uni-leipzig.de
RI Wachter, Rolf/AAA-4037-2020
FU German Federal Ministry of Education and Research (German Heart Failure
   Network)Federal Ministry of Education & Research (BMBF) [TP 7 (FKZ
   01GI0205)]; German Federal Ministry of Education and Research (clinical
   trial program Aldo-DHF) [FKZ 01KG0506]
FX This work was supported by grants from the German Federal Ministry of
   Education and Research (German Heart Failure Network, TP 7 (FKZ
   01GI0205) and clinical trial program Aldo-DHF (FKZ 01KG0506)).
CR Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366
   Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079
   Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0
   Campos-Rodriguez F, 2012, ANN INTERN MED, V156, P115, DOI 10.7326/0003-4819-156-2-201201170-00006
   Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3
   Iber C., 2007, AASM MANUAL SCORING
   Javaheri S, 2017, J AM COLL CARDIOL, V69, P841, DOI 10.1016/j.jacc.2016.11.069
   Lavie P, 2009, J SLEEP RES, V18, P397, DOI 10.1111/j.1365-2869.2009.00754.x
   Lee JE, 2013, J CLIN SLEEP MED, V9, P997, DOI 10.5664/jcsm.3068
   Lindberg E, 2007, RESP MED, V101, P1283, DOI 10.1016/j.rmed.2006.10.015
   Liu BX, 2014, SCI WORLD J, DOI 10.1155/2014/908582
   Luthje L, 2008, SLEEP MED REV, V12, P19, DOI 10.1016/j.smrv.2007.08.002
   Malhotra A, 2015, LANCET RESP MED, V3, P397, DOI 10.1016/S2213-2600(15)00051-X
   Marshall NS, 2014, J CLIN SLEEP MED, V10, P355, DOI 10.5664/jcsm.3600
   McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599
   McNicholas WT, 2007, EUR RESPIR J, V29, P156, DOI 10.1183/09031936.00027406
   Newman AB, 2000, J AM GERIATR SOC, V48, P115, DOI 10.1111/j.1532-5415.2000.tb03901.x
   O'Connor GT, 2009, AM J RESP CRIT CARE, V179, P1159, DOI 10.1164/rccm.200712-1809OC
   Pan L, 2016, SLEEP BREATH, V20, P345, DOI 10.1007/s11325-015-1295-7
   Peker Y, 2016, AM J RESP CRIT CARE, V194, P613, DOI 10.1164/rccm.201601-0088OC
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132
   Schulz R, 2007, EUR RESPIR J, V29, P1201, DOI 10.1183/09031936.00037106
   Somers VK, 2008, CIRCULATION, V118, P1080, DOI [10.1161/CIRCULATIONAHA.107.189420, 10.1161/CIRCULATIONAHA.107.189375]
   Stahrenberg R, 2010, DIABETOLOGIA, V53, P1331, DOI 10.1007/s00125-010-1718-8
   Uchoa CHG, 2015, CHEST, V147, P1352, DOI 10.1378/chest.14-2152
   Wachter R, 2013, EUR RESPIR J, V41, P376, DOI 10.1183/09031936.00218211
   Wannamethee SG, 2016, THORAX, V71, P526, DOI 10.1136/thoraxjnl-2014-206724
   Wu XF, 2015, CHEST, V147, P708, DOI 10.1378/chest.14-1634
   Young T, 2008, SLEEP, V31, P1071
NR 30
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 127
EP 132
DI 10.1016/j.rmed.2019.06.019
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800020
PM 31252205
DA 2020-05-18
ER

PT J
AU Farkas, A
   Szipocs, A
   Horvath, A
   Horvath, I
   Galffy, G
   Varga, J
   Galambos, K
   Kugler, S
   Nagy, A
   Szalai, Z
AF Farkas, Arpad
   Szipocs, Annamaria
   Horvath, Alpar
   Horvath, Ildiko
   Galffy, Gabriella
   Varga, Janos
   Galambos, Kristof
   Kugler, Szilvia
   Nagy, Attila
   Szalai, Zsuzsanna
TI Establishment of relationships between native and inhalation device
   specific spirometric parameters as a step towards patient tailored
   inhalation device selection
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Management of COPD patients; Personalized device selection; Patient and
   device specific spirometric parameters
ID IN-VITRO; FLOW-RATE; RESISTANCE; INHALER; THERAPY; TIME
AB Introduction: Drug emission from DPIs is dependent on the inspiratory flow parameters through them, which are not directly measured by standard spirometry. Their estimation based on native spirometric data could help in choosing the appropriate device and optimizing the drug deposition.
   Objectives: The aim of this study was to survey patient preferences and to find correlations between breathing parameters of COPD patients through DPI devices and their baseline spirometric data, age, gender, disease severity and anthropometric characteristics. Another objective was to establish relationships between peak inspiratory flows (PIFdev) through Breezhaler (R), Genuair (R) and Turbuhaler (R) inhalers and their determinants.
   Methods: Breathing parameters of 49 patients with previously diagnosed COPD and currently using one of the above inhalers were recorded by normal spirometry and while inhaling through the selected DPIs. Statistical analysis of the measured data was completed. All specific data are provided as (mean +/- standard deviation).
   Results: More than 60% of the patients stated that their current device is the easiest to use. The means of the measured PIFdev values were 91.4 L/min, 77.1 L/min and 77.5 L/min for Breezhaler (R), Genuair (R), and Turbuhaler (R), respectively. PIFdev values were significantly higher for males than for females, but differences upon age, BMI and disease severity group were not significant (at p=0.05). Peak inspiratory flows through the inhalers (PIFdev) correlated best with their native spirometric counterparts (PIF) and linear PIFdev-PIF relationships could be determined (Breezhaler (R) : r=0.60, p=0.002, Genuair (R) : r=0.55, p=0.001, Turbuhaler (R) : r=0.57, p=0.002). Physical background of the deduced equations was also provided.
   Conclusions: Present correlations may be used to assess the success of inhalation of COPD patients through the studied devices and to choose the appropriate device for each patient. As a consequence, the amount of the drug emitted by the device can be optimized, the deposition efficiency within the lungs increased and the related therapeutic effect improved.
C1 [Farkas, Arpad] Hungarian Acad Sci, Ctr Energy Res, Konkoly Thege Miklos Ut 29-33, H-1121 Budapest, Hungary.
   [Szipocs, Annamaria; Szalai, Zsuzsanna] Petz Aladar Cty Teaching Hosp, Pulmonol Dept, Vasvari Pal U 2-4, H-9024 Gyor, Hungary.
   [Horvath, Alpar] Chiesi Hungary Ltd, Dunavirag U 2, H-1138 Budapest, Hungary.
   [Horvath, Alpar; Galffy, Gabriella] Cty Inst Pulmonol, Dept Pulmonol, Munkacsy M U 70, H-2045 Torokbalint, Hungary.
   [Horvath, Ildiko; Varga, Janos] Natl Koranyi Inst Pulmonol, Piheno U 1, H-1121 Budapest, Hungary.
   [Galambos, Kristof; Kugler, Szilvia; Nagy, Attila] Hungarian Acad Sci, Wigner Res Ctr Phys, Konkoly Thege Miklos Ut 29-33, H-1121 Budapest, Hungary.
RP Farkas, A (reprint author), Hungarian Acad Sci, Ctr Energy Res, Konkoly Thege Miklos Ut 29-33, H-1121 Budapest, Hungary.
EM farkas.arpad@energia.mta.hu
OI Horvath, Alpar/0000-0003-3620-1691; Varga, Janos/0000-0002-8552-1336
FU Bolyai Janos Scholarship of the Hungarian Academy of SciencesHungarian
   Academy of Sciences [KTIA_AIK_12-1-2012-0019]
FX This work has been supported by the KTIA_AIK_12-1-2012-0019 project. The
   work of AF was supported by the Bolyai Janos Scholarship of the
   Hungarian Academy of Sciences.
CR Abdelrahim ME, 2010, RESP MED, V104, P682, DOI 10.1016/j.rmed.2009.11.014
   BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069
   Buttini F, 2016, J AEROSOL MED PULM D, V29, P167, DOI 10.1089/jamp.2015.1220
   Ciciliani AM, 2017, INT J CHRONIC OBSTR, V12, P1565, DOI 10.2147/COPD.S115886
   De Muth J. E., 2014, BASIC STAT PHARM STA
   Dorosz A, 2016, J AEROSOL SCI, V101, P104, DOI 10.1016/j.jaerosci.2016.07.014
   Haidl P, 2016, RESP MED, V118, P65, DOI 10.1016/j.rmed.2016.07.013
   Haughney J, 2010, RESP MED, V104, P1237, DOI 10.1016/j.rmed.2010.04.012
   Horvath A, 2017, EUR J PHARM SCI, V104, P145, DOI 10.1016/j.ejps.2017.03.047
   Jaeger M.J., 1970, AIRWAY DYNAMICS
   JAFFRIN MY, 1974, J APPL PHYSIOL, V36, P354
   Janssens W, 2008, EUR RESPIR J, V31, P78, DOI 10.1183/09031936.00024807
   Jarvis S, 2007, AGE AGEING, V36, P213, DOI 10.1093/ageing/afl174
   Kamin W., 2015, PNEUMOLOGIE, V69
   Kamin WES, 2003, J AEROSOL MED, V16, P21, DOI 10.1089/089426803764928329
   Kawamatawong T, 2017, J ASTHMA ALLERGY, V10, P17, DOI 10.2147/JAA.S127580
   Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410
   Malmberg L Pekka, 2010, Int J Chron Obstruct Pulmon Dis, V5, P257
   Ower E., 1977, MEASUREMENT AIRFLOW
   Rohrer F, 1915, PFLUG ARCH GES PHYS, V162, P225, DOI 10.1007/BF01681259
   Sanders MJ, 2017, PULM MED, V2017, DOI 10.1155/2017/1495867
   Sarvis CA, 2004, J PHARM PRACT, V17, P275, DOI DOI 10.1177/0897190004270027
   Seheult JN, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-496
NR 23
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 133
EP 140
DI 10.1016/j.rmed.2019.06.021
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800021
PM 31252206
OA Green Accepted
DA 2020-05-18
ER

PT J
AU McDonnell, MJ
   Duignan, N
   Campbell, CD
   Rutherford, RM
AF McDonnell, Melissa J.
   Duignan, Niamh
   Campbell, Chistina D.
   Rutherford, Robert M.
TI Bendopnoea in exercise limited patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Bendopnoea; Breathlessness; Symptoms
AB Dyspnoea on bending over (bendopnoea) is most commonly associated with systolic heart failure. COPD patients often also complain of bendopnoea but little is known about this symptom in this patient group. We objectively assessed 44 COPD patients attending pulmonary rehabilitation for bendopnoea in a tertiary referral centre to determine the potential mechanism and clinical implications of this symptom. Bendopnoea was assessed by timing the duration of onset to breathlessness on bending forward at the waist for 30 s. BORG score, oxygen saturations and blood pressure measurements were obtained before and after. Of 44 patients (mean age +/- SD 66.7 +/- 8.4 years; 22 male, BMI 28.1 +/- 6.4), bendopnoea was present in 23 (52.3%) patients. This was significantly associated with a lower FEV1% (p=0.02) and TLCO% (< 0.001) and higher CAT score (p=0.03). A strong trend was also noted with higher waist/hip ratio (p=0.06). There were no associations with age, BMI, oxygen saturation, static lung volumes, exercise capacity or non-invasive haemodynamic markers such as proBNP, physiological changes or echocardiography findings.
C1 [McDonnell, Melissa J.; Duignan, Niamh; Campbell, Chistina D.; Rutherford, Robert M.] Galway Univ Hosp, Resp Med, Newcastle Rd, Galway, Ireland.
RP McDonnell, MJ (reprint author), Galway Univ Hosp, Dept Resp Med, Galway, Ireland.
EM melissa.mcdonnell@nuigalway.ie
CR [Anonymous], 2018, GLOBAL STRATEGY FOR
   Baeza-Trinidad R, 2018, EUR J INTERN MED, V50, pE21, DOI 10.1016/j.ejim.2017.11.007
   Baeza-Trinidad R, 2017, EUR J HEART FAIL, V19, P111, DOI 10.1002/ejhf.610
   Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Brandon N, 2013, J HEART LUNG TRANSPL, V32, P844, DOI 10.1016/j.healun.2013.06.006
   Dominguez-Rodriguez A, 2016, J CARD FAIL, V22, P163, DOI 10.1016/j.cardfail.2015.12.013
   Thibodeau JT, 2018, JACC-HEART FAIL, V6, P543, DOI 10.1016/j.jchf.2018.04.005
   Thibodeau JT, 2017, AM HEART J, V183, P102, DOI 10.1016/j.ahj.2016.09.011
   Thibodeau JT, 2014, JACC-HEART FAIL, V2, P24, DOI 10.1016/j.jchf.2013.07.009
NR 9
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 141
EP 143
DI 10.1016/j.rmed.2019.05.011
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800022
PM 31255956
DA 2020-05-18
ER

PT J
AU Dimitrova, D
   Youroukova, V
   Ivanova-Todorova, E
   Tumangelova-Yuzeir, K
   Velikova, T
AF Dimitrova, Denitsa
   Youroukova, Vania
   Ivanova-Todorova, Ekaterina
   Tumangelova-Yuzeir, Kalina
   Velikova, Tsvetelina
TI Serum levels of IL-5, IL-6, IL-8, IL-13 and IL-17A in pre-defined groups
   of adult patients with moderate and severe bronchial asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Moderate and severe asthma; IL-5; IL-6; IL-8; IL-13; IL-17A
ID EXHALED NITRIC-OXIDE; BODY-MASS INDEX; CLUSTER-ANALYSIS; ALLERGIC
   DISEASES; CURRENT KNOWLEDGE; TNF-ALPHA; T-CELLS; PHENOTYPES; FUTURE;
   BIOMARKERS
AB Background: Bronchial asthma (BA) is a complex disease characterised by persistent inflammation. Exhaled nitric oxide (FeNO) and blood eosinophil count (b-Eos) are biomarkers for type 2 endotype of BA.
   Objective: To analyse a panel of serum interleukins and total IgE in predefined by FeNO and b-Eos groups of moderate and severe BA patients.
   Methods: Serum levels of IL-5, IL-6, IL-8, IL-13 and IL-17A (ELISA) were measured in 30 healthy controls (HC) and 80 adult BA patients. BA patients were split into 4 groups. Group 1: Low FeNO/Low b-Eos (n=23; 28.8%); Group 2: Low FeNO/High b-Eos (n=17; 21.3%); Group 3: High FeNO/Low b-Eos (n=15; 18.8%); Group 4: High FeNO/High b-Eos (n=25; 31.3%).
   Results: All interleukins and total IgE were significantly higher in patients with BA as compared with HC. IL-5 levels were highest in Group 2 (p < 0.05). IL-6, IL-13 and IL-17A levels were elevated in Groups 2, 3 and 4 as compared with HC (p < 0.05). Higher IL-8 levels were associated with a pattern of current smokers. Highest IL-17A levels were found in type 2 high groups with frequent exacerbations, mostly uncontrolled and severe BA. We have found a distinct pattern for each group based on demographic, clinical, functional, immunological and inflammatory characteristics.
   Conclusion: FeNO and b-Eos are useful in the identification of severe type 2 BA subgroups with frequent exacerbations. IL-5, IL-6, IL-13 and IL-17A are involved in the persistent type 2 immune response in moderate and severe BA. We have identified a pattern of refractory, severe type 2/IL-17A high BA in the real clinical practice.
C1 [Dimitrova, Denitsa; Youroukova, Vania] Med Univ Sofia, Med Fac, Dept Pulm Dis, MHATPD St, Sofia, Bulgaria.
   [Ivanova-Todorova, Ekaterina] Med Univ Sofia, Univ Hosp St Ivan Rilski, Dept Clin Lab & Clin Immunol, Clin Immunol Lab Clin Immunol,Med Fac, Sofia, Bulgaria.
   [Tumangelova-Yuzeir, Kalina] Med Univ Sofia, Univ Hosp St Ivan Rilski, Med Fac, Lab Clin Immunol, Sofia, Bulgaria.
   [Velikova, Tsvetelina] Univ Hosp Lozenetz, Clin Immunol, Sofia, Bulgaria.
RP Dimitrova, D (reprint author), 19 Acad Ivan Geshov Blv, Sofia 1431, Bulgaria.
EM ddimitrova87@abv.bg; vania_youroukova@hotmail.com; Katty_iv@yahoo.com;
   kullhem000@gmail.com; Ts_velikova@abv.bg
OI Dimitrova, Denitsa/0000-0001-6755-6044
FU GRANT project [308/2015, 75/2015]
FX The research was funded by GRANT project ID 308/2015, contract. 75/2015
   to Council of Medical Science, Medical University Sofia, Bulgaria
CR Agache I, 2016, ALLERGY, V71, P1192, DOI 10.1111/all.12906
   Agache I, 2016, ALLERGOL INT, V65, P243, DOI 10.1016/j.alit.2016.04.011
   Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018
   Akiki Z, 2017, RESP MED, V125, P57, DOI 10.1016/j.rmed.2017.03.002
   Amaral R, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0201-3
   American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   Bates JHT, 2017, ANN AM THORAC SOC, V14, pS395, DOI 10.1513/AnnalsATS.201702-122AW
   Buhl R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00634-2017
   Cerveri I, 2012, INT ARCH ALLERGY IMM, V158, P175, DOI 10.1159/000330900
   Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012
   Demoly P, 2012, EUR RESPIR REV, V21, P66, DOI 10.1183/09059180.00008111
   Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC
   Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC
   Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871
   Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010
   Froidure A, 2016, EUR RESPIR J, V47, P304, DOI 10.1183/13993003.01824-2014
   Gao J, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0248-7
   Gao J, 2018, J ASTHMA ALLERGY, V11, P73, DOI 10.2147/JAA.S155379
   Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035
   Gibson PG, 2011, EUR RESPIR MONOGR, P208, DOI 10.1183/1025448x.10002110
   Glenda A. S., 2014, J GENET SYNDR GENE T, V5, P218, DOI [10.4172/2157-7412.1000218, DOI 10.4172/2157-7412.1000218, 10. 4172/2157-7412. 1000218]
   Global Initiative for Asthma, 2018, 2018 GINA REP GLOB S, DOI [10.1002/uog.8947, DOI 10.1002/UOG.8947]
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Hanania NA, 2018, CURR OPIN PULM MED, V24, P1, DOI 10.1097/MCP.0000000000000444
   Harnan SE, 2015, HEALTH TECHNOL ASSES, V19, pI, DOI 10.3310/hta19820
   Hasegawa T, 2017, EUR CYTOKINE NETW, V28, P8, DOI 10.1684/ecn.2017.0390
   Hosoki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126035
   Huang AX, 2016, MED SCI MONITOR, V22, P2800, DOI 10.12659/MSM.896458
   Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038
   Jacinto T, 2017, J BREATH RES, V11, DOI 10.1088/1752-7163/aa746b
   Jiang XG, 2018, J ASTHMA, V55, P111, DOI 10.1080/02770903.2017.1318141
   Joseph Jose, 2004, BMC Pulm Med, V4, P2, DOI 10.1186/1471-2466-4-2
   Ko HK, 2015, J CELL PHYSIOL, V230, P1781, DOI 10.1002/jcp.24881
   Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684
   Liang ZY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003774
   Linden A, 2014, EUR RESPIR J, V44, P1319, DOI 10.1183/09031936.00002314
   Mogensen I, 2018, CLIN EXP ALLERGY, V48, P935, DOI 10.1111/cea.13137
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Nagasaki T, 2013, CLIN EXP ALLERGY, V43, P608, DOI 10.1111/cea.12073
   Neveu WA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-28
   Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218
   Papaioannou AI, 2018, RESP MED, V142, P15, DOI 10.1016/j.rmed.2018.07.006
   Parulekar AD, 2018, CURR OPIN PULM MED, V24, P50, DOI 10.1097/MCP.0000000000000436
   Parulekar AD, 2016, CURR OPIN PULM MED, V22, P59, DOI 10.1097/MCP.0000000000000231
   Perez-de-Llano LA, 2010, EUR RESPIR J, V35, P1221, DOI 10.1183/09031936.00118809
   Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0
   Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036
   Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205
   Petsky HL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011440.pub2
   Poynter ME, 2016, EUR RESPIR J, V48, P979, DOI 10.1183/13993003.01597-2016
   Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.9
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874
   Schneider A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009676
   Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125
   Seys SF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0524-y
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   Shrimanker R, 2017, BIODRUGS, V31, P93, DOI 10.1007/s40259-017-0215-8
   Silkoff PE, 2017, J ALLERGY CLIN IMMUN, V140, P710, DOI 10.1016/j.jaci.2016.11.038
   Sivapalan P, 2015, CURR OPIN PULM MED, V21, P80, DOI 10.1097/MCP.0000000000000119
   Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037
   Soma T, 2018, ALLERGOL INT, V67, pS3, DOI 10.1016/j.alit.2018.04.003
   Stapleton M, 2011, J AM BOARD FAM MED, V24, P313, DOI 10.3122/jabfm.2011.03.100180
   Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631
   Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005
   Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032
   Thomson NC, 2013, J ALLERGY CLIN IMMUN, V131, P1008, DOI 10.1016/j.jaci.2012.12.1574
   Tran TN, 2016, ANN ALLERG ASTHMA IM, V116, P37, DOI 10.1016/j.anai.2015.10.027
   Trevor JL, 2014, ALLERGY, V69, P817, DOI 10.1111/all.12412
   Tseliou E, 2010, CHEST, V138, P107, DOI 10.1378/chest.09-1257
   Wang YH, 2011, CURR ALLERGY ASTHM R, V11, P388, DOI 10.1007/s11882-011-0210-y
   Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678
   Yanagibashi T, 2017, CYTOKINE, V98, P59, DOI 10.1016/j.cyto.2016.11.011
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
   YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354, DOI 10.1164/ajrccm.151.5.7735584
   Zeiger RS, 2011, J ALLERGY CLIN IMMUN, V128, P412, DOI 10.1016/j.jaci.2011.06.008
NR 78
TC 3
Z9 4
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 144
EP 154
DI 10.1016/j.rmed.2019.06.024
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800023
PM 31260861
DA 2020-05-18
ER

PT J
AU Judson, MA
AF Judson, Marc A.
TI Screening sarcoidosis patients for cardiac sarcoidosis: What the data
   really show
SO RESPIRATORY MEDICINE
LA English
DT Editorial Material
DE Sarcoidosis; Cardiac sarcoidosis; Screening; Symptoms
ID PROGNOSTIC VALUE; DEATH
C1 [Judson, Marc A.] Albany Med Coll, Div Pulm & Crit Care Med, MC-91, Albany, NY 12208 USA.
RP Judson, MA (reprint author), Albany Med Coll, Div Pulm & Crit Care Med, MC-91, Albany, NY 12208 USA.
EM judsonm@mail.amc.edu
OI Judson, Marc/0000-0002-4663-7985
CR Affairs AMACoS, 2005, A03 AFF AMACOS
   Birnie DH, 2014, HEART RHYTHM, V11, P1304, DOI 10.1016/j.hrthm.2014.03.043
   Blankstein R, 2014, J AM COLL CARDIOL, V63, P329, DOI 10.1016/j.jacc.2013.09.022
   Coleman GC, 2017, JACC-CARDIOVASC IMAG, V10, P411, DOI 10.1016/j.jcmg.2016.05.009
   Date T, 2007, CARDIOLOGY, V107, P277, DOI 10.1159/000095518
   Felekos I, 2018, ECHOCARDIOGR-J CARD, V35, P804, DOI 10.1111/echo.13846
   Hamzeh N, 2015, NAT REV CARDIOL, V12, P278, DOI 10.1038/nrcardio.2015.22
   Hamzeh NY, 2012, CHEST, V141, P154, DOI 10.1378/chest.11-0263
   Hena KM, 2018, CHEST, V153, P114, DOI 10.1016/j.chest.2017.10.014
   Herman Cheryl, 2006, Virtual Mentor, V8, P34, DOI 10.1001/virtualmentor.2006.8.1.cprl1-0601
   Hu XW, 2016, SARCOIDOSIS VASC DIF, V33, P275
   HUANG CT, 1981, EUR J RESPIR DIS, V62, P231
   Hunninghake G W, 1999, Sarcoidosis Vasc Diffuse Lung Dis, V16, P149
   Judson MA, 2017, EXPERT REV RESP MED, V11, P111, DOI 10.1080/17476348.2017.1281745
   Kandolin R, 2015, AM J CARDIOL, V116, P960, DOI 10.1016/j.amjcard.2015.06.021
   Kim JS, 2009, AM HEART J, V157, P9, DOI 10.1016/j.ahj.2008.09.009
   Kouranos V, 2017, JACC-CARDIOVASC IMAG, V10, P1437, DOI 10.1016/j.jcmg.2016.11.019
   Mehta D, 2008, CHEST, V133, P1426, DOI 10.1378/chest.07-2784
   PERRY A, 1995, ARCH PATHOL LAB MED, V119, P167
   Prezant DJ, 1999, CHEST, V116, P1183, DOI 10.1378/chest.116.5.1183
   Schuller JL, 2011, ANN NONINVAS ELECTRO, V16, P70, DOI 10.1111/j.1542-474X.2010.00411.x
   SILVERMAN KJ, 1978, CIRCULATION, V58, P1204, DOI 10.1161/01.CIR.58.6.1204
   Tavora F, 2009, AM J CARDIOL, V104, P571, DOI 10.1016/j.amjcard.2009.03.068
NR 23
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL-AUG
PY 2019
VL 154
BP 155
EP 157
DI 10.1016/j.rmed.2019.05.007
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IH9JD
UT WOS:000474821800024
PM 31126731
DA 2020-05-18
ER

PT J
AU Eriksson, G
   Nolte, H
   Ljorring, C
   Riis, B
   Virchow, JC
AF Eriksson, Goran
   Nolte, Hendrik
   Ljorring, Christian
   Riis, Bente
   Virchow, Johann Christian
TI Comparison of the novel CompEx asthma exacerbation endpoint to the
   ATS/ERS adapted moderate/severe asthma exacerbation definition used in
   the MITRA trial
SO RESPIRATORY MEDICINE
LA English
DT Editorial Material
C1 [Eriksson, Goran] Lund Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden.
   [Nolte, Hendrik] ALK, Round Rock, TX USA.
   [Ljorring, Christian; Riis, Bente] ALK, Horsholm, Denmark.
   [Virchow, Johann Christian] Univ Rostock, Dept Pneumol Intens Care Med, Rostock, Germany.
RP Riis, B (reprint author), ALK, Horsholm, Denmark.
EM clinicaltrials@alk.net
FU ALK
FX The trial included in this study was sponsored by ALK.
CR Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983
   Fuhlbrigge AL, 2017, LANCET RESP MED, V5, P577, DOI 10.1016/S2213-2600(17)30218-7
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964
   Virchow JC, 2015, RESP MED, V109, P547, DOI 10.1016/j.rmed.2015.01.012
NR 5
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 1
EP 2
DI 10.1016/j.rmed.2019.04.014
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200001
PM 31136926
DA 2020-05-18
ER

PT J
AU Matera, MG
   Calzetta, L
   Rogliani, P
   Cazzola, M
AF Matera, Maria Gabriella
   Calzetta, Luigino
   Rogliani, Paola
   Cazzola, Mario
TI Monoclonal antibodies for severe asthma: Pharmacokinetic profiles
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Monoclonal antibodies; Omalizumab; Mepolizumab; Reslizumab;
   Benralizumab; Dupilumab pharmacokinetics
ID ANTI-IGE ANTIBODY; POPULATION PHARMACOKINETICS; FC-RECEPTOR;
   PHARMACODYNAMICS; OMALIZUMAB; MEPOLIZUMAB; BENRALIZUMAB;
   BIOAVAILABILITY; GLYCOSYLATION; MECHANISMS
AB Several monoclonal antibodies (mAbs) (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) are currently approved for the treatment of severe asthma. They have complex pharmacokinetic profiles. These profiles are unique in that they are dependent on their structure as well as can be markedly influenced by the biology of their target antigen, but their general behaviour can still be considered a class property, similar to their endogenous IgG counterpart. They cannot be administered by oral route, have a slow distribution into tissue, are metabolized to peptides and amino acids in several tissues but are protected from degradation by binding to protective receptors (the FcRn), which explains their long elimination half-lives. Their clearance is nonlinear because of the saturation of the target-mediated elimination. Also anti-drug antibody (ADA) response and off-target binding, as well as their glycosylation pattern, can influence the pharmacokinetics of mAbs.
C1 [Matera, Maria Gabriella] Univ Campania Luigi Vanvitelli, Dept Expt Med, Pharmacol Unit, Naples, Italy.
   [Calzetta, Luigino; Rogliani, Paola; Cazzola, Mario] Univ Roma Tor Vergata, Dept Expt Med, Resp Med Unit, Rome, Italy.
RP Cazzola, M (reprint author), Univ Roma Tor Vergata, Dept Expt Med, Resp Med Unit, Rome, Italy.
EM mario.cazzola@uniroma2.it
OI Rogliani, Paola/0000-0001-7801-5040
CR Abrahams V. M., 2000, ARTHRITIS RHEUM, V43
   Aitken AE, 2007, DRUG METAB DISPOS, V35, P1687, DOI 10.1124/dmd.107.015511
   BISBERG D, 1996, J CLIN PHARMACOL, V36, P859
   Bodier-Montagutelli E, 2018, EXPERT OPIN DRUG DEL, V15, P729, DOI 10.1080/17425247.2018.1503251
   Boswell CA, 2010, BIOCONJUGATE CHEM, V21, P2153, DOI 10.1021/bc100261d
   Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083
   Burgess G, 2018, EBIOMEDICINE, V35, P67, DOI 10.1016/j.ebiom.2018.07.035
   Busse W. W., 2010, J ALLERGY CLIN IMMUN, V125
   Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1
   Cazzola M, 2018, EXPERT OPIN DRUG SAF, V17, P429, DOI 10.1080/14740338.2018.1446940
   Cork M. J., 2017, ANN M AM AC DERM
   Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203
   DAVIS JD, 2017, CLIN PHARMACOL THER, V101, pS61
   Deeks ED, 2017, DRUGS, V77, P777, DOI 10.1007/s40265-017-0740-2
   Deeks ED, 2016, BIODRUGS, V30, P361, DOI 10.1007/s40259-016-0182-5
   Deng R, 2012, EXPERT OPIN DRUG MET, V8, P141, DOI 10.1517/17425255.2012.643868
   Dirks NL, 2010, CLIN PHARMACOKINET, V49, P633, DOI 10.2165/11535960-000000000-00000
   Dorokhov YL, 2016, BIOCHEMISTRY-MOSCOW+, V81, P835, DOI 10.1134/S0006297916080058
   Dostalek M, 2013, CLIN PHARMACOKINET, V52, P83, DOI 10.1007/s40262-012-0027-4
   Ehrlich P., 1891, DEUT MED WOCHENSCHR, V17, P976, DOI DOI 10.1055/S-0029-1206682
   European Medicines Agency, 2016, CINQ RESL PUBL ASS R
   F. D. A. US, 2017, DUP DUP INJ SUBC US
   Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023, DOI 10.1164/ajrccm.160.3.9810012
   Fathallah AM, 2015, J PHARM SCI-US, V104, P301, DOI 10.1002/jps.24277
   Ferri N, 2016, PHARMACOL RES, V111, P592, DOI 10.1016/j.phrs.2016.07.015
   Fitzgerald G, 2018, EXPERT REV CARDIOVAS, V16, P567, DOI 10.1080/14779072.2018.1497975
   Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC
   Flynn E., 2007, XPHARM COMPREHENSIVE, P1
   Fox J. A., 1997, Pharmaceutical Research (New York), V14, pS217
   Garg A, 2007, J PHARMACOKINET PHAR, V34, P687, DOI 10.1007/s10928-007-9065-1
   Glassman PM, 2019, DRUG METAB PHARMACOK, V34, P3, DOI 10.1016/j.dmpk.2018.11.002
   Glassman PM, 2015, J CLIN PHARMACOL, V55, pS29, DOI 10.1002/jcph.365
   Gossage D., 2010, EUR RESP SOC 20 ANN, pP1177
   Hart TK, 2001, J ALLERGY CLIN IMMUN, V108, P250, DOI 10.1067/mai.2001.116576
   Hayashi N, 2007, BRIT J CLIN PHARMACO, V63, P548, DOI 10.1111/j.1365-2125.2006.02803.x
   Hendeles L, 2007, ANN PHARMACOTHER, V41, P1397, DOI 10.1345/aph.1K005
   Higel F, 2016, EUR J PHARM BIOPHARM, V100, P94, DOI 10.1016/j.ejpb.2016.01.005
   Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010
   Imamura CK, 2019, DRUG METAB PHARMACOK, V34, P14, DOI 10.1016/j.dmpk.2018.11.003
   Irani V, 2015, MOL IMMUNOL, V67, P171, DOI 10.1016/j.molimm.2015.03.255
   Jaworowicz D, 2016, AM J RESP CRIT CARE, V193
   Jin F., 2010, EUR RESP SOC 20 ANN, pP4553
   Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280-000000000-00000
   Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kornmann O, 2014, PULM PHARMACOL THER, V28, P149, DOI 10.1016/j.pupt.2014.03.003
   Kovalenko P, 2016, CPT-PHARMACOMET SYST, V5, P617, DOI 10.1002/psp4.12136
   Lawrence MG, 2018, ANN ALLERG ASTHMA IM, V120, P376, DOI 10.1016/j.anai.2018.01.009
   Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6
   Lightwood D, 2013, J MOL BIOL, V425, P577, DOI 10.1016/j.jmb.2012.11.036
   Liu LM, 2018, PROTEIN CELL, V9, P15, DOI 10.1007/s13238-017-0408-4
   Liu LM, 2015, J PHARM SCI-US, V104, P1866, DOI 10.1002/jps.24444
   Lowe PJ, 2015, REGUL TOXICOL PHARM, V71, P68, DOI 10.1016/j.yrtph.2014.12.002
   Luu M, 2016, EXPERT OPIN DRUG MET, V12, P1503, DOI 10.1080/17425255.2016.1248403
   Maillet A, 2011, PHARM RES-DORDR, V28, P2147, DOI 10.1007/s11095-011-0442-5
   Marsh CB, 1999, J IMMUNOL, V162, P6217
   Matera MG, 2017, DRUG TODAY, V53, P633, DOI 10.1358/dot.2017.53.12.2736670
   Matera MG, 2018, EXPERT OPIN DRUG MET, V14, P239, DOI 10.1080/17425255.2018.1421170
   Matera MG, 2017, EXPERT OPIN DRUG MET, V13, P1007, DOI 10.1080/17425255.2017.1359253
   Matera MG, 2016, DRUGS, V76, P1257, DOI 10.1007/s40265-016-0625-9
   May RD, 2015, CYTOKINE, V75, P89, DOI 10.1016/j.cyto.2015.05.018
   Moore CD, 2013, DRUG METAB DISPOS, V41, P379, DOI 10.1124/dmd.112.046318
   Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302
   Mould DR, 2016, BIODRUGS, V30, P275, DOI 10.1007/s40259-016-0181-6
   Mould DR, 2010, BIODRUGS, V24, P23, DOI 10.2165/11530560-000000000-00000
   Ortega H, 2014, CLIN PHARM DRUG DEV, V3, P57, DOI 10.1002/cpdd.60
   Pouliquen IJ, 2015, INT J CLIN PHARM TH, V53, P1015, DOI 10.5414/CP202446
   Respaud R, 2015, EXPERT OPIN DRUG DEL, V12, P1027, DOI 10.1517/17425247.2015.999039
   Richter WF, 2012, AAPS J, V14, P559, DOI 10.1208/s12248-012-9367-0
   Rispens T, 2014, ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY, P159
   Roman VRG, 2014, ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY, P1
   Ryman JT, 2017, CPT-PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Saito S, 2015, AM J RESP CRIT CARE, V191
   Sastre J, 2018, J INVEST ALLERG CLIN, V28, P139, DOI 10.18176/jiaci.0254
   SCHOENHOFF M, 1995, J ALLERGY CLIN IMMUN, V95, P356
   Schoenhoff M., 1995, PHARMACOL RES S, V12, P411
   Secher T, 2018, PHARMACOL THERAPEUT, V189, P149, DOI 10.1016/j.pharmthera.2018.05.003
   Lopez-Matencio JMS, 2018, MED CLIN-BARCELONA, V151, P148, DOI 10.1016/j.medcli.2017.10.037
   Shine S. J., 2015, MONOCLONAL ANTIBODIE, P131
   Smith DA, 2011, CLIN PHARMACOKINET, V50, P215, DOI 10.2165/11584340-000000000-00000
   Sun P, 2014, ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY, P131
   Tabrizi M, 2010, AAPS J, V12, P33, DOI 10.1208/s12248-009-9157-5
   Teillaud J. L., 2012, ANTIBODY DEPENDENT C, DOI [10.1002/9780470015902.a0000498.pub2eLS, DOI 10.1002/9780470015902.A0000498.PUB2ELS]
   Thomson NC, 2012, CLIN MED INSIGHTS-CI, V6, P27, DOI 10.4137/CCRPM.S7793
   Trevaskis NL, 2015, NAT REV DRUG DISCOV, V14, P781, DOI 10.1038/nrd4608
   Tsukamoto N, 2016, CLIN PHARM DRUG DEV, V5, P102, DOI 10.1002/cpdd.205
   Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003
   Tzaban S, 2009, J CELL BIOL, V185, P673, DOI 10.1083/jcb.200809122
   Viola M, 2018, J CONTROL RELEASE, V286, P301, DOI 10.1016/j.jconrel.2018.08.001
   Waller D. G., 2018, MED PHARM THER, P33
   Wang B, 2017, CPT-PHARMACOMET SYST, V6, P249, DOI 10.1002/psp4.12160
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   WEINSTEIN JN, 1992, INT J IMMUNOPHARMACO, V14, P457, DOI 10.1016/0192-0561(92)90176-L
   WEINSTEIN JN, 1984, CANCER TREAT REP, V68, P257
   Williams K, 2017, BIOANALYSIS, V9, P1207, DOI 10.4155/bio-2017-0102
   Zhang L., 2018, ANN M POP APPR GROUP, P27
   Zhao L, 2013, J CLIN PHARMACOL, V53, P314, DOI 10.1002/jcph.4
   Zhou HH, 2011, ANNU REV PHARMACOL, V51, P359, DOI 10.1146/annurev-pharmtox-010510-100510
   Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266
NR 99
TC 3
Z9 3
U1 2
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 3
EP 13
DI 10.1016/j.rmed.2019.05.005
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200002
PM 31136930
DA 2020-05-18
ER

PT J
AU Montalbano, L
   Ferrante, G
   Cilluffo, G
   Gentile, M
   Arrigo, M
   La Guardia, D
   Allegra, M
   Malizia, V
   Gagliardo, RP
   Bonini, M
   La Grutta, S
AF Montalbano, Laura
   Ferrante, Giuliana
   Cilluffo, Giovanna
   Gentile, Manuel
   Arrigo, Marco
   La Guardia, Dario
   Allegra, Mario
   Malizia, Velia
   Gagliardo, Rosalia Paola
   Bonini, Matteo
   La Grutta, Stefania
TI Targeting quality of life in asthmatic children: The MyTEP pilot
   randomized trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Children; Quality of life; Therapeutic education; Mobile health
ID THERAPEUTIC EDUCATION-PROGRAM; SELF-MANAGEMENT; EXACERBATIONS;
   INTERVENTION; ADHERENCE; ALLERGY; FLOW
AB Background: Quality of life (QoL) is an important outcome in the management of children with asthma. Mobile Health (m-Health) and Therapeutic Education Programs (TEPs) are increasingly recognized as essential components of pediatric asthma management to improve disease outcomes.
   Objective: To evaluate the effect of an education program (MyTherapeutic Education Program, MyTEP) that couples multidisciplinary TEP intervention with an m-Health Program (mHP) in improving QoL in asthmatic children.
   Methods: This single-center study employed a nonblinded randomized clinical trial design. Italian-speaking children (6-11 years) with mild-moderate asthma were eligible for participation. Participants were randomly paired 1: 1 with a control group that received mHP (smartphone app) or an intervention group that received MyTEP (TEP plus a smartphone app). Patients were followed up for 3 months. Descriptive statistics, Least Square (LS) mean change and Generalized Linear Mixed model were used for analysis.
   Results: Fifty patients were enrolled. The Pediatric Asthma Quality of Life Questionnaire (PAQLQ) score improved in both MyTEP (p=0.014) and mHP (p=0.046) with the minimally clinically significant difference of >= 0.5 points reached in 23% of MyTEP and in 16% of mHP. Changes in PAQLQ scores were significantly greater in MyTEP than in mHP (LS mean difference: 0.269 p=0.05). PAQLQ score was: positively associated with MyTEP (p=0.023) and study time (p=0.002); and inversely associated with current passive smoke exposure (p=0.003).
   Conclusion: Despite the small sample size and short observation period, this study demonstrated that implementing a multidisciplinary TEP with an m-Health program results in gains in QoL of children with asthma.
C1 [Montalbano, Laura; Cilluffo, Giovanna; Malizia, Velia; Gagliardo, Rosalia Paola; La Grutta, Stefania] Natl Res Council CNR, Inst Biomed & Mol Immunol IBIM, Via Ugo La Malfa 153, I-90146 Palermo, Italy.
   [Ferrante, Giuliana] Univ Palermo, Dipartimento Sci Promoz Salute Maternoinfantile M, Palermo, Italy.
   [Gentile, Manuel; Arrigo, Marco; La Guardia, Dario; Allegra, Mario] Natl Res Council CNR, ITD, Palermo, Italy.
   [Bonini, Matteo] IRCCS, Fdn Policlin Univ A Gemelli, Dept Cardiovasc & Thorac Sci, Rome, Italy.
RP Cilluffo, G (reprint author), Natl Res Council CNR, Inst Biomed & Mol Immunol IBIM, Via Ugo La Malfa 153, I-90146 Palermo, Italy.
EM giovanna.cilluffo@ibim.cnr.it
RI Cilluffo, Giovanna/AAC-6724-2019; Ferrante, Giuliana/AAA-2478-2019;
   Montalbano, Laura/AAM-2884-2020; Bonini, Matteo/AAB-1093-2019
OI Cilluffo, Giovanna/0000-0003-4305-3981; Montalbano,
   Laura/0000-0002-3540-4801; 
CR Alquran A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15112403
   [Anonymous], 2016 GINA REP GLOB S
   Baiardini I, 2010, ALLERGY, V65, P290, DOI 10.1111/j.1398-9995.2009.02263.x
   Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5
   Bonini M, 2018, CURR OPIN PULM MED, V24, P63, DOI 10.1097/MCP.0000000000000439
   Bonini M, 2017, CURR OPIN PULM MED, V23, P21, DOI 10.1097/MCP.0000000000000336
   Boyd M, 2009, COCHRANE DB SYST REV, V15
   Brand PLP, 2015, EUR RESPIR REV, V24, P187, DOI 10.1183/16000617.00003614
   Brouwer AFJ, 2008, EUR RESPIR J, V32, P1262, DOI 10.1183/09031936.00148107
   Brouwer AFJ, 2006, EUR RESPIR J, V28, P1131, DOI 10.1183/09031936.06.00118205
   Brouwer AFJ, 2007, PEDIATR PULM, V42, P813, DOI 10.1002/ppul.20660
   Brown W, 2015, J ALLER CL IMM-PRACT, V3, P300, DOI 10.1016/j.jaip.2014.10.003
   Busse WW, 2007, J ALLERGY CLIN IMMUN, V120, P1012, DOI 10.1016/j.jaci.2007.09.016
   Chini L, 2011, J ASTHMA, V48, P419, DOI 10.3109/02770903.2011.563808
   Cibella F, 2011, PEDIAT ALLERG IMM-UK, V22, P60, DOI 10.1111/j.1399-3038.2010.01097.x
   Crocker DD, 2011, AM J PREV MED, V41, pS5, DOI 10.1016/j.amepre.2011.05.012
   de la Sante O. M., 1998, EUROPE ED THERAPEUTI
   Ferrante G, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00186
   Guarnaccia S, 2018, PEDIAT ALLERG IMM-UK, V29, P180, DOI 10.1111/pai.12839
   Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502
   Indinnimeo L, 2009, PEDIATR ALLERGY IMMU, V20, P654, DOI 10.1111/j.1399-3038.2009.00857.x
   Johnson KB, 2016, J AM MED INFORM ASSN, V23, P449, DOI 10.1093/jamia/ocv158
   Julian V, 2015, PEDIATR PULM, V50, P213, DOI 10.1002/ppul.23013
   Kalyva E, 2016, INT J BEHAV MED, V23, P730, DOI 10.1007/s12529-016-9558-7
   Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662
   Magar Y, 2005, PATIENT EDUC COUNS, V58, P41, DOI 10.1016/j.pec.2004.05.016
   Mascheroni G, 2016, NEW MEDIA SOC, V18, P1657, DOI 10.1177/1461444814567986
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Montalbano L, 2016, PEDIAT ALLERG IMM-UK, V27, P514, DOI 10.1111/pai.12571
   Mosnaim G, 2015, J ALLER CL IMM-PRACT, V3, P288, DOI 10.1016/j.jaip.2014.10.011
   Perry TT, 2017, ANN ALLERG ASTHMA IM, V118, P298, DOI 10.1016/j.anai.2016.11.028
   Praena-Crespo M, 2017, ALLERGOL IMMUNOPATH, V45, P375, DOI 10.1016/j.aller.2016.10.022
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Shah S, 2001, BRIT MED J, V322, P583, DOI 10.1136/bmj.322.7286.583
   Shields MD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190031
   Stukus DR, 2018, ANN ALLERG ASTHMA IM, V120, P395, DOI 10.1016/j.anai.2018.02.006
   van Bragt S, 2015, J ASTHMA, V52, P211, DOI 10.3109/02770903.2014.952439
   Voorend-van Bergen S, 2014, J ALLERGY CLIN IMMUN, V133, P1599, DOI 10.1016/j.jaci.2013.10.005
   Walter Helen, 2016, JBI Database System Rev Implement Rep, V14, P113
   Watson WTA, 2009, CAN MED ASSOC J, V181, P257, DOI 10.1503/cmaj.080947
   Wolf F, 2002, COCHRANE DB SYST REV, V4, P1, DOI DOI 10.1002/14651858.CD000326
NR 41
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 14
EP 19
DI 10.1016/j.rmed.2019.05.008
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200003
PM 31136927
DA 2020-05-18
ER

PT J
AU Martynowicz, H
   Kornafel-Flak, O
   Urbanik, D
   Laczmanski, L
   Sobieszczanska, M
   Mazur, G
   Poreba, R
   Gac, P
AF Martynowicz, Helena
   Kornafel-Flak, Olga
   Urbanik, Dominika
   Laczmanski, Lukasz
   Sobieszczanska, Malgorzata
   Mazur, Grzegorz
   Poreba, Rafal
   Gac, Pawel
TI Coexistence of obstructive sleep apnea and telomerase activity,
   concentration of selected adipose tissue hormones and vascular
   endothelial function in patients with arterial hypertension
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Obstructive sleep apnea; Telomerase activity; Visfatin concentration;
   Adipsin concentration; Flow-mediated dilatation
ID OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; ASSOCIATION; LENGTH; HEART;
   LEUKOCYTE; RISK; MEN; HYPOPNEA; PRESSURE
AB Aim.: The aim of the present study was to determine the effect of obstructive sleep apnea (OSA) with hypertension on telomerase activity, visfatin and adipsine concentration in the blood and vascular endothelial function assessed by ultrasound measured flow-mediated dilatation of the brachial artery (FMD).
   Material and methods: The study involved a group of 106 people (average age: 54.79 years). The determination of telomerase activity and blood visfatin and adipsine concentrations, brachial artery ultrasound examination with endothelium-dependent dilatation evaluation (FMD) and polysomnography were carried out.
   Results: Patients with hypertension without OSA were characterized by significantly greater FMD in comparison to patients with arterial hypertension and OSA (8.13 +/- 5.12 % vs. 6.82 +/- 5.36%; p < 0.05). Negative linear relationship between apnea-hypopnea index (AHI) and FMD (r=-0.22, p < 0.05) has been demonstrated. Negative linear relationship between adipsine concentration in the blood and length of REM (Rapid Eye Movement) sleep (r=-0.21, p < 0.05) was found. Positive linear relationship between the concentration of visfatin in the blood and the length of REM sleep (r=0.22, p < 0.05) was also observed. Higher body mass index, higher total cholesterol, triglyceride and glucose levels have been shown to be independent predictors of higher AHI values, while greater telomerase activity, greater FMD and use of angiotensin converting enzyme inhibitors are independent predicators for lower AHI values.
   Conclusion: Higher values of AHI index in polysomnography in hypertensive patients can be related to lower telomerase activity in the blood and impaired function of vascular endothelial function assessed using ultrasound.
C1 [Martynowicz, Helena; Kornafel-Flak, Olga; Urbanik, Dominika; Laczmanski, Lukasz; Mazur, Grzegorz; Poreba, Rafal; Gac, Pawel] Wroclaw Med Univ, Dept Internal Med Occupat Dis & Hypertens, Borowska 213, PL-50556 Wroclaw, Poland.
   [Kornafel-Flak, Olga; Gac, Pawel] 4th Mil Hosp, Dept Radiol & Diagnost Imaging, Weigla 5, PL-50981 Wroclaw, Poland.
   [Sobieszczanska, Malgorzata] Wroclaw Med Univ, Dept Geriatr, Curie Sklodowskiej 66, PL-50369 Wroclaw, Poland.
   [Gac, Pawel] Wroclaw Med Univ, Dept Hyg, Mikulicza Radeckiego 7, PL-50368 Wroclaw, Poland.
RP Gac, P (reprint author), Wroclaw Med Univ, Dept Hyg, Mikulicza Radeckiego 7, PL-50368 Wroclaw, Poland.
EM pawel.gac@umed.wroc.pl
OI Gac, Pawel/0000-0001-8366-0239; Mazur, Grzegorz/0000-0001-6610-2008
FU Wroclaw Medical University
FX This work was supported by the Wroclaw Medical University.
CR Arzt M, 2005, AM J RESP CRIT CARE, V172, P1447, DOI 10.1164/rccm.200505-702OC
   Beccuti G, 2011, CURR OPIN CLIN NUTR, V14, P402, DOI 10.1097/MCO.0b013e3283479109
   Boyer L, 2016, ANN AM THORAC SOC, V13, P1136, DOI 10.1513/AnnalsATS.201510-718OC
   BRYS M, 2012, FOLIA MED LODZ, V2, P293
   Chow CK, 2013, JAMA-J AM MED ASSOC, V310, P959, DOI 10.1001/jama.2013.184182
   Ciccone MM, 2012, INT J CARDIOL, V158, P383, DOI 10.1016/j.ijcard.2011.01.065
   Covassin N, 2016, SLEEP MED CLIN, V11, P81, DOI 10.1016/j.jsmc.2015.10.007
   D'Mello MJJ, 2015, CIRC-CARDIOVASC GENE, V8, P82, DOI 10.1161/CIRCGENETICS.113.000485
   Della Rocca D. G., 2011, KARDIOL DYPLOMIE, V10, P14
   Demissie S, 2006, AGING CELL, V5, P325, DOI 10.1111/j.1474-9726.2006.00224.x
   Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011
   Faraj M, 2004, BIOCHEM CELL BIOL, V82, P170, DOI 10.1139/o03-078
   Forouzanfar MH, 2017, JAMA-J AM MED ASSOC, V317, P165, DOI 10.1001/jama.2016.19043
   Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018
   Ge XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069432
   Gilat H, 2014, MEDICINE, V93, P1
   Godo S, 2017, ARTERIOSCL THROM VAS, V37, pE108, DOI 10.1161/ATVBAHA.117.309813
   Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801
   Hayes AL, 2011, SLEEP, V34, P147, DOI 10.1093/sleep/34.2.147
   Huang P, 2018, SLEEP MED, V48, P107, DOI 10.1016/j.sleep.2017.09.034
   Jelic S, 2008, CIRCULATION, V117, P2270, DOI 10.1161/CIRCULATIONAHA.107.741512
   Khan MS, 2017, SLEEP MED CLIN, V12, P167, DOI 10.1016/j.jsmc.2017.01.005
   Kim KS, 2016, AGING DIS, V7, P604, DOI 10.14336/AD.2016.0215
   Knutson KL, 2008, ANN NY ACAD SCI, V1129, P287, DOI 10.1196/annals.1417.033
   Kwon Hyokjoon, 2013, Front Endocrinol (Lausanne), V4, P71, DOI 10.3389/fendo.2013.00071
   Lavie L, 2009, EUR RESPIR J, V33, P1467, DOI 10.1183/09031936.00086608
   Lee WJ, 2009, INT J OBESITY, V33, P465, DOI 10.1038/ijo.2009.24
   Leproult R, 2010, ENDOCR DEV, V17, P11, DOI 10.1159/000262524
   Malecki TM, 2006, KARDIOL POL S6, V64, P561
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   Mazurek T, 2009, KARDIOL POL, V67, P1119
   Mraz M, 2014, J ENDOCRINOL, V222, pR113, DOI 10.1530/JOE-14-0283
   Muller M, 2014, EUR HEART J, V35, P3245, DOI 10.1093/eurheartj/ehu252
   Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829
   Pepine CJ, 2010, J AM COLL CARDIOL, V55, P2825, DOI 10.1016/j.jacc.2010.01.054
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106
   Premer Courtney, 2019, Mayo Clin Proc Innov Qual Outcomes, V3, P1, DOI 10.1016/j.mayocpiqo.2018.12.006
   Raschenberger J, 2013, ATHEROSCLEROSIS, V229, P469, DOI 10.1016/j.atherosclerosis.2013.05.027
   Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC
   Romacho T, 2013, MEDIAT INFLAMM, V2013, P1
   Saddi-Rosa P, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-21
   Schrover IM, 2018, EUR J PREV CARDIOL, V25, P1548, DOI 10.1177/2047487318790722
   Schwarz EI, 2015, RESPIROLOGY, V20, P889, DOI 10.1111/resp.12573
   Selim BJ, 2016, J CLIN SLEEP MED, V12, P829, DOI 10.5664/jcsm.5880
   Sorajja D, 2008, CHEST, V133, P927, DOI 10.1378/chest.07-2544
   Tempaku PF, 2016, ONCOTARGET, V7, P69216, DOI 10.18632/oncotarget.12293
   Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Wang J., 2015, J AM HEART ASSOC, V4, P1
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   Zepeda RJ, 2012, BASIC CLIN PHARMACOL, V111, P309, DOI 10.1111/j.1742-7843.2012.00911.x
NR 51
TC 1
Z9 1
U1 2
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 20
EP 25
DI 10.1016/j.rmed.2019.05.009
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200004
PM 31136928
DA 2020-05-18
ER

PT J
AU Koskela, HO
   Latti, AM
   Pekkanen, J
AF Koskela, Heikki O.
   Latti, Anne M.
   Pekkanen, Juha
TI Subfreezing air as a cough trigger and multiple triggers are strongly
   associated with the presence of asthma in chronic cough
SO RESPIRATORY MEDICINE
LA English
DT Article
ID VALIDITY; PATIENT
AB Background: Management of chronic cough relies on the recognition of cough background disorders. It is not known whether certain cough triggers are associated with specific background disorders.
   Methods: This was an e-mail study to public service employees of two towns in Finland. The questionnaire included twelve triggers. Current asthma was defined as doctor's diagnosis of asthma and current wheezing. Chronic rhinosinusitis was defined as either nasal blockage or nasal discharge and either facial pain/pressure or reduction/loss of smell for more than three months. Gastroesophageal reflux disease was defined as heartburn and/or regurgitation on at least one day a week during the last three months. Idiopathic cough was defined as absence of any of them.
   Results: There were 421 subjects with current cough that had lasted at least eight weeks. Subfreezing air as a cough trigger was associated with an adjusted odds ratio (aOR) of 7.27 (4.09-12.9), (p < 0.001), for current asthma. The number of cough triggers was largest in asthma, followed by chronic rhinosinusitis, gastro-esophageal reflux, and idiopathic cough (7.05 (6.14-7.96), 4.94 (4.35-5.54), 4.60 (3.77-5.43), and 3.44 (3.02-3.86), respectively, p < 0.001). Presence of five or more triggers was associated with an aOR of 7.49 (3.96-14.2), (p < 0.001) for current asthma. Absence of any cough triggers increased the probability of idiopathic cough (aOR 2.71 (1.54-4.77), p= 0.001).
   Conclusions: Subfreezing air as a cough trigger and multiple triggers are strongly associated with the presence of current asthma in chronic cough. Absence of any cough triggers increases the probability of idiopathic cough.
C1 [Koskela, Heikki O.; Latti, Anne M.] Kuopio Univ Hosp, Div Pulm, Unit Med & Clin Res, PL 100, FI-70029 Kuopio, Finland.
   [Koskela, Heikki O.; Latti, Anne M.] Kuopio Univ Hosp, PL 100, FI-70029 Kys, Finland.
   [Koskela, Heikki O.; Latti, Anne M.] Univ Eastern Finland, Fac Hlth Sci, Inst Clin Sci, Sch Med, PL 1627, FI-70211 Kuopio, Finland.
   [Pekkanen, Juha] Univ Helsinki, Dept Publ Hlth, PL 63, FI-00014 Helsinki, Finland.
   [Pekkanen, Juha] Natl Inst Hlth & Welf, Environm Hlth Unit, PL 95, FI-70701 Kuopio, Finland.
RP Koskela, HO (reprint author), Kuopio Univ Hosp, Div Pulm, Unit Med & Clin Res, PL 100, FI-70029 Kuopio, Finland.
EM heikki.koskela@kuh.fi; anne.latti@kuh.fi; juha.pekkanen@helsinki.fi
FU foundations Kuopion Seudun Hengityssaatio and Hengityssairauksien
   Tutkimussaatio
FX This work was supported by the foundations Kuopion Seudun Hengityssaatio
   and Hengityssairauksien Tutkimussaatio.
CR ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4
   Centers for Disease Control and Prevention, 2015, NAT AMB MED CAR SURV
   Chung KF, 2011, PULM PHARMACOL THER, V24, P267, DOI 10.1016/j.pupt.2011.01.012
   Croicu C, 2014, MED CLIN N AM, V98, P1079, DOI 10.1016/j.mcna.2014.06.007
   El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269
   Everett CF, 2007, RESP MED, V101, P345, DOI 10.1016/j.rmed.2006.05.006
   Fokkens WJ, 2012, RHINOLOGY, V50, P1
   Irwin RS, 2018, CHEST, V153, P196, DOI 10.1016/j.chest.2017.10.016
   Kanemitsu Y, 2016, RESPIR INVESTIG, V54, P413, DOI 10.1016/j.resinv.2016.07.002
   Koskela HO, 2008, CLIN EXP ALLERGY, V38, P1100, DOI 10.1111/j.1365-2222.2008.02996.x
   Koskela HO, 2005, CHEST, V128, P3329, DOI 10.1378/chest.128.5.3329
   Koskela HO, 2004, CHEST, V125, P1985, DOI 10.1378/chest.125.6.1985
   Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Latti AM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022950
   Lederer DJ, 2019, ANN AM THORAC SOC, V16, P22, DOI 10.1513/AnnalsATS.201808-564PS
   Matsumoto H, 2017, ANN AM THORAC SOC, V14, P698, DOI 10.1513/AnnalsATS.201608-616BC
   Matsumoto H, 2012, ALLERGOL INT, V61, P123, DOI 10.2332/allergolint.10-OA-0295
   Morice AH, 2010, LUNG, V188, pS87, DOI 10.1007/s00408-009-9185-z
   Purokivi Minna, 2011, Cough, V7, P8, DOI 10.1186/1745-9974-7-8
   Sa-Sousa A, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-24
   Vertigan AE, 2011, J VOICE, V25, P596, DOI 10.1016/j.jvoice.2010.07.009
   Wandell P, 2013, FAM PRACT, V30, P506, DOI 10.1093/fampra/cmt033
NR 23
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 26
EP 30
DI 10.1016/j.rmed.2019.05.004
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200005
PM 31136929
DA 2020-05-18
ER

PT J
AU Nguyen, TS
   Nguyen, TLH
   Pham, TTV
   Hua, S
   Ngo, QC
   Li, SC
AF Tu-Son Nguyen
   Thi Lien Huong Nguyen
   Thi Thuy Van Pham
   Hua, Susan
   Quy Chau Ngo
   Li, Shu Chuen
TI Impact of pharmaceutical care in the improvement of medication adherence
   and quality of life for COPD patients in Vietnam
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Pharmacists; Medication adherence; MMAS; Quality of life; EQ-5D-5L
ID OBSTRUCTIVE PULMONARY-DISEASE; PHARMACIST-LED INTERVENTION; INHALED
   THERAPIES; ASTHMA; PREVALENCE; COSTS
AB Background: Medication adherence is an important factor in the management of chronic obstructive pulmonary disease (COPD). However, the rate of non-adherence to medications is high in COPD and is associated with worsened clinical outcomes and health-related quality of life for patients.
   Objectives: Our study aimed to evaluate the impact of a pharmaceutical care program led by pharmacists in the improvement of medication adherence and quality of life for COPD patients in Vietnam.
   Methods: A pre-and post-intervention study was conducted over 12 months. Pharmacists provided brief counselling which focused on the role of COPD medications and the importance of adherence. Morisky Medication Adherence Scale was used to evaluate patients' adherence. Quality of life was assessed using the EQ-5D-5L questionnaire and clinical outcomes were evaluated by symptom scores. These outcomes were reassessed at baseline (T0), after 3 months (T1), 6 months (T2) and 12 months (T3).
   Results: Study participants consisted of 211 COPD patients (mean age: 66.6 +/- 8.2 years). The percentage of patients with good adherence significantly increased from 37.4% to 53.2% (p < 0.001) after the program. Mean medication adherence scores improved from 6.7 (T0) to 7.4 (T2) and 7.4 (T3) (p < 0.001). EQ-5D-5L index values also increased from 0.47 (T0) to 0.59 (T3) (p < 0.001). There was no significant change in symptom scores across the duration of the study.
   Conclusions: Medication adherence and quality of life of COPD patients improved considerably after implementation of a pharmaceutical care program, thus supporting a vital role for pharmacists alongside physicians in the management of COPD.
C1 [Tu-Son Nguyen; Thi Lien Huong Nguyen; Thi Thuy Van Pham] Hanoi Univ Pharm, Dept Clin Pharm, Hanoi, Vietnam.
   [Quy Chau Ngo] Bach Mai Hosp, Resp Ctr, Hanoi, Vietnam.
   [Tu-Son Nguyen; Hua, Susan; Li, Shu Chuen] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Newcastle, NSW, Australia.
RP Li, SC (reprint author), Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.
EM shuchuen.li@newcastle.edu.au
OI Ngo, Quy Chau/0000-0002-6787-2757
FU Ministry of Education and Training of Vietnam; University of Newcastle
FX The authors would like to thank the patients that participated in the
   study and the pharmacists in the Department of Pharmacy at Bach Mai
   Hospital, especially Mrs. Nguyen Hoai Thu, Miss Do Thi Thu Hien and Miss
   Kim Huyen Trang. The authors also wish to thank the Board of Directors
   of Bach Mai Hospital and members of the Department of Clinical Pharmacy
   at Hanoi University of Pharmacy for supporting the study. Tu-Son Nguyen
   wishes to thank the Ministry of Education and Training of Vietnam and
   the University of Newcastle for awarding a 911 scholarship to support
   his PhD study in Australia.
CR A. M. Association, 2015, MED ADH IMPR HLTH YO
   Abdulsalim S, 2018, RES SOC ADMIN PHARM, V14, P909, DOI 10.1016/j.sapharm.2017.10.008
   Agh T, 2015, RESP CARE, V60, P297, DOI 10.4187/respcare.03123
   Agh T, 2011, RESPIRATION, V82, P328, DOI 10.1159/000324453
   Axtell Samantha, 2017, J Pharm Pract, V30, P195, DOI 10.1177/0897190016628961
   Barnestein-Fonseca P, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-6
   Basu S, 2018, RES SOC ADMIN PHARM, V14, P401, DOI 10.1016/j.sapharm.2017.11.016
   Cecere LM, 2012, COPD, V9, P251, DOI 10.3109/15412555.2011.650241
   Dekhuijzen R., 2018, ADDRESSING IMPACT UN, V6
   DETULLIO PL, 1987, J CLIN PHARM THER, V12, P19
   Garfield S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-149
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017, GLOB STRAT DIAGN MAN
   Hammerlein A, 2011, J EVAL CLIN PRACT, V17, P61, DOI 10.1111/j.1365-2753.2010.01369.x
   Krousel-Wood M, 2009, AM J MANAG CARE, V15, P59
   Le TTL, 2011, J FR VIETNAM ASS PUL, V2, P46
   Nguyen LH, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0771-0
   Makela MJ, 2013, RESP MED, V107, P1481, DOI 10.1016/j.rmed.2013.04.005
   Ministry of Health and Health Partnership Group, 2015, JOINT ANN HLTH REV 2
   Ministry-of-Health and Health-Partnership-Group, 2009, JOINT ANN HLTH REV 2
   Molken MPMHRV, 2006, CHEST, V130, P1117, DOI 10.1378/chest.130.4.1117
   Morisky D. E., 2011, J CLIN EPIDEMIOL, V64
   Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x
   Viet NN, 2015, RESPIROLOGY, V20, P602, DOI 10.1111/resp.12507
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Reenen MV, 2015, EQ 5D 5L USER GUIDE
   Restrepo Ruben D, 2008, Int J Chron Obstruct Pulmon Dis, V3, P371
   Rogliani P, 2017, RESP MED, V129, P117, DOI 10.1016/j.rmed.2017.06.007
   Sanduzzi A, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-60
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Suhaj A, 2016, J CLIN PHARM THER, V41, P78, DOI 10.1111/jcpt.12353
   Takemura M, 2011, INT J CHRONIC OBSTR, V6, P97, DOI 10.2147/COPD.S16173
   Tommelein E, 2014, BRIT J CLIN PHARMACO, V77, P756, DOI 10.1111/bcp.12242
   Nguyen TS, 2018, INT J CHRONIC OBSTR, V13, P1863, DOI 10.2147/COPD.S163826
   van Boven JFM, 2014, RESP MED, V108, P103, DOI 10.1016/j.rmed.2013.08.044
   van der Molen T, 2017, BRIT J CLIN PHARMACO, V83, P192, DOI 10.1111/bcp.13087
   Vestbo J, 2009, THORAX, V64, P939, DOI 10.1136/thx.2009.113662
   Wei L, 2014, J THORAC DIS, V6, P656, DOI 10.3978/j.issn.2072-1439.2014.06.20
   Wu MM, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0241-5
   Xin CW, 2016, PATIENT PREFER ADHER, V10, DOI 10.2147/PPA.S110167
   Zhong H, 2014, INT J CLIN PHARM-NET, V36, P1230, DOI 10.1007/s11096-014-0024-9
NR 40
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 31
EP 37
DI 10.1016/j.rmed.2019.05.006
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200006
PM 31136931
DA 2020-05-18
ER

PT J
AU Donohue, JF
   Kerwin, E
   Sethi, S
   Haumann, B
   Pendyala, S
   Dean, L
   Barnes, CN
   Moran, EJ
   Crater, G
AF Donohue, James F.
   Kerwin, Edward
   Sethi, Sanjay
   Haumann, Brett
   Pendyala, Srikanth
   Dean, Lorna
   Barnes, Chris N.
   Moran, Edmund J.
   Crater, Glenn
TI Revefenacin, a once-daily, lung-selective, long-acting muscarinic
   antagonist for nebulized therapy: Safety and tolerability results of a
   52-week phase 3 trial in moderate to very severe chronic obstructive
   pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Long-acting muscarinic antagonist; Once daily; Nebulized therapy;
   Safety; Revefenacin
ID TIOTROPIUM; COPD
AB Background: Prior replicate 12-week phase 3 trials demonstrated that once-daily doses of revefenacin inhalation solution at 88 mu g and 175 mu g produced significant bronchodilation over 24 h post dose in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The objective was to characterize the safety profile of revefenacin 88 mu g and 175 mu g over 52 weeks of treatment.
   Methods: In this randomized, parallel-group, 52-week trial (NCT02518139), 1055 participants with moderate to very severe COPD received revefenacin 88 mu g or 175 mu g in a double-blind manner, or open-label active control tiotropium.
   Results: Treatment-emergent adverse events (AEs) were comparable across all treatment groups (n [%] patients; revefenacin 88 mu g, 272 [74.7%]; 175 mu g, 242 [72.2%]; tiotropium, 275 [77.2%]). Numerically fewer COPD exacerbations (n [%] patients) were observed with revefenacin 175 mu g (73 [21.8%]) than with 88 mu g (107 [29.4%]) or tiotropium (100 [28.1%]). Serious AEs were comparable with revefenacin 88 mu g (58 [15.9%] and tiotropium (58 [16.3%]), but were lower with revefenacin 175 mu g (43 [12.8%]), and mortality was low. In patients using revefenacin 88 mu g or tiotropium with a concurrent long-acting beta-agonist (LABA) product, the incidence of AEs was slightly higher than without concurrent LABA. LABA did not affect the incidence of AEs for patients who received revefenacin 175 mu g.
   Conclusions: Revefenacin was generally well tolerated over 52 weeks of treatment, and had a safety profile that supports its use as a long-term once-daily bronchodilator for the nebulized treatment of COPD.
C1 [Donohue, James F.] Univ N Carolina, Sch Med, Pulm Med, Chapel Hill, NC 27515 USA.
   [Kerwin, Edward] Southern Oregon PC, Clin Res Inst, Medford, OR USA.
   [Sethi, Sanjay] SUNY Buffalo, Buffalo, NY USA.
   [Haumann, Brett; Pendyala, Srikanth; Dean, Lorna; Barnes, Chris N.; Moran, Edmund J.; Crater, Glenn] Theravance Biopharma US Inc, 901 Gateway Blvd, San Francisco, CA 94080 USA.
RP Crater, G (reprint author), Theravance Biopharma US Inc, 901 Gateway Blvd, San Francisco, CA 94080 USA.
EM gcrater@theravance.com
FU Theravance Biopharma, Ireland Limited Inc. (Dublin, Ireland); Mylan Inc.
   (Canonsburg, Pennsylvania, USA); Theravance Biopharma US, Inc. (South
   San Francisco, CA, USA)
FX This study was funded by Theravance Biopharma, Ireland Limited Inc.
   (Dublin, Ireland). Mylan Inc. (Canonsburg, Pennsylvania, USA) and
   Theravance Biopharma US, Inc. (South San Francisco, CA, USA) funded
   medical writing support.
CR Baldwin MR, 2013, AM J RESP CRIT CARE, V187
   Bateman Eric, 2010, Int J Chron Obstruct Pulmon Dis, V5, P197
   Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802
   Dhand R, 2012, COPD, V9, P58, DOI 10.3109/15412555.2011.630047
   Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335
   Donohue JF, 2014, CHEST, V146, P1531, DOI 10.1378/chest.14-0117
   Ferguson G. T., 2017, EUR RESP J S61, V50
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011, GLOBAL STRATEGY DIAG
   ICH, 2015, INT ADD ICH HARM GUI
   Ji YH, 2016, CHEST, V150, p970A, DOI 10.1016/j.chest.2016.08.1074
   Jones PW, 2012, EUR RESPIR J, V40
   Jones PW, 2015, INT J CHRONIC OBSTR, V10, P677, DOI 10.2147/COPD.S76520
   Lavorini F, 2011, RESP MED, V105, P1099, DOI 10.1016/j.rmed.2011.03.012
   Loh CH, 2017, ANN AM THORAC SOC, V14, P1305, DOI 10.1513/AnnalsATS.201611-903OC
   Mahler DA, 2014, J AEROSOL MED PULM D, V27, P103, DOI 10.1089/jamp.2013.1038
   Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007
   Quinn D, 2018, PULM PHARMACOL THER, V48, P71, DOI 10.1016/j.pupt.2017.10.003
   Spiriva-Handihaler, 2009, PRESCRIBING INFORM
   Steinfeld T, 2009, AM J RESP CRIT CARE, pA4553
   Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800
   Tashkin DP, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S114034
   US Food and Drug Adminstration, 2017, HIGHL PRESCR INF LON
   US Food and Drug Adminstration, 2018, HIGHL PRESCR INF YUP
   Usmani OS, 2015, COPD RES PRACT, V1, P1, DOI DOI 10.1186/S40749-015-0011-0
   2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
NR 25
TC 10
Z9 10
U1 1
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 38
EP 43
DI 10.1016/j.rmed.2019.05.010
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200007
PM 31150963
OA Bronze
DA 2020-05-18
ER

PT J
AU Nathan, SD
   Costabel, U
   Albera, C
   Behr, J
   Wuyts, WA
   Kirchgaessler, KU
   Stauffer, JL
   Morgenthien, E
   Chou, W
   Limb, SL
   Noble, PW
AF Nathan, Steven D.
   Costabel, Ulrich
   Albera, Carlo
   Behr, Juergen
   Wuyts, Wim A.
   Kirchgaessler, Klaus-Uwe
   Stauffer, John L.
   Morgenthien, Elizabeth
   Chou, Willis
   Limb, Susan L.
   Noble, Paul W.
TI Pirfenidone in patients with idiopathic pulmonary fibrosis and more
   advanced lung function impairment
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Pirfenidone; Dyspnoea; Mortality
ID NINTEDANIB; DIAGNOSIS; MORTALITY; EFFICACY; TRIALS; VALUES
AB Background: Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung function impairment. However, the efficacy of antifibrotics compared with placebo has not been assessed in patients with more advanced disease. This post-hoc analysis investigated the efficacy and safety of pirfenidone versus placebo in patients with IPF and more advanced lung function impairment, defined as percent predicted forced vital capacity (% FVC) < 50% and/or percent predicted carbon monoxide diffusing capacity<35%.
   Methods: Patients randomised to pirfenidone 2,403 mg/day or placebo in the ASCEND (NCT01366209) and CAPACITY (NCT00287716; NCT00287729) trials with more advanced baseline lung function impairment (pirfenidone, n= 90; placebo, n= 80) were included. Mortality, lung function, hospitalisation, exercise capacity and dyspnoea were investigated over 52 weeks.
   Results: At Week 52 versus placebo, pirfenidone was associated with significantly lower risks of all-cause mortality (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.09-0.86; p= 0.0180), >= 10% absolute % FVC decline or all-cause mortality (HR 0.40; 95% CI 0.23-0.69; p= 0.0006) and >= 10% absolute % FVC decline or respiratory-related hospitalisation or all-cause mortality (HR 0.46; 95% CI 0.28-0.76; p= 0.0018). At Week 52, median treatment differences favouring pirfenidone were 36.7m for 6-min walk distance and -8.0 points for the University of California-San Diego Shortness of Breath Questionnaire total score. Treatment-emergent adverse events (TEAEs) led to discontinuation in 14.4% and 21.3% of patients with pirfenidone and placebo, respectively.
   Conclusion: Pirfenidone demonstrated clinically relevant benefits across multiple domains in patients with IPF and more advanced disease without an increased risk of discontinuation due to TEAEs.
C1 [Nathan, Steven D.] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, 8110 Gatehouse Rd, Falls Church, VA 22042 USA.
   [Costabel, Ulrich] Univ Duisburg Essen, Univ Hosp, Ruhrlandklin, Tuschener Weg 40, D-45239 Essen, Germany.
   [Albera, Carlo] Univ Turin, Dept Clin & Biol Sci, Turin, Italy.
   [Behr, Juergen] Univ Munich LMU, Dept Internal Med 5, Comprehens Pneumol Ctr, Robert Koch Allee 2, D-82131 Munich, Germany.
   [Behr, Juergen] Asklepios Fachkliniken Munchen Gauting, Robert Koch Allee 2, D-82131 Munich, Germany.
   [Behr, Juergen] German Ctr Lung Res DZL, Robert Koch Allee 2, D-82131 Munich, Germany.
   [Wuyts, Wim A.] Univ Hosp Leuven, Dept Resp Med, Herestr 49, B-3000 Leuven, Belgium.
   [Kirchgaessler, Klaus-Uwe] F Hoffmann La Roche Ltd, Konzern Hauptsitz, Grenzacherstr 124, CH-4070 Basel, Switzerland.
   [Stauffer, John L.; Morgenthien, Elizabeth; Chou, Willis; Limb, Susan L.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
   [Noble, Paul W.] Cedars Sinai Med Ctr, Dept Med, 87000 Beverly Blvd, Los Angeles, CA 90048 USA.
   [Albera, Carlo] Molinette Univ Hosp, Corso Bramante 88, I-10126 Turin, Italy.
   [Chou, Willis] FibroGen Inc, 409 Illinois St, San Francisco, CA 94158 USA.
RP Nathan, SD (reprint author), Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, 8110 Gatehouse Rd, Falls Church, VA 22042 USA.
EM Steven.Nathan@inova.org; ulrich.costabel@rlk.uk-essen.de;
   carlo.albera@yahoo.it; juergen.behr@med.uni-muenchen.de;
   wim.wuyts@uzleuven.be; klaus-uwe.kirchgaessler@roche.com;
   stauffer.john@gene.com; morgente@gene.com; willis.chou@att.net;
   limb.susan@gene.com; paul.noble@cshs.org
FU GenentechRoche HoldingGenentech; F. Hoffmann-La RocheHoffmann-La Roche;
   F. Hoffmann-La Roche, Ltd., Basel, SwitzerlandHoffmann-La Roche
FX This analysis was supported by Genentech. and F. Hoffmann-La Roche. This
   analysis used data from studies sponsored by F. Hoffmann-La Roche, Ltd.,
   Basel, Switzerland, which was involved in study design and in the
   collection, analysis and interpretation of the data. The analysis
   presented here was designed and conducted by F. Hoffmann-La Roche, Ltd.
   in collaboration with the academic authors. The authors made the
   decision to submit the article for publication.
CR Aragaki-Nakahodo AA, 2017, RESP MED, V131, P65, DOI 10.1016/j.rmed.2017.08.003
   Costabel U, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA1813
   CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185
   European Medicines Agency, 2018, SUMM PROD CHAR ESBR
   European Medicines Agency, 2018, SUMM PROD CHAR OF NI
   Flaherty KR, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00230-2018
   Food and Drug Administration, 2018, HIGHL PRESCR INF OF
   Food and Drug Administration, 2017, HIGHL PRESCR INF ESB
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   Hutchinson J, 2015, EUR RESPIR J, V46, P795, DOI 10.1183/09031936.00185114
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Lancaster L, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000105
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Maher T., 2015, BRIT THOR SOC WINT M, P356
   Meltzer EB, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-8
   NATHAN SD, 2017, AM J RESP CRIT CARE, V195
   Nathan SD, 2017, LANCET RESP MED, V5, P33, DOI 10.1016/S2213-2600(16)30326-5
   Nathan SD, 2016, THORAX, V71, P429, DOI 10.1136/thoraxjnl-2015-207011
   Nathan SD, 2011, CHEST, V140, P221, DOI 10.1378/chest.10-2572
   Noble P, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA1810
   Noble PW, 2016, EUR RESPIR J, V47, P243, DOI 10.1183/13993003.00026-2015
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Ogura T, 2015, RESPIR INVESTIG, V53, P232, DOI 10.1016/j.resinv.2015.06.001
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Russell AM, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0171-y
   Sakamoto S, 2013, INTERNAL MED, V52, P2495, DOI 10.2169/internalmedicine.52.8498
   Vancheri C, 2018, AM J RESP CRIT CARE, V197, P356, DOI 10.1164/rccm.201706-1301OC
   Wuyts WA, 2016, LUNG, V194, P739, DOI 10.1007/s00408-016-9912-1
NR 29
TC 5
Z9 5
U1 0
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 44
EP 51
DI 10.1016/j.rmed.2019.04.016
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200008
PM 31153107
OA Other Gold
DA 2020-05-18
ER

PT J
AU Schieppati, D
   Germon, R
   Galli, F
   Rigamonti, MG
   Stucchi, M
   Boffito, DC
AF Schieppati, Dalma
   Germon, Remi
   Galli, Federico
   Rigamonti, Marco Giulio
   Stucchi, Marta
   Boffito, Daria Camilla
TI Influence of frequency and amplitude on the mucus viscoelasticity of the
   novel mechano-acoustic Frequencer (TM)
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cystic fibrosis; Frequencer (TM); Saline solution; Mechano-acoustic
   vibration; Infrasound; Frequency; Amplitude
ID CYSTIC-FIBROSIS GENE; LUNG; THERAPY; MUCINS; IDENTIFICATION;
   PATHOGENESIS; CLEARANCE; DISEASE; SALINE; BENCH
AB Background: Cystic fibrosis affects 1/3200 Caucasians. This genetic disease disturbs the ion and water home-ostasis across epithelia, thus rendering mucus more viscous and harder to expel. Conventional treatments rely on the clapping method coupled with postural drainage. Despite the effectiveness of these procedures, they are invasive and enervating.
   Methods: Here we study a new mechano-acoustic treatment device to help patients expectorate excess mucus, the Frequencer (TM). We test both normal and pathological synthetic mucin solutions (1 % and 4 % by weight) in vitro. We varied the frequency applied (from 20 Hz to 60 Hz) as well as the amplitude (from 50 % to 100 % intensity). Moreover, we assessed the effect of NaCl on mucus rehydration.
   Results: A frequency of 40 Hz coupled with a 0.5 gL(-1) NaCl solution provokes partial mucus rehydration, regardless of the amplitude selected, as the work of adhesion measurements evidenced.
   Conclusions: Mechanical solicitation is fundamental to help patients affected by cystic fibrosis expectorate mucus. With an operating frequency of 20 Hz to 65 Hz, the Frequencer (TM) provides a gentler therapy than traditional methods (conventional chest physiotherapy). The Frequencer (TM) proved to be effective in the homogenization of synthetic mucin solutions in vitro in 20 min and elicited improved effectiveness in a mucin-rich environment.
C1 [Schieppati, Dalma; Germon, Remi; Rigamonti, Marco Giulio; Boffito, Daria Camilla] Polytech Montreal, Dept Chem Engn, CP 6079,Succ CV, Montreal, PQ H3C 3A7, Canada.
   [Galli, Federico; Stucchi, Marta] Univ Milan, Dipartimento Chim, Via Golgi 19, I-20133 Milan, Italy.
RP Boffito, DC (reprint author), Polytech Montreal, Dept Chem Engn, CP 6079,Succ CV, Montreal, PQ H3C 3A7, Canada.
EM daria-camilla.boffito@polymtl.ca
RI Galli, Federico/L-3574-2016; Boffito, Daria Camilla/N-4405-2015
OI Galli, Federico/0000-0002-6230-4646; Boffito, Daria
   Camilla/0000-0002-5252-5752; Rigamonti, Marco Giulio/0000-0003-2570-797X
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Canada Research Chairs programCanada Research Chairs
FX The authors gratefully acknowledge the support of the Natural Sciences
   and Engineering Research Council of Canada (NSERC) to provide support
   through the Engage program. This research was undertaken, in part,
   thanks to funding from the Canada Research Chairs program. We are very
   thankful to the company Dymedso, which provided us with The Frequencer
   (TM) used for the tests, technical input and helpful discussion during
   the realization of the project. We acknowledge Caterina Rocca and
   Claudio Boffito for the graphic support.
CR ADAM NK, 1958, NATURE, V182, P128, DOI 10.1038/182128a0
   Becq F, 2011, J CYST FIBROS, V10, pS129, DOI 10.1016/S1569-1993(11)60018-0
   Boucher RC, 2002, ADV DRUG DELIVER REV, V54, P1359, DOI 10.1016/S0169-409X(02)00144-8
   Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086
   Cabillic M, 2014, KINESITHERAPIE REV, V14, P43, DOI DOI 10.1016/J.KINE.2014.09.009
   Campbell P., 1997, NIH CONS DEV C GEN T, VI, P23
   Cantin AM, 2006, CLIN INVEST MED, V29, P159
   Cantin AM, 2015, J CYST FIBROS, V14, P419, DOI 10.1016/j.jcf.2015.03.003
   Cone A. R., 1999, MUCOSAL IMMUNOLOGY
   Conese M, 2011, J CYST FIBROS, V10, pS114, DOI 10.1016/S1569-1993(11)60017-9
   Cui YY, 2015, SMALL, V11, P5118, DOI 10.1002/smll.201501245
   Doring G, 2012, J CYST FIBROS, V11, P461, DOI 10.1016/j.jcf.2012.10.004
   Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891
   Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900
   HILLS BA, 1990, BRIT J ANAESTH, V65, P13
   HOGAN J, 1986, BRIT J DIS CHEST, V80, P13, DOI 10.1016/0007-0971(86)90004-5
   Hwang S., 1969, RHEOL ACTA, V8, P438, DOI DOI 10.1007/BF01976227
   Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   KING M, 1980, FED PROC, V39, P3080
   Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537
   Lafforgue O, 2018, J BIOMED MATER RES A, V106, P386, DOI 10.1002/jbm.a.36251
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Li H, 2016, J ZHEJIANG UNIV-SC B, V17, P181, DOI 10.1631/jzus.B1500201
   LUCOTTE G, 1995, HUM BIOL, V67, P797
   MCCUTCHE.CW, 1969, J LUBRIC TECH-T ASME, V91, P371, DOI 10.1115/1.3554940
   MCINTOSH I, 1992, FASEB J, V6, P2775
   Perez-Vilar J, 2004, FREE RADICAL BIO MED, V37, P1564, DOI 10.1016/j.freeradbiomed.2004.07.027
   Plante L, 2002, US Patent, Patent No. [US7232417B2, 7232417]
   Pryor JA, 2010, J CYST FIBROS, V9, P187, DOI 10.1016/j.jcf.2010.01.004
   PUCHELLE E, 1995, RESPIRATION, V62, P2
   Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307
   Reeves EP, 2012, SCI WORLD J, DOI 10.1100/2012/465230
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Rogan MP, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-29
   ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657
   Rubin BK, 2007, PAEDIATR RESPIR REV, V8, P4, DOI 10.1016/j.prrv.2007.02.004
   Scharfman A, 1995, BIOCHEM SOC T, V23, P836, DOI 10.1042/bst0230836
   Sheppard David N., 1999, Physiological Reviews, V79, pS23
   Sigma, 1999, PAR M PROD INF
   Silva I., 2016, LA REV, V16, P86, DOI [10.1016/j.kine.2016.06.001, DOI 10.1016/J.KINE.2016.06.001]
   Stephenson AL, 2017, ANN INTERN MED, V166, P537, DOI 10.7326/M16-0858
   SUGIHARA T, 1971, J APPL PHYSIOL, V30, P874
   Tabatabaei SA, 2018, ARCH PEDIATR INFECT, V6, DOI 10.5812/pedinfect.12063
   Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702
   Wark P, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001506.pub4
   Yates D., 1997, PHYSICOCHEMICAL PROP
   ZACH MS, 1987, INFECTION, V15, P381, DOI 10.1007/BF01647750
NR 48
TC 0
Z9 0
U1 3
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 52
EP 59
DI 10.1016/j.rmed.2019.04.011
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200009
PM 31163350
DA 2020-05-18
ER

PT J
AU Galindo, VC
   Alcoforado, L
   Rattes, C
   Paiva, DN
   Brandao, SCS
   Fink, JB
   de Andrade, AD
AF Galindo-Filho, Valdecir Castor
   Alcoforado, Luciana
   Rattes, Catarina
   Paiva, Dulciane Nunes
   Soares Brandao, Simone Cristina
   Fink, James B.
   de Andrade, Armele Dornelas
TI A mesh nebulizer is more effective than jet nebulizer to nebulize
   bronchodilators during non-invasive ventilation of subjects with COPD: A
   randomized controlled trial with radiolabeled aerosols
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Vibrating mesh nebulizers; Jet nebulizer; Noninvasive ventilation;
   Pulmonary scintigraphy; Radioaerosol; COPD
ID OBSTRUCTIVE PULMONARY-DISEASE; POSITIVE-PRESSURE VENTILATION;
   EXACERBATIONS; DEPOSITION; INHALER; DELIVERY; LUNG
AB Background: Beneficial effects from non-invasive ventilation (NIV) in acute COPD are well-established, but the impact of nebulization during NIV has not been well described.
   Aim: To compare pulmonary deposition and distribution across regions of interest with administration of radiolabeled aerosols generated by vibrating mesh nebulizers (VMN) and jet nebulizer (JN) during NIV.
   Methods: A crossover single dose study involving 9 stable subjects with moderate to severe COPD randomly allocated to receive aerosol administration by the VMN Aerogen and the MistyNeb jet nebulizer operating with oxygen at 8 lpm during NIV. Radiolabeled bronchodilators (fill volume of 3 mL: 0.5 mL salbutamol 2.5 mg + 0.125 mL ipratropium 0.25 mg and physiologic saline up to 3 mL) were delivered until sputtering during NIV (pressures of 12 cmH2O and 5 cmH2O - inspiratory and expiratory, respectively) using an oro-nasal facemask. Radioactivity counts were performed using a gamma camera and regions of interest (ROIs) were delimited. Aerosol mass balance based on counts from the lungs, upper airways, stomach, nebulizer, circuit, inspiratory and expiratory filters, and mask were determined and expressed as a percentage of the total.
   Results: Both inhaled and lung doses were greater with VMN (22.78 +/- 3.38% and 12.05 +/- 2.96%, respectively) than JN (12.51 +/- 6.31% and 3.14 +/- 1.71%; p=0.008). Residual drug volume was lower in VMN than in JN (3.08 +/- 1.3% versus 46.44 +/- 5.83%, p=0.001). Peripheral deposition of radioaerosol was significantly lower with JN than VMN.
   Conclusions: VMN deposited > 3 fold more radioaerosol into the lungs of moderate to severe COPD patients than JN during NIV.
C1 [Galindo-Filho, Valdecir Castor; Alcoforado, Luciana; Rattes, Catarina; Paiva, Dulciane Nunes; de Andrade, Armele Dornelas] Univ Fed Pernambuco, Dept Physicaltherapy, Recife, PE, Brazil.
   [Soares Brandao, Simone Cristina] Hosp Clin Pernambuco, Dept Nucl Med, Recife, PE, Brazil.
   [Fink, James B.] Rush Med Sch, Div Resp Care, Chicago, IL USA.
RP de Andrade, AD (reprint author), Ave Jornalista Anibal Fernandes Sn, BR-50740560 Recife, PE, Brazil.
EM vcastorgalindo@yahoo.com; lucalcoforado@yahoo.com.br;
   catarina_rattes@hotmail.com; dulciane@unisc.br;
   sbrandaonuclearufpe@gmail.com; fink.jim@gmail.com;
   armeledornelas@yahoo.com
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq) [PVE
   400801/13-2, 150454/2018-0]; Fundacao de Amparo a Ciencia e Tecnologia
   do Estado de Pernambuco - FACEPE - APQ FACEPE - APQ [0154-4.08/15]
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (grant number PVE 400801/13-2 and PDJ grant
   number 150454/2018-0) and Fundacao de Amparo a Ciencia e Tecnologia do
   Estado de Pernambuco - FACEPE - APQ FACEPE - APQ (grant number
   0154-4.08/15).
CR Abdelrahim ME, 2011, INT J PHARMACEUT, V420, P313, DOI 10.1016/j.ijpharm.2011.09.005
   Abdelrahim ME, 2010, J PHARM PHARMACOL, V62, P966, DOI 10.1111/j.2042-7158.2010.01134.x
   Alcoforado L, 2013, RESP MED, V107, P1178, DOI 10.1016/j.rmed.2013.03.020
   AlQuaimi M, 2017, J RESP MED LUNG DIS, V2, P1018
   Bardi G, 2000, EUR RESPIR J, V15, P98, DOI 10.1183/09031936.00.15109800
   Branconnier Matthew P, 2005, Respir Care, V50, P1649
   CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
   Chen W, 2005, CHINESE MED J-PEKING, V118, P2034
   Dhand R, 2012, COPD, V9, P58, DOI 10.3109/15412555.2011.630047
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   Dubus JC, 2005, PEDIATR RES, V58, P10, DOI 10.1203/01.PDR.0000156244.84422.55
   Fink B. J., 2003, J ALLERGY CLIN IMMUN, V111, pS143
   Fink B. J., 2001, CHEST, V120, pS227
   Fink J. B., 2013, INHALERS DEVICES PAT, V10, P1
   Franca EET, 2006, RESP MED, V100, P721, DOI 10.1016/j.rmed.2005.07.012
   Galindo VC, 2013, RESP CARE, V58, P241, DOI 10.4187/respcare.01371
   *GOLD, 2013, GLOB STRAT DIAGN MAN
   Haidl P, 2016, RESP MED, V118, P65, DOI 10.1016/j.rmed.2016.07.013
   Hassan A, 2017, EXP LUNG RES, V43, P19, DOI 10.1080/01902148.2017.1282993
   Hess Dean R, 2004, Respir Care, V49, P810
   Hochrainer D, 2005, J AEROSOL MED, V18, P273, DOI 10.1089/jam.2005.18.273
   Keenan SP, 2003, ANN INTERN MED, V138, P861, DOI 10.7326/0003-4819-138-11-200306030-00007
   Leach C, 2009, J ALLERGY CLIN IMMUN, V124, pS88, DOI 10.1016/j.jaci.2009.09.050
   Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185
   Lopez AD, 2006, EUR RESPIR J, V27, P397, DOI 10.1183/09031936.06.00025805
   MACINTYRE NR, 1985, CRIT CARE MED, V13, P81, DOI 10.1097/00003246-198502000-00005
   McPeck M., 2012, ATS INT C MAY 18 23
   Michotte J. B., 2012, ERS ANN C
   Newman SP, 2003, ADV DRUG DELIVER REV, V55, P851, DOI 10.1016/S0169-409X(03)00081-4
   Newman S, 2012, J AEROSOL MED PULM D, V25, pS10, DOI 10.1089/jamp.2012.1Su4
   Nobre MEP, 2007, RESP PHYSIOL NEUROBI, V155, P41, DOI 10.1016/j.resp.2006.04.005
   Penuelas O., 2007, CMAJ CAN MED ASS J, V177
   Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0
   PLEGUEZUELOS E, 2013, EUR RESPIR J S57, V42
   Press VG, 2011, J GEN INTERN MED, V26, P635, DOI 10.1007/s11606-010-1624-2
   Ram FS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004104.PUB3
   Vincken W, 2010, PRIM CARE RESP J, V19, P10, DOI 10.4104/pcrj.2009.00062
NR 37
TC 3
Z9 3
U1 2
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 60
EP 67
DI 10.1016/j.rmed.2019.05.016
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200010
PM 31170543
DA 2020-05-18
ER

PT J
AU Corsico, AG
   Braido, F
   Contoli, M
   Di Marco, F
   Rogliani, P
   Scognamillo, C
   Olivi, I
   Santus, P
   Scichilone, N
   Lazzaro, C
AF Corsico, Angelo G.
   Braido, Fulvio
   Contoli, Marco
   Di Marco, Fabiano
   Rogliani, Paola
   Scognamillo, Carla
   Olivi, Irene
   Santus, Pierachille
   Scichilone, Nicola
   Lazzaro, Carlo
TI Healthcare costs of the SATisfaction and adherence to COPD treatment
   (SAT) study follow-up
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD management; Econometric model; Healthcare costs
ID OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATION; IMPACT; LIFE
AB Background: Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year.
   Methods: We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro ((sic)) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient.
   Results: Most of the centres were public institutions (90%; public university hospital: 30%). The total average cost of COPD was (sic)2647.38/patient and ICS/LABA/LAMA therapy contributed the most ((sic)1541.45). The average cost was (sic)6206.19/patient for severe COPD (+139.67% vs the cost/patient with mild or moderate COPD). The regression model showed that, others things being equal, increases in the predicted average logged cost per patient were due to liquid oxygen therapy (+468.31%), three COPD exacerbations during the follow-up (+254.54%), and ICS/LABA or ICS/LABA/LAMA associated therapy (+59.26%). Moreover, a 1.19% increment was observed for each additional score of the CAT questionnaire. Conversely, a 36.52% reduction in the predicted average logged cost was reported for hospitals managed by local healthcare authorities.
   Conclusions: The health econometric approach is innovative in the management of COPD patients in Italy. The results of the random effects log-linear panel data regression model may help clinicians estimate INHS costs when managing COPD patients.
C1 [Corsico, Angelo G.] Univ Pavia, IRCCS Policlin San Matteo Fdn, Div Resp Dis, Viale Golgi 19, I-27100 Pavia, Italy.
   [Corsico, Angelo G.] Univ Pavia, Dept Internal Med & Therapeut, Viale Golgi 19, I-27100 Pavia, Italy.
   [Braido, Fulvio] Univ Genoa, Dept Internal Med DiMI, Genoa, Italy.
   [Contoli, Marco] Univ Ferrara, Dept Med Sci, Ferrara, Italy.
   [Di Marco, Fabiano] Univ Milan, Dept Biomed & Clin Sci DIBIC, Milan, Italy.
   [Rogliani, Paola] Univ Roma Tor Vergata, Dept Expt Med & Surg, Resp Unit, Rome, Italy.
   [Scognamillo, Carla; Olivi, Irene] Boehringer Ingelheim GmbH & Co KG, Milan, Italy.
   [Santus, Pierachille] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Scichilone, Nicola] Univ Palermo, DIBIMIS, Palermo, Italy.
   [Lazzaro, Carlo] Studio Econ Sanit, Milan, Italy.
RP Corsico, AG (reprint author), Univ Pavia, IRCCS Policlin San Matteo Fdn, Div Resp Dis, Viale Golgi 19, I-27100 Pavia, Italy.; Corsico, AG (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Viale Golgi 19, I-27100 Pavia, Italy.
EM corsico@unipv.it
RI Corsico, Angelo Guido/AAC-8138-2019; Contoli, Marco/K-3947-2018; SANTUS,
   PIERACHILLE/T-4688-2017
OI Corsico, Angelo Guido/0000-0002-8716-4694; Lazzaro,
   Carlo/0000-0003-4795-1834; Contoli, Marco/0000-0002-2731-5809; di marco,
   fabiano/0000-0002-1743-0504; SANTUS, PIERACHILLE/0000-0003-3462-8253;
   Rogliani, Paola/0000-0001-7801-5040; Scichilone,
   Nicola/0000-0001-6400-6573
FU Boehringer Ingelheim S.p.A, Italy
FX This study was supported by Boehringer Ingelheim S.p.A, Italy.
CR Agenzia Italiana del Farmaco, 2015, GAZZETTA UFFICIALE, P73
   Andress H.-J., 2013, APPL PANEL DATA ANAL
   [Anonymous], 2015, OSMED US FARM IT
   Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Bettoncelli G, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-25
   Blasi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101228
   Brusco NK, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1039-1
   Contoli M, 2017, COPD, V14, P641, DOI 10.1080/15412555.2017.1385056
   Cope S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-100
   Corrado A, 2012, RESP MED, V106, P989, DOI 10.1016/j.rmed.2012.03.008
   Dal Negro RW, 2008, RESP MED, V102, P92, DOI 10.1016/j.rmed.2007.08.001
   Dal Negro RW, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7010035
   Dal Negro RW, 2015, CLINICOECONOMIC OUTC, V7, P153, DOI 10.2147/CEOR.S77504
   Detournay B, 2004, VALUE HEALTH, V7, P168, DOI 10.1111/j.1524-4733.2004.72329.x
   Di Napoli A, 2017, EPIDEMIOL PREV, V41, P41, DOI 10.19191/EP17.3-4S1.P041.064
   Drummond MF, 2015, METHODS EC EVALUATIO
   GOLD Global Initiative for Chronic Obstructive Lung Disease, 2018, GLOB STRAT DIAGN MAN
   Italian Ministry of Health, 2013, GAZZETTA UFFICIALE, V23
   Italian Ministry of Health Progetto Mattoni SSN, 2007, PROG MATT SSN PRONT
   Jansson SA, 2013, RESP MED, V107, P1931, DOI 10.1016/j.rmed.2013.07.012
   Jinjuvadia C, 2017, COPD, V14, P72, DOI 10.1080/15412555.2016.1199669
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Kim S, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-35
   Klein J. P., 2003, SURVIVAL ANAL TECHNI
   Laurendeau C, 2015, REV MAL RESPIR, V32, P682, DOI 10.1016/j.rmr.2014.10.731
   Lohr S., 2010, SAMPLING DESIGN ANAL
   Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC
   Stock J. H., 2007, INTRO ECONOMETRICS
   Terzano C, 2017, EUR REV MED PHARMACO, V21, P3680
   Wedzicha JA, 2016, NEW ENGL J MED, V374, P2222, DOI 10.1056/NEJMoa1516385
   Wedzicha JA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-181
   Wedzicha JA, 2012, EUR RESPIR J, V40, P1545, DOI 10.1183/09031936.00048912
   Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1
   Young TA, 2005, PHARMACOECONOMICS, V23, P1229, DOI 10.2165/00019053-200523120-00007
NR 34
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 68
EP 75
DI 10.1016/j.rmed.2019.05.017
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200011
PM 31174106
DA 2020-05-18
ER

PT J
AU Herman, DD
   Thomson, CC
   Brosnhan, S
   Patel, R
   Trosini-Desert, V
   Bilaceroglu, S
   Poston, JT
   Liberman, M
   Shah, PL
   Ost, DE
   Chatterjee, R
   Michaud, GC
AF Herman, D. D.
   Thomson, C. C.
   Brosnhan, S.
   Patel, R.
   Trosini-Desert, V.
   Bilaceroglu, S.
   Poston, J. T.
   Liberman, M.
   Shah, P. L.
   Ost, D. E.
   Chatterjee, R.
   Michaud, G. C.
TI Risk of bleeding in patients undergoing pulmonary procedures on
   antiplatelet or anticoagulants: A systematic review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Anticoagulant; Antiplatelet; Bronchoscopy; Pleural disease; Percutaneous
   tracheostomy; Thoracentesis
ID CHEST TUBE INSERTION; PERCUTANEOUS DILATATIONAL TRACHEOSTOMY; ROUTINE
   CLOPIDOGREL USE; ENDOBRONCHIAL ULTRASOUND; RESPIRATORY ENDOSCOPY;
   FLEXIBLE BRONCHOSCOPY; JAPAN SOCIETY; COMPLICATIONS; SAFETY; THERAPY
AB As many as 25% of all patients undergoing invasive pulmonary procedures are receiving at least one antiplatelet or anticoagulant agent. For those undergoing elective procedures, the decision-making process is uncomplicated and the procedure may be postponed until the antiplatelet or anticoagulant agent may be safely held. However, many invasive pulmonary procedures are semi-elective or emergent in nature in which case a risk-benefit calculation and discussion occur between the provider and patient or surrogate decision-maker. Therefore, it is critical for providers to have an awareness of the risk of bleeding complications with different pulmonary procedures on various antiplatelet and anticoagulant agents. This systematic review summarizes the bleeding complications associated with different pulmonary procedures in patients on various antiplatelet or anticoagulant agents in the literature and reveals a paucity of high-quality evidence across a wide spectrum of pulmonary procedures and antiplatelet or anticoagulant agents. The results of this review can help inform providers of the bleeding risk in these patients to aid in the shared decision-making process and risk vs benefit discussion.
C1 [Herman, D. D.] Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, 201L Dorothy M Davis Heart & Lung Res Inst, 473W 12th Ave, Columbus, OH 43210 USA.
   [Thomson, C. C.] Mt Auburn Hosp, Dept Med, Div Pulm & Crit Care Med, 300 Mt Auburn St 419, Cambridge, MA 02138 USA.
   [Brosnhan, S.] NYU Lagone Hlth, Dept Internal Med, Div Pulm & Crit Care Med, 550 1st Ave, New York, NY 10016 USA.
   [Patel, R.] Univ Ottawa, Dept Crit Care Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
   [Patel, R.] Univ Ottawa, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
   [Trosini-Desert, V.] Grp Hosp Pitie Salpetriere, Serv Pneumol & Reanimat, Unite Endoscopie Bronch, 7 Ave Republ, F-94200 Ivry, France.
   [Bilaceroglu, S.] Hlth Sci Univ, Dept Pulm Med, Izmir Dr Suat Seren Training & Res Hosp Thorac Me, TR-35110 Izmir, Turkey.
   [Poston, J. T.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Liberman, M.] Univ Montreal, Div Thorac Surg, CHUM Endoscosp Tracheobronchial & Oesophageal Ctr, Dept Surg,Bur D, 1560 Rue Sherbrooke Est 8e CD Pavillon Lachapelle, Montreal, PQ H2L 4M1, Canada.
   [Shah, P. L.] Royal Brompton Hosp, Dept Resp Med, London, England.
   [Shah, P. L.] Imperial Coll London, Natl Heart & Lung Inst, South Kensington Campus, London SW7 2AZ, England.
   [Ost, D. E.] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, 1515 Holcombe Blvd 853, Houston, TX 77030 USA.
   [Chatterjee, R.] Brooke Army Med Ctr, 3551 Roger Brooke Dr, Jbsa Ft Sam Houston, TX 78234 USA.
   [Michaud, G. C.] NYU Lagone Hlth, Dept Internal Med, Div Pulm & Crit Care Med, HCC, 530 1st Ave,Suite 5D, New York, NY 10016 USA.
RP Herman, DD (reprint author), Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, 201L Dorothy M Davis Heart & Lung Res Inst, 473W 12th Ave, Columbus, OH 43210 USA.
EM derrick.herman@osumc.edu
RI Shah, Pallav L/AAB-2758-2019; Thomson, Carey/AAF-3905-2019
OI Shah, Pallav L/0000-0002-9052-4638; Michaud,
   Gaetane/0000-0002-2623-1021; Brosnahan, Shari/0000-0002-2092-3633
CR Abouzgheib W, 2013, J BRONCHOL INTERN PU, V20, P322, DOI 10.1097/LBR.0000000000000023
   Abouzgheib W, 2012, RESPIROLOGY, V17, P1222, DOI 10.1111/j.1440-1843.2012.02230.x
   Agli LL, 2002, CHEST, V122, P1106, DOI 10.1378/chest.122.3.1106
   Al Dawood Abdulaziz, 2007, Middle East Journal of Anesthesiology, V19, P37
   Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x
   Ault MJ, 2015, THORAX, V70, P127, DOI 10.1136/thoraxjnl-2014-206114
   Barnett AM, 2016, J BRONCHOL INTERN PU, V23, P22, DOI 10.1097/LBR.0000000000000251
   Baron T. H., 2013, N ENGL J MED, V368
   Baron TH, 2013, NEW ENGL J MED, V368, P2113, DOI 10.1056/NEJMra1206531
   Barton CA, 2012, J TRAUMA ACUTE CARE, V72, P815, DOI 10.1097/TA.0b013e31824fbadf
   Beiderlinden M, 2007, ANAESTHESIA, V62, P342, DOI 10.1111/j.1365-2044.2007.04979.x
   Braune S, 2013, INTENS CARE MED, V39, P1792, DOI 10.1007/s00134-013-3023-8
   Cabrini L, 2008, MINERVA ANESTESIOL, V74, P565
   CANNEGIETER SC, 1994, CIRCULATION, V89, P635, DOI 10.1161/01.CIR.89.2.635
   Carr IM, 2012, RESPIRATION, V84, P312, DOI 10.1159/000339507
   Chen Alexander, 2014, Ann Am Thorac Soc, V11, P578, DOI 10.1513/AnnalsATS.201311-384OC
   Dammert P, 2013, J BRONCHOL INTERN PU, V20, P16, DOI 10.1097/LBR.0b013e31828194f9
   Dangers L., 2016, ANN INTENSIVE CARE, V6
   Delaney A, 2006, CRIT CARE, V10, DOI 10.1186/cc4887
   Deppe AC, 2013, THORAC CARDIOV SURG, V61, P234, DOI 10.1055/s-0032-1322608
   Douketis JD, 2012, CHEST, V141, pE326S, DOI 10.1378/chest.11-2298
   Drummond M., 2003, J BRONCHOL, P177
   Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618
   Eapen GA, 2013, CHEST, V143, P1044, DOI 10.1378/chest.12-0350
   Ernst A, 2006, CHEST, V129, P734, DOI 10.1378/chest.129.3.734
   Facciolongo N, 2009, Monaldi Arch Chest Dis, V71, P8
   Gross A, 2011, RESPIRATION, V82, P56, DOI 10.1159/000323870
   Harris K, 2016, THER ADV RESPIR DIS, V10, P318, DOI 10.1177/1753465816646049
   Harris K, 2015, HEART LUNG CIRC, V24, pE68, DOI 10.1016/j.hlc.2015.01.009
   Hautmann H, 2016, PNEUMOLOGIE, V70, P110, DOI 10.1055/s-0041-110288
   Herth FJF, 2002, CHEST, V122, P1461, DOI 10.1378/chest.122.4.1461
   Irugulapati L., 2012, CHEST, V142
   Jaffe TA, 2015, AM J ROENTGENOL, V205, P421, DOI 10.2214/AJR.14.13342
   Karnyski J, 2015, ANN AM THORAC SOC, V12, P1733, DOI 10.1513/AnnalsATS.201507-402LE
   Kondapaneni M, 2014, AM J RESP CRIT CARE, V189
   Kruit N, 2018, J CARDIOTHOR VASC AN, V32, P1162, DOI 10.1053/j.jvca.2017.08.010
   Levine GN, 2016, J THORAC CARDIOV SUR, V152, P1243, DOI 10.1016/j.jtcvs.2016.07.044
   Mahmood Kamran, 2014, Ann Am Thorac Soc, V11, P73, DOI 10.1513/AnnalsATS.201303-050OC
   Mariani R, 2015, MINERVA ANESTESIOL, V81, P816
   Martin R. T., 2014, AM J RESP CRIT CARE, V189
   Meena N, 2016, J BRONCHOL INTERN PU, V23, P303, DOI 10.1097/LBR.0000000000000312
   Mellinger CS, 2011, AM J RESP CRIT CARE, V183
   Metintas M, 2013, J BRONCHOL INTERN PU, V20, P224, DOI 10.1097/LBR.0b013e31829ebdbb
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Niwa H, 2009, RESPIROLOGY, V14, P282, DOI 10.1111/j.1440-1843.2008.01463.x
   Ohara G, 2013, CENT EUR J MED, V8, P406, DOI 10.2478/s11536-013-0166-5
   Ost DE, 2015, CHEST, V148, P450, DOI 10.1378/chest.14-1530
   Parks C., 2010, AM J RESP CRIT CARE, V181
   Pasin L, 2015, ANN CARD ANAESTH, V18, P329, DOI 10.4103/0971-9784.159802
   Patel IJ, 2012, J VASC INTERV RADIOL, V23, P727, DOI 10.1016/j.jvir.2012.02.012
   Perl S, 2018, AM J RESP CRIT CARE, V197
   Puchalski Jonathan T, 2013, Ann Am Thorac Soc, V10, P336, DOI 10.1513/AnnalsATS.201210-088OC
   Rajagopal A., 2017, AM J RESP CRIT CARE, V195
   Raval AN, 2017, CIRCULATION, V135, pE604, DOI 10.1161/CIR.0000000000000477
   Schaefer A, 2016, ASAIO J, V62, P715, DOI 10.1097/MAT.0000000000000426
   Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x
   Stather DR, 2012, RESPIRATION, V83, P330, DOI 10.1159/000335254
   Swiatek K., 2017, INT J RESP PULMONARY
   Torky M, 2017, J BRONCHOL INTERN PU, V24, pE39, DOI 10.1097/LBR.0000000000000393
   Voigt I NC, 2012, CRIT CARE SHOCK, V15, P2
   Wahidi MM, 2005, RESPIRATION, V72, P285, DOI 10.1159/000085370
   Wolfe K. S., 2016, CHEST, V150
   Zalt MB, 2012, J BRONCHOL INTERN PU, V19, P284, DOI 10.1097/LBR.0b013e3182720428
NR 63
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 76
EP 84
DI 10.1016/j.rmed.2019.05.018
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200012
PM 31176274
DA 2020-05-18
ER

PT J
AU Goobie, GC
   Ford-Sahibzada, CA
   Fritzler, MJ
   Johannson, KA
   Fell, CD
AF Goobie, Gillian C.
   Ford-Sahibzada, Chelsea A.
   Fritzler, Marvin J.
   Johannson, Kerri A.
   Fell, Charlene D.
TI Autoantibody status is not associated with change in lung function or
   survival in patients with idiopathic pulmonary fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Antibodies; Antinuclear antibody; Idiopathic pulmonary fibrosis;
   Interstitial lung diseases; Pulmonary function tests
ID ANTINUCLEAR ANTIBODIES; CLINICAL-SIGNIFICANCE; SYSTEMIC-SCLEROSIS;
   PREVALENCE; DISEASE; DIAGNOSIS
AB Introduction: A proportion of patients with idiopathic pulmonary fibrosis (IPF) have autoantibodies directed against intracellular targets. This study aimed to determine the relationship between serologic status, lung function decline and survival.
   Methods: IPF patients assessed for antinuclear antibody (ANA) and related antigen-specific serology detected by addressable laser bead immunoassay (ALBIA) were included. Demographics, serial pulmonary function tests and survival were compared between patients with and without autoantibodies. Linear mixed models were used to estimate changes in forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) over time. Cox-proportional hazards models were used to compare survival, adjusted for a composite score including age, sex and baseline lung function.
   Results: Of 61 included patients, the mean baseline age was 70 years (SD = 9), 77% were male, and 87% were Caucasian. Either ANA or antigen-specific serology by ALBIA was positive in 25 (41%) during follow-up. ANA was detected in 23 (38%), and specific autoantibodies by ALBIA in 6 (10%). There was no difference in age, sex, race, smoking status, anti-fibrotic use or baseline FVC or DLCO in patients with and without autoantibodies. There was no association between autoantibody status and survival (HR = 1.18, 95% CI 0.61, 2.29), rate of decline in FVC or DLCO (difference in FVC = 4.2 mL/year, p = 0.82; difference in DLCO = 4.6* 10(-4) mL/min/mmHg/year, p= 0.20).
   Conclusion: These data suggest that autoantibodies are common in IPF and that patients with a subset of autoantibodies, but without features of autoimmunity, demonstrate similar disease behaviour to those without autoantibodies.
C1 [Goobie, Gillian C.] Univ British Columbia, Dept Med, Div Respirol, Vancouver, BC, Canada.
   [Ford-Sahibzada, Chelsea A.] Univ Calgary, Cumming Sch Med, Bachelor Hlth Sci Program, Calgary, AB, Canada.
   [Fritzler, Marvin J.] Univ Calgary, Cumming Sch Med, Div Rheumatol, Calgary, AB, Canada.
   [Johannson, Kerri A.; Fell, Charlene D.] Univ Calgary, Cumming Sch Med, Div Respirol, Calgary, AB, Canada.
RP Fell, CD (reprint author), 4448 Front St SE, Calgary, AB T3M 1M4, Canada.
EM gcgoobie@alumni.ubc.ca; cfell@ucalgary.ca
OI Goobie, Gillian/0000-0001-7982-5635
CR Alsumrain M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0644-4
   Bouros D, 2002, AM J RESP CRIT CARE, V165, P1581, DOI 10.1164/rccm.2106012
   Collard HR, 2010, AM J RESP CRIT CARE, V181, P771, DOI 10.1164/rccm.201001-0049ED
   Collard HR, 2003, AM J RESP CRIT CARE, V168, P538, DOI 10.1164/rccm.200211-1311OC
   COTTON CV, 2018, RHEUMATOLOGY S3, V57
   Fischer A, 2010, CHEST, V138, P251, DOI 10.1378/chest.10-0194
   Flaherty KR, 2006, AM J RESP CRIT CARE, V174, P803, DOI 10.1164/rccm.200604-488OC
   Ford-Sahibzada CA, 2017, AM J RESP CRIT CARE, V195
   Gunnarsson R, 2016, RHEUMATOLOGY, V55, P103, DOI 10.1093/rheumatology/kev300
   Guo Ya-Ping, 2014, Curr Ther Res Clin Exp, V76, P116, DOI 10.1016/j.curtheres.2014.06.004
   Hudson M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3763
   Kang BH, 2013, J KOREAN MED SCI, V28, P731, DOI 10.3346/jkms.2013.28.5.731
   Kim EJ, 2010, EUR RESPIR J, V35, P1322, DOI 10.1183/09031936.00092309
   Kim ES, 2015, CHEST, V147, P430, DOI 10.1378/chest.14-0453
   Lee JS, 2013, RESP MED, V107, P249, DOI 10.1016/j.rmed.2012.10.018
   Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Li QZ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3271
   MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Moua T, 2014, MAYO CLIN PROC, V89, P319, DOI 10.1016/j.mayocp.2013.11.018
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   RUFFATTI A, 1990, GERONTOLOGY, V36, P104, DOI 10.1159/000213183
   Satoh M, 2012, ARTHRITIS RHEUM-US, V64, P2319, DOI 10.1002/art.34380
   Song JW, 2009, CHEST, V136, P23, DOI 10.1378/chest.08-2572
   Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909
   Tzouvelekis A, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-31
   Vij R, 2011, CHEST, V140, P1292, DOI 10.1378/chest.10-2662
   Wodkowski M, 2015, CLIN EXP RHEUMATOL, V33, pS131
NR 31
TC 0
Z9 0
U1 0
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2019
VL 153
BP 85
EP 90
DI 10.1016/j.rmed.2019.05.019
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA IC8VN
UT WOS:000471260200013
PM 31176275
DA 2020-05-18
ER

PT J
AU Rubio-Rivas, M
   Corbella, X
   Mana, J
AF Rubio-Rivas, Manuel
   Corbella, Xavier
   Mana, Juan
TI Elderly sarcoidosis: A comparative study from a 42-year single-centre
   experience
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Elderly; Prognosis
ID LATE-ONSET SARCOIDOSIS; CLINICAL CHARACTERISTICS; PULMONARY SARCOIDOSIS;
   OLDER; DIAGNOSIS; PROGNOSIS; DEMENTIA
AB Objectives: To describe the clinical features and outcomes in elderly patients with sarcoidosis and to compare them with younger patients.
   Material and methods: Retrospective study of a large cohort of 668 consecutive patients with sarcoidosis prospectively collected during 42 years at the Bellvitge University Hospital, a tertiary care single-centre in Barcelona, Spain. Elderly sarcoidosis was defined as sarcoidosis diagnosed in patients >= 65 years-old.
   Results: Elderly sarcoidosis was diagnosed in 47 (7%) patients. In younger patients, Lofgren's syndrome was the predominant mode of onset (8.5% vs. 42.2%, p < 0.001). At diagnosis, elderly patients more frequently demonstrated radiographic stage III and IV sarcoidosis (21.3% vs. 7.6%, p= 0.001), isolated extrapulmonary involvement (21.3% vs. 8.2%, p= 0.003), subcutaneous nodules (17% vs. 3.4%, p < 0.001) and intraabdominal/ retroperitoneal lymph nodes (23.4% vs. 9.5%, p= 0.003). Furthermore, patients with elderly sarcoidosis achieved remission (spontaneous and under treatment) less frequently during the follow-up period (14 patients, 35% vs. 305 patients, 53%, p= 0.027) and had a higher incidence of pulmonary fibrosis (15% vs. 6.1%, p= 0.029). Death related to sarcoidosis was more prevalent in elderly patients (6.4% vs. 1.3%, p= 0.036).
   Conclusions: Sarcoidosis in elderly patients requires a high index of suspicion. Aged pulmonary sarcoidosis patients presented with more severe disease at presentation and worse outcomes compared to younger patients. Isolated extrapulmonary involvement at diagnosis and certain particular extrapulmonary organ involvement were more frequent in elderly sarcoidosis. Remission was less frequent in elderly sarcoidosis.
C1 [Rubio-Rivas, Manuel; Corbella, Xavier; Mana, Juan] Bellvitge Univ Hosp IDIBELL, Dept Internal Med, Autoimmune Dis Unit, Barcelona, Spain.
   [Corbella, Xavier] Univ Int Catalunya, Fac Med & Hlth Sci, Barcelona, Spain.
RP Rubio-Rivas, M (reprint author), Bellvitge Univ Hosp IDIBELL, Dept Internal Med, Autoimmune Dis Unit, Barcelona, Spain.
EM mrubio@bellvitgehospital.cat
CR Baughman RP, 2014, SARCOIDOSIS VASC DIF, V31, P275
   Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046
   BROWN IG, 1981, BRIT MED J, V283, P190, DOI 10.1136/bmj.283.6285.190
   Byg KE, 2003, SARCOIDOSIS VASC DIF, V20, P46
   Chevalet P, 2004, CHEST, V126, P1423, DOI 10.1378/chest.126.5.1423
   CONANT EF, 1988, RADIOLOGY, V169, P315, DOI 10.1148/radiology.169.2.3174979
   CORDINGLEY G, 1981, NEUROLOGY, V31, P1148, DOI 10.1212/WNL.31.9.1148
   Gur C, 2007, J CLIN GASTROENTEROL, V41, P329, DOI 10.1097/01.mcg.0000212653.51397.f6
   Hsieh CW, 2006, J FORMOS MED ASSOC, V105, P269, DOI 10.1016/S0929-6646(09)60117-0
   Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149
   JAMES DG, 1976, ANN NY ACAD SCI, V278, P321, DOI 10.1111/j.1749-6632.1976.tb47043.x
   Jamilloux Y, 2013, DRUG AGING, V30, P969, DOI 10.1007/s40266-013-0125-5
   Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
   Judson MA, 2012, SARCOIDOSIS VASC DIF, V29, P119
   Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75
   Kiesmann M, 2015, J AM GERIATR SOC, V63, P198, DOI 10.1111/jgs.13214
   Kobak Senol, 2018, Reumatol Clin, DOI 10.1016/j.reuma.2018.06.004
   Lenner R, 2002, SARCOIDOSIS VASC DIF, V19, P143
   MANA J, 1994, RESPIRATION, V61, P219
   Mana J, 1999, AM J MED, V107, P240, DOI 10.1016/S0002-9343(99)00223-5
   Mana J, 2003, SARCOIDOSIS VASC DIF, V20, P212
   Mana J, 1992, Sarcoidosis, V9, P118
   Mana J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007595
   Mana J, 2013, SARCOIDOSIS VASC DIF, V30, P268
   MARGOLIS ML, 1983, GERIATRICS, V38, P121
   MERTEN DF, 1980, AM J ROENTGENOL, V135, P673, DOI 10.2214/ajr.135.4.673
   Morimoto T, 2008, EUR RESPIR J, V31, P372, DOI 10.1183/09031936.00075307
   Ramanantsoa A, 2015, J AM GERIATR SOC, V63, P1039, DOI 10.1111/jgs.13400
   Sanson M, 1996, J NEUROL, V243, P484, DOI 10.1007/BF00900506
   SCADDING JG, 1961, BRIT MED J, V2, P1165, DOI 10.1136/bmj.2.5261.1165
   Schielke E, 2001, J NEUROL, V248, P522, DOI 10.1007/s004150170164
   Semenzato G, 2005, SARCOIDOSIS VASC DIF, V22, P83
   SHARMA OP, 1973, GERIATRICS, V28, P76
   Stadnyk A N, 1988, Sarcoidosis, V5, P121
   Tachibana T, 2010, CURR OPIN PULM MED, V16, P465, DOI 10.1097/MCP.0b013e32833ae508
   Torchio M, 2014, ONCOL LETT, V8, P1299, DOI 10.3892/ol.2014.2241
   Valeyre D, 2015, CLIN CHEST MED, V36, P631, DOI 10.1016/j.ccm.2015.08.006
   Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7
   Varron L, 2012, MEDICINE, V91, P137, DOI 10.1097/MD.0b013e3182569f91
   Yanardag H, 2004, SOUTH MED J, V97, P472, DOI 10.1097/00007611-200405000-00011
NR 40
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 1
EP 6
DI 10.1016/j.rmed.2019.03.013
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900001
PM 31128602
DA 2020-05-18
ER

PT J
AU Sikjaer, MG
   Hilberg, O
   Insen, R
   Bock, K
   Lokke, A
AF Sikjaer, Melina Gade
   Hilberg, Ole
   Insen, Rikke
   Bock, Kathrine
   Lokke, Anders
TI Direct and indirect economic and health consequences related to
   sarcoidosis in Denmark: A national register-based study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Economic burden; Health costs; Socioeconomic consequences;
   Health economics
ID BURDEN; RISK
AB Background: Sarcoidosis is a systemic disease that primarily affects the younger population. Longitudinal studies of the economic burden of sarcoidosis are scarce. This study evaluates overall the economic burden of sarcoidosis in Denmark before and after initial diagnosis.
   Methods: We identified patients with sarcoidosis in the Danish National Patient Registry (1998-2010). All controls were randomly selected and matched concerning age, gender and residence. Data on direct and indirect costs, including frequency of primary and secondary sector contacts and procedures, medication, unemployment benefits and social transfer payments were extracted from national databases for patients and controls.
   Results: We identified 9119 patients with sarcoidosis and 36,432 matching controls. Patients with sarcoidosis had significantly higher rates of health-related contacts, higher usage of medication and more received unemployment and social payments compared with controls.
   The total health expenses were significantly higher in the sarcoidosis group 11 years before and 11 years after diagnosis than among controls.
   Income from public transfer payments was significantly higher in the sarcoidosis group five years prior of diagnosis until nine years post diagnosis. Especially women between 40 and 59 years have a lower income than their controls.
   Conclusion: Sarcoidosis has a socioeconomic impact on adults especially during their prime working and providing years and this is evident several years prior to and post diagnosis. The authors advocate that further research should focus on identifying the proportion of patients with sarcoidosis that imposes the largest economic burden. Increased focus on early diagnosis and disease management may reduce the socioeconomic burden of sarcoidosis.
C1 [Sikjaer, Melina Gade] Aarhus Univ Hosp, Dept Resp Med & Allergol, Norrebrogade 44, DK-8000 Aarhus C, Denmark.
   [Hilberg, Ole; Bock, Kathrine; Lokke, Anders] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Norrebrogade 44, DK-8000 Aarhus C, Denmark.
   [Insen, Rikke] I2minds, Mollegade 32, DK-8000 Aarhus C, Denmark.
   [Sikjaer, Melina Gade] Silkeborg Reg Hosp, Diagnost Ctr, Falkevej 1, DK-8600 Silkeborg, Denmark.
   [Hilberg, Ole; Bock, Kathrine; Lokke, Anders] Lillebaelt Hosp, Dept Med, Beriderbakken 4, DK-7100 Vejle, Denmark.
RP Sikjaer, MG (reprint author), Aarhus Univ Hosp, Dept Resp Med & Allergol, Norrebrogade 44, DK-8000 Aarhus C, Denmark.; Sikjaer, MG (reprint author), Silkeborg Reg Hosp, Diagnost Ctr, Falkevej 1, DK-8600 Silkeborg, Denmark.
EM Melgad@rm.dk; ole.hilberg@rsyd.dk; Rikke@i2minds.dk; annebock@rm.dk;
   andeotte@rm.dk
CR Agresti A, 2002, CATEGORICAL DATA ANA
   Arkema EV, 2016, EUR RESPIR J, V48, P1690, DOI 10.1183/13993003.00477-2016
   Baughman RP, 2016, ANN AM THORAC SOC, V13, P1244, DOI 10.1513/AnnalsATS.201511-760OC
   Brito-Zeron P, 2018, LUNG, V196, P239, DOI 10.1007/s00408-017-0076-4
   Byg KE, 2003, SARCOIDOSIS VASC DIF, V20, P46
   Chen ES, 2015, CLIN REV ALLERG IMMU, V49, P6, DOI 10.1007/s12016-015-8481-z
   Chopra A, 2018, CHEST, V154, P664, DOI 10.1016/j.chest.2018.03.056
   Drent M, 2015, CLIN CHEST MED, V36, P727, DOI 10.1016/j.ccm.2015.08.013
   Efron B., 1993, INTRO BOOTSTRAP
   Gerke AK, 2017, ANN AM THORAC SOC, V14, pS421, DOI 10.1513/AnnalsATS.201707-564OT
   Gerke AK, 2014, CURR OPIN PULM MED, V20, P472, DOI 10.1097/MCP.0000000000000080
   Gerke AK, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-19
   HILLERDAL G, 1984, AM REV RESPIR DIS, V130, P29
   Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
   Kawalec PP, 2015, EXPERT REV PHARM OUT, V15, P667, DOI 10.1586/14737167.2015.1065733
   Kreider ME, 2005, CHEST, V128, P207, DOI 10.1378/chest.128.1.207
   Le Burel S, 2017, EUR J CANCER, V82, P34, DOI 10.1016/j.ejca.2017.05.032
   Lee EY, 2009, AUTOIMMUN REV, V8, P379, DOI 10.1016/j.autrev.2008.12.002
   Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482
   Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965
   Pohle S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151940
   Rice JB, 2017, J MANAG CARE SPEC PH, V23, P1261, DOI 10.18553/jmcp.2017.17203
   Rice JB, 2017, J MED ECON, V20, P1048, DOI 10.1080/13696998.2017.1351371
   ROMER F K, 1990, Ugeskrift for Laeger, V152, P76
   Rossides M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01815-2017
   Sogaard KK, 2015, EUR RESPIR J, V45, P269, DOI 10.1183/09031936.00084414
   Spagnolo P, 2018, LANCET RESP MED, V6, P389, DOI 10.1016/S2213-2600(18)30064-X
   Ungprasert P., 2017, SMOKING OBESITY RISK, P87, DOI [10.1016/j.rmed.2016.10.003, DOI 10.1016/J.RMED.2016.10.003]
   Ungprasert P, 2017, ANN AM THORAC SOC, V14, P676, DOI [10.1513/AnnalsATS.201610-750OC, 10.1513/annalsats.201610-750oc]
   Ungprasert P, 2016, MAYO CLIN PROC, V91, P183, DOI 10.1016/j.mayocp.2015.10.024
   Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7
NR 31
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 7
EP 13
DI 10.1016/j.rmed.2019.04.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900002
PM 31128613
DA 2020-05-18
ER

PT J
AU Judson, MA
   Preston, S
   Hu, K
   Zhang, R
   Jou, S
   Modi, A
   Sukhu, I
   Ilyas, F
   Rosoklija, G
   Yucel, R
AF Judson, Marc A.
   Preston, Sara
   Hu, Kurt
   Zhang, Robert
   Jou, Stephanie
   Modi, Aakash
   Sukhu, Indrawattie
   Ilyas, Furqan
   Rosoklija, Gavril
   Yucel, Recai
TI Quantifying the relationship between symptoms at presentation and the
   prognosis of sarcoidosis
SO RESPIRATORY MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; PULMONARY SARCOIDOSIS; CORTICOSTEROIDS; DIAGNOSIS;
   THERAPY; DEATH
AB Background: Although it is the general consensus that sarcoidosis patients who present with sarcoidosis-related symptoms have a worse outcome than patients whose disease is detected incidentally without symptoms, this premise has not been rigorously examined.
   Methods: Consecutive patients followed longitudinally at one US university sarcoidosis clinic were questioned concerning the onset and description of sarcoidosis-related symptoms at disease presentation. The patients were classified into those with no sarcoidosis-related symptoms at presentation (NSP group) and those with symptoms at presentation (SP group). The following outcomes were examined in the NSP and SP groups: most recent spirometry, organ involvement, need for sarcoidosis therapy, most recent health related quality of life (HRQOL) as measured by the Sarcoidosis Assessment Tool (SAT), most recent chest imaging Scadding stage results.
   Results: 660 sarcoidosis patients were analyzed, with 175 in the NSP group and 485 in the SP group. Compared to the NSP group, the SP group had a more frequent requirement for any sarcoidosis treatment, corticosteroid treatment, and non-corticosteroid treatment at some time and within the most recent year of follow up (at least 50% more than the NP group with strong statistical differences with p values all 0.01 or less). In addition, the SP group had significantly more organ involvement (p < 0.001) and several worse SAT domains (p < 0.022) than the NP group. There were no differences between the groups in terms of final spirometry or development of Scadding stage 4 chest radiographs. These findings held even after adjusting for age, sex, race, and time between presentation and the most recent follow-up visit using a multivariable logistic regression framework.
   Conclusions: In our sarcoidosis cohort, compared to the absence of symptoms at presentation, the presence of symptoms was associated with a greater need for treatment, more organ involvement, and worse HRQOL.
C1 [Judson, Marc A.; Preston, Sara; Hu, Kurt; Modi, Aakash; Sukhu, Indrawattie; Ilyas, Furqan] Albany Med Coll, Div Pulm & Crit Care Med, MC-91, Albany, NY 12208 USA.
   [Zhang, Robert; Jou, Stephanie; Rosoklija, Gavril] Albany Med Ctr, Dept Med, Albany, NY USA.
   [Yucel, Recai] SUNY Albany, Dept Epidemiol & Biostat, Sch Publ Hlth, Albany, NY 12222 USA.
   [Preston, Sara] St Georges Univ, Sch Med, True Blue, Grenada.
RP Judson, MA (reprint author), Albany Med Coll, Div Pulm & Crit Care Med, MC-91, Albany, NY 12208 USA.
EM judsonm@mail.amc.edu
OI Judson, Marc/0000-0002-4663-7985
CR Baughman RP, 2011, SARCOIDOSIS VASC DIF, V28, P56
   Baughman RP, 2017, SARCOIDOSIS VASC DIF, V34, P280
   Baughman RP, 2016, RESP MED, V110, P66, DOI 10.1016/j.rmed.2015.11.007
   Baughman RP, 2013, EUR RESPIR J, V41, P1424, DOI 10.1183/09031936.00060612
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   Hu XW, 2016, SARCOIDOSIS VASC DIF, V33, P275
   Hunninghake G W, 1999, Sarcoidosis Vasc Diffuse Lung Dis, V16, P149
   Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
   Judson MA, 2012, SARCOIDOSIS VASC DIF, V29, P119
   Judson MA, 1999, CHEST, V115, P1158, DOI 10.1378/chest.115.4.1158
   Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75
   Judson MA, 2008, CLIN CHEST MED, V29, P415, DOI 10.1016/j.ccm.2008.03.009
   Judson MA, 2017, SEMIN RESP CRIT CARE, V38, P546, DOI 10.1055/s-0037-1602589
   Judson MA, 2015, CLIN CHEST MED, V36, P739, DOI 10.1016/j.ccm.2015.08.014
   Judson MA, 2015, CLIN REV ALLERG IMMU, V49, P63, DOI 10.1007/s12016-014-8450-y
   Judson MA, 2015, AM J RESP CRIT CARE, V191, P786, DOI 10.1164/rccm.201410-1785OC
   Judson Marc A, 2014, F1000Prime Rep, V6, P89, DOI 10.12703/P6-89
   Judson MA, 2014, RESP MED, V108, P189, DOI 10.1016/j.rmed.2013.11.019
   Khan NA, 2017, RESP MED, V132, P9, DOI 10.1016/j.rmed.2017.09.003
   MANA J, 1994, RESPIRATION, V61, P219
   Padala SK, 2017, INT J CARDIOL, V227, P565, DOI 10.1016/j.ijcard.2016.10.101
   PERRY A, 1995, ARCH PATHOL LAB MED, V119, P167
   Pietinalho A, 2000, SARCOIDOSIS VASC DIF, V17, P158
   ROMER FK, 1982, DAN MED BULL, V29, P27
   SCADDING JG, 1961, BRIT MED J, V2, P1165, DOI 10.1136/bmj.2.5261.1165
   Smedema JP, 2005, CHEST, V128, P30, DOI 10.1378/chest.128.1.30
   Swigris JJ, 2011, AM J RESP CRIT CARE, V183, P1524, DOI 10.1164/rccm.201010-1679OC
   Tavora F, 2009, AM J CARDIOL, V104, P571, DOI 10.1016/j.amjcard.2009.03.068
   VESTBO J, 1994, SARCOIDOSIS, V11, P123
NR 29
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 14
EP 19
DI 10.1016/j.rmed.2019.03.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900003
PM 31128604
DA 2020-05-18
ER

PT J
AU Maniscalco, M
   Calabrese, C
   D'Amato, M
   Guida, P
   Molino, A
   Aliani, M
   De Tullio, R
   Barbaro, MF
   Ricciardolo, FLM
   Carpagnano, GE
AF Maniscalco, Mauro
   Calabrese, Cecilia
   D'Amato, Maria
   Guida, Pietro
   Molino, Antonio
   Aliani, Maria
   De Tullio, Renato
   Barbaro, Mariapia Foschino
   Ricciardolo, Fabio Luigi Massimo
   Carpagnano, Giovanna Elisiana
TI Association between exhaled nitric oxide and nasal polyposis in severe
   asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Biomarkers; Exhaled; Breath; Lung; Disability
ID CHRONIC RHINOSINUSITIS; BIOMARKERS; PHENOTYPES; EOSINOPHILIA; EFFICACY;
   ADULTS
AB Background: Although several contributions exist on the role of fractional exhaled NO (FeNO) in diagnosis and management of asthma, no studies have analysed the association between FeNO in patients with severe asthma and nasal polyposis.
   Aim: We investigated the potential association between FeNO and the presence of nasal polyps in patients affected by severe asthma.
   Methods: Study population included 93 severe asthmatic adult patients consecutively enrolled from four Italian specialist clinic centres from 2015 to 2018. In these patients lung function, asthma control, FeNO, blood eosinophils and CT scan of paranasal sinuses were evaluated.
   Results: Nasal polyposis was observed in 28 patients (30%). Among univariate predictors (lower BMI, higher FeNO, eosinophil and neutrophil count), recursive partitioning analysis identified as best predictors of nasal polyposis high values of eosinophil count (>= 6.5% or> 420 cells/mm(3)) and FeNO (>= 39 ppb). The 40 patients with low eosinophil count and FeNO had a significant lower occurrence of nasal polyposis than those with higher values (8% vs 58%; p < 0.001). The stratification algorithm had a good performance in discriminate patients with and without nasal polyposis (area under the receiver operating characteristic curve of 0.768).
   Conclusions: Our results show that FeNO might improve to detect nasal polyposis in patients with severe asthma and a low level of blood eosinophils counts, identifying individuals with high susceptibility to this condition.
C1 [Maniscalco, Mauro; Guida, Pietro] ICS Maugeri SpA, Pulm Rehabil Unit, Telese Terme, Benevento, Italy.
   [Calabrese, Cecilia; D'Amato, Maria; Molino, Antonio] Univ Federico II, Dept Resp Med, Naples, Italy.
   [Aliani, Maria; De Tullio, Renato] ICS Maugeri SpA, IRCCS, Pulm Rehabil Unit, Bari, Italy.
   [Barbaro, Mariapia Foschino; Carpagnano, Giovanna Elisiana] Univ Foggia, Inst Resp Dis, Dept Med & Surg Sci, Foggia, Italy.
   [Ricciardolo, Fabio Luigi Massimo] Univ Torino, Dept Clin & Biol Sci, Turin, Italy.
RP Maniscalco, M (reprint author), Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.
EM mauromaniscalco@hotmail.com
RI maniscalco, mauro/B-1915-2018; molino, antonio/N-8133-2016; D'AMATO,
   Maria/H-3074-2012
OI maniscalco, mauro/0000-0001-6751-9921; molino,
   antonio/0000-0001-6966-9640; D'AMATO, Maria/0000-0002-5906-5701;
   Ricciardolo, Fabio Luigi Massimo/0000-0003-1826-5018
CR Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052
   American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330
   Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019
   Buhl R, 2016, RESP MED, V115, P7, DOI 10.1016/j.rmed.2016.04.001
   Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064
   Coumou H, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01785-2017
   Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC
   Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572
   Gratziou C, 2008, INT J IMMUNOPATH PH, V21, P949, DOI 10.1177/039463200802100419
   Guida G, 2010, CHEST, V137, P658, DOI 10.1378/chest.09-0667
   Kobayashi Y, 2015, J ASTHMA, V52, P1060, DOI 10.3109/02770903.2015.1054404
   Kupczyk M, 2012, J INTERN MED, V272, P121, DOI 10.1111/j.1365-2796.2012.02558.x
   Maio S, 2018, ALLERGY, V73, P683, DOI 10.1111/all.13342
   Maniscalco M, 2019, NITRIC OXIDE-BIOL CH, V83, P19, DOI 10.1016/j.niox.2018.12.005
   Micheletto C, 2010, EUR ANN ALLERGY CLIN, V42, P120
   Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC
   Panettieri RA, 2018, LANCET RESP MED, V6, P511, DOI 10.1016/S2213-2600(18)30184-X
   Pavlidis S, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00938-2018
   Rivero A, 2017, ANN OTO RHINOL LARYN, V126, P739, DOI 10.1177/0003489417731782
   Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007
   Schleich FN, 2014, EUR RESPIR J, V44, P97, DOI [10.1183/09031936.00201813, 10.1183/09031936.00118014]
   Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC
   Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979
   Tsilogianni Z, 2017, ARCH IMMUNOL THER EX, V65, P1, DOI 10.1007/s00005-016-0407-9
   Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5
   Wu DW, 2017, ANN ALLERG ASTHMA IM, V118, P318, DOI 10.1016/j.anai.2016.12.018
   Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
   Yilmaz I, 2019, J ASTHMA, V56, P111, DOI 10.1080/02770903.2018.1443469
   Zhu R, 2017, PULM PHARMACOL THER, V46, P88, DOI 10.1016/j.pupt.2017.08.010
NR 34
TC 0
Z9 0
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 20
EP 24
DI 10.1016/j.rmed.2019.04.017
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900004
PM 31128605
DA 2020-05-18
ER

PT J
AU Frank, AL
   Kreuter, M
   Schwarzkopf, L
AF Frank, Anna Lena
   Kreuter, Michael
   Schwarzkopf, Larissa
TI Economic burden of incident interstitial lung disease (ILD) and the
   impact of comorbidity on costs of care
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic interstitial pneumonia; Idiopathic pulmonary fibrosis;
   Sarcoidosis; Diffuse parenchymal lung diseases; Claims data;
   Expenditures
ID IDIOPATHIC PULMONARY-FIBROSIS; OBSTRUCTIVE SLEEP-APNEA; SARCOIDOSIS;
   PREVALENCE; RISK
AB Introduction: Evidence about the economic burden related to interstitial lung diseases (ILDs) and the cost-driving factors is sparse. In the knowledge that distinct comorbidities affect the clinical course of ILDs, our study investigates their impact on costs of care within first year after diagnosis.
   Methods: Using claims data of individuals diagnosed with Idiopathic Interstitial Pneumonia (IIP) (n= 14 453) or sarcoidosis (n= 9106) between 2010 and 2013, we calculated total and ILD-associated mean annual per capita costs adjusted by age, sex and comorbidity burden via Generalized Linear Gamma models. Then, we assessed the cost impact of chronic obstructive pulmonary disease (COPD), diabetes, coronary artery disease, depression, gastro-esophageal reflux disease, pulmonary hypertension (PH), obstructive sleep apnoea syndrome (OSAS) and lung cancer using the model-based parameter estimates.
   Results: Total mean annual per capita costs were (sic)11 131 in the pooled cohort, (sic)12 111 in IIP and (sic)8793 in sarcoidosis, each with a 1/3 share of ILD-associated cost. Most comorbidities had a significant cost-driving effect, which was most pronounced for lung cancer in total (1.989 pooled, 2.491 sarcoidosis, 1.696 IIP) and for PH in ILD-associated costs (2.606 pooled, 2.347 IIP, 3.648 sarcoidosis). The lung-associated comorbidities COPD, PH, OSAS more strongly affected ILD-associated than total costs.
   Conclusion: Comorbidities increase the already substantial costs of care in ILDs. To support patient-centred ILD care, not only highly cost-driving conditions that are inherent with high mortality themselves require systematic management. Moreover, conditions that are more rather restricting the patient's activities of daily living should be addressed-despite a low-cost impact.
C1 [Frank, Anna Lena; Schwarzkopf, Larissa] Helmholtz Zentrum Munchen, Comprehens Pneumol Ctr Munich CPC M, Inst Hlth Econ & Hlth Care Management, German Ctr Lung Res DZL,German Res Ctr Environm H, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.
   [Kreuter, Michael] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis, German Ctr Lung Res DZL, Pneumol & Resp Crit Care Med,Thoraxklin,Translat, Roentgenstr 1, D-69126 Heidelberg, Germany.
RP Frank, AL (reprint author), Helmholtz Zentrum Munchen, Comprehens Pneumol Ctr Munich CPC M, Inst Hlth Econ & Hlth Care Management, German Ctr Lung Res DZL,German Res Ctr Environm H, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.
EM anna.frank@helmholtz-muenchen.de
RI Schwarzkopf, Larissa/O-5157-2015
OI Schwarzkopf, Larissa/0000-0002-9402-7700
CR Ando Katsutoshi, 2011, Nihon Kokyuki Gakkai Zasshi, V49, P800
   AOK-Bundesverband, 2009, ZAHL FAKT, P56
   Basu A, 2006, HEALTH ECON, V15, P1091, DOI 10.1002/hec.1099
   Baughman RP, 2016, ANN AM THORAC SOC, V13, P1244, DOI 10.1513/AnnalsATS.201511-760OC
   Bosi M, 2017, LUNG, V195, P643, DOI 10.1007/s00408-017-0031-4
   Bosse-Henck A, 2015, SLEEP MED, V16, P570, DOI 10.1016/j.sleep.2014.12.025
   Brito-Zeron P, 2018, LUNG, V196, P239, DOI 10.1007/s00408-017-0076-4
   Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005
   Collard HR, 2015, ANN AM THORAC SOC, V12, P981, DOI 10.1513/AnnalsATS.201412-553OC
   Collard Harold R, 2012, J Med Econ, V15, P829, DOI 10.3111/13696998.2012.680553
   Cottin V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0166462
   Deb P, 2018, ANNU REV PUBL HEALTH, V39, P489, DOI 10.1146/annurev-publhealth-040617-013517
   Dong FS, 2015, INT J CLIN EXP MED, V8, P8617
   Esposito DB, 2015, AM J RESP CRIT CARE, V192, P1200, DOI 10.1164/rccm.201504-0818OC
   European Respiratory Society E. L. F, EUR LUNG WHIT BOOK, P256
   Hyldgaard C, 2014, RESP MED, V108, P647, DOI 10.1016/j.rmed.2014.01.008
   King CS, 2017, LANCET RESP MED, V5, P72, DOI 10.1016/S2213-2600(16)30222-3
   Kreuter M., HLTH SERVICES RES PU, pA4927
   Kreuter M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151425
   Lal C, 2015, CHEST, V148, P1105, DOI 10.1378/chest.15-0584
   Lancaster LH, 2009, CHEST, V136, P772, DOI 10.1378/chest.08-2776
   Margaritopoulos GA, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0027-2016
   Martusewicz-Boros MM, 2015, SARCOIDOSIS VASC DIF, V32, P115
   Mermigkis C, 2015, SLEEP BREATH, V19, P385, DOI 10.1007/s11325-014-1033-6
   Nathan SD, 2007, AM J RESP CRIT CARE, V175, P875, DOI 10.1164/rccm.200608-1153CC
   Neubauer S, 2017, EUR J HEALTH ECON, V18, P533, DOI 10.1007/s10198-016-0849-3
   Nowinski A, 2017, CLIN RESPIR J, V11, P648, DOI 10.1111/crj.12398
   Patterson KC, 2013, CHEST, V143, P1562, DOI 10.1378/chest.12-1524
   Pohle S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151940
   Raghu G, 2006, EUR RESPIR J, V27, P136, DOI 10.1183/09031936.06.00037005
   Raimundo K, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-015-0165-1
   Rapti A, 2013, LUNG, V191, P61, DOI 10.1007/s00408-012-9442-4
   Rice JB, 2017, J MANAG CARE SPEC PH, V23, P1261, DOI 10.18553/jmcp.2017.17203
   Schiza S, 2015, EUR RESPIR REV, V24, P327, DOI 10.1183/16000617.00009114
   Schwarzkopf L, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0769-0
   Sogaard KK, 2015, EUR RESPIR J, V45, P269, DOI 10.1183/09031936.00084414
   Swart E, 2015, GESUNDHEITSWESEN, V77, P120, DOI 10.1055/s-0034-1396815
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7
   Wu N, 2015, J MED ECON, V18, P249, DOI 10.3111/13696998.2014.991789
   Zhang LJ, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0300-7
NR 41
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 25
EP 31
DI 10.1016/j.rmed.2019.04.009
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900005
PM 31128606
DA 2020-05-18
ER

PT J
AU Lepainteur, M
   Ogna, A
   Clair, B
   Dinh, A
   Tarragon, C
   Prigent, H
   Davido, B
   Barbot, F
   Vaugier, I
   Afif, M
   Roux, AL
   Rottman, M
   Orlikowski, D
   Herrmann, JL
   Annane, D
   Lawrence, C
AF Lepainteur, Margaux
   Ogna, Adam
   Clair, Bernard
   Dinh, Aurelien
   Tarragon, Catherine
   Prigent, Helene
   Davido, Benjamin
   Barbot, Frederic
   Vaugier, Isabelle
   Afif, Muriel
   Roux, Anne-Laure
   Rottman, Martin
   Orlikowski, David
   Herrmann, Jean-Louis
   Annane, Djillali
   Lawrence, Christine
TI Risk factors for respiratory tract bacterial colonization in adults with
   neuromuscular or neurological disorders and chronic tracheostomy
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Tracheal colonization; Chronic tracheostomised adults
ID OBSTRUCTIVE PULMONARY-DISEASE; NEGATIVE BACILLARY CARRIAGE;
   SPINAL-CORD-INJURY; INFECTION; AIRWAYS
AB The aim of this study was to describe the endotracheal respiratory flora in a population of adults suffering from neuromuscular or neurological disorders requiring a long-term tracheostomy and to identify risk factors for colonization. We conducted a prospective and single-center observational study among patients with chronic tracheostomy admitted for planned respiratory assessment between February 2015 and December 2016. Data were collected from patient interview and medical charts with a standardized questionnaire. A tracheal aspiration was performed for each patient. Humidifiers were analysed for bacteriological contamination. Overall 77 tracheal aspirates (TA) were obtained from patients included. Pathogenic bacteria were found in 90% of cases (69/77) with a majority of Pseudomonas aeruginosa (32/77, 41%), Staphylococcus aureus (34/77, 44%) and Serratia marcesens. (22/79, 38%) Amoxicillin + Clavulanic-acid and Cefotaxime were adapted for respectively in only 28% and 35% of the subjects due to the natural resistance of organisms. No pathogenic bacteria were isolated from humidifier samples. Risk factors significantly associated with P. aeruginosa colonization were residence in a medical-care home (p = 0.01, OR = 3.8 [1.1; 15.1]) and the presence of a cuff (p = 0.003, OR = 4.4 [1.1; 20.6]). Significant quantities of pathogenic bacteria are frequently isolated from TA of tracheostomised patients in the absence of infection. The frequent resistance of these pathogens to Amoxicillin + Clavulanic-acid precludes the use of this antibiotic in the empiric treatment of pneumonia in this population.
C1 [Lepainteur, Margaux; Roux, Anne-Laure; Rottman, Martin; Herrmann, Jean-Louis; Lawrence, Christine] Hop Univ Paris Ile France Ouest, AP HP, Lab Microbiol, Site R Poincare, F-92380 Garches, France.
   [Lepainteur, Margaux; Roux, Anne-Laure; Rottman, Martin; Herrmann, Jean-Louis; Lawrence, Christine] Hop Univ Paris Ile France Ouest, AP HP, Unite Hyg Hosp, Site R Poincare, F-92380 Garches, France.
   [Ogna, Adam; Clair, Bernard; Tarragon, Catherine; Prigent, Helene; Orlikowski, David; Annane, Djillali] Hop Univ Paris Ile France Ouest, AP HP, Reanimat Adultes, Site R Poincare, F-92380 Garches, France.
   [Dinh, Aurelien; Davido, Benjamin] Hop Univ Paris Ile France Ouest, AP HP, Malad Infect, Site R Poincare, F-92380 Garches, France.
   [Barbot, Frederic; Vaugier, Isabelle; Orlikowski, David] Hop Univ Paris Ile France Ouest, AP HP, INSERM CIC1429, Site R Poincare, F-92380 Garches, France.
   [Afif, Muriel] Hop Univ Paris Ile France Ouest, AP HP, Pharm Hosp, Site R Poincare, F-92380 Garches, France.
   [Roux, Anne-Laure; Rottman, Martin; Herrmann, Jean-Louis; Lawrence, Christine] Versailles St Quentin Univ, UFR Simone Veil, INSERM U1173, F-78180 St Quentin En Yvelines, France.
RP Lawrence, C (reprint author), Hop Raymond Poincare, Lab Microbiol, 104 Bd R Poincare, F-92380 Garches, France.; Lawrence, C (reprint author), Hop Raymond Poincare, Unite Hyg Hosp, 104 Bd R Poincare, F-92380 Garches, France.
EM christine.lawrence@aphp.fr
CR Agence Nationale de Securite des Medicaments et produits de sante, 2013, DISP MED ASS RESP UT
   [Anonymous], 2010, DIAGN MICR INF BRONC, P93
   Bach JR, 1998, AM J PHYS MED REHAB, V77, P8, DOI 10.1097/00002060-199801000-00003
   BARTLETT JG, 1978, CHEST, V74, P635, DOI 10.1378/chest.74.6.635
   Cabello H, 1997, EUR RESPIR J, V10, P1137, DOI 10.1183/09031936.97.10051137
   Harlid R, 1996, AM J RESP CRIT CARE, V154, P124, DOI 10.1164/ajrccm.154.1.8680667
   Lusuardi M, 2000, RESP MED, V94, P436, DOI 10.1053/rmed.1999.0761
   Lusuardi M, 2003, RESP MED, V97, P1205, DOI 10.1016/S0954-6111(03)00231-2
   McCaleb R, 2016, RESP CARE, V61, P447, DOI 10.4187/respcare.03518
   Mobbs KJ, 1999, RESP MED, V93, P540, DOI 10.1016/S0954-6111(99)90152-X
   Mobbs KJ, 1999, CHEST, V115, P1570, DOI 10.1378/chest.115.6.1570
   Mylotte JM, 2000, AM J INFECT CONTROL, V28, P291, DOI 10.1067/mic.2000.107424
   NIEDERMAN MS, 1984, CHEST, V85, P39, DOI 10.1378/chest.85.1.39
   PALMER LB, 1995, AM J RESP CRIT CARE, V151, P1063
   Park YJ, 2015, ANN REHABIL MED-ARM, V39, P964, DOI 10.5535/arm.2015.39.6.964
   Pignatti P, 2009, RESP MED, V103, P201, DOI 10.1016/j.rmed.2008.09.008
   Suda KJ, 2016, SPINAL CORD, V54, P1001, DOI 10.1038/sc.2016.38
   Thom J D, 1999, J Spinal Cord Med, V22, P125
NR 18
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 32
EP 36
DI 10.1016/j.rmed.2019.04.015
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900006
PM 31128607
DA 2020-05-18
ER

PT J
AU Rebordosa, C
   Aguado, J
   Plana, E
   Thomas, S
   Frances, A
   Lei, A
   Garcia-Gil, E
   Nuevo, J
   Perez-Gutthann, S
   Castellsague, J
AF Rebordosa, Cristina
   Aguado, Jaume
   Plana, Estel
   Thomas, Steven
   Frances, Ana
   Lei, Alejhandra
   Garcia-Gil, Esther
   Nuevo, Javier
   Perez-Gutthann, Susana
   Castellsague, Jordi
TI Use of aclidinium did not increase the risk of death in a
   noninterventional cohort study in the Clinical Practice Research
   Datalink (CPRD), United Kingdom
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Aclidinium; LAMA; Mortality; United Kingdom
ID EVENTS; BIAS; COPD
AB Background: Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA). Although the initial potential increased cardiovascular and mortality risk among users of tiotropium has been ruled out by several observational studies, and clinical trials, there are still concerns related to the use of newer LAMA medications. The current study aimed to evaluate the risk of death among users of aclidinium and other LAMAs.
   Methods: We conducted a cohort and nested case-control study among patients with COPD aged 40 years or older to compare the risk of all-cause mortality among users of aclidinium and other COPD medications with the risk among users of long-acting beta 2 agonists (LABA), in the Clinical Practice Research Datalink (CPRD) in the United Kingdom (2012-2017).
   Results: Mortality rates per 1,000 person-years were 32.9 for aclidinium, 43.8 for tiotropium, 38.0 for other LAMA, 47.1 for LABA/ICS, and 38.1 for LABA. The RR of death compared with current use of LABA was 0.54 (confidence interval [95% CI], 0.40-0.72) for aclidinium, 0.96 (95% CI, 0.76-1.21) for tiotropium, 0.76 (95% CI, 0.58-0.99) for other LAMA, and 1.08 (95% CI, 0.90-1.31) for LABA/ICS. Decreased risk for death observed among users of aclidinium was driven by overall current single use (RR= 0.41; 95% CI, 0.22-0.79), which corresponded to 26% of the aclidinium users (< 15 cases) and not by multiple use (RR= 1.02; 95% CI, 0.71-1.48).
   Conclusion: Use of aclidinium, tiotropium, other LAMA, or LABA/ICS was not associated with an increased risk of all-cause mortality as compared with the use of LABAs.
C1 [Rebordosa, Cristina; Aguado, Jaume; Plana, Estel; Perez-Gutthann, Susana; Castellsague, Jordi] RTI Hlth Solut, Av Diagonal 605,9-1, Barcelona 08028, Spain.
   [Thomas, Steven] RTI Hlth Solut, 200 Pk Off Dr, Res Triangle Pk, NC 27709 USA.
   [Frances, Ana; Lei, Alejhandra; Garcia-Gil, Esther] AstraZeneca, Avda Diagonal,615 2nd Floor, Barcelona 08028, Spain.
   [Nuevo, Javier] AstraZeneca, Serrano Galvache 56, Madrid 28033, Spain.
RP Rebordosa, C (reprint author), Av Diagonal 605,9-1, Barcelona 08028, Spain.
EM crebordosa@rti.org
OI Rebordosa, Cristina/0000-0002-8064-5997
FU AstraZenecaAstraZeneca
FX This work was supported by AstraZeneca. The contracts provide the
   research team independent publication rights. The sponsors had no role
   in the data collection or analysis; however, in line with the Guideline
   on Good Pharmacovigilance Practices: Module VIII: Post-authorisation
   Safety Studies of the European Medicines Agency, the sponsors had the
   opportunity to view the results and interpretations included in the
   manuscript and provide comments before submission of the manuscript for
   publication.
CR Arana A, 2011, EPIDEMIOLOGY, V22, P876, DOI [10.1097/EDE.0b013e3182093a0f, 10.1097/EDE.0b013e31823198fc]
   AstraZeneca, 2014, SUMM RISK MAN PLAN R
   AstraZeneca, 2012, SUMMARY PRODUCT CHAR
   Brunk D., 2018, CHEST PHYS      0610
   Celli B, 2009, AM J RESP CRIT CARE, V180, P948, DOI 10.1164/rccm.200906-0876OC
   Chalmers JD, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0040-z
   Glaxo Group Ltd, 2014, SUMM RISK MAN PLAN R
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2016, GLOB STRAT DIAGN MAN
   GOLD, 2018, GLOB STRAT DIAGN MAN
   Novartis Europharm Limited, 2012, SUMMARY PRODUCT CHAR
   PETRI H, 1991, STAT MED, V10, P577, DOI 10.1002/sim.4780100409
   Price D, 2014, INT J CHRONIC OBSTR, V9, P889, DOI 10.2147/COPD.S62750
   Rivero-Ferrer E, 2018, PHARMACOEPIDEM DR S, V27, P122
   Rothman K.J., 2008, MODERN EPIDEMIOLOGY
   Stock J., 2015, IMPLEMENTING GLI 201
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
   Suissa S, 2012, DIABETES CARE, V35, P2665, DOI 10.2337/dc12-0788
   Wang MT, 2018, JAMA INTERN MED, V178, P229, DOI 10.1001/jamainternmed.2017.7720
   Wise RA, 2018, CHRON OBSTR PULM DIS, V5, P5, DOI 10.15326/jcopdf.5.1.2017.0149
   Wise RA, 2013, NEW ENGL J MED, V369, P1491, DOI 10.1056/NEJMoa1303342
NR 20
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 37
EP 43
DI 10.1016/j.rmed.2019.04.018
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900007
PM 31128608
DA 2020-05-18
ER

PT J
AU Shioya, S
   Masuda, T
   Yamaguchi, K
   Sakamoto, S
   Horimasu, Y
   Nakashima, T
   Miyamoto, S
   Senoo, T
   Iwamoto, H
   Ohshimo, S
   Fujitaka, K
   Hamada, H
   Hattori, N
AF Shioya, Sachiko
   Masuda, Takeshi
   Yamaguchi, Kakuhiro
   Sakamoto, Shinjiro
   Horimasu, Yasushi
   Nakashima, Taku
   Miyamoto, Shintaro
   Senoo, Tadashi
   Iwamoto, Hiroshi
   Ohshimo, Shinichiro
   Fujitaka, Kazunori
   Hamada, Hironobu
   Hattori, Noboru
TI Comparison of anti-aminoacyl-tRNA synthetase antibody-related and
   idiopathic non-specific interstitial pneumonia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Anti-aminoacyl-tRNA synthetase antibody; Non-specific interstitial
   pneumonia; Computed tomography; Bronchoalveolar lavage fluid
ID CONNECTIVE-TISSUE DISEASE; COMPUTED-TOMOGRAPHY FINDINGS;
   PULMONARY-FIBROSIS; LUNG-DISEASE; ANTISYNTHETASE SYNDROME; CLINICAL
   CHARACTERISTICS; ACUTE EXACERBATION; SURVIVAL; DIAGNOSIS; FEATURES
AB Background and purpose: Patients with anti-aminoacyl-tRNA synthetase (ARS) antibodies frequently experience complications of interstitial pneumonia (ARS-IP), and the computed tomography (CT) of ARS-IP frequently shows nonspecific interstitial pneumonia (NSIP) pattern. The CT pattern of ARS-IP might be different from that of idiopathic IP. However, the clinical differences in patients with ARS-IP and idiopathic IP showing the similar CT patterns have not yet been well studied. The objective of this study was to evaluate the clinical differences between patients with ARS-NSIP and idiopathic NSIP (I-NSIP).
   Methods: Two groups of 34 patients each, with ARS-NSIP and I-NSIP, who visited Hiroshima University Hospital between January 2005 and December 2017, were enrolled. Clinical features and outcomes were retrospectively compared between the two groups.
   Results: The ARS-NSIP group included more female patients and significantly younger patients than the I-NSIP group. The percentage of lymphocytes in bronchoalveolar lavage fluid (BALF) was significantly higher, and the CD4/CD8 ratio in BALF was significantly lower in the ARS-NSIP group compared with the I-NSIP group. The proportion of patients with traction bronchiectasis detected by CT was significantly higher in I-NSIP compared with ARS-NSIP. The number of patients who received corticosteroid and/or immunosuppressant therapy was significantly larger in the ARS-NSIP group than in the I-NSIP group. In addition, the patients in the I-NSIP group who underwent the immunosuppressive therapy demonstrated shorter survival than those who underwent no treatment; this tendency was not observed in the ARS-NSIP group. The 10-year survival rate of patients in the ARS-NSIP group was significantly higher than that of patients in the I-NSIP group (91.8% vs. 43.0%; log-rank, p= 0.012). The multivariate survival analysis revealed that positive anti-ARS antibody was an independent favorable prognostic factor in the patients with NSIP (OR, [95% CI]: 0.12 [0.02-0.55], p= 0.013).
   Conclusions: Patients with ARS-NSIP had a significantly better prognosis than those with I-NSIP; this may be associated with the sensitivity to immunosuppressive therapies, and the different findings of BALF and HRCT between the two groups.
C1 [Shioya, Sachiko; Iwamoto, Hiroshi; Fujitaka, Kazunori; Hattori, Noboru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol & Internal Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
   [Masuda, Takeshi; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Miyamoto, Shintaro] Hiroshima Univ Hosp, Dept Resp Internal Med, Minami Ku, 12-3 Kasumi, Hiroshima 7348551, Japan.
   [Senoo, Tadashi] Hiroshima Univ Hosp, Dept Clin Oncol, Minami Ku, 12-3 Kasumi, Hiroshima 7348551, Japan.
   [Ohshimo, Shinichiro] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Emergency & Crit Care Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
   [Hamada, Hironobu] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Phys Anal & Therapeut Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
RP Masuda, T (reprint author), Hiroshima Univ Hosp, Dept Resp Internal Med, Minami Ku, 12-3 Kasumi, Hiroshima 7348551, Japan.
EM ta-masuda@hiroshima-u.ac.jp
RI Nakashima, Taku/D-1517-2011; Ohshimo, Shinichiro/B-4572-2018
OI Nakashima, Taku/0000-0002-0035-674X; Iwamoto,
   Hiroshi/0000-0003-4922-5334; Ohshimo, Shinichiro/0000-0003-1119-3322;
   Yamaguchi, Kakuhiro/0000-0002-9117-1934
CR Akira M, 2009, RADIOLOGY, V251, P271, DOI 10.1148/radiol.2511080917
   Belloli EA, 2016, RESPIROLOGY, V21, P259, DOI 10.1111/resp.12674
   Cavagna L, 2013, J RHEUMATOL, V40, P484, DOI 10.3899/jrheum.121026
   Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI
   Elliot TL, 2005, J COMPUT ASSIST TOMO, V29, P339, DOI 10.1097/01.rct.0000162153.55253.d3
   Enomoto K, 2003, RESPIROLOGY, V8, P149, DOI 10.1046/j.1440-1843.2003.00445.x
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Flaherty KR, 2003, THORAX, V58, P143, DOI 10.1136/thorax.58.2.143
   Hervier B, 2012, AUTOIMMUN REV, V12, P210, DOI 10.1016/j.autrev.2012.06.006
   Katzap E, 2011, CURR RHEUMATOL REP, V13, P175, DOI 10.1007/s11926-011-0176-8
   Kelly BT, 2018, RESPIROLOGY, V23, P600, DOI 10.1111/resp.13254
   Kocheril SV, 2005, ARTHRIT RHEUM-ARTHR, V53, P549, DOI 10.1002/art.21322
   Koo SM, 2017, KOREAN J INTERN MED, V32, P600, DOI 10.3904/kjim.2016.212
   Kourakata H, 1999, Respirology, V4, P223, DOI 10.1046/j.1440-1843.1999.00179.x
   Mahler M, 2014, AUTOIMMUN REV, V13, P367, DOI 10.1016/j.autrev.2014.01.022
   Mathai SC, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6819
   Nakabayashi R, 2014, PLANT SIGNAL BEHAV, V9, DOI 10.4161/psb.29518
   Nakamura Y, 2003, SARCOIDOSIS VASC DIF, V20, P235
   Nunes H, 2015, EUR RESPIR J, V45, P746, DOI 10.1183/09031936.00148613
   Park JH, 2007, AM J RESP CRIT CARE, V175, P705, DOI 10.1164/rccm.200607-912OC
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Sumikawa H, 2008, AM J RESP CRIT CARE, V177, P433, DOI 10.1164/rccm.200611-1696OC
   Suzuki H, 2011, SURG TODAY, V41, P914, DOI 10.1007/s00595-010-4384-z
   Sverzellati N, 2010, RADIOLOGY, V254, P957, DOI 10.1148/radiol.0990898
   Tanizawa K, 2017, RESP MED, V127, P57, DOI 10.1016/j.rmed.2017.04.007
   Wallace B, 2016, CURR OPIN RHEUMATOL, V28, P236, DOI 10.1097/BOR.0000000000000270
   Waseda Y, 2016, EUR J RADIOL, V85, P1421, DOI 10.1016/j.ejrad.2016.05.012
   Watanabe K, 2011, RESP MED, V105, P1238, DOI 10.1016/j.rmed.2011.03.022
   Wells AU, 2008, THORAX, V63, DOI 10.1136/thx.2008.101691
   Wilkes MR, 2005, ARTHRITIS RHEUM-US, V52, P2439, DOI 10.1002/art.21240
   Yamadori I, 2000, LUNG, V178, P361, DOI 10.1007/s004080000037
   Yoshimura K, 2018, RESP MED, V137, P167, DOI 10.1016/j.rmed.2018.02.024
   Yura H, 2017, RESP MED, V132, P189, DOI 10.1016/j.rmed.2017.10.020
NR 33
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 44
EP 50
DI 10.1016/j.rmed.2019.04.023
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900008
PM 31128609
DA 2020-05-18
ER

PT J
AU Tyrak, KE
   Kuprys-Lipinska, I
   Czarnobilska, E
   Jakiela, B
   Pajdzik, K
   Cmiel, A
   Plutecka, H
   Koziej, M
   Gawronska, A
   Konduracka, E
   Kuna, P
   Sanak, M
   Mastalerz, L
AF Tyrak, Katarzyna Ewa
   Kuprys-Lipinska, Izabela
   Czarnobilska, Ewa
   Jakiela, Bogdan
   Pajdzik, Kinga
   Cmiel, Adam
   Plutecka, Hanna
   Koziej, Mateusz
   Gawronska, Aleksandra
   Konduracka, Ewa
   Kuna, Piotr
   Sanak, Marek
   Mastalerz, Lucyna
TI Sputum biomarkers during aspirin desensitization in nonsteroidal
   anti-inflammatory drugs exacerbated respiratory disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Aspirin desensitization; Nonsteroidal anti-inflammatory drugs;
   exacerbated respiratory disease; Periostin; Eicosanoids; Induced sputum;
   Nasal lavage
ID CHRONIC RHINOSINUSITIS; NASAL POLYPOSIS; LEUKOTRIENE; ASTHMA;
   PROSTAGLANDIN; EXPRESSION; CHALLENGE; PERIOSTIN; DIAGNOSIS; SUBTYPES
AB Background: Aspirin desensitization (AD) is an effective and safe therapeutic option for patients with nonsteroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD). The mechanisms driving its beneficial effects remain poorly understood.
   Objective: To investigate the effect of long-term AD on clinical, biochemical and radiological changes in N-ERD patients.
   Methods: The study group consisted of twenty-three individuals with N-ERD who underwent AD, followed by ingestion of 325 mg aspirin twice daily. Twenty patients completed the 52 weeks of AD. The following evaluations were conducted at baseline and in the 52nd week of AD: (i) clinical: asthma exacerbations, Asthma Control Test (ACT), Visual Analogue Scale (VAS) for the assessment of nasal symptoms; (ii) blood and induced sputum supernatant (ISS) periostin, (iii) phenotypes based on induced sputum (IS) cells, (iiii) ISS and nasal lavage (NL) concentration of prostaglandin D-2 (PGD(2)), prostaglandin E-2 (PGE(2)), tetranor-PGD-M, tetranor-PGE-M, 8-iso-PGE(2), leukotriene B-4 (LTB4), LTC4, LTD4 and LTE4, and urine LTE4.
   Results: A significant improvement was observed in ACT (P= 0.02) and VAS score (P= 0.008) in the 52nd week of AD. ISS periostin and IS eosinophil count decreased significantly in the 52nd week of AD (P= 0.04 and P= 0.01, respectively). ISS and NL eicosanoid concentrations did not change following long-term AD.
   Conclusion: and Clinical Relevance: AD is associated with a decrease in sputum periostin biosynthesis, which may prevent the recruitment of eosinophils into respiratory tissue and be one of explanation of the clinical benefits of AD. Long-term aspirin administration does not lead to an imbalance between pro-and anti-inflammatory ISS eicosanoids.
C1 [Tyrak, Katarzyna Ewa; Jakiela, Bogdan; Pajdzik, Kinga; Plutecka, Hanna; Sanak, Marek; Mastalerz, Lucyna] Jagiellonian Univ, Dept Internal Med 2, Med Coll, Krakow, Poland.
   [Kuprys-Lipinska, Izabela; Kuna, Piotr] Med Univ Lodz, Dept Internal Med Asthma & Allergy, Lodz, Poland.
   [Czarnobilska, Ewa] Jagiellonian Univ, Dept Clin & Environm Allergol, Med Coll, Krakow, Poland.
   [Cmiel, Adam] AGH Univ Sci & Technol, Dept Appl Math, Krakow, Poland.
   [Koziej, Mateusz] Jagiellonian Univ, Dept Anat, Med Coll, Krakow, Poland.
   [Gawronska, Aleksandra] Univ Hosp Cracow, Dept Radiol Diagnost Imaging, Krakow, Poland.
   [Konduracka, Ewa] Jagiellonian Univ, John Paul II Hosp, Coronary & Heart Failure Dept, Sch Med, Krakow, Poland.
RP Mastalerz, L (reprint author), Jagiellonian Univ, Dept Internal Med, Med Coll, 8 Skawinska Str, PL-31066 Krakow, Poland.
EM lucyna.mastalerz@uj.edu.pl
OI Kuna, Piotr/0000-0003-2401-0070
FU National Science Centre, Poland [UMO-2015/19/B/NZ5/00096]; Jagiellonian
   University Medical College, Cracow, Poland [K/ZDS/006162]
FX This work was supported by the National Science Centre, Poland [grant
   number UMO-2015/19/B/NZ5/00096]; and by the Jagiellonian University
   Medical College, Cracow, Poland [grant number K/ZDS/006162].
CR Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044
   Bobolea I, 2018, RESP MED, V143, P39, DOI 10.1016/j.rmed.2018.08.009
   Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020
   Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031
   Castano R, 2009, THORAX, V64, P50, DOI 10.1136/thx.2008.102822
   Comert S, 2013, ALLERGY, V68, P1443, DOI 10.1111/all.12269
   Cortellini G, 2017, CURR OPIN ALLERGY CL, V17, P247, DOI 10.1097/ACI.0000000000000374
   Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102
   Eastman JJ, 2017, J ALLERGY CLIN IMMUN, V140, P101, DOI 10.1016/j.jaci.2016.11.023
   Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977
   Jerschow E, 2019, J ALLER CL IMM-PRACT, V7, P1580, DOI 10.1016/j.jaip.2018.12.014
   Kanaoka Y, 2014, ALLERGY ASTHMA IMMUN, V6, P288, DOI 10.4168/aair.2014.6.4.288
   Kanemitsu Y, 2014, AM J RESP CRIT CARE, V190, P472, DOI 10.1164/rccm.201403-0562LE
   Katial RK, 2010, J ALLERGY CLIN IMMUN, V126, P738, DOI 10.1016/j.jaci.2010.06.036
   Kowalski ML, 2019, CURR OPIN PULM MED, V25, P64, DOI 10.1097/MCP.0000000000000530
   Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599
   Kowalski ML, 2015, ALLERGY ASTHMA IMMUN, V7, P312, DOI 10.4168/aair.2015.7.4.312
   Laidlaw TM, 2019, J ALLERGY CLIN IMMUN, V143, P316, DOI 10.1016/j.jaci.2018.06.001
   Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826
   Levy JM, 2016, INT FORUM ALLERGY RH, V6, P1273, DOI 10.1002/alr.21826
   Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905
   Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6
   Makowska JS, 2016, ALLERGY ASTHMA PROC, V37, P216, DOI 10.2500/aap.2016.37.3935
   Mastalerz L, 2015, CLIN EXP ALLERGY, V45, P1779, DOI 10.1111/cea.12654
   Mastalerz L, 2014, ALLERGY, V69, P1550, DOI 10.1111/all.12512
   Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x
   Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029
   Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x
   Simpson JL, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0230-4
   Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508
   Stankovic KM, 2008, LARYNGOSCOPE, V118, P881, DOI 10.1097/MLG.0b013e31816b4b6f
   Steinke JW, 2016, ANN ALLERG ASTHMA IM, V117, P234, DOI 10.1016/j.anai.2016.06.006
   Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9
   Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019
   Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041
   SZCZEKLIK A, 1995, LANCET, V345, P1056, DOI 10.1016/S0140-6736(95)90799-8
   Takahashi T, 2017, J ALLERGY CLIN IMMUN, V140, P720, DOI 10.1016/j.jaci.2017.01.022
   Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046
   Waldram J, 2018, J ALLERGY CLIN IMMUN, V141, P250, DOI 10.1016/j.jaci.2017.05.006
   Walters KM, 2018, AM J RHINOL ALLERGY, V32, P280, DOI 10.1177/1945892418770260
   Warner TD, 2011, BRIT J CLIN PHARMACO, V72, P619, DOI 10.1111/j.1365-2125.2011.03943.x
   White AA, 2018, AM J RHINOL ALLERGY, V32, P7, DOI 10.2500/ajra.2018.32.4498
   Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104
   Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972
NR 44
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 51
EP 59
DI 10.1016/j.rmed.2019.04.021
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900009
PM 31128610
DA 2020-05-18
ER

PT J
AU Graff, S
   Demarche, S
   Henket, M
   Paulus, V
   Louis, R
   Schleich, F
AF Graff, Sophie
   Demarche, Sophie
   Henket, Monique
   Paulus, Virginie
   Louis, Renaud
   Schleich, Florence
TI Increase in blood eosinophils during follow-up is associated with lung
   function decline in adult asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Humans; Asthma; Airway inflammation; Eosinophils; Lung diseases; Lung
   function decline
ID PULMONARY-FUNCTION; AGE; FEV1; RESPONSIVENESS; EXACERBATIONS;
   QUESTIONNAIRE; IMPAIRMENT; PHENOTYPES; SMOKING; BURDEN
AB Background: Asthma is associated with accelerated rate of lung function (FEV1) decline.
   Objective: To determine predictive factors associated with FEV1 decline in adult asthma.
   Methods: A retrospective study was conducted in 229 asthmatics recruited from the University Asthma Clinic of Liege. Subjects had at least two visits with post-bronchodilation (post-BD) FEV1 and minimum one year between them. A multivariable linear regression analysis was conducted in order to come up with factors associated with lung function decline.
   Results: Post-BD FEV1 decline in % predicted. y(-1) was 0.2 (95% CI -2.0 to 2.8) in the overall population. Our population was made up of mild to moderate asthmatics [1] for 58%, aged 50 (41-60) years old, 62% were female and 59% were atopic. Median ICS dose was 1000 mu g beclomethasone equivalent (CFC)/day with 81% treated at baseline. Time between visits was 46.8 +/- 32.1 months. The univariate linear regression analysis revealed a negative association between % predicted FEV1 decline and baseline ACQ (p < 0.0001) and blood eosinophils (% and/mm(3)) (p < 0.0001 and p < 0.0001). A positive association was found between % predicted FEV1 decline and baseline pre-BD FEV1 (mL) values (p= 0.001), blood neutrophils (%) (p= 0.02), change in blood eosinophils (%) (p < 0.0001), time between visits (months) (p < 0.0001). The predictive variables for accelerated decline highlighted by the multivariable analysis (r(2)= 0.39) were change in blood eosinophils (%) over time (p= 0.002) and time between visits (months) (p < 0.0001).
   Conclusion: These findings highlight a new value for blood eosinophil counts as their increase over time predicts greater lung function decline in asthma.
C1 [Graff, Sophie; Demarche, Sophie; Henket, Monique; Paulus, Virginie; Louis, Renaud; Schleich, Florence] Univ Liege, Dept Resp Med, CHU Liege, Res Grp,GIGA I3, Liege, Belgium.
RP Graff, S (reprint author), Quartier Hop, GIGA 4, CHU B34, Ave Hop 11, B-4000 Liege, Belgium.
EM sgraff@uliege.be
FU European Union (Interreg EMR Meuse Rhine 5a); Interuniversity Attraction
   Poles ProgramBelgian Federal Science Policy Office
FX This work was supported by the European Union (Interreg EMR Meuse Rhine
   5a) and Interuniversity Attraction Poles Program.
CR Almeida PCA, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0302-5
   Aziz-Ur-Rehman A, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0190-0
   Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106
   Bai TR, 2005, CLIN SCI, V108, P463, DOI 10.1042/CS20040342
   Broekema M, 2010, RESP MED, V104, P1254, DOI 10.1016/j.rmed.2010.03.030
   Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241
   BURROWS B, 1987, AM REV RESPIR DIS, V135, P788, DOI 10.1164/arrd.1987.135.4.788
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Cibella F, 2002, CHEST, V122, P1944, DOI 10.1378/chest.122.6.1944
   CONNOLLY CK, 1988, POSTGRAD MED J, V64, P422, DOI 10.1136/pgmj.64.752.422
   Coumou H, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01785-2017
   Demarche SF, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018186
   Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Enright PL, 2002, RESP MED, V96, P444, DOI 10.1053/rmed.2001.1270
   FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987
   GINA-Global Initiative for Asthma, GLOB STRAT ASTHM MAN
   Guiot J, 2017, JOVE-J VIS EXP, DOI 10.3791/56612
   Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC
   Hancox RJ, 2018, EUR RESP J, V51
   James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC
   Janssens JP, 1999, EUR RESPIR J, V13, P197, DOI 10.1034/j.1399-3003.1999.13a36.x
   Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x
   JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76
   Kanemitsu Y, 2014, ALLERGOL INT, V63, P181, DOI 10.2332/allergolint.13-RA-0670
   Kerstjens HAM, 1997, THORAX, V52, P820, DOI 10.1136/thx.52.9.820
   Lang DM, 2015, ALLERGY ASTHMA PROC, V36, P418, DOI 10.2500/aap.2015.36.3908
   Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703
   Lewis SA, 2001, CHEST, V119, P105, DOI 10.1378/chest.119.1.105
   Louis R., 2011, NONINVASIVE ASSESSME, P113
   Nadif R, 2016, EUR RESPIR J, V48, P1040, DOI 10.1183/13993003.00336-2016
   Newby C, 2014, J ALLERGY CLIN IMMUN, V134, P287, DOI 10.1016/j.jaci.2014.04.005
   Ortega H, 2018, J ALLER CL IMM-PRACT, V6, P980, DOI 10.1016/j.jaip.2017.12.019
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9
   PEAT JK, 1987, EUR J RESPIR DIS, V70, P171
   Porsbjerg C, 2015, RESP MED, V109, P821, DOI 10.1016/j.rmed.2015.04.012
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011
   Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007
   Schleich F, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA3035
   Schleich FN, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-11
   Schleich FN, 2014, EUR RESPIR J, V44, P97, DOI [10.1183/09031936.00201813, 10.1183/09031936.00118014]
   Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367
   Sposato Bruno, 2016, Open Respir Med J, V10, P70, DOI 10.2174/1874306401610010070
   TAYLOR RG, 1985, THORAX, V40, P9, DOI 10.1136/thx.40.1.9
   ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026
   Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011
   ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330
   ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14
   Ulrik CS, 1998, ANN ALLERG ASTHMA IM, V80, P487, DOI 10.1016/S1081-1206(10)63072-4
   ULRIK CS, 1995, RESP MED, V89, P547, DOI 10.1016/0954-6111(95)90156-6
   van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907
   Yuan R, 2009, THORAX, V64, P944, DOI 10.1136/thx.2008.112433
NR 55
TC 1
Z9 1
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 60
EP 66
DI 10.1016/j.rmed.2019.04.020
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900010
PM 31128611
OA Green Published
DA 2020-05-18
ER

PT J
AU Mu, G
   Zhou, Y
   Ma, JX
   Guo, YJ
   Xiao, LL
   Zhou, M
   Cao, LM
   Li, W
   Wang, B
   Yuan, J
   Chen, WH
AF Mu, Ge
   Zhou, Yun
   Ma, Jixuan
   Guo, Yanjun
   Xiao, Lili
   Zhou, Min
   Cao, Limin
   Li, Wei
   Wang, Bin
   Yuan, Jing
   Chen, Weihong
TI Combined effect of central obesity and urinary PAH metabolites on lung
   function: A cross-sectional study in urban adults
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Combined effect; Central obesity; Polycyclic aromatic hydrocarbon; Lung
   function
ID POLYCYCLIC AROMATIC-HYDROCARBONS; ABDOMINAL OBESITY; SYSTEMIC
   INFLAMMATION; OXIDATIVE STRESS; FAT DISTRIBUTION; NITRIC-OXIDE;
   ASSOCIATION; EXPOSURE; MEN
AB Background: Central obesity and polycyclic aromatic hydrocarbons (PAHs) exposure were reported as independent risk factors for lung function decline. However, the interaction between central obesity and PAHs exposure on lung function is still unclear.
   Objectives: To evaluate the impact of central obesity, urinary polycyclic aromatic hydrocarbon metabolites (OH-PAHs) and their combined effects on lung function in general population.
   Methods: Lung function and urinary OH-PAHs were measured for 3,749 participants from the Wuhan-Zhuhai cohort. Central obesity was evaluated by waist-to-hip ratio. Generalized linear regression was used to estimate combined effect of central obesity and OH-PAHs on lung function.
   Results: Compared with participants without central obesity and with low urinary total OH-PAHs (SOH-PAHs) level, those with central obesity and high urinary SOH-PAHs level had 59.4 mL and 61.0 mL reductions for forced vital capacity (FVC) and forced expiratory volume in 1s (FEV1), respectively (P < 0.05). The reductions were more evident in smokers and males. Additive interactions between central obesity and urinary SOH-PAHs on lung function were observed, especially on FEV1 (P < 0.05). Each 1-unit increase in log-transformed value of SOH-PAHs was associated with -34.4 ml (95% confidence interval [CI]: -66.9, -1.8) and -34.8 mL (-61.1, -8.5) changes in FVC and FEV1 among those without central obesity, while -21.4 ml (-49.9, 7.1) and -19.7 ml (-43.4, 4.0) changes among those with central obesity.
   Conclusion: Polycyclic aromatic hydrocarbons exposure has combined effect with central obesity on lung function parameters.
C1 [Mu, Ge; Zhou, Yun; Ma, Jixuan; Guo, Yanjun; Xiao, Lili; Zhou, Min; Cao, Limin; Li, Wei; Wang, Bin; Yuan, Jing; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430030, Hubei, Peoples R China.
   [Mu, Ge; Zhou, Yun; Ma, Jixuan; Guo, Yanjun; Xiao, Lili; Zhou, Min; Cao, Limin; Li, Wei; Wang, Bin; Yuan, Jing; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Key Lab Environm & Hlth, Minist Educ, Wuhan 430030, Hubei, Peoples R China.
   [Mu, Ge; Zhou, Yun; Ma, Jixuan; Guo, Yanjun; Xiao, Lili; Zhou, Min; Cao, Limin; Li, Wei; Wang, Bin; Yuan, Jing; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Minist Environm Protect, State Key Lab Environm Hlth Incubating,Sch Publ H, Wuhan 430030, Hubei, Peoples R China.
RP Chen, WH (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430030, Hubei, Peoples R China.
EM wchen@mails.tjmu.edu.cn
RI Chen, Weihong/D-2177-2011
OI Chen, Weihong/0000-0001-8689-7311
FU Key Project of the National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [91543207]; National Key Research
   and Development Program of China [2016YFC1303903]
FX This work was supported by the Key Project of the National Natural
   Science Foundation of China [grant number 91543207]; and the National
   Key Research and Development Program of China [grant number
   2016YFC1303903].
CR Ahmadi-Abhari S, 2014, AM J EPIDEMIOL, V179, P48, DOI 10.1093/aje/kwt208
   Alshaarawy O, 2013, ENVIRON RES, V126, P98, DOI 10.1016/j.envres.2013.07.006
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Arteaga-Solis E, 2013, CELL METAB, V17, P35, DOI 10.1016/j.cmet.2012.12.004
   Breyer MK, 2011, RESP MED, V105, P1046, DOI 10.1016/j.rmed.2011.02.001
   Cakmak S, 2017, ENVIRON POLLUT, V228, P1, DOI 10.1016/j.envpol.2017.05.013
   Canoy D, 2004, AM J EPIDEMIOL, V159, P1140, DOI 10.1093/aje/kwh155
   Chen WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108989
   Choe EK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193516
   Clapp BR, 2004, CARDIOVASC RES, V64, P172, DOI 10.1016/j.cardiores.2004.06.020
   Delfino RJ, 2010, EPIDEMIOLOGY, V21, P892, DOI 10.1097/EDE.0b013e3181f20e6c
   Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   El-Wakkad A, 2013, CYTOKINE, V61, P682, DOI 10.1016/j.cyto.2012.11.010
   Everett CJ, 2010, ENVIRON RES, V110, P79, DOI 10.1016/j.envres.2009.09.010
   Fang H, 2018, COMPR PHYSIOL, V8, P1031, DOI 10.1002/cphy.c170046
   Harik-Khan RI, 2001, J CLIN EPIDEMIOL, V54, P399, DOI 10.1016/S0895-4356(00)00318-8
   Huang XJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26021-3
   Joos L, 2001, THORAX, V56, P863, DOI 10.1136/thorax.56.11.863
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Kuang D, 2013, ENVIRON SCI TECHNOL, V47, P7446, DOI 10.1021/es401639x
   Leone N, 2009, AM J RESP CRIT CARE, V179, P509, DOI 10.1164/rccm.200807-1195OC
   Li XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044562
   Lu H, 2007, J HAZARD MATER, V139, P193, DOI 10.1016/j.jhazmat.2006.06.011
   Ludescher B, 2009, INVEST RADIOL, V44, P712, DOI 10.1097/RLI.0b013e3181afbb1e
   McLaughlin T, 2014, ARTERIOSCL THROM VAS, V34, P2637, DOI 10.1161/ATVBAHA.114.304636
   Dat ND, 2017, SCI TOTAL ENVIRON, V609, P682, DOI 10.1016/j.scitotenv.2017.07.204
   Ochs-Balcom HM, 2006, CHEST, V129, P853, DOI 10.1378/chest.129.4.853
   Olza J, 2014, PUBLIC HEALTH NUTR, V17, P2378, DOI 10.1017/S1368980013003285
   Pekkarinen E, 2012, CLIN PHYSIOL FUNCT I, V32, P83, DOI 10.1111/j.1475-097X.2011.01064.x
   Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3
   Song YC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-994
   Sun HZ, 2017, CHEMOSPHERE, V174, P506, DOI 10.1016/j.chemosphere.2017.01.104
   Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011
   Thijs W, 2014, RESP MED, V108, P351, DOI 10.1016/j.rmed.2013.10.003
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   World Health Organization, 2008, WAIST CIRCUMFERENCE
   Yang LY, 2017, SCI TOTAL ENVIRON, V574, P1649, DOI 10.1016/j.scitotenv.2016.08.211
   Yang QY, 2015, ENVIRON SCI POLLUT R, V22, P1760, DOI 10.1007/s11356-014-3284-y
   Yuan JM, 2014, CARCINOGENESIS, V35, P339, DOI 10.1093/carcin/bgt352
   Zhou Y, 2018, SCI TOTAL ENVIRON, V618, P542, DOI 10.1016/j.scitotenv.2017.10.294
   Zhou Y, 2016, AM J RESP CRIT CARE, V193, P835, DOI 10.1164/rccm.201412-2279OC
NR 41
TC 0
Z9 0
U1 4
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 67
EP 73
DI 10.1016/j.rmed.2019.05.002
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900011
PM 31128612
DA 2020-05-18
ER

PT J
AU Furuuchi, K
   Morimoto, K
   Yoshiyama, T
   Tanaka, Y
   Fujiwara, K
   Okumura, M
   Izumi, K
   Shiraishi, Y
   Mitarai, S
   Ogata, H
   Kurashima, A
   Yoshimori, K
   Ohta, K
   Goto, H
   Sasaki, Y
AF Furuuchi, Koji
   Morimoto, Kozo
   Yoshiyama, Takashi
   Tanaka, Yoshiaki
   Fujiwara, Keiji
   Okumura, Masao
   Izumi, Kiyohiko
   Shiraishi, Yuji
   Mitarai, Satoshi
   Ogata, Hideo
   Kurashima, Atsuyuki
   Yoshimori, Kozo
   Ohta, Ken
   Goto, Hajime
   Sasaki, Yuka
TI Interrelational changes in the epidemiology and clinical features of
   nontuberculous mycobacterial pulmonary disease and tuberculosis in a
   referral hospital in Japan
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Nontuberculous mycobacteria; Tuberculosis; Clinical features;
   Epidemiology; Japan
ID IDENTIFICATION; PREVALENCE; ABSCESSUS; AVIUM
AB Background and objectives: The incidence of nontuberculous mycobacterial pulmonary disease NTM-PD) is increasing, while that of tuberculosis TB) is decreasing in many industrialized countries, including Japan. However, the long-term evaluation of clinico-epidemiological features of NTM-PD in relation to TB are limited. We aimed to clarify the long-term changes in the epidemiology and clinical features of NTM-PD in relation to those of TB at a nationally-designated TB center in Japan.
   Methods: We reviewed all mycobacterial examination records at Fukujuji Hospital between 2006 and 2016. Cases of NTM-PD were defined according to the 2007 American Thoracic Society/Infectious Disease Society of America microbiologic criteria. The current characteristics of Mycobacterium avium complex pulmonary disease MAC-PD) were compared with those in the 1980s and circa 2000.
   Results: We identified a total of 3,546 pulmonary TB cases and 2,155 NTM-PD cases. While the annual number of incident pulmonary TB cases remained stable over the study period P= 0.59), that of NTM-PD cases increased significantly from 165 to 278 P < 0.01). The mean age of pulmonary TB cases increased from 59.7 +/- 16.3 to 66.2 +/- 21.7 years, whereas that of NTM-PD cases remained unchanged. Regarding the age distribution, the greatest increases were observed in patients over 75 years for TB and in patients 50-74 years for NTM. The most common causative organism for NTM was Mycobacterium avium complex 87.3%), M. abscessus complex 5.5%) and M. kansasii 3.9%). Among patients with MAC-PD, the proportion of the nodular bronchiectatic NB) form increased significantly from 60.0% to 84.4% between circa 2000 and 2016 P < 0.01). Significant increases in the NB form were observed in both males 33.3%-70.7%, P < 0.01) and females 71.3%-89.2%, P < 0.01).
   Conclusions: The annual number of incident NTM-PD cases increased markedly. In contrast to patients with TB, the mean age of new NTM-PD patients did not increase in the last 10 years. Among MAC-PD patients, the proportions accounted for by the NB form increased significantly in both sexes.
C1 [Furuuchi, Koji; Morimoto, Kozo; Yoshiyama, Takashi; Tanaka, Yoshiaki; Fujiwara, Keiji; Okumura, Masao; Shiraishi, Yuji; Ogata, Hideo; Kurashima, Atsuyuki; Yoshimori, Kozo; Ohta, Ken; Goto, Hajime; Sasaki, Yuka] Japan AntiTB Assoc, Resp Dis Ctr, Fukujuji Hosp, Tokyo, Japan.
   [Morimoto, Kozo] Japan AntiTB Assoc, Div Clin Res, Fukujuji Hosp, Tokyo, Japan.
   [Izumi, Kiyohiko] Japan AntiTB Assoc, Dept Epidemiol & Clin Res, Res Inst TB, Tokyo, Japan.
   [Mitarai, Satoshi] Japan AntiTB Assoc, Dept Mycobacterium Reference & Res, Res Inst TB, Tokyo, Japan.
RP Morimoto, K (reprint author), Japan AntiTB Assoc, Dept Resp Med, Fukujuji Hosp, 3-1-24 Matsuyama, Kiyose, Tokyo 2048522, Japan.
EM morimotok@fukujuji.org
RI Morimoto, Kozo/V-6505-2019
OI Morimoto, Kozo/0000-0002-8239-9275
FU Japan Agency for Medical Research and Development (AMED)Japan Agency for
   Medical Research and Development (AMED) [JP15fk0108022h0102]
FX This work was supported by the Japan Agency for Medical Research and
   Development, (AMED; JP15fk0108022h0102).
CR Adjemian J, 2012, AM J RESP CRIT CARE, V185, P881, DOI 10.1164/rccm.201111-2016OC
   Arnow PM, 2000, CLIN INFECT DIS, V31, P472, DOI 10.1086/313940
   Brode SK, 2014, INT J TUBERC LUNG D, V18, P1370, DOI 10.5588/ijtld.14.0120
   Chikamatsu Kinuyo, 2016, Kekkaku, V91, P623
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Henkle E, 2015, ANN AM THORAC SOC, V12, P642, DOI 10.1513/AnnalsATS.201412-559OC
   Kim BJ, 1999, J CLIN MICROBIOL, V37, P1714, DOI 10.1128/JCM.37.6.1714-1720.1999
   Ko RE, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e65
   Koh WJ, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02503-2016
   KUSUNOKI S, 1991, J CLIN MICROBIOL, V29, P1596, DOI 10.1128/JCM.29.8.1596-1603.1991
   Mitarai S, 2014, VACCINE, V32, P304, DOI 10.1016/j.vaccine.2013.04.089
   Mizutani S., 1987, KOKYUU, V9, P968
   Morimoto K, 2018, RESP MED, V145, P14, DOI 10.1016/j.rmed.2018.10.012
   Morimoto K, 2017, ANN AM THORAC SOC, V14, P49, DOI [10.1513/AnnalsATS.201607-573OC, 10.1513/annalsats.201607-573oc]
   Morimoto K, 2015, T ROY SOC TROP MED H, V109, P589, DOI 10.1093/trstmh/trv058
   Morimoto Kozo, 2014, Ann Am Thorac Soc, V11, P1, DOI 10.1513/AnnalsATS.201303-067OC
   Nakanaga K, 2014, J CLIN MICROBIOL, V52, P251, DOI 10.1128/JCM.01327-13
   Namkoong H, 2016, EMERG INFECT DIS, V22, P1116, DOI 10.3201/eid2206.151086
   Okumura M, 2008, INTERNAL MED, V47, P1465, DOI 10.2169/internalmedicine.47.1114
   SAITO H, 1989, J CLIN MICROBIOL, V27, P994, DOI 10.1128/JCM.27.5.994-997.1989
   Sexton P, 2008, EUR RESPIR J, V31, P1322, DOI 10.1183/09031936.00140007
   Thomson RM, 2010, EMERG INFECT DIS, V16, P1576, DOI 10.3201/eid1610.091201
   Tuberculosis Surveillance Center, 2016, TUB SURV CTR TUB JAP
   Vesosky B, 2005, IMMUNOL REV, V205, P229, DOI 10.1111/j.0105-2896.2005.00257.x
   Winthrop KL, 2010, AM J RESP CRIT CARE, V182, P977, DOI 10.1164/rccm.201003-0503OC
   Yoshida S, 2018, INT J TUBERC LUNG D, V22, P413, DOI 10.5588/ijtld.17.0673
NR 26
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 74
EP 80
DI 10.1016/j.rmed.2019.05.001
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900012
PM 31128614
DA 2020-05-18
ER

PT J
AU Husebo, GR
   Nielsen, R
   Hardie, J
   Bakke, PS
   Lerner, L
   D'Alessandro-Gabazza, C
   Gyuris, J
   Gabazza, E
   Aukrust, P
   Eagan, T
AF Husebo, Gunnar R.
   Nielsen, Rune
   Hardie, Jon
   Bakke, Per Sigvald
   Lerner, Lorena
   D'Alessandro-Gabazza, Corina
   Gyuris, Jeno
   Gabazza, Esteban
   Aukrust, Pal
   Eagan, Tomas
TI Risk factors for lung cancer in COPD - results from the Bergen COPD
   cohort study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Lung cancer; Phenotypes; Inflammation
ID OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROIDS;
   PHYSICAL-ACTIVITY; MASS INDEX; INFLAMMATION; PROPIONATE; MORTALITY;
   EMPHYSEMA; OBESITY; AIRWAYS
AB Background: COPD patients have an increased risk of developing lung cancer, but the underlying mechanisms are poorly understood. We aimed to identify risk factors for lung cancer in patients from the Bergen COPD Cohort Study.
   Methods: We compared 433 COPD patients with 279 healthy controls, all former or current smokers. All COPD patients had FEV1< 80% and FEV1/FVC-ratio < 0.7. Baseline predictors were sex, age, spirometry, body composition, smoking history, emphysema assessed by CT, chronic bronchitis, prior exacerbation frequency, Charlson Comorbidity Score, inhalation medication and 44 serum/plasma inflammatory biomarkers. Patients were followed up for 9 years recording incidence of lung cancer. Cox-regression models were fitted for the statistical analyses. The biomarkers were evaluated using principal component analysis.
   Results: 28 COPD patients and 3 controls developed lung cancer, COPD patients had a significantly higher risk of developing lung cancer, (HR 5.0; 95% CI 1.5-17.1, p < 0.01, adjusted values). Among COPD patients, emphysema (HR 4.4; 1.7-10.8, p < 0.01) and obesity (HR 3.3; 1.3-8.5, p= 0.02) were associated with a higher cancer rate. Use of inhaled steroids was associated with a lower rate (HR 0.4; 0.2-0.9, p= 0.03). Smoking status, pack-years smoked or levels of systemic inflammatory markers, except for interferon gamma-induced protein 10, did not affect the lung cancer rate in patients with COPD.
   Conclusion: Patients with COPD have a higher lung cancer rate compared to healthy controls adjusted for smoking. The presence of emphysema and obesity in COPD predicted a higher lung cancer risk in COPD patients. Systemic inflammation was not associated with increased lung cancer risk.
C1 [Husebo, Gunnar R.; Nielsen, Rune; Eagan, Tomas] Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway.
   [Husebo, Gunnar R.; Hardie, Jon; Bakke, Per Sigvald; Eagan, Tomas] Univ Bergen, Dept Clin Sci, Bergen, Norway.
   [Lerner, Lorena; Gyuris, Jeno] AVEO Oncol, Cambridge, MA USA.
   [D'Alessandro-Gabazza, Corina; Gabazza, Esteban] Mie Univ, Dept Immunol, Tsu, Mie, Japan.
   [Aukrust, Pal] Oslo Univ Hosp, Res Inst Internal Med, Rikshosp, Oslo, Norway.
   [Aukrust, Pal] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Rikshosp, Oslo, Norway.
   [Aukrust, Pal] Univ Oslo, Inst Clin Med, Oslo, Norway.
RP Husebo, GR (reprint author), Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway.
EM Gunnar.Husebo@uib.no
RI Eagan, Tomas ML/P-3554-2014
OI Eagan, Tomas ML/0000-0001-8725-9960; Gabazza,
   Esteban/0000-0001-5748-1499; Husebo, Gunnar Reksten/0000-0001-6880-8215
CR Abdi L. J., 2010, PRINCIPAL COMPONENT
   Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873
   Agusti A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037483
   Atwater T, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.46
   Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC
   Barreiro E, 2013, FREE RADICAL BIO MED, V65, P859, DOI 10.1016/j.freeradbiomed.2013.08.006
   Barrera L, 2015, ANN ONCOL, V26, P428, DOI 10.1093/annonc/mdu549
   Betakova T, 2017, CURR PHARM DESIGN, V23, P2616, DOI 10.2174/1381612823666170316123736
   Brody Jerome S, 2006, Proc Am Thorac Soc, V3, P535, DOI 10.1513/pats.200603-089MS
   Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   D'Amelio AM, 2010, BRIT J CANCER, V103, P423, DOI 10.1038/sj.bjc.6605759
   de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490
   de-Torres JP, 2016, CHEST, V149, P936, DOI 10.1378/chest.15-1868
   Eagan TML, 2010, EUR RESPIR J, V35, P540, DOI 10.1183/09031936.00088209
   Eide HA, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.65
   Ferkol Thomas, 2014, Ann Am Thorac Soc, V11, P404, DOI 10.1513/AnnalsATS.201311-405PS
   Gagnat AA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01162-2016
   Gibson GJ, 2013, EUR RESPIR J, V42, P559, DOI 10.1183/09031936.00105513
   Gomperts BN, 2011, SEMIN RESP CRIT CARE, V32, P32, DOI 10.1055/s-0031-1272867
   Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477
   Kaminska J, 2006, ONCOLOGY-BASEL, V70, P115, DOI 10.1159/000093002
   Kiri VA, 2009, RESP MED, V103, P85, DOI 10.1016/j.rmed.2008.07.024
   LANGE P, 1990, AM REV RESPIR DIS, V141, P613, DOI 10.1164/ajrccm/141.3.613
   Larsen IK, 2009, EUR J CANCER, V45, P1218, DOI 10.1016/j.ejca.2008.10.037
   Lee CH, 2013, RESP MED, V107, P1222, DOI 10.1016/j.rmed.2012.12.002
   Lee IM, 1999, INT J EPIDEMIOL, V28, P620, DOI 10.1093/ije/28.4.620
   Malhotra J, 2016, EUR RESPIR J, V48, P889, DOI 10.1183/13993003.00359-2016
   Parimon T, 2007, AM J RESP CRIT CARE, V175, P712, DOI 10.1164/rccm.200608-1125OC
   Patel AV, 2017, CANCER CAUSE CONTROL, V28, P1357, DOI 10.1007/s10552-017-0949-0
   Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503
   Quint JK, 2010, CHEST, V137, P812, DOI 10.1378/chest.09-1541
   Raymakers AJN, 2017, RESPIROLOGY, V22, P61, DOI 10.1111/resp.12919
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Schutz Y, 2002, INT J OBESITY, V26, P953, DOI 10.1038/sj.ijo.0802037
   SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503
   Spaks A, 2015, ANTICANCER RES, V35, P6979
   Tanoue LT, 2015, AM J RESP CRIT CARE, V191, P19, DOI 10.1164/rccm.201410-1777CI
   TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512
   van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004
   Wagner PD, 2008, EUR RESPIR J, V31, P492, DOI 10.1183/09031936.00074807
   Wilson DO, 2008, AM J RESP CRIT CARE, V178, P738, DOI 10.1164/rccm.200803-435OC
   Yang Y, 2013, INT J CANCER, V132, P1162, DOI 10.1002/ijc.27719
   Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208
   Yu DX, 2018, JNCI-J NATL CANCER I, V110, P831, DOI 10.1093/jnci/djx286
NR 45
TC 0
Z9 0
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 81
EP 88
DI 10.1016/j.rmed.2019.04.019
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900013
PM 31128615
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Arger, NK
   Ho, M
   Woodruff, PG
   Koth, LL
AF Arger, Nicholas K.
   Ho, Melissa
   Woodruff, Prescott G.
   Koth, Laura L.
TI Serum CXCL11 correlates with pulmonary outcomes and disease burden in
   sarcoidosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; CXCL11; CXCL9; CXCL10; Interferon-gamma; Chemokine
ID CXCR3 LIGANDS; CHEMOKINE RECEPTOR; INTERFERON-GAMMA; UCSD SHORTNESS;
   T-CELLS; EXPRESSION; BLOOD; INDUCTION; CYTOKINES; LUNG
AB Background: Sarcoidosis is a systemic granulomatous disease of unknown etiology that affects the lungs in 90% of patients, but has a wide range of disease manifestations and outcomes including chronic and progressive courses. Noninvasive biomarkers are needed to assess these outcomes and guide decisions for long term monitoring and treatment. Interferon-gamma (IFN-gamma)-inducible chemotactic cytokines (chemokines), CXCL9, CXCL10 and CXCL11, show promise in this regard because they have been implicated in the pathogenesis of and reflect the burden of granulomatous inflammation. CXCL11 has been reported to have unique functional properties in modulating adaptive immunity in model systems so our goal was to examine serum levels of CXCL11 in relation to clinical outcomes in a heterogeneous cohort of sarcoidosis subjects.
   Methods: CXCL19, CXCL10, and CXCL11 serum levels were measured in sarcoidosis and healthy subjects using ELISA assay. We determined relationships between CXCL11 and standard clinical inflammatory markers, expression of IFN-gamma-related genes in whole blood, organ involvement, dyspnea scores, and measures of pulmonary function.
   Results: In a cross-sectional analysis of 104 sarcoidosis subjects, serum CXCL11 was significantly elevated compared to 49 healthy controls (p < 0.001). CXCL11 was positively correlated with CXCL9 and CXCL10 (p < 0.001), sedimentation rate (p < 0.01), and mean expression of three IFN-gamma-related genes in whole blood (GBP1, STAT1, and STAT2) (p < 0.001). CXCL11 was inversely correlated with FVC % predicted (% pred) and FEV1 % pred and higher levels were associated with higher patient-reported dyspnea scores. We found positive correlations between CXCL11 and number of organs involved. Using survival analyses, we found that CXCL11 levels were predictive of future pulmonary function test (PFT) decline (log rank< 0.001 and HR of log(10)(CXCL11)= 5.1, 95% CI 1.2-21, p= 0.026).
   Conclusions: The pattern of expression of serum CXCL11 in sarcoidosis patients suggests that this blood measure could be helpful in identifying patients that need longer-term monitoring for progressive thoracic and extrathoracic sarcoidosis.
C1 [Arger, Nicholas K.; Ho, Melissa; Woodruff, Prescott G.; Koth, Laura L.] Univ Calif San Francisco, Div Pulm & Crit Care, 505 Parnassus Ave, San Francisco, CA 94143 USA.
RP Arger, NK (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM nicholas.arger@ucsf.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R56IO87652,
   T32HL007185]
FX This work was supported by the National Institutes of Health (R56IO87652
   and T32HL007185).
CR Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046
   Benn BS, 2017, LUNG, V195, P553, DOI 10.1007/s00408-017-0037-y
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Chappell AG, 2000, SARCOIDOSIS VASC DIF, V17, P167
   Chung W, 2015, INT J TUBERC LUNG D, V19, P1476, DOI 10.5588/ijtld.15.0325
   Delaigle A, 2009, J AM STAT ASSOC, V104, P348, DOI 10.1198/jasa.2009.0114
   Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619
   Foley PJ, 1999, AM J RESP CRIT CARE, V160, P1009, DOI 10.1164/ajrccm.160.3.9810032
   Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Hunninghake G W, 1999, Sarcoidosis Vasc Diffuse Lung Dis, V16, P149
   Inui N, 2001, J ALLERGY CLIN IMMUN, V107, P337, DOI 10.1067/mai.2001.112273
   Kamphuis LS, 2014, J BONE MINER RES, V29, P2498, DOI 10.1002/jbmr.2262
   Keir G, 2010, SEMIN RESP CRIT CARE, V31, P409, DOI 10.1055/s-0030-1262209
   Kim DS, 1999, CHEST, V115, P1059, DOI 10.1378/chest.115.4.1059
   Kim S, 2015, J MOL DIAGN, V17, P90, DOI 10.1016/j.jmoldx.2014.08.005
   Korniejewska A, 2011, IMMUNOLOGY, V132, P503, DOI 10.1111/j.1365-2567.2010.03384.x
   Koth LL, 2011, AM J RESP CRIT CARE, V184, P1153, DOI 10.1164/rccm.201106-1143OC
   Kriegova E, 2011, EUR RESPIR J, V38, P1136, DOI 10.1183/09031936.00089910
   Lee K, 2015, INT J TUBERC LUNG D, V19, P191, DOI 10.5588/ijtld.14.0525
   Li HY, 2017, GENE, V596, P98, DOI 10.1016/j.gene.2016.09.037
   LINTON O, 1995, BIOMETRIKA, V82, P93, DOI 10.1093/biomet/82.1.93
   Loos T, 2006, LAB INVEST, V86, P902, DOI 10.1038/labinvest.3700453
   Ma WS, 2013, J BIOL CHEM, V288, P15481, DOI 10.1074/jbc.M112.445510
   Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585
   McDonnell MJ, 2016, SARCOIDOSIS VASC DIF, V33, P331
   Moller DR, 2015, ANN AM THORAC SOC, V12, P1561, DOI 10.1513/AnnalsATS.201503-172OT
   Mollers M, 2001, THORAX, V56, P487, DOI 10.1136/thorax.56.6.487
   Nishioka Y, 2007, CLIN EXP IMMUNOL, V149, P317, DOI 10.1111/j.1365-2249.2007.03423.x
   Piotrowski WJ, 2014, POL ARCH MED WEWN, V124, P395, DOI 10.20452/pamw.2349
   Prasse A, 2000, CLIN EXP IMMUNOL, V122, P241, DOI 10.1046/j.1365-2249.2000.01365.x
   PRIOR C, 1991, AM REV RESPIR DIS, V143, P53, DOI 10.1164/ajrccm/143.1.53
   Proost P, 2004, J LEUKOCYTE BIOL, V75, P777, DOI 10.1189/jlb.1003524
   ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852
   Schiffer R, 2002, INFLAMM RES, V51, P403, DOI 10.1007/PL00000321
   Schnerch J, 2016, AM J RESP CELL MOL, V55, P749, DOI 10.1165/rcmb.2015-0278OC
   Su R, 2014, EUR RESPIR J, V44, P985, DOI 10.1183/09031936.00039714
   Su R, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-121
   Swigris JJ, 2012, RESP MED, V106, P1447, DOI 10.1016/j.rmed.2012.06.018
   Swigris JJ, 2010, RESP MED, V104, P1350, DOI 10.1016/j.rmed.2010.03.027
   Torraca V, 2015, DIS MODEL MECH, V8, P253, DOI 10.1242/dmm.017756
   Van Raemdonck K, 2015, CYTOKINE GROWTH F R, V26, P311, DOI 10.1016/j.cytogfr.2014.11.009
   Wahlstrom J, 2001, AM J RESP CRIT CARE, V163, P115, DOI 10.1164/ajrccm.163.1.9906071
   Zohar Y, 2014, J CLIN INVEST, V124, P2009, DOI 10.1172/JCI71951
NR 44
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 89
EP 96
DI 10.1016/j.rmed.2019.04.005
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900014
PM 31128616
DA 2020-05-18
ER

PT J
AU Mulgirigama, A
   Barnes, N
   Fletcher, M
   Pedersen, S
   Pizzichini, E
   Tsiligianni, I
AF Mulgirigama, Aruni
   Barnes, Neil
   Fletcher, Monica
   Pedersen, Soren
   Pizzichini, Emilio
   Tsiligianni, Ioanna
TI A review of the burden and management of mild asthma in adults -
   Implications for clinical practice
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Mild asthma; Corticosteroids; Intermittent corticosteroids; Medication
   adherence; Primary healthcare; Anti-asthmatic agents
ID INHALED CORTICOSTEROID TREATMENT; HEALTH-CARE COSTS; EARLY INTERVENTION;
   PERSISTENT ASTHMA; BUDESONIDE-FORMOTEROL; MOMETASONE FUROATE; DISEASE
   BURDEN; DOUBLE-BLIND; FOLLOW-UP; ADHERENCE
AB Mild asthma is present in 50-75% of patients with asthma and is defined by the Global Initiative for Asthma as asthma that can be well controlled with low-intensity treatments (Steps 1 and 2). Despite this definition, 'mild' asthma is often not well controlled in reality, and can have a significant impact on an individual's symptom burden and quality of life.
   We performed a PubMed literature search to investigate the burden of 'mild' asthma in the lives of patients, including future risk and asthma control, and the current management strategies. While clinical guidelines recommend long-term, daily, low-dose inhaled corticosteroids (ICS) for 'mild' asthma, published data suggest that ICS are often under-prescribed or used intermittently as symptoms arise. Furthermore, patients and physicians tend to overestimate disease control, impacting the accuracy of diagnosing 'mild asthma' and subsequent management. This disconnect may be amplified by miscommunication between patients and physicians, limited objective assessment of control, and differences in guidelines.
   As with moderate and severe asthma, current evidence supports early initiation of regular ICS in 'mild' asthma to address the underlying inflammation, achieve symptom control and reduce risk of exacerbations. Adherence to ICS treatment is key and can be improved by educating both patients and healthcare professionals. The results of this literature search challenge the term 'mild' asthma and suggest strategies to improve the proactive management of the disease to enable patients to live symptom-free.
C1 [Mulgirigama, Aruni; Barnes, Neil; Fletcher, Monica; Pizzichini, Emilio] GSK, 980 Great West Rd, Brentford TW8 9GS, Middx, England.
   [Barnes, Neil] Barts & London Queen Marys Sch Med & Dent, 4 Newark St, London E1 2AT, England.
   [Fletcher, Monica] Univ Edinburgh, 9 Little France Rd, Edinburgh EH16 4UX, Midlothian, Scotland.
   [Pedersen, Soren] Univ Southern Denmark, Kolding Hosp, Dept Paediat, Sygehusvej 24, DK-6000 Kolding, Denmark.
   [Pizzichini, Emilio] Univ Fed Santa Catarina, NUPAIVA Asthma Res Ctr, BR-88040970 Florianopolis, SC, Brazil.
   [Tsiligianni, Ioanna] Univ Crete, Dept Social Med, Fac Med, GR-71003 Iraklion, Voutes, Greece.
RP Barnes, N (reprint author), GSK, Resp Med Franchise, 980 Great West Rd, Brentford TW8 9GS, Middx, England.
EM aruni.x.mulgirigama@gsk.com; neil.c.barnes@gsk.com;
   monica.x.fletcher@gsk.com; sp@spconforsk.dk; e.x.pizzichini@gsk.com;
   i.tsiligianni@uoc.gr
RI Pizzichini, Emilio/L-2252-2014
OI Pizzichini, Emilio/0000-0001-7046-9996
FU GSKGlaxoSmithKline
FX This review was funded by GSK.
CR [Anonymous], 2014, NATL REV ASTHMA DEAT
   Apter AJ, 2013, J ALLERGY CLIN IMMUN, V132, P321, DOI 10.1016/j.jaci.2013.02.014
   Bakirtas A, 2017, RESP MED, V131, P236, DOI 10.1016/j.rmed.2017.08.029
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Bateman ED, 2018, NEW ENGL J MED, V378, P1877, DOI 10.1056/NEJMoa1715275
   Baxter M, 2017, BRIT J DIAB, V17, P24, DOI 10.15277/bjd.2017.113
   Beasley R, 2014, J ALLERGY CLIN IMMUN, V133, P39, DOI 10.1016/j.jaci.2013.10.053
   Bender BG, 2008, ANN ALLERG ASTHMA IM, V101, P382, DOI 10.1016/S1081-1206(10)60314-6
   Boulet LP, 2015, RESP MED, V109, P991, DOI 10.1016/j.rmed.2015.05.004
   Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552
   British Thoracic Society, 2016, BRIT GUID MAN ASTHM
   Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1167, DOI 10.1016/j.jaci.2008.02.029
   Chapman KR, 2005, RESP MED, V99, P1350, DOI 10.1016/j.rmed.2005.03.020
   Colice G, 2007, J ASTHMA, V44, P479, DOI 10.1080/02770900701424124
   Colice GL, 2012, ANN ALLERG ASTHMA IM, V108, P157, DOI 10.1016/j.anai.2011.12.017
   de Vries F, 2010, EUR RESPIR J, V36, P494, DOI 10.1183/09031936.00124209
   Demoly P, 2012, EUR RESPIR REV, V21, P66, DOI 10.1183/09059180.00008111
   Ding B, 2018, RESPIROLOGY, V23, P369, DOI 10.1111/resp.13189
   Ding B, 2017, ADV THER, V34, P1109, DOI 10.1007/s12325-017-0520-0
   Doherty S R, 2006, Rural Remote Health, V6, P529
   Dusser D, 2007, ALLERGY, V62, P591, DOI 10.1111/j.1398-9995.2007.01394.x
   Friedman HS, 2010, J ASTHMA, V47, P994, DOI 10.1080/02770903.2010.513076
   Friedman HS, 2010, AM J MANAG CARE, V16, pE151
   Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057
   Gerald JK, 2015, J ALLER CL IMM-PRACT, V3, P957, DOI 10.1016/j.jaip.2015.06.021
   *GLOB IN ASTHM, 2006, GLOB STRAT ASTHM MAN
   Global Asthma Network, 2014, GLOB ASTHM REP
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Guilbert TW, 2011, J ASTHMA, V48, P126, DOI 10.3109/02770903.2010.535879
   Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699
   Haahtela T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00470-2017
   Haahtela T, 2009, J ALLERGY CLIN IMMUN, V124, P1180, DOI 10.1016/j.jaci.2009.09.036
   Haughney John, 2004, Prim Care Respir J, V13, P28, DOI 10.1016/j.pcrj.2003.11.007
   Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x
   Hyland Michael E, 2009, Prim Care Respir J, V18, P114, DOI 10.3132/pcrj.2008.00066
   International Primary Care Respiratory Group, 2012, IMPR CAR AD DIFF MAN
   International Primary Care Respiratory Group, 2013, NAT RESP GUID US PRI
   International Primary Care Respiratory Group, 2016, ASTHM CONTR TOOLS US
   Ishmael F, 2011, JAOA, V7, P11
   Kew KM, 2016, COCHRANE DB SYST REV, V6
   Ko FWS, 2018, RESPIROLOGY, V23, P348, DOI 10.1111/resp.13198
   Kocks JWH, 2018, CURR OPIN PULM MED, V24, P18, DOI 10.1097/MCP.0000000000000447
   LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4
   *NAT ASTHM ED PREV, 2007, 3 NAT ASTHM ED PREV
   Nathan RA, 2015, J ALLER CL IMM-PRACT, V3, P734, DOI 10.1016/j.jaip.2015.04.013
   National Institute for Heath and Care Excellence, 2017, ASTHM DIAGN MON CHRO
   Navaratnam P, 2010, PATIENT PREFER ADHER, V4, P197
   Ni Chroinin M, 2009, COCHRANE DB SYST REV, V4
   Nunes Carlos, 2017, Asthma Res Pract, V3, P1, DOI 10.1186/s40733-016-0029-3
   O'Byrne PM, 2018, NEW ENGL J MED, V378, P1865, DOI 10.1056/NEJMoa1715274
   O'Byrne PM, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01103-2017
   O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC
   O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102
   O'Conor R, 2015, CHEST, V147, P1307, DOI 10.1378/chest.14-0914
   Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861
   Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7
   Peters SP, 2006, J NATL MED ASSOC, V98, P851
   Plakas S, 2016, OPEN J NURS, V6, P158, DOI [DOI 10.4236/OJN.2016.63017, 10.4236/ojn.2016.63017]
   Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.9
   Reddel HK, 2017, LANCET, V389, P157, DOI 10.1016/S0140-6736(16)31399-X
   Rodrigo GJ, 2013, RESP MED, V107, P1133, DOI 10.1016/j.rmed.2013.05.005
   Sadatsafavi M, 2010, CAN RESPIR J, V17, P74, DOI 10.1155/2010/361071
   Shimoda T, 2016, ALLERGY ASTHMA PROC, V37, P387, DOI 10.2500/aap.2016.37.3975
   Shimoda T, 2013, INT ARCH ALLERGY IMM, V162, P323, DOI 10.1159/000353910
   Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880
   Sundstrom J, 2015, ANN INTERN MED, V162, P184, DOI 10.7326/M14-0773
   Tan Wan C, 2007, Paediatr Drugs, V9, P219, DOI 10.2165/00148581-200709040-00003
   van der Molen T, 1998, AM J RESP CRIT CARE, V158, P121, DOI 10.1164/ajrccm.158.1.9707035
   Wang G., 2017, SHOCK VIB, V2, P1, DOI DOI 10.1063/1.4973238
   Ye Q, 2017, PULM THER, V3, P1, DOI DOI 10.1007/S41030-017-0043-5
NR 70
TC 1
Z9 1
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 97
EP 104
DI 10.1016/j.rmed.2019.04.024
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900015
PM 31128617
DA 2020-05-18
ER

PT J
AU Mantyla, J
   Mazur, W
   Torola, T
   Bergman, P
   Saarinen, T
   Kauppi, P
AF Mantyla, Jarkko
   Mazur, Witold
   Torola, Tanja
   Bergman, Paula
   Saarinen, Tuomas
   Kauppi, Paula
TI Asthma as aetiology of bronchiectasis in Finland
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Comorbidity; COPD; Extensive disease
ID CYSTIC FIBROSIS BRONCHIECTASIS; ADULT PATIENTS; DISEASE; COHORT
AB Background: By definition bronchiectasis (BE) means destructed structure of normal bronchus as a consequence of frequent bacterial infections and inflammation. In many senses, BE is a neglected orphan disease. A recent pan-European registry study, EMBARC, has been set up in order to better understand its pathophysiology, better phenotype patients, and to individualize their management.
   Aim: To examine the aetiology and co-morbidity of BE in the capital area in Finland.
   Methods: Two hundred five patients with BE diagnosis and follow up visits between 2016 and 2017 in Helsinki University Hospital were invited to participate in the study. Baseline demographics, lung functions, imaging, microbiological, and therapeutic data, together with co-morbidities were entered into EMBARC database. Clinical characteristics, aetiologic factors, co-morbidities, and risk factors for extensive BE were explored.
   Results: To the study included 95 adult patients and seventy nine percent of the BE patients were women. The mean age was 69 years (SD +/- 13). Asthma was a comorbid condition in 68% of the patients but in 26% it was estimated to be the cause of BE. Asthma was aetiological factor for BE if it had been diagnosed earlier than BE. As 41% BE were idiopathic, in 11% the disorder was postinfectious and others were associated to rheumatic disease, Alpha-1-antitrypsin deficiency, IgG deficiency and Kartagener syndrome. The most common co-morbidities in addition to asthma were cardiovascular disease (30%), gastroesophageal reflux disease (26%), overweight (22%), diabetes (16%), inactive neoplasia (15%), and immunodeficiency (12%). Extensive BE was found in 68% of BE patients in whom four or more lobes were affected. Risk factors for extensive BE were asthma (OR 2.7), asthma as aetiology for BE (OR 4.3), and rhinosinusitis (OR 3.1).
   Conclusions: Asthma was associated to BE in 68% and it was estimated as aetiology in every fourth patient. However, retrospectively, it is difficult to exclude asthma as a background cause in patients with asthma-like symptoms and respiratory infections. We propose asthma as an aetiology factor for BE if it is diagnosed earlier than BE. Asthma and rhinosinusitis were predictive for extensive BE.
C1 [Mantyla, Jarkko; Mazur, Witold; Torola, Tanja; Kauppi, Paula] Univ Helsinki, Helsinki, Finland.
   [Mantyla, Jarkko; Kauppi, Paula] Helsinki Univ Hosp, Resp Dis & Allergol, Helsinki, Finland.
   [Mantyla, Jarkko; Mazur, Witold; Torola, Tanja] Helsinki Univ Hosp, Resp Dis, Helsinki, Finland.
   [Bergman, Paula] Univ Helsinki, Dept Publ Hlth, Biostat Consulting, Helsinki, Finland.
   [Saarinen, Tuomas] Tampere Univ Hosp, Radiol Dept, Tampere, Finland.
RP Mantyla, J (reprint author), Helsinki Univ Hosp, Skin & Allergy Hosp, Meilahdentie 2,POB 160, FI-00029 Helsinki, Finland.
EM jarkko.mantyla@hus.fi
OI Mantyla, Jarkko Mikael/0000-0002-5114-4106; Bergman, Paula
   Hannele/0000-0003-4672-2554
FU Foundation of the Finnish Anti-Tuberculosis Association, Finland;
   Finnish Research Foundation of the Pulmonary Diseases, Finland; HUS EVO,
   Finland
FX Supported by:; Foundation of the Finnish Anti-Tuberculosis Association,
   Finland.; The Finnish Research Foundation of the Pulmonary Diseases,
   Finland.; HUS EVO, Finland.; In relation to this presentation, I declare
   that there are no conflicts of interest.
CR Aksamit TR, 2017, CHEST, V151, P982, DOI 10.1016/j.chest.2016.10.055
   Amorim A, 2015, REV PORT PNEUMOL, V21, P5, DOI 10.1016/j.rppnen.2014.06.009
   Buscot M, 2016, RESPIRATION, V92, P1, DOI 10.1159/000446923
   Chalmers JD, 2016, EUROPEAN RESP J, V2, P00081, DOI [10.1183/23120541.00081-2015, DOI 10.1183/23120541.00081-2015]
   Chandrasekaran R., 2018, BMC PULM MED, V18, P1
   Coman I, 2018, ANN ALLERG ASTHMA IM, V120, P409, DOI 10.1016/j.anai.2018.02.016
   Dimakou K, 2016, RESP MED, V116, P1, DOI 10.1016/j.rmed.2016.05.001
   Flume PA, 2018, LANCET, V392, P880, DOI 10.1016/S0140-6736(18)31767-7
   G. Initiative, GLOB STRAT GLOB STRA
   Gao YH, 2016, RESPIROLOGY, V21, P1376, DOI 10.1111/resp.12832
   Goeminne P.C., 2012, RESP RES, V13, P1
   Hu ZW, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-34
   Jousilahti P., 2012, ASTHMA RESP ALLERGY, P985
   Kainu A, 2013, PRIM CARE RESP J, V22, P64, DOI 10.4104/pcrj.2013.00002
   Lonni S, 2015, ANN AM THORAC SOC, V12, P1764, DOI 10.1513/AnnalsATS.201507-472OC
   Mannino DM, 2010, THORAX, V65, P1, DOI 10.1136/thx.2009.118778
   Mao B., ASTHMA BRONCHIECTASI, P1680
   McCallister JW, 2011, THER ADV RESPIR DIS, V5, P143, DOI DOI 10.1177/1753465810384606
   McDonnell MJ, 2015, RESPIROLOGY, V20, P749, DOI 10.1111/resp.12522
   NAIDICH DP, 1982, J COMPUT ASSIST TOMO, V6, P437, DOI 10.1097/00004728-198206000-00001
   Olveira C, 2017, ARCH BRONCONEUMOL, V53, P366, DOI 10.1016/j.arbres.2016.12.003
   Sat O., 2018, REV ETIOLOGY CLIN PR, V137, P35
   Saynajakangas O, 1997, ALLERGY, V52, P1120, DOI 10.1111/j.1398-9995.1997.tb00186.x
   Sears M. R., 2014, TRENDS PREVALENCE AS, P219
   Shoemark A, 2007, RESP MED, V101, P1163, DOI 10.1016/j.rmed.2006.11.008
NR 25
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JUN
PY 2019
VL 152
BP 105
EP 111
DI 10.1016/j.rmed.2019.04.022
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HZ1QO
UT WOS:000468622900016
PM 31128603
DA 2020-05-18
ER

PT J
AU Moon, SM
   Jhun, BW
   Baek, SY
   Kim, S
   Jeon, K
   Ko, RE
   Shin, SH
   Lee, H
   Kwon, OJ
   Huh, HJ
   Ki, CS
   Lee, NY
   Chung, MJ
   Lee, KS
   Shin, SJ
   Daley, CL
   Koh, WJ
AF Moon, Seong Mi
   Jhun, Byung Woo
   Baek, Sun-Young
   Kim, Seonwoo
   Jeon, Kyeongman
   Ko, Ryoung-Eun
   Shin, Sun Hye
   Lee, Hyun
   Kwon, O. Jung
   Huh, Hee Jae
   Ki, Chang-Seok
   Lee, Nam Yong
   Chung, Myung Jin
   Lee, Kyung Soo
   Shin, Sung Jae
   Daley, Charles L.
   Koh, Won-Jung
TI Long-term natural history of non-cavitary nodular bronchiectatic
   nontuberculous mycobacterial pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Nontuberculous mycobacteria; Mycobacterium avium complex; Mycobacterium
   abscessus; Natural history
ID COMPLEX LUNG-DISEASE; RISK-FACTORS; CLINICAL-SIGNIFICANCE; TREATMENT
   OUTCOMES; AVIUM; ABSCESSUS; MASSILIENSE; DIAGNOSIS; THERAPY;
   DIFFERENTIATION
AB Background: Information about the natural history of nontuberculous mycobacterial pulmonary disease (NTM-PD) is limited. The purpose of this study was to evaluate the long-term natural history of non-cavitary nodular bronchiectatic NTM-PD and the factors associated with treatment initiation and the frequency of spontaneous sputum culture conversion after diagnosis of NTM-PD.
   Methods: We evaluated 1,021 patients with newly diagnosed non-cavitary nodular bronchiectatic NTM-PD caused by Mycobacterium avium complex or M. abscessus between 2003 and 2013.
   Results: Of 1,021 patients, 562 (55%) initiated antibiotic treatment and 459 (45%) did not. Young age (adjusted hazard ratio [aHR] = 0.99; 95% confidence interval [CI] = 0.98-0.99), low body mass index (aHR = 0.96; 95% CI = 0.93-0.99), previous history of tuberculosis (aHR = 1.23; 95% CI = 1.01-1.50), respiratory complaints such as cough (aHR = 1.36; 95% CI = 1.05-1.75) and sputum production (aHR = 1.47; 95% CI = 1.13-1.91), and high number of involved lobes on high-resolution computed tomography (aHR = 1.22; 95% CI = 1.14-1.31) were associated with treatment initiation. Of 459 patients who did not initiate treatment, 157 (34%) showed spontaneous sputum culture conversion. None of the clinical factors was associated with spontaneous conversion. After spontaneous culture conversion, 26 of 157 (17%) showed redeveloped NTM-PD caused by a species different from the original species.
   Conclusions: The natural history of non-cavitary nodular bronchiectatic NTM-PD is variable. After diagnosis, the decision to initiate antibiotic therapy should be individualized based on consideration of the risk factors for disease progression. However, for patients who do not start antibiotic therapy, continuous and lifetime follow-up is recommended to manage underlying bronchiectasis and the possibility of late progression of NTM-PD.
C1 [Moon, Seong Mi; Jhun, Byung Woo; Jeon, Kyeongman; Ko, Ryoung-Eun; Shin, Sun Hye; Lee, Hyun; Kwon, O. Jung; Koh, Won-Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Baek, Sun-Young; Kim, Seonwoo] Samsung Med Ctr, Stat & Data Ctr, Seoul, South Korea.
   [Huh, Hee Jae; Ki, Chang-Seok; Lee, Nam Yong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med & Genet, Seoul, South Korea.
   [Chung, Myung Jin; Lee, Kyung Soo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul, South Korea.
   [Shin, Sung Jae] Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea.
   [Shin, Sung Jae] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.
   [Shin, Sung Jae] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea.
   [Daley, Charles L.] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO USA.
   [Daley, Charles L.] Univ Colorado, Dept Med, Aurora, CO USA.
RP Koh, WJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM wjkoh@skku.edu
RI Ki, Chang-Seok/G-7559-2014; Jeon, Kyeongman/F-5963-2019
OI Ki, Chang-Seok/0000-0001-7679-8731; Jeon, Kyeongman/0000-0002-4822-1772
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea; Korea government (MSIT)Korean Government
   [NRF-2018R1A2A1A05018309]
FX This research was supported by the National Research Foundation of Korea
   (NRF) founded by the Korea government (MSIT) (NRF-2018R1A2A1A05018309).
   The sponsor had no role in the design of the study, the collection and
   analysis of the data, or the preparation of the manuscript.
CR [Anonymous], 1974, Bull World Health Organ, V51, P473
   Boyle DP, 2016, ANN AM THORAC SOC, V13, P1956, DOI 10.1513/AnnalsATS.201605-344BC
   Boyle DP, 2015, AM J RESP CRIT CARE, V191, P1310, DOI 10.1164/rccm.201501-0067OC
   Chan ED, 2013, SEMIN RESP CRIT CARE, V34, P110, DOI 10.1055/s-0033-1333573
   Cowman SA, 2018, AM J RESP CELL MOL, V58, P510, DOI 10.1165/rcmb.2017-0230OC
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141
   Gochi M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008058
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2015, CHEST, V147, P1369, DOI 10.1378/chest.14-1297
   Harada T, 2012, J CLIN MICROBIOL, V50, P3556, DOI 10.1128/JCM.01175-12
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Hayashi M, 2012, AM J RESP CRIT CARE, V185, P575, DOI 10.1164/rccm.201107-1203OC
   Henkle E, 2017, ANN AM THORAC SOC, V14, P1120, DOI 10.1513/AnnalsATS.201610-801OC
   Honda JR, 2015, CLIN CHEST MED, V36, P1, DOI 10.1016/j.ccm.2014.10.001
   Huh HJ, 2018, INFECT GENET EVOL, VS1567-S1348, P30784
   Hwang JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00537-2016
   Jeong BH, 2015, AM J RESP CRIT CARE, V191, P96, DOI 10.1164/rccm.201408-1545OC
   Jhun BW, 2018, AM J RESP CRIT CARE, V198, P1322, DOI [10.1164/rccm.201802-0321OC, 10.1164/rccm.201802-0321oc]
   Kikuchi T, 2009, THORAX, V64, P901, DOI 10.1136/thx.2009.114603
   Kim SJ, 2014, INT J TUBERC LUNG D, V18, P730, DOI 10.5588/ijtld.13.0792
   Kim SJ, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0349-3
   Kim SY, 2017, DIAGN MICR INFEC DIS, V88, P125, DOI 10.1016/j.diagmicrobio.2017.02.017
   Kitada S, 2012, INT J TUBERC LUNG D, V16, P660, DOI 10.5588/ijtld.11.0534
   Koh WJ, 2014, INT J TUBERC LUNG D, V18, P1141, DOI 10.5588/ijtld.14.0134
   Koh WJ, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02503-2016
   Koh WJ, 2017, CLIN INFECT DIS, V64, P309, DOI 10.1093/cid/ciw724
   Koh WJ, 2016, CHEST, V150, P1211, DOI 10.1016/j.chest.2016.05.003
   Koh WJ, 2012, CHEST, V142, P1482, DOI 10.1378/chest.12-0494
   Koh WJ, 2011, AM J RESP CRIT CARE, V183, P405, DOI 10.1164/rccm.201003-0395OC
   Lee BY, 2015, ANTIMICROB AGENTS CH, V59, P2972, DOI 10.1128/AAC.04577-14
   Lee Geewon, 2013, Ann Am Thorac Soc, V10, P299, DOI 10.1513/AnnalsATS.201303-062OC
   Lee MR, 2012, J INFECTION, V64, P228, DOI 10.1016/j.jinf.2011.11.006
   Lyu J, 2014, RESP MED, V108, P1706, DOI 10.1016/j.rmed.2014.09.002
   Min J, 2015, INT J TUBERC LUNG D, V19, P1239, DOI 10.5588/ijtld.14.0139
   Moon SM, 2016, DIAGN MICR INFEC DIS, V86, P382, DOI 10.1016/j.diagmicrobio.2016.09.016
   Orme IM, 2014, INFECT IMMUN, V82, P3516, DOI 10.1128/IAI.01606-13
   Pan SW, 2017, CLIN INFECT DIS, V65, P927, DOI 10.1093/cid/cix479
   Park J, 2017, CLIN INFECT DIS, V64, P301, DOI 10.1093/cid/ciw723
   Philley JV, 2015, CLIN CHEST MED, V36, P79, DOI 10.1016/j.ccm.2014.10.005
   Prevots DR, 2015, CLIN CHEST MED, V36, P13, DOI 10.1016/j.ccm.2014.10.002
   Ryu YJ, 2016, TUBERC RESPIR DIS, V79, P74, DOI 10.4046/trd.2016.79.2.74
   Shin SJ, 2013, CLIN INFECT DIS, V57, P32, DOI 10.1093/cid/cit172
   Stout JE, 2016, INT J INFECT DIS, V45, P123, DOI 10.1016/j.ijid.2016.03.006
   Thomson RM, 2009, RESPIROLOGY, V14, P12, DOI 10.1111/j.1440-1843.2008.01408.x
   Tiemersma EW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017601
   Uchiya K, 2017, SCI REP-UK, V7, DOI 10.1038/srep39750
   Wallace RJ, 2014, CHEST, V146, P276, DOI 10.1378/chest.13-2538
   Wallace RJ, 1997, AM J RESP CRIT CARE, V156, pS1
   Zweijpfenning S, 2017, RESP MED, V131, P220, DOI 10.1016/j.rmed.2017.08.031
NR 49
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 1
EP 7
DI 10.1016/j.rmed.2019.03.014
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200001
PM 31047103
DA 2020-05-18
ER

PT J
AU Jurisch, P
   Gall, H
   Richter, MJ
   Seeger, W
   Nahrlich, L
   Volkel, S
   Hirche, TO
   Schulz, R
AF Jurisch, Peter
   Gall, Henning
   Richter, Manuel Jonas
   Seeger, Werner
   Naehrlich, Lutz
   Voelkel, Sebastian
   Hirche, Tim Oliver
   Schulz, Richard
TI Increased frequency of the restless legs syndrome in adults with cystic
   fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Restless legs syndrome; Sleep; Cystic fibrosis
ID IRON-DEFICIENCY
AB Background: Patients with cystic fibrosis (CF) may suffer from iron deficiency which is a known risk factor for the restless legs syndrome (RLS), however, its prevalence has not yet been investigated in these subjects.
   Patients and methods: Adult out-patients with CF (n=39) and healthy volunteers (n=32) were recruited for this study. A diagnosis of RLS was made based on the diagnostic criteria established by the International Restless Legs Syndrome Study Group (IRLSSG). The IRLSSG rating scale was used to assess the severity of the disease. Furthermore, in the CF group, parameters of iron metabolism were measured in peripheral venous blood samples.
   Results: The RLS occurred more frequently in the CF patients than the controls (n=13/33,3% vs. n=2/6,3%; p<0,05). In the CF patients suffering from RLS, the mean score of the IRLSSG rating scale was 17,2 +/- 9,4 indicating moderate disease severity. Iron deficiency was present in the majority of the CF patients investigated (n=33/84,6%), however, serum iron, ferritin and transferrin levels as well as transferrin saturation were similar in those with vs. without RLS.
   Conclusions: The frequency of the RLS is increased in adult patients with CF. On an average, its severity is moderate and it is not related to iron deficiency as evaluated by serum parameters of iron metabolism.
C1 [Jurisch, Peter] Clin Waldhof Elgershausen, Greifenstein, Germany.
   [Jurisch, Peter; Gall, Henning; Richter, Manuel Jonas; Seeger, Werner; Schulz, Richard] Univ Hosp Giessen, Dept Pulm Med, Giessen, Germany.
   [Naehrlich, Lutz] Univ Hosp Giessen, Dept Pediat Pneumol, Giessen, Germany.
   [Voelkel, Sebastian; Hirche, Tim Oliver; Schulz, Richard] Helios Dr Horst Schmidt Kliniken, Dept Pulm Med, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany.
   [Gall, Henning; Richter, Manuel Jonas; Seeger, Werner] German Ctr Lung Res DZL, Giessen, Germany.
RP Schulz, R (reprint author), Helios Dr Horst Schmidt Kliniken, Dept Pulm Med, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany.
EM Richard.Schulz@helios-gesundheit.de
RI Naehrlich, Lutz/F-4574-2015
OI Naehrlich, Lutz/0000-0002-7146-6997; Seeger, Werner/0000-0003-1946-0894
CR Allen RP, 2014, SLEEP MED, V15, P860, DOI 10.1016/j.sleep.2014.03.025
   Allen RP, 2001, NEUROLOGY, V56, P263, DOI 10.1212/WNL.56.2.263
   Bouka A, 2012, RESP MED, V106, P1244, DOI 10.1016/j.rmed.2012.06.010
   Dignass Axel, 2018, Int J Chronic Dis, V2018, P9394060, DOI 10.1155/2018/9394060
   Earley CJ, 2000, NEUROLOGY, V54, P1698, DOI 10.1212/WNL.54.8.1698
   Garcia-Borreguero D, 2014, CURR OPIN NEUROL, V27, P493, DOI 10.1097/WCO.0000000000000117
   Gungen AC, 2018, CLIN RESPIR J, V12, P1460, DOI 10.1111/crj.12684
   Hayes D, 2007, J CYST FIBROS, V6, P234, DOI 10.1016/j.jcf.2006.07.003
   Lo Coco D, 2009, SLEEP MED, V10, P572, DOI 10.1016/j.sleep.2008.04.014
   Minai OA, 2008, J HEART LUNG TRANSPL, V27, P335, DOI 10.1016/j.healun.2007.12.008
   Pond MN, 1996, RESP MED, V90, P409, DOI 10.1016/S0954-6111(96)90114-6
   Salminen AV, 2014, NEUROLOGY, V82, P1856, DOI 10.1212/WNL.0000000000000454
   Verbraecken J, 2004, SARCOIDOSIS VASC DIF, V21, P137
   Walters AS, 2003, SLEEP MED, V4, P121, DOI 10.1016/S1389-9457(02)00258-7
   Weinstock LB, 2012, SLEEP MED REV, V16, P341, DOI 10.1016/j.smrv.2011.09.003
NR 15
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 8
EP 10
DI 10.1016/j.rmed.2019.03.009
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200002
PM 31047121
DA 2020-05-18
ER

PT J
AU Sampaio, MS
   Vieira, WD
   Bernardino, ID
   Herval, AM
   Flores-Mir, C
   Paranhos, LR
AF Sampaio, Marcelo S.
   Vieira, Walbert de A.
   Bernardino, Italo de M.
   Herval, Alex Moreira
   Flores-Mir, Carlos
   Paranhos, Luiz R.
TI Chronic obstructive pulmonary disease as a risk factor for suicide: A
   systematic review and meta-analysis
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Chronic obstructive pulmonary disease; Suicide; Risk factors
ID QUALITY-OF-LIFE; OLDER-ADULTS; PHYSICAL ILLNESS; GLOBAL BURDEN;
   DEPRESSION; PREVALENCE; IDEATION; COPD; INDIVIDUALS; ASSOCIATION
AB Background: Patients living with chronic obstructive pulmonary disease (COPD) commonly present several limitations in their daily activities, high depression rates, and low quality of life, which makes this population a risk group for suicide. This study aims to systematically assess the literature on the association between CPOD and the likelihood of suicide.
   Methods: The protocol was registered in PROSPERO (CRD42018096618). The Latin-American and Caribbean Health Sciences Literature (LILACS), PubMed, SciELO, Scopus, LIVIVO, Web of Science, and PsychNET databases were used as primary study sources. OpenThesis and OpenGrey were used to partially capture the "grey literature". A manual search was also performed through a systematized analysis of the references of eligible articles. The risk of bias among the studies included was assessed with the Joanna Briggs Institute Critical Appraisal Tools for Systematic Reviews. A random effects meta-analysis was performed to estimate the variation in odds ratio (OR) and 95% confidence intervals (95% CI).
   Results: The search provided 4762 results, from which only seven met the eligibility criteria and were ultimately included in the qualitative assessment of the review. The studies were published from 2002 to 2015. All studies presented low risk of bias. The total sample included 1390 suicide cases of COPD patients. The meta-analysis, which was based on five eligible case control studies, found that people with history of COPD are more likely to commit suicide (OR=1.90; 95% CI=1.27-2.48; p=0.002).
   Conclusion: COPD patients are 1.9 times more likely to commit suicide than people without COPD.
C1 [Sampaio, Marcelo S.] Univ Estadual Campinas, Sch Dent, Dept Social Dent, Piracicaba, SP, Brazil.
   [Vieira, Walbert de A.] Univ Estadual Campinas, UNICAMP, Sch Dent Piracicaba, Dept Restorat Dent,Endodont Div, Piracicaba, Brazil.
   [Bernardino, Italo de M.] State Univ Paraiba, Dept Dent, Campina Grande, Paraiba, Brazil.
   [Herval, Alex Moreira] Univ Fed Minas Gerais, Sch Dent, Dept Prevent & Community Dent, Belo Horizonte, MG, Brazil.
   [Flores-Mir, Carlos] Univ Alberta, Sch Dent, Dept Orthodont, Edmonton, AB, Canada.
   [Paranhos, Luiz R.] Univ Fed Uberlandia, Sch Dent, Dept Prevent & Community Dent, Uberlandia, MG, Brazil.
RP Paranhos, LR (reprint author), Univ Fed Uberlandia, Dept Prevent & Community Dent, Campus Umuarama,Av Para 1720,Bloco 2G,Sala 1, BR-38405320 Uberlandia, MG, Brazil.
EM paranhos.lrp@gmail.com
RI Herval, Alex Moreira/AAF-6963-2019; Paranhos, Luiz Renato R/H-8386-2012;
   Vieira, Walbert/S-6111-2019
OI Paranhos, Luiz Renato R/0000-0002-7599-0120; Vieira,
   Walbert/0000-0001-8872-2865; Herval, Alex Moreira/0000-0001-6649-2616
CR Atlantis E, 2013, CHEST, V144, P766, DOI 10.1378/chest.12-1911
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Baltieri L, 2017, SAO PAULO MED J, V135, P332, DOI 10.1590/1516-3180.2016.0342250217
   Barker E, 2015, EUR RESPIR J, V46, P96, DOI 10.1183/09031936.00011415
   Bolton JM, 2015, PSYCHOL MED, V45, P495, DOI 10.1017/S0033291714001639
   Brown CR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4371-z
   Cavalcante FG, 2015, CIENC SAUDE COLETIVA, V20, P1655, DOI 10.1590/1413-81232015206.06462015
   Chung JH, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.94
   Ciulla L, 2014, J AFFECT DISORDERS, V152, P513, DOI 10.1016/j.jad.2013.05.090
   Crump C, 2014, PSYCHOL MED, V44, P279, DOI 10.1017/S0033291713000810
   De Leo D, 2015, CRISIS, V36, P1, DOI 10.1027/0227-5910/a000315
   Erlangsen A, 2015, SOC PSYCH PSYCH EPID, V50, P1427, DOI 10.1007/s00127-015-1051-0
   Esteban C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161710
   Fassberg MM, 2016, AGING MENT HEALTH, V20, P166, DOI 10.1080/13607863.2015.1083945
   Fleehart S, 2014, INT J CHRONIC OBSTR, V9, P1321, DOI 10.2147/COPD.S65507
   Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017, GLOB STRAT DIAGN MAN
   Handley TE, 2014, AM J GERIAT PSYCHIAT, V22, P1325, DOI 10.1016/j.jagp.2013.05.009
   Hawton K, 2013, J AFFECT DISORDERS, V147, P17, DOI 10.1016/j.jad.2013.01.004
   Hegerl U, 2014, EUR RESPIR J, V44, P734, DOI 10.1183/09031936.00193213
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Jang SY, 2014, GERIATR GERONTOL INT, V14, P983, DOI 10.1111/ggi.12202
   Jiang Yongwen, 2016, R I Med J (2013), V99, P42
   Joshi P, 2017, INDIAN J PSYCHIAT, V59, P352, DOI [10.4103/psychiatry.indianjpsychiatry_282_16, 10.4103/psychiatry.IndianJPsychiatry_282_16]
   Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179
   Kato K, 2013, PSYCHIAT CLIN NEUROS, V67, P119, DOI 10.1111/pcn.12023
   Katz PP, 2010, CHEST, V137, P838, DOI 10.1378/chest.09-1939
   Kayahan B., 2006, JUN RESP MED, V100
   Kim SH, 2016, GERIATR NURS, V37, P9, DOI 10.1016/j.gerinurse.2015.07.006
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Littner M. R., 2011, ANN INTERN MED, V154
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4
   Matte DL, 2016, RESP MED, V117, P154, DOI 10.1016/j.rmed.2016.06.006
   Miravitlles M, 2014, RESP MED, V108, P1615, DOI 10.1016/j.rmed.2014.08.010
   Moola S., 2017, JOANN BRIGGS I REV M
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Phillips B, 2009, OXFORD CTR EVIDENCE
   Pinto LM, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0208-4
   Pinto LW, 2012, CIENC SAUDE COLETIVA, V17, P1963, DOI 10.1590/S1413-81232012000800007
   Quan H, 2002, SOC PSYCH PSYCH EPID, V37, P190, DOI 10.1007/s001270200014
   Rodriguez-Prat A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151435
   Salte K, 2015, DAN MED J, V62
   Shao YQ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012227
   Shin KM, 2013, AGING MENT HEALTH, V17, P109, DOI 10.1080/13607863.2012.702732
   Sinyor M, 2017, CURR OPIN PSYCHIATR, V30, P1, DOI 10.1097/YCO.0000000000000296
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Spiegel B, 2007, ALIMENT PHARM THER, V26, P183, DOI 10.1111/j.1365-2036.2007.03357.x
   Strid JMC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006363
   The Joanna Briggs Institute Joanna Briggs Institute Reviewers' Manual, 2014, J BRIGGS I REV MAN 2
   Vasiliadis HM, 2017, INT PSYCHOGERIATR, V29, P249, DOI 10.1017/S1041610216001290
   Webb RT, 2012, ARCH GEN PSYCHIAT, V69, P256, DOI 10.1001/archgenpsychiatry.2011.1561
   WHO, WHO MORT DAT
   World Health Organization, QUAL SUIC MORT DAT
   Xu HL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010914
   2012, SCHIZOPHR RES, V134, P111, DOI DOI 10.1016/J.SCHRES.2011.09.032
   2016, LANCET, V387, P1227, DOI DOI 10.1016/S0140-6736(15)00234-2
NR 57
TC 3
Z9 4
U1 2
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 11
EP 18
DI 10.1016/j.rmed.2019.03.018
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200003
PM 31047105
DA 2020-05-18
ER

PT J
AU Liu, CJ
   Huang, HL
   Cheng, MH
   Lu, PL
   Shu, CC
   Wang, JY
   Chong, IW
AF Liu, Chia-Jung
   Huang, Hung-Ling
   Cheng, Meng-Hsuan
   Lu, Po-Liang
   Shu, Chin-Chung
   Wang, Jann-Yuan
   Chong, Inn-Wen
TI Outcome of patients with and poor prognostic factors for Mycobacterium
   kansasii-pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Acid-fast smear; Mycobacterium kansasii; Prognosis; Pulmonary disease;
   Radiographic progression
AB Background: Aggressive therapy for Mycobacterium kansasii-pulmonary disease (MK-PD) is recommended because of the virulence of MK. However, some clinicians may be concerned regarding the lengthy course and numerous adverse effects. This study evaluated the natural course of MK-PD and investigated its prognostic factors.
   Methods: Radiographic outcome, prognostic factors, and mortality within 1 year for MK-PD were obtained from patients in 6 hospitals in Taiwan from 2010 to 2014 (derivation cohort) and validated using patients in 2015 and 2016 (validation cohort).
   Results: Of the 109 patients with MK-PD in the derivation cohort, radiographic progression occurred in 70 (64%), with a 1-year mortality rate of 43% and median survival of 71 days, whereas none of the 39 cases without radiographic progression died. All patients with acid-fast smear (AFS) grade >= 3 experienced radiographic progression. For the others, the independent risk factors of radiographic progression were fibroCavitary pattern, Leucocyte count>9000/mu L, Old age (age>65 years), pUre MK in sputum (no other mycobacteria), and no Diabetes mellitus (the CLOUD factors). By applying these criteria to the validation cohort (n=112), 3 (9%) of the 33 patients with MK-PD who initially had AFS grade < 3 and < 3 CLOUD risk factors experienced radiographic progression, and none of the 3 died of MK-PD.
   Conclusions: Because of the high risk of radiographic progression and subsequent fatal outcome, immediate anti-MK treatment is recommended. For patients with MK-PD who have sputum AFS grade < 3 and < 3 CLOUD risk factors, regular follow-up may be an alternative.
C1 [Liu, Chia-Jung; Shu, Chin-Chung; Wang, Jann-Yuan] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan.
   [Huang, Hung-Ling] Kaohsiung Municipal Tatung Hosp, Dept Internal Med, Kaohsiung, Taiwan.
   [Huang, Hung-Ling; Cheng, Meng-Hsuan; Lu, Po-Liang; Chong, Inn-Wen] Kaohsiung Med Univ Hosp, Dept Internal Med, 100,Tzyou 1st Rd, Kaohsiung 80756, Taiwan.
   [Lu, Po-Liang] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan.
   [Chong, Inn-Wen] Kaohsiung Med Univ Hosp, Dept Resp Therapy, Kaohsiung, Taiwan.
   [Huang, Hung-Ling; Cheng, Meng-Hsuan; Lu, Po-Liang; Chong, Inn-Wen] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
RP Chong, IW (reprint author), Kaohsiung Med Univ Hosp, Dept Internal Med, 100,Tzyou 1st Rd, Kaohsiung 80756, Taiwan.
EM chong@kmu.edu.tw
RI Lu, Po-Liang/D-4499-2009
OI Lu, Po-Liang/0000-0002-7423-6783; Huang, Hung Ling/0000-0001-8809-0546;
   WANG, JANN-YUAN/0000-0003-3406-366X
FU Taiwan Ministry of Science and Technology [MOST107-2314-B-037-106-MY3];
   Kaohsiung Medical University Hospital Research Program [KMUH106-6M07,
   KMUH107-7R12]
FX This study was supported by the Taiwan Ministry of Science and
   Technology (MOST107-2314-B-037-106-MY3) and Kaohsiung Medical University
   Hospital Research Program (KMUH106-6M07, KMUH107-7R12). The funders had
   no role in the study design, data analysis, or manuscript writing.
CR Andrejak C, 2010, AM J RESP CRIT CARE, V181, P514, DOI 10.1164/rccm.200905-0778OC
   Carlson  R., 1977, TROPHIC STATE INDEX
   Elkington PT, 2011, EUR RESPIR J, V38, P456, DOI 10.1183/09031936.00015411
   Gharagozlian S, 2009, BMC CLIN PATHOL, V9, DOI 10.1186/1472-6890-9-7
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2002, CLIN CHEST MED, V23, P613, DOI 10.1016/S0272-5231(02)00016-3
   Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
   Hoefsloot W, 2013, EUR RESPIR J, V42, P1604, DOI 10.1183/09031936.00149212
   Hrabec E, 2002, INT J TUBERC LUNG D, V6, P713
   Huang H, 2017, NAT SCI REP, V7, P1
   Hwang JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00537-2016
   Korol EE, 2017, ONCOL THER, V5, P1, DOI 10.1007/s40487-016-0039-6
   Lewandowski KC, 2011, ARCH MED SCI, V7, P294, DOI 10.5114/aoms.2011.22081
   Lowery EM, 2013, CLIN INTERV AGING, V8, P1489, DOI 10.2147/CIA.S51152
   Marras TK, 2017, EMERG INFECT DIS, V23, P468, DOI 10.3201/eid2303.161927
   Moon SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139621
   Park HK, 2010, YONSEI MED J, V51, P552, DOI 10.3349/ymj.2010.51.4.552
   Perrin FMR, 2010, INT J TUBERC LUNG D, V14, P1596
   Philley Julie V, 2016, Curr Treat Options Infect Dis, V8, P275, DOI 10.1007/s40506-016-0086-4
   Piccirillo JF, 2008, CRIT REV ONCOL HEMAT, V67, P124, DOI 10.1016/j.critrevonc.2008.01.013
   Santin M, 2009, EUR RESPIR J, V33, P148, DOI 10.1183/09031936.00024008
   SNIDER GL, 1971, AM REV RESPIR DIS, V103, P625
   Snitker S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066277
   Stout Jason E, 2006, Expert Rev Anti Infect Ther, V4, P981, DOI 10.1586/14787210.4.6.981
   Stout JE, 2016, INT J INFECT DIS, V45, P123, DOI 10.1016/j.ijid.2016.03.006
   Tayebjee MH, 2005, DIABETIC MED, V22, P1628, DOI 10.1111/j.1464-5491.2005.01675.x
   van Ingen J, 2009, THORAX, V64, P502, DOI 10.1136/thx.2008.110957
   van Ingen J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00170-2018
   Wu DY, 2008, J LEUKOCYTE BIOL, V84, P900, DOI 10.1189/jlb.0108023
   Yamazaki Y, 1999, AM J RESP CRIT CARE, V160, P1851, DOI 10.1164/ajrccm.160.6.9902019
NR 30
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 19
EP 26
DI 10.1016/j.rmed.2019.03.015
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200004
PM 31047113
OA Other Gold
DA 2020-05-18
ER

PT J
AU Fragoso, CAV
   Gill, TM
   Leo-Summers, LS
   Van Ness, PH
AF Fragoso, Carlos A. Vaz
   Gill, Thomas M.
   Leo-Summers, Linda S.
   Van Ness, Peter H.
TI Re-evaluation of combination therapy in chronic obstructive pulmonary
   disease (COPD)
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Spirometry; Pharmacotherapy; Mortality; Pneumonia
ID RESPIRATORY IMPAIRMENT; OLDER PERSONS; LUNG; SPIROMETRY; MANAGEMENT;
   SEVERITY; QUALITY; VALUES; HEART; CARE
AB Background: Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from Towards a Revolution in COPD Health (TORCH).
   Methods: Of the 6112 TORCH participants, 5688 (93.1%) had GLI-based moderate-to-severe COPD (mean age 64.8 years). The primary outcome was all-cause mortality and the primary comparison was combination therapy vs. placebo. Secondary outcomes included COPD and cardiovascular (CV) mortality and pneumonia. A modified intention-to-treat analysis evaluated differences in time-to-event over a three-year period, using Cox proportional hazards models with statistical significance at p < 0.010 (acknowledging repeated significance testing).
   Results: Relative to placebo, combination therapy yielded a statistically non-significant reduction in all-cause mortality-adjusted hazard ratio [adjHR] 0.78 (95% confidence interval [CI]: 0.64, 0.95), p=0.012. Relative to placebo, combination therapy also yielded statistically non-significant reductions in COPD and CV mortality-adjHR 0.75 (95% CI: 0.55, 1.02), p=0.068 and adjHR 0.76 (95% CI: 0.53, 1.09), p=0.135, respectively. In contrast, combination therapy yielded a statistically significant increased risk of pneumonia, relative to placebo-adjHR 1.80 (95% CI: 1.46, 2.21), p < 0.001.
   Conclusion: In GLI-based moderate-to-severe COPD, combination therapy yields a statistically significant increased risk of pneumonia but the reductions in mortality are not statistically significant, although could potentially be clinically meaningful.
C1 [Fragoso, Carlos A. Vaz] Vet Affairs VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Fragoso, Carlos A. Vaz; Gill, Thomas M.; Leo-Summers, Linda S.; Van Ness, Peter H.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
RP Fragoso, CAV (reprint author), 950 Campbell Ave, West Haven, CT 06516 USA.
EM carlos.fragoso@yale.edu
OI Gill, Thomas/0000-0002-6450-0368
FU National Institutes of Health/National Institute on AgingUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [R03AG057450, P30AG021342];
   Academic Leadership Award from the National Institute on Aging
   [K07AG043587]
FX The current study was funded by the National Institutes of
   Health/National Institute on Aging (R03AG057450) and conducted at the
   Yale Claude D. Pepper Older Americans Independence Center (supported by
   P30AG021342). Dr. Gill is the recipient of an Academic Leadership Award
   (K07AG043587) from the National Institute on Aging. The funding sponsors
   provided no input or contributions in the development of the research
   and manuscript.
CR Allen SC, 2006, AGE AGEING, V35, P304, DOI 10.1093/ageing/afj090
   Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716
   Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
   Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659
   Cooper BG, 2017, BREATHE, V13, pE56, DOI 10.1183/20734735.012717
   Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717
   Fragoso CAV, 2015, AM J RESP CRIT CARE, V192, P817, DOI 10.1164/rccm.201503-0463OC
   Fragoso CAV, 2013, AM J MED, V126, P49, DOI 10.1016/j.amjmed.2012.07.016
   Fragoso CAV, 2012, EUR RESPIR J, V40, P37, DOI 10.1183/09031936.00128711
   Fragoso CAV, 2011, J AM GERIATR SOC, V59, P1847, DOI 10.1111/j.1532-5415.2011.03596.x
   Fried TR, 2012, JAMA-J AM MED ASSOC, V308, P1254, DOI 10.1001/jama.2012.12422
   Gershon A, 2013, JAMA INTERN MED, V173, P1175, DOI 10.1001/jamainternmed.2013.1016
   Hansen JE, 2007, CHEST, V131, P349, DOI 10.1378/chest.06-1349
   Howden LM, 2010, AGE SEX COMPOSITION
   Leblais V, 2008, CARDIOVASC RES, V77, P202, DOI 10.1093/cvr/cvm008
   Li GW, 2017, INT J EPIDEMIOL, V46, P746, DOI 10.1093/ije/dyw320
   Mannino David M, 2007, Proc Am Thorac Soc, V4, P502, DOI 10.1513/pats.200701-001FM
   Miller MR, 2015, EUR RESPIR J, V45, P322, DOI 10.1183/09031936.00199414
   Miller MR, 2011, CHEST, V139, P52, DOI 10.1378/chest.10-0189
   Pellegrino R, 2010, EUR RESPIR J, V35, P952, DOI 10.1183/09031936.00003410
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Quanjer PH, 2014, EUR RESPIR J, V43, P505, DOI 10.1183/09031936.00086313
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Rabe KF, 2007, NEW ENGL J MED, V356, P851, DOI 10.1056/NEJMe068307
   Richter Daphne C, 2008, Int J Chron Obstruct Pulmon Dis, V3, P693
   Sabroe I, 2013, THORAX, V68, P1085, DOI 10.1136/thoraxjnl-2013-203773
   Simpson PC, 2015, CIRC RES, V117, P592, DOI 10.1161/CIRCRESAHA.115.307246
   Smith BM, 2013, CHEST, V144, P1143, DOI 10.1378/chest.13-0183
   Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC
   Vaz Fragoso CA, 2012, J GERONTOL A-BIOL, V67, P264, DOI 10.1093/gerona/glr198
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Wang MT, 2018, JAMA INTERN MED, V178, P229, DOI 10.1001/jamainternmed.2017.7720
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
   World Health Organization, 2012, GOOD HLTH ADDS LIF Y
   2016, AM J RESP CRIT CARE, V193, P727, DOI DOI 10.1164/RCCM.201508-1603OC
   2017, RESP CARE, V62, P1137, DOI DOI 10.4187/RESPCARE.05515
   2018, COPD, V15, P17, DOI DOI 10.1080/15412555.2018.1424815
   2018, AM J RESP CRIT CARE, V197, P963, DOI DOI 10.1164/RCCM.201709-1789LE
   2018, RESP MED, V137, P40, DOI DOI 10.1016/J.RMED.2018.02.018
NR 42
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 27
EP 34
DI 10.1016/j.rmed.2019.03.020
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200005
PM 31047114
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Kerwin, EM
   Hickey, L
   Small, CJ
AF Kerwin, Edward M.
   Hickey, Lisa
   Small, Calvin J.
TI Relationship between handheld and clinic-based spirometry measurements
   in asthma patients receiving beclomethasone
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Spirometry; Handheld; In-clinic; Daily FEV1; At-home
   diagnostics; Safety; Clinical trial
ID ACCURACY; INHALER
AB Introduction: Handheld spirometers for home use by patients allow longitudinal spirometry data to be collected daily and may overcome some of the limitations of in-clinic spirometry (long intervals between measurements, results can be affected by site-based coaching and patient's asthma status during a given visit).
   Objectives: To determine the relationship between spirometry values measured by clinic-based and handheld spirometers during a clinical trial.
   Methods: A post hoc correlation analysis of data from a 6-week phase 3 study of beclomethasone dipropionate (BDP; delivered by breath-actuated inhaler: BAI) versus placebo in patients aged >= 12 years with persistent asthma. During the study, forced expiratory volume in 1 s (FEV1) was assessed by both office-based spirometry at Weeks 2, 4 and 6, and daily by handheld spirometer as a secondary study endpoint.
   Results: There was a high correlation between FEV1 values measured at home and in-clinic (overall correlation coefficient=0.8393, R=0.81921, 0.85927, 0.85369 and 0.83734 for BAI 320 mu g/day, BAI 640 mu g/day, BDP metered dose inhaler 320 mu g/day and placebo treatment groups, respectively), with the scatterplot showing an upward trend for all treatment groups. Nearly all patients achieved home FEV1 values close to clinic FEV1 values, with very few outliers.
   Conclusions: Clinic-based and handheld spirometry demonstrated comparable treatment effects relative to placebo, suggesting that home spirometry could be used to help patients monitor their asthma severity. Daily measurement of FEV1 provides more comprehensive data than can be achieved through clinic visits, and may lead to a new approach to clinical trial design.
C1 [Kerwin, Edward M.] Clin Res Inst Southern Oregon, Medford, OR USA.
   [Hickey, Lisa; Small, Calvin J.] Teva Pharmaceut Inc, Frazer, PA USA.
RP Kerwin, EM (reprint author), Clinical Res Inst Southern Oregon Inc, Crisor LLC, 3860 Crater Lake Ave, Medford, OR 97504 USA.
EM ekerwin@criresearch.com; Lisa.Hickey@tevapharm.com;
   Calvin.Small@tevapharm.com
FU Teva Pharmaceuticals Inc.
FX This study was sponsored by Teva Pharmaceuticals Inc.
CR Accordini S, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0008-0
   Brouwer AFJ, 2007, PEDIATR PULM, V42, P813, DOI 10.1002/ppul.20660
   Carpenter DM, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0809-3
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Lavorini Federico, 2013, ISRN Allergy, V2013, P102418, DOI 10.1155/2013/102418
   Levy ML, 2013, PRIM CARE RESP J, V22, P406, DOI 10.4104/pcrj.2013.00084
   Ostrom NK, 2018, ALLERGY ASTHMA PROC, V39, P117, DOI 10.2500/aap.2018.39.4115
   Pawanka  R., 2014, WORLD ALLERGY ORGAN, V7
   Petty TL, 2003, SIMPLE OFFICE SPIROM
   Rebuck DA, 1996, CHEST, V109, P152, DOI 10.1378/chest.109.1.152
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Rodriguez-Roisin R, 2016, INT J CHRONIC OBSTR, V11, P1973, DOI 10.2147/COPD.S106142
   Rothe T, 2012, J ASTHMA, V49, P45, DOI 10.3109/02770903.2011.643522
   Ruppel GL, 2012, RESP CARE, V57, P165, DOI [10.4187/respcare.01640, 10.4187.respcare.01640.edu]
   Sundbom F, 2016, J ASTHMA, V53, P398, DOI 10.3109/02770903.2015.1126846
   Wilson SR, 2019, J ALLERGY CLIN IMMUN, V143, P395, DOI 10.1016/j.jaci.2018.02.056
NR 16
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 35
EP 42
DI 10.1016/j.rmed.2019.03.010
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200006
PM 31047115
DA 2020-05-18
ER

PT J
AU Cazzola, M
   Rogliani, P
   Calzetta, L
   Matera, MG
AF Cazzola, Mario
   Rogliani, Paola
   Calzetta, Luigino
   Matera, Maria Gabriella
TI Bronchodilators in subjects with asthma-related comorbidities
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Asthma; Comorbidities; beta(2)-agonists; Muscarinic agonists; Xanthines
ID OBSTRUCTIVE PULMONARY-DISEASE; GASTROESOPHAGEAL-REFLUX; IPRATROPIUM
   BROMIDE; CARDIOVASCULAR-DISEASE; ANTICHOLINERGIC AGENT;
   CARDIAC-ARRHYTHMIAS; HEART-FAILURE; BETA-AGONISTS; RISK; ASSOCIATION
AB Asthma is often associated with different comorbidities such as cardiovascular diseases, depression, diabetes mellitus, dyslipidaemia, osteoporosis, rhinosinusitis and mainly gastro-oesophageal reflux disease and allergic rhinitis. Although bronchodilators play an important role in the treatment of asthma, there is no overall description of their impact on comorbid asthma, regardless of whether favourable or negative. This narrative review examines the potential effects of bronchodilators on comorbidities of asthma.
C1 [Cazzola, Mario; Rogliani, Paola; Calzetta, Luigino] Univ Roma Tor Vergata, Dept Expt Med, Chair Resp Med, Rome, Italy.
   [Matera, Maria Gabriella] Univ Campania Luigi Vanvitelli, Dept Expt Med, Chair Pharmacol, Naples, Italy.
RP Cazzola, M (reprint author), Univ Roma Tor Vergata, Dept Expt Med, Chair Resp Med, Rome, Italy.
EM Mario.cazzola@uniroma2.it
OI Rogliani, Paola/0000-0001-7801-5040
CR Adedinsewo D, 2018, J AM COLL CARDIOL, V71, P868, DOI 10.1016/S0735-1097(18)31409-8
   Adimadhyam S, 2014, PHARMACOTHERAPY, V34, P315, DOI 10.1002/phar.1336
   Appleton SL, 2009, J ALLERGY CLIN IMMUN, V123, P124, DOI 10.1016/j.jaci.2008.10.032
   Au DH, 2004, AM HEART J, V148, P915, DOI 10.1016/j.ahj.2004.03.048
   Au DH, 2002, CHEST, V121, P846, DOI 10.1378/chest.121.3.846
   Bermingham M, 2011, EUR J HEART FAIL, V13, P885, DOI 10.1093/eurjhf/hfr063
   BITTAR G, 1991, CHEST, V99, P1415, DOI 10.1378/chest.99.6.1415
   BORUM P, 1983, EUR J RESPIR DIS, V64, P44
   Brehm JM, 2015, AM J RESP CRIT CARE, V192, P47, DOI 10.1164/rccm.201501-0037OC
   Burggraaf J, 2001, THORAX, V56, P567, DOI 10.1136/thorax.56.7.567
   Calzetta L, 2018, PULM PHARMACOL THER, V53, P20, DOI 10.1016/j.pupt.2018.09.007
   Carlson S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179091
   Cazzola M, 2002, CLIN PHARMACOKINET, V41, P19, DOI 10.2165/00003088-200241010-00003
   Cazzola M, 2005, DRUGS, V65, P1595, DOI 10.2165/00003495-200565120-00001
   Cazzola M, 2011, EUR RESPIR J, V38, P42, DOI 10.1183/09031936.00140310
   Cazzola M, 2017, DRUGS, V77, P721, DOI 10.1007/s40265-017-0731-3
   Cazzola M, 2013, PULM PHARMACOL THER, V26, P307, DOI 10.1016/j.pupt.2012.12.006
   Cazzola M, 2013, CURR OPIN PULM MED, V19, P36, DOI 10.1097/MCP.0b013e32835b113a
   Cazzola M, 2012, RESP MED, V106, P249, DOI 10.1016/j.rmed.2011.07.021
   Cepelis A, 2018, JAMA CARDIOL, V3, P721, DOI 10.1001/jamacardio.2018.1901
   Chan WL, 2014, INT J CARDIOL, V176, P464, DOI 10.1016/j.ijcard.2014.07.087
   Christiansen SC, 2016, J ALLER CL IMM-PRACT, V4, P76, DOI 10.1016/j.jaip.2015.07.009
   COLEMAN JJ, 1986, CHEST, V90, P45, DOI 10.1378/chest.90.1.45
   CRANE J, 1987, NEW ZEAL MED J, V100, P309
   Crowell MD, 2001, CHEST, V120, P1184, DOI 10.1378/chest.120.4.1184
   Cui Y, 2010, EUR RESPIR J, V35, P1370, DOI 10.1183/09031936.00139909
   Del Grande LM, 2016, J GASTROINTEST SURG, V20, P1679, DOI 10.1007/s11605-016-3192-1
   EKSTROM T, 1988, EUR J CLIN PHARMACOL, V35, P353, DOI 10.1007/BF00561363
   Favreau H, 2012, RESP MED, V106, P933, DOI 10.1016/j.rmed.2011.10.023
   Galvan DL, 2017, KIDNEY INT, V92, P14, DOI 10.1016/j.kint.2017.03.024
   GEORGITIS JW, 1992, J ALLERGY CLIN IMMUN, V90, P1071, DOI 10.1016/0091-6749(92)90125-L
   Giesler A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0741-z
   Global Initiative for Asthma, GINA REP GLOB STRAT
   Han YY, 2016, J ALLER CL IMM-PRACT, V4, P68, DOI 10.1016/j.jaip.2015.10.004
   Hiquet J, 2012, REV MED LEG, V3, P95
   Holt S, 2000, ALLERGY, V55, P1198, DOI 10.1034/j.1398-9995.2000.00830.x
   Hou MH, 2017, MOL MED REP, V16, P6558, DOI 10.3892/mmr.2017.7411
   Hung MJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001880
   Kaiser HB, 1998, ALLERGY ASTHMA PROC, V19, P23, DOI 10.2500/108854198778557962
   KARNIK AM, 1990, BIOMED PHARMACOTHER, V44, P47, DOI 10.1016/0753-3322(90)90069-L
   LAABAN JP, 1988, CHEST, V94, P496, DOI 10.1378/chest.94.3.496
   LEHRER PM, 1994, CHEST, V105, P1701, DOI 10.1378/chest.105.6.1701
   Maak CA, 2011, J EMERG MED, V40, P135, DOI 10.1016/j.jemermed.2007.11.056
   Macie Christine, 2008, Int J Chron Obstruct Pulmon Dis, V3, P163
   Matera MG, 2018, EXPERT OPIN DRUG MET, V14, P1101, DOI 10.1080/17425255.2018.1530215
   Matera MG, 2010, PULM PHARMACOL THER, V23, P1, DOI 10.1016/j.pupt.2009.10.001
   McGarry ME, 2015, CHEST, V147, P1591, DOI 10.1378/chest.14-2689
   MCNEILL RS, 1964, LANCET, V2, P1101
   MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P2, DOI 10.1016/S0091-6749(06)80005-9
   Minasian AG, 2013, HEART LUNG, V42, P208, DOI 10.1016/j.hrtlng.2012.11.007
   Mohammad HA, 2014, EGYPT J CHEST DIS TU, V63, P529, DOI 10.1016/j.ejcdt.2014.03.010
   Morales DR, 2014, CHEST, V145, P779, DOI 10.1378/chest.13-1235
   Nie ZY, 2014, AM J RESP CELL MOL, V51, P251, DOI 10.1165/rcmb.2013-0452OC
   Philipson L. H., 2002, Journal of Allergy and Clinical Immunology, V110, pS313, DOI 10.1067/mai.2002.129702
   Rinaldi B, 2015, BRIT J PHARMACOL, V172, P3627, DOI 10.1111/bph.13148
   ROBIN ED, 1992, CHEST, V101, P1699, DOI 10.1378/chest.101.6.1699
   Rogliani P, 2014, ACTA DIABETOL, V51, P933, DOI 10.1007/s00592-014-0584-0
   Rossinen J, 1998, J INTERN MED, V243, P361
   Sengstock DM, 2002, J CARD FAIL, V8, P232, DOI 10.1054/jcaf.2002.127771
   SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W
   Squire I, 2009, J HYPERTENS, V27, P1358, DOI 10.1097/HJH.0b013e32832c4e06
   Thottathil P, 2008, AM J CARDIOL, V102, P871, DOI 10.1016/j.amjcard.2008.05.029
   TOTTRUP A, 1990, PHARMACOL TOXICOL, V67, P340, DOI 10.1111/j.1600-0773.1990.tb00841.x
   Van Lieshout RJ, 2009, PSYCHOSOM MED, V71, P187, DOI 10.1097/PSY.0b013e3181907012
   van Soest EM, 2008, EXPERT OPIN DRUG SAF, V7, P173, DOI [10.1517/14740338.7.2.173, 10.1517/14740338.7.2.173 ]
   Wood LG, 2011, J ALLERGY CLIN IMMUN, V127, P1133, DOI 10.1016/j.jaci.2011.01.036
   Yawn BP, 2017, MAYO CLIN PROC, V92, P1697, DOI 10.1016/j.mayocp.2017.08.005
   Zerbib F, 2002, AM J RESP CRIT CARE, V166, P1206, DOI 10.1164/rccm.200110-033OC
   Zhang B, 2009, J HYPERTENS, V27, P1485, DOI 10.1097/HJH.0b013e32832af68d
   2006, J ASTHMA, V43, P553, DOI DOI 10.1080/02770900600859123
   2004, CHEST, V125, P2309
   2018, PULM PHARMACOL THER, V52, P41, DOI DOI 10.1016/J.PUPT.2018.08.005
   2002, INT J CARDIOL, V86, P299
   2008, EXPERT OPIN PHARMACO, V9, P1531, DOI DOI 10.1517/14656560802160848
   2003, CHEST, V124, P795
NR 75
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 43
EP 48
DI 10.1016/j.rmed.2019.04.001
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200007
PM 31047116
DA 2020-05-18
ER

PT J
AU de Llano, LP
   Martinez-Moragon, E
   Moral, VP
   Alonso, AT
   Sanchez, CA
   Callejas, FJ
   Vera, E
   Campos, JGS
   Rivera, CM
   Navarrete, BA
   Landa, IU
   Rivero, JLG
   Galo, AP
   Gutierrez, FA
   Landete, P
   Gonzalez, JR
   Aracil, CF
   Gracia, JAC
   Lluch, I
   Puente, L
   Andujar-Espinosa, R
   Cosio, BG
AF Perez de Llano, Luis
   Martinez-Moragon, Eva
   Plaza Moral, Vicente
   Trisan Alonso, Andrea
   Almonacid Sanchez, Carlos
   Javier Callejas, Francisco
   Vera, Elisabeth
   Soto Campos, Jose Gregorio
   Martinez Rivera, Carlos
   Alcazar Navarrete, Bernardino
   Urrutia Landa, Isabel
   Garcia Rivero, Juan Luis
   Padilla Galo, Alicia
   Alvarez Gutierrez, Francisco
   Landete, Pedro
   Ramos Gonzalez, Jacinto
   Fernandez Aracil, Cleofe
   Carretero Gracia, Jose Angel
   Lluch, Inmaculada
   Puente, Luis
   Andujar-Espinosa, Ruben
   Garcia Cosio, Borja
TI Unmet therapeutic goals and potential treatable traits in a population
   of patients with severe uncontrolled asthma in Spain. ENEAS study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Control asthma; Severe asthma; Treatable traits; Serum biomarkers;
   Therapeutic goals; IL-8
ID CLUSTER-ANALYSIS; EXACERBATIONS; RISK; PHENOTYPES; ADHERENCE
C1 [Perez de Llano, Luis] Hosp Univ Lucus Augusti, Inst Invest Sanitaria Santiago De Compostela IDIS, Spain Grp BIOCHUS, Pneumol Serv,EOXI Lugo Cervo & Monforte, Santiago De Compostela, Spain.
   [Martinez-Moragon, Eva] Hosp Univ Doctor Peset, Pneumol Serv, Valencia, Spain.
   [Plaza Moral, Vicente] Univ Autonoma Barcelona, Inst Invest Biomed St Pau IIB St Pau, Hosp Santa Creu & St Pau, Dept Med,Dept Resp Med, Barcelona, Spain.
   [Trisan Alonso, Andrea] Hosp Univ Puerta Hierro, Madrid, Spain.
   [Almonacid Sanchez, Carlos] Hosp Ramon & Cajal, Madrid, Spain.
   [Javier Callejas, Francisco] Complejo Hosp Univ Albacete, Albacete, Spain.
   [Vera, Elisabeth] Hosp Univ Miguel Servet, Zaragoza, Spain.
   [Soto Campos, Jose Gregorio] Hosp Jerez, Cadiz, Spain.
   [Martinez Rivera, Carlos] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
   [Alcazar Navarrete, Bernardino] Hosp Loja, Granada, Spain.
   [Urrutia Landa, Isabel] Hosp Galdakao, Galdakao, Vizcaya, Spain.
   [Garcia Rivero, Juan Luis] Hosp Laredo, Laredo, Cantabria, Spain.
   [Padilla Galo, Alicia] Hosp Costa Sol, Malaga, Spain.
   [Alvarez Gutierrez, Francisco] Hosp Virgen Rocio, Seville, Spain.
   [Landete, Pedro] Hosp La Princesa, Madrid, Spain.
   [Ramos Gonzalez, Jacinto] Hosp Univ Salamanca, Salamanca, Spain.
   [Fernandez Aracil, Cleofe] Hosp Gen Alicante, Alicante, Spain.
   [Carretero Gracia, Jose Angel] Hosp Royo Villanova, Zaragoza, Spain.
   [Puente, Luis] Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
   [Lluch, Inmaculada] Hosp La Ribera, Valencia, Spain.
   [Andujar-Espinosa, Ruben] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain.
   [Garcia Cosio, Borja] Hosp Univ Son Espases IdISBa CIBERES, Palma De Mallorca, Islas Baleares, Spain.
RP Martinez-Moragon, E (reprint author), Hosp Univ Doctor Peset, Pneumol Serv, Valencia, Spain.
EM evamartinezmoragon@gmail.com
RI Campos, Jose Gregorio JGSC Soto/Q-2888-2017; Alcazar Navarrete,
   Bernardino/X-8947-2018
OI Campos, Jose Gregorio JGSC Soto/0000-0003-4052-0417; Plaza,
   Vicente/0000-0003-2567-5496; alvarez gutierrez, francisco
   javier/0000-0002-0175-2824; Puente-Maestu, Luis/0000-0001-8501-0117;
   Andujar-Espinosa, Ruben/0000-0002-6714-9438; Alcazar Navarrete,
   Bernardino/0000-0003-2356-9366
FU AstraZeneca, SpainAstraZeneca
FX The authors thank to GOC (Barcelona, Spain) its participation in the
   project management, monitoring, data management and statistical analysis
   of this study. We would like to acknowledge AstraZeneca, Spain, for for
   their financial support.
CR Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015
   American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   Buhl  R., 2017, ERS C MIL
   Buhl R, 2016, RESP MED, V115, P7, DOI 10.1016/j.rmed.2016.04.001
   Calhoun WJ, 2014, J ALLER CL IMM-PRACT, V2, P193, DOI 10.1016/j.jaip.2013.11.013
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   de Groot JC, 2015, AM J RESP CRIT CARE, V192, P899, DOI 10.1164/rccm.201505-1003LE
   Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC
   Engelkes M, 2015, EUR RESPIR J, V45, P396, DOI 10.1183/09031936.00075614
   Garcia-Rio F, 2013, ARCH BRONCONEUMOL, V49, P388, DOI 10.1016/j.arbres.2013.04.001
   Hekking PP, 2018, J ALLER CL IMM-PRACT, V6, P108, DOI 10.1016/j.jaip.2017.06.008
   Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170
   Kerkhof M, 2018, THORAX, V73, P116, DOI 10.1136/thoraxjnl-2017-210531
   Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875
   Martinez-Moragon E, 2009, ARCH BRONCONEUMOL, V45, P481, DOI 10.1016/j.arbres.2009.04.006
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Mukherjee M, 2015, LANCET RESP MED, V3, P824, DOI 10.1016/S2213-2600(15)00419-1
   Normansell R, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012226.pub2
   Pavord I. D., 2017, LANCET
   Plaza V, 2016, J AEROSOL MED PULM D, V29, P142, DOI 10.1089/jamp.2015.1212
   Quirce S, 2011, J INVEST ALLERG CLIN, V21, P466
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007
   Seys SF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0524-y
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   Silkoff PE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0299-y
   Taille  C., 2018, REV MAL RESP
   Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044
   2006, CLIN EXP ALLERGY, V36, P1373, DOI DOI 10.1111/J.1365-2222.2006.02502.X
   2009, AM J RESP CRIT CARE, V180, P817, DOI DOI 10.1164/RCCM.200902-0166OC
   2018, ARCH BRONCONEUMOL, V54, P175, DOI DOI 10.1016/J.ARBRES.2018.01.004
NR 31
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 49
EP 54
DI 10.1016/j.rmed.2019.03.006
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200008
PM 31047117
DA 2020-05-18
ER

PT J
AU Wang, YQ
   Hao, CL
   Ji, W
   Lu, YH
   Wu, M
   Chen, SN
   Wang, K
   Shao, XJ
AF Wang, Yuqing
   Hao, Chuangli
   Ji, Wei
   Lu, Yanhong
   Wu, Min
   Chen, Sainan
   Wang, Kun
   Shao, Xuejun
TI Detecting respiratory viruses in children with protracted bacterial
   bronchitis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Protracted bacterial bronchitis; Children; Broncho-alveolar lavage;
   Virus; Bacteria
ID HAEMOPHILUS-INFLUENZAE; YOUNG-CHILDREN; CHRONIC COUGH; INFLAMMATION;
   MANAGEMENT; BIOFILMS; OLD
AB Objective: This study is to investigate the status and clinical significance of respiratory viruses in bronch-oalveolar lavage fluid (BALF) of children with PBB.
   Methods: Sixty-eight children with PBB aged from 3 months to 5 years were enrolled and retrospectively reviewed from January 2014 to December 2017. Thirty-five children with persistent pneumonia or chronic pneumonia were matched as controls. Bronchoalveolar lavage fluid samples were collected for respiratory virus detection and bacterial culture.
   Results: The detection rate of bacteria in BALF of children with PBB was 61.8%, which was significantly higher than that of control group (20%) (P < 0.001). The detection rate of virus in BALF of children with PBB was 23.5%, including 6 (8.8%) of rhinovirus, 4 (5.9%) of parainfluenza virus type 3, 2(2.9%) of bocavirus, 2 (2.9%) of respiratory syncytial virus 1 (1.5%) of human metapneumonia virus and 1 (1.5%) of influenza virus A. 10 cases (28.6%) of virus were detected in the control group, including 3 (8.6%) respiratory syncytial virus, 3 (8.6%) rhinovirus and 2 (5.7%) bocavirus. There was no significant difference of viral detection rate between the two groups (P=0.577).
   Conclusion: Respiratory viruses can be detected in BALF of children with PBB, However, there is no evidence that PBB is virus-induced.
C1 [Wang, Yuqing; Hao, Chuangli; Ji, Wei; Lu, Yanhong; Wu, Min; Chen, Sainan; Wang, Kun] Soochow Univ, Childrens Hosp, Dept Resp Med, Jingde Rd 303, Suzhou 215003, Peoples R China.
   [Shao, Xuejun] Soochow Univ, Childrens Hosp, Dept Lab Med, Jingde Rd 303, Suzhou 215003, Peoples R China.
RP Wang, YQ (reprint author), Soochow Univ, Childrens Hosp, Dept Resp Med, Jingde Rd 303, Suzhou 215003, Peoples R China.
EM wang_yu_qing@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81573167]; Science and Technology Support Program
   of Jiangsu Province [BE2017657]; People's livehood Science and
   Technology Projects of Suzhou [SYS201646]
FX This work was supported by National Natural Science Foundation of China
   (Approval no. 81573167), Science and Technology Support Program of
   Jiangsu Province (Approval no. BE2017657) and People's livehood Science
   and Technology Projects of Suzhou (Approval no. SYS201646).
CR Advani S, 2012, PEDIATR INFECT DIS J, V31, P1221, DOI 10.1097/INF.0b013e318265a804
   Asilsoy S, 2008, CHEST, V134, P1122, DOI 10.1378/chest.08-0885
   Chang AB, 2006, MED J AUSTRALIA, V184, P398, DOI 10.5694/j.1326-5377.2006.tb00290.x
   Chang AB, 2005, CURR PEDIATR REV, V1, P283, DOI 10.2174/157339605774575015
   Chang AB, 2012, CHEST, V142, P943, DOI 10.1378/chest.11-2725
   Clinical Research Coordination Group of Chronic Cough; The Subspecialty Group of Respiratory Diseases; The Society of Pediatrics; Chinese Medical Association, 2014, ZHONGHUA ER KE ZA ZH, V52, P184
   Craven V, 2013, ARCH DIS CHILD, V98, P72, DOI 10.1136/archdischild-2012-302760
   De Baets F, 2012, EUR RESPIR J, V39, P392, DOI 10.1183/09031936.00035111
   de Blic J, 2000, EUR RESPIR J, V15, P217
   De Schutter I, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-83
   Douros K, 2011, CHEST, V140, P317, DOI 10.1378/chest.10-3050
   Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202
   Honkinen M, 2012, CLIN MICROBIOL INFEC, V18, P300, DOI 10.1111/j.1469-0691.2011.03603.x
   Jiang WJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2891-x
   Kompare M, 2012, J PEDIATR-US, V160, P88, DOI 10.1016/j.jpeds.2011.06.049
   Lai Kefang, 2013, Cough, V9, P18, DOI 10.1186/1745-9974-9-18
   Le Bourgeois M, 2002, CHEST, V122, P791, DOI 10.1378/chest.122.3.791
   Marchant J, 2012, THORAX, V67, P689, DOI 10.1136/thoraxjnl-2011-201506
   Marchant JM, 2008, PEDIATR PULM, V43, P1092, DOI 10.1002/ppul.20906
   Marchant JM, 2006, CHEST, V129, P1132, DOI 10.1378/chest.129.5.1132
   Priftis KN, 2013, CHEST, V143, P152, DOI 10.1378/chest.12-0623
   Shafik CF, 2011, J TROP MED, DOI 10.1155/2011/781919
   Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370
   Starner TD, 2006, AM J RESP CRIT CARE, V174, P213, DOI 10.1164/rccm.200509-1459OC
   Techasaensiri B, 2010, PEDIATR INFECT DIS J, V29, P519, DOI 10.1097/INF.0b013e3181cdafc2
   Wurzel DF, 2016, CHEST, V150, P1101, DOI 10.1016/j.chest.2016.06.030
   Wurzel DF, 2014, CLIN INFECT DIS, V59, P34, DOI 10.1093/cid/ciu225
   Wurzel DF, 2014, CHEST, V145, P1271, DOI 10.1378/chest.13-2442
   Zgherea D, 2012, PEDIATRICS, V129, pE364, DOI 10.1542/peds.2011-0805
   2006, THORAX, V61, P694, DOI DOI 10.1136/THX.2005.056986
   EUR RESP J, V16, P1109
   2011, CURR DRUG TARGETS, V12, P521
NR 32
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 55
EP 58
DI 10.1016/j.rmed.2019.04.003
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200009
PM 31047118
DA 2020-05-18
ER

PT J
AU Bai, CX
   Jiang, D
   Wang, LW
   Xue, FZ
   Chen, O
AF Bai, Chenxiao
   Jiang, Di
   Wang, Liwen
   Xue, Fuzhong
   Chen, Ou
TI A high blood eosinophil count may be a risk factor for incident asthma
   in population at risk
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Blood eosinophil counts; Incident asthma; Risk factor
ID ADULT-ONSET ASTHMA; EXACERBATIONS; PREVALENCE; ROLES
AB Background: Eosinophilia is considered to be associated with allergic disease and may predict asthma exacerbation. Eosinophils contribute to the pathophysiology and pathogenesis of asthma. However, studies on high blood eosinophil counts (BECs) and incident asthma remain scarce.
   Objective: To examine whether high BECs are positively associated with incident asthma in adults.
   Methods: Our study included 57975 participants aged from 20 to 79 years from the Shandong multi-center health check-up longitudinal study for Health Management. All patients with determined baseline BECs were >= 20 years old and free from asthma. We defined incident asthma as self-reported new-onset asthma occurring during the 10-year follow-up period. Multivariate modeling employed Poisson regression and Cox proportional hazards models to verify the association between BEC and incident asthma by adjusting demographics and some relevant comorbidities (rhinitis, nasal polyps, pneumonia, bronchitis, and chronic obstructive pulmonary disease).
   Results: A BEC >= 110 cells/mu L was a risk factor for incident asthma (adjusted IRR=1.62, 95% CI: 1.05-2.50, P=.028) in the Poisson regression. In the Cox proportional hazards model, the BEC cutoff point for incident asthma was also determined to be 110 cells/mu L (HR=1.59, 95% CI: 1.01-2.51, P=.045).
   Conclusion: A high BEC is a risk factor for incident asthma, especially when the BEC exceeds 110 cells/mu L. This suggests that adults with high BECs are more likely to develop asthma.
C1 [Bai, Chenxiao; Jiang, Di; Wang, Liwen; Chen, Ou] Shandong Univ, Sch Nursing, Jinan, Shandong, Peoples R China.
   [Xue, Fuzhong] Shandong Univ, Sch Publ Hlth, Dept Biostat, Jinan, Shandong, Peoples R China.
RP Xue, FZ; Chen, O (reprint author), ADD 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xuefzh@sdu.edu.cn; chenou@sdu.edu.cn
RI Xue, Fuzhong/AAG-4808-2020
OI Chen, Ou/0000-0002-6765-1655; Jiang, Di/0000-0002-0040-1512
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81400072]; Natural Science Foundation of Shandong
   ProvinceNatural Science Foundation of Shandong Province [2013HQ047];
   Medicine and health development plan of Shandong Province [2017WS113];
   humanities and social sciences youth team project of Shandong University
   [IFYT18036]
FX This work was supported by National Natural Science Foundation of China
   (grant numbers 81400072); the Natural Science Foundation of Shandong
   Province (grant numbers 2013HQ047); the Medicine and health development
   plan of Shandong Province (grant numbers 2017WS113); and the humanities
   and social sciences youth team project of Shandong University (grant
   numbers IFYT18036). This research did not receive any specific grant
   from funding agencies in the public, commercial, or not-for-profit
   sectors.
CR Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136
   BERNARD J, 1952, Sem Hop, V28, P3744
   Bonsignore MR, 2018, J SLEEP RES, V27, DOI 10.1111/jsr.12729
   Brumpton B, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01327-2016
   Brumpton BM, 2013, EUR RESPIR J, V42, P1495, DOI 10.1183/09031936.00046013
   Brunner WM, 2014, AM J RESP CRIT CARE, V189, P1044, DOI 10.1164/rccm.201307-1349OC
   Brusselle G, 2017, PULM PHARMACOL THER, V43, P39, DOI 10.1016/j.pupt.2017.01.011
   Choy D, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA4751
   de Marco R, 1998, EUR RESPIR J, V11, P599
   Fireman EM, 2004, ENVIRON HEALTH PERSP, V112, P1564, DOI 10.1289/ehp.7233
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Gonzalez-Barcala FJ, 2018, EUR J INTERN MED, V53, P34, DOI 10.1016/j.ejim.2018.02.034
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Ilmarinen P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/514868
   Kazeros A, 2013, J ASTHMA, V50, P25, DOI 10.3109/02770903.2012.743149
   Kerkhof M, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA3994
   Khoury P, 2014, NAT REV RHEUMATOL, V10, P474, DOI 10.1038/nrrheum.2014.98
   Kita H, 2011, IMMUNOL REV, V242, P161, DOI 10.1111/j.1600-065X.2011.01026.x
   Lavinskiene S, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0065-4
   Lin JT, 2018, RESP MED, V137, P48, DOI 10.1016/j.rmed.2018.02.010
   LIU  Yafei, 2017, J SHANDONG U HLTH SC, P30, DOI [10.6040/j.issn.1671-7554.0.2017.376, DOI 10.6040/J.ISSN.1671-7554.0.2017.376]
   Ma J, 2010, ALLERGY, V65, P1455, DOI 10.1111/j.1398-9995.2010.02402.x
   Matucci A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0813-0
   Matulonga-Diakiese B, 2018, MATURITAS, V118, P44, DOI 10.1016/j.maturitas.2018.10.006
   Nelson W, 2000, TECHNOMETRICS, V42, P12, DOI 10.2307/1271428
   Pennington AF, 2016, PEDIAT ALLERG IMM-UK, V27, P591, DOI 10.1111/pai.12586
   Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266
   Pham DL, 2017, CLIN EXP ALLERGY, V47, P57, DOI 10.1111/cea.12859
   Price D, 2016, J ASTHMA ALLERGY, V9, P1, DOI 10.2147/JAA.S97973
   Racine G, 2017, J ALLER CL IMM-PRACT, V5, P1371, DOI 10.1016/j.jaip.2017.02.001
   Rantala A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027912
   Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011
   Sastre B, 2018, J INVEST ALLERG CLIN, V28, P289, DOI 10.18176/jiaci.0295
   Shen TC, 2017, EPIDEMIOL PSYCH SCI, V26, P664, DOI 10.1017/S2045796016000664
   Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011
   Westerhof  G., 2016, AM J RESP CRIT CARE, P193
   Westerhof GA, 2018, J ALLERGY CLIN IMMUN, V141, P104, DOI 10.1016/j.jaci.2017.03.034
   World Health Organization, 2019, CHRON RESP DIS SCOP
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
   Yap E, 2013, INTERN MED J, V43, P46, DOI 10.1111/j.1445-5994.2011.02565.x
   Zeiger RS, 2014, J ALLER CL IMM-PRACT, V2, P741, DOI 10.1016/j.jaip.2014.06.005
   2018, CURR DRUG TARGETS, V19, P1882, DOI DOI 10.2174/1389450119666180212120012
NR 42
TC 2
Z9 2
U1 3
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 59
EP 65
DI 10.1016/j.rmed.2019.03.016
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200010
PM 31047119
DA 2020-05-18
ER

PT J
AU Pan, J
   Adab, P
   Jiang, CQ
   Zhang, WS
   Zhu, F
   Jin, YL
   Thomas, GN
   Lam, TH
AF Pan, Jing
   Adab, Peymane
   Jiang, Chao Qiang
   Zhang, Wei Sen
   Zhu, Feng
   Jin, Ya Li
   Thomas, G. Neil
   Lam, Tai Hing
TI All-cause and cause-specific mortality from restrictive and obstructive
   spirometric patterns in Chinese adults with and without dyspnea:
   Guangzhou Biobank Cohort Study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Restriction on spirometry; Airflow obstruction; Dyspnea; Mortality
ID NUTRITION EXAMINATION SURVEY; LUNG-FUNCTION DECLINE; 1ST
   NATIONAL-HEALTH; GENERAL-POPULATION; PULMONARY-FUNCTION; UNITED-STATES;
   HONG-KONG; DISEASE; RISK; DYSFUNCTION
AB Objective: To study whether abnormal spirometric patterns were associated with differential mortality in Chinese adults with and without dyspnea.
   Methods: Guangzhou Biobank Cohort Study (GBCS) participants were classified by spirometric patterns and presence of dyspnea into 6 groups: normal spirometry (NS), restriction on spirometry (ROS) and airflow obstruction (AO), each with and without dyspnea. Adjusted hazard ratios (aHRs) were calculated for mortality using Cox models.
   Results: Among 16777 subjects, 1595 (9.5%) had ROS, 1036 (6.2%) had AO and 1009 (6.0%) had dyspnea. A total of 1993 deaths (11.9%) occurred during 11-year follow-up. Using NS without dyspnea as reference, NS with dyspnea was significantly associated with increased cardiovascular mortality risk (aHRs 1.61 (95% confidence interval (CI) 1.18-2.19); ROS with and without dyspnea were associated with increased risks of all-cause (aHRs 1.46 (95% CI 1.28-1.66) and 1.81 (95% CI 1.33-2.47)) and cardiovascular mortality (aHRs 1.89 (95% CI 1.55-2.31) and 1.85 (95% CI 1.12-3.03)), but not of lung cancer mortality (aHRs 1.33 (95% CI 0.91-1.94) and 1.35 (95% CI 0.49-3.70)); AO with and without dyspnea were associated with increased risks of all-cause (aHRs 1.59 (95% CI 1.36-1.86) and 2.36 (95% CI 1.77-3.15)), cardiovascular (aHRs 1.43 (95% CI 1.08-1.90) and 1.61 (95% CI 0.91-2.82)) and lung cancer mortality (aHRs 1.91 (95% CI 1.29-2.84) and 3.01 (95% CI 1.46-6.23)). These associations did not vary by sex or smoking status (all P-values for interaction > 0.05).
   Conclusion: Both ROS and AO, with and without dyspnea, were associated with increased all-cause and cardiovascular disease mortality. The increased risk of all-cause was greater and that of cardiovascular mortality was lower for AO than ROS. AO showed significantly increased risk of lung cancer but ROS did not. (272 words).
C1 [Pan, Jing; Jiang, Chao Qiang; Zhang, Wei Sen; Zhu, Feng; Jin, Ya Li; Lam, Tai Hing] Guangzhou 12 Hosp, Guangzhou, Guangdong, Peoples R China.
   [Adab, Peymane; Thomas, G. Neil] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
   [Lam, Tai Hing] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China.
RP Jiang, CQ (reprint author), Guangzhou 12 Hosp, Guangzhou, Guangdong, Peoples R China.; Adab, P (reprint author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
EM jcdaise@163.com; P.ADAB@bham.ac.uk; cqianggz@163.com; zwsgzcn@163.com;
   chifengzhu@hotmail.com; jinyali22@163.com; g.n.thomas@bham.ac.uk;
   hrmrlth@hku.hk
RI Adab, Peymane/B-5360-2013; Lam, Tai Hing/C-4317-2009
OI Adab, Peymane/0000-0001-9087-3945; Lam, Tai Hing/0000-0002-2033-9971;
   pan, jing/0000-0002-3748-4294
FU Guangdong Provincial Medical Science Research Fundation, Guangdong,
   China [A2018141]; National Key R&D Program of China [2017YFC0907100];
   Guangzhou Science and Technology Bureau, Guangzhou, China [2002Z2-E2051,
   2012J5100041, 201704030132]; Guangzhou Science and Technology Bureau,
   Guangzhou [2002Z2-E2051, 2012J5100041]; University of Hong Kong
   Foundation for Educational Development and Research, Hong KongUniversity
   of Hong Kong [C20400.28505200, SN/1f/HKUF-DC]; Guangzhou Public Health
   Bureau, Guangzhou, China [201102A211004011]; University of Birmingham,
   UK
FX This work was supported by the Guangdong Provincial Medical Science
   Research Fundation, Guangdong, China (A2018141), and the National Key
   R&D Program of China (2017YFC0907100) and the Guangzhou Science and
   Technology Bureau, Guangzhou, China (2002Z2-E2051; 2012J5100041;
   201704030132). The GBCS was funded by the Guangzhou Science and
   Technology Bureau, Guangzhou (No. 2002Z2-E2051; No. 2012J5100041); the
   University of Hong Kong Foundation for Educational Development and
   Research, Hong Kong (No. SN/1f/HKUF-DC; C20400.28505200); the Guangzhou
   Public Health Bureau, Guangzhou (No. 201102A211004011), China; and the
   University of Birmingham, UK.
CR Berraho M, 2013, J NUTR HEALTH AGING, V17, P908, DOI 10.1007/s12603-013-0347-6
   Casanova C, 2015, CHEST, V148, P159, DOI 10.1378/chest.14-2449
   Celli BR, 2015, EUR RESPIR J, V45, P879, DOI 10.1183/09031936.00009015
   Choudhary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084264
   Fang LW, 2018, LANCET RESP MED, V6, P421, DOI 10.1016/S2213-2600(18)30103-6
   Feng L, 2012, COPD, V9, P555, DOI 10.3109/15412555.2012.706341
   Figarska SM, 2012, EUR J EPIDEMIOL, V27, P867, DOI 10.1007/s10654-012-9736-0
   Fimognari FL, 2007, J GERONTOL A-BIOL, V62, P760, DOI 10.1093/gerona/62.7.760
   Ford ES, 2013, CHEST, V143, P1395, DOI 10.1378/chest.12-1135
   Ford ES, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-115
   Fragoso CAV, 2011, J INVEST MED, V59, P1089, DOI 10.2310/JIM.0b013e31822bb213
   Georgiopoulou VV, 2011, AM J MED, V124, P334, DOI 10.1016/j.amjmed.2010.12.006
   Global Strategy for the Diagnosis Management and Prevention of COPD., 2017, GLOBAL STRATEGY DIAG
   Guerra S, 2010, THORAX, V65, P499, DOI 10.1136/thx.2009.126052
   Honda Y, 2017, INT J CARDIOL, V241, P395, DOI 10.1016/j.ijcard.2017.04.049
   Ip MSM, 2006, CHEST, V129, P384, DOI 10.1378/chest.129.2.384
   Jiang CQ, 2006, INT J EPIDEMIOL, V35, P844, DOI 10.1093/ije/dyl131
   Lederer DJ, 2009, AM J RESP CRIT CARE, V180, P407, DOI 10.1164/rccm.200812-1966OC
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Maltais F, 2000, CLIN CHEST MED, V21, P665, DOI 10.1016/S0272-5231(05)70176-3
   Mannino DM, 2006, THORAX, V61, P472, DOI 10.1136/thx.2005.052449
   Mannino DM, 2006, AM J RESP CRIT CARE, V173, P985, DOI 10.1164/rccm.200508-1344OC
   Mannino DM, 2006, RESP MED, V100, P115, DOI 10.1016/j.rmed.2005.03.035
   Mannino DM, 2005, INT J TUBERC LUNG D, V9, P613
   Mannino DM, 2003, J INTERN MED, V254, P540, DOI 10.1111/j.1365-2796.2003.01211.x
   Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388
   Pan J, 2017, RESP MED, V132, P102, DOI 10.1016/j.rmed.2017.10.003
   Pellegrino R, 2005, EUR RESPIR J, V26, P1104, DOI 10.1183/09031936.05.00026705
   Pesola GR, 2016, CLIN RESPIR J, V10, P142, DOI 10.1111/crj.12191
   Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013
   Rubin D.B., 2009, J MARKETING RES, V137, P180
   Scarlata S, 2008, RESP MED, V102, P1349, DOI 10.1016/j.rmed.2008.02.021
   Tessier JF, 2001, EUR J EPIDEMIOL, V17, P223, DOI 10.1023/A:1017977715073
   U.P.S.T. Force, 2016, JAMA-J AM MED ASSOC, V315, P1372
   Waller K, 2014, MED SCI SPORT EXER, V46, P1538, DOI 10.1249/MSS.0000000000000255
   Wan ES, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0089-y
   Wang C, 2018, LANCET, V391, P1706, DOI [10.1016/S0140-6736(18)30841-9, 10.1016/s0140-6736(18)30841-9]
   Yang GH, 2006, INT J EPIDEMIOL, V35, P741, DOI 10.1093/ije/dyi181
   Yin P, 2007, LANCET, V370, P751, DOI 10.1016/S0140-6736(07)61378-6
   2015, J KOREAN MED SCI, V30, P725, DOI DOI 10.3346/JKMS.2015.30.6.725
NR 40
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 66
EP 80
DI 10.1016/j.rmed.2019.04.002
PG 15
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200011
PM 31047120
DA 2020-05-18
ER

PT J
AU Sehgal, S
   Small, B
   Highland, KB
AF Sehgal, Sameep
   Small, Bronwyn
   Highland, Kristin B.
TI Activity monitors in pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Mesh terms; Exercise; Accelerometry; Pulmonary disease; Chronic
   obstructive; Hypertension; Pulmonary; Interstitial lung disease
ID DAILY PHYSICAL-ACTIVITY; ACTIVITY COUNSELING PROGRAM; QUALITY-OF-LIFE;
   ARTERIAL-HYPERTENSION; ENERGY-EXPENDITURE; ELDERLY-PATIENTS;
   CLINICAL-TRIALS; COPD; REHABILITATION; CHILDREN
AB Physical activity is reduced in patients with chronic pulmonary diseases. Activity monitors can measure physical activity objectively and accurately over prolonged periods of time. Research grade and commercially available devices, using accelerometer technology, are being increasingly used in clinical studies. Physical activity levels have been found to have a moderate to strong correlation with important measures such as pulmonary function, exercise capacity, quality of life, and mortality and hospitalizations in patients with COPD, interstitial lung disease, pulmonary arterial hypertension and cystic fibrosis. Their use as a clinical trial end-point and as a tool to augment rehabilitation efforts has also been explored in patients with COPD with variable results. Due to the ease of use, economic viability, widespread availability and good patient compliance, their use in adult and pediatric medicine is expanding. This narrative review summarizes the current evidence of use of activity monitors in COPD, interstitial lung disease, asthma, pulmonary arterial hypertension, cystic fibrosis and lung transplant patients for the purposes of prognostication, monitoring, outcome measures and intervention.
C1 [Sehgal, Sameep] Temple Univ, Lewis Katz Sch Med, Dept Thorac Med & Surg, Philadelphia, PA 19122 USA.
   [Small, Bronwyn; Highland, Kristin B.] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.
RP Sehgal, S (reprint author), 3401 N Broad St,Suite 710C, Philadelphia, PA 19140 USA.
EM sameep.sehgal@tuhs.temple.edu
RI sehgal, sameep/AAG-9985-2020
CR Altenburg WA, 2015, RESP MED, V109, P112, DOI 10.1016/j.rmed.2014.10.020
   Andersson M, 2014, COPD, V11, P560, DOI 10.3109/15412555.2014.898033
   [Anonymous], 2009, NUTR REV, V67, P114, DOI 10.1111/j.1753-4887.2008.00136.x
   Atkins C, 2017, CHRON RESP DIS, V14, P161, DOI 10.1177/1479972316661926
   Aznar S, 2014, J CYST FIBROS, V13, P335, DOI 10.1016/j.jcf.2013.10.004
   Bahmer T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01827-2016
   Bahmer T, 2016, RESPIRATION, V91, P497, DOI 10.1159/000446607
   Bassett DR, 2017, SPORTS MED, V47, P1303, DOI 10.1007/s40279-016-0663-1
   Belza B, 2001, NURS RES, V50, P195, DOI 10.1097/00006199-200107000-00003
   Boers M, 2014, J CLIN EPIDEMIOL, V67, P745, DOI 10.1016/j.jclinepi.2013.11.013
   Bossenbrock L, 2009, J HEART LUNG TRANSPL, V28, P149, DOI 10.1016/j.healun.2008.11.905
   Bossenbroek L, 2011, RESPIRATION, V82, P28, DOI 10.1159/000322833
   Burger CD, 2014, CHEST, V146, P1263, DOI 10.1378/chest.14-0193
   Byrom B, 2016, CONTEMP CLIN TRIALS, V47, P172, DOI 10.1016/j.cct.2016.01.006
   Cassim R, 2016, J ASTHMA, V53, P882, DOI 10.1080/02770903.2016.1175474
   Castleberry AW, 2015, AM J RESP CRIT CARE, V192, P843, DOI 10.1164/rccm.201409-1698OC
   Chawla Harsh, 2014, Ann Am Thorac Soc, V11, P1203, DOI 10.1513/AnnalsATS.201405-198OC
   Corder K, 2007, CURR OPIN CLIN NUTR, V10, P597, DOI 10.1097/MCO.0b013e328285d883
   Coronado Marcos, 2003, J Cardiopulm Rehabil, V23, P357, DOI 10.1097/00008483-200309000-00006
   Dale MT, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-1
   Dallas M I, 2009, Chron Respir Dis, V6, P217, DOI 10.1177/1479972309346760
   de Blok BMJ, 2006, PATIENT EDUC COUNS, V61, P48, DOI 10.1016/j.pec.2005.02.005
   Demeyer H, 2017, THORAX, V72, P415, DOI 10.1136/thoraxjnl-2016-209026
   Dhillon SS, 2015, ARCH PHYS MED REHAB, V96, P2079, DOI 10.1016/j.apmr.2015.05.015
   Donaire-Gonzalez D, 2013, EUR RESPIR J, V42, P993, DOI 10.1183/09031936.00101512
   Egan C, 2012, RESP MED, V106, P1671, DOI 10.1016/j.rmed.2012.08.016
   Ehsan Mohsin, 2013, Ann Am Thorac Soc, V10, P559, DOI 10.1513/AnnalsATS.201304-100OC
   Eliason G, 2011, COPD, V8, P369, DOI 10.3109/15412555.2011.605403
   Evenson KR, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0183-7
   Firrincieli V, 2005, PEDIATR PULM, V40, P57, DOI 10.1002/ppul.20214
   FITTING JW, 1989, EUR RESPIR J, V2, P840
   Gaine S, 2013, EUR RESPIR REV, V22, P487, DOI 10.1183/09059180.00006213
   Garcia-Rio F, 2012, CHEST, V142, P338, DOI 10.1378/chest.11-2014
   Garcia-Rio F, 2009, AM J RESP CRIT CARE, V180, P506, DOI 10.1164/rccm.200812-1873OC
   Gimeno-Santos E, 2015, EUR RESPIR J, V46, P988, DOI 10.1183/09031936.00183014
   Hartman JE, 2016, RESP MED, V117, P116, DOI 10.1016/j.rmed.2016.06.009
   Hebestreit H, 2006, EUR RESPIR J, V28, P734, DOI 10.1183/09031936.06.00128605
   Hospes G, 2009, PATIENT EDUC COUNS, V75, P274, DOI 10.1016/j.pec.2008.10.005
   Hugli O, 1996, AM J RESP CRIT CARE, V153, P294, DOI 10.1164/ajrccm.153.1.8542132
   Kavanagh JJ, 2008, GAIT POSTURE, V28, P1, DOI 10.1016/j.gaitpost.2007.10.010
   Kawagoshi A, 2015, RESP MED, V109, P364, DOI 10.1016/j.rmed.2015.01.008
   Khiroya Heena, 2015, Open Respir Med J, V9, P15, DOI 10.2174/1874306401509010015
   Kooiman TJM, 2015, BMC SPORTS SCI MED R, V7, DOI 10.1186/s13102-015-0018-5
   Langer D, 2012, AM J TRANSPLANT, V12, P1584, DOI 10.1111/j.1600-6143.2012.04000.x
   Langer D, 2012, RESP MED, V106, P747, DOI 10.1016/j.rmed.2012.01.003
   Langer D, 2009, J HEART LUNG TRANSPL, V28, P572, DOI 10.1016/j.healun.2009.03.007
   Mador MJ, 2011, J CARDIOPULM REHABIL, V31, P52, DOI 10.1097/HCR.0b013e3181ebf2ef
   Mainguy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027993
   Mancuso CA, 2013, J ASTHMA, V50, P103, DOI 10.3109/02770903.2012.743150
   Matura LA, 2016, CHEST, V150, P46, DOI 10.1016/j.chest.2016.02.633
   Moy ML, 2015, CHEST, V148, P128, DOI 10.1378/chest.14-1466
   Moy ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060400
   Nakayama M, 2015, RESPIROLOGY, V20, P640, DOI 10.1111/resp.12500
   NHLBI NIH, WHAT IS PHYS ACT
   Nolan CM, 2017, AM J RESP CRIT CARE, V195, P1344, DOI 10.1164/rccm.201607-1372OC
   Nolan  M., 2016, VALIDITY APPLE IPHON, P759
   O'Donnell DE, 2011, RESP MED, V105, P1030, DOI 10.1016/j.rmed.2011.03.014
   Okumus G, 2018, CLIN RESPIR J, V12, P119, DOI 10.1111/crj.12495
   Patel Sanjay A, 2007, COPD, V4, P107, DOI 10.1080/15412550701246658
   Pitta F, 2006, EUR RESPIR J, V27, P1040, DOI 10.1183/09031936.06.00064105
   Pitta F, 2006, CHEST, V129, P536, DOI 10.1378/chest.129.3.536
   Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC
   Pitta F, 2008, CHEST, V134, P273, DOI 10.1378/chest.07-2655
   Pugh ME, 2012, CHEST, V142, P1391, DOI 10.1378/chest.12-0150
   Pulford J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158780
   Rabinovich RA, 2013, EUR RESPIR J, V42, P1205, DOI 10.1183/09031936.00134312
   Radtke T, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002768.pub4
   Ritz T, 2010, CHEST, V138, P913, DOI 10.1378/chest.08-3073
   Ruf KC, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-43
   Rundle A, 2009, J ASTHMA, V46, P803, DOI 10.3109/02770900903114564
   Sameep Sehgal K. B. H., 2017, AM J RESP CRIT CARE, V195, DOI [10.1164/AJRCCM-CONFERENCE.2017.195.1_MEETINGABSTRACTS.A3110, DOI 10.1164/AJRCCM-CONFERENCE.2017.195.1_MEETINGABSTRACTS.A3110]
   Sasaki  D., 2016, COMPUT WEB BASED INN, P33, DOI [10.1016/B978-0-12-802075-3.00002-4, DOI 10.1016/B978-0-12-802075-3.00002-4]
   Sasaki JE, 2018, J SPORT SCI, V36, P1572, DOI 10.1080/02640414.2017.1403527
   Saunders T, 2016, J PHYS ACT HEALTH, V13, P1275, DOI 10.1123/jpah.2016-0087
   Savi D, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0151-7
   Savi D, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0036-9
   Savi D, 2013, RESP MED, V107, P1888, DOI 10.1016/j.rmed.2013.09.012
   Sewell L, 2005, CHEST, V128, P1194, DOI 10.1378/chest.128.3.1194
   Sousa AW, 2014, J ASTHMA, V51, P493, DOI 10.3109/02770903.2014.888571
   Steele BG, 2000, CHEST, V117, P1359, DOI 10.1378/chest.117.5.1359
   Taichman DB, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-92
   Thorpe O, 2014, INT J CHRONIC OBSTR, V9, P115, DOI 10.2147/COPD.S54457
   Thorpe O, 2012, J CARDIOPULM REHABIL, V32, P359, DOI 10.1097/HCR.0b013e318262d7df
   Troosters T, 2018, AM J RESP CRIT CARE, V198, P1021, DOI 10.1164/rccm.201706-1288OC
   Troosters T, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.3
   Trost SG, 2005, MED SCI SPORT EXER, V37, pS531, DOI 10.1249/01.mss.0000185657.86065.98
   Tsai SY, 2012, NURS RES, V61, P252, DOI 10.1097/NNR.0b013e318255679c
   Ulrich S, 2013, RESPIRATION, V86, P45, DOI 10.1159/000342351
   Vaes A. W., 2019, RESP MED, V151, P81
   Vaes AW, 2013, ANN MED, V45, P397, DOI 10.3109/07853890.2013.810891
   Vahlkvist S, 2010, ALLERGY, V65, P1464, DOI 10.1111/j.1398-9995.2010.02406.x
   Van Remoortel H, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-84
   Vooijs M, 2014, INTERACT J MED RES, V3, P12, DOI 10.2196/ijmr.3056
   Walker PP, 2008, THORAX, V63, P683, DOI 10.1136/thx.2007.087130
   Wallaert B, 2013, CHEST, V144, P1652, DOI 10.1378/chest.13-0806
   Walsh JR, 2016, J HEART LUNG TRANSPL, V35, P1041, DOI 10.1016/j.healun.2016.05.013
   Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521
   Watz H, 2009, EUR RESPIR J, V33, P262, DOI 10.1183/09031936.00024608
   Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814
   Wickerson L, 2015, PHYS THER, V95, P517, DOI 10.2522/ptj.20140173
   Wickerson L, 2013, J CARDIOPULM REHABIL, V33, P106, DOI 10.1097/HCR.0b013e3182839293
   willemijn R. M. F. B., 2017, AM J PREV MED, P1
   Zijlstra WMH, 2017, AM J RESP CRIT CARE, V196, P220, DOI 10.1164/rccm.201608-1576OC
   2009, J BRAS PNEUMOL, V35, P949, DOI DOI 10.1590/S1806-37132009001000002
NR 104
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 81
EP 95
DI 10.1016/j.rmed.2019.03.019
PG 15
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200012
PM 31047122
DA 2020-05-18
ER

PT J
AU Cohen-Cymberknoh, M
   Atia, O
   Gileles-Hillel, A
   Kerem, E
   Reitera, J
AF Cohen-Cymberknoh, Malena
   Atia, Ohad
   Gileles-Hillel, Alex
   Kerem, Eitan
   Reitera, Joel
TI Sleep disorders in patients with primary ciliary dyskinesia, cystic
   fibrosis with and without pancreatic insufficiency
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sleep; Quality of life; Cystic fibrosis; Primary ciliary dyskinesia;
   Pancreatic sufficiency; Pancreatic insufficiency
ID QUALITY-OF-LIFE; DISTURBANCE SCALE; CHILDREN SDSC; ADOLESCENTS;
   INSTRUMENT; PAIN
AB Background: Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are characterized by impaired mucociliary clearance causing sinopulmonary infections and airway inflammation. However, they differ in many aspects including multisystemic involvement and disease severity.
   Aim: To compare sleep disorders and their correlation with quality of life (QOL) in three distinct patient populations: CF and pancreatic insufficiency (CF-PI), pancreatic sufficiency (CF-PS) and PCD.
   Methods: Patients completed age appropriate sleep quality questionnaires (SDSC, PSQI), quality of life questionnaires (PedQL, QOL-BE) and the Epworth sleepiness scale (ESS). Medical records were reviewed for clinical data.
   Results: Eighty patients, 33 CF-PI, 27 CF-PS, and 20 PCD; 40 females; 41 adults and 39 children completed the study. In adults, 66% slept less than 7 h per night, and sleep quality was reduced in 26.5%, 53% reported night wakings and 47% nocturnal snoring or coughing. In children 78% slept more than 8 h, SDSC scores were mostly in the normal range. A significant correlation was found between sleep quality and QOL in both age groups. Global sleep scores were correlated with hemoglobin levels. Despite differences in disease severity and QOL, there were no significant differences in sleep quality between the three groups.
   Conclusion: Sleep disorders are common and correlate with QOL in CF and PCD. Despite differences in disease characteristics and severity, there are no differences in terms of sleep disorders between CF-PI, CF-PS and PCD patients, suggesting that they may represent indirect outcomes of disease.
C1 [Cohen-Cymberknoh, Malena; Gileles-Hillel, Alex; Kerem, Eitan; Reitera, Joel] Hadassah Hebrew Univ, Med Ctr, Pediat Pulm Unit, Jerusalem, Israel.
   [Cohen-Cymberknoh, Malena; Gileles-Hillel, Alex; Kerem, Eitan; Reitera, Joel] Hadassah Hebrew Univ, Med Ctr, CF Ctr, Jerusalem, Israel.
   [Atia, Ohad] Hebrew Univ Jerusalem, Sch Med, Jerusalem, Israel.
   [Gileles-Hillel, Alex; Reitera, Joel] Hadassah Hebrew Univ, Med Ctr, Sleep Unit, Jerusalem, Israel.
RP Reitera, J (reprint author), Hadassah Med Ctr, Dept Pediat, Pediat Pulmonol, IL-91120 Jerusalem, Israel.
EM rjoely@hadassah.org.il
OI Gileles-Hillel, Alex/0000-0002-0656-905X
FU Israel Lung Association, Tel Aviv, Israel
FX None, this study was conducted as part of the MD thesis required by the
   Hebrew University - Hadassah Medical School, Jerusalem, Israel. This
   study was supported in part by a grant from the Israel Lung Association,
   Tel Aviv, Israel.
CR Amin R, 2005, CHEST, V128, P1357, DOI 10.1378/chest.128.3.1357
   Bruni O, 1996, J SLEEP RES, V5, P251, DOI 10.1111/j.1365-2869.1996.00251.x
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Cohen-Cymberknoh M, 2014, CHEST, V145, P738, DOI 10.1378/chest.13-1162
   Dancey DR, 2002, EUR RESPIR J, V19, P504, DOI 10.1183/09031936.02.00088702
   de la Vega R., 2018, PAIN
   Flume PA, 2009, J CYST FIBROS, V8, P321, DOI 10.1016/j.jcf.2009.07.004
   Forte GC, 2015, RESP CARE, V60, P1459, DOI 10.4187/respcare.03665
   Jankelowitz L, 2005, CHEST, V127, P1593, DOI 10.1378/chest.127.5.1593
   Johns M, 1997, SLEEP, V20, P844, DOI 10.1093/sleep/20.10.844
   Katz ES, 2014, CLIN CHEST MED, V35, P495, DOI 10.1016/j.ccm.2014.06.005
   Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8
   Milross Maree A, 2002, Sleep Med, V3, P205, DOI 10.1016/S1389-9457(01)00157-5
   Miyazaki T, 2015, CIRC J, V79, P2632, DOI 10.1253/circj.CJ-15-0654
   Naqvi SK, 2008, SLEEP BREATH, V12, P77, DOI 10.1007/s11325-007-0123-0
   O'connor T M, 2002, J Cyst Fibros, V1, P31, DOI 10.1016/S1569-1993(01)00004-2
   Oktem S, 2013, PEDIATR PULM, V48, P897, DOI 10.1002/ppul.22710
   Perin C, 2012, SLEEP BREATH, V16, P1041, DOI 10.1007/s11325-011-0599-5
   Roeser Karolin, 2012, Front Psychiatry, V3, P76, DOI 10.3389/fpsyt.2012.00076
   Romeo DM, 2013, EUR J PAEDIATR NEURO, V17, P374, DOI 10.1016/j.ejpn.2012.12.009
   Ronnlund H, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3425
   Rosenstein BJ, 1998, J PEDIATR-US, V132, P589, DOI 10.1016/S0022-3476(98)70344-0
   Shapiro AJ, 2018, AM J RESP CRIT CARE, V197, pE24, DOI 10.1164/rccm.201805-0819ST
   Silva AM, 2016, REV PORT PNEUMOL, V22, P202, DOI 10.1016/j.rppnen.2016.02.007
   Simanovsky N, 2013, CHEST, V144, P208, DOI 10.1378/chest.12-1226
   Spicuzza L, 2012, ARCH PEDIAT ADOL MED, V166, P1165, DOI 10.1001/archpediatrics.2012.1177
   Tomaszek L, 2019, HEART LUNG, V48, P159, DOI 10.1016/j.hrtlng.2018.08.003
   Valrie CR, 2013, J DEV BEHAV PEDIATR, V34, P120, DOI 10.1097/DBP.0b013e31827d5848
   van der Giessen L, 2009, PEDIATR PULM, V44, P859, DOI 10.1002/ppul.21004
   Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003
   Walkowiak J, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e7
   2012, RESP MED, V106, P1244, DOI DOI 10.1016/J.RMED.2012.06.010
   2016, SLEEP, V39, P2005, DOI DOI 10.5665/SLEEP.6232
   2014, RESPIROLOGY, V19, P570, DOI DOI 10.1111/RESP.12273
   2003, AMBUL PEDIAT, V3, P329
   2018, PAIN MANAG NURS, V19, P340, DOI DOI 10.1016/J.PMN.2017.11.011
   2018, PEDIAT PULMONOL, V53, P1436, DOI DOI 10.1002/PPUL.24133
   1996, THORAX, V51, P936
   2014, QUAL LIFE RES, V23, P1279, DOI DOI 10.1007/S11136-013-0560-0
NR 39
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 96
EP 101
DI 10.1016/j.rmed.2019.03.022
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200013
PM 31047123
DA 2020-05-18
ER

PT J
AU Domvri, K
   Porpodis, K
   Tzimagiorgis, G
   Chatzopoulou, F
   Kontakiotis, T
   Kyriazis, G
   Papakosta, D
AF Domvri, Kalliopi
   Porpodis, Konstantinos
   Tzimagiorgis, Georgios
   Chatzopoulou, Fani
   Kontakiotis, Theodoros
   Kyriazis, George
   Papakosta, Despina
TI Th2/Th17 cytokine profile in phenotyped Greek asthmatics and
   relationship to biomarkers of inflammation
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cytokines; Th2/Th17; Asthma; Allergy; Eosinophlis; Biomarkers
ID GROWTH-FACTOR BETA-1; NITRIC-OXIDE; TH17 CELLS; PLASTICITY; IL-23; FENO;
   POLYMORPHISMS; MECHANISMS; DIVERSITY; SEVERITY
AB Objective: The aim of the present study was to investigate the Th2/Th17 pathway in asthmatic patients and also the relationship to asthma severity and biomarkers of inflammation.
   Methods: 90 asthmatic patients, 51 patients with severe, 39 patients with mild asthma and 98 healthy controls were included. Skin prick tests, blood eosinophils, total serum IgE and exhaled FeNO were evaluated. Serum levels of IL-4, IL-5, IL-13, IL-6, IL-17A, IL-23 and TGF beta 1 were determined by Flow Cytometry using a panel kit (AimPlex Biosciences). The SNP of IL17A (rs17880588) was genotyped using reverse transcriptase polymerase chain reaction (RT-PCR).
   Results: The genotype of the SNP in IL17A (rs 17880588) was similar among all three groups. Serum levels of IL4, IL-5, IL-13, IL-6, IL-17A and IL-23 were higher in asthmatics compared to controls (p < 0.05). In addition, IL17A and IL-4 serum levels were found significantly elevated in patients with allergic asthma (p < 0.05). Furthermore, IL-4, IL-5, IL-13 and IL-23 were found significantly higher in patients with eosinophil cut off values above 300 cells/mu l (p < 0.05). IL-17A levels were positively correlated with FeNO values in severe asthmatics with eosinophils > 400 cells/mu l.
   Conclusions: The above findings suggest the coexistence of Th2/Th17 pathway in severe, eosinophilic and in allergic asthma.
C1 [Domvri, Kalliopi; Porpodis, Konstantinos; Kontakiotis, Theodoros; Kyriazis, George; Papakosta, Despina] Aristotle Univ Thessaloniki, Gen Hosp G Papanikolaou, Dept Pneumonol, Thessaloniki, Greece.
   [Tzimagiorgis, Georgios; Chatzopoulou, Fani] Aristotle Univ Thessaloniki, Sch Hlth Sci, Med Dept, Lab Biol Chem, Thessaloniki, Greece.
RP Papakosta, D (reprint author), Aristotle Univ Thessaloniki, G Papanikolaou Hosp, Pulm Dept, Thessaloniki 57010, Greece.
EM kdomvrid@auth.gr; kporpodis@yahoo.com; tzimagio@med.auth.gr;
   fchatzop@auth.gr; kontak@auth.gr; kyriazis@med.auth.gr;
   dpapakos@med.auth.gr
OI Chatzopoulou, Fani/0000-0003-4695-5753
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Afshar R, 2008, CLIN EXP ALLERGY, V38, P1847, DOI 10.1111/j.1365-2222.2008.03119.x
   Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018
   Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001
   Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X
   Antczak A, 2016, INT J IMMUNOPATH PH, V29, P195, DOI 10.1177/0394632015623794
   Bajoriuniene I, 2012, LUNG, V190, P487, DOI 10.1007/s00408-012-9411-y
   Bazzi MD, 2011, J INVEST ALLERG CLIN, V21, P551
   Bourdin A, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01393-2018
   Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC
   Chiang CH, 2013, RESP CARE, V58, P1343, DOI 10.4187/respcare.02187
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Ciprandi G, 2012, INT ARCH ALLERGY IMM, V159, P183, DOI 10.1159/000336418
   Cosmi L., 2010, ALLERGY CLIN IMMUNOL, V125
   Djukanovic R, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01671-2018
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM
   Fajt ML, 2014, J ASTHMA, V51, P669, DOI 10.3109/02770903.2014.910221
   Fattahi F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161433
   Global Initiative for Asthma, 2017, GLOB STRAT ASTHM MAN
   Global Initiative for Asthma (GINA), 2015, GLOB STRAT ASTHM MAN
   Halwani R, 2017, J ASTHMA, V54, P893, DOI 10.1080/02770903.2017.1283696
   Heck S, 2015, INT ARCH ALLERGY IMM, V168, P241, DOI 10.1159/000443930
   Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038
   Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   Li HL, 2007, HUM GENET, V121, P529, DOI 10.1007/s00439-007-0337-z
   Lin YL, 2016, J MOL MED, V94, P51, DOI 10.1007/s00109-015-1325-8
   Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442
   Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899
   Naji N, 2014, INT ARCH ALLERGY IMM, V165, P27, DOI 10.1159/000367789
   Neelamegan R, 2016, J CLIN DIAGN RES, V10, pFC1, DOI 10.7860/JCDR/2016/20656.8950
   O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334
   Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160
   Papakosta D, 2011, J ASTHMA, V48, P901, DOI 10.3109/02770903.2011.611958
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874
   Tizaoui K, 2017, CURR MOL MED, V17, P647, DOI 10.2174/1566524018666180322162646
   Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634
   Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC
   Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8
   Wenzel SE, 2013, PULM PHARMACOL THER, V26, P710, DOI 10.1016/j.pupt.2013.07.003
   Westerhof GA, 2015, EUR RESPIR J, V46, P688, DOI 10.1183/09031936.00012415
   Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC
   Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7
   Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007
   Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488
   Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001
   2007, IRAN J ALLERGY ASTHM, V6, P67
   2011, J ALLERGY CLIN IMMUN, V127, P355, DOI DOI 10.1016/J.JACI.2010.11.037
NR 50
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 102
EP 110
DI 10.1016/j.rmed.2019.03.017
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200014
PM 31047104
DA 2020-05-18
ER

PT J
AU Armas, LH
   Turino, C
   Cordero-Guevara, J
   Manjon, JL
   Duran-Carro, J
   Barbe, F
   Vaca, R
   Duran-Cantolla, J
   Ullate, J
   Carrillo, J
   Sanchez-de-la-Torre, M
   Ingles, S
   Egea, C
AF Hidalgo Armas, Laura
   Turino, Cecilia
   Cordero-Guevara, Jose
   Luis Manjon, Jose
   Duran-Carro, Joaquin
   Barbe, Ferran
   Vaca, Rafaela
   Duran-Cantolla, Joaquin
   Ullate, Jorge
   Carrillo, Juan
   Sanchez-de-la-Torre, Manuel
   Ingles, Sandra
   Egea, Carlos
CA Spanish Sleep Network
TI A new postural device for the treatment of positional obstructive sleep
   apnea. A pilot study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE AHI; OSA; Positional treatment; Postural device; Supine position
ID TENNIS BALL TECHNIQUE; SUPINE POSITION; HYPOPNEA; PRESSURE; NCPAP; CPAP
AB Background: Approximately 60% of obstructive sleep apnea (OSA) diagnoses are position-dependent, and avoidance of the supine position could represent an effective treatment. Nevertheless, the majority of the available anti-supine treatments result in discomfort and low adherence. This study evaluated the effectiveness of a new vibrating supine avoidance device in reducing time spent in the supine position and the apnea-hypopnea index (AHI) without affecting sleep structure. Furthermore, the tolerability and satisfaction were also scored.
   Methods: Observational prospective study of patients suffering from positional OSA. They were treated with a vibrating device and followed up at the first and fourth weeks after starting the treatment, and further polysomnographic studies were conducted while patients' wore the device. The comparison of the results was carried out through non-parametric tests. Significance level was 5%.
   Results: Twelve patients had complete data. The device reduced time spent in the supine position (from 51.5 +/- 14.8% to 25.2 +/- 21.0%, p = 0.005), median AHI (from 30.7 (23.2-38.2) at baseline to 21.5 (12.4-24.3) at the fourth week, p = 0.002). Also an improvement in the minimum SaO(2) (from 82.2 +/- 7.5 to 87.2 +/- 3.6 at the 4th week) was also observed. No variations in sleep quality or quantity were identified. All patients evaluated the device positively.
   Conclusion: Our device was effective in reducing the time spent in the supine position and improving AHI, SaO(2) variables and sleep architecture. The device was well tolerated by the patients.
C1 [Hidalgo Armas, Laura] OSI Araba Hosp Univ, Inst Invest Bioaraba, Unidad Ensayos Clin, Vitoria, Spain.
   [Turino, Cecilia; Barbe, Ferran; Vaca, Rafaela] IRBlleida, Translat Res Resp Med, Lleida, Spain.
   [Cordero-Guevara, Jose; Duran-Cantolla, Joaquin] OSI Araba Hosp Univ, Inst Invest Bioaraba, Unidad Metodol & Estadist, Vitoria, Spain.
   [Luis Manjon, Jose; Duran-Carro, Joaquin; Duran-Cantolla, Joaquin] Hosp OSI Araba Hosp Univ, Unidad Trastornos Sueno, Vitoria, Spain.
   [Luis Manjon, Jose; Duran-Carro, Joaquin; Duran-Cantolla, Joaquin] OSI Araba Hosp Univ, Inst Invest Bioaraba, Serv Invest, Vitoria, Spain.
   [Barbe, Ferran; Duran-Cantolla, Joaquin] ISCIII, CIBER Enfermedades Resp CibeRes, Madrid, Spain.
   [Duran-Cantolla, Joaquin] Univ Basque Country, UPV EHU, Dept Med, Fac Med, Pais Vasco, Spain.
RP Duran-Cantolla, J (reprint author), OSI Araba Hosp Univ, Inst Invest Bioraba, Planta 4a C,C Jose Achotegui S-N, Pais Vasco 01009, Spain.
EM joaquin.durancantolla@gmail.com
FU National Health Institute [ISCIII PI112/00243]; Health Department of the
   Basque Government; Spanish Respiratory Society
FX Financed by the National Health Institute (ISCIII PI112/00243), the
   Health Department of the Basque Government (DSGV 2013) and the Spanish
   Respiratory Society (SEPAR 2014).
CR Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135
   Barnes H, 2017, SLEEP MED REV, V36, P107, DOI 10.1016/j.smrv.2016.11.004
   Berger M, 1997, J HUM HYPERTENS, V11, P657, DOI 10.1038/sj.jhh.1000510
   Berry RB, 2012, AASM MANUAL SCORING
   Bignold JJ, 2011, J CLIN SLEEP MED, V7, P376, DOI 10.5664/JCSM.1194
   CARTWRIGHT RD, 1985, SLEEP, V8, P87, DOI 10.1093/sleep/8.2.87
   CARTWRIGHT RD, 1984, SLEEP, V7, P110, DOI 10.1093/sleep/7.2.110
   Dieltjens M, 2015, SLEEP BREATH, V19, P637, DOI 10.1007/s11325-014-1068-8
   Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065
   Duran-Cantolla J, 2005, ARCH BRONCONEUMOL, V41, P645, DOI 10.1016/S1579-2129(06)60330-3
   Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5991
   Eijsvogel MM, 2015, J CLIN SLEEP MED, V11, P139, DOI 10.5664/jcsm.4460
   Gay P, 2006, SLEEP, V29, P381, DOI 10.1093/sleep/29.3.381
   Giles TL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001106.pub2
   HOOD J. D., 1962, JOUR ACOUSTICAL SOC AMER, V34, P1325, DOI 10.1121/1.1918339
   Joosten SA, 2014, SLEEP MED REV, V18, P7, DOI 10.1016/j.smrv.2013.01.005
   Mar J, 2003, EUR RESPIR J, V21, P515, DOI 10.1183/09031936.03.00040903
   Myers KA, 2013, JAMA-J AM MED ASSOC, V310, P731, DOI 10.1001/jama.2013.276185
   Oksenberg A, 2000, CHEST, V118, P1018, DOI 10.1378/chest.118.4.1018
   Oksenberg A, 1997, CHEST, V112, P629, DOI 10.1378/chest.112.3.629
   Permut I, 2010, J CLIN SLEEP MED, V6, P238
   Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132
   Sharma SK, 2011, NEW ENGL J MED, V365, P2277, DOI 10.1056/NEJMoa1103944
   Skinner MA, 2008, RESPIROLOGY, V13, P708, DOI 10.1111/j.1440-1843.2008.01328.x
   Skinner Margot A, 2004, Sleep Breath, V8, P193
   Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104
   van Kesteren ER, 2011, SLEEP, V34, P1075, DOI 10.5665/SLEEP.1164
   Van Maanen JP, 2012, J SLEEP RES, V21, P322, DOI 10.1111/j.1365-2869.2011.00974.x
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
NR 29
TC 0
Z9 0
U1 1
U2 10
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 111
EP 117
DI 10.1016/j.rmed.2019.02.005
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200015
PM 31047106
DA 2020-05-18
ER

PT J
AU Licari, A
   Brambilla, I
   Sacchi, L
   Marseglia, G
   Ciprandi, G
AF Licari, Amelia
   Brambilla, Ilaria
   Sacchi, Lucia
   Marseglia, Gianluigi
   Ciprandi, Giorgio
TI Periostin, type 2 biomarker, is not associated with asthma control grade
   in asthmatic allergic children
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Asthma control; Children; Inflammation; Eosinophils; Periostin
ID SERUM PERIOSTIN; FENO
AB Background: Allergic asthma is characterized by type 2 inflammation. Periostin has been proposed as type 2 biomarker.
   Objective: To test the hypothesis that serum periostin could be associated with the asthma control grade in a group of children with allergic asthma and recruited in clinical practice.
   Patients and methods: 121 consecutive children (71 males, 50 females, mean age 11.6 +/- 3.2 years) with allergic asthma were visited for the first time at a third-level paediatric clinic. Serum periostin was evaluated with gender, BMI and z score BMI, lung function, FeNO, ACT questionnaire, VAS of breathing perception, peripheral eosinophils, total serum IgE, oral corticosteroid (CS) use in the past year, control asthma grade and asthma severity (according to GINA document).
   Results: Serum periostin was not associated with the asthma control grade and did not correlate with blood eosinophils and FeNO. In addition, peripheral eosinophils, serum IgE, and FeNO were not associated with the asthma control grade. On the contrary, gender, FEV1, FEV1/FVC ratio, FEF25-75, ACT, VAS of breathing perception, oral corticosteroid use, and asthma severity grade were associated with the asthma control grade.
   Conclusions: Serum periostin seems to be scarcely useful to assess the asthma control in children with allergic asthma in clinical practice. There is the need to identify reliable inflammation biomarkers able to correlate with the asthma control grade.
C1 [Licari, Amelia; Brambilla, Ilaria; Marseglia, Gianluigi] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Pediat, Pavia, Italy.
   [Sacchi, Lucia] Univ Pavia, Dept Elect Comp & Biomed Engn, Lab Biomed Informat Mario Stefanelli, Pavia, Italy.
   [Ciprandi, Giorgio] Villa Montallegro, Allergy Clin, Genoa, Italy.
RP Ciprandi, G (reprint author), Via P Boselli 5, I-16146 Genoa, Italy.
EM gio.cip@libero.it
RI Licari, Amelia/J-5898-2016; MARSEGLIA, GIAN LUIGI/AAL-2254-2020;
   Brambilla, Ilaria/AAB-8837-2019
OI Licari, Amelia/0000-0002-1773-6482; MARSEGLIA, GIAN
   LUIGI/0000-0003-3662-0159; Brambilla, Ilaria/0000-0002-7139-6060;
   SACCHI, LUCIA/0000-0002-1390-9825
CR Agache I, 2017, ALLERGY ASTHMA IMMUN, V9, P466, DOI 10.4168/aair.2017.9.6.466
   Bobolea I, 2015, ALLERGY, V70, P540, DOI 10.1111/all.12580
   Ciprandi G., 2018, J ASTHMA, V17, P1
   Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC
   Global Initiative for Asthma GINA Guidelines, 2018, GINA GUID
   Kanemitsu Y, 2014, AM J RESP CRIT CARE, V190, P472, DOI 10.1164/rccm.201403-0562LE
   Li W., 2018, SEVERE ASTHMA, P59
   Licari A, 2018, PEDIAT ALLER IMM PUL, V31, P44, DOI 10.1089/ped.2018.0886
   Mansur AH, 2018, RESP MED, V143, P31, DOI 10.1016/j.rmed.2018.08.005
   Matsusaka M, 2015, ALLERGOL INT, V64, P175, DOI 10.1016/j.alit.2014.07.003
   Menzella F, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/2049-6958-10-1
   Nagasaki T, 2014, AM J RESP CRIT CARE, V190, P1449, DOI 10.1164/rccm.201407-1290LE
   Nakagome K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02220
   Nakamura Y, 2015, ALLERGOL INT, V64, P209, DOI 10.1016/j.alit.2015.01.001
   Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
   Simpson JL, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0230-4
   Song JS, 2015, ALLERGY, V70, P674, DOI 10.1111/all.12599
   Valero A, 2019, J INVEST ALLERG CLIN, V29, P15, DOI 10.18176/jiaci.0345
   Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634
   Yon DK, 2018, ALLERGY ASTHMA IMMUN, V10, P716, DOI 10.4168/aair.2018.10.6.716
NR 20
TC 2
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 118
EP 120
DI 10.1016/j.rmed.2019.04.010
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200016
PM 31047107
DA 2020-05-18
ER

PT J
AU Diel, R
   Ewig, S
   Blaas, S
   Jacob, C
   Juelich, F
   Korfmann, G
   Sohrab, S
   Sutharsan, S
   Rademacher, J
AF Diel, Roland
   Ewig, Santiago
   Blaas, Stefan
   Jacob, Christian
   Juelich, Fabian
   Korfmann, Gisela
   Sohrab, Sebastian
   Sutharsan, Sivagurunathan
   Rademacher, Jessica
TI Incidence of patients with non-cystic fibrosis bronchiectasis in Germany
   - A healthcare insurance claims data analysis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiectasis; Incidence; Resource use; Hospitalization; Comorbidities
ID PREVALENCE; ADULTS
AB Background: Incidence and prevalence of patients with non-cystic fibrosis bronchiectasis (NCFB) appear to be increasing worldwide but supporting epidemiological data are scarce. This study assesses the incidence of NCFB patients in Germany in 2013 and analyzes comorbidities and basic patterns of resource use.
   Methods: A representative sample of 3.988.648 anonymized persons covered by German public statutory health insurances was used to identify incident patients with NCFB in 2013.
   Results: After extrapolation to the general population of the 728 patients found in the reference insurance database, we estimate that a total of 17,095 NCFB patients were newly diagnosed across the country in 2013 as having NCFB. This corresponds to an incidence of 21.23 per 100.000 inhabitants. The majority of NCFB patients (98.4%) was at least 18 years old, and 52.7% of the NCFB patients were male. Trend analysis shows a rise of NCFB incidence in Germany from 2011 through 2013.
   COPD (41.4%), asthma (32.8%) and gastroesophageal reflux (18.3%) were the most frequent predisposing conditions. Coronary heart disease was observed in more than one quarter of NCFB patients (28.2%). 58.4% of the NCFB outpatients received antiobstructive inhalative medication. Of the adult NCFB patients, 51.6% were prescribed antibiotics to treat NCFB by settled doctors (outpatient treatment); 51.5% of those patients were males. The peak of antibiotic treatment was observed in the 75-79 age group for males and 70-74 and 75-79 years for females. The majority of diagnosed patients (54.1%) received at least two prescriptions during 2013. Bacterial pathogens were coded for a total of 10.7% of NCFB patients, while Pseudomonas aeruginosa was only documented in 2.3%.
   Among those diagnosed in 2013, 8.0% of the adult NCFB patients who received antibiotic treatment had to be hospitalized.
   Conclusions: Although hospital admissions due to exacerbation in the first year of diagnosing NCFB are not rare, outpatient burden and costs must also be considered a major part of care. Given the increasing recognition of NCFB, a better understanding of the economic burden of the disease is required, with a view towards improving patient management. For this, more detailed, prospective studies are needed.
C1 [Diel, Roland] Univ Med Hosp Schleswig Holstein, Inst Epidemiol, Campus Kiel,Niemannsweg 11, D-24015 Kiel, Germany.
   [Diel, Roland] German Ctr Lung Res DZL, Germany Airway Res Ctr North ARCN, LungClin Grosshansdorf, Hannover, Germany.
   [Ewig, Santiago] Augusta Kliniken, Pneumol Klin, Bochum, Germany.
   [Blaas, Stefan] Zentrum Pneumol, Donaustauf, Germany.
   [Jacob, Christian] Xcenda GmbH, Hannover, Germany.
   [Juelich, Fabian; Korfmann, Gisela] Bayer Vital GmbH, Leverkusen, Germany.
   [Sohrab, Sebastian] Neudorfer Lungenpraxis, Duisburg, Germany.
   [Sutharsan, Sivagurunathan] Univ Med Essen Ruhrlandklin, West German Lung Ctr, Dept Resp Med, Essen, Germany.
   [Rademacher, Jessica] Hannover Med Sch, German Ctr Lung Res BREATH, Dept Resp Med, Hannover, Germany.
RP Diel, R (reprint author), Univ Med Hosp Schleswig Holstein, Inst Epidemiol, Campus Kiel,Niemannsweg 11, D-24015 Kiel, Germany.
EM roland.diel@epi.uni-kiel.de
FU Bayer Vita GmbH
FX Collecting and basic analysis of statutory health insurance data
   included into the study was performed by Xcenda GmbH and financially
   supported by Bayer Vita GmbH.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI [10.7189/jogh.05-020415, 10.7189/jogh.05.020415]
   Blanchette C, 2017, MED SCI, V5, P1
   Faner R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02086-2016
   Global Initiative for Chronic Lung Disease, 2013, GLOBAL STRATEGY DIAG
   Hill AT, 2011, PRIM CARE RESP J, V20, P135, DOI 10.4104/pcrj.2011.00007
   Hilliam Y, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02108-2016
   Hoffken G., 2009, PNEUMOLOGIE, V63
   Hu ZW, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-34
   Joish VN, 2013, VALUE HEALTH, V16, pA188, DOI 10.1016/j.jval.2013.03.944
   King Paul T, 2009, Int J Chron Obstruct Pulmon Dis, V4, P411
   McDonnell MJ, 2016, THORAX, V71, P1110, DOI 10.1136/thoraxjnl-2016-208481
   Navaratnam V, 2018, ANN AM THORAC SOC, V15, P315, DOI 10.1513/AnnalsATS.201706-488OC
   Quint JK, 2016, EUR RESPIR J, V47, P186, DOI 10.1183/13993003.01033-2015
   Ringshausen F. C., 2013, PLOS ONE, V8
   Saynajakangas O, 1998, Cent Eur J Public Health, V6, P235
   Statistisches Bundesamt, 2014, BEV GRUNDL ZENS 2011
   Statistisches Bundesamt, 2014, BEV ERW VORL ERG BEV
   Statistisches Bundesamt, 2012, BEV ERW 1
   Twiss J, 2005, ARCH DIS CHILD, V90, P737, DOI 10.1136/adc.2004.066472
   Weycker D, 2017, CHRON RESP DIS, V14, P377, DOI 10.1177/1479972317709649
   Zaid A A, 2010, Ir Med J, V103, P77
NR 21
TC 1
Z9 1
U1 3
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 121
EP 127
DI 10.1016/j.rmed.2019.04.007
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200017
PM 31047108
DA 2020-05-18
ER

PT J
AU Trethewey, SP
   Edgar, RG
   Morlet, J
   Mukherjee, R
   Turner, AM
AF Trethewey, Samuel P.
   Edgar, Ross G.
   Morlet, Julien
   Mukherjee, Rahul
   Turner, Alice M.
TI Late presentation of acute hypercapnic respiratory failure carries a
   high mortality risk in COPD patients treated with ward-based NIV
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; Acute exacerbation; Ward-based;
   Non-invasive ventilation; Acute hypercapnic respiratory failure;
   Mortality
ID OBSTRUCTIVE PULMONARY-DISEASE; NONINVASIVE VENTILATION; ACUTE
   EXACERBATIONS; SEVERITY; OUTCOMES; DEATH; CARE
AB Introduction: Non-invasive ventilation (NIV) is recommended for treatment of acute hypercapnic respiratory failure (AHRF) refractory to medical management in patients with COPD. This study investigated the relationship between time from hospital presentation to diagnosis of AHRF and in-hospital mortality.
   Methods: Retrospective analysis of hospitalised COPD patients treated with a first episode of ward-based NIV for AHRF at a large UK teaching hospital between 2004 and 2017. Data collected prospectively as part of NIV service evaluation. Multivariable logistic regression performed to identify predictors of in-hospital mortality.
   Results: In total, 547 unique patients were studied comprising 245 males (44.8%), median age 70.6 years, median FEV1% predicted 34%. Overall in-hospital mortality was 19% (n = 104); median survival was 1.7 years. In univariate analysis, a longer time between hospital presentation to diagnosis of AHRF was associated with inhospital mortality (median [IQR]: 8.7 [0.7-75.8] hours vs. 1.9 [0.3-13.6] hours, p < 0.0001). In multivariable logistic regression, significant predictors of in-hospital mortality were AHRF > 24 h after hospital presentation (odds ratio [95% CI]: 2.29 [1.33-3.95], p = 0.003), pneumonia on admission (1.81 [1.07-3.08], p = 0.027), increased age (1.10 [1.07-1.14], p < 0.001) and NIV as ceiling of treatment (5.86 [2.87-11.94], p < 0.001).
   Conclusions: Hospitalised COPD patients with late presentation of AHRF, requiring acute ward-based NIV, may have increased in-hospital mortality. These patients may benefit from closer monitoring and earlier specialist respiratory review.
C1 [Trethewey, Samuel P.; Morlet, Julien; Mukherjee, Rahul; Turner, Alice M.] Univ Hosp Birmingham NHS Fdn Trust, Resp Med, Birmingham, W Midlands, England.
   [Edgar, Ross G.] Univ Hosp Birmingham NHS Fdn Trust, Therapy Serv, Birmingham, W Midlands, England.
   [Edgar, Ross G.; Turner, Alice M.] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
RP Turner, AM (reprint author), Heartlands Hosp, Dept Resp Med & Physiol, Ground Floor,Bordesley Green East, Birmingham B9 5SS, W Midlands, England.
EM a.m.turner@bham.ac.uk
RI Mukherjee, Rahul/B-6972-2012; Edgar, Ross G/W-7396-2019
OI Mukherjee, Rahul/0000-0003-4466-0660; Edgar, Ross G/0000-0002-5971-3035;
   Turner, Alice/0000-0002-5947-3254
FU Clinical Doctoral Research Fellowship - National Institute for Health
   Research (NIHR) [CDRF-2014-05-044]; Health Education England (HEE)
FX This research did not receive any specific grant from funding agencies
   in the public, commercial, or not-for-profit sectors. RGE is supported
   by a Clinical Doctoral Research Fellowship (CDRF-2014-05-044), funded by
   the National Institute for Health Research (NIHR) and Health Education
   England (HEE), outside of the scope of this work.
CR AGARWAL S, 2012, THORAX S2, V67, pA16, DOI DOI 10.1136/THORAXJNL-2012-202678.281
   Andreas  S., 2018, ADV CARE PLANNING SE
   [Anonymous], 2017, CONFIDENTIAL TN ENQU
   Beasley R, 2011, LANCET, V378, P969, DOI 10.1016/S0140-6736(11)61431-1
   Boryslawskyj  H., 2014, P297 EFFECT BTS RECO
   British Thoracic Society, 2013, BTS NIV AUD REP
   Cameron L, 2012, POSTGRAD MED J, V88, P684, DOI 10.1136/postgradmedj-2012-130809
   Cao C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043892
   Carlucci A, 2003, INTENS CARE MED, V29, P419, DOI 10.1007/s00134-002-1574-1
   Dave C, 2014, RESPIROLOGY, V19, P1241, DOI 10.1111/resp.12366
   Hartl S, 2016, EUR RESPIR J, V47, P113, DOI 10.1183/13993003.01391-2014
   Lindenauer PK, 2018, AM J RESP CRIT CARE, V197, P1009, DOI 10.1164/rccm.201709-1852OC
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Merinopoulou E, 2016, INT J CHRONIC OBSTR, V11, P697, DOI 10.2147/COPD.S100250
   Moretti M, 2000, THORAX, V55, P819, DOI 10.1136/thorax.55.10.819
   Muellerova H, 2015, CHEST, V147, P999, DOI 10.1378/chest.14-0655
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   National Institute for Health and Care Excellence, 2016, 10QS10 NAT I HLTH CA
   National Institute for Health and Care Excellence, 2018, CHRON OBSTR PULM DIS
   Osadnik CR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004104.pub4
   Parker K, 2018, RESPIROLOGY, V23, P492, DOI 10.1111/resp.13228
   Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0
   Raluy-Callado M, 2015, INT J CHRONIC OBSTR, V10, P925, DOI 10.2147/COPD.S82064
   Roberts CM, 2011, THORAX, V66, P43, DOI 10.1136/thx.2010.153114
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rothnie KJ, 2018, AM J RESP CRIT CARE, V198, P464, DOI 10.1164/rccm.201710-2029OC
   Shafuddin E, 2018, CLIN RESPIR J, V12, P2668, DOI 10.1111/crj.12973
   Smith TA, 2017, PALLIATIVE MED, V31, P566, DOI 10.1177/0269216316670286
   Trethewey SP, 2019, CLIN RESPIR J, V13, P184, DOI 10.1111/crj.12994
   Trethewey SP, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6040145
   Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016
   2016, THORAX S2, V71, P1, DOI DOI 10.1136/THORAXJNL-2015-208209
NR 32
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 128
EP 132
DI 10.1016/j.rmed.2019.04.013
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200018
PM 31047109
DA 2020-05-18
ER

PT J
AU Fesen, K
   Silveyra, P
   Fuentes, N
   Nicoleau, M
   Rivera, L
   Kitch, D
   Graff, GR
   Siddaiah, R
AF Fesen, Katherine
   Silveyra, Patricia
   Fuentes, Nathalie
   Nicoleau, Marvin
   Rivera, Lidys
   Kitch, Diane
   Graff, Gavin R.
   Siddaiah, Roopa
TI The role of microRNAs in chronic pseudomonas lung infection in Cystic
   fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cystic fibrosis; Pediatrics; Pseudomonas infection; MicroRNA
ID CELLS; IDENTIFICATION; DISCOVERY; APOPTOSIS
AB Background: Cystic Fibrosis (CF) is the most common life limiting genetic disorder, characterized by chronic respiratory failure secondary to inflammation and chronic bacterial lung infection. Pseudomonas aeruginosa lung infection is associated with more severe lung disease and rapid progression of respiratory failure when compared to Staphylococcus aureus infection. We hypothesized that a specific signature of epigenetic factors targeting specific gene transcripts contributes to the increased morbidity seen in CF patients with chronic Pseudomonas infection.
   Methods: We collected exhaled breath condensate (EBC) from 27 subjects and evaluated miRNA signatures in these samples using commercial PCR array. We identified predicted mRNA targets and associated signaling pathways using Ingenuity Pathway Analysis.
   Results: We found 11 differentially expressed miRNAs in EBC of patients infected with Pseudomonas aeruginosa compared to EBC from CF patients who were not chronically infected with Pseudomonas aeruginosa (p < 0.05). Six of these miRNAs (hsa-miRNA-1247, hsa-miRNA-1276, hsa-miRNA-449c, hsa-miRNA-3170, hsa-miRNA-432-5p and hsa-miR-548) were significantly different in the CF Pseudomonas positive group when compared to both the CF Pseudomonas negative group and healthy control group. Ingenuity pathway analysis (IPA) revealed organismal injury and abnormalities, reproductive system disease and cancer as the top diseases and bio functions associated with these miRNAs. IPA also detected RELA, JUN, TNF, IL-10, CTNNB1, IL-13, SERPINB8, CALM1, STARD3NL, SFI1, CD55, RPS6KA4, TTC36 and HIST1H3D as the top target genes for these miRNAs.
   Conclusion: Our study identified 6 miRNAs as epigenetic factors specifically associated with chronic Pseudomonas infection in patients with CF.
C1 [Fesen, Katherine; Silveyra, Patricia; Fuentes, Nathalie; Nicoleau, Marvin; Rivera, Lidys; Kitch, Diane; Graff, Gavin R.; Siddaiah, Roopa] Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA.
   [Silveyra, Patricia] Univ N Carolina, Sch Nursing, Biobehav Lab, Chapel Hill, NC 27599 USA.
RP Siddaiah, R (reprint author), Penn State Univ, Coll Med, 500 Univ Dr,H085, Hershey, PA 17033 USA.
EM rsiddaiah@pennstatehealth.psu.edu
RI Silveyra, Patricia/A-7136-2018
OI Silveyra, Patricia/0000-0001-7083-8915
FU Department of Pediatrics, Penn State Hershey Children's Hospital,
   Hershey, PA
FX This research was funded by the Department of Pediatrics, Penn State
   Hershey Children's Hospital, Hershey, PA 17033.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blouquit S, 2006, AM J RESP CRIT CARE, V174, P299, DOI 10.1164/rccm.200506-987OC
   Cannon CL, 2003, AM J RESP CELL MOL, V29, P188, DOI 10.1165/rcmb.4898
   Coutinho Henrique Douglas M, 2008, Int Arch Med, V1, P24, DOI 10.1186/1755-7682-1-24
   Dhupal M, 2018, INT J NANOMED, V13, P6735, DOI 10.2147/IJN.S176087
   Fuentes N, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0177-7
   Gillen AE, 2011, BIOCHEM J, V438, P25, DOI 10.1042/BJ20110672
   Granchelli AM, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00354-18
   Guo JJ, 2018, BIOMED PHARMACOTHER, V104, P60, DOI 10.1016/j.biopha.2018.05.012
   Guo X, 2017, CANCER GENE THER, V24, P333, DOI 10.1038/cgt.2017.23
   Hunt J, 2007, IMMUNOL ALLERGY CLIN, V27, P587, DOI 10.1016/j.iac.2007.09.001
   Jiang N, 2015, ONCOTARGET, V6, P7866, DOI 10.18632/oncotarget.3492
   Ke H, 2016, GENE REGUL SYST BIO, V10, P10, DOI 10.4137/GRSB.S29414
   Liu KS, 2016, ONCOTARGET, V7, P64030, DOI 10.18632/oncotarget.11747
   Mall MA, 2014, EUR RESPIR J, V44, P1042, DOI 10.1183/09031936.00228013
   Marcet B, 2011, NAT CELL BIOL, V13, P693, DOI 10.1038/ncb2241
   McKiernan PJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/529642
   Persson H, 2011, CANCER RES, V71, P78, DOI 10.1158/0008-5472.CAN-10-1869
   Pier GB, 1996, AM J RESP CRIT CARE, V154, pS175, DOI 10.1164/ajrccm/154.4_Pt_2.S175
   Pier GB, 2002, CURR OPIN MICROBIOL, V5, P81, DOI 10.1016/S1369-5274(02)00290-4
   Pittman JE, 2017, ANN AM THORAC SOC, V14, P1548, DOI [10.1513/annalsats.201702-121oc, 10.1513/AnnalsATS.201702-121OC]
   Sessa R, 2013, PULM CIRC, V3, P315, DOI 10.4103/2045-8932.114758
   Sharma N, 2016, SCI REP-UK, V6, DOI 10.1038/srep27685
   Sinha A, 2013, J ALLERGY CLIN IMMUN, V132, P219, DOI 10.1016/j.jaci.2013.03.035
   Tabary O, 2006, CELL SIGNAL, V18, P652, DOI 10.1016/j.cellsig.2005.06.004
   Wu TT, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0162-y
   Yu H, 2018, ONCOTARGETS THER, V11, P7429, DOI 10.2147/OTT.S178151
   Zhou F, 2014, BBA-GENE REGUL MECH, V1839, P344, DOI 10.1016/j.bbagrm.2014.01.006
NR 28
TC 0
Z9 0
U1 2
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 133
EP 138
DI 10.1016/j.rmed.2019.04.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200019
PM 31047110
DA 2020-05-18
ER

PT J
AU Yancey, SW
   Bradford, ES
   Keene, ON
AF Yancey, Steven W.
   Bradford, Eric S.
   Keene, Oliver N.
TI Disease burden and efficacy of mepolizumab in patients with severe
   asthma and blood eosinophil counts of >= 150-300 cells/mu L
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Mepolizumab; Efficacy; Disease burden; Severe eosinophilic asthma; Blood
   eosinophil counts
ID DOUBLE-BLIND; MULTICENTER; DREAM
AB Background: In patients with severe eosinophilic asthma, treatment decisions can be determined by blood eosinophil counts; however, a specific blood eosinophil threshold has not been defined for starting mepolizumab treatment.
   Methods: We summarized the disease burden and efficacy of mepolizumab in patients with severe eosinophilic asthma and baseline blood eosinophil counts of >= 150-300 cells/mu L and >= 300 cells/mu L using data from the mepolizumab clinical development program (DREAM [NCT01000506], MENSA [NCT01691521], SIRIUS [NCT01691508] and MUSCA [NCT02281318]).
   Results: The morbidity of asthma in patients with baseline blood eosinophil counts >= 150-300 cells/mu L was similar to that in patients with blood eosinophil counts >= 300 cells/mu L, with similar rates of exacerbations (2.8-3.5 events/year versus 2.8-3.8 events/year, respectively), asthma related emergency room visits, intubations and near fatal events. Use of maintenance oral corticosteroids (OCS) was similar across blood eosinophil count subgroups. Reductions in the rates of clinically significant exacerbations with mepolizumab versus placebo ranged from 27 to 49% in patients with blood eosinophil counts of >= 150-300 cells/mu L for DREAM, MENSA and MUSCA. The odds of achieving a reduction in OCS in SIRIUS was 2.03 (95% CI: 0.53, 7.75) versus 1.79 (95% CI: 0.71, 4.52) in patients with blood eosinophil counts >= 150-300 cells/mu L and >= 300 cells/mu L, respectively.
   Conclusion: There is a high unmet clinical need in patients with blood eosinophil counts >= 150-300 cells/mu L, and a clinically meaningful benefit is seen with mepolizumab in this subgroup. Mepolizumab is an efficacious treatment option for patients with blood eosinophil counts >= 150 cells/mu L.
C1 [Yancey, Steven W.; Bradford, Eric S.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA.
   [Keene, Oliver N.] GSK, Clin Stat, Stockley Pk, West Drayton, Middx, England.
RP Yancey, SW (reprint author), 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.
EM steve.w.yancey@gsk.com; eric.s.bradford@gsk.com; oliver.n.keene@gsk.com
FU GSKGlaxoSmithKline [NCT01000506/MEA112997, NCT01691508/MEA115575,
   NCT02281318/200862, NCT01691521/MEA115588]
FX The primary studies (DREAM, MENSA, SIRIUS, and MUSCA) and the secondary
   analyses of DREAM, MENSA, SIRIUS, and MUSCA were funded by GSK
   (NCT01000506/MEA112997; NCT01691508/MEA115575; NCT02281318/200862;
   NCT01691521/MEA115588). Editorial support (in the form of writing
   assistance, including development of the initial draft, assembling
   tables and figures, collating author comments, grammatical editing, and
   referencing) was provided by Elizabeth Hutchinson, CMPP, PhD, at
   Fishawack Indicia Ltd, UK, and was funded by GSK.
CR Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
   Brussino L, 2018, BIOMED RES INT, DOI 10.1155/2018/7582057
   Chung KF, 2015, LANCET, V386, P1086, DOI 10.1016/S0140-6736(15)00157-9
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   GlaxoSmithKline, 2017, MEP NUCALA US PRESCR
   GlaxoSmithKline, 2018, EU SUMM CHAR
   Husereau D, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0241-1
   Lefebvre P, 2015, J ALLERGY CLIN IMMUN, V136, P1488, DOI 10.1016/j.jaci.2015.07.046
   Menzella F, 2016, THER ADV CHRONIC DIS, V7, P260, DOI 10.1177/2040622316659863
   Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639
   Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8
   Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005
NR 15
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 139
EP 141
DI 10.1016/j.rmed.2019.04.008
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200020
PM 31047111
DA 2020-05-18
ER

PT J
AU Gulart, AA
   Munari, AB
   Silva, IJCS
   Alexandre, HF
   Karloh, M
   Mayer, AF
AF Gulart, Aline Almeida
   Munari, Anelise Bauer
   Cristiana Santos Silva, Isabela Julia
   Alexandre, Hellen Fontao
   Karloh, Manuela
   Mayer, Anamaria Fleig
TI Baseline characteristics associated to improvement of patients with COPD
   in physical activity in daily life level after pulmonary rehabilitation
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pulmonary disease; Chronic obstructive; Physical activity; Minimal
   clinically important difference; Exercise therapy
ID RESPIRATORY SOCIETY STATEMENT; SEDENTARY BEHAVIOR; EXERCISE CAPACITY;
   PREDICTORS; MORTALITY
AB Background: Knowing the patients with chronic obstructive pulmonary disease (COPD) that increase the physical activity of daily living (PADL) after pulmonary rehabilitation (PR) is a challenge. Aims: to compare baseline characteristics between patients who achieved and failed to achieve the minimal important difference (MID) of PADL post-PR; to verify which baseline variables better predict the change and identify a cut-off point to discriminate MID achievers.
   Methods: Fifty-three patients with COPD (FEV1: 38.3; 95% CI 34.4-42.2% pred) were evaluated for spirometry, dyspnea, quality of life, functional capacity, mortality risk and PADL level. After 24 sessions of PR had their PADL level revaluated.
   Results: The MID achievers presented lower FEV1, functional capacity, time walking, number of steps, active time, energy expenditure (EE) walking, time on PADL=3 metabolic equivalent of task (METs) and higher time on PADL< 1.5MET. Inactive patients and with severe physical inactivity presented a hazard ratio of 4.27 and 6.90 (95% CI: 1.31-13.9, p=0.02; 95% CI: 1.99-23.9, p=0.002; respectively) for achieving the MID. The variables of predictive model for the change in the PADL were EE walking and time on PADL< 1.5MET (R-2: 0.37; p=0.002). The cut-off point of 6525 steps [sensitivity=95%; specificity=61%; AUC=0.82 (95% CI: 0.71-0.93), p < 0.001] was able to discriminate patients who achieved and failed to achieve the MID.
   Conclusion: Patients with worse lung function, functional capacity and lower PADL level before PR are those that improve the PADL level. EE walking and time on PADL< 1.5MET better predict this change. The cut-off point of 6525 steps can help to identify patients with higher chances of improving the PADL level.
C1 [Gulart, Aline Almeida; Munari, Anelise Bauer; Cristiana Santos Silva, Isabela Julia; Alexandre, Hellen Fontao; Karloh, Manuela; Mayer, Anamaria Fleig] Univ Estado Santa Catarina UDESC, Nucleo Assistencia Ensino & Pesquisa Reabilitacao, Florianopolis, SC, Brazil.
   [Gulart, Aline Almeida; Munari, Anelise Bauer; Mayer, Anamaria Fleig] Univ Estado Santa Catarina UDESC, Ctr Ciencias Saude & Esporte CEFID, Programa Posgrad Ciencias Movimento Humano, Florianopolis, SC, Brazil.
   [Alexandre, Hellen Fontao; Mayer, Anamaria Fleig] Univ Estado Santa Catarina UDESC, Ctr Ciencias Saude & Esporte CEFID, Programa Posgrad Fisioterapia, Florianopolis, SC, Brazil.
RP Mayer, AF (reprint author), Univ Estado Santa Catarina, Nucleo Assistencia Ensino & Pesquisa Reabilitacao, Dept Fisioterapia, Rua Pascoal Simone 358, BR-88080350 Florianopolis, SC, Brazil.
EM aline.gulart@hotmail.com; anelisebauer@gmail.com;
   isabelajuliaa@gmail.com; hellenalexandre@hotmail.com;
   manukarloh@gmail.com; anamaria.mayer@udesc.br
RI Mayer, Anamaria F/D-4997-2014
OI Mayer, Anamaria F/0000-0003-0320-4810
FU Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina -
   FAPESC/Brazil [01/2016- Termo de Outorga 2017TR645]
FX This research was supported in part by the Fundacao de Amparo a Pesquisa
   e Inovacao do Estado de Santa Catarina - FAPESC/Brazil (PAP UDESC -
   Chamada Publica No 01/2016- Termo de Outorga 2017TR645).
CR Altenburg WA, 2012, RESP MED, V106, P694, DOI 10.1016/j.rmed.2011.11.008
   Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4
   Carpes Marta Fioravante, 2008, J. bras. pneumol., V34, P143, DOI 10.1590/S1806-37132008000300004
   Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322
   Cho HL, 2017, INT J NURS PRACT, V23, DOI 10.1111/ijn.12530
   Demeyer H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154587
   Depew ZS, 2012, RESPIROLOGY, V17, P1026, DOI 10.1111/j.1440-1843.2012.02207.x
   Furlanetto KC, 2017, RESP CARE, V62, P579, DOI 10.4187/respcare.05306
   Garcia-Aymerich J, 2014, CLIN CHEST MED, V35, P363, DOI 10.1016/j.ccm.2014.02.011
   Garrod R, 2006, EUR RESPIR J, V27, P788, DOI 10.1183/09031936.06.00130605
   Garrod Rachel, 2008, Int J Chron Obstruct Pulmon Dis, V3, P791
   Hill K, 2015, INTERN MED J, V45, P474, DOI 10.1111/imj.12570
   Kovelis Demetria, 2008, J. bras. pneumol., V34, P1008, DOI 10.1590/S1806-37132008001200005
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Ng LWC, 2012, CHRON RESP DIS, V9, P17, DOI 10.1177/1479972311430335
   Osadnik CR, 2018, INT J CHRONIC OBSTR, V13, P3515, DOI 10.2147/COPD.S174827
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC
   Pitta F, 2008, CHEST, V134, P273, DOI 10.1378/chest.07-2655
   Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012
   Rumsey D. J., 2016, STAT DUMMIES
   Souza TC, 2000, J PNEUMOL, V26, P119, DOI DOI 10.1590/S0102-35862000000300004
   Spruit MA, 2015, EUR RESPIR J, V46, P1625, DOI 10.1183/13993003.00350-2015
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Troosters T, 1999, EUR RESPIR J, V14, P270, DOI 10.1034/j.1399-3003.1999.14b06.x
   Vagaggini B, 2009, RESP MED, V103, P1224, DOI 10.1016/j.rmed.2009.01.023
   Vorrink SNW, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-33
   Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521
   Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814
   Zanini A, 2013, BIOMED RES INT, DOI 10.1155/2013/483162
   2011, RESP MED, V105, P1846, DOI DOI 10.1016/J.RMED.2011.07.003
NR 31
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAY
PY 2019
VL 151
BP 142
EP 147
DI 10.1016/j.rmed.2019.04.006
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HV7GJ
UT WOS:000466149200021
PM 31047112
DA 2020-05-18
ER

PT J
AU Stanford, RH
   Parker, ED
   Reinsch, TK
   Buikema, AR
   Blauer-Peterson, C
AF Stanford, Richard H.
   Parker, Emily D.
   Reinsch, Tyler K.
   Buikema, Ami R.
   Blauer-Peterson, Cori
TI Assessment of COPD-related outcomes in patients initiating a once daily
   or twice daily ICS/LABA
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; COPD; Adherence; Fluticasone
   furoate/vilanterol; Budesonide/formoterol; Cost
ID EXACERBATIONS; PREVALENCE
AB Background: Use of inhaled corticosteroids and long acting beta agonist (ICS/LABA) combination therapy has been shown to decrease the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In this population, adherence to treatment is associated with better disease control and lower risk of COPD-related exacerbations in the future. Using a treatment with a more convenient regimen or easier-to-use device could improve patient adherence, improve disease control, decrease the frequency of exacerbations and minimize the COPD-related economic burden. Real-world information on the impact on healthcare costs and exacerbation risk of initiating once-daily or twice daily ICS/LABA in this patient population is limited.
   The objective of this study was to assess COPD-related healthcare costs, adherence, and exacerbations in COPD patients initiating treatment with fluticasone furoate/vilanterol 100/25 (FF/VI) or budesonide/formoterol 160/4.5 (BUD/F) using a large managed care database in the US.
   Methods: This was a retrospective cohort study among COPD patients initiating FF/VI or BUD/F between January 01, 2014 and June 30, 2016. The analysis used the Optum Research Database (ORD) which contains patients from commercial and Medicare Advantage Prescription Drug (MAPD) plans. The study included new initiators of ICS/LABA as either FF/VI or BUD/F for COPD, >= 40 years of age at index, >= 15 months of continuous enrollment (12 months pre-index and >= 3 months post-index). New users of FF/VI or BUD/F were matched on baseline characteristics using propensity score matching (PSM) methods. Multivariate models including ordinary least squares regression, Lin's regression, logistic regression, and Cox proportional hazards were used to assess differences between the cohorts on outcomes of interest.
   Results: A total of 18,652 subjects met all inclusion and exclusion criteria with 5044 initiating FF/VI and 13,608 initiating BUD/F. Of these, 9026 subjects were matched at a 1:1 ratio (4513 patients in each cohort) and were included in the final analyses.
   Proportion of days covered (PDC), was significantly better for FF/VI (mean PDC [SD]: FF/VI: 0.46 [0.31], BUD/F: 0.41 [0.29], p < 0.001) while FF/VI was associated with a 9% lower risk (adj. hazard ratio (HR): 0.91, 95% CI: 0.85-0.96) of having a moderate or severe COPD-related exacerbation. However, COPD-related healthcare costs were not significantly different, $11,521 vs $10,986, p = 0.41 for FF/VI and BUD/F, respectively.
   Conclusions: Patients initiating once-daily FF/VI were more adherent, and were associated with a lower risk of subsequent COPD-related exacerbations compared with twice-daily BUD/F, however this was not associated with a significant difference in costs. (GSK Study HO1617333/206702).
C1 [Stanford, Richard H.; Reinsch, Tyler K.] GlaxoSmithKline, US Value Evidence & Outcomes, Res Triangle Pk, NC USA.
   [Parker, Emily D.; Buikema, Ami R.; Blauer-Peterson, Cori] Optum Inc, Hlth Econ & Outcomes Res, Eden Prairie, MN USA.
   [Reinsch, Tyler K.] Univ N Carolina, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC 27515 USA.
RP Stanford, RH (reprint author), 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM richard.h.stanford@gsk.com
OI Buikema, Ami/0000-0002-2481-4872
CR AbuDagga A, 2013, INT J CHRONIC OBSTR, V8, P175, DOI 10.2147/COPD.S40437
   [Anonymous], 2010, SYMB 160 4 5 BUD 160
   [Anonymous], 2011, GLOBAL STRATEGY DIAG
   Berk ML, 2001, HEALTH AFFAIR, V20, P9, DOI 10.1377/hlthaff.20.2.9
   Dalal AA, 2011, RESP MED, V105, P454, DOI 10.1016/j.rmed.2010.09.003
   Ellipta  Breo, 2017, BREO ELL FLUT FUR VI
   Ford ES, 2015, CHEST, V147, P989, DOI 10.1378/chest.14-2146
   Heron Melonie, 2016, NCHS Data Brief, P1
   Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563
   Kern DM, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0210-x
   Lin DY., 2000, BIOSTATISTICS, V1, P35
   Malehi AS, 2015, HEALTH ECON REV, V5, DOI 10.1186/s13561-015-0045-7
   Mintz ML, 2011, MAYO CLIN PROC, V86, P375, DOI 10.4065/mcp.2010.0787
   Perera PN, 2012, COPD, V9, P131, DOI 10.3109/15412555.2011.650239
   Raebel MA, 2013, MED CARE, V51, pS11, DOI 10.1097/MLR.0b013e31829b1d2a
   Roberts Melissa H, 2015, Drugs Real World Outcomes, V2, P163
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenberg SR, 2015, SEMIN RESP CRIT CARE, V36, P457, DOI 10.1055/s-0035-1555607
   Stanford RH, 2018, AM J MANAG CARE, V24, pE45
   Stanford RH, 2016, ANN AM THORAC SOC, V13, P1067, DOI 10.1513/AnnalsATS.201508-493OC
   Svedsater H, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.19
   Torpy Janet M, 2010, JAMA, V303, P2430, DOI 10.1001/jama.303.23.2430
   Toy EL, 2011, RESP MED, V105, P435, DOI 10.1016/j.rmed.2010.09.006
   U.S. Department of Labor Bureau Labor Statistics, CONS PRIC IND ALL UR
   van der Molena T, 2010, PRIM CARE RESP J, V19, P326, DOI 10.4104/pcrj.2010.00053
   van der Palen J, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2016.79
NR 26
TC 3
Z9 3
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 1
EP 7
DI 10.1016/j.rmed.2019.01.019
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700001
PM 30961933
DA 2020-05-18
ER

PT J
AU Lee, E
   Shim, JY
   Kim, HY
   Suh, DI
   Choi, YJ
   Han, MY
   Baek, KS
   Kwon, JW
   Cho, J
   Jung, M
   Kim, YS
   Sol, IS
   Kim, BS
   Chung, EH
   Lee, S
   Jeong, K
   Jang, YY
   Jang, GC
   Hyun, MC
   Yang, HJ
   Shin, M
   Kim, JT
   Kim, JH
   Hwang, YH
   Ahn, JY
   Seo, JH
   Jung, JA
   Kim, HS
   Oh, MY
   Park, Y
   Lee, MH
   Lee, SY
   Jung, S
   Hong, SJ
   Ahn, YM
AF Lee, Eun
   Shim, Jung Yeon
   Kim, Hyung Young
   Suh, Dong In
   Choi, Yun Jung
   Han, Man Young
   Baek, Kyung Suk
   Kwon, Ji-Won
   Cho, Joongbum
   Jung, Minyoung
   Kim, Young Suh
   Sol, In Suk
   Kim, Bong-Seong
   Chung, Eun Hee
   Lee, Sooyoung
   Jeong, Kyunguk
   Jang, Yoon Young
   Jang, Gwang Cheon
   Hyun, Myung Chul
   Yang, Hyeon-Jong
   Shin, Meeyong
   Kim, Jin Tack
   Kim, Ja Hyeong
   Hwang, Yoon Ha
   Ahn, Ji Young
   Seo, Ju-Hee
   Jung, Jin A.
   Kim, Hwan Soo
   Oh, Moo Young
   Park, Yang
   Lee, Mi-Hee
   Lee, So-Yeon
   Jung, Sungsu
   Hong, Soo-Jong
   Ahn, Young Min
CA Pediat Resp Dis Study Party
TI Clinical characteristics and etiologies of bronchiectasis in Korean
   children: A multicenter retrospective study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiectasis; Children; Etiology; Lung function; Prognosis
ID CYSTIC-FIBROSIS BRONCHIECTASIS; LUNG-FUNCTION; DISEASE; DIAGNOSIS;
   ORPHAN
AB Background: Bronchiectasis is a chronic pulmonary disease characterized by progressive and irreversible bronchial dilatation. The aim of the present study was to investigate the etiologies and clinical features of bronchiectasis in Korean children.
   Methods: We performed a retrospective review of the medical records for children diagnosed with bronchiectasis between 2000 and 2017 at 28 secondary or tertiary hospitals in South Korea.
   Results: A total of 387 cases were enrolled. The mean age at diagnosis was 9.2 +/- 5.1 years and 53.5% of the patients were boys. The most common underlying cause of bronchiectasis was preexisting respiratory infection (55.3%), post-infectious bronchiolitis obliterans (14.3%), pulmonary tuberculosis (12.3%), and heart diseases (5.6%). Common initial presenting symptoms included chronic cough (68.0%), recurrent pneumonia (36.4%), fever (31.1%), and dyspnea (19.7%). The most predominantly involved lesions were left lower lobe (53.9%), right lower lobe (47.1%) and right middle lobe (40.2%). No significant difference was observed in the distribution of these involved lesions by etiology. The forced expiratory volume in 1 s (FEV1) levels were lowest in cases with interstitial lung disease-associated bronchiectasis, followed by those with recurrent aspiration and primary immunodeficiency.
   Conclusions: Bronchiectasis should be strongly considered in children with chronic cough and recurrent pneumonia. Long-term follow-up studies on pediatric bronchiectasis are needed to further clarify the prognosis and reduce the disease burden in these patients.
C1 [Lee, Eun] Chonnam Natl Univ, Med Sch, Chonnam Natl Univ Hosp, Dept Pediat, Gwangju, South Korea.
   [Shim, Jung Yeon] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pediat, Seoul, South Korea.
   [Kim, Hyung Young] Pusan Natl Univ, Childrens Hosp, Dept Pediat, Yangsan, South Korea.
   [Suh, Dong In] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Seoul, South Korea.
   [Choi, Yun Jung] Sowha Childrens Hosp, Seoul, South Korea.
   [Han, Man Young; Baek, Kyung Suk] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Pediat, Seongnam, South Korea.
   [Kwon, Ji-Won] Seoul Natl Univ, Bundang Hosp, Dept Pediat, Seongnam, South Korea.
   [Cho, Joongbum; Jung, Minyoung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea.
   [Kim, Young Suh; Sol, In Suk] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea.
   [Kim, Bong-Seong] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pediat, Kangnung, South Korea.
   [Chung, Eun Hee] Chungnam Natl Univ, Sch Med, Dept Pediat, Daejeon, South Korea.
   [Lee, Sooyoung; Jeong, Kyunguk] Ajou Univ, Sch Med, Dept Pediat, Suwon, South Korea.
   [Jang, Yoon Young] Daegu Catholic Univ, Med Ctr Pediat, Dept Pediat, Daegu, South Korea.
   [Jang, Gwang Cheon] Natl Hlth Insurance Serv Ilsan Hosp, Dept Pediat, Ilsan, South Korea.
   [Hyun, Myung Chul] Kyungpook Natl Univ, Coll Med, Dept Pediat, Daegu, South Korea.
   [Yang, Hyeon-Jong] Soonchunhyang Univ, Seoul Hosp, Dept Pediat, Pediat Allergy & Resp Ctr, Seoul, South Korea.
   [Shin, Meeyong] Soonchunhyang Univ, Coll Med, Dept Pediat, Bucheon Hosp, Bucheon, South Korea.
   [Kim, Jin Tack; Kim, Hwan Soo] Catholic Univ Korea, Coll Med, Dept Pediat, Seoul, South Korea.
   [Kim, Ja Hyeong] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Pediat, Ulsan, South Korea.
   [Hwang, Yoon Ha] Busan St Marys Hosp, Dept Pediat, Busan, South Korea.
   [Ahn, Ji Young] Kyungpook Natl Univ, Sch Med, Dept Pediat, Seoul, South Korea.
   [Seo, Ju-Hee] Dankook Univ, Med Sch, Dankuk Univ Hosp, Dept Pediat, Cheonan, South Korea.
   [Jung, Jin A.] Dong A Univ, Coll Med, Dept Pediat, Busan, South Korea.
   [Oh, Moo Young] Inje Univ, Busan Paik Hosp, Coll Med, Dept Pediat, Busan, South Korea.
   [Park, Yang] Wonkwang Univ, Sanbon Hosp, Dept Pediat, Gunpo, South Korea.
   [Lee, Mi-Hee] Incheon Med Ctr, Dept Pediat, Incheon, South Korea.
   [Lee, So-Yeon; Jung, Sungsu; Hong, Soo-Jong] Univ Ulsan, Coll Med, Childhood Asthma Atopy Ctr, Dept Pediat,Environm Hlth Ctr,Asan Med Ctr, 88 Olympic Ro 43 Gil, Seoul 05505, South Korea.
   [Ahn, Young Min] Eulji Univ, Sch Med, Eulji Gen Hosp, Dept Pediat, Hangeulbiseokro 68, Seoul 01830, South Korea.
RP Hong, SJ (reprint author), Univ Ulsan, Coll Med, Childhood Asthma Atopy Ctr, Dept Pediat,Environm Hlth Ctr,Asan Med Ctr, 88 Olympic Ro 43 Gil, Seoul 05505, South Korea.; Ahn, YM (reprint author), Eulji Univ, Sch Med, Eulji Gen Hosp, Dept Pediat, Hangeulbiseokro 68, Seoul 01830, South Korea.
EM sjhong@amc.seoul.kr; aym3216@eulji.ac.kr
OI Chung, Eun Hee/0000-0001-9380-0151; Jung, Minyoung/0000-0003-2851-9480;
   Han, Man Yong/0000-0002-9077-5779
CR Bahali K, 2014, GEN HOSP PSYCHIAT, V36, P528, DOI 10.1016/j.genhosppsych.2014.05.019
   Brower Kelly S, 2014, BMC Pediatr, V14, P4, DOI 10.1186/s12887-014-0299-y
   Chang AB, 2018, LANCET, V392, P866, DOI 10.1016/S0140-6736(18)31554-X
   Evans SA, 1996, EUR RESPIR J, V9, P1601, DOI 10.1183/09031936.96.09081601
   Goeminne PC, 2016, EUR RESPIR J, V47, P10, DOI 10.1183/13993003.01567-2015
   Goyal V, 2018, LANCET, V392, P1197, DOI 10.1016/S0140-6736(18)31723-9
   Goyal V, 2016, PEDIATR PULM, V51, P450, DOI 10.1002/ppul.23380
   Healy F, 2012, PAEDIATR RESPIR REV, V13, P10, DOI 10.1016/j.prrv.2011.01.007
   Javidan-Nejad Cylen, 2010, Thorac Surg Clin, V20, P85, DOI 10.1016/j.thorsurg.2009.12.007
   Joish VN, 2013, APPL HEALTH ECON HEA, V11, P299, DOI 10.1007/s40258-013-0027-z
   Kapur N, 2018, COCHRANE DB SYST REV, V5
   Karadag B, 2005, RESPIRATION, V72, P233, DOI 10.1159/000085362
   Kelly C, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012406.pub2
   Kim HY, 2011, ALLERGY ASTHMA IMMUN, V3, P39, DOI 10.4168/aair.2011.3.1.39
   Kumar A, 2015, INDIAN PEDIATR, V52, P35, DOI 10.1007/s13312-015-0563-8
   Li AM, 2005, EUR RESPIR J, V26, P8, DOI 10.1183/09031936.05.00127704
   McGuinness G, 2002, RADIOL CLIN N AM, V40, P1, DOI 10.1016/S0033-8389(03)00105-2
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Nathan Anna Marie, 2017, Front Pediatr, V5, P84, DOI 10.3389/fped.2017.00084
   Park YK, 2013, TUBERC RESPIR DIS, V74, P104, DOI 10.4046/trd.2013.74.3.104
   Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017
   Pulmonology Portuguese Society Bronchiectasis Study Group, 2006, REV PORT PNEUMOL, V22, P222
   Redding GJ, 2011, PAEDIATR RESPIR REV, V12, P119, DOI 10.1016/j.prrv.2010.10.012
   Redondo M, 2016, BREATHE, V12, P223, DOI 10.1183/20734735.007516
   Sarria EE, 2011, EUR RESPIR J, V38, P918, DOI 10.1183/09031936.00172310
   Satirer O, 2018, RESP MED, V137, P35, DOI 10.1016/j.rmed.2018.02.013
   Spencer S, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012579.pub2
   Stahl M, 2017, AM J RESP CRIT CARE, V195, P349, DOI 10.1164/rccm.201604-0893OC
   Suarez-Cuartin G, 2016, RESP MED, V116, P70, DOI 10.1016/j.rmed.2016.05.014
   Wark P., 2018, COCHRANE DB SYST REV, V9
   Wurzel DF, 2017, EXPERT REV RESP MED, V11, P517, DOI 10.1080/17476348.2017.1335197
NR 31
TC 0
Z9 0
U1 1
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 8
EP 14
DI 10.1016/j.rmed.2019.01.018
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700002
PM 30961955
DA 2020-05-18
ER

PT J
AU Suzuki, A
   Kondoh, Y
   Swigris, JJ
   Matsuda, T
   Kimura, T
   Kataoka, K
   Ando, M
   Hashimoto, N
   Sakamoto, K
   Hasegawa, Y
AF Suzuki, Atsushi
   Kondoh, Yasuhiro
   Swigris, Jeffrey James
   Matsuda, Toshiaki
   Kimura, Tomoki
   Kataoka, Kensuke
   Ando, Masahiko
   Hashimoto, Naozumi
   Sakamoto, Koji
   Hasegawa, Yoshinori
TI Performance of the COPD Assessment Test in patients with connective
   tissue disease-associated interstitial lung disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Connective tissue disease-associated interstitial lung disease; CTD-ILD;
   Quality of life; Health status; COPD Assessment Test; CAT
ID GEORGES RESPIRATORY QUESTIONNAIRE; IDIOPATHIC PULMONARY-FIBROSIS;
   QUALITY-OF-LIFE; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA;
   INTRAINDIVIDUAL CHANGES; AMERICAN-COLLEGE; REVISED CRITERIA;
   HEALTH-STATUS; STANDARDIZATION
AB Background: Patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) often experience impaired health status. In daily clinical practice, a short and easy instrument for assessing health status would be useful to help better understand the patient's condition. The COPD Assessment Test (CAT) is a simple questionnaire about respiratory symptoms and their impact. We aimed to examine the CAT's performance characteristics and to generate data to support its reliability and validity in patients with CTD-ILD.
   Methods: We used data from 132 CTD-ILD patients evaluated at Tosei General Hospital from July 2011 to July 2016 to assess the cross-sectional and longitudinal validity of the CAT.
   Results: The mean age of the patients was 64.5 years and 87 (66%) were women. There were no significant differences in CAT score between any of the CTD subgroups. Internal consistency (Cronbach's alpha = 0.881) and repeatability (intraclass correlation coefficient [ICC] = 0.803) for the CAT score were acceptable. At baseline, CAT score was significantly associated with clinically meaningful measures of physiologic function, exercise capacity, and dyspnea. Change in CAT score over 6-12 months was also associated with change in other measures. In the distribution-and anchor-based analyses, the estimated minimal clinically important difference of CAT score was 1-4 points.
   Conclusion: These data support the validity and reliability of CAT as a sensitive measure for assessing health status in patients with CTD-ILD.
C1 [Suzuki, Atsushi; Kondoh, Yasuhiro; Matsuda, Toshiaki; Kimura, Tomoki; Kataoka, Kensuke] Tosei Gen Hosp, Dept Resp Med & Allergy, 160 Nishioiwake Cho, Seto, Aichi 4898642, Japan.
   [Suzuki, Atsushi; Hashimoto, Naozumi; Sakamoto, Koji; Hasegawa, Yoshinori] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan.
   [Swigris, Jeffrey James] Natl Jewish Hlth, Dept Med, Denver, CO USA.
   [Ando, Masahiko] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan.
RP Kondoh, Y (reprint author), Tosei Gen Hosp, Dept Resp Med & Allergy, 160 Nishioiwake Cho, Seto, Aichi 4898642, Japan.
EM suzukia@med.nagoya-u.ac.jp; konyasu2003@yahoo.co.jp;
   SwigrisJ@NJHealth.org; tmatsuda@tosei.or.jp; tomoki_kimura@tosei.or.jp;
   kataoka@tosei.or.jp; mando.tsuru@gmail.com; hashinao@med.nagoya-u.ac.jp;
   sakakoji@med.nagoya-u.ac.jp; yhasega@med.nagoya-u.ac.jp
RI HASHIMOTO, NAOZUMI/I-1979-2012
OI swigris, jeff/0000-0002-9874-8265
FU Ministry of Health, Labour, and Welfare, JapanMinistry of Health, Labour
   and Welfare, Japan
FX This work was partially supported by a grant to the Diffuse Lung Disease
   Research Group from the Ministry of Health, Labour, and Welfare, Japan.
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007-1179OC, 10.1164/rccm.201007.1179OC]
   Fischer A, 2012, LANCET, V380, P689, DOI 10.1016/S0140-6736(12)61079-4
   Gutsche M, 2012, CURR PULMONOL REP, V1, P224, DOI 10.1007/s13665-012-0028-7
   Hinkle D. E., 1988, APPL STAT BEHAV SCI
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Khadawardi H, 2017, RESPIROLOGY, V22, P501, DOI 10.1111/resp.12945
   Khanna D, 2015, J RHEUMATOL, V42, P2168, DOI 10.3899/jrheum.141182
   Kon SSC, 2014, LANCET RESP MED, V2, P195, DOI 10.1016/S2213-2600(14)70001-3
   Lammi MR, 2015, CURR RESPIR MED REV, V11, P163, DOI 10.2174/1573398X11666150619183527
   MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905
   Matsuda T, 2017, RESPIROLOGY, V22, P721, DOI 10.1111/resp.12936
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mittoo S, 2015, CURR RESPIR MED REV, V11, P175, DOI 10.2174/1573398X11666150619182624
   Morishita-Katsu M, 2016, INT J CHRONIC OBSTR, V11, P1543, DOI 10.2147/COPD.S104947
   Nagata K, 2012, RESPIROLOGY, V17, P506, DOI 10.1111/j.1440-1843.2012.02131.x
   Natalini JG, 2017, RESP MED, V127, P1, DOI 10.1016/j.rmed.2017.04.002
   Nishiyama O, 2010, EUR RESPIR J, V36, P1067, DOI 10.1183/09031936.00152609
   Olson AL, 2012, IMMUNOL ALLERGY CLIN, V32, P513, DOI 10.1016/j.iac.2012.09.002
   Padilla A, 2007, ARCH BRONCONEUMOL, V43, P205, DOI 10.1016/S1579-2129(07)60052-4
   Smolen JS, 1998, ARTHRITIS RHEUM, V41, P768, DOI 10.1002/1529-0131(199805)41:5<768::AID-ART3>3.0.CO;2-Z
   Sontheimer RD, 2003, J AM ACAD DERMATOL, V48, P797, DOI 10.1067/mjd.2003.199
   Sontheimer RD, 2002, J AM ACAD DERMATOL, V46, P626, DOI 10.1067/mjd.2002.120621
   Suzuki A, 2018, RESPIROLOGY, V23, P851, DOI 10.1111/resp.13293
   Suzuki A, 2017, EXPERT REV RESP MED, V11, P591, DOI 10.1080/17476348.2017.1335600
   Swigris JJ, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01788-2016
   Swigris JJ, 2013, CHEST, V143, P1671, DOI 10.1378/chest.12-0161
   Swigris JJ, 2010, RESP MED, V104, P1350, DOI 10.1016/j.rmed.2010.03.027
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Tsuda T, 2012, RESPIR INVESTIG, V50, P34, DOI 10.1016/j.resinv.2012.05.003
   van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098
   VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309
   Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006
   Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2
NR 39
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 15
EP 20
DI 10.1016/j.rmed.2019.01.017
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700003
PM 30961943
DA 2020-05-18
ER

PT J
AU Khazdair, MR
   Boskabady, MH
AF Khazdair, Mohammad Reza
   Boskabady, Mohammad Hossein
TI The effect of carvacrol on inflammatory mediators and respiratory
   symptoms in veterans exposed to sulfur mustard, a randomized,
   placebo-controlled trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Carvacrol; Sulfur mustard; Cytokines; Chemokine; Respiratory symptoms
ID LAVAGE BAL FLUID; PULMONARY-FUNCTION; ZATARIA-MULTIFLORA; DOUBLE-BLIND;
   DIFFERENTIAL WBC; WATER PIPE; FIBROSIS; INTOXICATION; CONSTITUENT;
   PREVALENCE
AB Background: The aim of this study was to evaluate the effect of carvacrol on serum level of inflammatory mediators and respiratory symptoms in the veterans exposed to sulfur mustard (SM).
   Methods: Twenty-one patients who were exposed to SM more than two decades' ago were divided to placebo and carvacrol (1.2 mg/kg/day) treated groups. Serum levels of Tumor Necrosis Factor-alpha (TNF-alpha), Monocyte chemotactic protein-1 (MCP-1), Vascular endothelial growth factor (VEGF), Epidermal growth factor (EGF), forced expiratory volume-one second (FEV1) and respiratory symptoms including; Chest wheeze (CW), night wheeze (NW), night cough (NC) and cough and wheeze during exercise (ECW) were assessed at the baseline (step 0), one and two months after starting treatment (step I and II, respectively).
   Findings: FEV1 value was significantly increased in carvacrol treated group in step II compared to step 0 (p < 0.001) and also increased in step II compared to step I (p < 0.05). The respiratory symptoms including; CW and NW was significant decreased in carvacrol treated group in step I and II compared to step 0 (p < 0.01 to p < 0.001), NC and ECW were significantly decreased only in step II compared to step 0 (p < 0.01, for both cases). The serum levels of TNF-alpha, EGF and VEGF were decrease in carvacrol treated group in step I and II compared to step 0 (p < 0.05 to p < 0.001). The serum level of MCP-1 was decrease in carvacrol treated group only in the step II compared to step 0 (p < 0.05).
   Interpretation: Two months' treatment with carvacrol reduced inflammatory cytokine and chemokine while increased anti-inflammatory cytokines and improved respiratory symptom and FEV1 value in SM exposed patients.
C1 [Khazdair, Mohammad Reza] Torbat Jam Fac Med Sci, Clin Res Unit, Torbat Jam, Iran.
   [Khazdair, Mohammad Reza] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Khazdair, Mohammad Reza; Boskabady, Mohammad Hossein] Mashhad Univ Med Sci, Dept Physiol, Sch Med, Mashhad 9177948564, Razavi Khorasan, Iran.
   [Boskabady, Mohammad Hossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran.
RP Boskabady, MH (reprint author), Mashhad Univ Med Sci, Dept Physiol, Sch Med, Mashhad 9177948564, Razavi Khorasan, Iran.; Boskabady, MH (reprint author), Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran.
EM boskabadymh@mums.ac.ir
RI Khazdair, Mohammad Reza/X-1804-2019
OI Khazdair, Mohammad Reza/0000-0001-9854-6121
FU research council of Mashhad University of Medical Sciences, Iran
FX This study was financially supported by a grant from research council of
   Mashhad University of Medical Sciences, Iran. The authors also would
   like to thank all participant for participation in this study.
CR Ahmed H. H., 2013, WORLD J PHARM PHARM, V2, P2367
   Alavinezhad A, 2018, PHYTOTHER RES, V32, P151, DOI 10.1002/ptr.5967
   Alavinezhad A, 2017, AVICENNA J PHYTOMEDI, V7, P531
   Aristatile B, 2013, ASIAN PAC J TROP MED, V6, P205, DOI 10.1016/S1995-7645(13)60024-3
   Balali-Mood M, 2006, BASIC CLIN PHARMACOL, V99, P273, DOI 10.1111/j.1742-7843.2006.pto_429.x
   Boskabady MH, 2011, PHYTOTHER RES, V25, P530, DOI 10.1002/ptr.3290
   Boskabady MH, 2003, PHARMAZIE, V58, P661
   Boskabady MH, 2002, RESPIROLOGY, V7, P267, DOI 10.1046/j.1440-1843.2002.00398.x
   Boskabady MH., 2010, EVIDENCE BASED COMPL, V2011
   Boskabady MH, 2008, RESPIROLOGY, V13, P288, DOI 10.1111/j.1440-1843.2007.01157.x
   Boskabady MH, 2008, J ALTERN COMPLEM MED, V14, P1137, DOI 10.1089/acm.2008.0049
   Boskabady MH, 2014, LUNG INDIA, V31, P237, DOI 10.4103/0970-2113.135763
   Boskabady MH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0574-y
   Boskabady MH, 2014, J FUNCT FOODS, V11, P49, DOI 10.1016/j.jff.2014.08.021
   Boskabady MH, 2013, EXP BIOL MED, V238, P200, DOI 10.1177/1535370212474604
   Boskabady MH, 2012, FUND CLIN PHARMACOL, V26, P609, DOI 10.1111/j.1472-8206.2011.00971.x
   Boskabady MH, 2012, RESPIROLOGY, V17, P950, DOI 10.1111/j.1440-1843.2012.02194.x
   CALVET JH, 1994, J APPL PHYSIOL, V76, P681
   CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632
   Chen F, 2009, BIOTECHNOL BIOENG, V104, P30, DOI 10.1002/bit.22363
   Colombo C, 2005, PEDIATR PULM, V40, P15, DOI 10.1002/ppul.20237
   De Vincenzi M, 2004, FITOTERAPIA, V75, P801, DOI 10.1016/j.fitote.2004.05.002
   Emad A, 1997, CHEST, V112, P734, DOI 10.1378/chest.112.3.734
   Emad A, 2007, TOXICOLOGY, V240, P60, DOI 10.1016/j.tox.2007.07.014
   Emad A, 2007, RESP MED, V101, P786, DOI 10.1016/j.rmed.2006.08.003
   Emad A, 2007, J INTERF CYTOK RES, V27, P38, DOI 10.1089/jir.2006.0084
   Evison D, 2002, BRIT MED J, V324, P332, DOI 10.1136/bmj.324.7333.332
   Ezhumalai M, 2015, BIOCHIMIE, V110, P129, DOI 10.1016/j.biochi.2014.12.005
   Ghabili K, 2010, J APPL TOXICOL, V30, P627, DOI 10.1002/jat.1581
   Ghorani V., 2019, AVICENNA J PHYTOMEDI, DOI [10.22038/AJP.2018.11679, DOI 10.22038/AJP.2018.11679]
   Ghotbi L, 2002, INT IMMUNOPHARMACOL, V2, P981, DOI 10.1016/S1567-5769(02)00053-X
   Guimaraes AG, 2012, N-S ARCH PHARMACOL, V385, P253, DOI 10.1007/s00210-011-0715-x
   Gunal M. Y., 2014, Pharmacognosy Journal, V6, P10, DOI 10.5530/pj.2014.3.2
   Hassan ZM, 2002, IMMUNOL LETT, V83, P151, DOI 10.1016/S0165-2478(02)00076-7
   Hoseini K., 1999, REVERSIBILITY AIRFLO
   Hussein J, 2017, BIOMED PHARMACOTHER, V90, P880, DOI 10.1016/j.biopha.2017.04.020
   Jaafari A, 2012, REV BRAS FARMACOGN, V22, P534, DOI 10.1590/S0102-695X2012005000021
   Jalali S, 2013, IRAN J BASIC MED SCI, V16, P615
   Kara M, 2015, INFLAMMATION, V38, P1020, DOI 10.1007/s10753-014-0066-0
   Karami Ali, 2011, Oman Med J, V26, P118, DOI 10.5001/omj.2011.29
   Karbasi-Afshar R, 2013, ANN CARD ANAESTH, V16, P188, DOI 10.4103/0971-9784.114242
   Khazdair MR, 2018, J CLIN PHARM THER, V43, P664, DOI 10.1111/jcpt.12684
   Khazdair M.R., 2018, DRUG CHEM TOXICOL, P1
   Khazdair M.R., 2017, FUNDAMENTAL CLIN PHA
   Khazdair MR, 2015, INHAL TOXICOL, V27, P731, DOI 10.3109/08958378.2015.1114056
   Khazdair MR, 2012, IRAN RED CRESCENT ME, V14, P727, DOI 10.5812/ircmj.4134
   Kim E., 2013, EVIDENCE BASED COMPL, V2013
   Koparal AT, 2003, ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 13, P207
   Landa P, 2009, ARCH PHARM RES, V32, P75, DOI 10.1007/s12272-009-1120-6
   Lima MD, 2013, EUR J PHARMACOL, V699, P112, DOI 10.1016/j.ejphar.2012.11.040
   Mahtaj LG, 2015, PHARMACOL REP, V67, P140, DOI 10.1016/j.pharep.2014.08.017
   Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742
   Mishra NC, 2012, INT IMMUNOPHARMACOL, V13, P101, DOI 10.1016/j.intimp.2012.03.010
   Molloy RM, 2005, CLIN CHEM LAB MED, V43, P1303, DOI 10.1515/CCLM.2005.224
   Nostro A., 2012, DRUG DISCOVERY, V7, P28, DOI DOI 10.2174/157489112799829684
   Panahi Y, 2015, DRUG RES, V65, P567, DOI 10.1055/s-0034-1389986
   Panahi Y., 2017, CRIT REV EUKARYOT GE, V27
   Shohrati M, 2008, RESP MED, V102, P443, DOI 10.1016/j.rmed.2007.10.004
   Silva Y. M. S., 2014, Journal of Medicinal Plants Research, V8, P881
   SOMANI SM, 1989, INT J CLIN PHARM TH, V27, P419
   Yaraee R, 2013, INT IMMUNOPHARMACOL, V17, P968, DOI 10.1016/j.intimp.2012.12.024
   Yaraee R, 2009, INT IMMUNOPHARMACOL, V9, P1466, DOI 10.1016/j.intimp.2009.09.001
   Zhang L, 2012, MOL BIOL REP, V39, P5085, DOI 10.1007/s11033-011-1304-2
NR 63
TC 2
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 21
EP 29
DI 10.1016/j.rmed.2019.01.020
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700004
PM 30961947
DA 2020-05-18
ER

PT J
AU Amundson, WH
   Racila, E
   Allen, T
   Dincer, HE
   Tomic, R
   Bhargava, M
   Perlman, DM
   Kim, HJ
AF Amundson, William H.
   Racila, Emilian
   Allen, Tadashi
   Dincer, H. Erhan
   Tomic, Rade
   Bhargava, Maneesh
   Perlman, David M.
   Kim, Hyun Joo
TI Acute exacerbation of interstitial lung disease after procedures
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Acute exacerbation of interstitial lung disease; Acute exacerbation;
   Interstitial lung disease; AE-ILD; Lung biopsy
ID IDIOPATHIC PULMONARY-FIBROSIS; CONSECUTIVE PATIENTS; RISK-FACTORS;
   BIOPSY; MORTALITY; SURGERY; EFFICACY; FEATURES; SAFETY
AB Interstitial lung disease (ILD) is a category of diffuse parenchymal lung diseases characterized by inflammation and/or fibrosis. The best characterized ILD is idiopathic pulmonary fibrosis (IPF). Acute exacerbation of IPF is a dreaded occurrence with grim prognosis and suboptimal treatment options. There have been recent reports that acute exacerbation can occur in other ILDs (AE-ILD). Of note, some of these acute exacerbations follow lung procedures. This review summarizes the available information on AE-ILD and discusses the procedures reported to cause AE-ILD. We also discuss proposed mechanisms, risk factors, treatment and prognosis. This review should help to inform decision-making about risks versus benefits of procedures that are commonly recommended to diagnose ILD.
C1 [Amundson, William H.; Dincer, H. Erhan; Bhargava, Maneesh; Perlman, David M.; Kim, Hyun Joo] Univ Minnesota, Dept Med, Div Pulm Allergy Crit Care & Sleep, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Racila, Emilian] Univ Minnesota, Dept Pathol, Minneapolis, MN 55455 USA.
   [Allen, Tadashi] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA.
   [Tomic, Rade] Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA.
RP Kim, HJ (reprint author), MMC 276,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM kimxx015@umn.edu
OI Bhargava, Maneesh/0000-0002-1294-6181
CR Bando M, 2009, J BRONCHOL INTERN PU, V16, P229, DOI 10.1097/LBR.0b013e3181b767cc
   Bango-Alvarez Antonio, 2017, ERJ Open Res, V3, DOI 10.1183/23120541.00148-2016
   Casoni GL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086716
   Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP
   Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI
   Cosgrove GP, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-017-0560-x
   Dhooria S, 2018, CLIN RESPIR J, V12, P1711, DOI 10.1111/crj.12734
   Donahoe M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127771
   Fibla JJ, 2012, INTERACT CARDIOV TH, V15, P276, DOI 10.1093/icvts/ivs174
   Ghatol A, 2012, LUNG, V190, P373, DOI 10.1007/s00408-012-9389-5
   HIWATARI N, 1994, TOHOKU J EXP MED, V174, P379, DOI 10.1620/tjem.174.379
   Hutchinson JP, 2016, AM J RESP CRIT CARE, V193, P1161, DOI 10.1164/rccm.201508-1632OC
   Hyzy R, 2007, CHEST, V132, P1652, DOI 10.1378/chest.07-0299
   Ito Hiroyuki, 2014, Asian Cardiovasc Thorac Ann, V22, P948, DOI 10.1177/0218492314526187
   Iwata T, 2016, ANN THORAC SURG, V102, P1905, DOI 10.1016/j.athoracsur.2016.05.094
   Kadoch M, 2018, RESP MED, V137, P55, DOI 10.1016/j.rmed.2018.02.017
   Kannapiran  M., 2012, CLIN PULM MED, V19, P71, DOI [10.1097/CPM.0b013e318247c735, DOI 10.1097/CPM.0B013E318247C735]
   Kim DS, 2012, CLIN CHEST MED, V33, P59, DOI 10.1016/j.ccm.2012.01.001
   Kim DS, 2006, EUR RESPIR J, V27, P143, DOI 10.1183/09031936.06.00114004
   Kim HJ, 2015, RESP MED, V109, P661, DOI 10.1016/j.rmed.2015.02.002
   KONDOH Y, 1993, CHEST, V103, P1808, DOI 10.1378/chest.103.6.1808
   Kondoh Y, 2006, RESP MED, V100, P1753, DOI 10.1016/j.rmed.2006.02.002
   Lumb Andrew B, 2012, Anesthesiol Clin, V30, P591, DOI 10.1016/j.anclin.2012.07.009
   Ma XJ, 2016, J CLIN ANESTH, V34, P518, DOI 10.1016/j.jclinane.2016.06.006
   Maeda H, 2017, SURG TODAY, V47, P1072, DOI 10.1007/s00595-017-1476-z
   Oyama Kunihiro, 2017, Korean J Thorac Cardiovasc Surg, V50, P177, DOI 10.5090/kjtcs.2017.50.3.177
   Parambil JG, 2005, CHEST, V128, P3310, DOI 10.1378/chest.128.5.3310
   Park JH, 2007, EUR J CARDIO-THORAC, V31, P1115, DOI 10.1016/j.ejcts.2007.02.035
   Perlman DM, 2014, CLIN PULM MED, V21, P262
   Plones T, 2013, RESP MED, V107, P629, DOI 10.1016/j.rmed.2012.11.020
   Rachman-Tzemah C, 2017, CELL REP, V19, P774, DOI 10.1016/j.celrep.2017.04.005
   Raghu G, 2004, CLIN CHEST MED, V25, P409, DOI 10.1016/j.ccm.2004.05.007
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Rice AJ, 2003, AM J CLIN PATHOL, V119, P709, DOI 10.1309/UVARMDY8FE9FJDKU
   Richeldi  L., 2011, N ENGL J MED NATL JE, P1079
   Rotolo N, 2015, SARCOIDOSIS VASC DIF, V32, P251
   Sakamoto K, 2012, RESP MED, V106, P436, DOI 10.1016/j.rmed.2011.11.006
   Sakamoto S, 2011, INTERNAL MED, V50, P77, DOI 10.2169/internalmedicine.50.3390
   Samejima Joji, 2015, Asian Cardiovasc Thorac Ann, V23, P191, DOI 10.1177/0218492314550724
   Sato T, 2014, J THORAC CARDIOV SUR, V147, P1604, DOI 10.1016/j.jtcvs.2013.09.050
   Shimura T, 2017, INTERACT CARDIOV TH, V25, P191, DOI 10.1093/icvts/ivx075
   Shintani Y, 2010, GEN THORAC CARDIOVAS, V58, P182, DOI 10.1007/s11748-009-0569-z
   Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709
   Spagnolo P, 2017, CURR OPIN PULM MED, V23, P411, DOI 10.1097/MCP.0000000000000405
   Sugizaki Yoichiro, 2018, J Cardiol Cases, V18, P171, DOI 10.1016/j.jccase.2018.07.005
   Tomic R, 2017, J BRONCHOL INTERN PU, V24, P319, DOI 10.1097/LBR.0000000000000369
   Toyoda Y, 2016, J MED INVESTIG, V63, P294, DOI 10.2152/jmi.63.294
   Watanabe A, 2011, PULM MED, V2011, DOI 10.1155/2011/960316
   Woodske M, 2012, TRANSFUSION, V52, P589, DOI 10.1111/j.1537-2995.2011.03296.x
   Yamazoe M, 2018, BMJ OPEN RESPIR RES, V5, DOI 10.1136/bmjresp-2018-000342
NR 50
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 30
EP 37
DI 10.1016/j.rmed.2019.02.012
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700005
PM 30961948
DA 2020-05-18
ER

PT J
AU Kwon, JW
   Jung, H
   Kim, SH
   Chang, YS
   Cho, YS
   Nahm, DH
   Jang, AS
   Park, JW
   Yoon, HJ
   Cho, SH
   Cho, YJ
   Choi, BW
   Moon, HB
   Kim, TB
AF Kwon, Jae-Woo
   Jung, Heewon
   Kim, Sae-Hoon
   Chang, Yoon-Seok
   Cho, You Sook
   Nahm, Dong-Ho
   Jang, An-Soo
   Park, Jung-Won
   Yoon, Ho Joo
   Cho, Sang-Heon
   Cho, Young-Joo
   Choi, Byoung Whui
   Moon, Hee-Bom
   Kim, Tae-Bum
CA COREA Investigators
TI High ACT score is not sufficient to reduce the risk of asthma
   exacerbations in asthma with low lung function
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Asthma control test; Forced expiratory volume
ID CLUSTER-ANALYSIS; ADULT ASTHMA; POOR ASTHMA; IDENTIFICATION;
   MEPOLIZUMAB; MANAGEMENT; STRATEGY; ATTACKS; FEV1
AB Background: Low forced expiratory volume in 1 s (FEV1) is a risk factor for asthma exacerbations (AEs). We aimed to determine if asthma control could reduce the future risk of AEs in patients with low FEV1. This study was conducted to evaluate the future risks of AEs within six months according to Asthma Control Test T (ACT) score and FEV1.
   Methods: A total of 565 patients with asthma were enrolled from the COREA cohort. The ACT score, lung function test, and number of AEs were assessed at baseline, three-month follow-up, and six-month follow-up with conventional asthma treatments by asthma specialists in real clinical settings.
   Results: Female sex, low ACT score, low FEV1, low FVC, and AE history in the previous three months were related with increased AEs within six months. AEs during six-month follow-up occurred in 24% of patients with ACT < 20 and FEV1 < 60% at baseline. Among patients with an ACT score >= 20, 3.4% of patients with an FEV1 < 2.16 L and 9.8% of patients with FEV1 >= 2.16 L had experienced AEs (P = 0.01), although no differences were observed in the presence of AEs within six months according to the predicted FEV1 (FEV1 >= 60% vs. FEV1 < 60%, 5.66% vs. 8.51%, P = 0.65).
   Conclusion: Patient with low FEV1 seemed to show higher risk of AEs than those with near-normal FEV1 despite ACT score >= 20 and asthma treatments. Therefore, treatment strategies that prevent AEs are needed in high-risk asthmatic patients.
C1 [Kwon, Jae-Woo] Kangwon Natl Univ, Coll Med, Dept Allergy & Clin Immunol, Chunchon, South Korea.
   [Jung, Heewon; Cho, You Sook; Moon, Hee-Bom; Kim, Tae-Bum] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Kim, Sae-Hoon; Chang, Yoon-Seok; Cho, Sang-Heon] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Nahm, Dong-Ho] Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon, South Korea.
   [Jang, An-Soo] Soonchunhyang Univ, Sch Med, Bucheon Hosp, Dept Internal Med, Bucheon, South Korea.
   [Park, Jung-Won] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Park, Jung-Won] Yonsei Univ, Coll Med, Allergy Inst, Seoul, South Korea.
   [Yoon, Ho Joo] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Cho, Young-Joo] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Choi, Byoung Whui] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [COREA Investigators] Cohort Real & Evolut Adult Asthma Korea COREA Res, Seoul, South Korea.
RP Kim, TB (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM tbkim@amc.seoul.kr
RI Chang, Yoon-Seok/J-5628-2012
OI Chang, Yoon-Seok/0000-0003-3157-0447; Kwon, Jae-Woo/0000-0003-1639-3606
FU Korea Health Industry Development Institute - Ministry of Health &
   Welfare, Republic of Korea [HC15C1335]; Basic Science Research Program
   via the National Research Foundation of Korea (NRF) - Ministry of
   Education [2017R1D1A3B03034684]
FX This research was supported by a grant awarded to the Korea Health
   Technology R&D Project via the Korea Health Industry Development
   Institute, which is funded by the Ministry of Health & Welfare, Republic
   of Korea (Grant No. HC15C1335). This research was also supported by the
   Basic Science Research Program via the National Research Foundation of
   Korea (NRF), which is funded by the Ministry of Education
   (2017R1D1A3B03034684).
CR Gutierrez FJA, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0422-6
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Blakey JD, 2013, PRIM CARE RESP J, V22, P344, DOI 10.4104/pcrj.2013.00063
   Cajigal S., 2017, J ALLERGY CLIN IMMUN, V5
   Frey U, 2007, CURR OPIN ALLERGY CL, V7, P223, DOI 10.1097/ACI.0b013e32810fd771
   Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590
   Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983
   Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991
   Haselkorn T., 2009, J ALLERGY CLIN IMMUN, V124
   Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811
   Kim TB, 2009, ANN ALLERG ASTHMA IM, V103, P311, DOI 10.1016/S1081-1206(10)60530-3
   Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875
   Ko FWS, 2012, RESPIROLOGY, V17, P370, DOI 10.1111/j.1440-1843.2011.02105.x
   LI D, 1995, AM J RESP CRIT CARE, V151, P647
   McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084
   Park SG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055378
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574
   Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5
   Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081
   Sato R, 2009, J ASTHMA, V46, P677, DOI 10.1080/02770900902972160
   Schatz M., 2009, J ALLERGY CLIN IMMUN, V124
   Schatz M., 2010, AM J MANAG CARE, V16
   Thomas Mike, 2009, Prim Care Respir J, V18, P41, DOI 10.4104/pcrj.2009.00010
   Thomson Neil C, 2008, BMC Pulm Med, V8, P27, DOI 10.1186/1471-2466-8-27
   Turner S, 2009, ARCH DIS CHILD, V94, P16, DOI 10.1136/adc.2008.140681
NR 31
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 38
EP 44
DI 10.1016/j.rmed.2019.02.010
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700006
PM 30961949
DA 2020-05-18
ER

PT J
AU Kwon, BS
   Lee, JH
   Koh, Y
   Kim, WS
   Song, JW
   Oh, YM
   Lee, SD
   Lee, SW
   Lee, JS
   Lim, CM
   Choi, CM
   Huh, JW
   Hong, SB
   Shim, TS
   Jo, KW
AF Kwon, Byoung Soo
   Lee, Jun Hee
   Koh, Younsuck
   Kim, Woo-Sung
   Song, Jin-Woo
   Oh, Yeon-Mok
   Lee, Sang-Do
   Lee, Sei Won
   Lee, Jae-Seung
   Lim, Chae-Man
   Choi, Chang-Min
   Huh, Jin-Won
   Hong, Sang-Bum
   Shim, Tae Sun
   Jo, Kyung-Wook
TI The natural history of non-cavitary nodular bronchiectatic Mycobacterium
   avium complex lung disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Clinical course; Conversion; MAC; Treatment
ID PULMONARY-DISEASE; RISK-FACTORS; IDENTIFICATION; INTRACELLULARE;
   DETERIORATION; DIAGNOSIS
AB Purpose: We aimed to investigate the natural history of non-cavitary nodular bronchiectatic (NC-NB) Mycobacterium avium complex (MAC) lung disease (LD).
   Methods: Among all patients diagnosed with NC-NB MAC LD between March 2000 and December 2013, 551 patients who were followed until December 2017 were enrolled at a tertiary referral center in South Korea. Patients were subdivided into progressive and stationary groups, depending on whether treatment was initiated within 3 years after diagnosis. We investigated the proportion of patients not receiving anti-MAC treatment within 3 years after the diagnosis. The rate for spontaneous sputum conversion in the untreated group was also calculated.
   Results: The mean age of 551 patients was 61.1 years. During the median 5.8 years of follow-up, 323 (58.6%) patients received treatment within 3 years (progressive group), whereas the remaining 228 (41.4%) patients did not (stationary group). Multivariate analysis revealed that age <= 60 years, a positive sputum smear, the presence of systemic symptoms, body mass index > 18.5 kg/m(2), and the involvement of >= 4 lobes were predictors of receiving treatment. Additionally, during the median of 5.0 years follow-up, spontaneous sputum conversion occurred in 52.2% of patients who did not receive treatment.
   Conclusions: Among patients diagnosed with NC-NB MAC LD, approximately 40% did not receive antibiotic treatment within 3 years of diagnosis. Moreover, about 50% of untreated patients experienced spontaneous sputum conversion.
C1 [Kwon, Byoung Soo; Koh, Younsuck; Kim, Woo-Sung; Song, Jin-Woo; Oh, Yeon-Mok; Lee, Sang-Do; Lee, Sei Won; Lee, Jae-Seung; Lim, Chae-Man; Choi, Chang-Min; Huh, Jin-Won; Hong, Sang-Bum; Shim, Tae Sun; Jo, Kyung-Wook] Univ Ulsan, Coll Med, Asan Med Ctr, Div Pulmonol & Crit Care Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Lee, Jun Hee] Univ Ulsan, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
RP Jo, KW (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Div Pulmonol & Crit Care Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM heathcliff6800@hanmail.net
RI Lee, Sei Won/AAG-9977-2019; Song, Jinwoo/X-9215-2018
OI Song, Jinwoo/0000-0001-5121-3522
CR Adjemian Jennifer, 2014, Ann Am Thorac Soc, V11, P9, DOI 10.1513/AnnalsATS.201304-085OC
   Falkinham JO, 2015, CLIN CHEST MED, V36, P35, DOI 10.1016/j.ccm.2014.10.003
   Fleshner M, 2016, INT J TUBERC LUNG D, V20, P582, DOI 10.5588/ijtld.15.0807
   Gochi M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008058
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00110-2017
   Hayashi M, 2012, AM J RESP CRIT CARE, V185, P575, DOI 10.1164/rccm.201107-1203OC
   Hoefsloot W, 2013, EUR RESPIR J, V42, P1604, DOI 10.1183/09031936.00149212
   Hwang JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00537-2016
   Kim SJ, 2014, INT J TUBERC LUNG D, V18, P730, DOI 10.5588/ijtld.13.0792
   Kim SJ, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0349-3
   Koh WJ, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02503-2016
   Koh WJ, 2012, CHEST, V142, P1482, DOI 10.1378/chest.12-0494
   Kumagai S, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2544-0
   Kwon YS, 2019, TUBERC RESPIR DIS, V82, P15, DOI 10.4046/trd.2018.0060
   Lee BY, 2015, ANTIMICROB AGENTS CH, V59, P2972, DOI 10.1128/AAC.04577-14
   Lee Geewon, 2013, Ann Am Thorac Soc, V10, P299, DOI 10.1513/AnnalsATS.201303-062OC
   Lee H, 2000, J CLIN MICROBIOL, V38, P2966, DOI 10.1128/JCM.38.8.2966-2971.2000
   McShane PJ, 2015, CHEST, V148, P1517, DOI 10.1378/chest.15-0458
   Narvaiz de Kantor I, 1998, LAB SERVICES TUBERCU
   POLLOCK HM, 1977, J CLIN MICROBIOL, V5, P329
   Sanguinetti M, 1998, J CLIN MICROBIOL, V36, P1530, DOI 10.1128/JCM.36.6.1530-1533.1998
   Stout JE, 2016, INT J INFECT DIS, V45, P123, DOI 10.1016/j.ijid.2016.03.006
   Yamazaki Y, 1999, AM J RESP CRIT CARE, V160, P1851, DOI 10.1164/ajrccm.160.6.9902019
NR 24
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 45
EP 50
DI 10.1016/j.rmed.2019.02.007
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700007
PM 30961950
DA 2020-05-18
ER

PT J
AU Katsaounou, P
   Buhl, R
   Brusselle, G
   Pfister, P
   Martinez, R
   Wahn, U
   Bousquet, J
AF Katsaounou, Paraskevi
   Buhl, Roland
   Brusselle, Guy
   Pfister, Pascal
   Martinez, Rafael
   Wahn, Ulrich
   Bousquet, Jean
TI Omalizumab as alternative to chronic use of oral corticosteroids in
   severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Systemic/injectable/oral corticosteroids; Asthma; Biologics;
   Immunoglobulin E/IgE; Interleukin-5
ID SEVERE ALLERGIC-ASTHMA; ADD-ON THERAPY; GLUCOCORTICOID-INDUCED
   OSTEOPOROSIS; SEVERE PERSISTENT ASTHMA; EOSINOPHILIC ASTHMA; SYSTEMIC
   CORTICOSTEROIDS; WHEEZING EPISODES; DEPENDENT ASTHMA; DOUBLE-BLIND;
   CHILDREN
AB Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacerbation due to the lack of availability of effective alternatives. Fortunately, in the last decade several biologics have been proven safe and effective for patients with uncontrolled severe asthma. This has led to the Global Initiative for Asthma (GINA) recommending the use of biologics, instead of maintenance OCS, in patients with severe asthma (GINA Step 5). These include one biologic targeting immunoglobulin E (IgE) (omalizumab), and different biologics targeting interleukin-5 (IL-5), the IL-5 receptor (IL-5R) or IL-4 receptor alpha-unit (IL-4R alpha), including mepolizumab (subcutaneous), reslizumab (intravenous), benralizumab (subcutaneous) and dupilumab (subcutaneous).
   Omalizumab for the treatment of severe allergic asthma reduces exacerbations, irrespective of blood eosinophil levels. Anti-IL-5/IL-5R biologics are indicated in patients with severe eosinophilic asthma and repetitive exacerbations, irrespective of the presence or absence of allergy. Recently, an anti-IL4R alpha biologic has been approved by the FDA for eosinophilic phenotype or oral corticosteroid-dependent asthma. Finally, physicians should consider using biologics as an alternative to chronic OCS therapy.
C1 [Katsaounou, Paraskevi] Univ Athens, ICU Evangelismos Hosp 1, Sch Med, Athens, Greece.
   [Buhl, Roland] Mainz Univ Hosp, Pulm Dept, Mainz, Germany.
   [Brusselle, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.
   [Brusselle, Guy] Erasmus MC, Dept Epidemiol & Resp Med, Rotterdam, Netherlands.
   [Pfister, Pascal; Martinez, Rafael] Novartis Pharma AG, Global Med Dept, Basel, Switzerland.
   [Wahn, Ulrich] Charite Univ Med Berlin, Dept Paediat Pneumol & Immunol, Berlin, Germany.
   [Bousquet, Jean] Hop Arnaud de Villeneuve, Serv Malad Resp, Montpellier, France.
RP Bousquet, J (reprint author), Hop Arnaud de Villeneuve, Serv Malad Resp, Montpellier, France.
EM paraskevikatsaounou@gmail.com; roland.buhl@unimedizin-mainz.de;
   guy.brusselle@ugent.be; pascal.pfister@novartis.com;
   ulrich.wahn@gmail.com; jean.bousquet@orange.fr
OI Brusselle, Guy/0000-0001-7021-8505
FU Novartis Pharma AG, Basel, Switzerland
FX Development of this review article was funded by Novartis Pharma AG,
   Basel, Switzerland.
CR Albers F., 2018, ALLERGY, V73, P134
   Aljebab F, 2016, ARCH DIS CHILD, V101, P365, DOI [10.1136/archdischild-2015-309522, 10.1136/archdischild-2016-311535.57]
   Alvares K. P., 2017, ISPOR 20 ANN EUR C 4
   [Anonymous], 2007, EXP PAN REP 3 GUID D
   Arabkhazaeli A, 2016, J ASTHMA, V53, P1012, DOI 10.1080/02770903.2016.1185439
   Arellano FM, 2011, PEDIAT ALLERG IMM-UK, V22, P469, DOI 10.1111/j.1399-3038.2010.01121.x
   Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x
   Barnes N, 2013, J ASTHMA, V50, P529, DOI 10.3109/02770903.2013.790419
   Barra CB, 2017, REV ASSOC MED BRAS, V63, P899, DOI 10.1590/1806-9282.63.10.899
   Barry LE, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0614-x
   Bateman ED, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00670-2017
   Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033
   Becker AB, 2017, CURR OPIN ALLERGY CL, V17, P99, DOI 10.1097/ACI.0000000000000346
   Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
   Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182, DOI 10.1016/S1081-1206(10)62175-8
   Bhogal SK, 2012, ANN EMERG MED, V60, P84, DOI 10.1016/j.annemergmed.2011.12.027
   Bhutani M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183869
   Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032
   Bloechliger M, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0742-y
   Bourdin A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01486-2017
   Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011
   Bousquet J, 2011, ALLERGY, V66, P671, DOI 10.1111/j.1398-9995.2010.02522.x
   Bousquet J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01782-2017
   Bousquet J, 2017, EUR CLIN RESPIR J, V4, DOI 10.1080/20018525.2016.1270077
   Braunstahl GJ, 2013, RESP MED, V107, P1141, DOI 10.1016/j.rmed.2013.04.017
   Braunstahl GJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-47
   British Thoracic Society, 2016, BRIT GUID MAN ASTHM
   Brodlie M, 2012, ARCH DIS CHILD, V97, P604, DOI 10.1136/archdischild-2011-301570
   Brusselle G, 2009, RESP MED, V103, P1633, DOI 10.1016/j.rmed.2009.06.014
   Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092
   Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]
   Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC
   Castro-Rodriguez JA, 2016, PEDIATR PULM, V51, P868, DOI 10.1002/ppul.23429
   Cazzola M, 2010, RESP MED, V104, P1410, DOI 10.1016/j.rmed.2010.04.013
   Choo XN, 2016, THORAX, V71, P302, DOI 10.1136/thoraxjnl-2015-208242
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   Collins AD, 2014, THER ADV RESPIR DIS, V8, P182, DOI 10.1177/1753465814552283
   Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064
   Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018
   Costello RW, 2011, IRISH J MED SCI, V180, P637, DOI 10.1007/s11845-011-0716-2
   Dalal Anand A, 2016, J Manag Care Spec Pharm, V22, P833, DOI 10.18553/jmcp.2016.22.7.833
   Deleskog A, 2011, DIABETES RES CLIN PR, V92, P288, DOI 10.1016/j.diabres.2011.02.014
   Deschildre A, 2013, EUR RESPIR J, V42, P1224, DOI 10.1183/09031936.00149812
   Domingo C, 2011, CURR MED RES OPIN, V27, P45, DOI 10.1185/03007995.2010.536208
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365-2796.1998.00408.x
   Egbuonu Francis, 2014, Open Respir Med J, V8, P101, DOI 10.2174/1874306401408010101
   Eisner MD, 2012, J ASTHMA, V49, P642, DOI 10.3109/02770903.2012.690477
   Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871
   Farber HJ, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4146
   Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN
   Gouder C, 2015, INT J CLIN PHARM-NET, V37, P36, DOI 10.1007/s11096-014-0034-7
   Grimaldi-Bensouda L, 2013, CHEST, V143, P398, DOI 10.1378/chest.12-1372
   Hochberg MC, 1996, ARTHRITIS RHEUM-US, V39, P1791
   Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x
   Hopkins RL, 2005, ENDOCRIN METAB CLIN, V34, P371, DOI 10.1016/j.ecl.2005.01.013
   Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x
   Humbert M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02523-2017
   Katsaounou P. A., 2017, CIVETTA TAYLOR KIRBY
   Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC
   Korn S, 2009, RESP MED, V103, P1725, DOI 10.1016/j.rmed.2009.05.002
   Lafeuille MH, 2012, ANN ALLERG ASTHMA IM, V109, P59, DOI 10.1016/j.anai.2012.04.015
   Lefebvre P, 2015, J ALLERGY CLIN IMMUN, V136, P1488, DOI 10.1016/j.jaci.2015.07.046
   Lex C, 2007, PEDIATR PULM, V42, P298, DOI 10.1002/ppul.20570
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   Manson SC, 2009, RESP MED, V103, P975, DOI 10.1016/j.rmed.2009.01.003
   Mansur AH, 2017, RESP MED, V124, P36, DOI 10.1016/j.rmed.2017.01.008
   Milgrom H, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e36
   Molimard M, 2010, RESP MED, V104, P1381, DOI 10.1016/j.rmed.2010.06.001
   Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501
   Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435
   National Institute for Health and Clinical Excellence, 2017, NIC TECHN APPR GUID, P431
   Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4
   O'Byrne PM, 2013, CHEST, V143, P511, DOI 10.1378/chest.12-0412
   Ortiz B., 2018, PEDIAT ALLERGY ASTHM, DOI [10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A2040A2040-A2040, DOI 10.1164/AJRCCM-CONFERENCE.2018.197.1_MEETINGABSTRACTS.A2040A2040-A2040]
   Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Pelaia G, 2011, INT J CLIN PHARM TH, V49, P713, DOI 10.5414/CP201586
   Philip Jim, 2014, Open Respir Med J, V8, P66, DOI 10.2174/1874306401408010066
   Poetker DM, 2010, OTOLARYNG CLIN N AM, V43, P753, DOI 10.1016/j.otc.2010.04.003
   Powell C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub2
   Price D, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA3621
   Price D, 2017, CHEST, V152, p14A, DOI 10.1016/j.chest.2017.08.044
   Puente-Maestu L., 2018, BIOMED HUB, V3
   Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093
   Rachelefsky G, 2003, PEDIATRICS, V112, P382, DOI 10.1542/peds.112.2.382
   Randhawa I, 2007, ANN ALLERG ASTHMA IM, V99, P291, DOI 10.1016/S1081-1206(10)60543-1
   Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144
   Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194
   Rottem M, 2012, J ASTHMA, V49, P78, DOI 10.3109/02770903.2011.637598
   Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002178
   Ryan D, 2016, J ALLERGY CLIN IMMUN, V138, P308, DOI 10.1016/j.jaci.2015.11.044
   Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012
   Schatz M, 2018, J ALLER CL IMM-PRACT, V6, P328, DOI 10.1016/j.jaip.2017.12.016
   Schellenberg RR, 2007, CAN RESP J SC, V14, p1C 
   Schuetz Philipp, 2008, BMC Pulm Med, V8, P1, DOI 10.1186/1471-2466-8-1
   Siergiejko Z, 2011, CURR MED RES OPIN, V27, P2223, DOI 10.1185/03007995.2011.620950
   Smith M, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002886, DOI 10.1002/14651858.CD002886]
   Sousa AS, 2015, REV PORT PNEUMOL, V21, P327, DOI 10.1016/j.rppnen.2015.03.002
   Sullivan PW, 2018, J ALLERGY CLIN IMMUN, V141, P110, DOI 10.1016/j.jaci.2017.04.009
   Sweeney J, 2016, THORAX, V71, P339, DOI 10.1136/thoraxjnl-2015-207630
   Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008
   To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204
   TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F
   Walker-Bone K, 2004, CLIN MED, V4, P431, DOI 10.7861/clinmedicine.4-5-431
   Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279
   Zazzali JL, 2015, ALLERGY ASTHMA PROC, V36, P268, DOI 10.2500/aap.2015.36.3863
   Zeiger RS, 2017, J ALLER CL IMM-PRACT, V5, P1050, DOI 10.1016/j.jaip.2016.12.023
NR 108
TC 4
Z9 4
U1 2
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 51
EP 62
DI 10.1016/j.rmed.2019.02.003
PG 12
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700008
PM 30961951
DA 2020-05-18
ER

PT J
AU Brusca, RM
   Pinal-Fernandez, I
   Psoter, K
   Paik, JJ
   Albayda, J
   Mecoli, C
   Tiniakou, E
   Mammen, AL
   Christopher-Stine, L
   Danoff, S
   Johnson, C
AF Brusca, Rebeccah M.
   Pinal-Fernandez, Iago
   Psoter, Kevin
   Paik, Julie J.
   Albayda, Jemima
   Mecoli, Christopher
   Tiniakou, Eleni
   Mammen, Andrew L.
   Christopher-Stine, Lisa
   Danoff, Sonye
   Johnson, Cheilonda
TI The ILD-GAP risk prediction model performs poorly in myositis-associated
   interstitial lung disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Myositis; Lung diseases; Interstitial; Calibration; Cross-sectional
   studies
ID POLYMYOSITIS; VALIDATION; MORTALITY
AB Purpose: Myositis-associated interstitial lung disease (MA-ILD) is associated with increased mortality, but no prognostic model exists in this population. The ILD-GAP index was developed to predict mortality risk across all subtypes of chronic ILD. The purpose of this study was to validate the ILD-GAP risk prediction model in patients with MA-ILD.
   Procedures: We completed a retrospective cross-sectional study of patients enrolled in the Johns Hopkins Myositis Center database between 2006 and 2017. Cumulative mortality rates were estimated using the Kaplan-Meier test. Model calibration was determined by using standardized mortality ratios of observed versus expected deaths.
   Main findings: 179 participants with MA-ILD were included. The mean baseline percent predicted forced vital capacity was 65.2 +/- 20.6%, forced expiratory volume in the first second 65.4 +/- 20.4%, and carbon monoxide diffusing capacity 61.6 +/- 20.0%. Thirty-two participants died (17.9%). The ILD-GAP model had poor discriminative performance and calibration.
   Conclusions: The ILD-GAP risk prediction model is a poor predictor of mortality among individuals with MA-ILD. The identification of a better predictive model for MA-ILD is needed to help guide care in this patient population.
C1 [Brusca, Rebeccah M.; Pinal-Fernandez, Iago; Psoter, Kevin; Paik, Julie J.; Albayda, Jemima; Mecoli, Christopher; Tiniakou, Eleni; Mammen, Andrew L.; Christopher-Stine, Lisa; Danoff, Sonye; Johnson, Cheilonda] Johns Hopkins Univ, Sch Med, 1830 East Monument St,Suite 500, Baltimore, MD 21224 USA.
   [Pinal-Fernandez, Iago; Mammen, Andrew L.] NIAMSD, NIH, Muscle Dis Unit, Lab Muscle Stem Cells & Gene Regulat, 9000 Rockville Pike Bldg 50, Bethesda, MD 20892 USA.
RP Johnson, C (reprint author), Div Pulm Allergy & Crit Care Med, 3400 Spruce St,9054 Gates Bldg, Philadelphia, PA 19104 USA.
EM Cheilonda.Johnson@uphs.upenn.edu
RI Tiniakou, Eleni/W-1249-2019; Johnson, Cheilonda/AAB-4555-2020
OI Tiniakou, Eleni/0000-0003-4749-870X; Johnson,
   Cheilonda/0000-0003-3040-4981
FU Huayi and Siuling Zhang Discovery Fund; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [K01HL135459]
FX This research was supported by the Huayi and Siuling Zhang Discovery
   Fund, and the NIH grant K01HL135459.
CR ATS/ERS, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
   BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
   Fathi M, 2005, CURR OPIN RHEUMATOL, V17, P701, DOI 10.1097/01.bor.0000179949.65895.53
   Johnson C, 2016, LUNG, V194, P733, DOI 10.1007/s00408-016-9896-x
   Kim ES, 2015, CHEST, V147, P430, DOI 10.1378/chest.14-0453
   Kondoh S, 2016, RESPIR INVESTIG, V54, P327, DOI 10.1016/j.resinv.2016.02.009
   Lee S, 2016, BIOSTATISTICS, V17, P1, DOI 10.1093/biostatistics/kxv033
   Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
   Marie I, 2002, ARTHRIT RHEUM-ARTHR, V47, P614, DOI 10.1002/art.10794
   Mimori T, 2012, CURR RHEUMATOL REP, V14, P264, DOI 10.1007/s11926-012-0246-6
   Ryerson CJ, 2014, CHEST, V145, P723, DOI 10.1378/chest.13-1474
   Saketkoo LA, 2010, CURR RHEUMATOL REV, V6, P108, DOI 10.2174/157339710791330740
   Solomon J, 2011, J BRAS PNEUMOL, V37, P100, DOI 10.1590/S1806-37132011000100015
   Woo JH, 2013, MOD RHEUMATOL, V23, P503, DOI 10.1007/s10165-012-0673-2
NR 14
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 63
EP 65
DI 10.1016/j.rmed.2019.02.015
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700009
PM 30961952
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Tariq, K
   Schofield, JPR
   Nicholas, BL
   Burg, D
   Brandsma, J
   Bansal, AT
   Wilson, SJ
   Lutter, R
   Fowler, SJ
   Bakke
   Caruso, M
   Dahlen, B
   Horvath, I
   Krug, N
   Montuschi, P
   Sanak, M
   Sandstrom, T
   Geiser, T
   Pandis, I
   Sousa, AR
   Adcock, IM
   Shaw, DE
   Auffray, C
   Howarth, PH
   Sterk, PJ
   Chung, KF
   Skipp, PJ
   Dimitrov, B
   Djukanovic, R
AF Tariq, K.
   Schofield, J. P. R.
   Nicholas, B. L.
   Burg, D.
   Brandsma, J.
   Bansal, A. T.
   Wilson, S. J.
   Lutter, R.
   Fowler, S. J.
   Bakke
   Caruso, M.
   Dahlen, B.
   Horvath, I.
   Krug, N.
   Montuschi, P.
   Sanak, M.
   Sandstrom, T.
   Geiser, T.
   Pandis, I.
   Sousa, A. R.
   Adcock, I. M.
   Shaw, D. E.
   Auffray, C.
   Howarth, P. H.
   Sterk, P. J.
   Chung, K. F.
   Skipp, P. J.
   Dimitrov, B.
   Djukanovic, R.
CA U-BIOPRED Study Grp
TI Sputum proteomic signature of gastro-oesophageal reflux in patients with
   severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
ID PREVALENCE; METAANALYSIS; MACROPHAGES; PHENOTYPES; INHIBITORS;
   LIPOCALINS; SYMPTOMS; RISK
AB Gastro-oesophageal reflux disease (GORD) has long been associated with poor asthma control without an established cause-effect relationship.
   610 asthmatics (421 severe/88 mild-moderate) and 101 healthy controls were assessed clinically and a subset of 154 severe asthmatics underwent proteomic analysis of induced sputum using untargeted mass spectrometry, LC-IMS-MSE. Univariate and multiple logistic regression analyses (MLR) were conducted to identify proteins associated with GORD in this cohort.
   When compared to mild/moderate asthmatics and healthy individuals, respectively, GORD was three-and ten-fold more prevalent in severe asthmatics and was associated with increased asthma symptoms and oral corticosteroid use, poorer quality of life, depression/anxiety, obesity and symptoms of sino-nasal disease. Comparison of sputum proteomes in severe asthmatics with and without active GORD showed five differentially abundant proteins with described roles in antimicrobial defences, systemic inflammation and epithelial integrity. Three of these were associated with active GORD by multiple linear regression analysis: Ig lambda variable 1-47 (p = 0.017) and plasma protease C1 inhibitor (p = 0.043), both in lower concentrations, and lipocalin-1 (p = 0.034) in higher concentrations in active GORD.
   This study provides evidence which suggests that reflux can cause subtle perturbation of proteins detectable in the airways lining fluid and that severe asthmatics with GORD may represent a distinct phenotype of asthma.
C1 [Tariq, K.; Schofield, J. P. R.; Nicholas, B. L.; Burg, D.; Brandsma, J.; Wilson, S. J.; Howarth, P. H.; Dimitrov, B.; Djukanovic, R.] Univ Hosp Southampton, NIHR Southampton Resp Biomed Res Ctr, Southampton, Hants, England.
   [Schofield, J. P. R.; Burg, D.; Skipp, P. J.] Univ Southampton, Ctr Prote Res, Southampton, Hants, England.
   [Tariq, K.; Nicholas, B. L.; Howarth, P. H.; Djukanovic, R.] Univ Southampton, Univ Hosp Southampton, Clin Expt Sci Unit, Fac Med, South Acad Block, Southampton, Hants, England.
   [Bansal, A. T.] Acclarogen Ltd, Cambridge, England.
   [Lutter, R.] Univ Amsterdam, Dept Expt Immunol, AMC, Amsterdam, Netherlands.
   [Lutter, R.; Sterk, P. J.] Univ Amsterdam, Dept Resp Med, AMC, Amsterdam, Netherlands.
   [Chung, K. F.] Imperial Coll, Natl Heart & Lung Inst, Airways Dis, London, England.
   [Chung, K. F.] Royal Brompton NIHR Biomed Res Unit, London, England.
   [Fowler, S. J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Infect Immun & Resp Med, Sch Biol Sci,Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Fowler, S. J.] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England.
   [Shaw, D. E.] Univ Nottingham, Resp Res Unit, Nottingham, England.
   [Bakke] Univ Bergen, Dept Clin Sci, Bergen, Norway.
   [Caruso, M.] Univ Catania, Policlin Vittorio Emanuele, Dept Clin & Expt Med, Hosp Univ, Catania, Italy.
   [Dahlen, B.] Karolinska Univ, Hosp Huddinge, Dept Med, Div Resp Med & Allergy, Stockholm, Sweden.
   [Horvath, I.] Semmelweis Univ, Dept Pulmonol, Budapest, Hungary.
   [Krug, N.] Fraunhofer Inst Toxicol & Expt Med Hannover, Hannover, Germany.
   [Montuschi, P.] Univ Cattolica Sacro Cuore, Dept Pharmacol, Fac Med, Rome, Italy.
   [Sanak, M.] Jagiellonian Univ, Med Coll, Div Mol Biol & Clin Genet, Krakow, Poland.
   [Sandstrom, T.] Umea Univ, Dept Med, Dept Publ Hlth, Umea, Sweden.
   [Sandstrom, T.] Umea Univ, Clin Med Resp Med Unit, Umea, Sweden.
   [Geiser, T.] Univ Hosp Bern, Bern, Switzerland.
   [Pandis, I.] Imperial Coll, Data Sci Inst, London, England.
   [Sousa, A. R.] GSK, Resp Therapeut Unit, Stockley Pk, England.
   [Adcock, I. M.] Imperial Coll London, Natl Heart & Lung Inst, Cell & Mol Biol Grp, Airways Dis Sect, Dovehouse St, London, England.
   [Auffray, C.] CNRS, INSERM, European Inst Syst Biol & Med, ENS,UCBL, Lyon, France.
RP Djukanovic, R (reprint author), Southampton Univ Hosp, Sir Henry Wellcome Labs, Mailpoint 810,Level F,South Block, Southampton SO16 6YD, Hants, England.
EM rd1@soton.ac.uk
RI Caruso, Massimo/P-4161-2016; Chung, Kian Fan/B-1872-2012; Sterk,
   P.J./AAK-8175-2020
OI Caruso, Massimo/0000-0002-4412-2080; Chung, Kian
   Fan/0000-0001-7101-1426; Fowler, Stephen/0000-0002-4524-1663; MONTUSCHI,
   Paolo/0000-0001-5589-1750
FU Innovative Medicines Initiative Joint Undertaking under the European
   Union's Seventh Framework Programme (FP7/2007-2013) [115010]; EFPIA
   companies; IMI (EU) [115446]
FX U-BIOPRED was supported through an Innovative Medicines Initiative Joint
   Undertaking under grant agreement no. 115010, resources of which were
   composed of a financial contribution from the European Union's Seventh
   Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind
   contribution (www.imi.europa.eu). We would also like to acknowledge help
   from the IMI-funded eTRIKS project (EU Grant Code no. 115446).
CR Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136
   Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643
   Bohnhorst I, 2015, AM J RHINOL ALLERGY, V29, pE70, DOI 10.2500/ajra.2015.29.4167
   Braber S, 2012, AM J RESP CRIT CARE, V185, P817, DOI 10.1164/rccm.201104-0761OC
   Cohen G, 2001, KIDNEY INT, V59, pS48, DOI 10.1046/j.1523-1755.2001.59780048.x
   Dittrich AM, 2013, CLIN EXP ALLERGY, V43, P503, DOI 10.1111/cea.12025
   Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102
   Emilsson OI, 2013, EUR RESPIR J, V41, P1347, DOI 10.1183/09031936.00052512
   Field SK, 1996, CHEST, V109, P316, DOI 10.1378/chest.109.2.316
   Gibeon D, 2014, RESP MED, V108, P71, DOI 10.1016/j.rmed.2013.10.005
   Hampel H, 2005, ANN INTERN MED, V143, P199, DOI 10.7326/0003-4819-143-3-200508020-00006
   Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290
   Harding SM, 2000, AM J RESP CRIT CARE, V162, P34, DOI 10.1164/ajrccm.162.1.9907072
   Jensen-Jarolim E, 2016, ALLERGY, V71, P286, DOI 10.1111/all.12797
   Joo NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116756
   KAHRILAS PJ, 1990, GUT, V31, P4, DOI 10.1136/gut.31.1.4
   Kalsheker N, 2002, BIOCHEM SOC T, V30, P93, DOI 10.1042/BST0300093
   Katle EJ, 2012, EUR ARCH OTO-RHINO-L, V269, P121, DOI 10.1007/s00405-011-1675-y
   Katz PO, 2013, AM J GASTROENTEROL, V108, P308, DOI 10.1038/ajg.2012.444
   Kiljander T., 2012, CLIN RESPIR  J, V7, P218
   McQuaid KR, 2005, CLIN GASTROENTEROL H, V3, P553, DOI 10.1016/S1542-3565(05)00023-6
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Nicholas BL, 2010, AM J RESP CRIT CARE, V181, P1049, DOI 10.1164/rccm.200906-0857OC
   Parameswaran K, 2000, EUR RESPIR J, V16, P1119, DOI 10.1034/j.1399-3003.2000.16f17.x
   Schofield J., 2016, PROTEOME FINGERPRINT
   Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015
   SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W
   Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631
   ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905
   VANDEGRAAF EA, 1991, LUNG, V169, P275, DOI 10.1007/BF02714163
   Vincent D, 1997, EUR RESPIR J, V10, P2255, DOI 10.1183/09031936.97.10102255
   Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025
NR 32
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 66
EP 73
DI 10.1016/j.rmed.2019.02.008
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700010
PM 30961953
DA 2020-05-18
ER

PT J
AU Segura-Medina, P
   Vargas, MH
   Aguilar-Romero, JM
   Arreola-Ramirez, JL
   Miguel-Reyes, JL
   Salas-Hernandez, J
AF Segura-Medina, Patricia
   Vargas, Mario H.
   Manuel Aguilar-Romero, Jose
   Luis Arreola-Ramirez, Jose
   Luis Miguel-Reyes, Jose
   Salas-Hernandez, Jorge
TI Mold burden in house dust and its relationship with asthma control
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Fungi; Aspergillus; Aureobasidium; Stachybotrys; Alternaria;
   Cladosporium; Epicoccum; ERMI; Spirometry
ID RELATIVE MOLDINESS INDEX; HYPERSENSITIVITY PNEUMONITIS SECONDARY;
   STACHYBOTRYS-CHARTARUM; ASPERGILLUS-FUMIGATUS; AUREOBASIDIUM-PULLULANS;
   ALTERNARIA-ALTERNATA; AIRWAY INFLAMMATION; FUNGAL DIVERSITY;
   RISK-FACTOR; SENSITIZATION
AB Objective: Some evidences indicate that exposure to molds or their products can be relevant for the loss of asthma control. Thus, we measured the mold burden present inside houses of subjects with asthma, and evaluated its relationship with asthma control.
   Methods: Markers of asthma control in adult patients residing in Mexico City were evaluated through questionnaires and spirometry. Dust was collected from the patients' houses and its fungal content was determined by mold specific quantitative PCR (MSQPCR) for 36 fungal species.
   Results: Forty-two patients with asthma (12 males, 30 females) with a mean age of 45 years (18-76 years) were included in the study. The level of asthma control measured through the Asthma Control Test ranged from 9 to 25 (mean 20.9). The FEV1/FVC ratio fluctuated from 38 to 106 %predicted (mean, 87.4 %predicted). Associations between mold burden and asthma control differed between males and females. Thus, concentrations of some molds, particularly Aspergillus fumigatus, Aureobasidium pullulans, Stachybotrys chartarum, Alternaria alternata, Cladosporium cladosporioides 2, Cladosporium herbarum, and Epicoccum nigrum, were negatively associated with parameters of asthma control in male subjects, but not in female patients.
   Conclusion: Our results showed that potential indoor exposure to some molds is associated with less asthma control in male subjects.
C1 [Segura-Medina, Patricia; Vargas, Mario H.; Manuel Aguilar-Romero, Jose; Luis Arreola-Ramirez, Jose; Luis Miguel-Reyes, Jose; Salas-Hernandez, Jorge] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Calzada de Tlalpan 4502, Mexico City 14080, DF, Mexico.
RP Vargas, MH (reprint author), Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Calzada de Tlalpan 4502, Mexico City 14080, DF, Mexico.
EM mhvargasb@yahoo.com.mx
RI Segura-Medina, Patricia/O-5460-2016
OI Segura-Medina, Patricia/0000-0002-5562-1715; Vargas, Mario
   H./0000-0002-8420-980X
CR Agarwal R, 2011, MYCOSES, V54, pE531, DOI 10.1111/j.1439-0507.2010.01971.x
   AHMED SA, 1990, BAILLIERE CLIN RHEUM, V4, P13, DOI 10.1016/S0950-3579(05)80241-9
   [Anonymous], 2015, GLOBAL INITIATIVE AS
   Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056
   Basu T, 2018, J ALLERGY CLIN IMMUN, V141, P423, DOI 10.1016/j.jaci.2017.07.034
   Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x
   Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027
   Bousquet PJ, 2007, CLIN EXP ALLERGY, V37, P780, DOI 10.1111/j.1365-2222.2007.02714.x
   Breitenbach M, 2008, INT ARCH ALLERGY IMM, V145, P58, DOI 10.1159/000107578
   Brodska P, 2014, DERMATITIS, V25, P120, DOI 10.1097/DER.0000000000000040
   BUNDGAARD A, 1986, EUR J RESPIR DIS, V68, P37
   Carr TF, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0131-2
   Chen JC, 2011, J BIOL CHEM, V286, P26667, DOI 10.1074/jbc.M110.193987
   Chung YJ, 2010, INHAL TOXICOL, V22, P460, DOI 10.3109/08958370903380712
   Dannemiller KC, 2014, INDOOR AIR, V24, P236, DOI 10.1111/ina.12072
   Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705
   DIXIT AB, 1992, J ALLERGY CLIN IMMUN, V90, P11, DOI 10.1016/S0091-6749(06)80006-0
   Engelhart S, 2009, INT J HYG ENVIR HEAL, V212, P18, DOI 10.1016/j.ijheh.2008.01.001
   Farrant J, 2016, J ASTHMA, V53, P732, DOI 10.3109/02770903.2016.1154073
   Gabriel MF, 2016, ENVIRON INT, V89-90, P71, DOI 10.1016/j.envint.2016.01.003
   Greenberger PA, 2014, J ALLER CL IMM-PRACT, V2, P703, DOI 10.1016/j.jaip.2014.08.007
   Hair J.F., 1998, MULTIVARIATE DATA AN
   Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031
   Harley KG, 2009, THORAX, V64, P353, DOI 10.1136/thx.2007.090241
   Haugland RA, 2004, SYST APPL MICROBIOL, V27, P198, DOI 10.1078/072320204322881826
   Heinzerling LM, 2009, ALLERGY, V64, P1498, DOI 10.1111/j.1398-9995.2009.02093.x
   Hogan MB, 1996, CHEST, V110, P854, DOI 10.1378/chest.110.3.854
   Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003
   Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x
   Klein SL, 2010, SEX HORMONES AND IMMUNITY TO INFECTION, P93, DOI 10.1007/978-3-642-02155-8_4
   Klein SL, 2004, PARASITE IMMUNOL, V26, P247, DOI 10.1111/j.0141-9838.2004.00710.x
   Korpi A, 2002, INHAL TOXICOL, V14, P521, DOI 10.1080/089583701753678607
   Leino MS, 2006, AM J RESP CRIT CARE, V173, P512, DOI 10.1164/rccm.200503-466OC
   McSharry C, 2015, CLIN EXP ALLERGY, V45, P902, DOI 10.1111/cea.12482
   Meng J, 2012, CLIN EXP ALLERGY, V42, P1448, DOI 10.1111/j.1365-2222.2012.04001.x
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2
   Niedoszytko M, 2007, ANN ALLERG ASTHMA IM, V98, P153, DOI 10.1016/S1081-1206(10)60688-6
   Noble JA, 1997, J MED VET MYCOL, V35, P405
   Norbaeck D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088303
   O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4
   Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022
   Perez-Padilla R, 2007, ARCH BRONCONEUMOL, V43, P530, DOI 10.1157/13110877
   Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018
   Rettew JA, 2010, SEX HORMONES AND IMMUNITY TO INFECTION, P123, DOI 10.1007/978-3-642-02155-8_5
   Rodriguez-Goncer I, 2017, MED MYCOL CASE REP, V16, P31, DOI 10.1016/j.mmcr.2017.04.005
   Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002
   Tanaka A, 2016, ANN ALLERG ASTHMA IM, V117, P163, DOI 10.1016/j.anai.2016.06.001
   Temprano J, 2007, ANN ALLERG ASTHMA IM, V99, P562, DOI 10.1016/S1081-1206(10)60387-0
   Tham R, 2017, ENVIRON RES, V154, P42, DOI 10.1016/j.envres.2016.12.016
   Vesper S, 2007, J OCCUP ENVIRON MED, V49, P829, DOI 10.1097/JOM.0b013e3181255e98
   Vesper S, 2015, PEDIAT ALLERG IMM-UK, V26, P49, DOI 10.1111/pai.12324
   Viana ME, 2002, TOXICOL SCI, V70, P98, DOI 10.1093/toxsci/70.1.98
   Weber RW, 2012, ANN ALLERG ASTHMA IM, V108, pA9, DOI 10.1016/j.anai.2012.04.018
   WHO Regional Office for Europe, 2009, WHO GUID IND AIR QUA
   Williams PB, 2016, J ALLER CL IMM-PRACT, V4, P386, DOI 10.1016/j.jaip.2015.11.016
   Wuthrich B, 1996, INT ARCH ALLERGY IMM, V111, P396, DOI 10.1159/000237398
   Yike I, 2004, ADV APPL MICROBIOL, V55, P241, DOI 10.1016/S0065-2164(04)55009-8
   Zhang ZH, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0667-9
   Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411
NR 61
TC 0
Z9 0
U1 1
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 74
EP 80
DI 10.1016/j.rmed.2019.02.014
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700011
PM 30961954
DA 2020-05-18
ER

PT J
AU Brendish, NJ
   Malachira, AK
   Beard, KR
   Armstrong, L
   Lillie, PJ
   Clark, TW
AF Brendish, Nathan J.
   Malachira, Ahalya K.
   Beard, Kate R.
   Armstrong, Lawrence
   Lillie, Patrick J.
   Clark, Tristan W.
TI Hospitalised adults with pneumonia are frequently misclassified as
   another diagnosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pneumonia; Diagnosis
ID COMMUNITY-ACQUIRED PNEUMONIA
AB Using data from a large randomised controlled trial of adults hospitalised with acute respiratory illness, we examined the reliability of pneumonia diagnosis on discharge documentation. 50 (28.2%) of 177 patients with a pneumonia diagnosis had no radiological evidence of pneumonia. 67 (34.9%) of 192 patients with clinico-radiological evidence of pneumonia did not have a diagnosis of pneumonia listed; 'COPD exacerbation' or 'lower respiratory tract infection' was often listed instead. These patients more frequently had a respiratory comorbidity and lower oxygen saturations, CRP and temperature at presentation. Pneumonia diagnoses misclassification on discharge documentation may have clinical, financial, and research data implications.
C1 [Brendish, Nathan J.; Beard, Kate R.; Clark, Tristan W.] Univ Southampton, Acad Unit Clin & Expt Sci, Southampton, Hants, England.
   [Brendish, Nathan J.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil, Tremona Rd, Southampton, Hants, England.
   [Malachira, Ahalya K.; Armstrong, Lawrence; Lillie, Patrick J.; Clark, Tristan W.] Univ Hosp Southampton NHS Fdn Trust, Dept Infect, Southampton, Hants, England.
   [Lillie, Patrick J.] Hull & East Yorkshire Hosp NHS Trust, Dept Infect Dis, Kingston Upon Hull, N Humberside, England.
   [Clark, Tristan W.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Clark, Tristan W.] NIHR Postdoctoral Fellowship Programme, Southampton, Hants, England.
RP Brendish, NJ (reprint author), Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil, Tremona Rd, Southampton, Hants, England.
EM Nathan.Brendish@uhs.nhs.uk
OI Lillie, Patrick/0000-0002-4811-4774
FU University of Southampton
FX University of Southampton.
CR Brendish NJ, 2017, LANCET RESP MED, V5, P401, DOI [10.1016/S2213-2600(17)30120-0, 10.1016/s2213-2600(17)30120-0]
   Brendish NJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2219-x
   Claessens YE, 2015, AM J RESP CRIT CARE, V192, P974, DOI 10.1164/rccm.201501-0017OC
   Clark TW, 2014, J INFECTION, V69, P507, DOI 10.1016/j.jinf.2014.07.023
   Daniel P, 2017, THORAX, V72, P376, DOI 10.1136/thoraxjnl-2016-209405
   Le Bel J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1083-6
   Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   van De Garde EMW, 2007, J CLIN EPIDEMIOL, V60, P834, DOI 10.1016/j.jclinepi.2006.10.018
   Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502
   Wilcox CR, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00703-2017
NR 11
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 81
EP 84
DI 10.1016/j.rmed.2019.02.013
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700012
PM 30961956
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Wang, MM
   Liu, MC
   Wang, CR
   Xiao, Y
   An, T
   Zou, MJ
   Cheng, G
AF Wang, Mingming
   Liu, Meicen
   Wang, Cairu
   Xiao, Yue
   An, Tong
   Zou, Meijuan
   Cheng, Gang
TI Association between vitamin D status and asthma control: A meta-analysis
   of randomized trials
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Asthma; Vitamin D; Treatment; Meta-analysis; RCTs
ID D SUPPLEMENTATION; D DEFICIENCY; 25-HYDROXYVITAMIN D; CHILDHOOD ASTHMA;
   CHILDREN; ADULTS; INFLAMMATION; THERAPY
AB Background: There is a controversy in terms of the efficacy of vitamin D supplementation in improving asthma symptom control. Moreover, whether there is a difference in the treatment effect with respect to baseline vitamin D status remains unknown. This meta-analysis was to assess the correlations of vitamin D status with asthma-related respiratory outcomes.
   Methods: PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials of vitamin D supplementation in patients with asthma. Primary outcomes were the rate of asthma exacerbation and predicted percentage of forced expiratory volume in first second (FEV1%). Secondary outcomes were asthma control test (ACT) scores, fractional exhaled nitric oxide (FeNO), interleukin-10 (IL-10) and adverse events.
   Results: A total of 14 randomized controlled trials (1421 participants) fulfilled the inclusion. Vitamin D supplementation was associated with a significant reduction in the rate of asthma exacerbation by 27% (RR: 0.73 95%Cl (0.58-0.92)). In subgroup analysis, the protective effect of exacerbation was restricted in patients with vitamin D insufficiency (vitamin D < 30 ng/ml) (RR: 0.76 95%Cl (0.61-0.95)). An improvement of FEV1% was demonstrated in patients with vitamin D insufficiency and air limitation (FEV1% < 80%) (MD: 8.3 95%Cl (5.95-10.64). No significant difference was observed in ACT scores, FeNO, IL-10 and adverse events.
   Conclusions: Vitamin D supplementation reduced the rate of asthma exacerbation, especially in patients with vitamin D insufficiency. Additionally, the benefit of vitamin D had a positive effect on pulmonary function in patients with air limitation and vitamin D insufficiency.
C1 [Wang, Mingming; Wang, Cairu; Xiao, Yue; An, Tong] Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceutis, Shenyang 110016, Liaoning, Peoples R China.
   [Liu, Meicen] Shenyang Mil Area, Gen Hosp, Dept Resp, Shenyang 110016, Liaoning, Peoples R China.
   [Zou, Meijuan; Cheng, Gang] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China.
RP Cheng, G (reprint author), Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China.
EM chenggang63@hotmail.com
CR Abbas R. S., 2016, INT J PHARM PHARM SC, V9, P139, DOI [10.22159/ijpps.2017v9i1.15487, DOI 10.22159/IJPPS.2017V9I1.15487]
   Ali AM, 2017, ANN ALLERG ASTHMA IM, V118, P557, DOI 10.1016/j.anai.2017.02.014
   Ali NS, 2017, CUREUS, V9, DOI 10.7759/cureus.1288
   [Anonymous], 2017, J POSTGRAD MED I, V31, P310
   Arshi S, 2014, ANN ALLERG ASTHMA IM, V113, P404, DOI 10.1016/j.anai.2014.07.005
   Babar MZM, 2017, PAK J MED SCI, V33, P1144, DOI 10.12669/pjms.335.12990
   Bar Yoseph R, 2015, PEDIATR PULM, V50, P747, DOI 10.1002/ppul.23076
   Baris S, 2014, ALLERGY, V69, P246, DOI 10.1111/all.12278
   Brown SD, 2012, DERM-ENDOCRINOL, V4, P137, DOI 10.4161/derm.20434
   Brumpton B, 2018, RESP MED, V136, P65, DOI 10.1016/j.rmed.2018.01.017
   Cassim R, 2015, ALLERGY, V70, P339, DOI 10.1111/all.12583
   Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052
   de Groot JC, 2015, J ALLERGY CLIN IMMUN, V135, P670, DOI 10.1016/j.jaci.2014.11.033
   Fares Munes M, 2015, BMC Res Notes, V8, P23, DOI 10.1186/s13104-014-0961-3
   Global Initiative for Asthma (GINA), 2018, GLOB STRAT ASTHM MAN
   Hall SC, 2017, CLIN THER, V39, P917, DOI 10.1016/j.clinthera.2017.04.002
   Han YY, 2017, J ALLER CL IMM-PRACT, V5, P790, DOI 10.1016/j.jaip.2016.10.013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Janeva-Jovanovska E., 2017, OPEN ACCESS MACED J, V5, P899, DOI [10.3889/oamjms.2017.190, DOI 10.3889/OAMJMS.2017.190]
   Jensen ME, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1483-1
   Jolliffe DA, 2018, J STEROID BIOCHEM, V175, P88, DOI 10.1016/j.jsbmb.2016.11.004
   Jolliffe DA, 2017, LANCET RESP MED, V5, P881, DOI [10.1016/s2213-2600(17)30306-5, 10.1016/S2213-2600(17)30306-5]
   Kang QH, 2018, EXP THER MED, V15, P727, DOI 10.3892/etm.2017.5436
   Kerley CP, 2016, PEDIAT ALLERG IMM-UK, V27, P404, DOI 10.1111/pai.12547
   Korn S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-25
   Lewis E, 2012, ANN ALLERG ASTHMA IM, V108, P281, DOI 10.1016/j.anai.2012.01.003
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd
   Luo J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002185
   Majak P, 2009, CLIN EXP ALLERGY, V39, P1830, DOI 10.1111/j.1365-2222.2009.03357.x
   Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016
   Mann EH, 2014, ANN NY ACAD SCI, V1317, P57, DOI 10.1111/nyas.12410
   Martineau AR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011511.pub2
   Martineau AR, 2015, THORAX, V70, P451, DOI 10.1136/thoraxjnl-2014-206449
   Pfeffer PE, 2018, CHEST, V153, P1229, DOI 10.1016/j.chest.2017.09.005
   Pfeffer PE, 2018, EXPERT REV CLIN IMMU, V14, P241, DOI 10.1080/1744666X.2018.1440207
   Pojsupap S, 2015, J ASTHMA, V52, P382, DOI 10.3109/02770903.2014.980509
   Rajanandh MG, 2015, J PHARMACOL PHARMACO, V6, P142, DOI 10.4103/0976-500X.162022
   Riverin BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136841
   Schou AJ, 2003, PEDIATR PULM, V36, P399, DOI 10.1002/ppul.10379
   Searing DA, 2010, IMMUNOL ALLERGY CLIN, V30, P397, DOI 10.1016/j.iac.2010.05.005
   Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094
   WORTH H, 1994, AM J RESP CRIT CARE, V150, P394, DOI 10.1164/ajrccm.150.2.8049820
   Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759
NR 45
TC 5
Z9 5
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 85
EP 94
DI 10.1016/j.rmed.2019.02.016
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700013
PM 30961957
DA 2020-05-18
ER

PT J
AU Zampogna, E
   Spanevello, A
   Lucioni, AM
   Facchetti, C
   Sotgiu, G
   Saderi, L
   Ambrosino, N
   Visca, D
AF Zampogna, Elisabetta
   Spanevello, Antonio
   Lucioni, Anna Maria
   Facchetti, Cristina
   Sotgiu, Giovanni
   Saderi, Laura
   Ambrosino, Nicolino
   Visca, Dina
TI Adherence to Continuous Positive Airway Pressure in patients with
   Obstructive Sleep Apnoea. A ten year real life study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE OSA; CPAP; Adherence; Epworth sleepiness scale; Rehabilitation;
   Education
ID LONG-TERM COMPLIANCE; CPAP ADHERENCE; APNEA; PREDICTORS; THERAPY;
   TITRATION; MODERATE; WEIGHT; OSA
AB Objective: To assess the predictive factors at 12 month and 10 year adherence to Continuous Positive Airway Pressure (CPAP) in patients with Obstructive Sleep Apnoea (OSA).
   Methods: Retrospective data analysis of patients starting CPAP between 2006 and 2009. After 12 months (T1) from start and during a 10 year follow up the following data were recorded: Body Mass Index (BMI), Time of night use, Epworth Sleepiness Scale (ESS) score.
   Results: Out of 315 patients, 147 fulfilled inclusion criteria and were evaluated. According to CPAP nighttime use during the first year, patients were divided into two groups: those using the device less < 4.5 h (Poor Adherence (PA): 61 patients), and those using >= 4.5 h: (Good Adherence (GA): 86 patients). Patients of PA group were significantly younger, had greater BMI and required more unscheduled visits during the first year. After 12 months, there were 11 (7.5%) dropouts, all in PA group. Patients using the nasal mask showed a greater prevalence among GA as compared to those using the oro-nasal mask (76.5% vs 57.8% respectively, p = 0.04). After 10 years 83 out of 147 (56.4%) patients were still under CPAP, 51 (59.3% of GA) and 32 (52.4% of PA group) respectively. Dropouts were significantly more frequent during the first 5 years (p = 0.04).
   Conclusion: Ten years after prescription the majority of patients with OSA undergoing periodical controls, still perform CPAP independent of their adherence to therapy after one year of use. Use of nasal mask may be associate to better adherence.
C1 [Zampogna, Elisabetta; Spanevello, Antonio; Lucioni, Anna Maria; Facchetti, Cristina; Visca, Dina] UO Pneumol Riabilitat Tradate, Ist Clin Sci Maugeri IRCCS, Via Roncaccio 16, Tradate, VA, Italy.
   [Spanevello, Antonio] Univ Insubria, Malattie Apparato Resp, Dipartimento Med & Chirurg, Varese, Italy.
   [Sotgiu, Giovanni; Saderi, Laura] Univ Sassari, Dept Biomed Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
   [Ambrosino, Nicolino] Ist Clin Sci Maugeri IRCCS, Ist Sci Montescano, Via Montescano, Pavia, Italy.
RP Zampogna, E (reprint author), UO Pneumol Riabilitat IRCCS Tradate, Ist Clin Sci Maugeri, Via Roncaccio 16, I-21049 Tradate, Italy.
EM elisabetta.zampogna@icsmaugeri.it; antonio.spanevello@icsmaugeri.it;
   annamaria.lucioni@icsmaugeri.it; cristina.facchetti@icsmaugeri.it;
   gsotgiu@uniss.it; lsaderi@uniss.it; nico.ambrosino@gmail.com;
   dina.visca@icsmaugeri.it
RI Visca, Dina/AAC-3109-2020; Ambrosino, Nicolino/AAC-2005-2020;
   SPANEVELLO, ANTONIO/AAB-9503-2020; Zampogna, Elisabetta/AAB-8847-2020;
   Sotgiu, Giovanni/N-1032-2017
OI Ambrosino, Nicolino/0000-0002-5331-1393; SPANEVELLO,
   ANTONIO/0000-0002-3595-9903; Zampogna, Elisabetta/0000-0003-0927-1694;
   Sotgiu, Giovanni/0000-0002-1600-4474; Saderi, Laura/0000-0002-5131-9367
CR Aloia MS, 2005, J CLIN SLEEP MED, V1, P346
   Balakrishnan K, 2016, J CLIN SLEEP MED, V12, P849, DOI 10.5664/jcsm.5884
   Billings ME, 2011, SLEEP, V34, P1653, DOI 10.5665/sleep.1428
   Bouloukaki I, 2014, EUR RESPIR J, V44, P1262, DOI 10.1183/09031936.00021314
   Brown DL, 2011, J CLIN SLEEP MED, V7, P103
   Budhiraja R, 2007, SLEEP, V30, P320
   Campos-Rodriguez F, 2016, SLEEP MED, V17, P1, DOI 10.1016/j.sleep.2015.07.038
   Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304
   Chai-Coetzer CL, 2013, SLEEP, V36, P1929, DOI 10.5665/sleep.3232
   Chen YF, 2015, KAOHSIUNG J MED SCI, V31, P83, DOI 10.1016/j.kjms.2014.11.004
   Darien I. L., 2014, INT CLASSIFICATION S, DOI [10.1378/chest.14-0970, DOI 10.1378/CHEST.14-0970]
   Drager LF, 2015, THORAX, V70, P258, DOI 10.1136/thoraxjnl-2014-205361
   Feldstein CA, 2016, CLIN EXP HYPERTENS, V38, P337, DOI 10.3109/10641963.2016.1148156
   Ghosh D, 2013, RESP MED, V107, P936, DOI 10.1016/j.rmed.2012.10.008
   Goodwin S, 2002, CLIN NURSE SPEC, V16, P164
   Jacobsen AR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189614
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kohler M, 2010, THORAX, V65, P829, DOI 10.1136/thx.2010.135848
   Krieger J, 1996, SLEEP, V19, pS136, DOI 10.1093/sleep/19.suppl_9.S136
   Kushida CA, 2008, J CLIN SLEEP MED, V4, P157
   Law M, 2014, J CLIN SLEEP MED, V10, P163, DOI 10.5664/jcsm.3444
   Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418
   May AM, 2018, CHEST, V154, P567, DOI 10.1016/j.chest.2018.04.010
   May AM, 2014, SEMIN RESP CRIT CARE, V35, P531, DOI 10.1055/s-0034-1390023
   McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111
   Myllyla BM, 2016, J CLIN SLEEP MED, V12, P519, DOI 10.5664/jcsm.5680
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Poulet C, 2009, SLEEP MED, V10, P993, DOI 10.1016/j.sleep.2009.01.007
   Riachy M, 2017, SLEEP BREATH, V21, P295, DOI 10.1007/s11325-016-1408-y
   Sawyer AM, 2011, SLEEP MED REV, V15, P343, DOI 10.1016/j.smrv.2011.01.003
   Schreiber A, 2018, COPD, V15, P265, DOI 10.1080/15412555.2018.1500533
   Shapiro GK, 2010, SLEEP BREATH, V14, P323, DOI 10.1007/s11325-010-0391-y
   Sin DD, 2002, CHEST, V121, P430, DOI 10.1378/chest.121.2.430
   Truong KK, 2018, J CLIN SLEEP MED, V14, P183, DOI 10.5664/jcsm.6928
   Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG
   Woehrle H, 2011, SLEEP MED, V12, P1034, DOI 10.1016/j.sleep.2011.05.008
   Wohlgemuth WK, 2015, SLEEP MED, V16, P336, DOI 10.1016/j.sleep.2014.08.013
NR 38
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 95
EP 100
DI 10.1016/j.rmed.2019.02.017
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700014
PM 30961958
DA 2020-05-18
ER

PT J
AU Bellanger, AP
   Reboux, G
   Rouzet, A
   Barrera, C
   Rocchi, S
   Scherer, E
   Millon, L
AF Bellanger, Anne-Pauline
   Reboux, Gabriel
   Rouzet, Adeline
   Barrera, Coralie
   Rocchi, Steffi
   Scherer, Emeline
   Millon, Laurence
TI Hypersensitivity pneumonitis: A new strategy for serodiagnosis and
   environmental surveys
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Hypersensitivity pneumonitis; Serodiagnosis; Recombinant antigen;
   Etiologic agents; Environmental survey
ID FARMERS LUNG-DISEASE; BIRD FANCIERS LUNG; PRECIPITATING ANTIBODIES;
   IMMUNOREACTIVE PROTEINS; FUNGAL CONTAMINATION; METALWORKING FLUIDS;
   ANTIGENS; EXPOSURE; DIAGNOSIS; PIGEON
AB We propose a strategy for serodiagnosis of hypersensitivity pneumonitis (HP): 1) question patients about their private or occupational activity, or visit him on site; 2) select panels of six somatic specific antigens appropriate for each type of exposure; 3) and use ELISA to test concomitantly two recombinant antigens highly specific to Farmer's lung, Metalworking-fluid HP, and for Bird fancier's lung. The serodiagnosis provides an immunological argument that may complete radiological, functional lung exploration and clinical features; 4) If the serodiagnosis is negative but the suspicion of HP is strong, a microbial analysis of the patient's specific exposure is conducted; 5) "A la carte" antigens are produced from the microorganisms isolated in the patient's environment sample and tested; 6) Finally, the patient may be asked to undergo a specific inhalation challenge with the offending antigens in a safety cabin, or to avoid his usual environment for a few days.
C1 [Bellanger, Anne-Pauline; Reboux, Gabriel; Rouzet, Adeline; Barrera, Coralie; Rocchi, Steffi; Scherer, Emeline; Millon, Laurence] Univ Bourgogne Franche Comte, Univ Hosp Besancon, Dept Parasitol Mycol, UMR CNRS 6249,Chronoenvironm Res Team, Besancon, France.
RP Reboux, G (reprint author), Jean Minjoz Univ Hosp, 2 Bd Fleming, F-25030 Besancon, France.
EM gabriel.reboux@univ-fcomte.fr
RI Millon, laurence/AAK-5980-2020
OI Rocchi, steffi/0000-0001-9262-1127
CR Ameille J, 2000, REV MAL RESPIR, V17, P915
   AZNAR C, 1988, J CLIN MICROBIOL, V26, P443, DOI 10.1128/JCM.26.3.443-447.1988
   Barrera C, 2014, PROTEOM CLIN APPL, V8, P971, DOI 10.1002/prca.201400024
   Barrera C, 2014, AM J IND MED, V57, P195, DOI 10.1002/ajim.22270
   Bellanger AP, 2009, LETT APPL MICROBIOL, V49, P260, DOI 10.1111/j.1472-765X.2009.02653.x
   Bene M., 1997, FUNCTIONAL EXPLORATI
   BERNSTEIN DI, 1995, CHEST, V108, P636, DOI 10.1378/chest.108.3.636
   Burton CM, 2012, ANN OCCUP HYG, V56, P374, DOI 10.1093/annhyg/mer121
   Chan AL, 2012, CLIN REV ALLERG IMMU, V43, P69, DOI 10.1007/s12016-011-8282-y
   Cooper CJ, 2014, AM J CASE REP, V15, P155, DOI 10.12659/AJCR.890184
   Cormier Y, 2004, EUR RESPIR J, V23, P523, DOI 10.1183/09031936.04.00021104
   Dalphin JC, 2000, REV MAL RESPIR, V17, P869
   DALPHIN JC, 1994, THORAX, V49, P50, DOI 10.1136/thx.49.1.50
   DECASTRO FR, 1993, CHEST, V103, P1059, DOI 10.1378/chest.103.4.1059
   Faerden K, 2014, INT J OCCUP ENV HEAL, V20, P167, DOI 10.1179/2049396714Y.0000000063
   Fenoglio CM, 2007, EUR RESPIR J, V29, P706, DOI 10.1183/09031936.00001006
   Fink JN, 2005, AM J RESP CRIT CARE, V171, P792, DOI 10.1164/rccm.200409-1205WS
   Girard M, 2009, ALLERGY, V64, P322, DOI 10.1111/j.1398-9995.2009.01949.x
   GRUCHOW HW, 1981, AM REV RESPIR DIS, V124, P411
   Hanak V, 2007, MAYO CLIN PROC, V82, P812, DOI 10.4065/82.7.812
   Heidelberger M, 1935, J EXP MED, V61, P563, DOI 10.1084/jem.61.4.563
   HENDRICK DJ, 1978, BRIT MED J, V2, P81, DOI 10.1136/bmj.2.6130.81
   HOMMA Y, 1986, RESPIRATION, V49, P300, DOI 10.1159/000194895
   Jacobs RL, 2008, J ALLERGY CLIN IMMUN, V122, P428, DOI 10.1016/j.jaci.2008.05.045
   Jargot D, 2013, ENVIRON SCI-PROC IMP, V15, P633, DOI 10.1039/c2em30566f
   KATILA ML, 1986, CLIN ALLERGY, V16, P459, DOI 10.1111/j.1365-2222.1986.tb01981.x
   King J, 2017, THORAX, V72, P380, DOI 10.1136/thoraxjnl-2016-208751
   Lacasse Y, 2003, AM J RESP CRIT CARE, V168, P952, DOI 10.1164/rccm.200301-137OC
   McSharry C, 2000, CLIN EXP ALLERGY, V30, P1221
   Metzger F, 2010, CHEST, V138, P724, DOI 10.1378/chest.09-2991
   Millon L., 2012, HYPERSENSITIVITY PNE, DOI [10.1016/S2211-9698(12)56858-5, DOI 10.1016/S2211-9698(12)56858-5]
   Millon L, 2016, J ALLERGY CLIN IMMUN, V138, P1738, DOI 10.1016/j.jaci.2016.06.037
   Millon L, 2014, CURR PROTEIN PEPT SC, V15, P430, DOI 10.2174/1389203715666140512121733
   Morell F, 2013, LANCET RESP MED, V1, P685, DOI 10.1016/S2213-2600(13)70191-7
   Murat JB, 2012, APPL ENVIRON MICROB, V78, P34, DOI 10.1128/AEM.06230-11
   Nademi Z, 2013, MOL IMMUNOL, V54, P227, DOI 10.1016/j.molimm.2012.12.007
   Nogueira R, 2019, PULMONOLOGY, V25, P97, DOI 10.1016/j.pulmoe.2018.07.003
   Paris C, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0013-3
   Pepys J., 1994, ACI NEWS, V6, P68
   Perez ERF, 2013, CHEST, V144, P1644, DOI 10.1378/chest.12-2685
   Quirce S, 2016, ALLERGY, V71, P765, DOI 10.1111/all.12866
   Ramirez-Venegas A, 1998, AM J RESP CRIT CARE, V158, P862, DOI 10.1164/ajrccm.158.3.9710036
   Reboux G, 2009, INDOOR AIR, V19, P446, DOI 10.1111/j.1600-0668.2009.00598.x
   Reboux G, 2001, AM J RESP CRIT CARE, V163, P1534, DOI 10.1164/ajrccm.163.7.2006077
   Reboux G., 2004, J MYCOL MED, V14, P148
   Reboux G, 2007, J MED MICROBIOL, V56, P1317, DOI 10.1099/jmm.0.46953-0
   RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7
   Rickman OB, 2002, MAYO CLIN PROC, V77, P1233, DOI 10.4065/77.11.1233
   Robbins C A, 2000, Appl Occup Environ Hyg, V15, P773
   Rocchi S, 2017, J MICROBIOL METH, V139, P107, DOI 10.1016/j.mimet.2017.05.014
   Rochat I., 2008, 18 EUR C CLIN MICR I
   ROELANDT M, 1995, ACTA CLIN BELG, V50, P260, DOI 10.1080/17843286.1995.11718459
   Rognon B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160888
   Roussel S, 2005, MYCOPATHOLOGIA, V160, P273, DOI 10.1007/s11046-005-0155-6
   Roussel S, 2004, OCCUP ENVIRON MED, V61
   Roussel S, 2013, ENVIRON INT, V55, P20, DOI 10.1016/j.envint.2013.02.002
   Roussel S, 2011, INT J MED MICROBIOL, V301, P150, DOI 10.1016/j.ijmm.2010.07.002
   Rouzet A, 2018, J INVEST ALLERG CLIN, V28, P182, DOI 10.18176/jiaci.0223
   Rouzet A, 2017, J MED MICROBIOL, V66, P1467, DOI 10.1099/jmm.0.000586
   Rouzet A, 2017, J IMMUNOL METHODS, V450, P58, DOI 10.1016/j.jim.2017.07.012
   Rouzet A, 2014, J TOXICOL ENV HEAL A, V77, P724, DOI 10.1080/15287394.2014.889616
   Ryerson CJ, 2014, CHEST, V145, P723, DOI 10.1378/chest.13-1474
   Saltoun CA, 2000, ANN ALLERG ASTHMA IM, V84, P84, DOI 10.1016/S1081-1206(10)62745-7
   Scherer E, 2014, SCI TOTAL ENVIRON, V466, P716, DOI 10.1016/j.scitotenv.2013.07.054
   Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x
   Selman Moises, 2010, Proc Am Thorac Soc, V7, P229, DOI 10.1513/pats.200906-041AL
   Soumagne T, 2015, REV MAL RESPIR, V32, P275, DOI 10.1016/j.rmr.2014.04.104
   Soumagne T, 2019, SCI TOTAL ENVIRON, V646, P727, DOI 10.1016/j.scitotenv.2018.07.284
   Soumagne T, 2018, EXPERT REV RESP MED, V12, P493, DOI 10.1080/17476348.2018.1473036
   Tao B G, 1988, Biomed Environ Sci, V1, P13
   Tillie-Leblond I, 2011, EUR RESPIR J, V37, P640, DOI 10.1183/09031936.00195009
   Vasakova M, 2017, AM J RESP CRIT CARE, V196, P680, DOI 10.1164/rccm.201611-2201PP
   Viegas C, 2015, ENVIRON MONIT ASSESS, V187, DOI 10.1007/s10661-015-4412-y
   Wethasinghe J, 2015, RESPIROL CASE REP, V3, P19, DOI 10.1002/rcr2.91
   Winck JC, 2004, ALLERGY, V59, P739, DOI 10.1111/j.1398-9995.2004.00472.x
   Xaubet A, 2004, SARCOIDOSIS VASC DIF, V21, P64
NR 76
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 101
EP 106
DI 10.1016/j.rmed.2019.02.019
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700015
PM 30961934
DA 2020-05-18
ER

PT J
AU Wang, SW
   Cui, H
   Zhu, CS
   Wu, R
   Meng, LK
   Yu, QJ
   Huang, XH
   Xiao, MH
   Wang, SY
AF Wang, Shengwei
   Cui, Hao
   Zhu, Changsheng
   Wu, Rong
   Meng, Liukun
   Yu, Qinjun
   Huang, Xiaohong
   Xiao, Minghu
   Wang, Shuiyun
TI Obstructive sleep apnea causes impairment of the carotid artery in
   patients with hypertrophic obstructive cardiomyopathy
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Obstructive sleep apnea; Hypertrophic cardiomyopathy; Carotid
   intima-media thickness; Syncope
ID 2011 ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; INTIMA-MEDIA THICKNESS;
   HIGH PREVALENCE; DIAGNOSIS; RISK; ATHEROSCLEROSIS; SEVERITY; SYNCOPE;
   DISEASE
AB Background: Obstructive sleep apnea (OSA) prevalence is high among patients with hypertrophic cardiomyopathy (HCM). OSA can cause increase in carotid intima-media thickness (CIMT) in the general population. However, whether this phenomenon is applicable to patients with HCM is unclear.
   Methods: A total of 130 consecutive patients with a confirmed diagnosis of hypertrophic obstructive cardiomyopathy (HOCM) at Fuwai Hospital between September 2017 and May 2018 were analyzed.
   Results: 72 patients (55.4%) were diagnosed with OSA. Patients with OSA were older. Compared to those in patients without OSA, the left, right, and mean CIMTs were significantly increased in patients with OSA. In the multiple linear regression model, age (beta = 0.341, p < 0.001), apnea-hypopnea index (AHI) (beta = 0.421, p < 0.001), and fasting glucose level (beta = 0.167, p < 0.03) were independently associated with mean CIMT increase (adjusted R-2 = 0.458, p < 0.001). In the receiver operating characteristic curve analysis, the area under the curve for CIMT was 0.813 (95% CI, 0.717-0.909, p < 0.001) with a sensitivity and specificity of 0.84 and 0.70 for unexplained syncope, respectively. In the multivariate logistic regression model, we found that the mean CIMT (OR = 10.4, 95% CI = 3.16-34.11, p < 0.001), left ventricular ejection fraction (LVEF) (OR = 0.90, 95% CI = 0.83-0.99, p = 0.03), and amaurosis (OR = 5.07, 95% CI = 1.47-17.49, p = 0.01) were independently associated with unexplained syncope occurrence.
   Conclusions: In patients with HOCM, CIMT increased with OSA severity. Age, AHI, and fasting plasma glucose level were independently associated with mean CIMT increase. Moreover, amaurosis, LVEF, and higher mean CIMT were independently associated with unexplained syncope in patients with HOCM.
C1 [Wang, Shengwei; Zhu, Changsheng; Wu, Rong; Meng, Liukun; Yu, Qinjun; Wang, Shuiyun] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Dept Cardiovasc Surg, Beijing, Peoples R China.
   [Wang, Shengwei; Zhu, Changsheng; Wu, Rong; Meng, Liukun; Yu, Qinjun; Huang, Xiaohong; Xiao, Minghu; Wang, Shuiyun] Peking Union Med Coll, Beijing, Peoples R China.
   [Cui, Hao] Mayo Clin, Dept Cardiovasc Surg, Rochester, MN USA.
   [Huang, Xiaohong] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Dept Special Med Treatment Ctr, Beijing, Peoples R China.
   [Xiao, Minghu] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Dept Echocardiog,State Key Lab Cardiovasc Dis, Beijing, Peoples R China.
RP Wang, SY (reprint author), 167 Beilishi Rd, Beijing 100037, Peoples R China.
EM wsymd@sina.com
RI Zhu, CS/P-5359-2019
OI Zhu, CS/0000-0001-5054-491X; Wang, Shuiyun/0000-0003-3928-7945
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570276]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81570276).
CR Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0
   BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386
   Cordina SM, 2009, MINERVA MED, V100, P321
   Drager LF, 2007, AM J RESP CRIT CARE, V176, P706, DOI 10.1164/rccm.200703-500OC
   Ehrhardt J, 2015, CHEST, V147, P1029, DOI 10.1378/chest.14-1655
   Eleid MF, 2009, J AM COLL CARDIOL, V54, P1805, DOI 10.1016/j.jacc.2009.07.030
   Elliott PM, 2014, EUR HEART J, V35, P2733, DOI 10.1093/eurheartj/ehu284
   Eren M, 2004, HEART, V90, P37, DOI 10.1136/heart.90.1.37
   Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667
   Fox N, 2014, LUNG, V192, P297, DOI 10.1007/s00408-014-9556-y
   Gersh BJ, 2011, J AM COLL CARDIOL, V58, pE212, DOI 10.1016/j.jacc.2011.06.011
   Gersh BJ, 2011, J THORAC CARDIOV SUR, V142, pE153, DOI 10.1016/j.jtcvs.2011.10.020
   Gunbatar H, 2014, MED SCI MONITOR, V20, P2199, DOI 10.12659/MSM.891001
   Hui DS, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-22
   Konecny T, 2015, CHEST, V147, P1574, DOI 10.1378/chest.14-1498
   Konecny T, 2010, AM J CARDIOL, V105, P1597, DOI 10.1016/j.amjcard.2010.01.023
   Kvickstrom P, 2016, CLIN OPHTHALMOL, V10, P2165, DOI 10.2147/OPTH.S115656
   Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875
   Monahan K, 2011, CURR OPIN CARDIOL, V26, P541, DOI 10.1097/HCO.0b013e32834b806a
   Nerbass FB, 2013, SLEEP MED REV, V17, P201, DOI 10.1016/j.smrv.2012.06.006
   Pedrosa RP, 2010, CHEST, V137, P1078, DOI 10.1378/chest.09-2335
   PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399
   Salepci B, 2015, SLEEP BREATH, V19, P239, DOI 10.1007/s11325-014-1002-0
   Schaefer CA, 2015, CLIN RES CARDIOL, V104, P719, DOI 10.1007/s00392-015-0834-3
   Sengupta PP, 2009, NAT CLIN PRACT CARD, V6, P14, DOI 10.1038/ncpcardio1401
   Williams L, 2007, EUROPACE, V9, P817, DOI 10.1093/europace/eum093
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
NR 28
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 107
EP 112
DI 10.1016/j.rmed.2019.03.002
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700016
PM 30961935
DA 2020-05-18
ER

PT J
AU Aarab, R
   Vijverberg, SJH
   Prins, M
   Snijder, MB
   van Ree, R
   Fokkens, WJ
   Zwinderman, AH
   Bel, EHD
   van der Zee, AHM
AF Aarab, R.
   Vijverberg, S. J. H.
   Prins, M.
   Snijder, M. B.
   van Ree, R.
   Fokkens, W. J.
   Zwinderman, A. H.
   Bel, E. H. D.
   van der Zee, A. H. Maitland
TI Prevalence of and factors associated with adult-onset asthma in
   different ethnic groups: The HELIUS study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Adult-onset asthma; Epidemiology; Risk factors; Ethnic disparities
ID AGE
AB Little is known about adult-onset asthma in different ethnic groups. The aim of this study was to examine ethnic differences in the prevalence of adult-onset asthma and factors associated with this phenotype.
   Cross-sectional data of 23,356 participants of the HELIUS study were used, including Dutch, South-Asian Surinamese, African Surinamese, Moroccan, Turkish and Ghanaian origin participants. Adult-onset asthma was defined as: self-reported asthma symptoms or start of asthma-medication at age >= 18 years combined with a smoking history < 10 pack years. The prevalence of adult-onset asthma and its association with potential risk factors were assessed by logistic regression analyses.
   The adjusted prevalence of adult-onset asthma was higher in the Turkish, Moroccan and South-Asian Surinamese groups (4.9-6.0%) compared to the Dutch, Ghanaian and African Surinamese origin groups (2.4-2.6%). In addition to ethnicity, age, female sex, BMI, and doctors' diagnosis of nasal allergy/hay fever and chronic sinusitis/polyps were independently associated with adult-onset asthma.
   There are significant differences in the adjusted prevalence of adult-onset asthma among six ethnic groups.
C1 [Aarab, R.; Vijverberg, S. J. H.; Bel, E. H. D.; van der Zee, A. H. Maitland] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, Amsterdam, Netherlands.
   [Prins, M.] Publ Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands.
   [Prins, M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis, Amsterdam, Netherlands.
   [Snijder, M. B.] Amsterdam Publ Hlth Res Inst, Acad Med Ctr, Dept Publ Hlth, Amsterdam, Netherlands.
   [Snijder, M. B.; Zwinderman, A. H.] Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.
   [van Ree, R.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands.
   [van Ree, R.; Fokkens, W. J.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands.
RP Aarab, R (reprint author), Acad Med Ctr, Dept Pulmonol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM r.aarab@olvg.nl
OI Vijverberg, Susanne/0000-0002-4579-4081
FU Dutch Heart FoundationNetherlands Heart Foundation; Netherlands
   Organisation for Health Research and DevelopmentNetherlands Organization
   for Health Research and Development; European Union (FP-7)European Union
   (EU); European Fund for the Integration of non-EU immigrants (EIF)
FX The HELIUS study is conducted by the Academic Medical Center Amsterdam
   and the Public Health Service of Amsterdam. Both organizations provided
   core support for HELIUS. The HELIUS study is also funded by the Dutch
   Heart Foundation, the Netherlands Organisation for Health Research and
   Development, the European Union (FP-7), and the European Fund for the
   Integration of non-EU immigrants (EIF). We gratefully acknowledge the
   AMC Biobank for their support in biobank management and high-quality
   storage of collected samples. We are most grateful to the participants
   of the HELIUS study and the management team, research nurses,
   interviewers, research assistants and other staff who have taken part in
   gathering the data of this study.
CR [Anonymous], 2003, ASTHM COPD RICHTL
   Barr RG, 2016, AM J RESP CRIT CARE, V193, P386, DOI 10.1164/rccm.201506-1211OC
   Cabieses B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105347
   Castro-Giner F, 2009, ENVIRON HEALTH PERSP, V117, P1919, DOI 10.1289/ehp.0900589
   de Nijs SB, 2013, EUR RESPIR REV, V22, P44, DOI 10.1183/09059180.00007112
   Dixon AE, 2016, AM J RESP CELL MOL, V54, P601, DOI 10.1165/rcmb.2016-0017PS
   Ekerljung L, 2010, CLIN RESPIR J, V4, P147, DOI 10.1111/j.1752-699X.2009.00164.x
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Harel O, 2018, AM J EPIDEMIOL, V187, P576, DOI 10.1093/aje/kwx349
   Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390
   Ilmarinen P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/514868
   Jacquemin B, 2012, SEMIN RESP CRIT CARE, V33, P606, DOI 10.1055/s-0032-1325191
   Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x
   Le Souef PN, 2000, LANCET, V356, P242
   Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Rantala A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027912
   Rose D, 2006, AM J PUBLIC HEALTH, V96, P880, DOI 10.2105/AJPH.2004.050039
   Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4
   Silverberg JI, 2014, ANN ALLERG ASTHMA IM, V113, P410, DOI 10.1016/j.anai.2014.07.006
   Snijder MB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017873
   Sood Akshay, 2013, Ann Am Thorac Soc, V10, P188, DOI 10.1513/AnnalsATS.201212-115OC
   Stronks K, 2009, ETHNIC HEALTH, V14, P255, DOI 10.1080/13557850802509206
   Tam A, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-24
   Tarlo SM, 2014, NEW ENGL J MED, V370, P640, DOI 10.1056/NEJMra1301758
   Tetrault JM, 2007, ARCH INTERN MED, V167, P221, DOI 10.1001/archinte.167.3.221
   To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204
   TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600
   Triebner K, 2016, J ALLERGY CLIN IMMUN, V137, P50, DOI 10.1016/j.jaci.2015.08.019
   Wang LY, 2016, ANN ALLERG ASTHMA IM, V117, P50, DOI 10.1016/j.anai.2016.05.005
   Yatagai Y, 2016, J ALLERGY CLIN IMMUN, V138, P281, DOI 10.1016/j.jaci.2015.11.023
NR 31
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 113
EP 119
DI 10.1016/j.rmed.2019.02.018
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700017
PM 30961936
DA 2020-05-18
ER

PT J
AU Wuyts, W
   Antin-Ozerkis, D
   Huggins, JT
   LaCamera, PP
   Spagnolo, P
   Vasakova, M
   Wijsenbeek, MS
   Polman, B
   Kirchgaessler, KU
   Scholand, MB
AF Wuyts, Wim
   Antin-Ozerkis, Danielle
   Huggins, J. Terrill
   LaCamera, Peter P.
   Spagnolo, Paolo
   Vasakova, Martina
   Wijsenbeek, Marlies S.
   Polman, Boris
   Kirchgaessler, Klaus-Uwe
   Scholand, Mary Beth
TI Serious adverse events in patients with idiopathic pulmonary fibrosis in
   the placebo arms of 6 clinical trials
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Interstitial lung disease; Safety
ID ACUTE EXACERBATION; DIAGNOSIS; PIRFENIDONE; CAPACITY; DECLINE; CANCER
AB Background: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by irreversible loss of lung function and an unpredictable course of disease progression.
   Methods: The safety data for patients with IPF who received placebo in 6 clinical trials were pooled to examine the categories and frequencies of serious adverse events (SAEs) in this population.
   Results: In 1082 patients with IPF who received placebo, 673 SAEs were reported. Of these, 93 SAEs resulted in death (8.6% of patients). Respiratory-related conditions were the most frequently reported SAE (225 events, 16.33 per 100 patient-exposure years [PEY]), followed by infections and infestations (136 events, 9.87 per 100 PEY) and cardiac disorders (79 events, 5.73 per 100 PEY); these categories also had the most fatal outcomes (60, 10, and 10 deaths, respectively). The most frequently reported fatal respiratory-related SAEs were IPF and respiratory failure (38 and 11 patients, respectively), and the most frequently reported fatal infections and infestations and cardiac disorders were pneumonia (5 patients) and myocardial infarction (3 patients), respectively.
   Conclusions: This pooled analysis has value as a comparator for safety in future studies of IPF and provides insights in the natural evolution of both IPF and common comorbidities.
C1 [Wuyts, Wim] Univ Hosp Leuven, Leuven, Belgium.
   [Antin-Ozerkis, Danielle] Yale Sch Med, New Haven, CT USA.
   [Huggins, J. Terrill] Med Univ South Carolina, Charleston, SC 29425 USA.
   [LaCamera, Peter P.] St Elizabeths Med Ctr, Boston, MA USA.
   [Spagnolo, Paolo] Univ Hosp Padua, Resp Dis Unit, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
   [Vasakova, Martina] Charles Univ Prague, Med Fac 1, Prague, Czech Republic.
   [Vasakova, Martina] Thomayer Hosp, Prague, Czech Republic.
   [Wijsenbeek, Marlies S.] Univ Med Ctr, Erasmus MC, Dept Resp Med, Rotterdam, Netherlands.
   [Polman, Boris] Genentech Inc, San Francisco, CA 94080 USA.
   [Kirchgaessler, Klaus-Uwe] F Hoffmann La Roche Ltd, Basel, Switzerland.
   [Scholand, Mary Beth] Univ Utah, Salt Lake City, UT USA.
RP Wuyts, W (reprint author), Univ Hosp Leuven, Dept Resp Med, Unit Interstitial Lung Dis, Herestr 49, B-3000 Leuven, Belgium.
EM wim.wuyts@uzleuven.be
OI Wijsenbeek, Marlies/0000-0002-4527-6962
FU InterMune, Inc.; F. Hoffmann-La Roche Ltd.Hoffmann-La Roche; Genentech,
   Inc.Roche HoldingGenentech
FX InterMune, Inc., sponsored the GIPF-001, GIPF-002, and INSPIRE trials.
   F. Hoffmann-La Roche Ltd. sponsored the ASCEND and CAPACITY trials. F.
   Hoffmann-La Roche Ltd. and Genentech, Inc., provided funding and support
   for the analysis presented.
CR Fernandez-Perez ER, 2010, CHEST, V137, P242, DOI [10.1378/chest.09-1871, 10.1378/chest.09-1002]
   GLASSBERG M, 2016, AM J RESP CRIT CARE, V193
   Huie TJ, 2010, RESPIROLOGY, V15, P909, DOI 10.1111/j.1440-1843.2010.01774.x
   Kim Dong Soon, 2006, Proc Am Thorac Soc, V3, P285, DOI 10.1513/pats.200601-005TK
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1
   Kreuter M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151425
   Le Jeune I, 2007, RESP MED, V101, P2534, DOI 10.1016/j.rmed.2007.07.012
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   Lynch DA, 2018, LANCET RESP MED, V6, P138, DOI 10.1016/S2213-2600(17)30433-2
   Nathan SD, 2010, RESP MED, V104, P1035, DOI 10.1016/j.rmed.2010.02.008
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Oda K, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0109-y
   Oldham JM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00123
   Ozawa Y, 2009, RESPIROLOGY, V14, P723, DOI 10.1111/j.1440-1843.2009.01547.x
   Paterniti MO, 2017, ANN AM THORAC SOC, V14, P1395, DOI 10.1513/AnnalsATS.201606-458OC
   Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2015, EUR RESPIR J, V46, P1113, DOI 10.1183/13993003.02316-2014
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Sgalla G, 2016, RESPIROLOGY, V21, P427, DOI 10.1111/resp.12683
   Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709
   Strieter RM, 2004, AM J RESP CRIT CARE, V170, P133, DOI 10.1164/rccm.200312-1670OC
NR 24
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 120
EP 125
DI 10.1016/j.rmed.2019.02.021
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700018
PM 30961937
OA Other Gold, Green Published
DA 2020-05-18
ER

PT J
AU Awerbach, JD
   Stackhouse, KA
   Lee, J
   Dahhan, T
   Parikh, KS
   Krasuski, RA
AF Awerbach, Jordan D.
   Stackhouse, Kathryn A.
   Lee, Joanne
   Dahhan, Talal
   Parikh, Kishan S.
   Krasuski, Richard A.
TI Outcomes of lung disease-associated pulmonary hypertension and impact of
   elevated pulmonary vascular resistance
SO RESPIRATORY MEDICINE
LA English
DT Article; Proceedings Paper
CT 67th Annual Scientific Sessions and Expo of the
   American-College-of-Cardiology (ACC)
CY MAR 10-12, 2018
CL Orlando, FL
SP Amer Coll Cardiol
ID INHALED TREPROSTINIL; PATHOPHYSIOLOGY; DIAGNOSIS; FIBROSIS
AB Background: The clinical characteristics, hemodynamic changes and outcomes of lung disease-associated pulmonary hypertension (LD-PH) are poorly defined.
   Methods: A prospective cohort of PH patients undergoing initial hemodynamic assessment was collected, from which 51 patients with LD-PH were identified. Baseline characteristics and long-term survival were compared with 83 patients with idiopathic pulmonary arterial hypertension (iPAH).
   Results: Mean age (+/- standard deviation) of LD-PH patients was 64 +/- 10 years, 30% were female and 78% were New York Heart Association class III-IV. The LD-PH group was older than the iPAH group (64 +/- 10 vs 56 +/- 18 years, respectively, P = 0.003) with a lower percentage of women (30% vs 70%, P = 0.007). LD-PH patients had smaller right ventricular sizes (P = 0.02) and less tricuspid regurgitation (P = 0.03) by echocardiogram, and lower mean pulmonary arterial pressures (mPAP) (P = 0.01) and pulmonary vascular resistance (PVR) (P = 0.001) at catheterization. Despite these findings, mortality was equally high in both groups (P = 0.16). 5-year survival was lower in patients with interstitial lung disease compared to those with obstructive pulmonary disease (P = 0.05). Among the LD-PH population, those with mild to moderately elevated mPAP and those with PVR < 7 Wood units demonstrated significantly improved survival (P = 0.04 and P = 0.001, respectively). Vasoreactivity was not associated with improved survival (P = 0.64). A PVR >= 7 Wood units was associated with increased risk of mortality (hazard ratio (95% confidence interval), 3.59 (1.27-10.19), P = 0.02).
   Conclusions: Despite less severe PH and less right heart sequelae, LD-PH has an equally poor clinical outcome when compared to iPAH. A PVR >= 7 Wood units in LD-PH patients was associated with 3-fold higher mortality.
C1 [Awerbach, Jordan D.; Parikh, Kishan S.; Krasuski, Richard A.] Duke Univ, Med Ctr, Div Cardiovasc Med, Durham, NC USA.
   [Stackhouse, Kathryn A.] Best Israel Deaconess Med Ctr, Boston, MA USA.
   [Lee, Joanne] Cleveland Clin, Cleveland, OH 44106 USA.
   [Dahhan, Talal] Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC USA.
RP Krasuski, RA (reprint author), Duke Univ, Med Ctr, Dept Cardiovasc Med, 2301 Erwin Rd, Durham, NC 27710 USA.
EM richard.krasuski@duke.edu
RI Krasuski, Richard/AAI-8177-2020
OI Krasuski, Richard/0000-0003-3150-5215
FU Actelion Pharmaceuticals
FX RK is a consultant for, and receives research funding from, Actelion
   Pharmaceuticals. He also serves as an investigator for Abbott and
   Edwards Lifesciences and is an unpaid member of the scientific advisory
   board for Ventripoint. JA, KS, JL, KP and MF have no conflicts of
   interest to disclose.
CR Barbera JA, 2009, DRUGS, V69, P1153, DOI 10.2165/00003495-200969090-00002
   Andersen CU, 2013, INT J CARDIOL, V168, P1795, DOI 10.1016/j.ijcard.2013.06.033
   Bajwa AA, 2017, PULM CIRC, V7, P82, DOI 10.1086/689291
   Benza RL, 2010, CIRCULATION, V122, P164, DOI 10.1161/CIRCULATIONAHA.109.898122
   Chaouat A, 2008, EUR RESPIR J, V32, P1371, DOI 10.1183/09031936.00015608
   Collum SD, 2017, CAN RESPIR J, DOI 10.1155/2017/1430350
   Corte TJ, 2009, THORAX, V64, P883, DOI 10.1136/thx.2008.112847
   Faria-Urbina M, 2018, LUNG, V196, P139, DOI 10.1007/s00408-017-0081-7
   Farkas L, 2011, AM J RESP CELL MOL, V45, P1, DOI 10.1165/rcmb.2010-0365TR
   Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009
   Hoeper MM, 2009, J AM COLL CARDIOL, V54, pS85, DOI 10.1016/j.jacc.2009.04.008
   Hurdman J, 2013, EUR RESPIR J, V41, P1292, DOI 10.1183/09031936.00079512
   Minai OA, 2010, RESP MED, V104, P741, DOI 10.1016/j.rmed.2009.12.015
   Rosenkranz S, 2015, EUR RESPIR REV, V24, P642, DOI 10.1183/16000617.0062-2015
   Ryu JH, 2007, MAYO CLIN PROC, V82, P342
   Seeger W, 2013, J AM COLL CARDIOL, V62, pD109, DOI 10.1016/j.jacc.2013.10.036
   Shorr AF, 2007, EUR RESPIR J, V30, P715, DOI 10.1183/09031936.00107206
   Simonneau G, 2013, J AM COLL CARDIOL, V62, pD34, DOI 10.1016/j.jacc.2013.10.029
   Singh I, 2016, AM J MED, V129, P366, DOI 10.1016/j.amjmed.2015.11.026
   Strange C, 2005, CURR OPIN PULM MED, V11, P452, DOI 10.1097/01.mcp.0000174250.38188.6d
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
NR 21
TC 2
Z9 2
U1 2
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 126
EP 130
DI 10.1016/j.rmed.2019.03.004
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700019
PM 30961938
DA 2020-05-18
ER

PT J
AU Petrauskas, LA
   Saketkoo, LA
   Kazecki, T
   Saito, S
   Jaligam, V
   Deboisblanc, BP
   Lammi, MR
AF Petrauskas, Laura A.
   Saketkoo, Lesley Ann
   Kazecki, Thomas
   Saito, Shigeki
   Jaligam, Vijay
   deboisblanc, Bennett P.
   Lammi, Matthew R.
TI Use of red cell distribution width in a population at high risk for
   pulmonary hypertension
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Biomarker; High risk pulmonary hypertension populations; Pulmonary
   arterial hypertension; Red cell distribution width; Systemic sclerosis
ID CLINICAL-USEFULNESS; PROGNOSTIC MARKER; DYSFUNCTION
AB Background: Pulmonary hypertension (PH) often presents with non-specific symptoms making early diagnosis difficult. Red cell distribution width (RDW) is a parameter routinely reported on an automated complete blood cell count that has been associated with numerous disease states. The purpose of this study was to further evaluate RDW as a biomarker for PH in at-risk populations.
   Methods: In a retrospective, cross-sectional analysis of patients seen at a PH center over 1 year, we examined both patients with PH and patients at risk for but without PH (e.g. systemic sclerosis, [SSc]). We also studied a group of age-and sex-matched, non-diseased controls. Relevant characteristics were compared among the 3 groups using one-way ANOVA. Similar comparisons were made across World Health Organization (WHO) PH groups 1-4.
   Results: RDW was highest in the PH patients (n = 181), intermediate in the at-risk for PH patients (n = 52), and lowest in matched controls (n = 100) (15.9 +/- 2.8 vs 14.8 +/- 2.8 vs 14.2 +/- 1.1%, respectively; p < 0.0001). There were no significant differences in RDW across WHO PH groups (p = 0.50). SSc patients with PH had significantly higher RDW values compared to SSc patients without PH (16.0 +/- 2.2 vs 14.4 +/- 1.9%, respectively; p = 0.03).
   Conclusions: RDW is significantly higher in PH patients, without regard to disease etiology, when compared to age-and sex-matched non-diseased controls. Importantly, RDW is also higher in PH patients compared to at-risk patients, particularly in the SSc cohort. The ease of obtaining RDW as a biomarker may help detect incident PH at earlier stages among patients who are at high risk for development of PH.
C1 [Petrauskas, Laura A.; Kazecki, Thomas] Louisiana State Univ, Hlth Sci Ctr, Sch Med, New Orleans, LA USA.
   [Saketkoo, Lesley Ann; Saito, Shigeki; deboisblanc, Bennett P.; Lammi, Matthew R.] Univ Med Ctr, Comprehens Pulm Hypertens Ctr, New Orleans, LA USA.
   [Saketkoo, Lesley Ann; Saito, Shigeki] Tulane Univ, Sch Med, New Orleans Scleroderma & Sarcoidosis Patient Car, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Jaligam, Vijay] Louisiana State Univ, Hlth Sci Ctr, Cardiol Sect, Cardiol JenCare NOLA, New Orleans, LA USA.
   [deboisblanc, Bennett P.; Lammi, Matthew R.] Louisiana State Univ, Hlth Sci Ctr, Sect Pulm Crit Care & Allergy Immunol, New Orleans, LA 70112 USA.
RP Lammi, MR (reprint author), Univ Med Ctr, Comprehens Pulm Hypertens Ctr, New Orleans, LA USA.; Lammi, MR (reprint author), Louisiana State Univ, Hlth Sci Ctr, Sect Pulm Crit Care & Allergy Immunol, New Orleans, LA 70112 USA.
EM mlammi@lsuhsc.edu
OI Lammi, Matthew/0000-0001-5125-1801
FU National Institute of General Medical Sciences of the National
   Institutes of Health (COBRE Pilot Program) [1P306M106392-01A1, 1 U54
   GM104940]
FX This work was supported in part by the National Institute of General
   Medical Sciences of the National Institutes of Health (COBRE Pilot
   Program grant number 1P306M106392-01A1 to [MRL] and 1 U54 GM104940,
   which funds the Louisiana Clinical and Translational Science Center to
   [MRL])
CR Abul Y, 2014, CHRON RESP DIS, V11, P73, DOI 10.1177/1479972314525057
   Agapian JV, 2017, J AM COLL SURGEONS, V225, pE174, DOI 10.1016/j.jamcollsurg.2017.07.1001
   Chung L, 2014, ARTHRIT CARE RES, V66, P489, DOI 10.1002/acr.22121
   Farkas N, 2014, RHEUMATOLOGY, V53, P1439, DOI 10.1093/rheumatology/keu022
   Felker GM, 2007, J AM COLL CARDIOL, V50, P40, DOI 10.1016/j.jacc.2007.02.067
   Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858
   Galie N, 2008, LANCET, V371, P2093, DOI 10.1016/S0140-6736(08)60919-8
   Girish R., 2016, INDIAN HEART J, V67, pS102
   Hampole CV, 2009, AM J CARDIOL, V104, P868, DOI 10.1016/j.amjcard.2009.05.016
   Hao YJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0517-5
   Hoeper MM, 2013, J AM COLL CARDIOL, V62, pD42, DOI 10.1016/j.jacc.2013.10.032
   Hu LH, 2017, ONCOTARGET, V8, P16027, DOI 10.18632/oncotarget.13784
   Huang Y-F, 2014, PLOS ONE, V9
   Lippi G, 2009, CLIN CHEM LAB MED, V47, P353, DOI 10.1515/CCLM.2009.066
   Lippi G, 2008, SCAND J CLIN LAB INV, V68, P745, DOI 10.1080/00365510802213550
   Lu YA, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0766-4
   Montagnana M, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.50
   Morrisroe K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1250-z
   Ozgul G, 2017, ARCH BRONCONEUMOL, V53, P107, DOI 10.1016/j.arbres.2016.05.021
   PARK K I, 1987, Yonsei Medical Journal, V28, P282
   Salvagno GL, 2015, CRIT REV CL LAB SCI, V52, P86, DOI 10.3109/10408363.2014.992064
   Sharma PR, 1990, CLIN METHODS HIST PH, P720
   Shenavandeh Saeedeh, 2017, Reumatologia (Warsaw), V55, P163, DOI 10.5114/reum.2017.69776
   Simonneau G, 2013, J AM COLL CARDIOL, V62, pD34, DOI 10.1016/j.jacc.2013.10.029
   Sincer I, 2012, HEART LUNG, V41, P238, DOI 10.1016/j.hrtlng.2011.07.011
   Solak Y, 2014, AM J MED SCI, V347, P118, DOI 10.1097/MAJ.0b013e3182996a96
   Wonnerth A, 2016, EUR J CLIN INVEST, V46, P198, DOI 10.1111/eci.12584
   Zhao JL, 2018, CLIN RHEUMATOL, V37, P979, DOI 10.1007/s10067-017-3918-9
NR 28
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 131
EP 135
DI 10.1016/j.rmed.2019.03.003
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700020
PM 30961939
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Machado-Carvalho, L
   Roca-Ferrer, J
   Picado, C
AF Machado-Carvalho, Liliana
   Roca-Ferrer, Jordi
   Picado, Cesar
TI IL-4/IFN-gamma inflammatory cytokine profile induces a deficient
   regulation of the IL-1 beta/IL-1RI/EP2/COX-2 pathway in nasal mucosa
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Cyclooxygenase; EP2; Nasal mucosa; Nasal polyp; Th1; Th2
ID PROSTAGLANDIN E-2; ASPIRIN; RHINOSINUSITIS; LEUKOTRIENE; EXPRESSION;
   POLYPS; GAMMA
AB Background: We hypothesized that the peculiar mixed interleukin-4 (IL-4/Th2) and interferon gamma INF-gamma (INF-gamma/Th1) inflammatory milieu found in the airways of patients with aspirin-exacerbated respiratory disease (AERD) is responsible for the altered regulation of the IL-1 beta/IL-1RI-/EP2/COX-2 autocrine loop also found in these patients. The objective of the study is to demonstrate that IL-4 and INF-gamma cytokines, are capable of inducing in healthy nasal mucosa (NM) the dysregulation of the autocrine loop of COX reported in AERD.
   Subjects and methods: Fibroblasts were obtained from NM (n = 8). To evaluate the role of IL-4 and IFN-gamma on the autocrine loop, fibroblasts were incubated with or without IL-1 beta, in the presence or absence of IL-4 and/or IFN-gamma for 48 h. After this period, the expression of EP2, EP3, EP4, IL-1RI, COX-2 and mPGES-1 was measured by Western blot.
   Results: Stimulation of fibroblasts with IL-1 beta significantly increased the expression of EP2, but had no effects on EP3 and EP4 expression Incubation with IL-4 or IFN-gamma alone was not able to modify the expression of any of the components of the autocrine loop. In contrast, co-treatment with IL-4 and IFN-gamma was able to significantly inhibit IL-1 beta-induced EP2, IL-1RI, COX-2 and mPGES-1.
   Conclusion: These results suggest that the mixed Th1/Th2 inflammatory pattern found in the airways of AERD patients might be responsible for the altered regulation of the COX pathway also reported in these asthma patients.
C1 [Machado-Carvalho, Liliana; Roca-Ferrer, Jordi; Picado, Cesar] Univ Barcelona, Hosp Clin, Ctr Invest Red Enfermedades Resp CIBERES, Inst Invest Biomed August PI & Sunyer, Barcelona, Spain.
RP Picado, C (reprint author), Hosp Clin Barcelona, Serv Pneumol, C Villarroel 170, Barcelona 08036, Spain.
EM cpicado@ub.edu
OI Picado, Cesar/0000-0001-7400-4993
CR Cahill KN, 2017, J ALLERGY CLIN IMMUN, V139, P764, DOI 10.1016/j.jaci.2016.09.025
   Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031
   Endo T, 1998, AM J RESP CELL MOL, V19, P300, DOI 10.1165/ajrcmb.19.2.2915
   Hayashi Y, 2000, CYTOKINE, V12, P603, DOI 10.1006/cyto.1999.0622
   Machado-Carvalho L, 2016, J ALLERGY CLIN IMMUN, V137, P99, DOI 10.1016/j.jaci.2015.09.028
   Mullol J, 2013, IMMUNOL ALLERGY CLIN, V33, P163, DOI 10.1016/j.iac.2012.11.002
   Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029
   PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65
   Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491
   Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065
   Steinke JW, 2013, J ALLERGY CLIN IMMUN, V132, P856, DOI 10.1016/j.jaci.2013.05.008
   Steinke John W, 2012, J Allergy (Cairo), V2012, P182090, DOI 10.1155/2012/182090
   Woessner KM, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0673-6
NR 13
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 136
EP 140
DI 10.1016/j.rmed.2019.03.008
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700021
PM 30961940
DA 2020-05-18
ER

PT J
AU Miravitlles, M
   Koblizek, V
   Esquinas, C
   Milenkovic, B
   Barczyk, A
   Tkacova, R
   Somfay, A
   Zykov, K
   Tudoric, N
   Kostov, K
   Zbozinkova, Z
   Svoboda, M
   Sorli, J
   Krams, A
   Valipour, A
AF Miravitlles, Marc
   Koblizek, Vladimir
   Esquinas, Cristina
   Milenkovic, Branislava
   Barczyk, Adam
   Tkacova, Ruzena
   Somfay, Attila
   Zykov, Kirill
   Tudoric, Neven
   Kostov, Kosta
   Zbozinkova, Zuzana
   Svoboda, Michal
   Sorli, Jurij
   Krams, Alvils
   Valipour, Arschang
TI Determinants of CAT (COPD Assessment Test) scores in a population of
   patients with COPD in central and Eastern Europe: The POPE study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; CAT; mMRC; Comorbidities; GOLD classification
ID GOLD CLASSIFICATION; QUESTIONNAIRE; SYMPTOMS; GUIDELINES; PHENOTYPES;
   DIAGNOSIS; OUTCOMES; DYSPNEA
AB Background: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants.
   Methods: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy.
   Results: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups.
   Conclusions: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT > 10 is not equivalent to mMRC > 2 for assessing symptom burden.
C1 [Miravitlles, Marc; Esquinas, Cristina] Hosp Univ Vall dHebron, Vall dHebron Res Inst VHIR, CIBER Enfermedades Resp CIBERES, Dept Pneumol, Barcelona, Spain.
   [Koblizek, Vladimir] Charles Univ Prague, Fac Med Hradec Kralove, Univ Hosp Hradec Kralove, Dept Pneumol, Hradec Kralove, Czech Republic.
   [Milenkovic, Branislava] Clin Ctr Serbia, Fac Med, Clin Pulm Dis, Belgrade, Serbia.
   [Barczyk, Adam] Med Univ Silesia, Sch Med Katowice, Dept Pneumol, Katowice, Poland.
   [Tkacova, Ruzena] Safarik Univ, Fac Med, Dept Resp Med & TB, Kosice, Slovakia.
   [Somfay, Attila] Univ Szeged, Dept Pulmonol, Deszk, Hungary.
   [Zykov, Kirill] Moscow State Univ Med & Dent, Pulmonol Sci Res Inst FMBA Russia, Moscow, Russia.
   [Tudoric, Neven] Univ Hosp Dubrava, Sch Med Zagreb, Zagreb, Croatia.
   [Kostov, Kosta] Mil Med Acad, Clin Pulm Dis, Sofia, Bulgaria.
   [Zbozinkova, Zuzana; Svoboda, Michal] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno, Czech Republic.
   [Sorli, Jurij] Topolsica Hosp, Dept Pulm, Topolsica, Slovenia.
   [Krams, Alvils] Univ Latvia, Fac Med, Riga, Latvia.
   [Krams, Alvils] Riga East Univ Hosp, Riga, Latvia.
   [Valipour, Arschang] Otto Wagner Spital, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Dept Resp & Crit Care Med, Vienna, Austria.
RP Miravitlles, M (reprint author), Hosp Univ Vall dHebron, Vall dHebron Res Inst VHIR, Dept Pneumol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.
EM mmiravitlles@vhebron.net
RI Miravitlles, Marc/AAH-5284-2019; Koblizek, Vladimir/AAC-5374-2019
OI Miravitlles, Marc/0000-0002-9850-9520; Koblizek,
   Vladimir/0000-0002-2446-2790; Zykov, Kirill/0000-0003-3385-2632;
   Milenkovic, Branislava/0000-0002-0767-6869
FU Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology,
   Vienna, Austria; Boehringer Ingelheim RCV GmbH Co. KG; MH CZ - DRO
   (UHHK) [00179906]
FX The authors want to thank the staff of all of the study centers for
   their cooperation in collecting the study data. The sponsor of the POPE
   study is the Ludwig Boltzmann Institute for COPD and Respiratory
   Epidemiology, Vienna, Austria. This research institute received an
   unrestricted research grant from Boehringer Ingelheim RCV GmbH & Co. KG,
   which provided partial support for this study but had no influence on
   the rationale, methodology, or analysis. Participation by the Czech
   Republic was additionally supported by MH CZ - DRO (UHHK, 00179906).
CR Arkhipov V, 2017, INT J CHRONIC OBSTR, V12, P3255, DOI 10.2147/COPD.S142997
   Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Casanova C, 2015, CHEST, V148, P159, DOI 10.1378/chest.14-2449
   Casas A, 2018, INT J CHRONIC OBSTR, V13, P1545, DOI 10.2147/COPD.S154097
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Dal Negro RW, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-15
   Garcia-Rivero JL, 2017, COPD, V14, P164, DOI 10.1080/15412555.2016.1260538
   Garcia-Sidro P, 2015, RESP MED, V109, P1546, DOI 10.1016/j.rmed.2015.10.011
   Gupta N, 2014, EUR RESPIR J, V44, P873, DOI 10.1183/09031936.00025214
   Harryanto H, 2018, INT J CHRONIC OBSTR, V13, P955, DOI 10.2147/COPD.S152950
   Jo YS, 2018, INT J CHRONIC OBSTR, V13, P101, DOI 10.2147/COPD.S149805
   Jones PW, 2011, EUR RESPIR J, V38, P29, DOI 10.1183/09031936.00177210
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Kania A, 2018, INT J CHRONIC OBSTR, V13, P1613, DOI 10.2147/COPD.S154716
   Karloh M, 2016, CHEST, V149, P413, DOI 10.1378/chest.15-1752
   Koblizek V, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01446-2016
   Koblizek V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111078
   Koblizek V, 2013, BIOMED PAP, V157, P189, DOI 10.5507/bp.2013.039
   Lopez-Campos JL, 2015, INT J CHRONIC OBSTR, V10, P975, DOI 10.2147/COPD.S82781
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miravitlles M, 2018, INT J CHRONIC OBSTR, V13, P823, DOI 10.2147/COPD.S154791
   Miravitlles M, 2017, ARCH BRONCONEUMOL, V53, P324, DOI 10.1016/j.arbres.2017.03.018
   Miravitlles M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0548-3
   Miravitlles M, 2015, INT J CHRONIC OBSTR, V10, P2571, DOI 10.2147/COPD.S91163
   Mittal R, 2017, COPD, V14, P1, DOI 10.1080/15412555.2016.1230844
   Reiger G, 2018, WIEN KLIN WOCHENSCHR, V130, P382, DOI 10.1007/s00508-018-1347-7
   Rieger-Reyes C, 2014, ARCH BRONCONEUMOL, V50, P129, DOI 10.1016/j.arbres.2013.09.014
   Smid DE, 2017, J AM MED DIR ASSOC, V18, P1097
   Vogelmeier CF, 2017, ARCH BRONCONEUMOL, V53, P128, DOI 10.1016/j.arbres.2017.02.001
   Zbozinkova Z, 2016, INT J CHRONIC OBSTR, V11, P611, DOI 10.2147/COPD.S88846
NR 30
TC 1
Z9 1
U1 2
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 141
EP 148
DI 10.1016/j.rmed.2019.03.007
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700022
PM 30961941
DA 2020-05-18
ER

PT J
AU Bar-Yoseph, R
   Haddad, J
   Hanna, M
   Kessel, I
   Kugelman, A
   Hakim, F
   Bentur, L
AF Bar-Yoseph, Ronen
   Haddad, Julie
   Hanna, Monnera
   Kessel, Irena
   Kugelman, Amir
   Hakim, Fahed
   Bentur, Lea
TI Long term follow-up of Palivizumab administration in children born at
   29-32 weeks of gestation
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Respiratory syncytial virus; Palivizumab; Preterm; Cytokines
ID RESPIRATORY-SYNCYTIAL-VIRUS; METHACHOLINE CHALLENGE; PRETERM INFANTS;
   YOUNG-CHILDREN; ASTHMA; BRONCHIOLITIS; INFECTION; ALLERGY; PROPHYLAXIS;
   PREVENTION
AB Background: Severe respiratory syncytial virus (RSV) bronchiolitis requiring hospitalization induces long term immunological and respiratory abnormalities. The long-term immunomodulation effect of Palivizumab (RSV monoclonal antibody) prophylaxis and its impact on the development of asthma remain controversial. Our aim was to evaluate airway hyper-reactivity, systemic inflammatory markers, allergic parameters and respiratory morbidity, 5-7 years following Palivizumab administration to children born at 29-32 weeks of gestation (WGA).
   Methods: Children born at 29-32 WGA were evaluated at age 5-7 years. Methacholine challenge test (MCT), serum inflammatory cytokines, fractional exhaled nitric oxide (FeNO), blood tests for eosinophil count, IgE and assessment of respiratory morbidity by questionnaire were compared between those born before Palivizumab prophylaxis was extended to 29-32 WGA and those who received Palivizumab prophylaxis.
   Results: Of 42 children recruited, 27 received Palivizumab and 15 did not. The mean gestational age and weight were lower in the Palivizumab group. Similar values of spirometry, MCT, FeNO and allergic parameters were observed in the two groups. The Palivizumab group had higher IL4, IL5 and IL13 (Th2 cytokines), IL6, IL17 alpha, and G-CSF (Th17 activation), and lower IL12 and higher INF-gamma (Th1 cytokines).
   Conclusion: Compared to children who did not receive immunoprophylaxis, among children who received Palivizumab, no beneficial effects on long-term respiratory morbidity, airway reactivity or allergic parameters were observed, and levels of Th2 and Th17 cytokines implicated in the pathogenesis of asthma were higher. These findings cast doubt on the potential long-term beneficial effect of Palivizumab on asthma inception.
C1 [Bar-Yoseph, Ronen; Hanna, Monnera; Hakim, Fahed; Bentur, Lea] Rambam Hlth Care Campus, Ruth Childrens Hosp, Pediat Pulm Inst, Haifa, Israel.
   [Haddad, Julie; Kugelman, Amir] Rambam Hlth Care Campus, Ruth Childrens Hosp, Dept Neonatol & Neonatal Intens Care, Haifa, Israel.
   [Kessel, Irena] Carmel Hosp, Neonatal Intens Care, Haifa, Israel.
   [Kugelman, Amir; Hakim, Fahed; Bentur, Lea] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel.
   [Hakim, Fahed] Nazareth Hosp EMMS, Nazareth, Israel.
RP Bentur, L (reprint author), Rambam Hlth Care Campus, Ruth Childrens Hosp, POB 9602, IL-31096 Haifa, Israel.
EM l_bentur@rambam.health.gov.il
FU Abbot
FX The study was supported by an investigator-initiated grant (principal
   investigator Lea Bentur) from Abbot.
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST
   Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917
   Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777
   Cockcroft DW, 2003, CLIN REV ALLERG IMMU, V24, P19, DOI 10.1385/CRIAI:24:1:19
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Faber TE, 2012, J MED VIROL, V84, P1084, DOI 10.1002/jmv.23291
   Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211
   Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731
   Jafri HS, 2004, J INFECT DIS, V189, P1856, DOI 10.1086/386372
   Kim HB, 2016, ALLERGY ASTHMA IMMUN, V8, P12, DOI 10.4168/aair.2016.8.1.12
   Kivastik J, 2007, RESP MED, V101, P2555, DOI 10.1016/j.rmed.2007.07.002
   Kneyber M, 2000, ACTA PAEDIATR, V89, P654, DOI 10.1080/080352500750043945
   Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058
   Larranaga CL, 2009, PEDIATR INFECT DIS J, V28, P867, DOI 10.1097/INF.0b013e3181a3ea71
   Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008
   Mochizuki H, 2017, AM J RESP CRIT CARE, V196, P29, DOI [10.1164/rccm.201609-1812oc, 10.1164/rccm.201609-1812OC]
   Prais D, 2016, CHEST, V149, P801, DOI 10.1378/chest.15-0328
   Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050
   Scheltema NM, 2018, LANCET RESP MED, V6, P257, DOI 10.1016/S2213-2600(18)30055-9
   Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC
   SIGURS N, 1995, PEDIATRICS, V95, P500
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076
   Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3
   Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032
   Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026
   Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5
   Vilozni D, 2009, PEDIATR PULM, V44, P720, DOI 10.1002/ppul.20978
   Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC
   Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438
NR 31
TC 1
Z9 1
U1 1
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 149
EP 153
DI 10.1016/j.rmed.2019.03.001
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700023
PM 30961942
DA 2020-05-18
ER

PT J
AU Sambataro, G
   Sambataro, D
   Torrisi, SE
   Vancheri, A
   Colaci, M
   Pavone, M
   Pignataro, F
   Del Papa, N
   Palmucci, S
   Vancheri, C
AF Sambataro, Gianluca
   Sambataro, Domenico
   Torrisi, Sebastiano Emanuele
   Vancheri, Ada
   Colaci, Michele
   Pavone, Mauro
   Pignataro, Francesca
   Del Papa, Nicoletta
   Palmucci, Stefano
   Vancheri, Carlo
TI Clinical, serological and radiological features of a prospective cohort
   of Interstitial Pneumonia with Autoimmune Features (IPAF) patients
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Diagnosis; Idiopathic pulmonary fibrosis; Interstitial lung disease;
   Interstitial Pneumonia with autoimmune features; Undifferentiated
   connective tissue disease; Classification criteria
ID CLASSIFICATION CRITERIA; RHEUMATOLOGY/EUROPEAN LEAGUE;
   SYSTEMIC-SCLEROSIS; AMERICAN-COLLEGE; LUNG-DISEASE; HISTOLOGICAL
   CHARACTERISTICS; STATEMENT; GUIDELINES; SOCIETY; ECHOCARDIOGRAPHY
AB Background: The term Interstitial Pneumonia with Autoimmune Features (IPAF) describes patients with Interstitial Lung Diseases (ILDs) and clinical or serological features of autoimmune diseases insufficient to reach a specific classification of a Connective Tissue Disease (CTD). Currently, retrospective studies on IPAF patients have proven to be heterogeneous in general characteristics, outcomes and High-Resolution Computed Tomography (HRCT) pattern. This study aims to describe for the first time the clinical, serological and radiological features of a prospective cohort of IPAF patients. This cohort is then compared to a group of patients with Idiopathic Pulmonary Fibrosis (IPF).
   Material and methods: From 626 consecutive ILD patients evaluated, 45 IPAF and a comparison cohort of 143 IPF patients were enrolled. All patients underwent clinical assessment with rheumatologic and respiratory evaluation, HRCT, Pulmonary Function Tests and Nailfold Videocapillaroscopy.
   Results: The IPAF patients had a predominance of female gender (62.12%) with a median age of 66 years. The most common findings were: Nonspecific Interstitial Pneumonia (NSIP, 68.89%), Antinuclear Antibody positivity (17.77%) and Raynaud Phenomenon (31.11%). In comparison with IPF, IPAF patients showed younger age, better performances in Pulmonary Function Tests, less necessity of O-2 support and predominance of female sex and NSIP pattern.
   Discussion: This is the first report of a prospective cohort of IPAF patients. IPAF patients seem to have a less severe lung disease than IPF. IPAF criteria probably need to be revisited and validated, but their capacity to recruit patients with incomplete forms or early onset of CTD could be useful for further research.
C1 [Sambataro, Gianluca; Torrisi, Sebastiano Emanuele; Vancheri, Ada; Pavone, Mauro; Vancheri, Carlo] Univ Catania, Dept Clin & Expt Med, AOU Policlin Vittorio Emanuele, Reg Referral Ctr Rare Lung Dis, Catania, Italy.
   [Sambataro, Gianluca; Sambataro, Domenico] Artroreuma SRL, Rheumatol Outpatient, Natl Hlth Syst, Corso S Vito 53, I-95030 Mascalucia, CT, Italy.
   [Sambataro, Domenico; Colaci, Michele] Univ Catania, Cannizzaro Hosp, Rheumatol Sect, Dept Clin & Expt Med,Internal Med Unit, Via Messina 829, I-95126 Catania, Italy.
   [Pignataro, Francesca; Del Papa, Nicoletta] ASST G Pini CTO, Day Hosp Rheumatol, Dept Rheumatol, Milan, Italy.
   [Palmucci, Stefano] Univ Catania, Policlin Vittorio Emanuele, Dept Radiol, Catania, Italy.
RP Sambataro, G (reprint author), Univ Catania, Dept Clin & Expt Med, AOU Policlin Vittorio Emanuele, Reg Referral Ctr Rare Lung Dis, Catania, Italy.
EM dottorsambataro@gmail.com
RI Sambataro, Gianluca/K-9528-2016; Torrisi, Sebastiano
   Emanuele/K-8020-2018
OI Sambataro, Gianluca/0000-0001-9933-1202; Torrisi, Sebastiano
   Emanuele/0000-0002-6660-3563
FU Departmental Project #A Objective 2 Group of Analysis 2, "molecular,
   clinical and instrumental early markers in metabolic and
   chronic-degenerative diseases" of the Clinical and Experimental Medicine
   Dept, University of Catania
FX This study was supported by the Departmental Project #A Objective 2
   Group of Analysis 2, "molecular, clinical and instrumental early markers
   in metabolic and chronic-degenerative diseases" of the Clinical and
   Experimental Medicine Dept, University of Catania.
CR Ahmad K, 2017, RESP MED, V127, P67, DOI 10.1016/j.rmed.2017.04.003
   Ahmad K, 2017, RESP MED, V123, P56, DOI 10.1016/j.rmed.2016.10.017
   Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   American Thoracic Society, 2002, Am J Respir Crit Care Med, V165, P277
   Andracco R, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1354-5
   Bartoloni E, 2017, AUTOIMMUN REV, V16, P253, DOI 10.1016/j.autrev.2017.01.008
   Bertolazzi C, 2017, SEMIN ARTHRITIS RHEU, V47, P432, DOI 10.1016/j.semarthrit.2017.06.001
   BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807
   BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
   Caminati A, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0047-2017
   Cavagna L, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0047-2018
   Chartrand S, 2016, RESP MED, V119, P150, DOI 10.1016/j.rmed.2016.09.002
   Cottin V, 2016, EUR RESPIR J, V48, P1274, DOI 10.1183/13993003.01633-2016
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Cutolo M, 2013, BEST PRACT RES CL RH, V27, P237, DOI 10.1016/j.berh.2013.03.001
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Ito Y, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0453-z
   Koenig M, 2008, ARTHRITIS RHEUM-US, V58, P3902, DOI 10.1002/art.24038
   Kovacs SO, 1998, J AM ACAD DERMATOL, V39, P899, DOI 10.1016/S0190-9622(98)70263-4
   Levi Y, 2018, J RHEUMATOL, V45, P1509, DOI 10.3899/jrheum.171314
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mosca M, 2012, BEST PRACT RES CL RH, V26, P73, DOI 10.1016/j.berh.2012.01.005
   Mukerjee D, 2004, RHEUMATOLOGY, V43, P461, DOI 10.1093/rheumatology/keh067
   Oldham JM, 2016, EUR RESPIR J, V47, P1767, DOI 10.1183/13993003.01565-2015
   Ortega-Hernandez OD, 2012, BEST PRACT RES CL RH, V26, P61, DOI 10.1016/j.berh.2012.01.009
   Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473
   Pinal-Fernandez I, 2017, RHEUMATOLOGY, V56, P999, DOI 10.1093/rheumatology/kex021
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010
   Sambataro D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0462-8
   Sambataro G, 2019, RESPIR MED CASE REP, V26, P126, DOI 10.1016/j.rmcr.2018.12.014
   Sambataro G, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0139-2017
   Sambataro G, 2017, RESP MED, V127, P65, DOI 10.1016/j.rmed.2017.03.004
   Sebastiani M, 2009, ARTHRIT RHEUM-ARTHR, V61, P688, DOI 10.1002/art.24394
   Sebastiani M, 2019, J RHEUMATOL, V46, P279, DOI 10.3899/jrheum.180355
   Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI 10.1136/annrheumdis-2016-210571
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098
   Zavorsky GS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00962-2016
NR 39
TC 7
Z9 7
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 154
EP 160
DI 10.1016/j.rmed.2019.03.011
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700024
PM 30961944
DA 2020-05-18
ER

PT J
AU Niven, R
   Aubier, M
   Bonta, P
   Puente-Maestu, L
   Facciolongo, N
   Ryan, D
AF Niven, Robert
   Aubier, Michel
   Bonta, Peter
   Puente-Maestu, Luis
   Facciolongo, Nicola
   Ryan, Dorothy
TI European consensus meeting/statement on Bronchial Thermoplasty Who?
   Where? How?
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Thermoplasty; Consensus
ID REDUCTION; ASTHMA; SAFETY
AB Background: Bronchial Thermoplasty (BT) is a bronchoscopic treatment for severe asthma. Following research trials there remains a need to guide BT treatment in clinical practice, specifically in the fields of patient assessment, selection and positioning of BT within the range of treatment modalities, BT treatment protocols and post-BT management and follow-up. Consensus statements can bridge the gap between evidence-based medicine and real world clinical practice.
   Methods: We performed a modified RAND consensus analysis using a baseline list of statements derived from ATS/ERS Guidelines on Severe Asthma, Cochrane review and UK commissioning guidance. A panel of 5 European BT experts, individually scored the statements and following a day of discussion, rescored a revised final list independently.
   Results: An initial list of 132 statements, were independently scored. These were modified to 108 following group discussion. Consensus/total agreement was reached for 68 (63%) of the statements; 8 (7.4%) statements achieving total disagreement. For only 17 statements, could some form of consensus not be achieved.
   Conclusions: The consensus document could be applied to guide BT clinical practice and used to serve as a minimum acceptable level of assessment for BT, drive the development of clinical practice protocols and help define quality indicators
C1 [Niven, Robert] Univ Manchester, MAHSC, Manchester, Lancs, England.
   [Niven, Robert] Manchester Fdn Trust, Manchester, Lancs, England.
   [Aubier, Michel] Univ Paris Diderot, Hop Bichat, Serv Pneumol A, Inserm,U1152, Paris, France.
   [Bonta, Peter] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Pulmonol, Amsterdam, Netherlands.
   [Puente-Maestu, Luis] Univ Complutense Madrid, Sch Med, Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
   [Facciolongo, Nicola] Azienda USL Reggio Emilia IRCCS, Arcispedale Santa Maria Nuova, Dept Med Specialties, Pneumol Unit, Reggio Emilia, Italy.
   [Ryan, Dorothy] Beaumont Hosp Dublin, Dept Resp Med, Dublin, Ireland.
   [Ryan, Dorothy] Univ Royal Coll Surg Ireland, Dublin, Ireland.
RP Niven, R (reprint author), Univ Manchester, MAHSC, Manchester, Lancs, England.; Niven, R (reprint author), Manchester Fdn Trust, Manchester, Lancs, England.
EM robert.niven@mft.nhs.uk
RI facciolongo, nicola/AAB-9796-2019; Facciolongo, Nicola
   Cosimo/AAC-1238-2019
OI Facciolongo, Nicola Cosimo/0000-0001-9921-2051; Puente-Maestu,
   Luis/0000-0001-8501-0117; Niven, Robert/0000-0003-2249-960X
CR Brook R H, 1986, Int J Technol Assess Health Care, V2, P53
   Brown RH, 2005, EUR RESPIR J, V26, P277, DOI 10.1183/09031936.05.00006605
   Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816
   Castro M, 2011, ANN ALLERG ASTHMA IM, V107, P65, DOI 10.1016/j.anai.2011.03.005
   Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Chupp G, 2017, EUR RESP J, V50
   Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707
   Facciolongo N, 2015, EUR RESPIR J, V46, P59
   JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376
   National Institute for Health and Care Excellence, 2012, INT PROC GUID IPG419
   Naylor CD, 1998, NEW ENGL J MED, V338, P1918, DOI 10.1056/NEJM199806253382612
   Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC
   Pretolani M, 2014, AM J RESP CRIT CARE, V190, P1452, DOI 10.1164/rccm.201407-1374LE
   Ryan D, 2016, J ALLERGY CLIN IMMUN, V138, P308, DOI 10.1016/j.jaci.2015.11.044
   Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607
   Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8
   Torrego A, 2014, COCHRANE DB SYST REV, V3
   Trivedi A, 2016, LANCET RESP MED, V4, P585, DOI 10.1016/S2213-2600(16)30018-2
NR 19
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 161
EP 164
DI 10.1016/j.rmed.2019.02.020
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700025
PM 30961945
DA 2020-05-18
ER

PT J
AU Ichikawa, T
   Panariti, A
   Audusseau, S
   Mogas, AK
   Olivenstein, R
   Chakir, J
   Laviolette, M
   Allakhverdi, Z
   Al Heialy, S
   Martin, JG
   Hamid, Q
AF Ichikawa, Tomohiro
   Panariti, Alice
   Audusseau, Severine
   Mogas, Andrea Karen
   Olivenstein, Ronald
   Chakir, Jamila
   Laviolette, Michel
   Allakhverdi, Zoulfia
   Al Heialy, Saba
   Martin, James G.
   Hamid, Qutayba
TI Effect of bronchial thermoplasty on structural changes and inflammatory
   mediators in the airways of subjects with severe asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchial thermoplasty; Severe asthma; Airway smooth muscle; Airway
   remodeling; Airway nerves; Inflammatory mediators
ID SEVERE REFRACTORY ASTHMA; SMOOTH-MUSCLE; OPTION; SAFETY
AB Background: Bronchial thermoplasty (BT) is a novel technique used in the treatment of subjects with severe refractory asthma. Radiofrequency is provided to airway walls during bronchoscopy in order to reduce airway remodeling. Several clinical studies have reported an improvement in subjects' symptoms following BT. However, how BT affects the airway architectures and inflammatory mediators in the airways has not been yet fully elucidated.
   Methods: Fourteen subjects with severe asthma were recruited in this study according to the criteria of ATS severe asthma definition. The study subjects undertook bronchial biopsy during the bronchoscopy procedure at baseline and 6 weeks after the initial BT treatment. The obtained samples were stained with antibodies for alpha-smooth muscle actin (alpha-SMA); protein gene product (PGP) 9.5, a specific nerve marker; von Willebrand factor (vWF), a marker for blood vessels; interleukin-17A (IL-17A) and transforming growth factor-beta 1 (TGF-beta 1).
   Results: The expression of alpha-SMA and PGP9.5 were significantly reduced post-BT. There was no significant difference in the number of blood vessels between baseline and post-BT. In addition, BT did not affect the production of IL-17A and TGF-beta 1 in the airways. The changes in the expression of alpha-SMA and PGP9.5 had no significant correlation with the improvement of pulmonary function.
   Conclusion: and Clinical Relevance: This study suggests that BT reduces airway smooth muscle mass and the airway innervation without affecting vasculature and the production of inflammatory mediators in the airways of subjects with severe asthma.
C1 [Ichikawa, Tomohiro; Panariti, Alice; Audusseau, Severine; Mogas, Andrea Karen; Olivenstein, Ronald; Allakhverdi, Zoulfia; Martin, James G.; Hamid, Qutayba] McGill Univ, Ctr Hlth, Res Inst, Meakins Christie Labs, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.
   [Ichikawa, Tomohiro] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Miyagi, Japan.
   [Chakir, Jamila; Laviolette, Michel] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
   [Al Heialy, Saba] Mohammed bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.
   [Hamid, Qutayba] Univ Sharjah, Coll Med, Sharjah, U Arab Emirates.
RP Hamid, Q (reprint author), McGill Univ, Ctr Hlth, Res Inst, Meakins Christie Labs, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.
EM qutayba.hamid@mcgill.ca
RI Allakhverdi, Zoulfia/AAG-1379-2019
OI Ichikawa, Tomohiro/0000-0003-0093-6362
FU Richard and Edith Strauss Foundation; Banyu Fellowship Program - Banyu
   Life Science Foundation International
FX This study was supported by Richard and Edith Strauss Foundation. TI was
   supported by the Banyu Fellowship Program sponsored by Banyu Life
   Science Foundation International. The authors thank the staff at the
   Biobank of the Respiratory Health Network, RI-MUHC Meakins-Christie
   Laboratories site.
CR Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047
   [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341
   Audrit KJ, 2017, CELL TISSUE RES, V367, P571, DOI 10.1007/s00441-016-2559-7
   Bergeron Celine, 2009, Proc Am Thorac Soc, V6, P301, DOI 10.1513/pats.200808-089RM
   Boulet LP, 2018, CURR OPIN PULM MED, V24, P56, DOI 10.1097/MCP.0000000000000441
   Canning B.J., 2012, J ALLERGY
   Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC
   Chakir J, 2015, ANN AM THORAC SOC, V12, P1612, DOI 10.1513/AnnalsATS.201504-208OC
   Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707
   Denner DR, 2015, ANN AM THORAC SOC, V12, P1302, DOI 10.1513/AnnalsATS.201502-082OC
   Dombret MC, 2014, EUR RESPIR REV, V23, P510, DOI 10.1183/09059180.00005114
   Ebina Masahito, 2008, Allergol Int, V57, P165, DOI 10.2332/allergolint.O-07-497
   El-Chemaly S, 2008, ANN NY ACAD SCI, V1131, P195, DOI 10.1196/annals.1413.017
   Facciolongo N, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-017-0554-8
   Gazzola M, 2017, AM J PHYSIOL-LUNG C, V312, P1348, DOI 10.1152/ajplung.00400.2016
   Harkness LM, 2015, PHARMACOL THERAPEUT, V148, P17, DOI 10.1016/j.pharmthera.2014.11.010
   Harkness LM, 2014, PULM PHARMACOL THER, V29, P144, DOI 10.1016/j.pupt.2014.09.003
   Keglowich L F, 2015, Open Respir Med J, V9, P70, DOI 10.2174/1874306401509010070
   LeBlanc A, 2007, ALLERGY, V62, P120, DOI 10.1111/j.1398-9995.2006.01194.x
   Menzella F, 2017, J ASTHMA ALLERGY, V10, P237, DOI 10.2147/JAA.S144100
   Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC
   Perrin L F, 1993, Eur J Med, V2, P164
   Poon AH, 2012, CLIN EXP ALLERGY, V42, P625, DOI 10.1111/j.1365-2222.2012.03983.x
   Pretolani M, 2017, J ALLERGY CLIN IMMUN, V139, P1176, DOI 10.1016/j.jaci.2016.08.009
   Pretolani M, 2014, AM J RESP CRIT CARE, V190, P1452, DOI 10.1164/rccm.201407-1374LE
   Salem IH, 2016, ANN AM THORAC SOC, V13, P1426, DOI 10.1513/AnnalsATS.201603-182LE
   Song WJ, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0069-4
   Thomson NC, 2012, CURR OPIN ALLERGY CL, V12, P241, DOI 10.1097/ACI.0b013e32835335ca
   West PW, 2015, AM J RESP CRIT CARE, V192, P30, DOI 10.1164/rccm.201412-2293OC
   Zanini A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-132
NR 30
TC 3
Z9 3
U1 2
U2 6
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD APR
PY 2019
VL 150
BP 165
EP 172
DI 10.1016/j.rmed.2019.03.005
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HS1MY
UT WOS:000463627700026
PM 30961946
DA 2020-05-18
ER

PT J
AU Tanizawa, K
   Handa, T
   Nagai, S
   Oga, T
   Kubo, T
   Ito, Y
   Aihara, K
   Ikezoe, K
   Sokai, A
   Nakatsuka, Y
   Hirai, T
   Chin, KZ
   Mishima, M
   Izumi, T
AF Tanizawa, Kiminobu
   Handa, Tomohiro
   Nagai, Sonoko
   Oga, Toru
   Kubo, Takeshi
   Ito, Yutaka
   Aihara, Kensaku
   Ikezoe, Kohei
   Sokai, Akihiko
   Nakatsuka, Yoshinari
   Hirai, Toyohiro
   Chin, Kazuo
   Mishima, Michiaki
   Izumi, Takateru
TI Can the Sarcoidosis Health Questionnaire predict the long-term outcomes
   in Japanese sarcoidosis patients?
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Health-related quality of life; Health status;
   Questionnaire; Outcomes
ID QUALITY-OF-LIFE; VALIDATION; DISEASE; SF-36
AB Rationale: The Sarcoidosis Health Questionnaire (SHQ) is the first sarcoidosis-specific health status questionnaire ever developed. Worse health status, as evaluated by the SHQ, may indicate higher risk for deterioration in the following 5 years.
   Objectives: To evaluate the association between SHQ scores and deterioration defined clinically at 5-year follow-up.
   Methods: 122 patients with biopsy-supported sarcoidosis completed the SHQ and underwent evaluation with respect to organ involvement, chest radiograph, electrocardiogram, serum biomarker measurements, pulmonary function tests, and echocardiogram. Of these 122, 88 (72.1%) were available for pulmonary, cardiac, and nonpulmonary, non-cardiac deterioration assessment during the following 5 years.
   Measurements and main results: Five-year deterioration was observed in 20 patients (23%). The SHQ total score was significantly associated with 5-year deterioration, after adjusting for cardiac involvement at baseline, with adjusted odds ratio (OR) of 0.54 (95% confidence interval 95% CI], 0.29-0.99). The association of the total SHQ with 5-year outcome was not significant when adjusted for left ventricular ejection fraction (LVEF) at baseline (adjusted OR, 0.61 0.32-1.16]), whereas LVEF was significantly associated with 5-year outcome (adjusted OR, 0.92 0.86-0.99]). The association between total SHQ score and 5-year deterioration was marginal when adjusted for baseline usage of systemic corticosteroid (CS)/immunosuppressive (IS) agents (adjusted OR, 0.58 0.31-1.10]), whereas systemic CS/IS usage significantly predicted 5-year deterioration (adjusted odds ratio OR], 3.46 1.12-10.7]). There was a marginal correlation between the total SHQ and LVEF (rho=0.19, p=0.07) and a weak association between the total SHQ and systemic CS/IS usage (rho=-0.23, p=0.03). The Physical Functioning domain scores of the SHQ were significantly associated with 5-year deterioration (adjusted OR, 0.45-0.51).
   Conclusions: Worse health status, as assessed by the SHQ score, can be a risk factor for 5-year deterioration of sarcoidosis, although usage of the CS/IS at baseline and lower LVEF at baseline are more predictive of 5-year deterioration.
C1 [Tanizawa, Kiminobu; Oga, Toru; Chin, Kazuo] Kyoto Univ, Grad Sch Med, Dept Resp Care & Sleep Control Med, Kyoto, Japan.
   [Handa, Tomohiro; Ikezoe, Kohei; Sokai, Akihiko; Nakatsuka, Yoshinari; Hirai, Toyohiro] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan.
   [Nagai, Sonoko; Izumi, Takateru] Kyoto Cent Clin, Clin Res Ctr, Kyoto, Japan.
   [Kubo, Takeshi] Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Kyoto, Japan.
   [Ito, Yutaka] Nagoya City Univ, Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan.
   [Aihara, Kensaku; Mishima, Michiaki] Saiseikai Noe Hosp, Dept Resp Med, Osaka, Japan.
RP Handa, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.
EM tanizawa@kuhp.kyoto-u.ac.jp; hanta@kuhp.kyoto-u.ac.jp; nagai@chuo-c.jp;
   ogato@kuhp.kyoto-u.ac.jp; tkubo@kuhp.kyoto-u.ac.jp;
   yutaka@med.nagoya-cu.ac.jp; kensaku.aihara@noe.saiseikai.or.jp;
   koikezoe@kuhp.kyoto-u.ac.jp; socky@hotmail.co.jp;
   yosnaka@kuhp.kyoto-u.ac.jp; t_hirai@kuhp.kyoto-u.ac.jp;
   chink@kuhp.kyoto-u.ac.jp; mishima@kuhp.kyoto-u.ac.jp; izumi@chuo-c.jp
FU Ministry of Health, Labour and Welfare of JapanMinistry of Health,
   Labour and Welfare, Japan; Respiratory Failure Study Group, Scientific
   Research/Research on Intractable Diseases; Japan Society for the
   Promotion of Science KAKENHIMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JJP25860642,
   JJP16K09534, JJP26461187]; Japan Intractable Diseases Research
   Foundation; Ms. Mieko Sonoda Memorial Research Fund for Interstitial
   Lung Diseases
FX This study was supported in part by a grant from the Ministry of Health,
   Labour and Welfare of Japan awarded to the Study Group on Diffuse
   Pulmonary Disorders and the Respiratory Failure Study Group, Scientific
   Research/Research on Intractable Diseases. Other support includes the
   Japan Society for the Promotion of Science KAKENHI (Grant Numbers
   JJP25860642, JJP16K09534, and JJP26461187); a grant from the Japan
   Intractable Diseases Research Foundation; and the Ms. Mieko Sonoda
   Memorial Research Fund for Interstitial Lung Diseases.
CR Baughman RP, 2011, SARCOIDOSIS VASC DIF, V28, P56
   Casanova N, 2015, CLIN CHEST MED, V36, P621, DOI 10.1016/j.ccm.2015.08.005
   Cox CE, 2003, AM J RESP CRIT CARE, V168, P323, DOI 10.1164/rccm.200211-1343OC
   Cox CE, 2004, CHEST, V125, P997, DOI 10.1378/chest.125.3.997
   DEREMEE RA, 1983, CHEST, V83, P128, DOI 10.1378/chest.83.1.128
   Drent M, 2012, EUR RESPIR J, V40, P255, DOI 10.1183/09031936.00002512
   Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X
   Hajiro T, 1998, AM J RESP CRIT CARE, V157, P785, DOI 10.1164/ajrccm.157.3.9703055
   Handa T, 2006, CHEST, V129, P1246, DOI 10.1378/chest.129.5.1246
   Hinz A, 2012, SARCOIDOSIS VASC DIF, V29, P139
   Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
   IWAI K, 1994, SARCOIDOSIS, V11, P26
   IWATA N, 1989, AM J PUBLIC HEALTH, V79, P1486, DOI 10.2105/AJPH.79.11.1486
   Jastrzebski D, 2015, ADV EXP MED BIOL, V833, P31, DOI 10.1007/5584_2014_18
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75
   Judson MA, 2015, CLIN CHEST MED, V36, P739, DOI 10.1016/j.ccm.2015.08.014
   Judson MA, 2015, AM J RESP CRIT CARE, V191, P786, DOI 10.1164/rccm.201410-1785OC
   Judson MA, 2015, RESP MED, V109, P526, DOI 10.1016/j.rmed.2015.01.019
   KASAHARA Y, 1981, CLIN CHEM, V27, P1922
   Keir G, 2010, SEMIN RESP CRIT CARE, V31, P409, DOI 10.1055/s-0030-1262209
   Marcellis RGJ, 2014, SARCOIDOSIS VASC DIF, V31, P117
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miyoshi S, 2010, CHEST, V137, P1391, DOI 10.1378/chest.09-1975
   Moody A, 2004, THORAX, V59, P1
   Morimoto T, 2008, EUR RESPIR J, V31, P372, DOI 10.1183/09031936.00075307
   Nagai S, 2008, CLIN CHEST MED, V29, P565, DOI 10.1016/j.ccm.2008.03.006
   Patel AS, 2013, THORAX, V68, P57, DOI 10.1136/thoraxjnl-2012-201962
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rybicki B A, 1998, Semin Respir Infect, V13, P166
   Tanizawa K, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-34
   The Committee of Pulmonary Physiology JRS, 2004, GUID PULM FUNCT TEST
   Umeda Y, 2011, RESPIROLOGY, V16, P713, DOI 10.1111/j.1440-1843.2011.01966.x
   Valeyre D, 2014, LANCET, V383, P1155, DOI 10.1016/S0140-6736(13)60680-7
   Victorson DE, 2014, QUAL LIFE RES, V23, P89, DOI 10.1007/s11136-013-0438-1
   Walsh SLF, 2014, LANCET RESP MED, V2, P123, DOI 10.1016/S2213-2600(13)70276-5
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
NR 37
TC 0
Z9 0
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 1
EP 8
DI 10.1016/j.rmed.2019.01.001
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100001
PM 30885423
DA 2020-05-18
ER

PT J
AU Alves, SF
   Zanetti, G
   de Melo, ASA
   Souza, AS
   Souza, LS
   Meirelles, GDP
   Irion, KL
   Hochhegger, B
   Marchiori, E
AF Alves Junior, Sergio Ferreira
   Zanetti, Glaucia
   Alves de Melo, Alessandro Severo
   Souza, Arthur Soares, Jr.
   Souza, Luciana Soares
   Portes Meirelles, Gustavo de Souza
   Irion, Klaus Loureiro
   Hochhegger, Bruno
   Marchiori, Edson
TI Neurofibromatosis type 1: State-of-the-art review with emphasis on
   pulmonary involvement
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Neurofibromatosis type 1; Interstitial lung disease; Computed
   tomography; Pulmonary hypertension; Pulmonary diseases
ID LUNG-DISEASE; RECKLINGHAUSENS DISEASE; FIBROSING ALVEOLITIS;
   HYPERTENSION; DIAGNOSIS; CANCER; CT
AB Neurofibromatosis type 1 (NF-1), also known as von Recklinghausen's disease, is an autosomal dominant dysplasia of the ectoderm and mesoderm with a variable clinical expression, but near-complete penetrance before the age of 5 years. The estimated incidence is 1 in 3000 births. NF-1 is characterized by collections of neurofibromas, cafe-au-lait spots, axillary and inguinal freckling, and pigmented hamartomas in the iris (Lisch nodules). Pulmonary manifestations of NF-1, which usually include bilateral basal reticulations and apical bullae and cysts, are reported in 10-20% of adult patients. Clinically, neurofibromatosis-associated diffuse lung disease (NF-DLD) usually presents with nonspecific respiratory symptoms, including dyspnea on exertion, shortness of breath, and chronic cough or chest pain, at the time of diagnosis. Computed tomography (CT) is highly accurate for the identification and characterization of NF-DLD; it is the most reliable method for the diagnosis of this lung involvement. Various CT findings of NF-DLD, including cysts, bullae, ground-glass opacities, bibasilar reticular opacities, and emphysema, have been described in patients with NF-1. The typical CT pattern, however, is characterized by upper-lobe cystic and bullous disease, and basilar interstitial lung disease. Currently, the goal of NF-DLD treatment is the earliest possible diagnosis, focusing on symptom relief and interventions that positively alter the course of the disease, such as smoking cessation. The aim of this review is to describe the main clinical, pathological, and imaging aspects of NF-1, with a focus on pulmonary involvement.
C1 [Alves Junior, Sergio Ferreira; Zanetti, Glaucia; Marchiori, Edson] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Alves de Melo, Alessandro Severo] Univ Fed Fluminense, Rio De Janeiro, Brazil.
   [Souza, Arthur Soares, Jr.; Souza, Luciana Soares] Fac Med Sao Jose Do Rio Preto Famerp, Sao Jose Do Rio Preto, SP, Brazil.
   [Souza, Arthur Soares, Jr.; Souza, Luciana Soares] Ultra X, Sao Jose Do Rio Preto, SP, Brazil.
   [Portes Meirelles, Gustavo de Souza] Univ Fed Sao Paulo UNIFESP, Sao Paulo, SP, Brazil.
   [Portes Meirelles, Gustavo de Souza] Grp Fleury, Sao Paulo, SP, Brazil.
   [Irion, Klaus Loureiro] Univ Manchester, Manchester, Lancs, England.
   [Hochhegger, Bruno] Santa Casa Porto Alegre, Porto Alegre, RS, Brazil.
RP Marchiori, E (reprint author), Rua Thomaz Cameron 438, BR-25685120 Petropolis, RJ, Brazil.
EM sergio_faj@hotmail.com; glauciazanetti@gmail.com; alesevero@gmail.com;
   asouzajr@gmail.com; luciana.soaressouza@gmail.com; gmeirelles@gmail.com;
   klaus.irion@btinternet.com; brunohochhegger@gmail.com;
   edmarchiori@gmail.com
RI Hochhegger, Bruno/AAH-9945-2019; Irion, Klaus/M-2774-2013
OI Marchiori, Edson/0000-0001-8797-7380; Irion, Klaus/0000-0002-7860-7879
CR [Anonymous], 1988, Neurofibromatosis, V1, P172
   Antonio JR, 2013, AN BRAS DERMATOL, V88, P329, DOI 10.1590/abd1806-4841.20132125
   Arazi-Kleinmann T, 2002, EUR J RADIOL, V42, P69, DOI 10.1016/S0720-048X(01)00452-1
   Bouchentouf Rachid, 2016, Tunis Med, V94, P412
   Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051
   Casal A, 2018, PULMONOLOGY, V24, P269, DOI 10.1016/j.pulmoe.2018.06.001
   Chaddha U, 2017, CHEST, V152, pE89, DOI 10.1016/j.chest.2017.05.014
   Chan Jane W, 2012, Int Ophthalmol Clin, V52, P73, DOI 10.1097/IIO.0b013e318259df76
   Cho DG, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0374-y
   Davies PBD, 1963, THORAX, V18, P198
   de Andrade GC, 2003, ARQ NEURO-PSIQUIAT, V61, P677, DOI 10.1590/S0004-282X2003000400029
   Della SA, 2012, REV PNEUMOL CLIN, V68, P202, DOI 10.1016/j.pneumo.2011.08.001
   Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943
   Espig A. F., 2008, REV BRAS CIENCIA MOV, V6, P243
   Farid M, 2014, ONCOLOGIST, V19, P193, DOI 10.1634/theoncologist.2013-0328
   Plaza AF, 2014, RADIOLOGIA-MADRID, V56, P376, DOI 10.1016/j.rx.2012.06.009
   Ferner RE, 2007, J MED GENET, V44, P81, DOI 10.1136/jmg.2006.045906
   Fischer-Huchzermeyer S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187700
   Fortman BJ, 2001, RADIOGRAPHICS, V21, P601, DOI 10.1148/radiographics.21.3.g01ma05601
   Hirsch NP, 2001, BRIT J ANAESTH, V86, P555, DOI 10.1093/bja/86.4.555
   Hsu A, 2015, CLIN CASE REP, V3, P990, DOI 10.1002/ccr3.416
   HUNT JC, 1961, RADIOLOGY, V76, P1
   Jutant EM, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0053-2018
   Listernick R, 2007, ANN NEUROL, V61, P189, DOI 10.1002/ana.21107
   Louza GF, 2018, ARCH BRONCONEUMOL, V54, P106, DOI 10.1016/j.arbres.2017.07.011
   Lu-Emerson Christine, 2009, Rev Neurol Dis, V6, pE47
   MASSARO D, 1966, AM REV RESPIR DIS, V93, P934
   Montani D, 2011, MEDICINE, V90, P201, DOI 10.1097/MD.0b013e31821be2b7
   Muniz Marcos Pontes, 2010, Radiol Bras, V43, P167, DOI 10.1590/S0100-39842010000300007
   Nalepa Piotr, 2012, Pneumonol Alergol Pol, V80, P152
   Oikonomou A., 2013, CASE REP RADIOL, V2013
   Oikonomou A, 2011, EUR J RADIOL, V80, pE520, DOI 10.1016/j.ejrad.2010.11.033
   Pasmant E, 2015, EUR J HUM GENET, V23, P596, DOI 10.1038/ejhg.2014.145
   PATCHEFS.AS, 1973, CHEST, V64, P459, DOI 10.1378/chest.64.4.459
   Reviron-Rabec L, 2016, REV MAL RESPIR, V33, P460, DOI 10.1016/j.rmr.2014.09.010
   RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704
   Rodrigues D, 2018, RESPIR MED CASE REP, V24, P8, DOI 10.1016/j.rmcr.2018.03.008
   Rossi SE, 1999, AM J ROENTGENOL, V173, P1631, DOI 10.2214/ajr.173.6.10584812
   Ryu JH, 2005, CHEST, V128, P2381, DOI 10.1378/chest.128.4.2381
   SHIMIZU E, 1993, CANCER, V71, P725, DOI 10.1002/1097-0142(19930201)71:3<725::AID-CNCR2820710312>3.0.CO;2-F
   Shino MY, 2012, SEMIN RESP CRIT CARE, V33, P572, DOI 10.1055/s-0032-1325165
   Tonsgard James H, 2006, Semin Pediatr Neurol, V13, P2, DOI 10.1016/j.spen.2006.01.005
   Ueda K, 2015, EUR J RADIOL, V84, P1191, DOI [10.1016/j.jrad.2015.02.024, 10.1016/j.ejrad.2015.02.024]
   Vijapura C, 2017, RADIOGRAPHICS, V37, P258, DOI 10.1148/rg.2017160057
   Wakely SL, 2006, RADIOLOGY, V239, P607, DOI 10.1148/radiol.2392040224
   WEBB WR, 1977, RADIOLOGY, V122, P289, DOI 10.1148/122.2.289
   Zamora AC, 2007, EUR RESPIR J, V29, P210, DOI 10.1183/09031936.06.00044006
   Zuo Tao, 2014, Asian Cardiovasc Thorac Ann, V22, P219, DOI 10.1177/0218492312475293
NR 48
TC 2
Z9 2
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 9
EP 15
DI 10.1016/j.rmed.2019.01.002
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100002
PM 30885426
DA 2020-05-18
ER

PT J
AU Kuruvilla, ME
   Vanijcharoenkarn, K
   Shih, JA
   Lee, FEH
AF Kuruvilla, Merin E.
   Vanijcharoenkarn, Kristine
   Shih, Jennifer A.
   Lee, Frances Eun-Hyung
TI Epidemiology and risk factors for asthma
SO RESPIRATORY MEDICINE
LA English
DT Review
ID DUST-MITE ALLERGEN; EARLY-LIFE; CHILDHOOD ASTHMA; UNITED-STATES;
   EXPOSURE; PREVALENCE; CHILDREN; OBESITY; LUNG; SENSITIZATION
C1 [Kuruvilla, Merin E.; Vanijcharoenkarn, Kristine; Shih, Jennifer A.; Lee, Frances Eun-Hyung] Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.
RP Kuruvilla, ME (reprint author), Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.
EM merin.kuruvilla@emoryhealthcare.org
RI Kuruvilla, Merin/AAH-8832-2019
CR Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025
   Al-Alwan A, 2014, AM J RESP CRIT CARE, V189, P1494, DOI 10.1164/rccm.201401-0178OC
   Ali Z, 2013, CHEST, V143, P1649, DOI 10.1378/chest.12-2289
   Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271
   Bacharier L. B., 2012, J ALLERGY CLIN IMMUN, V130
   Baffi CW, 2016, CHEST, V149, P1525, DOI 10.1016/j.chest.2015.12.034
   Baur X, 2014, INT ARCH OCC ENV HEA, V87, P339, DOI 10.1007/s00420-013-0866-9
   Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030
   Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018
   Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196
   Cabieses B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105347
   Cardet JC, 2016, EUR RESPIR J, V48, P403, DOI 10.1183/13993003.00246-2016
   Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037
   Croisant S, 2014, ADV EXP MED BIOL, V795, P17, DOI 10.1007/978-1-4614-8603-9_2
   D'Amato G, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0036-x
   Dinakar C, 2016, NEW ENGL J MED, V375, P1372, DOI 10.1056/NEJMra1502466
   Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107
   Dunn RM, 2018, ALLERGY, V73, P284, DOI 10.1111/all.13258
   Ebmeier S, 2017, LANCET, V390, P935, DOI [10.1016/S0140-6736(17)31448-4, 10.1016/s0140-6736(17)31448-4]
   Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308
   Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801
   Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302
   Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807
   Forno E, 2015, J ALLERGY CLIN IMMUN, V136, P304, DOI 10.1016/j.jaci.2015.01.010
   Fu Liang, 2014, Ann Am Thorac Soc, V11, P939, DOI 10.1513/AnnalsATS.201402-084OC
   Fuseini H, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0686-1
   Gaga M, 2005, CLIN EXP ALLERGY, V35, P954, DOI 10.1111/j.1365-2222.2005.02281.x
   Genuneit J, 2014, AM J RESP CRIT CARE, V190, P588, DOI 10.1164/rccm.201403-0428LE
   Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037
   Ghosh A, 2018, AM J RESP CRIT CARE, V198, P67, DOI 10.1164/rccm.201710-2033OC
   Gibson PG, 2010, LANCET, V376, P803, DOI 10.1016/S0140-6736(10)61087-2
   Godtfredsen NS, 2001, EUR RESPIR J, V18, P549, DOI 10.1183/09031936.01.00100801
   Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021
   Guilbert T, 2019, J ALLER CL IMM-PRACT, V7, P568, DOI 10.1016/j.jaip.2018.07.050
   Hardin M, 2014, EUR RESPIR J, V44, P341, DOI 10.1183/09031936.00216013
   Hernandez ML, 2018, J ALLERGY CLIN IMMUN, V142, P1974, DOI 10.1016/j.jaci.2018.08.003
   Holbreich M, 2012, J ALLERGY CLIN IMMUN, V129, P1671, DOI 10.1016/j.jaci.2012.03.016
   Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801
   Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP
   Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L
   Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0
   Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125
   Liccardi G, 2016, EUR ANN ALLERGY CLIN, V48, P61
   Liu AH, 2016, J ALLERGY CLIN IMMUN, V138, P1042, DOI 10.1016/j.jaci.2016.06.060
   Lodge CJ, 2011, J ALLERGY CLIN IMMUN, V128, P782, DOI 10.1016/j.jaci.2011.06.038
   Loftus PA, 2016, CURR OPIN OTOLARYNGO, V24, P245, DOI 10.1097/MOO.0000000000000262
   Lukkarinen M, 2017, J ALLERGY CLIN IMMUN, V140, P988, DOI 10.1016/j.jaci.2016.12.991
   Mandelcwajg A, 2010, J PEDIATR-US, V157, P505, DOI 10.1016/j.jpeds.2010.04.067
   Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588
   Morales DR, 2014, CHEST, V145, P779, DOI 10.1378/chest.13-1235
   Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097
   Mushtaq A, 2018, LANCET RESP MED, V6, P335, DOI 10.1016/S2213-2600(18)30143-7
   Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2
   Nunes Carlos, 2017, Asthma Res Pract, V3, P1, DOI 10.1186/s40733-016-0029-3
   Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC
   Nyenhuis SM, 2010, J ALLERGY CLIN IMMUN, V125, P1163, DOI 10.1016/j.jaci.2010.02.015
   Ober C, 2016, ANN AM THORAC SOC, V13, pS85, DOI 10.1513/AnnalsATS.201507-459MG
   Oren E., 2017, J ALLERGY CLIN IMMUN, V5
   Ownby DR, 2013, J ALLERGY CLIN IMMUN, V132, P836, DOI 10.1016/j.jaci.2013.06.046
   Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169
   Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043
   Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004
   Phan JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092163
   Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796
   Pite H, 2014, RESP MED, V108, P1117, DOI 10.1016/j.rmed.2014.05.002
   Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045
   Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304
   Rosenberg SL, 2014, J ALLERGY CLIN IMMUN, V134, P1009, DOI 10.1016/j.jaci.2014.07.005
   Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049
   Rutkowski K, 2014, POSTEP DERM ALERGOL, V31, P77, DOI 10.5114/pdia.2014.40936
   Smith AM, 2011, IMMUNOL ALLERGY CLIN, V31, P663, DOI 10.1016/j.iac.2011.07.009
   Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002
   Sood A, 2010, ANN ALLERG ASTHMA IM, V104, P355, DOI 10.1016/j.anai.2010.01.010
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Spindel ER, 2016, AM J RESP CRIT CARE, V193, P486, DOI 10.1164/rccm.201510-2013PP
   Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749
   Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042
   Szefler S. J., 2011, ANN ALLERG ASTHMA IM, V107
   Takkouche B, 2008, ALLERGY, V63, P857, DOI 10.1111/j.1398-9995.2008.01732.x
   Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015
   Teague WG, 2017, J ALLER CL IMM-PRACT, V5, P979, DOI 10.1016/j.jaip.2017.03.023
   Tischer C, 2016, ENVIRON HEALTH PERSP, V124, P1919, DOI 10.1289/EHP158
   Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC
   TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630
   Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018
   Wang DX, 2013, RESPIROLOGY, V18, P313, DOI 10.1111/resp.12005
   Wang HY, 2008, CAN MED ASSOC J, V179, P1133, DOI 10.1503/cmaj.071797
   Wlasiuk G, 2012, CURR OPIN ALLERGY CL, V12, P461, DOI 10.1097/ACI.0b013e328357a3bc
   Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025
   Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547
   Zein JG, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0528-y
   Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108
   Ziska LH, 2012, J ALLERGY CLIN IMMUN, V129, P27, DOI 10.1016/j.jaci.2011.10.032
NR 93
TC 0
Z9 0
U1 1
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 16
EP 22
DI 10.1016/j.rmed.2019.01.014
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100003
PM 30885424
DA 2020-05-18
ER

PT J
AU Judson, MA
   Elicker, BM
   Colby, TV
   Kwon, S
   de Windt, E
   Chalkias, S
   Prada, C
   Smirnakis, K
   Singhal, P
AF Judson, Marc A.
   Elicker, Brett M.
   Colby, Thomas V.
   Kwon, Sooyeon
   de Windt, Elizabeth
   Chalkias, Spyros
   Prada, Claudia
   Smirnakis, Karen
   Singhal, Priya
TI The development of sarcoidosis in patients receiving daclizumab: A case
   series from multiple clinical trials
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Sarcoidosis; Daclizumab; Diagnosis; Drug reaction
ID ADVERSE EVENTS; SCLEROSIS
AB Introduction: Several drugs have been associated with druginduced sarcoidosis-like reactions (DISRs) that are clinically indistinguishable from sarcoidosis. Daclizumab is a humanized monoclonal IgG1 antibody that binds to CD25 that has been studied for the treatment of multiple sclerosis (MS). During MS clinical trials of daclizumab, 12 subjects developed clinical conditions potentially consistent with sarcoidosis. Therefore, an independent adjudication committee of individuals with expertise in sarcoidosis was organized to determine the likelihood of these cases representing sarcoidosis.
   Methods: The adjudication committee consisted of a pulmonologist, pathologist, and radiologist with clinical experience in sarcoidosis. The committee had access to the subjects' laboratory data, narratives of all suspect adverse reaction reports, radiographic imaging and histology from biopsies. A priori, a grading system was developed to determine criteria to establish the likelihood that the patient had developed sarcoidosis.
   Results: The adjudication confirmed sarcoidosis in 11/12 subjects. The committee's decisions were unanimous in all cases. Biopsies were available in 7/11 of these. In the 4 subjects who did not have a biopsy, they all had presentations, clinical findings, and/or laboratory findings that were highly specific for sarcoidosis. Alternative causes for these clinical findings were reasonably excluded in all cases. The lung (8/11) and skin (6/11) were the most common organs involved. The mean daclizumab dose given when signs or symptoms of sarcoidosis occurred was 5413 +/- 2704 mg and the median time from first daclizumab dose was 996 days. The incidence rate of developing sarcoidosis in those participating in these daclizumab trials was 154/100,000 patient-years compared with incidence rates of sarcoidosis in the United States of 3.2-17.8/100,000/year. These data suggest that these sarcoidosis cases may have represented DISRs related to daclizumab therapy.
   Conclusions: Given the clinical presentation and subsequent evaluation of these 11 subjects, we suspect that they had DISRs from daclizumab.
C1 [Judson, Marc A.] Albany Med Coll, Dept Med, Div Pulm & Crit Care Med, Albany, NY 12211 USA.
   [Elicker, Brett M.] Univ Calif San Francisco, Sch Med, Dept Radiol & Biomed Imaging, San Francisco, CA USA.
   [Colby, Thomas V.] Mayo Clin Arizona, Dept Pathol & Lab Med, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.
   [Kwon, Sooyeon] Ctr Rheumatol, Albany, NY USA.
   [de Windt, Elizabeth; Chalkias, Spyros; Prada, Claudia; Smirnakis, Karen; Singhal, Priya] Biogen, Cambridge, MA USA.
RP Judson, MA (reprint author), Albany Med Coll, Dept Med, Div Pulm & Crit Care Med, Albany, NY 12211 USA.
EM judsonm@mail.amc.edu
OI Judson, Marc/0000-0002-4663-7985
FU BiogenBiogen
FX The authors wish to acknowledge the expertise of Dr. James G. Krueger, a
   dermatologist who consulted specifically on some of the DZISR cases with
   skin involvement. Biogen funded the adjudication process described in
   this manuscript.
CR Baughman R. P., 2016, ANN AM THORACIC SOC, V13
   Bielekova B, 2011, NEUROLOGY, V77, P1877, DOI 10.1212/WNL.0b013e318239f7ef
   Carbonelli C, 2012, Monaldi Arch Chest Dis, V77, P29
   Chen TW, 2015, ANN ONCOL, V26, P1824, DOI 10.1093/annonc/mdv182
   Chopra A, 2018, CHEST, V154, P664, DOI 10.1016/j.chest.2018.03.056
   Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
   Kappos L, 2015, NEW ENGL J MED, V373, P1418, DOI 10.1056/NEJMoa1501481
   Le Burel S, 2017, EUR J CANCER, V82, P34, DOI 10.1016/j.ejca.2017.05.032
   Lycke J, 2015, THER ADV NEUROL DISO, V8, P274, DOI 10.1177/1756285615605429
   Petousi Nayia, 2012, J Med Case Rep, V6, P344, DOI 10.1186/1752-1947-6-344
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Rhone EE, 2018, MULT SCLER RELAT DIS, V20, P25, DOI 10.1016/j.msard.2017.12.011
   Sahraian Mohammad Ali, 2013, J Med Case Rep, V7, P270, DOI 10.1186/1752-1947-7-270
   Snyder-Cappione JE, 2013, EUR J IMMUNOL, V43, P2194, DOI 10.1002/eji.201243185
   Tondell A, 2014, SARCOIDOSIS VASC DIF, V31, P316
NR 15
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 23
EP 27
DI 10.1016/j.rmed.2019.01.015
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100004
PM 30885425
DA 2020-05-18
ER

PT J
AU Gerke, AK
AF Gerke, Alicia K.
TI Sarcoidosis: No longer a benign disease?
SO RESPIRATORY MEDICINE
LA English
DT Editorial Material
ID UNITED-STATES; MORTALITY
C1 [Gerke, Alicia K.] Univ Iowa, Pulm & Crit Care Med, 200 Hawkins Dr C33-GH, Iowa City, IA 52242 USA.
RP Gerke, AK (reprint author), Univ Iowa, Pulm & Crit Care Med, 200 Hawkins Dr C33-GH, Iowa City, IA 52242 USA.
EM alicia-gerke@uiowa.edu
CR Baughman RP, 1999, J CLIN EPIDEMIOL, V52, P1173
   Cozier YC, 2011, CHEST, V139, P144, DOI 10.1378/chest.10-0413
   Gideon NM, 1996, AM J MED, V100, P423, DOI 10.1016/S0002-9343(97)89518-6
   Hu XW, 2016, SARCOIDOSIS VASC DIF, V33, P275
   Hunninghake G W, 1999, Sarcoidosis Vasc Diffuse Lung Dis, V16, P149
   Janssen F, 2004, B WORLD HEALTH ORGAN, V82, P904
   Kearney GD, 2019, RESP MED, V149, P30, DOI 10.1016/j.rmed.2018.11.010
   Kirkil G, 2018, CHEST, V153, P105, DOI 10.1016/j.chest.2017.07.008
   Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120
   MORIYAMA IM, 1961, AM REV RESPIR DIS, V84, P116
   Nardi A, 2011, EUR RESPIR J, V38, P1368, DOI 10.1183/09031936.00187410
   National Research Council, 2009, VIT STAT SUMM WORKSH
   Rossides M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01815-2017
   Swigris JJ, 2011, AM J RESP CRIT CARE, V183, P1524, DOI 10.1164/rccm.201010-1679OC
NR 14
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 28
EP 29
DI 10.1016/j.rmed.2019.02.002
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100005
PM 30777310
DA 2020-05-18
ER

PT J
AU Kearney, GD
   Obi, ON
   Maddipati, V
   Mohan, A
   Malur, A
   Carter, JC
   Thomassen, MJ
AF Kearney, Gregory D.
   Obi, Ogugua Ndili
   Maddipati, Veeranna
   Mohan, Arjun
   Malur, Anagha
   Carter, J. Christopher
   Thomassen, Mary Jane
TI Sarcoidosis deaths in the United States: 1999-2016
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pulmonary; Mortality; Epidemiology; Disease burden; Sarcoidosis
ID MORTALITY; EPIDEMIOLOGY
AB Background: It has been over a decade since a comprehensive study has been published that has examined sarcoidosis deaths at the national level. The purpose of this study was to analyze sarcoidosis as the underlying cause of death using current national death certificate data. Results from this project can be used to evaluate and compare trends of sarcoidosis reported deaths across the U.S.
   Methods: Mortality data from 1999 to 2016 were provided by the National Vital Statistics System (NVSS) with sarcoidosis (ICD-D86.X) as the underlying cause of death from all resident death certificates filed in the 50 states and the District of Columbia (DC). Data were analyzed using CDC WONDER, a web-based public health database and analysis tool. Queries were used to generate number of deaths, along with unadjusted and age-adjusted death rates with 95% confidence intervals and standard errors for groups including year, census region, gender, age group, race/ethnicity and state. Joinpoint regression analysis was used to test the significance of trends in race and gender-specific rates for the 1999-2016 study period.
   Results: From 1999 to 2016, there were a total of 16,665 sarcoidosis reported deaths in the U.S. The overall age-adjusted mortality rate increased from 2.1 (deaths per 1,000,000) in 1999 to 3.1 in 2002, but then remained relatively stable thereafter until the end of the study period. Female deaths increased 32.0% (from 2.5 to 3.3 per 1,000,000), while male deaths increased 73.3% (from 1.5 to 2.6 deaths per 1,000,000). The highest age-adjusted death rates were among black females (17.0 deaths per 1,000,000), and black males (12.4 deaths per 1,000,000). At the regional level, the southern U.S. had the highest overall mean age-adjusted mortality rate (3.7 deaths per 1,000,000), while black females in the Midwest (18.7 per 1,000,000) had the highest race-specific reported death rate.
   Discussion: The detected increase in the total number of deaths and age-adjusted rates of sarcoidosis deaths in the U.S. is a serious health concern. Factors that contribute to sarcoidosis deaths remain uncertain and more epidemiological research studies are needed to compliment current bench science to explore and examine factors that contribute to this multifactorial, chronic disease.
C1 [Kearney, Gregory D.; Carter, J. Christopher] East Carolina Univ, Brody Sch Med, Dept Publ Hlth, Greenville, NC 27858 USA.
   [Obi, Ogugua Ndili; Maddipati, Veeranna; Mohan, Arjun; Malur, Anagha] East Carolina Univ, Dept Internal Med, Div Pulm & Crit Care, Brody Sch Med, Greenville, NC 27858 USA.
   [Thomassen, Mary Jane] East Carolina Univ, Brody Sch Med, Div Pulm & Crit Care, Program Lung Cell Biol & Translat Res, Greenville, NC 27858 USA.
RP Kearney, GD (reprint author), East Carolina Heart Inst, 115 Heart Dr,MS 660, Greenville, NC 27834 USA.
EM Kearneyg@ecu.edu; Obio@ecu.edu; Maddipativ15@ecu.edu; Mohana14@ecu.edu;
   Malura@ecu.edu; carterjoh14@students.ecu.edu; Thomassenm@ecu.edu
RI Mohan, Arjun/AAH-9715-2019
OI Obi, Ogugua Ndili/0000-0002-4692-1345; Kearney, Greg/0000-0001-9684-9516
CR Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
   Baughman RP, 2007, CLIN DERMATOL, V25, P231, DOI 10.1016/j.clindermatol.2007.03.014
   Baughman RP, 2011, AM J RESP CRIT CARE, V183, P1446, DOI 10.1164/rccm.201103-0409ED
   Baughman RP, 1997, SARCOIDOSIS VASC DIF, V14, P154
   Celada LJ, 2015, CLIN CHEST MED, V36, P561, DOI 10.1016/j.ccm.2015.08.001
   Centers for Disease Control and Prevention, CDC WONDER
   Chopra A, 2016, EXPERT REV CLIN IMMU, V12, P1191, DOI 10.1080/1744666X.2016.1196135
   Cozier YC, 2016, EUR RESPIR J, V48, P1545, DOI 10.1183/13993003.01819-2016
   Culver DA, 2016, CURR OPIN PULM MED, V22, P466, DOI 10.1097/MCP.0000000000000310
   Dubrey S, 2014, POSTGRAD MED J, V90, P582, DOI 10.1136/postgradmedj-2014-132584
   Erdal BS, 2012, RESP MED, V106, P893, DOI 10.1016/j.rmed.2012.02.007
   Gerke AK, 2017, ANN AM THORAC SOC, V14, pS421, DOI 10.1513/AnnalsATS.201707-564OT
   Gerke AK, 2014, CURR OPIN PULM MED, V20, P472, DOI 10.1097/MCP.0000000000000080
   Gideon NM, 1996, AM J MED, V100, P423, DOI 10.1016/S0002-9343(97)89518-6
   Gribbin J, 2006, THORAX, V61, P980, DOI 10.1136/thx.2006.062836
   Hu XW, 2016, SARCOIDOSIS VASC DIF, V33, P275
   Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
   Kirkil G, 2018, CHEST, V153, P105, DOI 10.1016/j.chest.2017.07.008
   Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120
   Reich JM, 2002, CHEST, V121, P32, DOI 10.1378/chest.121.1.32
   Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532
   Statistical Methodology and Applications Branch Surveillance Research Program National Cancer Institute, 2018, JOINP REGR PROGR 4 6
   Swigris JJ, 2011, AM J RESP CRIT CARE, V183, P1524, DOI 10.1164/rccm.201010-1679OC
   Tukey MH, 2013, SARCOIDOSIS VASC DIF, V30, P128
NR 24
TC 3
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 30
EP 35
DI 10.1016/j.rmed.2018.11.010
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100006
PM 30471894
DA 2020-05-18
ER

PT J
AU Terwiel, M
   Moorsel, CHM
AF Terwiel, Michelle
   van Moorsel, Coline H. M.
TI Clinical epidemiology of familial sarcoidosis: A systematic literature
   review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Familial sarcoidosis; Prevalence; Heritability; Familial risk; Relative
   risks; Clinical findings
ID AFRICAN-AMERICAN; RISK; BTNL2; GENE; GRANULOMATOSIS; ASSOCIATION;
   MUTATIONS; ARTHRITIS; ETIOLOGY
AB Introduction: Although the presence of familial sarcoidosis has been confirmed, clinical and epidemiological data on its characteristics are scattered and sometimes paradoxical. The objective of this review is to assess what is known on the clinical epidemiology of familial sarcoidosis, by combining data from early case reports with recent population based data; aiming to support in clinical decision making and providing information to patients.
   Method: A systematic review of the literature in PubMed was done and 27 studies with clinical or epidemiological data on familial sarcoidosis, published between 1947 and 2017, were included.
   Results: The pooled prevalence proportion of familial sarcoidosis, based on twelve study populations, was 9.5% (CI 4.6-16.1), highest in French, African American, Dutch and Irish patients. A heritability of 60-70% was estimated in diverse studies. Relative types and relationships most often reported in familial sarcoidosis were siblings and mother-child relationships. Familial risk is heterogeneous. In African Americans specific environmental factors have been associated with familial sarcoidosis (OR between 1.5 and 3.2). European American and African American subjects had different relative risks for first degree familial relationships (OR of 16.6 vs 3.1) and relative risk differed between relative types. Clinical findings in familial sarcoidosis are still obscure.
   Conclusions: Prevalence of familial sarcoidosis is high in specific study populations from countries worldwide. The estimated heritability of 60-70%, suggests a shared determinant, and the heterogeneous familial risk, associated with both genetic and environmental factors. Familial relative risks and clinical phenotypes may differ between ethnic groups and relative types, but require further study.
C1 [Terwiel, Michelle; van Moorsel, Coline H. M.] St Antonius Hosp, St Antonius ILD Ctr Excellence, Dept Pulmonol, Nieuwegein, Netherlands.
   [van Moorsel, Coline H. M.] Univ Med Ctr Utrecht, Div Heart & Lung, Utrecht, Netherlands.
RP Moorsel, CHM (reprint author), St Antonius Hosp, Dept Pulmonol, Interstitial Lung Dis Ctr Excellence, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.
EM c.van.moorsel@antoniusziekenhuis.nl
FU ZonMwNetherlands Organization for Health Research and Development
   [842002001]
FX The authors thank Ms Carla Sloof, librarian at St. Antonius hospital,
   Nieuwegein, for her effort in setting up a systematic PubMed search; Ms
   Ellen Tromp, epidemiologist at St. Antonius hospital, Nieuwegein, for
   her consultation in statistical analyses. This study is part of the
   TopZorg Lung grant funded by ZonMw (nr 842002001).
CR Agyemang C, 2005, J EPIDEMIOL COMMUN H, V59, P1014, DOI 10.1136/jech.2005.035964
   BAMBERY P, 1991, THORAX, V46, P919, DOI 10.1136/thx.46.12.919
   Beijer E, 2017, SEMIN RESP CRIT CARE, V38, P404, DOI 10.1055/s-0037-1603087
   BRENNAN NJ, 1984, THORAX, V39, P14, DOI 10.1136/thx.39.1.14
   CARMICHAEL AJ, 1989, ACTA DERM-VENEREOL, V69, P531
   CHENG DS, 1979, SOUTHERN MED J, V72, P645, DOI 10.1097/00007611-197906000-00004
   Coudurier M, 2009, SARCOIDOSIS VASC DIF, V26, P162
   Elford J, 2000, THORAX, V55, P343, DOI 10.1136/thorax.55.4.343
   Fite E, 1998, RESPIRATION, V65, P34, DOI 10.1159/000029225
   Frisell T, 2016, NAT REV RHEUMATOL, V12, P335, DOI 10.1038/nrrheum.2016.52
   Goldberg MF, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0005-2013
   HEADINGS VE, 1976, ANN NY ACAD SCI, V278, P377, DOI 10.1111/j.1749-6632.1976.tb47049.x
   Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
   Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
   Judson MA, 2006, CHEST, V130, P855, DOI 10.1378/chest.130.3.855
   Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972
   KREMER JM, 1986, J RHEUMATOL, V13, P593
   Kucera GP, 2003, CHEST, V123, P1527, DOI 10.1378/chest.123.5.1527
   Luisetti M, 1988, Sarcoidosis, V5, P90
   McGrath DS, 2000, THORAX, V55, P751, DOI 10.1136/thorax.55.9.751
   Musellim B, 2009, RESP MED, V103, P907, DOI 10.1016/j.rmed.2008.12.011
   NOWINSKI T, 1983, OPHTHALMOLOGY, V90, P909
   Lazzarini LCO, 2008, RESPIRATION, V76, P356, DOI 10.1159/000101013
   Pacheco Y, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0546-4
   Permg RP, 2007, J FORMOS MED ASSOC, V106, P499
   Pietinalho A, 1999, RESP MED, V93, P408, DOI 10.1053/rmed.1999.0579
   Piotrowski WJ, 2014, AM J CASE REP, V15, P216, DOI 10.12659/AJCR.890014
   Prasse A, 2008, AM J RESP CRIT CARE, V177, P330, DOI 10.1164/rccm.200705-742OC
   Rossman MD, 2008, SARCOIDOSIS VASC DIF, V25, P125
   Rybicki BA, 1996, GENET EPIDEMIOL, V13, P23
   Rybicki BA, 1999, SARCOIDOSIS VASC DIF, V16, P203
   Rybicki BA, 2005, AM J HUM GENET, V77, P491, DOI 10.1086/444435
   Rybicki BA, 2004, SARCOIDOSIS VASC DIF, V21, P49
   Rybicki BA, 2001, AM J EPIDEMIOL, V153, P188, DOI 10.1093/aje/153.2.188
   Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001
   Schurmann M, 2000, AM J RESP CRIT CARE, V162, P861, DOI 10.1164/ajrccm.162.3.9901099
   Schurmann M, 2003, EUR RESPIR J, V22, P748, DOI 10.1183/09031936.03.00040602
   Soria L M, 1990, Sarcoidosis, V7, P133
   Sverrild A, 2008, THORAX, V63, P894, DOI 10.1136/thx.2007.094060
   TURNER RG, 1975, BRIT J OPHTHALMOL, V59, P657, DOI 10.1136/bjo.59.11.657
   Valentonyte R, 2005, NAT GENET, V37, P357, DOI 10.1038/ng1519
   Wirnsberger RM, 1998, NETH J MED, V53, P53, DOI 10.1016/S0300-2977(98)00058-8
NR 42
TC 4
Z9 4
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 36
EP 41
DI 10.1016/j.rmed.2018.11.022
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100007
PM 30587386
DA 2020-05-18
ER

PT J
AU Valentin, R
   Hyde, R
   Gomez-Manjarres, D
   Patel, DC
AF Valentin, Ramon
   Hyde, Ryan
   Gomez-Manjarres, Diana
   Patel, Divya C.
TI Untitled
SO RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Valentin, Ramon; Hyde, Ryan; Gomez-Manjarres, Diana; Patel, Divya C.] Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL 32611 USA.
RP Patel, DC (reprint author), Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL 32611 USA.
EM Divya.Patel@medicine.ufl.edu
OI Patel, Divya/0000-0001-5405-8409
CR Collins BF, 2018, RESP MED, V144, pS20, DOI 10.1016/j.rmed.2018.08.008
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Salisbury ML, 2019, CHEST, V155, P699, DOI 10.1016/j.chest.2018.08.1076
NR 3
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 42
EP 42
DI 10.1016/j.rmed.2018.10.011
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100008
PM 30528974
DA 2020-05-18
ER

PT J
AU Collins, BF
   Raghu, G
AF Collins, Bridget F.
   Raghu, Ganesh
TI Response to Letter to Editor regarding "Sarcoidosis and IPF in the same
   patient-a coincidence, an association or a phenotype?"
SO RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Collins, Bridget F.; Raghu, Ganesh] Univ Washington, Med Ctr, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
RP Raghu, G (reprint author), Univ Washington, Med Ctr, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
EM graghu@uw.edu
CR Collins BF, 2018, RESP MED, V144, pS20, DOI 10.1016/j.rmed.2018.08.008
   US National Library of Medicine, EFF SAF NINT PAT PRO
NR 2
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 43
EP 44
DI 10.1016/j.rmed.2018.10.029
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100009
PM 30389206
DA 2020-05-18
ER

PT J
AU Kosse, RC
   Bouvy, ML
   de Vries, TW
   Koster, ES
AF Kosse, Richelle C.
   Bouvy, Marcel L.
   de Vries, Tjalling W.
   Koster, Ellen S.
TI Effect of a mHealth intervention on adherence in adolescents with
   asthma: A randomized controlled trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE adherence; Adolescents; Asthma; Clinical trial; Inhaled corticosteroids;
   mHealth
ID QUALITY-OF-LIFE; MEDICATION ADHERENCE; SELF-MANAGEMENT; ALLERGIC
   RHINITIS; PEDIATRIC ASTHMA; DUTCH CHILDREN; VALIDATION; COMMUNITY;
   VALIDITY
AB Background: Adherence rates among asthma patients are generally low and decrease during adolescence, resulting in poorly controlled asthma. The aim of our study was to evaluate the effectiveness of the ADolescent Adherence Patient Tool (ADAPT), an interactive mobile health (mHealth) intervention, in supporting self-management and improving inhaled corticosteroid adherence in adolescents with asthma.
   Methods: We conducted a cluster randomized controlled trial in 66 Dutch community pharmacies. Asthma patients aged 12-18 years were invited to participate, based on pharmacy medication refill records. The main study outcome was self-reported medication adherence, measured with the Medication Adherence Report Scale (MARS). Secondary outcomes were asthma control and quality of life. Outcomes were measured at start (t=0 months) and at the end of follow-up (t=6 months). Mixed-effects models were used to analyze the effect.
   Results: In total, 234 adolescents (147 in the control group and 87 in the intervention group) completed the study; mean age 15.1 +/- 1.9 years and 52.6% females. Adherence rates of patients with low baseline adherence (MARS scores <= 19; n=76) increased with 1.42 points in the intervention group (n=26). Adherence rates of patients in the control group (n=50) decreased with 0.70 points. Thus there was a positive effect of the intervention on medication adherence (MARS +2.12, p=0.04). This effect was stronger (MARS +2.52, p=0.02) in poor adherent adolescents with uncontrolled asthma (n=74). No effect of the intervention was observed on asthma control or quality of life.
   Conclusions: The ADAPT intervention increases medication adherence in adolescents with asthma having poor adherence rates at baseline. Healthcare providers should consider a tailored mHealth approach to improve the asthma treatment.
C1 [Kosse, Richelle C.; Bouvy, Marcel L.; Koster, Ellen S.] Univ Utrecht, Fac Sci, UIPS, Div Pharmacoepidemiol & Clin Pharmacol, POB 80082, NL-3508 TB Utrecht, Netherlands.
   [de Vries, Tjalling W.] MCL, Dept Pediat, Leeuwarden, Netherlands.
RP Koster, ES (reprint author), Univ Utrecht, Fac Sci, UIPS, Div Pharmacoepidemiol & Clin Pharmacol, POB 80082, NL-3508 TB Utrecht, Netherlands.
EM R.C.Kosse@uu.nl; M.L.Bouvy@uu.nl; Tjalling.de.Vries@ZNB.nl;
   E.Koster@uu.nl
OI Kosse, Richelle/0000-0001-9059-1278
FU Netherlands Organization for Health Research and Development
   (ZonMw)Netherlands Organization for Health Research and Development
   [836031002]; Umenz Benelux BV
FX The authors thank the pharmacists and adolescents who participated in
   the study, Sjanne van Roijen for her assistance with the inclusion,
   Svetlana Belitser for the statistical help, and Piet van der Wal and
   Pieter-Joep Huige for their help with the intervention. For this study,
   unrestricted funding was received from the Netherlands Organization for
   Health Research and Development (ZonMw) [project number 836031002] and
   from Umenz Benelux BV.
CR [Anonymous], 2014, MIJN KIND ONLINE
   Azevedo P, 2013, PRIM CARE RESP J, V22, P112, DOI 10.4104/pcrj.2013.00012
   Badawy SM, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.7798
   Barnes CB, 2015, RESP CARE, V60, P455, DOI 10.4187/respcare.03200
   Belisario JSM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010013.pub2
   Bonini M, 2018, CURR OPIN PULM MED, V24, P63, DOI 10.1097/MCP.0000000000000439
   Choudhry NK, 2017, JAMA INTERN MED, V177, P624, DOI 10.1001/jamainternmed.2016.9627
   Dawson LA, 2019, ARCH DIS CHILDHOOD-E, V104, P49, DOI 10.1136/archdischild-2017-312820
   De Simoni A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015245
   DiMatteo MR, 2012, HEALTH PSYCHOL REV, V6, P74, DOI 10.1080/17437199.2010.537592
   Emons JAM, 2017, PEDIAT ALLERG IMM-UK, V28, P185, DOI 10.1111/pai.12678
   Engelkes M, 2015, EUR RESPIR J, V45, P396, DOI 10.1183/09031936.00075614
   Fuchs O, 2017, LANCET RESP MED, V5, P224, DOI 10.1016/S2213-2600(16)30187-4
   Haughney J, 2008, RESP MED, V102, P1681, DOI 10.1016/j.rmed.2008.08.003
   Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S
   Huckvale K, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-144
   Jentzsch Nulma S., 2019, J. Pediatr. (Rio J.), V95, P69, DOI 10.1016/j.jped.2017.10.008
   Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967
   Kosse RC, 2017, J ADOLESCENT HEALTH, V61, P619, DOI 10.1016/j.jadohealth.2017.05.027
   Kosse RC, 2017, PATIENT PREFER ADHER, V11, P571, DOI 10.2147/PPA.S124615
   Koster ES, 2015, J ASTHMA, V52, P831, DOI 10.3109/02770903.2015.1020388
   Koster ES, 2014, INT J CLIN PHARM-NET, V36, P669, DOI 10.1007/s11096-014-9954-5
   L'Engle KL, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0884
   McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022
   Mossialos E, 2015, HEALTH POLICY, V119, P628, DOI 10.1016/j.healthpol.2015.02.007
   Mulder B, 2016, EUR J CLIN PHARMACOL, V72, P73, DOI 10.1007/s00228-015-1940-x
   Nieuwlaat R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub4
   Peters D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6994
   Raat H, 2005, QUAL LIFE RES, V14, P265, DOI 10.1007/s11136-004-0798-7
   Rhee H, 2011, ARCH PEDIAT ADOL MED, V165, P513, DOI 10.1001/archpediatrics.2011.79
   Sattoe JNT, 2015, PATIENT EDUC COUNS, V98, P704, DOI 10.1016/j.pec.2015.03.004
   Sjolander M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003551
   Sundberg R, 2009, RESP MED, V103, P1580, DOI 10.1016/j.rmed.2009.04.023
   Taddeo D, 2008, PAED CHILD HEALT-CAN, V13, P19, DOI 10.1093/pch/13.1.19
   Thompson K, 2000, SCHIZOPHR RES, V42, P241, DOI 10.1016/S0920-9964(99)00130-9
   Vasbinder EC, 2016, EUR RESPIR J, V48, P758, DOI 10.1183/13993003.01698-2015
   Wu AC, 2015, J ALLER CL IMM-PRACT, V3, P446, DOI 10.1016/j.jaip.2014.12.011
NR 37
TC 7
Z9 7
U1 1
U2 12
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 45
EP 51
DI 10.1016/j.rmed.2019.02.009
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100010
PM 30803885
DA 2020-05-18
ER

PT J
AU Moy, ML
   Harrington, KF
   Sternberg, AL
   Krishnan, JA
   Albert, RK
   Au, DH
   Casaburi, R
   Criner, GJ
   Diaz, P
   Kanner, RE
   Panos, RJ
   Stibolt, T
   Stoller, JK
   Tonascia, J
   Yusen, RD
   Tan, AYM
   Fuhlbrigge, AL
AF Moy, Marilyn L.
   Harrington, Kathleen F.
   Sternberg, Alice L.
   Krishnan, Jerry A.
   Albert, Richard K.
   Au, David H.
   Casaburi, Richard
   Criner, Gerard J.
   Diaz, Philip
   Kanner, Richard E.
   Panos, Ralph J.
   Stibolt, Thomas
   Stoller, James K.
   Tonascia, James
   Yusen, Roger D.
   Tan, Ai-Yui M.
   Fuhlbrigge, Anne L.
CA LOTT Res Grp
TI Characteristics at the time of oxygen initiation associated with its
   adherence: Findings from the COPD Long-term Oxygen Treatment Trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE LTOT; COPD; Adherence; Self-efficacy; Readiness; Confidence
ID OBSTRUCTIVE PULMONARY-DISEASE; AMBULATORY OXYGEN; RANDOMIZED-TRIAL;
   THERAPY; CONCENTRATORS; PRESCRIPTION; DESIGN; LTOT; HOME
AB Rationale: Characteristics associated with adherence to long-term oxygen therapy (LTOT) in COPD remain unclear.
   Objectives: To identify patient characteristics at the time of oxygen initiation associated with its adherence.
   Methods: We conducted a secondary analysis of data from 359 COPD participants assigned to oxygen in the Long-term Oxygen Treatment Trial. Participants were prescribed continuous (n=214) or intermittent (n=145) oxygen based on desaturation patterns at study entry. At the time of initial prescription, participants rated their perceived readiness, confidence, and importance to use oxygen on a 0-10 scale (0=not at all, 10=very much). During follow-up, they self-reported average hours per day of use (adherence). Adherence was averaged over short-term (0-30 days), medium-term (months 9-12), and long-term (month 13 to last follow-up) intervals. Multivariable logistic regression models explored characteristics associated with high adherence (>= 16 h/day [continuous] or >= 8 h/day [intermittent]) during each time interval.
   Results: Participant readiness, confidence, and importance at the time of oxygen initiation were associated with high short- and medium-term adherence. For each unit increase in baseline readiness, the odds of high short-term adherence increased by 21% (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.05-1.40) and 94% (OR 1.94, 95% CI 1.45-2.59) in the continuous and intermittent groups, respectively. In both groups, high adherence in the medium-term was associated with high adherence in the long-term (continuous, OR 12.49, 95% CI 4.90-31.79; intermittent, OR 38.08, 95% CI 6.96-208.20).
   Conclusions: Readiness, confidence, and importance to use LTOT at initiation, and early high adherence, are significantly associated with long-term oxygen adherence.
C1 [Moy, Marilyn L.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA.
   [Moy, Marilyn L.] Harvard Med Sch, Boston, MA 02115 USA.
   [Harrington, Kathleen F.] Univ Alabama Birmingham, Sch Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA.
   [Sternberg, Alice L.] Johns Hopkins Univ, Dept Epidemiol, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Krishnan, Jerry A.] Univ Illinois, Coll Med, Chicago, IL USA.
   [Albert, Richard K.; Fuhlbrigge, Anne L.] Univ Colorado, Sch Med, Aurora, CO USA.
   [Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Au, David H.] Univ Washington, Seattle, WA 98195 USA.
   [Casaburi, Richard] Harbor UCLA Med Ctr, Rehabil Clin Trials Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
   [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Diaz, Philip] Ohio State Univ, Pulm Allergy Crit Care & Sleep Med Div, Columbus, OH 43210 USA.
   [Kanner, Richard E.] Univ Utah, Hlth Sci Ctr, Div Pulm Med, Salt Lake City, UT USA.
   [Panos, Ralph J.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
   [Panos, Ralph J.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
   [Stibolt, Thomas] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Stoller, James K.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Tonascia, James] Johns Hopkins Univ, Dept Biostat, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Yusen, Roger D.] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA.
   [Tan, Ai-Yui M.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
RP Moy, ML (reprint author), Harvard Med Sch, VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
EM marilyn.moy@va.gov
FU National Heart, Lung, and Blood Institute, National Institutes of
   Health, Department of Health and Human ServicesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HHSN268200736183C,
   HHSN268200736-184C, HHSN268200736185C, HHSN268200736186C,
   HHSN268200-736187C, HHSN268200736188C, HHSN268200736189C]; Centers for
   Medicare and Medicaid Services, Department of Health and Human Services;
   [HHSN268-200736190C];  [HHSN268200736191C];  [HHSN268200736192C]; 
   [HHSN-268200736193C];  [HHSN268200736194C];  [HHSN268200736195C]; 
   [HHSN268200736196C];  [HHSN268200736197C];  [Y1-HR-7019-01]; 
   [Y1-HR-8076-01]
FX The Long-term Oxygen Treatment Trial (LOTT) was supported through
   federal funding from the National Heart, Lung, and Blood Institute,
   National Institutes of Health, Department of Health and Human Services
   [contracts HHSN268200736183C, HHSN268200736-184C, HHSN268200736185C,
   HHSN268200736186C, HHSN268200-736187C, HHSN268200736188C,
   HHSN268200736189C, HHSN268-200736190C, HHSN268200736191C,
   HHSN268200736192C, HHSN-268200736193C, HHSN268200736194C,
   HHSN268200736195C, HHSN268200736196C, HHSN268200736197C, Y1-HR-7019-01,
   and Y1-HR-8076-01] in cooperation with the Centers for Medicare and
   Medicaid Services, Department of Health and Human Services.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Albert RK, 2016, NEW ENGL J MED, V375, P1617, DOI 10.1056/NEJMoa1604344
   [Anonymous], 1980, ANN INTERN MED, V93, P391
   Arnold E, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-9
   Casaburi R, 2012, COPD, V9, P3, DOI 10.3109/15412555.2011.630048
   Croxton TL, 2006, AM J RESP CRIT CARE, V174, P373, DOI 10.1164/rccm.200507-1161WS
   Cullen D L, 2006, Chron Respir Dis, V3, P217, DOI 10.1177/1479972306070506
   Earnest MA, 2002, J GEN INTERN MED, V17, P749, DOI 10.1046/j.1525-1497.2002.20218.x
   EVANS TW, 1983, BRIT MED J, V287, P459, DOI 10.1136/bmj.287.6390.459
   Global Initiative for Chronic Lung Disease, 2017, GLOBAL STRATEGY DIAG
   Granados A, 1997, RESP MED, V91, P89, DOI 10.1016/S0954-6111(97)90073-1
   Holm KE, 2016, PATIENT, V9, P271, DOI 10.1007/s40271-015-0150-z
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   HOWARD P, 1992, EUR RESPIR J, V5, P128
   Jacobs SS, 2018, ANN AM THORAC SOC, V15, P24, DOI 10.1513/AnnalsATS.201703-209OC
   Katsenos S, 2011, PULM MED, V2011, DOI 10.1155/2011/325362
   Lacasse Y, 2005, EUR RESPIR J, V25, P1032, DOI 10.1183/09031936.05.00113504
   Lacasse Y, 2018, AM J RESP CRIT CARE, V197, P1254, DOI 10.1164/rccm.201802-0382CI
   Lin SKV, 2006, RESP CARE, V51, P266
   Lindsey C, 2015, STATA J, V15, P1046, DOI 10.1177/1536867X1501500406
   Peckham DG, 1998, RESP MED, V92, P1203, DOI 10.1016/S0954-6111(98)90422-X
   Pepin JL, 1996, CHEST, V109, P1144, DOI 10.1378/chest.109.5.1144
   RESTRICK LJ, 1993, THORAX, V48, P708, DOI 10.1136/thx.48.7.708
   Ringbaek T, 1999, RESP MED, V93, P333, DOI 10.1016/S0954-6111(99)90314-1
   ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203
   Verduri A, 2014, INTERN EMERG MED, V9, P319, DOI 10.1007/s11739-012-0898-2
   VERGERET J, 1989, EUR RESPIR J, V2, P20
   WALSHAW MJ, 1990, RESP MED, V84, P331, DOI 10.1016/S0954-6111(08)80062-5
   WALSHAW MJ, 1988, BRIT MED J, V297, P1030, DOI 10.1136/bmj.297.6655.1030
   Wang Z, 2000, STATA TECH B, V54, P57
   Yusen RD, 2018, ANN AM THORAC SOC, V15, P89, DOI 10.1513/AnnalsATS.201705-374SD
NR 31
TC 2
Z9 2
U1 1
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 52
EP 58
DI 10.1016/j.rmed.2019.02.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100011
PM 30803886
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Jeminiwa, R
   Hohmann, L
   Qian, JJ
   Garza, K
   Hansen, R
   Fox, BI
AF Jeminiwa, Ruth
   Hohmann, Lindsey
   Qian, Jingjing
   Garza, Kimberly
   Hansen, Richard
   Fox, Brent I.
TI Impact of eHealth on medication adherence among patients with asthma: A
   systematic review and meta-analysis
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Asthma; eHealth; mHealth; telehealth; Medication adherence;
   Meta-analysis
ID AUDIOVISUAL REMINDER FUNCTION; IMPROVE ADHERENCE; INTERVENTION;
   CHILDREN; HEALTH; THERAPY; PILOT
AB Background: Asthma is an important public health issue in the United States. eHealth technology offers a potential solution to asthma treatment adherence, but the relative effect of various types of eHealth interventions has not been systematically studied.
   Objectives: To systematically review the effectiveness of eHealth in improving adherence to inhaled corticosteroids (ICS) among patients with persistent asthma, as well as the satisfaction of patients undergoing eHealth interventions.
   Methods: Literature searches were conducted in five databases in August 2018. Included studies were randomized controlled trials comparing eHealth interventions versus usual care in improving adherence among patients prescribed ICS for persistent asthma. Quantitative synthesis was performed using a random effects model.
   Results: Eighty records were identified after removal of duplicates. Fifteen trials were eligible for qualitative synthesis. Included trials utilized: social media (n=1), electronic health records (n=1), telehealth (n=6), and mHealth (n=7). Twelve trials were eligible for quantitative synthesis. Results show a small but significant overall effect of eHealth interventions on adherence to ICS (Standardized Mean Difference (SMD)=0.41, 95% CI=0.02-0.79). Among the different types of eHealth interventions, a significant improvement in adherence was observed for mHealth interventions compared to usual care in a pooled analysis of 4 trials (SMD=0.96, 95% CI=0.28-1.64). However, there was considerable heterogeneity among studies. Patient satisfaction was evaluated in 5 trials comparing telehealth (n=2) and mHealth (n=3) with usual care. Participants found the interventions to be helpful and satisfactory.
   Conclusion: eHealth interventions, especially mHealth interventions, are effective and acceptable in improving patient adherence to ICS.
C1 [Jeminiwa, Ruth; Hohmann, Lindsey; Qian, Jingjing; Garza, Kimberly; Hansen, Richard; Fox, Brent I.] Auburn Univ, Harrison Sch Pharm, Dept Hlth Outcomes Res & Policy, Auburn, AL 36849 USA.
RP Fox, BI (reprint author), Auburn Univ, Harrison Sch Pharm, Dept Hlth Outcomes Res & Policy, Auburn, AL 36849 USA.
EM Rnm0016@auburn.edu; Lah0036@auburn.edu; Jzq0004@auburn.edu;
   Kbl0005@auburn.edu; Rah0019@auburn.edu; foxbren@auburn.edu
CR Angst F, 2017, J CLIN EPIDEMIOL, V82, P128, DOI 10.1016/j.jclinepi.2016.11.016
   [Anonymous], 2018, HLTH PEOPL 2020 RESP
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Bender BG, 2005, IMMUNOL ALLERGY CLIN, V25, P107, DOI 10.1016/j.iac.2004.09.005
   Bender Bruce G, 2004, Curr Opin Allergy Clin Immunol, V4, P191, DOI 10.1097/00130832-200406000-00009
   Bender BG, 2015, JAMA PEDIATR, V169, P317, DOI 10.1001/jamapediatrics.2014.3280
   Bender BG, 2010, J AM BOARD FAM MED, V23, P159, DOI 10.3122/jabfm.2010.02.090112
   Centers for Disease Control and Prevention, 2016, CDC ASTHM TABL 4 1 C
   Centers for Disease Control and Prevention, 2017, CDC ASTHM MOST REC A
   Chan AHY, 2015, LANCET RESP MED, V3, P210, DOI 10.1016/S2213-2600(15)00008-9
   Chan PWK, 2000, PEDIATR INT, V42, P547, DOI 10.1046/j.1442-200x.2000.01278.x
   Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700
   Chatkin JM, 2006, J ASTHMA, V43, P263, DOI 10.1080/02770900600620459
   Chen SY, 2010, J NURS RES, V18, P266, DOI 10.1097/NRJ.0b013e3181fbe33f
   Cote I, 2003, QUAL LIFE RES, V12, P621, DOI 10.1023/A:1025180524614
   Cramer H, 2016, ADV INTEGR MED, V3, P114, DOI 10.1016/j.aimed.2017.02.004
   Elbert NJ, 2014, J MED INTERNET RES, V16, P182, DOI 10.2196/jmir.2790
   Engelkes M, 2015, EUR RESPIR J, V45, P396, DOI 10.1183/09031936.00075614
   Fletcher BR, 2015, AM J HYPERTENS, V28, P1209, DOI 10.1093/ajh/hpv008
   Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006
   Gustafson D, 2012, J MED INTERNET RES, V14, P41, DOI 10.2196/jmir.1964
   Harrison Brian, 2005, Prim Care Respir J, V14, P303, DOI 10.1016/j.pcrj.2005.08.004
   Higgins J.P.T., 2011, COCHRANE HDB SYSTEMA, V2018
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jennett PA, 2003, J TELEMED TELECARE, V9, P311, DOI 10.1258/135763303771005207
   Johnson KB, 2016, J AM MED INFORM ASSN, V23, P449, DOI 10.1093/jamia/ocv158
   Kok PE, 2011, J CLIN NURS, V20, P2997, DOI 10.1111/j.1365-2702.2011.03743.x
   Koufopoulos JT, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4963
   Linn AJ, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1738
   Lycett H, 2018, RESP MED, V141, P180, DOI 10.1016/j.rmed.2018.06.032
   MacDonell KK, 2016, J ADOLESCENT HEALTH, V59, P465, DOI 10.1016/j.jadohealth.2016.05.016
   Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4
   Miller L, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.7168
   Moher David, 2009, Open Med, V3, pe123
   Morrison D, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2814
   Tran N, 2014, J ASTHMA, V51, P536, DOI 10.3109/02770903.2014.888572
   Nijland N, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1603
   Niznik JD, 2018, RES SOC ADMIN PHARM, V14, P707, DOI 10.1016/j.sapharm.2017.10.011
   Normansell R., 2017, COCHRANE DATABASE SY, V4
   Normansell R, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012226.pub2
   Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC
   Petrie KJ, 2012, BRIT J HEALTH PSYCH, V17, P74, DOI 10.1111/j.2044-8287.2011.02033.x
   RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69, DOI 10.1164/ajrccm/149.2_Pt_2.S69
   Sabate E., 2003, ADHERENCE LONG TERM
   Strandbygaard U, 2010, RESP MED, V104, P166, DOI 10.1016/j.rmed.2009.10.003
   Toney Blake, 2015, Hosp Pharm, V50, P644, DOI 10.1310/hpj5007-644
   Vollmer William M, 2011, Am J Manag Care, V17, pSP79
   WHO, 2018, EHEALTH
   Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034
   Young HN, 2012, TELEMED E-HEALTH, V18, P427, DOI 10.1089/tmj.2011.0194
NR 50
TC 5
Z9 5
U1 2
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 149
BP 59
EP 68
DI 10.1016/j.rmed.2019.02.011
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HP0DP
UT WOS:000461336100012
PM 30803887
DA 2020-05-18
ER

PT J
AU Ferri, S
   Crimi, C
   Heffler, E
   Campisi, R
   Noto, A
   Crimi, N
AF Ferri, S.
   Crimi, C.
   Heffler, E.
   Campisi, R.
   Noto, A.
   Crimi, N.
TI Vitamin D and disease severity in bronchiectasis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Bronchiectasis; Vitamin D; Biomarker; Exacerbation; Severity
ID D DEFICIENCY; CYSTIC-FIBROSIS; ADULTS; EXACERBATIONS; TUBERCULOSIS;
   PREVALENCE; INFECTION; HEALTH; RISK; LUNG
AB Background: Bronchiectasis is a complex respiratory disease characterised by permanent dilatation of bronchi. Vitamin D plays a role in infective disease by modulating the inflammation. Patients affected by bronchiectasis are frequently Vitamin D deficient and it correlates with lung function decline. We want to understand if there is a correlation between Vitamin D and clinical and radiological severity of bronchiectasis.
   Methods: We included 57 patients (17 males/40 female with mean age 60 +/- 12 years) between October 2017 and March 2018. We excluded patients with cystic fibrosis, traction bronchiectasis and reporting Vitamin D supplementation. Bronchiectasis severity index (BSI) and Bhalla score were calculated, blood inflammatory markers and Vit. D were measured and lung function tests were performed.
   Results: Vitamin D is deficient in 64% of patients, sufficient in 36% and normal in 7%. Mean BSI is 7.5 +/- 5 and mean Bhalla score is 16 +/- 4. Vitamin D levels correlate with Bhalla score (R-2 = 0.68, p < 0.001) and BSI (R-2 = 0.58, p < 0.0001). The correlation appears to be stronger than other markers of inflammation such as ESR and CRP [R-2 = 0.33, p = 0.001 and R-2 = 0.39, p = 0.001 respectively].
   Conclusions: We consider Vitamin D as a good predictor of clinical and radiological severity of bronchiectasis.
C1 [Ferri, S.; Crimi, C.; Campisi, R.; Crimi, N.] Univ Catania, AOU Policlin Vittorio Emanuele, Resp Med, Catania, Italy.
   [Heffler, E.] IRCCS, Humanitas Clin & Res Ctr, Personalized Med Asthma & Allergy, Via Alessandro Manzoni 56, I-20090 Rozzano, MI, Italy.
   [Heffler, E.] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy.
   [Noto, A.] Univ Messina, AOU Policlin G Martino, Dept Anesthesia & Crit Care, Messina, Italy.
RP Heffler, E (reprint author), IRCCS, Humanitas Clin & Res Ctr, Personalized Med Asthma & Allergy, Via Alessandro Manzoni 56, I-20090 Rozzano, MI, Italy.
EM enrico.heffler@hunimed.eu
RI Crimi, Nunzio/AAL-2994-2020; Campisi, Raffaele/K-4485-2018; Campisi,
   Raffaele/AAL-1578-2020
OI Crimi, Nunzio/0000-0002-8591-4535; Campisi,
   Raffaele/0000-0001-9305-6748; Campisi, Raffaele/0000-0001-9305-6748
CR Allaart M., 2017, TEMIS UV INDEX UV DO
   Anwar GA, 2013, RESP MED, V107, P1001, DOI 10.1016/j.rmed.2013.04.013
   Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755
   Bartley J, 2013, CURR INFECT DIS REP, V15, P148, DOI 10.1007/s11908-013-0321-9
   BHALLA M, 1991, RADIOLOGY, V179, P783, DOI 10.1148/radiology.179.3.2027992
   Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442
   Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052
   Chalmers JD, 2014, AM J RESP CRIT CARE, V189, P576, DOI 10.1164/rccm.201309-1575OC
   Chalmers JD, 2013, THORAX, V68, P39, DOI 10.1136/thoraxjnl-2012-202125
   Chishimba L, 2010, THORAX, V65, P456, DOI 10.1136/thx.2009.128793
   COLE PJ, 1986, EUR J RESPIR DIS, V69, P6
   Dancer RCA, 2015, THORAX, V70, P617, DOI 10.1136/thoraxjnl-2014-206680
   Foong RE, 2013, NUTRIENTS, V5, P2880, DOI 10.3390/nu5082880
   Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560
   Herr C, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-31
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Jolliffe DA, 2013, J STEROID BIOCHEM, V136, P321, DOI 10.1016/j.jsbmb.2012.11.017
   Kim C, 2016, RESPIRATION, V91, P351, DOI 10.1159/000445266
   Korn S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-25
   Kunisaki KM, 2012, AM J RESP CRIT CARE, V185, P286, DOI 10.1164/rccm.201109-1644OC
   Kwak HJ, 2010, TOHOKU J EXP MED, V222, P237, DOI 10.1620/tjem.222.237
   Lonni S, 2015, ANN AM THORAC SOC, V12, P1764, DOI 10.1513/AnnalsATS.201507-472OC
   Malinovschi A, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0131-0
   McDonnell MJ, 2013, QJM-INT J MED, V106, P709, DOI 10.1093/qjmed/hct109
   McShane PJ, 2013, AM J RESP CRIT CARE, V188, P647, DOI 10.1164/rccm.201303-0411CI
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mirra V, 2015, ITAL J PEDIATR, V41, DOI 10.1186/s13052-015-0119-5
   Moustaki Maria, 2017, World J Clin Pediatr, V6, P132, DOI 10.5409/wjcp.v6.i3.132
   Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247
   Odler B, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S91654
   Quraishi SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081120
   Seitz AE, 2012, CHEST, V142, P432, DOI 10.1378/chest.11-2209
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
   Weycker D., 2005, Clinical Pulmonary Medicine, V12, P205, DOI 10.1097/01.cpm.0000171422.98696.ed
   Weycker D, 2017, CHRON RESP DIS, V14, P377, DOI 10.1177/1479972317709649
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
NR 37
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 1
EP 5
DI 10.1016/j.rmed.2019.01.009
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100001
PM 30827468
DA 2020-05-18
ER

PT J
AU Sheth, JS
   Xia, M
   Murray, S
   Martinez, CH
   Meldrum, CA
   Belloli, EA
   Salisbury, ML
   White, ES
   Holtze, CH
   Flaherty, KR
AF Sheth, Jamie S.
   Xia, Meng
   Murray, Susan
   Martinez, Carlos H.
   Meldrum, Catherine A.
   Belloli, Elizabeth A.
   Salisbury, Margaret L.
   White, Eric S.
   Holtze, Colin H.
   Flaherty, Kevin R.
TI Frailty and geriatric conditions in older patients with idiopathic
   pulmonary fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Frailty; Geriatric conditions; Body
   composition
ID UCSD SHORTNESS; MORTALITY; REHABILITATION; DISABILITY; HEALTH; MUSCLE;
   RISK; PIRFENIDONE; PREVALENCE; VALIDATION
AB Background: Functional status, an important predictor of health outcomes in older patients, has not been studied in an IPF population. This study aimed to determine the prevalence of frailty and geriatric conditions in older patients with IPF.
   Methods: IPF patients age >= 65 years were identified prospectively at the University of Michigan. Frailty was assessed using the Fried frailty phenotype. Questionnaires addressing functional status, geriatric conditions and symptoms were administered. Quantitative measurement of pectoralis muscle area was performed. Patient variables were compared among different frailty groups.
   Results: Of the 50 participants, 48% were found to be frail and 40% had >= 2 geriatric conditions. Frailty was associated with increased age, lower lung function, shorter 6-min walk distance, higher symptom scores and a greater number of comorbidities, geriatric conditions and functional limitations (p < 0.05). Pectoralis muscle area was nearly significant (p = 0.08). Self-reported fatigue score (odds ratio [OR] = 2.13, confidence interval [CI] 95% 1.23-3.70, p = 0.0068) and diffusion capacity (OR = 0.54 CI 95% 0.35-0.85, p = 0.0071) were independent predictors of frailty.
   Conclusions: Frailty and geriatric conditions are common in older patients with IPF. The presence of frailty was associated with objective (diffusion capacity) and subjective (self-reported fatigue score) data. Longitudinal evaluation is necessary to determine impact of frailty on disease-related outcomes in IPF.
C1 [Sheth, Jamie S.; Martinez, Carlos H.; Meldrum, Catherine A.; Belloli, Elizabeth A.; Salisbury, Margaret L.; White, Eric S.; Holtze, Colin H.; Flaherty, Kevin R.] Univ Michigan Hlth Syst, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA.
   [Xia, Meng; Murray, Susan] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
RP Sheth, JS (reprint author), Taubman Ctr, 1500 E Med Ctr Dr 3916, Ann Arbor, MI 48109 USA.
EM jvotava@med.umich.edu
OI Murray, Susan/0000-0003-4387-7673; Salisbury,
   Margaret/0000-0001-8217-6955
FU National Institutes of Health NHLBIUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01 HL91743, T32 HL00749, K24
   HL111316]
FX National Institutes of Health NHLBI grants R01 HL91743, T32 HL00749 and
   K24 HL111316 (Kevin R. Flaherty).
CR Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262
   Cameron ID, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-65
   Cawthon PM, 2007, J AM GERIATR SOC, V55, P1216, DOI 10.1111/j.1532-5415.2007.01259.x
   Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004
   Cigolle CT, 2011, J GEN INTERN MED, V26, P272, DOI 10.1007/s11606-010-1510-y
   Cigolle CT, 2009, J AM GERIATR SOC, V57, P830, DOI 10.1111/j.1532-5415.2009.02225.x
   Diaz AA, 2014, ACAD RADIOL, V21, P1255, DOI 10.1016/j.acra.2014.05.013
   Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619
   Ensrud KE, 2007, J GERONTOL A-BIOL, V62, P744, DOI 10.1093/gerona/62.7.744
   Fairhall N, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-83
   Ferreira A, 2009, CHEST, V135, P442, DOI 10.1378/chest.08-1458
   Fragoso CAV, 2012, AM J MED, V125, P79, DOI 10.1016/j.amjmed.2011.06.024
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Galizia G, 2011, AGING CLIN EXP RES, V23, P118, DOI 10.1007/BF03351076
   Guerri R, 2010, RESP MED, V104, P378, DOI 10.1016/j.rmed.2009.10.015
   GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85
   Holland AE, 2008, THORAX, V63, P549, DOI 10.1136/thx.2007.088070
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kreuter M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151425
   KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022
   Kupferberg David H, 2005, J Cardiopulm Rehabil, V25, P370, DOI 10.1097/00008483-200511000-00011
   Lahousse L, 2014, EUR J EPIDEMIOL, V29, P419, DOI 10.1007/s10654-014-9924-1
   Langa KM, 2005, NEUROEPIDEMIOLOGY, V25, P181, DOI 10.1159/000087448
   Lederer DJ, 2006, AM J RESP CRIT CARE, V174, P659, DOI 10.1164/rccm.200604-520OC
   Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801
   Maddocks M, 2016, THORAX, V71, P988, DOI 10.1136/thoraxjnl-2016-208460
   Marquis K, 2002, AM J RESP CRIT CARE, V166, P809, DOI 10.1164/rccm.2107031
   McDonald Merry-Lynn N, 2014, Ann Am Thorac Soc, V11, P326, DOI 10.1513/AnnalsATS.201307-229OC
   Meyer KC, 2015, CHEST, V148, P242, DOI 10.1378/chest.14-2475
   Nishiyama O, 2008, RESPIROLOGY, V13, P394, DOI 10.1111/j.1440-1843.2007.01205.x
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Racz M, 2005, J AM GERIATR SOC, V53, pS245, DOI 10.1111/j.1532-5415.2005.53350.x
   Raghu G, 2014, LANCET RESP MED, V2, P566, DOI 10.1016/S2213-2600(14)70101-8
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Ramsay SE, 2015, HEART, V101, P616, DOI 10.1136/heartjnl-2014-306472
   Richeldi L, 2014, RESP MED, V108, P1023, DOI 10.1016/j.rmed.2014.04.011
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Rockwood K, 2007, J GERONTOL A-BIOL, V62, P738, DOI 10.1093/gerona/62.7.738
   Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21
   Singer JP, 2015, AM J RESP CRIT CARE, V192, P1325, DOI 10.1164/rccm.201506-1150OC
   Spector WD, 1998, J GERONTOL B-PSYCHOL, V53, pS46, DOI 10.1093/geronb/53B.1.S46
   Strawbridge WJ, 1998, J GERONTOL B-PSYCHOL, V53, pS9, DOI 10.1093/geronb/53B.1.S9
   Swigris JJ, 2012, RESP MED, V106, P1447, DOI 10.1016/j.rmed.2012.06.018
   Thannickal VJ, 2008, AM J RESP CRIT CARE, V178, P663, DOI 10.1164/rccm.200807-1127ED
NR 45
TC 3
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 6
EP 12
DI 10.1016/j.rmed.2019.01.008
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100002
PM 30827476
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Kameyama, N
   Chubachi, S
   Sasaki, M
   Tsutsumi, A
   Irie, H
   Sakurai, K
   Sayama, K
   Nakamura, H
   Asano, K
   Betsuyaku, T
   Fukunaga, K
AF Kameyama, Naofumi
   Chubachi, Shotaro
   Sasaki, Mamoru
   Tsutsumi, Akihiro
   Irie, Hidehiro
   Sakurai, Kaori
   Sayama, Koichi
   Nakamura, Hidetoshi
   Asano, Koichiro
   Betsuyaku, Tomoko
   Fukunaga, Koichi
TI Predictive and modifying factors of bone mineral density decline in
   patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Comorbidity; Osteoporosis; Vertebral fracture; Bisphosphonate
ID OBSTRUCTIVE PULMONARY-DISEASE; OSTEOPOROSIS; EMPHYSEMA; FRACTURES; RISK;
   CT; EXACERBATION; ALENDRONATE; PREVALENCE; IMPACT
AB Rationale: Various determinants of osteoporosis have been previously identified. However, only a few longitudinal studies have examined related factors. We aimed to investigate factors predicting and modifying rapid decline of bone mineral density in patients with chronic obstructive pulmonary disease.
   Methods: We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111). We divided annual per cent changes of bone mineral density in different body parts into tertiles. Rapid decliners (n = 33) were defined as those with the largest decline in at least two parts; all other participants were defined as non-rapid decliners (n = 78).
   Results: At enrollment, bone mineral density did not differ between the two groups. However, rapid decliners had a significantly greater rate of new vertebral fractures over 3 years compared with non-rapid decliners. On multivariate logistic regression analysis, age, moderate to severe emphysema, no daily exercise habits, and anemia increased the likelihood of rapid decliners. Furthermore, patients who newly started and continued bisphosphonate exhibited higher annual per cent changes of bone mineral density than did those without bisphosphonate use.
   Conclusions: A rapid decline in bone mineral density correlates to a higher likelihood of vertebral fracture. We clarified the predictors of bone mineral density decline and demonstrated that bisphosphonate use might modify bone mineral density in patients with chronic obstructive pulmonary disease.
C1 [Kameyama, Naofumi; Chubachi, Shotaro; Sasaki, Mamoru; Tsutsumi, Akihiro; Irie, Hidehiro; Sakurai, Kaori; Betsuyaku, Tomoko; Fukunaga, Koichi] Keio Univ, Sch Med, Dept Med, Div Pulm Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Sayama, Koichi] Kawasaki Municipal Hosp, Div Pulm Med, Kawasaki Ku, 12-1 Shinkawadori, Kawasaki, Kanagawa 2100013, Japan.
   [Nakamura, Hidetoshi] Saitama Med Univ Hosp, Div Pulm Med, 38 Morohongo, Moroyama, Saitama 3500495, Japan.
   [Asano, Koichiro] Tokai Univ, Sch Med, Dept Med, Div Pulm Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
RP Chubachi, S (reprint author), Keio Univ, Sch Med, Dept Med, Div Pulm Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM bachibachi472000@live.jp
RI Fukunaga, Koichi/R-5338-2019
CR Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
   Bai P, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-157
   Barrett-Connor E B. D., 2003, TECH REP SER, V921, P1
   BLACK DM, 1992, J BONE MINER RES, V7, P633
   Bolton CE, 2004, AM J RESP CRIT CARE, V170, P1286, DOI 10.1164/rccm.200406-754OC
   Bon  J., 2018, ANN AM THORAC SOC
   Bon J, 2011, AM J RESP CRIT CARE, V183, P885, DOI 10.1164/rccm.201004-0666OC
   Chubachi S, 2016, RESP MED, V117, P272, DOI 10.1016/j.rmed.2016.07.002
   Chubachi S, 2015, RESPIROLOGY, V20, P286, DOI 10.1111/resp.12429
   de Luise C, 2008, EUR J EPIDEMIOL, V23, P115, DOI 10.1007/s10654-007-9211-5
   Ferguson GT, 2009, CHEST, V136, P1456, DOI 10.1378/chest.08-3016
   Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Graat-Verboom L, 2009, EUR RESPIR J, V34, P209, DOI 10.1183/09031936.50130408
   Graat-Verboom L, 2012, BONE, V50, P1234, DOI 10.1016/j.bone.2012.02.638
   Graat-Verboom L, 2011, J BONE MINER RES, V26, P561, DOI 10.1002/jbmr.257
   Hajiro T, 1998, AM J RESP CRIT CARE, V158, P1185, DOI 10.1164/ajrccm.158.4.9802091
   Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Iqbal F, 1999, CHEST, V116, P1616, DOI 10.1378/chest.116.6.1616
   Irie H, 2017, RESP MED, V131, P101, DOI 10.1016/j.rmed.2017.08.012
   Johnell O, 2002, EUR RESPIR J, V19, P1058, DOI 10.1183/09031936.02.00276602
   JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Kiyokawa H, 2012, COPD, V9, P235, DOI 10.3109/15412555.2011.650243
   Kjensli A, 2009, EUR RESPIR J, V33, P1018, DOI 10.1183/09031936.00073908
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin CW, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S85432
   Loke YK, 2011, THORAX, V66, P699, DOI 10.1136/thx.2011.160028
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miyazaki M, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-13
   Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120
   Ohara T, 2008, CHEST, V134, P1244, DOI 10.1378/chest.07-3054
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Romme EAPM, 2013, ANN MED, V45, P91, DOI 10.3109/07853890.2012.671536
   Romme EAPM, 2012, J BONE MINER RES, V27, P2338, DOI 10.1002/jbmr.1678
   Rutten EPA, 2013, COPD, V10, P286, DOI 10.3109/15412555.2012.744390
   Sato M, 2016, INT J CHRONIC OBSTR, V11, P1269, DOI 10.2147/COPD.S105454
   Smith B J, 2004, Chron Respir Dis, V1, P131, DOI 10.1191/1479972304cd025oa
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Watanabe R, 2015, J BONE MINER METAB, V33, P392, DOI 10.1007/s00774-014-0605-7
NR 42
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 13
EP 23
DI 10.1016/j.rmed.2019.01.005
PG 11
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100003
PM 30827469
DA 2020-05-18
ER

PT J
AU Zeren, M
   Cakir, E
   Gurses, HN
AF Zeren, Melih
   Cakir, Erkan
   Gurses, Hulya Nilgun
TI Effects of inspiratory muscle training on postural stability, pulmonary
   function and functional capacity in children with cystic fibrosis: A
   randomised controlled trial
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cystic fibrosis; Pediatric chest diseases; Pulmonary rehabilitation;
   Inspiratory muscle training; Postural stability
ID EXERCISE TOLERANCE; LUNG-FUNCTION; BALANCE; ADULTS; STRENGTH; GUIDELINES
AB Background: Previous research has found conflictive results regarding the benefits of inspiratory muscle training (IMT) for cystic fibrosis (CF) patients. Also, involvement of postural stability is a rising concern in chronic lung diseases but its role in CF patients is poorly understood. Our aim was to investigate the effects of IMT in CF patients as well as analysing the factors which may be related to postural stability.
   Methods: Thirty-six children aged between 8 and 18 years with CF were randomly allocated to either "comprehensive chest PT" group (PT) or "IMT alongside comprehensive chest PT" group (PT + IMT). Both groups trained for 8 weeks. Dynamic and static postural stability tests on Biodex Balance system (R), spirometry, respiratory muscle strength and 6-min walk distance (6MWD) was assessed at baseline and after 8 weeks of training. Determinants of postural stability was also analysed on baseline values.
   Results: Maximum expiratory pressure (MEP) was found to be an independent predictor for overall limits of stability (LOS) score explaining %26 of variance (R = 0.514, p = 0.003). Overall LOS score, FVC, FEV1, peak expiratory flow, MEP and 6MWD significantly improved in both groups, with no significant differences between groups. Maximum inspiratory pressure (MIP) also improved in both groups but the magnitude of improvement in MIP was greater in PT + IMT group (38 cmH(2)O vs 13 cmH(2)O; p < 0.001).
   Conclusions: Combining IMT with chest PT failed to provide further improvements, except for MIP, suggesting that a comprehensive chest PT program may be individually effective in improving overall LOS score, spirometry, respiratory muscle strength and 6MWD.
C1 [Zeren, Melih; Gurses, Hulya Nilgun] Bezmialem Vakif Univ, Fac Hlth Sci, Div Physiotherapy & Rehabil, Dept Cardiopulm Physiotherapy & Rehabil, TR-34060 Istanbul, Turkey.
   [Cakir, Erkan] Bezmialem Vakif Univ, Fac Med, Dept Pediat, Div Pediat Chest Dis, TR-34093 Istanbul, Turkey.
RP Gurses, HN (reprint author), Bezmialem Vakif Univ, Fac Hlth Sci, Div Physiotherapy & Rehabil, Silahtaraga St 189, TR-34060 Istanbul, Turkey.
EM fzt.zeren@hotmail.com; erkancakir1@yahoo.com; gursesnil@yahoo.com
RI Gurses, H. Nilgun/AAD-3070-2020
OI GURSES, HULYA NILGUN/0000-0002-5846-6781; Zeren,
   Melih/0000-0002-9749-315X
FU Scientific Research Projects Unit of Bezmialem Vakif University
   [BVU6.2017/1]
FX The study was funded by Scientific Research Projects Unit of Bezmialem
   Vakif University, project number BVU6.2017/1.
CR Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Arikan H, 2015, RES DEV DISABIL, V45-46, P147, DOI 10.1016/j.ridd.2015.07.020
   Assaiante Christine, 2005, Neural Plasticity, V12, P109, DOI 10.1155/NP.2005.109
   Beauchamp MK, 2012, CHEST, V141, P1496, DOI 10.1378/chest.11-1708
   Cachupe W., 2001, MEASUREMENTS PHYS ED, V5, P97, DOI DOI 10.1207/S15327841MPEE0502_
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Dassios T, 2013, PEDIATR PULM, V48, P865, DOI 10.1002/ppul.22709
   De Jong W, 2001, RESP MED, V95, P31, DOI 10.1053/rmed.2000.0966
   Dunnink MA, 2009, J CYST FIBROS, V8, P31, DOI 10.1016/j.jcf.2008.07.006
   Elborn JS, 2016, LANCET, V388, P2519, DOI 10.1016/S0140-6736(16)00576-6
   Enright S, 2004, CHEST, V126, P405, DOI 10.1378/chest.126.2.405
   Farrell PM, 2008, J PEDIATR-US, V153, pS4, DOI 10.1016/j.jpeds.2008.05.005
   Flume PA, 2009, RESP CARE, V54, P522
   Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810
   Hilton N, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006112.pub4
   Janssens L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057949
   Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027
   Mckoy NA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007862.pub4
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Morrison L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006842.pub4
   Pastre J, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-74
   Penafortes JTS, 2013, BRAZ J PHYS THER, V17, P450, DOI 10.1590/S1413-35552012005000111
   Porto EF, 2015, INT J CHRONIC OBSTR, V10, P1233, DOI 10.2147/COPD.S63955
   Radtke T, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002768.pub4
   Rasekaba T, 2009, INTERN MED J, V39, P495, DOI 10.1111/j.1445-5994.2008.01880.x
   Ratjen F, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.10
   Reid WD, 2008, CLIN REHABIL, V22, P1003, DOI 10.1177/0269215508090619
   Santana-Sosa E, 2014, BRIT J SPORT MED, V48, P1513, DOI 10.1136/bjsports-2012-091892
   SAWYER EH, 1993, CHEST, V104, P1490, DOI 10.1378/chest.104.5.1490
   Smith MD, 2016, GAIT POSTURE, V43, P101, DOI 10.1016/j.gaitpost.2015.09.004
   Smith MD, 2010, GAIT POSTURE, V31, P456, DOI 10.1016/j.gaitpost.2010.01.022
   Smyth AR, 2014, J CYST FIBROS, V13, pS23, DOI 10.1016/j.jcf.2014.03.010
   Souza H, 2014, J GERONTOL A-BIOL, V69, P1545, DOI 10.1093/gerona/glu182
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Swisher, 2015, CARDIOPULM PHYS THER, V26, P85, DOI DOI 10.1097/CPT.0000000000000016
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   Troosters T, 2009, EUR RESPIR J, V33, P99, DOI 10.1183/09031936.00091607
   Urquhart DM, 2005, GAIT POSTURE, V22, P295, DOI 10.1016/j.gaitpost.2004.09.012
   Warnock L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001401.pub3
NR 39
TC 0
Z9 0
U1 2
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 24
EP 30
DI 10.1016/j.rmed.2019.01.013
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100004
PM 30827470
DA 2020-05-18
ER

PT J
AU Sasso, F
   Izard, M
   Beneteau, T
   Rakotozandry, T
   Ramadour, M
   Annesi-Maesano, I
   Robin, D
   Charpin, D
AF Sasso, Fabien
   Izard, Mathieu
   Beneteau, Thomas
   Rakotozandry, Thierry
   Ramadour, Myriam
   Annesi-Maesano, Isabella
   Robin, Dominique
   Charpin, Denis
TI 18-year evolution of asthma and allergic diseases in French urban
   schoolchildren in relation to indoor air pollutant levels
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Allergy; Prevalence; Epidemiology; Air pollution; Children
ID SENSITIZATION; PREVALENCE; EXPOSURE; BIRTH; MOLD
AB Background: An initial epidemiological study carried out 18 years ago in Marseilles indicated that the air quality in schools was poor and that there was an association between the level of fine particulates and the occurrence of asthma in children. The aim of the present study was to evaluate the change in the prevalence of childhood asthma and allergic diseases and their link with the levels of air pollutants and other factors of potential risk.
   Methods: In 2016, using a questionnaire identical to the one used for the 1st survey in 1998-1999, we collected information regarding the symptoms, the diagnosis, and the potential confounding factors. We measured the main indoor and outdoor pollutants at the schools.
   Results: Overall, the prevalence of asthma and of allergic diseases exhibited an increasing trend in the time interval between the two studies, significant only for dry cough and pollen allergy. The level of air pollutants decreased significantly indoors. In spite of this, we found a correlation and a dose-effect relationship between the level of PM2.5 and the prevalence of asthma. A family history of asthma and allergies, the insalubrity of the place of residence, and a non-Mediterranean diet were also associated with the risk of these diseases.
   Conclusion: In the time interval between the two studies, which were 18 years apart, despite a reduction in the level of air pollutants in classrooms, asthma was still related to PM2.5. Other potentially causative or contributing environmental factors were also related to asthma and allergies.
C1 [Sasso, Fabien; Rakotozandry, Thierry; Charpin, Denis] La Timone Hosp, Pulmonol Unit, Marseille, France.
   [Sasso, Fabien; Rakotozandry, Thierry; Charpin, Denis] Aix Marseille Univ, Marseille, France.
   [Izard, Mathieu; Robin, Dominique] Atmo Sud, Marseille, France.
   [Beneteau, Thomas; Annesi-Maesano, Isabella] INSERM, UMR S 1136, IPLESP, EPAR, Paris, France.
   [Beneteau, Thomas; Annesi-Maesano, Isabella] UPMC Paris 6, Sorbonne Univ, Med Sch St Antoine, Paris, France.
   [Ramadour, Myriam] Cent Serv, Luminy Campus, Marseille, France.
RP Charpin, D (reprint author), Grp Hosp Timone, Pulmonol Unit, 264 Rue St Pierre, F-13385 Marseille 05, France.
EM denis-andre.charpin@ap-hm.fr
RI Annesi-Maesano, Isabella/D-9173-2016
OI Annesi-Maesano, Isabella/0000-0002-6340-9300
FU Conseil Regional [2014-05681, 2016-12144]; Agence Regionale de Sante [C
   2015-000]; Ville de MarseilleRegion Provence-Alpes-Cote d'Azur
   [2016-80704]; Atmo-Sud
FX Conseil Regional (Grant 2014-05681 and 2016-12144), Agence Regionale de
   Sante (Grant C 2015-000), Ville de Marseille (Grant 2016-80704) and
   Atmo-Sud (Ploughing back of profits).
CR Annesi-Maesano I, 2012, THORAX, V67, P682, DOI 10.1136/thoraxjnl-2011-200391
   Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561
   Delmas MC, 2017, REV MAL RESPIR, V34, P525, DOI 10.1016/j.rmr.2016.09.002
   Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]
   Laboratoire central de surveillance de la qualite de l'air, 2017, AN TEND NAT MAT QUAL
   Saadeh D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2320-2
   Shorter C, 2018, INDOOR AIR, V28, P6, DOI 10.1111/ina.12413
   Thacher JD, 2017, ALLERGY, V72, P967, DOI 10.1111/all.13102
NR 8
TC 2
Z9 2
U1 2
U2 13
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 31
EP 36
DI 10.1016/j.rmed.2019.01.007
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100005
PM 30827471
DA 2020-05-18
ER

PT J
AU Moon, SM
   Choe, J
   Jhun, BW
   Jeon, K
   Kwon, OJ
   Huh, HJ
   Lee, NY
   Daley, CL
   Koh, WJ
AF Moon, Seong Mi
   Choe, Junsu
   Jhun, Byung Woo
   Jeon, Kyeongman
   Kwon, O. Jung
   Huh, Hee Jae
   Lee, Nam Yong
   Daley, Charles L.
   Koh, Won-Jung
TI Treatment with a macrolide-containing regimen for Mycobacterium kansasii
   pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Nontuberculous mycobacteria; Mycobacterium kansasii; Treatment;
   Macrolide
ID SERUM ITRACONAZOLE LEVELS; LUNG-DISEASE; NONTUBERCULOUS MYCOBACTERIA;
   RADIOLOGICAL FEATURES; TREATMENT OUTCOMES; CLINICAL-FEATURES; INFECTION;
   SUSCEPTIBILITY; EPIDEMIOLOGY; DIAGNOSIS
AB Background: Mycobacterium kansasii is a major pathogen associated with nontuberculous mycobacterial pulmonary disease. For treatment of M. kansasii pulmonary disease, daily therapy with isoniazid, rifampin, and ethambutol is traditionally recommended. Although a regimen containing a macrolide, instead of isoniazid, has been recently recommended, supporting data are limited. We compared the treatment outcomes of a macrolide-containing regimen (macrolide group) and an isoniazid-containing regimen (isoniazid group) on patients with M. kansasii pulmonary disease.
   Methods: A total of 49 patients were identified between January 2002 and December 2016. Treatment outcomes for the isoniazid group (n = 24) and the macrolide group (n = 25) were compared.
   Results: Baseline characteristics of the isoniazid and macrolide groups were similar. Favorable outcomes did not differ between the isoniazid group (79%, n = 19) and macrolide group (88%, n = 22, P = 0.463). Total treatment duration (median 17.9 months vs. 15.4 months; P = 0.712) and time to culture conversion (median 2.0 months vs. 1.2 months; P = 0.838) were also similar between the isoniazid and macrolide groups. Five patients who completed three-times-weekly intermittent treatment containing a macrolide for non-cavitary M. kansasii pulmonary disease achieved negative sputum culture conversion within 12 months of treatment. Only one patient experienced recurrence of M. kansasii pulmonary disease in the isoniazid group.
   Conclusions: A macrolide-containing regimen appears to be as effective as an isoniazid-containing regimen for treatment of M. kansasii pulmonary disease. Additionally, intermittent therapy containing a macrolide could be an alternative treatment option for non-cavitary M. kansasii pulmonary disease.
C1 [Moon, Seong Mi; Choe, Junsu; Jhun, Byung Woo; Jeon, Kyeongman; Kwon, O. Jung; Koh, Won-Jung] Sungkyunkwan Univ, Div Pulm & Crit Care Med, Dept Med, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Huh, Hee Jae; Lee, Nam Yong] Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Daley, Charles L.] Natl Jewish Hlth, Dept Med, Div Mycobacterial & Resp Infect, Denver, CO USA.
RP Koh, WJ (reprint author), Sungkyunkwan Univ, Div Pulm & Crit Care Med, Dept Med, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM wjkoh@skku.edu
RI Jeon, Kyeongman/F-5963-2019
OI Jeon, Kyeongman/0000-0002-4822-1772; Choe, Junsu/0000-0003-3233-450X
FU National Research Foundation of Korea - Korean government (MSIT)
   [NRF-2018R1A2A1A05018309]
FX This work was supported by the National Research Foundation of Korea
   funded by the Korean government (MSIT) (NRF-2018R1A2A1A05018309).
CR Adjemian J, 2018, SEMIN RESP CRIT CARE, V39, P325, DOI 10.1055/s-0038-1651491
   AHN CH, 1981, REV INFECT DIS, V3, P1028
   Bakula Z., 2018, ANTIMICROB AGENTS CH, V62
   Bakula Z, 2018, RESP MED, V139, P91, DOI 10.1016/j.rmed.2018.05.007
   Basille D, 2018, SEMIN RESP CRIT CARE, V39, P377, DOI 10.1055/s-0038-1660473
   BIEHLE J, 1992, ANTIMICROB AGENTS CH, V36, P2039, DOI 10.1128/AAC.36.9.2039
   CHRISTENSEN EE, 1981, CHEST, V80, P132, DOI 10.1378/chest.80.2.132
   Cowman S, 2016, J INFECTION, V72, P324, DOI 10.1016/j.jinf.2015.12.007
   DeStefano MS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02271
   Diel R, 2017, CHEST, V152, P120, DOI 10.1016/j.chest.2017.04.166
   Evans AJ, 1996, THORAX, V51, P1243, DOI 10.1136/thx.51.12.1243
   Graybill JR, 2001, J ANTIMICROB CHEMOTH, V47, P417, DOI 10.1093/jac/47.4.417
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Griffith DE, 2003, CLIN INFECT DIS, V37, P1178, DOI 10.1086/378742
   Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927
   Hoefsloot W, 2013, EUR RESPIR J, V42, P1604, DOI 10.1183/09031936.00149212
   Jeong BH, 2015, AM J RESP CRIT CARE, V191, P96, DOI 10.1164/rccm.201408-1545OC
   Ko RE, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e65
   Koh WJ, 2006, CHEST, V129, P341, DOI 10.1378/chest.129.2.341
   Koh WJ, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02503-2016
   Koh WJ, 2017, CLIN INFECT DIS, V64, P309, DOI 10.1093/cid/ciw724
   Kwon YS, 2016, J KOREAN MED SCI, V31, P649, DOI 10.3346/jkms.2016.31.5.649
   Matveychuk A, 2012, RESP MED, V106, P1472, DOI 10.1016/j.rmed.2012.06.023
   Moon SM, 2017, J INFECT CHEMOTHER, V23, P658, DOI 10.1016/j.jiac.2017.02.004
   Moon SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139621
   Moon SM, 2015, ANTIMICROB AGENTS CH, V59, P663, DOI 10.1128/AAC.04075-14
   Morimoto K, 2017, ANN AM THORAC SOC, V14, P49, DOI [10.1513/AnnalsATS.201607-573OC, 10.1513/annalsats.201607-573oc]
   Park HK, 2010, YONSEI MED J, V51, P552, DOI 10.3349/ymj.2010.51.4.552
   PEZZIA W, 1981, REV INFECT DIS, V3, P1035
   Philley JV, 2015, CLIN CHEST MED, V36, P79, DOI 10.1016/j.ccm.2014.10.005
   Prevots DR, 2015, CLIN CHEST MED, V36, P13, DOI 10.1016/j.ccm.2014.10.002
   Ryu YJ, 2016, TUBERC RESPIR DIS, V79, P74, DOI 10.4046/trd.2016.79.2.74
   Santin M, 2009, EUR RESPIR J, V33, P148, DOI 10.1183/09031936.00024008
   SAURET J, 1995, TUBERCLE LUNG DIS, V76, P104, DOI 10.1016/0962-8479(95)90550-2
   Shitrit D, 2007, EUR J CLIN MICROBIOL, V26, P679, DOI 10.1007/s10096-007-0331-3
   Shitrit D, 2006, CHEST, V129, P771, DOI 10.1378/chest.129.3.771
   Shitrit D, 2008, RESP MED, V102, P1598, DOI 10.1016/j.rmed.2008.05.004
   Stout JE, 2016, INT J INFECT DIS, V45, P123, DOI 10.1016/j.ijid.2016.03.006
   van Ingen J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00170-2018
   van Ingen J, 2013, EXPERT REV ANTI-INFE, V11, P1065, DOI 10.1586/14787210.2013.830413
   Wallace RJ, 2014, CHEST, V146, P276, DOI 10.1378/chest.13-2538
NR 41
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 37
EP 42
DI 10.1016/j.rmed.2019.01.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100006
PM 30827472
DA 2020-05-18
ER

PT J
AU Cen, J
   Ma, HY
   Chen, ZB
   Weng, L
   Deng, ZC
AF Cen, Jie
   Ma, Hongying
   Chen, Zhongbo
   Weng, Lei
   Deng, Zaichun
TI Monitoring peak expiratory flow could predict COPD exacerbations: A
   prospective observational study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; PEF; Predict
ID OBSTRUCTIVE PULMONARY-DISEASE; TIME-COURSE; VARIABILITY; ASTHMA;
   MANAGEMENT; OUTCOMES; DECLINE
AB Background: Exacerbation of chronic obstructive pulmonary disease (ECOPD) is an important event during the course of the disease. It causes a more rapid decline in lung function, which is associated with hospitalization and the risk of death. Therefore, it is essential to discover approaches to early detection and prevention of ECOPD. Peak expiratory flow (PEF) can be safely used instead of spirometry which can assess the severity of COPD as a standard tool. We hypothesized that monitoring PEF could possibly be used to predict the ECOPD.
   Method: To verify this hypothesis, daily morning PEF was monitored for 6 months in 53 patients with moderate to severe COPD (mean FEV1 31.53% predicted) who were enrolled in Ningbo, China.
   Result: A total of 69 exacerbations of COPD (63 of gradual onset, six of sudden onset) were recorded in this study. Thirty cases (43.5%) of gradual onset exacerbations needed to be hospitalized, and the mean PEF significantly decreased (vs baseline) during the 5 days that preceded those exacerbations (from 161.9 +/- 39.4 L/min to 137.9 +/- 36.1 L/min, P < 0.05, statistical power = 0.92). However, this was not the case with non-hospitalized exacerbations (from 175.4 +/- 42.5 L/min to 161.5 +/- 39.3 L/min, P = 0.172, statistical power = 0.63). The ROC analysis demonstrated that 24 h before hospitalized exacerbation, the optimal cutoff value of Delta PEF for its prediction was 28 L/min (17% from baseline), with a sensitivity and specificity of 76.7% and 72.7%, respectively (area under the curve [AUC] = 0.84, P < 0.05, statistical power = 0.78). While 48 h before hospitalized exacerbation, the optimal cutoff value of Delta PEF for its prediction was 14 L/min (9% from baseline), with a sensitivity and specificity of 86.7% and 66.7%, respectively (AUC = 0.863, P < 0.05, statistical power = 0.87).
   Conclusions: As a rapid, inexpensive method, PEF could be used for the prediction and early detection of hospitalized exacerbation of COPD. This may provide opportunity for early intervention of ECOPD.
C1 [Cen, Jie; Ma, Hongying; Chen, Zhongbo; Deng, Zaichun] Ningbo Univ, Sch Med, Affiliated Hosp, Dept Resp Med, 247 Renmin Rd, Ningbo 315020, Zhejiang, Peoples R China.
   [Cen, Jie; Weng, Lei] Ningbo 9 Hosp, Dept Resp Med, 68 Xiangbei Rd, Ningbo 315020, Zhejiang, Peoples R China.
RP Deng, ZC (reprint author), Ningbo Univ, Sch Med, Affiliated Hosp, Dept Resp Med, 247 Renmin Rd, Ningbo 315020, Zhejiang, Peoples R China.; Weng, L (reprint author), Ningbo 9 Hosp, Dept Resp Med, 68 Xiangbei Rd, Ningbo 315020, Zhejiang, Peoples R China.
EM wengjensen@sina.com; dzcrespiratory123@163.com
CR Aaron SD, 2012, THORAX, V67, P238, DOI 10.1136/thoraxjnl-2011-200768
   Agarwal Dipti, 2007, Ann Thorac Med, V2, P103, DOI 10.4103/1817-1737.33697
   Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
   BOEZEN HM, 1995, THORAX, V50, P121, DOI 10.1136/thx.50.2.121
   Dai MY, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S92160
   Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
   Emerman CL, 1996, ANN EMERG MED, V27, P159, DOI 10.1016/S0196-0644(96)70317-7
   HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368
   Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017
   Kelly JL, 2012, RESPIRATION, V84, P193, DOI 10.1159/000336549
   Kodgule RR, 2014, J POSTGRAD MED, V60, P123, DOI 10.4103/0022-3859.132311
   Kokturk N, 2005, PULM PHARMACOL THER, V18, P416, DOI 10.1016/j.pupt.2005.03.003
   Lahdensuo A, 1996, BRIT MED J, V312, P748
   Muellerova H, 2015, CHEST, V147, P999, DOI 10.1378/chest.14-0655
   Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032
   Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022
   Soriano JB, 2015, LANCET RESP MED, V3, P443, DOI 10.1016/S2213-2600(15)00157-5
   Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100
   van den Berge M, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-44
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC
   ZUREIK M, 1995, CHEST, V107, P418, DOI 10.1378/chest.107.2.418
NR 22
TC 1
Z9 1
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 43
EP 48
DI 10.1016/j.rmed.2019.01.010
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100007
PM 30827473
DA 2020-05-18
ER

PT J
AU Farah, CS
   Badal, T
   Reed, N
   Rogers, PG
   King, GG
   Thamrin, C
   Peters, MJ
   Seccombe, LM
AF Farah, Claude S.
   Badal, Tanya
   Reed, Nicola
   Rogers, Peter G.
   King, Gregory G.
   Thamrin, Cindy
   Peters, Matthew J.
   Seccombe, Leigh M.
TI Mepolizumab improves small airway function in severe eosinophilic asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Asthma; Interleukin-5; Nitrogen washout test; Small airways; Ventilation
   heterogeneity
ID VENTILATION HETEROGENEITY; LUNG-FUNCTION; THERAPY; HYPERRESPONSIVENESS;
   EXACERBATIONS; SPIROMETRY
AB Background and objective: Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. The time course of any changes in small airway function is unknown.
   Objective: To describe changes in ventilation inhomogeneity, a marker of small airway function, after commencing mepolizumab.
   Methods: Prospective cohort of 20 adults (12 male) with SEA commencing monthly mepolizumab. Measurements at baseline, Week 4 and Week 26 included the Asthma Control Questionnaire (ACQ-5), spirometry, fraction of exhaled nitric oxide (FeNO) and multiple breath nitrogen washout to measure global (Lung Clearance Index, [LCI]) and regional ventilation inhomogeneity in acinar (Sacin) and conducting (Scond) airways. Other asthma therapy remained unchanged between baseline and Week 4. Treatment related changes were assessed using RM-ANOVA and paired t-tests. Relationships between changes in lung function and symptoms were assessed by Pearson's correlation.
   Results: At Week 4, ACQ-5, spirometry, LCI and Sacin improved significantly (p < 0.04) and all were sustained at Week 26. The change in ACQ-5 correlated with the change in Sacin (r = 0.48, p = 0.03) and FRC (r = 0.46, p = 0.04), but not spirometry.
   Conclusion: Improved symptom control improved rapidly after commencing mepolizumab in patients with SEA. The early improvement in small airway function was associated with asthma control and may be a significant contributor to the therapeutic response.
C1 [Farah, Claude S.; Badal, Tanya; Reed, Nicola; Rogers, Peter G.; Peters, Matthew J.; Seccombe, Leigh M.] Concord Hosp, Dept Thorac Med, Level 7 West, Sydney, NSW 2139, Australia.
   [Farah, Claude S.; Badal, Tanya; King, Gregory G.; Thamrin, Cindy] Woolcock Inst Med Res, Glebe, NSW, Australia.
   [Farah, Claude S.; King, Gregory G.; Thamrin, Cindy; Peters, Matthew J.; Seccombe, Leigh M.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Farah, Claude S.; Peters, Matthew J.] Macquarie Univ, Fac Med & Hlth Sci, N Ryde, NSW, Australia.
RP Farah, CS (reprint author), Concord Hosp, Dept Thorac Med, Level 7 West, Sydney, NSW 2139, Australia.
EM claude.farah@sydney.edu.au
OI Seccombe, Leigh/0000-0001-8037-3824; Farah, Claude/0000-0003-2489-227X;
   Peters, Matthew/0000-0002-9649-8741
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   Davies J, 2013, LANCET RESP MED, V1, P630, DOI 10.1016/S2213-2600(13)70182-6
   de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055
   Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Farah CS, 2012, J ALLERGY CLIN IMMUN, V130, P61, DOI 10.1016/j.jaci.2012.02.015
   Global Initiative for Asthma, GLOB STRAT ASTHM MAN
   Gobbi A, 2017, AM J RESP CRIT CARE, V195, P265, DOI 10.1164/rccm.201603-0537LE
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026
   Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991
   Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3
   Jabbal S, 2016, J ALLERGY CLIN IMMUN, V138, P601, DOI 10.1016/j.jaci.2015.12.1336
   Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008
   Kjellberg S, 2016, RESP MED, V117, P92, DOI 10.1016/j.rmed.2016.05.028
   Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013
   Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6
   Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI 10.1183/09031936.00069712
   Thompson BR, 2013, J ALLERGY CLIN IMMUN, V131, P1322, DOI 10.1016/j.jaci.2013.01.054
   Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490
   Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017
   Verbanck S, 2010, J ALLERGY CLIN IMMUN, V125, P611, DOI 10.1016/j.jaci.2009.10.053
   Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048
NR 29
TC 4
Z9 4
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 49
EP 53
DI 10.1016/j.rmed.2019.01.016
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100008
PM 30827474
DA 2020-05-18
ER

PT J
AU Schulze, J
   Smith, HJ
   Eichhorn, C
   Salzmann-Manrique, E
   Dressler, M
   Zielen, S
AF Schulze, Johannes
   Smith, Hans-Juergen
   Eichhorn, Celine
   Salzmann-Manrique, Emilia
   Dressler, Melanie
   Zielen, Stefan
TI Correlation of spirometry and body plethysmography during
   exercise-induced bronchial obstruction
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Body plethysmography; Spirometry; Exercise challenge; Exercise-induced
   bronchoconstriction
ID METHACHOLINE CHALLENGE; RESPIRATORY IMPEDANCE; DEEP INSPIRATION;
   CHILDREN
AB Background: The exercise challenge is the gold standard for diagnosing exercise-induced bronchoconstriction (EIB). Airway obstructions appear up to 30 min after the challenge, with a maximum decrease in spirometry and a maximum increase in airway resistance. There is evidence that changes in body plethysmography parameters are more sensitive to the exercise challenge and precede those in spirometry.
   Purpose: To compare changes in body plethysmography and spirometry parameters after exercise challenges and to verify the cut-off values of sReff in EIB.
   Procedures: In 82 subjects with suspected EIB, a total of 473 lung function tests were measured at baseline and at 5, 10, 15, and 30 min after exercise challenges at different stages of bronchial obstruction.
   Findings: The maximum changes in the body plethysmography parameter sReff significantly preceded the maximum changes in the spirometry parameter FEV1 (sReff: 12.2 min +/- 8.8, FEV1: 15.2 min +/- 9.3, p < 0.005). The parameters of sReff and FEV1 had a strong negative correlation (r = -0.63, p < 0.0001) with a nonlinear, polynomial relationship. Furthermore, sReff and Reff had a strong linear correlation (r = 0.86, p < 0.001), and Reff and Rtot had a perfect linear correlation (r = 0.99, p < 0.001). Based on baseline values and on quantile regression, an increase of 0.25 kPa s in sReff was defined as significant. Using this cut-off value, FEV1 and sReff almost equally detected EIB.
   Conclusion: The changes in sReff were more sensitive and better indicated lung impairment than did the changes in FEV1, which underestimated the degree of hyperinflation.
C1 [Schulze, Johannes; Eichhorn, Celine; Dressler, Melanie; Zielen, Stefan] Goethe Univ, Univ Hosp Frankfurt, Dept Children & Adolescents Allergy Pulmonol & Cy, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
   [Smith, Hans-Juergen] Res Resp Diagnost, Berlin, Germany.
   [Salzmann-Manrique, Emilia] Goethe Univ, Univ Hosp Frankfurt, Inst Biostat & Math Modeling, Dept Med, Frankfurt, Germany.
RP Schulze, J (reprint author), Goethe Univ, Univ Hosp Frankfurt, Dept Children & Adolescents Allergy Pulmonol & Cy, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM johannes.schulze@kgu.de; H.Smith@arcor.de; celine-eichhorn@gmx.de;
   Emilia.Salzmann@kgu.de; Melanie.Dressler@kgu.de; Stefan.Zielen@kgu.de
RI Zielen, Stefan/AAD-7243-2020
CR Allen ND, 2005, CHEST, V128, P4018, DOI 10.1378/chest.128.6.4018
   ANDERSSON LG, 1988, CLIN PHYSIOL, V8, P113, DOI 10.1111/j.1475-097X.1988.tb00199.x
   Calogero C, 2013, PEDIATR PULM, V48, P707, DOI 10.1002/ppul.22699
   Christensen PM, 2013, PRIM CARE RESP J, V22, P306, DOI 10.4104/pcrj.2013.00067
   Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P951, DOI 10.1016/j.jaci.2006.02.007
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Criee CP, 2011, RESP MED, V105, P959, DOI 10.1016/j.rmed.2011.02.006
   Criee C-P, 2006, Pneumologie, V60, P576, DOI 10.1055/s-2006-944245
   Dressler M, 2018, NITRIC OXIDE-BIOL CH, V76, P45, DOI 10.1016/j.niox.2018.03.004
   Jerzynska J, 2015, ANN ALLERG ASTHMA IM, V115, P272, DOI 10.1016/j.anai.2015.07.002
   Johansson H, 2015, THORAX, V70, P57, DOI 10.1136/thoraxjnl-2014-205738
   Kraemer R, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0470-0
   MATTHYS H, 1975, RESPIRATION, V32, P121
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Nensa F, 2013, ADV EXP MED BIOL, V755, P1, DOI 10.1007/978-94-007-4546-9_1
   Nensa F, 2009, EUR J MED RES, V14, P170
   O'Donnell CR, 2010, CHEST, V137, P1108, DOI 10.1378/chest.09-1504
   Oostveen E, 2013, EUR RESPIR J, V42, P1513, DOI 10.1183/09031936.00126212
   OREHEK J, 1975, BMJ-BRIT MED J, V1, P123, DOI 10.1136/bmj.1.5950.123
   Parsons JP, 2013, AM J RESP CRIT CARE, V187, P1016, DOI 10.1164/rccm.201303-0437ST
   Provokationstests A. B., 1998, PNEUMOLOGIE, V52, P214
   Ruhle  K.-H., 2013, SPEZIELLE LUNGENFUNK
   Schlegel J, 1995, Pneumologie, V49, P383
   Schulze J, 2012, RESP MED, V106, P627, DOI 10.1016/j.rmed.2012.01.007
   Scichilone N, 2001, AM J RESP CRIT CARE, V163, P413, DOI 10.1164/ajrccm.163.2.2003119
   Ulmer W. T., LUNGENFUNKTION METHO
NR 26
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 54
EP 59
DI 10.1016/j.rmed.2019.01.011
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100009
PM 30827475
DA 2020-05-18
ER

PT J
AU Stolk, J
   Aggarwal, N
   Hochnadel, I
   Wrenger, S
   Martinez-Delgado, B
   Welte, T
   Yevsa, T
   Janciauskiene, S
AF Stolk, J.
   Aggarwal, N.
   Hochnadel, I.
   Wrenger, S.
   Martinez-Delgado, B.
   Welte, T.
   Yevsa, T.
   Janciauskiene, S.
TI Blood monocyte profiles in COPD patients with PiMM and PiZZ alpha
   1-antitrypsin
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; alpha1-antitrypsin deficiency; Monocytes; Flow cytometry
ID SUBSETS
AB Human blood monocytes are divided into populations based on the differential expression of CD14 and CD16 receptors: CD14 (+) CD16(classical), CD14 (+) CD16 (+) (intermediate), and CD14(-)CD16(+) (non-classical). Given their functional differences and their role in pathogenesis of chronic obstructive pulmonary disease (COPD), monocyte profiling is of clinical interest. Here we investigated blood monocyte subsets in clinically stable COPD patients with alpha1-antitrypsin (AAT) deficiency (PiZZ, n = 7) and with normal AAT variant (PiMM, n = 7). Peripheral whole blood was collected in sodium heparin tubes and incubated with LPS (from E. coli; 1 mu g/ml) or placebo for 6 h at 37 degrees C, 5% CO2. To profile monocyte subsets we performed flow cytometry analysis based on HLA-DR and CD14/CD16 staining. HLA-DR + subsets of cells did not differ between PiZZ and PiMM COPD, and healthy controls (n = 7), used as a reference. Monocyte profiling, which express the CD14 and CD16, but not the HLA-DR (HLA-DR-) showed that intermediate monocytes subset was lowest in PiZZ group, and almost totally disappeared from blood treated with LPS. The non-classical subset was almost absent in PiZZ patients independently of LPS treatment. Recent studies demonstrate that non-classical monocytes exhibit a unique ability to protect the vascular endothelium under both homeostatic and inflammatory conditions whereas intermediate monocytes are recruited at a later stage of inflammation, and are associated with secretion of cytokines/chemokines and wound healing. Evident alterations in blood monocyte subsets together with a partial reduction of AAT levels, an important anti-inflammatory protein, can be key factors for the early manifestation of emphysema in some PiZZ AATD carriers.
C1 [Stolk, J.] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands.
   [Aggarwal, N.; Wrenger, S.; Welte, T.; Janciauskiene, S.] Hannover Med Sch, Dept Resp Med, Biomed Res End Stage & Obstruct Lung Dis Hannover, Hannover, Germany.
   [Aggarwal, N.; Wrenger, S.; Welte, T.; Janciauskiene, S.] German Ctr Lung Res DZL, Hannover, Germany.
   [Hochnadel, I.; Yevsa, T.] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.
   [Martinez-Delgado, B.] IIER, Mol Genet Unit, Madrid, Spain.
RP Janciauskiene, S (reprint author), Hannover Univ, Sch Med, German Ctr Lung Res DZL, Dept Pulm & Infect Dis, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM janciauskiene.sabina@mh-hannover.de
OI Yevsa, Tetyana/0000-0003-0377-9198; Aggarwal, Nupur/0000-0002-7992-0023
CR Ahout IML, 2016, PEDIATR INFECT DIS J, V35, pE89, DOI 10.1097/INF.0000000000001007
   Aldonyte R, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-11
   Barnes Peter J, 2004, COPD, V1, P59, DOI 10.1081/COPD-120028701
   Boyette LB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176460
   Cornwell WD, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0664-y
   Olingy CE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00477-1
   Parr DG, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-21
   Sprangers S, 2016, J IMMUNOL RES, DOI 10.1155/2016/1475435
   Tak T, 2017, J INNATE IMMUN, V9, P464, DOI 10.1159/000475665
   Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228
   Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1
NR 11
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD MAR
PY 2019
VL 148
BP 60
EP 62
DI 10.1016/j.rmed.2019.02.001
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HN0WC
UT WOS:000459908100010
PM 30827477
DA 2020-05-18
ER

PT J
AU Keller, K
   Hobohm, L
   Munzel, T
   Ostad, MA
   Espinola-Klein, C
AF Keller, Karsten
   Hobohm, Lukas
   Muenzel, Thomas
   Ostad, Mir Abolfazl
   Espinola-Klein, Christine
TI Impact of chronic obstructive pulmonary disease on the outcomes of
   patients with peripheral artery disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Peripheral artery disease; Chronic obstructive pulmonary disease;
   Complications; Mortality; Amputation
ID BODY-MASS INDEX; INTERMITTENT CLAUDICATION; VENOUS THROMBOEMBOLISM;
   MORTALITY; COPD; RISK; SMOKING; PREVALENCE; TRENDS; AMPUTATION
AB Background: Peripheral artery disease (PAD) and chronic obstructive pulmonary disease (COPD) are both related with high in-hospital mortality. We aimed to investigate the impact of COPD on the in-hospital outcomes in PAD.
   Methods: PAD patients were selected based on ICD-code I70.2 of the German nationwide database, stratified for COPD and compared regarding adverse in-hospital outcomes.
   Results: Between 01/2005-12/2015, 5,611,827 inpatients (64.8% males) were diagnosed with PAD; of those, 13.6% were coded additionally with COPD. Overall, 277,894 PAD patients (5.0%) died during in-hospital course. Prevalence of cardiovascular diseases as well as cancer (12.1% vs. 7.0%, P < 0.001) was higher in PAD patients with COPD compared to PAD patients without COPD. PAD patients with COPD showed more often lower PAD stages according to Fontaine classification (PAD stage I: 27.1% vs. 19.3%, P < 0.001; PAD stage IIa: 34.9% vs. 35.5%, P < 0.001; PAD stage IIb: 14.5% vs. 13.6%, P < 0.001; PAD stage III: 11.8% vs. 14.8%, P < 0.001; PAD stage IV: 13.8% vs. 19.6%, P < 0.001).
   The all-cause in-hospital mortality was significantly higher in PAD patients with COPD compared to those without COPD (6.5% vs. 4.7%, P < 0.001). Cardiovascular events comprising pulmonary embolism and myocardial infarction occurred more often in coprevalence with PAD and COPD. COPD was an independent predictor of in-hospital death (OR 1.16 (95% CI 1.15-1.17) P < 0.001) and an independent predictor for pulmonary embolism (PE, OR 1.44 (1.40-1.49), P < 0.001) in PAD patients.
   Conclusion: COPD was associated with a high in-hospital mortality in PAD patients probably driven by higher frequencies of PE and cancer.
C1 [Keller, Karsten; Hobohm, Lukas; Muenzel, Thomas] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, CTH, Langenbeckstr 1, D-55131 Mainz, Germany.
   [Keller, Karsten; Hobohm, Lukas; Muenzel, Thomas; Ostad, Mir Abolfazl; Espinola-Klein, Christine] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Cardiol 1, Dept Cardiol, Mainz, Germany.
   [Muenzel, Thomas] German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Mainz, Germany.
RP Keller, K (reprint author), Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, CTH, Langenbeckstr 1, D-55131 Mainz, Germany.
EM Karsten.Keller@unimedizin-mainz.de
OI Keller, Karsten/0000-0002-0820-9584
FU German Federal Ministry of Education and ResearchFederal Ministry of
   Education & Research (BMBF) [BMBF 01EO1003, BMBF 01EO1503]
FX This study was supported by the German Federal Ministry of Education and
   Research (BMBF 01EO1003 and BMBF 01EO1503). The authors are responsible
   for the contents of this publication.
CR Aboyans V, 2017, EUR HEART J, V2017
   Barnes PJ, 2011, AM J RESP CRIT CARE, V184, P866, DOI 10.1164/rccm.201108-1436ED
   Borvik T, 2016, EUR RESPIR J, V47, P473, DOI 10.1183/13993003.00402-2015
   BOWLIN SJ, 1994, AM J EPIDEMIOL, V140, P418, DOI 10.1093/oxfordjournals.aje.a117264
   Brusselle G, 2017, AM J RESP CRIT CARE, V195, P148, DOI 10.1164/rccm.201608-1712ED
   Burney PGJ, 2015, EUR RESPIR J, V45, P1239, DOI 10.1183/09031936.00142414
   Carter BD, 2015, NEW ENGL J MED, V372, P631, DOI 10.1056/NEJMsa1407211
   Chen WJ, 2015, LANCET RESP MED, V3, P631, DOI 10.1016/S2213-2600(15)00241-6
   CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768
   CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605
   Curb JD, 1996, ARTERIOSCL THROM VAS, V16, P1495, DOI 10.1161/01.ATV.16.12.1495
   Durham AL, 2015, LUNG CANCER, V90, P121, DOI 10.1016/j.lungcan.2015.08.017
   FONTAINE R, 1954, Helv Chir Acta, V21, P499
   Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197
   Galal W, 2008, CHEST, V134, P925, DOI 10.1378/chest.08-0418
   Godtfredsen NS, 2008, EUR RESPIR J, V32, P844, DOI 10.1183/09031936.00160007
   Golledge J, 2013, ATHEROSCLEROSIS, V229, P549, DOI 10.1016/j.atherosclerosis.2013.04.030
   Houben-Wilkes S, 2017, AM J RESP CRIT CARE, V195, P189, DOI 10.1164/rccm.201602-0354OC
   Humphries MD, 2016, ANN VASC SURG, V30, P123, DOI 10.1016/j.avsg.2015.04.089
   INGOLFSSON IO, 1994, J CLIN EPIDEMIOL, V47, P1237, DOI 10.1016/0895-4356(94)90128-7
   Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419
   Ix JH, 2011, AM J EPIDEMIOL, V174, P1036, DOI 10.1093/aje/kwr228
   Kroger K, 2017, DTSCH ARZTEBL INT, V114, P130, DOI 10.3238/arztebl.2017.0130
   Lahousse L, 2013, AM J RESP CRIT CARE, V187, P58, DOI 10.1164/rccm.201206-1046OC
   Laniado-Laborin R, 2009, INT J ENV RES PUB HE, V6, P209, DOI 10.3390/ijerph6010209
   Lankeit M, 2016, EUR RESPIR J, V47, P369, DOI 10.1183/13993003.01679-2015
   Leung JM, 2016, AM J RESP CRIT CARE, V193, P227, DOI 10.1164/rccm.201510-1977ED
   Malyar N, 2013, EUR HEART J, V34, P2706, DOI 10.1093/eurheartj/eht288
   Meijer WT, 2000, ARCH INTERN MED, V160, P2934, DOI 10.1001/archinte.160.19.2934
   Murabito JM, 2002, AM HEART J, V143, P961, DOI 10.1067/mhj.2002.122871
   Pecci R, 2012, INT ANGIOL, V31, P444
   Roversi S, 2014, EUR J CLIN INVEST, V44, P93, DOI 10.1111/eci.12181
   Stein PD, 2007, J CARDIOVASC MED, V8, P253, DOI 10.2459/01.JCM.0000263509.35573.2c
   Suominen V, 2010, EUR J VASC ENDOVASC, V39, P316, DOI 10.1016/j.ejvs.2009.12.003
   Thukkani AK, 2015, CIRC RES, V116, P1599, DOI 10.1161/CIRCRESAHA.116.303503
   Thun MJ, 2013, NEW ENGL J MED, V368, P351, DOI 10.1056/NEJMsa1211127
   Tillie-Leblond I, 2006, ANN INTERN MED, V144, P390, DOI 10.7326/0003-4819-144-6-200603210-00005
NR 37
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 1
EP 6
DI 10.1016/j.rmed.2018.12.010
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800001
PM 30704692
DA 2020-05-18
ER

PT J
AU Ciolkowski, J
   Emeryk, A
   Hydzik, P
   Emeryk-Maksymiuk, J
   Kosmala, E
   Stasiowska, B
AF Ciolkowski, Janusz
   Emeryk, Andrzej
   Hydzik, Pawel
   Emeryk-Maksymiuk, Justyna
   Kosmala, Elwira
   Stasiowska, Barbara
TI Eosinophilic airway inflammation is a main feature of unstable asthma in
   adolescents
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Adolescents; Sputum eosinophils; Bronchial hiperresponsiveness; Unstable
   asthma; Airway inflammation
ID SPUTUM EOSINOPHILS; NITRIC-OXIDE; MAST-CELLS; CHILDREN; CHILDHOOD;
   MANNITOL; SUBTYPES; MARKERS; RESPONSIVENESS; VALIDATION
AB Background: Stability of asthma is a clinical phenotype of the disease based on long-term evaluation of control of asthma symptoms and its exacerbations. A relationship between airway inflammation and clinical classification of asthma based on stability criterion has not been well studied.
   Objectives: The purpose of our study was to analyze the inflammation profile of stable and unstable asthma in adolescents treated with moderate and high doses of inhaled corticosteroids.
   Methods: 139 young asthmatics of 16.8 (3.25) years were classified in the stable group (N= 72) and unstable group (N= 67) after a 3-month prospective observation. Inflammatory markers including cytogram of the induced sputum (IS), fractional exhaled nitric oxide (FeNO) and bronchial hyperresponsiveness (BHR) following provocation with hypertonic saline and exercises, as well as clinical and spirometric parameters in both groups were compared.
   Results: 75% of patients with unstable asthma revealed elevated percentage of eosinophils in the induced sputum (> 2.5%), and mean values were significantly higher in comparison with stable asthma: 2.0 (0,5-4,2) vs 5,5 (2,6-11,3), p < 0,001. Bronchial hyperresponsiveness was markedly higher in unstable asthma, especially in asthma with eosinophilic profile; statistically significant differences also related to functional pulmonary tests. In multivariate analysis, asthma instability was significantly associated with sEos (p=0.005), BHR (p=0.001) but not FeNO (p=0.24).
   Conclusion (and clinical relevance): Eosinophilic inflammation, relatively resistant to high doses of inhaled corticosteroids, is a dominant type of inflammation in unstable asthma in adolescents. Asthma instability is also associated with higher bronchial hyperresponsiveness and lower spirometric parameters. In the light of the new studies and progress in biological methods of therapy of eosinophilic inflammation, unstable asthma, especially in case of severe course, requires extended diagnostics with determination of inflammatory phenotype.
C1 [Ciolkowski, Janusz; Stasiowska, Barbara] Reg Publ Hosp, Kochanowskiego 2, PL-38600 Lesko, Poland.
   [Emeryk, Andrzej; Kosmala, Elwira] Med Univ Lublin, Dept Lung Dis & Rheumatol, Lublin, Poland.
   [Hydzik, Pawel] Rzeszow Univ Technol, Dept Quantitat Methods, Rzeszow, Poland.
   [Emeryk-Maksymiuk, Justyna] Med Univ Lublin, Dept Internal Med Nursing, Chair Internal Med, Lublin, Poland.
RP Ciolkowski, J (reprint author), Reg Publ Hosp, Kochanowskiego 2, PL-38600 Lesko, Poland.
EM ciolkowski.janusz@gmail.com
RI Hydzik, Pawel/AAI-1323-2019
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   [Anonymous], 2010, GLOB STRAT ASTHM MAN
   Banovcin P, 2009, EUR J MED RES, V14, P9, DOI 10.1186/2047-783X-14-S4-9
   Brooks CR, 2016, RESPIROLOGY, V21, P460, DOI 10.1111/resp.12701
   Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1
   Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848
   Chmielowicz Beata, 2008, Pneumonol Alergol Pol, V76, P378
   Choi BS, 2011, J KOREAN MED SCI, V26, P1265, DOI 10.3346/jkms.2011.26.10.1265
   Ciolkowski J, 2016, PULM PHARMACOL THER, V39, P7, DOI 10.1016/j.pupt.2016.05.002
   Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722
   Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC
   Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019
   Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116
   Henderson J, 2013, AUST FAM PHYSICIAN, V42, P739
   Juczynski Z., 2001, MEASUREMENT TOOLS PR, p[55, 168]
   Lang A, 2010, PEDIAT ALLERG IMM-UK, V21, P945, DOI 10.1111/j.1399-3038.2010.01072.x
   Lee YJ, 2013, ACTA PAEDIATR, V102, P53, DOI 10.1111/apa.12046
   Leuppi JD, 2005, RESPIRATION, V72, P52, DOI 10.1159/000083401
   Lex C, 2005, PEDIATR PULM, V39, P318, DOI 10.1002/ppul.20159
   Lezmi G, 2016, EUR RESPIR J, V48, P1320, DOI 10.1183/13993003.00947-2016
   Lovett CJ, 2007, CLIN EXP ALLERGY, V37, P1594, DOI 10.1111/j.1365-2222.2007.02839.x
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Mroczek B, 2017, ADV EXP MED BIOL, V968, P49, DOI 10.1007/5584_2016_192
   Ntontsi P, 2017, ALLERGY, V72, P1761, DOI 10.1111/all.13184
   Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x
   Porsbjerg C, 2009, J ASTHMA, V46, P606, DOI 10.1080/02770900903015654
   Santanello NC, 2001, J ALLERGY CLIN IMMUN, V107, pS465, DOI 10.1067/mai.2001.114948
   Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x
   Souza Ana C. T. G., 2005, J. Pediatr. (Rio J.), V81, P65, DOI 10.1590/S0021-75572005000100013
   Sverrild A, 2016, CLIN EXP ALLERGY, V46, P288, DOI 10.1111/cea.12609
   Tomasiak-Lozowska MM, 2012, INT ARCH ALLERGY IMM, V159, P121, DOI 10.1159/000335674
   Ullmann N, 2013, ALLERGY, V68, P402, DOI 10.1111/all.12101
   Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634
   Wilson NM, 2001, PEDIATR ALLERGY IMMU, V12, P125, DOI 10.1034/j.1399-3038.2001.012003125.x
   Wood LG, 2010, CLIN EXP ALLERGY, V40, P232, DOI 10.1111/j.1365-2222.2009.03371.x
NR 35
TC 2
Z9 2
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 7
EP 12
DI 10.1016/j.rmed.2018.12.009
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800002
PM 30704702
DA 2020-05-18
ER

PT J
AU Formiga, MF
   Vital, I
   Urdaneta, G
   Campos, MA
   Cahalin, LP
AF Formiga, Magno F.
   Vital, Isabel
   Urdaneta, Gisel
   Campos, Michael A.
   Cahalin, Lawrence P.
TI Beyond inspiratory muscle strength: Clinical utility of single-breath
   work capacity assessment in veterans with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Inspiratory muscle function; Single-breath work capacity
ID PULMONARY; VALIDATION; MORTALITY; ENDURANCE; RATIO
AB Background: Inspiratory muscle function in COPD has been traditionally described in terms of maximal inspiratory pressure (MIP). Arguably, however, is the day-to-day relevance of MIP, given that individuals rarely need maximal inspiratory forces to perform general tasks, but rather repeated breathing muscle contractions which demand endurance. The sustained maximal inspiratory pressure (SMIP) reflects the ability of the respiratory muscles to maintain force over time (i. e. single-breath work capacity). We investigated the relationships between SMIP and COPD-related clinical outcomes, hypothesizing that SMIP would have superior correlational and discriminatory value when compared to MIP.
   Methods: 61 males with mild-to-very severe airflow obstruction underwent measures of spirometry, whole-body plethysmography, symptomatology, comorbidity, quality of life, exacerbations and mental health. MIP and SMIP were obtained via the Test of Incremental Respiratory Endurance.
   Results: The mean +/- SD MIP and SMIP were 77.2 +/- 22.9 cm H2O and 407.9 +/- 122.8 PTU. Both MIP and SMIP positively correlated with pulmonary function, with SMIP displaying the highest correlations. We found significant differences in spirometry, hyperinflation, symptomatology, exacerbation frequency, comorbidity, quality of life and anxiety in subjects grouped as having reduced or normal single-breath work capacity. Finally, significantly lower SMIP values were found in individuals with an IC/TLC ratio 25%. <=
   Conclusions: The assessment of SMIP appears to have superior clinical value than MIP in COPD. Our analyses revealed that subjects whose SMIP was reduced experienced more severe airflow obstruction, greater hyperinflation, as well as worse health and mental status with increased symptomatology and impaired quality of life.
C1 [Formiga, Magno F.; Cahalin, Lawrence P.] Univ Miami, Miller Sch Med, Dept Phys Therapy, 5915 Ponce Leon Blvd,5th Floor, Coral Gables, FL 33146 USA.
   [Formiga, Magno F.] CAPES Fdn, Minist Educ Brazil, Brasilia, DF, Brazil.
   [Vital, Isabel; Urdaneta, Gisel; Campos, Michael A.] Miami Vet Adm Med Ctr, Pulm Sect, Miami, FL USA.
   [Campos, Michael A.] Univ Miami, Miller Sch Med, Div Pulm Allergy Crit Care & Sleep Med, Miami, FL 33136 USA.
RP Formiga, MF; Cahalin, LP (reprint author), Univ Miami, Miller Sch Med, Dept Phys Therapy, 5915 Ponce Leon Blvd,5th Floor, Coral Gables, FL 33146 USA.
EM magno@miami.edu; l.cahalin@miami.edu
RI Formiga, Magno F./T-1649-2018; Campos, Michael/X-2025-2019
OI Formiga, Magno F./0000-0003-0327-9695; 
CR Akkoca O., 2003, EFFECT HYPERINFLATIO
   Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Barr JT, 2000, CLIN THER, V22, P1121, DOI 10.1016/S0149-2918(00)80089-2
   Casanova C, 2005, AM J RESP CRIT CARE, V171, P591, DOI 10.1164/rccm.200407-867OC
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cohen J., 1988, STAT POWER ANAL BEHA
   Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC
   Formiga MF, 2018, INT J CHRONIC OBSTR, V13, P1569, DOI 10.2147/COPD.S160512
   French A, 2015, INT J CHRONIC OBSTR, V10, P1305, DOI 10.2147/COPD.S76739
   Hafez MR, 2012, EGYPTIAN J HOSP MED, V49, P661
   Hajiro T, 1998, AM J RESP CRIT CARE, V158, P1185, DOI 10.1164/ajrccm.158.4.9802091
   Hill K, 2007, EUR RESPIR J, V30, P479, DOI 10.1183/09031936.00095406
   Jamaati H., 2009, RELATIONSHIP SEVERIT
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Loring SH, 2009, J APPL PHYSIOL, V107, P309, DOI 10.1152/japplphysiol.00008.2009
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Nambiar V., 2018, INDIAN J RESP CARE, V7, P88
   O'Donnell DE, 2006, EUR RESPIR REV, V15, P61, DOI 10.1183/09059180.00010002
   O'Donnell DE, 2015, COPD RES PRACTICE, V1, P1
   Papava I, 2016, INT J CHRONIC OBSTR, V11, P1343, DOI 10.2147/COPD.S106765
   Pitta F, 2008, RESP MED, V102, P1203, DOI 10.1016/j.rmed.2008.03.004
   Terzano C, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-8
   Tudorache Voicu, 2010, Int J Chron Obstruct Pulmon Dis, V5, P119
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   Zaman M, 2010, AM J MED SCI, V339, P411, DOI 10.1097/MAJ.0b013e3181d6578c
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zugic V., 2015, EVALUATION RESP MUSC
NR 27
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 13
EP 18
DI 10.1016/j.rmed.2018.12.012
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800003
PM 30704693
DA 2020-05-18
ER

PT J
AU Bjermer, L
   Eriksson, G
   Radner, F
   Peterson, S
   Warner, JO
AF Bjermer, L.
   Eriksson, G.
   Radner, F.
   Peterson, Stefan
   Warner, J. O.
TI Time to onset of improvements in Quality of Life from
   Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Temperature-controlled Laminar Airflow; Severe allergic asthma; Quality
   of Life; AQLQ; Allergen avoidance; Sleep
ID EOSINOPHILIC ASTHMA; ATOPIC ASTHMA; COSTS; FENO; UK
AB Background: Allergen avoidance is important in allergic asthma management. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett (R)) has been shown to provide significant reduction of exposure to allergens in the breathing zone, leading to long-term reduction in airway inflammation and improvement in quality of life. Allergic asthma patients uncontrolled on GINA step 4 were found to benefit the most. A frequently asked question from clinicians and funders is related to time to onset (TTO) of improvements for patients using TLA.
   Methods: Asthma Quality of Life Questionnaire (AQLQ) scores were collected in a previous study. TTO of improvements in Quality of Life was analysed for difference (TLA-placebo) in Area-under-Curve using backwards deletion from 12, 9, 6, 3 down to 1 month for the AQLQ total score, the four individual domains and specifically the sleep question.
   Results: Patients with uncontrolled asthma on GINA step 4 (n=87)) reported a statistically significant and clinically relevant (>= 0.5 point) improvement in total AQLQ score (0.57; p=0.009) after 3 months treatment for TLA over placebo. The shortest TTO was within 1 month for the environmental domain (0.68; p=0.016) and the sleep question (0.771; p=0.037). TTO for the emotional and symptom domains was 3 months (0.66; p=0.020 and 0.64; p=0.014 respectively) and for the activity domain 6 months (0.47; p=0.036).
   Conclusion: Nocturnal avoidance of allergens using TLA provided a statistically significant and clinically relevant improvement in total AQLQ score within 3 months in patients in the GINA 4 + ACT< 18 group. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.
C1 [Bjermer, L.; Eriksson, G.; Radner, F.] Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden.
   [Peterson, Stefan] StatMind Stat & Math Modelling Innovat & Design A, Lund, Sweden.
   [Warner, J. O.] Imperial Coll, Dept Med Paediat, London, England.
RP Bjermer, L (reprint author), Lund Univ, Dept Clin Sci, Div Resp Med & Allergol, Skane Univ Hosp, S-22100 Lund, Sweden.
EM leif.bjermer@med.lu.se
RI Warner, John/AAF-9587-2020
FU Airsonett AB, Sweden
FX Airsonett AB, Sweden was the sponsor of the study. However, the paper
   was written without any influence from the sponsor and represent the
   author's views alone.
CR [Anonymous], 2018, GLOBAL INITIATIVE AS
   Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24
   Borak J, 2016, OCCUP MED-OXFORD, V66, P95, DOI 10.1093/occmed/kqv158
   Boyle RJ, 2012, THORAX, V67, P215, DOI 10.1136/thoraxjnl-2011-200665
   Brazier P, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000117
   Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
   Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST
   Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204
   Healthcare Improvement Scotland, 2015, AIRS INN MED TECHN O, V003
   Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042
   JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1
   Kerkhof M, 2018, THORAX, V73, P116, DOI 10.1136/thoraxjnl-2017-210531
   Munakata M, 2012, ALLERGOL INT, V61, P365, DOI 10.2332/allergolint.12-RAI-0461
   O'Neill S, 2015, THORAX, V70, P376, DOI 10.1136/thoraxjnl-2013-204114
   Pedroletti C, 2009, RESP MED, V103, P1313, DOI 10.1016/j.rmed.2009.03.020
   Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR
   Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053
   Swedish Medical Products Agency, 2015, REC TREATM ASTHM, V3, P26
   The National Institute for Health and Care Excellence (NICE), 2014, AIRS TEMP CONTR LAM, V8
   Warner JO, 2017, THER ADV RESPIR DIS, V11, P181, DOI 10.1177/1753465817690505
   Zeiger RS, 2016, J ALLER CL IMM-PRACT, V4, P120, DOI 10.1016/j.jaip.2015.08.003
   Zervas E., 2018, ERJ OPEN RES, V4
NR 22
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 19
EP 25
DI 10.1016/j.rmed.2018.12.006
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800004
PM 30704694
DA 2020-05-18
ER

PT J
AU Harder, EM
   Fares, WH
AF Harder, Eileen M.
   Fares, Wassim H.
TI Hospitalizations with hereditary hemorrhagic telangiectasia and
   pulmonary hypertension in the United States from 2000 to 2014
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pulmonary hypertension; Hereditary hemorrhagic telangiectasia;
   Hospitalizations; Mortality; Epidemiology
ID PREVALENCE
AB Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease that causes widespread abnormal vasculature development, resulting in multiple complications including pulmonary hypertension (PH). Despite the potential severity of PH, there is a lack of data on hospitalization characteristics and outcomes in the HHT-PH population. The purpose of this analysis was to describe trends and outcomes of HHTPH hospitalizations within the National (Nationwide) Inpatient Sample (NIS).
   Methods: Adult hospitalizations (age >= 18 years) with a principal or secondary diagnosis of HHT were identified from the 2000-2014 NIS. Records were stratified by a concurrent PH diagnosis. Trends, characteristics, and outcomes of hospitalizations with HHT and PH were analyzed.
   Results: There were 55,189 adult hospitalizations with HHT from 2000 to 2014, of which 4602 (8.3%) had a concurrent diagnosis of PH. HHT-PH hospitalizations rose steadily from 165 (5.1%) in 2000 to 540 (13.8%) in 2014 (p < 0.001). They were more common in females (vs. HHT without PH, 71.6% vs. 59.2%, p < 0.001) and were associated with a higher comorbidity burden (total 4.0 +/- 0.1 vs. 2.4 +/- 0.03, p < 0.001). Inpatient mortality was higher in HHT-PH hospitalizations than in HHT without PH (3.5% vs. 1.8%, p < 0.001). On multivariable logistic regression, the diagnosis of PH remained significantly associated with a higher risk of inpatient death (odds ratio 1.71, 95% confidence interval 1.11-2.63, p= 0.015) in HHT hospitalizations.
   Conclusions: HHT-PH hospitalizations rose from 2000 to 2014. Notably, HHT patients with a concurrent PH diagnosis were at significantly higher risk of in-hospital mortality.
C1 [Harder, Eileen M.] Yale Univ, Sch Med, Dept Internal Med, POB 208030, New Haven, CT 06520 USA.
   [Fares, Wassim H.] Actel Clin Res, Allschwil, Switzerland.
RP Harder, EM (reprint author), Yale Univ, Sch Med, Dept Internal Med, POB 208030, New Haven, CT 06520 USA.
EM eileen.harder@yale.edu; wfares@its.jnj.com
CR Chizinga M, 2017, AM J RESP CRIT CARE, V196, P1353, DOI 10.1164/rccm.201702-0267LE
   Cottin V, 2007, RESPIRATION, V74, P361, DOI 10.1159/000103205
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Ginon I, 2013, EUR J INTERN MED, V24, pE35, DOI 10.1016/j.ejim.2012.12.013
   Girerd B, 2010, AM J RESP CRIT CARE, V181, P851, DOI 10.1164/rccm.200908-1284OC
   Li W, 2018, PULM CIRC, V8, DOI 10.1177/2045894018759918
   Lyle MA, 2016, CHEST, V149, P362, DOI 10.1378/chest.15-0535
   Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735
   Olivieri C, 2006, GENET MED, V8, P183, DOI 10.1097/01.gim.0000204463.77319.1c
   Revuz S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184227
   Sopena B, 2013, EUR J INTERN MED, V24, pE30, DOI 10.1016/j.ejim.2012.11.012
   Vorselaars V. M. M., 2015, EUR RESP J S59, V46
   Vorselaars VMM, 2015, WORLD J CARDIOL, V7, P230, DOI 10.4330/wjc.v7.i5.230
NR 13
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 26
EP 30
DI 10.1016/j.rmed.2018.12.013
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800005
PM 30704695
DA 2020-05-18
ER

PT J
AU Bennett, D
   Mazzei, MA
   Collins, B
   Bargagli, E
   Pipavath, S
   Spina, D
   Valentini, ML
   Rinaldi, C
   Bettini, G
   Ginori, A
   Refini, RM
   Rottoli, P
   Raghu, G
AF Bennett, David
   Mazzei, Maria Antonietta
   Collins, Bridget
   Bargagli, Elena
   Pipavath, Sudhakar
   Spina, Donatella
   Valentini, Maria Lucia
   Rinaldi, Cesare
   Bettini, Gloria
   Ginori, Alessandro
   Refini, Rosa Metella
   Rottoli, Paola
   Raghu, Ganesh
TI Diagnosis of idiopathic pulmonary fibrosis by virtual means using
   "IPFdatabase"- a new software
SO RESPIRATORY MEDICINE
LA English
DT Article
DE IPF; Database; Diagnosis; Software
ID PIRFENIDONE; PLACEBO; TRIAL
AB Background: The diagnostic algorithm for idiopathic pulmonary fibrosis (IPF) guidelines has some shortcomings. The aim of the present study was to develop a novel software, "IPFdatabase", that could readily apply the diagnostic criteria per IPF guidelines and make a 'virtual' diagnosis of IPF.
   Methods: Software was developed as a step-by-step compilation of necessary information according to guidelines to enable a diagnosis of IPF. Software accuracy was validated primarily by comparing software diagnoses to those previously made at a Center for Interstitial Lung Diseases.
   Results: Clinical validation on 98 patients (68 male, age 61.0 +/- 8.5 years), revealed high software accuracy for IPF diagnosis when compared to historical diagnoses (sensitivity 95.5%, specificity 96.2%; positive predictive value 95.5%, negative predictive value 96.2%). A general radiologist and a general pathologist reviewed relevant data with and without the new software: interobserver agreement increased when they used the IPFdatabase (kappa 0.18 to 0.64 for radiology, 0.13 to 0.59 for pathology).
   Conclusion: IPFdatabase is a useful diagnostic tool for typical cases of IPF, and potentially restricts the need for MDDs to atypical and complex cases. We propose this web-designed software for instant accurate diagnosis of IPF by virtual means and for educational purposes; the software is readily accessed with mobile apps, allows incorporation of updated version of guidelines, can be utilized for gathering data useful for future studies and give physicians rapid feedback in daily practice.
C1 [Bennett, David; Bargagli, Elena; Valentini, Maria Lucia; Rinaldi, Cesare; Refini, Rosa Metella; Rottoli, Paola] Univ Siena, AOUS, Resp Dis & Lung Transplantat Unit, Siena, Italy.
   [Bennett, David; Mazzei, Maria Antonietta; Bargagli, Elena; Valentini, Maria Lucia; Rinaldi, Cesare; Refini, Rosa Metella; Rottoli, Paola] Univ Siena, Dept Med & Surg Sci & Neurosci, Siena, Italy.
   [Mazzei, Maria Antonietta] Univ Siena, AOUS, Diagnost Imaging Unit, Siena, Italy.
   [Collins, Bridget; Pipavath, Sudhakar; Raghu, Ganesh] Univ Washington, Div Pulm Crit Care & Sleep Med, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
   [Pipavath, Sudhakar] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
   [Spina, Donatella] AOUS, Pathol Unit, Siena, Italy.
   [Bettini, Gloria] AOUP, Emergency Dept, Radiol Unit, Pisa, Italy.
   [Ginori, Alessandro] Azienda USL Toscana Nord Ovest, Apuane Hosp, Pathol Unit, Carrara, Italy.
RP Raghu, G (reprint author), Univ Washington, Div Pulm Crit Care & Sleep Med, Ctr Interstitial Lung Dis, Seattle, WA 98195 USA.
EM graghu@uw.edu
RI Bennett, David/V-2756-2019
OI Bennett, David/0000-0001-5354-152X
CR Bennett D., 2014, ERS INT C MUN
   Bennett D, 2017, RESP MED, V126, P75, DOI 10.1016/j.rmed.2017.03.020
   Martinez-Franco AI, 2018, DIAGNOSIS, V5, P71, DOI 10.1515/dx-2017-0045
   Jo HE, 2016, RESPIROLOGY, V21, P1438, DOI 10.1111/resp.12850
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Leuschner G, 2017, J HEART LUNG TRANSPL, V17, P31886
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Noth I, 2012, AM J RESP CRIT CARE, V186, P88, DOI 10.1164/rccm.201202-0314OC
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2017, LANCET RESP MED, V5, P22, DOI 10.1016/S2213-2600(16)30421-0
   Raghu G, 2015, AM J RESP CRIT CARE, V191, P252, DOI 10.1164/rccm.201411-2044ED
   Raghu G, 2013, ANN INTERN MED, V158, P641, DOI 10.7326/0003-4819-158-9-201305070-00003
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Raimundo K, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-015-0165-1
   Smith JS, 2013, AM J MED SCI, V346, P221, DOI 10.1097/MAJ.0b013e31827871dc
   Walsh SLF, 2016, LANCET RESP MED, V4, P557, DOI 10.1016/S2213-2600(16)30033-9
   Zhang LJ, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0300-7
NR 17
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 31
EP 36
DI 10.1016/j.rmed.2018.12.011
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800006
PM 30704696
DA 2020-05-18
ER

PT J
AU Papi, A
   Zheng, JP
   Criner, GJ
   Fabbri, LM
   Calverley, PMA
AF Papi, Alberto
   Zheng, Jinping
   Criner, Gerard J.
   Fabbri, Leonardo M.
   Calverley, Peter M. A.
TI Impact of smoking status and concomitant medications on the effect of
   high-dose N-acetylcysteine on chronic obstructive pulmonary disease
   exacerbations: A post-hoc analysis of the PANTHEON study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Mucolytic; Chronic obstructive pulmonary disease; Exacerbations
ID DOUBLE-BLIND; TRIPLE THERAPY; COPD EXACERBATIONS; CHRONIC-BRONCHITIS;
   PARALLEL-GROUP; PLACEBO; PREVENTION; SALMETEROL; TIOTROPIUM; TRIAL
AB Background: N-acetylcysteine (NAC) 600 mg twice daily is a well-tolerated oral antioxidant mucolytic that reduces the risk of moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations. PANTHEON was one of the largest studies to evaluate NAC in COPD. It recruited current, ex-and never-smokers, concomitantly treated with other medications, and used a symptom-based definition of COPD exacerbations rather than the conventional healthcare resource utilisation (HCU) criteria.
   Methods: This manuscript reports post-hoc analyses of the PANTHEON dataset investigating whether smoking status or use of concomitant medications influenced the efficacy of NAC in terms of reducing exacerbations, defined according to HCU.
   Results: Compared with placebo (N=482), NAC (N=482) reduced the rate of HCU events by 20% (p=0.0027), with a larger effect in current/ex-smokers (23%; p < 0.01). In patients receiving NAC and longacting inhaled bronchodilator(s) but no ICS, there was a 60% reduction in the rate of exacerbations compared to those receiving placebo, long-acting bronchodilator(s) and ICS (p < 0.0001).
   Conclusions: Overall, these post-hoc hypothesis-generating analyses confirm that NAC reduces the rate of COPD exacerbations, particularly in patients with COPD who have a significant smoking history, and in those not treated with ICS. NAC may provide an alternative to ICS-containing combinations in these patient subgroups.
C1 [Papi, Alberto; Fabbri, Leonardo M.] Univ Ferrara, Dept Med Sci, Sect Cardioresp & Internal Med, Ferrara, Italy.
   [Zheng, Jinping] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou 510120, Guangdong, Peoples R China.
   [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Fabbri, Leonardo M.] Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Med, COPD Ctr, Gothenburg, Sweden.
   [Calverley, Peter M. A.] Univ Liverpool, Sch Aging & Chron Dis, Liverpool, Merseyside, England.
RP Papi, A (reprint author), Univ Ferrara, Res Ctr Asthma & COPD, Ferrara, Italy.
EM ppa@unife.it
RI Papi, alberto/AAC-1888-2019
OI PAPI, ALBERTO/0000-0002-6924-4500
FU Hainan Zambon Pharmaceutical Co. Ltd.; Zambon SpA
FX This study was sponsored by Hainan Zambon Pharmaceutical Co. Ltd. The
   funding source had no role in the study design, data collection,
   analysis, or interpretation. Writing support for this manuscript was
   provided by David Young of Young Medical Communications and Consulting
   Ltd. This support, which included assisting the authors with creating
   the first draft and incorporating comments into subsequent drafts, was
   funded by Zambon SpA.
CR Aaron SD, 2007, ANN INTERN MED, V146, P545, DOI 10.7326/0003-4819-146-8-200704170-00152
   Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623
   Andersson F, 2002, RESP MED, V96, P700, DOI 10.1053/rmed.2002.1334
   ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196
   Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
   Carraro S, 2014, EUR RESPIR J, V44, P1682, DOI 10.1183/09031936.00084114
   Cazzola M, 2015, EUR RESPIR REV, V24, P451, DOI 10.1183/16000617.00002215
   Chapman KR, 2013, COPD, V10, P243, DOI 10.3109/15412555.2012.733463
   Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2
   Dhamane AD, 2015, INT J CHRONIC OBSTR, V10, P2609, DOI 10.2147/COPD.S90148
   Ferguson GT, 2018, LANCET RESP MED, V6, P747, DOI 10.1016/S2213-2600(18)30327-8
   Global Initiative for Chronic Obstructive Lung Disease, 2019, GLOBAL STRATEGY DIAG, DOI [10.2147/COPD.S90148, DOI 10.2147/COPD.S90148]
   Grigsby M, 2016, INT J CHRONIC OBSTR, V11, P2497, DOI 10.2147/COPD.S111145
   Tse HN, 2013, CHEST, V144, P106, DOI 10.1378/chest.12-2357
   Jones PW, 2014, AM J RESP CRIT CARE, V189, P250, DOI 10.1164/rccm.201310-1863PP
   Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901
   Lipson DA, 2017, AM J RESP CRIT CARE, V196, P438, DOI 10.1164/rccm.201703-0449OC
   Martinez FJ, 2015, LANCET, V385, P857, DOI 10.1016/S0140-6736(14)62410-7
   Miele CH, 2016, COPD, V13, P186, DOI 10.3109/15412555.2015.1067765
   Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1
   Punekar YS, 2014, INT J CHRONIC OBSTR, V9, DOI 10.2147/COPD.S54417
   Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9
   Singh D, 2016, LANCET, V388, P963, DOI 10.1016/S0140-6736(16)31354-X
   Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800
   Thomas M, 2014, COPD, V11, P300, DOI 10.3109/15412555.2013.841671
   Vestbo J, 2017, LANCET, V389, P1919, DOI 10.1016/S0140-6736(17)30188-5
   Yang IA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002991.pub3
   Zheng JP, 2014, LANCET RESP MED, V2, P187, DOI 10.1016/S2213-2600(13)70286-8
   Zheng JP, 2013, COPD, V10, P164, DOI 10.3109/15412555.2012.732628
NR 29
TC 3
Z9 3
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 37
EP 43
DI 10.1016/j.rmed.2018.12.014
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800007
PM 30704697
DA 2020-05-18
ER

PT J
AU Ban, GY
   Jeong, YJ
   Lee, SH
   Shin, SS
   Shin, YS
   Park, HS
   Kim, SH
   Ye, YM
AF Ban, Ga-Young
   Jeong, Yoon-Jeong
   Lee, So-Hee
   Shin, Seung-Soo
   Shin, Yoo-Seob
   Park, Hae-Sim
   Kim, Seung-Hyun
   Ye, Young-Min
TI Efficacy and tolerability of desensitization in the treatment of delayed
   drug hypersensitivities to anti-tuberculosis medications
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Desensitization; Delayed drug hypersensitivity; Anti-tuberculosis
   medication
ID RAPID ORAL DESENSITIZATION; ALLERGIC REACTIONS; SYSTEMIC SYMPTOMS;
   RIFAMPIN
AB Background: Delayed drug hypersensitivity to first-line anti-tuberculosis medication is a major challenge in tuberculosis treatment. Objective: This study was performed to investigate the efficacy/tolerability of desensitization therapy in treatment of first-line anti-tuberculosis medication hypersensitivity and the usefulness of immunologic evaluation therein.
   Methods: This study was conducted as a prospective, observational cohort study. Subjects who experienced hypersensitivity reactions, including maculopapular exanthema (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS), to first-line anti-tuberculosis medications (isoniazid [INH], ethambutol [EMB], rifampin [RFP], and pyrazinamide [PZA]) were enrolled. Patch, intradermal, lymphocyte transformation, and oral provocation tests were performed to determine culprit drugs, which were desensitized with rapid and graded challenge protocols. Breakthrough reactions (BTRs) during or after desensitization were assessed.
   Results: In total, 31 desensitization treatments (INH, 8; EMB, 8; RFP, 11; PZA, 4) to 12 patients (8 with MPE and 4 with DRESS) were performed. The overall success rate of desensitization was 80.7%. All the study subjects except one completed the full course of anti-tuberculosis treatment. The overall BTR free rate was 64.5%. Sixteen (80%) treatments for MPE and four (36.4%) for DRESS were BTR free (P=0.023). Drugs that were positive on any two of three immunologic studies showed significantly high BTR rates (P=0.014), although this was not correlated with desensitization failure rate.
   Conclusion: Rapid desensitization therapy to multiple anti-tuberculosis medications for delayed drug hypersensitivity was safe and successful. Combination of multiple immunologic evaluations may predict BTR although it needs validation in larger studies.
C1 [Ban, Ga-Young] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Dept Pulm Allergy & Crit Care Med, Seoul 05355, South Korea.
   [Jeong, Yoon-Jeong; Shin, Seung-Soo] Ajou Univ, Sch Med, Dept Pulmonol & Crit Care Med, Suwon 16499, South Korea.
   [Lee, So-Hee; Shin, Yoo-Seob; Park, Hae-Sim; Ye, Young-Min] Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, 164 Worldcup Ro, Suwon 16499, South Korea.
   [Kim, Seung-Hyun] Ajou Univ, Med Ctr, Clin Trial Ctr, Translat Res Lab Inflammatory Dis, 164 Worldcup Ro, Suwon 16499, South Korea.
RP Ye, YM (reprint author), Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, 164 Worldcup Ro, Suwon 16499, South Korea.; Kim, SH (reprint author), Ajou Univ, Med Ctr, Clin Trial Ctr, Translat Res Lab Inflammatory Dis, 164 Worldcup Ro, Suwon 16499, South Korea.
EM kimsh@ajou.ac.kr; ye9007@ajou.ac.kr
RI Park, Hae-Sim/S-7974-2019
OI Kim, Seung-Hyun/0000-0003-1789-8964; Park, Hae-Sim/0000-0003-2614-0303;
   Ye, Young-Min/0000-0002-7517-1715
FU Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [HI16C0992]; Ministry of Food and Drug
   SafetyMinistry of Food & Drug Safety (MFDS)
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI16C0992) and a grant from the Ministry of Food and Drug
   Safety for operation of the Regional Pharmacovigilance Center in 2018.
CR Barbaud A, 2009, ANN DERMATOL VENER, V136, P635, DOI 10.1016/j.annder.2009.06.021
   Barbaud A, 2009, IMMUNOL ALLERGY CLIN, V29, P517, DOI 10.1016/j.iac.2009.04.010
   Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029
   Carroll MW, 2012, INT J TUBERC LUNG D, V16, P961, DOI 10.5588/ijtld.11.0574
   Cernadas JR, 2013, CASE REP MED, DOI 10.1155/2013/208797
   Dona I, 2017, ALLERGY ASTHMA IMMUN, V9, P288, DOI 10.4168/aair.2017.9.4.288
   HOLLAND CL, 1990, CHEST, V98, P1518, DOI 10.1378/chest.98.6.1518
   김상훈, 2007, [The Korean Journal of Medicine, 대한내과학회지], V73, P496
   Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x
   Kim JH, 2003, ALLERGY, V58, P540, DOI 10.1034/j.1398-9995.2003.00152.x
   Kobashi Y, 2010, INTERNAL MED, V49, P2297, DOI 10.2169/internalmedicine.49.3590
   Logsdon S, 2014, PEDIAT ALLERG IMM-UK, V25, P404, DOI 10.1111/pai.12191
   Madrigal-Burgaleta R, 2013, ALLERGY, V68, P853, DOI 10.1111/all.12105
   MATZ J, 1994, AM J RESP CRIT CARE, V149, P815, DOI 10.1164/ajrccm.149.3.8118654
   Mayorga C, 2016, ALLERGY, V71, P1103, DOI 10.1111/all.12886
   Palmero D, 2013, INT J TUBERC LUNG D, V17, P76, DOI 10.5588/ijtld.12.0441
   Scherer K, 2013, ALLERGY, V68, P844, DOI 10.1111/all.12161
   Siripassorn K, 2018, INT J INFECT DIS, V68, P61, DOI 10.1016/j.ijid.2018.01.006
   Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019
   Thong BYH, 2014, ASIA PAC ALLERGY, V4, P156, DOI 10.5415/apallergy.2014.4.3.156
   WHO, 2018, GLOB TUB REP 2018, P1, DOI DOI 10.1126/SCIENCE.1223389
   Yang MS, 2017, ALLERGY ASTHMA RESPI, V5, P239, DOI 10.4168/aard.2017.5.5.239
   Ye YM, 2017, BRIT J DERMATOL, V176, P378, DOI 10.1111/bjd.14839
NR 23
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 44
EP 50
DI 10.1016/j.rmed.2018.12.017
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800008
PM 30704698
DA 2020-05-18
ER

PT J
AU Bosi, M
   Milioli, G
   Parrino, L
   Fanfulla, F
   Tomassetti, S
   Melpignano, A
   Trippi, I
   Vaudano, AE
   Ravaglia, C
   Mascetti, S
   Poletti, V
AF Bosi, Marcello
   Milioli, Giulia
   Parrino, Liborio
   Fanfulla, Francesco
   Tomassetti, Sara
   Melpignano, Andrea
   Trippi, Irene
   Vaudano, Anna Elisabetta
   Ravaglia, Claudia
   Mascetti, Susanna
   Poletti, Venerino
TI Quality of life in idiopathic pulmonary fibrosis: The impact of sleep
   disordered breathing
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic pulmonary fibrosis; Quality of sleep; Quality of life
ID NOCTURNAL DESATURATION; OXYGEN DESATURATION; APNEA; COPD; THERAPY;
   DIAGNOSIS; INDEX; CPAP; HYPOXEMIA; CAP
AB Purpose: the study aims at describing the role of sleep disordered breathing (SDB) on daytime symptoms, quality of sleep and quality of life (QoL) in patients with moderate-severe IPF.
   Methods: we enrolled 34 consecutive room air breathing IPF outpatients who received a full-night polysomnography. The following questionnaires were administered: Epworth Sleepiness Score (ESS), Pittsburg Sleep Quality Index (PSQI), StGeorge's Questionnaire (StGQ).
   Results: patients were classified in 3 groups: Group A (NO-SDB, 9 patients), Group B(OSAS without sleep-related hypoxemia, 17 patients), Group C(OSAS with sleep-related hypoxemia, 8 patients). Although sleep parameters showed no significant differences among the 3 groups, worse measures were found in group C. 50% of patients (17/34) reported a StGQ score indicating a reduced QoL and the StGQ score was significantly higher in group C patients compared to group A (p < 0.05). In the stepwise multiple regression analysis, 75% of StGQ score variability was significantly predicted by FVC(Forced Vital Capacity) %, DLco (diffusion lung capacity for carbon monoxide)%, PSQI and ESS.
   Conclusions: in patients with IPF both subjective and polysomnographic poor sleep quality are extremely common features, they are predicted by variables associated with SBD severity and are linked to low QoL. IPF with more severe SDB present poor sleep quality and a worse QoL compared to SDB-free or OSAS-only.
C1 [Bosi, Marcello; Tomassetti, Sara; Ravaglia, Claudia; Mascetti, Susanna; Poletti, Venerino] GB Morgagni L Pierantoni Hosp, Dept Dis Thorax, Asl Romagna, Forli, Italy.
   [Milioli, Giulia; Parrino, Liborio; Melpignano, Andrea; Trippi, Irene; Vaudano, Anna Elisabetta] Univ Parma, Dept Med & Surg, Sleep Disorders Ctr, Via Gramsci 14, I-43126 Parma, PR, Italy.
   [Fanfulla, Francesco] IRCCS, Sci Inst Pavia, Ist Clin Sci Maugeri, Sleep Med Unit, Pavia, Italy.
   [Poletti, Venerino] Aarhus Univ Hosp, Dept Resp Dis & Allerg, Aarhus, Denmark.
RP Milioli, G (reprint author), Univ Parma, Dept Med & Surg, Sleep Disorders Ctr, Via Gramsci 14, I-43126 Parma, PR, Italy.
EM giulia.milioli@gmail.com
RI Parrino, Liborio/J-7260-2018
OI Parrino, Liborio/0000-0002-4035-6234
CR Aboussouan LS, 2015, AM J RESP CRIT CARE, V191, P979, DOI 10.1164/rccm.201412-2224CI
   Agarwal S, 2009, SLEEP MED, V10, P947, DOI 10.1016/j.sleep.2009.01.004
   [Anonymous], 2014, AASM MANUAL SCORING
   Bosi M, 2017, LUNG, V195, P643, DOI 10.1007/s00408-017-0031-4
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Chilosi M, 2010, SARCOIDOSIS VASC DIF, V27, P7
   Corte TJ, 2012, SARCOIDOSIS VASC DIF, V29, P41
   de Boer K, 2016, RESPIROLOGY, V21, P995, DOI 10.1111/resp.12622
   De Vries J, 2001, EUR RESPIR J, V17, P954, DOI 10.1183/09031936.01.17509540
   Drent M, 2003, CURR OPIN PULM MED, V9, P411, DOI 10.1097/00063198-200309000-00013
   Dudley KA, 2014, SLEEP MED CLIN, V9, P365, DOI 10.1016/j.jsmc.2014.05.008
   Ergan B, 2017, COPD, V14, P351, DOI 10.1080/15412555.2017.1319918
   Ferrer M, 2002, EUR RESPIR J, V19, P405, DOI 10.1183/09031936.02.00213202
   Gille T, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01934-2016
   Guilleminault C, 2007, SLEEP, V30, P641, DOI 10.1093/sleep/30.5.641
   Halasz P, 2014, SLEEP MED, V15, P1184, DOI 10.1016/j.sleep.2014.06.006
   Hilberg O, 2018, RESPIROLOGY, V23, P606, DOI 10.1111/resp.13234
   International Classification of Sleep Disorders, 2014, AM ACAD SLEEP MED
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kent BD, 2011, INT J CHRONIC OBSTR, V6, P199, DOI 10.2147/COPD.S10611
   Kolilekas L, 2013, J CLIN SLEEP MED, V9, P593, DOI 10.5664/jcsm.2758
   Kreuter M, 2016, LANCET RESP MED, V4, P381, DOI [10.1016/S2213-2600(16)00067-9, 10.1016/S2213-2600(16)30235-1]
   Kreuter M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151425
   Krishnan V, 2008, CHEST, V134, P693, DOI 10.1378/chest.08-0173
   Lancaster LH, 2009, CHEST, V136, P772, DOI 10.1378/chest.08-2776
   Lewis CA, 2009, THORAX, V64, P133, DOI 10.1136/thx.2007.088930
   Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
   Mavroudi M, 2018, SLEEP BREATH, V22, P393, DOI 10.1007/s11325-017-1579-1
   Mermigkis C, 2009, MED PRIN PRACT, V18, P10, DOI 10.1159/000163039
   Mermigkis C, 2007, LUNG, V185, P173, DOI 10.1007/s00408-007-9004-3
   Mermigkis C, 2015, SLEEP BREATH, V19, P385, DOI 10.1007/s11325-014-1033-6
   Mermigkis C, 2013, SLEEP BREATH, V17, P1137, DOI 10.1007/s11325-013-0813-8
   Milioli G, 2016, SLEEP MED REV, V26, P57, DOI 10.1016/j.smrv.2015.03.005
   Orth M, 2008, Pneumologie, V62, P11, DOI 10.1055/s-2007-980129
   Parrino L, 2005, CLIN NEUROPHYSIOL, V116, P2228, DOI 10.1016/j.clinph.2005.05.005
   Parrino L, 2001, SLEEP, V24, P881, DOI 10.1093/sleep/24.8.881
   Parrino L, 2000, NEUROLOGY, V54, P1633, DOI 10.1212/WNL.54.8.1633
   Parrino L, 2012, SLEEP MED REV, V16, P27, DOI 10.1016/j.smrv.2011.02.003
   PEREZPADILLA R, 1985, AM REV RESPIR DIS, V132, P224
   Poletti V, 2013, RESPIRATION, V86, P5, DOI 10.1159/000353580
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Swigris JJ, 2005, THORAX, V60, P588, DOI 10.1136/thx.2004.035220
   Terzano MG, 2001, SLEEP MED, V2, P537, DOI 10.1016/S1389-9457(01)00149-6
   Terzano MG, 1996, J CLIN NEUROPHYSIOL, V13, P145, DOI 10.1097/00004691-199603000-00005
   Troy Lauren K, 2014, World J Clin Cases, V2, P828, DOI 10.12998/wjcc.v2.i12.828
NR 45
TC 2
Z9 2
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 51
EP 57
DI 10.1016/j.rmed.2018.12.018
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800009
PM 30704699
DA 2020-05-18
ER

PT J
AU Bakerly, ND
   Woodcock, A
   Collier, S
   Leather, DA
   New, JP
   Crawford, J
   Harvey, C
   Vestbo, J
   Boucot, I
AF Bakerly, Nawar Diar
   Woodcock, Ashley
   Collier, Susan
   Leather, David A.
   New, John P.
   Crawford, Jodie
   Harvey, Catherine
   Vestbo, Jorgen
   Boucot, Isabelle
TI Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung
   Study in chronic obstructive pulmonary disease (SLS COPD) according to
   baseline patient characteristics and treatment subgroups
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; Effectiveness; Exacerbation;
   Fluticasone furoate; Inhaled corticosteroid; Salford Lung Study;
   Vilanterol
ID RANDOMIZED CONTROLLED-TRIALS; EXACERBATIONS; VILANTEROL; FUROATE; LIFE
AB Background: SLS COPD was the first open-label randomised controlled trial demonstrating a reduction in moderate/severe COPD exacerbations with once-daily inhaled fluticasone furoate/vilanterol (FF/VI) in everyday clinical practice. Here we report FF/VI effectiveness and safety in predefined patient subgroups.
   Methods: Patients with COPD, exacerbation history, and receiving maintenance inhaler therapy, were randomised to initiate FF/VI 100/25 mu g or continue usual care (UC) with 12 months' follow-up. Annual rates of moderate/severe exacerbations (primary outcome), selected secondary outcomes, and incidence of pneumonia serious adverse events of special interest (SAESI) were compared between randomisation groups across various patient subgroups/baseline treatment strata. SAESI rates by actual treatment were also assessed.
   Results: Lower exacerbation rates were observed for FF/VI versus UC across all subgroups/strata, including ICS + LABA therapy subset (8.0% [0.1, 15.4]), except in patients without baseline airflow limitation (-0.5% [-29.8, 22.1]). Larger reductions compared to the overall analysis were observed for patients on ICS-containing regimens (excluding LAMA) before the study (15.6% [3.4, 26.3]), and with baseline CAT score< 10 (25.3% [-0.4, 44.4]). Pneumonia SAESI rates were similar for FF/VI versus UC across all subgroups/strata, except the LABA, LAMA or LABA+ LAMA stratum (incidence ratio 2.8 [0.9, 8.5]). SAESI rates were not increased for FF/VI versus other ICS + LABA.
   Conclusions: Initiating FF/VI versus continuing UC reduced exacerbation rates without increased pneumonia SAESI risk compared to other ICS-containing regimens and in various patient subgroups, consistent with primary study findings. FF/VI may be a therapeutic option for a broad population of COPD patients, including those with more severe disease.
C1 [Bakerly, Nawar Diar; New, John P.] Salford Royal NHS Fdn Trust, Salford M6 8HD, Lancs, England.
   [Bakerly, Nawar Diar; Woodcock, Ashley; Vestbo, Jorgen] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Infect Immun & Resp Med, Oxford Rd, Manchester M13 9PL, Lancs, England.
   [Woodcock, Ashley; Vestbo, Jorgen] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England.
   [Collier, Susan] GlaxoSmithKline Plc, UK Med, Stockley Pk West,1-3 Ironbridge Rd, Uxbridge UB11 1BT, Middx, England.
   [Crawford, Jodie] GlaxoSmithKline Plc, Clin Stat, Stockley Pk West,1-3 Ironbridge Rd, Brentford TW8 9GS, Middx, England.
   [Harvey, Catherine] GlaxoSmithKline Plc, Global Clin Safety & Pharmacovigilance Safety Eva, Stockley Pk West,1-3 Ironbridge Rd, Uxbridge UB11 1BT, Middx, England.
RP Bakerly, ND (reprint author), Salford Royal NHS Fdn Trust, Dept Resp Med, Stott Lane, Salford M6 8HD, Lancs, England.
EM nawar.bakerly@srft.nhs.uk; ashley.woodcock@manchester.ac.uk;
   sue.d.collier@gsk.com; david.a.leather@gsk.com;
   john.p.new@manchester.ac.uk; jodie.v.crawford@gsk.com;
   cath_m_harvey@gsk.com; Jorgen.Vestbo@manchester.ac.uk;
   isabelle.i.boucot@gsk.com
RI Vestbo, Jorgen/Y-2912-2019
OI Woodcock, Ashley/0000-0002-5428-8578; Vestbo, Jorgen/0000-0001-6355-6362
FU GlaxoSmithKline plcGlaxoSmithKline [HZC115151, NCT01551758]
FX This study was funded by GlaxoSmithKline plc. (study HZC115151;
   NCT01551758). Employees of the sponsor were involved in study design,
   analysis and interpretation of the data, and manuscript
   preparation/review.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI [10.7189/jogh.05-020415, 10.7189/jogh.05.020415]
   Agusti A, 2014, CHRON OBSTR PULM DIS, V1, P166, DOI 10.15326/jcopdf.1.2.2014.0134
   Bakerly ND, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0267-6
   Chalkidou K, 2012, CLIN TRIALS, V9, P436, DOI 10.1177/1740774512450097
   Crim C, 2015, ANN AM THORAC SOC, V12, P27, DOI 10.1513/AnnalsATS.201409-413OC
   Dransfield MT, 2013, LANCET RESP MED, V1, P210, DOI 10.1016/S2213-2600(13)70040-7
   European Medicines Agency, EMA4882802016
   European Medicines Agency, EMA3300212016
   Foo J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152618
   GOLD, 2018, GLOB STRAT DIAGN MAN
   Halpin DMG, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0433-5
   Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026
   Jones PW, 2013, COPD, V10, P269, DOI 10.3109/15412555.2013.776920
   Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   National Institute for Health and Care Excellence, 2018, CHRON OBSTR PULM DIS
   New JP, 2014, THORAX, V69, P1152, DOI 10.1136/thoraxjnl-2014-205259
   Scichilone N, 2014, RESPIRATION, V87, P11, DOI 10.1159/000355082
   Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032
   Singal AG, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2013.13
   Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011
   Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37
   Vestbo J, 2016, NEW ENGL J MED, V375, P1253, DOI 10.1056/NEJMoa1608033
   Walker S, 2013, THORAX, V68, P1066, DOI 10.1136/thoraxjnl-2013-203724
   Wedzicha JA, 2007, LANCET, V370, P786, DOI 10.1016/S0140-6736(07)61382-8
   Woodcock A, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01531-2017
NR 26
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 58
EP 65
DI 10.1016/j.rmed.2018.12.016
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800010
PM 30704700
OA Other Gold
DA 2020-05-18
ER

PT J
AU Roehmel, JF
   Kallinich, T
   Staab, D
   Schwarz, C
AF Roehmel, Jobst F.
   Kallinich, Tilmann
   Staab, Doris
   Schwarz, Carsten
TI Clinical manifestations and risk factors of arthropathy in cystic
   fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
ID MUSCULOSKELETAL MANIFESTATIONS; LUNG-DISEASE; INFLAMMATION; ARTHRITIS
AB Background: Recurrent joint pain is frequently observed in patients with CF and can lead to reduced activity and quality of life. We conducted this observational study to assess the clinical manifestations, frequency, and risk factors of CF associated arthropathy.
   Methods: Clinical data were collected using a digital quality management system, medical records, and by conducting structured interviews. Univariate and multivariate statistical analysis were performed for statistical interpretation. Study design: retrospective observational study including 186 patients.
   Results: Of 186 patients (Demographics: Mean age 27 years, female gender 104/186 (57%), CFTR F508del homozygous 82/186 (44%) included in the study, 54/186 (29%) had experienced joint symptoms. Joint pain and swelling were the most frequent symptoms. The joints of the hands (JOH) followed by the joints of the feet were most affected. No specific pattern of autoantibodies was discovered.
   The level of total serum IgG, age, female gender, and pulmonary exacerbations per year were significant risk factors for arthropathy in the study cohort.
   Conclusions: Joint symptoms in CF are a frequent and clinically relevant phenomenon with a distinct clinical pattern. Pulmonary exacerbations and elevated levels of total serum IgG may reflect chronic inflammation in patients with CF and may lead to a specific arthropathy associated with this condition.
C1 [Roehmel, Jobst F.; Staab, Doris; Schwarz, Carsten] Charite Univ Med Berlin, CF Ctr, Dept Pediat Pneumol Immunol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Kallinich, Tilmann] Charite Univ Med Berlin, Pediat Rheumatol Ctr, Dept Pediat Pneumol Immunol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany.
RP Schwarz, C (reprint author), Charite Univ Med Berlin, CF Ctr, Dept Pediat Pneumol Immunol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM carsten.schwarz@charite.de
OI Roehmel, Jobst/0000-0002-1535-8852
CR Adelsten T, 2016, SCAND J RHEUMATOL, V45, P330, DOI 10.3109/03009742.2015.1122834
   Albersmeyer MP, 2012, RHEUMATOLOGY, V51, P1730, DOI 10.1093/rheumatology/kes040
   Bilton D., 2011, PULMONARY EXACERBATI, pS79, DOI [10.1016/S1569-1993(11)60012-X, DOI 10.1016/S1569-1993(11)60012-X]
   Botton E, 2003, JOINT BONE SPINE, V70, P327, DOI 10.1016/S1297-319X(03)00063-0
   Braun J., 2000, 4 INT WORKSH REACT A, P2185
   Cantin AM, 2015, J CYST FIBROS, V14, P419, DOI 10.1016/j.jcf.2015.03.003
   Casserly B, 2009, LUNG, V187, P149, DOI 10.1007/s00408-009-9138-6
   Colmegna I, 2004, CLIN MICROBIOL REV, V17, P348, DOI 10.1128/CMR.17.2.348-369.2004
   Costantino F, 2015, ANN RHEUM DIS, V74, P689, DOI 10.1136/annrheumdis-2013-204436
   Elborn JS, 2017, CTS-CLIN TRANSL SCI, V10, P28, DOI 10.1111/cts.12428
   Fitch G., 2016, J CYST FIBROS, DOI [10.1016/j.jcf.2015.12.0220, DOI 10.1016/J.JCF.2015.12.0220]
   Iannitti RG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10791
   JOHNSON S, 1994, RESP MED, V88, P567, DOI 10.1016/S0954-6111(05)80003-4
   Koch AK, 2008, J RHEUMATOL, V35, P1882
   Merkel PA, 1999, ARTHRITIS RHEUM-US, V42, P1563, DOI 10.1002/1529-0131(199908)42:8<1563::AID-ANR1>3.0.CO;2-H
   Parkins Michael D, 2011, Ther Adv Respir Dis, V5, P105, DOI 10.1177/1753465810386051
   Peckham D, 2017, J PATHOL, V241, P123, DOI 10.1002/path.4812
   Roehmel JF, 2014, J CYST FIBROS, V13, P205, DOI 10.1016/j.jcf.2013.10.002
   Thornton J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006838.pub4
   Turner MA, 1997, J ROY SOC MED, V90, P13, DOI 10.1177/014107689709031S04
   Visser S, 2012, LUNG, V190, P579, DOI 10.1007/s00408-012-9393-9
NR 21
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 66
EP 71
DI 10.1016/j.rmed.2019.01.003
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800011
PM 30704701
DA 2020-05-18
ER

PT J
AU Bonhomme, O
   Duysinx, B
   Heinen, V
   Detrembleur, N
   Corhay, JL
   Louis, R
AF Bonhomme, O.
   Duysinx, B.
   Heinen, V.
   Detrembleur, N.
   Corhay, J. -L.
   Louis, R.
TI First report of probe based confocal laser endomicroscopy during medical
   thoracoscopy
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Probe based confocal laser endomicroscopy; pCLE; Pleural carcinomatosis;
   Malignant mesothelioma; Thoracoscopy; Optical biopsies
AB Probe based confocal laser endomicroscopy (pCLE) is a new optical endoscopic technique, generating fluorescent light emission from the tissue of interest and allowing in vivo live imaging at a cellular level ("optical biopsies").
   To the best of our knowledge, this article is the first to present pCLE images during medical thoracoscopy. We present here 3 different patients referred for various health problems. A precise description of pleural cavity pCLE images after intravenous fluorescein injection (a fluorophore) together with corresponding macroscopical and histological studies is performed. This led to the diagnosis of normal pleura in one case, carcinomatous pleuritis in another case and a malignant mesothelioma in the third case.
   We believe that optical biopsies could help clinicians to make an early diagnosis, thereby allowing rapid therapeutic intervention (talc pleurodesis for example). Furthermore, it could help to guide biopsies when affected zones are not obvious to macroscopic examination.
   In a near future, new fluorophores could be developed to stain some pathophysiological processes, therapeutic targets, or enzymes activities bringing new insights in endoscopic pleural disease work-up.
C1 [Bonhomme, O.; Duysinx, B.; Heinen, V.; Corhay, J. -L.; Louis, R.] Domaine Univ Sart Tilman, CHU Liege, Pneumol Dept, B35, B-4000 Liege, Belgium.
   [Detrembleur, N.] Domaine Univ Sart Tilman, CHU Liege, Pathol Dept, B35, B-4000 Liege, Belgium.
RP Bonhomme, O (reprint author), Domaine Univ Sart Tilman, CHU Liege, Pneumol Dept, B35, B-4000 Liege, Belgium.
EM obonhomme@chuliege.be
CR Hassan T, 2015, LUNG, V193, P773, DOI 10.1007/s00408-015-9769-8
   Hassan T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189846
   Hsiung PL, 2008, NAT MED, V14, P454, DOI 10.1038/nm1692
   Janssen J, 2018, CLIN RESPIR J, V12, P2407, DOI 10.1111/crj.12940
   Karpathiou G, 2015, RESP MED, V109, P931, DOI 10.1016/j.rmed.2015.05.014
   Napoleon B, NEEDLE BASED CONFOCA
   Park CH, 2019, J GASTROEN HEPATOL, V34, P84, DOI 10.1111/jgh.14471
   Paull PE, 2011, ARCH PATHOL LAB MED, V135, P1343, DOI 10.5858/arpa.2010-0264-RA
   Salaun M, 2013, EUR RESPIR J, V42, P1646, DOI 10.1183/09031936.00191911
   Wijmans L., 2016, NEEDLE BASED CONFOCA, V1
   Xia H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087060
   Yserbyt J, 2018, THORAX, V73, P188, DOI 10.1136/thoraxjnl-2016-209746
   Yserbyt J, 2014, J HEART LUNG TRANSPL, V33, P492, DOI 10.1016/j.healun.2014.01.857
   Zirlik S, 2018, MED SCI MONITOR, V24, P5437, DOI 10.12659/MSM.909989
NR 14
TC 3
Z9 3
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 72
EP 75
DI 10.1016/j.rmed.2019.01.006
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800012
PM 30704703
DA 2020-05-18
ER

PT J
AU Taponen, S
   Uitti, J
   Karvala, K
   Luukkonen, R
   Lehtimaki, L
AF Taponen, Saara
   Uitti, Jukka
   Karvala, Kirsi
   Luukkonen, Ritva
   Lehtimaki, Lauri
TI Asthma diagnosed in late adulthood is linked to work disability and poor
   employment status
SO RESPIRATORY MEDICINE
LA English
DT Article
ID ONSET ASTHMA; RISK-FACTORS; PREDICTORS; PREVALENCE
AB Background: Age at asthma onset is associated with severity and outcomes of the disease.
   Objective: We studied if age at asthma diagnosis is related to employment and outcomes in working career.
   Patients and methods: A questionnaire was sent to 2613 adults with asthma in Tampere, Finland, and a follow-up questionnaire was sent after six years. Asthmatics were divided into groups based on their employment status: working full-time or work disability. Logistic regression was used to study the association of age at asthma diagnosis with employment status at baseline and with the risk of exiting full-time work during follow-up period.
   Results: In cross-sectional analysis, asthma diagnosed in late adulthood (50 + years) was associated with higher OR for having work-disability compared to childhood onset asthma (OR [95% CI] 3.60 [1.43-9.06]). During follow-up, asthma diagnosed in late adulthood was associated with higher OR for exiting full time work compared to childhood-onset asthma (OR 10.87 [3.25-36.40]).
   Conclusions: Asthma diagnosed in late adulthood is a higher risk for poor employment than asthma diagnosed earlier in life. Adult-onset of asthma is an important factor in view of work ability and early rehabilitation procedures.
C1 [Taponen, Saara] Valmet Technol Inc, Valmet Occupat Hlth, Lentokentankatu 11, Tampere 33101, Finland.
   [Taponen, Saara; Uitti, Jukka; Lehtimaki, Lauri] Univ Tampere, Fac Med & Life Sci, Tampere 33014, Finland.
   [Uitti, Jukka; Karvala, Kirsi] Finnish Inst Occupat Hlth, POB 63, Helsinki 00251, Finland.
   [Luukkonen, Ritva] Univ Helsinki, Fac Med, Clinicum, POB 63, FIN-00014 Helsinki, Finland.
   [Lehtimaki, Lauri] Tampere Univ Hosp, Allergy Ctr, POB 2000, Tampere 33521, Finland.
RP Taponen, S (reprint author), Valmet Technol Inc, Valmet Occupat Hlth, Lentokentankatu 11, Tampere 33101, Finland.
EM saara.taponen@fimnet.fi; jukka.uitti@tuni.fi; kirsi.karvala@ttl.fi;
   ritvaa.luukkonen@gmail.com; lauri.lehtimaki@tuni.fi
OI Lehtimaki, Lauri/0000-0003-1586-4998
FU Finnish Work Environment Fund [117428]
FX This work was supported by the Finnish Work Environment Fund, grant
   number 117428.
CR Balder B, 1998, RESP MED, V92, P729, DOI 10.1016/S0954-6111(98)90003-8
   Blanc PD, 2003, CHEST, V124, P1153, DOI 10.1378/chest.124.3.1153
   Eisner MD, 2006, AM J MED, V119, P884, DOI 10.1016/j.amjmed.2006.01.016
   Hansen CL, 2012, SCAND J PUBLIC HEALT, V40, P377, DOI 10.1177/1403494812449079
   Ilmarinen P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/514868
   Jamrozik E, 2009, RESPIROLOGY, V14, P814, DOI 10.1111/j.1440-1843.2009.01562.x
   Kankaanranta H, 2017, J ALLER CL IMM-PRACT, V5, P189, DOI 10.1016/j.jaip.2016.08.015
   Karjalainen A, 2002, SCAND J WORK ENV HEA, V28, P49, DOI 10.5271/sjweh.646
   Peters J, 2007, J OCCUP REHABIL, V17, P317, DOI 10.1007/s10926-007-9072-5
   Roorda RJ, 1996, THORAX, V51, pS7, DOI 10.1136/thx.51.Suppl_1.S7
   Saarinen K, 2003, EUR RESPIR J, V22, P305, DOI 10.1183/09031936.03.00100102
   Sood Akshay, 2013, Ann Am Thorac Soc, V10, P188, DOI 10.1513/AnnalsATS.201212-115OC
   Taponen S, 2018, J OCCUP MED TOXICOL, V13, DOI 10.1186/s12995-018-0189-6
   Toren K, 2009, THORAX, V64, P339, DOI 10.1136/thx.2008.105007
   Toren K, 2009, BMC PULM MED, V9
   Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678
NR 16
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 76
EP 78
DI 10.1016/j.rmed.2019.01.004
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800013
PM 30704704
OA Green Published
DA 2020-05-18
ER

PT J
AU Heukels, P
   Moor, CC
   von der Thusen, JH
   Wijsenbeek, MS
   Kool, M
AF Heukels, P.
   Moor, C. C.
   von der Thusen, J. H.
   Wijsenbeek, M. S.
   Kool, M.
TI Inflammation and immunity in IPF pathogenesis and treatment
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Idiopathic pulmonary fibrosis; Inflammation; Immunity; Treatment; Trials
ID IDIOPATHIC PULMONARY-FIBROSIS; INNATE LYMPHOID-CELLS; REGULATORY
   T-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; GAMMA-DELTA-T; MONOCYTE
   CHEMOATTRACTANT PROTEIN-1; INTERSTITIAL LUNG-DISEASE; GENOME-WIDE
   ASSOCIATION; GROWTH-FACTOR-BETA; CIRCULATING FIBROCYTES
AB Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial lung disease characterized by enhanced extracellular matrix deposition. Repetitive alveolar epithelial injury triggers the early development of fibrosis. These injuries, in combination with dysregulated wound repair and fibroblast dysfunction, lead to ongoing tissue remodelling and fibrosis seen in end-stage pulmonary fibrosis. Although the exact etiology in IPF is unknown and probably diverse, all stages of fibrosis are accompanied by innate and adaptive immune responses. The role of inflammation as an important component in IPF etiology is controversial and sometimes seen as an epiphenomenon of fibrosis. This view is partly the result of negative multicenter trials of anti-inflammatory drugs for IPF treatment. However, new insights on the role of macrophages, the loss of T-cell and B-cell tolerance leading auto-immune responses in IPF, and the interaction of immune cells with (myo) fibroblasts have led to a slow change of this opinion. Clearly, more insight is needed to integrate basic immune mechanisms into translational research and finally new IPF therapies.
   In this concise review, we will focus on the role of our innate and adaptive immune system in the initiation and perpetuation of IPF pathobiology. Next, we will discuss how immune responses are influenced by current anti-fibrotic treatments, such as pirfenidone and nintedanib and end with an overview of recent and upcoming therapeutic trials that target and modulate our immune system in patients with IPF.
C1 [Heukels, P.; Moor, C. C.; Wijsenbeek, M. S.; Kool, M.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.
   [von der Thusen, J. H.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands.
   [Heukels, P.] Amphia Hosp Breda, Dept Pulm Med, Breda, Netherlands.
RP Kool, M (reprint author), Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.; Heukels, P (reprint author), Dept Pulm Med, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.
EM Pheukels@amphia.nl; m.kool@erasmusmc.nl
OI Wijsenbeek, Marlies/0000-0002-4527-6962
CR Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782
   Akcora BO, 2017, SCI REP-UK, V7, DOI 10.1038/srep44545
   Alder JK, 2008, P NATL ACAD SCI USA, V105, P13051, DOI 10.1073/pnas.0804280105
   Andersson-Sjoland A, 2008, INT J BIOCHEM CELL B, V40, P2129, DOI 10.1016/j.biocel.2008.02.012
   Ando M, 2010, LUNG, V188, P247, DOI 10.1007/s00408-009-9223-x
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   [Anonymous], 2015, NAT IMMUNOL, V16, P17, DOI 10.1038/ni.3069
   Arras M, 2005, AM J PATHOL, V166, P107, DOI 10.1016/S0002-9440(10)62236-5
   Arras M, 2001, AM J RESP CELL MOL, V24, P368, DOI 10.1165/ajrcmb.24.4.4249
   Ashitani J, 1999, THORAX, V54, P1015, DOI 10.1136/thx.54.11.1015
   Bando M, 2016, INTERNAL MED, V55, P443, DOI 10.2169/internalmedicine.55.5272
   Bantsimba-Malanda C, 2010, AM J RESP CRIT CARE, V182, P385, DOI 10.1164/rccm.200907-1164OC
   Bianchetti L, 2014, BBA CLIN, V1, P52, DOI 10.1016/j.bbacli.2014.06.002
   Birjandi SZ, 2016, AM J PATHOL, V186, P2008, DOI 10.1016/j.ajpath.2016.03.020
   Bizargity P, 2012, TRANSPLANTATION, V94, P114, DOI 10.1097/TP.0b013e3182584879
   Boveda-Ruiz D, 2013, IMMUNOBIOLOGY, V218, P245, DOI 10.1016/j.imbio.2012.05.020
   Braun RK, 2008, INFLAMMATION, V31, P167, DOI 10.1007/s10753-008-9062-6
   Brunner SM, 2013, TRANSPLANT RES, V2, DOI 10.1186/2047-1440-2-16
   BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533
   Cai MT, 2013, RESP MED, V107, P1444, DOI 10.1016/j.rmed.2013.06.004
   CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632
   Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322
   Charrier A, 2014, IMMUNOLOGY, V141, P564, DOI 10.1111/imm.12215
   Chen Y, 2014, TOXICOL APPL PHARM, V275, P62, DOI 10.1016/j.taap.2013.11.012
   Chenivesse C, 2018, CYTOKINE, V109, P52, DOI 10.1016/j.cyto.2018.01.023
   Chesney J, 1998, J IMMUNOL, V160, P419
   Collard HR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-73
   Conte E, 2014, EUR J PHARM SCI, V58, P13, DOI 10.1016/j.ejps.2014.02.014
   Cox N, 2014, J IMMUNOL, V193, P1701, DOI 10.4049/jimmunol.1400281
   Craig VJ, 2015, AM J RESP CELL MOL, V53, P585, DOI 10.1165/rcmb.2015-0020TR
   de Alba CG, 2015, AM J RESP CRIT CARE, V191, P427, DOI 10.1164/rccm.201407-1334OC
   DePianto DJ, 2015, THORAX, V70, P48, DOI 10.1136/thoraxjnl-2013-204596
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Didiasova M, 2017, FASEB J, V31, P1916, DOI 10.1096/fj.201600892RR
   Dobashi N, 2000, LUNG, V178, P171, DOI 10.1007/s004080000020
   Donahoe M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127771
   Dong ZX, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0012-4
   du Bois RM, 2012, EUR RESPIR REV, V21, P141, DOI 10.1183/09059180.00000812
   Duerr CU, 2016, CYTOKINE, V87, P1, DOI 10.1016/j.cyto.2016.01.018
   Duru Nadire, 2016, World J Biol Chem, V7, P231
   EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677
   Faner R, 2012, AM J RESP CRIT CARE, V186, P306, DOI 10.1164/rccm.201202-0282PP
   Fernandes JS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/703653
   Fernandez IE, 2012, LANCET, V380, P680, DOI 10.1016/S0140-6736(12)61144-1
   Fingerlin TE, 2016, BMC GENET, V17, DOI 10.1186/s12863-016-0377-2
   Fingerlin TE, 2013, NAT GENET, V45, P613, DOI 10.1038/ng.2609
   Fischer A, 2012, LANCET, V380, P689, DOI 10.1016/S0140-6736(12)61079-4
   Freynet O, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0345-4
   Fu XY, 2015, CELL PHYSIOL BIOCHEM, V35, P489, DOI 10.1159/000369714
   Fujiwara A, 2012, RESPIROLOGY, V17, P693, DOI 10.1111/j.1440-1843.2012.02167.x
   Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P638, DOI 10.1016/j.intimp.2013.06.034
   GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410
   Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049
   Gregory AD, 2015, J LEUKOCYTE BIOL, V98, P143, DOI 10.1189/jlb.3HI1014-493R
   Gruber BL, 1997, J IMMUNOL, V158, P2310
   Gschwandtner M, 2017, CYTOKINE, V91, P65, DOI 10.1016/j.cyto.2016.12.008
   Gurcan HM, 2009, INT IMMUNOPHARMACOL, V9, P10, DOI 10.1016/j.intimp.2008.10.004
   Guiot J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171344
   Habiel DM, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/7934362
   Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111
   Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113
   Hawgood S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9970
   Heukels P, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0798-8
   Horsburgh S, 2018, IMMUNOL LETT, V195, P38, DOI 10.1016/j.imlet.2017.08.022
   Hou ZL, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0653-3
   Iyer SN, 1998, EXP LUNG RES, V24, P119, DOI 10.3109/01902149809046058
   IYER SN, 1995, J LAB CLIN MED, V125, P779
   Iyer SN, 2000, INFLAMMATION, V24, P477, DOI 10.1023/A:1007068313370
   IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1
   Jeffery HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188649
   Jones GW, 2016, IMMUNOLOGY, V147, P141, DOI 10.1111/imm.12554
   JORDANA M, 1988, THORAX, V43, P552, DOI 10.1136/thx.43.7.552
   Juge PA, 2018, NEW ENGL J MED, V379, P2209, DOI 10.1056/NEJMoa1801562
   Just SA, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0623-9
   Kahloon RA, 2013, AM J RESP CRIT CARE, V187, P768, DOI 10.1164/rccm.201203-0506OC
   Kamio K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0783-2
   Kaplan MH, 2015, NAT REV IMMUNOL, V15, P295, DOI 10.1038/nri3824
   Keane MP, 2001, AM J PHYSIOL-LUNG C, V281, pL92
   KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1
   Knuppel L, 2017, AM J RESP CELL MOL, V57, P77, DOI 10.1165/rcmb.2016-0217OC
   Konigshoff M, 2010, AM J RESP CELL MOL, V42, P21, DOI 10.1165/rcmb.2008-0485TR
   Kolahian S, 2016, AM J RESP CELL MOL, V55, P309, DOI 10.1165/rcmb.2016-0121TR
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kotsianidis I, 2009, AM J RESP CRIT CARE, V179, P1121, DOI 10.1164/rccm.200812-1936OC
   Kurosu K, 2008, J IMMUNOL, V181, P756, DOI 10.4049/jimmunol.181.1.756
   Lacy SH, 2018, AM J PHYSIOL-LUNG C, V314, P1569, DOI 10.1152/ajplung.00565.2016
   Landsman L, 2007, J IMMUNOL, V178, P2000, DOI 10.4049/jimmunol.178.4.2000
   Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001
   Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809
   Lee HY, 2017, EXP LUNG RES, V43, P187, DOI 10.1080/01902148.2017.1339141
   Lei L, 2016, CLIN EXP RHEUMATOL, V34, pS14
   Lescoat A, 2017, CLIN RHEUMATOL, V36, P1649, DOI 10.1007/s10067-017-3597-6
   Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011
   Liu H, 2017, AM J RESP CELL MOL, V57, P393, DOI 10.1165/rcmb.2017-0051PS
   Lo Re S, 2011, AM J RESP CRIT CARE, V184, P1270, DOI 10.1164/rccm.201103-0516OC
   Lo Re S, 2010, J IMMUNOL, V184, P6367, DOI 10.4049/jimmunol.0900459
   Luppi F, 2015, INTERN EMERG MED, V10, P401, DOI 10.1007/s11739-015-1204-x
   Madala SK, 2014, AM J RESP CELL MOL, V50, P777, DOI 10.1165/rcmb.2013-0042OC
   Magro CM, 2006, HUM IMMUNOL, V67, P284, DOI 10.1016/j.humimm.2006.02.026
   Maher TM, 2018, AM J RESP CRIT CARE, pA6168
   Maher TM, 2018, LANCET RESP MED, V6, P627, DOI 10.1016/S2213-2600(18)30181-4
   Marchal-Somme J, 2006, J IMMUNOL, V176, P5735, DOI 10.4049/jimmunol.176.10.5735
   Martinez FJ, 2014, NEW ENGL J MED, V370, P2093, DOI 10.1056/NEJMoa1401739
   Mathai SK, 2016, THORAX, V71, P1154, DOI 10.1136/thoraxjnl-2016-209172
   Mathai SK, 2010, LAB INVEST, V90, P812, DOI 10.1038/labinvest.2010.73
   Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023
   McGaha TL, 2003, ARTHRITIS RHEUM, V48, P2275, DOI 10.1002/art.11089
   Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018
   Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950
   Milger K, 2017, THORAX, V72, P1007, DOI 10.1136/thoraxjnl-2016-208423
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Moeller A, 2009, AM J RESP CRIT CARE, V179, P588, DOI 10.1164/rccm.200810-1534OC
   Moore BB, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00056
   Moretti S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14017
   Morishima Y, 2010, CURR OPIN INVEST DR, V11, P1229
   Mouratis MA, 2011, CURR OPIN PULM MED, V17, P355, DOI 10.1097/MCP.0b013e328349ac2b
   Murugaiyan G, 2009, J IMMUNOL, V183, P2435, DOI 10.4049/jimmunol.0900568
   Mushiroda T, 2008, J MED GENET, V45, P654, DOI 10.1136/jmg.2008.057356
   Nakashima T, 2012, J IMMUNOL, V188, P3573, DOI 10.4049/jimmunol.1100591
   Nathan SD, 2016, THORAX, V71, P429, DOI 10.1136/thoraxjnl-2015-207011
   Navarro-Partida J, 2012, EUR J PHARMACOL, V678, P71, DOI 10.1016/j.ejphar.2011.12.025
   Noth I, 2013, LANCET RESP MED, V1, P309, DOI 10.1016/S2213-2600(13)70045-6
   Nuovo GJ, 2012, MODERN PATHOL, V25, P416, DOI 10.1038/modpathol.2011.166
   O'Dwyer DN, 2015, EXPERT OPIN THER TAR, V19, P507, DOI 10.1517/14728222.2014.988706
   Ogushi Fumitaka, 2001, Journal of Medical Investigation, V48, P181
   Oikonomou N, 2012, AM J RESP CELL MOL, V47, P566, DOI 10.1165/rcmb.2012-0004OC
   Ozbilgin K, 2017, KAOHSIUNG J MED SCI, V33, P271, DOI 10.1016/j.kjms.2017.03.011
   Palmer SM, 2018, CHEST, V154, P1061, DOI 10.1016/j.chest.2018.08.1058
   Parker JM, 2018, AM J RESP CRIT CARE, V197, P94, DOI 10.1164/rccm.201704-0784OC
   Peng XY, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00080
   Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997
   Pilling D, 2007, J IMMUNOL, V179, P4035, DOI 10.4049/jimmunol.179.6.4035
   Pilling D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007475
   Pociask DA, 2011, AM J PATHOL, V178, P1167, DOI 10.1016/j.ajpath.2010.11.055
   Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC
   Qin SY, 2016, SCI REP-UK, V6, DOI 10.1038/srep18694
   Qiu H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01756
   Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005
   Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511
   Raghu G, 2008, AM J RESP CRIT CARE, V178, P948, DOI 10.1164/rccm.200709-1446OC
   Raghu G, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01130-2018
   Raghu G, 2018, JAMA-J AM MED ASSOC, V319, P2299, DOI 10.1001/jama.2018.6129
   Raghu G, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0071-2017
   Raghu G, 2017, LANCET RESP MED, V5, P22, DOI 10.1016/S2213-2600(16)30421-0
   Raghu G, 2016, EUR RESPIR J, V47, P1481, DOI 10.1183/13993003.01030-2015
   Raghu G, 2015, EUR RESPIR J, V46, P1740, DOI 10.1183/13993003.01558-2014
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Reilkoff RA, 2013, AM J RESP CRIT CARE, V187, P180, DOI 10.1164/rccm.201206-1109OC
   Reilkoff RA, 2011, NAT REV IMMUNOL, V11, P427, DOI 10.1038/nri2990
   RICHELDI L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002880
   Richeldi L, 2016, RESP MED, V113, P74, DOI 10.1016/j.rmed.2016.02.001
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X
   Rottoli P, 2005, PROTEOMICS, V5, P1423, DOI 10.1002/pmic.200301007
   Saito A, 2003, INT ARCH ALLERGY IMM, V132, P168, DOI 10.1159/000073718
   Schiller HB, 2017, AM J RESP CRIT CARE, V196, P1298, DOI 10.1164/rccm.201611-2263OC
   Schmitt E, 2014, TRENDS IMMUNOL, V35, P61, DOI 10.1016/j.it.2013.10.004
   SCHRIER DJ, 1983, AM REV RESPIR DIS, V127, P614, DOI 10.1164/arrd.1983.127.5.614
   Schupp JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116775
   Shum AK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006998
   Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657
   Singh SR, 2014, ALLERGY, V69, P1189, DOI 10.1111/all.12444
   Snetselaar R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189467
   Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053
   Suga H, 2014, STEM CELLS, V32, P1347, DOI 10.1002/stem.1648
   Suga M, 1999, EUR RESPIR J, V14, P376, DOI 10.1034/j.1399-3003.1999.14b23.x
   Sumida A, 2008, ARCH MED RES, V39, P503, DOI 10.1016/j.arcmed.2008.02.005
   Swigris J. O. T., 2018, AM J RESP CRIT CARE, V197, pA166
   Taille C, 2011, AM J RESP CRIT CARE, V183, P759, DOI 10.1164/rccm.201001-0076OC
   Takemasa A, 2012, EUR RESPIR J, V40, P1475, DOI 10.1183/09031936.00127011
   Tashiro J, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00118
   ten Klooster L, 2015, CLIN EXP IMMUNOL, V181, P357, DOI 10.1111/cei.12636
   Thien M, 2004, IMMUNITY, V20, P785, DOI 10.1016/j.immuni.2004.05.010
   Todd NW, 2013, J INFLAMM RES, V6, P63, DOI 10.2147/JIR.S40673
   Togami K, 2013, BIOL PHARM BULL, V36, P1525, DOI 10.1248/bpb.b13-00452
   Tsoumakidou M, 2009, RESPIRATION, V78, P446, DOI 10.1159/000226244
   Tsui J. L., 2018, ERJ OPEN RES, V4
   van den Brle S, 2007, AM J RESP CELL MOL, V37, P202, DOI 10.1165/rcmb.2006-0397OC
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Veerappan A, 2013, DNA CELL BIOL, V32, P206, DOI 10.1089/dna.2013.2005
   Veeraraghavan S, 2003, EUR RESPIR J, V22, P239, DOI 10.1183/09031936.03.00105202
   Vermaelen K, 2005, AM J RESP CRIT CARE, V172, P530, DOI 10.1164/rccm.200410-1384SO
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   Vincent FB, 2013, CYTOKINE GROWTH F R, V24, P203, DOI 10.1016/j.cytogfr.2013.04.003
   Visner GA, 2009, TRANSPLANTATION, V88, P330, DOI 10.1097/TP.0b013e3181ae3392
   Vuga LJ, 2014, AM J RESP CRIT CARE, V189, P966, DOI 10.1164/rccm.201309-1592OC
   Walker JA, 2018, NAT REV IMMUNOL, V18, P121, DOI 10.1038/nri.2017.118
   WALLS AF, 1991, CLIN SCI, V81, P183, DOI 10.1042/cs0810183
   Wang BZ, 2014, EXP LUNG RES, V40, P77, DOI 10.3109/01902148.2013.872210
   Watkin LB, 2015, NAT GENET, V47, P654, DOI 10.1038/ng.3279
   Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev-immunol-032712-095937
   Wick G, 2010, TRENDS IMMUNOL, V31, P110, DOI 10.1016/j.it.2009.12.001
   Wijsenbeek M. S., 2018, EUR RESP J, V52
   Wilson MS, 2009, MUCOSAL IMMUNOL, V2, P103, DOI 10.1038/mi.2008.85
   Wohlfahrt T, 2016, ANN RHEUM DIS, V75, P623, DOI 10.1136/annrheumdis-2015-207388
   Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914
   Wollin L, 2014, J PHARMACOL EXP THER, V349, P209, DOI 10.1124/jpet.113.208223
   Wygrecka M, 2011, AM J RESP CRIT CARE, V183, P1703, DOI 10.1164/rccm.201009-1479OC
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551
   Xue JM, 2013, J IMMUNOL, V191, P2089, DOI 10.4049/jimmunol.1203476
   Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818
   Yang Y, 2002, CLIN EXP IMMUNOL, V128, P169, DOI 10.1046/j.1365-2249.2002.01811.x
   Yazdani R, 2019, ALLERGOL IMMUNOPATH, V47, P90, DOI 10.1016/j.aller.2018.02.003
   Zhou Y, 2012, J BIOL CHEM, V287, P41991, DOI 10.1074/jbc.M112.356824
   Ziegler-Heitbrock L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00023
   Zimmermann HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011049
NR 218
TC 9
Z9 10
U1 3
U2 15
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2019
VL 147
BP 79
EP 91
DI 10.1016/j.rmed.2018.12.015
PG 13
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HJ0CD
UT WOS:000456823800014
PM 30704705
DA 2020-05-18
ER

PT J
AU Paine, NJ
   Bacon, SL
   Bourbeau, J
   Tan, WC
   Lavoie, KL
   Aaron, SD
   Chapman, KR
   FitzGerald, JM
   Hernandez, P
   Marciniuk, DD
   Maltais, F
   O'Donnell, DE
   Sin, D
   Walker, BL
AF Paine, Nicola J.
   Bacon, Simon L.
   Bourbeau, Jean
   Tan, Wan C.
   Lavoie, Kim L.
   Aaron, Shawn D.
   Chapman, Kenneth R.
   FitzGerald, J. Mark
   Hernandez, Paul
   Marciniuk, Darcy D.
   Maltais, Francois
   O'Donnell, Denis E.
   Sin, Don
   Walker, Brandie L.
CA CanCOLD Study Investigators
   Canadian Resp Res Network
   Teh CanCOLD Collaborative Res Grp
TI Psychological distress is related to poor health behaviours in COPD and
   non-COPD patients: Evidence from the CanCOLD study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Depression; Anxiety; Smoking; Physical activity; CanCOLD
ID OBSTRUCTIVE PULMONARY-DISEASE; PHYSICAL-ACTIVITY; CIGARETTE-SMOKING;
   HOSPITAL ANXIETY; DEPRESSION; EXACERBATIONS; POPULATION; CESSATION;
   ASSOCIATION; PREVALENCE
AB Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health behaviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies have assessed associations between psychological distress and these behaviours among patients with vs without COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological disorders (depression, anxiety) and poor health behaviours (smoking, PA).
   Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD stage and COPD status.
   Results: Across the whole sample, we observed relationships between depression (beta = 1.107 +/- 0.197; 95% CI= 0.691-1.462; p < .001) and anxiety (beta = 0.780 +/- 0.170; 95% CI= 0.446-1.114; p < .001) and pack years. Higher depression (beta = -0.220 +/- 0.028; 95% CI = -0.275 to -0.165; p < .001) and anxiety (beta = -0.091 +/- 0.025; 95% CI = -0.139 to -0.043; p < .001) scores were related to lower PA. These associations were comparable across COPD and non-COPD patients.
   Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in this population.
C1 [Paine, Nicola J.] Loughborough Univ, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England.
   [Paine, Nicola J.; Bacon, Simon L.; Lavoie, Kim L.] Hop Sacre Coeur Montreal, Montreal Behav Med Ctr, Ctr Integree Univ Serv Sante & Serv Sociaux Nord, 5400 Blvd Gouin Ouest, Montreal, PQ, Canada.
   [Bacon, Simon L.] Concordia Univ, Dept Exercise Sci, Montreal, PQ, Canada.
   [Bourbeau, Jean] McGill Univ, Hlth Ctr, Res Inst, Resp Epidemiol & Clin Res Unit, Montreal, PQ, Canada.
   [Tan, Wan C.] Univ British Columbia, Dept Med, Vancouver, BC, Canada.
   [Lavoie, Kim L.] Univ Quebec Montreal, Dept Psychol, Montreal, PQ, Canada.
   [Aaron, Shawn D.] Univ Ottawa, Ottawa, ON, Canada.
   [Chapman, Kenneth R.] Univ Toronto, Toronto, ON, Canada.
   [FitzGerald, J. Mark; Sin, Don] Univ British Columbia, Vancouver, BC, Canada.
   [Hernandez, Paul] Dalhousie Univ, Halifax, NS, Canada.
   [Marciniuk, Darcy D.] Univ Saskatchewan, Saskatoon, SK, Canada.
   [Maltais, Francois] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
   [O'Donnell, Denis E.] Queens Univ, Kingston, ON, Canada.
   [Walker, Brandie L.] Univ Calgary, Calgary, AB, Canada.
RP Lavoie, KL (reprint author), Univ Quebec Montreal UQAM, Dept Psychol, CP 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.
EM lavoie.kim@uqam.ca
RI Lavoie, Kim L/J-8969-2014
FU CIHRCanadian Institutes of Health Research (CIHR) [93326]
CR Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Bacon SL, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2015-000083
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Bourbeau J, 2014, COPD, V11, P125, DOI 10.3109/15412555.2012.665520
   Bryant J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-493
   Clancy N, 2013, FAM PRACT, V30, P587, DOI 10.1093/fampra/cmt032
   Fidler JA, 2009, NICOTINE TOB RES, V11, P1182, DOI 10.1093/ntr/ntp120
   Fluharty M, 2017, NICOTINE TOB RES, V19, P3, DOI 10.1093/ntr/ntw140
   Gallo LC, 2014, PSYCHOSOM MED, V76, P468, DOI 10.1097/PSY.0000000000000069
   Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145
   Garcia-Aymerich J, 2007, AM J RESP CRIT CARE, V175, P458, DOI 10.1164/rccm.200607-896OC
   Global Strategy for the Diagnosis Management and Prevention of COPD, 2017, GLOBAL INITIATIVE CH
   John U, 2004, J CLIN PSYCHIAT, V65, P169
   Lerman C, 1996, ADDICT BEHAV, V21, P9, DOI 10.1016/0306-4603(95)00032-1
   Mak S, 2016, CAN RESPIR J, DOI 10.1155/2016/9304505
   McEwen A, 2008, NICOTINE TOB RES, V10, P843, DOI 10.1080/14622200802027248
   Mittmann N, 2008, RESP MED, V102, P413, DOI 10.1016/j.rmed.2007.10.010
   National Cancer Institute, DEF SMOK PACK YEARS
   Ouellet K, 2012, NICOTINE TOB RES, V14, P961, DOI 10.1093/ntr/ntr315
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Rebar AL, 2015, HEALTH PSYCHOL REV, V9, P366, DOI 10.1080/17437199.2015.1022901
   Rosenbaum S, 2014, J CLIN PSYCHIAT, V75, P964, DOI 10.4088/JCP.13r08765
   Scarapicchia TMF, 2014, PREV MED, V66, P45, DOI 10.1016/j.ypmed.2014.05.017
   Schuch F, 2017, J AFFECT DISORDERS, V210, P139, DOI 10.1016/j.jad.2016.10.050
   Slopen N, 2013, CANCER CAUSE CONTROL, V24, P1849, DOI 10.1007/s10552-013-0262-5
   Slopen N, 2012, NICOTINE TOB RES, V14, P1161, DOI 10.1093/ntr/nts011
   Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527
   Soto MTS, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-40
   Stein RJ, 2008, MIL MED, V173, P271, DOI 10.7205/MILMED.173.3.271
   Stepankova L, 2017, ANN BEHAV MED, V51, P454, DOI 10.1007/s12160-016-9869-6
   Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010
   Taylor G, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1151
   Thompson B, 2003, NICOTINE TOB RES, V5, P923, DOI 10.1080/14622200310001615277
   van der Meer RM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006102.pub2
   Weinberger AH, 2017, AM J DRUG ALCOHOL AB, V43, P416, DOI 10.3109/00952990.2016.1171327
   World Health Organization, WHO GLOB SURV PREV C
   Xu WN, 2008, AM J RESP CRIT CARE, V178, P913, DOI 10.1164/rccm.200804-619OC
   Yohannes AM, 2010, INT J GERIATR PSYCH, V25, P1209, DOI 10.1002/gps.2463
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 40
TC 3
Z9 3
U1 1
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 1
EP 9
DI 10.1016/j.rmed.2018.11.006
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000001
PM 30665505
OA Green Published, Other Gold, Green Accepted
DA 2020-05-18
ER

PT J
AU Baldacci, S
   Simoni, M
   Maio, S
   Angino, A
   Martini, F
   Sarno, G
   Cerrai, S
   Silvi, P
   Pala, AP
   Bresciani, M
   Paggiaro, P
   Viegi, G
   Angino, A
   Baldacci, S
   Bresciani, M
   Cerrai, S
   Di Pede, F
   Maio, S
   Martini, F
   Piegaia, BB
   Sarno, G
   Silvi, P
   Viegi, G
   Mangione, M
   Pala, AP
   Bacci, E
   Carrozzi, L
   Dente, F
   Paggiaro, P
   Pistelli, F
   Bancalari, L
   Foschino, MP
   Pelucchi, A
   Moscato, G
   Pierimarchi, P
   Brunetto, B
   Iacovacci, P
   Pini, C
   Tinghino, R
   Forastiere, F
   Perucci, CA
   Porta, D
   Ancona, L
   Protasi, S
   Lazazzera, B
   Ziroli, V
   D'Armini, E
   Campanile, SF
   Ferri, M
   Lorusso, P
   Pistelli, R
   Salotti, R
   Santagati, M
   Agea, E
   Casciari, C
   Murgia, N
   Spinozzi, F
   Bonifazi, F
   Antonicelli, L
   Braschi, MC
   Conti, V
   Filippelli, A
   Corbi, GM
   Russomanno, G
   Braido, F
   Canonica, W
   Balbi, F
   Cerveri, I
   Corsico, A
   Grosso, A
AF Baldacci, Sandra
   Simoni, Marzia
   Maio, Sara
   Angino, Anna
   Martini, Franca
   Sarno, Giuseppe
   Cerrai, Sonia
   Silvi, Patrizia
   Pala, Anna Paola
   Bresciani, Megon
   Paggiaro, Pierluigi
   Viegi, Giovanni
   Angino, Anna
   Baldacci, Sandra
   Bresciani, Megon
   Cerrai, Sonia
   Di Pede, Francesco
   Maio, Sara
   Martini, Franca
   Piegaia, Bona Barbara
   Sarno, Giuseppe
   Silvi, Patrizia
   Viegi, Giovanni
   Mangione, Maurizio
   Pala, Anna Paola
   Bacci, Elena
   Carrozzi, Laura
   Dente, Federico
   Paggiaro, Pierluigi
   Pistelli, Francesco
   Bancalari, Lorenza
   Foschino, Maria Pia
   Pelucchi, Andrea
   Moscato, Gianna
   Pierimarchi, Pasquale
   Brunetto, Barbara
   Iacovacci, Patrizia
   Pini, Carlo
   Tinghino, Raffaella
   Forastiere, Francesco
   Perucci, Carlo Alberto
   Porta, Daniela
   Ancona, Laura
   Protasi, Sara
   Lazazzera, Barbara
   Ziroli, Valentina
   D'Armini, Eleonora
   Campanile, Sabella Festa
   Ferri, Monica
   Lorusso, Paola
   Pistelli, Riccardo
   Salotti, Rita
   Santagati, Marco
   Agea, Elisabetta
   Casciari, Chiara
   Murgia, Nicola
   Spinozzi, Fabrizio
   Bonifazi, Floriano
   Antonicelli, Leonardo
   Braschi, Maria Chiara
   Conti, Valeria
   Filippelli, Amelia
   Corbi, Grazia Maria
   Russomanno, Giusy
   Braido, Fulvio
   Canonica, Walter
   Balbi, Francesco
   Cerveri, Isa
   Corsico, Angelo
   Grosso, Amelia
CA ARGA Collaborative Grp
TI Prescriptive adherence to GINA guidelines and asthma control: An Italian
   cross sectional study in general practice
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cross sectional study; Asthma; Allergic rhinitis; Drug prescriptions;
   Adherence; GINA guidelines; Control
ID INHALED CORTICOSTEROIDS; COMBINATION THERAPY; ALLERGIC RHINITIS;
   UNITED-STATES; MANAGEMENT; POPULATION; PREVALENCE; PRACTITIONERS;
   COHORT; YOUNG
AB Background: Although general practitioners (GPs) are frequently the first healthcare professionals whom asthma patients refer to for their symptoms, few studies have explored the extent of adherence to guidelines for asthma management based on data provided directly by GPs.
   Aims of the present study were to assess drug prescriptions for asthma by GPs and to evaluate prescriptive adherence to GINA guidelines (GL) and its relationship with disease control in real life.
   Methods: 995 asthmatic patients (45% males, mean age 43.3 +/- 17.7 yrs) were enrolled by 107 Italian GPs distributed throughout the country. Data on diagnosis, disease severity, prescribed anti-asthmatic drugs and control were collected through questionnaires filled out by GPs taking into consideration the 2009 GINA Guidelines. Data on drug use and chronic sinusitis, nasal polyposis, chronic bronchitis, emphysema were reported by patients through a self-administered questionnaire.
   Results: The large majority of patients were classified by GPs as having intermittent (48.4%) or mild persistent asthma (25.3%); 61% had co-morbid allergic rhinitis (AR). The prevalent therapeutic regimen used by patients was a combination of inhaled corticosteroids (ICS) plus long-acting beta(2)-agonists (LABA) (54.1%), even in the intermittent/mild persistent group. ICS as mono-therapy or in combination with other drugs but LABA, was the second most frequently adopted treatment (14.4%). In general, the GPs adherence to GL treatment indications was 28.8%, with a significant association with a good asthma control (OR 1.85, 95% CI 1.18-2.92). On the other hand, comorbidity (OR 0.52, 95% CI 0.32-0.84), moderate (0.44, 0.28-0.69) and severe (0.06, 0.02-0.20) persistent asthma showed significant negative effects on asthma control.
   Conclusions: Our results show that over-treatment of intermittent/mild persistent asthma is frequent in the GPs setting while therapeutic regimens are more appropriately applied for moderate/severe asthma. In general, we found low adherence to GINA GL treatment recommendations even if its relevance in asthma control was confirmed.
C1 [Baldacci, Sandra; Simoni, Marzia; Maio, Sara; Angino, Anna; Martini, Franca; Sarno, Giuseppe; Cerrai, Sonia; Silvi, Patrizia; Bresciani, Megon; Viegi, Giovanni; Angino, Anna; Baldacci, Sandra; Bresciani, Megon; Cerrai, Sonia; Di Pede, Francesco; Maio, Sara; Martini, Franca; Piegaia, Bona Barbara; Sarno, Giuseppe; Silvi, Patrizia; Viegi, Giovanni] CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol, Via Trieste 41, I-56126 Pisa, Italy.
   [Pala, Anna Paola; Mangione, Maurizio; Pala, Anna Paola] CNR, Technosci Unit, Inst Clin Physiol, Via G Moruzzi 1, I-56124 Pisa, Italy.
   [Paggiaro, Pierluigi; Bacci, Elena; Carrozzi, Laura; Dente, Federico; Paggiaro, Pierluigi; Pistelli, Francesco] Univ Pisa, Dept Surg Med Mol Biol & Crit Care, Via Paradisa 2, I-56124 Pisa, Italy.
   [Viegi, Giovanni; Viegi, Giovanni] CNR, Inst Biomed & Mol Immunol A Monroy, Via U La Malfa 153, I-90146 Palermo, Italy.
   [Bancalari, Lorenza] La Spezia Hosp, Pneumol Unit, La Spezia, Italy.
   [Foschino, Maria Pia] Univ Foggia, Resp Dis Clin, Foggia, Italy.
   [Pelucchi, Andrea] Resp Physiopathol Unit, Sesto San Giovanni, MI, Italy.
   [Moscato, Gianna] Maugeri Fdn, Pavia, Italy.
   [Pierimarchi, Pasquale] CNR, Neurobiol & Mol Med, Rome, Italy.
   [Brunetto, Barbara; Iacovacci, Patrizia; Pini, Carlo; Tinghino, Raffaella] Natl Hlth Inst, Rome, Italy.
   [Forastiere, Francesco; Perucci, Carlo Alberto; Porta, Daniela; Ancona, Laura; Protasi, Sara; Lazazzera, Barbara; Ziroli, Valentina; D'Armini, Eleonora; Campanile, Sabella Festa; Ferri, Monica; Lorusso, Paola] Reg Hlth Serv, Epidemiol Dept, Rome, Italy.
   [Pistelli, Riccardo] Univ Cattolica Sacro Cuore, Gemelli Hosp, Rome, Italy.
   [Salotti, Rita; Santagati, Marco] Italian Soc Hosp Pharm & Pharmaceut Serv Hlth Com, Milan, Italy.
   [Agea, Elisabetta; Casciari, Chiara; Murgia, Nicola; Spinozzi, Fabrizio] Univ Perugia, Dept Clin & Expt Med, Internal Med & Oncol Sci, Perugia, Italy.
   [Bonifazi, Floriano; Antonicelli, Leonardo; Braschi, Maria Chiara] Univ Hosp, Allergol Unit, Ancona, Italy.
   [Conti, Valeria; Filippelli, Amelia; Corbi, Grazia Maria; Russomanno, Giusy] II Univ Naples, Dept Expt Med, Farmacol Unit, Naples, Italy.
   [Braido, Fulvio; Canonica, Walter; Balbi, Francesco] Univ Genoa, Dept Internal Med & Med Specialties, Tisiol & Pneumol Clin, Genoa, Italy.
   [Cerveri, Isa; Corsico, Angelo; Grosso, Amelia] Univ Pavia, Dept Hematol Pneumol Cardiovasc Med & Surg Sci, Pavia, Italy.
RP Baldacci, S (reprint author), CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol, Via Trieste 41, I-56126 Pisa, Italy.
RI Corsico, Angelo Guido/AAC-8138-2019; Corbi, Graziamaria/G-2582-2011;
   Dente, Federico/AAK-9791-2020; Grosso, Amelia/Y-9632-2019; Pistelli,
   Francesco/Y-8270-2019; Porta, Daniela/J-9042-2016; MAIO,
   SARA/K-4065-2016; Russomanno, Giusy/L-6178-2017
OI Corsico, Angelo Guido/0000-0002-8716-4694; Corbi,
   Graziamaria/0000-0002-3441-889X; Pistelli,
   Francesco/0000-0001-5612-6364; Filippelli, Amelia/0000-0002-8235-9118;
   Porta, Daniela/0000-0002-3431-2729; Grosso, Amelia/0000-0002-4442-8522;
   Cerveri, Isa/0000-0003-0337-043X; MAIO, SARA/0000-0001-6363-8544; conti,
   valeria/0000-0001-6964-2739; Russomanno, Giusy/0000-0002-3378-5524
CR [Anonymous], 2009, GLOBAL STRATEGY ASTH
   Bhulani N, 2011, PRIM CARE RESP J, V20, P448, DOI 10.4104/pcrj.2011.00096
   Blanchette CM, 2009, CLIN THER, V31, P2574, DOI 10.1016/j.clinthera.2009.11.007
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Braido F, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/549252
   Bregnhoj L, 2007, PHARM WORLD SCI, V29, P109, DOI 10.1007/s11096-007-9108-0
   Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x
   Chou CL, 2015, CLIN THER, V37, P2275, DOI 10.1016/j.clinthera.2015.07.024
   Chung KF, 2009, EUR J CLIN PHARMACOL, V65, P853, DOI 10.1007/s00228-009-0682-z
   Cloutier MM, 2016, CURR OPIN ALLERGY CL, V16, P142, DOI 10.1097/ACI.0000000000000242
   Corsico AG, 2007, RESP MED, V101, P1363, DOI 10.1016/j.rmed.2006.11.012
   de Marco R, 2005, INT ARCH ALLERGY IMM, V138, P225, DOI 10.1159/000088723
   Fromer L, 2010, SOUTH MED J, V103, P1038, DOI 10.1097/SMJ.0b013e3181ebec5c
   Galassi C, 2006, PEDIATRICS, V117, P34, DOI 10.1542/peds.2004-2709
   Gibson J, 2013, EUROPEAN LUNG WHITE BOOK: RESPIRATORY HEALTH AND DISEASE IN EUROPE, P1
   Hull SA, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2016.49
   Hussain SF, 2004, INT J TUBERC LUNG D, V8, P414
   Ko Fanny W. S., 2010, Hong Kong Medical Journal, V16, P86
   Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201
   Lucas AEM, 2008, FAM PRACT, V25, P86, DOI 10.1093/fampra/cmn006
   Lugtenberg M, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-98
   Maio S, 2016, RESP MED, V110, P58, DOI 10.1016/j.rmed.2015.11.006
   Navaratnam P, 2008, J AM GERIATR SOC, V56, P1312, DOI 10.1111/j.1532-5415.2008.01767.x
   Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC
   Poole P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001287.pub4
   Sweeney J, 2014, PRIM CARE RESP J, V23, P74, DOI 10.4104/pcrj.2014.00007
   Van Ganse E, 2006, RESP MED, V100, P140, DOI 10.1016/j.rmed.2005.03.041
NR 27
TC 4
Z9 4
U1 1
U2 7
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 10
EP 17
DI 10.1016/j.rmed.2018.11.001
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000002
PM 30665506
DA 2020-05-18
ER

PT J
AU Hill, K
   Ng, C
   Wootton, SL
   McKeough, ZJ
   Eastwood, PR
   Hillman, DR
   Jenkins, C
   Spencer, L
   Jenkins, SC
   Cecins, NM
   Alison, JA
AF Hill, Kylie
   Ng, Cindy
   Wootton, Sally L.
   McKeough, Zoe J.
   Eastwood, Peter R.
   Hillman, David R.
   Jenkins, Christine
   Spencer, Lissa
   Jenkins, Sue C.
   Cecins, Nola M.
   Alison, Jennifer A.
TI The minimal detectable difference for endurance shuttle walk test
   performance in people with COPD on completion of a program of
   high-intensity ground-based walking
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Endurance shuttle walk test; Minimal detectable difference; Exercise
   training; Chronic obstructive pulmonary disease
ID QUALITY-OF-LIFE; PULMONARY REHABILITATION; EXERCISE CAPACITY; DISTANCE
AB Background: In people with moderate-to-severe chronic obstructive pulmonary disease (COPD), the minimal detectable difference (MDD) in endurance shuttle walk test (ESWT) performance following exercise training is unclear. We sought to determine the MDD for ESWT performance following supervised ground-based walking training using anchor- and distribution-based approaches and report whether these values exceeded random variation in test performance.
   Methods: Participants with COPD trained for 30-45 min, 2-3 times weekly for 8-10 weeks. The ESWT was performed before and after the training period. Immediately after training, participants rated their change in walking ability using a Global Rating of Change scale. Receiver Operating Characteristic curves were used to derive the value that best separated those who perceived their improvement in walking ability to be at least 'a little' better from 'almost the same, hardly any change'. These values were compared with those calculated using a distribution-based method. Random variation in test performance was defined as the minimal detectable change (MDC), calculated using the standard error of measurement.
   Results: 78 participants (aged 70 +/- 8 yr and FEV1 43 +/- 15% predicted) completed the ESWT before and after training. The value that best separated those who perceived their walking ability as 'a little' better was 70 s. The 95% confidence intervals around this estimate traversed zero. The distribution-based estimate was 156 s. The MDC was 227 s.
   Conclusions: The MDD established using the anchor- and distribution-based approaches differed considerably. Large variation in test performance cautions against using the MDD to interpret changes in an individual.
C1 [Hill, Kylie; Ng, Cindy; Eastwood, Peter R.; Jenkins, Sue C.] Curtin Univ, Fac Hlth Sci, Sch Physiotherapy & Exercise Sci, Perth, WA, Australia.
   [Hill, Kylie; Jenkins, Sue C.; Cecins, Nola M.] Sir Charles Gairdner Hosp, Inst Resp Hlth, Nedlands, WA, Australia.
   [Ng, Cindy] Singapore Gen Hosp, Physiotherapy Dept, Singapore, Singapore.
   [Wootton, Sally L.; McKeough, Zoe J.; Alison, Jennifer A.] Univ Sydney, Fac Hlth Sci, Discipline Physiotherapy, Sydney, NSW, Australia.
   [Wootton, Sally L.] Northern Sydney Local Hlth Dist, Chron Dis Community Rehabil Serv, St Leonards, NSW, Australia.
   [Eastwood, Peter R.; Hillman, David R.] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Nedlands, WA, Australia.
   [Eastwood, Peter R.; Hillman, David R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Ctr Sleep Sci, Nedlands, WA, Australia.
   [Jenkins, Christine] Concord Hosp, Dept Thorac Med, Concord West, NSW, Australia.
   [Spencer, Lissa; Alison, Jennifer A.] Sydney Local Hlth Dist, Campsie, NSW, Australia.
   [Jenkins, Sue C.; Cecins, Nola M.] Sir Charles Gairdner Hosp, Physiotherapy Dept, Nedlands, WA, Australia.
RP Hill, K (reprint author), Curtin Univ, Sch Physiotherapy & Exercise Sci, GPO Box U1987, Perth, WA 6845, Australia.
EM K.Hill@curtin.edu.au
RI Eastwood, Peter R/H-9129-2014; McKeough, Zoe/B-5405-2015
OI Eastwood, Peter R/0000-0002-4490-4138; McKeough,
   Zoe/0000-0002-3657-7229; Hillman, David/0000-0001-9987-539X
FU Australian NHMRCNational Health and Medical Research Council of
   Australia [570814]; National Health and Medical Research Council Senior
   Research FellowshipNational Health and Medical Research Council of
   Australia [1042341]
FX This study was supported by an Australian NHMRC project grant: 570814.
   PR Eastwood is funded by a National Health and Medical Research Council
   Senior Research Fellowship [No. 1042341].
CR Altenburg WA, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0182-x
   Borel B, 2013, PULM MED, V2013, DOI 10.1155/2013/410748
   Copay AG, 2007, SPINE J, V7, P541, DOI 10.1016/j.spinee.2007.01.008
   Granger CL, 2015, CHRON RESP DIS, V12, P146, DOI 10.1177/1479972315575715
   Hill K, 2012, RESPIROLOGY, V17, P278, DOI 10.1111/j.1440-1843.2011.02089.x
   Holland AE, 2010, ARCH PHYS MED REHAB, V91, P221, DOI 10.1016/j.apmr.2009.10.017
   Jenkins S, 2010, RESPIROLOGY, V15, P1157, DOI 10.1111/j.1440-1843.2010.01849.x
   Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163
   Lee AL, 2014, RESP MED, V108, P1303, DOI 10.1016/j.rmed.2014.07.006
   Leung RWM, 2010, J PHYSIOTHER, V56, P105, DOI 10.1016/S1836-9553(10)70040-0
   Make Barry, 2007, COPD, V4, P191
   McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3
   Nixon A, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0427-5
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Pepin V, 2011, THORAX, V66, P115, DOI 10.1136/thx.2010.146159
   Puente-Maestu L, 2009, EUR RESPIR J, V34, P340, DOI 10.1183/09031936.00078308
   Puhan MA, 2011, EUR RESPIR J, V37, P784, DOI 10.1183/09031936.00063810
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46
   Revill SM, 1999, THORAX, V54, P213, DOI 10.1136/thx.54.3.213
   Spruit MA, 2015, EUR RESPIR J, V46, P1625, DOI 10.1183/13993003.00350-2015
   Turner D, 2010, J CLIN EPIDEMIOL, V63, P28, DOI 10.1016/j.jclinepi.2009.01.024
   Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1
   Wootton SL, 2014, EUR RESPIR J, V44, P885, DOI 10.1183/09031936.00078014
   Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x
NR 24
TC 0
Z9 0
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 18
EP 22
DI 10.1016/j.rmed.2018.11.013
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000003
PM 30665513
DA 2020-05-18
ER

PT J
AU Bermea, RS
   Adegunsoye, A
   Oldham, J
   Ventura, I
   Lee, C
   Chung, JH
   Montner, S
   Noth, I
   Strek, ME
   Vij, R
AF Bermea, Rene S.
   Adegunsoye, Ayodeji
   Oldham, Justin
   Ventura, Iazsmin
   Lee, Cathryn
   Chung, Jonathan H.
   Montner, Steven
   Noth, Imre
   Strek, Mary E.
   Vij, Rekha
TI Anti-RNA binding protein positivity in idiopathic interstitial pneumonia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Idiopathic interstitial pneumonia; Anti-RNA binding protein antibodies;
   Interstitial lung disease
ID IFN-ALPHA; PULMONARY; DIAGNOSIS; CLASSIFICATION; HYPERTENSION;
   GUIDELINES; ANTIBODIES
AB Introduction: Idiopathic interstitial pneumonias (IIP) are diffuse lung diseases whose cause is unknown and often present with features of autoimmunity despite not meeting criteria for a connective tissue disease (CTD). Recent studies suggest that anti-RNA binding protein (anti-RBP) antibodies, which include anti-SSA, anti-SSB, anti-Sm, and anti-RNP, play a role in the loss of immune tolerance and severity of pulmonary hypertension (PH) in CTDs. We hypothesized that anti-RBP positive (RBP+) subjects would have worse measures of lung function, radiographic findings, PH, and survival than anti-RBP negative (RBP-) subjects.
   Methods: Subjects with both IIP and serologies for review were identified retrospectively and stratified based on anti-RBP antibody seropositivity. Baseline cohort characteristics, pulmonary function tests (PFT), ambulatory oxygen requirement, radiographic characteristics, markers of PH, and transplant-free survival were compared between anti-RBP positive and negative groups.
   Results: Five hundred twenty patients with IIP were identified, of which ten percent (n = 53) were anti-RBP positive. RBP+ as compared to RBP- subjects had significantly worse PFTs as indicated by FEV1 (59.6 vs. 64.9, p = 0.046) and FVC (71.6 vs. 78.8, p = 0.018). There was a higher prevalence of radiographic honeycombing (49.1% vs. 38.3%, p = 0.006) and emphysema (22.6% vs. 5.1%, p < 0.001) in the RBP+ group despite no difference in smoking history. The Pulmonary Artery-Aorta ratio was also larger in the RBP+ group (0.93 vs. 0.88, p = 0.040). There was no difference in transplant-free survival between groups (log rank = 0.912).
   Conclusion: Anti-RBP+ IIP patients may have worse lung function, increased chest radiographic abnormalities, and PH compared with those without these antibodies.
C1 [Bermea, Rene S.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Adegunsoye, Ayodeji; Lee, Cathryn; Strek, Mary E.; Vij, Rekha] Univ Chicago, Dept Med, Sect Pulm & Crit Care, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Oldham, Justin] Univ Calif Davis, Dept Med, Div Pulm Crit Care & Sleep Med, Davis, CA 95616 USA.
   [Ventura, Iazsmin] Univ Chicago, Dept Med, Sect Rheumatol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Chung, Jonathan H.; Montner, Steven] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
   [Noth, Imre] Univ Virginia, Dept Med, Div Pulm & Crit Care, Charlottesville, VA USA.
RP Bermea, RS (reprint author), 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.
EM rbermea@uchicago.edu
RI Adegunsoye, Ayodeji/Y-4760-2019
OI Adegunsoye, Ayodeji/0000-0002-7015-9610; Oldham,
   Justin/0000-0003-4957-8869
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [K23HL138190,
   R01HL130796]; Boehringer-IngelheimBoehringer Ingelheim; GenentechRoche
   HoldingGenentech
FX Oldham, J - Has received speaking and advsiroy board fees from Genentech
   and Boehringer Ingelheim. Dr. Oldham is supported by a career
   development award from the National Heart, Lung, and Blood Institute
   (K23HL138190).; Noth, I - Has received honoraria for advsiroy boards
   with Boehringer Ingelheim, InterMune, and Anthera within the last 12
   months related to IPF. He has also received speaking honoraria from GSK
   and receives consulting fees for Immuneworks. He also has study
   contracts with the NIH, Stromedix, Sanofi, and BI for the conduct of
   clinical trials in IPF. Dr. Noth is also supports by an award from the
   National Heart, Lung, and Blood Institute (R01HL130796).; Strek, M - Has
   received institutional funding for interstitial lung disease research
   from Boehringer-Ingelheim and Genentech and honoraria from Boehringer
   Ingelheim for speaking, educational products, and serving on an advisory
   board.; Vij, R - Has received a grant from Genentech to study the
   genomics of autoimmune interstitial lung diseases.
CR Al-Naamani K, 2008, INT J CARDIOL, V127, P214, DOI 10.1016/j.ijcard.2007.06.005
   Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890
   Chung JH, 2017, EUR RADIOL, V27, P5127, DOI 10.1007/s00330-017-4936-3
   Fertig N, 2009, ARTHRIT RHEUM-ARTHR, V61, P958, DOI 10.1002/art.24586
   Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015
   Galie N, 2015, EUR RESPIR J, V46, P903, DOI 10.1183/13993003.01032-2015
   Gunnarsson R, 2016, RHEUMATOLOGY, V55, P103, DOI 10.1093/rheumatology/kev300
   Hachulla E, 2018, CHEST, V153, P143, DOI 10.1016/j.chest.2017.08.014
   Hochberg MC, 2015, RHEUMATOLOGY
   Ko K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00309
   McGoon MD, 2012, EUR RESPIR REV, V21, P8, DOI 10.1183/09059180.00008211
   Mileti LM, 2009, JCR-J CLIN RHEUMATOL, V15, P254, DOI 10.1097/RHU.0b013e3181b0e910
   Niewold TB, 2007, GENES IMMUN, V8, P492, DOI 10.1038/sj.gene.6364408
   Oldham JM, 2016, EUR RESPIR J, V47, P1767, DOI 10.1183/13993003.01565-2015
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Ruocco G, 2015, RESP MED, V109, P406, DOI 10.1016/j.rmed.2014.12.011
   Shiboski C. H., 2016, ARTHRITIS RHEUMATOL, DOI [10.1002/art.398592016, DOI 10.1002/ART.398592016]
   Tan EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI DOI 10.1002/ART.1780251101.1271E17
   Tani C, 2014, J AUTOIMMUN, V48-49, P46, DOI 10.1016/j.jaut.2014.01.008
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Wang J, 2017, LUPUS, V26, P1390, DOI 10.1177/0961203317702255
NR 21
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 23
EP 27
DI 10.1016/j.rmed.2018.11.015
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000004
PM 30665514
DA 2020-05-18
ER

PT J
AU Katsoulis, K
   Ismailos, G
   Kipourou, M
   Kostikas, K
AF Katsoulis, Konstantinos
   Ismailos, Georgios
   Kipourou, Maria
   Kostikas, Konstantinos
TI Microbiota and asthma: Clinical implications
SO RESPIRATORY MEDICINE
LA English
DT Review
ID RESPIRATORY SYNCYTIAL VIRUS; MYCOPLASMA-PNEUMONIAE; GUT MICROBIOTA;
   CHLAMYDIA-PNEUMONIAE; AIRWAY MICROBIOME; VIRAL-INFECTIONS; CHILDHOOD
   ASTHMA; ALLERGIC DISEASE; OM-85 BV; INFANTS
C1 [Katsoulis, Konstantinos; Kipourou, Maria] 424 Army Gen Hosp, Pulm Dept, Thessaloniki 56429, Greece.
   [Ismailos, Georgios] ELPEN Pharmaceut, Expt Res Ctr ELPEN, Leoforos Marathonos 95, Pikermi 19009, Attika, Greece.
   [Kostikas, Konstantinos] Univ Athens, Attikon Hosp, Med Sch, Resp Med Dept 2, Athens, Greece.
RP Kipourou, M (reprint author), 424 Army Gen Hosp, Pulm Dept, Thessaloniki 56429, Greece.
EM mariakipo@hotmail.com
OI Kipourou, Maria/0000-0002-2358-2117; Kostikas,
   Konstantinos/0000-0003-0774-3942
CR Allan K, 2011, J AM DIET ASSOC, V111, P258, DOI 10.1016/j.jada.2010.10.048
   Armann J, 2010, EUR RESPIR J, V36, P469, DOI 10.1183/09031936.00041410
   Atkinson TP, 2013, CURR ALLERGY ASTHM R, V13, P702, DOI 10.1007/s11882-013-0390-8
   Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x
   Baxi S. N., 2016, ALLERGY CLINIMMUNOLP, V4, P396
   Bengmark Stig, 2005, Nutr Clin Pract, V20, P244, DOI 10.1177/0115426505020002244
   Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632
   Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978
   Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917
   Boman J, 2000, J INFECT DIS, V181, pS452, DOI 10.1086/315609
   Bridgman SL, 2016, ANN ALLERG ASTHMA IM, V116, P99, DOI 10.1016/j.anai.2015.10.001
   Chen YS, 2010, PEDIATR PULM, V45, P1111, DOI 10.1002/ppul.21296
   Chu HW, 2004, J INFECT DIS, V189, P1119, DOI 10.1086/382050
   Chu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140443
   Comhair SAA, 2015, J IMMUNOL, V195, P643, DOI 10.4049/jimmunol.1500736
   Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705
   Dickson RP, 2017, THORAX, V72, P10, DOI 10.1136/thoraxjnl-2016-209180
   Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009
   Drever N, 2010, CURR ALLERGY ASTHM R, V10, P453, DOI 10.1007/s11882-010-0136-9
   Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055
   Durack J, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0631-8
   Edwards MR, 2018, ALLERGY, V73, P50, DOI 10.1111/all.13257
   Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801
   Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160
   Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244
   Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e
   Farrant J, 2016, J ASTHMA, V53, P732, DOI 10.3109/02770903.2016.1154073
   Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007
   Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378
   Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC
   Gollwitzer ES, 2014, PHARMACOL THERAPEUT, V141, P32, DOI 10.1016/j.pharmthera.2013.08.002
   Good JT, 2012, CURR OPIN PULM MED, V18, P76, DOI 10.1097/MCP.0b013e32834daff8
   Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645
   Gronlund MM, 2007, CLIN EXP ALLERGY, V37, P1764, DOI 10.1111/j.1365-2222.2007.02849.x
   Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007
   Gutkowski P, 2010, CENT EUR J IMMUNOL, V35, P233
   Hammerschlag MR, 2004, CLIN INFECT DIS, V39, P1251, DOI 10.1086/424451
   Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183
   Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P535, DOI 10.1111/j.1348-0421.2002.tb02731.x
   Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC
   Hevia A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147809
   Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578
   Hollams EM, 2010, EUR RESPIR J, V36, P509, DOI 10.1183/09031936.00184109
   Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017
   Hosoki K, 2013, INT ARCH ALLERGY IMM, V161, P16, DOI 10.1159/000350338
   Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007
   Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044
   Huang Yvonne J, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS48, DOI 10.1513/AnnalsATS.201306-187MG
   Huang YJ, 2013, CURR ALLERGY ASTHM R, V13, P453, DOI 10.1007/s11882-013-0355-y
   Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048
   Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108
   Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC
   Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004
   Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237
   Kaplan JL, 2011, PEDIATR RES, V69, P465, DOI 10.1203/PDR.0b013e318217638a
   KAPLAN M A, 1958, Antibiot Annu, V6, P273
   Kjaer BB, 2008, PEDIATR PULM, V43, P567, DOI 10.1002/ppul.20813
   Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166
   Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092
   Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782
   Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036
   Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051
   Lapin B, 2015, ANN ALLERG ASTHMA IM, V114, P203, DOI 10.1016/j.anai.2014.11.014
   Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031
   Leyer GJ, 2009, PEDIATRICS, V124, pE172, DOI 10.1542/peds.2008-2666
   Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012
   Lotz MT, 2012, CURR ALLERGY ASTHM R, V12, P380, DOI 10.1007/s11882-012-0278-z
   Luoto R, 2014, J ALLERGY CLIN IMMUN, V133, P405, DOI 10.1016/j.jaci.2013.08.020
   Madan JC, 2012, MBIO, V3, DOI 10.1128/mBio.00251-12
   Marc E, 2000, PEDIATR INFECT DIS J, V19, P706, DOI 10.1097/00006454-200008000-00007
   Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013
   Marsland Benjamin J, 2013, Ann Am Thorac Soc, V10 Suppl, pS165, DOI 10.1513/AnnalsATS.201305-118AW
   Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563
   Martinez Fernando D, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS7, DOI 10.1513/AnnalsATS.201306-186MG
   Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800
   Medina JL, 2012, AM J RESP CELL MOL, V46, P815, DOI 10.1165/rcmb.2011-0135OC
   Metz G, 2010, IMMUNOL ALLERGY CLIN, V30, P575, DOI 10.1016/j.iac.2010.08.003
   Millares L, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-0933-6
   Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51
   Peeling RW, 1996, EMERG INFECT DIS, V2, P307, DOI 10.3201/eid0204.960406
   Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164
   Peters J, 2011, CHEST, V140, P401, DOI 10.1378/chest.11-0221
   Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038
   Ruedler D, 2014, LANCET RESP MED, V2, P647, DOI 10.1016/S2213-2600(14)70129-8
   Russell SL, 2013, GUT MICROBES, V4, P158, DOI 10.4161/gmic.23567
   Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32
   Schaad UB, 2010, WORLD J PEDIATR, V6, P5, DOI 10.1007/s12519-010-0001-x
   Shore SA, 2016, AM J RESP CELL MOL, V54, P609, DOI 10.1165/rcmb.2016-0052PS
   Sibley CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022702
   Singanayagam A, 2017, CURR OPIN PULM MED, V23, P41, DOI [10.1097/mcp.0000000000000333, 10.1097/MCP.0000000000000333]
   Sipka S, 2014, INT ARCH ALLERGY IMM, V165, P1, DOI 10.1159/000366100
   Slater M, 2014, THORAX, V69, P673, DOI 10.1136/thoraxjnl-2013-204517
   Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024
   Smits HH, 2016, J ALLERGY CLIN IMMUN, V137, P690, DOI 10.1016/j.jaci.2016.01.004
   Sokolowska Milena, 2018, Asthma Res Pract, V4, P1, DOI 10.1186/s40733-017-0037-y
   Specjalski K, 2011, ALLERGY ASTHMA PROC, V32, pE9, DOI 10.2500/aap.2011.32.3431
   Steinmeyer S, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0524-2
   Stiemsma LT, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0173-6
   Suau A, 1999, APPL ENVIRON MICROB, V65, P4799
   Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415
   Tanaka A, 2016, ANN ALLERG ASTHMA IM, V117, P163, DOI 10.1016/j.anai.2016.06.001
   Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044
   Tomassen P, 2013, ALLERGY, V68, P1289, DOI 10.1111/all.12230
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444
   Vael C, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-68
   van de Pol MA, 2011, ALLERGY, V66, P39, DOI 10.1111/j.1398-9995.2010.02454.x
   Wenzel SE, 2016, AM J RESP CELL MOL, V55, P1, DOI 10.1165/rcmb.2016-0141PS
   West CE, 2016, EXPERT REV CLIN IMMU, V12, P625, DOI 10.1586/1744666X.2016.1147955
   Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003
   WONGTIM S, 1995, ASIAN PAC J ALLERGY, V13, P5
   Wood PR, 2013, ANN ALLERG ASTHMA IM, V110, P328, DOI 10.1016/j.anai.2013.01.022
   Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/ERI.11.92, 10.1586/eri.11.92]
   Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC
   Yasui H, 2004, CLIN DIAGN LAB IMMUN, V11, P675, DOI 10.1128/CDLI.11.4.675-679.2004
   Yoo Jennifer, 2007, Proc Am Thorac Soc, V4, P277, DOI 10.1513/pats.200702-033AW
   Zelante T, 2016, SEMIN IMMUNOPATHOL, V38, P239, DOI 10.1007/s00281-015-0523-3
NR 117
TC 1
Z9 1
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 28
EP 35
DI 10.1016/j.rmed.2018.11.016
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000005
PM 30665515
DA 2020-05-18
ER

PT J
AU Charbonnier, JP
   Pompe, E
   Moore, C
   Humphries, S
   van Ginneken, B
   Make, B
   Regan, E
   Crapo, JD
   van Rikxoort, EM
   Lynch, DA
AF Charbonnier, Jean-Paul
   Pompe, Esther
   Moore, Camille
   Humphries, Stephen
   van Ginneken, Bram
   Make, Barry
   Regan, Elizabeth
   Crapo, James D.
   van Rikxoort, Eva M.
   Lynch, David A.
CA COPDGene Investigators
TI Airway wall thickening on CT: Relation to smoking status and severity of
   COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Smoking cessation; Quality of life; Computed tomography; Airway wall
   inflammation
ID EMPHYSEMA; SMOKERS; DISEASE
AB Airway wall thickening in cigarette smokers is thought to be a result of inflammatory changes and airway remodeling. This study investigates if CT-derived airway wall thickening associates to disease severity in smokers with and without COPD and if airway wall thickening is reversible by smoking cessation.
   We examined 2000 smokers and 46 never-smokers who returned for a 5-year follow-up visit in the COPDGene-study. Multivariable regression analyses were performed at visit 1 to associate airway wall thickness (expressed as Pi10) with percent predicted forced expiratory volume in 1 s (FEV1%-predicted), 6-min walking distance (6MWD), and St. George Respiratory Questionnaire (SGRQ). Longitudinal analyses were performed to assess the effect of smoking cessation on Pi10 using linear mixed models.
   A higher Pi10 was significantly associated with worse FEV1%-predicted, 6MWD, and SGRQ in all GOLD-stages. Longitudinal analyses showed that subjects that quit smoking significantly decreased in Pi10 (Delta Pi10 = -0.18 mm, p < 0.001). Subjects that started smoking had a significant increase in Pi10 (Delta Pi10 = 0.14 mm, p < 0.001).
   Pi10 is a clinically relevant biomarker of smoking-related airway injury in smokers with and without COPD. The change in Pi10 with change in smoking status suggests that it can quantify a reversible component of smoking-related airway inflammation.
C1 [Charbonnier, Jean-Paul; van Rikxoort, Eva M.] Thirona, Nijmegen, Netherlands.
   [Charbonnier, Jean-Paul; van Ginneken, Bram; van Rikxoort, Eva M.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands.
   [Pompe, Esther] Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands.
   [Moore, Camille] Natl Jewish Hlth, Dept Biostat & Bioinformat, Denver, CO USA.
   [Humphries, Stephen] Natl Jewish Hlth, Dept Radiol, Denver, CO USA.
   [Make, Barry; Regan, Elizabeth; Crapo, James D.] Natl Jewish Hlth, Dept Med, Denver, CO USA.
RP Charbonnier, JP (reprint author), Toernooiveld 300, NL-6525 EC Nijmegen, Netherlands.
EM jeanpaulcharbonnier@thirona.eu
RI van Ginneken, Bram/A-3728-2012
OI van Ginneken, Bram/0000-0003-2028-8972; Pompe,
   Esther/0000-0002-1749-0208; Regan, Elizabeth/0000-0003-0624-9184
FU Netherlands Organisation for Scientific Research (NWO)Netherlands
   Organization for Scientific Research (NWO) [612.001.204]; National
   Heart, Lung, and Blood InstituteUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01 HL089897, R01 HL089856]; COPD
   Foundation
FX This work was financed by the Netherlands Organisation for Scientific
   Research (NWO, project number: 612.001.204) and supported by Award
   Number R01 HL089897 and Award Number R01 HL089856 from the National
   Heart, Lung, and Blood Institute. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Heart, Lung, and Blood Institute or the
   National Institutes of Health. The COPDGene (R) project is also
   supported by the COPD Foundation through contributions made to an
   Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim,
   GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion.
CR Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Diaz AA, 2013, CHEST, V143, P687, DOI 10.1378/chest.12-0039
   Dransfield MT, 2017, AM J RESP CRIT CARE, V195, P324, DOI 10.1164/rccm.201605-1014OC
   Hoesein FAAM, 2015, EUR RESPIR J, V45, P644, DOI 10.1183/09031936.00020714
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   Kim V, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0084-3
   Lutey BA, 2013, CHEST, V143, P1321, DOI 10.1378/chest.12-0034
   Mets OM, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-59
   Mets OM, 2011, JAMA-J AM MED ASSOC, V306, P1775, DOI 10.1001/jama.2011.1531
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Patel BD, 2008, AM J RESP CRIT CARE, V178, P500, DOI 10.1164/rccm.200801-059OC
   Regan EA, 2015, JAMA INTERN MED, V175, P1539, DOI 10.1001/jamainternmed.2015.2735
   Regan EA, 2010, COPD, V7, P32, DOI 10.3109/15412550903499522
   Sasaki T, 2014, AM J ROENTGENOL, V203, P78, DOI 10.2214/AJR.13.11748
   Schmidt M., 2010, REPROD AIRWAY WALL T
   Schroeder JD, 2013, AM J ROENTGENOL, V201, pW460, DOI 10.2214/AJR.12.10102
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wan ES, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0089-y
   Washko GR, 2014, J APPL PHYSIOL, V116, P668, DOI 10.1152/japplphysiol.00004.2013
   Zach JA, 2012, INVEST RADIOL, V47, P596, DOI 10.1097/RLI.0b013e318262292e
NR 21
TC 4
Z9 4
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 36
EP 41
DI 10.1016/j.rmed.2018.11.014
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000006
PM 30665516
OA Green Accepted
DA 2020-05-18
ER

PT J
AU Brown, KK
   Flaherty, KR
   Cottin, V
   Raghu, G
   Inoue, Y
   Azuma, A
   Huggins, JT
   Richeldi, L
   Stowasser, S
   Stansen, W
   Schlenker-Herceg, R
   Maher, TM
   Wells, AU
AF Brown, Kevin K.
   Flaherty, Kevin R.
   Cottin, Vincent
   Raghu, Ganesh
   Inoue, Yoshikazu
   Azuma, Arata
   Huggins, John T.
   Richeldi, Luca
   Stowasser, Susanne
   Stansen, Wibke
   Schlenker-Herceg, Rozsa
   Maher, Toby M.
   Wells, Athol U.
TI Lung function outcomes in the INPULSIS (R) trials of nintedanib in
   idiopathic pulmonary fibrosis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Vital capacity; Respiratory function tests; Pulmonary gas exchange;
   Interstitial lung diseases; Protein-tyrosine kinases
ID FORCED VITAL CAPACITY; EFFICACY; INHIBITOR; SUBGROUPS; SURVIVAL; IMPACT
AB Background: In the INPULSIS (R) trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using pooled data from the INPULSIS (R) trials.
   Methods: Post-hoc analyses included changes in FVC over time, cumulative distribution of patients by change in FVC % predicted, and annual rate of decline in FVC in subgroups by diffusing capacity of the lung for carbon monoxide (DLco) and composite physiologic index (CPI) at baseline. Changes from baseline in DLco and oxygen saturation by pulse oximetry (SpO(2)) were pre-specified.
   Results: Nintedanib significantly reduced FVC decline versus placebo from week 12. A higher proportion of patients treated with nintedanib than placebo had an improvement or no decline in FVC % predicted, whereas a smaller proportion had absolute declines in FVC >= 5% or >= 10% predicted from baseline to week 52. The effect of nintedanib on FVC decline was similar in patients with baseline DLco > 40% versus <= 40% predicted or CPI <= 45 versus > 45. There were no significant differences between nintedanib and placebo in change from baseline in DLco % predicted, CPI, or SpO(2) at week 52. However, change (deterioration) in CPI was significantly lower with nintedanib versus placebo in patients with CPI > 45 at baseline (1.0 versus 2.9) and CPI > 55 at baseline (-1.2 versus 3.3).
   Conclusions: A range of physiologic outcome measures in the INPULSIS (R) trials support the effect of nintedanib on reducing disease progression in patients with IPF.
C1 [Brown, Kevin K.] Natl Jewish Hlth, Denver, CO USA.
   [Flaherty, Kevin R.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Cottin, Vincent] Claude Bernard Univ Lyon 1, Hosp Civils Lyon, Louis Pradel Hosp, Lyon, France.
   [Raghu, Ganesh] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Inoue, Yoshikazu] Natl Hosp Org Kinki Chuo Chest Med Ctr, Clin Res Ctr, Osaka, Japan.
   [Azuma, Arata] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan.
   [Huggins, John T.] Med Univ South Carolina, Charleston, SC 29425 USA.
   [Richeldi, Luca] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Rome, Italy.
   [Stowasser, Susanne] Boehringer Ingelheim Int GmbH, Ingelheim, Germany.
   [Stansen, Wibke] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
   [Schlenker-Herceg, Rozsa] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.
   [Maher, Toby M.] Royal Brompton Hosp, Natl Inst Hlth Res, Biomed Res Unit, London, England.
   [Maher, Toby M.] Imperial Coll London, Natl Heart & Lung Inst, Fibrosis Res Grp, London, England.
   [Wells, Athol U.] Imperial Coll London, Natl Inst Hlth Res, Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England.
   [Wells, Athol U.] Imperial Coll London, Natl Heart & Lung Inst, London, England.
RP Wells, AU (reprint author), Imperial Coll London, Natl Inst Hlth Res, Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England.; Wells, AU (reprint author), Imperial Coll London, Natl Heart & Lung Inst, London, England.
EM rbhild@rbht.nhs.uk
RI Maher, Toby M/C-1575-2008; Maher, Toby/AAM-1618-2020
OI Richeldi, Luca/0000-0001-8594-1448; Cottin, Vincent/0000-0002-5591-0955;
   Inoue, Yoshikazu/0000-0003-3994-874X; Maher, Toby/0000-0001-7192-9149;
   Azuma, Arata/0000-0003-0506-9966
FU Boehringer IngelheimBoehringer Ingelheim
FX The INPULSIS (R) trials were funded by Boehringer Ingelheim.
CR Ackermann M, 2017, ANGIOGENESIS, V20, P359, DOI 10.1007/s10456-017-9543-z
   Boehringer Ingelheim, 2017, OF NINT SUMM PROD CH
   Boehringer Ingelheim Pharmaceuticals Inc, 2017, OF NINT PRESCR INF
   Collard HR, 2003, AM J RESP CRIT CARE, V168, P538, DOI 10.1164/rccm.200211-1311OC
   Costabel U, 2016, AM J RESP CRIT CARE, V193, P178, DOI 10.1164/rccm.201503-0562OC
   Cottin V, 2013, EUR RESPIR REV, V22, P153, DOI 10.1183/09059180.00000813
   CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P893
   Crestani B, 2016, EUR RESPIR J, V48, P60
   du Bois RM, 2012, AM J RESP CRIT CARE, V186, P712, DOI 10.1164/rccm.201206-1010PP
   du Bois RM, 2011, AM J RESP CRIT CARE, V184, P1382, DOI 10.1164/rccm.201105-0840OC
   Flaherty KR, 2003, AM J RESP CRIT CARE, V168, P543, DOI 10.1164/rccm.200209-1112OC
   Glaser S, 2009, RESP MED, V103, P317, DOI 10.1016/j.rmed.2008.08.005
   Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307
   Hostettler KE, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0157-3
   Huang J, 2017, ANN RHEUM DIS, V76, P1941, DOI 10.1136/annrheumdis-2016-210823
   Karimi-Shah BA, 2015, NEW ENGL J MED, V372, P1189, DOI 10.1056/NEJMp1500526
   King TE, 2011, AM J RESP CRIT CARE, V184, P92, DOI 10.1164/rccm.201011-1874OC
   Kolb M, 2017, THORAX, V72, P340, DOI 10.1136/thoraxjnl-2016-208710
   Latsi PI, 2003, AM J RESP CRIT CARE, V168, P531, DOI 10.1164/rccm.200210-1245OC
   Ley B, 2016, AM J RESP CRIT CARE, V194, P711, DOI 10.1164/rccm.201508-1546OC
   Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
   MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905
   Maher TM, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.OA4499
   Martinez Fernando J, 2006, Proc Am Thorac Soc, V3, P315, DOI 10.1513/pats.200602-022TK
   Martinez FJ, 2014, NEW ENGL J MED, V370, P2093, DOI 10.1056/NEJMoa1401739
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Raghu G, 2017, AM J RESP CRIT CARE, V195, P78, DOI 10.1164/rccm.201602-0402OC
   Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST
   Raghu G, 2013, EUR RESPIR J, V42, P1622, DOI 10.1183/09031936.00104612
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Richeldi L, 2014, RESP MED, V108, P1023, DOI 10.1016/j.rmed.2014.04.011
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Richeldi L, 2011, NEW ENGL J MED, V365, P1079, DOI 10.1056/NEJMoa1103690
   Salisbury ML, 2016, CHEST, V149, P491, DOI 10.1378/chest.15-0530
   Schmidt SL, 2014, CHEST, V145, P579, DOI 10.1378/chest.13-0844
   Tandon K, 2017, AM J RESP CRIT CARE, V195
   Wells AU, 2003, AM J RESP CRIT CARE, V167, P962, DOI 10.1164/rccm.2111053
   Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914
   Zappala CJ, 2010, EUR RESPIR J, V35, P830, DOI 10.1183/09031936.00155108
NR 39
TC 10
Z9 10
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 42
EP 48
DI 10.1016/j.rmed.2018.11.012
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000007
PM 30665517
DA 2020-05-18
ER

PT J
AU Sciriha, A
   Lungaro-Mifsud, S
   Fsadni, P
   Scerri, J
   Montefort, S
AF Sciriha, Anabel
   Lungaro-Mifsud, Stephen
   Fsadni, Peter
   Scerri, Josianne
   Montefort, Stephen
TI Pulmonary Rehabilitation in patients with Interstitial Lung Disease: The
   effects of a 12-week programme
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pulmonary Rehabilitation; Exercise; Quality of life; Function;
   Interstitial lung disease
ID FIBROSIS; LIMITATION; DEPRESSION; ANXIETY
AB Background: The inclusion of Pulmonary Rehabilitation as part of the management of Interstitial Lung Disease, although being highly recommended in most recent guidelines, still has limited studies exploring the outcomes from such an intervention. The present study aims to contribute to the available literature by investigating the effects of a high intensity, 12 week PR programme on functional and quality of life measures in patients with a diagnosis of Interstitial Lung Disease.
   Method: ology: This paper reports outcomes of an observational, prospective, quasi experimental type of study. A total of 120 participants were recruited: 60 patients formed part of the active group, and another 60 patients were enrolled in an inactive group. Each participant was classified according to the modified Medical Research Council dyspnoea scale and placed in one of 5 categories (0-4) according to self-perceived breathlessness during daily activities. The following outcomes were measured: Lung function tests including plethysmography and diffusion capacity of carbon monoxide (DLCO), functional tests (6-min walking distance test, Dyspnoea Borg Scale) and health status measures (St George's Respiratory Questionnaire and Hospital Anxiety and Depression Score).
   Results: A 12-week PR programme for patients with Interstitial Lung Disease, led to significant improvements in the active group of patients in the 6 min walking distance test, the modified Borg Scale, mMRC scores and in the health status measures. Lung function measures did not show any significant improvement following this intervention.
   Conclusion: This 12week Pulmonary Rehabilitation programme resulted in improvements in functional aspects for patients with Interstitial Lung Disease. Further studies are recommended as Pulmonary Rehabilitation for Interstitial Lung Disease may have an impact at both an individual level and at global organisational/ financial levels.
C1 [Sciriha, Anabel] Univ Malta, Mater Hosp, Block A,Level 1,Room 16, Msida, Malta.
   [Lungaro-Mifsud, Stephen; Scerri, Josianne; Montefort, Stephen] Univ Malta, Msida, Malta.
   [Fsadni, Peter] Univ Malta, Mater Hosp, Msida, Malta.
RP Sciriha, A (reprint author), Univ Malta, Mater Hosp, Block A,Level 1,Room 16, Msida, Malta.
EM a.sciriha14@gmail.com; stephen.lungaro-mifsud@um.edu.mt;
   peter.fsadni@gov.mt; josianne.scerri@um.edu.mt; stevemonte@gmail.com
CR Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Dowman L., 2014, PULMONARY REHABILITA
   Ferreira A, 2009, CHEST, V135, P442, DOI 10.1378/chest.08-1458
   Furukawa T, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0503-3
   Gouder C., 2012, INTERSTITIAL LUNG DI
   Jackson RM, 2014, LUNG, V192, P367, DOI 10.1007/s00408-014-9566-9
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Kenn K, 2013, RESPIRATION, V86, P89, DOI 10.1159/000354112
   Navaratnam V, 2011, THORAX, V66, P462, DOI 10.1136/thx.2010.148031
   Nishiyama O, 2010, EUR RESPIR J, V36, P1067, DOI 10.1183/09031936.00152609
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Rifaat N, 2014, EGYPT J CHEST DIS TU, V63, P1013, DOI 10.1016/j.ejcdt.2014.06.004
   Sciriha A, 2013, EUR RESPIR J, V42, pP2243
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Tonelli R, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0476-5
   Vainshelboim B, 2014, RESPIRATION, V88, P378, DOI 10.1159/000367899
   Xu WN, 2008, AM J RESP CRIT CARE, V178, P913, DOI 10.1164/rccm.200804-619OC
NR 19
TC 4
Z9 4
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 49
EP 56
DI 10.1016/j.rmed.2018.11.007
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000008
PM 30665518
DA 2020-05-18
ER

PT J
AU Zhu, FR
   Ding, R
   Lei, RQ
   Cheng, H
   Liu, J
   Shen, CW
   Zhang, C
   Xu, YC
   Xiao, CC
   Li, XR
   Zhang, JQ
   Cao, JY
AF Zhu, Furong
   Ding, Rui
   Lei, Ruoqian
   Cheng, Han
   Liu, Jie
   Shen, Chaowei
   Zhang, Chao
   Xu, Yachun
   Xiao, Changchun
   Li, Xiaoru
   Zhang, Junqing
   Cao, Jiyu
TI The short-term effects of air pollution on respiratory diseases and lung
   cancer mortality in Hefei: A time-series analysis
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Respiratory disease; Lung cancer; Mortality; Air pollutants; Generalized
   additive model
ID PARTICULATE MATTER; LIFE LOST; EXPOSURE; CHINA; BURDEN; FINE;
   HOSPITALIZATIONS; ASSOCIATION; TEMPERATURE; PARTICLES
AB Accumulating evidence has shown the effects of air pollution on respiratory disease and lung cancer mortality, but the evidence is still inconclusive to date. We conducted a time-series analysis, which included 10388 subjects, to assess the short-term effects of air pollution on respiratory disease and lung cancer mortality in Hefei, China, from 2009 to 2015. The mean concentrations of pollutants (PM10, NO2 and SO2) were 106.35, 30.40, and 20.66 mu g/m(3), respectively, during the study period. An increase of 10 mu g/m(3) in SO2, NO2, and PM10 was associated with 7.69% (95% CI: 3.41%-12.15%), 4.38% (95% CI: 1.33%-7.53%), and 1.55% (95% CI: 0.80%-2.30%) increase of respiratory diseases mortality, respectively. In contrast, lung cancer mortality was only significantly associated with SO2 level. Subgroup analyses showed that female in respiratory disease patients were more sensitive to air pollution than male. Studies about seasonality of pollutants on respiratory and lung cancer mortality were inconsistent. Further analyses with multiple-pollutant model showed that the effects of pollutants were generally decreased after the other pollutants were adjusted, except the effects of SO2 on lung cancer. These findings demonstrated that air pollution could evidently increase the respiratory disease and lung cancer mortality.
C1 [Zhu, Furong; Ding, Rui; Lei, Ruoqian; Cheng, Han; Liu, Jie; Shen, Chaowei; Zhang, Chao; Xu, Yachun; Cao, Jiyu] Anhui Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Environm Hlth, 81Meishan Rd, Hefei 230032, Anhui, Peoples R China.
   [Xiao, Changchun; Li, Xiaoru; Zhang, Junqing] Hefei Ctr Dis Control & Prevent Anhui, Hefei, Anhui, Peoples R China.
RP Cao, JY (reprint author), Anhui Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Environm Hlth, 81Meishan Rd, Hefei 230032, Anhui, Peoples R China.
EM qshq@163.com
OI Ding, Rui/0000-0002-4939-3840
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81872580]; Key Projects of Natural Science research
   in Universities of Anhui Province [KJ2018A0167]; Student's Platform for
   Innovation and Entrepreneurship Training Program of China [201610366021]
FX This work was supported by National Natural Science Foundation of China
   (Grand Number: 81872580), Key Projects of Natural Science research in
   Universities of Anhui Province (Grand Number: KJ2018A0167), Student's
   Platform for Innovation and Entrepreneurship Training Program of China
   (Grand Number: 201610366021).
CR AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359
   Ban J, 2017, ENVIRON INT, V106, P19, DOI 10.1016/j.envint.2017.05.019
   Bell ML, 2004, ANNU REV PUBL HEALTH, V25, P247, DOI 10.1146/annurev.publhealth.25.102802.124329
   Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254
   Carugno M, 2016, ENVIRON RES, V147, P415, DOI 10.1016/j.envres.2016.03.003
   Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI [10.1164/rccm.201612-2427OC, 10.1164/rccm.201609-1862oc, 10.1164/rccm.201609-1862OC]
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen X, 2016, SCI TOTAL ENVIRON, V571, P855, DOI 10.1016/j.scitotenv.2016.07.064
   Cheng J, 2017, ENVIRON INT, V109, P10, DOI 10.1016/j.envint.2017.09.012
   Cox LA, 2017, ENVIRON RES, V155, P92, DOI 10.1016/j.envres.2017.01.003
   Ding R, 2017, FREE RADICAL BIO MED, V113, P452, DOI 10.1016/j.freeradbiomed.2017.10.386
   Dominici F, 2003, ENVIRON HEALTH PERSP, V111, P39, DOI 10.1289/ehp.5181
   Guo YS, 2017, ENVIRON SCI POLLUT R, V24, P20261, DOI 10.1007/s11356-017-9502-7
   Hamra GB, 2015, ENVIRON HEALTH PERSP, V123, P1107, DOI 10.1289/ehp.1408882
   Han M, 2017, ENVIRON SCI POLLUT R, V24, P27843, DOI 10.1007/s11356-017-0402-7
   Hao YH, 2017, INT J ENVIRON HEAL R, V27, P126, DOI 10.1080/09603123.2017.1292497
   He TF, 2016, SCI REP-UK, V6, DOI 10.1038/srep22485
   Khaniabadi YO, 2017, ENVIRON SCI POLLUT R, V24, P2781, DOI 10.1007/s11356-016-8038-6
   Knutsen S. F., 2016, ENV HLTH PERSPECT, V125, P40482
   Lai HK, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-360
   Lee H, 2015, ENVIRON POLLUT, V207, P43, DOI 10.1016/j.envpol.2015.08.036
   Li L, 2016, CHINA SCI REP, V6, P25900, DOI DOI 10.1038/SREP25900
   Li R., 2015, ENVIRON SCI POLLUT R, V22, P4
   Li XJ, 2018, TOXICOL LETT, V285, P43, DOI 10.1016/j.toxlet.2017.12.020
   Lin RL, 2015, ONCOTARGETS THER, V8, P3549, DOI 10.2147/OTT.S92518
   Lopez-Villarrubia E, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-8
   Lu F, 2015, SCI TOTAL ENVIRON, V536, P123, DOI 10.1016/j.scitotenv.2015.07.048
   Miri M, 2016, ENVIRON RES, V151, P451, DOI 10.1016/j.envres.2016.07.039
   Ortiz C, 2017, ENVIRON POLLUT, V224, P541, DOI 10.1016/j.envpol.2017.02.037
   Parnia S, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-22
   Phung D, 2016, SCI TOTAL ENVIRON, V557, P322, DOI 10.1016/j.scitotenv.2016.03.070
   Ren M., 2017, SCI REP, V7, P20167
   Rom WN, 2006, AM J RESP CRIT CARE, V173, P365, DOI 10.1164/rccm.2601003
   Ronca R, 2015, EXPERT OPIN THER TAR, V19, P1361, DOI 10.1517/14728222.2015.1062475
   Samoli E, 2001, ENVIRON HEALTH PERSP, V109, P349, DOI 10.2307/3454893
   Shahadin MS, 2018, LUNG CANCER, V118, P69, DOI 10.1016/j.lungcan.2018.01.016
   Shen YS, 2017, SCI REP-UK, V7, DOI 10.1038/srep42854
   Sun XL, 2017, TOXICOL LETT, V278, P1, DOI 10.1016/j.toxlet.2017.07.853
   Tseng CY, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-4
   Tsui HC, 2018, ENVIRON POLLUT, V236, P953, DOI 10.1016/j.envpol.2017.10.092
   Uccelli R, 2017, EUR J PUBLIC HEALTH, V27, P178, DOI 10.1093/eurpub/ckw203
   Wu SW, 2016, ENVIRON INT, V94, P76, DOI 10.1016/j.envint.2016.05.004
   Yang Y, 2015, SCI TOTAL ENVIRON, V508, P178, DOI 10.1016/j.scitotenv.2014.11.070
   Zhang C, 2017, ENVIRON POLLUT, V229, P790, DOI 10.1016/j.envpol.2017.06.022
   Zhang FY, 2011, INT J ENV RES PUB HE, V8, P2109, DOI 10.3390/ijerph8062109
   Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6
   Zhu JY, 2017, ENVIRON POLLUT, V224, P689, DOI 10.1016/j.envpol.2017.02.053
NR 47
TC 4
Z9 4
U1 2
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 57
EP 65
DI 10.1016/j.rmed.2018.11.019
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000009
PM 30665519
DA 2020-05-18
ER

PT J
AU Fujita, K
   Kim, YH
   Kanai, O
   Yoshida, H
   Mio, T
   Hirai, T
AF Fujita, Kohei
   Kim, Young Hak
   Kanai, Osamu
   Yoshida, Hironori
   Mio, Tadashi
   Hirai, Toyohiro
TI Emerging concerns of infectious diseases in lung cancer patients
   receiving immune checkpoint inhibitor therapy
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Cancer immunotherapy; Immune checkpoint inhibitor; Immune related
   adverse event; Infectious diseases; Nivolumab
ID ANTIBODY TREATMENT; T-CELLS; BLOCKADE; EXPRESSION; NIVOLUMAB; DOCETAXEL
AB Backgrounds: Cancer immunotherapy using immune checkpoint inhibitors has received a remarkable amount of attention in patients with non-small cell lung cancer (NSCLC). The unique adverse effects known as immune-related adverse events (irAEs) associated with immune checkpoint inhibitors are not known however, and neither is the incidence of infectious disease among patients receiving immune checkpoint inhibitors. The aims of this study were to investigate the incidence of infections during nivolumab treatment, and the risk factors associated with infections.
   Methods: We retrospectively reviewed NSCLC patients who received nivolumab in two teaching hospitals (National Hospital Organization Kyoto Medical Center and Kyoto University Hospital, Kyoto, Japan) between December 2015 and June 2017. We counted any infectious diseases occurring at any time after the initiation of nivolumab until 3 months after its discontinuation. In the current study, "infectious disease" was defined as any infection requiring the administration of any antimicrobial agent.
   Results: Of a total of 167 NSCLC patients reviewed, 32 (19.2%) experienced infectious diseases. Of the 33 infections in 32 patients, 25 were bacterial, 2 were fungal, and 6 were viral. Twenty-seven of the patients with infections used corticosteroids during their treatment course. There was no statistically significant difference in the use of immunosuppressive agents between patients with and without infections. A history of diabetes mellitus was significantly associated with infection (odds ratio 3.61, 95% confidence interval 1.14-11.4, p = 0.028).
   Conclusions: Lung cancer patients receiving nivolumab have a certain level of risk for developing infectious diseases. In the current study, a history of diabetes mellitus was an independent risk factor for infectious disease development. Clinicians should pay attention to occult infectious diseases in patients receiving lung cancer treatment with immune checkpoint inhibitors, especially those with the history of diabetes mellitus.
C1 [Fujita, Kohei; Kanai, Osamu; Mio, Tadashi] Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Resp Med, Kyoto, Japan.
   [Kim, Young Hak; Yoshida, Hironori; Hirai, Toyohiro] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan.
RP Fujita, K (reprint author), Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Resp Med, Fushimi Ku, 1-1 Fukakusa Mukaihata Cho, Kyoto, Japan.
EM kfujita-oka@umin.ac.jp
OI Fujita, Kohei/0000-0002-6902-9085; yoshida,
   hironori/0000-0002-1676-0173; Kanai, Osamu/0000-0003-0736-3317
FU National Hospital Organization fiduciary funds; KAKENHI, Japan Society
   for the Promotion of Science, JapanMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [17K16067]
FX This study was partly supported by a grant from the National Hospital
   Organization fiduciary funds and a Grant-in-Aid for Young Scientists
   (B), KAKENHI, Japan Society for the Promotion of Science, Japan (grant
   number 17K16067).
CR Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
   Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
   Chu Yi-Chun, 2017, J Thorac Oncol, V12, pe111, DOI 10.1016/j.jtho.2017.03.012
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Del Castillo M, 2016, CLIN INFECT DIS, V63, P1490, DOI 10.1093/cid/ciw539
   Fujita K, 2016, J THORAC ONCOL, V11, P2238, DOI 10.1016/j.jtho.2016.07.006
   Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7
   Kyi C, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-19
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7
   Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016
   Peng GP, 2008, MOL IMMUNOL, V45, P963, DOI 10.1016/j.molimm.2007.07.038
   Reungwetwattana T, 2016, J THORAC ONCOL, V11, P2048, DOI 10.1016/j.jtho.2016.10.008
   Salem ML, 2015, WORLD J HEPATOL, V7, P2449, DOI 10.4254/wjh.v7.i23.2449
   Tang ZS, 2016, MOL MED REP, V14, P1107, DOI 10.3892/mmr.2016.5396
NR 14
TC 10
Z9 11
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 66
EP 70
DI 10.1016/j.rmed.2018.11.021
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000010
PM 30665520
DA 2020-05-18
ER

PT J
AU Yoo, IY
   Huh, HJ
   Kang, OK
   Jhun, BW
   Koh, WJ
   Lee, NY
AF Yoo, In Young
   Huh, Hee Jae
   Kang, On-Kyun
   Jhun, Byung Woo
   Koh, Won-Jung
   Lee, Nam Yong
TI Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed
   rpoB mutation-specific probes in a routine clinical laboratory setting
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Mycobacterium tuberculosis; AdvanSure MDR-TB GenoBlot assay; MGIT 960
   system; Absolute concentration method; Isoniazid; Rifampin
ID ISONIAZID-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RAPID
   DIAGNOSIS; MULTIPLEX PCR; RIFAMPIN; MANAGEMENT; STRAINS
AB Background: The AdvanSure MDR-TB GenoBlot Assay detects isoniazid-and rifampin-resistant tuberculosis using mutation-specific probes, including probes to disputed rpoB mutations. The aim of this study was to evaluate the clinical usefulness of molecular drug susceptibility testing (DST) using the AdvanSure assay with weekly batch testing in routine clinical laboratory settings in a country with an intermediate tuberculosis burden.
   Methods: The AdvanSure assay was evaluated against an absolute concentration (AC) method and the Mycobacterial Growth Indicator Tube (MGIT) 960 System, which are phenotypic DST methods, using 496 Mycobacterium tuberculosis (MTB) isolates. We retrospectively reviewed and compared DST results and turnaround times (TATs), the time intervals from MTB culture identification to final reporting, for these methods.
   Results: For rifampin, the AdvanSure assay showed 99.2% (492/496) concordance with both the AC and MGIT methods. AdvanSure also detected an rpoB mutation (D516Y) conferring low-level resistance in three isolates categorized as rifampin-susceptible by both phenotypic DST methods. For isoniazid, AdvanSure concordance rates with the AC method and MGIT DST were 96.6% (479/496) and 95.4% (473/496), respectively. The median TAT of AdvanSure in weekly batch testing was 5.8 days, shorter than the times for the phenotypic DST methods, which were 35.1 days for the AC method and 8.9 days for MGIT DST.
   Conclusions: AdvanSure shows promising clinical usefulness for rapid detection of rifampin-and/or isoniazid-resistant tuberculosis when used as a complementary method to phenotypic DST assays in weekly batch testing. Furthermore, MTB isolates with disputed mutations for rifampin resistance were detectable by the AdvanSure assay.
C1 [Yoo, In Young; Huh, Hee Jae; Kang, On-Kyun; Lee, Nam Yong] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Lab Med & Genet, 81 Irwon Ro, Seoul 06351, South Korea.
   [Jhun, Byung Woo; Koh, Won-Jung] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.
RP Lee, NY (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Lab Med & Genet, 81 Irwon Ro, Seoul 06351, South Korea.; Koh, WJ (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM wjkoh@skku.edu; micro.lee@samsung.com
CR Abanda NN, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.11.021
   Abanda NN, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2489-3
   Anek-vorapong R, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-123
   Chakravorty S, 2017, J CLIN MICROBIOL, V55, P183, DOI 10.1128/JCM.01771-16
   Daley CL, 2018, SEMIN RESP CRIT CARE, V39, P310, DOI 10.1055/s-0038-1661383
   Dheda K, 2017, LANCET RESP MED, V5, P291, DOI [10.1016/S2213-2600(17)30079-6, 10.1016/s2213-2600(17)30079-6]
   Falzon D, 2011, EUR RESPIR J, V38, P516, DOI 10.1183/09031936.00073611
   Fregonese F, 2018, LANCET RESP MED, V6, P265, DOI 10.1016/S2213-2600(18)30078-X
   Gegia M, 2017, LANCET INFECT DIS, V17, P223, DOI 10.1016/S1473-3099(16)30407-8
   Han S. B., 2012, LAB MED ONLINE, V2, P34
   Hillemann D, 2007, J CLIN MICROBIOL, V45, P2635, DOI 10.1128/JCM.00521-07
   Jo KW, 2017, TUBERC RESPIR DIS, V80, P270, DOI 10.4046/trd.2017.80.3.270
   Jureen P, 2004, TUBERCULOSIS, V84, P311, DOI 10.1016/j.tube.2003.12.001
   Koh WJ, 2012, ANN LAB MED, V32, P264, DOI 10.3343/alm.2012.32.4.264
   Kumari R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159651
   Lange C, 2018, RESPIROLOGY, V23, P656, DOI 10.1111/resp.13304
   Lekhak SP, 2016, TUBERCULOSIS, V100, P1, DOI 10.1016/j.tube.2016.05.016
   Makinen J, 2006, J CLIN MICROBIOL, V44, P350, DOI 10.1128/JCM.44.2.350-352.2006
   Miotto P, 2006, J CLIN MICROBIOL, V44, P2485, DOI 10.1128/JCM.00083-06
   Moon HW, 2015, J CLIN LAB ANAL, V29, P142, DOI 10.1002/jcla.21742
   Nathavitharana RR, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01075-2016
   Nathavitharana RR, 2016, J CLIN MICROBIOL, V54, P1624, DOI 10.1128/JCM.00251-16
   Ocheretina O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090569
   Perez-Osorio AC, 2012, J CLIN MICROBIOL, V50, P326, DOI 10.1128/JCM.05570-11
   Rahman A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152694
   Seifert M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119628
   Stagg HR, 2017, INT J TUBERC LUNG D, V21, P129, DOI 10.5588/ijtld.16.0716
   Van Deun A, 2013, J CLIN MICROBIOL, V51, P2633, DOI 10.1128/JCM.00553-13
   World Health Organisation, 2018, WHOCDSTB201820
   World Health Organization (WHO), 2018, WHO TREATM GUID IS R
   Yadav RN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072036
   Zhang M, 2005, J CLIN MICROBIOL, V43, P5477, DOI 10.1128/JCM.43.11.5477-5482.2005
NR 32
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 71
EP 75
DI 10.1016/j.rmed.2018.12.001
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000011
PM 30665521
DA 2020-05-18
ER

PT J
AU Yasui, H
   Inui, N
   Karayama, M
   Mori, K
   Hozumi, H
   Suzuki, Y
   Furuhashi, K
   Enomoto, N
   Fujisawa, T
   Nakamura, Y
   Watanabe, H
   Suda, T
AF Yasui, Hideki
   Inui, Naoki
   Karayama, Masato
   Mori, Kazutaka
   Hozumi, Hironao
   Suzuki, Yuzo
   Furuhashi, Kazuki
   Enomoto, Noriyuki
   Fujisawa, Tomoyuki
   Nakamura, Yutaro
   Watanabe, Hiroshi
   Suda, Takafumi
TI Correlation of the modified Medical Research Council dyspnea scale with
   airway structure assessed by three-dimensional CT in patients with
   chronic obstructive pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; Dyspnea; Modified medical
   research council dyspnea scale; Three-dimensional computed tomography
ID GLOBAL STRATEGY; HEALTH-STATUS; COPD; EMPHYSEMA; EXACERBATION;
   DISABILITY; PREVENTION; MANAGEMENT; DIAGNOSIS; BURDEN
AB Background: Dyspnea is a common symptom in chronic obstructive pulmonary disease (COPD). The modified Medical Research Council (mMRC) dyspnea scale is a widely used questionnaire to assess dyspnea. However, the relationship of the mMRC dyspnea scale with morphological airway structures in COPD remains unclear. We evaluated the correlation between the mMRC dyspnea scale and imaging-based airway structures in patients with COPD.
   Methods: The wall area (WA) and airway inner luminal area (Ai) of third- to sixth-generation bronchi and the percentage of low attenuation area with less than-950 HU (% LAA) of the lungs were measured using three-dimensional computed tomography in patients with COPD. WA and Ai were corrected by body surface area (BSA).
   Results: Forty-two clinically stable patients with COPD were enrolled. The median (range) mMRC dyspnea scale was 2 (0-3). The mMRC dyspnea scale score was significantly correlated with WA/BSA of fifth-and sixth-generation bronchi (Spearman correlation coefficient rho = 0.386, rho = 0.012;.= 0.484, rho = 0.001, respectively). Partial rank correlation analysis showed that the mMRC dyspnea scale score was significantly correlated with WA/BSA of sixth-generation bronchi, independent of the confounding factors of age, body mass index, % predicted forced expiratory volume in 1 s, % LAA, and Ai/BSA (rho=0.481, p=0.003). However, the % LAA and Ai/BSA were not correlated with this dyspnea scale.
   Conclusion: Bronchial WA assessed by three-dimensional computed tomography may be used as an assessment tool for dyspnea in patients with COPD.
C1 [Yasui, Hideki; Inui, Naoki; Karayama, Masato; Mori, Kazutaka; Hozumi, Hironao; Suzuki, Yuzo; Furuhashi, Kazuki; Enomoto, Noriyuki; Fujisawa, Tomoyuki; Nakamura, Yutaro; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Inui, Naoki; Watanabe, Hiroshi] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
RP Inui, N (reprint author), Hamamatsu Univ Sch Med, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
EM inui@hama-med.ac.jp
RI Suzuki, Yuzo/AAE-6747-2020
OI Suzuki, Yuzo/0000-0001-6154-9791; Furuhashi, Kazuki/0000-0003-4079-5509
CR Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Black PN, 2008, EUR RESPIR J, V31, P998, DOI 10.1183/09031936.00017207
   Boschetto P, 2006, THORAX, V61, P1037, DOI 10.1136/thx.2006.058321
   Lopez CC, 2018, AM J RESP CRIT CARE, V197, P463, DOI 10.1164/rccm.201707-1363OC
   Camiciottoli G, 2006, CHEST, V129, P558, DOI 10.1378/chest.129.3.558
   Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322
   Chan Hiang Ping, 2016, Int J Chron Obstruct Pulmon Dis, V11, P823, DOI 10.2147/COPD.S96790
   Chhabra SK, 2009, ANN THORAC MED, V4, P128, DOI 10.4103/1817-1737.53351
   COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303
   Ferrari K, 1997, LUNG, V175, P311, DOI 10.1007/PL00007577
   Grydeland TB, 2010, AM J RESP CRIT CARE, V181, P353, DOI 10.1164/rccm.200907-1008OC
   HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Hoshino M, 2013, RESPIRATION, V86, P280, DOI 10.1159/000351116
   Jones PW, 2013, EUR RESPIR J, V42, P647, DOI 10.1183/09031936.00125612
   Karayama M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41709
   Koo HK, 2018, LANCET RESP MED, V6, P591, DOI 10.1016/S2213-2600(18)30196-6
   Lange P, 2012, AM J RESP CRIT CARE, V186, P975, DOI 10.1164/rccm.201207-1299OC
   Lee YK, 2008, LUNG, V186, P157, DOI 10.1007/s00408-008-9071-0
   Lynch DA, 2014, CHRON OBSTR PULM DIS, V1, P73, DOI 10.15326/jcopdf.1.1.2014.0125
   MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751
   Martinez CH, 2012, THORAX, V67, P399, DOI 10.1136/thoraxjnl-2011-201185
   Matsunaga K, 2015, RESPIR INVESTIG, V53, P82, DOI 10.1016/j.resinv.2014.10.006
   McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955
   Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2
   Natori H, 2016, INTERNAL MED, V55, P15, DOI 10.2169/internalmedicine.55.4490
   Van Tho,, 2015, ANN AM THORAC SOC, V12, P988, DOI 10.1513/AnnalsATS.201411-501OC
   Nishimoto K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10504-w
   Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434
   O'Donnell Denis E, 2007, COPD, V4, P225, DOI 10.1080/15412550701480455
   Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4
   Perez T, 2015, INT J CHRONIC OBSTR, V10, P1663, DOI 10.2147/COPD.S82408
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Rock Laura K, 2007, Curr Opin Support Palliat Care, V1, P102, DOI 10.1097/SPC.0b013e3282ef5e74
   Van Brabandt H., 1983, J APPL PHYSL RESP EN, V55
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   YANAI M, 1992, J APPL PHYSIOL, V72, P1016
   Yasui H, 2013, PULM PHARMACOL THER, V26, P336, DOI 10.1016/j.pupt.2013.01.005
NR 39
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 76
EP 80
DI 10.1016/j.rmed.2018.11.020
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000012
PM 30665522
DA 2020-05-18
ER

PT J
AU Sakpal, SV
   Donahue, S
   Crespo, HS
   Auvenshine, C
   Agarwal, SK
   Nazir, J
   Santella, RN
   Steers, J
AF Sakpal, Sujit Vijay
   Donahue, Steven
   Crespo, Hector Saucedo
   Auvenshine, Christopher
   Agarwal, Suresh Kumar
   Nazir, Jawad
   Santella, Robert N.
   Steers, Jeffery
TI Utility of fiber-optic bronchoscopy in pulmonary infections among
   abdominal solid-organ transplant patients: A comprehensive review
SO RESPIRATORY MEDICINE
LA English
DT Review
DE Fiber-optic bronchoscopy; Abdominal solid-organ transplantation;
   Pulmonary infections
ID PNEUMOCYSTIS-CARINII-PNEUMONIA; BRONCHOALVEOLAR LAVAGE; FLEXIBLE
   BRONCHOSCOPY; RECIPIENTS; TUBERCULOSIS; DIAGNOSIS; SAFETY; EXPERIENCE;
   BIOPSY
AB Pulmonary infections are frequent complications in abdominal solid-organ transplantation (aSOT) which may threaten patient and allograft survival. Accurate diagnosis and treatment of pulmonary infections in this population can be challenging. Immunosuppressive therapy not only increases the risk of acquiring opportunistic and non-opportunistic infections, but it also impairs the inflammatory responses associated with microbial invasion which in an otherwise normal host produce clinical and radiologic responses that allow for early identification of the offending pathogen. Serologic testing is not a reliable diagnostic modality. Direct microbiological sampling is often necessary to make a definitive diagnosis early in the clinical course to optimize timely, targeted therapy while reducing the risk of developing antimicrobial resistance, and minimize adverse effects of therapy, if any. Fiber-optic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) or transbronchial lung biopsy (TBB) offers such diagnostic advantage and possesses a potential therapeutic value too. This comprehensive review discusses the potential benefits of FOB alongside its risks and complications, indications and contraindications, and techniques. Additionally, the essay highlights FOB's utility and yield specifically with regard to type and timing of infections in aSOT patients.
C1 [Sakpal, Sujit Vijay; Crespo, Hector Saucedo; Auvenshine, Christopher; Nazir, Jawad; Santella, Robert N.; Steers, Jeffery] Avera McKennan Hosp, Sioux Falls, SD USA.
   [Sakpal, Sujit Vijay; Crespo, Hector Saucedo; Auvenshine, Christopher; Nazir, Jawad; Santella, Robert N.; Steers, Jeffery] Univ Hlth Ctr, Avera Med Grp Transplant & Liver Surg, Sioux Falls, SD USA.
   [Sakpal, Sujit Vijay; Donahue, Steven; Crespo, Hector Saucedo; Auvenshine, Christopher] Univ South Dakota, Sanford Sch Med, Dept Surg, Sioux Falls, SD USA.
   [Sakpal, Sujit Vijay] Univ South Dakota, Sanford Sch Med, Dept Internal Med, Sioux Falls, SD USA.
   [Agarwal, Suresh Kumar] Duke Univ, Dept Surg, Div Acute Care, Surg Crit Care,Trauma, Durham, NC USA.
RP Sakpal, SV (reprint author), Plaza 3-1315 S Cliff Ave,Suite 1100, Sioux Falls, SD 57105 USA.
EM Sujit.Sakpal@avera.org
RI Sakpal, Sujit/M-1797-2019
OI Sakpal, Sujit/0000-0002-1752-4105
CR Barcan Laura A, 2002, Transpl Infect Dis, V4, P93, DOI 10.1034/j.1399-3062.2002.t01-1-00006.x
   Benito N, 2015, CLIN MICROBIOL INFEC, V21, P651, DOI 10.1016/j.cmi.2015.03.010
   Chang GC, 2004, CHEST, V125, P541, DOI 10.1378/chest.125.2.541
   Diaz-Fuentes G, 2016, RESPIRATION, V92, P182, DOI 10.1159/000448848
   Dunagan DP, 1998, CHEST, V114, P1660, DOI 10.1378/chest.114.6.1660
   Ernst A, 2006, CHEST, V129, P734, DOI 10.1378/chest.129.3.734
   Facciolongo N, 2009, Monaldi Arch Chest Dis, V71, P8
   Garcia-Goez JF, 2009, TRANSPL P, V41, P2268, DOI 10.1016/j.transproceed.2009.06.080
   Gordon SM, 1999, CLIN INFECT DIS, V28, P240, DOI 10.1086/515126
   Harris Bianca, 2013, Ann Am Thorac Soc, V10, P39, DOI 10.1513/AnnalsATS.201212-114FR
   Hasegawa S, 1996, SURGERY, V119, P198, DOI 10.1016/S0039-6060(96)80169-3
   HEDEMARK LL, 1982, AM REV RESPIR DIS, V126, P981
   Hilbert G, 2001, CRIT CARE MED, V29, P249, DOI 10.1097/00003246-200102000-00004
   IKEDA S, 1968, Keio Journal of Medicine, V17, P1
   Joos L, 2007, RESP MED, V101, P93, DOI 10.1016/j.rmed.2006.04.006
   Kupeli E, 2011, TRANSPL P, V43, P543, DOI 10.1016/j.transproceed.2011.01.015
   Li JYZ, 2009, CLIN EXP NEPHROL, V13, P92, DOI 10.1007/s10157-008-0079-9
   Lindholm C E, 1974, Crit Care Med, V2, P250, DOI 10.1097/00003246-197409000-00004
   Mehta NL, 2005, J BRONCHOL INTERN PU, V12, P81, DOI 10.1097/01.laboratory.0000154043.28615.01
   Nandagopal L, 2016, TRANSFUSION, V56, P344, DOI 10.1111/trf.13348
   Nusair S, 1999, RESP MED, V93, P621, DOI 10.1016/S0954-6111(99)90101-4
   Ozen Z. E., 2013, TRANSPLANT P, V45
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993
   Starobin D, 2003, TRANSPLANT P, V35, P659, DOI 10.1016/S0041-1345(03)00026-5
   STERNBERG RI, 1993, AM J MED, V95, P358, DOI 10.1016/0002-9343(93)90303-7
   Tepeoglu M, 2015, EXP CLIN TRANSPLANT, V13, P331, DOI 10.6002/ect.mesot2014.P179
   Wahidi MM, 2005, RESPIRATION, V72, P285, DOI 10.1159/000085370
   WILLCOX PA, 1990, RESP MED, V84, P297, DOI 10.1016/S0954-6111(08)80057-1
NR 28
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 81
EP 86
DI 10.1016/j.rmed.2018.12.002
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000013
PM 30665523
DA 2020-05-18
ER

PT J
AU Reijnders, T
   Schuler, M
   Wittmann, M
   Jelusic, D
   Troosters, T
   Janssens, W
   Stenzel, NM
   Schultz, K
   von Leupoldt, A
AF Reijnders, Thomas
   Schuler, Michael
   Wittmann, Michael
   Jelusic, Danijel
   Troosters, Thierry
   Janssens, Wim
   Stenzel, Nikola M.
   Schultz, Konrad
   von Leupoldt, Andreas
TI The impact of disease-specific fears on outcome measures of pulmonary
   rehabilitation in patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE COPD; Pulmonary rehabilitation; Disease-specific fears; Anxiety;
   Functional capacity; Quality of life
ID QUALITY-OF-LIFE; LOW-BACK-PAIN; PHYSICAL-ACTIVITY; SELF-MANAGEMENT;
   HEALTH SURVEY; ANXIETY; DEPRESSION; DYSPNEA; SF-36; ASSOCIATION
AB Anxiety is a highly prevalent psychological comorbidity in patients with chronic obstructive pulmonary disease (COPD) and has detrimental effects on pulmonary rehabilitation (PR) outcomes. It has been suggested that disease-specific fears could play an even more important role in COPD patients' disease progression. However, little is known about how different disease-specific fears impact COPD. This study examined how different disease-specific fears relate to different PR outcome measures in COPD patients and how these relationships evolve over the course of PR. Before and after a 3-week inpatient PR program, COPD patients (N = 104) underwent a 6-min walking test to measure functional exercise capacity. Disease-specific fears (fear of physical activity, fear of dyspnea, fear of disease progression, fear of social exclusion) were assessed with the COPD-Anxiety-Questionnaire-Revised. Health-related quality of life (HQoL), COPD health status, dyspnea in daily life, depression, and anxiety were measured using validated questionnaires. Multiple regression showed that greater disease-specific fears at the start of PR were associated with worse functional exercise capacity, HQoL, health status, and depression at the start and end of PR (controlling for age, sex, lung function, smoking status, and general anxiety). Patients who showed a stronger decrease in disease-specific fears improved more in PR outcome measures over the course of PR. Furthermore, different disease-specific fears were related to different PR outcome measures. The results show that disease-specific fears are associated with treatment outcome measures, both cross-sectionally and prospectively. Therefore, disease-specific fears should be addressed in COPD patients as they might play a significant role in disease progression.
C1 [Reijnders, Thomas; von Leupoldt, Andreas] Univ Leuven, Hlth Psychol, Tiensestr 102, B-3000 Louvain, Belgium.
   [Schuler, Michael] Univ Wurzburg, Inst Psychotherapy & Med Psychol, Wurzburg, Germany.
   [Wittmann, Michael; Jelusic, Danijel; Schultz, Konrad] Clin Bad Reichenhall, Ctr Rehabil Pneumol & Orthoped, Bad Reichenhall, Germany.
   [Troosters, Thierry] Univ Leuven, Cardiovasc & Resp Rehabil, Leuven, Belgium.
   [Janssens, Wim] Univ Leuven, Pneumol, Leuven, Belgium.
   [Stenzel, Nikola M.] Berlin Psychol Univ, Clin Psychol & Psychotherapy, Berlin, Germany.
RP Reijnders, T (reprint author), Univ Leuven, Hlth Psychol, Tiensestr 102, B-3000 Louvain, Belgium.
EM thomas.reijnders@kuleuven.be
OI Reijnders, Thomas/0000-0002-2184-8727; Schuler,
   Michael/0000-0001-6502-9232
FU Research Fund KU Leuven, BelgiumKU Leuven [STRT/13/002];
   Herculesstichting, Belgium [AKUL/13/07]; "Asthenes'' long-term
   structural funding Methusalem grant by the Flemish Government, Belgium
   [METH/15/011]; Deutsche Rentenversicherung, Germany [DRKS00004609]
FX This work was supported by a research grant from the Research Fund KU
   Leuven, Belgium (STRT/13/002), by an infrastructure grant from the
   Herculesstichting, Belgium (AKUL/13/07), and by the "Asthenes''
   long-term structural funding Methusalem grant (METH/15/011) by the
   Flemish Government, Belgium. The main RIMTCORE trial (DRKS00004609) was
   funded by the Deutsche Rentenversicherung, Germany. The funders had no
   role in the design of the study, the collection and analysis of data, or
   the preparation of the manuscript.
CR Alonso J, 1998, J CLIN EPIDEMIOL, V51, P1087, DOI 10.1016/S0895-4356(98)00100-0
   Asenlof P, 2010, CLIN REHABIL, V24, P422, DOI 10.1177/0269215509353264
   Atlantis E, 2013, CHEST, V144, P766, DOI 10.1378/chest.12-1911
   Bailey PH, 2004, QUAL HEALTH RES, V14, P760, DOI 10.1177/1049732304265973
   Barnett M, 2005, J CLIN NURS, V14, P805, DOI 10.1111/j.1365-2702.2005.01125.x
   Bellizzi KM, 2008, UROLOGY, V72, P1269, DOI 10.1016/j.urology.2007.12.084
   Bentsen SB, 2010, PATIENT EDUC COUNS, V81, P5, DOI 10.1016/j.pec.2009.11.019
   Benzo RP, 2016, PATIENT EDUC COUNS, V99, P617, DOI 10.1016/j.pec.2015.10.031
   CARRIERIKOHLMAN V, 1993, HEART LUNG, V22, P226
   Coventry PA, 2007, J PSYCHOSOM RES, V63, P551, DOI 10.1016/j.jpsychores.2007.08.002
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Davis AHT, 2006, J PAIN SYMPTOM MANAG, V32, P60, DOI 10.1016/j.jpainsymman.2006.01.012
   Elofsson LC, 2004, PALLIATIVE MED, V18, P611, DOI 10.1191/0269216304pm922oa
   Fischer MJ, 2012, INT J BEHAV MED, V19, P39, DOI 10.1007/s12529-010-9130-9
   Geidl W, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2124-z
   Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7
   Guell R, 2006, CHEST, V129, P899, DOI 10.1378/chest.129.4.899
   Halding AG, 2010, DISABIL REHABIL, V32, P1272, DOI 10.3109/09638280903464471
   Herschbach P, 2010, SUPPORT CARE CANCER, V18, P471, DOI 10.1007/s00520-009-0696-1
   Hu J, 2005, HEART LUNG, V34, P415, DOI 10.1016/j.hrtlng.2005.03.008
   Hutchinson A, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01477-2017
   Irvine EJ, 2004, ALIMENT PHARM THER, V20, P54, DOI 10.1111/j.1365-2036.2004.02053.x
   Janssens T, 2011, CHEST, V140, P618, DOI 10.1378/chest.10-3257
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Jones PW, 2012, CHEST, V142, P134, DOI 10.1378/chest.11-0309
   Keil DC, 2014, CHRON RESP DIS, V11, P31, DOI 10.1177/1479972313516881
   Kocks JWH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-62
   Koho P, 2011, J REHABIL MED, V43, P794, DOI 10.2340/16501977-0850
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Leeuw M, 2008, PAIN, V138, P192, DOI 10.1016/j.pain.2007.12.009
   Livermore N, 2015, RESP PHYSIOL NEUROBI, V216, P35, DOI 10.1016/j.resp.2015.05.013
   Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006
   Macedo LG, 2010, PHYS THER, V90, P860, DOI 10.2522/ptj.20090303
   Maurer J, 2008, CHEST, V134, p43S, DOI 10.1378/chest.08-0342
   McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Monninkhof E, 2003, THORAX, V58, P394, DOI 10.1136/thorax.58.5.394
   Myers SB, 2013, GYNECOL ONCOL, V128, P120, DOI 10.1016/j.ygyno.2012.10.014
   N. I. C. IBM Corp, 2005, IBM SPSS STAT MAC
   Pitta F, 2006, EUR RESPIR J, V27, P1040, DOI 10.1183/09031936.06.00064105
   Puhan MA, 2011, EUR RESPIR J, V37, P784, DOI 10.1183/09031936.00063810
   Puhan MA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005305.pub4
   Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418
   Schuler M, 2018, J AFFECT DISORDERS, V232, P268, DOI 10.1016/j.jad.2018.02.037
   Schultz K., EUR RESP J INSPIRATO
   Seamark DA, 2004, PALLIATIVE MED, V18, P619, DOI 10.1191/0269216304pm928oa
   Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700
   Solomon BK, 2015, J PSYCHOSOM RES, V79, P62, DOI 10.1016/j.jpsychores.2014.11.020
   Spathis A, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0024-z
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Stenzel N, 2012, Pneumologie, V66, P111, DOI 10.1055/s-0031-1291637
   Stenzel NM, 2015, PSYCHOL HEALTH, V30, P1017, DOI 10.1080/08870446.2015.1014816
   Swigris JJ, 2010, RESP MED, V104, P296, DOI 10.1016/j.rmed.2009.09.006
   Thomas M, 2013, PRIM CARE RESP J, V22, P101, DOI 10.4104/pcrj.2013.00025
   Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1
   Vanfleteren LEGW, 2013, AM J RESP CRIT CARE, V187, P728, DOI 10.1164/rccm.201209-1665OC
   Vlaeyen JWS, 2002, CLIN J PAIN, V18, P251, DOI 10.1097/00002508-200207000-00006
   von Leupoldt A, 2007, RESP MED, V101, P411, DOI 10.1016/j.rmed.2006.06.011
   von Leupoldt A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01352-2017
   von Leupoldt A, 2016, EXPERT REV RESP MED, V10, P835, DOI 10.1080/17476348.2016.1198697
   von Leupoldt A, 2013, CURR OPIN PSYCHIATR, V26, P458, DOI 10.1097/YCO.0b013e328363c1fc
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Willgoss TG, 2013, RESP CARE, V58, P858, DOI 10.4187/respcare.01862
   Woby SR, 2004, EUR J PAIN, V8, P201, DOI 10.1016/j.ejpain.2003.08.002
   Yohannes AM, 2014, EUR RESPIR REV, V23, P345, DOI 10.1183/09059180.00007813
   Zoeckler N, 2014, J PSYCHOSOM RES, V76, P146, DOI 10.1016/j.jpsychores.2013.11.021
NR 67
TC 5
Z9 5
U1 4
U2 11
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 87
EP 95
DI 10.1016/j.rmed.2018.12.004
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000014
PM 30665524
DA 2020-05-18
ER

PT J
AU Diez, SC
   Casas, AV
   Rivero, JLG
   Caro, JCL
   Portal, FO
   Saez, GD
AF Conde Diez, Susana
   Viejo Casas, Ana
   Garcia Rivero, Juan Luis
   Lopez Caro, Juan Carlos
   Ortiz Portal, Felix
   Diaz Saez, Gualberto
TI Impact of a homeopathic medication on upper respiratory tract infections
   in COPD patients: Results of an observational, prospective study
   (EPOXILO)
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease; Exacerbation; Homeopathy;
   Influenza like illness; Upper respiratory tract infections;
   Oscillococcinum (R); Observational study
ID OBSTRUCTIVE PULMONARY-DISEASE; INFLUENZA VACCINATION; ACUTE
   EXACERBATIONS; CHRONIC-BRONCHITIS; RISK-FACTORS; PREVALENCE;
   DETERMINANTS; DYSPNEA; HEALTH; INDEX
AB Background: Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder in which airflow is obstructed. Viral or bacterial upper respiratory tract infections (URTIs) may lead to exacerbations. Homeopathic medication administration to COPD patients during the influenza-exposure period may help to reduce the frequency of common URTIs.
   Methods: This prospective, observational, multicenter study was carried out in Cantabria, Spain. Patients with COPD were divided into two groups: group 1 received conventional treatment + homeopathic medication (diluted and dynamized extract of duck liver and heart; Boiron) (OG); group 2 received conventional treatment only (CG). The primary endpoint was the number of URTIs between the 4-5 months follow up (mean 4.72 +/- 0.96) from basal to last visit. Secondary endpoints included the duration of URTIs, number and duration of COPD exacerbations, use of COPD drugs, changes in quality of life (QoL), compliance, and adverse events (AEs).
   Results: 219 patients were analyzed (OG = 109, CG = 110). There was a significant reduction in mean number of URTIs during the follow-up period in OG compared to CG (0.514 +/- 0.722 vs. 1.037 +/- 1.519, respectively; p = 0.014). Logistic regression analysis showed a 3.3-times higher probability of suffering = 2 URTI episodes in CG (p = 0.003, n = 72). OG patients having >= 1 URTI also had a significant reduction in mean URTI duration per episode (3.57 +/- 2.44 days OG vs. 5.22 +/- 4.17 days CG; p = 0.012). There was no significant difference in mean number of exacerbations, mean duration of exacerbations, or QoL between OG and CG. There was a greater decrease in proportion of patients using corticosteroids for exacerbations between baseline and visit 2 in OG compared to CG (22.1% vs. 7.5% fewer respectively, p = 0.005). Exacerbator phenotype patients had a significant decrease in number of URTIs (0.54 +/- 0.72 vs. 1.31 +/- 1.81; p = 0.011), and fewer COPD exacerbations (0.9 +/- 1.3 vs. 1.5 +/- 1.7; p = 0.037) in OG vs. CG, respectively.
   Conclusions: Homeopathic medication use during the influenza-exposure period may have a beneficial impact at reducing URTIs' number and duration in COPD patients and at reducing the number of COPD exacerbations in patients with the exacerbator phenotype. Further studies are needed to confirm the effects observed in this study.
C1 [Conde Diez, Susana] Ctr Salud Jose Barros Camargo, Avda Bilbao S-N Muriedas, Cantabria 39600, Spain.
   [Viejo Casas, Ana] Ctr Salud Pisuena Cayon, C El Ferial S-N, Saron 39620, Cantabria, Spain.
   [Garcia Rivero, Juan Luis] Hosp Laredo, Serv Neumol, Cantabria, Spain.
   [Lopez Caro, Juan Carlos] Ctr Salud Cotolino, C San Andres S-N Castro Urdiales, Cantabria 39700, Spain.
   [Ortiz Portal, Felix] Hosp Univ Marques Valdecilla, Santander, Spain.
   [Diaz Saez, Gualberto] BOIRON SIH, Former Med Director, Madrid, Spain.
   [Diaz Saez, Gualberto] CEDH, Alcobendas, Spain.
RP Diez, SC (reprint author), Ctr Salud Jose Barros Camargo, Avda Bilbao S-N Muriedas, Cantabria 39600, Spain.
EM sue_santander@yahoo.es; afvcasas@gmail.com; jgarcianml@gmail.com;
   jcarloslopezcaro@hotmail.com; ortizportal@gmail.com; diazgual@yahoo.es
RI Diaz-Saez, Gualberto/I-7294-2017
OI Diaz-Saez, Gualberto/0000-0001-9792-3060
CR Agusti A, 2014, CHRON OBSTR PULM DIS, V1, P166, DOI 10.15326/jcopdf.1.2.2014.0134
   Akturk UA, 2017, BALK MED J, V34, P206, DOI 10.4274/balkanmedj.2016.1028
   Ancochea J, 2009, ARCH BRONCONEUMOL, V45, P41, DOI 10.1016/j.arbres.2008.06.001
   Ancochea J, 2013, ARCH BRONCONEUMOL, V49, P223, DOI 10.1016/j.arbres.2012.11.010
   Beghi GM, 2016, MULTIDISCIP RESP MED, V11, DOI 10.1186/s40248-016-0049-0
   Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Burge S, 2003, EUR RESPIR J, V41, P46, DOI DOI 10.1183/09031936.03.00078002
   Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322
   Chiatti C, 2011, HUM VACCINES, V7, P1021, DOI 10.4161/hv.7.10.16849
   Ciblak MA, 2013, VACCINE, V31, P518, DOI 10.1016/j.vaccine.2012.11.022
   Cimen P, 2015, RESP CARE, V60, P239, DOI 10.4187/respcare.03350
   Department of Health and Human Services Centers for Disease Control and Prevention National Immunization Program Advisory Committee on Immunization Practices, P ATL GA 29 30 JUN
   Diaz Saez G., 2016, SEMERGEN, V42, P1
   Diaz-Guzman E, 2014, CLIN CHEST MED, V35, P7, DOI 10.1016/j.ccm.2013.10.002
   Donaldson GC, 2003, EUR RESPIR J, V22, P931, DOI 10.1183/09031936.03.00038303
   Dransfield MT, 2017, AM J RESP CRIT CARE, V195, P324, DOI 10.1164/rccm.201605-1014OC
   FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x
   Garcia-Olmos L, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-11
   Garrastazu R, 2016, ARCH BRONCONEUMOL, V52, P88, DOI 10.1016/j.arbres.2015.09.001
   GdSD, 2012, ARCH BRONCONEUMOL S, V48, P2
   Global initiative for chronic obstructive lung disease, POCK GUID COPD DIAGN
   Grimaldi-Bensouda L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089990
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Jones PW, 2011, EUR RESPIR J, V38, P29, DOI 10.1183/09031936.00177210
   Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
   Soler-Cataluna JJ, 2009, RESP MED, V103, P692, DOI 10.1016/j.rmed.2008.12.005
   Leong P, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0646-2
   Mackay AJ, 2012, MED CLIN N AM, V96, P789, DOI 10.1016/j.mcna.2012.02.008
   Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC
   Mathie RT, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001957.pub6
   Miravitlles M, 2003, CHEST, V123, P784, DOI 10.1378/chest.123.3.784
   Miravitlles M, 2017, ARCH BRONCONEUMOL, V53, P89, DOI 10.1016/j.arbres.2017.01.001
   Miravitlles M, 2014, ARCH BRONCONEUMOL, V50, P1, DOI 10.1016/S0300-2896(14)70070-5
   Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC
   PAPP R, 1998, BR HOM J, V87, P69
   Parasuramalu B G, 2014, Indian J Public Health, V58, P45, DOI 10.4103/0019-557X.128166
   Pasquale MK, 2012, INT J CHRONIC OBSTR, V7, P757, DOI 10.2147/COPD.S36997
   Plans-Rubio Pedro, 2007, Int J Chron Obstruct Pulmon Dis, V2, P41, DOI 10.2147/copd.2007.2.1.41
   Raherison C, 2009, EUR RESPIR REV, V18, P213, DOI 10.1183/09059180.00003609
   Rubio MC, 2017, INT J CHRONIC OBSTR, V12, P2373, DOI 10.2147/COPD.S137872
   Salvi S, 2014, CLIN CHEST MED, V35, P17, DOI 10.1016/j.ccm.2013.09.011
   Santibanez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158727
   Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Stockley RA, 2000, CHEST, V117, P1638, DOI 10.1378/chest.117.6.1638
   Thomashow BM, 2014, CHRON OBSTR PULM DIS, V1, P4, DOI 10.15326/jcopdf.1.1.2014.0122
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Vickers A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001957.pub4
   Viejo Banuelos J L, 2004, Arch Bronconeumol, V40 Suppl 6, P3, DOI 10.1157/13077906
   Wedzicha JA, 2014, CLIN CHEST MED, V35, P157, DOI 10.1016/j.ccm.2013.11.001
NR 50
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 96
EP 105
DI 10.1016/j.rmed.2018.11.011
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000015
PM 30665525
DA 2020-05-18
ER

PT J
AU Alsumrain, M
   De Giacomi, F
   Nasim, F
   Koo, CW
   Bartholmai, BJ
   Levin, DL
   Moua, T
AF Alsumrain, Mohammad
   De Giacomi, Federica
   Nasim, Faria
   Koo, Chi Wan
   Bartholmai, Brian J.
   Levin, David L.
   Moua, Teng
TI Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity:
   Characterization of presenting lung fibrosis and implications for
   survival
SO RESPIRATORY MEDICINE
LA English
DT Article
DE CPFE; Combined pulmonary fibrosis and emphysema; Survival
ID CHRONIC HYPERSENSITIVITY PNEUMONITIS; NONSPECIFIC INTERSTITIAL
   PNEUMONIA; CLINICAL CHARACTERISTICS; FEATURES; OUTCOMES
AB Background: The prevalence of classifiable and unclassifiable causes of lung fibrosis and its implications for survival are mostly unknown in combined pulmonary fibrosis and emphysema (CPFE).
   Materials and methods: Patients with > 10% involvement of both emphysema and lung fibrosis seen over 11 years at our institution were reviewed independently by expert radiologists for fibrotic and emphysematous findings and overall fibrotic CT pattern. Underlying interstitial lung disease (ILD) diagnoses and baseline demographic and clinical characteristics were collated and assessed for predictors of comparative survival.
   Results: In this retrospective cohort, 179 CPFE patients were identified and categorized as 58 usual interstitial pneumonia/idiopathic pulmonary fibrosis (UIP/IPF) (32%), 42 secondary ILD (23%), and 79 unclassifiable ILD (44%). The most prevalent (47%) radiologic pattern was 'unclassifiable', followed by 'consistent' and 'possible' UIP pattern in 38%. Adjusted predictors of mortality for the cohort as a whole included age (HR 1.03[1.01-1.06], P = 0.002), percent predicted diffusing capacity for carbon monoxide (unit HR 0.97 [0.96-0.99], P = 0.001), honeycombing (HR 1.58 [1.02-2.43], P = 0.04), and right ventricular dysfunction (HR 2.28 [1.39-3.97], P = 0.002). Survival was similar between CPFE with secondary ILD and CPFE with UIP/IPF, while CPFE with unclassifiable ILD had better comparative survival (Log rank = 0.026).
   Conclusions: Our findings suggest only about a third of CPFE patients represent suspected UIP/IPF; the majority were clinically and radiologically unclassifiable ILD whose survival was comparatively better. Identifiable or secondary causes of lung fibrosis in CPFE occurred in about a fifth of presenting patients.
C1 [Alsumrain, Mohammad; De Giacomi, Federica; Nasim, Faria; Moua, Teng] Mayo Clin, Div Pulm & Crit Care Med, 200 First St SW, Rochester, MN 55905 USA.
   [De Giacomi, Federica] Univ Milano Bicocca, ASST Monza, San Gerardo Hosp, Dipartimento Cardiotoracovasc, Resp Unit Via Pergolesi, Monza, IT, Italy.
   [Koo, Chi Wan; Bartholmai, Brian J.; Levin, David L.] Mayo Clin, Dept Radiol, Rochester, MN USA.
RP Moua, T (reprint author), Mayo Clin, Div Pulm & Crit Care Med, 200 First St SW, Rochester, MN 55905 USA.
EM alsumrain@yahoo.com; i.fede@live.it; nasim.faria@mayo.edu;
   koo.chiwan@mayo.edu; bartholmai.brian@mayo.edu; levin.david@mayo.edu;
   moua.teng@mayo.edu
RI Moua, Teng/AAG-7445-2019
CR Chae KJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162231
   Chae KJ, 2015, EUR RADIOL, V25, P2326, DOI 10.1007/s00330-015-3617-3
   Cottin V, 2005, EUR RESPIR J, V26, P586, DOI 10.1183/09031936.05.00021005
   Cottin V, 2011, ARTHRITIS RHEUM-US, V63, P295, DOI 10.1002/art.30077
   Gocho K, 2015, RESPIR MED CASE REP, V15, P128, DOI 10.1016/j.rmcr.2015.02.004
   Katzenstein ALA, 2013, J CLIN PATHOL, V66, P882, DOI 10.1136/jclinpath-2012-201338
   Kim YJ, 2014, TUBERC RESPIR DIS, V77, P18, DOI 10.4046/trd.2014.77.1.18
   Kishaba T, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000988
   Kitaguchi Y, 2014, INT J CHRONIC OBSTR, V9, P805, DOI 10.2147/COPD.S65621
   Kitaguchi Y, 2013, RESP MED, V107, P1986, DOI 10.1016/j.rmed.2013.06.015
   Mejia M, 2009, CHEST, V136, P10, DOI 10.1378/chest.08-2306
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Ryerson CJ, 2013, CHEST, V144, P234, DOI 10.1378/chest.12-2403
   Sahin H, 2007, RADIOLOGY, V244, P591, DOI 10.1148/radiol.2442060640
   Schmidt SL, 2011, EUR RESPIR J, V38, P176, DOI 10.1183/09031936.00114010
   Silva CIS, 2008, RADIOLOGY, V246, P288, DOI 10.1148/radiol.2453061881
   Soumagne T., 2015, BMJ CASE REP, V2015
   Sugino K, 2015, SARCOIDOSIS VASC DIF, V32, P129
   Sugino K, 2014, RESPIROLOGY, V19, P239, DOI 10.1111/resp.12207
   Travis WD, 2008, AM J RESP CRIT CARE, V177, P1338, DOI 10.1164/rccm.200611-1685OC
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Tzouvelekis A, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-31
   Tzouvelekis A, 2012, EUR RESPIR J, V40, P505, DOI 10.1183/09031936.00216311
   Wendling D, 2013, JOINT BONE SPINE, V80, P670, DOI 10.1016/j.jbspin.2013.03.009
   WIGGINS J, 1990, RESP MED, V84, P365, DOI 10.1016/S0954-6111(08)80070-4
   Zhang LJ, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0300-7
NR 26
TC 4
Z9 4
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 106
EP 112
DI 10.1016/j.rmed.2018.12.003
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000016
PM 30665507
DA 2020-05-18
ER

PT J
AU Oostveen, E
   Derom, E
   Vints, AM
   Liistro, G
AF Oostveen, Ellie
   Derom, Eric
   Vints, Anne-Marie
   Liistro, Giuseppe
TI Comparison of ERS'93 to the newly published GLI'17 reference values for
   carbon monoxide transfer factor
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Carbon monoxide transfer factor; Pulmonary function tests; Reference
   values
ID SPIROMETRY
AB Background: The new predicted values for the carbon monoxide transfer factor (TL, CO) for Caucasians by the Global Lung Function Initiative are available since September 2017. Several authors have previously shown that the predicted values of Cotes et al. (ERS'93), overestimated TL, CO. However, the GLI'17 authors omitted to compare their predicted values with the ERS'93 equations, still in use throughout Europe.
   We present the differences between the two sets of predicted values, and in an attempt to improve the readability, used the contour plots instead of the classical 2-dimensional representations.
   Methods: Predicted values were computed for males and females for ages between 18 and 70 years and heights between 155 and 180 cm using Matlab software with increments of one unit (1 yr, 1 cm).
   Results: We demonstrate that GLI-'17 predicted values of TL, CO are systematically lower than those of ERS-'93, but also that the magnitude of the differences varies according to age, height and sex. More specifically, differences increase in both males and females by decreasing age and height, reaching up to 16% in males and 24% in females.
   Conclusion: The predicted values of TL, CO by Cotes at al. are systematically larger than the new GLI' 17 values. Plotting all the possible differences between predicted variables using contour graphs allows to identify the groups of subjects in whom significant changes in their predicted values will occur. Our findings should prompt physicians to investigate how switching to GLI-17 equations affects the clinical interpretation of TL, CO measurements in a real-live setting.
C1 [Oostveen, Ellie; Vints, Anne-Marie] Antwerp Univ Hosp, Dept Resp Med, Antwerp, Belgium.
   [Oostveen, Ellie; Vints, Anne-Marie] Univ Antwerp, Antwerp, Belgium.
   [Derom, Eric] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.
   [Liistro, Giuseppe] UCL, Inst Expt & Clin Res, Pole Pneumol ENT & Dermatol, Brussels, Belgium.
   [Liistro, Giuseppe] Clin Univ St Luc, Dept Pneumol, Brussels, Belgium.
RP Liistro, G (reprint author), Univ St Luc, 10 Ave Hippocrate, B-1200 Brussels, Belgium.
EM giuseppe.liistro@uclouvain.be
CR COTES JE, 1993, EUR RESPIR J, V6, P41, DOI 10.1183/09041950.041s1693
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693
   Quanjer PH, 2013, EUR RESPIR J, V42, P1046, DOI 10.1183/09031936.00195512
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354
   Soumagne T, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00528-2018
   Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC
   Stanojevic S, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00010-2017
NR 9
TC 0
Z9 0
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 113
EP 115
DI 10.1016/j.rmed.2018.12.005
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000017
PM 30665508
DA 2020-05-18
ER

PT J
AU Carsin, AE
   Fuertes, E
   Schaffner, E
   Jarvis, D
   Anto, JM
   Heinrich, J
   Bellisario, V
   Svanes, C
   Keidel, D
   Imboden, M
   Weyler, J
   Nowak, D
   Martinez-Moratalla, J
   Gullon, JA
   Ramos, JLS
   Caviezel, S
   Beckmeyer-Borowko, A
   Raherison, C
   Pin, I
   Demoly, P
   Cerveri, I
   Accordini, S
   Gislason, T
   Toren, K
   Forsberg, B
   Janson, C
   Jogia, R
   Emtner, M
   Real, FG
   Raza, W
   Leynaert, B
   Pascual, S
   Guerra, S
   Dharmage, SC
   Probst-Hensch, N
   Garcia-Aymerich, J
AF Carsin, Anne-Elie
   Fuertes, Elaine
   Schaffner, Emmanuel
   Jarvis, Debbie
   Anto, Josep M.
   Heinrich, Joachim
   Bellisario, Valeria
   Svanes, Cecilie
   Keidel, Dirk
   Imboden, Medea
   Weyler, Joost
   Nowak, Dennis
   Martinez-Moratalla, Jesus
   Gullon, Jose-Antonio
   Sanchez Ramos, Jose Luis
   Caviezel, Seraina
   Beckmeyer-Borowko, Anna
   Raherison, Chantal
   Pin, Isabelle
   Demoly, Pascal
   Cerveri, Isa
   Accordini, Simone
   Gislason, Thorarinn
   Toren, Kjell
   Forsberg, Bertil
   Janson, Christer
   Jogia, Rain
   Emtner, Margareta
   Gomez Real, Francisco
   Raza, Wasif
   Leynaert, Benedicte
   Pascual, Silvia
   Guerra, Stefano
   Dharmage, Shyamali C.
   Probst-Hensch, Nicole
   Garcia-Aymerich, Judith
TI Restrictive spirometry pattern is associated with low physical activity
   levels. A population based international study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Restrictive spirometry pattern; Body mass index; Epidemiology; Lung
   function; Physical activity
ID LUNG-FUNCTION; ACTIVITY QUESTIONNAIRE; NATIONAL-HEALTH; MORTALITY;
   DISEASE; IMPAIRMENT; DISORDER; EVENTS; RISK
AB Introduction: Restrictive spirometry pattern is an under-recognised disorder with a poor morbidity and mortality prognosis. We compared physical activity levels between adults with a restrictive spirometry pattern and with normal spirometry.
   Methods: Restrictive spirometry pattern was defined as a having post-bronchodilator FEV1/FVC >= Lower Limit of Normal and a FVC< 80% predicted in two population-based studies (ECRHS-III and SAPALDIA3). Physical activity was measured using the International Physical Activity Questionnaire. The odds of having low physical activity (< 1st study-specific tertile) was evaluated using adjusted logistic regression models.
   Results: Subjects with a restrictive spirometry pattern (n = 280/4721 in ECRHS, n = 143/3570 in SAPALDIA) reported lower levels of physical activity than those with normal spirometry (median of 1770 vs 2253 MET.min/week in ECRHS, and 3519 vs 3945 MET.min/week in SAPALDIA). Subjects with a restrictive spirometry pattern were more likely to report low physical activity (meta-analysis odds ratio: 1.41 [95% CI 1.07-1.86]) than those with a normal spirometry. Obesity, respiratory symptoms, co-morbidities and previous physical activity levels did not fully explain this finding.
   Conclusion: Adults with a restrictive spirometry pattern were more likely to report low levels of physical activity than those with normal spirometry. These results highlight the need to identify and act on this understudied but prevalent condition.
C1 [Carsin, Anne-Elie; Fuertes, Elaine; Anto, Josep M.; Guerra, Stefano; Garcia-Aymerich, Judith] ISGlobal, Barcelona, Spain.
   [Carsin, Anne-Elie; Fuertes, Elaine; Anto, Josep M.; Garcia-Aymerich, Judith] Univ Pompeu Fabra, Barcelona, Spain.
   [Carsin, Anne-Elie; Fuertes, Elaine; Anto, Josep M.; Garcia-Aymerich, Judith] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain.
   [Carsin, Anne-Elie; Anto, Josep M.] IMIM Hosp Mar Med Res Inst, Barcelona, Spain.
   [Jarvis, Debbie] Imperial Coll London, MRC PHE Ctr Environm & Hlth, London, England.
   [Jarvis, Debbie] Imperial Coll London, Natl Heart & Lung Inst, Populat Hlth & Occupat Dis, London, England.
   [Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany.
   [Heinrich, Joachim; Nowak, Dennis] Ludwig Maximilians Univ Munchen, Comprehens Pneumol Ctr Munich, Inst & Clin Occupat Social & Environm Med, Univ Hosp,German Ctr Lung Res DZL, Munich, Germany.
   [Bellisario, Valeria] Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy.
   [Svanes, Cecilie] Univ Bergen, Ctr Int Hlth, Bergen, Norway.
   [Svanes, Cecilie] Haukeland Hosp, Dept Occupat Med, Bergen, Norway.
   [Schaffner, Emmanuel; Keidel, Dirk; Imboden, Medea; Caviezel, Seraina; Beckmeyer-Borowko, Anna; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Schaffner, Emmanuel; Keidel, Dirk; Imboden, Medea; Caviezel, Seraina; Beckmeyer-Borowko, Anna; Probst-Hensch, Nicole] Univ Basel, Basel, Switzerland.
   [Weyler, Joost] Univ Antwerp, Dept Epidemiol & Social Med ESOC, Stat UA Stat Ctr, Fac Med & Hlth Sci, Antwerp, Belgium.
   [Martinez-Moratalla, Jesus] Univ Castilla La Mancha, Fac Med, Complejo Hosp Univ Albacete, Serv Neumol, Albacete, Spain.
   [Gullon, Jose-Antonio] Hosp San Agustin, Dept Pneumol, Aviles, Asturias, Spain.
   [Sanchez Ramos, Jose Luis] Univ Huelva, Dept Nursing, Huelva, Spain.
   [Raherison, Chantal] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Team EPICENE,UMR 1219, Bordeaux, France.
   [Pin, Isabelle] CHU Grenoble Alpes, Dept Pediatrie, INSERM,IAB,U1209, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France.
   [Demoly, Pascal] Sorbonne Univ, Univ Hosp Montpellier, Montpellier, France.
   [Cerveri, Isa] Univ Pavia, San Matteo Hosp Fdn, IRCCS, Pavia, Italy.
   [Accordini, Simone] Univ Verona, Dept Diagnost & Publ Hlth, Unit Epidemiol & Med Stat, Verona, Italy.
   [Gislason, Thorarinn] Landspitali Univ Hosp, Dept Resp Med & Sleep, Reykjavik, Iceland.
   [Toren, Kjell] Inst Med, Dept Publ Hlth & Community Med, Gothenburg, Sweden.
   [Forsberg, Bertil; Raza, Wasif] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
   [Janson, Christer; Emtner, Margareta] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden.
   [Jogia, Rain] Tartu Univ Hosp, Lung Clin, Tartu, Estonia.
   [Gomez Real, Francisco] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway.
   [Leynaert, Benedicte] INSERM, UMR 1152, Pathophysiol & Epidemiol Resp Dis, Paris, France.
   [Leynaert, Benedicte] Univ Paris Diderot Paris, UMR 1152, Paris, France.
   [Pascual, Silvia] Galdakao Hosp, Resp Dept, OSI Barrualde Galdakao, Biscay, Spain.
   [Guerra, Stefano] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA.
   [Dharmage, Shyamali C.] Univ Melbourne, Sch Populat & Global Hlth, Allergy & Lung Hlth Unit, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
RP Garcia-Aymerich, J (reprint author), Barcelona Inst Global Hlth ISGlobal, Doctor Aiguader 88, Barcelona 08003, Spain.
EM judith.garcia@isglobal.org
RI Demoly, Pascal/Y-9938-2019; PIN, Isabelle/N-3020-2013; J,
   Garcia-Aymerich/G-6867-2014; Sanchez-Ramos, Jose Luis/G-1259-2011;
   Raherison, Chantal/T-3556-2019; Weyler, Joost JJ/O-8594-2016; Heinrich,
   Joachim/N-1720-2013
OI Demoly, Pascal/0000-0001-7827-7964; J,
   Garcia-Aymerich/0000-0002-7097-4586; Sanchez-Ramos, Jose
   Luis/0000-0001-7187-9989; Weyler, Joost JJ/0000-0001-7271-5492; Carsin,
   Anne-Elie/0000-0003-3981-977X; Leynaert, Benedicte/0000-0001-5045-2492;
   Heinrich, Joachim/0000-0002-9620-1629; Dharmage,
   Shyamali/0000-0001-6063-1937; Gullon, Jose Antonio/0000-0002-3007-0873;
   Cerveri, Isa/0000-0003-0337-043X; Fuertes, Elaine/0000-0003-0205-9025;
   Jarvis, Deborah/0000-0002-1753-3896
FU European Union's Horizon 2020 research and innovation programme
   [633212]; National Science FoundationNational Science Foundation (NSF)
   [33CS30-177506]; European Union's Horizon 2020 research and innovation
   programme under the Marie Sklodowska-Curie Individual Fellowship scheme
   (H2020-MSCA-IF-2015) [704268]
FX The present analyses are part of the Ageing Lungs in European Cohorts
   (ALEC) Study (www.alecstudy.org), which has received funding from the
   European Union's Horizon 2020 research and innovation programme under
   grant agreement No. 633212. The local investigators and funding agencies
   for the European Community Respiratory Health Survey (ECRHS II and ECRHS
   III) are reported in the Supplementary Material. SAPALDIA is funded by
   the National Science Foundation Grant Nr. 33CS30-177506. Elaine Fuertes
   was funded from the European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie Individual
   Fellowship scheme (H2020-MSCA-IF-2015; proposal number 704268). ISGlobal
   is a member of CERCA Programme/Generalitat de Catalunya.
CR Aaron SD, 1999, CHEST, V115, P869, DOI 10.1378/chest.115.3.869
   Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5
   Backman H, 2016, RESP MED, V120, P116, DOI 10.1016/j.rmed.2016.10.005
   Benck LR, 2017, AM J RESP CRIT CARE, V195, P1236, DOI 10.1164/rccm.201610-2089OC
   Bermudez VJ, 2013, AM J THER, V20, P448, DOI 10.1097/MJT.0b013e318235f1f2
   Bridevaux PO, 2015, AM J EPIDEMIOL, V181, P752, DOI 10.1093/aje/kwu352
   BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Fragoso CAV, 2016, AM J RESP CRIT CARE, V193, P727, DOI 10.1164/rccm.201508-1603OC
   Fuertes E, 2018, THORAX, V73, P376, DOI 10.1136/thoraxjnl-2017-210947
   Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145
   Godfrey MS, 2016, CHEST, V149, P238, DOI 10.1378/chest.15-1045
   Goodwin RD, 2007, AM J EPIDEMIOL, V165, P383, DOI 10.1093/aje/kwk026
   Guerra S, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02096-2016
   Guerra S, 2010, THORAX, V65, P499, DOI 10.1136/thx.2009.126052
   Honda Y, 2017, INT J CARDIOL, V241, P395, DOI 10.1016/j.ijcard.2017.04.049
   Johnston AK, 2008, THORAX, V63, P599, DOI 10.1136/thx.2007.088112
   Kurth L, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0003-6
   Lear SA, 2017, LANCET, V390, P2643, DOI 10.1016/S0140-6736(17)31634-3
   Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
   Mannino DM, 2013, RESPIROLOGY, V18, P1083, DOI 10.1111/resp.12119
   Mannino DM, 2003, J INTERN MED, V254, P540, DOI 10.1111/j.1365-2796.2003.01211.x
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Pellegrino R., 2005, EUR RESP J, V26
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Scarlata S, 2008, RESP MED, V102, P1349, DOI 10.1016/j.rmed.2008.02.021
   Shaaban R, 2007, THORAX, V62, P403, DOI 10.1136/thx.2006.068205
   Sperandio EF, 2016, J BRAS PNEUMOL, V42, P22, DOI 10.1590/S1806-37562016000000030
   Sun SS, 2003, AM J CLIN NUTR, V77, P331
   Wannamethee SG, 2010, DIABETES CARE, V33, P1990, DOI 10.2337/dc10-0324
   Wanner Miriam, 2016, Prev Med Rep, V3, P250, DOI 10.1016/j.pmedr.2016.03.003
   World Health Organization, 2010, GLOB REC PHYS ACT HL
NR 32
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 116
EP 123
DI 10.1016/j.rmed.2018.11.017
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000018
PM 30665509
OA Green Published, Other Gold
DA 2020-05-18
ER

PT J
AU Nygaard, M
   Hilberg, O
   Rasmussen, F
   Bendstrup, E
AF Nygaard, Mette
   Hilberg, Ole
   Rasmussen, Finn
   Bendstrup, Elisabeth
TI Tracheal collapsibility in adults is dynamic over time
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Excessive Dynamic Airway Collapse; Dynamic; Morphology; Infection;
   Pulmonary function test
ID PULMONARY-FUNCTION; FORCED EXPIRATION; TRACHEOBRONCHOMALACIA;
   TRACHEOMALACIA; CT
AB Background: Tracheal collapse is a weakness of the tracheal wall leading to expiratory central airway collapse of more than 50% compared to inspiration. It has previously been discussed whether the collapsibility of the greater airways is a stable or a dynamic condition. Indeed, other well-known lung diseases such as asthma are characterized by dynamic changes with respect to pulmonary function indices. There are several different morphologies of the trachea related to collapsibility such as the crescent type and the saber-sheath type both involving the tracheal cartilage and excess dynamic airway collapse only involving the posterior membranous part of the trachea. Is the morphology of the trachea important for the course of the disease? The effect or adverse effects of inhaled corticosteroids are thought to play a role in the increasing incidence of the excess tracheal collapse. In this pilot study, we hypothesized that the excess collapsibility of the tracheal wall is dynamic.
   Methods: We prospectively examined 20 patients with excessive tracheal collapse on previous CT scans performed primarily due to bronchiectasis. A repeat CT scan was performed in order to evaluate the collapsibility. Before the repeat scan, patients were trained in maximal inspiration, expiration and breathholding. CT was performed in full inspiration and at end-expiration. Image assessment was performed on a dedicated CT workstation using standard lung window display settings. The percentage expiratory collapse based on cross sectional areas from carina to the thoracic inlet was calculated. Pulmonary function tests were performed and analysed in accordance with the American Thoracic Society and the European Respiratory Society guidelines.
   Results: Repeat CT scan were performed after 24 month +/-7.2. Six of the 20 participants (30%) were males. Mean age was 67 +/-11.3 years. Mean FEV1 was 83% of predicted, FVC 96.6 % of predicted and FEV1/FVC-ratio 71%. In 45% of the patients tracheal expiratory collapse improved (by more than 10%) based on percentage change in cross sectional areas in expiration compared to inspiration. 35% of patients showed disease progression with increased collapse and in 20% the collapsibility remained unchanged.
   Conclusion: We demonstrate that the collapsibility in a large fraction of the patients had actually improved at the follow up examination. We do not find any dependency of the change in collapsibility on the morphology of the trachea after end expiration, use of corticosteroid, or recurrent infections. In addition, no correlation between the changes in collapse and changes in the pulmonary function tests and the symptoms is observed.
C1 [Nygaard, Mette] Horsens Reg Hosp, Dept Internal Med, Horsens, Denmark.
   [Hilberg, Ole] Vejle Hosp, Med Dept, Vejle, Denmark.
   [Hilberg, Ole] Univ Southern Denmark, Odense, Denmark.
   [Rasmussen, Finn] Aarhus Univ Hosp, Dept Radiol, Aarhus, Denmark.
   [Bendstrup, Elisabeth] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Aarhus, Denmark.
RP Nygaard, M (reprint author), Horsens Reg Hosp, Dept Internal Med, Horsens, Denmark.
EM metnygch@rm.dk
OI Bendstrup, Elisabeth/0000-0002-4238-6963
CR Bhatt SP, 2016, JAMA-J AM MED ASSOC, V315, P498, DOI 10.1001/jama.2015.19431
   Boiselle PM, 2006, J THORAC IMAG, V21, P190, DOI 10.1097/01.rti.0000213647.42041.d0
   Boiselle PM, 2010, ACAD RADIOL, V17, P1186, DOI 10.1016/j.acra.2010.04.016
   Boiselle PM, 2009, RADIOLOGY, V252, P255, DOI 10.1148/radiol.2521081958
   CAMPBELL AH, 1965, AM REV RESPIR DIS, V92, P781
   Carden KA, 2005, CHEST, V127, P984, DOI 10.1378/chest.127.3.984
   Choo EM, 2013, IMMUNOL ALLERGY CLIN, V33, P23, DOI 10.1016/j.iac.2012.10.005
   GAMSU G, 1982, AM J ROENTGENOL, V139, P321, DOI 10.2214/ajr.139.2.321
   Gilkeson RC, 2001, AM J ROENTGENOL, V176, P205, DOI 10.2214/ajr.176.1.1760205
   GREENE R, 1975, RADIOLOGY, V115, P265, DOI 10.1148/115.2.265
   Husta BC, 2017, CHEST, V152, P1296, DOI 10.1016/j.chest.2017.08.013
   Imaizumi Hitoshi, 1995, Journal of Emergency Medicine, V13, P43, DOI 10.1016/0736-4679(94)00111-1
   JOKINEN K, 1977, ANN CLIN RES, V9, P52
   Kandaswamy C, 2009, CURR OPIN PULM MED, V15, P113, DOI 10.1097/MCP.0b013e328321832d
   Kauczor HU, 1998, AM J ROENTGENOL, V171, P1091, DOI 10.2214/ajr.171.4.9763003
   Majid A, 2013, RESP CARE, V58, P1521, DOI 10.4187/respcare.02277
   Murgu S, 2013, CLIN CHEST MED, V34, P527, DOI 10.1016/j.ccm.2013.05.003
   Murgu SD, 2007, RESPIROLOGY, V12, P543, DOI 10.1111/j.1440-1843.2007.01094.x
   Murgu SD, 2006, RESPIROLOGY, V11, P388, DOI 10.1111/j.1440-1843.2006.00862.x
   NUUTINEN J, 1977, ANN CLIN RES, V9, P350
   Nygaard E. B. Mette, THE EFFECT OF BREATH
   Nygaard M, 2017, EUR CLIN RESPIR J, V4, DOI 10.1080/20018525.2017.1407624
   Stenton C, 2008, OCCUP MED-OXFORD, V58, P226, DOI 10.1093/occmed/kqm162
   STERN EJ, 1993, RADIOLOGY, V187, P27, DOI 10.1148/radiology.187.1.8451427
   WEBB WR, 1993, RADIOLOGY, V186, P117, DOI 10.1148/radiology.186.1.8416550
NR 25
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 124
EP 128
DI 10.1016/j.rmed.2018.11.018
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000019
PM 30665510
DA 2020-05-18
ER

PT J
AU Egerod, I
   Kaldan, G
   Shaker, SB
   Guldin, MB
   Browatski, A
   Marsaa, K
   Overgaard, D
AF Egerod, Ingrid
   Kaldan, Gudrun
   Shaker, Saher Burhan
   Guldin, Mai-Britt
   Browatski, Andrea
   Marsaa, Kristoffer
   Overgaard, Dorthe
TI Spousal bereavement after fibrotic interstitial lung disease: A
   qualitative study
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Advance care planning; Bereavement care; Family centred nursing; Grief;
   Idiopathic pulmonary fibrosis; Interstitial lung disease; Palliative
   care
ID COMPLICATED GRIEF; PALLIATIVE CARE; EXPERIENCE; CAREGIVERS; RELATIVES;
   DIARIES
AB Introduction: Fibrotic interstitial lung disease ( f-ILD) comprises a group of diseases with lung scarring and reduced life expectancy. The short time from diagnosis to death affects the patients' bereaved spouses, who risk developing prolonged grief. In Denmark palliative care is most often offered to cancer patients.
   Aim: We aimed to investigate the experience of spouses of f-ILD patients during the final stages of illness and up to the first year after the patient's death to investigate if palliative care could ease the transition and prevent PGD.
   Methods: Our study had a qualitative design triangulating in-depth interviews, field notes, participant diaries and the prolonged grief questionnaire PG-13. We included 20 spouses and applied thematic analysis. Initial coding was performed deductively according to the chronological stages of before, during and after the death of the patient. We subsequently coded inductively within the stages.
   Results: During the final days the spouses experienced emotional ambivalence shifting between hope, acceptance and despair. Factors affecting the spouses during the final hours were the timing, location, and process of death. After the patient's death the spouses experienced feelings of grief and optimism as they moved toward a new life on their own.
   Conclusions: Some of the factors affecting the spouses and potentially causing prolonged grief might be alleviated by offering palliative/supportive care and advance care planning to f-ILD patients and their family.
C1 [Egerod, Ingrid] Univ Copenhagen, Intens Care Unit, Rigshosp, Copenhagen, Denmark.
   [Kaldan, Gudrun] Copenhagen Univ Hosp, Abdominal Ctr, Rigshosp, Copenhagen, Denmark.
   [Shaker, Saher Burhan] Univ Copenhagen, Gentofte Hosp, Dept Resp Med, Copenhagen, Denmark.
   [Guldin, Mai-Britt] Univ Aarhus, Res Unit Gen Practice, Aarhus, Denmark.
   [Browatski, Andrea] North Zealand Univ Hosp, Dept Pulm & Infect Dis, Hillerod, Denmark.
   [Marsaa, Kristoffer] Univ Copenhagen, Herlev & Gentofte Hosp, Palliat Unit, Copenhagen, Denmark.
   [Overgaard, Dorthe] Copenhagen Univ Coll, Inst Nursing & Nutr, Fac Hlth & Technol, Copenhagen, Denmark.
RP Egerod, I (reprint author), Rigshosp, Intens Care Unit 4131, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM Ingrid.egerod@regionh.dk
OI Egerod, Ingrid/0000-0002-9576-4390
FU Danish Lung Association
FX Danish Lung Association.
CR Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Connor S., 2013, PALL CAR
   Duck A, 2015, J ADV NURS, V71, P1055, DOI 10.1111/jan.12587
   Egerod I, 2017, INTENS CRIT CARE NUR, V41, P57, DOI 10.1016/j.iccn.2017.02.004
   Egerod I, 2011, NURS INQ, V18, P235, DOI 10.1111/j.1440-1800.2011.00540.x
   Egerod I, 2011, CRIT CARE MED, V39, P1922, DOI 10.1097/CCM.0b013e31821e89c8
   Guldin MB, 2013, PSYCHO-ONCOLOGY, V22, P1152, DOI 10.1002/pon.3120
   Habraken JM, 2009, J PAIN SYMPTOM MANAG, V37, P973, DOI 10.1016/j.jpainsymman.2008.07.010
   Hyldgaard C, 2014, RESP MED, V108, P793, DOI 10.1016/j.rmed.2013.09.002
   Kruglanski AW, 1996, PSYCHOL REV, V103, P263, DOI 10.1037/0033-295X.103.2.263
   Lindell KO, 2015, CHEST, V147, P423, DOI 10.1378/chest.14-1127
   Mc Veigh C, 2018, J ADV NURS, V74, P383, DOI 10.1111/jan.13453
   Nielsen MK, 2017, J PAIN SYMPTOM MANAG, V53, P540, DOI 10.1016/j.jpainsymman.2016.09.013
   Overgaard D, 2016, EUR RESPIR J, V47, P1472, DOI 10.1183/13993003.01566-2015
   Phillippi J, 2018, QUAL HEALTH RES, V28, P381, DOI 10.1177/1049732317697102
   Pifer PM, 2018, AM J HOSP PALLIAT ME, V35, P1287, DOI 10.1177/1049909118763592
   Prigerson HG, 1995, PSYCHIAT RES, V59, P65, DOI 10.1016/0165-1781(95)02757-2
   Prigerson HG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000121
   Ryerson CJ, 2017, AM J RESP CRIT CARE, V196, P1249, DOI 10.1164/rccm.201702-0400PP
   Shear MK, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0406-z
   Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201
   Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007
   SST, 2017, ANB PALL INDS
   Stroebe M, 2010, OMEGA-J DEATH DYING, V61, P273, DOI 10.2190/OM.61.4.b
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
NR 25
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 129
EP 136
DI 10.1016/j.rmed.2018.12.008
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000020
PM 30665511
DA 2020-05-18
ER

PT J
AU Kyomoto, Y
   Kanazawa, H
   Tochino, Y
   Watanabe, T
   Asai, K
   Kawaguchi, T
AF Kyomoto, Yohkoh
   Kanazawa, Hiroshi
   Tochino, Yoshihiro
   Watanabe, Tetsuya
   Asai, Kaziuhisa
   Kawaguchi, Tomoya
TI Possible role of airway microvascular permeability on airway obstruction
   in patients with chronic obstructive pulmonary disease
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Airway microvascular system; Bronchoscopic microsampling technique;
   Chronic obstructive pulmonary disease; Epithelial lining fluid;
   Peripheral airways
ID EPITHELIAL LINING FLUID; ENDOTHELIAL GROWTH-FACTOR
AB Background: Airway microvascular system participates in the airway inflammation that is central to the pathophysiology of inflammatory lung disorders.
   Objective: To examine the role of airway microvascular permeability on airway obstruction in patients with chronic obstructive pulmonary disease (COPD).
   Methods: We measured the airway microvascular permeability index (AMPI) separately in the central or peripheral airways using a bronchoscopic microsampling technique in 9 non-smokers, 18 smokers without COPD (10 former smokers and 8 current smokers), and 26 smokers with COPD (12 former smokers and 14 current smokers).
   Results: AMPI in the central airways was relatively low, and this index was comparable among the five groups. In contrast, AMPI in the peripheral airways was significantly higher in smokers with or without COPD compared with non-smokers. Moreover, AMPI in the peripheral airways was significantly higher in current smokers than in former smokers with COPD. Especially, AMPI in the peripheral airways, but not in the central airways, showed a significant correlation with the degree of airway obstruction in former or current smokers with COPD. However, AMPI in the peripheral airways was not correlated with the diffusing capacity of the lung in former or current smokers with COPD.
   Conclusion: Airway microvascular permeability in the peripheral airways is increased in patients with COPD, and is associated with the severity of airway obstruction. We may need to consider this characteristic feature as a target in any therapeutic strategy for the treatment of the disease.
C1 [Kyomoto, Yohkoh; Kanazawa, Hiroshi; Tochino, Yoshihiro; Watanabe, Tetsuya; Asai, Kaziuhisa; Kawaguchi, Tomoya] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan.
RP Kanazawa, H (reprint author), Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
EM kanazawa-h@med.osaka-cu.ac.jp
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26461166,
   17K09622]
FX This work was supported by JSPS KAKENHI Grant Number 26461166& 17K09622.
CR Allinson JP, 2016, AM J RESP CRIT CARE, V193, P662, DOI 10.1164/rccm.201511-2210OC
   Angelis N., J THORAC DIS, V6
   Berg K, 2016, ARCH PATHOL LAB MED, V140, P1423, DOI 10.5858/arpa.2015-0455-RS
   Bhatt SP, 2016, AM J RESP CRIT CARE, V194, P178, DOI 10.1164/rccm.201511-2219OC
   Decramer M, 2012, LANCET, V379, P1341, DOI 10.1016/S0140-6736(11)60968-9
   GOLDIE RG, 1995, CLIN EXP PHARMACOL P, V22, P387, DOI 10.1111/j.1440-1681.1995.tb02028.x
   Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350
   Hogg JC, 2017, PHYSIOL REV, V97, P529, DOI 10.1152/physrev.00025.2015
   Hogg JC, 2013, CHEST, V143, P1436, DOI 10.1378/chest.12-1766
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Hueper K, 2015, AM J RESP CRIT CARE, V192, P570, DOI 10.1164/rccm.201411-2120OC
   Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
   Jones RL, 2016, RESPIROLOGY, V21, P1347, DOI 10.1111/resp.12841
   Kanazawa H, 2005, CHEST, V128, P3191, DOI 10.1378/chest.128.5.3191
   Kanazawa H, 2004, AM J RESP CRIT CARE, V169, P1125, DOI 10.1164/rccm.200401-123OC
   Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166
   Kanazawa H, 2009, CLIN EXP ALLERGY, V39, P1330, DOI 10.1111/j.1365-2222.2009.03262.x
   Kanazawa H, 2014, CHEST, V146, P1159, DOI 10.1378/chest.14-0373
   Kanazawa H, 2012, EUR J CLIN INVEST, V42, P419, DOI 10.1111/j.1365-2362.2011.02598.x
   Kanazawa H, 2010, CLIN SCI, V119, P143, DOI 10.1042/CS20100096
   Kodama T, 2009, RESP MED, V103, P35, DOI 10.1016/j.rmed.2008.09.004
   Koo HK, 2018, LANCET RESP MED, V6, P591, DOI 10.1016/S2213-2600(18)30196-6
   Mahmood MQ, 2015, INT J CHRONIC OBSTR, V10, P1515, DOI 10.2147/COPD.S81032
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Pellegrino R., 2005, EUR RESP J, V26
   Rennard SI, 2015, LANCET, V385, P1778, DOI 10.1016/S0140-6736(15)60647-X
   Van Rensen E. L. J., 2002, AM J RESP CRIT CARE, V165
   Vogelmeier CF, 2017, EUR RESPIR J, V49, P1
NR 28
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD JAN
PY 2019
VL 146
BP 137
EP 141
DI 10.1016/j.rmed.2018.12.007
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA HH9QM
UT WOS:000456074000021
PM 30665512
DA 2020-05-18
ER

EF